Tricuspid	6794356	0	B
valve	-	10	I
regurgitation	-	16	I
and	-	30	O
lithium	-	34	O
carbonate	-	42	O
toxicity	-	52	B
in	-	61	O
a	-	64	O
newborn	-	66	O
infant	-	74	O
.	-	80	O

A	6794356	82	O
newborn	-	84	O
with	-	92	O
massive	-	97	O
tricuspid	-	105	B
regurgitation	-	115	I
,	-	128	O
atrial	-	130	B
flutter	-	137	I
,	-	144	O
congestive	-	146	B
heart	-	157	I
failure	-	163	I
,	-	170	O
and	-	172	O
a	-	176	O
high	-	178	O
serum	-	183	O
lithium	-	189	O
level	-	197	O
is	-	203	O
described	-	206	O
.	-	215	O

This	6794356	217	O
is	-	222	O
the	-	225	O
first	-	229	O
patient	-	235	O
to	-	243	O
initially	-	246	O
manifest	-	256	O
tricuspid	-	265	B
regurgitation	-	275	I
and	-	289	O
atrial	-	293	B
flutter	-	300	I
,	-	307	O
and	-	309	O
the	-	313	O
11th	-	317	O
described	-	322	O
patient	-	332	O
with	-	340	O
cardiac	-	345	B
disease	-	353	I
among	-	361	O
infants	-	367	O
exposed	-	375	O
to	-	383	O
lithium	-	386	O
compounds	-	394	O
in	-	404	O
the	-	407	O
first	-	411	O
trimester	-	417	O
of	-	427	O
pregnancy	-	430	O
.	-	439	O

Sixty	6794356	441	O
-	-	446	O
three	-	447	O
percent	-	453	O
of	-	461	O
these	-	464	O
infants	-	470	O
had	-	478	O
tricuspid	-	482	O
valve	-	492	O
involvement	-	498	O
.	-	509	O

Lithium	6794356	511	O
carbonate	-	519	O
may	-	529	O
be	-	533	O
a	-	536	O
factor	-	538	O
in	-	545	O
the	-	548	O
increasing	-	552	O
incidence	-	563	O
of	-	573	O
congenital	-	576	B
heart	-	587	I
disease	-	593	I
when	-	601	O
taken	-	606	O
during	-	612	O
early	-	619	O
pregnancy	-	625	O
.	-	634	O

It	6794356	636	O
also	-	639	O
causes	-	644	O
neurologic	-	651	B
depression	-	662	I
,	-	672	O
cyanosis	-	674	B
,	-	682	O
and	-	684	O
cardiac	-	688	B
arrhythmia	-	696	I
when	-	707	O
consumed	-	712	O
prior	-	721	O
to	-	727	O
delivery	-	730	O
.	-	738	O

Phenobarbital	6504332	0	O
-	-	13	O
induced	-	14	O
dyskinesia	-	22	B
in	-	33	O
a	-	36	O
neurologically	-	38	B
-	-	52	I
impaired	-	53	I
child	-	62	O
.	-	67	O

A	6504332	69	O
2	-	71	O
-	-	72	O
year	-	73	O
-	-	77	O
old	-	78	O
child	-	82	O
with	-	88	O
known	-	93	O
neurologic	-	99	B
impairment	-	110	I
developed	-	121	O
a	-	131	O
dyskinesia	-	133	B
soon	-	144	O
after	-	149	O
starting	-	155	O
phenobarbital	-	164	O
therapy	-	178	O
for	-	186	O
seizures	-	190	B
.	-	198	O

Known	6504332	200	O
causes	-	206	O
of	-	213	O
movement	-	216	B
disorders	-	225	I
were	-	235	O
eliminated	-	240	O
after	-	251	O
evaluation	-	257	O
.	-	267	O

On	6504332	269	O
repeat	-	272	O
challenge	-	279	O
with	-	289	O
phenobarbital	-	294	O
,	-	307	O
the	-	309	O
dyskinesia	-	313	B
recurred	-	324	O
.	-	332	O

Phenobarbital	6504332	334	O
should	-	348	O
be	-	355	O
added	-	358	O
to	-	364	O
the	-	367	O
list	-	371	O
of	-	376	O
anticonvulsant	-	379	O
drugs	-	394	O
that	-	400	O
can	-	405	O
cause	-	409	O
movement	-	415	B
disorders	-	424	I
.	-	433	O

Acute	6436733	0	O
changes	-	6	O
of	-	14	O
blood	-	17	O
ammonia	-	23	O
may	-	31	O
predict	-	35	O
short	-	43	O
-	-	48	O
term	-	49	O
adverse	-	54	O
effects	-	62	O
of	-	70	O
valproic	-	73	O
acid	-	82	O
.	-	86	O

Valproic	6436733	88	O
acid	-	97	O
(	-	102	O
VPA	-	103	O
)	-	106	O
was	-	108	O
given	-	112	O
to	-	118	O
24	-	121	O
epileptic	-	124	B
patients	-	134	O
who	-	143	O
were	-	147	O
already	-	152	O
being	-	160	O
treated	-	166	O
with	-	174	O
other	-	179	O
antiepileptic	-	185	O
drugs	-	199	O
.	-	204	O

A	6436733	206	O
standardized	-	208	O
loading	-	221	O
dose	-	229	O
of	-	234	O
VPA	-	237	O
was	-	241	O
administered	-	245	O
,	-	257	O
and	-	259	O
venous	-	263	O
blood	-	270	O
was	-	276	O
sampled	-	280	O
at	-	288	O
0	-	291	O
,	-	292	O
1	-	294	O
,	-	295	O
2	-	297	O
,	-	298	O
3	-	300	O
,	-	301	O
and	-	303	O
4	-	307	O
hours	-	309	O
.	-	314	O

Ammonia	6436733	316	O
(	-	324	O
NH3	-	325	O
)	-	328	O
was	-	330	O
higher	-	334	O
in	-	341	O
patients	-	344	O
who	-	353	O
,	-	356	O
during	-	358	O
continuous	-	365	O
therapy	-	376	O
,	-	383	O
complained	-	385	O
of	-	396	O
drowsiness	-	399	B
(	-	410	O
7	-	411	O
patients	-	413	O
)	-	421	O
than	-	423	O
in	-	428	O
those	-	431	O
who	-	437	O
were	-	441	O
symptom	-	446	O
-	-	453	O
free	-	454	O
(	-	459	O
17	-	460	O
patients	-	463	O
)	-	471	O
,	-	472	O
although	-	474	O
VPA	-	483	O
plasma	-	487	O
levels	-	494	O
were	-	501	O
similar	-	506	O
in	-	514	O
both	-	517	O
groups	-	522	O
.	-	528	O

By	6436733	530	O
measuring	-	533	O
VPA	-	543	O
-	-	546	O
induced	-	547	O
changes	-	555	O
of	-	563	O
blood	-	566	O
NH3	-	572	O
content	-	576	O
,	-	583	O
it	-	585	O
may	-	588	O
be	-	592	O
possible	-	595	O
to	-	604	O
identify	-	607	O
patients	-	616	O
at	-	625	O
higher	-	628	O
risk	-	635	O
of	-	640	O
obtundation	-	643	O
when	-	655	O
VPA	-	660	O
is	-	664	O
given	-	667	O
chronically	-	673	O
.	-	684	O

Effects	6293644	0	O
of	-	8	O
calcitonin	-	11	O
on	-	22	O
rat	-	25	O
extrapyramidal	-	29	O
motor	-	44	O
system	-	50	O
:	-	56	O
behavioral	-	58	O
and	-	69	O
biochemical	-	73	O
data	-	85	O
.	-	89	O

The	6293644	91	O
effects	-	95	O
of	-	103	O
i	-	106	O
.	-	107	O
v	-	108	O
.	-	109	O
c	-	110	O
.	-	111	O

injection	6293644	113	O
of	-	123	O
human	-	126	O
and	-	132	O
salmon	-	136	O
calcitonin	-	143	O
on	-	154	O
biochemical	-	157	O
and	-	169	O
behavioral	-	173	O
parameters	-	184	O
related	-	195	O
to	-	203	O
the	-	206	O
extrapyramidal	-	210	O
motor	-	225	O
system	-	231	O
,	-	237	O
were	-	239	O
investigated	-	244	O
in	-	257	O
male	-	260	O
rats	-	265	O
.	-	269	O

Calcitonin	6293644	271	O
injection	-	282	O
resulted	-	292	O
in	-	301	O
a	-	304	O
potentiation	-	306	O
of	-	319	O
haloperidol	-	322	O
-	-	333	O
induced	-	334	O
catalepsy	-	342	B
and	-	352	O
a	-	356	O
partial	-	358	O
prevention	-	366	O
of	-	377	O
apomorphine	-	380	O
-	-	391	O
induced	-	392	O
hyperactivity	-	400	B
.	-	413	O

Moreover	6293644	415	O
calcitonin	-	424	O
induced	-	435	O
a	-	443	O
significant	-	445	O
decrease	-	457	O
in	-	466	O
nigral	-	469	O
GAD	-	476	O
activity	-	480	O
but	-	489	O
no	-	493	O
change	-	496	O
in	-	503	O
striatal	-	506	O
DA	-	515	O
and	-	518	O
DOPAC	-	522	O
concentration	-	528	O
or	-	542	O
GAD	-	545	O
activity	-	549	O
.	-	557	O

The	6293644	559	O
results	-	563	O
are	-	571	O
discussed	-	575	O
in	-	585	O
view	-	588	O
of	-	593	O
a	-	596	O
primary	-	598	O
action	-	606	O
of	-	613	O
calcitonin	-	616	O
on	-	627	O
the	-	630	O
striatonigral	-	634	O
GABAergic	-	648	O
pathway	-	658	O
mediating	-	666	O
the	-	676	O
DA	-	680	O
-	-	682	O
related	-	683	O
behavioral	-	691	O
messages	-	702	O
of	-	711	O
striatal	-	714	O
origin	-	723	O
.	-	729	O

Development	6203632	0	O
of	-	12	O
isoproterenol	-	15	O
-	-	28	O
induced	-	29	O
cardiac	-	37	B
hypertrophy	-	45	I
.	-	56	O

The	6203632	58	O
development	-	62	O
of	-	74	O
cardiac	-	77	B
hypertrophy	-	85	I
was	-	97	O
studied	-	101	O
in	-	109	O
adult	-	112	O
female	-	118	O
Wistar	-	125	O
rats	-	132	O
following	-	137	O
daily	-	147	O
subcutaneous	-	153	O
injections	-	166	O
of	-	177	O
isoproterenol	-	180	O
(	-	194	O
ISO	-	195	O
)	-	198	O
(	-	200	O
0	-	201	O
.	-	202	O
3	-	203	O
mg	-	205	O
/	-	207	O
kg	-	208	O
body	-	211	O
weight	-	216	O
)	-	222	O
.	-	223	O

A	6203632	225	O
time	-	227	O
course	-	232	O
was	-	239	O
established	-	243	O
for	-	255	O
the	-	259	O
change	-	263	O
in	-	270	O
tissue	-	273	O
mass	-	280	O
,	-	284	O
RNA	-	286	O
and	-	290	O
DNA	-	294	O
content	-	298	O
,	-	305	O
as	-	307	O
well	-	310	O
as	-	315	O
hydroxyproline	-	318	O
content	-	333	O
.	-	340	O

Heart	6203632	342	O
weight	-	348	O
increased	-	355	O
44	-	365	O
%	-	367	O
after	-	369	O
8	-	375	O
days	-	377	O
of	-	382	O
treatment	-	385	O
with	-	395	O
a	-	400	O
half	-	402	O
time	-	407	O
of	-	412	O
3	-	415	O
.	-	416	O
4	-	417	O
days	-	419	O
.	-	423	O

Ventricular	6203632	425	O
RNA	-	437	O
content	-	441	O
was	-	449	O
elevated	-	453	O
26	-	462	O
%	-	464	O
after	-	466	O
24	-	472	O
h	-	475	O
of	-	477	O
a	-	480	O
single	-	482	O
injection	-	489	O
and	-	499	O
reached	-	503	O
a	-	511	O
maximal	-	513	O
level	-	521	O
following	-	527	O
8	-	537	O
days	-	539	O
of	-	544	O
therapy	-	547	O
.	-	554	O

The	6203632	556	O
half	-	560	O
time	-	565	O
for	-	570	O
RNA	-	574	O
accumulation	-	578	O
was	-	591	O
2	-	595	O
.	-	596	O
0	-	597	O
days	-	599	O
.	-	603	O

The	6203632	605	O
total	-	609	O
content	-	615	O
of	-	623	O
hydroxyproline	-	626	O
remained	-	641	O
stable	-	650	O
during	-	657	O
the	-	664	O
first	-	668	O
2	-	674	O
days	-	676	O
of	-	681	O
treatment	-	684	O
but	-	694	O
increased	-	698	O
46	-	708	O
%	-	710	O
after	-	712	O
4	-	718	O
days	-	720	O
of	-	725	O
therapy	-	728	O
.	-	735	O

Ventricular	6203632	737	O
DNA	-	749	O
content	-	753	O
was	-	761	O
unchanged	-	765	O
during	-	775	O
the	-	782	O
early	-	786	O
stage	-	792	O
(	-	798	O
1	-	799	O
-	-	800	O
4	-	801	O
days	-	803	O
)	-	807	O
of	-	809	O
hypertrophic	-	812	B
growth	-	825	O
but	-	832	O
increased	-	836	O
to	-	846	O
a	-	849	O
new	-	851	O
steady	-	855	O
-	-	861	O
state	-	862	O
level	-	868	O
19	-	874	O
%	-	876	O
above	-	878	O
the	-	884	O
controls	-	888	O
after	-	897	O
8	-	903	O
days	-	905	O
of	-	910	O
treatment	-	913	O
.	-	922	O

Intraventricular	6203632	924	O
pressures	-	941	O
and	-	951	O
coronary	-	955	O
flow	-	964	O
measures	-	969	O
were	-	978	O
similar	-	983	O
for	-	991	O
control	-	995	O
and	-	1003	O
experimental	-	1007	O
animals	-	1020	O
following	-	1028	O
4	-	1038	O
days	-	1040	O
of	-	1045	O
developed	-	1048	O
hypertrophy	-	1058	B
.	-	1069	O

However	6203632	1071	O
,	-	1078	O
dP	-	1080	O
/	-	1082	O
dt	-	1083	O
in	-	1086	O
the	-	1089	O
ISO	-	1093	O
-	-	1096	O
treated	-	1097	O
hearts	-	1105	O
was	-	1112	O
slightly	-	1116	O
but	-	1125	O
significantly	-	1129	O

(	6203632	1143	O
P	-	1144	O
less	-	1146	O
than	-	1151	O
0	-	1156	O
.	-	1157	O
05	-	1158	O
)	-	1160	O
elevated	-	1162	O
.	-	1170	O

These	6203632	1172	O
data	-	1178	O
indicate	-	1183	O
that	-	1192	O
the	-	1197	O
adaptive	-	1201	O
response	-	1210	O
to	-	1219	O
ISO	-	1222	O
shows	-	1226	O
an	-	1232	O
early	-	1235	O
hypertrophic	-	1241	B
phase	-	1254	O
(	-	1260	O
1	-	1261	O
-	-	1262	O
4	-	1263	O
days	-	1265	O
)	-	1269	O
characterized	-	1271	O
by	-	1285	O
a	-	1288	O
substantial	-	1290	O
increase	-	1302	O
in	-	1311	O
RNA	-	1314	O
content	-	1318	O
and	-	1326	O
cardiac	-	1330	O
mass	-	1338	O
in	-	1343	O
the	-	1346	O
absence	-	1350	O
of	-	1358	O
changes	-	1361	O
in	-	1369	O
DNA	-	1372	O
.	-	1375	O

However	6203632	1377	O
,	-	1384	O
prolonged	-	1386	O
stimulation	-	1396	O
(	-	1408	O
8	-	1409	O
-	-	1410	O
12	-	1411	O
days	-	1414	O
)	-	1418	O
appears	-	1420	O
to	-	1428	O
represent	-	1431	O
a	-	1441	O
complex	-	1443	O
integration	-	1451	O
of	-	1463	O
both	-	1466	O
cellular	-	1471	O
hypertrophy	-	1480	B
and	-	1492	O
hyperplasia	-	1496	B
within	-	1508	O
the	-	1515	O
heart	-	1519	O
.	-	1524	O

Co	3131282	0	O
-	-	2	O
carcinogenic	-	3	B
effect	-	16	O
of	-	23	O
retinyl	-	26	O
acetate	-	34	O
on	-	42	O
forestomach	-	45	B
carcinogenesis	-	57	I
of	-	72	O
male	-	75	O
F344	-	80	O
rats	-	85	O
induced	-	90	O
with	-	98	O
butylated	-	103	O
hydroxyanisole	-	113	O
.	-	127	O

The	3131282	129	O
potential	-	133	O
modifying	-	143	O
effect	-	153	O
of	-	160	O
retinyl	-	163	O
acetate	-	171	O
(	-	179	O
RA	-	180	O
)	-	182	O
on	-	184	O
butylated	-	187	O
hydroxyanisole	-	197	O
(	-	212	O
BHA	-	213	O
)	-	216	O
-	-	217	O
induced	-	218	O
rat	-	226	O
forestomach	-	230	B
tumorigenesis	-	242	I
was	-	256	O
examined	-	260	O
.	-	268	O

Male	3131282	270	O
F344	-	275	O
rats	-	280	O
,	-	284	O
5	-	286	O
weeks	-	288	O
of	-	294	O
age	-	297	O
,	-	300	O
were	-	302	O
maintained	-	307	O
on	-	318	O
diet	-	321	O
containing	-	326	O
1	-	337	O
%	-	338	O
or	-	340	O
2	-	343	O
%	-	344	O
BHA	-	346	O
by	-	350	O
weight	-	353	O
and	-	360	O
simultaneously	-	364	O
on	-	379	O
drinking	-	382	O
water	-	391	O
supplemented	-	397	O
with	-	410	O
RA	-	415	O
at	-	418	O
various	-	421	O
concentrations	-	429	O
(	-	444	O
w	-	445	O
/	-	446	O
v	-	447	O
)	-	448	O
for	-	450	O
52	-	454	O
weeks	-	457	O
.	-	462	O

In	3131282	464	O
groups	-	467	O
given	-	474	O
2	-	480	O
%	-	481	O
BHA	-	483	O
,	-	486	O
although	-	488	O
marked	-	497	O
hyperplastic	-	504	O
changes	-	517	O
of	-	525	O
the	-	528	O
forestomach	-	532	O
epithelium	-	544	O
were	-	555	O
observed	-	560	O
in	-	569	O
all	-	572	O
animals	-	576	O
,	-	583	O
co	-	585	O
-	-	587	O
administration	-	588	O
of	-	603	O
0	-	606	O
.	-	607	O
25	-	608	O
%	-	610	O
RA	-	612	O
significantly	-	615	O
(	-	629	O
P	-	630	O
less	-	632	O
than	-	637	O
0	-	642	O
.	-	643	O
05	-	644	O
)	-	646	O
increased	-	648	O
the	-	658	O
incidence	-	662	O
of	-	672	O
forestomach	-	675	B
tumors	-	687	I
(	-	694	O
squamous	-	695	B
cell	-	704	I
papilloma	-	709	I
and	-	719	O
carcinoma	-	723	B
)	-	732	O
to	-	734	O
60	-	737	O
%	-	739	O
(	-	741	O
9	-	742	O
/	-	743	O
15	-	744	O
,	-	746	O
2	-	748	O
rats	-	750	O
with	-	755	O
carcinoma	-	760	B
)	-	769	O
from	-	771	O
15	-	776	O
%	-	778	O
(	-	780	O
3	-	781	O
/	-	782	O
20	-	783	O
,	-	785	O
one	-	787	O
rat	-	791	O
with	-	795	O
carcinoma	-	800	B
)	-	809	O
in	-	811	O
the	-	814	O
group	-	818	O
given	-	824	O
RA	-	830	O
-	-	832	O
free	-	833	O
water	-	838	O
.	-	843	O

In	3131282	845	O
rats	-	848	O
given	-	853	O
1	-	859	O
%	-	860	O
BHA	-	862	O
,	-	865	O
RA	-	867	O
co	-	870	O
-	-	872	O
administered	-	873	O
at	-	886	O
a	-	889	O
dose	-	891	O
of	-	896	O
0	-	899	O
.	-	900	O
05	-	901	O
,	-	903	O
0	-	905	O
.	-	906	O
1	-	907	O
,	-	908	O
0	-	910	O
.	-	911	O
2	-	912	O
or	-	914	O
0	-	917	O
.	-	918	O
25	-	919	O
%	-	921	O
showed	-	923	O
a	-	930	O
dose	-	932	O
-	-	936	O
dependent	-	937	O
enhancing	-	947	O
effect	-	957	O
on	-	964	O
the	-	967	O
development	-	971	O
of	-	983	O
the	-	986	O
BHA	-	990	O
-	-	993	O
induced	-	994	O
epithelial	-	1002	B
hyperplasia	-	1013	I
.	-	1024	O

Tumors	3131282	1026	B
,	-	1032	O
all	-	1034	O
papillomas	-	1038	B
,	-	1048	O
were	-	1050	O
induced	-	1055	O
in	-	1063	O
3	-	1066	O
rats	-	1068	O
(	-	1073	O
17	-	1074	O
%	-	1076	O
)	-	1077	O
with	-	1079	O
0	-	1084	O
.	-	1085	O
25	-	1086	O
%	-	1088	O
RA	-	1090	O
and	-	1093	O
in	-	1097	O
one	-	1100	O
rat	-	1104	O
(	-	1108	O
10	-	1109	O
%	-	1111	O
)	-	1112	O
with	-	1114	O
0	-	1119	O
.	-	1120	O
05	-	1121	O
%	-	1123	O
RA	-	1125	O
co	-	1128	O
-	-	1130	O
administration	-	1131	O
.	-	1145	O

RA	3131282	1147	O
alone	-	1150	O
did	-	1156	O
not	-	1160	O
induce	-	1164	O
hyperplastic	-	1171	O
changes	-	1184	O
in	-	1192	O
the	-	1195	O
forestomach	-	1199	O
.	-	1210	O

These	3131282	1212	O
findings	-	1218	O
indicate	-	1227	O
that	-	1236	O
RA	-	1241	O
acted	-	1244	O
as	-	1250	O
a	-	1253	O
co	-	1255	O
-	-	1257	O
carcinogen	-	1258	O
in	-	1269	O
the	-	1272	O
BHA	-	1276	O
forestomach	-	1280	B
carcinogenesis	-	1292	I
of	-	1307	O
the	-	1310	O
rat	-	1314	O
.	-	1317	O

Ketanserin	3115150	0	O
pretreatment	-	11	O
reverses	-	24	O
alfentanil	-	33	O
-	-	43	O
induced	-	44	O
muscle	-	52	B
rigidity	-	59	I
.	-	67	O

Systemic	3115150	69	O
pretreatment	-	78	O
with	-	91	O
ketanserin	-	96	O
,	-	106	O
a	-	108	O
relatively	-	110	O
specific	-	121	O
type	-	130	O
-	-	134	O
2	-	135	O
serotonin	-	137	O
receptor	-	147	O
antagonist	-	156	O
,	-	166	O
significantly	-	168	O
attenuated	-	182	O
the	-	193	O
muscle	-	197	B
rigidity	-	204	I
produced	-	213	O
in	-	222	O
rats	-	225	O
by	-	230	O
the	-	233	O
potent	-	237	O
short	-	244	O
-	-	249	O
acting	-	250	O
opiate	-	257	O
agonist	-	264	O
alfentanil	-	272	O
.	-	282	O

Following	3115150	284	O
placement	-	294	O
of	-	304	O
subcutaneous	-	307	O
electrodes	-	320	O
in	-	331	O
each	-	334	O
animal	-	339	O
's	-	345	O
left	-	348	O
gastrocnemius	-	353	O
muscle	-	367	O
,	-	373	O
rigidity	-	375	B
was	-	384	O
assessed	-	388	O
by	-	397	O
analyzing	-	400	O
root	-	410	O
-	-	414	O
mean	-	415	O
-	-	419	O
square	-	420	O
electromyographic	-	427	O
activity	-	445	O
.	-	453	O

Intraperitoneal	3115150	455	O
ketanserin	-	471	O
administration	-	482	O
at	-	497	O
doses	-	500	O
of	-	506	O
0	-	509	O
.	-	510	O
63	-	511	O
and	-	514	O
2	-	518	O
.	-	519	O
5	-	520	O
mg	-	522	O
/	-	524	O
kg	-	525	O
prevented	-	528	O
the	-	538	O
alfentanil	-	542	O
-	-	552	O
induced	-	553	O
increase	-	561	O
in	-	570	O
electromyographic	-	573	O
activity	-	591	O
compared	-	600	O
with	-	609	O
animals	-	614	O
pretreated	-	622	O
with	-	633	O
saline	-	638	O
.	-	644	O

Chlordiazepoxide	3115150	646	O
at	-	663	O
doses	-	666	O
up	-	672	O
to	-	675	O
10	-	678	O
mg	-	681	O
/	-	683	O
kg	-	684	O
failed	-	687	O
to	-	694	O
significantly	-	697	O
influence	-	711	O
the	-	721	O
rigidity	-	725	B
produced	-	734	O
by	-	743	O
alfentanil	-	746	O
.	-	756	O

Despite	3115150	758	O
the	-	766	O
absence	-	770	O
of	-	778	O
rigidity	-	781	B
,	-	789	O
animals	-	791	O
that	-	799	O
received	-	804	O
ketanserin	-	813	O
(	-	824	O
greater	-	825	O
than	-	833	O
0	-	838	O
.	-	839	O
31	-	840	O
mg	-	843	O
/	-	845	O
kg	-	846	O
i	-	849	O
.	-	850	O
p	-	851	O
.	-	852	O
)	-	853	O
followed	-	855	O
by	-	864	O
alfentanil	-	867	O
were	-	878	O
motionless	-	883	O
,	-	893	O
flaccid	-	895	O
,	-	902	O
and	-	904	O
less	-	908	O
responsive	-	913	O
to	-	924	O
external	-	927	O
stimuli	-	936	O
than	-	944	O
were	-	949	O
animals	-	954	O
receiving	-	962	O
alfentanil	-	972	O
alone	-	983	O
.	-	988	O

Rats	3115150	990	O
that	-	995	O
received	-	1000	O
ketanserin	-	1009	O
and	-	1020	O
alfentanil	-	1024	O
exhibited	-	1035	O
less	-	1045	O
rearing	-	1050	O
and	-	1058	O
exploratory	-	1062	O
behavior	-	1074	O
at	-	1083	O
the	-	1086	O
end	-	1090	O
of	-	1094	O
the	-	1097	O
60	-	1101	O
-	-	1103	O
min	-	1104	O
recording	-	1108	O
period	-	1118	O
than	-	1125	O
did	-	1130	O
animals	-	1134	O
that	-	1142	O
received	-	1147	O
ketanserin	-	1156	O
alone	-	1167	O
.	-	1172	O

These	3115150	1174	O
results	-	1180	O
,	-	1187	O
in	-	1189	O
combination	-	1192	O
with	-	1204	O
previous	-	1209	O
work	-	1218	O
,	-	1222	O
suggest	-	1224	O
that	-	1232	O
muscle	-	1237	B
rigidity	-	1244	I
,	-	1252	O
a	-	1254	O
clinically	-	1256	O
relevant	-	1267	O
side	-	1276	O
-	-	1280	O
effect	-	1281	O
of	-	1288	O
parenteral	-	1291	O
narcotic	-	1302	O
administration	-	1311	O
,	-	1325	O
may	-	1327	O
be	-	1331	O
partly	-	1334	O
mediated	-	1341	O
via	-	1350	O
serotonergic	-	1354	O
pathways	-	1367	O
.	-	1375	O

Pretreatment	3115150	1377	O
with	-	1390	O
type	-	1395	O
-	-	1399	O
2	-	1400	O
serotonin	-	1402	O
antagonists	-	1412	O
may	-	1424	O
be	-	1428	O
clinically	-	1431	O
useful	-	1442	O
in	-	1449	O
attenuating	-	1452	O
opiate	-	1464	O
-	-	1470	O
induced	-	1471	O
rigidity	-	1479	B
,	-	1487	O
although	-	1489	O
further	-	1498	O
studies	-	1506	O
will	-	1514	O
be	-	1519	O
necessary	-	1522	O
to	-	1532	O
assess	-	1535	O
the	-	1542	O
interaction	-	1546	O
of	-	1558	O
possibly	-	1561	O
enhanced	-	1570	O
CNS	-	1579	O
,	-	1582	O
cardiovascular	-	1584	B
,	-	1598	I
and	-	1600	I
respiratory	-	1604	I
depression	-	1616	I
.	-	1626	O

Glycopyrronium	2917114	0	O
requirements	-	15	O
for	-	28	O
antagonism	-	32	O
of	-	43	O
the	-	46	O
muscarinic	-	50	O
side	-	61	O
effects	-	66	O
of	-	74	O
edrophonium	-	77	O
.	-	88	O

We	2917114	90	O
have	-	93	O
compared	-	98	O
,	-	106	O
in	-	108	O
60	-	111	O
adult	-	114	O
patients	-	120	O
,	-	128	O
the	-	130	O
cardiovascular	-	134	O
effects	-	149	O
of	-	157	O
glycopyrronium	-	160	O
5	-	175	O
micrograms	-	177	O
kg	-	188	O
-	-	190	O
1	-	191	O
and	-	193	O
10	-	197	O
micrograms	-	200	O
kg	-	211	O
-	-	213	O
1	-	214	O
given	-	216	O
either	-	222	O
simultaneously	-	229	O
or	-	244	O
1	-	247	O
min	-	249	O
before	-	253	O
edrophonium	-	260	O
1	-	272	O
mg	-	274	O
kg	-	277	O
-	-	279	O
1	-	280	O
.	-	281	O

Significant	2917114	283	O
differences	-	295	O
between	-	307	O
the	-	315	O
four	-	319	O
groups	-	324	O
were	-	331	O
detected	-	336	O
(	-	345	O
P	-	346	O
less	-	348	O
than	-	353	O
0	-	358	O
.	-	359	O
001	-	360	O
)	-	363	O
.	-	364	O

Both	2917114	366	O
groups	-	371	O
receiving	-	378	O
10	-	388	O
micrograms	-	391	O
kg	-	402	O
-	-	404	O
1	-	405	O
showed	-	407	O
increases	-	414	O
in	-	424	O
heart	-	427	O
rate	-	433	O
of	-	438	O
up	-	441	O
to	-	444	O
30	-	447	O
beat	-	450	O
min	-	455	O
-	-	458	O
1	-	459	O
(	-	461	O
95	-	462	O
%	-	464	O
confidence	-	466	O
limits	-	477	O
28	-	484	O
-	-	486	O
32	-	487	O
beat	-	490	O
min	-	495	O
-	-	498	O
1	-	499	O
)	-	500	O
.	-	501	O

Use	2917114	503	O
of	-	507	O
glycopyrronium	-	510	O
5	-	525	O
micrograms	-	527	O

kg	2917114	538	O
-	-	540	O
1	-	541	O
provided	-	543	O
greater	-	552	O
cardiovascular	-	560	O
stability	-	575	O
and	-	585	O
,	-	588	O
given	-	590	O
1	-	596	O
min	-	598	O
before	-	602	O
the	-	609	O
edrophonium	-	613	O
,	-	624	O
was	-	626	O
sufficient	-	630	O
to	-	641	O
minimize	-	644	O
early	-	653	O
,	-	658	O
edrophonium	-	660	O
-	-	671	O
induced	-	672	O
bradycardias	-	680	B
.	-	692	O

This	2917114	694	O
low	-	699	O
dose	-	703	O
of	-	708	O
glycopyrronium	-	711	O
provided	-	726	O
good	-	735	O
control	-	740	O
of	-	748	O
oropharyngeal	-	751	O
secretions	-	765	O
.	-	775	O

Involvement	2564649	0	O
of	-	12	O
locus	-	15	O
coeruleus	-	21	O
and	-	31	O
noradrenergic	-	35	O
neurotransmission	-	49	O
in	-	67	O
fentanyl	-	70	O
-	-	78	O
induced	-	79	O
muscular	-	87	B
rigidity	-	96	I
in	-	105	O
the	-	108	O
rat	-	112	O
.	-	115	O

Whereas	2564649	117	O
muscular	-	125	B
rigidity	-	134	I
is	-	143	O
a	-	146	O
well	-	148	O
-	-	152	O
known	-	153	O
side	-	159	O
effect	-	164	O
that	-	171	O
is	-	176	O
associated	-	179	O
with	-	190	O
high	-	195	O
-	-	199	O
dose	-	200	O
fentanyl	-	205	O
anesthesia	-	214	O
,	-	224	O
a	-	226	O
paucity	-	228	O
of	-	236	O
information	-	239	O
exists	-	251	O
with	-	258	O
regard	-	263	O
to	-	270	O
its	-	273	O
underlying	-	277	O
mechanism	-	288	O
(	-	297	O
s	-	298	O
)	-	299	O
.	-	300	O

We	2564649	302	O
investigated	-	305	O
in	-	318	O
this	-	321	O
study	-	326	O
the	-	332	O
possible	-	336	O
engagement	-	345	O
of	-	356	O
locus	-	359	O
coeruleus	-	365	O
of	-	375	O
the	-	378	O
pons	-	382	O
in	-	387	O
this	-	390	O
phenomenon	-	395	O
,	-	405	O
using	-	407	O
male	-	413	O
Sprague	-	418	O
-	-	425	O
Dawley	-	426	O
rats	-	433	O
anesthetized	-	438	O
with	-	451	O
ketamine	-	456	O
.	-	464	O

Under	2564649	466	O
proper	-	472	O
control	-	479	O
of	-	487	O
respiration	-	490	O
,	-	501	O
body	-	503	O
temperature	-	508	O
and	-	520	O
end	-	524	O
-	-	527	O
tidal	-	528	O
CO2	-	534	O
,	-	537	O
intravenous	-	539	O
administration	-	551	O
of	-	566	O
fentanyl	-	569	O
(	-	578	O
50	-	579	O
or	-	582	O
100	-	585	O
micrograms	-	589	O
/	-	599	O
kg	-	600	O
)	-	602	O
consistently	-	604	O
promoted	-	617	O
an	-	626	O
increase	-	629	O
in	-	638	O
electromyographic	-	641	O
activity	-	659	O
recorded	-	668	O
from	-	677	O
the	-	682	O
gastrocnemius	-	686	O
and	-	700	O
abdominal	-	704	O
rectus	-	714	O
muscles	-	721	O
.	-	728	O

Such	2564649	730	O
an	-	735	O
induced	-	738	O
muscular	-	746	B
rigidity	-	755	I
by	-	764	O
the	-	767	O
narcotic	-	771	O
agent	-	780	O
was	-	786	O
significantly	-	790	O
antagonized	-	804	O
or	-	816	O
even	-	819	O
reduced	-	824	O
by	-	832	O
prior	-	835	O
electrolytic	-	841	O
lesions	-	854	O
of	-	862	O
the	-	865	O
locus	-	869	O
coeruleus	-	875	O
or	-	885	O
pretreatment	-	888	O
with	-	901	O
the	-	906	O
alpha	-	910	O
-	-	915	O
adrenoceptor	-	916	O
blocker	-	929	O
,	-	936	O
prazosin	-	938	O
.	-	946	O

Microinjection	2564649	948	O
of	-	963	O
fentanyl	-	966	O
(	-	975	O
2	-	976	O
.	-	977	O
5	-	978	O
micrograms	-	980	O
/	-	990	O
50	-	991	O
nl	-	994	O
)	-	996	O
directly	-	998	O
into	-	1007	O
this	-	1012	O
pontine	-	1017	O
nucleus	-	1025	O
,	-	1032	O
on	-	1034	O
the	-	1037	O
other	-	1041	O
hand	-	1047	O
,	-	1051	O
elicited	-	1053	O
discernible	-	1062	O
electromyographic	-	1074	O
excitation	-	1092	O
.	-	1102	O

It	2564649	1104	O
is	-	1107	O
speculated	-	1110	O
that	-	1121	O
the	-	1126	O
induction	-	1130	O
of	-	1140	O
muscular	-	1143	B
rigidity	-	1152	I
by	-	1161	O
fentanyl	-	1164	O
may	-	1173	O
involve	-	1177	O
the	-	1185	O
coerulospinal	-	1189	O
noradrenergic	-	1203	O
fibers	-	1217	O
to	-	1224	O
the	-	1227	O
spinal	-	1231	O
motoneurons	-	1238	O
.	-	1249	O

Cerebral	2339463	0	B
sinus	-	9	I
thrombosis	-	15	I
as	-	26	O
a	-	29	O
potential	-	31	O
hazard	-	41	O
of	-	48	O
antifibrinolytic	-	51	O
treatment	-	68	O
in	-	78	O
menorrhagia	-	81	B
.	-	92	O

We	2339463	94	O
describe	-	97	O
a	-	106	O
42	-	108	O
-	-	110	O
year	-	111	O
-	-	115	O
old	-	116	O
woman	-	120	O
who	-	126	O
developed	-	130	O
superior	-	140	O
sagittal	-	149	B
and	-	158	I
left	-	162	I
transverse	-	167	I
sinus	-	178	I
thrombosis	-	184	I
associated	-	195	O
with	-	206	O
prolonged	-	211	O
epsilon	-	221	O
-	-	228	O
aminocaproic	-	229	O
acid	-	242	O
therapy	-	247	O
for	-	255	O
menorrhagia	-	259	B
.	-	270	O

This	2339463	272	O
antifibrinolytic	-	277	O
agent	-	294	O
has	-	300	O
been	-	304	O
used	-	309	O
in	-	314	O
women	-	317	O
with	-	323	O
menorrhagia	-	328	B
to	-	340	O
promote	-	343	O
clotting	-	351	O
and	-	360	O
reduce	-	364	O
blood	-	371	B
loss	-	377	I
.	-	381	O

Although	2339463	383	O
increased	-	392	O
risk	-	402	O
of	-	407	O
thromboembolic	-	410	B
disease	-	425	I
has	-	433	O
been	-	437	O
reported	-	442	O
during	-	451	O
treatment	-	458	O
with	-	468	O
epsilon	-	473	O
-	-	480	O
aminocaproic	-	481	O
acid	-	494	O
,	-	498	O
cerebral	-	500	B
sinus	-	509	I
thrombosis	-	515	I
has	-	526	O
not	-	530	O
been	-	534	O
previously	-	539	O
described	-	550	O
.	-	559	O

Careful	2339463	561	O
use	-	569	O
of	-	573	O
epsilon	-	576	O
-	-	583	O
aminocaproic	-	584	O
acid	-	597	O
therapy	-	602	O
is	-	610	O
recommended	-	613	O
.	-	624	O

Hemorrhagic	1545575	0	B
cystitis	-	12	I
complicating	-	21	O
bone	-	34	O
marrow	-	39	O
transplantation	-	46	O
.	-	61	O

Hemorrhagic	1545575	63	B
cystitis	-	75	I
is	-	84	O
a	-	87	O
potentially	-	89	O
serious	-	101	O
complication	-	109	O
of	-	122	O
high	-	125	O
-	-	129	O
dose	-	130	O
cyclophosphamide	-	135	O
therapy	-	152	O
administered	-	160	O
before	-	173	O
bone	-	180	O
marrow	-	185	O
transplantation	-	192	O
.	-	207	O

As	1545575	209	O
standard	-	212	O
practice	-	221	O
at	-	230	O
our	-	233	O
institution	-	237	O
,	-	248	O
patients	-	250	O
who	-	259	O
are	-	263	O
scheduled	-	267	O
to	-	277	O
receive	-	280	O
a	-	288	O
bone	-	290	O
marrow	-	295	O
transplant	-	302	O
are	-	313	O
treated	-	317	O
prophylactically	-	325	O
with	-	342	O
forced	-	347	O
hydration	-	354	O
and	-	364	O
bladder	-	368	O
irrigation	-	376	O
.	-	386	O

In	1545575	388	O
an	-	391	O
attempt	-	394	O
to	-	402	O
obviate	-	405	O
the	-	413	O
inconvenience	-	417	O
of	-	431	O
bladder	-	434	O
irrigation	-	442	O
,	-	452	O
we	-	454	O
conducted	-	457	O
a	-	467	O
feasibility	-	469	O
trial	-	481	O
of	-	487	O
uroprophylaxis	-	490	O
with	-	505	O
mesna	-	510	O
,	-	515	O
which	-	517	O
neutralizes	-	523	O
the	-	535	O
hepatic	-	539	O
metabolite	-	547	O
of	-	558	O
cyclophosphamide	-	561	O
that	-	578	O
causes	-	583	O
hemorrhagic	-	590	B
cystitis	-	602	I
.	-	610	O

Of	1545575	612	O
97	-	615	O
patients	-	618	O
who	-	627	O
received	-	631	O
standard	-	640	O
prophylaxis	-	649	O
,	-	660	O
4	-	662	O
had	-	664	O
symptomatic	-	668	O
hemorrhagic	-	680	B
cystitis	-	692	I
.	-	700	O

In	1545575	702	O
contrast	-	705	O
,	-	713	O
two	-	715	O
of	-	719	O
four	-	722	O
consecutive	-	727	O
patients	-	739	O
who	-	748	O
received	-	752	O
mesna	-	761	O
uroprophylaxis	-	767	O
before	-	782	O
allogeneic	-	789	O
bone	-	800	O
marrow	-	805	O
transplantation	-	812	O
had	-	828	O
severe	-	832	O
hemorrhagic	-	839	B
cystitis	-	851	I
for	-	860	O
at	-	864	O
least	-	867	O
2	-	873	O
weeks	-	875	O
.	-	880	O

Because	1545575	882	O
of	-	890	O
this	-	893	O
suboptimal	-	898	O
result	-	909	O
,	-	915	O
we	-	917	O
resumed	-	920	O
the	-	928	O
use	-	932	O
of	-	936	O
bladder	-	939	O
irrigation	-	947	O
and	-	958	O
forced	-	962	O
hydration	-	969	O
to	-	979	O
minimize	-	982	O
the	-	991	O
risk	-	995	O
of	-	1000	O
hemorrhagic	-	1003	B
cystitis	-	1015	I
.	-	1023	O

Reversal	1286498	0	O
of	-	9	O
central	-	12	O
benzodiazepine	-	20	O
effects	-	35	O
by	-	43	O
flumazenil	-	46	O
after	-	57	O
intravenous	-	63	O
conscious	-	75	O
sedation	-	85	O
with	-	94	O
diazepam	-	99	O
and	-	108	O
opioids	-	112	O
:	-	119	O
report	-	121	O
of	-	128	O
a	-	131	O
double	-	133	O
-	-	139	O
blind	-	140	O
multicenter	-	146	O
study	-	158	O
.	-	163	O

The	1286498	165	O
Flumazenil	-	169	O
in	-	180	O
Intravenous	-	183	O
Conscious	-	195	O
Sedation	-	205	O
with	-	214	O
Diazepam	-	219	O
Multicenter	-	228	O
Study	-	240	O
Group	-	246	O
II	-	252	O
.	-	254	O

The	1286498	256	O
efficacy	-	260	O
and	-	269	O
safety	-	273	O
of	-	280	O
a	-	283	O
new	-	285	O
benzodiazepine	-	289	O
antagonist	-	304	O
,	-	314	O
flumazenil	-	316	O
,	-	326	O
were	-	328	O
assessed	-	333	O
in	-	342	O
a	-	345	O
double	-	347	O
-	-	353	O
blind	-	354	O
multicenter	-	360	O
study	-	372	O
.	-	377	O

Flumazenil	1286498	379	O
(	-	390	O
mean	-	391	O
dose	-	396	O
,	-	400	O
0	-	402	O
.	-	403	O
76	-	404	O
mg	-	407	O
)	-	409	O
or	-	411	O
placebo	-	414	O
(	-	422	O
mean	-	423	O
dose	-	428	O
,	-	432	O
8	-	434	O
.	-	435	O
9	-	436	O
ml	-	438	O
)	-	440	O
was	-	442	O
administered	-	446	O
intravenously	-	459	O
to	-	473	O
130	-	476	O
and	-	480	O
67	-	484	O
patients	-	487	O
,	-	495	O
respectively	-	497	O
,	-	509	O
who	-	511	O
had	-	515	O
been	-	519	O
given	-	524	O
diazepam	-	530	O
in	-	539	O
conjunction	-	542	O
with	-	554	O
an	-	559	O
opioid	-	562	O
(	-	569	O
fentanyl	-	570	O
,	-	578	O
meperidine	-	580	O
,	-	590	O
or	-	592	O
morphine	-	595	O
)	-	603	O
for	-	605	O
the	-	609	O
induction	-	613	O
and	-	623	O
maintenance	-	627	O
of	-	639	O
intravenous	-	642	O
conscious	-	654	O
sedation	-	664	O
for	-	673	O
diagnostic	-	677	O
or	-	688	O
therapeutic	-	691	O
surgical	-	703	O
procedures	-	712	O
.	-	722	O

The	1286498	724	O
group	-	728	O
assessable	-	734	O
for	-	745	O
efficacy	-	749	O
comprised	-	758	O
122	-	768	O
patients	-	772	O
treated	-	781	O
with	-	789	O
flumazenil	-	794	O
and	-	805	O
64	-	809	O
patients	-	812	O
given	-	821	O
placebo	-	827	O
.	-	834	O

After	1286498	836	O
5	-	842	O
minutes	-	844	O
,	-	851	O
80	-	853	O
/	-	855	O
115	-	856	O
(	-	860	O
70	-	861	O
%	-	863	O
)	-	864	O
flumazenil	-	866	O
-	-	876	O
treated	-	877	O
patients	-	885	O
,	-	893	O
compared	-	895	O
with	-	904	O
21	-	909	O
/	-	911	O
63	-	912	O
(	-	915	O
33	-	916	O
%	-	918	O
)	-	919	O
placebo	-	921	O
-	-	928	O
treated	-	929	O
patients	-	937	O
,	-	945	O
were	-	947	O
completely	-	952	O
awake	-	963	O
and	-	969	O
alert	-	973	O
,	-	978	O
as	-	980	O
indicated	-	983	O
by	-	993	O
a	-	996	O
score	-	998	O
of	-	1004	O
5	-	1007	O
on	-	1009	O
the	-	1012	O
Observer	-	1016	O
's	-	1024	O
Assessment	-	1027	O
of	-	1038	O
Alertness	-	1041	O
/	-	1050	O
Sedation	-	1051	O
Scale	-	1060	O
.	-	1065	O

Ninety	1286498	1067	O
-	-	1073	O
five	-	1074	O
percent	-	1079	O
of	-	1087	O
patients	-	1090	O
in	-	1099	O
each	-	1102	O
group	-	1107	O
who	-	1113	O
attained	-	1117	O
a	-	1126	O
score	-	1128	O
of	-	1134	O
5	-	1137	O
at	-	1139	O
the	-	1142	O
5	-	1146	O
-	-	1147	O
minute	-	1148	O
assessment	-	1155	O
showed	-	1166	O
no	-	1173	O
loss	-	1176	O
of	-	1181	O
alertness	-	1184	O
throughout	-	1194	O
the	-	1205	O
180	-	1209	O
-	-	1212	O
minute	-	1213	O
assessment	-	1220	O
period	-	1231	O
.	-	1237	O

Flumazenil	1286498	1239	O
-	-	1249	O
treated	-	1250	O
patients	-	1258	O
also	-	1267	O
performed	-	1272	O
significantly	-	1282	O
better	-	1296	O
on	-	1303	O
the	-	1306	O
Finger	-	1310	O
-	-	1316	O
to	-	1317	O
-	-	1319	O
Nose	-	1320	O
Test	-	1325	O
and	-	1330	O
the	-	1334	O
recall	-	1338	O
of	-	1345	O
pictures	-	1348	O
shown	-	1357	O
at	-	1363	O
the	-	1366	O
5	-	1370	O
-	-	1371	O
minute	-	1372	O
assessment	-	1379	O
.	-	1389	O

Flumazenil	1286498	1391	O
was	-	1402	O
well	-	1406	O
tolerated	-	1411	O
,	-	1420	O
with	-	1422	O
no	-	1427	O
serious	-	1430	O
adverse	-	1438	O
effects	-	1446	O
reported	-	1454	O
.	-	1462	O

Thirty	1286498	1464	O
-	-	1470	O
nine	-	1471	O
(	-	1476	O
30	-	1477	O
%	-	1479	O
)	-	1480	O
of	-	1482	O
flumazenil	-	1485	O
-	-	1495	O
treated	-	1496	O
patients	-	1504	O
,	-	1512	O
compared	-	1514	O
with	-	1523	O
17	-	1528	O
(	-	1531	O
25	-	1532	O
%	-	1534	O
)	-	1535	O
of	-	1537	O
placebo	-	1540	O
-	-	1547	O
treated	-	1548	O
patients	-	1556	O
had	-	1565	O
one	-	1569	O
or	-	1573	O
more	-	1576	O
drug	-	1581	O
-	-	1585	O
related	-	1586	O
adverse	-	1594	O
experiences	-	1602	O
.	-	1613	O

The	1286498	1615	O
most	-	1619	O
common	-	1624	O
adverse	-	1631	O
effects	-	1639	O
were	-	1647	O
nausea	-	1652	B
and	-	1659	O
vomiting	-	1663	B
in	-	1672	O
the	-	1675	O
flumazenil	-	1679	O
group	-	1690	O
and	-	1696	O
nausea	-	1700	B
and	-	1707	O
injection	-	1711	O
-	-	1720	O
site	-	1721	O
pain	-	1726	B
in	-	1731	O
the	-	1734	O
placebo	-	1738	O
group	-	1746	O
.	-	1751	O

Flumazenil	1286498	1753	O
was	-	1764	O
found	-	1768	O
to	-	1774	O
promptly	-	1777	O
reverse	-	1786	O
sedation	-	1794	O
induced	-	1803	O
by	-	1811	O
diazepam	-	1814	O
in	-	1823	O
the	-	1826	O
presence	-	1830	O
of	-	1839	O
opioids	-	1842	O
.	-	1849	O

Hepatic	839274	0	O
adenomas	-	8	B
and	-	17	O
focal	-	21	B
nodular	-	27	I
hyperplasia	-	35	I
of	-	47	O
the	-	50	O
liver	-	54	O
in	-	60	O
young	-	63	O
women	-	69	O
on	-	75	O
oral	-	78	O
contraceptives	-	83	O
:	-	97	O
case	-	99	O
reports	-	104	O
.	-	111	O

Two	839274	113	O
cases	-	117	O
of	-	123	O
hepatic	-	126	O
adenoma	-	134	B
and	-	142	O
one	-	146	O
of	-	150	O
focal	-	153	B
nodular	-	159	I
hyperplasia	-	167	I
presumably	-	179	O
associated	-	190	O
with	-	201	O
the	-	206	O
use	-	210	O
of	-	214	O
oral	-	217	O
contraceptives	-	222	O
,	-	236	O
are	-	238	O
reported	-	242	O
.	-	250	O

Special	839274	252	O
reference	-	260	O
is	-	270	O
made	-	273	O
to	-	278	O
their	-	281	O
clinical	-	287	O
presentation	-	296	O
,	-	308	O
which	-	310	O
may	-	316	O
be	-	320	O
totally	-	323	O
asymptomatic	-	331	O
.	-	343	O

Liver	839274	345	O
-	-	350	O
function	-	351	O
tests	-	360	O
are	-	366	O
of	-	370	O
little	-	373	O
diagnostic	-	380	O
value	-	391	O
,	-	396	O
but	-	398	O
valuable	-	402	O
information	-	411	O
may	-	423	O
be	-	427	O
obtained	-	430	O
from	-	439	O
both	-	444	O
liver	-	449	O
scanning	-	455	O
and	-	464	O
hepatic	-	468	O
angiography	-	476	O
.	-	487	O

Histologic	839274	489	O
differences	-	500	O
and	-	512	O
clinical	-	516	O
similarities	-	525	O
between	-	538	O
hepatic	-	546	O
adenoma	-	554	B
and	-	562	O
focal	-	566	B
nodular	-	572	I
hyperplasia	-	580	I
of	-	592	O
the	-	595	O
liver	-	599	O
are	-	605	O
discussed	-	609	O
.	-	618	O

Arterial	591536	0	O
thromboembolism	-	9	B
in	-	25	O
patients	-	28	O
receiving	-	37	O
systemic	-	47	O
heparin	-	56	O
therapy	-	64	O
:	-	71	O
a	-	73	O
complication	-	75	O
associated	-	88	O
with	-	99	O
heparin	-	104	O
-	-	111	O
induced	-	112	O
thrombocytopenia	-	120	B
.	-	136	O

Arterial	591536	138	O
thromboembolism	-	147	B
is	-	163	O
a	-	166	O
recognized	-	168	O
complication	-	179	O
of	-	192	O
systemic	-	195	O
heparin	-	204	O
therapy	-	212	O
.	-	219	O

Characteristic	591536	221	O
of	-	236	O
the	-	239	O
entity	-	243	O
is	-	250	O
arterial	-	253	B
occlusion	-	262	I
by	-	272	O
platelet	-	275	O
-	-	283	O
fibrin	-	284	O
thrombi	-	291	B
with	-	299	O
distal	-	304	O
ischemia	-	311	B
occurring	-	320	O
four	-	330	O
to	-	335	O
twenty	-	338	O
days	-	345	O
after	-	350	O
the	-	356	O
initiation	-	360	O
of	-	371	O
heparin	-	374	O
therapy	-	382	O
,	-	389	O
preceded	-	391	O
by	-	400	O
profound	-	403	O
thrombocytopenia	-	412	B
with	-	429	O
platelet	-	434	O
counts	-	443	O
in	-	450	O
the	-	453	O
range	-	457	O
of	-	463	O
30	-	466	O
,	-	468	O
000	-	469	O
to	-	473	O
40	-	476	O
,	-	478	O
000	-	479	O
per	-	483	O
cubic	-	487	O
millimeter	-	493	O
.	-	503	O

The	591536	505	O
clinically	-	509	O
apparent	-	520	O
occlusion	-	529	O
may	-	539	O
be	-	543	O
preceded	-	546	O
by	-	555	O
gastrointestinal	-	558	B
and	-	575	I
musculoskeletal	-	579	I
symptoms	-	595	I
that	-	604	O
appear	-	609	O
to	-	616	O
be	-	619	O
ischemic	-	622	B
in	-	631	O
origin	-	634	O
,	-	640	O
and	-	642	O
might	-	646	O
serve	-	652	O
to	-	658	O
warn	-	661	O
the	-	666	O
clinician	-	670	O
of	-	680	O
these	-	683	O
complications	-	689	O
.	-	702	O

Previous	591536	704	O
reports	-	713	O
of	-	721	O
these	-	724	O
phenomena	-	730	O
as	-	740	O
well	-	743	O
as	-	748	O
recent	-	751	O
studies	-	758	O
of	-	766	O
the	-	769	O
effect	-	773	O
of	-	780	O
heparin	-	783	O
are	-	791	O
reviewed	-	795	O
.	-	803	O

The	591536	805	O
common	-	809	O
factor	-	816	O
relating	-	823	O
thromboembolism	-	832	B
and	-	848	O
thrombocytopenia	-	852	B
is	-	869	O
heparin	-	872	O
-	-	879	O
induced	-	880	O
platelet	-	888	B
aggregation	-	897	I
.	-	908	O

Appropriate	591536	910	O
treatment	-	922	O
consists	-	932	O
of	-	941	O
discontinuation	-	944	O
of	-	960	O
heparin	-	963	O
,	-	970	O
and	-	972	O
anticoagulation	-	976	O
with	-	992	O
sodium	-	997	O
warfarin	-	1004	O
if	-	1013	O
necessary	-	1016	O
.	-	1025	O

Vascular	591536	1027	O
procedures	-	1036	O
are	-	1047	O
performed	-	1051	O
as	-	1061	O
indicated	-	1064	O
.	-	1073	O

Long	20735774	0	O
-	-	4	O
term	-	5	O
prognosis	-	10	O
for	-	20	O
transplant	-	24	O
-	-	34	O
free	-	35	O
survivors	-	40	O
of	-	50	O
paracetamol	-	53	O
-	-	64	O
induced	-	65	O
acute	-	73	B
liver	-	79	I
failure	-	85	I
.	-	92	O

BACKGROUND	20735774	94	O
:	-	104	O

The	20735774	106	O
prognosis	-	110	O
for	-	120	O
transplant	-	124	O
-	-	134	O
free	-	135	O
survivors	-	140	O
of	-	150	O
paracetamol	-	153	O
-	-	164	O
induced	-	165	O
acute	-	173	B
liver	-	179	I
failure	-	185	I
remains	-	193	O
unknown	-	201	O
.	-	208	O

AIM	20735774	210	O
:	-	213	O

To	20735774	215	O
examine	-	218	O
whether	-	226	O
paracetamol	-	234	O
-	-	245	O
induced	-	246	O
acute	-	254	B
liver	-	260	I
failure	-	266	I
increases	-	274	O
long	-	284	O
-	-	288	O
term	-	289	O
mortality	-	294	O
.	-	303	O

METHODS	20735774	305	O
:	-	312	O

We	20735774	314	O
followed	-	317	O
up	-	326	O
all	-	329	O
transplant	-	333	O
-	-	343	O
free	-	344	O
survivors	-	349	O
of	-	359	O
paracetamol	-	362	O
-	-	373	O
induced	-	374	O
acute	-	382	B
liver	-	388	I
injury	-	394	I
,	-	400	O
hospitalized	-	402	O
in	-	415	O
a	-	418	O
Danish	-	420	O
national	-	427	O
referral	-	436	O
centre	-	445	O
during	-	452	O
1984	-	459	O
-	-	463	O
2004	-	464	O
.	-	468	O

We	20735774	470	O
compared	-	473	O
age	-	482	O
-	-	485	O
specific	-	486	O
mortality	-	495	O
rates	-	505	O
from	-	511	O
1	-	516	O
year	-	518	O
post	-	523	O
-	-	527	O
discharge	-	528	O
through	-	538	O
2008	-	546	O
between	-	551	O
those	-	559	O
in	-	565	O
whom	-	568	O
the	-	573	O
liver	-	577	B
injury	-	583	I
led	-	590	O
to	-	594	O
an	-	597	O
acute	-	600	B
liver	-	606	I
failure	-	612	I
and	-	620	O
those	-	624	O
in	-	630	O
whom	-	633	O
it	-	638	O
did	-	641	O
not	-	645	O
.	-	648	O

RESULTS	20735774	650	O
:	-	657	O

We	20735774	659	O
included	-	662	O
641	-	671	O
patients	-	675	O
.	-	683	O

On	20735774	685	O
average	-	688	O
,	-	695	O
age	-	697	O
-	-	700	O
specific	-	701	O
mortality	-	710	O
rates	-	720	O
were	-	726	O
slightly	-	731	O
higher	-	740	O
for	-	747	O
the	-	751	O
101	-	755	O
patients	-	759	O
whose	-	768	O
paracetamol	-	774	O
-	-	785	O
induced	-	786	O
liver	-	794	B
injury	-	800	I
had	-	807	O
caused	-	811	O
an	-	818	O
acute	-	821	B
liver	-	827	I
failure	-	833	I
(	-	841	O
adjusted	-	842	O
mortality	-	851	O
rate	-	861	O
ratio	-	866	O
=	-	872	O
1	-	874	O
.	-	875	O
70	-	876	O
,	-	878	O
95	-	880	O
%	-	882	O
CI	-	884	O
1	-	887	O
.	-	888	O
02	-	889	O
-	-	891	O
2	-	892	O
.	-	893	O
85	-	894	O
)	-	896	O
,	-	897	O
but	-	899	O
the	-	903	O
association	-	907	O
was	-	919	O
age	-	923	O
-	-	926	O
dependent	-	927	O
,	-	936	O
and	-	938	O
no	-	942	O
survivors	-	945	O
of	-	955	O
acute	-	958	B
liver	-	964	I
failure	-	970	I
died	-	978	O
of	-	983	O
liver	-	986	B
disease	-	992	I
,	-	999	O
whereas	-	1001	O
suicides	-	1009	O
were	-	1018	O
frequent	-	1023	O
in	-	1032	O
both	-	1035	O
groups	-	1040	O
.	-	1046	O

These	20735774	1048	O
observations	-	1054	O
speak	-	1067	O
against	-	1073	O
long	-	1081	O
-	-	1085	O
term	-	1086	O
effects	-	1091	O
of	-	1099	O
acute	-	1102	B
liver	-	1108	I
failure	-	1114	I
.	-	1121	O

More	20735774	1123	O
likely	-	1128	O
,	-	1134	O
the	-	1136	O
elevated	-	1140	O
mortality	-	1149	O
rate	-	1159	O
ratio	-	1164	O
resulted	-	1170	O
from	-	1179	O
incomplete	-	1184	O
adjustment	-	1195	O
for	-	1206	O
the	-	1210	O
greater	-	1214	O
prevalence	-	1222	O
of	-	1233	O
substance	-	1236	B
abuse	-	1246	I
among	-	1252	O
survivors	-	1258	O
of	-	1268	O
acute	-	1271	B
liver	-	1277	I
failure	-	1283	I
.	-	1290	O

CONCLUSIONS	20735774	1292	O
:	-	1303	O

Paracetamol	20735774	1305	O
-	-	1316	O
induced	-	1317	O
acute	-	1325	B
liver	-	1331	I
failure	-	1337	I
did	-	1345	O
not	-	1349	O
affect	-	1353	O
long	-	1360	O
-	-	1364	O
term	-	1365	O
mortality	-	1370	O
.	-	1379	O

Clinical	20735774	1381	O
follow	-	1390	O
-	-	1396	O
up	-	1397	O
may	-	1400	O
be	-	1404	O
justified	-	1407	O
by	-	1417	O
the	-	1420	O
cause	-	1424	O
of	-	1430	O
the	-	1433	O
liver	-	1437	B
failure	-	1443	I
,	-	1450	O
but	-	1452	O
not	-	1456	O
by	-	1460	O
the	-	1463	O
liver	-	1467	B
failure	-	1473	I
itself	-	1481	O
.	-	1487	O

Serotonin	20705401	0	O
6	-	10	O
receptor	-	12	O
gene	-	21	O
is	-	26	O
associated	-	29	O
with	-	40	O
methamphetamine	-	45	O
-	-	60	O
induced	-	61	O
psychosis	-	69	B
in	-	79	O
a	-	82	O
Japanese	-	84	O
population	-	93	O
.	-	103	O

BACKGROUND	20705401	105	O
:	-	115	O

Altered	20705401	117	O
serotonergic	-	125	O
neural	-	138	O
transmission	-	145	O
is	-	158	O
hypothesized	-	161	O
to	-	174	O
be	-	177	O
a	-	180	O
susceptibility	-	182	O
factor	-	197	O
for	-	204	O
psychotic	-	208	B
disorders	-	218	I
such	-	228	O
as	-	233	O
schizophrenia	-	236	B
.	-	249	O

The	20705401	251	O
serotonin	-	255	O
6	-	265	O
(	-	267	O
5	-	268	O
-	-	269	O
HT6	-	270	O
)	-	273	O
receptor	-	275	O
is	-	284	O
therapeutically	-	287	O
targeted	-	303	O
by	-	312	O
several	-	315	O
second	-	323	O
generation	-	330	O
antipsychotics	-	341	O
,	-	355	O
such	-	357	O
as	-	362	O
clozapine	-	365	O
and	-	375	O
olanzapine	-	379	O
,	-	389	O
and	-	391	O
d	-	395	O
-	-	396	O
amphetamine	-	397	O
-	-	408	O
induced	-	409	O
hyperactivity	-	417	B
in	-	431	O
rats	-	434	O
is	-	439	O
corrected	-	442	O
with	-	452	O
the	-	457	O
use	-	461	O
of	-	465	O
a	-	468	O
selective	-	470	O
5	-	480	O
-	-	481	O
HT6	-	482	O
receptor	-	486	O
antagonist	-	495	O
.	-	505	O

In	20705401	507	O
addition	-	510	O
,	-	518	O
the	-	520	O
disrupted	-	524	O
prepulse	-	534	O
inhibition	-	543	O
induced	-	554	O
by	-	562	O
d	-	565	O
-	-	566	O
amphetamine	-	567	O
or	-	579	O
phencyclidine	-	582	O
was	-	596	O
restored	-	600	O
by	-	609	O
5	-	612	O
-	-	613	O
HT6	-	614	O
receptor	-	618	O
antagonist	-	627	O
in	-	638	O
an	-	641	O
animal	-	644	O
study	-	651	O
using	-	657	O
rats	-	663	O
.	-	667	O

These	20705401	669	O
animal	-	675	O
models	-	682	O
were	-	689	O
considered	-	694	O
to	-	705	O
reflect	-	708	O
the	-	716	O
positive	-	720	O
symptoms	-	729	O
of	-	738	O
schizophrenia	-	741	B
,	-	754	O
and	-	756	O
the	-	760	O
above	-	764	O
evidence	-	770	O
suggests	-	779	O
that	-	788	O
altered	-	793	O
5	-	801	O
-	-	802	O
HT6	-	803	O
receptors	-	807	O
are	-	817	O
involved	-	821	O
in	-	830	O
the	-	833	O
pathophysiology	-	837	O
of	-	853	O
psychotic	-	856	B
disorders	-	866	I
.	-	875	O

The	20705401	877	O
symptoms	-	881	O
of	-	890	O
methamphetamine	-	893	O
(	-	909	O
METH	-	910	O
)	-	914	O
-	-	915	O
induced	-	916	O
psychosis	-	924	B
are	-	934	O
similar	-	938	O
to	-	946	O
those	-	949	O
of	-	955	O
paranoid	-	958	B
type	-	967	I
schizophrenia	-	972	I
.	-	985	O

Therefore	20705401	987	O
,	-	996	O
we	-	998	O
conducted	-	1001	O
an	-	1011	O
analysis	-	1014	O
of	-	1023	O
the	-	1026	O
association	-	1030	O
of	-	1042	O
the	-	1045	O
5	-	1049	O
-	-	1050	O
HT6	-	1051	O
gene	-	1055	O
(	-	1060	O
HTR6	-	1061	O
)	-	1065	O
with	-	1067	O
METH	-	1072	O
-	-	1076	O
induced	-	1077	O
psychosis	-	1085	B
.	-	1094	O

METHOD	20705401	1096	O
:	-	1102	O

Using	20705401	1104	O
five	-	1110	O
tagging	-	1115	O
SNPs	-	1123	O
(	-	1128	O
rs6693503	-	1129	O
,	-	1138	O
rs1805054	-	1140	O
,	-	1149	O
rs4912138	-	1151	O
,	-	1160	O
rs3790757	-	1162	O
and	-	1172	O
rs9659997	-	1176	O
)	-	1185	O
,	-	1186	O
we	-	1188	O
conducted	-	1191	O
a	-	1201	O
genetic	-	1203	O
association	-	1211	O
analysis	-	1223	O
of	-	1232	O
case	-	1235	O
-	-	1239	O
control	-	1240	O
samples	-	1248	O
(	-	1256	O
197	-	1257	O
METH	-	1261	O
-	-	1265	O
induced	-	1266	O
psychosis	-	1274	B
patients	-	1284	O
and	-	1293	O
337	-	1297	O
controls	-	1301	O
)	-	1309	O
in	-	1311	O
the	-	1314	O
Japanese	-	1318	O
population	-	1327	O
.	-	1337	O

The	20705401	1339	O
age	-	1343	O
and	-	1347	O
sex	-	1351	O
of	-	1355	O
the	-	1358	O
control	-	1362	O
subjects	-	1370	O
did	-	1379	O
not	-	1383	O
differ	-	1387	O
from	-	1394	O
those	-	1399	O
of	-	1405	O
the	-	1408	O
methamphetamine	-	1412	O
dependence	-	1428	O
patients	-	1439	O
.	-	1447	O

RESULTS	20705401	1449	O
:	-	1456	O

rs6693503	20705401	1458	O
was	-	1468	O
associated	-	1472	O
with	-	1483	O
METH	-	1488	O
-	-	1492	O
induced	-	1493	O
psychosis	-	1501	B
patients	-	1511	O
in	-	1520	O
the	-	1523	O
allele	-	1527	O
/	-	1533	O
genotype	-	1534	O
-	-	1542	O
wise	-	1543	O
analysis	-	1548	O
.	-	1556	O

Moreover	20705401	1558	O
,	-	1566	O
this	-	1568	O
association	-	1573	O
remained	-	1585	O
significant	-	1594	O
after	-	1606	O
Bonferroni	-	1612	O
correction	-	1623	O
.	-	1633	O

In	20705401	1635	O
the	-	1638	O
haplotype	-	1642	O
-	-	1651	O
wise	-	1652	O
analysis	-	1657	O
,	-	1665	O
we	-	1667	O
detected	-	1670	O
an	-	1679	O
association	-	1682	O
between	-	1694	O
two	-	1702	O
markers	-	1706	O
(	-	1714	O
rs6693503	-	1715	O
and	-	1725	O
rs1805054	-	1729	O
)	-	1738	O
and	-	1740	O
three	-	1744	O
markers	-	1750	O
(	-	1758	O
rs6693503	-	1759	O
,	-	1768	O
rs1805054	-	1770	O
and	-	1780	O
rs4912138	-	1784	O
)	-	1793	O
in	-	1795	O
HTR6	-	1798	O
and	-	1803	O
METH	-	1807	O
-	-	1811	O
induced	-	1812	O
psychosis	-	1820	B
patients	-	1830	O
,	-	1838	O
respectively	-	1840	O
.	-	1852	O

CONCLUSION	20705401	1854	O
:	-	1864	O

HTR6	20705401	1866	O
may	-	1871	O
play	-	1875	O
an	-	1880	O
important	-	1883	O
role	-	1893	O
in	-	1898	O
the	-	1901	O
pathophysiology	-	1905	O
of	-	1921	O
METH	-	1924	O
-	-	1928	O
induced	-	1929	O
psychosis	-	1937	B
in	-	1947	O
the	-	1950	O
Japanese	-	1954	O
population	-	1963	O
.	-	1973	O

Effect	19105845	0	O
of	-	7	O
increasing	-	10	O
intraperitoneal	-	21	O
infusion	-	37	O
rates	-	46	O
on	-	52	O
bupropion	-	55	O
hydrochloride	-	65	O
-	-	78	O
induced	-	79	O
seizures	-	87	B
in	-	96	O
mice	-	99	O
.	-	103	O

BACKGROUND	19105845	105	O
:	-	115	O
It	-	117	O
is	-	120	O
not	-	123	O
known	-	127	O
if	-	133	O
there	-	136	O
is	-	142	O
a	-	145	O
relationship	-	147	O
between	-	160	O
input	-	168	O
rate	-	174	O
and	-	179	O
incidence	-	183	O
of	-	193	O
bupropion	-	196	O
-	-	205	O
induced	-	206	O
seizures	-	214	B
.	-	222	O

This	19105845	224	O
is	-	229	O
important	-	232	O
,	-	241	O
since	-	243	O
different	-	249	O
controlled	-	259	O
release	-	270	O
formulations	-	278	O
of	-	291	O
bupropion	-	294	O
release	-	304	O
the	-	312	O
active	-	316	O
drug	-	323	O
at	-	328	O
different	-	331	O
rates	-	341	O
.	-	346	O

METHODS	19105845	348	O
:	-	355	O

We	19105845	357	O
investigated	-	360	O
the	-	373	O
effect	-	377	O
of	-	384	O
varying	-	387	O
the	-	395	O
intraperitoneal	-	399	O
infusion	-	415	O
rates	-	424	O
of	-	430	O
bupropion	-	433	O
HCl	-	443	O
120	-	447	O
mg	-	451	O
/	-	453	O
kg	-	454	O
,	-	456	O
a	-	458	O
known	-	460	O
convulsive	-	466	B
dose	-	477	O
50	-	482	O
(	-	485	O
CD50	-	486	O
)	-	490	O
,	-	491	O
on	-	493	O
the	-	496	O
incidence	-	500	O
and	-	510	O
severity	-	514	O
of	-	523	O
bupropion	-	526	O
-	-	535	O
induced	-	536	O
convulsions	-	544	B
in	-	556	O
the	-	559	O
Swiss	-	563	O
albino	-	569	O
mice	-	576	O
.	-	580	O

A	19105845	582	O
total	-	584	O
of	-	590	O
69	-	593	O
mice	-	596	O
,	-	600	O
approximately	-	602	O
7	-	616	O
weeks	-	618	O
of	-	624	O
age	-	627	O
,	-	630	O
and	-	632	O
weighing	-	636	O
21	-	645	O
.	-	647	O
0	-	648	O
to	-	650	O
29	-	653	O
.	-	655	O
1	-	656	O
g	-	658	O
were	-	660	O
randomly	-	665	O
assigned	-	674	O
to	-	683	O
bupropion	-	686	O
HCl	-	696	O
120	-	700	O
mg	-	704	O
/	-	706	O
kg	-	707	O
treatment	-	710	O
by	-	720	O
intraperitoneal	-	723	O
(	-	739	O
IP	-	740	O
)	-	742	O
administration	-	744	O
in	-	759	O
7	-	762	O
groups	-	764	O
(	-	771	O
9	-	772	O
to	-	774	O
10	-	777	O
animals	-	780	O
per	-	788	O
group	-	792	O
)	-	797	O
.	-	798	O

Bupropion	19105845	800	O
HCl	-	810	O
was	-	814	O
infused	-	818	O
through	-	826	O
a	-	834	O
surgically	-	836	O
implanted	-	847	O
IP	-	857	O
dosing	-	860	O
catheter	-	867	O
with	-	876	O
infusions	-	881	O
in	-	891	O
each	-	894	O
group	-	899	O
of	-	905	O
0	-	908	O
min	-	910	O
,	-	913	O
15	-	915	O
min	-	918	O
,	-	921	O
30	-	923	O
min	-	926	O
,	-	929	O
60	-	931	O
min	-	934	O
,	-	937	O
90	-	939	O
min	-	942	O
,	-	945	O
120	-	947	O
min	-	951	O
,	-	954	O
and	-	956	O
240	-	960	O
min	-	964	O
.	-	967	O

The	19105845	969	O
number	-	973	O
,	-	979	O
time	-	981	O
of	-	986	O
onset	-	989	O
,	-	994	O
duration	-	996	O
and	-	1005	O
the	-	1009	O
intensity	-	1013	O
of	-	1023	O
the	-	1026	O
convulsions	-	1030	B
or	-	1042	O
absence	-	1045	O
of	-	1053	O
convulsions	-	1056	B
were	-	1068	O
recorded	-	1073	O
.	-	1081	O

RESULTS	19105845	1083	O
:	-	1090	O

The	19105845	1092	O
results	-	1096	O
showed	-	1104	O
that	-	1111	O
IP	-	1116	O
administration	-	1119	O
of	-	1134	O
bupropion	-	1137	O
HCl	-	1147	O
120	-	1151	O
mg	-	1155	O
/	-	1157	O
kg	-	1158	O
by	-	1161	O
bolus	-	1164	O
injection	-	1170	O
induced	-	1180	O
convulsions	-	1188	B
in	-	1200	O
6	-	1203	O
out	-	1205	O
of	-	1209	O
10	-	1212	O
mice	-	1215	O
(	-	1220	O
60	-	1221	O
%	-	1223	O
of	-	1225	O
convulsing	-	1228	O
mice	-	1239	O
)	-	1243	O
in	-	1245	O
group	-	1248	O
1	-	1254	O
.	-	1255	O

Logistic	19105845	1257	O
regression	-	1266	O
analysis	-	1277	O
revealed	-	1286	O
that	-	1295	O
infusion	-	1300	O
time	-	1309	O
was	-	1314	O
significant	-	1318	O
(	-	1330	O
p	-	1331	O
=	-	1333	O
0	-	1335	O
.	-	1336	O
0004	-	1337	O
;	-	1341	O
odds	-	1343	O
ratio	-	1348	O
=	-	1354	O
0	-	1356	O
.	-	1357	O
974	-	1358	O
)	-	1361	O
and	-	1363	O
increasing	-	1367	O
the	-	1378	O
IP	-	1382	O
infusion	-	1385	O
time	-	1394	O
of	-	1399	O
bupropion	-	1402	O
HCl	-	1412	O
120	-	1416	O
mg	-	1420	O
/	-	1422	O
kg	-	1423	O
was	-	1426	O
associated	-	1430	O
with	-	1441	O
a	-	1446	O
91	-	1448	O
%	-	1450	O
reduced	-	1452	O
odds	-	1460	O
of	-	1465	O
convulsions	-	1468	B
at	-	1480	O
infusion	-	1483	O
times	-	1492	O
of	-	1498	O
15	-	1501	O
to	-	1504	O
90	-	1507	O
min	-	1510	O
compared	-	1514	O
to	-	1523	O
bolus	-	1526	O
injection	-	1532	O
.	-	1541	O

Further	19105845	1543	O
increase	-	1551	O
in	-	1560	O
infusion	-	1563	O
time	-	1572	O
resulted	-	1577	O
in	-	1586	O
further	-	1589	O
reduction	-	1597	O
in	-	1607	O
the	-	1610	O
odds	-	1614	O
of	-	1619	O
convulsions	-	1622	B
to	-	1634	O
99	-	1637	O
.	-	1639	O
8	-	1640	O
%	-	1641	O
reduction	-	1643	O
at	-	1653	O
240	-	1656	O
min	-	1660	O
.	-	1663	O

CONCLUSION	19105845	1665	O
:	-	1675	O

In	19105845	1677	O
conclusion	-	1680	O
,	-	1690	O
the	-	1692	O
demonstration	-	1696	O
of	-	1710	O
an	-	1713	O
inverse	-	1716	O
relationship	-	1724	O
between	-	1737	O
infusion	-	1745	O
time	-	1754	O
of	-	1759	O
a	-	1762	O
fixed	-	1764	O
and	-	1770	O
convulsive	-	1774	B
dose	-	1785	O
of	-	1790	O
bupropion	-	1793	O
and	-	1803	O
the	-	1807	O
risk	-	1811	O
of	-	1816	O
convulsions	-	1819	B
in	-	1831	O
a	-	1834	O
prospective	-	1836	O
study	-	1848	O
is	-	1854	O
novel	-	1857	O
.	-	1862	O

Detailed	18657397	0	O
spectral	-	9	O
profile	-	18	O
analysis	-	26	O
of	-	35	O
penicillin	-	38	O
-	-	48	O
induced	-	49	O
epileptiform	-	57	B
activity	-	70	I
in	-	79	O
anesthetized	-	82	O
rats	-	95	O
.	-	99	O

Penicillin	18657397	101	O
model	-	112	O
is	-	118	O
a	-	121	O
widely	-	123	O
used	-	130	O
experimental	-	135	O
model	-	148	O
for	-	154	O
epilepsy	-	158	B
research	-	167	O
.	-	175	O

In	18657397	177	O
the	-	180	O
present	-	184	O
study	-	192	O
we	-	198	O
aimed	-	201	O
to	-	207	O
portray	-	210	O
a	-	218	O
detailed	-	220	O
spectral	-	229	O
analysis	-	238	O
of	-	247	O
penicillin	-	250	O
-	-	260	O
induced	-	261	O
epileptiform	-	269	B
activity	-	282	I
in	-	291	O
comparison	-	294	O
with	-	305	O
basal	-	310	O
brain	-	316	O
activity	-	322	O
in	-	331	O
anesthetized	-	334	O
Wistar	-	347	O
rats	-	354	O
.	-	358	O

Male	18657397	360	O
Wistar	-	365	O
rats	-	372	O
were	-	377	O
anesthetized	-	382	O
with	-	395	O
i	-	400	O
.	-	401	O
p	-	402	O
.	-	403	O

urethane	18657397	405	O
and	-	414	O
connected	-	418	O
to	-	428	O
an	-	431	O
electrocorticogram	-	434	O
setup	-	453	O
.	-	458	O

After	18657397	460	O
a	-	466	O
short	-	468	O
period	-	474	O
of	-	481	O
basal	-	484	O
activity	-	490	O
recording	-	499	O
,	-	508	O
epileptic	-	510	B
focus	-	520	O
was	-	526	O
induced	-	530	O
by	-	538	O
injecting	-	541	O
400IU	-	551	O
/	-	556	O
2	-	557	O
microl	-	559	O
penicillin	-	566	O
-	-	576	O
G	-	577	O
potassium	-	579	O
into	-	589	O
the	-	594	O
left	-	598	O
lateral	-	603	O
ventricle	-	611	O
while	-	621	O
the	-	627	O
cortical	-	631	O
activity	-	640	O
was	-	649	O
continuously	-	653	O
recorded	-	666	O
.	-	674	O

Basal	18657397	676	O
activity	-	682	O
,	-	690	O
latent	-	692	O
period	-	699	O
and	-	706	O
the	-	710	O
penicillin	-	714	O
-	-	724	O
induced	-	725	O
epileptiform	-	733	B
activity	-	746	I
periods	-	755	O
were	-	763	O
then	-	768	O
analyzed	-	773	O
using	-	782	O
both	-	788	O
conventional	-	793	O
methods	-	806	O
and	-	814	O
spectral	-	818	O
analysis	-	827	O
.	-	835	O

Spectral	18657397	837	O
analyses	-	846	O
were	-	855	O
conducted	-	860	O
by	-	870	O
dividing	-	873	O
the	-	882	O
whole	-	886	O
spectrum	-	892	O
into	-	901	O
different	-	906	O
frequency	-	916	O
bands	-	926	O
including	-	932	O
delta	-	942	O
,	-	947	O
theta	-	949	O
(	-	955	O
slow	-	956	O
and	-	961	O
fast	-	965	O
)	-	969	O
,	-	970	O
alpha	-	972	O
-	-	977	O
sigma	-	978	O
,	-	983	O
beta	-	985	O
(	-	990	O
1	-	991	O
and	-	993	O
2	-	997	O
)	-	998	O
and	-	1000	O
gamma	-	1004	O
(	-	1010	O
1	-	1011	O
and	-	1013	O
2	-	1017	O
)	-	1018	O
bands	-	1020	O
.	-	1025	O

Our	18657397	1027	O
results	-	1031	O
show	-	1039	O
that	-	1044	O
the	-	1049	O
most	-	1053	O
affected	-	1058	O
frequency	-	1067	O
bands	-	1077	O
were	-	1083	O
delta	-	1088	O
,	-	1093	O
theta	-	1095	O
,	-	1100	O
beta	-	1102	O
-	-	1106	O
2	-	1107	O
and	-	1109	O
gamma	-	1113	O
-	-	1118	O
2	-	1119	O
bands	-	1121	O
during	-	1127	O
the	-	1134	O
epileptiform	-	1138	B
activity	-	1151	I
and	-	1160	O
there	-	1164	O
were	-	1170	O
marked	-	1175	O
differences	-	1182	O
in	-	1194	O
terms	-	1197	O
of	-	1203	O
spectral	-	1206	O
densities	-	1215	O
between	-	1225	O
three	-	1233	O
investigated	-	1239	O
episodes	-	1252	O
(	-	1261	O
basal	-	1262	O
activity	-	1268	O
,	-	1276	O
latent	-	1278	O
period	-	1285	O
and	-	1292	O
epileptiform	-	1296	B
activity	-	1309	I
)	-	1317	O
.	-	1318	O

Our	18657397	1320	O
results	-	1324	O
may	-	1332	O
help	-	1336	O
to	-	1341	O
analyze	-	1344	O
novel	-	1352	O
data	-	1358	O
obtained	-	1363	O
using	-	1372	O
similar	-	1378	O
experimental	-	1386	O
models	-	1399	O
and	-	1406	O
the	-	1410	O
simple	-	1414	O
analysis	-	1421	O
method	-	1430	O
described	-	1437	O
here	-	1447	O
can	-	1452	O
be	-	1456	O
used	-	1459	O
in	-	1464	O
similar	-	1467	O
studies	-	1475	O
to	-	1483	O
investigate	-	1486	O
the	-	1498	O
basic	-	1502	O
neuronal	-	1508	O
mechanism	-	1517	O
of	-	1527	O
this	-	1530	O
or	-	1535	O
other	-	1538	O
types	-	1544	O
of	-	1550	O
experimental	-	1553	O
epilepsies	-	1566	B
.	-	1576	O

High	18363626	0	O
dose	-	5	O
dexmedetomidine	-	10	O
as	-	26	O
the	-	29	O
sole	-	33	O
sedative	-	38	O
for	-	47	O
pediatric	-	51	O
MRI	-	61	O
.	-	64	O

OBJECTIVE	18363626	66	O
:	-	75	O

This	18363626	77	O
large	-	82	O
-	-	87	O
scale	-	88	O
retrospective	-	94	O
review	-	108	O
evaluates	-	115	O
the	-	125	O
sedation	-	129	O
profile	-	138	O
of	-	146	O
dexmedetomidine	-	149	O
.	-	164	O

AIM	18363626	166	O
:	-	169	O

To	18363626	171	O
determine	-	174	O
the	-	184	O
hemodynamic	-	188	O
responses	-	200	O
,	-	209	O
efficacy	-	211	O
and	-	220	O
adverse	-	224	O
events	-	232	O
associated	-	239	O
with	-	250	O
the	-	255	O
use	-	259	O
of	-	263	O
high	-	266	O
dose	-	271	O
dexmedetomidine	-	276	O
as	-	292	O
the	-	295	O
sole	-	299	O
sedative	-	304	O
for	-	313	O
magnetic	-	317	O
resonance	-	326	O
imaging	-	336	O
(	-	344	O
MRI	-	345	O
)	-	348	O
studies	-	350	O
.	-	357	O

BACKGROUND	18363626	359	O
:	-	369	O

Dexmedetomidine	18363626	371	O
has	-	387	O
been	-	391	O
used	-	396	O
at	-	401	O
our	-	404	O
institution	-	408	O
since	-	420	O
2005	-	426	O
to	-	431	O
provide	-	434	O
sedation	-	442	O
for	-	451	O
pediatric	-	455	O
radiological	-	465	O
imaging	-	478	O
studies	-	486	O
.	-	493	O

Over	18363626	495	O
time	-	500	O
,	-	504	O
an	-	506	O
effective	-	509	O
protocol	-	519	O
utilizing	-	528	O
high	-	538	O
dose	-	543	O
dexmedetomidine	-	548	O
as	-	564	O
the	-	567	O
sole	-	571	O
sedative	-	576	O
agent	-	585	O
has	-	591	O
evolved	-	595	O
.	-	602	O

METHODS	18363626	604	O
/	-	611	O
MATERIALS	-	612	O
:	-	621	O

As	18363626	623	O
part	-	626	O
of	-	631	O
the	-	634	O
ongoing	-	638	O
Quality	-	646	O
Assurance	-	654	O
process	-	664	O
,	-	671	O
data	-	673	O
on	-	678	O
all	-	681	O
sedations	-	685	O
are	-	695	O
reviewed	-	699	O
monthly	-	708	O
and	-	716	O
protocols	-	720	O
modified	-	730	O
as	-	739	O
needed	-	742	O
.	-	748	O

Data	18363626	750	O
were	-	755	O
analyzed	-	760	O
from	-	769	O
all	-	774	O
747	-	778	O
consecutive	-	782	O
patients	-	794	O
who	-	803	O
received	-	807	O
dexmedetomidine	-	816	O
for	-	832	O
MRI	-	836	O
sedation	-	840	O
from	-	849	O
April	-	854	O
2005	-	860	O
to	-	865	O
April	-	868	O
2007	-	874	O
.	-	878	O

RESULTS	18363626	880	O
:	-	887	O

Since	18363626	889	O
2005	-	895	O
,	-	899	O
the	-	901	O
10	-	905	O
-	-	907	O
min	-	908	O
loading	-	912	O
dose	-	920	O
of	-	925	O
our	-	928	O
dexmedetomidine	-	932	O
protocol	-	948	O
increased	-	957	O
from	-	967	O
2	-	972	O
to	-	974	O
3	-	977	O
microg	-	979	O
.	-	985	O
kg	-	986	O
(	-	988	O
-	-	989	O
1	-	990	O
)	-	991	O
,	-	992	O
and	-	994	O
the	-	998	O
infusion	-	1002	O
rate	-	1011	O
increased	-	1016	O
from	-	1026	O
1	-	1031	O
to	-	1033	O
1	-	1036	O
.	-	1037	O
5	-	1038	O
to	-	1040	O
2	-	1043	O
microg	-	1045	O
.	-	1051	O
kg	-	1052	O
(	-	1054	O
-	-	1055	O
1	-	1056	O
)	-	1057	O
.	-	1058	O
h	-	1059	O
(	-	1060	O
-	-	1061	O
1	-	1062	O
)	-	1063	O
.	-	1064	O

The	18363626	1066	O
current	-	1070	O
sedation	-	1078	O
protocol	-	1087	O
progressively	-	1096	O
increased	-	1110	O
the	-	1120	O
rate	-	1124	O
of	-	1129	O
successful	-	1132	O
sedation	-	1143	O
(	-	1152	O
able	-	1153	O
to	-	1158	O
complete	-	1161	O
the	-	1170	O
imaging	-	1174	O
study	-	1182	O
)	-	1187	O
when	-	1189	O
using	-	1194	O
dexmedetomidine	-	1200	O
alone	-	1216	O
from	-	1222	O
91	-	1227	O
.	-	1229	O
8	-	1230	O
%	-	1231	O
to	-	1233	O
97	-	1236	O
.	-	1238	O
6	-	1239	O
%	-	1240	O
(	-	1242	O
P	-	1243	O
=	-	1245	O
0	-	1247	O
.	-	1248	O
009	-	1249	O
)	-	1252	O
,	-	1253	O
reducing	-	1255	O
the	-	1264	O
requirement	-	1268	O
for	-	1280	O
adjuvant	-	1284	O
pentobarbital	-	1293	O
in	-	1307	O
the	-	1310	O
event	-	1314	O
of	-	1320	O
sedation	-	1323	O
failure	-	1332	O
with	-	1340	O
dexmedetomidine	-	1345	O
alone	-	1361	O
and	-	1367	O
decreased	-	1371	O
the	-	1381	O
mean	-	1385	O
recovery	-	1390	O
time	-	1399	O
by	-	1404	O
10	-	1407	O
min	-	1410	O
(	-	1414	O
P	-	1415	O
<	-	1417	O
0	-	1419	O
.	-	1420	O
001	-	1421	O
)	-	1424	O
.	-	1425	O

Although	18363626	1427	O
dexmedetomidine	-	1436	O
sedation	-	1452	O
was	-	1461	O
associated	-	1465	O
with	-	1476	O
a	-	1481	O
16	-	1483	O
%	-	1485	O
incidence	-	1487	O
of	-	1497	O
bradycardia	-	1500	B
,	-	1511	O
all	-	1513	O
concomitant	-	1517	O
mean	-	1529	O
arterial	-	1534	O
blood	-	1543	O
pressures	-	1549	O
were	-	1559	O
within	-	1564	O
20	-	1571	O
%	-	1573	O
of	-	1575	O
age	-	1578	O
-	-	1581	O
adjusted	-	1582	O
normal	-	1591	O
range	-	1598	O
and	-	1604	O
oxygen	-	1608	O
saturations	-	1615	O
were	-	1627	O
95	-	1632	O
%	-	1634	O
or	-	1636	O
higher	-	1639	O
.	-	1645	O

CONCLUSION	18363626	1647	O
:	-	1657	O

Dexmedetomidine	18363626	1659	O
in	-	1675	O
high	-	1678	O
doses	-	1683	O
provides	-	1689	O
adequate	-	1698	O
sedation	-	1707	O
for	-	1716	O
pediatric	-	1720	O
MRI	-	1730	O
studies	-	1734	O
.	-	1741	O

While	18363626	1743	O
use	-	1749	O
of	-	1753	O
high	-	1756	O
dose	-	1761	O
dexmedetomidine	-	1766	O
is	-	1782	O
associated	-	1785	O
with	-	1796	O
decreases	-	1801	O
in	-	1811	O
heart	-	1814	O
rate	-	1820	O
and	-	1825	O
blood	-	1829	O
pressure	-	1835	O
outside	-	1844	O
the	-	1852	O
established	-	1856	O
'	-	1868	O
awake	-	1869	O
'	-	1874	O
norms	-	1876	O
,	-	1881	O
this	-	1883	O
deviation	-	1888	O
is	-	1898	O
generally	-	1901	O
within	-	1911	O
20	-	1918	O
%	-	1920	O
of	-	1922	O
norms	-	1925	O
,	-	1930	O
and	-	1932	O
is	-	1936	O
not	-	1939	O
associated	-	1943	O
with	-	1954	O
adverse	-	1959	O
sequelae	-	1967	O
.	-	1975	O

Dexmedetomidine	18363626	1977	O
is	-	1993	O
useful	-	1996	O
as	-	2003	O
the	-	2006	O
sole	-	2010	O
sedative	-	2015	O
for	-	2024	O
pediatric	-	2028	O
MRI	-	2038	O
.	-	2041	O

Methamphetamine	16192988	0	O
causes	-	16	O
alterations	-	23	O
in	-	35	O
the	-	38	O
MAP	-	42	O
kinase	-	46	O
-	-	52	O
related	-	53	O
pathways	-	61	O
in	-	70	O
the	-	73	O
brains	-	77	O
of	-	84	O
mice	-	87	O
that	-	92	O
display	-	97	O
increased	-	105	O
aggressiveness	-	115	B
.	-	129	O

Aggressive	16192988	131	B
behaviors	-	142	I
have	-	152	O
been	-	157	O
reported	-	162	O
in	-	171	O
patients	-	174	O
who	-	183	O
suffer	-	187	O
from	-	194	O
some	-	199	O
psychiatric	-	204	B
disorders	-	216	I
,	-	225	O
and	-	227	O
are	-	231	O
common	-	235	O
in	-	242	O
methamphetamine	-	245	O
(	-	261	O
METH	-	262	O
)	-	266	O
abusers	-	268	O
.	-	275	O

Herein	16192988	277	O
,	-	283	O
we	-	285	O
report	-	288	O
that	-	295	O
multiple	-	300	O
(	-	309	O
but	-	310	O
not	-	314	O
single	-	318	O
)	-	324	O
injections	-	326	O
of	-	337	O
METH	-	340	O
significantly	-	345	O
increased	-	359	O
aggressiveness	-	369	B
in	-	384	O
male	-	387	O
CD	-	392	O
-	-	394	O
1	-	395	O
mice	-	397	O
.	-	401	O

This	16192988	403	O
increase	-	408	O
in	-	417	O
aggressiveness	-	420	B
was	-	435	O
not	-	439	O
secondary	-	443	O
to	-	453	O
METH	-	456	O
-	-	460	O
induced	-	461	O
hyperactivity	-	469	B
.	-	482	O

Analysis	16192988	484	O
of	-	493	O
protein	-	496	O
expression	-	504	O
using	-	515	O
antibody	-	521	O
microarrays	-	530	O
and	-	542	O
Western	-	546	O
blotting	-	554	O
revealed	-	563	O
differential	-	572	O
changes	-	585	O
in	-	593	O
MAP	-	596	O
kinase	-	600	O
-	-	606	O
related	-	607	O
pathways	-	615	O
after	-	624	O
multiple	-	630	O
and	-	639	O
single	-	643	O
METH	-	650	O
injections	-	655	O
.	-	665	O

There	16192988	667	O
were	-	673	O
statistically	-	678	O
significant	-	692	O
(	-	704	O
p	-	705	O
<	-	706	O
0	-	707	O
.	-	708	O
05	-	709	O
)	-	711	O
decreases	-	713	O
in	-	723	O
MEK1	-	726	O
,	-	730	O
Erk2p	-	732	O
,	-	737	O
GSK3alpha	-	739	O
,	-	748	O
14	-	750	O
-	-	752	O
3	-	753	O
-	-	754	O
3e	-	755	O
,	-	757	O
and	-	759	O
MEK7	-	763	O
in	-	768	O
the	-	771	O
striata	-	775	O
of	-	783	O
mice	-	786	O
after	-	791	O
multiple	-	797	O
injections	-	806	O
of	-	817	O
METH	-	820	O
.	-	824	O

MEK1	16192988	826	O
was	-	831	O
significantly	-	835	O
decreased	-	849	O
also	-	859	O
after	-	864	O
a	-	870	O
single	-	872	O
injection	-	879	O
of	-	889	O
METH	-	892	O
,	-	896	O
but	-	898	O
to	-	902	O
a	-	905	O
much	-	907	O
lesser	-	912	O
degree	-	919	O
than	-	926	O
after	-	931	O
multiple	-	937	O
injections	-	946	O
of	-	957	O
METH	-	960	O
.	-	964	O

In	16192988	966	O
the	-	969	O
frontal	-	973	O
cortex	-	981	O
,	-	987	O
there	-	989	O
was	-	995	O
a	-	999	O
statistically	-	1001	O
significant	-	1015	O
decrease	-	1027	O
in	-	1036	O
GSK3alpha	-	1039	O
after	-	1049	O
multiple	-	1055	O
(	-	1064	O
but	-	1065	O
not	-	1069	O
single	-	1073	O
)	-	1079	O
injections	-	1081	O
of	-	1092	O
METH	-	1095	O
.	-	1099	O

These	16192988	1101	O
findings	-	1107	O
suggest	-	1116	O
that	-	1124	O
alterations	-	1129	O
in	-	1141	O
MAP	-	1144	O
kinase	-	1148	O
-	-	1154	O
related	-	1155	O
pathways	-	1163	O
in	-	1172	O
the	-	1175	O
prefronto	-	1179	O
-	-	1188	O
striatal	-	1189	O
circuitries	-	1198	O
might	-	1210	O
be	-	1216	O
involved	-	1219	O
in	-	1228	O
the	-	1231	O
manifestation	-	1235	O
of	-	1249	O
aggressive	-	1252	B
behaviors	-	1263	I
in	-	1273	O
mice	-	1276	O
.	-	1280	O

Lamotrigine	16157917	0	O
associated	-	12	O
with	-	23	O
exacerbation	-	28	O
or	-	41	O
de	-	44	O
novo	-	47	O
myoclonus	-	52	B
in	-	62	O
idiopathic	-	65	B
generalized	-	76	I
epilepsies	-	88	I
.	-	98	O

Five	16157917	100	O
patients	-	105	O
with	-	114	O
idiopathic	-	119	B
generalized	-	130	I
epilepsies	-	142	I
(	-	153	O
IGE	-	154	B
)	-	157	O
treated	-	159	O
with	-	167	O
lamotrigine	-	172	O
(	-	184	O
LTG	-	185	O
)	-	188	O
experienced	-	190	O
exacerbation	-	202	O
or	-	215	O
de	-	218	O
novo	-	221	O
appearance	-	226	O
of	-	237	O
myoclonic	-	240	B
jerks	-	250	I
(	-	256	O
MJ	-	257	B
)	-	259	O
.	-	260	O

In	16157917	262	O
three	-	265	O
patients	-	271	O
,	-	279	O
LTG	-	281	O
exacerbated	-	285	O
MJ	-	297	B
in	-	300	O
a	-	303	O
dose	-	305	O
-	-	309	O
dependent	-	310	O
manner	-	320	O
with	-	327	O
early	-	332	O
aggravation	-	338	O
during	-	350	O
titration	-	357	O
.	-	366	O

MJ	16157917	368	B
disappeared	-	371	O
when	-	383	O
LTG	-	388	O
dose	-	392	O
was	-	397	O
decreased	-	401	O
by	-	411	O
25	-	414	O
to	-	417	O
50	-	420	O
%	-	422	O
.	-	423	O

In	16157917	425	O
two	-	428	O
patients	-	432	O
,	-	440	O
LTG	-	442	O
exacerbated	-	446	O
MJ	-	458	B
in	-	461	O
a	-	464	O
delayed	-	466	O
but	-	474	O
more	-	478	O
severe	-	483	O
manner	-	490	O
,	-	496	O
with	-	498	O
myoclonic	-	503	B
status	-	513	I
that	-	520	O
only	-	525	O
ceased	-	530	O
after	-	537	O
LTG	-	543	O
withdrawal	-	547	O
.	-	557	O

rTMS	16116131	0	O
of	-	5	O
supplementary	-	8	O
motor	-	22	O
area	-	28	O
modulates	-	33	O
therapy	-	43	O
-	-	50	O
induced	-	51	O
dyskinesias	-	59	B
in	-	71	O
Parkinson	-	74	B
disease	-	84	I
.	-	91	O

The	16116131	93	O
neural	-	97	O
mechanisms	-	104	O
and	-	115	O
circuitry	-	119	O
involved	-	129	O
in	-	138	O
levodopa	-	141	O
-	-	149	O
induced	-	150	O
dyskinesia	-	158	B
are	-	169	O
unclear	-	173	O
.	-	180	O

Using	16116131	182	O
repetitive	-	188	O
transcranial	-	199	O
magnetic	-	212	O
stimulation	-	221	O
(	-	233	O
rTMS	-	234	O
)	-	238	O
over	-	240	O
the	-	245	O
supplementary	-	249	O
motor	-	263	O
area	-	269	O
(	-	274	O
SMA	-	275	O
)	-	278	O
in	-	280	O
a	-	283	O
group	-	285	O
of	-	291	O
patients	-	294	O
with	-	303	O
advanced	-	308	O
Parkinson	-	317	B
disease	-	327	I
,	-	334	O
the	-	336	O
authors	-	340	O
investigated	-	348	O
whether	-	361	O
modulation	-	369	O
of	-	380	O
SMA	-	383	O
excitability	-	387	O
may	-	400	O
result	-	404	O
in	-	411	O
a	-	414	O
modification	-	416	O
of	-	429	O
a	-	432	O
dyskinetic	-	434	B
state	-	445	O
induced	-	451	O
by	-	459	O
continuous	-	462	O
apomorphine	-	473	O
infusion	-	485	O
.	-	493	O

rTMS	16116131	495	O
at	-	500	O
1	-	503	O
Hz	-	505	O
was	-	508	O
observed	-	512	O
to	-	521	O
markedly	-	524	O
reduce	-	533	O
drug	-	540	B
-	-	544	I
induced	-	545	I
dyskinesias	-	553	I
,	-	564	O
whereas	-	566	O
5	-	574	O
-	-	575	O
Hz	-	576	O
rTMS	-	579	O
induced	-	584	O
a	-	592	O
slight	-	594	O
but	-	601	O
not	-	605	O
significant	-	609	O
increase	-	621	O
.	-	629	O

Assessment	15930398	0	O
of	-	11	O
the	-	14	O
onset	-	18	O
and	-	24	O
persistence	-	28	O
of	-	40	O
amnesia	-	43	B
during	-	51	O
procedural	-	58	O
sedation	-	69	O
with	-	78	O
propofol	-	83	O
.	-	91	O

OBJECTIVES	15930398	93	O
:	-	103	O

To	15930398	105	O
assess	-	108	O
patients	-	115	O
'	-	123	O
ability	-	125	O
to	-	133	O
repeat	-	136	O
and	-	143	O
recall	-	147	O
words	-	154	O
presented	-	160	O
to	-	170	O
them	-	173	O
while	-	178	O
undergoing	-	184	O
procedural	-	195	O
sedation	-	206	O
with	-	215	O
propofol	-	220	O
,	-	228	O
and	-	230	O
correlate	-	234	O
their	-	244	O
recall	-	250	O
with	-	257	O
their	-	262	O
level	-	268	O
of	-	274	O
awareness	-	277	O
as	-	287	O
measured	-	290	O
by	-	299	O
bispectral	-	302	O
index	-	313	O
(	-	319	O
BIS	-	320	O
)	-	323	O
monitoring	-	325	O
.	-	335	O

METHODS	15930398	337	O
:	-	344	O

This	15930398	346	O
was	-	351	O
a	-	355	O
prospective	-	357	O
,	-	368	O
single	-	370	O
-	-	376	O
intervention	-	377	O
study	-	390	O
of	-	396	O
consenting	-	399	O
adult	-	410	O
patients	-	416	O
undergoing	-	425	O
procedural	-	436	O
sedation	-	447	O
with	-	456	O
propofol	-	461	O
between	-	470	O
December	-	478	O
28	-	487	O
,	-	489	O
2002	-	491	O
,	-	495	O
and	-	497	O
October	-	501	O
31	-	509	O
,	-	511	O
2003	-	513	O
.	-	517	O

BIS	15930398	519	O
monitoring	-	523	O
was	-	534	O
initiated	-	538	O
starting	-	548	O
3	-	557	O
minutes	-	559	O
before	-	567	O
the	-	574	O
procedure	-	578	O
and	-	588	O
continuing	-	592	O
until	-	603	O
the	-	609	O
patient	-	613	O
had	-	621	O
regained	-	625	O
baseline	-	634	O
mental	-	643	O
status	-	650	O
.	-	656	O

At	15930398	658	O
1	-	661	O
-	-	662	O
minute	-	663	O
intervals	-	670	O
during	-	680	O
the	-	687	O
procedural	-	691	O
sedation	-	702	O
,	-	710	O
until	-	712	O
the	-	718	O
patient	-	722	O
regained	-	730	O
baseline	-	739	O
mental	-	748	O
status	-	755	O
at	-	762	O
the	-	765	O
end	-	769	O
of	-	773	O
the	-	776	O
procedure	-	780	O
,	-	789	O
a	-	791	O
word	-	793	O
from	-	798	O
a	-	803	O
standardized	-	805	O
list	-	818	O
was	-	823	O
read	-	827	O
aloud	-	832	O
,	-	837	O
and	-	839	O
the	-	843	O
patient	-	847	O
was	-	855	O
asked	-	859	O
to	-	865	O
immediately	-	868	O
repeat	-	880	O
the	-	887	O
word	-	891	O
to	-	896	O
the	-	899	O
investigator	-	903	O
.	-	915	O

The	15930398	917	O
BIS	-	921	O
score	-	925	O
at	-	931	O
the	-	934	O
time	-	938	O
the	-	943	O
word	-	947	O
was	-	952	O
read	-	956	O
and	-	961	O
the	-	965	O
patient	-	969	O
's	-	976	O
ability	-	979	O
to	-	987	O
repeat	-	990	O
the	-	997	O
word	-	1001	O
were	-	1006	O
recorded	-	1011	O
.	-	1019	O

After	15930398	1021	O
the	-	1027	O
procedure	-	1031	O
,	-	1040	O
the	-	1042	O
patient	-	1046	O
was	-	1054	O
asked	-	1058	O
to	-	1064	O
state	-	1067	O
all	-	1073	O
of	-	1077	O
the	-	1080	O
words	-	1084	O
from	-	1090	O
the	-	1095	O
list	-	1099	O
that	-	1104	O
he	-	1109	O
or	-	1112	O
she	-	1115	O
could	-	1119	O
recall	-	1125	O
,	-	1131	O
and	-	1133	O
to	-	1137	O
identify	-	1140	O
the	-	1149	O
last	-	1153	O
word	-	1158	O
recalled	-	1163	O
from	-	1172	O
prior	-	1177	O
to	-	1183	O
the	-	1186	O
start	-	1190	O
of	-	1196	O
the	-	1199	O
procedure	-	1203	O
and	-	1213	O
the	-	1217	O
first	-	1221	O
word	-	1227	O
recalled	-	1232	O
from	-	1241	O
after	-	1246	O
the	-	1252	O
procedure	-	1256	O
was	-	1266	O
completed	-	1270	O
.	-	1279	O

RESULTS	15930398	1281	O
:	-	1288	O

Seventy	15930398	1290	O
-	-	1297	O
five	-	1298	O
consenting	-	1303	O
patients	-	1314	O
were	-	1323	O
enrolled	-	1328	O
;	-	1336	O
one	-	1338	O
patient	-	1342	O
was	-	1350	O
excluded	-	1354	O
from	-	1363	O
data	-	1368	O
analysis	-	1373	O
for	-	1382	O
a	-	1386	O
protocol	-	1388	O
violation	-	1397	O
.	-	1406	O

No	15930398	1408	O
serious	-	1411	O
adverse	-	1419	O
events	-	1427	O
were	-	1434	O
noted	-	1439	O
during	-	1445	O
the	-	1452	O
procedural	-	1456	O
sedations	-	1467	O
.	-	1476	O

The	15930398	1478	O
mean	-	1482	O
(	-	1487	O
+	-	1488	O
/	-	1489	O
-	-	1490	O
standard	-	1491	O
deviation	-	1500	O
)	-	1509	O
time	-	1511	O
of	-	1516	O
data	-	1519	O
collection	-	1524	O
was	-	1535	O
16	-	1539	O
.	-	1541	O
4	-	1542	O
minutes	-	1544	O
(	-	1552	O
+	-	1553	O
/	-	1554	O
-	-	1555	O
7	-	1556	O
.	-	1557	O
1	-	1558	O
;	-	1559	O
range	-	1561	O
5	-	1567	O
to	-	1569	O
34	-	1572	O
minutes	-	1575	O
)	-	1582	O
.	-	1583	O

The	15930398	1585	O
mean	-	1589	O
initial	-	1594	O
(	-	1602	O
preprocedure	-	1603	O
)	-	1615	O
BIS	-	1617	O
score	-	1621	O
was	-	1627	O
97	-	1631	O
.	-	1633	O
1	-	1634	O
(	-	1636	O
+	-	1637	O
/	-	1638	O
-	-	1639	O
2	-	1640	O
.	-	1641	O
3	-	1642	O
;	-	1643	O
range	-	1645	O
92	-	1651	O
to	-	1654	O
99	-	1657	O
)	-	1659	O
.	-	1660	O

The	15930398	1662	O
mean	-	1666	O
lowest	-	1671	O
BIS	-	1678	O
score	-	1682	O
occurring	-	1688	O
during	-	1698	O
these	-	1705	O
procedural	-	1711	O
sedations	-	1722	O
was	-	1732	O
66	-	1736	O
.	-	1738	O
9	-	1739	O
(	-	1741	O
+	-	1742	O
/	-	1743	O
-	-	1744	O
14	-	1745	O
.	-	1747	O
4	-	1748	O
;	-	1749	O
range	-	1751	O
33	-	1757	O
to	-	1760	O
91	-	1763	O
)	-	1765	O
.	-	1766	O

The	15930398	1768	O
mean	-	1772	O
lowest	-	1777	O
BIS	-	1784	O
score	-	1788	O
corresponding	-	1794	O
to	-	1808	O
the	-	1811	O
ability	-	1815	O
of	-	1823	O
the	-	1826	O
patient	-	1830	O
to	-	1838	O
immediately	-	1841	O
repeat	-	1853	O
words	-	1860	O
read	-	1866	O
from	-	1871	O
the	-	1876	O
list	-	1880	O
was	-	1885	O
77	-	1889	O
.	-	1891	O
1	-	1892	O
(	-	1894	O
95	-	1895	O
%	-	1897	O
CI	-	1899	O
=	-	1902	O
74	-	1904	O
.	-	1906	O
3	-	1907	O
to	-	1909	O
80	-	1912	O
.	-	1914	O
0	-	1915	O
)	-	1916	O
.	-	1917	O

The	15930398	1919	O
mean	-	1923	O
highest	-	1928	O
BIS	-	1936	O
score	-	1940	O
corresponding	-	1946	O
to	-	1960	O
the	-	1963	O
inability	-	1967	B
to	-	1977	I
repeat	-	1980	I
words	-	1987	I
was	-	1993	O
81	-	1997	O
.	-	1999	O
5	-	2000	O
(	-	2002	O
95	-	2003	O
%	-	2005	O
CI	-	2007	O
=	-	2010	O
78	-	2012	O
.	-	2014	O
1	-	2015	O
to	-	2017	O
84	-	2020	O
.	-	2022	O
8	-	2023	O
)	-	2024	O
.	-	2025	O

The	15930398	2027	O
mean	-	2031	O
BIS	-	2036	O
score	-	2040	O
corresponding	-	2046	O
to	-	2060	O
the	-	2063	O
last	-	2067	O
word	-	2072	O
recalled	-	2077	O
from	-	2086	O
prior	-	2091	O
to	-	2097	O
the	-	2100	O
initiation	-	2104	O
of	-	2115	O
the	-	2118	O
sedation	-	2122	O
was	-	2131	O
96	-	2135	O
.	-	2137	O
7	-	2138	O
(	-	2140	O
+	-	2141	O
/	-	2142	O
-	-	2143	O
2	-	2144	O
.	-	2145	O
4	-	2146	O
;	-	2147	O
range	-	2149	O
84	-	2155	O
to	-	2158	O
98	-	2161	O
)	-	2163	O
.	-	2164	O

The	15930398	2166	O
mean	-	2170	O
BIS	-	2175	O
score	-	2179	O
corresponding	-	2185	O
to	-	2199	O
the	-	2202	O
first	-	2206	O
word	-	2212	O
recalled	-	2217	O
after	-	2226	O
the	-	2232	O
procedure	-	2236	O
was	-	2246	O
completed	-	2250	O
was	-	2260	O
91	-	2264	O
.	-	2266	O
2	-	2267	O
(	-	2269	O
95	-	2270	O
%	-	2272	O
CI	-	2274	O
=	-	2277	O
88	-	2279	O
.	-	2281	O
1	-	2282	O
to	-	2284	O
94	-	2287	O
.	-	2289	O
3	-	2290	O
)	-	2291	O
.	-	2292	O

All	15930398	2294	O
patients	-	2298	O
recalled	-	2307	O
at	-	2316	O
least	-	2319	O
one	-	2325	O
word	-	2329	O
that	-	2334	O
had	-	2339	O
been	-	2343	O
read	-	2348	O
to	-	2353	O
them	-	2356	O
during	-	2361	O
the	-	2368	O
protocol	-	2372	O
.	-	2380	O

The	15930398	2382	O
mean	-	2386	O
lowest	-	2391	O
BIS	-	2398	O
score	-	2402	O
for	-	2408	O
any	-	2412	O
recalled	-	2416	O
word	-	2425	O
was	-	2430	O
91	-	2434	O
.	-	2436	O
5	-	2437	O
(	-	2439	O
+	-	2440	O
/	-	2441	O
-	-	2442	O
11	-	2443	O
.	-	2445	O
1	-	2446	O
;	-	2447	O
range	-	2449	O
79	-	2455	O
to	-	2458	O
98	-	2461	O
)	-	2463	O
,	-	2464	O
and	-	2466	O
no	-	2470	O
words	-	2473	O
were	-	2479	O
recalled	-	2484	O
when	-	2493	O
the	-	2498	O
corresponding	-	2502	O
BIS	-	2516	O
score	-	2520	O
was	-	2526	O
less	-	2530	O
than	-	2535	O
90	-	2540	O
.	-	2542	O

CONCLUSIONS	15930398	2544	O
:	-	2555	O

There	15930398	2557	O
is	-	2563	O
a	-	2566	O
range	-	2568	O
of	-	2574	O
BIS	-	2577	O
scores	-	2581	O
during	-	2588	O
which	-	2595	O
sedated	-	2601	O
patients	-	2609	O
are	-	2618	O
able	-	2622	O
to	-	2627	O
repeat	-	2630	O
words	-	2637	O
read	-	2643	O
to	-	2648	O
them	-	2651	O
but	-	2656	O
are	-	2660	O
not	-	2664	O
able	-	2668	O
to	-	2673	O
subsequently	-	2676	O
recall	-	2689	O
these	-	2696	O
words	-	2702	O
.	-	2707	O

Furthermore	15930398	2709	O
,	-	2720	O
patients	-	2722	O
had	-	2731	O
no	-	2735	O
recall	-	2738	O
of	-	2745	O
words	-	2748	O
repeated	-	2754	O
prior	-	2763	O
to	-	2769	O
procedural	-	2772	O
sedation	-	2783	O
in	-	2792	O
BIS	-	2795	O
ranges	-	2799	O
associated	-	2806	O
with	-	2817	O
recall	-	2822	O
after	-	2829	O
procedural	-	2835	O
sedation	-	2846	O
,	-	2854	O
suggestive	-	2856	O
of	-	2867	O
retrograde	-	2870	B
amnesia	-	2881	I
.	-	2888	O

Assessment	15867025	0	O
of	-	11	O
perinatal	-	14	O
hepatitis	-	24	B
B	-	34	I
and	-	36	O
rubella	-	40	B
prevention	-	48	O
in	-	59	O
New	-	62	O
Hampshire	-	66	O
delivery	-	76	O
hospitals	-	85	O
.	-	94	O

OBJECTIVE	15867025	96	O
:	-	105	O

To	15867025	107	O
evaluate	-	110	O
current	-	119	O
performance	-	127	O
on	-	139	O
recommended	-	142	O
perinatal	-	154	O
hepatitis	-	164	B
B	-	174	I
and	-	176	O
rubella	-	180	B
prevention	-	188	O
practices	-	199	O
in	-	209	O
New	-	212	O
Hampshire	-	216	O
.	-	225	O

METHODS	15867025	227	O
:	-	234	O

Data	15867025	236	O
were	-	241	O
extracted	-	246	O
from	-	256	O
2021	-	261	O
paired	-	266	O
mother	-	273	O
-	-	279	O
infant	-	280	O
records	-	287	O
for	-	295	O
the	-	299	O
year	-	303	O
2000	-	308	O
birth	-	313	O
cohort	-	319	O
in	-	326	O
New	-	329	O
Hampshire	-	333	O
's	-	342	O
25	-	345	O
delivery	-	348	O
hospitals	-	357	O
.	-	366	O

Assessment	15867025	368	O
was	-	379	O
done	-	383	O
on	-	388	O
the	-	391	O
following	-	395	O
:	-	404	O
prenatal	-	406	O
screening	-	415	O
for	-	425	O
hepatitis	-	429	B
B	-	439	I
and	-	441	O
rubella	-	445	B
,	-	452	O
administration	-	454	O
of	-	469	O
the	-	472	O
hepatitis	-	476	B
B	-	486	I
vaccine	-	488	O
birth	-	496	O
dose	-	502	O
to	-	507	O
all	-	510	O
infants	-	514	O
,	-	521	O
administration	-	523	O
of	-	538	O
hepatitis	-	541	B
B	-	551	I
immune	-	553	O
globulin	-	560	O
to	-	569	O
infants	-	572	O
who	-	580	O
were	-	584	O
born	-	589	O
to	-	594	O
hepatitis	-	597	O
B	-	607	O
surface	-	609	O
antigen	-	617	O
-	-	624	O
positive	-	625	O
mothers	-	634	O
,	-	641	O
rubella	-	643	B
immunity	-	651	O
,	-	659	O
and	-	661	O
administration	-	665	O
of	-	680	O
in	-	683	O
-	-	685	O
hospital	-	686	O
postpartum	-	695	O
rubella	-	706	B
vaccine	-	714	O
to	-	722	O
rubella	-	725	B
nonimmune	-	733	O
women	-	743	O
.	-	748	O

RESULTS	15867025	750	O
:	-	757	O

Prenatal	15867025	759	O
screening	-	768	O
rates	-	778	O
for	-	784	O
hepatitis	-	788	B
B	-	798	I
(	-	800	O
98	-	801	O
.	-	803	O
8	-	804	O
%	-	805	O
)	-	806	O
and	-	808	O
rubella	-	812	B
(	-	820	O
99	-	821	O
.	-	823	O
4	-	824	O
%	-	825	O
)	-	826	O
were	-	828	O
high	-	833	O
.	-	837	O

Hepatitis	15867025	839	B
B	-	849	I
vaccine	-	851	O
birth	-	859	O
dose	-	865	O
was	-	870	O
administered	-	874	O
to	-	887	O
76	-	890	O
.	-	892	O
2	-	893	O
%	-	894	O
of	-	896	O
all	-	899	O
infants	-	903	O
.	-	910	O

All	15867025	912	O
infants	-	916	O
who	-	924	O
were	-	928	O
born	-	933	O
to	-	938	O
hepatitis	-	941	O
B	-	951	O
surface	-	953	O
antigen	-	961	O
-	-	968	O
positive	-	969	O
mothers	-	978	O
also	-	986	O
received	-	991	O
hepatitis	-	1000	B
B	-	1010	I
immune	-	1012	O
globulin	-	1019	O
.	-	1027	O

Multivariate	15867025	1029	O
logistic	-	1042	O
regression	-	1051	O
showed	-	1062	O
that	-	1069	O
the	-	1074	O
month	-	1078	O
of	-	1084	O
delivery	-	1087	O
and	-	1096	O
infant	-	1100	O
birth	-	1107	O
weight	-	1113	O
were	-	1120	O
independent	-	1125	O
predictors	-	1137	O
of	-	1148	O
hepatitis	-	1151	B
B	-	1161	I
vaccination	-	1163	O
.	-	1174	O

The	15867025	1176	O
proportion	-	1180	O
of	-	1191	O
infants	-	1194	O
who	-	1202	O
were	-	1206	O
vaccinated	-	1211	O
in	-	1222	O
January	-	1225	O
and	-	1233	O
February	-	1237	O
2000	-	1246	O
(	-	1251	O
48	-	1252	O
.	-	1254	O
5	-	1255	O
%	-	1256	O
and	-	1258	O
67	-	1262	O
.	-	1264	O
5	-	1265	O
%	-	1266	O
,	-	1267	O
respectively	-	1269	O
)	-	1281	O
was	-	1283	O
less	-	1287	O
than	-	1292	O
any	-	1297	O
other	-	1301	O
months	-	1307	O
,	-	1313	O
whereas	-	1315	O
the	-	1323	O
proportion	-	1327	O
who	-	1338	O
were	-	1342	O
vaccinated	-	1347	O
in	-	1358	O
December	-	1361	O
2000	-	1370	O
(	-	1375	O
88	-	1376	O
.	-	1378	O
2	-	1379	O
%	-	1380	O
)	-	1381	O
was	-	1383	O
the	-	1387	O
highest	-	1391	O
.	-	1398	O

Women	15867025	1400	O
who	-	1406	O
were	-	1410	O
born	-	1415	O
between	-	1420	O
1971	-	1428	O
and	-	1433	O
1975	-	1437	O
had	-	1442	O
the	-	1446	O
highest	-	1450	O
rate	-	1458	O
of	-	1463	O
rubella	-	1466	B
nonimmunity	-	1474	O
(	-	1486	O
9	-	1487	O
.	-	1488	O
5	-	1489	O
%	-	1490	O
)	-	1491	O
.	-	1492	O

In	15867025	1494	O
-	-	1496	O
hospital	-	1497	O
postpartum	-	1506	O
rubella	-	1517	B
vaccine	-	1525	O
administration	-	1533	O
was	-	1548	O
documented	-	1552	O
for	-	1563	O
75	-	1567	O
.	-	1569	O
6	-	1570	O
%	-	1571	O
of	-	1573	O
nonimmune	-	1576	O
women	-	1586	O
.	-	1591	O

CONCLUSION	15867025	1593	O
:	-	1603	O

This	15867025	1605	O
study	-	1610	O
documents	-	1616	O
good	-	1626	O
compliance	-	1631	O
in	-	1642	O
New	-	1645	O
Hampshire	-	1649	O
's	-	1658	O
birthing	-	1661	O
hospitals	-	1670	O
with	-	1680	O
national	-	1685	O
guidelines	-	1694	O
for	-	1705	O
perinatal	-	1709	O
hepatitis	-	1719	B
B	-	1729	I
and	-	1731	O
rubella	-	1735	B
prevention	-	1743	O
and	-	1754	O
highlights	-	1758	O
potential	-	1769	O
areas	-	1779	O
for	-	1785	O
improvement	-	1789	O
.	-	1800	O

Expression	14975762	0	O
of	-	11	O
p300	-	14	O
protects	-	19	O
cardiac	-	28	O
myocytes	-	36	O
from	-	45	O
apoptosis	-	50	O
in	-	60	O
vivo	-	63	O
.	-	67	O

Doxorubicin	14975762	69	O
is	-	81	O
an	-	84	O
anti	-	87	O
-	-	91	O
tumor	-	92	B
agent	-	98	O
that	-	104	O
represses	-	109	O
cardiac	-	119	O
-	-	126	O
specific	-	127	O
gene	-	136	O
expression	-	141	O
and	-	152	O
induces	-	156	O
myocardial	-	164	O
cell	-	175	O
apoptosis	-	180	O
.	-	189	O

Doxorubicin	14975762	191	O
depletes	-	203	O
cardiac	-	212	O
p300	-	220	O
,	-	224	O
a	-	226	O
transcriptional	-	228	O
coactivator	-	244	O
that	-	256	O
is	-	261	O
required	-	264	O
for	-	273	O
the	-	277	O
maintenance	-	281	O
of	-	293	O
the	-	296	O
differentiated	-	300	O
phenotype	-	315	O
of	-	325	O
cardiac	-	328	O
myocytes	-	336	O
.	-	344	O

However	14975762	346	O
,	-	353	O
the	-	355	O
role	-	359	O
of	-	364	O
p300	-	367	O
in	-	372	O
protection	-	375	O
against	-	386	O
doxorubicin	-	394	O
-	-	405	O
induced	-	406	O
apoptosis	-	414	O
is	-	424	O
unknown	-	427	O
.	-	434	O

Transgenic	14975762	436	O
mice	-	447	O
overexpressing	-	452	O
p300	-	467	O
in	-	472	O
the	-	475	O
heart	-	479	O
and	-	485	O
wild	-	489	O
-	-	493	O
type	-	494	O
mice	-	499	O
were	-	504	O
subjected	-	509	O
to	-	519	O
doxorubicin	-	522	O
treatment	-	534	O
.	-	543	O

Compared	14975762	545	O
with	-	554	O
wild	-	559	O
-	-	563	O
type	-	564	O
mice	-	569	O
,	-	573	O
transgenic	-	575	O
mice	-	586	O
exhibited	-	591	O
higher	-	601	O
survival	-	608	O
rate	-	617	O
as	-	622	O
well	-	625	O
as	-	630	O
more	-	633	O
preserved	-	638	O
left	-	648	O
ventricular	-	653	O
function	-	665	O
and	-	674	O
cardiac	-	678	O
expression	-	686	O
of	-	697	O
alpha	-	700	O
-	-	705	O
sarcomeric	-	706	O
actin	-	717	O
.	-	722	O

Doxorubicin	14975762	724	O
induced	-	736	O
myocardial	-	744	O
cell	-	755	O
apoptosis	-	760	O
in	-	770	O
wild	-	773	O
-	-	777	O
type	-	778	O
mice	-	783	O
but	-	788	O
not	-	792	O
in	-	796	O
transgenic	-	799	O
mice	-	810	O
.	-	814	O

Expression	14975762	816	O
of	-	827	O
p300	-	830	O
increased	-	835	O
the	-	845	O
cardiac	-	849	O
level	-	857	O
of	-	863	O
bcl	-	866	O
-	-	869	O
2	-	870	O
and	-	872	O
mdm	-	876	O
-	-	879	O
2	-	880	O
,	-	881	O
but	-	883	O
not	-	887	O
that	-	891	O
of	-	896	O
p53	-	899	O
or	-	903	O
other	-	906	O
members	-	912	O
of	-	920	O
the	-	923	O
bcl	-	927	O
-	-	930	O
2	-	931	O
family	-	933	O
.	-	939	O

These	14975762	941	O
findings	-	947	O
demonstrate	-	956	O
that	-	968	O
overexpression	-	973	O
of	-	988	O
p300	-	991	O
protects	-	996	O
cardiac	-	1005	O
myocytes	-	1013	O
from	-	1022	O
doxorubicin	-	1027	O
-	-	1038	O
induced	-	1039	O
apoptosis	-	1047	O
and	-	1057	O
reduces	-	1061	O
the	-	1069	O
extent	-	1073	O
of	-	1080	O
acute	-	1083	O
heart	-	1089	B
failure	-	1095	I
in	-	1103	O
adult	-	1106	O
mice	-	1112	O
in	-	1117	O
vivo	-	1120	O
.	-	1124	O

Mitochondrial	14736955	0	O
DNA	-	14	O
and	-	18	O
its	-	22	O
respiratory	-	26	O
chain	-	38	O
products	-	44	O
are	-	53	O
defective	-	57	O
in	-	67	O
doxorubicin	-	70	O
nephrosis	-	82	B
.	-	91	O

BACKGROUND	14736955	93	O
:	-	103	O

Doxorubicin	14736955	105	O
induces	-	117	O
a	-	125	O
self	-	127	O
-	-	131	O
perpetuating	-	132	O
nephropathy	-	145	B
characterized	-	157	O
by	-	171	O
early	-	174	O
glomerular	-	180	B
and	-	191	I
late	-	195	I
-	-	199	I
onset	-	200	I
tubular	-	206	I
lesions	-	214	I
in	-	222	O
rats	-	225	O
.	-	229	O

We	14736955	231	O
investigated	-	234	O
the	-	247	O
potential	-	251	O
role	-	261	O
of	-	266	O
mitochondrial	-	269	B
injury	-	283	I
in	-	290	O
the	-	293	O
onset	-	297	O
of	-	303	O
these	-	306	O
lesions	-	312	O
.	-	319	O

METHODS	14736955	321	O
:	-	328	O

Rats	14736955	330	O
were	-	335	O
treated	-	340	O
with	-	348	O
intravenous	-	353	O
doxorubicin	-	365	O
(	-	377	O
1	-	378	O
mg	-	380	O
kg	-	383	O
(	-	385	O
-	-	386	O
1	-	387	O
)	-	388	O
week	-	390	O
(	-	394	O
-	-	395	O
1	-	396	O
)	-	397	O
)	-	398	O
for	-	400	O
7	-	404	O
weeks	-	406	O
and	-	412	O
were	-	416	O
sacrificed	-	421	O
either	-	432	O
1	-	439	O
week	-	441	O
(	-	446	O
'	-	447	O
short	-	448	O
-	-	453	O
term	-	454	O
'	-	458	O
)	-	459	O
or	-	461	O
30	-	464	O
weeks	-	467	O
(	-	473	O
'	-	474	O
long	-	475	O
-	-	479	O
term	-	480	O
'	-	484	O
)	-	485	O
following	-	487	O
the	-	497	O
last	-	501	O
dose	-	506	O
.	-	510	O

Additional	14736955	512	O
rats	-	523	O
received	-	528	O
a	-	537	O
single	-	539	O
dose	-	546	O
either	-	551	O
6	-	558	O
days	-	560	O
or	-	565	O
2	-	568	O
h	-	570	O
prior	-	572	O
to	-	578	O
euthanasia	-	581	O
.	-	591	O

All	14736955	593	O
rats	-	597	O
were	-	602	O
killed	-	607	O
at	-	614	O
48	-	617	O
weeks	-	620	O
of	-	626	O
age	-	629	O
.	-	632	O

Glomerular	14736955	634	B
and	-	645	I
tubular	-	649	I
injury	-	657	I
was	-	664	O
monitored	-	668	O
and	-	678	O
correlated	-	682	O
to	-	693	O
the	-	696	O
activity	-	700	O
or	-	709	O
expression	-	712	O
of	-	723	O
respiratory	-	726	O
chain	-	738	O
components	-	744	O
.	-	754	O

Finally	14736955	756	O
,	-	763	O
we	-	765	O
quantified	-	768	O
both	-	779	O
nuclear	-	784	O
and	-	792	O
mitochondrial	-	796	O
DNA	-	810	O
(	-	814	O
mtDNA	-	815	O
)	-	820	O
as	-	822	O
well	-	825	O
as	-	830	O
superoxide	-	833	O
production	-	844	O
and	-	855	O
the	-	859	O
4834	-	863	O
base	-	868	O
pair	-	873	O
'	-	878	O
common	-	879	O
'	-	885	O
mtDNA	-	887	O
deletion	-	893	O
.	-	901	O

RESULTS	14736955	903	O
:	-	910	O

The	14736955	912	O
'	-	916	O
long	-	917	O
-	-	921	O
term	-	922	O
'	-	926	O
group	-	928	O
had	-	934	O
significant	-	938	O
glomerular	-	950	B
and	-	961	I
tubular	-	965	I
lesions	-	973	I
,	-	980	O
depressed	-	982	O
activities	-	992	O
of	-	1003	O
mtDNA	-	1006	O
-	-	1011	O
encoded	-	1012	O
NADH	-	1020	O
dehydrogenase	-	1025	O
and	-	1039	O
cytochrome	-	1043	O
-	-	1053	O
c	-	1054	O
oxidase	-	1056	O
(	-	1064	O
COX	-	1065	O
)	-	1068	O
and	-	1070	O
increased	-	1074	O
citrate	-	1084	O
synthase	-	1092	O
activity	-	1101	O
.	-	1109	O

In	14736955	1111	O
addition	-	1114	O
,	-	1122	O
expression	-	1124	O
of	-	1135	O
the	-	1138	O
mtDNA	-	1142	O
-	-	1147	O
encoded	-	1148	O
COX	-	1156	O
subunit	-	1160	O
I	-	1168	O
was	-	1170	O
reduced	-	1174	O
and	-	1182	O
mtDNA	-	1186	O
levels	-	1192	O
were	-	1199	O
decreased	-	1204	O
.	-	1213	O

In	14736955	1215	O
'	-	1218	O
short	-	1219	O
-	-	1224	O
term	-	1225	O
'	-	1229	O
rats	-	1231	O
,	-	1235	O
there	-	1237	O
were	-	1243	O
fewer	-	1248	O
tubular	-	1254	B
lesions	-	1262	I
,	-	1269	O
but	-	1271	O
similar	-	1275	O
numbers	-	1283	O
of	-	1291	O
glomerular	-	1294	B
lesions	-	1305	I
activity	-	1313	O
.	-	1321	O

Among	14736955	1323	O
all	-	1329	O
animals	-	1333	O
,	-	1340	O
glomerular	-	1342	B
and	-	1353	I
tubular	-	1357	I
injury	-	1365	I
were	-	1372	O
inversely	-	1377	O
correlated	-	1387	O
with	-	1398	O
mtDNA	-	1403	O
levels	-	1409	O
,	-	1415	O
mtDNA	-	1417	O
-	-	1422	O
encoded	-	1423	O
respiratory	-	1431	O
chain	-	1443	O
activities	-	1449	O
and	-	1460	O
with	-	1464	O
the	-	1469	O
expression	-	1473	O
of	-	1484	O
the	-	1487	O
mtDNA	-	1491	O
-	-	1496	O
encoded	-	1497	O
respiratory	-	1505	O
chain	-	1517	O
subunit	-	1523	O
COX	-	1531	O
-	-	1534	O
I	-	1535	O
.	-	1536	O
Injury	-	1538	O
was	-	1545	O
positively	-	1549	O
correlated	-	1560	O
with	-	1571	O
superoxide	-	1576	O
production	-	1587	O
and	-	1598	O
the	-	1602	O
activities	-	1606	O
of	-	1617	O
nucleus	-	1620	O
-	-	1627	O
encoded	-	1628	O
mitochondrial	-	1636	O
or	-	1650	O
cytoplasmic	-	1653	O
enzymes	-	1665	O
.	-	1672	O

Kidneys	14736955	1674	O
from	-	1682	O
the	-	1687	O
'	-	1691	O
long	-	1692	O
-	-	1696	O
term	-	1697	O
'	-	1701	O
group	-	1703	O
showed	-	1709	O
more	-	1716	O
mtDNA	-	1721	O
deletions	-	1727	O
than	-	1737	O
in	-	1742	O
'	-	1745	O
short	-	1746	O
-	-	1751	O
term	-	1752	O
'	-	1756	O
animals	-	1758	O
and	-	1766	O
these	-	1770	O
were	-	1776	O
not	-	1781	O
observed	-	1785	O
in	-	1794	O
the	-	1797	O
other	-	1801	O
groups	-	1807	O
.	-	1813	O

CONCLUSIONS	14736955	1815	O
:	-	1826	O

These	14736955	1828	O
results	-	1834	O
suggest	-	1842	O
an	-	1850	O
important	-	1853	O
role	-	1863	O
for	-	1868	O
quantitative	-	1872	O
and	-	1885	O
qualitative	-	1889	O
mtDNA	-	1901	O
alterations	-	1907	O
through	-	1919	O
the	-	1927	O
reduction	-	1931	O
of	-	1941	O
mtDNA	-	1944	O
-	-	1949	O
encoded	-	1950	O
respiratory	-	1958	O
chain	-	1970	O
function	-	1976	O
and	-	1985	O
induction	-	1989	O
of	-	1999	O
superoxide	-	2002	O
in	-	2013	O
doxorubicin	-	2016	O
-	-	2027	O
induced	-	2028	O
renal	-	2036	B
lesions	-	2042	I
.	-	2049	O

Amphotericin	11573852	0	O
B	-	13	O
-	-	14	O
induced	-	15	O
seizures	-	23	B
in	-	32	O
a	-	35	O
patient	-	37	O
with	-	45	O
AIDS	-	50	B
.	-	54	O

OBJECTIVE	11573852	56	O
:	-	65	O

To	11573852	67	O
report	-	70	O
a	-	77	O
case	-	79	O
of	-	84	O
multiple	-	87	O
episodes	-	96	O
of	-	105	O
seizure	-	108	B
activity	-	116	O
in	-	125	O
an	-	128	O
AIDS	-	131	B
patent	-	136	O
following	-	143	O
amphotericin	-	153	O
B	-	166	O
infusion	-	168	O
.	-	176	O

CASE	11573852	178	O
SUMMARY	-	183	O
:	-	190	O

A	11573852	192	O
46	-	194	O
-	-	196	O
year	-	197	O
-	-	201	O
old	-	202	O
African	-	206	O
-	-	213	O
American	-	214	O
man	-	223	O
experienced	-	227	O
recurrent	-	239	O
grand	-	249	B
mal	-	255	I
seizures	-	259	I
during	-	268	O
intravenous	-	275	O
infusion	-	287	O
of	-	296	O
amphotericin	-	299	O
B	-	312	O
,	-	313	O
then	-	315	O
petit	-	320	O
mal	-	326	O
seizures	-	330	B
as	-	339	O
the	-	342	O
infusion	-	346	O
was	-	355	O
stopped	-	359	O
and	-	367	O
the	-	371	O
drug	-	375	O
concentrations	-	380	O
decreased	-	395	O
with	-	405	O
time	-	410	O
.	-	414	O

The	11573852	416	O
patients	-	420	O
concurrent	-	429	O
medications	-	440	O
included	-	452	O
didanosine	-	461	O
,	-	471	O
hydroxyzine	-	473	O
,	-	484	O
promethazine	-	486	O
,	-	498	O
hydrocortisone	-	500	O
,	-	514	O
and	-	516	O
prochlorperazine	-	520	O
.	-	536	O

Despite	11573852	538	O
administration	-	546	O
of	-	561	O
phenytoin	-	564	O
and	-	574	O
lorazepam	-	578	O
,	-	587	O
the	-	589	O
seizures	-	593	B
persisted	-	602	O
and	-	612	O
occurred	-	616	O
only	-	625	O
during	-	630	O
amphotercin	-	637	O
B	-	649	O
administration	-	651	O
.	-	665	O

DISCUSSION	11573852	667	O
:	-	677	O

AIDS	11573852	679	B
and	-	684	O
cryptococcal	-	688	B
meningitis	-	701	I
,	-	711	O
both	-	713	O
of	-	718	O
which	-	721	O
the	-	727	O
patient	-	731	O
had	-	739	O
,	-	742	O
can	-	744	O
potentially	-	748	O
cause	-	760	O
seizures	-	766	B
.	-	774	O

The	11573852	776	O
patient	-	780	O
had	-	788	O
a	-	792	O
history	-	794	O
of	-	802	O
alcohol	-	805	B
abuse	-	813	I
;	-	818	O
alcohol	-	820	O
intake	-	828	O
as	-	835	O
well	-	838	O
as	-	843	O
withdrawal	-	846	O
can	-	857	O
also	-	861	O
cause	-	866	O
seizures	-	872	B
.	-	880	O

Didanosine	11573852	882	O
also	-	893	O
has	-	898	O
a	-	902	O
potential	-	904	O
for	-	914	O
inducing	-	918	O
seizures	-	927	B
.	-	935	O

However	11573852	937	O
,	-	944	O
these	-	946	O
other	-	952	O
potential	-	958	O
causes	-	968	O
of	-	975	O
seizure	-	978	B
were	-	986	O
ruled	-	991	O
out	-	997	O
.	-	1000	O

The	11573852	1002	O
time	-	1006	O
course	-	1011	O
of	-	1018	O
events	-	1021	O
suggested	-	1028	O
that	-	1038	O
amphotericin	-	1043	O
B	-	1056	O
was	-	1058	O
the	-	1062	O
cause	-	1066	O
of	-	1072	O
the	-	1075	O
seizures	-	1079	B
in	-	1088	O
this	-	1091	O
AIDS	-	1096	B
patient	-	1101	O
.	-	1108	O

CONCLUSIONS	11573852	1110	O
:	-	1121	O

Amphotericin	11573852	1123	O
B	-	1136	O
seems	-	1138	O
to	-	1144	O
be	-	1147	O
the	-	1150	O
probable	-	1154	O
cause	-	1163	O
of	-	1169	O
the	-	1172	O
seizures	-	1176	B
.	-	1184	O

To	11573852	1186	O
date	-	1189	O
,	-	1193	O
only	-	1195	O
three	-	1200	O
cases	-	1206	O
of	-	1212	O
seizures	-	1215	B
associated	-	1224	O
with	-	1235	O
amphotericin	-	1240	O
B	-	1253	O
have	-	1255	O
been	-	1260	O
reported	-	1265	O
in	-	1274	O
the	-	1277	O
literature	-	1281	O
,	-	1291	O
but	-	1293	O
healthcare	-	1297	O
providers	-	1308	O
should	-	1318	O
be	-	1325	O
aware	-	1328	O
of	-	1334	O
the	-	1337	O
potential	-	1341	O
for	-	1351	O
this	-	1355	O
rare	-	1360	O
adverse	-	1365	O
effect	-	1373	O
.	-	1379	O

Therapeutic	9875685	0	O
drug	-	12	O
monitoring	-	17	O
of	-	28	O
tobramycin	-	31	O
:	-	41	O
once	-	43	O
-	-	47	O
daily	-	48	O
versus	-	54	O
twice	-	61	O
-	-	66	O
daily	-	67	O
dosage	-	73	O
schedules	-	80	O
.	-	89	O

OBJECTIVE	9875685	91	O
:	-	100	O
To	-	102	O
evaluate	-	105	O
the	-	114	O
effect	-	118	O
of	-	125	O
dosage	-	128	O
regimen	-	135	O
(	-	143	O
once	-	144	O
-	-	148	O
daily	-	149	O
vs	-	155	O
.	-	157	O
twice	-	159	O
-	-	164	O
daily	-	165	O
)	-	170	O
of	-	172	O
tobramicyn	-	175	O
on	-	186	O
steady	-	189	O
-	-	195	O
state	-	196	O
serum	-	202	O
concentrations	-	208	O
and	-	223	O
toxicity	-	227	B
.	-	235	O

MATERIALS	9875685	237	O
AND	-	247	O
METHODS	-	251	O
:	-	258	O

Patients	9875685	260	O
undergoing	-	269	O
treatment	-	280	O
with	-	290	O
i	-	295	O
.	-	296	O
v	-	297	O
.	-	298	O

tobramycin	9875685	300	O
(	-	311	O
4	-	312	O
mg	-	314	O
/	-	316	O
kg	-	317	O
/	-	319	O
day	-	320	O
)	-	323	O
were	-	325	O
randomised	-	330	O
to	-	341	O
two	-	344	O
groups	-	348	O
.	-	354	O

Group	9875685	356	O
OD	-	362	O
(	-	365	O
n	-	366	O
=	-	368	O
22	-	370	O
)	-	372	O
received	-	374	O
a	-	383	O
once	-	385	O
-	-	389	O
daily	-	390	O
dose	-	396	O
of	-	401	O
tobramycin	-	404	O
and	-	415	O
group	-	419	O
TD	-	425	O
(	-	428	O
n	-	429	O
=	-	431	O
21	-	433	O
)	-	435	O
received	-	437	O
the	-	446	O
same	-	450	O
dose	-	455	O
divided	-	460	O
into	-	468	O
two	-	473	O
doses	-	477	O
daily	-	483	O
.	-	488	O

Tobramycin	9875685	490	O
serum	-	501	O
concentrations	-	507	O
(	-	522	O
peak	-	523	O
and	-	528	O
trough	-	532	O
)	-	538	O
were	-	540	O
measured	-	545	O
by	-	554	O
enzyme	-	557	O
multiplied	-	564	O
immunoassay	-	575	O
.	-	586	O

The	9875685	588	O
renal	-	592	O
and	-	598	O
auditory	-	602	O
functions	-	611	O
of	-	621	O
the	-	624	O
patients	-	628	O
were	-	637	O
monitored	-	642	O
before	-	652	O
,	-	658	O
during	-	660	O
and	-	667	O
immediately	-	671	O
after	-	683	O
treatment	-	689	O
.	-	698	O

RESULTS	9875685	700	O
:	-	707	O

The	9875685	709	O
two	-	713	O
groups	-	717	O
were	-	724	O
comparable	-	729	O
with	-	740	O
respect	-	745	O
to	-	753	O
sex	-	756	O
,	-	759	O
age	-	761	O
,	-	764	O
body	-	766	O
weight	-	771	O
and	-	778	O
renal	-	782	O
function	-	788	O
.	-	796	O

No	9875685	798	O
statistically	-	801	O
significant	-	815	O
differences	-	827	O
were	-	839	O
found	-	844	O
in	-	850	O
mean	-	853	O
daily	-	858	O
dose	-	864	O
,	-	868	O
duration	-	870	O
of	-	879	O
treatment	-	882	O
,	-	891	O
or	-	893	O
cumulative	-	896	O
dose	-	907	O
.	-	911	O

Trough	9875685	913	O
concentrations	-	920	O
were	-	935	O
<	-	940	O
2	-	942	O
g	-	944	O
/	-	945	O
ml	-	946	O
in	-	949	O
the	-	952	O
two	-	956	O
groups	-	960	O
(	-	967	O
100	-	968	O
%	-	971	O
)	-	972	O
.	-	973	O

Peak	9875685	975	O
concentrations	-	980	O
were	-	995	O
>	-	1000	O
6	-	1002	O
microg	-	1004	O
/	-	1010	O
ml	-	1011	O
in	-	1014	O
100	-	1017	O
%	-	1020	O
of	-	1022	O
the	-	1025	O
OD	-	1029	O
group	-	1032	O
and	-	1038	O
in	-	1042	O
67	-	1045	O
%	-	1047	O
of	-	1049	O
the	-	1052	O
TD	-	1056	O
group	-	1059	O
(	-	1065	O
P	-	1066	O
<	-	1067	O
0	-	1069	O
.	-	1070	O
01	-	1071	O
)	-	1073	O
.	-	1074	O

Mean	9875685	1076	O
peak	-	1081	O
concentrations	-	1086	O
were	-	1101	O
markedly	-	1106	O
different	-	1115	O
:	-	1124	O

11	9875685	1126	O
.	-	1128	O
00	-	1129	O
+	-	1131	O
/	-	1132	O
-	-	1133	O
2	-	1134	O
.	-	1135	O
89	-	1136	O
microg	-	1139	O
/	-	1145	O
ml	-	1146	O
in	-	1149	O
OD	-	1152	O
vs	-	1155	O
.	-	1157	O
6	-	1159	O
.	-	1160	O
53	-	1161	O
+	-	1163	O
/	-	1164	O
-	-	1165	O
1	-	1166	O
.	-	1167	O
45	-	1168	O
microg	-	1171	O
/	-	1177	O
ml	-	1178	O
in	-	1181	O
TD	-	1184	O
(	-	1187	O
P	-	1188	O
<	-	1189	O
0	-	1191	O
.	-	1192	O
01	-	1193	O
)	-	1195	O
.	-	1196	O

The	9875685	1198	O
pharmacokinetics	-	1202	O
parameters	-	1219	O
were	-	1230	O
:	-	1234	O
Ke	-	1236	O
,	-	1238	O
(	-	1240	O
0	-	1241	O
.	-	1242	O
15	-	1243	O
+	-	1245	O
/	-	1246	O
-	-	1247	O
0	-	1248	O
.	-	1249	O
03	-	1250	O
/	-	1252	O
h	-	1253	O
in	-	1255	O
OD	-	1258	O
vs	-	1261	O
.	-	1263	O
0	-	1265	O
.	-	1266	O
24	-	1267	O
+	-	1269	O
/	-	1270	O
-	-	1271	O
0	-	1272	O
.	-	1273	O
06	-	1274	O
/	-	1276	O
h	-	1277	O
in	-	1279	O
TD	-	1282	O
)	-	1284	O
,	-	1285	O
t1	-	1287	O
/	-	1289	O
2	-	1290	O
,	-	1291	O
(	-	1293	O
4	-	1294	O
.	-	1295	O
95	-	1296	O
+	-	1298	O
/	-	1299	O
-	-	1300	O
1	-	1301	O
.	-	1302	O
41	-	1303	O
h	-	1306	O
in	-	1308	O
OD	-	1311	O
vs	-	1314	O
.	-	1316	O
3	-	1318	O
.	-	1319	O
07	-	1320	O
+	-	1322	O
/	-	1323	O
-	-	1324	O
0	-	1325	O
.	-	1326	O
71	-	1327	O
h	-	1330	O
in	-	1332	O
TD	-	1335	O
)	-	1337	O
,	-	1338	O
Vd	-	1340	O
(	-	1343	O
0	-	1344	O
.	-	1345	O
35	-	1346	O
+	-	1348	O
/	-	1349	O
-	-	1350	O
0	-	1351	O
.	-	1352	O
11	-	1353	O
l	-	1356	O
/	-	1357	O
kg	-	1358	O
in	-	1361	O
OD	-	1364	O
vs	-	1367	O
.	-	1369	O
0	-	1371	O
.	-	1372	O
33	-	1373	O
+	-	1375	O
/	-	1376	O
-	-	1377	O
0	-	1378	O
.	-	1379	O
09	-	1380	O
l	-	1383	O
/	-	1384	O
kg	-	1385	O
in	-	1388	O
TD	-	1391	O
)	-	1393	O
,	-	1394	O
Cl	-	1396	O
(	-	1399	O
0	-	1400	O
.	-	1401	O
86	-	1402	O
+	-	1404	O
/	-	1405	O
-	-	1406	O
0	-	1407	O
.	-	1408	O
29	-	1409	O
ml	-	1412	O
/	-	1414	O
min	-	1415	O
/	-	1418	O
kg	-	1419	O
in	-	1422	O
OD	-	1425	O
vs	-	1428	O
.	-	1430	O
1	-	1432	O
.	-	1433	O
28	-	1434	O
+	-	1436	O
/	-	1437	O
-	-	1438	O
0	-	1439	O
.	-	1440	O
33	-	1441	O
ml	-	1444	O
/	-	1446	O
min	-	1447	O
/	-	1450	O
kg	-	1451	O
in	-	1454	O
TD	-	1457	O
)	-	1459	O
.	-	1460	O

Increased	9875685	1462	O
serum	-	1472	O
creatinine	-	1478	O
was	-	1489	O
observed	-	1493	O
in	-	1502	O
73	-	1505	O
%	-	1507	O
of	-	1509	O
patients	-	1512	O
in	-	1521	O
OD	-	1524	O
versus	-	1527	O
57	-	1534	O
%	-	1536	O
of	-	1538	O
patients	-	1541	O
in	-	1550	O
TD	-	1553	O
,	-	1555	O
without	-	1557	O
evidence	-	1565	O
of	-	1574	O
nephrotoxicity	-	1577	B
.	-	1591	O

In	9875685	1593	O
TD	-	1596	O
group	-	1599	O
,	-	1604	O
three	-	1606	O
patients	-	1612	O
developed	-	1621	O
decreased	-	1631	B
auditory	-	1641	I
function	-	1650	I
,	-	1658	O
of	-	1660	O
which	-	1663	O
one	-	1669	O
presented	-	1673	O
with	-	1683	O
an	-	1688	O
auditory	-	1691	B
loss	-	1700	I
of	-	1705	O
-	-	1708	O
30	-	1709	O
dB	-	1712	O
,	-	1714	O
whereas	-	1716	O
in	-	1724	O
the	-	1727	O
OD	-	1731	O
group	-	1734	O
only	-	1740	O
one	-	1745	O
patient	-	1749	O
presented	-	1757	O
decreased	-	1767	B
auditory	-	1777	I
function	-	1786	I
.	-	1794	O

CONCLUSION	9875685	1796	O
:	-	1806	O

This	9875685	1808	O
small	-	1813	O
study	-	1819	O
suggests	-	1825	O
that	-	1834	O
a	-	1839	O
once	-	1841	O
-	-	1845	O
daily	-	1846	O
dosing	-	1852	O
regimen	-	1859	O
of	-	1867	O
tobramycin	-	1870	O
is	-	1881	O
at	-	1884	O
least	-	1887	O
as	-	1893	O
effective	-	1896	O
as	-	1906	O
and	-	1909	O
is	-	1913	O
no	-	1916	O
more	-	1919	O
and	-	1924	O
possibly	-	1928	O
less	-	1937	O
toxic	-	1942	O
than	-	1948	O
the	-	1953	O
twice	-	1957	O
-	-	1962	O
daily	-	1963	O
regimen	-	1969	O
.	-	1976	O

Using	9875685	1978	O
a	-	1984	O
single	-	1986	O
-	-	1992	O
dose	-	1993	O
therapy	-	1998	O
,	-	2005	O
peak	-	2007	O
concentration	-	2012	O
determination	-	2026	O
is	-	2040	O
not	-	2043	O
necessary	-	2047	O
,	-	2056	O
only	-	2058	O
trough	-	2063	O
samples	-	2070	O
should	-	2078	O
be	-	2085	O
monitored	-	2088	O
to	-	2098	O
ensure	-	2101	O
levels	-	2108	O
below	-	2115	O
2	-	2121	O
microg	-	2123	O
/	-	2129	O
ml	-	2130	O
.	-	2132	O

Chronic	9848575	0	O
effects	-	8	O
of	-	16	O
a	-	19	O
novel	-	21	O
synthetic	-	27	O
anthracycline	-	37	O
derivative	-	51	O
(	-	62	O
SM	-	63	O
-	-	65	O
5887	-	66	O
)	-	70	O
on	-	72	O
normal	-	75	O
heart	-	82	O
and	-	88	O
doxorubicin	-	92	O
-	-	103	O
induced	-	104	O
cardiomyopathy	-	112	B
in	-	127	O
beagle	-	130	O
dogs	-	137	O
.	-	141	O

This	9848575	143	O
study	-	148	O
was	-	154	O
designed	-	158	O
to	-	167	O
investigate	-	170	O
the	-	182	O
chronic	-	186	O
cardiotoxic	-	194	B
potential	-	206	O
of	-	216	O
SM	-	219	O
-	-	221	O
5887	-	222	O
and	-	227	O
a	-	231	O
possible	-	233	O
deteriorating	-	242	O
effect	-	256	O
of	-	263	O
SM	-	266	O
-	-	268	O
5887	-	269	O
on	-	274	O
low	-	277	O
-	-	280	O
grade	-	281	O
cardiotoxicity	-	287	B
pre	-	302	O
-	-	305	O
induced	-	306	O
by	-	314	O
doxorubicin	-	317	O
in	-	329	O
beagle	-	332	O
dogs	-	339	O
.	-	343	O

In	9848575	345	O
the	-	348	O
chronic	-	352	O
treatment	-	360	O
,	-	369	O
beagle	-	371	O
dogs	-	378	O
of	-	383	O
each	-	386	O
sex	-	391	O
were	-	395	O
given	-	400	O
intravenously	-	406	O
once	-	420	O
every	-	425	O
3	-	431	O
weeks	-	433	O
,	-	438	O
either	-	440	O
a	-	447	O
sublethal	-	449	O
dose	-	459	O
of	-	464	O
doxorubicin	-	467	O
(	-	479	O
1	-	480	O
.	-	481	O
5	-	482	O
mg	-	484	O
/	-	486	O
kg	-	487	O
)	-	489	O
or	-	491	O
SM	-	494	O
-	-	496	O
5887	-	497	O
(	-	502	O
2	-	503	O
.	-	504	O
5	-	505	O
mg	-	507	O
/	-	509	O
kg	-	510	O
)	-	512	O
.	-	513	O

The	9848575	515	O
experiment	-	519	O
was	-	530	O
terminated	-	534	O
3	-	545	O
weeks	-	547	O
after	-	553	O
the	-	559	O
ninth	-	563	O
dosing	-	569	O
.	-	575	O

Animals	9848575	577	O
which	-	585	O
received	-	591	O
over	-	600	O
six	-	605	O
courses	-	609	O
of	-	617	O
doxorubicin	-	620	O
demonstrated	-	632	O
the	-	645	O
electrocardiogram	-	649	O
(	-	667	O
ECG	-	668	O
)	-	671	O
changes	-	673	O
,	-	680	O
decrease	-	682	O
of	-	691	O
blood	-	694	O
pressure	-	700	O
and	-	709	O
high	-	713	O
-	-	717	O
grade	-	718	O
histopathological	-	724	O
cardiomyopathy	-	742	B
,	-	756	O
while	-	758	O
animals	-	764	O
which	-	772	O
were	-	778	O
terminally	-	783	O
sacrificed	-	794	O
after	-	805	O
the	-	811	O
SM	-	815	O
-	-	817	O
5887	-	818	O
administration	-	823	O
did	-	838	O
not	-	842	O
show	-	846	O
any	-	851	O
changes	-	855	O
in	-	863	O
ECG	-	866	O
,	-	869	O
blood	-	871	O
pressure	-	877	O
and	-	886	O
histopathological	-	890	O
examinations	-	908	O
.	-	920	O

To	9848575	922	O
examine	-	925	O
a	-	933	O
possibly	-	935	O
deteriorating	-	944	O
cardiotoxic	-	958	B
effect	-	970	O
of	-	977	O
SM	-	980	O
-	-	982	O
5887	-	983	O
,	-	987	O
low	-	989	O
-	-	992	O
grade	-	993	O
cardiomyopathy	-	999	B
was	-	1014	O
induced	-	1018	O
in	-	1026	O
dogs	-	1029	O
by	-	1034	O
four	-	1037	O
courses	-	1042	O
of	-	1050	O
doxorubicin	-	1053	O
(	-	1065	O
1	-	1066	O
.	-	1067	O
5	-	1068	O
mg	-	1070	O
/	-	1072	O
kg	-	1073	O
)	-	1075	O
.	-	1076	O

Nine	9848575	1078	O
weeks	-	1083	O
after	-	1089	O
pre	-	1095	O
-	-	1098	O
treatment	-	1099	O
,	-	1108	O
dogs	-	1110	O
were	-	1115	O
given	-	1120	O
four	-	1126	O
courses	-	1131	O
of	-	1139	O
either	-	1142	O
doxorubicin	-	1149	O
(	-	1161	O
1	-	1162	O
.	-	1163	O
5	-	1164	O
mg	-	1166	O
/	-	1168	O
kg	-	1169	O
)	-	1171	O
or	-	1173	O
SM	-	1176	O
-	-	1178	O
5887	-	1179	O
(	-	1184	O
2	-	1185	O
.	-	1186	O
5	-	1187	O
mg	-	1189	O
/	-	1191	O
kg	-	1192	O
)	-	1194	O
once	-	1196	O
every	-	1201	O
3	-	1207	O
weeks	-	1209	O
.	-	1214	O

The	9848575	1216	O
low	-	1220	O
-	-	1223	O
grade	-	1224	O
cardiotoxic	-	1230	B
changes	-	1242	O
were	-	1250	O
enhanced	-	1255	O
by	-	1264	O
the	-	1267	O
additional	-	1271	O
doxorubicin	-	1282	O
treatment	-	1294	O
.	-	1303	O

On	9848575	1305	O
the	-	1308	O
contrary	-	1312	O
,	-	1320	O
the	-	1322	O
SM	-	1326	O
-	-	1328	O
5887	-	1329	O
treatment	-	1334	O
did	-	1344	O
not	-	1348	O
progress	-	1352	O
the	-	1361	O
grade	-	1365	O
of	-	1371	O
cardiomyopathy	-	1374	B
.	-	1388	O

In	9848575	1390	O
conclusion	-	1393	O
,	-	1403	O
SM	-	1405	O
-	-	1407	O
5887	-	1408	O
does	-	1413	O
not	-	1418	O
have	-	1422	O
any	-	1427	O
potential	-	1431	O
of	-	1441	O
chronic	-	1444	O
cardiotoxicity	-	1452	B
and	-	1467	O
deteriorating	-	1471	O
effect	-	1485	O
on	-	1492	O
doxorubicin	-	1495	O
-	-	1506	O
induced	-	1507	O
cardiotoxicity	-	1515	B
in	-	1530	O
dogs	-	1533	O
.	-	1537	O

Posteroventral	9321531	0	O
medial	-	15	O
pallidotomy	-	22	O
in	-	34	O
advanced	-	37	O
Parkinson	-	46	B
's	-	55	I
disease	-	58	I
.	-	65	O

BACKGROUND	9321531	67	O
:	-	77	O
Posteroventral	-	79	O
medial	-	94	O
pallidotomy	-	101	O
sometimes	-	113	O
produces	-	123	O
striking	-	132	O
improvement	-	141	O
in	-	153	O
patients	-	156	O
with	-	165	O
advanced	-	170	O
Parkinson	-	179	B
's	-	188	I
disease	-	191	I
,	-	198	O
but	-	200	O
the	-	204	O
studies	-	208	O
to	-	216	O
date	-	219	O
have	-	224	O
involved	-	229	O
small	-	238	O
numbers	-	244	O
of	-	252	O
patients	-	255	O
and	-	264	O
short	-	268	O
-	-	273	O
term	-	274	O
follow	-	279	O
-	-	285	O
up	-	286	O
.	-	288	O

METHODS	9321531	290	O
:	-	297	O

Forty	9321531	299	O
patients	-	305	O
with	-	314	O
Parkinson	-	319	B
's	-	328	I
disease	-	331	I
underwent	-	339	O
serial	-	349	O
,	-	355	O
detailed	-	357	O
assessments	-	366	O
both	-	378	O
after	-	383	O
drug	-	389	O
withdrawal	-	394	O
(	-	405	O
""""	-	406	O
off	-	407	O
""""	-	410	O
period	-	412	O
)	-	418	O
and	-	420	O
while	-	424	O
taking	-	430	O
their	-	437	O
optimal	-	443	O
medical	-	451	O
regimens	-	459	O
(	-	468	O
""""	-	469	O
on	-	470	O
""""	-	472	O
period	-	474	O
)	-	480	O
.	-	481	O

All	9321531	483	O
patients	-	487	O
were	-	496	O
examined	-	501	O
preoperatively	-	510	O
and	-	525	O
39	-	529	O
were	-	532	O
examined	-	537	O
at	-	546	O
six	-	549	O
months	-	553	O
;	-	559	O
27	-	561	O
of	-	564	O
the	-	567	O
patients	-	571	O
were	-	580	O
also	-	585	O
examined	-	590	O
at	-	599	O
one	-	602	O
year	-	606	O
,	-	610	O
and	-	612	O
11	-	616	O
at	-	619	O
two	-	622	O
years	-	626	O
.	-	631	O

RESULTS	9321531	633	O
:	-	640	O

The	9321531	642	O
percent	-	646	O
improvements	-	654	O
at	-	667	O
six	-	670	O
months	-	674	O
were	-	681	O
as	-	686	O
follows	-	689	O
:	-	696	O
off	-	698	O
-	-	701	O
period	-	702	O
score	-	709	O
for	-	715	O
overall	-	719	O
motor	-	727	O
function	-	733	O
,	-	741	O
28	-	743	O
percent	-	746	O
(	-	754	O
95	-	755	O
percent	-	758	O
confidence	-	766	O
interval	-	777	O
,	-	785	O
19	-	787	O
to	-	790	O
38	-	793	O
percent	-	796	O
)	-	803	O
,	-	804	O
with	-	806	O
most	-	811	O
of	-	816	O
the	-	819	O
improvement	-	823	O
in	-	835	O
the	-	838	O
contralateral	-	842	O
limbs	-	856	O
;	-	861	O
off	-	863	O
-	-	866	O
period	-	867	O
score	-	874	O
for	-	880	O
activities	-	884	O
of	-	895	O
daily	-	898	O
living	-	904	O
,	-	910	O
29	-	912	O
percent	-	915	O
(	-	923	O
95	-	924	O
percent	-	927	O
confidence	-	935	O
interval	-	946	O
,	-	954	O
19	-	956	O
to	-	959	O
39	-	962	O
percent	-	965	O
)	-	972	O
;	-	973	O
on	-	975	O
-	-	977	O
period	-	978	O
score	-	985	O
for	-	991	O
contralateral	-	995	O
dyskinesias	-	1009	B
,	-	1020	O
82	-	1022	O
percent	-	1025	O
(	-	1033	O
95	-	1034	O
percent	-	1037	O
confidence	-	1045	O
interval	-	1056	O
,	-	1064	O
72	-	1066	O
to	-	1069	O
91	-	1072	O
percent	-	1075	O
)	-	1082	O
;	-	1083	O
and	-	1085	O
on	-	1089	O
-	-	1091	O
period	-	1092	O
score	-	1099	O
for	-	1105	O
ipsilateral	-	1109	O
dyskinesias	-	1121	B
,	-	1132	O
44	-	1134	O
percent	-	1137	O
(	-	1145	O
95	-	1146	O
percent	-	1149	O
confidence	-	1157	O
interval	-	1168	O
,	-	1176	O
29	-	1178	O
to	-	1181	O
59	-	1184	O
percent	-	1187	O
)	-	1194	O
.	-	1195	O

The	9321531	1197	O
improvements	-	1201	O
in	-	1214	O
dyskinesias	-	1217	B
and	-	1229	O
the	-	1233	O
total	-	1237	O
scores	-	1243	O
for	-	1250	O
off	-	1254	O
-	-	1257	O
period	-	1258	O
parkinsonism	-	1265	B
,	-	1277	O
contralateral	-	1279	O
bradykinesia	-	1293	B
,	-	1305	O
and	-	1307	O
rigidity	-	1311	B
were	-	1320	O
sustained	-	1325	O
in	-	1335	O
the	-	1338	O
11	-	1342	O
patients	-	1345	O
examined	-	1354	O
at	-	1363	O
two	-	1366	O
years	-	1370	O
.	-	1375	O

The	9321531	1377	O
improvement	-	1381	O
in	-	1393	O
ipsilateral	-	1396	O
dyskinesias	-	1408	B
was	-	1420	O
lost	-	1424	O
after	-	1429	O
one	-	1435	O
year	-	1439	O
,	-	1443	O
and	-	1445	O
the	-	1449	O
improvements	-	1453	O
in	-	1466	O
postural	-	1469	O
stability	-	1478	O
and	-	1488	O
gait	-	1492	O
lasted	-	1497	O
only	-	1504	O
three	-	1509	O
to	-	1515	O
six	-	1518	O
months	-	1522	O
.	-	1528	O

Approximately	9321531	1530	O
half	-	1544	O
the	-	1549	O
patients	-	1553	O
who	-	1562	O
had	-	1566	O
been	-	1570	O
dependent	-	1575	O
on	-	1585	O
assistance	-	1588	O
in	-	1599	O
activities	-	1602	O
of	-	1613	O
daily	-	1616	O
living	-	1622	O
in	-	1629	O
the	-	1632	O
off	-	1636	O
period	-	1640	O
before	-	1647	O
surgery	-	1654	O
became	-	1662	O
independent	-	1669	O
after	-	1681	O
surgery	-	1687	O
.	-	1694	O

The	9321531	1696	O
complications	-	1700	O
of	-	1714	O
surgery	-	1717	O
were	-	1725	O
generally	-	1730	O
well	-	1740	O
tolerated	-	1745	O
,	-	1754	O
and	-	1756	O
there	-	1760	O
were	-	1766	O
no	-	1771	O
significant	-	1774	O
changes	-	1786	O
in	-	1794	O
the	-	1797	O
use	-	1801	O
of	-	1805	O
medication	-	1808	O
.	-	1818	O

CONCLUSIONS	9321531	1820	O
:	-	1831	O

In	9321531	1833	O
late	-	1836	O
-	-	1840	O
stage	-	1841	O
Parkinson	-	1847	B
's	-	1856	I
disease	-	1859	I
,	-	1866	O
pallidotomy	-	1868	O
significantly	-	1880	O
reduces	-	1894	O
levodopa	-	1902	O
-	-	1910	O
induced	-	1911	O
dyskinesias	-	1919	B
and	-	1931	O
off	-	1935	O
-	-	1938	O
period	-	1939	O
disability	-	1946	O
.	-	1956	O

Much	9321531	1958	O
of	-	1963	O
the	-	1966	O
benefit	-	1970	O
is	-	1978	O
sustained	-	1981	O
at	-	1991	O
two	-	1994	O
years	-	1998	O
,	-	2003	O
although	-	2005	O
some	-	2014	O
improvements	-	2019	O
,	-	2031	O
such	-	2033	O
as	-	2038	O
those	-	2041	O
on	-	2047	O
the	-	2050	O
ipsilateral	-	2054	O
side	-	2066	O
and	-	2071	O
in	-	2075	O
axial	-	2078	O
symptoms	-	2084	O
,	-	2092	O
wane	-	2094	O
within	-	2099	O
the	-	2106	O
first	-	2110	O
year	-	2116	O
.	-	2120	O

The	9321531	2122	O
on	-	2126	O
-	-	2128	O
period	-	2129	O
symptoms	-	2136	O
that	-	2145	O
are	-	2150	O
resistant	-	2154	O
to	-	2164	O
dopaminergic	-	2167	O
therapy	-	2180	O
do	-	2188	O
not	-	2191	O
respond	-	2195	O
to	-	2203	O
pallidotomy	-	2206	O
.	-	2217	O

Neuropeptide	9305828	0	O
-	-	12	O
Y	-	13	O
immunoreactivity	-	15	O
in	-	32	O
the	-	35	O
pilocarpine	-	39	O
model	-	51	O
of	-	57	O
temporal	-	60	B
lobe	-	69	I
epilepsy	-	74	I
.	-	82	O

Neuropeptide	9305828	84	O
-	-	96	O
Y	-	97	O
(	-	99	O
NPY	-	100	O
)	-	103	O
is	-	105	O
expressed	-	108	O
by	-	118	O
granule	-	121	O
cells	-	129	O
and	-	135	O
mossy	-	139	O
fibres	-	145	O
of	-	152	O
the	-	155	O
hippocampal	-	159	O
dentate	-	171	O
gyrus	-	179	O
during	-	185	O
experimental	-	192	O
temporal	-	205	B
lobe	-	214	I
epilepsy	-	219	I
(	-	228	O
TLE	-	229	B
)	-	232	O
.	-	233	O

This	9305828	235	O
expression	-	240	O
may	-	251	O
represent	-	255	O
an	-	265	O
endogenous	-	268	O
damping	-	279	O
mechanism	-	287	O
since	-	297	O
NPY	-	303	O
has	-	307	O
been	-	311	O
shown	-	316	O
to	-	322	O
block	-	325	O
seizure	-	331	B
-	-	338	O
like	-	339	O
events	-	344	O
following	-	351	O
high	-	361	O
-	-	365	O
frequency	-	366	O
stimulation	-	376	O
in	-	388	O
hippocampal	-	391	O
slices	-	403	O
.	-	409	O

The	9305828	411	O
pilocarpine	-	415	O
(	-	427	O
PILO	-	428	O
)	-	432	O
model	-	434	O
of	-	440	O
epilepsy	-	443	B
is	-	452	O
characterized	-	455	O
by	-	469	O
an	-	472	O
acute	-	475	O
period	-	481	O
of	-	488	O
status	-	491	B
epilepticus	-	498	I
followed	-	510	O
by	-	519	O
spontaneous	-	522	O
recurrent	-	534	O
seizures	-	544	B
and	-	553	O
related	-	557	O
brain	-	565	B
damage	-	571	I
.	-	577	O

We	9305828	579	O
report	-	582	O
peroxidase	-	589	O
-	-	599	O
antiperoxidase	-	600	O
immunostaining	-	615	O
for	-	630	O
NPY	-	634	O
in	-	638	O
several	-	641	O
brain	-	649	O
regions	-	655	O
in	-	663	O
this	-	666	O
model	-	671	O
.	-	676	O

PILO	9305828	678	O
-	-	682	O
injected	-	683	O
animals	-	692	O
exhibited	-	700	O
NPY	-	710	O
immunoreactivity	-	714	O
in	-	731	O
the	-	734	O
region	-	738	O
of	-	745	O
the	-	748	O
mossy	-	752	O
fibre	-	758	O
terminals	-	764	O
,	-	773	O
in	-	775	O
the	-	778	O
dentate	-	782	O
gyrus	-	790	O
inner	-	796	O
molecular	-	802	O
layer	-	812	O
and	-	818	O
,	-	821	O
in	-	823	O
a	-	826	O
few	-	828	O
cases	-	832	O
,	-	837	O
within	-	839	O
presumed	-	846	O
granule	-	855	O
cells	-	863	O
.	-	868	O

NPY	9305828	870	O
immunoreactivity	-	874	O
was	-	891	O
also	-	895	O
dramatically	-	900	O
changed	-	913	O
in	-	921	O
the	-	924	O
entorhinal	-	928	O
cortex	-	939	O
,	-	945	O
amygdala	-	947	O
and	-	956	O
sensorimotor	-	960	O
areas	-	973	O
.	-	978	O

In	9305828	980	O
addition	-	983	O
,	-	991	O
PILO	-	993	O
injected	-	998	O
animals	-	1007	O
exhibited	-	1015	O
a	-	1025	O
reduction	-	1027	O
in	-	1037	O
the	-	1040	O
number	-	1044	O
of	-	1051	O
NPY	-	1054	O
-	-	1057	O
immunoreactive	-	1058	O
interneurons	-	1073	O
compared	-	1086	O
with	-	1095	O
controls	-	1100	O
.	-	1108	O

The	9305828	1110	O
results	-	1114	O
demonstrate	-	1122	O
that	-	1134	O
changes	-	1139	O
in	-	1147	O
NPY	-	1150	O
expression	-	1154	O
,	-	1164	O
including	-	1166	O
expression	-	1176	O
in	-	1187	O
the	-	1190	O
granule	-	1194	O
cells	-	1202	O
and	-	1208	O
mossy	-	1212	O
fibres	-	1218	O
and	-	1225	O
the	-	1229	O
loss	-	1233	O
of	-	1238	O
vulnerable	-	1241	O
NPY	-	1252	O
neurons	-	1256	O
,	-	1263	O
are	-	1265	O
present	-	1269	O
in	-	1277	O
the	-	1280	O
PILO	-	1284	O
model	-	1289	O
of	-	1295	O
TLE	-	1298	B
.	-	1301	O

However	9305828	1303	O
,	-	1310	O
the	-	1312	O
significance	-	1316	O
of	-	1329	O
this	-	1332	O
changed	-	1337	O
synthesis	-	1345	O
of	-	1355	O
NPY	-	1358	O
remains	-	1362	O
to	-	1370	O
be	-	1373	O
determined	-	1376	O
.	-	1386	O

Effect	9041081	0	O
of	-	7	O
myopic	-	10	O
excimer	-	17	O
laser	-	25	O
photorefractive	-	31	O
keratectomy	-	47	O
on	-	59	O
the	-	62	O
electrophysiologic	-	66	O
function	-	85	O
of	-	94	O
the	-	97	O
retina	-	101	O
and	-	108	O
optic	-	112	O
nerve	-	118	O
.	-	123	O

PURPOSE	9041081	125	O
:	-	132	O

To	9041081	134	O
assess	-	137	O
by	-	144	O
electrophysiologic	-	147	O
testing	-	166	O
the	-	174	O
effect	-	178	O
of	-	185	O
photorefractive	-	188	O
keratectomy	-	204	O
(	-	216	O
PRK	-	217	O
)	-	220	O
on	-	222	O
the	-	225	O
retina	-	229	O
and	-	236	O
optic	-	240	O
nerve	-	246	O
.	-	251	O

SETTING	9041081	253	O
:	-	260	O

Eye	9041081	262	O
Clinic	-	266	O
,	-	272	O
S	-	274	O
.	-	275	O
Salvatore	-	277	O
Hospital	-	287	O
,	-	295	O
L'Aquila	-	297	O
University	-	306	O
,	-	316	O
Italy	-	318	O
.	-	323	O

METHODS	9041081	325	O
:	-	332	O

Standard	9041081	334	O
pattern	-	343	O
electroretinograms	-	351	O
(	-	370	O
P	-	371	O
-	-	372	O
ERGs	-	373	O
)	-	377	O
and	-	379	O
standard	-	383	O
pattern	-	392	O
visual	-	400	O
evoked	-	407	O
potentials	-	414	O
(	-	425	O
P	-	426	O
-	-	427	O
VEPs	-	428	O
)	-	432	O
were	-	434	O
done	-	439	O
in	-	444	O
25	-	447	O
eyes	-	450	O
of	-	455	O
25	-	458	O
patients	-	461	O
who	-	470	O
had	-	474	O
myopic	-	478	O
PRK	-	485	O
for	-	489	O
an	-	493	O
attempted	-	496	O
correction	-	506	O
between	-	517	O
5	-	525	O
.	-	526	O
00	-	527	O
and	-	530	O
15	-	534	O
.	-	536	O
00	-	537	O
diopters	-	540	O
(	-	549	O
D	-	550	O
)	-	551	O
(	-	553	O
mean	-	554	O
8	-	559	O
.	-	560	O
00	-	561	O
D	-	564	O
)	-	565	O
.	-	566	O

Testing	9041081	568	O
was	-	576	O
done	-	580	O
preoperatively	-	585	O
and	-	600	O
3	-	604	O
,	-	605	O
6	-	607	O
,	-	608	O
12	-	610	O
,	-	612	O
and	-	614	O
18	-	618	O
months	-	621	O
postoperatively	-	628	O
.	-	643	O

The	9041081	645	O
contralateral	-	649	O
eyes	-	663	O
served	-	668	O
as	-	675	O
controls	-	678	O
.	-	686	O

During	9041081	688	O
the	-	695	O
follow	-	699	O
-	-	705	O
up	-	706	O
,	-	708	O
3	-	710	O
patients	-	712	O
(	-	721	O
12	-	722	O
%	-	724	O
)	-	725	O
developed	-	727	O
steroid	-	737	O
-	-	744	O
induced	-	745	O
elevated	-	753	B
intraocular	-	762	I
pressure	-	774	I
(	-	783	O
IOP	-	784	O
)	-	787	O
that	-	789	O
resolved	-	794	O
after	-	803	O
corticosteroid	-	809	O
therapy	-	824	O
was	-	832	O
discontinued	-	836	O
.	-	848	O

RESULTS	9041081	850	O
:	-	857	O

No	9041081	859	O
statistically	-	862	O
significant	-	876	O
differences	-	888	O
were	-	900	O
seen	-	905	O
between	-	910	O
treated	-	918	O
and	-	926	O
control	-	930	O
eyes	-	938	O
nor	-	943	O
between	-	947	O
treated	-	955	O
eyes	-	963	O
preoperatively	-	968	O
and	-	983	O
postoperatively	-	987	O
.	-	1002	O

CONCLUSION	9041081	1004	O
:	-	1014	O

Myopic	9041081	1016	O
excimer	-	1023	O
laser	-	1031	O
PRK	-	1037	O
did	-	1041	O
not	-	1045	O
seem	-	1049	O
to	-	1054	O
affect	-	1057	O
the	-	1064	O
posterior	-	1068	O
segment	-	1078	O
.	-	1085	O

The	9041081	1087	O
transient	-	1091	O
steroid	-	1101	O
-	-	1108	O
induced	-	1109	O
IOP	-	1117	B
rise	-	1121	I
did	-	1126	O
not	-	1130	O
seem	-	1134	O
to	-	1139	O
cause	-	1142	O
functional	-	1148	O
impairment	-	1159	O
.	-	1169	O

Liposomal	8305357	0	O
daunorubicin	-	10	O
in	-	23	O
advanced	-	26	O
Kaposi	-	35	B
's	-	41	I
sarcoma	-	44	I
:	-	51	O
a	-	53	O
phase	-	55	O
II	-	61	O
study	-	64	O
.	-	69	O

We	8305357	71	O
report	-	74	O
a	-	81	O
non	-	83	O
-	-	86	O
randomized	-	87	O
Phase	-	98	O
II	-	104	O
clinical	-	107	O
trial	-	116	O
to	-	122	O
assess	-	125	O
the	-	132	O
efficacy	-	136	O
and	-	145	O
safety	-	149	O
of	-	156	O
liposomal	-	159	O
daunorubicin	-	169	O
(	-	182	O
DaunoXome	-	183	O
)	-	192	O
in	-	194	O
the	-	197	O
treatment	-	201	O
of	-	211	O
AIDS	-	214	B
related	-	219	O
Kaposi	-	227	B
's	-	233	I
sarcoma	-	236	I
.	-	243	O

Eleven	8305357	245	O
homosexual	-	252	O
men	-	263	O
with	-	267	O
advanced	-	272	O
Kaposi	-	281	B
's	-	287	I
sarcoma	-	290	I
were	-	298	O
entered	-	303	O
in	-	311	O
the	-	314	O
trial	-	318	O
.	-	323	O

Changes	8305357	325	O
in	-	333	O
size	-	336	O
,	-	340	O
colour	-	342	O
and	-	349	O
associated	-	353	O
oedema	-	364	B
of	-	371	O
selected	-	374	O
'	-	383	O
target	-	384	O
'	-	390	O
lesions	-	392	O
were	-	400	O
measured	-	405	O
.	-	413	O

Clinical	8305357	415	O
,	-	423	O
biochemical	-	425	O
and	-	437	O
haematological	-	441	O
toxicities	-	456	B
were	-	467	O
assessed	-	472	O
.	-	480	O

Ten	8305357	482	O
subjects	-	486	O
were	-	495	O
evaluated	-	500	O
.	-	509	O

A	8305357	511	O
partial	-	513	O
response	-	521	O
was	-	530	O
achieved	-	534	O
in	-	543	O
four	-	546	O
,	-	550	O
of	-	552	O
whom	-	555	O
two	-	560	O
subsequently	-	564	O
relapsed	-	577	O
.	-	585	O

Stabilization	8305357	587	O
of	-	601	O
Kaposi	-	604	B
's	-	610	I
sarcoma	-	613	I
occurred	-	621	O
in	-	630	O
the	-	633	O
remaining	-	637	O
six	-	647	O
,	-	650	O
maintained	-	652	O
until	-	663	O
the	-	669	O
end	-	673	O
of	-	677	O
the	-	680	O
trial	-	684	O
period	-	690	O
in	-	697	O
four	-	700	O
.	-	704	O

The	8305357	706	O
drug	-	710	O
was	-	715	O
generally	-	719	O
well	-	729	O
tolerated	-	734	O
,	-	743	O
with	-	745	O
few	-	750	O
mild	-	754	O
symptoms	-	759	O
of	-	768	O
toxicity	-	771	B
.	-	779	O

The	8305357	781	O
main	-	785	O
problem	-	790	O
encountered	-	798	O
was	-	810	O
haematological	-	814	O
toxicity	-	829	B
,	-	837	O
with	-	839	O
three	-	844	O
subjects	-	850	O
experiencing	-	859	O
severe	-	872	O
neutropenia	-	879	B
(	-	891	O
neutrophil	-	892	O
count	-	903	O
<	-	909	O
0	-	911	O
.	-	912	O
5	-	913	O
x	-	915	O
10	-	917	O
(	-	919	O
9	-	920	O
)	-	921	O
/	-	922	O
l	-	923	O
)	-	924	O
.	-	925	O

There	8305357	927	O
was	-	933	O
no	-	937	O
evidence	-	940	O
of	-	949	O
cardiotoxicity	-	952	B
.	-	966	O

In	8305357	968	O
this	-	971	O
small	-	976	O
patient	-	982	O
sample	-	990	O
,	-	996	O
liposomal	-	998	O
daunorubicin	-	1008	O
was	-	1021	O
an	-	1025	O
effective	-	1028	O
and	-	1038	O
well	-	1042	O
tolerated	-	1047	O
agent	-	1057	O
in	-	1063	O
the	-	1066	O
treatment	-	1070	O
of	-	1080	O
Kaposi	-	1083	B
's	-	1089	I
sarcoma	-	1092	I
.	-	1099	O

Failure	8012887	0	O
of	-	8	O
ancrod	-	11	O
in	-	18	O
the	-	21	O
treatment	-	25	O
of	-	35	O
heparin	-	38	O
-	-	45	O
induced	-	46	O
arterial	-	54	O
thrombosis	-	63	B
.	-	73	O

The	8012887	75	O
morbidity	-	79	O
and	-	89	O
mortality	-	93	O
associated	-	103	O
with	-	114	O
heparin	-	119	O
-	-	126	O
induced	-	127	O
thrombosis	-	135	B
remain	-	146	O
high	-	153	O
despite	-	158	O
numerous	-	166	O
empirical	-	175	O
therapies	-	185	O
.	-	194	O

Ancrod	8012887	196	O
has	-	203	O
been	-	207	O
used	-	212	O
successfully	-	217	O
for	-	230	O
prophylaxis	-	234	O
against	-	246	O
development	-	254	O
of	-	266	O
thrombosis	-	269	B
in	-	280	O
patients	-	283	O
with	-	292	O
heparin	-	297	O
induced	-	305	O
platelet	-	313	B
aggregation	-	322	I
who	-	334	O
require	-	338	O
brief	-	346	O
reexposure	-	352	O
to	-	363	O
heparin	-	366	O
,	-	373	O
but	-	375	O
its	-	379	O
success	-	383	O
in	-	391	O
patients	-	394	O
who	-	403	O
have	-	407	O
developed	-	412	O
the	-	422	O
thrombosis	-	426	B
syndrome	-	437	O
is	-	446	O
not	-	449	O
well	-	453	O
defined	-	458	O
.	-	465	O

The	8012887	467	O
authors	-	471	O
present	-	479	O
a	-	487	O
case	-	489	O
of	-	494	O
failure	-	497	O
of	-	505	O
ancrod	-	508	O
treatment	-	515	O
in	-	525	O
a	-	528	O
patient	-	530	O
with	-	538	O
heparin	-	543	O
-	-	550	O
induced	-	551	O
thrombosis	-	559	B
.	-	569	O

Seizure	7651879	0	B
after	-	8	O
flumazenil	-	14	O
administration	-	25	O
in	-	40	O
a	-	43	O
pediatric	-	45	O
patient	-	55	O
.	-	62	O

Flumazenil	7651879	64	O
is	-	75	O
a	-	78	O
benzodiazepine	-	80	O
receptor	-	95	O
antagonist	-	104	O
used	-	115	O
to	-	120	O
reverse	-	123	O
sedation	-	131	O
and	-	140	O
respiratory	-	144	B
depression	-	156	I
induced	-	167	O
by	-	175	O
benzodiazepines	-	178	O
.	-	193	O

Seizures	7651879	195	B
and	-	204	O
cardiac	-	208	B
arrhythmias	-	216	I
have	-	228	O
complicated	-	233	O
its	-	245	O
use	-	249	O
in	-	253	O
adult	-	256	O
patients	-	262	O
.	-	270	O

Overdose	7651879	272	B
patients	-	281	O
who	-	290	O
have	-	294	O
coingested	-	299	O
tricyclic	-	310	O
antidepressants	-	320	O
have	-	336	O
a	-	341	O
higher	-	343	O
risk	-	350	O
of	-	355	O
these	-	358	O
complications	-	364	O
.	-	377	O

Little	7651879	379	O
information	-	386	O
exists	-	398	O
concerning	-	405	O
adverse	-	416	O
effects	-	424	O
of	-	432	O
flumazenil	-	435	O
in	-	446	O
children	-	449	O
.	-	457	O

We	7651879	459	O
report	-	462	O
the	-	469	O
occurrence	-	473	O
of	-	484	O
a	-	487	O
generalized	-	489	O
tonic	-	501	B
-	-	506	I
clonic	-	507	I
seizure	-	514	I
in	-	522	O
a	-	525	O
pediatric	-	527	O
patient	-	537	O
following	-	545	O
the	-	555	O
administration	-	559	O
of	-	574	O
flumazenil	-	577	O
.	-	587	O

Remodelling	3015327	0	O
of	-	12	O
nerve	-	15	O
structure	-	21	O
in	-	31	O
experimental	-	34	O
isoniazid	-	47	O
neuropathy	-	57	B
in	-	68	O
the	-	71	O
rat	-	75	O
.	-	78	O

The	3015327	80	O
neuropathy	-	84	B
caused	-	95	O
by	-	102	O
a	-	105	O
single	-	107	O
dose	-	114	O
of	-	119	O
isoniazid	-	122	O
in	-	132	O
rats	-	135	O
was	-	140	O
studied	-	144	O
with	-	152	O
a	-	157	O
computer	-	159	O
-	-	167	O
assisted	-	168	O
morphometric	-	177	O
method	-	190	O
.	-	196	O

Scatter	3015327	198	O
diagrams	-	206	O
of	-	215	O
the	-	218	O
g	-	222	O
ratio	-	224	O
(	-	230	O
quotient	-	231	O
fibre	-	240	O
diameter	-	246	O
/	-	254	O
axon	-	255	O
diameter	-	260	O
)	-	268	O
define	-	270	O
regenerating	-	277	O
fibres	-	290	O
as	-	297	O
a	-	300	O
distinct	-	302	O
population	-	311	O
,	-	321	O
distinguishable	-	323	O
from	-	339	O
the	-	344	O
surviving	-	348	O
fibres	-	358	O
by	-	365	O
reduced	-	368	O
sheath	-	376	O
thickness	-	383	O
and	-	393	O
reduced	-	397	O
axon	-	405	O
calibre	-	410	O
.	-	417	O

There	3015327	419	O
was	-	425	O
also	-	429	O
evidence	-	434	O
of	-	443	O
a	-	446	O
subtle	-	448	O
direct	-	455	O
toxic	-	462	O
effect	-	468	O
on	-	475	O
the	-	478	O
entire	-	482	O
fibre	-	489	O
population	-	495	O
,	-	505	O
causing	-	507	O
axon	-	515	O
shrinkage	-	520	O
masked	-	530	O
by	-	537	O
readjustment	-	540	O
of	-	553	O
the	-	556	O
myelin	-	560	O
sheath	-	567	O
.	-	573	O

Selective	2980315	0	O
injection	-	10	O
of	-	20	O
iopentol	-	23	O
,	-	31	O
iohexol	-	33	O
and	-	41	O
metrizoate	-	45	O
into	-	56	O
the	-	61	O
left	-	65	O
coronary	-	70	O
artery	-	79	O
of	-	86	O
the	-	89	O
dog	-	93	O
.	-	96	O

Induction	2980315	98	O
of	-	108	O
ventricular	-	111	B
fibrillation	-	123	I
and	-	136	O
decrease	-	140	O
of	-	149	O
aortic	-	152	O
pressure	-	159	O
.	-	167	O

In	2980315	169	O
twenty	-	172	O
beagle	-	179	O
dogs	-	186	O
selective	-	191	O
injections	-	201	O
were	-	212	O
made	-	217	O
into	-	222	O
the	-	227	O
left	-	231	O
coronary	-	236	O
artery	-	245	O
with	-	252	O
iopentol	-	257	O
,	-	265	O
iohexol	-	267	O
and	-	275	O
metrizoate	-	279	O
in	-	290	O
doses	-	293	O
of	-	299	O
4	-	302	O
ml	-	304	O
,	-	306	O
8	-	308	O
ml	-	310	O
and	-	313	O
16	-	317	O
ml	-	320	O
.	-	322	O

Thirty	2980315	324	O
-	-	330	O
six	-	331	O
iopentol	-	335	O
injections	-	344	O
,	-	354	O
35	-	356	O
iohexol	-	359	O
injections	-	367	O
and	-	378	O
37	-	382	O
metrizoate	-	385	O
injections	-	396	O
were	-	407	O
made	-	412	O
.	-	416	O

Frequencies	2980315	418	O
of	-	430	O
ventricular	-	433	B
fibrillation	-	445	I
were	-	458	O
significantly	-	463	O
lower	-	477	O
(	-	483	O
p	-	484	O
less	-	486	O
than	-	491	O
0	-	496	O
.	-	497	O
05	-	498	O
)	-	500	O
after	-	502	O
iopentol	-	508	O
(	-	517	O
0	-	518	O
%	-	519	O
)	-	520	O
and	-	522	O
iohexol	-	526	O
(	-	534	O
3	-	535	O
%	-	536	O
)	-	537	O
than	-	539	O
after	-	544	O
metrizoate	-	550	O
(	-	561	O
22	-	562	O
%	-	564	O
)	-	565	O
.	-	566	O

Iopentol	2980315	568	O
and	-	577	O
iohexol	-	581	O
also	-	589	O
produced	-	594	O
significantly	-	603	O
less	-	617	O
decrease	-	622	O
in	-	631	O
aortic	-	634	O
blood	-	641	O
pressure	-	647	O
than	-	656	O
metrizoate	-	661	O
at	-	672	O
the	-	675	O
different	-	679	O
doses	-	689	O
.	-	694	O

Magnetic	2819587	0	O
resonance	-	9	O
imaging	-	19	O
of	-	27	O
cerebral	-	30	O
venous	-	39	B
thrombosis	-	46	I
secondary	-	57	O
to	-	67	O
""""	-	70	O
low	-	71	O
-	-	74	O
dose	-	75	O
""""	-	79	O
birth	-	81	O
control	-	87	O
pills	-	95	O
.	-	100	O

The	2819587	102	O
clinical	-	106	O
and	-	115	O
radiographic	-	119	O
features	-	132	O
of	-	141	O
cerebral	-	144	O
deep	-	153	B
venous	-	158	I
thrombosis	-	165	I
in	-	176	O
a	-	179	O
21	-	181	O
-	-	183	O
year	-	184	O
-	-	188	O
old	-	189	O
white	-	193	O
woman	-	199	O
are	-	205	O
presented	-	209	O
.	-	218	O

This	2819587	220	O
nulliparous	-	225	O
patient	-	237	O
presented	-	245	O
with	-	255	O
relatively	-	260	O
mild	-	271	O
clinical	-	276	O
symptoms	-	285	O
and	-	294	O
progressing	-	298	O
mental	-	310	O
status	-	317	O
changes	-	324	O
.	-	331	O

The	2819587	333	O
only	-	337	O
known	-	342	O
risk	-	348	O
factor	-	353	O
was	-	360	O
""""	-	364	O
low	-	365	O
-	-	368	O
dose	-	369	O
""""	-	373	O
oral	-	375	O
contraceptive	-	380	O
pills	-	394	O
.	-	399	O

The	2819587	401	O
magnetic	-	405	O
resonance	-	414	O
image	-	424	O
(	-	430	O
MRI	-	431	O
)	-	434	O
showed	-	436	O
increased	-	443	O
signal	-	453	O
intensity	-	460	O
from	-	470	O
the	-	475	O
internal	-	479	O
cerebral	-	488	O
veins	-	497	O
,	-	502	O
vein	-	504	O
of	-	509	O
Galen	-	512	O
,	-	517	O
and	-	519	O
straight	-	523	O
sinus	-	532	O
.	-	537	O

The	2819587	539	O
diagnosis	-	543	O
was	-	553	O
confirmed	-	557	O
by	-	567	O
arterial	-	570	O
angiography	-	579	O
.	-	590	O

Relation	1564236	0	O
of	-	9	O
perfusion	-	12	O
defects	-	22	O
observed	-	30	O
with	-	39	O
myocardial	-	44	O
contrast	-	55	O
echocardiography	-	64	O
to	-	81	O
the	-	84	O
severity	-	88	O
of	-	97	O
coronary	-	100	B
stenosis	-	109	I
:	-	117	O
correlation	-	119	O
with	-	131	O
thallium	-	136	O
-	-	144	O
201	-	145	O
single	-	149	O
-	-	155	O
photon	-	156	O
emission	-	163	O
tomography	-	172	O
.	-	182	O

It	1564236	184	O
has	-	187	O
been	-	191	O
previously	-	196	O
shown	-	207	O
that	-	213	O
myocardial	-	218	O
contrast	-	229	O
echocardiography	-	238	O
is	-	255	O
a	-	258	O
valuable	-	260	O
technique	-	269	O
for	-	279	O
delineating	-	283	O
regions	-	295	O
of	-	303	O
myocardial	-	306	O
underperfusion	-	317	O
secondary	-	332	O
to	-	342	O
coronary	-	345	B
occlusion	-	354	I
and	-	364	O
to	-	368	O
critical	-	371	O
coronary	-	380	B
stenoses	-	389	I
in	-	398	O
the	-	401	O
presence	-	405	O
of	-	414	O
hyperemic	-	417	B
stimulation	-	427	O
.	-	438	O

The	1564236	440	O
aim	-	444	O
of	-	448	O
this	-	451	O
study	-	456	O
was	-	462	O
to	-	466	O
determine	-	469	O
whether	-	479	O
myocardial	-	487	O
contrast	-	498	O
echocardiography	-	507	O
performed	-	524	O
with	-	534	O
a	-	539	O
stable	-	541	O
solution	-	548	O
of	-	557	O
sonicated	-	560	O
albumin	-	570	O
could	-	578	O
detect	-	584	O
regions	-	591	O
of	-	599	O
myocardial	-	602	O
underperfusion	-	613	O
resulting	-	628	O
from	-	638	O
various	-	643	O
degrees	-	651	O
of	-	659	O
coronary	-	662	B
stenosis	-	671	I
.	-	679	O

The	1564236	681	O
perfusion	-	685	O
defect	-	695	O
produced	-	702	O
in	-	711	O
16	-	714	O
open	-	717	O
chest	-	722	O
dogs	-	728	O
was	-	733	O
compared	-	737	O
with	-	746	O
the	-	751	O
anatomic	-	755	O
area	-	764	O
at	-	769	O
risk	-	772	O
measured	-	777	O
by	-	786	O
the	-	789	O
postmortem	-	793	O
dual	-	804	O
-	-	808	O
perfusion	-	809	O
technique	-	819	O
and	-	829	O
with	-	833	O
thallium	-	838	O
-	-	846	O
201	-	847	O
single	-	851	O
-	-	857	O
photon	-	858	O
emission	-	865	O
tomography	-	874	O
(	-	885	O
SPECT	-	886	O
)	-	891	O
.	-	892	O

During	1564236	894	O
a	-	901	O
transient	-	903	O
(	-	913	O
20	-	914	O
-	-	916	O
s	-	917	O
)	-	918	O
coronary	-	920	B
occlusion	-	929	I
,	-	938	O
a	-	940	O
perfusion	-	942	O
defect	-	952	O
was	-	959	O
observed	-	963	O
with	-	972	O
contrast	-	977	O
echocardiography	-	986	O
in	-	1003	O
14	-	1006	O
of	-	1009	O
the	-	1012	O
15	-	1016	O
dogs	-	1019	O
in	-	1024	O
which	-	1027	O
the	-	1033	O
occlusion	-	1037	O
was	-	1047	O
produced	-	1051	O
.	-	1059	O

The	1564236	1061	O
perfusion	-	1065	O
defect	-	1075	O
correlated	-	1082	O
significantly	-	1093	O
with	-	1107	O
the	-	1112	O
anatomic	-	1116	O
area	-	1125	O
at	-	1130	O
risk	-	1133	O
(	-	1138	O
r	-	1139	O
=	-	1141	O
0	-	1143	O
.	-	1144	O
74	-	1145	O
;	-	1147	O
p	-	1149	O
less	-	1151	O
than	-	1156	O
0	-	1161	O
.	-	1162	O
002	-	1163	O
)	-	1166	O
.	-	1167	O

During	1564236	1169	O
dipyridamole	-	1176	O
-	-	1188	O
induced	-	1189	O
hyperemia	-	1197	B
,	-	1206	O
12	-	1208	O
of	-	1211	O
the	-	1214	O
16	-	1218	O
dogs	-	1221	O
with	-	1226	O
a	-	1231	O
partial	-	1233	O
coronary	-	1241	B
stenosis	-	1250	I
had	-	1259	O
a	-	1263	O
visible	-	1265	O
area	-	1273	O
of	-	1278	O
hypoperfusion	-	1281	O
by	-	1295	O
contrast	-	1298	O
echocardiography	-	1307	O
.	-	1323	O

The	1564236	1325	O
four	-	1329	O
dogs	-	1334	O
without	-	1339	O
a	-	1347	O
perfusion	-	1349	O
defect	-	1359	O
had	-	1366	O
a	-	1370	O
stenosis	-	1372	O
that	-	1381	O
resulted	-	1386	O
in	-	1395	O
a	-	1398	O
mild	-	1400	O
(	-	1405	O
0	-	1406	O
%	-	1407	O
to	-	1409	O
50	-	1412	O
%	-	1414	O
)	-	1415	O
reduction	-	1417	O
in	-	1427	O
dipyridamole	-	1430	O
-	-	1442	O
induced	-	1443	O
hyperemia	-	1451	B
.	-	1460	O

The	1564236	1462	O
size	-	1466	O
of	-	1471	O
the	-	1474	O
perfusion	-	1478	O
defect	-	1488	O
during	-	1495	O
stenosis	-	1502	O
correlated	-	1511	O
significantly	-	1522	O
with	-	1536	O
the	-	1541	O
anatomic	-	1545	O
area	-	1554	O
at	-	1559	O
risk	-	1562	O
(	-	1567	O
r	-	1568	O
=	-	1570	O
0	-	1572	O
.	-	1573	O
61	-	1574	O
;	-	1576	O
p	-	1578	O
=	-	1580	O
0	-	1582	O
.	-	1583	O
02	-	1584	O
)	-	1586	O
.	-	1587	O

Thallium	1564236	1589	O
-	-	1597	O
201	-	1598	O
SPECT	-	1602	O
demonstrated	-	1608	O
a	-	1621	O
perfusion	-	1623	O
defect	-	1633	O
in	-	1640	O
all	-	1643	O
14	-	1647	O
dogs	-	1650	O
analyzed	-	1655	O
during	-	1664	O
dipyridamole	-	1671	O
-	-	1683	O
induced	-	1684	O
hyperemia	-	1692	B
;	-	1701	O
the	-	1703	O
size	-	1707	O
of	-	1712	O
the	-	1715	O
perfusion	-	1719	O
defect	-	1729	O
correlated	-	1736	O
with	-	1747	O
the	-	1752	O
anatomic	-	1756	O
area	-	1765	O
at	-	1770	O
risk	-	1773	O
(	-	1778	O
r	-	1779	O
=	-	1781	O
0	-	1783	O
.	-	1784	O
58	-	1785	O
;	-	1787	O
p	-	1789	O
less	-	1791	O
than	-	1796	O
0	-	1801	O
.	-	1802	O
03	-	1803	O
)	-	1805	O
and	-	1807	O
with	-	1811	O
the	-	1816	O
perfusion	-	1820	O
defect	-	1830	O
by	-	1837	O
contrast	-	1840	O
echocardiography	-	1849	O
(	-	1866	O
r	-	1867	O
=	-	1869	O
0	-	1871	O
.	-	1872	O
58	-	1873	O
;	-	1875	O
p	-	1877	O
less	-	1879	O
than	-	1884	O
0	-	1889	O
.	-	1890	O
03	-	1891	O
)	-	1893	O
.	-	1894	O

Thus	1564236	1896	O
,	-	1900	O
myocardial	-	1902	O
contrast	-	1913	O
echocardiography	-	1922	O
can	-	1939	O
be	-	1943	O
used	-	1946	O
to	-	1951	O
visualize	-	1954	O
and	-	1964	O
quantitate	-	1968	O
the	-	1979	O
amount	-	1983	O
of	-	1990	O
jeopardized	-	1993	O
myocardium	-	2005	O
during	-	2016	O
moderate	-	2023	O
to	-	2032	O
severe	-	2035	O
degrees	-	2042	O
of	-	2050	O
coronary	-	2053	B
stenosis	-	2062	I
.	-	2070	O

The	1564236	2072	O
results	-	2076	O
obtained	-	2084	O
show	-	2093	O
a	-	2098	O
correlation	-	2100	O
with	-	2112	O
the	-	2117	O
anatomic	-	2121	O
area	-	2130	O
at	-	2135	O
risk	-	2138	O
similar	-	2143	O
to	-	2151	O
that	-	2154	O
obtained	-	2159	O
with	-	2168	O
thallium	-	2173	O
-	-	2181	O
201	-	2182	O
SPECT	-	2186	O
.	-	2191	O

Potential	1300436	0	O
deleterious	-	10	O
effect	-	22	O
of	-	29	O
furosemide	-	32	O
in	-	43	O
radiocontrast	-	46	O
nephropathy	-	60	B
.	-	71	O

The	1300436	73	O
purpose	-	77	O
of	-	85	O
the	-	88	O
study	-	92	O
was	-	98	O
to	-	102	O
determine	-	105	O
the	-	115	O
efficacy	-	119	O
of	-	128	O
furosemide	-	131	O
in	-	142	O
addition	-	145	O
to	-	154	O
intravenous	-	157	O
fluids	-	169	O
in	-	176	O
the	-	179	O
prevention	-	183	O
of	-	194	O
radiocontrast	-	197	O
nephropathy	-	211	B
.	-	222	O

18	1300436	224	O
patients	-	227	O
,	-	235	O
referred	-	237	O
to	-	246	O
a	-	249	O
radiocontrast	-	251	O
study	-	265	O
,	-	270	O
considered	-	272	O
at	-	283	O
risk	-	286	O
because	-	291	O
of	-	299	O
preexisting	-	302	O
renal	-	314	B
insufficiency	-	320	I
,	-	333	O
were	-	335	O
enrolled	-	340	O
in	-	349	O
a	-	352	O
prospective	-	354	O
,	-	365	O
randomized	-	367	O
,	-	377	O
controlled	-	379	O
trial	-	390	O
,	-	395	O
performed	-	397	O
at	-	407	O
the	-	410	O
secondary	-	414	O
care	-	424	O
center	-	429	O
of	-	436	O
a	-	439	O
1	-	441	O
,	-	442	O
100	-	443	O
-	-	446	O
bed	-	447	O
private	-	451	O
university	-	459	O
hospital	-	470	O
.	-	478	O

In	1300436	480	O
addition	-	483	O
to	-	492	O
fluids	-	495	O
,	-	501	O
the	-	503	O
treatment	-	507	O
group	-	517	O
received	-	523	O
furosemide	-	532	O
(	-	543	O
mean	-	544	O
dose	-	549	O
110	-	554	O
mg	-	558	O
)	-	560	O
intravenously	-	562	O
30	-	576	O
min	-	579	O
prior	-	583	O
to	-	589	O
the	-	592	O
injection	-	596	O
of	-	606	O
contrast	-	609	O
material	-	618	O
.	-	626	O

The	1300436	628	O
control	-	632	O
group	-	640	O
received	-	646	O
fluids	-	655	O
(	-	662	O
mean	-	663	O
3	-	668	O
liters	-	670	O
)	-	676	O
.	-	677	O

Radiological	1300436	679	O
studies	-	692	O
were	-	700	O
mostly	-	705	O
angiographies	-	712	O
performed	-	726	O
with	-	736	O
both	-	741	O
ionic	-	746	O
and	-	752	O
non	-	756	O
-	-	759	O
ionic	-	760	O
contrast	-	766	O
material	-	775	O
,	-	783	O
at	-	785	O
an	-	788	O
average	-	791	O
dose	-	799	O
of	-	804	O
245	-	807	O
ml	-	811	O
.	-	813	O

Renal	1300436	815	B
function	-	821	I
significantly	-	830	I
deteriorated	-	844	I
in	-	857	O
the	-	860	O
group	-	864	O
pretreated	-	870	O
with	-	881	O
furosemide	-	886	O
(	-	897	O
p	-	898	O
<	-	900	O
0	-	902	O
.	-	903	O
005	-	904	O
by	-	908	O
ANOVA	-	911	O
)	-	916	O
,	-	917	O
with	-	919	O
a	-	924	O
rise	-	926	O
in	-	931	O
serum	-	934	O
creatinine	-	940	O
from	-	951	O
145	-	956	O
+	-	960	O
/	-	961	O
-	-	962	O

13	1300436	964	O
to	-	967	O
182	-	970	O
+	-	974	O
/	-	975	O
-	-	976	O

16	1300436	978	O
mumol	-	981	O
/	-	986	O
l	-	987	O
at	-	989	O
24	-	992	O
h	-	995	O
,	-	996	O
while	-	998	O
no	-	1004	O
change	-	1007	O
occurred	-	1014	O
in	-	1023	O
the	-	1026	O
control	-	1030	O
group	-	1038	O
(	-	1044	O
from	-	1045	O
141	-	1050	O
+	-	1054	O
/	-	1055	O
-	-	1056	O

6	1300436	1058	O
to	-	1060	O
142	-	1063	O
+	-	1067	O
/	-	1068	O
-	-	1069	O

7	1300436	1071	O
mumol	-	1073	O
/	-	1078	O
l	-	1079	O
)	-	1080	O
.	-	1081	O

Renal	1300436	1083	B
failure	-	1089	I
was	-	1097	O
associated	-	1101	O
with	-	1112	O
weight	-	1117	B
loss	-	1124	I
in	-	1129	O
the	-	1132	O
furosemide	-	1136	O
-	-	1146	O
treated	-	1147	O
group	-	1155	O
.	-	1160	O

Furosemide	1300436	1162	O
may	-	1173	O
be	-	1177	O
deleterious	-	1180	O
in	-	1192	O
the	-	1195	O
prevention	-	1199	O
of	-	1210	O
radiocontrast	-	1213	O
nephropathy	-	1227	B
.	-	1238	O

The	1141447	0	O
renal	-	4	O
pathology	-	10	O
in	-	20	O
a	-	23	O
case	-	25	O
of	-	30	O
lithium	-	33	O
-	-	40	O
induced	-	41	O
diabetes	-	49	B
insipidus	-	58	I
.	-	67	O

A	1141447	69	O
case	-	71	O
of	-	76	O
lithium	-	79	O
-	-	86	O
induced	-	87	O
diabetes	-	95	B
insipidus	-	104	I
is	-	114	O
reported	-	117	O
.	-	125	O

At	1141447	127	O
necropsy	-	130	O
microscopy	-	139	O
shoed	-	150	O
unique	-	156	O
and	-	163	O
extensive	-	167	O
damage	-	177	O
to	-	184	O
cells	-	187	O
lining	-	193	O
the	-	200	O
distal	-	204	O
nephron	-	211	O
.	-	218	O

It	1141447	220	O
is	-	223	O
suggested	-	226	O
that	-	236	O
these	-	241	O
changes	-	247	O
represent	-	255	O
a	-	265	O
specific	-	267	O
toxic	-	276	O
effect	-	282	O
of	-	289	O
lithium	-	292	O
,	-	299	O
reported	-	301	O
here	-	310	O
for	-	315	O
the	-	319	O
first	-	323	O
time	-	329	O
in	-	334	O
man	-	337	O
.	-	340	O

Etiologic	188339	0	O
factors	-	10	O
in	-	18	O
the	-	21	O
pathogenesis	-	25	O
of	-	38	O
liver	-	41	B
tumors	-	47	I
associated	-	54	O
with	-	65	O
oral	-	70	O
contraceptives	-	75	O
.	-	89	O

Within	188339	91	O
the	-	98	O
last	-	102	O
several	-	107	O
years	-	115	O
,	-	120	O
previously	-	122	O
rare	-	133	O
liver	-	138	B
tumors	-	144	I
have	-	151	O
been	-	156	O
seen	-	161	O
in	-	166	O
young	-	169	O
women	-	175	O
using	-	181	O
oral	-	187	O
contraceptive	-	192	O
steroids	-	206	O
.	-	214	O

The	188339	216	O
Registry	-	220	O
for	-	229	O
Liver	-	233	B
Tumors	-	239	I
Associated	-	246	O
with	-	257	O
Oral	-	262	O
Contraceptives	-	267	O
at	-	282	O
the	-	285	O
University	-	289	O
of	-	300	O
California	-	303	O
,	-	313	O
Irvine	-	315	O
,	-	321	O
has	-	323	O
clearly	-	327	O
identified	-	335	O
27	-	346	O
cases	-	349	O
.	-	354	O

The	188339	356	O
recent	-	360	O
literature	-	367	O
contains	-	378	O
44	-	387	O
case	-	390	O
reports	-	395	O
.	-	402	O

Common	188339	404	O
to	-	411	O
these	-	414	O
71	-	420	O
cases	-	423	O
has	-	429	O
been	-	433	O
a	-	438	O
histopathologic	-	440	O
diagnosis	-	456	O
of	-	466	O
focal	-	469	B
nodular	-	475	I
hyperplasia	-	483	I
,	-	494	O
adenoma	-	496	B
,	-	503	O
hamartoma	-	505	B
,	-	514	O
and	-	516	O
hepatoma	-	520	B
.	-	528	O

Significant	188339	530	O
statistical	-	542	O
etiologic	-	554	O
factors	-	564	O
include	-	572	O
prolonged	-	580	O
uninterrupted	-	590	O
usage	-	604	O
of	-	610	O
oral	-	613	O
contraceptive	-	618	O
steroids	-	632	O
.	-	640	O

Eight	188339	642	O
deaths	-	648	O
and	-	655	O
liver	-	659	O
rupture	-	665	B
in	-	673	O
18	-	676	O
patients	-	679	O
attest	-	688	O
to	-	695	O
the	-	698	O
seriousness	-	702	O
of	-	714	O
this	-	717	O
new	-	722	O
potentially	-	726	O
lethal	-	738	O
adverse	-	745	O
phenomenon	-	753	O
.	-	763	O

Graft	19135948	0	B
-	-	5	I
versus	-	6	I
-	-	12	I
host	-	13	I
disease	-	18	I
prophylaxis	-	26	O
with	-	38	O
everolimus	-	43	O
and	-	54	O
tacrolimus	-	58	O
is	-	69	O
associated	-	72	O
with	-	83	O
a	-	88	O
high	-	90	O
incidence	-	95	O
of	-	105	O
sinusoidal	-	108	B
obstruction	-	119	I
syndrome	-	131	I
and	-	140	O
microangiopathy	-	144	B
:	-	159	O
results	-	161	O
of	-	169	O
the	-	172	O
EVTAC	-	176	O
trial	-	182	O
.	-	187	O

A	19135948	189	O
calcineurin	-	191	O
inhibitor	-	203	O
combined	-	213	O
with	-	222	O
methotrexate	-	227	O
is	-	240	O
the	-	243	O
standard	-	247	O
prophylaxis	-	256	O
for	-	268	O
graft	-	272	B
-	-	277	I
versus	-	278	I
-	-	284	I
host	-	285	I
disease	-	290	I
(	-	298	O
GVHD	-	299	B
)	-	303	O
after	-	305	O
allogeneic	-	311	O
hematopoietic	-	322	O
stem	-	336	O
cell	-	341	O
transplantation	-	346	O
(	-	362	O
HSCT	-	363	O
)	-	367	O
.	-	368	O

Everolimus	19135948	370	O
,	-	380	O
a	-	382	O
derivative	-	384	O
of	-	395	O
sirolimus	-	398	O
,	-	407	O
seems	-	409	O
to	-	415	O
mediate	-	418	O
antileukemia	-	426	O
effects	-	439	O
.	-	446	O

We	19135948	448	O
report	-	451	O
on	-	458	O
a	-	461	O
combination	-	463	O
of	-	475	O
everolimus	-	478	O
and	-	489	O
tacrolimus	-	493	O
in	-	504	O
24	-	507	O
patients	-	510	O
(	-	519	O
median	-	520	O
age	-	527	O
,	-	530	O
62	-	532	O
years	-	535	O
)	-	540	O
with	-	542	O
either	-	547	O
myelodysplastic	-	554	B
syndrome	-	570	I
(	-	579	O
MDS	-	580	B
;	-	583	O
n	-	585	O
=	-	587	O
17	-	589	O
)	-	591	O
or	-	593	O
acute	-	596	B
myeloid	-	602	I
leukemia	-	610	I
(	-	619	O
AML	-	620	B
;	-	623	O
n	-	625	O
=	-	627	O
7	-	629	O
)	-	630	O
undergoing	-	632	O
intensive	-	643	O
conditioning	-	653	O
followed	-	666	O
by	-	675	O
HSCT	-	678	O
from	-	683	O
related	-	688	O
(	-	696	O
n	-	697	O
=	-	699	O
4	-	701	O
)	-	702	O
or	-	704	O
unrelated	-	707	O
(	-	717	O
n	-	718	O
=	-	720	O
20	-	722	O
)	-	724	O
donors	-	726	O
.	-	732	O

All	19135948	734	O
patients	-	738	O
engrafted	-	747	O
,	-	756	O
and	-	758	O
only	-	762	O
1	-	767	O
patient	-	769	O
experienced	-	777	O
grade	-	789	O
IV	-	795	O
mucositis	-	798	B
.	-	807	O

Nine	19135948	809	O
patients	-	814	O
(	-	823	O
37	-	824	O
%	-	826	O
)	-	827	O
developed	-	829	O
acute	-	839	O
grade	-	845	O
II	-	851	O
-	-	853	O
IV	-	854	O
GVHD	-	857	B
,	-	861	O
and	-	863	O
11	-	867	O
of	-	870	O
17	-	873	O
evaluable	-	876	O
patients	-	886	O
(	-	895	O
64	-	896	O
%	-	898	O
)	-	899	O
developed	-	901	O
chronic	-	911	O
extensive	-	919	O
GVHD	-	929	B
.	-	933	O

Transplantation	19135948	935	B
-	-	950	I
associated	-	951	I
microangiopathy	-	962	I
(	-	978	O
TMA	-	979	B
)	-	982	O
occurred	-	984	O
in	-	993	O
7	-	996	O
patients	-	998	O
(	-	1007	O
29	-	1008	O
%	-	1010	O
)	-	1011	O
,	-	1012	O
with	-	1014	O
2	-	1019	O
cases	-	1021	O
of	-	1027	O
acute	-	1030	B
renal	-	1036	I
failure	-	1042	I
.	-	1049	O

The	19135948	1051	O
study	-	1055	O
was	-	1061	O
terminated	-	1065	O
prematurely	-	1076	O
because	-	1088	O
an	-	1096	O
additional	-	1099	O
6	-	1110	O
patients	-	1112	O
(	-	1121	O
25	-	1122	O
%	-	1124	O
)	-	1125	O
developed	-	1127	O
sinusoidal	-	1137	B
obstruction	-	1148	I
syndrome	-	1160	I
(	-	1169	O
SOS	-	1170	B
)	-	1173	O
,	-	1174	O
which	-	1176	O
was	-	1182	O
fatal	-	1186	O
in	-	1192	O
2	-	1195	O
cases	-	1197	O
.	-	1202	O

With	19135948	1204	O
a	-	1209	O
median	-	1211	O
follow	-	1218	O
-	-	1224	O
up	-	1225	O
of	-	1228	O
26	-	1231	O
months	-	1234	O
,	-	1240	O
the	-	1242	O
2	-	1246	O
-	-	1247	O
year	-	1248	O
overall	-	1253	O
survival	-	1261	O
rate	-	1270	O
was	-	1275	O
47	-	1279	O
%	-	1281	O
.	-	1282	O

Although	19135948	1284	O
this	-	1293	O
new	-	1298	O
combination	-	1302	O
appears	-	1314	O
to	-	1322	O
be	-	1325	O
effective	-	1328	O
as	-	1338	O
a	-	1341	O
prophylactic	-	1343	O
regimen	-	1356	O
for	-	1364	O
acute	-	1368	O
GVHD	-	1374	B
,	-	1378	O
the	-	1380	O
incidence	-	1384	O
of	-	1394	O
TMA	-	1397	B
and	-	1401	O
SOS	-	1405	B
is	-	1409	O
considerably	-	1412	O
higher	-	1425	O
than	-	1432	O
seen	-	1437	O
with	-	1442	O
other	-	1447	O
regimens	-	1453	O
.	-	1461	O

Effect	14704468	0	O
of	-	7	O
some	-	10	O
convulsants	-	15	O
on	-	27	O
the	-	30	O
protective	-	34	O
activity	-	45	O
of	-	54	O
loreclezole	-	57	O
and	-	69	O
its	-	73	O
combinations	-	77	O
with	-	90	O
valproate	-	95	O
or	-	105	O
clonazepam	-	108	O
in	-	119	O
amygdala	-	122	O
-	-	130	O
kindled	-	131	O
rats	-	139	O
.	-	143	O

Loreclezole	14704468	145	O
(	-	157	O
5	-	158	O
mg	-	160	O
/	-	162	O
kg	-	163	O
)	-	165	O
exerted	-	167	O
a	-	175	O
significant	-	177	O
protective	-	189	O
action	-	200	O
in	-	207	O
amygdala	-	210	O
-	-	218	O
kindled	-	219	O
rats	-	227	O
,	-	231	O
reducing	-	233	O
both	-	242	O
seizure	-	247	B
and	-	255	O
afterdischarge	-	259	O
durations	-	274	O
.	-	283	O

The	14704468	285	O
combinations	-	289	O
of	-	302	O
loreclezole	-	305	O
(	-	317	O
2	-	318	O
.	-	319	O
5	-	320	O
mg	-	322	O
/	-	324	O
kg	-	325	O
)	-	327	O
with	-	329	O
valproate	-	334	O
,	-	343	O
clonazepam	-	345	O
,	-	355	O
or	-	357	O
carbamazepine	-	360	O
(	-	374	O
applied	-	375	O
at	-	383	O
their	-	386	O
subprotective	-	392	O
doses	-	406	O
)	-	411	O
also	-	413	O
exhibited	-	418	O
antiseizure	-	428	O
effect	-	440	O
in	-	447	O
this	-	450	O
test	-	455	O
.	-	459	O

However	14704468	461	O
,	-	468	O
only	-	470	O
two	-	475	O
first	-	479	O
combinations	-	485	O
occurred	-	498	O
to	-	507	O
be	-	510	O
of	-	513	O
pharmacodynamic	-	516	O
nature	-	532	O
.	-	538	O

Among	14704468	540	O
several	-	546	O
chemoconvulsants	-	554	O
,	-	570	O
bicuculline	-	572	O
,	-	583	O
N	-	585	O
-	-	586	O
methyl	-	587	O
-	-	593	O
D	-	594	O
-	-	595	O
aspartic	-	596	O
acid	-	605	O
and	-	610	O
BAY	-	614	O
k	-	618	O
-	-	619	O
8644	-	620	O
(	-	625	O
the	-	626	O
opener	-	630	O
of	-	637	O
L	-	640	O
-	-	641	O
type	-	642	O
calcium	-	647	O
channels	-	655	O
)	-	663	O
reversed	-	665	O
the	-	674	O
protective	-	678	O
activity	-	689	O
of	-	698	O
loreclezole	-	701	O
alone	-	713	O
and	-	719	O
its	-	723	O
combination	-	727	O
with	-	739	O
valproate	-	744	O
.	-	753	O

On	14704468	755	O
the	-	758	O
other	-	762	O
hand	-	768	O
,	-	772	O
bicuculline	-	774	O
,	-	785	O
aminophylline	-	787	O
and	-	801	O
BAY	-	805	O
k	-	809	O
-	-	810	O
8644	-	811	O
inhibited	-	816	O
the	-	826	O
anticonvulsive	-	830	O
action	-	845	O
of	-	852	O
loreclezole	-	855	O
combined	-	867	O
with	-	876	O
clonazepam	-	881	O
.	-	891	O

The	14704468	893	O
results	-	897	O
support	-	905	O
the	-	913	O
hypothesis	-	917	O
that	-	928	O
the	-	933	O
protective	-	937	O
activity	-	948	O
of	-	957	O
loreclezole	-	960	O
and	-	972	O
its	-	976	O
combinations	-	980	O
with	-	993	O
other	-	998	O
antiepileptics	-	1004	O
may	-	1019	O
involve	-	1023	O
potentiation	-	1031	O
of	-	1044	O
GABAergic	-	1047	O
neurotransmission	-	1057	O
and	-	1075	O
blockade	-	1079	O
of	-	1088	O
L	-	1091	O
-	-	1092	O
type	-	1093	O
of	-	1098	O
calcium	-	1101	O
channels	-	1109	O
.	-	1117	O

Acute	12549952	0	B
liver	-	6	I
failure	-	12	I
with	-	20	O
concurrent	-	25	O
bupropion	-	36	O
and	-	46	O
carbimazole	-	50	O
therapy	-	62	O
.	-	69	O

OBJECTIVE	12549952	71	O
:	-	80	O

To	12549952	82	O
report	-	85	O
a	-	92	O
case	-	94	O
of	-	99	O
fatal	-	102	O
liver	-	108	B
failure	-	114	I
possibly	-	122	O
associated	-	131	O
with	-	142	O
concurrent	-	147	O
use	-	158	O
of	-	162	O
bupropion	-	165	O
and	-	175	O
carbimazole	-	179	O
.	-	190	O

CASE	12549952	192	O
SUMMARY	-	197	O
:	-	204	O

A	12549952	206	O
41	-	208	O
-	-	210	O
year	-	211	O
-	-	215	O
old	-	216	O
Chinese	-	220	O
man	-	228	O
with	-	232	O
a	-	237	O
history	-	239	O
of	-	247	O
hyperthyroidism	-	250	B
had	-	266	O
been	-	270	O
treated	-	275	O
with	-	283	O
carbimazole	-	288	O
and	-	300	O
propranolol	-	304	O
for	-	316	O
the	-	320	O
past	-	324	O
5	-	329	O
years	-	331	O
.	-	336	O

He	12549952	338	O
received	-	341	O
a	-	350	O
10	-	352	O
-	-	354	O
day	-	355	O
course	-	359	O
of	-	366	O
bupropion	-	369	O
as	-	379	O
an	-	382	O
aid	-	385	O
for	-	389	O
smoking	-	393	O
cessation	-	401	O
10	-	411	O
weeks	-	414	O
prior	-	420	O
to	-	426	O
presentation	-	429	O
.	-	441	O

He	12549952	443	O
developed	-	446	O
acute	-	456	B
liver	-	462	I
failure	-	468	I
with	-	476	O
rapid	-	481	O
deterioration	-	487	O
of	-	501	O
renal	-	504	O
function	-	510	O
.	-	518	O

Liver	12549952	520	O
biopsy	-	526	O
showed	-	533	O
evidence	-	540	O
of	-	549	O
nonspecific	-	552	O
drug	-	564	B
-	-	568	I
induced	-	569	I
acute	-	577	I
liver	-	583	I
injury	-	589	I
.	-	595	O

His	12549952	597	O
condition	-	601	O
was	-	611	O
further	-	615	O
complicated	-	623	O
by	-	635	O
sepsis	-	638	B
and	-	645	O
coagulopathy	-	649	B
.	-	661	O

Death	12549952	663	O
resulted	-	669	O
19	-	678	O
days	-	681	O
after	-	686	O
the	-	692	O
onset	-	696	O
of	-	702	O
symptoms	-	705	O
.	-	713	O

The	12549952	715	O
likelihood	-	719	O
that	-	730	O
bupropion	-	735	O
induced	-	745	O
hepatotoxicity	-	753	B
in	-	768	O
our	-	771	O
patient	-	775	O
was	-	783	O
possible	-	787	O
,	-	795	O
based	-	797	O
on	-	803	O
the	-	806	O
Naranjo	-	810	O
probability	-	818	O
scale	-	830	O
.	-	835	O

DISCUSSION	12549952	837	O
:	-	847	O

Although	12549952	849	O
there	-	858	O
is	-	864	O
increasing	-	867	O
evidence	-	878	O
of	-	887	O
hepatotoxicity	-	890	B
induced	-	905	O
by	-	913	O
bupropion	-	916	O
,	-	925	O
this	-	927	O
is	-	932	O
the	-	935	O
first	-	939	O
case	-	945	O
of	-	950	O
fatality	-	953	O
that	-	962	O
could	-	967	O
have	-	973	O
resulted	-	978	O
from	-	987	O
acute	-	992	B
liver	-	998	I
failure	-	1004	I
in	-	1012	O
a	-	1015	O
patient	-	1017	O
receiving	-	1025	O
bupropion	-	1035	O
while	-	1045	O
on	-	1051	O
concomitant	-	1054	O
treatment	-	1066	O
with	-	1076	O
carbimazole	-	1081	O
.	-	1092	O

CONCLUSIONS	12549952	1094	O
:	-	1105	O

Clinicians	12549952	1107	O
should	-	1118	O
be	-	1125	O
aware	-	1128	O
of	-	1134	O
the	-	1137	O
possibility	-	1141	O
of	-	1153	O
acute	-	1156	B
liver	-	1162	I
insult	-	1168	I
induced	-	1175	O
by	-	1183	O
bupropion	-	1186	O
given	-	1196	O
concurrently	-	1202	O
with	-	1215	O
other	-	1220	O
hepatotoxic	-	1226	B
drugs	-	1238	O
.	-	1243	O

Long	19370593	0	O
term	-	5	O
hormone	-	10	O
therapy	-	18	O
for	-	26	O
perimenopausal	-	30	O
and	-	45	O
postmenopausal	-	49	O
women	-	64	O
.	-	69	O

BACKGROUND	19370593	71	O
:	-	81	O

Hormone	19370593	83	O
therapy	-	91	O
(	-	99	O
HT	-	100	O
)	-	102	O
is	-	104	O
widely	-	107	O
used	-	114	O
for	-	119	O
controlling	-	123	O
menopausal	-	135	O
symptoms	-	146	O
and	-	155	O
has	-	159	O
also	-	163	O
been	-	168	O
used	-	173	O
for	-	178	O
the	-	182	O
management	-	186	O
and	-	197	O
prevention	-	201	O
of	-	212	O
cardiovascular	-	215	B
disease	-	230	I
,	-	237	O
osteoporosis	-	239	B
and	-	252	O
dementia	-	256	B
in	-	265	O
older	-	268	O
women	-	274	O
.	-	279	O

This	19370593	281	O
is	-	286	O
an	-	289	O
updated	-	292	O
version	-	300	O
of	-	308	O
the	-	311	O
original	-	315	O
Cochrane	-	324	O
review	-	333	O
first	-	340	O
published	-	346	O
in	-	356	O
2005	-	359	O
.	-	363	O

OBJECTIVES	19370593	365	O
:	-	375	O

To	19370593	377	O
assess	-	380	O
the	-	387	O
effect	-	391	O
of	-	398	O
long	-	401	O
-	-	405	O
term	-	406	O
HT	-	411	O
on	-	414	O
mortality	-	417	O
,	-	426	O
cardiovascular	-	428	O
outcomes	-	443	O
,	-	451	O
cancer	-	453	B
,	-	459	O
gallbladder	-	461	B
disease	-	473	I
,	-	480	O
cognition	-	482	O
,	-	491	O
fractures	-	493	B
and	-	503	O
quality	-	507	O
of	-	515	O
life	-	518	O
.	-	522	O

SEARCH	19370593	524	O
STRATEGY	-	531	O
:	-	539	O

We	19370593	541	O
searched	-	544	O
the	-	553	O
following	-	557	O
databases	-	567	O
to	-	577	O
November	-	580	O
2007	-	589	O
:	-	593	O
Trials	-	595	O
Register	-	602	O
of	-	611	O
the	-	614	O
Cochrane	-	618	O
Menstrual	-	627	B
Disorders	-	637	I
and	-	647	O
Subfertility	-	651	O
Group	-	664	O
,	-	669	O
Cochrane	-	671	O
Central	-	680	O
Register	-	688	O
of	-	697	O
Controlled	-	700	O
Trials	-	711	O
,	-	717	O
MEDLINE	-	719	O
,	-	726	O
EMBASE	-	728	O
,	-	734	O
Biological	-	736	O
Abstracts	-	747	O
.	-	756	O

Also	19370593	758	O
relevant	-	763	O
non	-	772	O
-	-	775	O
indexed	-	776	O
journals	-	784	O
and	-	793	O
conference	-	797	O
abstracts	-	808	O
.	-	817	O

SELECTION	19370593	819	O
CRITERIA	-	829	O
:	-	837	O

Randomised	19370593	839	O
double	-	850	O
-	-	856	O
blind	-	857	O
trials	-	863	O
of	-	870	O
HT	-	873	O
versus	-	876	O
placebo	-	883	O
,	-	890	O
taken	-	892	O
for	-	898	O
at	-	902	O
least	-	905	O
one	-	911	O
year	-	915	O
by	-	920	O
perimenopausal	-	923	O
or	-	938	O
postmenopausal	-	941	O
women	-	956	O
.	-	961	O

HT	19370593	963	O
included	-	966	O
oestrogens	-	975	O
,	-	985	O
with	-	987	O
or	-	992	O
without	-	995	O
progestogens	-	1003	O
,	-	1015	O
via	-	1017	O
oral	-	1021	O
,	-	1025	O
transdermal	-	1027	O
,	-	1038	O
subcutaneous	-	1040	O
or	-	1053	O
transnasal	-	1056	O
routes	-	1067	O
.	-	1073	O

DATA	19370593	1075	O
COLLECTION	-	1080	O
AND	-	1091	O
ANALYSIS	-	1095	O
:	-	1103	O

Two	19370593	1105	O
authors	-	1109	O
independently	-	1117	O
assessed	-	1131	O
trial	-	1140	O
quality	-	1146	O
and	-	1154	O
extracted	-	1158	O
data	-	1168	O
.	-	1172	O

MAIN	19370593	1174	O
RESULTS	-	1179	O
:	-	1186	O

Nineteen	19370593	1188	O
trials	-	1197	O
involving	-	1204	O
41	-	1214	O
,	-	1216	O
904	-	1217	O
women	-	1221	O
were	-	1227	O
included	-	1232	O
.	-	1240	O

In	19370593	1242	O
relatively	-	1245	O
healthy	-	1256	O
women	-	1264	O
,	-	1269	O
combined	-	1271	O
continuous	-	1280	O
HT	-	1291	O
significantly	-	1294	O
increased	-	1308	O
the	-	1318	O
risk	-	1322	O
of	-	1327	O
venous	-	1330	B
thrombo	-	1337	I
-	-	1344	I
embolism	-	1345	I
or	-	1354	O
coronary	-	1357	O
event	-	1366	O
(	-	1372	O
after	-	1373	O
one	-	1379	O
year	-	1383	O
's	-	1387	O
use	-	1390	O
)	-	1393	O
,	-	1394	O
stroke	-	1396	B
(	-	1403	O
after	-	1404	O
three	-	1410	O
years	-	1416	O
)	-	1421	O
,	-	1422	O
breast	-	1424	B
cancer	-	1431	I
and	-	1438	O
gallbladder	-	1442	B
disease	-	1454	I
.	-	1461	O

Long	19370593	1463	O
-	-	1467	O
term	-	1468	O
oestrogen	-	1473	O
-	-	1482	O
only	-	1483	O
HT	-	1488	O
significantly	-	1491	O
increased	-	1505	O
the	-	1515	O
risk	-	1519	O
of	-	1524	O
venous	-	1527	B
thrombo	-	1534	I
-	-	1541	I
embolism	-	1542	I
,	-	1550	O
stroke	-	1552	B
and	-	1559	O
gallbladder	-	1563	B
disease	-	1575	I
(	-	1583	O
after	-	1584	O
one	-	1590	O
to	-	1594	O
two	-	1597	O
years	-	1601	O
,	-	1606	O
three	-	1608	O
years	-	1614	O
and	-	1620	O
seven	-	1624	O
years	-	1630	O
'	-	1635	O
use	-	1637	O
respectively	-	1641	O
)	-	1653	O
,	-	1654	O
but	-	1656	O
did	-	1660	O
not	-	1664	O
significantly	-	1668	O
increase	-	1682	O
the	-	1691	O
risk	-	1695	O
of	-	1700	O
breast	-	1703	B
cancer	-	1710	I
.	-	1716	O

The	19370593	1718	O
only	-	1722	O
statistically	-	1727	O
significant	-	1741	O
benefits	-	1753	O
of	-	1762	O
HT	-	1765	O
were	-	1768	O
a	-	1773	O
decreased	-	1775	O
incidence	-	1785	O
of	-	1795	O
fractures	-	1798	B
and	-	1808	O
(	-	1812	O
for	-	1813	O
combined	-	1817	O
HT	-	1826	O
)	-	1828	O
colon	-	1830	B
cancer	-	1836	I
,	-	1842	O
with	-	1844	O
long	-	1849	O
-	-	1853	O
term	-	1854	O
use	-	1859	O
.	-	1862	O

Among	19370593	1864	O
women	-	1870	O
aged	-	1876	O
over	-	1881	O
65	-	1886	O
who	-	1889	O
were	-	1893	O
relatively	-	1898	O
healthy	-	1909	O
(	-	1917	O
i	-	1918	O
.	-	1919	O
e	-	1920	O
.	-	1921	O
generally	-	1923	O
fit	-	1933	O
,	-	1936	O
without	-	1938	O
overt	-	1946	O
disease	-	1952	O
)	-	1959	O
and	-	1961	O
taking	-	1965	O
continuous	-	1972	O
combined	-	1983	O
HT	-	1992	O
,	-	1994	O
there	-	1996	O
was	-	2002	O
a	-	2006	O
statistically	-	2008	O
significant	-	2022	O
increase	-	2034	O
in	-	2043	O
the	-	2046	O
incidence	-	2050	O
of	-	2060	O
dementia	-	2063	B
.	-	2071	O

Among	19370593	2073	O
women	-	2079	O
with	-	2085	O
cardiovascular	-	2090	B
disease	-	2105	I
,	-	2112	O
long	-	2114	O
-	-	2118	O
term	-	2119	O
use	-	2124	O
of	-	2128	O
combined	-	2131	O
continuous	-	2140	O
HT	-	2151	O
significantly	-	2154	O
increased	-	2168	O
the	-	2178	O
risk	-	2182	O
of	-	2187	O
venous	-	2190	B
thrombo	-	2197	I
-	-	2204	I
embolism	-	2205	I
.	-	2213	O

One	19370593	2214	O
trial	-	2218	O
analysed	-	2224	O
subgroups	-	2233	O
of	-	2243	O
2839	-	2246	O
relatively	-	2251	O
healthy	-	2262	O
50	-	2270	O
to	-	2273	O
59	-	2276	O
year	-	2279	O
old	-	2284	O
women	-	2288	O
taking	-	2294	O
combined	-	2301	O
continuous	-	2310	O
HT	-	2321	O
and	-	2324	O
1637	-	2328	O
taking	-	2333	O
oestrogen	-	2340	O
-	-	2349	O
only	-	2350	O
HT	-	2355	O
,	-	2357	O
versus	-	2359	O
similar	-	2366	O
-	-	2373	O
sized	-	2374	O
placebo	-	2380	O
groups	-	2388	O
.	-	2394	O

The	19370593	2396	O
only	-	2400	O
significantly	-	2405	O
increased	-	2419	O
risk	-	2429	O
reported	-	2434	O
was	-	2443	O
for	-	2447	O
venous	-	2451	B
thrombo	-	2458	I
-	-	2465	I
embolism	-	2466	I
in	-	2475	O
women	-	2478	O
taking	-	2484	O
combined	-	2491	O
continuous	-	2500	O
HT	-	2511	O
:	-	2513	O
their	-	2515	O
absolute	-	2521	O
risk	-	2530	O
remained	-	2535	O
low	-	2544	O
,	-	2547	O
at	-	2549	O
less	-	2552	O
than	-	2557	O
1	-	2562	O
/	-	2563	O
500	-	2564	O
.	-	2567	O

However	19370593	2569	O
,	-	2576	O
this	-	2578	O
study	-	2583	O
was	-	2589	O
not	-	2593	O
powered	-	2597	O
to	-	2605	O
detect	-	2608	O
differences	-	2615	O
between	-	2627	O
groups	-	2635	O
of	-	2642	O
younger	-	2645	O
women	-	2653	O
.	-	2658	O

AUTHORS	19370593	2660	O
'	-	2667	O
CONCLUSIONS	-	2669	O
:	-	2680	O

HT	19370593	2682	O
is	-	2685	O
not	-	2688	O
indicated	-	2692	O
for	-	2702	O
the	-	2706	O
routine	-	2710	O
management	-	2718	O
of	-	2729	O
chronic	-	2732	O
disease	-	2740	O
.	-	2747	O

We	19370593	2749	O
need	-	2752	O
more	-	2757	O
evidence	-	2762	O
on	-	2771	O
the	-	2774	O
safety	-	2778	O
of	-	2785	O
HT	-	2788	O
for	-	2791	O
menopausal	-	2795	O
symptom	-	2806	O
control	-	2814	O
,	-	2821	O
though	-	2823	O
short	-	2830	O
-	-	2835	O
term	-	2836	O
use	-	2841	O
appears	-	2845	O
to	-	2853	O
be	-	2856	O
relatively	-	2859	O
safe	-	2870	O
for	-	2875	O
healthy	-	2879	O
younger	-	2887	O
women	-	2895	O
.	-	2900	O

Passage	17019386	0	O
of	-	8	O
mannitol	-	11	O
into	-	20	O
the	-	25	O
brain	-	29	O
around	-	35	O
gliomas	-	42	B
:	-	49	O
a	-	51	O
potential	-	53	O
cause	-	63	O
of	-	69	O
rebound	-	72	O
phenomenon	-	80	O
.	-	90	O

A	17019386	92	O
study	-	94	O
on	-	100	O
21	-	103	O
patients	-	106	O
.	-	114	O

AIM	17019386	116	O
:	-	119	O

Widespread	17019386	121	O
use	-	132	O
of	-	136	O
mannitol	-	139	O
to	-	148	O
reduce	-	151	O
brain	-	158	B
edema	-	164	I
and	-	170	O
lower	-	174	O
elevated	-	180	B
ICP	-	189	I
in	-	193	O
brain	-	196	B
tumor	-	202	I
patients	-	208	O
continues	-	217	O
to	-	227	O
be	-	230	O
afflicted	-	233	O
by	-	243	O
the	-	246	O
so	-	250	O
-	-	252	O
called	-	253	O
rebound	-	260	O
phenomenon	-	268	O
.	-	278	O

Leakage	17019386	280	O
of	-	288	O
mannitol	-	291	O
into	-	300	O
the	-	305	O
brain	-	309	O
parenchyma	-	315	O
through	-	326	O
an	-	334	O
altered	-	337	O
BBB	-	345	O
and	-	349	O
secondary	-	353	O
reversal	-	363	O
of	-	372	O
osmotic	-	375	O
gradient	-	383	O
is	-	392	O
considered	-	395	O
the	-	406	O
major	-	410	O
cause	-	416	O
of	-	422	O
rebound	-	425	O
.	-	433	O

This	17019386	435	O
has	-	440	O
only	-	444	O
been	-	449	O
demonstrated	-	454	O
experimentally	-	467	O
in	-	482	O
animals	-	485	O
.	-	492	O

As	17019386	494	O
a	-	497	O
contribution	-	499	O
to	-	512	O
this	-	515	O
issue	-	520	O
we	-	526	O
decided	-	529	O
to	-	537	O
research	-	540	O
the	-	549	O
possible	-	553	O
passage	-	562	O
of	-	570	O
mannitol	-	573	O
into	-	582	O
the	-	587	O
brain	-	591	O
after	-	597	O
administration	-	603	O
to	-	618	O
21	-	621	O
brain	-	624	B
tumor	-	630	I
patients	-	636	O
.	-	644	O

METHODS	17019386	646	O
:	-	653	O
Mannitol	-	655	O
(	-	664	O
18	-	665	O
%	-	667	O
solution	-	669	O
;	-	677	O
1	-	679	O
g	-	681	O
/	-	682	O
kg	-	683	O
)	-	685	O
was	-	687	O
administered	-	691	O
as	-	704	O
a	-	707	O
bolus	-	709	O
to	-	715	O
patients	-	718	O
(	-	727	O
ten	-	728	O
had	-	732	O
malignant	-	736	B
glioma	-	746	I
,	-	752	O
seven	-	754	O
brain	-	760	O
metastases	-	766	B
and	-	777	O
four	-	781	O
meningioma	-	786	B
)	-	796	O
about	-	798	O
30	-	804	O
minutes	-	807	O
before	-	815	O
craniotomy	-	822	O
.	-	832	O

During	17019386	834	O
resection	-	841	O
,	-	850	O
a	-	852	O
sample	-	854	O
of	-	861	O
the	-	864	O
surrounding	-	868	O
edematous	-	880	B
white	-	890	O
matter	-	896	O
was	-	903	O
taken	-	907	O
at	-	913	O
the	-	916	O
same	-	920	O
time	-	925	O
as	-	930	O
a	-	933	O
10	-	935	O
ml	-	938	O
venous	-	941	O
blood	-	948	O
sample	-	954	O
.	-	960	O

Mannitol	17019386	962	O
concentrations	-	971	O
were	-	986	O
measured	-	991	O
in	-	1000	O
plasma	-	1003	O
and	-	1010	O
white	-	1014	O
matter	-	1020	O
by	-	1027	O
a	-	1030	O
modified	-	1032	O
version	-	1041	O
of	-	1049	O
the	-	1052	O
enzyme	-	1056	O
assay	-	1063	O
of	-	1069	O
Blonquist	-	1072	O
et	-	1082	O
al	-	1085	O
.	-	1087	O

RESULTS	17019386	1089	O
:	-	1096	O

In	17019386	1098	O
most	-	1101	O
glioma	-	1106	B
patients	-	1113	O
,	-	1121	O
mannitol	-	1123	O
concentrations	-	1132	O
in	-	1147	O
white	-	1150	O
matter	-	1156	O
were	-	1163	O
2	-	1168	O
to	-	1170	O
6	-	1173	O
times	-	1175	O
higher	-	1181	O
than	-	1188	O
in	-	1193	O
plasma	-	1196	O
(	-	1203	O
mean	-	1204	O
3	-	1209	O
.	-	1210	O
5	-	1211	O
times	-	1213	O
)	-	1218	O
.	-	1219	O

In	17019386	1221	O
meningioma	-	1224	B
and	-	1235	O
metastases	-	1239	B
patients	-	1250	O
plasma	-	1259	O
concentrations	-	1266	O
of	-	1281	O
mannitol	-	1284	O
were	-	1293	O
higher	-	1298	O
than	-	1305	O
white	-	1310	O
matter	-	1316	O
concentrations	-	1323	O
except	-	1338	O
in	-	1345	O
three	-	1348	O
cases	-	1354	O
with	-	1360	O
infiltration	-	1365	O
by	-	1378	O
neoplastic	-	1381	O
cells	-	1392	O
.	-	1397	O

CONCLUSIONS	17019386	1399	O
:	-	1410	O

The	17019386	1412	O
results	-	1416	O
of	-	1424	O
our	-	1427	O
study	-	1431	O
show	-	1437	O
that	-	1442	O
even	-	1447	O
after	-	1452	O
a	-	1458	O
single	-	1460	O
bolus	-	1467	O
,	-	1472	O
mannitol	-	1474	O
may	-	1483	O
leak	-	1487	O
through	-	1492	O
the	-	1500	O
altered	-	1504	O
BBB	-	1512	O
near	-	1516	O
gliomas	-	1521	B
,	-	1528	O
reversing	-	1530	O
the	-	1540	O
initial	-	1544	O
plasma	-	1552	O
-	-	1558	O
to	-	1559	O
-	-	1561	O
blood	-	1562	O
osmotic	-	1568	O
gradient	-	1576	O
,	-	1584	O
aggravating	-	1586	O
peritumoral	-	1598	O
edema	-	1610	B
and	-	1616	O
promoting	-	1620	O
rebound	-	1630	O
of	-	1638	O
ICP	-	1641	O
.	-	1644	O

Can	12452237	0	O
lidocaine	-	4	O
reduce	-	14	O
succinylcholine	-	21	O
induced	-	37	O
postoperative	-	45	B
myalgia	-	59	I
?	-	66	O

This	12452237	68	O
study	-	73	O
was	-	79	O
undertaken	-	83	O
to	-	94	O
determine	-	97	O
the	-	107	O
effect	-	111	O
of	-	118	O
lidocaine	-	121	O
pretreatment	-	131	O
on	-	144	O
reduction	-	147	O
of	-	157	O
succinylcholine	-	160	O
-	-	175	O
induced	-	176	O
myalgia	-	184	B
in	-	192	O
patients	-	195	O
undergoing	-	204	O
general	-	215	O
anesthesia	-	223	O
for	-	234	O
gynecological	-	238	O
surgery	-	252	O
.	-	259	O

One	12452237	261	O
hundred	-	265	O
and	-	273	O
thirty	-	277	O
-	-	283	O
five	-	284	O
patients	-	289	O
were	-	298	O
assigned	-	303	O
to	-	312	O
one	-	315	O
of	-	319	O
three	-	322	O
groups	-	328	O
in	-	335	O
a	-	338	O
prospective	-	340	O
,	-	351	O
double	-	353	O
blind	-	360	O
,	-	365	O
randomized	-	367	O
manner	-	378	O
.	-	384	O

Group	12452237	386	O
PS	-	392	O
,	-	394	O
the	-	396	O
control	-	400	O
group	-	408	O
,	-	413	O
received	-	415	O
normal	-	424	O
saline	-	431	O
and	-	438	O
succinylcholine	-	442	O
1	-	458	O
.	-	459	O
5	-	460	O
mg	-	462	O
x	-	465	O
kg	-	467	O
(	-	469	O
-	-	470	O
1	-	471	O
)	-	472	O
;	-	473	O
Group	-	475	O
LS	-	481	O
,	-	483	O
lidocaine	-	485	O
1	-	495	O
.	-	496	O
5	-	497	O
mg	-	499	O
x	-	502	O
kg	-	504	O
(	-	506	O
-	-	507	O
1	-	508	O
)	-	509	O
and	-	511	O
succinylcholine	-	515	O
1	-	531	O
.	-	532	O
5	-	533	O
mg	-	535	O
x	-	538	O
kg	-	540	O
(	-	542	O
-	-	543	O
1	-	544	O
)	-	545	O
;	-	546	O
Group	-	548	O
PR	-	554	O
,	-	556	O
normal	-	558	O
saline	-	565	O
and	-	572	O
rocuronium	-	576	O
0	-	587	O
.	-	588	O
6	-	589	O
mg	-	591	O
x	-	594	O
kg	-	596	O
(	-	598	O
-	-	599	O
1	-	600	O
)	-	601	O
.	-	602	O

Morphine	12452237	604	O
0	-	613	O
.	-	614	O
1	-	615	O

mg	12452237	617	O
x	-	620	O
kg	-	622	O
(	-	624	O
-	-	625	O
1	-	626	O
)	-	627	O

iv	12452237	629	O
was	-	632	O
given	-	636	O
for	-	642	O
premedication	-	646	O
and	-	660	O
all	-	664	O
patients	-	668	O
were	-	677	O
monitored	-	682	O
with	-	692	O
a	-	697	O
noninvasive	-	699	O
blood	-	711	O
pressure	-	717	O
monitor	-	726	O
,	-	733	O
ECG	-	735	O
and	-	739	O
pulse	-	743	O
oximetry	-	749	O
.	-	757	O

Anesthesia	12452237	759	O
was	-	770	O
induced	-	774	O
with	-	782	O
5	-	787	O
mg	-	789	O
.	-	791	O
kg	-	792	O
(	-	794	O
-	-	795	O
1	-	796	O
)	-	797	O
thiopental	-	799	O
iv	-	810	O
.	-	812	O

followed	12452237	814	O
by	-	823	O
succinylcholine	-	826	O
(	-	842	O
Group	-	843	O
PS	-	849	O
,	-	851	O
LS	-	853	O
)	-	855	O
or	-	857	O
rocuronium	-	860	O
(	-	871	O
Group	-	872	O
PR	-	878	O
)	-	880	O
for	-	882	O
tracheal	-	886	O
intubation	-	895	O
.	-	905	O

Following	12452237	907	O
administration	-	917	O
of	-	932	O
these	-	935	O
agents	-	941	O
,	-	947	O
the	-	949	O
presence	-	953	O
,	-	961	O
and	-	963	O
degree	-	967	O
of	-	974	O
fasciculation	-	977	B
were	-	991	O
assessed	-	996	O
visually	-	1005	O
on	-	1014	O
a	-	1017	O
four	-	1019	O
point	-	1024	O
scale	-	1030	O
by	-	1036	O
one	-	1039	O
investigator	-	1043	O
who	-	1056	O
was	-	1060	O
blinded	-	1064	O
to	-	1072	O
the	-	1075	O
drug	-	1079	O
administered	-	1084	O
.	-	1096	O

The	12452237	1098	O
blood	-	1102	O
pressure	-	1108	O
and	-	1117	O
heart	-	1121	O
rate	-	1127	O
of	-	1132	O
each	-	1135	O
patient	-	1140	O
were	-	1148	O
monitored	-	1153	O
on	-	1163	O
nine	-	1166	O
occasions	-	1171	O
.	-	1180	O

Twenty	12452237	1182	O
-	-	1188	O
four	-	1189	O
hours	-	1194	O
later	-	1200	O
,	-	1205	O
any	-	1207	O
myalgia	-	1211	B
experienced	-	1219	O
was	-	1231	O
assessed	-	1235	O
according	-	1244	O
to	-	1254	O
a	-	1257	O
structured	-	1259	O
questionaire	-	1270	O
and	-	1283	O
graded	-	1287	O
by	-	1294	O
a	-	1297	O
four	-	1299	O
point	-	1304	O
scale	-	1310	O
by	-	1316	O
one	-	1319	O
investigator	-	1323	O
blinded	-	1336	O
to	-	1344	O
the	-	1347	O
intraoperative	-	1351	O
management	-	1366	O
.	-	1376	O

The	12452237	1378	O
results	-	1382	O
indicate	-	1390	O
that	-	1399	O
muscle	-	1404	B
fasciculation	-	1411	I
was	-	1425	O
not	-	1429	O
found	-	1433	O
in	-	1439	O
Group	-	1442	O
PR	-	1448	O
while	-	1451	O
the	-	1457	O
patients	-	1461	O
in	-	1470	O
Group	-	1473	O
LS	-	1479	O
had	-	1482	O
a	-	1486	O
lower	-	1488	O
incidence	-	1494	O
of	-	1504	O
muscle	-	1507	B
fasciculation	-	1514	I
than	-	1528	O
those	-	1533	O
in	-	1539	O
Group	-	1542	O
PS	-	1548	O
(	-	1551	O
p	-	1552	O
<	-	1554	O
0	-	1556	O
.	-	1557	O
001	-	1558	O
)	-	1561	O
.	-	1562	O

At	12452237	1564	O
24	-	1567	O
h	-	1570	O
,	-	1571	O
the	-	1573	O
incidence	-	1577	O
of	-	1587	O
myalgia	-	1590	B
was	-	1598	O
higher	-	1602	O
in	-	1609	O
Group	-	1612	O
PS	-	1618	O
than	-	1621	O
in	-	1626	O
Group	-	1629	O
LS	-	1635	O
and	-	1638	O
PR	-	1642	O
(	-	1645	O
p	-	1646	O
<	-	1648	O
0	-	1650	O
.	-	1651	O
05	-	1652	O
)	-	1654	O
.	-	1655	O

A	12452237	1657	O
correlation	-	1659	O
was	-	1671	O
not	-	1675	O
found	-	1679	O
between	-	1685	O
the	-	1693	O
incidence	-	1697	O
of	-	1707	O
myalgia	-	1710	B
and	-	1718	O
the	-	1722	O
occurrence	-	1726	O
of	-	1737	O
muscle	-	1740	B
fasciculation	-	1747	I
.	-	1760	O

The	12452237	1762	O
changes	-	1766	O
in	-	1774	O
systolic	-	1777	O
and	-	1786	O
diastolic	-	1790	O
blood	-	1800	O
pressure	-	1806	O
and	-	1815	O
heart	-	1819	O
rate	-	1825	O
were	-	1830	O
not	-	1835	O
significant	-	1839	O
among	-	1851	O
the	-	1857	O
three	-	1861	O
groups	-	1867	O
.	-	1873	O

In	12452237	1875	O
conclusion	-	1878	O
,	-	1888	O
where	-	1890	O
succinylcholine	-	1896	O
is	-	1912	O
used	-	1915	O
,	-	1919	O
lidocaine	-	1921	O
is	-	1931	O
proven	-	1934	O
to	-	1941	O
be	-	1944	O
the	-	1947	O
useful	-	1951	O
pretreatment	-	1958	O
agent	-	1971	O
for	-	1977	O
the	-	1981	O
reduction	-	1985	O
of	-	1995	O
postoperative	-	1998	B
myalgia	-	2012	I
.	-	2019	O

Open	9564988	0	O
-	-	4	O
label	-	5	O
assessment	-	11	O
of	-	22	O
levofloxacin	-	25	O
for	-	38	O
the	-	42	O
treatment	-	46	O
of	-	56	O
acute	-	59	O
bacterial	-	65	O
sinusitis	-	75	B
in	-	85	O
adults	-	88	O
.	-	94	O

PURPOSE	9564988	96	O
:	-	103	O

To	9564988	105	O
evaluate	-	108	O
the	-	117	O
efficacy	-	121	O
and	-	130	O
safety	-	134	O
of	-	141	O
levofloxacin	-	144	O
(	-	157	O
500	-	158	O
mg	-	162	O
orally	-	165	O
once	-	172	O
daily	-	177	O
for	-	183	O
10	-	187	O
to	-	190	O
14	-	193	O
days	-	196	O
)	-	200	O
in	-	202	O
treating	-	205	O
adult	-	214	O
outpatients	-	220	O
with	-	232	O
acute	-	237	O
bacterial	-	243	O
sinusitis	-	253	B
.	-	262	O

PATIENTS	9564988	264	O
AND	-	273	O
METHODS	-	277	O
:	-	284	O

A	9564988	286	O
total	-	288	O
of	-	294	O
329	-	297	O
patients	-	301	O
enrolled	-	310	O
in	-	319	O
the	-	322	O
study	-	326	O
at	-	332	O
24	-	335	O
centers	-	338	O
.	-	345	O

All	9564988	347	O
patients	-	351	O
had	-	360	O
a	-	364	O
pre	-	366	O
-	-	369	O
therapy	-	370	O
Gram	-	378	O
's	-	382	O
stain	-	385	O
and	-	391	O
culture	-	395	O
of	-	403	O
sinus	-	406	O
exudate	-	412	O
obtained	-	420	O
by	-	429	O
antral	-	432	O
puncture	-	439	O
or	-	448	O
nasal	-	451	O
endoscopy	-	457	O
.	-	466	O

Clinical	9564988	468	O
response	-	477	O
was	-	486	O
assessed	-	490	O
on	-	499	O
the	-	502	O
basis	-	506	O
of	-	512	O
signs	-	515	O
and	-	521	O
symptoms	-	525	O
and	-	534	O
sinus	-	538	O
radiograph	-	544	O
or	-	555	O
computed	-	558	O
tomography	-	567	O
results	-	578	O
.	-	585	O

Microbiologic	9564988	587	O
cure	-	601	O
rates	-	606	O
were	-	612	O
determined	-	617	O
on	-	628	O
the	-	631	O
basis	-	635	O
of	-	641	O
presumed	-	644	O
plus	-	653	O
documented	-	658	O
eradication	-	669	O
of	-	681	O
the	-	684	O
pre	-	688	O
-	-	691	O
therapy	-	692	O
pathogen	-	700	O
(	-	708	O
s	-	709	O
)	-	710	O
.	-	711	O

RESULTS	9564988	713	O
:	-	720	O

The	9564988	722	O
most	-	726	O
common	-	731	O
pathogens	-	738	O
were	-	748	O
Haemophilus	-	753	O
influenzae	-	765	O
,	-	775	O
Streptococcus	-	777	O
pneumoniae	-	791	O
,	-	801	O
Staphylococcus	-	803	O
aureus	-	818	O
,	-	824	O
and	-	826	O
Moraxella	-	830	O
catarrhalis	-	840	O
.	-	851	O

Of	9564988	853	O
300	-	856	O
clinically	-	860	O
evaluable	-	871	O
patients	-	881	O
,	-	889	O
175	-	891	O
(	-	895	O
58	-	896	O
%	-	898	O
)	-	899	O
were	-	901	O
cured	-	906	O
and	-	912	O
90	-	916	O
(	-	919	O
30	-	920	O
%	-	922	O
)	-	923	O
were	-	925	O
improved	-	930	O
at	-	939	O
the	-	942	O
post	-	946	O
-	-	950	O
therapy	-	951	O
evaluation	-	959	O
,	-	969	O
resulting	-	971	O
in	-	981	O
a	-	984	O
clinical	-	986	O
success	-	995	O
rate	-	1003	O
of	-	1008	O
88	-	1011	O
%	-	1013	O
.	-	1014	O

Thirty	9564988	1016	O
-	-	1022	O
five	-	1023	O
patients	-	1028	O
(	-	1037	O
12	-	1038	O
%	-	1040	O
)	-	1041	O
clinically	-	1043	O
failed	-	1054	O
treatment	-	1061	O
.	-	1070	O

The	9564988	1072	O
microbiologic	-	1076	O
eradication	-	1090	O
rate	-	1102	O
(	-	1107	O
presumed	-	1108	O
plus	-	1117	O
documented	-	1122	O
)	-	1132	O
among	-	1134	O
138	-	1140	O
microbiologically	-	1144	O
evaluable	-	1162	O
patients	-	1172	O
was	-	1181	O
92	-	1185	O
%	-	1187	O
.	-	1188	O

Microbiologic	9564988	1190	O
eradication	-	1204	O
rates	-	1216	O
(	-	1222	O
presumed	-	1223	O
plus	-	1232	O
documented	-	1237	O
)	-	1247	O
of	-	1249	O
the	-	1252	O
most	-	1256	O
common	-	1261	O
pathogens	-	1268	O
ranged	-	1278	O
from	-	1285	O
93	-	1290	O
%	-	1292	O
(	-	1294	O
M	-	1295	O
.	-	1296	O
catarrhalis	-	1298	O
)	-	1309	O
to	-	1311	O
100	-	1314	O
%	-	1317	O
(	-	1319	O
S	-	1320	O
.	-	1321	O
pneumoniae	-	1323	O
)	-	1333	O
at	-	1335	O
the	-	1338	O
post	-	1342	O
-	-	1346	O
therapy	-	1347	O
visit	-	1355	O
.	-	1360	O

All	9564988	1362	O
but	-	1366	O
one	-	1370	O
of	-	1374	O
the	-	1377	O
265	-	1381	O
patients	-	1385	O
who	-	1394	O
were	-	1398	O
cured	-	1403	O
or	-	1409	O
improved	-	1412	O
at	-	1421	O
post	-	1424	O
-	-	1428	O
therapy	-	1429	O
returned	-	1437	O
for	-	1446	O
a	-	1450	O
long	-	1452	O
-	-	1456	O
term	-	1457	O
follow	-	1462	O
-	-	1468	O
up	-	1469	O
visit	-	1472	O
;	-	1477	O
243	-	1479	O
(	-	1483	O
92	-	1484	O
%	-	1486	O
)	-	1487	O
remained	-	1489	O
well	-	1498	O
4	-	1503	O
to	-	1505	O
6	-	1508	O
weeks	-	1510	O
after	-	1516	O
therapy	-	1522	O
;	-	1529	O
and	-	1531	O
21	-	1535	O
(	-	1538	O
8	-	1539	O
%	-	1540	O
)	-	1541	O
had	-	1543	O
a	-	1547	O
relapse	-	1549	O
of	-	1557	O
symptoms	-	1560	O
.	-	1568	O

Adverse	9564988	1570	O
events	-	1578	O
considered	-	1585	O
to	-	1596	O
be	-	1599	O
related	-	1602	O
to	-	1610	O
levofloxacin	-	1613	O
administration	-	1626	O
were	-	1641	O
reported	-	1646	O
by	-	1655	O
29	-	1658	O
patients	-	1661	O
(	-	1670	O
9	-	1671	O
%	-	1672	O
)	-	1673	O
.	-	1674	O

The	9564988	1676	O
most	-	1680	O
common	-	1685	O
drug	-	1692	O
-	-	1696	O
related	-	1697	O
adverse	-	1705	O
events	-	1713	O
were	-	1720	O
diarrhea	-	1725	B
,	-	1733	O
flatulence	-	1735	B
,	-	1745	O
and	-	1747	O
nausea	-	1751	B
;	-	1757	O
most	-	1759	O
adverse	-	1764	O
events	-	1772	O
were	-	1779	O
mild	-	1784	O
to	-	1789	O
moderate	-	1792	O
in	-	1801	O
severity	-	1804	O
.	-	1812	O

CONCLUSION	9564988	1814	O
:	-	1824	O

The	9564988	1826	O
results	-	1830	O
of	-	1838	O
this	-	1841	O
study	-	1846	O
indicate	-	1852	O
that	-	1861	O
levofloxacin	-	1866	O
500	-	1879	O
mg	-	1883	O
once	-	1886	O
daily	-	1891	O
is	-	1897	O
an	-	1900	O
effective	-	1903	O
and	-	1913	O
safe	-	1917	O
treatment	-	1922	O
for	-	1932	O
acute	-	1936	O
bacterial	-	1942	O
sinusitis	-	1952	B
.	-	1961	O

Clinical	7596955	0	O
evaluation	-	9	O
on	-	20	O
combined	-	23	O
administration	-	32	O
of	-	47	O
oral	-	50	O
prostacyclin	-	55	O
analogue	-	68	O
beraprost	-	77	O
and	-	87	O
phosphodiesterase	-	91	O
inhibitor	-	109	O
cilostazol	-	119	O
.	-	129	O

Among	7596955	131	O
various	-	137	O
oral	-	145	O
antiplatelets	-	150	O
,	-	163	O
a	-	165	O
combination	-	167	O
of	-	179	O
a	-	182	O
novel	-	184	O
prostacyclin	-	190	O
analogue	-	203	O
beraprost	-	212	O
(	-	222	O
BPT	-	223	O
)	-	226	O
and	-	228	O
a	-	232	O
potent	-	234	O
phosphodiesterase	-	241	O
inhibitor	-	259	O
cilostazol	-	269	O
(	-	280	O
CLZ	-	281	O
)	-	284	O
may	-	286	O
result	-	290	O
in	-	297	O
untoward	-	300	O
clinical	-	309	O
effects	-	318	O
due	-	326	O
to	-	330	O
possible	-	333	O
synergistic	-	342	O
elevation	-	354	O
of	-	364	O
intracellular	-	367	O
cAMP	-	381	O
(	-	386	O
cyclic	-	387	O
adenosine	-	394	O
3'	-	404	O
,	-	406	O
5'	-	407	O
-	-	409	O
monophosphate	-	410	O
)	-	423	O
.	-	424	O

Thereby	7596955	426	O
,	-	433	O
a	-	435	O
clinical	-	437	O
study	-	446	O
of	-	452	O
the	-	455	O
combined	-	459	O
administration	-	468	O
of	-	483	O
the	-	486	O
two	-	490	O
agents	-	494	O
was	-	501	O
attempted	-	505	O
.	-	514	O

Twelve	7596955	516	O
healthy	-	523	O
volunteers	-	531	O
were	-	542	O
assigned	-	547	O
to	-	556	O
take	-	559	O
BPT	-	564	O
/	-	567	O
CLZ	-	568	O
in	-	572	O
the	-	575	O
following	-	579	O
schedule	-	589	O
;	-	597	O
BPT	-	599	O
:	-	602	O
40	-	604	O
micrograms	-	607	O
at	-	618	O
day	-	621	O
1	-	625	O
and	-	627	O
120	-	631	O
micrograms	-	635	O
t	-	646	O
.	-	647	O
i	-	648	O
.	-	649	O
d	-	650	O
.	-	651	O
from	-	653	O
day	-	658	O
7	-	662	O
to	-	664	O
14	-	667	O
,	-	669	O
CLZ	-	671	O
:	-	674	O
200	-	676	O
mg	-	680	O
t	-	683	O
.	-	684	O
i	-	685	O
.	-	686	O
d	-	687	O
.	-	688	O
from	-	690	O
day	-	695	O
3	-	699	O
to	-	701	O
14	-	704	O
.	-	706	O

At	7596955	708	O
various	-	711	O
time	-	719	O
intervals	-	724	O
,	-	733	O
physical	-	735	O
examination	-	744	O
and	-	756	O
blood	-	760	O
collection	-	766	O
for	-	777	O
ex	-	781	O
vivo	-	784	O
platelet	-	789	B
aggregation	-	798	I
and	-	810	O
determination	-	814	O
of	-	828	O
intraplatelet	-	831	O
cAMP	-	845	O
were	-	850	O
performed	-	855	O
.	-	864	O

Throughout	7596955	866	O
the	-	877	O
observation	-	881	O
period	-	893	O
,	-	899	O
no	-	901	O
significant	-	904	O
alteration	-	916	O
in	-	927	O
vital	-	930	O
signs	-	936	O
was	-	942	O
observed	-	946	O
.	-	954	O

Seven	7596955	956	O
out	-	962	O
of	-	966	O
12	-	969	O
subjects	-	972	O
experienced	-	981	O
headache	-	993	B
of	-	1002	O
a	-	1005	O
short	-	1007	O
duration	-	1013	O
accompanying	-	1022	O
facial	-	1035	B
flush	-	1042	I
in	-	1048	O
one	-	1051	O
and	-	1055	O
nausea	-	1059	B
in	-	1066	O
one	-	1069	O
,	-	1072	O
especially	-	1074	O
after	-	1085	O
ingestion	-	1091	O
of	-	1101	O
CLZ	-	1104	O
.	-	1107	O

All	7596955	1109	O
of	-	1113	O
these	-	1116	O
symptoms	-	1122	O
,	-	1130	O
probably	-	1132	O
caused	-	1141	O
by	-	1148	O
the	-	1151	O
vasodilating	-	1155	O
effect	-	1168	O
of	-	1175	O
the	-	1178	O
two	-	1182	O
agents	-	1186	O
,	-	1192	O
were	-	1194	O
of	-	1199	O
mild	-	1202	O
degree	-	1207	O
and	-	1214	O
no	-	1218	O
special	-	1221	O
treatment	-	1229	O
was	-	1239	O
required	-	1243	O
.	-	1251	O

Intraplatelet	7596955	1253	O
cAMP	-	1267	O
content	-	1272	O
was	-	1280	O
gradually	-	1284	O
but	-	1294	O
significantly	-	1298	O
increased	-	1312	O
to	-	1322	O
9	-	1325	O
.	-	1326	O
84	-	1327	O
+	-	1330	O
/	-	1331	O
-	-	1332	O

4	7596955	1334	O
.	-	1335	O
59	-	1336	O
pmol	-	1339	O
per	-	1344	O
10	-	1348	O
(	-	1350	O
9	-	1351	O
)	-	1352	O
platelets	-	1354	O
at	-	1364	O
day	-	1367	O
14	-	1371	O
in	-	1374	O
comparison	-	1377	O
with	-	1388	O
the	-	1393	O
initial	-	1397	O
value	-	1405	O
(	-	1411	O
6	-	1412	O
.	-	1413	O
87	-	1414	O
+	-	1417	O
/	-	1418	O
-	-	1419	O

2	7596955	1421	O
.	-	1422	O
25	-	1423	O
pmol	-	1426	O
)	-	1430	O
.	-	1431	O

The	7596955	1433	O
platelet	-	1437	O
aggregability	-	1446	O
was	-	1460	O
significantly	-	1464	O
suppressed	-	1478	O
at	-	1489	O
various	-	1492	O
time	-	1500	O
intervals	-	1505	O
but	-	1515	O
no	-	1519	O
additive	-	1522	O
or	-	1531	O
synergistic	-	1534	O
inhibitory	-	1546	O
effect	-	1557	O
by	-	1564	O
the	-	1567	O
combined	-	1571	O
administration	-	1580	O
was	-	1595	O
noted	-	1599	O
.	-	1604	O

In	7596955	1606	O
conclusion	-	1609	O
,	-	1619	O
the	-	1621	O
combined	-	1625	O
administration	-	1634	O
of	-	1649	O
BPT	-	1652	O
/	-	1655	O
CLZ	-	1656	O
is	-	1660	O
safe	-	1663	O
at	-	1668	O
doses	-	1671	O
used	-	1677	O
in	-	1682	O
the	-	1685	O
study	-	1689	O
,	-	1694	O
though	-	1696	O
the	-	1703	O
beneficial	-	1707	O
clinical	-	1718	O
effect	-	1727	O
of	-	1734	O
the	-	1737	O
combined	-	1741	O
administration	-	1750	O
has	-	1765	O
yet	-	1769	O
to	-	1773	O
be	-	1776	O
elucidated	-	1779	O
.	-	1789	O

Gastrointestinal	17965424	0	O
tolerability	-	17	O
of	-	30	O
etoricoxib	-	33	O
in	-	44	O
rheumatoid	-	47	B
arthritis	-	58	I
patients	-	68	O
:	-	76	O
results	-	78	O
of	-	86	O
the	-	89	O
etoricoxib	-	93	O
vs	-	104	O
diclofenac	-	107	O
sodium	-	118	O
gastrointestinal	-	125	O
tolerability	-	142	O
and	-	155	O
effectiveness	-	159	O
trial	-	173	O
(	-	179	O
EDGE	-	180	O
-	-	184	O
II	-	185	O
)	-	187	O
.	-	188	O

OBJECTIVE	17965424	190	O
:	-	199	O

A	17965424	201	O
randomised	-	203	O
,	-	213	O
double	-	215	O
-	-	221	O
blind	-	222	O
study	-	228	O
to	-	234	O
compare	-	237	O
the	-	245	O
gastrointestinal	-	249	O
(	-	266	O
GI	-	267	O
)	-	269	O
tolerability	-	271	O
,	-	283	O
safety	-	285	O
and	-	292	O
efficacy	-	296	O
of	-	305	O
etoricoxib	-	308	O
and	-	319	O
diclofenac	-	323	O
in	-	334	O
patients	-	337	O
with	-	346	O
rheumatoid	-	351	B
arthritis	-	362	I
(	-	372	O
RA	-	373	B
)	-	375	O
.	-	376	O

PATIENTS	17965424	378	O
AND	-	387	O
METHODS	-	391	O
:	-	398	O

A	17965424	400	O
total	-	402	O
of	-	408	O
4086	-	411	O
patients	-	416	O
(	-	425	O
mean	-	426	O
age	-	431	O
60	-	435	O
.	-	437	O
8	-	438	O
years	-	440	O
)	-	445	O
diagnosed	-	447	O
with	-	457	O
RA	-	462	B
were	-	465	O
enrolled	-	470	O
and	-	479	O
received	-	483	O
etoricoxib	-	492	O
90	-	503	O
mg	-	506	O
daily	-	509	O
(	-	515	O
n	-	516	O
=	-	518	O
2032	-	520	O
)	-	524	O
or	-	526	O
diclofenac	-	529	O
75	-	540	O
mg	-	543	O
twice	-	546	O
daily	-	552	O
(	-	558	O
n	-	559	O
=	-	561	O
2054	-	563	O
)	-	567	O
.	-	568	O

Use	17965424	570	O
of	-	574	O
gastroprotective	-	577	O
agents	-	594	O
and	-	601	O
low	-	605	O
-	-	608	O
dose	-	609	O
aspirin	-	614	O
was	-	622	O
allowed	-	626	O
.	-	633	O

The	17965424	635	O
prespecified	-	639	O
primary	-	652	O
end	-	660	O
point	-	664	O
consisted	-	670	O
of	-	680	O
the	-	683	O
cumulative	-	687	O
rate	-	698	O
of	-	703	O
patient	-	706	O
discontinuations	-	714	O
due	-	731	O
to	-	735	O
clinical	-	738	O
and	-	747	O
laboratory	-	751	O
GI	-	762	O
adverse	-	765	O
experiences	-	773	O
(	-	785	O
AEs	-	786	O
)	-	789	O
.	-	790	O

General	17965424	792	O
safety	-	800	O
was	-	807	O
also	-	811	O
assessed	-	816	O
,	-	824	O
including	-	826	O
adjudicated	-	836	O
thrombotic	-	848	B
cardiovascular	-	859	I
event	-	874	O
data	-	880	O
.	-	884	O

Efficacy	17965424	886	O
was	-	895	O
evaluated	-	899	O
using	-	909	O
the	-	915	O
Patient	-	919	O
Global	-	927	O
Assessment	-	934	O
of	-	945	O
Disease	-	948	O
Status	-	956	O
(	-	963	O
PGADS	-	964	O
;	-	969	O
0	-	971	O
-	-	972	O
4	-	973	O
point	-	975	O
scale	-	981	O
)	-	986	O
.	-	987	O

RESULTS	17965424	989	O
:	-	996	O

Mean	17965424	998	O
(	-	1003	O
SD	-	1004	O
;	-	1006	O
maximum	-	1008	O
)	-	1015	O
duration	-	1017	O
of	-	1026	O
treatment	-	1029	O
was	-	1039	O
19	-	1043	O
.	-	1045	O
3	-	1046	O
(	-	1048	O
10	-	1049	O
.	-	1051	O
3	-	1052	O
;	-	1053	O
32	-	1055	O
.	-	1057	O
9	-	1058	O
)	-	1059	O
and	-	1061	O
19	-	1065	O
.	-	1067	O
1	-	1068	O
(	-	1070	O
10	-	1071	O
.	-	1073	O
4	-	1074	O
;	-	1075	O
33	-	1077	O
.	-	1079	O
1	-	1080	O
)	-	1081	O
months	-	1083	O
in	-	1090	O
the	-	1093	O
etoricoxib	-	1097	O
and	-	1108	O
diclofenac	-	1112	O
groups	-	1123	O
,	-	1129	O
respectively	-	1131	O
.	-	1143	O

The	17965424	1145	O
cumulative	-	1149	O
discontinuation	-	1160	O
rate	-	1176	O
due	-	1181	O
to	-	1185	O
GI	-	1188	B
AEs	-	1191	I
was	-	1195	O
significantly	-	1199	O
lower	-	1213	O
with	-	1219	O
etoricoxib	-	1224	O
than	-	1235	O
diclofenac	-	1240	O
(	-	1251	O
5	-	1252	O
.	-	1253	O
2	-	1254	O
vs	-	1256	O
8	-	1259	O
.	-	1260	O
5	-	1261	O
events	-	1263	O
per	-	1270	O
100	-	1274	O
patient	-	1278	O
-	-	1285	O
years	-	1286	O
,	-	1291	O
respectively	-	1293	O
;	-	1305	O
hazard	-	1307	O
ratio	-	1314	O
0	-	1320	O
.	-	1321	O
62	-	1322	O
(	-	1325	O
95	-	1326	O
%	-	1328	O
CI	-	1330	O
:	-	1332	O
0	-	1334	O
.	-	1335	O
47	-	1336	O
,	-	1338	O
0	-	1340	O
.	-	1341	O
81	-	1342	O
;	-	1344	O
p	-	1346	O
<	-	1347	O
or	-	1348	O
=	-	1350	O
0	-	1351	O
.	-	1352	O
001	-	1353	O
)	-	1356	O
)	-	1357	O
.	-	1358	O

The	17965424	1360	O
incidence	-	1364	O
of	-	1374	O
discontinuations	-	1377	O
for	-	1394	O
hypertension	-	1398	B
-	-	1410	O
related	-	1411	O
and	-	1419	O
oedema	-	1423	B
-	-	1429	O
related	-	1430	O
AEs	-	1438	O
were	-	1442	O
significantly	-	1447	O
higher	-	1461	O
with	-	1468	O
etoricoxib	-	1473	O
(	-	1484	O
2	-	1485	O
.	-	1486	O
5	-	1487	O
%	-	1488	O
and	-	1490	O
1	-	1494	O
.	-	1495	O
1	-	1496	O
%	-	1497	O
respectively	-	1499	O
)	-	1511	O
compared	-	1513	O
with	-	1522	O
diclofenac	-	1527	O
(	-	1538	O
1	-	1539	O
.	-	1540	O
5	-	1541	O
%	-	1542	O
and	-	1544	O
0	-	1548	O
.	-	1549	O
4	-	1550	O
%	-	1551	O
respectively	-	1553	O
;	-	1565	O
p	-	1567	O
<	-	1568	O
0	-	1569	O
.	-	1570	O
001	-	1571	O
for	-	1575	O
hypertension	-	1579	B
and	-	1592	O
p	-	1596	O
<	-	1597	O
0	-	1598	O
.	-	1599	O
01	-	1600	O
for	-	1603	O
oedema	-	1607	B
)	-	1613	O
.	-	1614	O

Etoricoxib	17965424	1616	O
and	-	1627	O
diclofenac	-	1631	O
treatment	-	1642	O
resulted	-	1652	O
in	-	1661	O
similar	-	1664	O
efficacy	-	1672	O
(	-	1681	O
PGADS	-	1682	O
mean	-	1688	O
changes	-	1693	O
from	-	1701	O
baseline	-	1706	O
-	-	1715	O
0	-	1716	O
.	-	1717	O
62	-	1718	O
vs	-	1721	O
-	-	1724	O
0	-	1725	O
.	-	1726	O
58	-	1727	O
,	-	1729	O
respectively	-	1731	O
)	-	1743	O
.	-	1744	O

CONCLUSIONS	17965424	1746	O
:	-	1757	O

Etoricoxib	17965424	1759	O
90	-	1770	O
mg	-	1773	O
demonstrated	-	1776	O
a	-	1789	O
significantly	-	1791	O
lower	-	1805	O
risk	-	1811	O
for	-	1816	O
discontinuing	-	1820	O
treatment	-	1834	O
due	-	1844	O
to	-	1848	O
GI	-	1851	B
AEs	-	1854	I
compared	-	1858	O
with	-	1867	O
diclofenac	-	1872	O
150	-	1883	O
mg	-	1887	O
.	-	1889	O

Discontinuations	17965424	1891	O
from	-	1908	O
renovascular	-	1913	O
AEs	-	1926	O
,	-	1929	O
although	-	1931	O
less	-	1940	O
common	-	1945	O
than	-	1952	O
discontinuations	-	1957	O
from	-	1974	O
GI	-	1979	B
AEs	-	1982	I
,	-	1985	O
were	-	1987	O
significantly	-	1992	O
higher	-	2006	O
with	-	2013	O
etoricoxib	-	2018	O
.	-	2028	O

Placebo	17042884	0	O
-	-	7	O
level	-	8	O
incidence	-	14	O
of	-	24	O
extrapyramidal	-	27	B
symptoms	-	42	I
(	-	51	O
EPS	-	52	B
)	-	55	O
with	-	57	O
quetiapine	-	62	O
in	-	73	O
controlled	-	76	O
studies	-	87	O
of	-	95	O
patients	-	98	O
with	-	107	O
bipolar	-	112	B
mania	-	120	I
.	-	125	O

OBJECTIVES	17042884	127	O
:	-	137	O

To	17042884	139	O
evaluate	-	142	O
extrapyramidal	-	151	B
symptoms	-	166	I
(	-	175	O
EPS	-	176	B
)	-	179	O
,	-	180	O
including	-	182	O
akathisia	-	192	B
,	-	201	O
with	-	203	O
quetiapine	-	208	O
in	-	219	O
patients	-	222	O
with	-	231	O
bipolar	-	236	B
mania	-	244	I
.	-	249	O

METHODS	17042884	251	O
:	-	258	O

Data	17042884	260	O
were	-	265	O
analyzed	-	270	O
from	-	279	O
four	-	284	O
similarly	-	289	O
designed	-	299	O
,	-	307	O
randomized	-	309	O
,	-	319	O
double	-	321	O
-	-	327	O
blind	-	328	O
,	-	333	O
3	-	335	O
-	-	336	O
to	-	338	O
12	-	341	O
-	-	343	O
week	-	344	O
studies	-	349	O
.	-	356	O

Two	17042884	358	O
studies	-	362	O
evaluated	-	370	O
quetiapine	-	380	O
monotherapy	-	391	O
(	-	403	O
up	-	404	O
to	-	407	O
800	-	410	O
mg	-	414	O
/	-	416	O
day	-	417	O
)	-	420	O

(	17042884	422	O
n	-	423	O
=	-	425	O
209	-	427	O
)	-	430	O
versus	-	432	O
placebo	-	439	O
(	-	447	O
n	-	448	O
=	-	450	O
198	-	452	O
)	-	455	O
,	-	456	O
with	-	458	O
lithium	-	463	O
or	-	471	O
haloperidol	-	474	O
monotherapy	-	486	O
as	-	498	O
respective	-	501	O
active	-	512	O
controls	-	519	O
.	-	527	O

Two	17042884	529	O
studies	-	533	O
evaluated	-	541	O
quetiapine	-	551	O
(	-	562	O
up	-	563	O
to	-	566	O
800	-	569	O
mg	-	573	O
/	-	575	O
day	-	576	O
)	-	579	O
in	-	581	O
combination	-	584	O
with	-	596	O
a	-	601	O
mood	-	603	O
stabilizer	-	608	O
(	-	619	O
lithium	-	620	O
or	-	628	O
divalproex	-	631	O
,	-	641	O
QTP	-	643	O
+	-	647	O
Li	-	649	O
/	-	651	O
DVP	-	652	O
)	-	655	O

(	17042884	657	O
n	-	658	O
=	-	660	O
196	-	662	O
)	-	665	O
compared	-	667	O
to	-	676	O
placebo	-	679	O
and	-	687	O
mood	-	691	O
stabilizer	-	696	O
(	-	707	O
PBO	-	708	O
+	-	712	O
Li	-	714	O
/	-	716	O
DVP	-	717	O
)	-	720	O

(	17042884	722	O
n	-	723	O
=	-	725	O
203	-	727	O
)	-	730	O
.	-	731	O

Extrapyramidal	17042884	733	B
symptoms	-	748	I
were	-	757	O
evaluated	-	762	O
using	-	772	O
the	-	778	O
Simpson	-	782	O
-	-	789	O
Angus	-	790	O
Scale	-	796	O
(	-	802	O
SAS	-	803	O
)	-	806	O
,	-	807	O
the	-	809	O
Barnes	-	813	O
Akathisia	-	820	O
Rating	-	830	O
Scale	-	837	O
(	-	843	O
BARS	-	844	O
)	-	848	O
,	-	849	O
adverse	-	851	O
event	-	859	O
reports	-	865	O
and	-	873	O
anticholinergic	-	877	O
drug	-	893	O
usage	-	898	O
.	-	903	O

RESULTS	17042884	905	O
:	-	912	O

The	17042884	914	O
incidence	-	918	O
of	-	928	O
EPS	-	931	B
-	-	934	O
related	-	935	O
adverse	-	943	O
events	-	951	O
,	-	957	O
including	-	959	O
akathisia	-	969	B
,	-	978	O
was	-	980	O
no	-	984	O
different	-	987	O
with	-	997	O
quetiapine	-	1002	O
monotherapy	-	1013	O
(	-	1025	O
12	-	1026	O
.	-	1028	O
9	-	1029	O
%	-	1030	O
)	-	1031	O
than	-	1033	O
with	-	1038	O
placebo	-	1043	O
(	-	1051	O
13	-	1052	O
.	-	1054	O
1	-	1055	O
%	-	1056	O
)	-	1057	O
.	-	1058	O

Similarly	17042884	1060	O
,	-	1069	O
EPS	-	1071	B
-	-	1074	O
related	-	1075	O
adverse	-	1083	O
events	-	1091	O
with	-	1098	O
QTP	-	1103	O
+	-	1107	O
Li	-	1109	O
/	-	1111	O
DVP	-	1112	O
(	-	1116	O
21	-	1117	O
.	-	1119	O
4	-	1120	O
%	-	1121	O
)	-	1122	O
were	-	1124	O
no	-	1129	O
different	-	1132	O
than	-	1142	O
with	-	1147	O
PBO	-	1152	O
+	-	1156	O
Li	-	1158	O
/	-	1160	O
DVP	-	1161	O
(	-	1165	O
19	-	1166	O
.	-	1168	O
2	-	1169	O
%	-	1170	O
)	-	1171	O
.	-	1172	O

Adverse	17042884	1174	O
events	-	1182	O
related	-	1189	O
to	-	1197	O
EPS	-	1200	B
occurred	-	1204	O
in	-	1213	O
59	-	1216	O
.	-	1218	O
6	-	1219	O
%	-	1220	O
of	-	1222	O
patients	-	1225	O
treated	-	1234	O
with	-	1242	O
haloperidol	-	1247	O
(	-	1259	O
n	-	1260	O
=	-	1262	O
99	-	1264	O
)	-	1266	O
monotherapy	-	1268	O
,	-	1279	O
whereas	-	1281	O
26	-	1289	O
.	-	1291	O
5	-	1292	O
%	-	1293	O
of	-	1295	O
patients	-	1298	O
treated	-	1307	O
with	-	1315	O
lithium	-	1320	O
(	-	1328	O
n	-	1329	O
=	-	1331	O
98	-	1333	O
)	-	1335	O
monotherapy	-	1337	O
experienced	-	1349	O
adverse	-	1361	O
events	-	1369	O
related	-	1376	O
to	-	1384	O
EPS	-	1387	B
.	-	1390	O

The	17042884	1392	O
incidence	-	1396	O
of	-	1406	O
akathisia	-	1409	B
was	-	1419	O
low	-	1423	O
and	-	1427	O
similar	-	1431	O
with	-	1439	O
quetiapine	-	1444	O
monotherapy	-	1455	O
(	-	1467	O
3	-	1468	O
.	-	1469	O
3	-	1470	O
%	-	1471	O
)	-	1472	O
and	-	1474	O
placebo	-	1478	O
(	-	1486	O
6	-	1487	O
.	-	1488	O
1	-	1489	O
%	-	1490	O
)	-	1491	O
,	-	1492	O
and	-	1494	O
with	-	1498	O
QTP	-	1503	O
+	-	1507	O
Li	-	1509	O
/	-	1511	O
DVP	-	1512	O
(	-	1516	O
3	-	1517	O
.	-	1518	O
6	-	1519	O
%	-	1520	O
)	-	1521	O
and	-	1523	O
PBO	-	1527	O
+	-	1531	O
Li	-	1533	O
/	-	1535	O
DVP	-	1536	O
(	-	1540	O
4	-	1541	O
.	-	1542	O
9	-	1543	O
%	-	1544	O
)	-	1545	O
.	-	1546	O

Lithium	17042884	1548	O
was	-	1556	O
associated	-	1560	O
with	-	1571	O
a	-	1576	O
significantly	-	1578	O
higher	-	1592	O
incidence	-	1599	O
(	-	1609	O
p	-	1610	O
<	-	1612	O
0	-	1614	O
.	-	1615	O
05	-	1616	O
)	-	1618	O
of	-	1620	O
tremor	-	1623	B
(	-	1630	O
18	-	1631	O
.	-	1633	O
4	-	1634	O
%	-	1635	O
)	-	1636	O
than	-	1638	O
quetiapine	-	1643	O
(	-	1654	O
5	-	1655	O
.	-	1656	O
6	-	1657	O
%	-	1658	O
)	-	1659	O
;	-	1660	O
cerebellar	-	1662	O
tremor	-	1673	B
,	-	1679	O
which	-	1681	O
is	-	1687	O
a	-	1690	O
known	-	1692	O
adverse	-	1698	O
effect	-	1706	O
of	-	1713	O
lithium	-	1716	O
,	-	1723	O
may	-	1725	O
have	-	1729	O
contributed	-	1734	O
to	-	1746	O
the	-	1749	O
elevated	-	1753	O
rate	-	1762	O
of	-	1767	O
tremor	-	1770	B
in	-	1777	O
patients	-	1780	O
receiving	-	1789	O
lithium	-	1799	O
therapy	-	1807	O
.	-	1814	O

Haloperidol	17042884	1816	O
induced	-	1828	O
a	-	1836	O
significantly	-	1838	O
higher	-	1852	O
incidence	-	1859	O
(	-	1869	O
p	-	1870	O
<	-	1872	O
0	-	1874	O
.	-	1875	O
001	-	1876	O
)	-	1879	O
of	-	1881	O
akathisia	-	1884	B
(	-	1894	O
33	-	1895	O
.	-	1897	O
3	-	1898	O
%	-	1899	O
versus	-	1901	O
5	-	1908	O
.	-	1909	O
9	-	1910	O
%	-	1911	O
)	-	1912	O
,	-	1913	O
tremor	-	1915	B
(	-	1922	O
30	-	1923	O
.	-	1925	O
3	-	1926	O
%	-	1927	O
versus	-	1929	O
7	-	1936	O
.	-	1937	O
8	-	1938	O
%	-	1939	O
)	-	1940	O
,	-	1941	O
and	-	1943	O
extrapyramidal	-	1947	B
syndrome	-	1962	I
(	-	1971	O
35	-	1972	O
.	-	1974	O
4	-	1975	O
%	-	1976	O
versus	-	1978	O
5	-	1985	O
.	-	1986	O
9	-	1987	O
%	-	1988	O
)	-	1989	O
than	-	1991	O
quetiapine	-	1996	O
.	-	2006	O

No	17042884	2008	O
significant	-	2011	O
differences	-	2023	O
were	-	2035	O
observed	-	2040	O
between	-	2049	O
quetiapine	-	2057	O
and	-	2068	O
placebo	-	2072	O
on	-	2080	O
SAS	-	2083	O
and	-	2087	O
BARS	-	2091	O
scores	-	2096	O
.	-	2102	O

Anticholinergic	17042884	2104	O
use	-	2120	O
was	-	2124	O
low	-	2128	O
and	-	2132	O
similar	-	2136	O
with	-	2144	O
quetiapine	-	2149	O
or	-	2160	O
placebo	-	2163	O
.	-	2170	O

CONCLUSIONS	17042884	2172	O
:	-	2183	O

In	17042884	2185	O
bipolar	-	2188	B
mania	-	2196	I
,	-	2201	O
the	-	2203	O
incidence	-	2207	O
of	-	2217	O
EPS	-	2220	B
,	-	2223	O
including	-	2225	O
akathisia	-	2235	B
,	-	2244	O
with	-	2246	O
quetiapine	-	2251	O
therapy	-	2262	O
is	-	2270	O
similar	-	2273	O
to	-	2281	O
that	-	2284	O
with	-	2289	O
placebo	-	2294	O
.	-	2301	O

Contribution	8586822	0	O
of	-	13	O
the	-	16	O
sympathetic	-	20	O
nervous	-	32	O
system	-	40	O
to	-	47	O
salt	-	50	O
-	-	54	O
sensitivity	-	55	O
in	-	67	O
lifetime	-	70	O
captopril	-	79	O
-	-	88	O
treated	-	89	O
spontaneously	-	97	O
hypertensive	-	111	B
rats	-	124	O
.	-	128	O

OBJECTIVE	8586822	130	O
:	-	139	O

To	8586822	141	O
test	-	144	O
the	-	149	O
hypothesis	-	153	O
that	-	164	O
,	-	168	O
in	-	170	O
lifetime	-	173	O
captopril	-	182	O
-	-	191	O
treated	-	192	O
spontaneously	-	200	O
hypertensive	-	214	B
rats	-	227	O
(	-	232	O
SHR	-	233	O
)	-	236	O
,	-	237	O
the	-	239	O
sympathetic	-	243	O
nervous	-	255	O
system	-	263	O
contributes	-	270	O
importantly	-	282	O
to	-	294	O
the	-	297	O
hypertensive	-	301	B
effect	-	314	O
of	-	321	O
dietary	-	324	O
sodium	-	332	O
chloride	-	339	O
supplementation	-	348	O
.	-	363	O

METHODS	8586822	365	O
:	-	372	O

Male	8586822	374	O
SHR	-	379	O
(	-	383	O
aged	-	384	O
6	-	389	O
weeks	-	391	O
)	-	396	O
that	-	398	O
had	-	403	O
been	-	407	O
treated	-	412	O
from	-	420	O
conception	-	425	O
onward	-	436	O
with	-	443	O
either	-	448	O
captopril	-	455	O
or	-	465	O
vehicle	-	468	O
remained	-	476	O
on	-	485	O
a	-	488	O
basal	-	490	O
sodium	-	496	O
chloride	-	503	O
diet	-	512	O
or	-	517	O
were	-	520	O
fed	-	525	O
a	-	529	O
high	-	531	O
sodium	-	536	O
chloride	-	543	O
diet	-	552	O
.	-	556	O

After	8586822	558	O
2	-	564	O
weeks	-	566	O
,	-	571	O
the	-	573	O
rats	-	577	O
were	-	582	O
subjected	-	587	O
to	-	597	O
ganglionic	-	600	O
blockade	-	611	O
and	-	620	O
2	-	624	O
days	-	626	O
later	-	631	O
,	-	636	O
an	-	638	O
infusion	-	641	O
of	-	650	O
clonidine	-	653	O
.	-	662	O

RESULTS	8586822	664	O
:	-	671	O

Lifetime	8586822	673	O
captopril	-	682	O
treatment	-	692	O
significantly	-	702	O
lowered	-	716	O
mean	-	724	O
arterial	-	729	O
pressure	-	738	O
in	-	747	O
both	-	750	O
groups	-	755	O
.	-	761	O

Intravenous	8586822	763	O
infusion	-	775	O
of	-	784	O
the	-	787	O
ganglionic	-	791	O
blocker	-	802	O
hexamethonium	-	810	O
resulted	-	824	O
in	-	833	O
a	-	836	O
rapid	-	838	O
decline	-	844	O
in	-	852	O
MAP	-	855	O
that	-	859	O
eliminated	-	864	O
the	-	875	O
dietary	-	879	O
sodium	-	887	O
chloride	-	894	O
-	-	902	O
induced	-	903	O
increase	-	911	B
in	-	920	I
MAP	-	923	I
in	-	927	O
both	-	930	O
groups	-	935	O
.	-	941	O

Infusion	8586822	943	O
of	-	952	O
the	-	955	O
central	-	959	O
nervous	-	967	O
system	-	975	O
alpha2	-	982	O
-	-	988	O
adrenergic	-	989	O
receptor	-	1000	O
agonist	-	1009	O
clonidine	-	1017	O
also	-	1027	O
resulted	-	1032	O
in	-	1041	O
a	-	1044	O
greater	-	1046	O
reduction	-	1054	O
in	-	1064	O
MAP	-	1067	O
in	-	1071	O
both	-	1074	O
groups	-	1079	O
of	-	1086	O
SHR	-	1089	O
that	-	1093	O
were	-	1098	O
fed	-	1103	O
the	-	1107	O
high	-	1111	O
(	-	1116	O
compared	-	1117	O
with	-	1126	O
the	-	1131	O
basal	-	1135	O
)	-	1140	O
sodium	-	1142	O
chloride	-	1149	O
diet	-	1158	O
.	-	1162	O

CONCLUSIONS	8586822	1164	O
:	-	1175	O

In	8586822	1177	O
both	-	1180	O
lifetime	-	1185	O
captopril	-	1194	O
-	-	1203	O
treated	-	1204	O
and	-	1212	O
control	-	1216	O
SHR	-	1224	O
,	-	1227	O
the	-	1229	O
sympathetic	-	1233	O
nervous	-	1245	O
system	-	1253	O
contributes	-	1260	O
to	-	1272	O
the	-	1275	O
pressor	-	1279	O
effects	-	1287	O
of	-	1295	O
a	-	1298	O
high	-	1300	O
sodium	-	1305	O
chloride	-	1312	O
diet	-	1321	O
.	-	1325	O

Dose	3961813	0	O
-	-	4	O
related	-	5	O
beneficial	-	13	O
and	-	24	O
adverse	-	28	O
effects	-	36	O
of	-	44	O
dietary	-	47	O
corticosterone	-	55	O
on	-	70	O
organophosphorus	-	73	O
-	-	89	O
induced	-	90	O
delayed	-	98	O
neuropathy	-	106	B
in	-	117	O
chickens	-	120	O
.	-	128	O

Tri	3961813	130	O
-	-	133	O
ortho	-	134	O
-	-	139	O
tolyl	-	140	O
phosphate	-	146	O
(	-	156	O
TOTP	-	157	O
)	-	161	O
,	-	162	O
360	-	164	O
mg	-	168	O
/	-	170	O
kg	-	171	O
,	-	173	O
po	-	175	O
,	-	177	O
and	-	179	O
0	-	183	O
,	-	184	O
0'	-	185	O
-	-	187	O
diisopropyl	-	188	O
phosphorofluoridate	-	200	O
(	-	220	O
DFP	-	221	O
)	-	224	O
,	-	225	O
1	-	227	O
mg	-	229	O
/	-	231	O
kg	-	232	O
sc	-	235	O
,	-	237	O
were	-	239	O
administered	-	244	O
to	-	257	O
adult	-	260	O
White	-	266	O
Leghorn	-	272	O
chickens	-	280	O
24	-	289	O
hr	-	292	O
after	-	295	O
they	-	301	O
were	-	306	O
placed	-	311	O
on	-	318	O
diets	-	321	O
containing	-	327	O
0	-	338	O
to	-	340	O
300	-	343	O
ppm	-	347	O
corticosterone	-	351	O
.	-	365	O

Supplemented	3961813	367	O
diets	-	380	O
were	-	386	O
continued	-	391	O
until	-	401	O
clinical	-	407	O
signs	-	416	O
and	-	422	O
lesions	-	426	O
of	-	434	O
delayed	-	437	O
neuropathy	-	445	B
appeared	-	456	O
.	-	464	O

Although	3961813	466	O
low	-	475	O
concentrations	-	479	O
(	-	494	O
less	-	495	O
than	-	500	O
or	-	505	O
equal	-	508	O
to	-	514	O
50	-	517	O
ppm	-	520	O
)	-	523	O
of	-	525	O
corticosterone	-	528	O
had	-	543	O
beneficial	-	547	O
effects	-	558	O
on	-	566	O
TOTP	-	569	O
-	-	573	O
induced	-	574	O
neuropathy	-	582	B
,	-	592	O
greater	-	594	O
than	-	602	O
or	-	607	O
equal	-	610	O
to	-	616	O
200	-	619	O
ppm	-	623	O
exacerbated	-	627	O
clinical	-	639	O
signs	-	648	O
in	-	654	O
chickens	-	657	O
given	-	666	O
either	-	672	O
TOTP	-	679	O
or	-	684	O
DFP	-	687	O
.	-	690	O

Neurotoxic	3961813	692	B
esterase	-	703	O
activities	-	712	O
24	-	723	O
hr	-	726	O
after	-	729	O
TOTP	-	735	O
or	-	740	O
DFP	-	743	O
were	-	747	O
less	-	752	O
than	-	757	O
20	-	762	O
%	-	764	O
of	-	766	O
values	-	769	O
measured	-	776	O
in	-	785	O
chickens	-	788	O
not	-	797	O
given	-	801	O
organophosphorous	-	807	O
compounds	-	825	O
.	-	834	O

Chickens	3961813	836	O
given	-	845	O
200	-	851	O
ppm	-	855	O
corticosterone	-	859	O
without	-	874	O
TOTP	-	882	O
or	-	887	O
DFP	-	890	O
had	-	894	O
significantly	-	898	O
elevated	-	912	O
activity	-	921	O
of	-	930	O
plasma	-	933	O
cholinesterase	-	940	O
and	-	955	O
significantly	-	959	O
inhibited	-	973	O
activity	-	983	O
of	-	992	O
liver	-	995	O
carboxylesterase	-	1001	O
.	-	1017	O

Degenerating	3961813	1019	B
myelinated	-	1032	I
fibers	-	1043	I
were	-	1050	O
also	-	1055	O
evident	-	1060	O
in	-	1068	O
distal	-	1071	O
levels	-	1078	O
of	-	1085	O
the	-	1088	O
peripheral	-	1092	O
nerves	-	1103	O
of	-	1110	O
chickens	-	1113	O
given	-	1122	O
TOTP	-	1128	O
or	-	1133	O
DFP	-	1136	O
.	-	1139	O

In	20973483	0	O
vivo	-	3	O
characterization	-	8	O
of	-	25	O
a	-	28	O
dual	-	30	O
adenosine	-	35	O
A2A	-	45	O
/	-	48	O
A1	-	49	O
receptor	-	52	O
antagonist	-	61	O
in	-	72	O
animal	-	75	O
models	-	82	O
of	-	89	O
Parkinson	-	92	B
's	-	101	I
disease	-	104	I
.	-	111	O

The	20973483	113	O
in	-	117	O
vivo	-	120	O
characterization	-	125	O
of	-	142	O
a	-	145	O
dual	-	147	O
adenosine	-	152	O
A	-	162	O
(	-	163	O
2A	-	164	O
)	-	166	O
/	-	167	O
A	-	168	O
(	-	169	O
1	-	170	O
)	-	171	O
receptor	-	173	O
antagonist	-	182	O
in	-	193	O
several	-	196	O
animal	-	204	O
models	-	211	O
of	-	218	O
Parkinson	-	221	B
's	-	230	I
disease	-	233	I
is	-	241	O
described	-	244	O
.	-	253	O

Discovery	20973483	255	O
and	-	265	O
scale	-	269	O
-	-	274	O
up	-	275	O
syntheses	-	278	O
of	-	288	O
compound	-	291	O
1	-	300	O
are	-	302	O
described	-	306	O
in	-	316	O
detail	-	319	O
,	-	325	O
highlighting	-	327	O
optimization	-	340	O
steps	-	353	O
that	-	359	O
increased	-	364	O
the	-	374	O
overall	-	378	O
yield	-	386	O
of	-	392	O
1	-	395	O
from	-	397	O
10	-	402	O
.	-	404	O
0	-	405	O
%	-	406	O
to	-	408	O
30	-	411	O
.	-	413	O
5	-	414	O
%	-	415	O
.	-	416	O

Compound	20973483	418	O
1	-	427	O
is	-	429	O
a	-	432	O
potent	-	434	O
A	-	441	O
(	-	442	O
2A	-	443	O
)	-	445	O
/	-	446	O
A	-	447	O
(	-	448	O
1	-	449	O
)	-	450	O
receptor	-	452	O
antagonist	-	461	O
in	-	472	O
vitro	-	475	O
(	-	481	O
A	-	482	O
(	-	483	O
2A	-	484	O
)	-	486	O
K	-	488	O
(	-	489	O
i	-	490	O
)	-	491	O
=	-	493	O

4	20973483	495	O
.	-	496	O
1	-	497	O
nM	-	499	O
;	-	501	O
A	-	503	O
(	-	504	O
1	-	505	O
)	-	506	O
K	-	508	O
(	-	509	O
i	-	510	O
)	-	511	O
=	-	513	O

17	20973483	515	O
.	-	517	O
0	-	518	O
nM	-	520	O
)	-	522	O
that	-	524	O
has	-	529	O
excellent	-	533	O
activity	-	543	O
,	-	551	O
after	-	553	O
oral	-	559	O
administration	-	564	O
,	-	578	O
across	-	580	O
a	-	587	O
number	-	589	O
of	-	596	O
animal	-	599	O
models	-	606	O
of	-	613	O
Parkinson	-	616	B
's	-	625	I
disease	-	628	I
including	-	636	O
mouse	-	646	O
and	-	652	O
rat	-	656	O
models	-	660	O
of	-	667	O
haloperidol	-	670	O
-	-	681	O
induced	-	682	O
catalepsy	-	690	B
,	-	699	O
mouse	-	701	O
model	-	707	O
of	-	713	O
reserpine	-	716	O
-	-	725	O
induced	-	726	O
akinesia	-	734	B
,	-	742	O
rat	-	744	O
6	-	748	O
-	-	749	O
hydroxydopamine	-	750	O
(	-	766	O
6	-	767	O
-	-	768	O
OHDA	-	769	O
)	-	773	O
lesion	-	775	O
model	-	782	O
of	-	788	O
drug	-	791	O
-	-	795	O
induced	-	796	O
rotation	-	804	O
,	-	812	O
and	-	814	O
MPTP	-	818	O
-	-	822	O
treated	-	823	O
non	-	831	O
-	-	834	O
human	-	835	O
primate	-	841	O
model	-	849	O
.	-	854	O

An	17511042	0	O
extremely	-	3	O
rare	-	13	O
case	-	18	O
of	-	23	O
delusional	-	26	B
parasitosis	-	37	I
in	-	49	O
a	-	52	O
chronic	-	54	B
hepatitis	-	62	I
C	-	72	I
patient	-	74	O
during	-	82	O
pegylated	-	89	O
interferon	-	99	O
alpha	-	110	O
-	-	115	O
2b	-	116	O
and	-	119	O
ribavirin	-	123	O
treatment	-	133	O
.	-	142	O

During	17511042	144	O
treatment	-	151	O
of	-	161	O
chronic	-	164	B
hepatitis	-	172	I
C	-	182	I
patients	-	184	O
with	-	193	O
interferon	-	198	O
and	-	209	O
ribavirin	-	213	O
,	-	222	O
a	-	224	O
lot	-	226	O
of	-	230	O
side	-	233	O
effects	-	238	O
are	-	246	O
described	-	250	O
.	-	259	O

Twenty	17511042	261	O
-	-	267	O
three	-	268	O
percent	-	274	O
to	-	282	O
44	-	285	O
%	-	287	O
of	-	289	O
patients	-	292	O
develop	-	301	O
depression	-	309	B
.	-	319	O

A	17511042	321	O
minority	-	323	O
of	-	332	O
patients	-	335	O
evolve	-	344	O
to	-	351	O
psychosis	-	354	B
.	-	363	O

To	17511042	365	O
the	-	368	O
best	-	372	O
of	-	377	O
our	-	380	O
knowledge	-	384	O
,	-	393	O
no	-	395	O
cases	-	398	O
of	-	404	O
psychogenic	-	407	B
parasitosis	-	419	I
occurring	-	431	O
during	-	441	O
interferon	-	448	O
therapy	-	459	O
have	-	467	O
been	-	472	O
described	-	477	O
in	-	487	O
the	-	490	O
literature	-	494	O
.	-	504	O

We	17511042	506	O
present	-	509	O
a	-	517	O
49	-	519	O
-	-	521	O
year	-	522	O
-	-	526	O
old	-	527	O
woman	-	531	O
who	-	537	O
developed	-	541	O
a	-	551	O
delusional	-	553	B
parasitosis	-	564	I
during	-	576	O
treatment	-	583	O
with	-	593	O
pegylated	-	598	O
interferon	-	608	O
alpha	-	619	O
-	-	624	O
2b	-	625	O
weekly	-	628	O
and	-	635	O
ribavirin	-	639	O
.	-	648	O

She	17511042	650	O
complained	-	654	O
of	-	665	O
seeing	-	668	O
parasites	-	675	O
and	-	685	O
the	-	689	O
larvae	-	693	O
of	-	700	O
fleas	-	703	O
in	-	709	O
her	-	712	O
stools	-	716	O
.	-	722	O

This	17511042	724	O
could	-	729	O
not	-	735	O
be	-	739	O
confirmed	-	742	O
by	-	752	O
any	-	755	O
technical	-	759	O
examination	-	769	O
.	-	780	O

All	17511042	782	O
the	-	786	O
complaints	-	790	O
disappeared	-	801	O
after	-	813	O
stopping	-	819	O
pegylated	-	828	O
interferon	-	838	O
alpha	-	849	O
-	-	854	O
2b	-	855	O
and	-	858	O
reappeared	-	862	O
after	-	873	O
restarting	-	879	O
it	-	890	O
.	-	892	O

She	17511042	894	O
had	-	898	O
a	-	902	O
complete	-	904	O
sustained	-	913	O
viral	-	923	O
response	-	929	O
.	-	937	O

Possible	16720068	0	O
neuroleptic	-	9	B
malignant	-	21	I
syndrome	-	31	I
related	-	40	O
to	-	48	O
concomitant	-	51	O
treatment	-	63	O
with	-	73	O
paroxetine	-	78	O
and	-	89	O
alprazolam	-	93	O
.	-	103	O

A	16720068	105	O
74	-	107	O
-	-	109	O
year	-	110	O
-	-	114	O
old	-	115	O
man	-	119	O
with	-	123	O
depressive	-	128	B
symptoms	-	139	I
was	-	148	O
admitted	-	152	O
to	-	161	O
a	-	164	O
psychiatric	-	166	B
hospital	-	178	O
due	-	187	O
to	-	191	O
insomnia	-	194	B
,	-	202	O
loss	-	204	B
of	-	209	I
appetite	-	212	I
,	-	220	O
exhaustion	-	222	O
,	-	232	O
and	-	234	O
agitation	-	238	B
.	-	247	O

Medical	16720068	249	O
treatment	-	257	O
was	-	267	O
initiated	-	271	O
at	-	281	O
a	-	284	O
daily	-	286	O
dose	-	292	O
of	-	297	O
20	-	300	O
mg	-	303	O
paroxetine	-	306	O
and	-	317	O
1	-	321	O
.	-	322	O
2	-	323	O
mg	-	325	O
alprazolam	-	328	O
.	-	338	O

On	16720068	340	O
the	-	343	O
10th	-	347	O
day	-	352	O
of	-	356	O
paroxetine	-	359	O
and	-	370	O
alprazolam	-	374	O
treatment	-	385	O
,	-	394	O
the	-	396	O
patient	-	400	O
exhibited	-	408	O
marked	-	418	O
psychomotor	-	425	B
retardation	-	437	I
,	-	448	O
disorientation	-	450	O
,	-	464	O
and	-	466	O
severe	-	470	O
muscle	-	477	B
rigidity	-	484	I
with	-	493	O
tremors	-	498	B
.	-	505	O

The	16720068	507	O
patient	-	511	O
had	-	519	O
a	-	523	O
fever	-	525	B
(	-	531	O
38	-	532	O
.	-	534	O
2	-	535	O
degrees	-	537	O
C	-	545	O
)	-	546	O
,	-	547	O
fluctuating	-	549	O
blood	-	561	O
pressure	-	567	O
(	-	576	O
between	-	577	O
165	-	585	O
/	-	588	O
90	-	589	O
and	-	592	O
130	-	596	O
/	-	599	O
70	-	600	O
mg	-	603	O
mm	-	606	O
Hg	-	609	O
)	-	611	O
,	-	612	O
and	-	614	O
severe	-	618	O
extrapyramidal	-	625	B
symptoms	-	640	I
.	-	648	O

Laboratory	16720068	650	O
tests	-	661	O
showed	-	667	O
an	-	674	O
elevation	-	677	O
of	-	687	O
creatine	-	690	O
phosphokinase	-	699	O
(	-	713	O
2218	-	714	O
IU	-	719	O
/	-	721	O
L	-	722	O
)	-	723	O
,	-	724	O
aspartate	-	726	O
aminotransferase	-	736	O
(	-	753	O
134	-	754	O
IU	-	758	O
/	-	760	O
L	-	761	O
)	-	762	O
,	-	763	O
alanine	-	765	O
aminotransferase	-	773	O
(	-	790	O
78	-	791	O
IU	-	794	O
/	-	796	O
L	-	797	O
)	-	798	O
,	-	799	O
and	-	801	O
BUN	-	805	O
(	-	809	O
27	-	810	O
.	-	812	O
9	-	813	O
mg	-	815	O
/	-	817	O
ml	-	818	O
)	-	820	O
levels	-	822	O
.	-	828	O

The	16720068	830	O
patient	-	834	O
received	-	842	O
bromocriptine	-	851	O
and	-	865	O
diazepam	-	869	O
to	-	878	O
treat	-	881	O
his	-	887	O
symptoms	-	891	O
.	-	899	O

7	16720068	901	O
days	-	903	O
later	-	908	O
,	-	913	O
the	-	915	O
fever	-	919	B
disappeared	-	925	O
and	-	937	O
the	-	941	O
patient	-	945	O
's	-	952	O
serum	-	955	O
CPK	-	961	O
levels	-	965	O
were	-	972	O
normalized	-	977	O
(	-	988	O
175	-	989	O
IU	-	993	O
/	-	995	O
L	-	996	O
)	-	997	O
.	-	998	O

This	16720068	1000	O
patient	-	1005	O
presented	-	1013	O
with	-	1023	O
symptoms	-	1028	O
of	-	1037	O
neuroleptic	-	1040	B
malignant	-	1052	I
syndrome	-	1062	I
(	-	1071	O
NMS	-	1072	B
)	-	1075	O
,	-	1076	O
thus	-	1078	O
demonstrating	-	1083	O
that	-	1097	O
NMS	-	1102	B
-	-	1105	O
like	-	1106	O
symptoms	-	1111	O
can	-	1120	O
occur	-	1124	O
after	-	1130	O
combined	-	1136	O
paroxetine	-	1145	O
and	-	1156	O
alprazolam	-	1160	O
treatment	-	1171	O
.	-	1180	O

The	16720068	1182	O
adverse	-	1186	O
drug	-	1194	O
reaction	-	1199	O
score	-	1208	O
obtained	-	1214	O
by	-	1223	O
the	-	1226	O
Naranjo	-	1230	O
algorithm	-	1238	O
was	-	1248	O
6	-	1252	O
in	-	1254	O
our	-	1257	O
case	-	1261	O
,	-	1265	O
indicating	-	1267	O
a	-	1278	O
probable	-	1280	O
relationship	-	1289	O
between	-	1302	O
the	-	1310	O
patient	-	1314	O
's	-	1321	O
NMS	-	1324	B
-	-	1327	O
like	-	1328	O
adverse	-	1333	O
symptoms	-	1341	O
and	-	1350	O
the	-	1354	O
combined	-	1358	O
treatment	-	1367	O
used	-	1377	O
in	-	1382	O
this	-	1385	O
case	-	1390	O
.	-	1394	O

The	16720068	1396	O
involvement	-	1400	O
of	-	1412	O
physiologic	-	1415	O
and	-	1427	O
environmental	-	1431	O
aspects	-	1445	O
specific	-	1453	O
to	-	1462	O
this	-	1465	O
patient	-	1470	O
was	-	1478	O
suspected	-	1482	O
.	-	1491	O

Several	16720068	1493	O
risk	-	1501	O
factors	-	1506	O
for	-	1514	O
NMS	-	1518	B
should	-	1522	O
be	-	1529	O
noted	-	1532	O
in	-	1538	O
elderly	-	1541	O
depressive	-	1549	B
patients	-	1560	O
whose	-	1569	O
symptoms	-	1575	O
often	-	1584	O
include	-	1590	O
dehydration	-	1598	B
,	-	1609	O
agitation	-	1611	B
,	-	1620	O
malnutrition	-	1622	B
,	-	1634	O
and	-	1636	O
exhaustion	-	1640	O
.	-	1650	O

Careful	16720068	1652	O
therapeutic	-	1660	O
intervention	-	1672	O
is	-	1685	O
necessary	-	1688	O
in	-	1698	O
cases	-	1701	O
involving	-	1707	O
elderly	-	1717	O
patients	-	1725	O
who	-	1734	O
suffer	-	1738	O
from	-	1745	O
depression	-	1750	B
.	-	1760	O

Pilocarpine	16596970	0	O
seizures	-	12	B
cause	-	21	O
age	-	27	O
-	-	30	O
dependent	-	31	O
impairment	-	41	B
in	-	52	I
auditory	-	55	I
location	-	64	I
discrimination	-	73	I
.	-	87	O

Children	16596970	89	O
who	-	98	O
have	-	102	O
status	-	107	B
epilepticus	-	114	I
have	-	126	O
continuous	-	131	O
or	-	142	O
rapidly	-	145	O
repeating	-	153	O
seizures	-	163	B
that	-	172	O
may	-	177	O
be	-	181	O
life	-	184	O
-	-	188	O
threatening	-	189	O
and	-	201	O
may	-	205	O
cause	-	209	O
life	-	215	O
-	-	219	O
long	-	220	O
changes	-	225	O
in	-	233	O
brain	-	236	O
and	-	242	O
behavior	-	246	O
.	-	254	O

The	16596970	256	O
extent	-	260	O
to	-	267	O
which	-	270	O
status	-	276	B
epilepticus	-	283	I
causes	-	295	O
deficits	-	302	B
in	-	311	I
auditory	-	314	I
discrimination	-	323	I
is	-	338	O
unknown	-	341	O
.	-	348	O

A	16596970	350	O
naturalistic	-	352	O
auditory	-	365	O
location	-	374	O
discrimination	-	383	O
method	-	398	O
was	-	405	O
used	-	409	O
to	-	414	O
evaluate	-	417	O
this	-	426	O
question	-	431	O
using	-	440	O
an	-	446	O
animal	-	449	O
model	-	456	O
of	-	462	O
status	-	465	B
epilepticus	-	472	I
.	-	483	O

Male	16596970	485	O
Sprague	-	490	O
-	-	497	O
Dawley	-	498	O
rats	-	505	O
were	-	510	O
injected	-	515	O
with	-	524	O
saline	-	529	O
on	-	536	O
postnatal	-	539	O
day	-	549	O
(	-	553	O
P	-	554	O
)	-	555	O
20	-	557	O
,	-	559	O
or	-	561	O
a	-	564	O
convulsant	-	566	O
dose	-	577	O
of	-	582	O
pilocarpine	-	585	O
on	-	597	O
P20	-	600	O
or	-	604	O
P45	-	607	O
.	-	610	O

Pilocarpine	16596970	612	O
on	-	624	O
either	-	627	O
day	-	634	O
induced	-	638	O
status	-	646	B
epilepticus	-	653	I
;	-	664	O
status	-	666	B
epilepticus	-	673	I
at	-	685	O
P45	-	688	O
resulted	-	692	O
in	-	701	O
CA3	-	704	O
cell	-	708	O
loss	-	713	O
and	-	718	O
spontaneous	-	722	O
seizures	-	734	B
,	-	742	O
whereas	-	744	O
P20	-	752	O
rats	-	756	O
had	-	761	O
no	-	765	O
cell	-	768	O
loss	-	773	O
or	-	778	O
spontaneous	-	781	O
seizures	-	793	B
.	-	801	O

Mature	16596970	803	O
rats	-	810	O
were	-	815	O
trained	-	820	O
with	-	828	O
sound	-	833	O
-	-	838	O
source	-	839	O
location	-	846	O
and	-	855	O
sound	-	859	O
-	-	864	O
silence	-	865	O
discriminations	-	873	O
.	-	888	O

Control	16596970	890	O
(	-	898	O
saline	-	899	O
P20	-	906	O
)	-	909	O
rats	-	911	O
acquired	-	916	O
both	-	925	O
discriminations	-	930	O
immediately	-	946	O
.	-	957	O

In	16596970	959	O
status	-	962	B
epilepticus	-	969	I
(	-	981	O
P20	-	982	O
)	-	985	O
rats	-	987	O
,	-	991	O
acquisition	-	993	O
of	-	1005	O
the	-	1008	O
sound	-	1012	O
-	-	1017	O
source	-	1018	O
location	-	1025	O
discrimination	-	1034	O
was	-	1049	O
moderately	-	1053	O
impaired	-	1064	O
.	-	1072	O

Status	16596970	1074	B
epilepticus	-	1081	I
(	-	1093	O
P45	-	1094	O
)	-	1097	O
rats	-	1099	O
failed	-	1104	O
to	-	1111	O
acquire	-	1114	O
either	-	1122	O
sound	-	1129	O
-	-	1134	O
source	-	1135	O
location	-	1142	O
or	-	1151	O
sound	-	1154	O
-	-	1159	O
silence	-	1160	O
discriminations	-	1168	O
.	-	1183	O

Status	16596970	1185	B
epilepticus	-	1192	I
in	-	1204	O
rat	-	1207	O
causes	-	1211	O
an	-	1218	O
age	-	1221	O
-	-	1224	O
dependent	-	1225	O
,	-	1234	O
long	-	1236	O
-	-	1240	O
term	-	1241	O
impairment	-	1246	B
in	-	1257	I
auditory	-	1260	I
discrimination	-	1269	I
.	-	1283	O

This	16596970	1285	O
impairment	-	1290	O
may	-	1301	O
explain	-	1305	O
one	-	1313	O
cause	-	1317	O
of	-	1323	O
impaired	-	1326	B
auditory	-	1335	I
location	-	1344	I
discrimination	-	1353	I
in	-	1368	O
humans	-	1371	O
.	-	1377	O

Cardiovascular	16586083	0	O
risk	-	15	O
with	-	20	O
cyclooxygenase	-	25	O
inhibitors	-	40	O
:	-	50	O
general	-	52	O
problem	-	60	O
with	-	68	O
substance	-	73	O
specific	-	83	O
differences	-	92	O
?	-	103	O

Randomised	16586083	105	O
clinical	-	116	O
trials	-	125	O
and	-	132	O
observational	-	136	O
studies	-	150	O
have	-	158	O
shown	-	163	O
an	-	169	O
increased	-	172	O
risk	-	182	O
of	-	187	O
myocardial	-	190	B
infarction	-	201	I
,	-	211	O
stroke	-	213	B
,	-	219	O
hypertension	-	221	B
and	-	234	O
heart	-	238	B
failure	-	244	I
during	-	252	O
treatment	-	259	O
with	-	269	O
cyclooxygenase	-	274	O
inhibitors	-	289	O
.	-	299	O

Adverse	16586083	301	O
cardiovascular	-	309	O
effects	-	324	O
occurred	-	332	O
mainly	-	341	O
,	-	347	O
but	-	349	O
not	-	353	O
exclusively	-	357	O
,	-	368	O
in	-	370	O
patients	-	373	O
with	-	382	O
concomitant	-	387	O
risk	-	399	O
factors	-	404	O
.	-	411	O

Cyclooxygenase	16586083	413	O
inhibitors	-	428	O
cause	-	439	O
complex	-	445	O
changes	-	453	O
in	-	461	O
renal	-	464	O
,	-	469	O
vascular	-	471	O
and	-	480	O
cardiac	-	484	O
prostanoid	-	492	O
profiles	-	503	O
thereby	-	512	O
increasing	-	520	O
vascular	-	531	O
resistance	-	540	O
and	-	551	O
fluid	-	555	O
retention	-	561	O
.	-	570	O

The	16586083	572	O
incidence	-	576	O
of	-	586	O
cardiovascular	-	589	O
adverse	-	604	O
events	-	612	O
tends	-	619	O
to	-	625	O
increase	-	628	O
with	-	637	O
the	-	642	O
daily	-	646	O
dose	-	652	O
and	-	657	O
total	-	661	O
exposure	-	667	O
time	-	676	O
.	-	680	O

A	16586083	682	O
comparison	-	684	O
of	-	695	O
individual	-	698	O
selective	-	709	O
and	-	719	O
unselective	-	723	O
cyclooxygenase	-	735	O
inhibitors	-	750	O
suggests	-	761	O
substance	-	770	O
-	-	779	O
specific	-	780	O
differences	-	789	O
,	-	800	O
which	-	802	O
may	-	808	O
depend	-	812	O
on	-	819	O
differences	-	822	O
in	-	834	O
pharmacokinetic	-	837	O
parameters	-	853	O
or	-	864	O
inhibitory	-	867	O
potency	-	878	O
and	-	886	O
may	-	890	O
be	-	894	O
contributed	-	897	O
by	-	909	O
prostaglandin	-	912	O
-	-	925	O
independent	-	926	O
effects	-	938	O
.	-	945	O

Diagnostic	16586083	947	O
markers	-	958	O
such	-	966	O
as	-	971	O
N	-	974	O
-	-	975	O
terminal	-	976	O
pro	-	985	O
brain	-	989	O
natriuretic	-	995	O
peptide	-	1007	O
(	-	1015	O
NT	-	1016	O
-	-	1018	O
proBNP	-	1019	O
)	-	1025	O
or	-	1027	O
high	-	1030	O
-	-	1034	O
sensitive	-	1035	O
C	-	1045	O
-	-	1046	O
reactive	-	1047	O
protein	-	1056	O
might	-	1064	O
help	-	1070	O
in	-	1075	O
the	-	1078	O
early	-	1082	O
identification	-	1088	O
of	-	1103	O
patients	-	1106	O
at	-	1115	O
risk	-	1118	O
,	-	1122	O
thus	-	1124	O
avoiding	-	1129	O
the	-	1138	O
occurrence	-	1142	O
of	-	1153	O
serious	-	1156	O
cardiovascular	-	1164	B
toxicity	-	1179	I
.	-	1187	O

Predictors	10539815	0	O
of	-	11	O
decreased	-	14	B
renal	-	24	I
function	-	30	I
in	-	39	O
patients	-	42	O
with	-	51	O
heart	-	56	B
failure	-	62	I
during	-	70	O
angiotensin	-	77	O
-	-	88	O
converting	-	89	O
enzyme	-	100	O
inhibitor	-	107	O
therapy	-	117	O
:	-	124	O
results	-	126	O
from	-	134	O
the	-	139	O
studies	-	143	O
of	-	151	O
left	-	154	B
ventricular	-	159	I
dysfunction	-	171	I
(	-	183	O
SOLVD	-	184	O
)	-	189	O
BACKGROUND	-	191	O
:	-	201	O
Although	-	203	O
angiotensin	-	212	O
-	-	223	O
converting	-	224	O
enzyme	-	235	O
inhibitor	-	242	O
therapy	-	252	O
reduces	-	260	O
mortality	-	268	O
rates	-	278	O
in	-	284	O
patients	-	287	O
with	-	296	O
congestive	-	301	B
heart	-	312	I
failure	-	318	I
(	-	326	O
CHF	-	327	B
)	-	330	O
,	-	331	O
it	-	333	O
may	-	336	O
also	-	340	O
cause	-	345	O
decreased	-	351	B
renal	-	361	I
function	-	367	I
.	-	375	O

Little	10539815	377	O
information	-	384	O
is	-	396	O
available	-	399	O
to	-	409	O
predict	-	412	O
which	-	420	O
patients	-	426	O
are	-	435	O
at	-	439	O
highest	-	442	O
risk	-	450	O
for	-	455	O
this	-	459	O
complication	-	464	O
.	-	476	O

OBJECTIVE	10539815	478	O
:	-	487	O

To	10539815	489	O
quantify	-	492	O
specific	-	501	O
clinical	-	510	O
predictors	-	519	O
of	-	530	O
reduction	-	533	B
in	-	543	I
renal	-	546	I
function	-	552	I
in	-	561	O
patients	-	564	O
with	-	573	O
CHF	-	578	B
who	-	582	O
are	-	586	O
prescribed	-	590	O
angiotensin	-	601	O
-	-	612	O
converting	-	613	O
enzyme	-	624	O
inhibitor	-	631	O
therapy	-	641	O
.	-	648	O

METHOD	10539815	650	O
:	-	656	O

We	10539815	658	O
analyzed	-	661	O
data	-	670	O
from	-	675	O
the	-	680	O
Studies	-	684	O
of	-	692	O
Left	-	695	B
Ventricular	-	700	I
Dysfunction	-	712	I
(	-	724	O
SOLVD	-	725	O
)	-	730	O
,	-	731	O
a	-	733	O
randomized	-	735	O
,	-	745	O
double	-	747	O
-	-	753	O
blind	-	754	O
,	-	759	O
placebo	-	761	O
-	-	768	O
controlled	-	769	O
trial	-	780	O
of	-	786	O
enalapril	-	789	O
for	-	799	O
the	-	803	O
treatment	-	807	O
of	-	817	O
CHF	-	820	B
.	-	823	O

There	10539815	825	O
were	-	831	O
3379	-	836	O
patients	-	841	O
randomly	-	850	O
assigned	-	859	O
to	-	868	O
enalapril	-	871	O
with	-	881	O
a	-	886	O
median	-	888	O
follow	-	895	O
-	-	901	O
up	-	902	O
of	-	905	O
974	-	908	O
days	-	912	O
and	-	917	O
3379	-	921	O
patients	-	926	O
randomly	-	935	O
assigned	-	944	O
to	-	953	O
placebo	-	956	O
with	-	964	O
a	-	969	O
mean	-	971	O
follow	-	976	O
-	-	982	O
up	-	983	O
of	-	986	O
967	-	989	O
days	-	993	O
.	-	997	O

Decreased	10539815	999	B
renal	-	1009	I
function	-	1015	I
was	-	1024	O
defined	-	1028	O
as	-	1036	O
a	-	1039	O
rise	-	1041	O
in	-	1046	O
serum	-	1049	O
creatinine	-	1055	O
>	-	1066	O
/	-	1067	O
=	-	1068	O
0	-	1069	O
.	-	1070	O
5	-	1071	O
mg	-	1073	O
/	-	1075	O
dL	-	1076	O
(	-	1079	O
44	-	1080	O
micromol	-	1083	O
/	-	1091	O
L	-	1092	O
)	-	1093	O
from	-	1095	O
baseline	-	1100	O
.	-	1108	O

We	10539815	1110	O
used	-	1113	O
time	-	1118	O
-	-	1122	O
to	-	1123	O
-	-	1125	O
event	-	1126	O
analysis	-	1132	O
to	-	1141	O
identify	-	1144	O
potential	-	1153	O
predictors	-	1163	O
of	-	1174	O
decrease	-	1177	O
in	-	1186	O
renal	-	1189	O
function	-	1195	O
including	-	1204	O
age	-	1214	O
,	-	1217	O
baseline	-	1219	O
ejection	-	1228	O
fraction	-	1237	O
,	-	1245	O
baseline	-	1247	O
creatinine	-	1256	O
,	-	1266	O
low	-	1268	O
systolic	-	1272	O
blood	-	1281	O
pressure	-	1287	O
(	-	1296	O
<	-	1297	O
100	-	1298	O
mm	-	1302	O
Hg	-	1305	O
)	-	1307	O
,	-	1308	O
history	-	1310	O
of	-	1318	O
hypertension	-	1321	B
,	-	1333	O
diabetes	-	1335	B
,	-	1343	O
and	-	1345	O
use	-	1349	O
of	-	1353	O
antiplatelet	-	1356	O
,	-	1368	O
diuretic	-	1370	O
,	-	1378	O
and	-	1380	O
beta	-	1384	O
-	-	1388	O
blocker	-	1389	O
therapy	-	1397	O
.	-	1404	O

RESULTS	10539815	1406	O
:	-	1413	O

Patients	10539815	1415	O
randomly	-	1424	O
assigned	-	1433	O
to	-	1442	O
enalapril	-	1445	O
had	-	1455	O
a	-	1459	O
33	-	1461	O
%	-	1463	O
greater	-	1465	O
likelihood	-	1473	O
of	-	1484	O
decreased	-	1487	B
renal	-	1497	I
function	-	1503	I
than	-	1512	O
controls	-	1517	O
(	-	1526	O
P	-	1527	O
=	-	1529	O
.	-	1530	O
003	-	1531	O
)	-	1534	O
.	-	1535	O

By	10539815	1537	O
multivariate	-	1540	O
analysis	-	1553	O
,	-	1561	O
in	-	1563	O
both	-	1566	O
the	-	1571	O
placebo	-	1575	O
and	-	1583	O
enalapril	-	1587	O
groups	-	1597	O
older	-	1604	O
age	-	1610	O
,	-	1613	O
diuretic	-	1615	O
therapy	-	1624	O
,	-	1631	O
and	-	1633	O
diabetes	-	1637	B
were	-	1646	O
associated	-	1651	O
with	-	1662	O
decreased	-	1667	B
renal	-	1677	I
function	-	1683	I
,	-	1691	O
whereas	-	1693	O
beta	-	1701	O
-	-	1705	O
blocker	-	1706	O
therapy	-	1714	O
and	-	1722	O
higher	-	1726	O
ejection	-	1733	O
fraction	-	1742	O
were	-	1751	O
renoprotective	-	1756	O
.	-	1770	O

Older	10539815	1772	O
age	-	1778	O
was	-	1782	O
associated	-	1786	O
with	-	1797	O
a	-	1802	O
greater	-	1804	O
risk	-	1812	O
of	-	1817	O
developing	-	1820	O
decreased	-	1831	B
renal	-	1841	I
function	-	1847	I
in	-	1856	O
both	-	1859	O
groups	-	1864	O
,	-	1870	O
but	-	1872	O
significantly	-	1876	O
more	-	1890	O
so	-	1895	O
in	-	1898	O
the	-	1901	O
enalapril	-	1905	O
group	-	1915	O
(	-	1921	O
enalapril	-	1922	O
:	-	1931	O
risk	-	1933	O
ratio	-	1938	O
[	-	1944	O
RR	-	1945	O
]	-	1947	O
1	-	1949	O
.	-	1950	O
42	-	1951	O
per	-	1954	O
10	-	1958	O
years	-	1961	O
,	-	1966	O
95	-	1968	O
%	-	1970	O
confidence	-	1972	O
interval	-	1983	O
[	-	1992	O
CI	-	1993	O
]	-	1995	O
1	-	1997	O
.	-	1998	O
32	-	1999	O
-	-	2001	O
1	-	2002	O
.	-	2003	O
52	-	2004	O
with	-	2007	O
enalapril	-	2012	O
;	-	2021	O
placebo	-	2023	O
:	-	2030	O
RR	-	2032	O
1	-	2035	O
.	-	2036	O
18	-	2037	O
,	-	2039	O
95	-	2041	O
%	-	2043	O
CI	-	2045	O
1	-	2048	O
.	-	2049	O
12	-	2050	O
-	-	2052	O
1	-	2053	O
.	-	2054	O
25	-	2055	O
)	-	2057	O
.	-	2058	O

Diuretic	10539815	2060	O
therapy	-	2069	O
was	-	2077	O
likewise	-	2081	O
associated	-	2090	O
with	-	2101	O
a	-	2106	O
greater	-	2108	O
risk	-	2116	O
of	-	2121	O
decreased	-	2124	B
renal	-	2134	I
function	-	2140	I
in	-	2149	O
the	-	2152	O
enalapril	-	2156	O
group	-	2166	O
(	-	2172	O
RR	-	2173	O
1	-	2176	O
.	-	2177	O
89	-	2178	O
,	-	2180	O
95	-	2182	O
%	-	2184	O
CI	-	2186	O
1	-	2189	O
.	-	2190	O
70	-	2191	O
-	-	2193	O
2	-	2194	O
.	-	2195	O
08	-	2196	O
)	-	2198	O
than	-	2200	O
in	-	2205	O
the	-	2208	O
placebo	-	2212	O
group	-	2220	O
(	-	2226	O
RR	-	2227	O
1	-	2230	O
.	-	2231	O
35	-	2232	O
,	-	2234	O
95	-	2236	O
%	-	2238	O
CI	-	2240	O
1	-	2243	O
.	-	2244	O
09	-	2245	O
-	-	2247	O
1	-	2248	O
.	-	2249	O
66	-	2250	O
)	-	2252	O
.	-	2253	O

Conversely	10539815	2255	O
,	-	2265	O
enalapril	-	2267	O
had	-	2277	O
a	-	2281	O
relative	-	2283	O
renoprotective	-	2292	O
effect	-	2307	O
(	-	2314	O
RR	-	2315	O
1	-	2318	O
.	-	2319	O
33	-	2320	O
,	-	2322	O
95	-	2324	O
%	-	2326	O
CI	-	2328	O
1	-	2331	O
.	-	2332	O
13	-	2333	O
-	-	2335	O
1	-	2336	O
.	-	2337	O
53	-	2338	O
)	-	2340	O
compared	-	2342	O
with	-	2351	O
placebo	-	2356	O
(	-	2364	O
RR	-	2365	O
1	-	2368	O
.	-	2369	O
96	-	2370	O
,	-	2372	O
95	-	2374	O
%	-	2376	O
CI	-	2378	O
1	-	2381	O
.	-	2382	O
57	-	2383	O
-	-	2385	O
2	-	2386	O
.	-	2387	O
44	-	2388	O
)	-	2390	O
in	-	2392	O
patients	-	2395	O
with	-	2404	O
diabetes	-	2409	B
.	-	2417	O

A	10539815	2419	O
lower	-	2421	O
risk	-	2427	O
of	-	2432	O
renal	-	2435	B
impairment	-	2441	I
was	-	2452	O
seen	-	2456	O
in	-	2461	O
both	-	2464	O
groups	-	2469	O
with	-	2476	O
beta	-	2481	O
-	-	2485	O
blocker	-	2486	O
therapy	-	2494	O
(	-	2502	O
RR	-	2503	O
0	-	2506	O
.	-	2507	O
70	-	2508	O
,	-	2510	O
95	-	2512	O
%	-	2514	O
CI	-	2516	O
0	-	2519	O
.	-	2520	O
57	-	2521	O
-	-	2523	O
0	-	2524	O
.	-	2525	O
85	-	2526	O
)	-	2528	O
and	-	2530	O
higher	-	2534	O
baseline	-	2541	O
ejection	-	2550	O
fraction	-	2559	O
(	-	2568	O
RR	-	2569	O
0	-	2572	O
.	-	2573	O
93	-	2574	O
per	-	2577	O
5	-	2581	O
%	-	2582	O
increment	-	2584	O
,	-	2593	O
95	-	2595	O
%	-	2597	O
CI	-	2599	O
0	-	2602	O
.	-	2603	O
91	-	2604	O
-	-	2606	O
0	-	2607	O
.	-	2608	O
96	-	2610	O
)	-	2612	O
.	-	2613	O

CONCLUSIONS	10539815	2615	O
:	-	2626	O

Enalapril	10539815	2628	O
use	-	2638	O
caused	-	2642	O
a	-	2649	O
33	-	2651	O
%	-	2653	O
increase	-	2655	O
in	-	2664	O
the	-	2667	O
risk	-	2671	O
of	-	2676	O
decreased	-	2679	B
renal	-	2689	I
function	-	2695	I
in	-	2704	O
patients	-	2707	O
with	-	2716	O
CHF	-	2721	B
.	-	2724	O

Diuretic	10539815	2726	O
use	-	2735	O
and	-	2739	O
advanced	-	2743	O
age	-	2752	O
increased	-	2756	O
this	-	2766	O
risk	-	2771	O
.	-	2775	O

Diabetes	10539815	2777	B
was	-	2786	O
associated	-	2790	O
with	-	2801	O
an	-	2806	O
increased	-	2809	O
risk	-	2819	O
of	-	2824	O
renal	-	2827	B
impairment	-	2833	I
in	-	2844	O
all	-	2847	O
patients	-	2851	O
with	-	2860	O
CHF	-	2865	B
,	-	2868	O
but	-	2870	O
this	-	2874	O
risk	-	2879	O
was	-	2884	O
reduced	-	2888	O
in	-	2896	O
the	-	2899	O
enalapril	-	2903	O
group	-	2913	O
compared	-	2919	O
with	-	2928	O
the	-	2933	O
placebo	-	2937	O
group	-	2945	O
.	-	2950	O

beta	10539815	2952	O
-	-	2956	O
Blocker	-	2957	O
therapy	-	2965	O
and	-	2973	O
higher	-	2977	O
ejection	-	2984	O
fraction	-	2993	O
were	-	3002	O
renoprotective	-	3007	O
in	-	3022	O
all	-	3025	O
patients	-	3029	O
regardless	-	3038	O
of	-	3049	O
therapy	-	3052	O
.	-	3059	O

Pemoline	9022662	0	O
induced	-	9	O
acute	-	17	O
choreoathetosis	-	23	B
:	-	38	O
case	-	40	O
report	-	45	O
and	-	52	O
review	-	56	O
of	-	63	O
the	-	66	O
literature	-	70	O
.	-	80	O

BACKGROUND	9022662	82	O
:	-	92	O
Pemoline	-	94	O
is	-	103	O
an	-	106	O
oxazolidine	-	109	O
derivative	-	121	O
that	-	132	O
is	-	137	O
structurally	-	140	O
different	-	153	O
from	-	163	O
amphetamines	-	168	O
and	-	181	O
used	-	185	O
in	-	190	O
the	-	193	O
treatment	-	197	O
of	-	207	O
attention	-	210	B
deficit	-	220	I
disorder	-	228	I
.	-	236	O

Pemoline	9022662	238	O
has	-	247	O
not	-	251	O
been	-	255	O
commonly	-	260	O
associated	-	269	O
in	-	280	O
the	-	283	O
literature	-	287	O
as	-	298	O
a	-	301	O
cause	-	303	O
of	-	309	O
acute	-	312	O
movement	-	318	B
disorders	-	327	I
.	-	336	O

The	9022662	338	O
following	-	342	O
case	-	352	O
describes	-	357	O
two	-	367	O
children	-	371	O
acutely	-	380	O
poisoned	-	388	O
with	-	397	O
pemoline	-	402	O
who	-	411	O
experienced	-	415	O
profound	-	427	O
choreoathetosis	-	436	B
.	-	451	O

CASE	9022662	453	O
REPORT	-	458	O
:	-	464	O

Two	9022662	466	O
,	-	469	O
3	-	471	O
-	-	472	O
year	-	473	O
-	-	477	O
old	-	478	O
male	-	482	O
,	-	486	O
identical	-	488	O
twin	-	498	O
siblings	-	503	O
presented	-	512	O
to	-	522	O
the	-	525	O
emergency	-	529	O
department	-	539	O
after	-	550	O
found	-	556	O
playing	-	562	O
with	-	570	O
a	-	575	O
an	-	577	O
empty	-	580	O
bottle	-	586	O
of	-	593	O
pemoline	-	596	O
originally	-	605	O
containing	-	616	O
59	-	627	O
tablets	-	630	O
.	-	637	O

The	9022662	639	O
children	-	643	O
had	-	652	O
a	-	656	O
medical	-	658	O
history	-	666	O
significant	-	674	O
for	-	686	O
attention	-	690	B
deficit	-	700	I
disorder	-	708	I
previously	-	717	O
treated	-	728	O
with	-	736	O
methylphenidate	-	741	O
without	-	757	O
success	-	765	O
.	-	772	O

This	9022662	774	O
was	-	779	O
their	-	783	O
first	-	789	O
day	-	795	O
of	-	799	O
pemoline	-	802	O
therapy	-	811	O
.	-	818	O

The	9022662	820	O
choreoathetoid	-	824	B
movements	-	839	O
began	-	849	O
45	-	855	O
min	-	858	O
to	-	862	O
1	-	865	O
h	-	867	O
after	-	869	O
ingestion	-	875	O
.	-	884	O

The	9022662	886	O
children	-	890	O
gave	-	899	O
no	-	904	O
history	-	907	O
of	-	915	O
prior	-	918	O
movement	-	924	B
disorders	-	933	I
and	-	943	O
there	-	947	O
was	-	953	O
no	-	957	O
family	-	960	O
history	-	967	O
of	-	975	O
movement	-	978	B
disorders	-	987	I
.	-	996	O

The	9022662	998	O
children	-	1002	O
received	-	1011	O
gastrointestinal	-	1020	O
decontamination	-	1037	O
and	-	1053	O
high	-	1057	O
doses	-	1062	O
of	-	1068	O
intravenous	-	1071	O
benzodiazepines	-	1083	O
in	-	1099	O
an	-	1102	O
attempt	-	1105	O
to	-	1113	O
control	-	1116	O
the	-	1124	O
choreoathetoid	-	1128	B
movements	-	1143	O
.	-	1152	O

Despite	9022662	1154	O
treatment	-	1162	O
,	-	1171	O
the	-	1173	O
children	-	1177	O
continued	-	1186	O
to	-	1196	O
have	-	1199	O
choreoathetosis	-	1204	B
for	-	1220	O
approximately	-	1224	O
24	-	1238	O
hours	-	1241	O
.	-	1246	O

Forty	9022662	1248	O
-	-	1253	O
eight	-	1254	O
hours	-	1260	O
after	-	1266	O
admission	-	1272	O
,	-	1281	O
the	-	1283	O
children	-	1287	O
appeared	-	1296	O
to	-	1305	O
be	-	1308	O
at	-	1311	O
their	-	1314	O
baseline	-	1320	O
and	-	1329	O
were	-	1333	O
discharged	-	1338	O
home	-	1349	O
.	-	1353	O

CONCLUSION	9022662	1355	O
:	-	1365	O

Pemoline	9022662	1367	O
associated	-	1376	O
movement	-	1387	B
disorder	-	1396	I
has	-	1405	O
been	-	1409	O
rarely	-	1414	O
reported	-	1421	O
in	-	1430	O
the	-	1433	O
acute	-	1437	O
toxicology	-	1443	O
literature	-	1454	O
.	-	1464	O

The	9022662	1466	O
possibility	-	1470	O
of	-	1482	O
choreoathetoid	-	1485	B
movements	-	1500	O
should	-	1510	O
be	-	1517	O
considered	-	1520	O
in	-	1531	O
patients	-	1534	O
presenting	-	1543	O
after	-	1554	O
pemoline	-	1560	O
overdose	-	1569	B
.	-	1577	O

Continuous	8677458	0	O
subcutaneous	-	11	O
administration	-	24	O
of	-	39	O
mesna	-	42	O
to	-	48	O
prevent	-	51	O
ifosfamide	-	59	O
-	-	69	O
induced	-	70	O
hemorrhagic	-	78	B
cystitis	-	90	I
.	-	98	O

Hemorrhagic	8677458	100	B
cystitis	-	112	I
is	-	121	O
a	-	124	O
major	-	126	O
potential	-	132	O
toxicity	-	142	B
of	-	151	O
ifosfamide	-	154	O
that	-	165	O
can	-	170	O
be	-	174	O
prevented	-	177	O
by	-	187	O
administering	-	190	O
mesna	-	204	O
along	-	210	O
with	-	216	O
the	-	221	O
cytotoxic	-	225	O
agent	-	235	O
.	-	240	O

Mesna	8677458	242	O
is	-	248	O
generally	-	251	O
administered	-	261	O
by	-	274	O
the	-	277	O
intravenous	-	281	O
route	-	293	O
,	-	298	O
although	-	300	O
experience	-	309	O
with	-	320	O
oral	-	325	O
delivery	-	330	O
of	-	339	O
the	-	342	O
drug	-	346	O
has	-	351	O
increased	-	355	O
.	-	364	O

The	8677458	366	O
continuous	-	370	O
subcutaneous	-	381	O
administration	-	394	O
of	-	409	O
mesna	-	412	O
has	-	418	O
the	-	422	O
advantage	-	426	O
of	-	436	O
not	-	439	O
requiring	-	443	O
intravenous	-	453	O
access	-	465	O
.	-	471	O

In	8677458	473	O
addition	-	476	O
,	-	484	O
subcutaneous	-	486	O
delivery	-	499	O
of	-	508	O
the	-	511	O
neutralizing	-	515	O
agent	-	528	O
will	-	534	O
not	-	539	O
be	-	543	O
associated	-	546	O
with	-	557	O
the	-	562	O
risk	-	566	O
of	-	571	O
inadequate	-	574	O
urinary	-	585	O
mesna	-	593	O
concentrations	-	599	O
,	-	613	O
such	-	615	O
as	-	620	O
in	-	623	O
a	-	626	O
patient	-	628	O
taking	-	636	O
oral	-	643	O
mesna	-	648	O
who	-	654	O
experiences	-	658	O
severe	-	670	O
ifosfamide	-	677	O
-	-	687	O
induced	-	688	O
emesis	-	696	B
and	-	703	O
is	-	707	O
unable	-	710	O
to	-	717	O
absorb	-	720	O
the	-	727	O
drug	-	731	O
.	-	735	O

Limited	8677458	737	O
clinical	-	745	O
experience	-	754	O
with	-	765	O
continuous	-	770	O
subcutaneous	-	781	O
mesna	-	794	O
administration	-	800	O
suggests	-	815	O
it	-	824	O
is	-	827	O
a	-	830	O
safe	-	832	O
,	-	836	O
practical	-	838	O
,	-	847	O
and	-	849	O
economic	-	853	O
method	-	862	O
of	-	869	O
drug	-	872	O
delivery	-	877	O
that	-	886	O
permits	-	891	O
ifosfamide	-	899	O
to	-	910	O
be	-	913	O
administered	-	916	O
successfully	-	929	O
in	-	942	O
the	-	945	O
outpatient	-	949	O
setting	-	960	O
.	-	967	O

Modification	6323692	0	O
of	-	13	O
drug	-	16	O
action	-	21	O
by	-	28	O
hyperammonemia	-	31	B
.	-	45	O

Pretreatment	6323692	47	O
with	-	60	O
ammonium	-	65	O
acetate	-	74	O
(	-	82	O
NH4Ac	-	83	O
)	-	88	O
(	-	90	O
6	-	91	O
mmol	-	93	O
/	-	97	O
kg	-	98	O
s	-	101	O
.	-	102	O
c	-	103	O
.	-	104	O
)	-	105	O
approximately	-	107	O
doubled	-	121	O
the	-	129	O
time	-	133	O
morphine	-	138	O
-	-	146	O
treated	-	147	O
mice	-	155	O
remained	-	160	O
on	-	169	O
a	-	172	O
hot	-	174	O
surface	-	178	O
and	-	186	O
similarly	-	190	O
increased	-	200	O
muscular	-	210	O
incoordination	-	219	B
by	-	234	O
diazepam	-	237	O
,	-	245	O
but	-	247	O
NH4Ac	-	251	O
treatment	-	257	O
alone	-	267	O
had	-	273	O
no	-	277	O
effect	-	280	O
.	-	286	O

Thus	6323692	288	O
,	-	292	O
hyperammonemia	-	294	B
is	-	309	O
capable	-	312	O
of	-	320	O
altering	-	323	O
drug	-	332	O
action	-	337	O
and	-	344	O
must	-	348	O
be	-	353	O
considered	-	356	O
along	-	367	O
with	-	373	O
impaired	-	378	O
drug	-	387	O
metabolism	-	392	O
in	-	403	O
enhanced	-	406	O
drug	-	415	O
responses	-	420	O
associated	-	430	O
with	-	441	O
liver	-	446	B
disease	-	452	I
.	-	459	O

Experiments	6323692	461	O
in	-	473	O
vitro	-	476	O
showed	-	482	O
that	-	489	O
acetylcholine	-	494	O
-	-	507	O
induced	-	508	O
catecholamine	-	516	O
release	-	530	O
from	-	538	O
bovine	-	543	O
adrenal	-	550	O
medulla	-	558	O
is	-	566	O
depressed	-	569	O
as	-	579	O
much	-	582	O
as	-	587	O
50	-	590	O
%	-	592	O
by	-	594	O
0	-	597	O
.	-	598	O
3	-	599	O
mM	-	601	O
NH4Ac	-	604	O
and	-	610	O
KCl	-	614	O
-	-	617	O
induced	-	618	O
contractions	-	626	O
of	-	639	O
guinea	-	642	O
-	-	648	O
pig	-	649	O
ileum	-	653	O
were	-	659	O
inhibited	-	664	O
20	-	674	O
%	-	676	O
by	-	678	O
5	-	681	O
mM	-	683	O
NH4Ac	-	686	O
.	-	691	O

Addition	6323692	693	O
of	-	702	O
excess	-	705	O
calcium	-	712	O
reversed	-	720	O
the	-	729	O
depression	-	733	B
in	-	744	O
both	-	747	O
tissues	-	752	O
,	-	759	O
but	-	761	O
calcium	-	765	O
-	-	772	O
independent	-	773	O
catecholamine	-	785	O
release	-	799	O
by	-	807	O
acetaldehyde	-	810	O
was	-	823	O
not	-	827	O
blocked	-	831	O
by	-	839	O
NH4Ac	-	842	O
.	-	847	O

These	6323692	849	O
results	-	855	O
suggested	-	863	O
that	-	873	O
ammonia	-	878	O
blocks	-	886	O
calcium	-	893	O
channels	-	901	O
.	-	909	O

Parallels	6323692	911	O
in	-	921	O
the	-	924	O
actions	-	928	O
of	-	936	O
NH4Ac	-	939	O
and	-	945	O
the	-	949	O
calcium	-	953	O
channel	-	961	O
blocker	-	969	O
verapamil	-	977	O
support	-	987	O
this	-	995	O
concept	-	1000	O
.	-	1007	O

Both	6323692	1009	O
verapamil	-	1014	O
(	-	1024	O
10	-	1025	O
mg	-	1028	O
/	-	1030	O
kg	-	1031	O
i	-	1034	O
.	-	1035	O
p	-	1036	O
.	-	1037	O
)	-	1038	O

and	6323692	1040	O
NH4Ac	-	1044	O
pretreatment	-	1050	O
enhanced	-	1063	O
morphine	-	1072	O

analgesia	6323692	1081	B
-	-	1090	O
and	-	1092	O
diazepam	-	1096	O
-	-	1104	O
induced	-	1105	O
muscular	-	1113	O
incoordination	-	1122	B
and	-	1137	O
antagonized	-	1141	O
amphetamine	-	1153	O
-	-	1164	O
induced	-	1165	O
motor	-	1173	O
activity	-	1179	O
,	-	1187	O
and	-	1189	O
neither	-	1193	O
verapamil	-	1201	O
nor	-	1211	O
NH4Ac	-	1215	O
affected	-	1221	O
the	-	1230	O
convulsant	-	1234	O
action	-	1245	O
of	-	1252	O
metrazol	-	1255	O
.	-	1263	O

The	6323692	1265	O
data	-	1269	O
suggest	-	1274	O
that	-	1282	O
hyperammonemia	-	1287	B
exerts	-	1302	O
a	-	1309	O
calcium	-	1311	O
channel	-	1319	O
blocking	-	1327	O
action	-	1336	O
which	-	1343	O
enhances	-	1349	O
the	-	1358	O
effects	-	1362	O
of	-	1370	O
central	-	1373	O
nervous	-	1381	O
system	-	1389	O
depressants	-	1396	O
and	-	1408	O
certain	-	1412	O
opioid	-	1420	O
analgesics	-	1427	O
.	-	1437	O

Risk	20195852	0	O
of	-	5	O
nephropathy	-	8	B
after	-	20	O
consumption	-	26	O
of	-	38	O
nonionic	-	41	O
contrast	-	50	O
media	-	59	O
by	-	65	O
children	-	68	O
undergoing	-	77	O
cardiac	-	88	O
angiography	-	96	O
:	-	107	O
a	-	109	O
prospective	-	111	O
study	-	123	O
.	-	128	O

Despite	20195852	130	O
increasing	-	138	O
reports	-	149	O
on	-	157	O
nonionic	-	160	O
contrast	-	169	O
media	-	178	O
-	-	183	O
induced	-	184	O
nephropathy	-	192	B
(	-	204	O
CIN	-	205	B
)	-	208	O
in	-	210	O
hospitalized	-	213	O
adult	-	226	O
patients	-	232	O
during	-	241	O
cardiac	-	248	O
procedures	-	256	O
,	-	266	O
the	-	268	O
studies	-	272	O
in	-	280	O
pediatrics	-	283	O
are	-	294	O
limited	-	298	O
,	-	305	O
with	-	307	O
even	-	312	O
less	-	317	O
focus	-	322	O
on	-	328	O
possible	-	331	O
predisposing	-	340	O
factors	-	353	O
and	-	361	O
preventive	-	365	O
measures	-	376	O
for	-	385	O
patients	-	389	O
undergoing	-	398	O
cardiac	-	409	O
angiography	-	417	O
.	-	428	O

This	20195852	430	O
prospective	-	435	O
study	-	447	O
determined	-	453	O
the	-	464	O
incidence	-	468	O
of	-	478	O
CIN	-	481	B
for	-	485	O
two	-	489	O
nonionic	-	493	O
contrast	-	502	O
media	-	511	O
(	-	517	O
CM	-	518	O
)	-	520	O
,	-	521	O
iopromide	-	523	O
and	-	533	O
iohexol	-	537	O
,	-	544	O
among	-	546	O
80	-	552	O
patients	-	555	O
younger	-	564	O
than	-	572	O
18	-	577	O
years	-	580	O
and	-	586	O
compared	-	590	O
the	-	599	O
rates	-	603	O
for	-	609	O
this	-	613	O
complication	-	618	O
in	-	631	O
relation	-	634	O
to	-	643	O
the	-	646	O
type	-	650	O
and	-	655	O
dosage	-	659	O
of	-	666	O
CM	-	669	O
and	-	672	O
the	-	676	O
presence	-	680	O
of	-	689	O
cyanosis	-	692	B
.	-	700	O

The	20195852	702	O
80	-	706	O
patients	-	709	O
in	-	718	O
the	-	721	O
study	-	725	O
consecutively	-	731	O
received	-	745	O
either	-	754	O
iopromide	-	761	O
(	-	771	O
group	-	772	O
A	-	778	O
,	-	779	O
n	-	781	O
=	-	783	O
40	-	785	O
)	-	787	O
or	-	789	O
iohexol	-	792	O
(	-	800	O
group	-	801	O
B	-	807	O
,	-	808	O
n	-	810	O
=	-	812	O
40	-	814	O
)	-	816	O
.	-	817	O

Serum	20195852	819	O
sodium	-	825	O
(	-	832	O
Na	-	833	O
)	-	835	O
,	-	836	O
potassium	-	838	O
(	-	848	O
K	-	849	O
)	-	850	O
,	-	851	O
and	-	853	O
creatinine	-	857	O
(	-	868	O
Cr	-	869	O
)	-	871	O
were	-	873	O
measured	-	878	O
24	-	887	O
h	-	890	O
before	-	892	O
angiography	-	899	O
as	-	911	O
baseline	-	914	O
values	-	923	O
,	-	929	O
then	-	931	O
measured	-	936	O
again	-	945	O
at	-	951	O
12	-	954	O
-	-	956	O
,	-	957	O
24	-	959	O
-	-	961	O
,	-	962	O
and	-	964	O
48	-	968	O
-	-	970	O
h	-	971	O
intervals	-	973	O
after	-	983	O
CM	-	989	O
use	-	992	O
.	-	995	O

Urine	20195852	997	O
samples	-	1003	O
for	-	1011	O
Na	-	1015	O
and	-	1018	O
Cr	-	1022	O
also	-	1025	O
were	-	1030	O
checked	-	1035	O
at	-	1043	O
the	-	1046	O
same	-	1050	O
intervals	-	1055	O
.	-	1064	O

Risk	20195852	1066	O
of	-	1071	O
renal	-	1074	B
failure	-	1080	I
,	-	1087	O
Injury	-	1089	B
to	-	1096	I
the	-	1099	I
kidney	-	1103	I
,	-	1109	O
Failure	-	1111	B
of	-	1119	I
kidney	-	1122	I
function	-	1129	I
,	-	1137	O
Loss	-	1139	B
of	-	1144	I
kidney	-	1147	I
function	-	1154	I
,	-	1162	O
and	-	1164	O
End	-	1168	O
-	-	1171	O
stage	-	1172	O
renal	-	1178	B
damage	-	1184	I
(	-	1191	O
RIFLE	-	1192	O
criteria	-	1198	O
)	-	1206	O
were	-	1208	O
used	-	1213	O
to	-	1218	O
define	-	1221	O
CIN	-	1228	B
and	-	1232	O
its	-	1236	O
incidence	-	1240	O
in	-	1250	O
the	-	1253	O
study	-	1257	O
population	-	1263	O
.	-	1273	O

Accordingly	20195852	1275	O
,	-	1286	O
among	-	1288	O
the	-	1294	O
15	-	1298	O
CIN	-	1301	B
patients	-	1305	O
(	-	1314	O
18	-	1315	O
.	-	1317	O
75	-	1318	O
%	-	1320	O
)	-	1321	O
,	-	1322	O
7	-	1324	O
.	-	1325	O
5	-	1326	O
%	-	1327	O
of	-	1329	O
the	-	1332	O
patients	-	1336	O
in	-	1345	O
group	-	1348	O
A	-	1354	O
had	-	1356	O
increased	-	1360	O
risk	-	1370	O
and	-	1375	O
3	-	1379	O
.	-	1380	O
75	-	1381	O
%	-	1383	O
had	-	1385	O
renal	-	1389	B
injury	-	1395	I
,	-	1401	O
whereas	-	1403	O
5	-	1411	O
%	-	1412	O
of	-	1414	O
group	-	1417	O
B	-	1423	O
had	-	1425	O
increased	-	1429	O
risk	-	1439	O
and	-	1444	O
2	-	1448	O
.	-	1449	O
5	-	1450	O
%	-	1451	O
had	-	1453	O
renal	-	1457	B
injury	-	1463	I
.	-	1469	O

Whereas	20195852	1471	O
33	-	1479	O
.	-	1481	O
3	-	1482	O
%	-	1483	O
of	-	1485	O
the	-	1488	O
patients	-	1492	O
with	-	1501	O
CIN	-	1506	B
were	-	1510	O
among	-	1515	O
those	-	1521	O
who	-	1527	O
received	-	1531	O
the	-	1540	O
proper	-	1544	O
dosage	-	1551	O
of	-	1558	O
CM	-	1561	O
,	-	1563	O
the	-	1565	O
percentage	-	1569	O
increased	-	1580	O
to	-	1590	O
66	-	1593	O
.	-	1595	O
6	-	1596	O
%	-	1597	O
among	-	1599	O
those	-	1605	O
who	-	1611	O
received	-	1615	O
larger	-	1624	O
doses	-	1631	O
,	-	1636	O
with	-	1638	O
a	-	1643	O
significant	-	1645	O
difference	-	1657	O
in	-	1668	O
the	-	1671	O
incidence	-	1675	O
of	-	1685	O
CIN	-	1688	B
related	-	1692	O
to	-	1700	O
the	-	1703	O
different	-	1707	O
dosages	-	1717	O
of	-	1725	O
CM	-	1728	O
(	-	1731	O
p	-	1732	O
=	-	1734	O
0	-	1736	O
.	-	1737	O
014	-	1738	O
)	-	1741	O
.	-	1742	O

Among	20195852	1744	O
the	-	1750	O
15	-	1754	O
patients	-	1757	O
with	-	1766	O
CIN	-	1771	B
,	-	1774	O
6	-	1776	O
had	-	1778	O
cyanotic	-	1782	O
congenital	-	1791	B
heart	-	1802	I
diseases	-	1808	I
,	-	1816	O
but	-	1818	O
the	-	1822	O
incidence	-	1826	O
did	-	1836	O
not	-	1840	O
differ	-	1844	O
significantly	-	1851	O
from	-	1865	O
that	-	1870	O
for	-	1875	O
the	-	1879	O
noncyanotic	-	1883	O
patients	-	1895	O
(	-	1904	O
p	-	1905	O
=	-	1907	O
0	-	1909	O
.	-	1910	O
243	-	1911	O
)	-	1914	O
.	-	1915	O

Although	20195852	1917	O
clinically	-	1926	O
silent	-	1937	O
,	-	1943	O
CIN	-	1945	B
is	-	1949	O
not	-	1952	O
rare	-	1956	O
in	-	1961	O
pediatrics	-	1964	O
.	-	1974	O

The	20195852	1976	O
incidence	-	1980	O
depends	-	1990	O
on	-	1998	O
dosage	-	2001	O
but	-	2008	O
not	-	2012	O
on	-	2016	O
the	-	2019	O
type	-	2023	O
of	-	2028	O
consumed	-	2031	O
nonionic	-	2040	O
CM	-	2049	O
,	-	2051	O
nor	-	2053	O
on	-	2057	O
the	-	2060	O
presence	-	2064	O
of	-	2073	O
cyanosis	-	2076	B
,	-	2084	O
and	-	2086	O
although	-	2090	O
CIN	-	2099	B
usually	-	2103	O
is	-	2111	O
reversible	-	2114	O
,	-	2124	O
more	-	2126	O
concern	-	2131	O
is	-	2139	O
needed	-	2142	O
for	-	2149	O
the	-	2153	O
prevention	-	2157	O
of	-	2168	O
such	-	2171	O
a	-	2176	O
complication	-	2178	O
in	-	2191	O
children	-	2194	O
.	-	2202	O

A	18997632	0	O
case	-	2	O
of	-	7	O
ventricular	-	10	B
tachycardia	-	22	I
related	-	34	O
to	-	42	O
caffeine	-	45	O
pretreatment	-	54	O
.	-	66	O

Suboptimal	18997632	68	O
seizure	-	79	B
duration	-	87	O
is	-	96	O
commonly	-	99	O
encountered	-	108	O
in	-	120	O
electroconvulsive	-	123	O
therapy	-	141	O
practice	-	149	O
,	-	157	O
especially	-	159	O
in	-	170	O
older	-	173	O
patients	-	179	O
with	-	188	O
higher	-	193	O
seizure	-	200	B
thresholds	-	208	O
.	-	218	O

Intravenous	18997632	220	O
caffeine	-	232	O
is	-	241	O
commonly	-	244	O
used	-	253	O
to	-	258	O
improve	-	261	O
seizure	-	269	B
duration	-	277	O
and	-	286	O
quality	-	290	O
in	-	298	O
such	-	301	O
patients	-	306	O
and	-	315	O
is	-	319	O
generally	-	322	O
well	-	332	O
tolerated	-	337	O
aside	-	347	O
from	-	353	O
occasional	-	358	O
reports	-	369	O
of	-	377	O
relatively	-	380	O
benign	-	391	O
ventricular	-	398	B
ectopy	-	410	I
.	-	416	O

We	18997632	418	O
describe	-	421	O
a	-	430	O
patient	-	432	O
with	-	440	O
no	-	445	O
previous	-	448	O
history	-	457	O
of	-	465	O
cardiac	-	468	B
disease	-	476	I
or	-	484	O
arrhythmia	-	487	B
who	-	498	O
developed	-	502	O
sustained	-	512	O
bigeminy	-	522	O
and	-	531	O
2	-	535	O
brief	-	537	O
runs	-	543	O
of	-	548	O
ventricular	-	551	B
tachycardia	-	563	I
after	-	575	O
caffeine	-	581	O
administration	-	590	O
.	-	604	O

Although	18997632	606	O
intravenous	-	615	O
caffeine	-	627	O
is	-	636	O
generally	-	639	O
well	-	649	O
tolerated	-	654	O
,	-	663	O
the	-	665	O
clinician	-	669	O
should	-	679	O
be	-	686	O
aware	-	689	O
of	-	695	O
the	-	698	O
potential	-	702	O
for	-	712	O
unpredictable	-	716	O
and	-	730	O
serious	-	734	O
ventricular	-	742	B
arrhythmias	-	754	I
.	-	765	O

Optical	15565293	0	O
coherence	-	8	O
tomography	-	18	O
can	-	29	O
measure	-	33	O
axonal	-	41	O
loss	-	48	O
in	-	53	O
patients	-	56	O
with	-	65	O
ethambutol	-	70	O
-	-	80	O
induced	-	81	O
optic	-	89	B
neuropathy	-	95	I
.	-	105	O

PURPOSE	15565293	107	O
:	-	114	O

To	15565293	116	O
map	-	119	O
and	-	123	O
identify	-	127	O
the	-	136	O
pattern	-	140	O
,	-	147	O
in	-	149	O
vivo	-	152	O
,	-	156	O
of	-	158	O
axonal	-	161	B
degeneration	-	168	I
in	-	181	O
ethambutol	-	184	O
-	-	194	O
induced	-	195	O
optic	-	203	B
neuropathy	-	209	I
using	-	220	O
optical	-	226	O
coherence	-	234	O
tomography	-	244	O
(	-	255	O
OCT	-	256	O
)	-	259	O
.	-	260	O

Ethambutol	15565293	262	O
is	-	273	O
an	-	276	O
antimycobacterial	-	279	O
agent	-	297	O
often	-	303	O
used	-	309	O
to	-	314	O
treat	-	317	O
tuberculosis	-	323	B
.	-	335	O

A	15565293	337	O
serious	-	339	O
complication	-	347	O
of	-	360	O
ethambutol	-	363	O
is	-	374	O
an	-	377	O
optic	-	380	B
neuropathy	-	386	I
that	-	397	O
impairs	-	402	O
visual	-	410	O
acuity	-	417	O
,	-	423	O
contrast	-	425	O
sensitivity	-	434	O
,	-	445	O
and	-	447	O
color	-	451	O
vision	-	457	O
.	-	463	O

However	15565293	465	O
,	-	472	O
early	-	474	O
on	-	480	O
,	-	482	O
when	-	484	O
the	-	489	O
toxic	-	493	O
optic	-	499	B
neuropathy	-	505	I
is	-	516	O
mild	-	519	O
and	-	524	O
partly	-	528	O
reversible	-	535	O
,	-	545	O
the	-	547	O
funduscopic	-	551	O
findings	-	563	O
are	-	572	O
often	-	576	O
subtle	-	582	O
and	-	589	O
easy	-	593	O
to	-	598	O
miss	-	601	O
.	-	605	O

METHODS	15565293	607	O
:	-	614	O

Three	15565293	616	O
subjects	-	622	O
with	-	631	O
a	-	636	O
history	-	638	O
of	-	646	O
ethambutol	-	649	O
(	-	660	O
EMB	-	661	O
)	-	664	O
-	-	665	O
induced	-	666	O
optic	-	674	B
neuropathy	-	680	I
of	-	691	O
short	-	694	O
-	-	699	O
,	-	700	O
intermediate	-	702	O
-	-	714	O
,	-	715	O
and	-	717	O
long	-	721	O
-	-	725	O
term	-	726	O
visual	-	731	B
deficits	-	738	I
were	-	747	O
administered	-	752	O
a	-	765	O
full	-	767	O
neuro	-	772	O
-	-	777	O
ophthalmologic	-	778	O
examination	-	793	O
including	-	805	O
visual	-	815	O
acuity	-	822	O
,	-	828	O
color	-	830	O
vision	-	836	O
,	-	842	O
contrast	-	844	O
sensitivity	-	853	O
,	-	864	O
and	-	866	O
fundus	-	870	O
examination	-	877	O
.	-	888	O

In	15565293	890	O
addition	-	893	O
,	-	901	O
OCT	-	903	O
(	-	907	O
OCT	-	908	O
3000	-	912	O
,	-	916	O
Humphrey	-	918	O
-	-	926	O
Zeiss	-	927	O
,	-	932	O
Dublin	-	934	O
,	-	940	O
CA	-	942	O
)	-	944	O
was	-	946	O
performed	-	950	O
on	-	960	O
both	-	963	O
eyes	-	968	O
of	-	973	O
each	-	976	O
subject	-	981	O
using	-	989	O
the	-	995	O
retinal	-	999	O
nerve	-	1007	O
fiber	-	1013	O
layer	-	1019	O
(	-	1025	O
RNFL	-	1026	O
)	-	1030	O
analysis	-	1032	O
protocol	-	1041	O
.	-	1049	O

OCT	15565293	1051	O
interpolates	-	1055	O
data	-	1068	O
from	-	1073	O
100	-	1078	O
points	-	1082	O
around	-	1089	O
the	-	1096	O
optic	-	1100	O
nerve	-	1106	O
to	-	1112	O
effectively	-	1115	O
map	-	1127	O
out	-	1131	O
the	-	1135	O
RNFL	-	1139	O
.	-	1143	O

RESULTS	15565293	1145	O
:	-	1152	O

The	15565293	1154	O
results	-	1158	O
were	-	1166	O
compared	-	1171	O
to	-	1180	O
the	-	1183	O
calculated	-	1187	O
average	-	1198	O
RNFL	-	1206	O
of	-	1211	O
normal	-	1214	O
eyes	-	1221	O
accumulated	-	1226	O
from	-	1238	O
four	-	1243	O
prior	-	1248	O
studies	-	1254	O
using	-	1262	O
OCT	-	1268	O
,	-	1271	O
n	-	1273	O
=	-	1274	O
661	-	1275	O
.	-	1278	O

In	15565293	1280	O
all	-	1283	O
subjects	-	1287	O
with	-	1296	O
history	-	1301	O
of	-	1309	O
EMB	-	1312	O
-	-	1315	O
induced	-	1316	O
optic	-	1324	B
neuropathy	-	1330	I
,	-	1340	O
there	-	1342	O
was	-	1348	O
a	-	1352	O
mean	-	1354	O
loss	-	1359	O
of	-	1364	O
72	-	1367	O
%	-	1369	O
nerve	-	1371	O
fiber	-	1377	O
layer	-	1383	O
thickness	-	1389	O
in	-	1399	O
the	-	1402	O
temporal	-	1406	O
quadrant	-	1415	O
(	-	1424	O
patient	-	1425	O
A	-	1433	O
,	-	1434	O
with	-	1436	O
eventual	-	1441	O
recovery	-	1450	O
of	-	1459	O
visual	-	1462	O
acuity	-	1469	O
and	-	1476	O
fields	-	1480	O
,	-	1486	O
58	-	1488	O
%	-	1490	O
loss	-	1492	O
;	-	1496	O
patient	-	1498	O
B	-	1506	O
,	-	1507	O
with	-	1509	O
intermediate	-	1514	O
visual	-	1527	B
deficits	-	1534	I
,	-	1542	O
68	-	1544	O
%	-	1546	O
loss	-	1548	O
;	-	1552	O
patient	-	1554	O
C	-	1562	O
,	-	1563	O
with	-	1565	O
chronic	-	1570	O
visual	-	1578	B
deficits	-	1585	I
,	-	1593	O
90	-	1595	O
%	-	1597	O
loss	-	1599	O
)	-	1603	O
,	-	1604	O
with	-	1606	O
an	-	1611	O
average	-	1614	O
mean	-	1622	O
optic	-	1627	O
nerve	-	1633	O
thickness	-	1639	O
of	-	1649	O
26	-	1652	O
+	-	1654	O
/	-	1655	O
-	-	1656	O
16	-	1657	O
microm	-	1660	O
.	-	1666	O

There	15565293	1668	O
was	-	1674	O
a	-	1678	O
combined	-	1680	O
mean	-	1689	O
loss	-	1694	O
of	-	1699	O
46	-	1702	O
%	-	1704	O
of	-	1706	O
fibers	-	1709	O
from	-	1716	O
the	-	1721	O
superior	-	1725	O
,	-	1733	O
inferior	-	1735	O
,	-	1743	O
and	-	1745	O
nasal	-	1749	O
quadrants	-	1755	O
in	-	1765	O
the	-	1768	O
(	-	1772	O
six	-	1773	O
)	-	1776	O
eyes	-	1778	O
of	-	1783	O
all	-	1786	O
three	-	1790	O
subjects	-	1796	O
(	-	1805	O
mean	-	1806	O
average	-	1811	O
thickness	-	1819	O
of	-	1829	O
55	-	1832	O
+	-	1834	O
/	-	1835	O
-	-	1836	O
29	-	1837	O
microm	-	1840	O
)	-	1846	O
.	-	1847	O

In	15565293	1849	O
both	-	1852	O
sets	-	1857	O
(	-	1862	O
four	-	1863	O
)	-	1867	O
of	-	1869	O
eyes	-	1872	O
of	-	1877	O
the	-	1880	O
subjects	-	1884	O
with	-	1893	O
persistent	-	1898	O
visual	-	1909	B
deficits	-	1916	I
(	-	1925	O
patients	-	1926	O
B	-	1935	O
and	-	1937	O
C	-	1941	O
)	-	1942	O
,	-	1943	O
there	-	1945	O
was	-	1951	O
an	-	1955	O
average	-	1958	O
loss	-	1966	O
of	-	1971	O
79	-	1974	O
%	-	1976	O
of	-	1978	O
nerve	-	1981	O
fiber	-	1987	O
thickness	-	1993	O
in	-	2003	O
the	-	2006	O
temporal	-	2010	O
quadrant	-	2019	O
.	-	2027	O

CONCLUSIONS	15565293	2029	O
:	-	2040	O

The	15565293	2042	O
OCT	-	2046	O
results	-	2050	O
in	-	2058	O
these	-	2061	O
patients	-	2067	O
with	-	2076	O
EMB	-	2081	O
-	-	2084	O
induced	-	2085	O
optic	-	2093	B
neuropathy	-	2099	I
show	-	2110	O
considerable	-	2115	O
loss	-	2128	O
especially	-	2133	O
of	-	2144	O
the	-	2147	O
temporal	-	2151	O
fibers	-	2160	O
.	-	2166	O

This	15565293	2168	O
is	-	2173	O
consistent	-	2176	O
with	-	2187	O
prior	-	2192	O
histopathological	-	2198	O
studies	-	2216	O
that	-	2224	O
show	-	2229	O
predominant	-	2234	O
loss	-	2246	O
of	-	2251	O
parvo	-	2254	O
-	-	2259	O
cellular	-	2260	O
axons	-	2269	O
(	-	2275	O
or	-	2276	O
small	-	2279	O
-	-	2284	O
caliber	-	2285	O
axons	-	2293	O
)	-	2298	O
within	-	2300	O
the	-	2307	O
papillo	-	2311	O
-	-	2318	O
macular	-	2319	O
bundle	-	2327	O
in	-	2334	O
toxic	-	2337	O
or	-	2343	O
hereditary	-	2346	O
optic	-	2357	B
neuropathies	-	2363	I
.	-	2375	O

OCT	15565293	2377	O
can	-	2381	O
be	-	2385	O
a	-	2388	O
valuable	-	2390	O
tool	-	2399	O
in	-	2404	O
the	-	2407	O
quantitative	-	2411	O
analysis	-	2424	O
of	-	2433	O
optic	-	2436	B
neuropathies	-	2442	I
.	-	2454	O

Additionally	15565293	2456	O
,	-	2468	O
in	-	2470	O
terms	-	2473	O
of	-	2479	O
management	-	2482	O
of	-	2493	O
EMB	-	2496	O
-	-	2499	O
induced	-	2500	O
optic	-	2508	B
neuropathy	-	2514	I
,	-	2524	O
it	-	2526	O
is	-	2529	O
important	-	2532	O
to	-	2542	O
properly	-	2545	O
manage	-	2554	O
ethambutol	-	2561	O
dosing	-	2572	O
in	-	2579	O
patients	-	2582	O
with	-	2591	O
renal	-	2596	B
impairment	-	2602	I
and	-	2613	O
to	-	2617	O
achieve	-	2620	O
proper	-	2628	O
transition	-	2635	O
to	-	2646	O
a	-	2649	O
maintenance	-	2651	O
dose	-	2663	O
once	-	2668	O
an	-	2673	O
appropriate	-	2676	O
loading	-	2688	O
dose	-	2696	O
has	-	2701	O
been	-	2705	O
reached	-	2710	O
.	-	2717	O

Effects	15266215	0	O
of	-	8	O
the	-	11	O
cyclooxygenase	-	15	O
-	-	29	O
2	-	30	O
specific	-	32	O
inhibitor	-	41	O
valdecoxib	-	51	O
versus	-	62	O
nonsteroidal	-	69	O
antiinflammatory	-	82	O
agents	-	99	O
and	-	106	O
placebo	-	110	O
on	-	118	O
cardiovascular	-	121	O
thrombotic	-	136	B
events	-	147	O
in	-	154	O
patients	-	157	O
with	-	166	O
arthritis	-	171	B
.	-	180	O

There	15266215	182	O
have	-	188	O
been	-	193	O
concerns	-	198	O
that	-	207	O
the	-	212	O
risk	-	216	O
of	-	221	O
cardiovascular	-	224	O
thrombotic	-	239	B
events	-	250	O
may	-	257	O
be	-	261	O
higher	-	264	O
with	-	271	O
cyclooxygenase	-	276	O
(	-	291	O
COX	-	292	O
)	-	295	O
-	-	296	O
2	-	297	O
-	-	298	O
specific	-	299	O
inhibitors	-	308	O
than	-	319	O
nonselective	-	324	O
nonsteroidal	-	337	O
antiinflammatory	-	350	O
drugs	-	367	O
(	-	373	O
NSAIDs	-	374	O
)	-	380	O
.	-	381	O

We	15266215	383	O
evaluated	-	386	O
cardiovascular	-	396	O
event	-	411	O
data	-	417	O
for	-	422	O
valdecoxib	-	426	O
,	-	436	O
a	-	438	O
new	-	440	O
COX	-	444	O
-	-	447	O
2	-	448	O
-	-	449	O
specific	-	450	O
inhibitor	-	459	O
in	-	469	O
approximately	-	472	O
8000	-	486	O
patients	-	491	O
with	-	500	O
osteoarthritis	-	505	B
and	-	520	O
rheumatoid	-	524	B
arthritis	-	535	I
treated	-	545	O
with	-	553	O
this	-	558	O
agent	-	563	O
in	-	569	O
randomized	-	572	O
clinical	-	583	O
trials	-	592	O
.	-	598	O

The	15266215	600	O
incidence	-	604	O
of	-	614	O
cardiovascular	-	617	O
thrombotic	-	632	B
events	-	643	O
(	-	650	O
cardiac	-	651	O
,	-	658	O
cerebrovascular	-	660	O
and	-	676	O
peripheral	-	680	O
vascular	-	691	O
,	-	699	O
or	-	701	O
arterial	-	704	O
thrombotic	-	713	B
)	-	723	O
was	-	725	O
determined	-	729	O
by	-	740	O
analyzing	-	743	O
pooled	-	753	O
valdecoxib	-	760	O
(	-	771	O
10	-	772	O
-	-	774	O
80	-	775	O
mg	-	778	O
daily	-	781	O
)	-	786	O
,	-	787	O
nonselective	-	789	O
NSAID	-	802	O
(	-	808	O
diclofenac	-	809	O
75	-	820	O
mg	-	823	O
bid	-	826	O
,	-	829	O
ibuprofen	-	831	O
800	-	841	O
mg	-	845	O
tid	-	848	O
,	-	851	O
or	-	853	O
naproxen	-	856	O
500	-	865	O
mg	-	869	O
bid	-	872	O
)	-	875	O
and	-	877	O
placebo	-	881	O
data	-	889	O
from	-	894	O
10	-	899	O
randomized	-	902	O
osteoarthritis	-	913	B
and	-	928	O
rheumatoid	-	932	B
arthritis	-	943	I
trials	-	953	O
that	-	960	O
were	-	965	O
6	-	970	O
-	-	971	O
52	-	972	O
weeks	-	975	O
in	-	981	O
duration	-	984	O
.	-	992	O

The	15266215	994	O
incidence	-	998	O
rates	-	1008	O
of	-	1014	O
events	-	1017	O
were	-	1024	O
determined	-	1029	O
in	-	1040	O
all	-	1043	O
patients	-	1047	O
(	-	1056	O
n	-	1057	O
=	-	1059	O
7934	-	1061	O
)	-	1065	O
and	-	1067	O
in	-	1071	O
users	-	1074	O
of	-	1080	O
low	-	1083	O
-	-	1086	O
dose	-	1087	O
(	-	1092	O
<	-	1093	O
or	-	1095	O
=	-	1098	O
325	-	1099	O
mg	-	1103	O
daily	-	1106	O
)	-	1111	O
aspirin	-	1113	O
(	-	1121	O
n	-	1122	O
=	-	1124	O
1051	-	1126	O
)	-	1130	O
and	-	1132	O
nonusers	-	1136	O
of	-	1145	O
aspirin	-	1148	O
(	-	1156	O
n	-	1157	O
=	-	1159	O
6883	-	1161	O
)	-	1165	O
.	-	1166	O

Crude	15266215	1168	O
and	-	1174	O
exposure	-	1178	O
-	-	1186	O
adjusted	-	1187	O
incidences	-	1196	O
of	-	1207	O
thrombotic	-	1210	B
events	-	1221	O
were	-	1228	O
similar	-	1233	O
for	-	1241	O
valdecoxib	-	1245	O
,	-	1255	O
NSAIDs	-	1257	O
,	-	1263	O
and	-	1265	O
placebo	-	1269	O
.	-	1276	O

The	15266215	1278	O
risk	-	1282	O
of	-	1287	O
serious	-	1290	O
thrombotic	-	1298	B
events	-	1309	O
was	-	1316	O
also	-	1320	O
similar	-	1325	O
for	-	1333	O
each	-	1337	O
valdecoxib	-	1342	O
dose	-	1353	O
.	-	1357	O

Thrombotic	15266215	1359	B
risk	-	1370	O
was	-	1375	O
consistently	-	1379	O
higher	-	1392	O
for	-	1399	O
users	-	1403	O
of	-	1409	O
aspirin	-	1412	O
users	-	1420	O
than	-	1426	O
nonusers	-	1431	O
of	-	1440	O
aspirin	-	1443	O
(	-	1451	O
placebo	-	1452	O
,	-	1459	O
1	-	1461	O
.	-	1462	O
4	-	1463	O
%	-	1464	O
vs	-	1466	O
.	-	1468	O
0	-	1470	O
%	-	1471	O
;	-	1472	O
valdecoxib	-	1474	O
,	-	1484	O
1	-	1486	O
.	-	1487	O
7	-	1488	O
%	-	1489	O
vs	-	1491	O
.	-	1493	O
0	-	1495	O
.	-	1496	O
2	-	1497	O
%	-	1498	O
;	-	1499	O
NSAIDs	-	1501	O
,	-	1507	O
1	-	1509	O
.	-	1510	O
9	-	1511	O
%	-	1512	O
vs	-	1514	O
.	-	1516	O
0	-	1518	O
.	-	1519	O
5	-	1520	O
%	-	1521	O
)	-	1522	O
.	-	1523	O

The	15266215	1525	O
rates	-	1529	O
of	-	1535	O
events	-	1538	O
in	-	1545	O
users	-	1548	O
of	-	1554	O
aspirin	-	1557	O
were	-	1565	O
similar	-	1570	O
for	-	1578	O
all	-	1582	O
3	-	1586	O
treatment	-	1588	O
groups	-	1598	O
and	-	1605	O
across	-	1609	O
valdecoxib	-	1616	O
doses	-	1627	O
.	-	1632	O

Short	15266215	1634	O
-	-	1639	O
and	-	1641	O
intermediate	-	1645	O
-	-	1657	O
term	-	1658	O
treatment	-	1663	O
with	-	1673	O
therapeutic	-	1678	O
(	-	1690	O
10	-	1691	O
or	-	1694	O
20	-	1697	O
mg	-	1700	O
daily	-	1703	O
)	-	1708	O
and	-	1710	O
supratherapeutic	-	1714	O
(	-	1731	O
40	-	1732	O
or	-	1735	O
80	-	1738	O
mg	-	1741	O
daily	-	1744	O
)	-	1749	O
valdecoxib	-	1751	O
doses	-	1762	O
was	-	1768	O
not	-	1772	O
associated	-	1776	O
with	-	1787	O
an	-	1792	O
increased	-	1795	O
incidence	-	1805	O
of	-	1815	O
thrombotic	-	1818	B
events	-	1829	O
relative	-	1836	O
to	-	1845	O
nonselective	-	1848	O
NSAIDs	-	1861	O
or	-	1868	O
placebo	-	1871	O
in	-	1879	O
osteoarthritis	-	1882	B
and	-	1897	O
rheumatoid	-	1901	B
arthritis	-	1912	I
patients	-	1922	O
in	-	1931	O
controlled	-	1934	O
clinical	-	1945	O
trials	-	1954	O
.	-	1960	O

A	14742097	0	O
randomized	-	2	O
,	-	12	O
placebo	-	14	O
-	-	21	O
controlled	-	22	O
,	-	32	O
crossover	-	34	O
study	-	44	O
of	-	50	O
ephedrine	-	53	O
for	-	63	O
SSRI	-	67	O
-	-	71	O
induced	-	72	O
female	-	80	O
sexual	-	87	B
dysfunction	-	94	I
.	-	105	O

The	14742097	107	O
objective	-	111	O
of	-	121	O
this	-	124	O
study	-	129	O
was	-	135	O
to	-	139	O
determine	-	142	O
whether	-	152	O
ephedrine	-	160	O
,	-	169	O
an	-	171	O
alpha	-	174	O
-	-	179	O
and	-	181	O
beta	-	185	O
-	-	189	O
adrenergic	-	190	O
agonist	-	201	O
previously	-	209	O
shown	-	220	O
to	-	226	O
enhance	-	229	O
genital	-	237	O
blood	-	245	O
flow	-	251	O
in	-	256	O
women	-	259	O
,	-	264	O
has	-	266	O
beneficial	-	270	O
effects	-	281	O
in	-	289	O
reversing	-	292	O
antidepressant	-	302	O
-	-	316	O
induced	-	317	O
sexual	-	325	B
dysfunction	-	332	I
.	-	343	O

Nineteen	14742097	345	O
sexually	-	354	B
dysfunctional	-	363	I
women	-	377	O
receiving	-	383	O
either	-	393	O
fluoxetine	-	400	O
,	-	410	O
sertraline	-	412	O
,	-	422	O
or	-	424	O
paroxetine	-	427	O
participated	-	438	O
in	-	451	O
an	-	454	O
eight	-	457	O
-	-	462	O
week	-	463	O
,	-	467	O
double	-	469	O
-	-	475	O
blind	-	476	O
,	-	481	O
placebo	-	483	O
-	-	490	O
controlled	-	491	O
,	-	501	O
cross	-	503	O
-	-	508	O
over	-	509	O
study	-	514	O
of	-	520	O
the	-	523	O
effects	-	527	O
of	-	535	O
ephedrine	-	538	O
(	-	548	O
50	-	549	O
mg	-	552	O
)	-	554	O
on	-	556	O
self	-	559	O
-	-	563	O
report	-	564	O
measures	-	571	O
of	-	580	O
sexual	-	583	O
desire	-	590	O
,	-	596	O
arousal	-	598	O
,	-	605	O
orgasm	-	607	O
,	-	613	O
and	-	615	O
sexual	-	619	O
satisfaction	-	626	O
.	-	638	O

Although	14742097	640	O
there	-	649	O
were	-	655	O
significant	-	660	O
improvements	-	672	O
relative	-	685	O
to	-	694	O
baseline	-	697	O
in	-	706	O
sexual	-	709	O
desire	-	716	O
and	-	723	O
orgasm	-	727	O
intensity	-	734	O
/	-	743	O
pleasure	-	744	O
on	-	753	O
50	-	756	O
mg	-	759	O
ephedrine	-	762	O
1	-	772	O
-	-	773	O
hr	-	774	O
prior	-	777	O
to	-	783	O
sexual	-	786	O
activity	-	793	O
,	-	801	O
significant	-	803	O
improvements	-	815	O
in	-	828	O
these	-	831	O
measures	-	837	O
,	-	845	O
as	-	847	O
well	-	850	O
as	-	855	O
in	-	858	O
sexual	-	861	O
arousal	-	868	O
and	-	876	O
orgasmic	-	880	O
ability	-	889	O
also	-	897	O
were	-	902	O
noted	-	907	O
with	-	913	O
placebo	-	918	O
.	-	925	O

These	14742097	927	O
findings	-	933	O
highlight	-	942	O
the	-	952	O
importance	-	956	O
of	-	967	O
conducting	-	970	O
placebo	-	981	O
-	-	988	O
controlled	-	989	O
trials	-	1000	O
for	-	1007	O
this	-	1011	O
condition	-	1016	O
.	-	1025	O

Erectile	11890511	0	B
dysfunction	-	9	I
occurs	-	21	O
following	-	28	O
substantia	-	38	O
nigra	-	49	O
lesions	-	55	O
in	-	63	O
the	-	66	O
rat	-	70	O
.	-	73	O

Erectile	11890511	75	O
function	-	84	O
was	-	93	O
assessed	-	97	O
6	-	106	O
weeks	-	108	O
following	-	114	O
uni	-	124	O
-	-	127	O
and	-	129	O
bilateral	-	133	O
injections	-	143	O
of	-	154	O
6	-	157	O
-	-	158	O
hydroxydopamine	-	159	O
in	-	175	O
the	-	178	O
substantia	-	182	O
nigra	-	193	O
nucleus	-	199	O
of	-	207	O
the	-	210	O
brain	-	214	O
.	-	219	O

Behavioral	11890511	221	O
apomorphine	-	232	O
-	-	243	O
induced	-	244	O
penile	-	252	O
erections	-	259	O
were	-	269	O
reduced	-	274	O
(	-	282	O
5	-	283	O
/	-	284	O
8	-	285	O
)	-	286	O
and	-	288	O
increased	-	292	O
(	-	302	O
3	-	303	O
/	-	304	O
8	-	305	O
)	-	306	O
in	-	308	O
uni	-	311	O
-	-	314	O
and	-	316	O
bilateral	-	320	O
lesioned	-	330	O
animals	-	339	O
.	-	346	O

Intracavernous	11890511	348	O
pressures	-	363	O
,	-	372	O
following	-	374	O
electrical	-	384	O
stimulation	-	395	O
of	-	407	O
the	-	410	O
cavernous	-	414	O
nerve	-	424	O
,	-	429	O
decreased	-	431	O
in	-	441	O
lesioned	-	444	O
animals	-	453	O
.	-	460	O

Lesions	11890511	462	O
of	-	470	O
the	-	473	O
substantia	-	477	O
nigra	-	488	O
were	-	494	O
confirmed	-	499	O
by	-	509	O
histology	-	512	O
.	-	521	O

Concentration	11890511	523	O
of	-	537	O
dopamine	-	540	O
and	-	549	O
its	-	553	O
metabolites	-	557	O
were	-	569	O
decreased	-	574	O
in	-	584	O
the	-	587	O
striatum	-	591	O
of	-	600	O
substantia	-	603	O
nigra	-	614	O
lesioned	-	620	O
rats	-	629	O
.	-	633	O

Lesions	11890511	635	O
of	-	643	O
the	-	646	O
substantia	-	650	O
nigra	-	661	O
are	-	667	O
therefore	-	671	O
associated	-	681	O
with	-	692	O
erectile	-	697	B
dysfunction	-	706	I
in	-	718	O
rats	-	721	O
and	-	726	O
may	-	730	O
serve	-	734	O
as	-	740	O
a	-	743	O
model	-	745	O
to	-	751	O
study	-	754	O
erectile	-	760	B
dysfunction	-	769	I
in	-	781	O
Parkinson	-	784	B
's	-	793	I
disease	-	796	I
.	-	803	O

Potential	9270571	0	O
therapeutic	-	10	O
use	-	22	O
of	-	26	O
the	-	29	O
selective	-	33	O
dopamine	-	43	O
D1	-	52	O
receptor	-	55	O
agonist	-	64	O
,	-	71	O
A	-	73	O
-	-	74	O
86929	-	75	O
:	-	80	O
an	-	82	O
acute	-	85	O
study	-	91	O
in	-	97	O
parkinsonian	-	100	B
levodopa	-	113	O
-	-	121	O
primed	-	122	O
monkeys	-	129	O
.	-	136	O

The	9270571	138	O
clinical	-	142	O
utility	-	151	O
of	-	159	O
dopamine	-	162	O
(	-	171	O
DA	-	172	O
)	-	174	O
D1	-	176	O
receptor	-	179	O
agonists	-	188	O
in	-	197	O
the	-	200	O
treatment	-	204	O
of	-	214	O
Parkinson	-	217	B
's	-	226	I
disease	-	229	I
(	-	237	O
PD	-	238	B
)	-	240	O
is	-	242	O
still	-	245	O
unclear	-	251	O
.	-	258	O

The	9270571	260	O
therapeutic	-	264	O
use	-	276	O
of	-	280	O
selective	-	283	O
DA	-	293	O
D1	-	296	O
receptor	-	299	O
agonists	-	308	O
such	-	317	O
as	-	322	O
SKF	-	325	O
-	-	328	O
82958	-	329	O
(	-	335	O
6	-	336	O
-	-	337	O
chloro	-	338	O
-	-	344	O
7	-	345	O
,	-	346	O
8	-	347	O
-	-	348	O
dihydroxy	-	349	O
-	-	358	O
3	-	359	O
-	-	360	O
allyl	-	361	O
-	-	366	O
1	-	367	O
-	-	368	O
phenyl	-	369	O
-	-	375	O
2	-	376	O
,	-	377	O
3	-	378	O
,	-	379	O
4	-	380	O
,	-	381	O
5	-	382	O
-	-	383	O
tetrahydro	-	384	O
-	-	394	O
1H	-	395	O
-	-	397	O
3	-	398	O
-	-	399	O
benzaze	-	400	O
pine	-	408	O
hydrobromide	-	413	O
)	-	425	O
and	-	427	O
A	-	431	O
-	-	432	O
77636	-	433	O
(	-	439	O
[	-	440	O
1R	-	441	O
,	-	443	O
3S	-	445	O
]	-	447	O
3	-	449	O
-	-	450	O
[	-	451	O
1'	-	452	O
-	-	454	O
admantyl	-	455	O
]	-	463	O
-	-	464	O
1	-	465	O
-	-	466	O
aminomethyl	-	467	O
-	-	478	O
3	-	479	O
,	-	480	O
4	-	481	O
-	-	482	O
dihydro	-	483	O
-	-	490	O
5	-	491	O
,	-	492	O
6	-	493	O
-	-	494	O
dihydroxy	-	495	O
-	-	504	O
1H	-	505	O
-	-	507	O
2	-	508	O
-	-	509	O
benzo	-	510	O
pyran	-	516	O
hydrochloride	-	522	O
)	-	535	O
seems	-	537	O
limited	-	543	O
because	-	551	O
of	-	559	O
their	-	562	O
duration	-	568	O
of	-	577	O
action	-	580	O
,	-	586	O
which	-	588	O
is	-	594	O
too	-	597	O
short	-	601	O
for	-	607	O
SKF	-	611	O
-	-	614	O
82958	-	615	O
(	-	621	O
<	-	622	O
1	-	624	O
hr	-	626	O
)	-	628	O
and	-	630	O
too	-	634	O
long	-	638	O
for	-	643	O
A	-	647	O
-	-	648	O
77636	-	649	O
(	-	655	O
>	-	656	O
20	-	658	O
hr	-	661	O
,	-	663	O
leading	-	665	O
to	-	673	O
behavioral	-	676	O
tolerance	-	687	O
)	-	696	O
.	-	697	O

We	9270571	699	O
therefore	-	702	O
conducted	-	712	O
the	-	722	O
present	-	726	O
acute	-	734	O
dose	-	740	O
-	-	744	O
response	-	745	O
study	-	754	O
in	-	760	O
four	-	763	O
1	-	768	O
-	-	769	O
methyl	-	770	O
-	-	776	O
4	-	777	O
-	-	778	O
phenyl	-	779	O
-	-	785	O
1	-	786	O
,	-	787	O
2	-	788	O
,	-	789	O
3	-	790	O
,	-	791	O
6	-	792	O
-	-	793	O
tetrahydropyridine	-	794	O
(	-	813	O
MPTP	-	814	O
)	-	818	O
-	-	819	O
exposed	-	820	O
cynomolgus	-	828	O
monkeys	-	839	O
primed	-	847	O
to	-	854	O
exhibit	-	857	O
levodopa	-	865	O
-	-	873	O
induced	-	874	O
dyskinesias	-	882	B
to	-	894	O
evaluate	-	897	O
the	-	906	O
locomotor	-	910	O
and	-	920	O
dyskinetic	-	924	B
effects	-	935	O
on	-	943	O
challenge	-	946	O
with	-	956	O
four	-	961	O
doses	-	966	O
(	-	972	O
from	-	973	O
0	-	978	O
.	-	979	O
03	-	980	O
to	-	983	O
1	-	986	O
.	-	987	O
0	-	988	O
mg	-	990	O
/	-	992	O
kg	-	993	O
)	-	995	O
of	-	997	O
A	-	1000	O
-	-	1001	O
86929	-	1002	O
(	-	1008	O
[	-	1009	O
-	-	1010	O
]	-	1011	O
-	-	1012	O
[	-	1013	O
5aR	-	1014	O
,	-	1017	O
11bS	-	1018	O
]	-	1022	O
-	-	1023	O
4	-	1024	O
,	-	1025	O
5	-	1026	O
,	-	1027	O
5a	-	1028	O
,	-	1030	O
6	-	1031	O
,	-	1032	O
7	-	1033	O
,	-	1034	O
11b	-	1035	O
-	-	1038	O
hexahydro	-	1039	O
-	-	1048	O
2	-	1049	O
-	-	1050	O
propyl	-	1051	O
-	-	1057	O
3	-	1058	O
-	-	1059	O
thia	-	1060	O
-	-	1064	O
5	-	1065	O
-	-	1066	O
+	-	1067	O
+	-	1069	O
+	-	1070	O
azacyclopent	-	1071	O
-	-	1083	O
1	-	1084	O
-	-	1085	O
ena	-	1087	O
[	-	1090	O
c	-	1091	O
]	-	1092	O
phenathrene	-	1093	O
-	-	1104	O
9	-	1105	O
-	-	1106	O
10	-	1107	O
-	-	1109	O
diol	-	1110	O
)	-	1114	O
,	-	1115	O
a	-	1117	O
selective	-	1119	O
and	-	1129	O
full	-	1133	O
DA	-	1138	O
D1	-	1141	O
-	-	1143	O
like	-	1144	O
receptor	-	1149	O
agonist	-	1158	O
with	-	1166	O
an	-	1171	O
intermediate	-	1174	O
duration	-	1187	O
of	-	1196	O
action	-	1199	O
.	-	1205	O

Levodopa	9270571	1207	O
and	-	1216	O
the	-	1220	O
DA	-	1224	O
D2	-	1227	O
-	-	1229	O
like	-	1230	O
receptor	-	1235	O
agonist	-	1244	O
,	-	1251	O
LY	-	1253	O
-	-	1255	O
171555	-	1256	O
(	-	1263	O
[	-	1264	O
4aR	-	1265	O
-	-	1268	O
trans	-	1269	O
]	-	1274	O
-	-	1275	O
4	-	1276	O
,	-	1277	O
4a	-	1278	O
,	-	1280	O
5	-	1281	O
,	-	1282	O
6	-	1283	O
,	-	1284	O
7	-	1285	O
,	-	1286	O
8	-	1287	O
,	-	1288	O
8a	-	1289	O
,	-	1291	O
9	-	1292	O
-	-	1293	O
o	-	1294	O
-	-	1295	O
dihydro	-	1296	O
-	-	1303	O
5n	-	1304	O
-	-	1306	O
propyl	-	1307	O
-	-	1313	O
2H	-	1314	O
-	-	1316	O
pyrazo	-	1317	O
lo	-	1324	O
-	-	1326	O
3	-	1327	O
-	-	1328	O
4	-	1329	O
-	-	1330	O
quinoline	-	1331	O
hydrochloride	-	1341	O
)	-	1354	O
were	-	1356	O
also	-	1361	O
used	-	1366	O
for	-	1371	O
comparison	-	1375	O
.	-	1385	O

Acute	9270571	1387	O
administration	-	1393	O
of	-	1408	O
A	-	1411	O
-	-	1412	O
86929	-	1413	O
was	-	1419	O
as	-	1423	O
efficacious	-	1426	O
in	-	1438	O
alleviating	-	1441	O
MPTP	-	1453	O
-	-	1457	O
induced	-	1458	O
parkinsonism	-	1466	B
as	-	1479	O
levodopa	-	1482	O
and	-	1491	O
LY	-	1495	O
-	-	1497	O
171555	-	1498	O
,	-	1504	O
but	-	1506	O
was	-	1510	O
less	-	1514	O
likely	-	1519	O
to	-	1526	O
reproduce	-	1529	O
the	-	1539	O
levodopa	-	1543	O
-	-	1551	O
induced	-	1552	O
dyskinesias	-	1560	B
in	-	1572	O
these	-	1575	O
animals	-	1581	O
than	-	1589	O
with	-	1594	O
either	-	1599	O
LY	-	1606	O
-	-	1608	O
171555	-	1609	O
or	-	1616	O
subsequent	-	1619	O
challenge	-	1630	O
of	-	1640	O
levodopa	-	1643	O
.	-	1651	O

Selective	9270571	1653	O
stimulation	-	1663	O
of	-	1675	O
the	-	1678	O
DA	-	1682	O
D1	-	1685	O
receptor	-	1688	O
may	-	1697	O
provide	-	1701	O
better	-	1709	O
integration	-	1716	O
of	-	1728	O
neural	-	1731	O
inputs	-	1738	O
transmitted	-	1745	O
to	-	1757	O
the	-	1760	O
internal	-	1764	O
segment	-	1773	O
of	-	1781	O
the	-	1784	O
globus	-	1788	O
pallidus	-	1795	O
(	-	1804	O
referred	-	1805	O
to	-	1814	O
as	-	1817	O
the	-	1820	O
basal	-	1824	O
ganglia	-	1830	O
output	-	1838	O
)	-	1844	O
compared	-	1846	O
with	-	1855	O
levodopa	-	1860	O
and	-	1869	O
selective	-	1873	O
DA	-	1883	O
D2	-	1886	O
receptor	-	1889	O
agonist	-	1898	O
.	-	1905	O

Potent	9270571	1907	O
DA	-	1914	O
D1	-	1917	O
receptor	-	1920	O
agents	-	1929	O
with	-	1936	O
an	-	1941	O
intermediate	-	1944	O
duration	-	1957	O
of	-	1966	O
efficacy	-	1969	O
such	-	1978	O
as	-	1983	O
A	-	1986	O
-	-	1987	O
86929	-	1988	O
(	-	1994	O
approximately	-	1995	O
4	-	2009	O
hr	-	2011	O
at	-	2014	O
higher	-	2017	O
doses	-	2024	O
tested	-	2030	O
)	-	2036	O
are	-	2038	O
potential	-	2042	O
therapeutic	-	2052	O
tools	-	2064	O
in	-	2070	O
PD	-	2073	B
and	-	2076	O
merit	-	2080	O
further	-	2086	O
attention	-	2094	O
.	-	2103	O

Deaths	7189975	0	O
from	-	7	O
local	-	12	O
anesthetic	-	18	O
-	-	28	O
induced	-	29	O
convulsions	-	37	B
in	-	49	O
mice	-	52	O
.	-	56	O

Median	7189975	58	O
convulsant	-	65	O
(	-	76	O
CD50	-	77	O
)	-	81	O
and	-	83	O
median	-	87	O
lethal	-	94	O

(	7189975	101	O
LD50	-	102	O
)	-	106	O
doses	-	108	O
of	-	114	O
three	-	117	O
representative	-	123	O
local	-	138	O
anesthetics	-	144	O
were	-	156	O
determined	-	161	O
in	-	172	O
adult	-	175	O
mice	-	181	O
to	-	186	O
evaluate	-	189	O
the	-	198	O
threat	-	202	O
to	-	209	O
life	-	212	O
of	-	217	O
local	-	220	O
anesthetic	-	226	O
-	-	236	O
induced	-	237	O
convulsions	-	245	B
.	-	256	O

The	7189975	258	O
CD50	-	262	O
and	-	267	O
LD50	-	271	O
,	-	275	O
respectively	-	277	O
,	-	289	O
were	-	291	O
57	-	296	O
.	-	298	O
7	-	299	O
and	-	301	O
58	-	305	O
.	-	307	O
7	-	308	O
mg	-	310	O
/	-	312	O
kg	-	313	O
for	-	316	O
bupivacaine	-	320	O
,	-	331	O
111	-	333	O
.	-	336	O
0	-	337	O
and	-	339	O
133	-	343	O
.	-	346	O
1	-	347	O
mg	-	349	O
/	-	351	O
kg	-	352	O
for	-	355	O
lidocaine	-	359	O
,	-	368	O
and	-	370	O
243	-	374	O
.	-	377	O
4	-	378	O
and	-	380	O
266	-	384	O
.	-	387	O
5	-	388	O
mg	-	390	O
/	-	392	O
kg	-	393	O
for	-	396	O
chloroprocaine	-	400	O
.	-	414	O

When	7189975	416	O
given	-	421	O
intraperitoneally	-	427	O
,	-	444	O
bupivacaine	-	446	O
thus	-	458	O
was	-	463	O
only	-	467	O
about	-	472	O
twice	-	478	O
as	-	484	O
toxic	-	487	O
as	-	493	O
lidocaine	-	496	O
and	-	506	O
four	-	510	O
times	-	515	O
as	-	521	O
toxic	-	524	O
as	-	530	O
chloroprocaine	-	533	O
.	-	547	O

Convulsions	7189975	549	B
always	-	561	O
preceded	-	568	O
death	-	577	O
,	-	582	O
except	-	584	O
after	-	591	O
precipitous	-	597	O
cardiopulmonary	-	609	B
arrest	-	625	I
from	-	632	O
extreme	-	637	O
doses	-	645	O
.	-	650	O

A	7189975	652	O
CD50	-	654	O
dose	-	659	O
of	-	664	O
local	-	667	O
anesthetic	-	673	O
(	-	684	O
causing	-	685	O
convulsions	-	693	B
in	-	705	O
50	-	708	O
%	-	710	O
of	-	712	O
mice	-	715	O
)	-	719	O
was	-	721	O
fatal	-	725	O
in	-	731	O
90	-	734	O
%	-	736	O
of	-	738	O
bupivacaine	-	741	O
-	-	752	O
induced	-	753	O
seizures	-	761	B
,	-	769	O
in	-	771	O
57	-	774	O
%	-	776	O
of	-	778	O
the	-	781	O
chloroprocaine	-	785	O
group	-	800	O
,	-	805	O
and	-	807	O
in	-	811	O
6	-	814	O
%	-	815	O
of	-	817	O
the	-	820	O
lidocaine	-	824	O
group	-	834	O
.	-	839	O

The	7189975	841	O
narrow	-	845	O
gap	-	852	O
between	-	856	O
convulsant	-	864	O
and	-	875	O
lethal	-	879	O
doses	-	886	O
of	-	892	O
local	-	895	O
anesthetics	-	901	O
indicates	-	913	O
that	-	923	O
untreated	-	928	O
convulsions	-	938	B
present	-	950	O
much	-	958	O
more	-	963	O
of	-	968	O
a	-	971	O
threat	-	973	O
to	-	980	O
life	-	983	O
than	-	988	O
heretofore	-	993	O
appreciated	-	1004	O
.	-	1015	O

Myoclonic	6415512	0	B
,	-	9	I
atonic	-	11	I
,	-	17	I
and	-	19	I
absence	-	23	I
seizures	-	31	I
following	-	40	O
institution	-	50	O
of	-	62	O
carbamazepine	-	65	O
therapy	-	79	O
in	-	87	O
children	-	90	O
.	-	98	O

Five	6415512	100	O
children	-	105	O
,	-	113	O
aged	-	115	O
3	-	120	O
to	-	122	O
11	-	125	O
years	-	128	O
,	-	133	O
treated	-	135	O
with	-	143	O
carbamazepine	-	148	O
for	-	162	O
epilepsy	-	166	B
,	-	174	O
had	-	176	O
an	-	180	O
acute	-	183	O
aberrant	-	189	O
reaction	-	198	O
characterized	-	207	O
by	-	221	O
the	-	224	O
onset	-	228	O
of	-	234	O
myoclonic	-	237	B
,	-	246	I
atypical	-	248	I
absence	-	257	I
and	-	265	I
/	-	268	I
or	-	269	I
atonic	-	272	I
(	-	279	I
minor	-	280	I
motor	-	286	I
)	-	291	I
seizures	-	293	I
within	-	302	O
a	-	309	O
few	-	311	O
days	-	315	O
.	-	319	O

When	6415512	321	O
the	-	326	O
carbamazepine	-	330	O
was	-	344	O
discontinued	-	348	O
,	-	360	O
two	-	362	O
of	-	366	O
the	-	369	O
children	-	373	O
returned	-	382	O
to	-	391	O
their	-	394	O
former	-	400	O
state	-	407	O
very	-	413	O
quickly	-	418	O
,	-	425	O
two	-	427	O
had	-	431	O
the	-	435	O
minor	-	439	O
motor	-	445	O
seizures	-	451	B
resolve	-	460	O
in	-	468	O
3	-	471	O
and	-	473	O
6	-	477	O
months	-	479	O
,	-	485	O
and	-	487	O
one	-	491	O
had	-	495	O
the	-	499	O
seizures	-	503	B
persist	-	512	O
.	-	519	O

The	6415512	521	O
child	-	525	O
in	-	531	O
whom	-	534	O
the	-	539	O
seizures	-	543	B
persisted	-	552	O
was	-	562	O
later	-	566	O
found	-	572	O
to	-	578	O
have	-	581	O
ceroid	-	586	B
lipofuscinosis	-	593	I
.	-	607	O

The	6415512	609	O
other	-	613	O
children	-	619	O
are	-	628	O
doing	-	632	O
well	-	638	O
on	-	643	O
other	-	646	O
anticonvulsants	-	652	O
.	-	667	O

Naloxone	1928887	0	O
reversal	-	9	O
of	-	18	O
hypotension	-	21	B
due	-	33	O
to	-	37	O
captopril	-	40	O
overdose	-	50	B
.	-	58	O

The	1928887	60	O
hemodynamic	-	64	O
effects	-	76	O
of	-	84	O
captopril	-	87	O
and	-	97	O
other	-	101	O
angiotensin	-	107	O
-	-	118	O
converting	-	119	O
enzyme	-	130	O
inhibitors	-	137	O
may	-	148	O
be	-	152	O
mediated	-	155	O
by	-	164	O
the	-	167	O
endogenous	-	171	O
opioid	-	182	O
system	-	189	O
.	-	195	O

The	1928887	197	O
opioid	-	201	O
antagonist	-	208	O
naloxone	-	219	O
has	-	228	O
been	-	232	O
shown	-	237	O
to	-	243	O
block	-	246	O
or	-	252	O
reverse	-	255	O
the	-	263	O
hypotensive	-	267	B
actions	-	279	O
of	-	287	O
captopril	-	290	O
.	-	299	O

We	1928887	301	O
report	-	304	O
a	-	311	O
case	-	313	O
of	-	318	O
an	-	321	O
intentional	-	324	O
captopril	-	336	O
overdose	-	346	B
,	-	354	O
manifested	-	356	O
by	-	367	O
marked	-	370	O
hypotension	-	377	B
,	-	388	O
that	-	390	O
resolved	-	395	O
promptly	-	404	O
with	-	413	O
the	-	418	O
administration	-	422	O
of	-	437	O
naloxone	-	440	O
.	-	448	O

To	1928887	450	O
our	-	453	O
knowledge	-	457	O
,	-	466	O
this	-	468	O
is	-	473	O
the	-	476	O
first	-	480	O
reported	-	486	O
case	-	495	O
of	-	500	O
captopril	-	503	O
-	-	512	O
induced	-	513	O
hypotension	-	521	B
treated	-	533	O
with	-	541	O
naloxone	-	546	O
.	-	554	O

Our	1928887	556	O
experience	-	560	O
demonstrates	-	571	O
a	-	584	O
possible	-	586	O
role	-	595	O
of	-	600	O
naloxone	-	603	O
in	-	612	O
the	-	615	O
reversal	-	619	O
of	-	628	O
hypotension	-	631	B
resulting	-	643	O
from	-	653	O
captopril	-	658	O
.	-	667	O

Carbamazepine	1728915	0	O
-	-	13	O
induced	-	14	O
cardiac	-	22	B
dysfunction	-	30	I
.	-	41	O

Characterization	1728915	43	O
of	-	60	O
two	-	63	O
distinct	-	67	O
clinical	-	76	O
syndromes	-	85	O
.	-	94	O

A	1728915	96	O
patient	-	98	O
with	-	106	O
sinus	-	111	O
bradycardia	-	117	B
and	-	129	O
atrioventricular	-	133	B
block	-	150	I
,	-	155	O
induced	-	157	O
by	-	165	O
carbamazepine	-	168	O
,	-	181	O
prompted	-	183	O
an	-	192	O
extensive	-	195	O
literature	-	205	O
review	-	216	O
of	-	223	O
all	-	226	O
previously	-	230	O
reported	-	241	O
cases	-	250	O
.	-	255	O

From	1728915	257	O
the	-	262	O
analysis	-	266	O
of	-	275	O
these	-	278	O
cases	-	284	O
,	-	289	O
two	-	291	O
distinct	-	295	O
forms	-	304	O
of	-	310	O
carbamazepine	-	313	O
-	-	326	O
associated	-	327	O
cardiac	-	338	B
dysfunction	-	346	I
emerged	-	358	O
.	-	365	O

One	1728915	367	O
patient	-	371	O
group	-	379	O
developed	-	385	O
sinus	-	395	B
tachycardias	-	401	I
in	-	414	O
the	-	417	O
setting	-	421	O
of	-	429	O
a	-	432	O
massive	-	434	O
carbamazepine	-	442	O

overdose	1728915	456	B
.	-	464	O

The	1728915	466	O
second	-	470	O
group	-	477	O
consisted	-	483	O
almost	-	493	O
exclusively	-	500	O
of	-	512	O
elderly	-	515	O
women	-	523	O
who	-	529	O
developed	-	533	O
potentially	-	543	O
life	-	555	O
-	-	559	O
threatening	-	560	O
bradyarrhythmias	-	572	B
or	-	589	O
atrioventricular	-	592	B
conduction	-	609	I
delay	-	620	I
,	-	625	O
associated	-	627	O
with	-	638	O
either	-	643	O
therapeutic	-	650	O
or	-	662	O
modestly	-	665	O
elevated	-	674	O
carbamazepine	-	683	O
serum	-	697	O
levels	-	703	O
.	-	709	O

Because	1728915	711	O
carbamazepine	-	719	O
is	-	733	O
widely	-	736	O
used	-	743	O
in	-	748	O
the	-	751	O
treatment	-	755	O
of	-	765	O
many	-	768	O
neurologic	-	773	O
and	-	784	O
psychiatric	-	788	B
conditions	-	800	O
,	-	810	O
the	-	812	O
recognition	-	816	O
of	-	828	O
the	-	831	O
latter	-	835	O
syndrome	-	842	O
has	-	851	O
important	-	855	O
implications	-	865	O
for	-	878	O
the	-	882	O
use	-	886	O
of	-	890	O
this	-	893	O
drug	-	898	O
in	-	903	O
elderly	-	906	O
patients	-	914	O
.	-	922	O

Glutamatergic	20558148	0	O
neurotransmission	-	14	O
mediated	-	32	O
by	-	41	O
NMDA	-	44	O
receptors	-	49	O
in	-	59	O
the	-	62	O
inferior	-	66	O
colliculus	-	75	O
can	-	86	O
modulate	-	90	O
haloperidol	-	99	O
-	-	110	O
induced	-	111	O
catalepsy	-	119	B
.	-	128	O

The	20558148	130	O
inferior	-	134	O
colliculus	-	143	O
(	-	154	O
IC	-	155	O
)	-	157	O
is	-	159	O
primarily	-	162	O
involved	-	172	O
in	-	181	O
the	-	184	O
processing	-	188	O
of	-	199	O
auditory	-	202	O
information	-	211	O
,	-	222	O
but	-	224	O
it	-	228	O
is	-	231	O
distinguished	-	234	O
from	-	248	O
other	-	253	O
auditory	-	259	O
nuclei	-	268	O
in	-	275	O
the	-	278	O
brainstem	-	282	O
by	-	292	O
its	-	295	O
connections	-	299	O
with	-	311	O
structures	-	316	O
of	-	327	O
the	-	330	O
motor	-	334	O
system	-	340	O
.	-	346	O

Functional	20558148	348	O
evidence	-	359	O
relating	-	368	O
the	-	377	O
IC	-	381	O
to	-	384	O
motor	-	387	O
behavior	-	393	O
derives	-	402	O
from	-	410	O
experiments	-	415	O
showing	-	427	O
that	-	435	O
activation	-	440	O
of	-	451	O
the	-	454	O
IC	-	458	O
by	-	461	O
electrical	-	464	O
stimulation	-	475	O
or	-	487	O
excitatory	-	490	O
amino	-	501	O
acid	-	507	O
microinjection	-	512	O
causes	-	527	O
freezing	-	534	O
,	-	542	O
escape	-	544	O
-	-	550	O
like	-	551	O
behavior	-	556	O
,	-	564	O
and	-	566	O
immobility	-	570	O
.	-	580	O

However	20558148	582	O
,	-	589	O
the	-	591	O
nature	-	595	O
of	-	602	O
this	-	605	O
immobility	-	610	O
is	-	621	O
still	-	624	O
unclear	-	630	O
.	-	637	O

The	20558148	639	O
present	-	643	O
study	-	651	O
examined	-	657	O
the	-	666	O
influence	-	670	O
of	-	680	O
excitatory	-	683	O
amino	-	694	O
acid	-	700	O
-	-	704	O
mediated	-	705	O
mechanisms	-	714	O
in	-	725	O
the	-	728	O
IC	-	732	O
on	-	735	O
the	-	738	O
catalepsy	-	742	B
induced	-	752	O
by	-	760	O
the	-	763	O
dopamine	-	767	O
receptor	-	776	O
blocker	-	785	O
haloperidol	-	793	O
administered	-	805	O
systemically	-	818	O
(	-	831	O
1	-	832	O
or	-	834	O
0	-	837	O
.	-	838	O
5	-	839	O
mg	-	841	O
/	-	843	O
kg	-	844	O
)	-	846	O
in	-	848	O
rats	-	851	O
.	-	855	O

Haloperidol	20558148	857	O
-	-	868	O
induced	-	869	O
catalepsy	-	877	B
was	-	887	O
challenged	-	891	O
with	-	902	O
prior	-	907	O
intracollicular	-	913	O
microinjections	-	929	O
of	-	945	O
glutamate	-	948	O
NMDA	-	958	O
receptor	-	963	O
antagonists	-	972	O
,	-	983	O
MK	-	985	O
-	-	987	O
801	-	988	O

(	20558148	992	O
15	-	993	O
or	-	996	O
30	-	999	O
mmol	-	1002	O
/	-	1006	O
0	-	1007	O
.	-	1008	O
5	-	1009	O
microl	-	1011	O
)	-	1017	O
and	-	1019	O
AP7	-	1023	O
(	-	1027	O
10	-	1028	O
or	-	1031	O
20	-	1034	O
nmol	-	1037	O
/	-	1041	O
0	-	1042	O
.	-	1043	O
5	-	1044	O
microl	-	1046	O
)	-	1052	O
,	-	1053	O
or	-	1055	O
of	-	1058	O
the	-	1061	O
NMDA	-	1065	O
receptor	-	1070	O
agonist	-	1079	O
N	-	1087	O
-	-	1088	O
methyl	-	1089	O
-	-	1095	O
d	-	1096	O
-	-	1097	O
aspartate	-	1098	O
(	-	1108	O
NMDA	-	1109	O
,	-	1113	O
20	-	1115	O
or	-	1118	O
30	-	1121	O
nmol	-	1124	O
/	-	1128	O
0	-	1129	O
.	-	1130	O
5	-	1131	O
microl	-	1133	O
)	-	1139	O
.	-	1140	O

The	20558148	1142	O
results	-	1146	O
showed	-	1154	O
that	-	1161	O
intracollicular	-	1166	O
microinjection	-	1182	O
of	-	1197	O
MK	-	1200	O
-	-	1202	O
801	-	1203	O
and	-	1207	O
AP7	-	1211	O
previous	-	1215	O
to	-	1224	O
systemic	-	1227	O
injections	-	1236	O
of	-	1247	O
haloperidol	-	1250	O
significantly	-	1262	O
attenuated	-	1276	O
the	-	1287	O
catalepsy	-	1291	B
,	-	1300	O
as	-	1302	O
indicated	-	1305	O
by	-	1315	O
a	-	1318	O
reduced	-	1320	O
latency	-	1328	O
to	-	1336	O
step	-	1339	O
down	-	1344	O
from	-	1349	O
a	-	1354	O
horizontal	-	1356	O
bar	-	1367	O
.	-	1370	O

Accordingly	20558148	1372	O
,	-	1383	O
intracollicular	-	1385	O
microinjection	-	1401	O
of	-	1416	O
NMDA	-	1419	O
increased	-	1424	O
the	-	1434	O
latency	-	1438	O
to	-	1446	O
step	-	1449	O
down	-	1454	O
the	-	1459	O
bar	-	1463	O
.	-	1466	O

These	20558148	1468	O
findings	-	1474	O
suggest	-	1483	O
that	-	1491	O
glutamate	-	1496	O
-	-	1505	O
mediated	-	1506	O
mechanisms	-	1515	O
in	-	1526	O
the	-	1529	O
neural	-	1533	O
circuits	-	1540	O
at	-	1549	O
the	-	1552	O
IC	-	1556	O
level	-	1559	O
influence	-	1565	O
haloperidol	-	1575	O
-	-	1586	O
induced	-	1587	O
catalepsy	-	1595	B
and	-	1605	O
participate	-	1609	O
in	-	1621	O
the	-	1624	O
regulation	-	1628	O
of	-	1639	O
motor	-	1642	O
activity	-	1648	O
.	-	1656	O

Metabotropic	19940105	0	O
glutamate	-	13	O
7	-	23	O
receptor	-	25	O
subtype	-	34	O
modulates	-	42	O
motor	-	52	O
symptoms	-	58	O
in	-	67	O
rodent	-	70	O
models	-	77	O
of	-	84	O
Parkinson	-	87	B
's	-	96	I
disease	-	99	I
.	-	106	O

Metabotropic	19940105	108	O
glutamate	-	121	O
(	-	131	O
mGlu	-	132	O
)	-	136	O
receptors	-	138	O
modulate	-	148	O
synaptic	-	157	O
transmission	-	166	O
in	-	179	O
the	-	182	O
central	-	186	O
nervous	-	194	O
system	-	202	O
and	-	209	O
represent	-	213	O
promising	-	223	O
therapeutic	-	233	O
targets	-	245	O
for	-	253	O
symptomatic	-	257	O
treatment	-	269	O
of	-	279	O
Parkinson	-	282	B
's	-	291	I
disease	-	294	I
(	-	302	O
PD	-	303	B
)	-	305	O
.	-	306	O

Among	19940105	308	O
the	-	314	O
eight	-	318	O
mGlu	-	324	O
receptor	-	329	O
subtypes	-	338	O
,	-	346	O
mGlu7	-	348	O
receptor	-	354	O
is	-	363	O
prominently	-	366	O
expressed	-	378	O
in	-	388	O
the	-	391	O
basal	-	395	O
ganglia	-	401	O
,	-	408	O
but	-	410	O
its	-	414	O
role	-	418	O
in	-	423	O
restoring	-	426	O
motor	-	436	O
function	-	442	O
in	-	451	O
animal	-	454	O
models	-	461	O
of	-	468	O
PD	-	471	B
is	-	474	O
not	-	477	O
known	-	481	O
.	-	486	O

The	19940105	488	O
effects	-	492	O
of	-	500	O
N	-	503	O
,	-	504	O
N'	-	505	O
-	-	507	O
dibenzhydrylethane	-	508	O
-	-	526	O
1	-	527	O
,	-	528	O
2	-	529	O
-	-	530	O
diamine	-	531	O
dihydrochloride	-	539	O
(	-	555	O
AMN082	-	556	O
)	-	562	O
,	-	563	O
the	-	565	O
first	-	569	O
selective	-	575	O
allosteric	-	585	O
activator	-	596	O
of	-	606	O
mGlu7	-	609	O
receptors	-	615	O
,	-	624	O
were	-	626	O
thus	-	631	O
tested	-	636	O
in	-	643	O
different	-	646	O
rodent	-	656	O
models	-	663	O
of	-	670	O
PD	-	673	B
.	-	675	O

Here	19940105	677	O
,	-	681	O
we	-	683	O
show	-	686	O
that	-	691	O
oral	-	696	O
(	-	701	O
5	-	702	O
mg	-	704	O
/	-	706	O
kg	-	707	O
)	-	709	O
or	-	711	O
intrastriatal	-	714	O
administration	-	728	O
(	-	743	O
0	-	744	O
.	-	745	O
1	-	746	O
and	-	748	O
0	-	752	O
.	-	753	O
5	-	754	O
nmol	-	756	O
)	-	760	O
of	-	762	O
AMN082	-	765	O
reverses	-	772	O
haloperidol	-	781	O
-	-	792	O
induced	-	793	O
catalepsy	-	801	B
in	-	811	O
rats	-	814	O
.	-	818	O

AMN082	19940105	820	O
(	-	827	O
2	-	828	O
.	-	829	O
5	-	830	O
and	-	832	O
5	-	836	O
mg	-	838	O
/	-	840	O
kg	-	841	O
)	-	843	O
reduces	-	845	O
apomorphine	-	853	O
-	-	864	O
induced	-	865	O
rotations	-	873	O
in	-	883	O
unilateral	-	886	O
6	-	897	O
-	-	898	O
hydroxydopamine	-	899	O
(	-	915	O
6	-	916	O
-	-	917	O
OHDA	-	918	O
)	-	922	O
-	-	923	O
lesioned	-	924	O
rats	-	933	O
.	-	937	O

In	19940105	939	O
a	-	942	O
more	-	944	O
complex	-	949	O
task	-	957	O
commonly	-	962	O
used	-	971	O
to	-	976	O
evaluate	-	979	O
major	-	988	O
akinetic	-	994	B
symptoms	-	1003	O
of	-	1012	O
PD	-	1015	B
patients	-	1018	O
,	-	1026	O
5	-	1028	O
mg	-	1030	O
/	-	1032	O
kg	-	1033	O
AMN082	-	1036	O
reverses	-	1043	O
the	-	1052	O
increased	-	1056	O
reaction	-	1066	O
time	-	1075	O
to	-	1080	O
respond	-	1083	O
to	-	1091	O
a	-	1094	O
cue	-	1096	O
of	-	1100	O
bilateral	-	1103	O
6	-	1113	O
-	-	1114	O
OHDA	-	1115	O
-	-	1119	O
lesioned	-	1120	O
rats	-	1129	O
.	-	1133	O

In	19940105	1135	O
addition	-	1138	O
,	-	1146	O
AMN082	-	1148	O
reduces	-	1155	O
the	-	1163	O
duration	-	1167	O
of	-	1176	O
haloperidol	-	1179	O
-	-	1190	O
induced	-	1191	O
catalepsy	-	1199	B
in	-	1209	O
a	-	1212	O
mGlu7	-	1214	O
receptor	-	1220	O
-	-	1228	O
dependent	-	1229	O
manner	-	1239	O
in	-	1246	O
wild	-	1249	O
-	-	1253	O
type	-	1254	O
but	-	1259	O
not	-	1263	O
mGlu7	-	1267	O
receptor	-	1273	O
knockout	-	1282	O
mice	-	1291	O
.	-	1295	O

Higher	19940105	1297	O
doses	-	1304	O
of	-	1310	O
AMN082	-	1313	O
(	-	1320	O
10	-	1321	O
and	-	1324	O
20	-	1328	O
mg	-	1331	O
/	-	1333	O
kg	-	1334	O
p	-	1337	O
.	-	1338	O
o	-	1339	O
.	-	1340	O
)	-	1341	O
have	-	1343	O
no	-	1348	O
effect	-	1351	O
on	-	1358	O
the	-	1361	O
same	-	1365	O
models	-	1370	O
of	-	1377	O
PD	-	1380	B
.	-	1382	O

Overall	19940105	1384	O
these	-	1392	O
findings	-	1398	O
suggest	-	1407	O
that	-	1415	O
mGlu7	-	1420	O
receptor	-	1426	O
activation	-	1435	O
can	-	1446	O
reverse	-	1450	O
motor	-	1458	O
dysfunction	-	1464	O
associated	-	1476	O
with	-	1487	O
reduced	-	1492	O
dopamine	-	1500	O
activity	-	1509	O
.	-	1517	O

Selective	19940105	1519	O
ligands	-	1529	O
of	-	1537	O
mGlu7	-	1540	O
receptor	-	1546	O
subtypes	-	1555	O
may	-	1564	O
thus	-	1568	O
be	-	1573	O
considered	-	1576	O
as	-	1587	O
promising	-	1590	O
compounds	-	1600	O
for	-	1610	O
the	-	1614	O
development	-	1618	O
of	-	1630	O
antiparkinsonian	-	1633	O
therapeutic	-	1650	O
strategies	-	1662	O
.	-	1672	O

Nimodipine	19923525	0	O
prevents	-	11	O
memory	-	20	B
impairment	-	27	I
caused	-	38	O
by	-	45	O
nitroglycerin	-	48	O
-	-	61	O
induced	-	62	O
hypotension	-	70	B
in	-	82	O
adult	-	85	O
mice	-	91	O
.	-	95	O

BACKGROUND	19923525	97	O
:	-	107	O
Hypotension	-	109	B
and	-	121	O
a	-	125	O
resultant	-	127	O
decrease	-	137	O
in	-	146	O
cerebral	-	149	O
blood	-	158	O
flow	-	164	O
have	-	169	O
been	-	174	O
implicated	-	179	O
in	-	190	O
the	-	193	O
development	-	197	O
of	-	209	O
cognitive	-	212	B
dysfunction	-	222	I
.	-	233	O

We	19923525	235	O
tested	-	238	O
the	-	245	O
hypothesis	-	249	O
that	-	260	O
nimodipine	-	265	O
(	-	276	O
NIMO	-	277	O
)	-	281	O
administered	-	283	O
at	-	296	O
the	-	299	O
onset	-	303	O
of	-	309	O
nitroglycerin	-	312	O
(	-	326	O
NTG	-	327	O
)	-	330	O
-	-	331	O
induced	-	332	O
hypotension	-	340	B
would	-	352	O
preserve	-	358	O
long	-	367	O
-	-	371	O
term	-	372	O
associative	-	377	O
memory	-	389	O
.	-	395	O

METHODS	19923525	397	O
:	-	404	O

The	19923525	406	O
passive	-	410	O
avoidance	-	418	O
(	-	428	O
PA	-	429	O
)	-	431	O
paradigm	-	433	O
was	-	442	O
used	-	446	O
to	-	451	O
assess	-	454	O
memory	-	461	O
retention	-	468	O
.	-	477	O

For	19923525	479	O
PA	-	483	O
training	-	486	O
,	-	494	O
latencies	-	496	O
(	-	506	O
seconds	-	507	O
)	-	514	O
were	-	516	O
recorded	-	521	O
for	-	530	O
entry	-	534	O
from	-	540	O
a	-	545	O
suspended	-	547	O
platform	-	557	O
into	-	566	O
a	-	571	O
Plexiglas	-	573	O
tube	-	583	O
where	-	588	O
a	-	594	O
shock	-	596	O
was	-	602	O
automatically	-	606	O
delivered	-	620	O
.	-	629	O

Latencies	19923525	631	O
were	-	641	O
recorded	-	646	O
48	-	655	O
h	-	658	O
later	-	660	O
for	-	666	O
a	-	670	O
testing	-	672	O
trial	-	680	O
.	-	685	O

Ninety	19923525	687	O
-	-	693	O
six	-	694	O
Swiss	-	698	O
-	-	703	O
Webster	-	704	O
mice	-	712	O
(	-	717	O
30	-	718	O
-	-	720	O
35	-	721	O
g	-	724	O
,	-	725	O
6	-	727	O
-	-	728	O
8	-	729	O
wk	-	731	O
)	-	733	O
,	-	734	O
were	-	736	O
randomized	-	741	O
into	-	752	O
6	-	757	O
groups	-	759	O
1	-	766	O
)	-	767	O
saline	-	769	O
(	-	776	O
control	-	777	O
)	-	784	O
,	-	785	O
2	-	787	O
)	-	788	O
NTG	-	790	O
immediately	-	794	O
after	-	806	O
learning	-	812	O
,	-	820	O
3	-	822	O
)	-	823	O
NTG	-	825	O
3	-	829	O
h	-	831	O
after	-	833	O
learning	-	839	O
,	-	847	O
4	-	849	O
)	-	850	O
NTG	-	852	O
and	-	856	O
NIMO	-	860	O
,	-	864	O
5	-	866	O
)	-	867	O
vehicle	-	869	O
,	-	876	O
and	-	878	O
6	-	882	O
)	-	883	O
NIMO	-	885	O
alone	-	890	O
.	-	895	O

The	19923525	897	O
extent	-	901	O
of	-	908	O
hypotension	-	911	B
and	-	923	O
changes	-	927	O
in	-	935	O
brain	-	938	O
tissue	-	944	O
oxygenation	-	951	O
(	-	963	O
PbtO	-	964	O
(	-	968	O
2	-	969	O
)	-	970	O
)	-	971	O
and	-	973	O
in	-	977	O
cerebral	-	980	O
blood	-	989	O
flow	-	995	O
were	-	1000	O
studied	-	1005	O
in	-	1013	O
a	-	1016	O
separate	-	1018	O
group	-	1027	O
of	-	1033	O
animals	-	1036	O
.	-	1043	O

RESULTS	19923525	1045	O
:	-	1052	O

All	19923525	1054	O
groups	-	1058	O
exhibited	-	1065	O
similar	-	1075	O
training	-	1083	O
latencies	-	1092	O
(	-	1102	O
17	-	1103	O
.	-	1105	O
0	-	1106	O
+	-	1108	O
/	-	1109	O
-	-	1110	O

4	19923525	1112	O
.	-	1113	O
6	-	1114	O
s	-	1116	O
)	-	1117	O
.	-	1118	O

Mice	19923525	1120	O
subjected	-	1125	O
to	-	1135	O
hypotensive	-	1138	B
episodes	-	1150	O
showed	-	1159	O
a	-	1166	O
significant	-	1168	O
decrease	-	1180	O
in	-	1189	O
latency	-	1192	O
time	-	1200	O
(	-	1205	O
178	-	1206	O
+	-	1210	O
/	-	1211	O
-	-	1212	O

156	19923525	1214	O
s	-	1218	O
)	-	1219	O
compared	-	1221	O
with	-	1230	O
those	-	1235	O
injected	-	1241	O
with	-	1250	O
saline	-	1255	O
,	-	1261	O
NTG	-	1263	O
+	-	1267	O
NIMO	-	1269	O
,	-	1273	O
or	-	1275	O
delayed	-	1278	O
NTG	-	1286	O
(	-	1290	O
580	-	1291	O
+	-	1295	O
/	-	1296	O
-	-	1297	O

81	19923525	1299	O
s	-	1302	O
,	-	1303	O
557	-	1305	O
+	-	1309	O
/	-	1310	O
-	-	1311	O
67	-	1313	O
s	-	1316	O
,	-	1317	O
and	-	1319	O
493	-	1323	O
+	-	1327	O
/	-	1328	O
-	-	1329	O

146	19923525	1331	O
s	-	1335	O
,	-	1336	O
respectively	-	1338	O
)	-	1350	O
.	-	1351	O

A	19923525	1353	O
Kruskal	-	1355	O
-	-	1362	O
Wallis	-	1363	O
1	-	1370	O
-	-	1371	O
way	-	1372	O
analysis	-	1376	O
of	-	1385	O
variance	-	1388	O
indicated	-	1397	O
a	-	1407	O
significant	-	1409	O
difference	-	1421	O
among	-	1432	O
the	-	1438	O
4	-	1442	O
treatment	-	1444	O
groups	-	1454	O
(	-	1461	O
H	-	1462	O
=	-	1464	O
15	-	1466	O
.	-	1468	O
34	-	1469	O
;	-	1471	O
P	-	1473	O
<	-	1475	O
0	-	1477	O
.	-	1478	O
001	-	1479	O
)	-	1482	O
.	-	1483	O

In	19923525	1485	O
a	-	1488	O
separate	-	1490	O
group	-	1499	O
of	-	1505	O
mice	-	1508	O
not	-	1513	O
subjected	-	1517	O
to	-	1527	O
behavioral	-	1530	O
studies	-	1541	O
,	-	1548	O
the	-	1550	O
same	-	1554	O
dose	-	1559	O
of	-	1564	O
NTG	-	1567	O
(	-	1571	O
n	-	1572	O
=	-	1574	O
3	-	1576	O
)	-	1577	O
and	-	1579	O
NTG	-	1583	O
+	-	1587	O
NIMO	-	1589	O
(	-	1594	O
n	-	1595	O
=	-	1597	O
3	-	1599	O
)	-	1600	O
caused	-	1602	O
mean	-	1609	O
arterial	-	1614	O
blood	-	1623	O
pressure	-	1629	O
to	-	1638	O
decrease	-	1641	O
from	-	1650	O
85	-	1655	O
.	-	1657	O
9	-	1658	O
+	-	1660	O
/	-	1661	O
-	-	1662	O

3	19923525	1664	O
.	-	1665	O
8	-	1666	O
mm	-	1668	O
Hg	-	1671	O
sem	-	1674	O
to	-	1678	O
31	-	1681	O
.	-	1683	O
6	-	1684	O
+	-	1686	O
/	-	1687	O
-	-	1688	O

0	19923525	1690	O
.	-	1691	O
8	-	1692	O
mm	-	1694	O
Hg	-	1697	O
sem	-	1700	O
and	-	1704	O
from	-	1708	O
86	-	1713	O
.	-	1715	O
2	-	1716	O
+	-	1718	O
/	-	1719	O
-	-	1720	O

3	19923525	1722	O
.	-	1723	O
7	-	1724	O
mm	-	1726	O
Hg	-	1729	O
sem	-	1732	O
to	-	1736	O
32	-	1739	O
.	-	1741	O
6	-	1742	O
+	-	1744	O
/	-	1745	O
-	-	1746	O

0	19923525	1748	O
.	-	1749	O
2	-	1750	O
mm	-	1752	O
Hg	-	1755	O
sem	-	1758	O
,	-	1761	O
respectively	-	1763	O
.	-	1775	O

Mean	19923525	1777	O
arterial	-	1782	O
blood	-	1791	O
pressure	-	1797	O
in	-	1806	O
mice	-	1809	O
treated	-	1814	O
with	-	1822	O
NIMO	-	1827	O
alone	-	1832	O
decreased	-	1838	O
from	-	1848	O
88	-	1853	O
.	-	1855	O
1	-	1856	O
+	-	1858	O
/	-	1859	O
-	-	1860	O

3	19923525	1862	O
.	-	1863	O
8	-	1864	O
mm	-	1866	O
Hg	-	1869	O
to	-	1872	O
80	-	1875	O
.	-	1877	O
0	-	1878	O
+	-	1880	O
/	-	1881	O
-	-	1882	O

2	19923525	1884	O
.	-	1885	O
9	-	1886	O
mm	-	1888	O
Hg	-	1891	O
.	-	1893	O

The	19923525	1895	O
intergroup	-	1899	O
difference	-	1910	O
was	-	1921	O
statistically	-	1925	O
significant	-	1939	O
(	-	1951	O
P	-	1952	O
<	-	1954	O
0	-	1956	O
.	-	1957	O
05	-	1958	O
)	-	1960	O
.	-	1961	O

PbtO	19923525	1963	O
(	-	1967	O
2	-	1968	O
)	-	1969	O
decreased	-	1971	O
from	-	1981	O
51	-	1986	O
.	-	1988	O
7	-	1989	O
+	-	1991	O
/	-	1992	O
-	-	1993	O

4	19923525	1995	O
.	-	1996	O
5	-	1997	O
mm	-	1999	O
Hg	-	2002	O
sem	-	2005	O
to	-	2009	O
33	-	2012	O
.	-	2014	O
8	-	2015	O
+	-	2017	O
/	-	2018	O
-	-	2019	O

5	19923525	2021	O
.	-	2022	O
2	-	2023	O
mm	-	2025	O

Hg	19923525	2028	O
sem	-	2031	O
in	-	2035	O
the	-	2038	O
NTG	-	2042	O
group	-	2046	O
and	-	2052	O
from	-	2056	O
38	-	2061	O
.	-	2063	O
6	-	2064	O
+	-	2066	O
/	-	2067	O
-	-	2068	O

6	19923525	2070	O
.	-	2071	O
1	-	2072	O
mm	-	2074	O
Hg	-	2077	O
sem	-	2080	O
to	-	2084	O
25	-	2087	O
.	-	2089	O
4	-	2090	O
+	-	2092	O
/	-	2093	O
-	-	2094	O

2	19923525	2096	O
.	-	2097	O
0	-	2098	O
mm	-	2100	O
Hg	-	2103	O
sem	-	2106	O
in	-	2110	O
the	-	2113	O
NTG	-	2117	O
+	-	2121	O
NIMO	-	2123	O
groups	-	2128	O
,	-	2134	O
respectively	-	2136	O
.	-	2148	O

There	19923525	2150	O
were	-	2156	O
no	-	2161	O
significant	-	2164	O
differences	-	2176	O
among	-	2188	O
groups	-	2194	O
.	-	2200	O

CONCLUSION	19923525	2202	O
:	-	2212	O

In	19923525	2214	O
a	-	2217	O
PA	-	2219	O
retention	-	2222	O
paradigm	-	2232	O
,	-	2240	O
the	-	2242	O
injection	-	2246	O
of	-	2256	O
NTG	-	2259	O
immediately	-	2263	O
after	-	2275	O
learning	-	2281	O
produced	-	2290	O
a	-	2299	O
significant	-	2301	O
impairment	-	2313	O
of	-	2324	O
long	-	2327	O
-	-	2331	O
term	-	2332	O
associative	-	2337	O
memory	-	2349	O
in	-	2356	O
mice	-	2359	O
,	-	2363	O
whereas	-	2365	O
delayed	-	2373	O
induced	-	2381	O
hypotension	-	2389	B
had	-	2401	O
no	-	2405	O
effect	-	2408	O
.	-	2414	O

NIMO	19923525	2416	O
attenuated	-	2421	O
the	-	2432	O
disruption	-	2436	O
in	-	2447	O
consolidation	-	2450	O
of	-	2464	O
long	-	2467	O
-	-	2471	O
term	-	2472	O
memory	-	2477	O
caused	-	2484	O
by	-	2491	O
NTG	-	2494	O
but	-	2498	O
did	-	2502	O
not	-	2506	O
improve	-	2510	O
latency	-	2518	O
in	-	2526	O
the	-	2529	O
absence	-	2533	O
of	-	2541	O
hypotension	-	2544	B
.	-	2555	O

The	19923525	2557	O
observed	-	2561	O
effect	-	2570	O
of	-	2577	O
NIMO	-	2580	O
may	-	2585	O
have	-	2589	O
been	-	2594	O
attributable	-	2599	O
to	-	2612	O
the	-	2615	O
preservation	-	2619	O
of	-	2632	O
calcium	-	2635	O
homeostasis	-	2643	O
during	-	2655	O
hypotension	-	2662	B
,	-	2673	O
because	-	2675	O
there	-	2683	O
were	-	2689	O
no	-	2694	O
differences	-	2697	O
in	-	2709	O
the	-	2712	O
PbtO	-	2716	O
(	-	2720	O
2	-	2721	O
)	-	2722	O
indices	-	2724	O
among	-	2732	O
groups	-	2738	O
.	-	2744	O

Fatal	19058474	0	O
haemopericardium	-	6	B
and	-	23	O
gastrointestinal	-	27	B
haemorrhage	-	44	I
due	-	56	O
to	-	60	O
possible	-	63	O
interaction	-	72	O
of	-	84	O
cranberry	-	87	O
juice	-	97	O
with	-	103	O
warfarin	-	108	O
.	-	116	O

We	19058474	118	O
report	-	121	O
a	-	128	O
case	-	130	O
of	-	135	O
fatal	-	138	O
internal	-	144	O
haemorrhage	-	153	B
in	-	165	O
an	-	168	O
elderly	-	171	O
man	-	179	O
who	-	183	O
consumed	-	187	O
only	-	196	O
cranberry	-	201	O
juice	-	211	O
for	-	217	O
two	-	221	O
weeks	-	225	O
while	-	231	O
maintaining	-	237	O
his	-	249	O
usual	-	253	O
dosage	-	259	O
of	-	266	O
warfarin	-	269	O
.	-	277	O

We	19058474	279	O
propose	-	282	O
that	-	290	O
naturally	-	295	O
occurring	-	305	O
compounds	-	315	O
such	-	325	O
as	-	330	O
flavonoids	-	333	O
,	-	343	O
which	-	345	O
are	-	351	O
present	-	355	O
in	-	363	O
fruit	-	366	O
juices	-	372	O
,	-	378	O
may	-	380	O
increase	-	384	O
the	-	393	O
potency	-	397	O
of	-	405	O
warfarin	-	408	O
by	-	417	O
competing	-	420	O
for	-	430	O
the	-	434	O
enzymes	-	438	O
that	-	446	O
normally	-	451	O
inactivate	-	460	O
warfarin	-	471	O
.	-	479	O

While	19058474	481	O
traditionally	-	487	O
regarded	-	501	O
as	-	510	O
foodstuffs	-	513	O
,	-	523	O
consumption	-	525	O
of	-	537	O
fruit	-	540	O
juices	-	546	O
should	-	553	O
be	-	560	O
considered	-	563	O
when	-	574	O
patients	-	579	O
develop	-	588	O
adverse	-	596	O
drug	-	604	O
reactions	-	609	O
.	-	618	O

Isoproterenol	18808529	0	O
induces	-	14	O
primary	-	22	O
loss	-	30	O
of	-	35	O
dystrophin	-	38	O
in	-	49	O
rat	-	52	O
hearts	-	56	O
:	-	62	O
correlation	-	64	O
with	-	76	O
myocardial	-	81	B
injury	-	92	I
.	-	98	O

The	18808529	100	O
mechanism	-	104	O
of	-	114	O
isoproterenol	-	117	O
-	-	130	O
induced	-	131	O
myocardial	-	139	B
damage	-	150	I
is	-	157	O
unknown	-	160	O
,	-	167	O
but	-	169	O
a	-	173	O
mismatch	-	175	O
of	-	184	O
oxygen	-	187	O
supply	-	194	O
vs	-	201	O
.	-	203	O
demand	-	205	O
following	-	212	O
coronary	-	222	O
hypotension	-	231	B
and	-	243	O
myocardial	-	247	B
hyperactivity	-	258	I
is	-	272	O
the	-	275	O
best	-	279	O
explanation	-	284	O
for	-	296	O
the	-	300	O
complex	-	304	O
morphological	-	312	O
alterations	-	326	O
observed	-	338	O
.	-	346	O

Severe	18808529	348	O
alterations	-	355	O
in	-	367	O
the	-	370	O
structural	-	374	O
integrity	-	385	O
of	-	395	O
the	-	398	O
sarcolemma	-	402	O
of	-	413	O
cardiomyocytes	-	416	O
have	-	431	O
been	-	436	O
demonstrated	-	441	O
to	-	454	O
be	-	457	O
caused	-	460	O
by	-	467	O
isoproterenol	-	470	O
.	-	483	O

Taking	18808529	485	O
into	-	492	O
account	-	497	O
that	-	505	O
the	-	510	O
sarcolemmal	-	514	O
integrity	-	526	O
is	-	536	O
stabilized	-	539	O
by	-	550	O
the	-	553	O
dystrophin	-	557	O
-	-	567	O
glycoprotein	-	568	O
complex	-	581	O
(	-	589	O
DGC	-	590	O
)	-	593	O
that	-	595	O
connects	-	600	O
actin	-	609	O
and	-	615	O
laminin	-	619	O
in	-	627	O
contractile	-	630	O
machinery	-	642	O
and	-	652	O
extracellular	-	656	O
matrix	-	670	O
and	-	677	O
by	-	681	O
integrins	-	684	O
,	-	693	O
this	-	695	O
study	-	700	O
tests	-	706	O
the	-	712	O
hypothesis	-	716	O
that	-	727	O
isoproterenol	-	732	O
affects	-	746	O
sarcolemmal	-	754	O
stability	-	766	O
through	-	776	O
changes	-	784	O
in	-	792	O
the	-	795	O
DGC	-	799	O
and	-	803	O
integrins	-	807	O
.	-	816	O

We	18808529	818	O
found	-	821	O
different	-	827	O
sensitivity	-	837	O
of	-	849	O
the	-	852	O
DGC	-	856	O
and	-	860	O
integrin	-	864	O
to	-	873	O
isoproterenol	-	876	O
subcutaneous	-	890	O
administration	-	903	O
.	-	917	O

Immunofluorescent	18808529	919	O
staining	-	937	O
revealed	-	946	O
that	-	955	O
dystrophin	-	960	O
is	-	971	O
the	-	974	O
most	-	978	O
sensitive	-	983	O
among	-	993	O
the	-	999	O
structures	-	1003	O
connecting	-	1014	O
the	-	1025	O
actin	-	1029	O
in	-	1035	O
the	-	1038	O
cardiomyocyte	-	1042	O
cytoskeleton	-	1056	O
and	-	1069	O
the	-	1073	O
extracellular	-	1077	O
matrix	-	1091	O
.	-	1097	O

The	18808529	1099	O
sarcomeric	-	1103	O
actin	-	1114	O
dissolution	-	1120	O
occurred	-	1132	O
after	-	1141	O
the	-	1147	O
reduction	-	1151	O
or	-	1161	O
loss	-	1164	O
of	-	1169	O
dystrophin	-	1172	O
.	-	1182	O

Subsequently	18808529	1184	O
,	-	1196	O
after	-	1198	O
lysis	-	1204	O
of	-	1210	O
myofilaments	-	1213	O
,	-	1225	O
gamma	-	1227	O
-	-	1232	O
sarcoglycan	-	1233	O
,	-	1244	O
beta	-	1246	O
-	-	1250	O
dystroglycan	-	1251	O
,	-	1263	O
beta1	-	1265	O
-	-	1270	O
integrin	-	1271	O
,	-	1279	O
and	-	1281	O
laminin	-	1285	O
alpha	-	1293	O
-	-	1298	O
2	-	1299	O
expressions	-	1301	O
were	-	1313	O
reduced	-	1318	O
followed	-	1326	O
by	-	1335	O
their	-	1338	O
breakdown	-	1344	O
,	-	1353	O
as	-	1355	O
epiphenomena	-	1358	O
of	-	1371	O
the	-	1374	O
myocytolytic	-	1378	O
process	-	1391	O
.	-	1398	O

In	18808529	1400	O
conclusion	-	1403	O
,	-	1413	O
administration	-	1415	O
of	-	1430	O
isoproterenol	-	1433	O
to	-	1447	O
rats	-	1450	O
results	-	1455	O
in	-	1463	O
primary	-	1466	O
loss	-	1474	O
of	-	1479	O
dystrophin	-	1482	O
,	-	1492	O
the	-	1494	O
most	-	1498	O
sensitive	-	1503	O
among	-	1513	O
the	-	1519	O
structural	-	1523	O
proteins	-	1534	O
that	-	1543	O
form	-	1548	O
the	-	1553	O
DGC	-	1557	O
that	-	1561	O
connects	-	1566	O
the	-	1575	O
extracellular	-	1579	O
matrix	-	1593	O
and	-	1600	O
the	-	1604	O
cytoskeleton	-	1608	O
in	-	1621	O
cardiomyocyte	-	1624	O
.	-	1637	O

These	18808529	1639	O
changes	-	1645	O
,	-	1652	O
related	-	1654	O
to	-	1662	O
ischaemic	-	1665	B
injury	-	1675	I
,	-	1681	O
explain	-	1683	O
the	-	1691	O
severe	-	1695	O
alterations	-	1702	O
in	-	1714	O
the	-	1717	O
structural	-	1721	O
integrity	-	1732	O
of	-	1742	O
the	-	1745	O
sarcolemma	-	1749	O
of	-	1760	O
cardiomyocytes	-	1763	O
and	-	1778	O
hence	-	1782	O
severe	-	1788	O
and	-	1795	O
irreversible	-	1799	O
injury	-	1812	O
induced	-	1819	O
by	-	1827	O
isoproterenol	-	1830	O
.	-	1843	O

High	18674790	0	O
fat	-	5	O
diet	-	9	O
-	-	13	O
fed	-	14	O
obese	-	18	B
rats	-	24	O
are	-	29	O
highly	-	33	O
sensitive	-	40	O
to	-	50	O
doxorubicin	-	53	O
-	-	64	O
induced	-	65	O
cardiotoxicity	-	73	B
.	-	87	O

Often	18674790	89	O
,	-	94	O
chemotherapy	-	96	O
by	-	109	O
doxorubicin	-	112	O
(	-	124	O
Adriamycin	-	125	O
)	-	135	O
is	-	137	O
limited	-	140	O
due	-	148	O
to	-	152	O
life	-	155	O
threatening	-	160	O
cardiotoxicity	-	172	B
in	-	187	O
patients	-	190	O
during	-	199	O
and	-	206	O
posttherapy	-	210	O
.	-	221	O

Recently	18674790	223	O
,	-	231	O
we	-	233	O
have	-	236	O
shown	-	241	O
that	-	247	O
moderate	-	252	O
diet	-	261	O
restriction	-	266	O
remarkably	-	278	O
protects	-	289	O
against	-	298	O
doxorubicin	-	306	O
-	-	317	O
induced	-	318	O
cardiotoxicity	-	326	B
.	-	340	O

This	18674790	342	O
cardioprotection	-	347	O
is	-	364	O
accompanied	-	367	O
by	-	379	O
decreased	-	382	O
cardiac	-	392	O
oxidative	-	400	O
stress	-	410	O
and	-	417	O
triglycerides	-	421	O
and	-	435	O
increased	-	439	O
cardiac	-	449	O
fatty	-	457	O
-	-	462	O
acid	-	463	O
oxidation	-	468	O
,	-	477	O
ATP	-	479	O
synthesis	-	483	O
,	-	492	O
and	-	494	O
upregulated	-	498	O
JAK	-	510	O
/	-	513	O
STAT3	-	514	O
pathway	-	520	O
.	-	527	O

In	18674790	529	O
the	-	532	O
current	-	536	O
study	-	544	O
,	-	549	O
we	-	551	O
investigated	-	554	O
whether	-	567	O
a	-	575	O
physiological	-	577	O
intervention	-	591	O
by	-	604	O
feeding	-	607	O
40	-	615	O
%	-	617	O
high	-	619	O
fat	-	624	O
diet	-	628	O
(	-	633	O
HFD	-	634	O
)	-	637	O
,	-	638	O
which	-	640	O
induces	-	646	O
obesity	-	654	B
in	-	662	O
male	-	665	O
Sprague	-	670	O
-	-	677	O
Dawley	-	678	O
rats	-	685	O
(	-	690	O
250	-	691	O
-	-	694	O
275	-	695	O
g	-	699	O
)	-	700	O
,	-	701	O
sensitizes	-	703	O
to	-	714	O
doxorubicin	-	717	O
-	-	728	O
induced	-	729	O
cardiotoxicity	-	737	B
.	-	751	O

A	18674790	753	O
LD	-	755	O
(	-	757	O
10	-	758	O
)	-	760	O
dose	-	762	O
(	-	767	O
8	-	768	O
mg	-	770	O
doxorubicin	-	773	O
/	-	784	O
kg	-	785	O
,	-	787	O
ip	-	789	O
)	-	791	O
administered	-	793	O
on	-	806	O
day	-	809	O
43	-	813	O
of	-	816	O
the	-	819	O
HFD	-	823	O
feeding	-	827	O
regimen	-	835	O
led	-	843	O
to	-	847	O
higher	-	850	O
cardiotoxicity	-	857	B
,	-	871	O
cardiac	-	873	B
dysfunction	-	881	I
,	-	892	O
lipid	-	894	O
peroxidation	-	900	O
,	-	912	O
and	-	914	O
80	-	918	O
%	-	920	O
mortality	-	922	O
in	-	932	O
the	-	935	O
obese	-	939	B
(	-	945	O
OB	-	946	B
)	-	948	O
rats	-	950	O
in	-	955	O
the	-	958	O
absence	-	962	O
of	-	970	O
any	-	973	O
significant	-	977	O
renal	-	989	B
or	-	995	I
hepatic	-	998	I
toxicity	-	1006	I
.	-	1014	O

Doxorubicin	18674790	1016	O
toxicokinetics	-	1028	O
studies	-	1043	O
revealed	-	1051	O
no	-	1060	O
change	-	1063	O
in	-	1070	O
accumulation	-	1073	O
of	-	1086	O
doxorubicin	-	1089	O
and	-	1101	O
doxorubicinol	-	1105	O
(	-	1119	O
toxic	-	1120	O
metabolite	-	1126	O
)	-	1136	O
in	-	1138	O
the	-	1141	O
normal	-	1145	O
diet	-	1152	O
-	-	1156	O
fed	-	1157	O
(	-	1161	O
ND	-	1162	O
)	-	1164	O
and	-	1166	O
OB	-	1170	B
hearts	-	1173	O
.	-	1179	O

Mechanistic	18674790	1181	O
studies	-	1193	O
revealed	-	1201	O
that	-	1210	O
OB	-	1215	B
rats	-	1218	O
are	-	1223	O
sensitized	-	1227	O
due	-	1238	O
to	-	1242	O
:	-	1244	O
(	-	1246	O
1	-	1247	O
)	-	1248	O
higher	-	1250	O
oxyradical	-	1257	O
stress	-	1268	O
leading	-	1275	O
to	-	1283	O
upregulation	-	1286	O
of	-	1299	O
uncoupling	-	1302	O
proteins	-	1313	O
2	-	1322	O
and	-	1324	O
3	-	1328	O
,	-	1329	O
(	-	1331	O
2	-	1332	O
)	-	1333	O
downregulation	-	1335	O
of	-	1350	O
cardiac	-	1353	O
peroxisome	-	1361	O
proliferators	-	1372	O
activated	-	1386	O
receptor	-	1396	O
-	-	1404	O
alpha	-	1405	O
,	-	1410	O
(	-	1412	O
3	-	1413	O
)	-	1414	O
decreased	-	1416	O
plasma	-	1426	O
adiponectin	-	1433	O
levels	-	1445	O
,	-	1451	O
(	-	1453	O
4	-	1454	O
)	-	1455	O
decreased	-	1457	O
cardiac	-	1467	O
fatty	-	1475	O
-	-	1480	O
acid	-	1481	O
oxidation	-	1486	O
(	-	1496	O
666	-	1497	O
.	-	1500	O
9	-	1501	O
+	-	1502	O
/	-	1503	O
-	-	1504	O
14	-	1505	O
.	-	1507	O
0	-	1508	O
nmol	-	1510	O
/	-	1514	O
min	-	1515	O
/	-	1518	O
g	-	1519	O
heart	-	1521	O
in	-	1527	O
ND	-	1530	O
versus	-	1533	O
400	-	1540	O
.	-	1543	O
2	-	1544	O
+	-	1545	O
/	-	1546	O
-	-	1547	O
11	-	1548	O
.	-	1550	O
8	-	1551	O
nmol	-	1553	O
/	-	1557	O
min	-	1558	O
/	-	1561	O
g	-	1562	O
heart	-	1564	O
in	-	1570	O
OB	-	1573	B
)	-	1575	O
,	-	1576	O
(	-	1578	O
5	-	1579	O
)	-	1580	O
decreased	-	1582	O
mitochondrial	-	1592	O
AMP	-	1606	O
-	-	1609	O
alpha2	-	1610	O
protein	-	1617	O
kinase	-	1625	O
,	-	1631	O
and	-	1633	O
(	-	1637	O
6	-	1638	O
)	-	1639	O
86	-	1641	O
%	-	1643	O
drop	-	1645	O
in	-	1650	O
cardiac	-	1653	O
ATP	-	1661	O
levels	-	1665	O
accompanied	-	1672	O
by	-	1684	O
decreased	-	1687	O
ATP	-	1697	O
/	-	1700	O
ADP	-	1701	O
ratio	-	1705	O
after	-	1711	O
doxorubicin	-	1717	O
administration	-	1729	O
.	-	1743	O

Decreased	18674790	1745	O
cardiac	-	1755	O
erythropoietin	-	1763	O
and	-	1778	O
increased	-	1782	O
SOCS3	-	1792	O
further	-	1798	O
downregulated	-	1806	O
the	-	1820	O
cardioprotective	-	1824	O
JAK	-	1841	O
/	-	1844	O
STAT3	-	1845	O
pathway	-	1851	O
.	-	1858	O

In	18674790	1860	O
conclusion	-	1863	O
,	-	1873	O
HFD	-	1875	O
-	-	1878	O
induced	-	1879	O
obese	-	1887	B
rats	-	1893	O
are	-	1898	O
highly	-	1902	O
sensitized	-	1909	O
to	-	1920	O
doxorubicin	-	1923	O
-	-	1934	O
induced	-	1935	O
cardiotoxicity	-	1943	B
by	-	1958	O
substantially	-	1961	O
downregulating	-	1975	O
cardiac	-	1990	O
mitochondrial	-	1998	O
ATP	-	2012	O
generation	-	2016	O
,	-	2026	O
increasing	-	2028	O
oxidative	-	2039	O
stress	-	2049	O
and	-	2056	O
downregulating	-	2060	O
the	-	2075	O
JAK	-	2079	O
/	-	2082	O
STAT3	-	2083	O
pathway	-	2089	O
.	-	2096	O

Complete	18441470	0	O
atrioventricular	-	9	B
block	-	26	I
secondary	-	32	O
to	-	42	O
lithium	-	45	O
therapy	-	53	O
.	-	60	O

Sinus	18441470	62	B
node	-	68	I
dysfunction	-	73	I
has	-	85	O
been	-	89	O
reported	-	94	O
most	-	103	O
frequently	-	108	O
among	-	119	O
the	-	125	O
adverse	-	129	O
cardiovascular	-	137	O
effects	-	152	O
of	-	160	O
lithium	-	163	O
.	-	170	O

In	18441470	172	O
the	-	175	O
present	-	179	O
case	-	187	O
,	-	191	O
complete	-	193	O
atrioventricular	-	202	B
(	-	219	I
AV	-	220	I
)	-	222	I
block	-	224	I
with	-	230	O
syncopal	-	235	B
attacks	-	244	I
developed	-	252	O
secondary	-	262	O
to	-	272	O
lithium	-	275	O
therapy	-	283	O
,	-	290	O
necessitating	-	292	O
permanent	-	306	O
pacemaker	-	316	O
implantation	-	326	O
.	-	338	O

Serum	18441470	340	O
lithium	-	346	O
levels	-	354	O
remained	-	361	O
under	-	370	O
or	-	376	O
within	-	379	O
the	-	386	O
therapeutic	-	390	O
range	-	402	O
during	-	408	O
the	-	415	O
syncopal	-	419	B
attacks	-	428	I
.	-	435	O

Lithium	18441470	437	O
should	-	445	O
be	-	452	O
used	-	455	O
with	-	460	O
extreme	-	465	O
caution	-	473	O
,	-	480	O
especially	-	482	O
in	-	493	O
patients	-	496	O
with	-	505	O
mild	-	510	O
disturbance	-	515	O
of	-	527	O
AV	-	530	O
conduction	-	533	O
.	-	543	O

Neuroleptic	17366349	0	B
malignant	-	12	I
syndrome	-	22	I
induced	-	31	O
by	-	39	O
ziprasidone	-	42	O
on	-	54	O
the	-	57	O
second	-	61	O
day	-	68	O
of	-	72	O
treatment	-	75	O
.	-	84	O

Neuroleptic	17366349	86	B
malignant	-	98	I
syndrome	-	108	I
(	-	117	O
NMS	-	118	B
)	-	121	O
is	-	123	O
the	-	126	O
rarest	-	130	O
and	-	137	O
most	-	141	O
serious	-	146	O
of	-	154	O
the	-	157	O
neuroleptic	-	161	O
-	-	172	O
induced	-	173	O
movement	-	181	B
disorders	-	190	I
.	-	199	O

We	17366349	201	O
describe	-	204	O
a	-	213	O
case	-	215	O
of	-	220	O
neuroleptic	-	223	B
malignant	-	235	I
syndrome	-	245	I
(	-	254	O
NMS	-	255	B
)	-	258	O
associated	-	260	O
with	-	271	O
the	-	276	O
use	-	280	O
of	-	284	O
ziprasidone	-	287	O
.	-	298	O

Although	17366349	300	O
conventional	-	309	O
neuroleptics	-	322	O
are	-	335	O
more	-	339	O
frequently	-	344	O
associated	-	355	O
with	-	366	O
NMS	-	371	B
,	-	374	O
atypical	-	376	O
antipsychotic	-	385	O
drugs	-	399	O
like	-	405	O
ziprasidone	-	410	O
may	-	422	O
also	-	426	O
be	-	431	O
a	-	434	O
cause	-	436	O
.	-	441	O

The	17366349	443	O
patient	-	447	O
is	-	455	O
a	-	458	O
24	-	460	O
-	-	462	O
year	-	463	O
-	-	467	O
old	-	468	O
male	-	472	O
with	-	477	O
a	-	482	O
history	-	484	O
of	-	492	O
schizophrenia	-	495	B
who	-	509	O
developed	-	513	O
signs	-	523	O
and	-	529	O
symptoms	-	533	O
of	-	542	O
NMS	-	545	B
after	-	549	O
2	-	555	O
days	-	557	O
of	-	562	O
treatment	-	565	O
with	-	575	O
an	-	580	O
80	-	583	O
-	-	585	O
mg	-	586	O
/	-	588	O
day	-	589	O
dose	-	593	O
of	-	598	O
orally	-	601	O
administrated	-	608	O
ziprasidone	-	622	O
.	-	633	O

This	17366349	635	O
case	-	640	O
is	-	645	O
the	-	648	O
earliest	-	652	O
(	-	661	O
second	-	662	O
day	-	669	O
of	-	673	O
treatment	-	676	O
)	-	685	O

NMS	17366349	687	B
due	-	691	O
to	-	695	O
ziprasidone	-	698	O
reported	-	710	O
in	-	719	O
the	-	722	O
literature	-	726	O
.	-	736	O

Role	16584858	0	O
of	-	5	O
mangiferin	-	8	O
on	-	19	O
biochemical	-	22	O
alterations	-	34	O
and	-	46	O
antioxidant	-	50	O
status	-	62	O
in	-	69	O
isoproterenol	-	72	O
-	-	85	O
induced	-	86	O
myocardial	-	94	B
infarction	-	105	I
in	-	116	O
rats	-	119	O
.	-	123	O

The	16584858	125	O
current	-	129	O
study	-	137	O
dealt	-	143	O
with	-	149	O
the	-	154	O
protective	-	158	O
role	-	169	O
of	-	174	O
mangiferin	-	177	O
,	-	187	O
a	-	189	O
polyphenol	-	191	O
from	-	202	O
Mangifera	-	207	O
indica	-	217	O
Linn	-	224	O
.	-	228	O

(	16584858	230	O
Anacardiaceae	-	231	O
)	-	244	O
,	-	245	O
on	-	247	O
isoproterenol	-	250	O
(	-	264	O
ISPH	-	265	O
)	-	269	O
-	-	270	O
induced	-	271	O
myocardial	-	279	B
infarction	-	290	I
(	-	301	O
MI	-	302	B
)	-	304	O
in	-	306	O
rats	-	309	O
through	-	314	O
its	-	322	O
antioxidative	-	326	O
mechanism	-	340	O
.	-	349	O

Subcutaneous	16584858	351	O
injection	-	364	O
of	-	374	O
ISPH	-	377	O
(	-	382	O
200	-	383	O
mg	-	387	O
/	-	389	O
kg	-	390	O
body	-	393	O
weight	-	398	O
in	-	405	O
1	-	408	O
ml	-	410	O
saline	-	413	O
)	-	419	O
to	-	421	O
rats	-	424	O
for	-	429	O
2	-	433	O
consecutive	-	435	O
days	-	447	O
caused	-	452	O
myocardial	-	459	B
damage	-	470	I
in	-	477	O
rat	-	480	O
heart	-	484	O
,	-	489	O
which	-	491	O
was	-	497	O
determined	-	501	O
by	-	512	O
the	-	515	O
increased	-	519	O
activity	-	529	O
of	-	538	O
serum	-	541	O
lactate	-	547	O
dehydrogenase	-	555	O
(	-	569	O
LDH	-	570	O
)	-	573	O
and	-	575	O
creatine	-	579	O
phosphokinase	-	588	O
isoenzymes	-	602	O
(	-	613	O
CK	-	614	O
-	-	616	O
MB	-	617	O
)	-	619	O
,	-	620	O
increased	-	622	O
uric	-	632	O
acid	-	637	O
level	-	642	O
and	-	648	O
reduced	-	652	O
plasma	-	660	O
iron	-	667	O
binding	-	672	O
capacity	-	680	O
.	-	688	O

The	16584858	690	O
protective	-	694	O
role	-	705	O
of	-	710	O
mangiferin	-	713	O
was	-	724	O
analyzed	-	728	O
by	-	737	O
triphenyl	-	740	O
tetrazolium	-	750	O
chloride	-	762	O
(	-	771	O
TTC	-	772	O
)	-	775	O
test	-	777	O
used	-	782	O
for	-	787	O
macroscopic	-	791	O
enzyme	-	803	O
mapping	-	810	O
assay	-	818	O
of	-	824	O
the	-	827	O
ischemic	-	831	B
myocardium	-	840	I
.	-	850	O

The	16584858	852	O
heart	-	856	O
tissue	-	862	O
antioxidant	-	869	O
enzymes	-	881	O
such	-	889	O
as	-	894	O
superoxide	-	897	O
dismutase	-	908	O
,	-	917	O
catalase	-	919	O
,	-	927	O
glutathione	-	929	O
peroxidase	-	941	O
,	-	951	O
glutathione	-	953	O
transferase	-	965	O
and	-	977	O
glutathione	-	981	O
reductase	-	993	O
activities	-	1003	O
,	-	1013	O
non	-	1015	O
-	-	1018	O
enzymic	-	1019	O
antioxidants	-	1027	O
such	-	1040	O
as	-	1045	O
cerruloplasmin	-	1048	O
,	-	1062	O
Vitamin	-	1064	O
C	-	1072	O
,	-	1073	O
Vitamin	-	1075	O
E	-	1083	O
and	-	1085	O
glutathione	-	1089	O
levels	-	1101	O
were	-	1108	O
altered	-	1113	O
in	-	1121	O
MI	-	1124	B
rats	-	1127	O
.	-	1131	O

Upon	16584858	1133	O
pretreatment	-	1138	O
with	-	1151	O
mangiferin	-	1156	O
(	-	1167	O
100	-	1168	O
mg	-	1172	O
/	-	1174	O
kg	-	1175	O
body	-	1178	O
weight	-	1183	O
suspended	-	1190	O
in	-	1200	O
2	-	1203	O
ml	-	1205	O
of	-	1208	O
dimethyl	-	1211	O
sulphoxide	-	1220	O
)	-	1230	O
given	-	1232	O
intraperitoneally	-	1238	O
for	-	1256	O
28	-	1260	O
days	-	1263	O
to	-	1268	O
MI	-	1271	B
rats	-	1274	O
protected	-	1279	O
the	-	1289	O
above	-	1293	O
-	-	1298	O
mentioned	-	1299	O
parameters	-	1309	O
to	-	1320	O
fall	-	1323	O
from	-	1328	O
the	-	1333	O
normal	-	1337	O
levels	-	1344	O
.	-	1350	O

Activities	16584858	1352	O
of	-	1363	O
heart	-	1366	O
tissue	-	1372	O
enzymic	-	1379	O
antioxidants	-	1387	O
and	-	1400	O
serum	-	1404	O
non	-	1410	O
-	-	1413	O
enzymic	-	1414	O
antioxidants	-	1422	O
levels	-	1435	O
rose	-	1442	O
significantly	-	1447	O
upon	-	1461	O
mangiferin	-	1466	O
administration	-	1477	O
as	-	1492	O
compared	-	1495	O
to	-	1504	O
ISPH	-	1507	O
-	-	1511	O
induced	-	1512	O
MI	-	1520	B
rats	-	1523	O
.	-	1527	O

From	16584858	1529	O
the	-	1534	O
present	-	1538	O
study	-	1546	O
it	-	1552	O
is	-	1555	O
concluded	-	1558	O
that	-	1568	O
mangiferin	-	1573	O
exerts	-	1584	O
a	-	1591	O
beneficial	-	1593	O
effect	-	1604	O
against	-	1611	O
ISPH	-	1619	O
-	-	1623	O
induced	-	1624	O
MI	-	1632	B
due	-	1635	O
to	-	1639	O
its	-	1642	O
antioxidant	-	1646	O
potential	-	1658	O
,	-	1667	O
which	-	1669	O
regulated	-	1675	O
the	-	1685	O
tissues	-	1689	O
defense	-	1697	O
system	-	1705	O
against	-	1712	O
cardiac	-	1720	B
damage	-	1728	I
.	-	1734	O

Remifentanil	16563323	0	O
pretreatment	-	13	O
reduces	-	26	O
myoclonus	-	34	B
after	-	44	O
etomidate	-	50	O
.	-	59	O

STUDY	16563323	61	O
OBJECTIVE	-	67	O
:	-	76	O

The	16563323	78	O
aim	-	82	O
of	-	86	O
the	-	89	O
study	-	93	O
was	-	99	O
to	-	103	O
compare	-	106	O
the	-	114	O
effect	-	118	O
of	-	125	O
pretreatment	-	128	O
with	-	141	O
remifentanil	-	146	O
1	-	159	O
microg	-	161	O
/	-	167	O
kg	-	168	O
and	-	171	O
the	-	175	O
effect	-	179	O
of	-	186	O
gender	-	189	O
on	-	196	O
the	-	199	O
incidence	-	203	O
of	-	213	O
myoclonus	-	216	B
after	-	226	O
anesthesia	-	232	O
induction	-	243	O
with	-	253	O
etomidate	-	258	O
.	-	267	O

DESIGN	16563323	269	O
:	-	275	O

This	16563323	277	O
was	-	282	O
a	-	286	O
randomized	-	288	O
,	-	298	O
double	-	300	O
-	-	306	O
blind	-	307	O
study	-	313	O
.	-	318	O

SETTING	16563323	320	O
:	-	327	O

The	16563323	329	O
study	-	333	O
was	-	339	O
conducted	-	343	O
at	-	353	O
a	-	356	O
university	-	358	O
hospital	-	369	O
.	-	377	O

PATIENTS	16563323	379	O
:	-	387	O

Sixty	16563323	389	O
patients	-	395	O
were	-	404	O
pretreated	-	409	O
in	-	420	O
a	-	423	O
randomized	-	425	O
double	-	436	O
-	-	442	O
blinded	-	443	O
fashion	-	451	O
with	-	459	O
remifentanil	-	464	O
1	-	477	O
microg	-	479	O
/	-	485	O
kg	-	486	O
or	-	489	O
placebo	-	492	O
.	-	499	O

Two	16563323	501	O
minutes	-	505	O
after	-	513	O
remifentanil	-	519	O
or	-	532	O
placebo	-	535	O
injection	-	543	O
,	-	552	O
etomidate	-	554	O
0	-	564	O
.	-	565	O
3	-	566	O
mg	-	568	O
/	-	570	O
kg	-	571	O
was	-	574	O
given	-	578	O
.	-	583	O

MEASUREMENTS	16563323	585	O
:	-	597	O

Myoclonus	16563323	599	B
was	-	609	O
recorded	-	613	O
with	-	622	O
a	-	627	O
scale	-	629	O
of	-	635	O
0	-	638	O
to	-	640	O
3	-	643	O
.	-	644	O

The	16563323	646	O
grade	-	650	O
of	-	656	O
sedation	-	659	O
(	-	668	O
none	-	669	O
,	-	673	O
mild	-	675	O
,	-	679	O
moderate	-	681	O
,	-	689	O
severe	-	691	O
)	-	697	O
,	-	698	O
nausea	-	700	B
,	-	706	O
pruritus	-	708	B
,	-	716	O
and	-	718	O
apnea	-	722	B
were	-	728	O
recorded	-	733	O
after	-	742	O
injection	-	748	O
of	-	758	O
both	-	761	O
drugs	-	766	O
.	-	771	O

MAIN	16563323	773	O
RESULTS	-	778	O
:	-	785	O

The	16563323	787	O
incidence	-	791	O
of	-	801	O
myoclonus	-	804	B
was	-	814	O
significantly	-	818	O
lower	-	832	O
in	-	838	O
the	-	841	O
remifentanil	-	845	O
group	-	858	O
(	-	864	O
6	-	865	O
.	-	866	O
7	-	867	O
%	-	868	O
)	-	869	O
than	-	871	O
in	-	876	O
the	-	879	O
placebo	-	883	O
group	-	891	O
(	-	897	O
70	-	898	O
%	-	900	O
)	-	901	O
(	-	903	O
P	-	904	O
<	-	906	O
0	-	908	O
.	-	909	O
001	-	910	O
)	-	913	O
.	-	914	O

None	16563323	916	O
of	-	921	O
the	-	924	O
patients	-	928	O
experienced	-	937	O
sedation	-	949	O
,	-	957	O
apnea	-	959	B
,	-	964	O
nausea	-	966	B
,	-	972	O
or	-	974	O
pruritus	-	977	B
after	-	986	O
injection	-	992	O
of	-	1002	O
both	-	1005	O
drugs	-	1010	O
.	-	1015	O

In	16563323	1017	O
the	-	1020	O
placebo	-	1024	O
group	-	1032	O
,	-	1037	O
male	-	1039	O
patients	-	1044	O
were	-	1053	O
associated	-	1058	O
with	-	1069	O
significantly	-	1074	O
increased	-	1088	O
incidence	-	1098	O
of	-	1108	O
myoclonus	-	1111	B
after	-	1121	O
etomidate	-	1127	O
administration	-	1137	O
.	-	1151	O

CONCLUSION	16563323	1153	O
:	-	1163	O

Pretreatment	16563323	1165	O
with	-	1178	O
remifentanil	-	1183	O
1	-	1196	O
microg	-	1198	O
/	-	1204	O
kg	-	1205	O
reduced	-	1208	O
myoclonus	-	1216	B
after	-	1226	O
etomidate	-	1232	O
induction	-	1242	O
without	-	1252	O
side	-	1260	O
effects	-	1265	O
such	-	1273	O
as	-	1278	O
sedation	-	1281	O
,	-	1289	O
apnea	-	1291	B
,	-	1296	O
nausea	-	1298	B
,	-	1304	O
or	-	1306	O
pruritus	-	1309	B
.	-	1317	O

Men	16563323	1319	O
experience	-	1323	O
increased	-	1334	O
incidence	-	1344	O
of	-	1354	O
myoclonus	-	1357	B
than	-	1367	O
women	-	1372	O
after	-	1378	O
etomidate	-	1384	O
administration	-	1394	O
.	-	1408	O

Daidzein	16428827	0	O
activates	-	9	O
choline	-	19	O
acetyltransferase	-	27	O
from	-	45	O
MC	-	50	O
-	-	52	O
IXC	-	53	O
cells	-	57	O
and	-	63	O
improves	-	67	O
drug	-	76	O
-	-	80	O
induced	-	81	O
amnesia	-	89	B
.	-	96	O

The	16428827	98	O
choline	-	102	O
acetyltransferase	-	110	O
(	-	128	O
ChAT	-	129	O
)	-	133	O
activator	-	135	O
,	-	144	O
which	-	146	O
enhances	-	152	O
cholinergic	-	161	O
transmission	-	173	O
via	-	186	O
an	-	190	O
augmentation	-	193	O
of	-	206	O
the	-	209	O
enzymatic	-	213	O
production	-	223	O
of	-	234	O
acetylcholine	-	237	O
(	-	251	O
ACh	-	252	O
)	-	255	O
,	-	256	O
is	-	258	O
an	-	261	O
important	-	264	O
factor	-	274	O
in	-	281	O
the	-	284	O
treatment	-	288	O
of	-	298	O
Alzheimer	-	301	B
's	-	310	I
disease	-	313	I
(	-	321	O
AD	-	322	B
)	-	324	O
.	-	325	O

Methanolic	16428827	327	O
extracts	-	338	O
from	-	347	O
Pueraria	-	352	O
thunbergiana	-	361	O
exhibited	-	374	O
an	-	384	O
activation	-	387	O
effect	-	398	O
(	-	405	O
46	-	406	O
%	-	408	O
)	-	409	O
on	-	411	O
ChAT	-	414	O
in	-	419	O
vitro	-	422	O
.	-	427	O

Via	16428827	429	O
the	-	433	O
sequential	-	437	O
isolation	-	448	O
of	-	458	O
Pueraria	-	461	O
thunbergiana	-	470	O
,	-	482	O
the	-	484	O
active	-	488	O
component	-	495	O
was	-	505	O
ultimately	-	509	O
identified	-	520	O
as	-	531	O
daidzein	-	534	O
(	-	543	O
4'	-	544	O
,	-	546	O
7	-	547	O
-	-	548	O
dihydroxy	-	549	O
-	-	558	O
isoflavone	-	559	O
)	-	569	O
.	-	570	O

In	16428827	572	O
order	-	575	O
to	-	581	O
investigate	-	584	O
the	-	596	O
effects	-	600	O
of	-	608	O
daidzein	-	611	O
from	-	620	O
Pueraria	-	625	O
thunbergiana	-	634	O
on	-	647	O
scopolamine	-	650	O
-	-	661	O
induced	-	662	O
impairments	-	670	B
of	-	682	I
learning	-	685	I
and	-	694	I
memory	-	698	I
,	-	704	O
we	-	706	O
conducted	-	709	O
a	-	719	O
series	-	721	O
of	-	728	O
in	-	731	O
vivo	-	734	O
tests	-	739	O
.	-	744	O

Administration	16428827	746	O
of	-	761	O
daidzein	-	764	O
(	-	773	O
4	-	774	O
.	-	775	O
5	-	776	O
mg	-	778	O
/	-	780	O
kg	-	781	O
body	-	784	O
weight	-	789	O
)	-	795	O
to	-	797	O
mice	-	800	O
was	-	805	O
shown	-	809	O
significantly	-	815	O
to	-	829	O
reverse	-	832	O
scopolamine	-	840	O
-	-	851	O
induced	-	852	O
amnesia	-	860	B
,	-	867	O
according	-	869	O
to	-	879	O
the	-	882	O
results	-	886	O
of	-	894	O
a	-	897	O
Y	-	899	O
-	-	900	O
maze	-	901	O
test	-	906	O
.	-	910	O

Injections	16428827	912	O
of	-	923	O
scopolamine	-	926	O
into	-	938	O
mice	-	943	O
resulted	-	948	O
in	-	957	O
impaired	-	960	O
performance	-	969	O
on	-	981	O
Y	-	984	O
-	-	985	O
maze	-	986	O
tests	-	991	O
(	-	997	O
a	-	998	O
37	-	1000	O
%	-	1002	O
decreases	-	1004	O
in	-	1014	O
alternation	-	1017	O
behavior	-	1029	O
)	-	1037	O
.	-	1038	O

By	16428827	1040	O
way	-	1043	O
of	-	1047	O
contrast	-	1050	O
,	-	1058	O
mice	-	1060	O
treated	-	1065	O
with	-	1073	O
daidzein	-	1078	O
prior	-	1087	O
to	-	1093	O
the	-	1096	O
scopolamine	-	1100	O
injections	-	1112	O
were	-	1123	O
noticeably	-	1128	O
protected	-	1139	O
from	-	1149	O
this	-	1154	O
performance	-	1159	O
impairment	-	1171	O
(	-	1182	O
an	-	1183	O
approximately	-	1186	O
12	-	1200	O
%	-	1202	O
-	-	1203	O
21	-	1204	O
%	-	1206	O
decrease	-	1208	O
in	-	1217	O
alternation	-	1220	O
behavior	-	1232	O
)	-	1240	O
.	-	1241	O

These	16428827	1243	O
results	-	1249	O
indicate	-	1257	O
that	-	1266	O
daidzein	-	1271	O
might	-	1280	O
play	-	1286	O
a	-	1291	O
role	-	1293	O
in	-	1298	O
acetylcholine	-	1301	O
biosynthesis	-	1315	O
as	-	1328	O
a	-	1331	O
ChAT	-	1333	O
activator	-	1338	O
,	-	1347	O
and	-	1349	O
that	-	1353	O
it	-	1358	O
also	-	1361	O
ameliorates	-	1366	O
scopolamine	-	1378	O
-	-	1389	O
induced	-	1390	O
amnesia	-	1398	B
.	-	1405	O

Possible	15985056	0	O
azithromycin	-	9	O
-	-	21	O
associated	-	22	O
hiccups	-	33	B
.	-	40	O

OBJECTIVE	15985056	42	O
:	-	51	O

To	15985056	53	O
report	-	56	O
a	-	63	O
case	-	65	O
of	-	70	O
persistent	-	73	O
hiccups	-	84	B
associated	-	92	O
by	-	103	O
azithromycin	-	106	O
therapy	-	119	O
.	-	126	O

CASE	15985056	128	O
SUMMARY	-	133	O
:	-	140	O

A	15985056	142	O
76	-	144	O
-	-	146	O
year	-	147	O
-	-	151	O
old	-	152	O
man	-	156	O
presented	-	160	O
with	-	170	O
persistent	-	175	O
hiccups	-	186	B
after	-	194	O
beginning	-	200	O
azithromycin	-	210	O
for	-	223	O
the	-	227	O
treatment	-	231	O
of	-	241	O
pharyngitis	-	244	B
.	-	255	O

Hiccups	15985056	257	B
were	-	265	O
persistent	-	270	O
and	-	281	O
exhausting	-	285	O
.	-	295	O

Discontinuation	15985056	297	O
of	-	313	O
azithromycin	-	316	O
and	-	329	O
therapy	-	333	O
with	-	341	O
baclofen	-	346	O
finally	-	355	O
resolved	-	363	O
hiccups	-	372	B
.	-	379	O

No	15985056	381	O
organic	-	384	O
cause	-	392	O
of	-	398	O
hiccups	-	401	B
was	-	409	O
identified	-	413	O
despite	-	424	O
extensive	-	432	O
investigation	-	442	O
.	-	455	O

DISCUSSION	15985056	457	O
:	-	467	O

Pharmacotherapeutic	15985056	469	O
agents	-	489	O
have	-	496	O
been	-	501	O
uncommonly	-	506	O
associated	-	517	O
with	-	528	O
hiccups	-	533	B
.	-	540	O

Corticosteroids	15985056	542	O
(	-	558	O
dexamethasone	-	559	O
and	-	573	O
methylprednisolone	-	577	O
)	-	595	O
,	-	596	O
benzodiazepines	-	598	O
(	-	614	O
midazolam	-	615	O
)	-	624	O
and	-	626	O
general	-	630	O
anaesthesia	-	638	O
have	-	650	O
been	-	655	O
the	-	660	O
specific	-	664	O
agents	-	673	O
mentioned	-	680	O
most	-	690	O
frequently	-	695	O
in	-	706	O
the	-	709	O
literature	-	713	O
as	-	724	O
being	-	727	O
associated	-	733	O
with	-	744	O
the	-	749	O
development	-	753	O
of	-	765	O
hiccups	-	768	B
.	-	775	O

Few	15985056	777	O
cases	-	781	O
of	-	787	O
drug	-	790	O
-	-	794	O
induced	-	795	O
hiccups	-	803	B
have	-	811	O
been	-	816	O
reported	-	821	O
related	-	830	O
to	-	838	O
macrolide	-	841	O
antimicrobials	-	851	O
.	-	865	O

Using	15985056	867	O
the	-	873	O
Naranjo	-	877	O
adverse	-	885	O
effect	-	893	O
reaction	-	900	O
probability	-	909	O
scale	-	921	O
this	-	927	O
event	-	932	O
could	-	938	O
be	-	944	O
classified	-	947	O
as	-	958	O
possible	-	961	O
(	-	970	O
score	-	971	O
5	-	977	O
points	-	979	O
)	-	985	O
,	-	986	O
mostly	-	988	O
because	-	995	O
of	-	1003	O
the	-	1006	O
close	-	1010	O
temporal	-	1016	O
sequence	-	1025	O
,	-	1033	O
previous	-	1035	O
reports	-	1044	O
on	-	1052	O
this	-	1055	O
reaction	-	1060	O
with	-	1069	O
other	-	1074	O
macrolides	-	1080	O
and	-	1091	O
the	-	1095	O
absence	-	1099	O
of	-	1107	O
any	-	1110	O
alternative	-	1114	O
explanation	-	1126	O
for	-	1138	O
hiccups	-	1142	B
.	-	1149	O

Our	15985056	1151	O
hypothesis	-	1155	O
is	-	1166	O
that	-	1169	O
a	-	1174	O
vagal	-	1176	O
mechanism	-	1182	O
mediated	-	1192	O
by	-	1201	O
azithromycin	-	1204	O
could	-	1217	O
be	-	1223	O
the	-	1226	O
pathogenesis	-	1230	O
of	-	1243	O
hiccups	-	1246	B
in	-	1254	O
our	-	1257	O
patient	-	1261	O
.	-	1268	O

CONCLUSIONS	15985056	1270	O
:	-	1281	O

Diagnosis	15985056	1283	O
of	-	1293	O
drug	-	1296	O
-	-	1300	O
induced	-	1301	O
hiccups	-	1309	B
is	-	1317	O
difficult	-	1320	O
and	-	1330	O
often	-	1334	O
achieved	-	1340	O
only	-	1349	O
by	-	1354	O
a	-	1357	O
process	-	1359	O
of	-	1367	O
elimination	-	1370	O
.	-	1381	O

However	15985056	1383	O
,	-	1390	O
macrolide	-	1392	O
antimicrobials	-	1402	O
have	-	1417	O
been	-	1422	O
reported	-	1427	O
to	-	1436	O
be	-	1439	O
associated	-	1442	O
with	-	1453	O
hiccups	-	1458	B
and	-	1466	O
vagal	-	1470	O
mechanism	-	1476	O
could	-	1486	O
explain	-	1492	O
the	-	1500	O
development	-	1504	O
of	-	1516	O
this	-	1519	O
side	-	1524	O
-	-	1528	O
effect	-	1529	O
.	-	1535	O

Time	15276120	0	O
trends	-	5	O
in	-	12	O
warfarin	-	15	O
-	-	23	O
associated	-	24	O
hemorrhage	-	35	B
.	-	45	O

The	15276120	47	O
annual	-	51	O
incidence	-	58	O
of	-	68	O
warfarin	-	71	O
-	-	79	O
related	-	80	O
bleeding	-	88	B
at	-	97	O
Brigham	-	100	O
and	-	108	O
Women	-	112	O
's	-	117	O
Hospital	-	120	O
increased	-	129	O
from	-	139	O
0	-	144	O
.	-	145	O
97	-	146	O
/	-	148	O
1	-	149	O
,	-	150	O
000	-	151	O
patient	-	155	O
admissions	-	163	O
in	-	174	O
the	-	177	O
first	-	181	O
time	-	187	O
period	-	192	O
(	-	199	O
January	-	200	O
1995	-	208	O
to	-	213	O
October	-	216	O
1998	-	224	O
)	-	228	O
to	-	230	O
1	-	233	O
.	-	234	O
19	-	235	O
/	-	237	O
1	-	238	O
,	-	239	O
000	-	240	O
patient	-	244	O
admissions	-	252	O
in	-	263	O
the	-	266	O
second	-	270	O
time	-	277	O
period	-	282	O
(	-	289	O
November	-	290	O
1998	-	299	O
to	-	304	O
August	-	307	O
2002	-	314	O
)	-	318	O
of	-	320	O
this	-	323	O
study	-	328	O
.	-	333	O

The	15276120	335	O
proportion	-	339	O
of	-	350	O
patients	-	353	O
with	-	362	O
major	-	367	O
and	-	373	O
intracranial	-	377	B
bleeding	-	390	I
increased	-	399	O
from	-	409	O
20	-	414	O
.	-	416	O
2	-	417	O
%	-	418	O
and	-	420	O
1	-	424	O
.	-	425	O
9	-	426	O
%	-	427	O
,	-	428	O
respectively	-	430	O
,	-	442	O
in	-	444	O
the	-	447	O
first	-	451	O
time	-	457	O
period	-	462	O
,	-	468	O
to	-	470	O
33	-	473	O
.	-	475	O
3	-	476	O
%	-	477	O
and	-	479	O
7	-	483	O
.	-	484	O
8	-	485	O
%	-	486	O
,	-	487	O
respectively	-	489	O
,	-	501	O
in	-	503	O
the	-	506	O
second	-	510	O
.	-	516	O

Fatal	11271907	0	O
haemorrhagic	-	6	B
myocarditis	-	19	I
secondary	-	31	O
to	-	41	O
cyclophosphamide	-	44	O
therapy	-	61	O
.	-	68	O

Haemorrhagic	11271907	70	B
myocarditis	-	83	I
is	-	95	O
a	-	98	O
rare	-	100	O
but	-	105	O
important	-	109	O
complication	-	119	O
of	-	132	O
cyclophosphamide	-	135	O
therapy	-	152	O
.	-	159	O

Echocardiographic	11271907	161	O
identification	-	179	O
of	-	194	O
the	-	197	O
disorder	-	201	O
can	-	210	O
be	-	214	O
made	-	217	O
.	-	221	O

We	11271907	223	O
believe	-	226	O
that	-	234	O
the	-	239	O
ultrasound	-	243	O
features	-	254	O
of	-	263	O
this	-	266	O
disorder	-	271	O
have	-	280	O
not	-	285	O
been	-	289	O
previously	-	294	O
reported	-	305	O
.	-	313	O

Glyceryl	10524660	0	O
trinitrate	-	9	O
induces	-	20	O
attacks	-	28	O
of	-	36	O
migraine	-	39	B
without	-	48	I
aura	-	56	I
in	-	61	O
sufferers	-	64	O
of	-	74	O
migraine	-	77	B
with	-	86	I
aura	-	91	I
.	-	95	O

Migraine	10524660	97	B
with	-	106	I
aura	-	111	I
and	-	116	O
migraine	-	120	B
without	-	129	I
aura	-	137	I
have	-	142	O
the	-	147	O
same	-	151	O
pain	-	156	B
phase	-	161	O
,	-	166	O
thus	-	168	O
indicating	-	173	O
that	-	184	O
migraine	-	189	B
with	-	198	I
aura	-	203	I
and	-	208	O
migraine	-	212	B
without	-	221	I
aura	-	229	I
share	-	234	O
a	-	240	O
common	-	242	O
pathway	-	249	O
of	-	257	O
nociception	-	260	O
.	-	271	O

In	10524660	273	O
recent	-	276	O
years	-	283	O
,	-	288	O
increasing	-	290	O
evidence	-	301	O
has	-	310	O
suggested	-	314	O
that	-	324	O
the	-	329	O
messenger	-	333	O
molecule	-	343	O
nitric	-	352	O
oxide	-	359	O
(	-	365	O
NO	-	366	O
)	-	368	O
is	-	370	O
involved	-	373	O
in	-	382	O
pain	-	385	B
mechanisms	-	390	O
of	-	401	O
migraine	-	404	B
without	-	413	I
aura	-	421	I
.	-	425	O

In	10524660	427	O
order	-	430	O
to	-	436	O
clarify	-	439	O
whether	-	447	O
the	-	455	O
same	-	459	O
is	-	464	O
true	-	467	O
for	-	472	O
migraine	-	476	B
with	-	485	I
aura	-	490	I
,	-	494	O
in	-	496	O
the	-	499	O
present	-	503	O
study	-	511	O
we	-	517	O
examined	-	520	O
the	-	529	O
headache	-	533	B
response	-	542	O
to	-	551	O
intravenous	-	554	O
infusion	-	566	O
of	-	575	O
glyceryl	-	578	O
trinitrate	-	587	O
(	-	598	O
GTN	-	599	O
)	-	602	O
(	-	604	O
0	-	605	O
.	-	606	O
5	-	607	O
microg	-	609	O
/	-	615	O
kg	-	616	O
/	-	618	O
min	-	619	O
for	-	623	O
20	-	627	O
min	-	630	O
)	-	633	O
in	-	635	O
12	-	638	O
sufferers	-	641	O
of	-	651	O
migraine	-	654	B
with	-	663	I
aura	-	668	I
.	-	672	O

The	10524660	674	O
specific	-	678	O
aim	-	687	O
was	-	691	O
to	-	695	O
elucidate	-	698	O
whether	-	708	O
an	-	716	O
aura	-	719	O
and	-	724	O
/	-	727	O
or	-	728	O
an	-	731	O
attack	-	734	O
of	-	741	O
migraine	-	744	B
without	-	753	I
aura	-	761	I
could	-	766	O
be	-	772	O
induced	-	775	O
.	-	782	O

Fourteen	10524660	784	O
healthy	-	793	O
subjects	-	801	O
served	-	810	O
as	-	817	O
controls	-	820	O
.	-	828	O

Aura	10524660	830	O
symptoms	-	835	O
were	-	844	O
not	-	849	O
elicited	-	853	O
in	-	862	O
any	-	865	O
subject	-	869	O
.	-	876	O

Headache	10524660	878	B
was	-	887	O
more	-	891	O
severe	-	896	O
in	-	903	O
migraineurs	-	906	B
than	-	918	O
in	-	923	O
the	-	926	O
controls	-	930	O
during	-	939	O
and	-	946	O
immediately	-	950	O
after	-	962	O
GTN	-	968	O
infusion	-	972	O
(	-	981	O
p	-	982	O
=	-	983	O
0	-	984	O
.	-	985	O
037	-	986	O
)	-	989	O
as	-	991	O
well	-	994	O
as	-	999	O
during	-	1002	O
the	-	1009	O
following	-	1013	O
11	-	1023	O
h	-	1026	O
(	-	1028	O
p	-	1029	O
=	-	1031	O
0	-	1033	O
.	-	1034	O
008	-	1035	O
)	-	1038	O
.	-	1039	O

In	10524660	1041	O
the	-	1044	O
controls	-	1048	O
,	-	1056	O
the	-	1058	O
GTN	-	1062	O
-	-	1065	O
induced	-	1066	O
headache	-	1074	B
gradually	-	1083	O
disappeared	-	1093	O
,	-	1104	O
whereas	-	1106	O
in	-	1114	O
migraineurs	-	1117	B
peak	-	1129	O
headache	-	1134	B
intensity	-	1143	O
occurred	-	1153	O
at	-	1162	O
a	-	1165	O
mean	-	1167	O
time	-	1172	O
of	-	1177	O
240	-	1180	O
min	-	1184	O
post	-	1188	O
-	-	1192	O
infusion	-	1193	O
.	-	1201	O

At	10524660	1203	O
this	-	1206	O
time	-	1211	O
the	-	1216	O
induced	-	1220	O
headache	-	1228	B
in	-	1237	O
6	-	1240	O
of	-	1242	O
12	-	1245	O
migraineurs	-	1248	B
fulfilled	-	1260	O
the	-	1270	O
diagnostic	-	1274	O
criteria	-	1285	O
for	-	1294	O
migraine	-	1298	B
without	-	1307	I
aura	-	1315	I
of	-	1320	O
the	-	1323	O
International	-	1327	O
Headache	-	1341	B
Society	-	1350	O
.	-	1357	O

The	10524660	1359	O
results	-	1363	O
therefore	-	1371	O
suggest	-	1381	O
that	-	1389	O
NO	-	1394	O
is	-	1397	O
involved	-	1400	O
in	-	1409	O
the	-	1412	O
pain	-	1416	B
mechanisms	-	1421	O
of	-	1432	O
migraine	-	1435	B
with	-	1444	I
aura	-	1449	I
.	-	1453	O

Since	10524660	1455	O
cortical	-	1461	O
spreading	-	1470	O
depression	-	1480	B
has	-	1491	O
been	-	1495	O
shown	-	1500	O
to	-	1506	O
liberate	-	1509	O
NO	-	1518	O
in	-	1521	O
animals	-	1524	O
,	-	1531	O
this	-	1533	O
finding	-	1538	O
may	-	1546	O
help	-	1550	O
our	-	1555	O
understanding	-	1559	O
of	-	1573	O
the	-	1576	O
coupling	-	1580	O
between	-	1589	O
cortical	-	1597	O
spreading	-	1606	O
depression	-	1616	B
and	-	1627	O
headache	-	1631	B
in	-	1640	O
migraine	-	1643	B
with	-	1652	I
aura	-	1657	I
.	-	1661	O

Stroke	9799166	0	B
and	-	7	O
cocaine	-	11	O
or	-	19	O
amphetamine	-	22	O
use	-	34	O
.	-	37	O

The	9799166	39	O
association	-	43	O
of	-	55	O
cocaine	-	58	O
and	-	66	O
amphetamine	-	70	O
use	-	82	O
with	-	86	O
hemorrhagic	-	91	O
and	-	103	O
ischemic	-	107	B
stroke	-	116	B
is	-	123	O
based	-	126	O
almost	-	132	O
solely	-	139	O
on	-	146	O
data	-	149	O
from	-	154	O
case	-	159	O
series	-	164	O
.	-	170	O

The	9799166	172	O
limited	-	176	O
number	-	184	O
of	-	191	O
epidemiologic	-	194	O
studies	-	208	O
of	-	216	O
stroke	-	219	B
and	-	226	O
use	-	230	O
of	-	234	O
cocaine	-	237	O
and	-	245	O
/	-	248	O
or	-	249	O
amphetamine	-	252	O
have	-	264	O
been	-	269	O
done	-	274	O
in	-	279	O
settings	-	282	O
that	-	291	O
serve	-	296	O
mostly	-	302	O
the	-	309	O
poor	-	313	O
and	-	318	O
/	-	321	O
or	-	322	O
minorities	-	325	O
.	-	335	O

This	9799166	337	O
case	-	342	O
-	-	346	O
control	-	347	O
study	-	355	O
was	-	361	O
conducted	-	365	O
in	-	375	O
the	-	378	O
defined	-	382	O
population	-	390	O
comprising	-	401	O
members	-	412	O
of	-	420	O
Kaiser	-	423	O
Permanente	-	430	O
of	-	441	O
Northern	-	444	O
and	-	453	O
Southern	-	457	O
California	-	466	O
.	-	476	O

We	9799166	478	O
attempted	-	481	O
to	-	491	O
identify	-	494	O
all	-	503	O
incident	-	507	O
strokes	-	516	B
in	-	524	O
women	-	527	O
ages	-	533	O
15	-	538	O
-	-	540	O
44	-	541	O
years	-	544	O
during	-	550	O
a	-	557	O
3	-	559	O
-	-	560	O
year	-	561	O
period	-	566	O
using	-	573	O
hospital	-	579	O
admission	-	588	O
and	-	598	O
discharge	-	602	O
records	-	612	O
,	-	619	O
emergency	-	621	O
department	-	631	O
logs	-	642	O
,	-	646	O
and	-	648	O
payment	-	652	O
requests	-	660	O
for	-	669	O
out	-	673	O
-	-	676	O
of	-	677	O
-	-	679	O
plan	-	680	O
hospitalizations	-	685	O
.	-	701	O

We	9799166	703	O
selected	-	706	O
controls	-	715	O
,	-	723	O
matched	-	725	O
on	-	733	O
age	-	736	O
and	-	740	O
facility	-	744	O
of	-	753	O
usual	-	756	O
care	-	762	O
,	-	766	O
at	-	768	O
random	-	771	O
from	-	778	O
healthy	-	783	O
members	-	791	O
of	-	799	O
the	-	802	O
health	-	806	O
plan	-	813	O
.	-	817	O

We	9799166	819	O
obtained	-	822	O
information	-	831	O
in	-	843	O
face	-	846	O
-	-	850	O
to	-	851	O
-	-	853	O
face	-	854	O
interviews	-	859	O
.	-	869	O

There	9799166	871	O
were	-	877	O
347	-	882	O
confirmed	-	886	O
stroke	-	896	B
cases	-	903	O
and	-	909	O
1	-	913	O
,	-	914	O
021	-	915	O
controls	-	919	O
.	-	927	O

The	9799166	929	O
univariate	-	933	O
matched	-	944	O
odds	-	952	O
ratio	-	957	O
for	-	963	O
stroke	-	967	B
in	-	974	O
women	-	977	O
who	-	983	O
admitted	-	987	O
to	-	996	O
using	-	999	O
cocaine	-	1005	O
and	-	1013	O
/	-	1016	O
or	-	1017	O
amphetamine	-	1020	O
was	-	1032	O
8	-	1036	O
.	-	1037	O
5	-	1038	O
(	-	1040	O
95	-	1041	O
%	-	1043	O
confidence	-	1045	O
interval	-	1056	O
=	-	1065	O
3	-	1067	O
.	-	1068	O
6	-	1069	O
-	-	1070	O
20	-	1071	O
.	-	1073	O
0	-	1074	O
)	-	1075	O
.	-	1076	O

After	9799166	1078	O
further	-	1084	O
adjustment	-	1092	O
for	-	1103	O
potential	-	1107	O
confounders	-	1117	O
,	-	1128	O
the	-	1130	O
odds	-	1134	O
ratio	-	1139	O
in	-	1145	O
women	-	1148	O
who	-	1154	O
reported	-	1158	O
using	-	1167	O
cocaine	-	1173	O
and	-	1181	O
/	-	1184	O
or	-	1185	O
amphetamine	-	1188	O
was	-	1200	O
7	-	1204	O
.	-	1205	O
0	-	1206	O
(	-	1208	O
95	-	1209	O
%	-	1211	O
confidence	-	1213	O
interval	-	1224	O
=	-	1233	O
2	-	1235	O
.	-	1236	O
8	-	1237	O
-	-	1238	O
17	-	1239	O
.	-	1241	O
9	-	1242	O
)	-	1243	O
.	-	1244	O

The	9799166	1246	O
use	-	1250	O
of	-	1254	O
cocaine	-	1257	O
and	-	1265	O
/	-	1268	O
or	-	1269	O
amphetamine	-	1272	O
is	-	1284	O
a	-	1287	O
strong	-	1289	O
risk	-	1296	O
factor	-	1301	O
for	-	1308	O
stroke	-	1312	B
in	-	1319	O
this	-	1322	O
socioeconomically	-	1327	O
heterogeneous	-	1345	O
,	-	1358	O
insured	-	1360	O
urban	-	1368	O
population	-	1374	O
.	-	1384	O

Prevention	9672273	0	O
of	-	11	O
breast	-	14	B
cancer	-	21	I
with	-	28	O
tamoxifen	-	33	O
:	-	42	O
preliminary	-	44	O
findings	-	56	O
from	-	65	O
the	-	70	O
Italian	-	74	O
randomised	-	82	O
trial	-	93	O
among	-	99	O
hysterectomised	-	105	O
women	-	121	O
.	-	126	O

Italian	9672273	128	O
Tamoxifen	-	136	O
Prevention	-	146	O
Study	-	157	O
.	-	162	O

BACKGROUND	9672273	164	O
:	-	174	O

Tamoxifen	9672273	176	O
is	-	186	O
a	-	189	O
candidate	-	191	O
chemopreventive	-	201	O
agent	-	217	O
in	-	223	O
breast	-	226	B
cancer	-	233	I
,	-	239	O
although	-	241	O
the	-	250	O
drug	-	254	O
may	-	259	O
be	-	263	O
associated	-	266	O
with	-	277	O
the	-	282	O
development	-	286	O
of	-	298	O
endometrial	-	301	B
cancer	-	313	I
.	-	319	O

Therefore	9672273	321	O
we	-	331	O
did	-	334	O
a	-	338	O
trial	-	340	O
in	-	346	O
hysterectomised	-	349	O
women	-	365	O
of	-	371	O
tamoxifen	-	374	O
as	-	384	O
a	-	387	O
chemopreventive	-	389	O
.	-	404	O

METHODS	9672273	406	O
:	-	413	O

In	9672273	415	O
October	-	418	O
,	-	425	O
1992	-	427	O
,	-	431	O
we	-	433	O
started	-	436	O
a	-	444	O
double	-	446	O
-	-	452	O
blind	-	453	O
placebo	-	459	O
-	-	466	O
controlled	-	467	O
,	-	477	O
randomised	-	479	O
trial	-	490	O
of	-	496	O
tamoxifen	-	499	O
in	-	509	O
women	-	512	O
(	-	518	O
mainly	-	519	O
in	-	526	O
Italy	-	529	O
)	-	534	O
who	-	536	O
did	-	540	O
not	-	544	O
have	-	548	O
breast	-	553	B
cancer	-	560	I
and	-	567	O
who	-	571	O
had	-	575	O
had	-	579	O
a	-	583	O
hysterectomy	-	585	O
.	-	597	O

Women	9672273	599	O
were	-	605	O
randomised	-	610	O
to	-	621	O
receive	-	624	O
tamoxifen	-	632	O
20	-	642	O
mg	-	645	O
per	-	648	O
day	-	652	O
or	-	656	O
placebo	-	659	O
,	-	666	O
both	-	668	O
orally	-	673	O
for	-	680	O
5	-	684	O
years	-	686	O
.	-	691	O

The	9672273	693	O
original	-	697	O
plan	-	706	O
was	-	711	O
to	-	715	O
follow	-	718	O
the	-	725	O
intervention	-	729	O
phase	-	742	O
by	-	748	O
5	-	751	O
years	-	753	O
'	-	758	O
follow	-	760	O
-	-	766	O
up	-	767	O
.	-	769	O

In	9672273	771	O
June	-	774	O
,	-	778	O
1997	-	780	O
,	-	784	O
the	-	786	O
trialists	-	790	O
and	-	800	O
the	-	804	O
data	-	808	O
-	-	812	O
monitoring	-	813	O
committee	-	824	O
decided	-	834	O
to	-	842	O
end	-	845	O
recruitment	-	849	O
primarily	-	861	O
because	-	871	O
of	-	879	O
the	-	882	O
number	-	886	O
of	-	893	O
women	-	896	O
dropping	-	902	O
out	-	911	O
of	-	915	O
the	-	918	O
study	-	922	O
.	-	927	O

Recruitment	9672273	929	O
ended	-	941	O
on	-	947	O
July	-	950	O
11	-	955	O
,	-	957	O
1997	-	959	O
,	-	963	O
and	-	965	O
the	-	969	O
study	-	973	O
will	-	979	O
continue	-	984	O
as	-	993	O
planned	-	996	O
.	-	1003	O

The	9672273	1005	O
primary	-	1009	O
endpoints	-	1017	O
are	-	1027	O
the	-	1031	O
occurrence	-	1035	O
of	-	1046	O
and	-	1049	O
deaths	-	1053	O
from	-	1060	O
breast	-	1065	B
cancer	-	1072	I
.	-	1078	O

This	9672273	1080	O
preliminary	-	1085	O
interim	-	1097	O
analysis	-	1105	O
is	-	1114	O
based	-	1117	O
on	-	1123	O
intention	-	1126	O
-	-	1135	O
to	-	1136	O
-	-	1138	O
treat	-	1139	O
.	-	1144	O

FINDINGS	9672273	1146	O
:	-	1154	O

5408	9672273	1156	O
women	-	1161	O
were	-	1167	O
randomised	-	1172	O
;	-	1182	O
participating	-	1184	O
women	-	1198	O
have	-	1204	O
a	-	1209	O
median	-	1211	O
follow	-	1218	O
-	-	1224	O
up	-	1225	O
of	-	1228	O
46	-	1231	O
months	-	1234	O
for	-	1241	O
major	-	1245	O
endpoints	-	1251	O
.	-	1260	O

41	9672273	1262	O
cases	-	1265	O
of	-	1271	O
breast	-	1274	B
cancer	-	1281	I
occurred	-	1288	O
so	-	1297	O
far	-	1300	O
;	-	1303	O
there	-	1305	O
have	-	1311	O
been	-	1316	O
no	-	1321	O
deaths	-	1324	O
from	-	1331	O
breast	-	1336	B
cancer	-	1343	I
.	-	1349	O

There	9672273	1351	O
is	-	1357	O
no	-	1360	O
difference	-	1363	O
in	-	1374	O
breast	-	1377	B
-	-	1383	I
cancer	-	1384	I
frequency	-	1391	O
between	-	1401	O
the	-	1409	O
placebo	-	1413	O
(	-	1421	O
22	-	1422	O
cases	-	1425	O
)	-	1430	O
and	-	1432	O
tamoxifen	-	1436	O
(	-	1446	O
19	-	1447	O
)	-	1449	O
arms	-	1451	O
.	-	1455	O

There	9672273	1457	O
is	-	1463	O
a	-	1466	O
statistically	-	1468	O
significant	-	1482	O
reduction	-	1494	O
of	-	1504	O
breast	-	1507	B
cancer	-	1514	I
among	-	1521	O
women	-	1527	O
receiving	-	1533	O
tamoxifen	-	1543	O
who	-	1553	O
also	-	1557	O
used	-	1562	O
hormone	-	1567	O
-	-	1574	O
replacement	-	1575	O
therapy	-	1587	O
during	-	1595	O
the	-	1602	O
trial	-	1606	O
:	-	1611	O
among	-	1613	O
390	-	1619	O
women	-	1623	O
on	-	1629	O
such	-	1632	O
therapy	-	1637	O
and	-	1645	O
allocated	-	1649	O
to	-	1659	O
placebo	-	1662	O
,	-	1669	O
we	-	1671	O
found	-	1674	O
eight	-	1680	O
cases	-	1686	O
of	-	1692	O
breast	-	1695	B
cancer	-	1702	I
compared	-	1709	O
with	-	1718	O
one	-	1723	O
case	-	1727	O
among	-	1732	O
362	-	1738	O
women	-	1742	O
allocated	-	1748	O
to	-	1758	O
tamoxifen	-	1761	O
.	-	1770	O

Compared	9672273	1772	O
with	-	1781	O
the	-	1786	O
placebo	-	1790	O
group	-	1798	O
,	-	1803	O
there	-	1805	O
was	-	1811	O
a	-	1815	O
significantly	-	1817	O
increased	-	1831	O
risk	-	1841	O
of	-	1846	O
vascular	-	1849	B
events	-	1858	I
and	-	1865	O
hypertriglyceridaemia	-	1869	B
among	-	1891	O
women	-	1897	O
on	-	1903	O
tamoxifen	-	1906	O
.	-	1915	O

INTERPRETATION	9672273	1917	O
:	-	1931	O

Although	9672273	1933	O
this	-	1942	O
preliminary	-	1947	O
analysis	-	1959	O
has	-	1968	O
low	-	1972	O
power	-	1976	O
,	-	1981	O
in	-	1983	O
this	-	1986	O
cohort	-	1991	O
of	-	1998	O
women	-	2001	O
at	-	2007	O
low	-	2010	O
-	-	2013	O
to	-	2014	O
-	-	2016	O
normal	-	2017	O
risk	-	2024	O
of	-	2029	O
breast	-	2032	B
cancer	-	2039	I
,	-	2045	O
the	-	2047	O
postulated	-	2051	O
protective	-	2062	O
effects	-	2073	O
of	-	2081	O
tamoxifen	-	2084	O
are	-	2094	O
not	-	2098	O
yet	-	2102	O
apparent	-	2106	O
.	-	2114	O

Women	9672273	2116	O
using	-	2122	O
hormone	-	2128	O
-	-	2135	O
replacement	-	2136	O
therapy	-	2148	O
appear	-	2156	O
to	-	2163	O
have	-	2166	O
benefited	-	2171	O
from	-	2181	O
use	-	2186	O
of	-	2190	O
tamoxifen	-	2193	O
.	-	2202	O

There	9672273	2204	O
were	-	2210	O
no	-	2215	O
deaths	-	2218	O
from	-	2225	O
breast	-	2230	B
cancer	-	2237	I
recorded	-	2244	O
in	-	2253	O
women	-	2256	O
in	-	2262	O
the	-	2265	O
study	-	2269	O
.	-	2274	O

It	9672273	2276	O
is	-	2279	O
essential	-	2282	O
to	-	2292	O
continue	-	2295	O
follow	-	2304	O
-	-	2310	O
up	-	2311	O
to	-	2314	O
quantify	-	2317	O
the	-	2326	O
long	-	2330	O
-	-	2334	O
term	-	2335	O
risks	-	2340	O
and	-	2346	O
benefits	-	2350	O
of	-	2359	O
tamoxifen	-	2362	O
therapy	-	2372	O
.	-	2379	O

A	8854309	0	O
measure	-	2	O
of	-	10	O
pupillary	-	13	B
oscillation	-	23	I
as	-	35	O
a	-	38	O
marker	-	40	O
of	-	47	O
cocaine	-	50	O
-	-	57	O
induced	-	58	O
paranoia	-	66	B
.	-	74	O

Cocaine	8854309	76	O
-	-	83	O
induced	-	84	O
paranoia	-	92	B
(	-	101	O
CIP	-	102	B
)	-	105	O
remains	-	107	O
an	-	115	O
important	-	118	O
drug	-	128	O
-	-	132	O
induced	-	133	O
model	-	141	O
of	-	147	O
idiopathic	-	150	O
paranoia	-	161	B
for	-	170	O
which	-	174	O
no	-	180	O
psychophysiologic	-	183	O
marker	-	201	O
has	-	208	O
yet	-	212	O
emerged	-	216	O
.	-	223	O

Measures	8854309	225	O
of	-	234	O
pupillary	-	237	B
oscillation	-	247	I
were	-	259	O
able	-	264	O
to	-	269	O
significantly	-	272	O
distinguish	-	286	O
a	-	298	O
group	-	300	O
of	-	306	O
abstinent	-	309	O
crack	-	319	O
cocaine	-	325	O
abusers	-	333	O
endorsing	-	341	O
past	-	351	O
CIP	-	356	B
(	-	360	O
n	-	361	O
=	-	363	O
32	-	365	O
)	-	367	O
from	-	369	O
another	-	374	O
group	-	382	O
of	-	388	O
crack	-	391	O
addicts	-	397	O
who	-	405	O
denied	-	409	O
past	-	416	O
CIP	-	421	B
(	-	425	O
n	-	426	O
=	-	428	O
29	-	430	O
)	-	432	O
.	-	433	O

Seizures	8473723	0	B
induced	-	9	O
by	-	17	O
combined	-	20	O
levomepromazine	-	29	O
-	-	44	O
fluvoxamine	-	45	O
treatment	-	57	O
.	-	66	O

We	8473723	68	O
report	-	71	O
a	-	78	O
case	-	80	O
of	-	85	O
combined	-	88	O
levomepromazine	-	97	O
-	-	112	O
fluvoxamine	-	113	O
treatment	-	125	O
-	-	134	O
induced	-	135	O
seizures	-	143	B
.	-	151	O

It	8473723	153	O
seems	-	156	O
that	-	162	O
combined	-	167	O
treatment	-	176	O
of	-	186	O
fluvoxamine	-	189	O
with	-	201	O
phenothiazines	-	206	O
may	-	221	O
possess	-	225	O
proconvulsive	-	233	O
activity	-	247	O
.	-	255	O

Why	6674249	0	O
may	-	4	O
epsilon	-	8	O
-	-	15	O
aminocaproic	-	16	O
acid	-	29	O
(	-	34	O
EACA	-	35	O
)	-	39	O
induce	-	41	O
myopathy	-	48	B
in	-	57	O
man	-	60	O
?	-	63	O

Report	6674249	65	O
of	-	72	O
a	-	75	O
case	-	77	O
and	-	82	O
literature	-	86	O
review	-	97	O
.	-	103	O

A	6674249	105	O
case	-	107	O
of	-	112	O
necrotizing	-	115	B
myopathy	-	127	I
due	-	136	O
to	-	140	O
a	-	143	O
short	-	145	O
epsilon	-	151	O
-	-	158	O
aminocaproic	-	159	O
acid	-	172	O
(	-	177	O
EACA	-	178	O
)	-	182	O
treatment	-	184	O
in	-	194	O
a	-	197	O
72	-	199	O
year	-	202	O
-	-	206	O
old	-	207	O
patient	-	211	O
with	-	219	O
subarachnoid	-	224	B
haemorrhage	-	237	I
(	-	249	O
SAH	-	250	B
)	-	253	O
is	-	255	O
described	-	258	O
.	-	267	O

Pathogenetic	6674249	269	O
hypotheses	-	282	O
are	-	293	O
discussed	-	297	O
.	-	306	O

Comparison	6150641	0	O
of	-	11	O
the	-	14	O
effectiveness	-	18	O
of	-	32	O
ranitidine	-	35	O
and	-	46	O
cimetidine	-	50	O
in	-	61	O
inhibiting	-	64	O
acid	-	75	O
secretion	-	80	O
in	-	90	O
patients	-	93	O
with	-	102	O
gastric	-	107	O
hypersecretory	-	115	O
states	-	130	O
.	-	136	O

The	6150641	138	O
H2	-	142	O
-	-	144	O
histamine	-	145	O
receptor	-	155	O
antagonists	-	164	O
ranitidine	-	176	O
and	-	187	O
cimetidine	-	191	O
were	-	202	O
compared	-	207	O
for	-	216	O
their	-	220	O
abilities	-	226	O
to	-	236	O
control	-	239	O
gastric	-	247	O
acid	-	255	O
hypersecretion	-	260	O
on	-	275	O
a	-	278	O
short	-	280	O
-	-	285	O
and	-	287	O
long	-	291	O
-	-	295	O
term	-	296	O
basis	-	301	O
in	-	307	O
22	-	310	O
patients	-	313	O
with	-	322	O
gastric	-	327	O
acid	-	335	O
hypersecretory	-	340	O
states	-	355	O
.	-	361	O

Nineteen	6150641	363	O
patients	-	372	O
had	-	381	O
Zollinger	-	385	B
-	-	394	I
Ellison	-	395	I
syndrome	-	403	I
,	-	411	O
one	-	413	O
patient	-	417	O
had	-	425	O
systemic	-	429	B
mastocytosis	-	438	I
,	-	450	O
and	-	452	O
two	-	456	O
patients	-	460	O
had	-	469	O
idiopathic	-	473	O
hypersecretion	-	484	O
.	-	498	O

The	6150641	500	O
rates	-	504	O
of	-	510	O
onset	-	513	O
of	-	519	O
the	-	522	O
action	-	526	O
of	-	533	O
cimetidine	-	536	O
and	-	547	O
ranitidine	-	551	O
were	-	562	O
the	-	567	O
same	-	571	O
.	-	575	O

The	6150641	577	O
actions	-	581	O
of	-	589	O
both	-	592	O
drugs	-	597	O
were	-	603	O
increased	-	608	O
by	-	618	O
anticholinergic	-	621	O
agents	-	637	O
,	-	643	O
and	-	645	O
there	-	649	O
was	-	655	O
a	-	659	O
close	-	661	O
correlation	-	667	O
between	-	679	O
the	-	687	O
daily	-	691	O
maintenance	-	697	O
dose	-	709	O
of	-	714	O
each	-	717	O
drug	-	722	O
needed	-	727	O
to	-	734	O
control	-	737	O
acid	-	745	O
secretion	-	750	O
.	-	759	O

However	6150641	761	O
,	-	768	O
ranitidine	-	770	O
was	-	781	O
threefold	-	785	O
more	-	795	O
potent	-	800	O
than	-	807	O
cimetidine	-	812	O
both	-	823	O
in	-	828	O
acute	-	831	O
inhibition	-	837	O
studies	-	848	O
and	-	856	O
in	-	860	O
the	-	863	O
median	-	867	O
maintenance	-	874	O
dose	-	886	O
needed	-	891	O
(	-	898	O
1	-	899	O
.	-	900	O
2	-	901	O
g	-	903	O
per	-	905	O
day	-	909	O
for	-	913	O
ranitidine	-	917	O
and	-	928	O
3	-	932	O
.	-	933	O
6	-	934	O
g	-	936	O
per	-	938	O
day	-	942	O
for	-	946	O
cimetidine	-	950	O
)	-	960	O
.	-	961	O

Sixty	6150641	963	O
percent	-	969	O
of	-	977	O
the	-	980	O
males	-	984	O
developed	-	990	O
breast	-	1000	O
changes	-	1007	O
or	-	1015	O
impotence	-	1018	B
while	-	1028	O
taking	-	1034	O
cimetidine	-	1041	O
and	-	1052	O
in	-	1056	O
all	-	1059	O
cases	-	1063	O
these	-	1069	O
changes	-	1075	O
disappeared	-	1083	O
when	-	1095	O
cimetidine	-	1100	O
was	-	1111	O
replaced	-	1115	O
by	-	1124	O
ranitidine	-	1127	O
.	-	1137	O

Treatment	6150641	1139	O
with	-	1149	O
high	-	1154	O
doses	-	1159	O
of	-	1165	O
cimetidine	-	1168	O
(	-	1179	O
one	-	1180	O
to	-	1184	O
60	-	1187	O
months	-	1190	O
;	-	1196	O
median	-	1198	O
,	-	1204	O
11	-	1206	O
months	-	1209	O
)	-	1215	O
or	-	1217	O
ranitidine	-	1220	O
(	-	1231	O
two	-	1232	O
to	-	1236	O
31	-	1239	O
months	-	1242	O
;	-	1248	O
median	-	1250	O
,	-	1256	O
14	-	1258	O
months	-	1261	O
)	-	1267	O
was	-	1269	O
not	-	1273	O
associated	-	1277	O
with	-	1288	O
hepatic	-	1293	B
or	-	1301	I
hematologic	-	1304	I
toxicity	-	1316	I
or	-	1325	O
alterations	-	1328	O
of	-	1340	O
serum	-	1343	O
gastrin	-	1349	O
concentrations	-	1357	O
,	-	1371	O
but	-	1373	O
ranitidine	-	1377	O
therapy	-	1388	O
was	-	1396	O
associated	-	1400	O
with	-	1411	O
a	-	1416	O
significantly	-	1418	O
lower	-	1432	O
serum	-	1438	O
creatinine	-	1444	O
level	-	1455	O
than	-	1461	O
seen	-	1466	O
with	-	1471	O
cimetidine	-	1476	O
therapy	-	1487	O
.	-	1494	O

The	6150641	1496	O
results	-	1500	O
show	-	1508	O
that	-	1513	O
both	-	1518	O
drugs	-	1523	O
can	-	1529	O
adequately	-	1533	O
inhibit	-	1544	O
acid	-	1552	O
secretion	-	1557	O
in	-	1567	O
patients	-	1570	O
with	-	1579	O
gastric	-	1584	O
hypersecretory	-	1592	O
states	-	1607	O
.	-	1613	O

Both	6150641	1615	O
are	-	1620	O
safe	-	1624	O
at	-	1629	O
high	-	1632	O
doses	-	1637	O
,	-	1642	O
but	-	1644	O
ranitidine	-	1648	O
is	-	1659	O
threefold	-	1662	O
more	-	1672	O
potent	-	1677	O
and	-	1684	O
does	-	1688	O
not	-	1693	O
cause	-	1697	O
the	-	1703	O
antiandrogen	-	1707	O
side	-	1720	O
effects	-	1725	O
frequently	-	1733	O
seen	-	1744	O
with	-	1749	O
high	-	1754	O
doses	-	1759	O
of	-	1765	O
cimetidine	-	1768	O
.	-	1778	O

A	3670965	0	O
catch	-	2	O
in	-	8	O
the	-	11	O
Reye	-	15	B
.	-	19	O

Twenty	3670965	21	O
-	-	27	O
six	-	28	O
cases	-	32	O
of	-	38	O
Reye	-	41	B
syndrome	-	46	I
from	-	55	O
The	-	60	O
Children	-	64	O
's	-	72	O
Hospital	-	75	O
,	-	83	O
Camperdown	-	85	O
,	-	95	O
Australia	-	97	O
,	-	106	O
occurring	-	108	O
between	-	118	O
1973	-	126	O
and	-	131	O
1982	-	135	O
were	-	140	O
reviewed	-	145	O
.	-	153	O

Of	3670965	155	O
these	-	158	O
,	-	163	O
20	-	165	O
cases	-	168	O
met	-	174	O
the	-	178	O
US	-	182	O
Public	-	185	O
Health	-	192	O
Service	-	199	O
Centers	-	207	O
for	-	215	O
Disease	-	219	O
Control	-	227	O
criteria	-	235	O
for	-	244	O
the	-	248	O
diagnosis	-	252	O
of	-	262	O
Reye	-	265	B
syndrome	-	270	I
.	-	278	O

Aspirin	3670965	280	O
or	-	288	O
salicylate	-	291	O
ingestion	-	302	O
had	-	312	O
occurred	-	316	O
in	-	325	O
only	-	328	O
one	-	333	O
of	-	337	O
the	-	340	O
20	-	344	O
cases	-	347	O
(	-	353	O
5	-	354	O
%	-	355	O
)	-	356	O
,	-	357	O
and	-	359	O
paracetamol	-	363	O
(	-	375	O
acetaminophen	-	376	O
)	-	389	O
had	-	391	O
been	-	395	O
administered	-	400	O
in	-	413	O
only	-	416	O
six	-	421	O
of	-	425	O
the	-	428	O
cases	-	432	O
(	-	438	O
30	-	439	O
%	-	441	O
)	-	442	O
.	-	443	O

Pathologic	3670965	445	O
confirmation	-	456	O
of	-	469	O
the	-	472	O
diagnosis	-	476	O
of	-	486	O
Reye	-	489	B
syndrome	-	494	I
was	-	503	O
accomplished	-	507	O
in	-	520	O
90	-	523	O
%	-	525	O
of	-	527	O
the	-	530	O
cases	-	534	O
.	-	539	O

The	3670965	541	O
incidence	-	545	O
of	-	555	O
Reye	-	558	B
syndrome	-	563	I
in	-	572	O
New	-	575	O
South	-	579	O
Wales	-	585	O
,	-	590	O
Australia	-	592	O
,	-	601	O
is	-	603	O
estimated	-	606	O
from	-	616	O
this	-	621	O
study	-	626	O
to	-	632	O
be	-	635	O
approximately	-	638	O
nine	-	652	O
cases	-	657	O
per	-	663	O
1	-	667	O
million	-	669	O
children	-	677	O
compared	-	686	O
with	-	695	O
recent	-	700	O
US	-	707	O
data	-	710	O
of	-	715	O
ten	-	718	O
to	-	722	O
20	-	725	O
cases	-	728	O
per	-	734	O
1	-	738	O
million	-	740	O
children	-	748	O
and	-	757	O
three	-	761	O
to	-	767	O
seven	-	770	O
cases	-	776	O
per	-	782	O
1	-	786	O
million	-	788	O
children	-	796	O
in	-	805	O
Great	-	808	O
Britain	-	814	O
.	-	821	O

The	3670965	823	O
mortality	-	827	O
for	-	837	O
these	-	841	O
Reye	-	847	B
syndrome	-	852	I
cases	-	861	O
in	-	867	O
Australia	-	870	O
was	-	880	O
45	-	884	O
%	-	886	O
as	-	888	O
compared	-	891	O
with	-	900	O
a	-	905	O
32	-	907	O
%	-	909	O
case	-	911	O
-	-	915	O
fatality	-	916	O
rate	-	925	O
in	-	930	O
the	-	933	O
United	-	937	O
States	-	944	O
.	-	950	O

In	3670965	952	O
Australia	-	955	O
,	-	964	O
the	-	966	O
pediatric	-	970	O
usage	-	980	O
of	-	986	O
aspirin	-	989	O
has	-	997	O
been	-	1001	O
extremely	-	1006	O
low	-	1016	O
for	-	1020	O
the	-	1024	O
past	-	1028	O
25	-	1033	O
years	-	1036	O
(	-	1042	O
less	-	1043	O
than	-	1048	O
1	-	1053	O
%	-	1054	O
of	-	1056	O
total	-	1059	O
dosage	-	1065	O
units	-	1072	O
sold	-	1078	O
)	-	1082	O
,	-	1083	O
with	-	1085	O
paracetamol	-	1090	O
(	-	1102	O
acetaminophen	-	1103	O
)	-	1116	O
dominating	-	1118	O
the	-	1129	O
pediatric	-	1133	O
analgesic	-	1143	O
and	-	1153	O
antipyretic	-	1157	O
market	-	1169	O
.	-	1175	O

Reye	3670965	1177	B
syndrome	-	1182	I
may	-	1191	O
be	-	1195	O
disappearing	-	1198	O
from	-	1211	O
Australia	-	1216	O
despite	-	1226	O
a	-	1234	O
total	-	1236	O
lack	-	1242	O
of	-	1247	O
association	-	1250	O
with	-	1262	O
salicylates	-	1267	O
or	-	1279	O
aspirin	-	1282	O
ingestion	-	1290	O
,	-	1299	O
since	-	1301	O
there	-	1307	O
were	-	1313	O
no	-	1318	O
cases	-	1321	O
found	-	1327	O
at	-	1333	O
The	-	1336	O
Children	-	1340	O
's	-	1348	O
Hospital	-	1351	O
in	-	1360	O
1983	-	1363	O
,	-	1367	O
1984	-	1369	O
,	-	1373	O
or	-	1375	O
1985	-	1378	O
.	-	1382	O

St	3300918	0	B
.	-	2	I
Anthony	-	4	I
's	-	11	I
fire	-	14	I
,	-	18	O
then	-	20	O
and	-	25	O
now	-	29	O
:	-	32	O
a	-	34	O
case	-	36	O
report	-	41	O
and	-	48	O
historical	-	52	O
review	-	63	O
.	-	69	O

A	3300918	71	O
rare	-	73	O
case	-	78	O
of	-	83	O
morbid	-	86	O
vasospasm	-	93	B
,	-	102	O
together	-	104	O
with	-	113	O
striking	-	118	O
angiographic	-	127	O
findings	-	140	O
,	-	148	O
is	-	150	O
described	-	153	O
secondary	-	163	O
to	-	173	O
the	-	176	O
ingestion	-	180	O
of	-	190	O
methysergide	-	193	O
by	-	206	O
a	-	209	O
48	-	211	O
-	-	213	O
year	-	214	O
-	-	218	O
old	-	219	O
woman	-	223	O
.	-	228	O

A	3300918	230	O
brief	-	232	O
review	-	238	O
of	-	245	O
the	-	248	O
literature	-	252	O
on	-	263	O
similar	-	266	O
cases	-	274	O
is	-	280	O
presented	-	283	O
.	-	292	O

A	3300918	294	O
discussion	-	296	O
of	-	307	O
the	-	310	O
history	-	314	O
of	-	322	O
ergot	-	325	O
includes	-	331	O
its	-	340	O
original	-	344	O
discovery	-	353	O
,	-	362	O
the	-	364	O
epidemics	-	368	O
of	-	378	O
gangrene	-	381	B
that	-	390	O
it	-	395	O
has	-	398	O
caused	-	402	O
through	-	409	O
the	-	417	O
ages	-	421	O
and	-	426	O
its	-	430	O
past	-	434	O
and	-	439	O
present	-	443	O
role	-	451	O
in	-	456	O
the	-	459	O
management	-	463	O
of	-	474	O
migraine	-	477	B
headache	-	486	I
.	-	494	O

Despite	3300918	496	O
the	-	504	O
advent	-	508	O
of	-	515	O
calcium	-	518	O
channel	-	526	O
blockers	-	534	O
and	-	543	O
beta	-	547	O
-	-	551	O
adrenergic	-	552	O
antagonists	-	563	O
,	-	574	O
ergot	-	576	O
preparations	-	582	O
continue	-	595	O
to	-	604	O
play	-	607	O
a	-	612	O
major	-	614	O
role	-	620	O
in	-	625	O
migraine	-	628	B
therapy	-	637	O
,	-	644	O
so	-	646	O
that	-	649	O
the	-	654	O
danger	-	658	O
of	-	665	O
St	-	668	B
.	-	670	I
Anthony	-	672	I
's	-	679	I
fire	-	682	I
persists	-	687	O
.	-	695	O

Beta	2826064	0	O
-	-	4	O
2	-	5	O
-	-	6	O
adrenoceptor	-	7	O
-	-	19	O
mediated	-	20	O
hypokalemia	-	29	B
and	-	41	O
its	-	45	O
abolishment	-	49	O
by	-	61	O
oxprenolol	-	64	O
.	-	74	O

The	2826064	76	O
time	-	80	O
course	-	85	O
and	-	92	O
concentration	-	96	O
-	-	109	O
effect	-	110	O
relationship	-	117	O
of	-	130	O
terbutaline	-	133	O
-	-	144	O
induced	-	145	O
hypokalemia	-	153	B
was	-	165	O
studied	-	169	O
,	-	176	O
using	-	178	O
computer	-	184	O
-	-	192	O
aided	-	193	O
pharmacokinetic	-	199	O
-	-	214	O
dynamic	-	215	O
modeling	-	223	O
.	-	231	O

Subsequently	2826064	233	O
we	-	246	O
investigated	-	249	O
the	-	262	O
efficacy	-	266	O
of	-	275	O
oxprenolol	-	278	O
in	-	289	O
antagonizing	-	292	O
such	-	305	O
hypokalemia	-	310	B
,	-	321	O
together	-	323	O
with	-	332	O
the	-	337	O
pharmacokinetic	-	341	O
interaction	-	357	O
between	-	369	O
both	-	377	O
drugs	-	382	O
.	-	387	O

Six	2826064	389	O
healthy	-	393	O
subjects	-	401	O
were	-	410	O
given	-	415	O
a	-	421	O
0	-	423	O
.	-	424	O
5	-	425	O
mg	-	427	O
subcutaneous	-	430	O
dose	-	443	O
of	-	448	O
terbutaline	-	451	O
on	-	463	O
two	-	466	O
occasions	-	470	O
:	-	479	O
1	-	481	O
hour	-	483	O
after	-	488	O
oral	-	494	O
administration	-	499	O
of	-	514	O
a	-	517	O
placebo	-	519	O
and	-	527	O
1	-	531	O
hour	-	533	O
after	-	538	O
80	-	544	O
mg	-	547	O
oxprenolol	-	550	O
orally	-	561	O
.	-	567	O

In	2826064	569	O
the	-	572	O
7	-	576	O
-	-	577	O
hour	-	578	O
period	-	583	O
after	-	590	O
terbutaline	-	596	O
administration	-	608	O
,	-	622	O
plasma	-	624	O
samples	-	631	O
were	-	639	O
taken	-	644	O
for	-	650	O
determination	-	654	O
of	-	668	O
plasma	-	671	O
potassium	-	678	O
levels	-	688	O
and	-	695	O
drug	-	699	O
concentrations	-	704	O
.	-	718	O

The	2826064	720	O
sigmoid	-	724	O
Emax	-	732	O
model	-	737	O
offered	-	743	O
a	-	751	O
good	-	753	O
description	-	758	O
of	-	770	O
the	-	773	O
relation	-	777	O
between	-	786	O
terbutaline	-	794	O
concentrations	-	806	O
and	-	821	O
potassium	-	825	O
effects	-	835	O
.	-	842	O

Oxprenolol	2826064	844	O
caused	-	855	O
decreases	-	862	O
of	-	872	O
65	-	875	O
%	-	877	O
and	-	879	O
56	-	883	O
%	-	885	O
of	-	887	O
terbutaline	-	890	O
volume	-	902	O
of	-	909	O
distribution	-	912	O
and	-	925	O
clearance	-	929	O
,	-	938	O
respectively	-	940	O
,	-	952	O
and	-	954	O
an	-	958	O
increase	-	961	O
of	-	970	O
130	-	973	O
%	-	976	O
of	-	978	O
its	-	981	O
AUC	-	985	O
.	-	988	O

In	2826064	990	O
spite	-	993	O
of	-	999	O
higher	-	1002	O
terbutaline	-	1009	O
concentrations	-	1021	O
after	-	1036	O
oxprenolol	-	1042	O
pretreatment	-	1053	O
,	-	1065	O
the	-	1067	O
hypokalemia	-	1071	B
was	-	1083	O
almost	-	1087	O
completely	-	1094	O
antagonized	-	1105	O
by	-	1117	O
the	-	1120	O
beta	-	1124	O
2	-	1129	O
-	-	1130	O
blocking	-	1131	O
action	-	1140	O
.	-	1146	O

Midline	2422478	0	O
B3	-	8	O
serotonin	-	11	O
nerves	-	21	O
in	-	28	O
rat	-	31	O
medulla	-	35	O
are	-	43	O
involved	-	47	O
in	-	56	O
hypotensive	-	59	B
effect	-	71	O
of	-	78	O
methyldopa	-	81	O
.	-	91	O

Previous	2422478	93	O
experiments	-	102	O
in	-	114	O
this	-	117	O
laboratory	-	122	O
have	-	133	O
shown	-	138	O
that	-	144	O
microinjection	-	149	O
of	-	164	O
methyldopa	-	167	O
onto	-	178	O
the	-	183	O
ventrolateral	-	187	O
cells	-	201	O
of	-	207	O
the	-	210	O
B3	-	214	O
serotonin	-	217	O
neurons	-	227	O
in	-	235	O
the	-	238	O
medulla	-	242	O
elicits	-	250	O
a	-	258	O
hypotensive	-	260	B
response	-	272	O
mediated	-	281	O
by	-	290	O
a	-	293	O
projection	-	295	O
descending	-	306	O
into	-	317	O
the	-	322	O
spinal	-	326	O
cord	-	333	O
.	-	337	O

The	2422478	339	O
present	-	343	O
experiments	-	351	O
were	-	363	O
designed	-	368	O
to	-	377	O
investigate	-	380	O
the	-	392	O
role	-	396	O
of	-	401	O
the	-	404	O
midline	-	408	O
cells	-	416	O
of	-	422	O
the	-	425	O
B3	-	429	O
serotonin	-	432	O
neurons	-	442	O
in	-	450	O
the	-	453	O
medulla	-	457	O
,	-	464	O
coinciding	-	466	O
with	-	477	O
the	-	482	O
raphe	-	486	O
magnus	-	492	O
.	-	498	O

In	2422478	500	O
spontaneously	-	503	O
hypertensive	-	517	B
,	-	529	O
stroke	-	531	B
-	-	537	O
prone	-	538	O
rats	-	544	O
,	-	548	O
microinjection	-	550	O
of	-	565	O
methyldopa	-	568	O
into	-	579	O
the	-	584	O
area	-	588	O
of	-	593	O
the	-	596	O
midline	-	600	O
B3	-	608	O
serotonin	-	611	O
cell	-	621	O
group	-	626	O
in	-	632	O
the	-	635	O
ventral	-	639	O
medulla	-	647	O
caused	-	655	O
a	-	662	O
potent	-	664	O
hypotension	-	671	B
of	-	683	O
30	-	686	O
-	-	688	O
40	-	689	O
mm	-	692	O
Hg	-	695	O
,	-	697	O
which	-	699	O
was	-	705	O
maximal	-	709	O
2	-	717	O
-	-	718	O
3	-	719	O
h	-	721	O
after	-	723	O
administration	-	729	O
and	-	744	O
was	-	748	O
abolished	-	752	O
by	-	762	O
the	-	765	O
serotonin	-	769	O
neurotoxin	-	779	O
5	-	790	O
,	-	791	O
7	-	792	O
-	-	793	O
dihydroxytryptamine	-	794	O
(	-	814	O
5	-	815	O
,	-	816	O
7	-	817	O
-	-	818	O
DHT	-	819	O
)	-	822	O
injected	-	824	O
intracerebroventricularly	-	833	O
.	-	858	O

However	2422478	860	O
,	-	867	O
intraspinal	-	869	O
injection	-	881	O
of	-	891	O
5	-	894	O
,	-	895	O
7	-	896	O
-	-	897	O
DHT	-	898	O
to	-	902	O
produce	-	905	O
a	-	913	O
more	-	915	O
selective	-	920	O
lesion	-	930	O
of	-	937	O
only	-	940	O
descending	-	945	O
serotonin	-	956	O
projections	-	966	O
in	-	978	O
the	-	981	O
spinal	-	985	O
cord	-	992	O
did	-	997	O
not	-	1001	O
affect	-	1005	O
this	-	1012	O
hypotension	-	1017	B
.	-	1028	O

Further	2422478	1030	O
,	-	1037	O
5	-	1039	O
,	-	1040	O
7	-	1041	O
-	-	1042	O
DHT	-	1043	O
lesion	-	1047	O
of	-	1054	O
serotonin	-	1057	O
nerves	-	1067	O
travelling	-	1074	O
in	-	1085	O
the	-	1088	O
median	-	1092	O
forebrain	-	1099	O
bundle	-	1109	O
,	-	1115	O
one	-	1117	O
of	-	1121	O
the	-	1124	O
main	-	1128	O
ascending	-	1133	O
pathways	-	1143	O
from	-	1152	O
the	-	1157	O
B3	-	1161	O
serotonin	-	1164	O
cells	-	1174	O
,	-	1179	O
did	-	1181	O
not	-	1185	O
affect	-	1189	O
the	-	1196	O
fall	-	1200	O
in	-	1205	O
blood	-	1208	O
pressure	-	1214	O
associated	-	1223	O
with	-	1234	O
a	-	1239	O
midline	-	1241	O
B3	-	1249	O
serotonin	-	1252	O
methyldopa	-	1262	O
injection	-	1273	O
.	-	1282	O

It	2422478	1284	O
is	-	1287	O
concluded	-	1290	O
therefore	-	1300	O
that	-	1310	O
,	-	1314	O
unlike	-	1316	O
the	-	1323	O
ventrolateral	-	1327	O
B3	-	1341	O
cells	-	1344	O
which	-	1350	O
mediate	-	1356	O
a	-	1364	O
methyldopa	-	1366	O
-	-	1376	O
induced	-	1377	O
hypotension	-	1385	B
via	-	1397	O
descending	-	1401	O
projections	-	1412	O
,	-	1423	O
the	-	1425	O
midline	-	1429	O
serotonin	-	1437	O
B3	-	1447	O
cells	-	1450	O
in	-	1456	O
the	-	1459	O
medulla	-	1463	O
contribute	-	1471	O
to	-	1482	O
the	-	1485	O
hypotensive	-	1489	B
action	-	1501	O
of	-	1508	O
methyldopa	-	1511	O
,	-	1521	O
either	-	1523	O
by	-	1530	O
way	-	1533	O
of	-	1537	O
an	-	1540	O
ascending	-	1543	O
projection	-	1553	O
which	-	1564	O
does	-	1570	O
not	-	1575	O
pass	-	1579	O
through	-	1584	O
the	-	1592	O
median	-	1596	O
forebrain	-	1603	O
bundle	-	1613	O
,	-	1619	O
or	-	1621	O
through	-	1624	O
a	-	1632	O
projection	-	1634	O
restricted	-	1645	O
to	-	1656	O
the	-	1659	O
caudal	-	1663	O
brainstem	-	1670	O
.	-	1679	O

Yohimbine	1535072	0	O
treatment	-	10	O
of	-	20	O
sexual	-	23	B
side	-	30	I
effects	-	35	I
induced	-	43	O
by	-	51	O
serotonin	-	54	O
reuptake	-	64	O
blockers	-	73	O
.	-	81	O

BACKGROUND	1535072	83	O
:	-	93	O

Preclinical	1535072	95	O
and	-	107	O
clinical	-	111	O
studies	-	120	O
suggest	-	128	O
that	-	136	O
yohimbine	-	141	O
facilitates	-	151	O
sexual	-	163	O
behavior	-	170	O
and	-	179	O
may	-	183	O
be	-	187	O
helpful	-	190	O
in	-	198	O
the	-	201	O
treatment	-	205	O
of	-	215	O
male	-	218	B
impotence	-	223	I
.	-	232	O

A	1535072	234	O
single	-	236	O
case	-	243	O
report	-	248	O
suggests	-	255	O
that	-	264	O
yohimbine	-	269	O
may	-	279	O
be	-	283	O
used	-	286	O
to	-	291	O
treat	-	294	O
the	-	300	O
sexual	-	304	B
side	-	311	I
effects	-	316	I
of	-	324	O
clomipramine	-	327	O
.	-	339	O

This	1535072	341	O
study	-	346	O
evaluated	-	352	O
yohimbine	-	362	O
as	-	372	O
a	-	375	O
treatment	-	377	O
for	-	387	O
the	-	391	O
sexual	-	395	B
side	-	402	I
effects	-	407	I
caused	-	415	O
by	-	422	O
serotonin	-	425	O
reuptake	-	435	O
blockers	-	444	O
.	-	452	O

METHOD	1535072	454	O
:	-	460	O

Six	1535072	462	O
patients	-	466	O
with	-	475	O
either	-	480	O
obsessive	-	487	B
compulsive	-	497	I
disorder	-	508	I
,	-	516	O
trichotillomania	-	518	B
,	-	534	O
anxiety	-	536	B
,	-	543	O
or	-	545	O
affective	-	548	B
disorders	-	558	I
who	-	568	O
suffered	-	572	O
sexual	-	581	B
side	-	588	I
effects	-	593	I
after	-	601	O
treatment	-	607	O
with	-	617	O
serotonin	-	622	O
reuptake	-	632	O
blockers	-	641	O
were	-	650	O
given	-	655	O
yohimbine	-	661	O
on	-	671	O
a	-	674	O
p	-	676	O
.	-	677	O
r	-	678	O
.	-	679	O
n	-	680	O
.	-	681	O
basis	-	683	O
in	-	689	O
an	-	692	O
open	-	695	O
clinical	-	700	O
trial	-	709	O
.	-	714	O

Various	1535072	716	O
doses	-	724	O
of	-	730	O
yohimbine	-	733	O
were	-	743	O
used	-	748	O
to	-	753	O
determine	-	756	O
the	-	766	O
ideal	-	770	O
dose	-	776	O
for	-	781	O
each	-	785	O
patient	-	790	O
.	-	797	O

RESULTS	1535072	799	O
:	-	806	O

Five	1535072	808	O
of	-	813	O
the	-	816	O
six	-	820	O
patients	-	824	O
experienced	-	833	O
improved	-	845	O
sexual	-	854	O
functioning	-	861	O
after	-	873	O
taking	-	879	O
yohimbine	-	886	O
.	-	895	O

One	1535072	897	O
patient	-	901	O
who	-	909	O
failed	-	913	O
to	-	920	O
comply	-	923	O
with	-	930	O
yohimbine	-	935	O
treatment	-	945	O
had	-	955	O
no	-	959	O
therapeutic	-	962	O
effects	-	974	O
.	-	981	O

Side	1535072	983	O
effects	-	988	O
of	-	996	O
yohimbine	-	999	O
included	-	1009	O
excessive	-	1018	O
sweating	-	1028	O
,	-	1036	O
increased	-	1038	O
anxiety	-	1048	B
,	-	1055	O
and	-	1057	O
a	-	1061	O
wound	-	1063	O
-	-	1068	O
up	-	1069	O
feeling	-	1072	O
in	-	1080	O
some	-	1083	O
patients	-	1088	O
.	-	1096	O

CONCLUSION	1535072	1098	O
:	-	1108	O

The	1535072	1110	O
results	-	1114	O
of	-	1122	O
this	-	1125	O
study	-	1130	O
indicate	-	1136	O
that	-	1145	O
yohimbine	-	1150	O
may	-	1160	O
be	-	1164	O
an	-	1167	O
effective	-	1170	O
treatment	-	1180	O
for	-	1190	O
the	-	1194	O
sexual	-	1198	B
side	-	1205	I
effects	-	1210	I
caused	-	1218	O
by	-	1225	O
serotonin	-	1228	O
reuptake	-	1238	O
blockers	-	1247	O
.	-	1255	O

Future	1535072	1257	O
controlled	-	1264	O
studies	-	1275	O
are	-	1283	O
needed	-	1287	O
to	-	1294	O
further	-	1297	O
investigate	-	1305	O
the	-	1317	O
effectiveness	-	1321	O
and	-	1335	O
safety	-	1339	O
of	-	1346	O
yohimbine	-	1349	O
for	-	1359	O
this	-	1363	O
indication	-	1368	O
.	-	1378	O

Hypersensitivity	1504402	0	B
immune	-	17	O
reaction	-	24	O
as	-	33	O
a	-	36	O
mechanism	-	38	O
for	-	48	O
dilevalol	-	52	O
-	-	61	O
associated	-	62	O
hepatitis	-	73	B
.	-	82	O

OBJECTIVE	1504402	84	O
:	-	93	O
To	-	95	O
assess	-	98	O
lymphocyte	-	105	O
reactivity	-	116	O
to	-	127	O
dilevalol	-	130	O
and	-	140	O
to	-	144	O
serum	-	147	O
containing	-	153	O
putative	-	164	O
ex	-	173	O
vivo	-	176	O
dilevalol	-	181	O
antigens	-	191	O
or	-	200	O
metabolites	-	203	O
in	-	215	O
a	-	218	O
case	-	220	O
of	-	225	O
dilevalol	-	228	O
-	-	237	O
induced	-	238	O
liver	-	246	B
injury	-	252	I
.	-	258	O

PATIENT	1504402	260	O
:	-	267	O

A	1504402	269	O
58	-	271	O
-	-	273	O
year	-	274	O
-	-	278	O
old	-	279	O
woman	-	283	O
with	-	289	O
a	-	294	O
clinical	-	296	O
diagnosis	-	305	O
of	-	315	O
dilevalol	-	318	O
-	-	327	O
induced	-	328	O
liver	-	336	B
injury	-	342	I
.	-	348	O

METHODS	1504402	350	O
:	-	357	O

Peripheral	1504402	359	O
blood	-	370	O
mononuclear	-	376	O
cells	-	388	O
collected	-	394	O
from	-	404	O
the	-	409	O
patient	-	413	O
were	-	421	O
cultured	-	426	O
in	-	435	O
the	-	438	O
presence	-	442	O
of	-	451	O
a	-	454	O
solution	-	456	O
of	-	465	O
dilevalol	-	468	O
and	-	478	O
also	-	482	O
with	-	487	O
sera	-	492	O
collected	-	497	O
from	-	507	O
a	-	512	O
volunteer	-	514	O
before	-	524	O
and	-	531	O
after	-	535	O
dilevalol	-	541	O
intake	-	551	O
.	-	557	O

A	1504402	559	O
similar	-	561	O
protocol	-	569	O
was	-	578	O
performed	-	582	O
with	-	592	O
lymphocytes	-	597	O
from	-	609	O
a	-	614	O
healthy	-	616	O
subject	-	624	O
.	-	631	O

RESULTS	1504402	633	O
:	-	640	O

No	1504402	642	O
lymphocyte	-	645	O
proliferation	-	656	O
was	-	670	O
observed	-	674	O
either	-	683	O
in	-	690	O
the	-	693	O
patient	-	697	O
or	-	705	O
in	-	708	O
the	-	711	O
healthy	-	715	O
volunteer	-	723	O
in	-	733	O
the	-	736	O
presence	-	740	O
of	-	749	O
dilevalol	-	752	O
solutions	-	762	O
.	-	771	O

A	1504402	773	O
significant	-	775	O
proliferative	-	787	O
response	-	801	O
to	-	810	O
serum	-	813	O
collected	-	819	O
after	-	829	O
dilevalol	-	835	O
intake	-	845	O
was	-	852	O
observed	-	856	O
in	-	865	O
the	-	868	O
case	-	872	O
of	-	877	O
the	-	880	O
patient	-	884	O
compared	-	892	O
with	-	901	O
the	-	906	O
proliferative	-	910	O
response	-	924	O
to	-	933	O
the	-	936	O
serum	-	940	O
collected	-	946	O
before	-	956	O
the	-	963	O
drug	-	967	O
intake	-	972	O
.	-	978	O

No	1504402	980	O
reactivity	-	983	O
was	-	994	O
found	-	998	O
when	-	1004	O
lymphocytes	-	1009	O
from	-	1021	O
the	-	1026	O
healthy	-	1030	O
subject	-	1038	O
were	-	1046	O
tested	-	1051	O
under	-	1058	O
similar	-	1064	O
conditions	-	1072	O
.	-	1082	O

CONCLUSIONS	1504402	1084	O
:	-	1095	O

The	1504402	1097	O
methodology	-	1101	O
used	-	1113	O
allowed	-	1118	O
the	-	1126	O
detection	-	1130	O
of	-	1140	O
lymphocyte	-	1143	O
sensitization	-	1154	O
to	-	1168	O
sera	-	1171	O
containing	-	1176	O
ex	-	1187	O
vivo	-	1190	O
-	-	1194	O
prepared	-	1195	O
dilevalol	-	1204	O
antigens	-	1214	O
,	-	1222	O
suggesting	-	1224	O
the	-	1235	O
involvement	-	1239	O
of	-	1251	O
an	-	1254	O
immunologic	-	1257	O
mechanism	-	1269	O
in	-	1279	O
dilevalol	-	1282	O
-	-	1291	O
induced	-	1292	O
liver	-	1300	B
injury	-	1306	I
.	-	1312	O

Reversible	19917396	0	O
myocardial	-	11	B
hypertrophy	-	22	I
induced	-	34	O
by	-	42	O
tacrolimus	-	45	O
in	-	56	O
a	-	59	O
pediatric	-	61	O
heart	-	71	O
transplant	-	77	O
recipient	-	88	O
:	-	97	O
case	-	99	O
report	-	104	O
.	-	110	O

Tacrolimus	19917396	112	O
is	-	123	O
a	-	126	O
potent	-	128	O
immunosuppressant	-	135	O
that	-	153	O
is	-	158	O
frequently	-	161	O
used	-	172	O
in	-	177	O
organ	-	180	O
transplantation	-	186	O
.	-	201	O

However	19917396	203	O
,	-	210	O
adverse	-	212	O
effects	-	220	O
include	-	228	O
cardiac	-	236	B
toxicity	-	244	I
.	-	252	O

Herein	19917396	254	O
we	-	261	O
describe	-	264	O
transient	-	273	O
myocardial	-	283	B
hypertrophy	-	294	I
induced	-	306	O
by	-	314	O
tacrolimus	-	317	O
after	-	328	O
heart	-	334	O
transplantation	-	340	O
.	-	355	O

The	19917396	357	O
hypertrophy	-	361	B
caused	-	373	O
no	-	380	O
clinical	-	383	O
symptoms	-	392	O
but	-	401	O
was	-	405	O
noted	-	409	O
because	-	415	O
of	-	423	O
elevation	-	426	O
of	-	436	O
plasma	-	439	O
brain	-	446	O
natriuretic	-	452	O
peptide	-	464	O
concentration	-	472	O
and	-	486	O
confirmed	-	490	O
at	-	500	O
echocardiography	-	503	O
.	-	519	O

Initially	19917396	521	O
,	-	530	O
allograft	-	532	O
rejection	-	542	O
was	-	552	O
feared	-	556	O
;	-	562	O
however	-	564	O
,	-	571	O
myocardial	-	573	O
biopsy	-	584	O
samples	-	591	O
revealed	-	599	O
only	-	608	O
interstitial	-	613	O
edema	-	626	B
and	-	632	O
mild	-	636	O
myocardial	-	641	B
hypertrophy	-	652	I
;	-	663	O
neither	-	665	O
cellular	-	673	O
nor	-	682	O
humoral	-	686	O
rejection	-	694	O
was	-	704	O
detected	-	708	O
.	-	716	O

The	19917396	718	O
blood	-	722	O
tacrolimus	-	728	O
concentration	-	739	O
was	-	753	O
higher	-	757	O
than	-	764	O
usual	-	769	O
at	-	775	O
that	-	778	O
time	-	783	O
;	-	787	O
thus	-	789	O
,	-	793	O
tacrolimus	-	795	O
dosage	-	806	O
was	-	813	O
reduced	-	817	O
.	-	824	O

Myocardial	19917396	826	B
hypertrophy	-	837	I
completely	-	849	O
resolved	-	860	O
upon	-	869	O
reducing	-	874	O
the	-	883	O
target	-	887	O
concentration	-	894	O
of	-	908	O
tacrolimus	-	911	O
and	-	922	O
did	-	926	O
not	-	930	O
recur	-	934	O
,	-	939	O
as	-	941	O
confirmed	-	944	O
at	-	954	O
echocardiography	-	957	O
and	-	974	O
myocardial	-	978	O
biopsy	-	989	O
.	-	995	O

Thus	19917396	997	O
,	-	1001	O
we	-	1003	O
conclude	-	1006	O
that	-	1015	O
tacrolimus	-	1020	O
induces	-	1031	O
reversible	-	1039	O
myocardial	-	1050	B
hypertrophy	-	1061	I
.	-	1072	O

In	19917396	1074	O
patients	-	1077	O
receiving	-	1086	O
tacrolimus	-	1096	O
therapy	-	1107	O
,	-	1114	O
blood	-	1116	O
concentration	-	1122	O
should	-	1136	O
be	-	1143	O
carefully	-	1146	O
controlled	-	1156	O
and	-	1167	O
extreme	-	1171	O
attention	-	1179	O
paid	-	1189	O
to	-	1194	O
cardiac	-	1197	O
involvement	-	1205	O
.	-	1216	O

Comparison	19234905	0	O
of	-	11	O
unilateral	-	14	O
pallidotomy	-	25	O
and	-	37	O
subthalamotomy	-	41	O
findings	-	56	O
in	-	65	O
advanced	-	68	O
idiopathic	-	77	B
Parkinson	-	88	I
's	-	97	I
disease	-	100	I
.	-	107	O

A	19234905	109	O
prospective	-	111	O
,	-	122	O
randomized	-	124	O
,	-	134	O
double	-	136	O
-	-	142	O
blind	-	143	O
pilot	-	149	O
study	-	155	O
to	-	161	O
compare	-	164	O
the	-	172	O
results	-	176	O
of	-	184	O
stereotactic	-	187	O
unilateral	-	200	O
pallidotomy	-	211	O
and	-	223	O
subthalamotomy	-	227	O
in	-	242	O
advanced	-	245	O
idiopathic	-	254	B
Parkinson	-	265	I
's	-	274	I
disease	-	277	I
(	-	285	O
PD	-	286	B
)	-	288	O
refractory	-	290	O
to	-	301	O
medical	-	304	O
treatment	-	312	O
was	-	322	O
designed	-	326	O
.	-	334	O

Ten	19234905	336	O
consecutive	-	340	O
patients	-	352	O
(	-	361	O
mean	-	362	O
age	-	367	O
,	-	370	O
58	-	372	O
.	-	374	O
4	-	375	O
+	-	377	O
/	-	378	O
-	-	379	O

6	19234905	381	O
.	-	382	O
8	-	383	O
years	-	385	O
;	-	390	O
7	-	392	O
men	-	394	O
,	-	397	O
3	-	399	O
women	-	401	O
)	-	406	O
with	-	408	O
similar	-	413	O
characteristics	-	421	O
at	-	437	O
the	-	440	O
duration	-	444	O
of	-	453	O
disease	-	456	O
(	-	464	O
mean	-	465	O
disease	-	470	O
time	-	478	O
,	-	482	O
8	-	484	O
.	-	485	O
4	-	486	O
+	-	488	O
/	-	489	O
-	-	490	O

3	19234905	492	O
.	-	493	O
5	-	494	O
years	-	496	O
)	-	501	O
,	-	502	O
disabling	-	504	O
motor	-	514	O
fluctuations	-	520	O
(	-	533	O
Hoehn	-	534	O
_	-	540	O
Yahr	-	542	O
stage	-	547	O
3	-	553	O
-	-	554	O
5	-	555	O
in	-	557	O
off	-	560	O
-	-	563	O
drug	-	564	O
phases	-	569	O
)	-	575	O
and	-	577	O
levodopa	-	581	O
-	-	589	O
induced	-	590	O
dyskinesias	-	598	B
were	-	610	O
selected	-	615	O
.	-	623	O

All	19234905	625	O
patients	-	629	O
had	-	638	O
bilateral	-	642	O
symptoms	-	652	O
and	-	661	O
their	-	665	O
levodopa	-	671	O
equivalent	-	680	O
dosing	-	691	O
were	-	698	O
analysed	-	703	O
.	-	711	O

Six	19234905	713	O
patients	-	717	O
were	-	726	O
operated	-	731	O
on	-	740	O
in	-	743	O
the	-	746	O
globus	-	750	O
pallidus	-	757	O
interna	-	766	O
(	-	774	O
GPi	-	775	O
)	-	778	O
and	-	780	O
four	-	784	O
in	-	789	O
the	-	792	O
subthalamic	-	796	O
nucleus	-	808	O
(	-	816	O
STN	-	817	O
)	-	820	O
.	-	821	O

Clinical	19234905	823	O
evaluation	-	832	O
included	-	843	O
the	-	852	O
use	-	856	O
of	-	860	O
the	-	863	O
Unified	-	867	O
Parkinson	-	875	B
's	-	884	I
Disease	-	887	I
Rating	-	895	O
Scale	-	902	O
(	-	908	O
UPDRS	-	909	O
)	-	914	O
,	-	915	O
Hoehn_Yahr	-	917	O
score	-	928	O
and	-	934	O
Schwab	-	938	O
England	-	945	O
activities	-	953	O
of	-	964	O
daily	-	967	O
living	-	973	O
(	-	980	O
ADL	-	981	O
)	-	984	O
score	-	986	O
in	-	992	O
'	-	995	O
on'	-	996	O
-	-	999	O
and	-	1001	O
'	-	1005	O
off'	-	1006	O
-	-	1010	O
drug	-	1011	O
conditions	-	1016	O
before	-	1027	O
surgery	-	1034	O
and	-	1042	O
6	-	1046	O
months	-	1048	O
after	-	1055	O
surgery	-	1061	O
.	-	1068	O

There	19234905	1070	O
was	-	1076	O
statistically	-	1080	O
significant	-	1094	O
improvement	-	1106	O
in	-	1118	O
all	-	1121	O
contralateral	-	1125	O
major	-	1139	O
parkinsonian	-	1145	B
motor	-	1158	O
signs	-	1164	O
in	-	1170	O
all	-	1173	O
patients	-	1177	O
followed	-	1186	O
for	-	1195	O
6	-	1199	O
months	-	1201	O
.	-	1207	O

Levodopa	19234905	1209	O
equivalent	-	1218	O
daily	-	1229	O
intake	-	1235	O
was	-	1242	O
significantly	-	1246	O
reduced	-	1260	O
in	-	1268	O
the	-	1271	O
STN	-	1275	O
group	-	1279	O
.	-	1284	O

Changes	19234905	1286	O
in	-	1294	O
UPDRS	-	1297	O
,	-	1302	O
Hoehn	-	1304	O
_	-	1310	O
Yahr	-	1312	O
and	-	1317	O
Schwab	-	1321	O
England	-	1328	O
ADL	-	1336	O
scores	-	1340	O
were	-	1347	O
similar	-	1352	O
in	-	1360	O
both	-	1363	O
groups	-	1368	O
.	-	1374	O

Cognitive	19234905	1376	O
functions	-	1386	O
were	-	1396	O
unchanged	-	1401	O
in	-	1411	O
both	-	1414	O
groups	-	1419	O
.	-	1425	O

Complications	19234905	1427	O
were	-	1441	O
observed	-	1446	O
in	-	1455	O
two	-	1458	O
patients	-	1462	O
:	-	1470	O
one	-	1472	O
had	-	1476	O
a	-	1480	O
left	-	1482	O
homonymous	-	1487	B
hemianopsia	-	1498	I
after	-	1510	O
pallidotomy	-	1516	O
and	-	1528	O
another	-	1532	O
one	-	1540	O
developed	-	1544	O
left	-	1554	O
hemiballistic	-	1559	O
movements	-	1573	O
3	-	1583	O
days	-	1585	O
after	-	1590	O
subthalamotomy	-	1596	O
which	-	1611	O
partly	-	1617	O
improved	-	1624	O
within	-	1633	O
1	-	1640	O
month	-	1642	O
with	-	1648	O
Valproate	-	1653	O
1000	-	1663	O
mg	-	1668	O
/	-	1670	O
day	-	1671	O
.	-	1674	O

The	19234905	1676	O
findings	-	1680	O
of	-	1689	O
this	-	1692	O
study	-	1697	O
suggest	-	1703	O
that	-	1711	O
lesions	-	1716	O
of	-	1724	O
the	-	1727	O
unilateral	-	1731	O
STN	-	1742	O
and	-	1746	O
GPi	-	1750	O
are	-	1754	O
equally	-	1758	O
effective	-	1766	O
treatment	-	1776	O
for	-	1786	O
patients	-	1790	O
with	-	1799	O
advanced	-	1804	O
PD	-	1813	B
refractory	-	1816	O
to	-	1827	O
medical	-	1830	O
treatment	-	1838	O
.	-	1847	O

Protective	18541230	0	O
effects	-	11	O
of	-	19	O
antithrombin	-	22	O
on	-	35	O
puromycin	-	38	O
aminonucleoside	-	48	O
nephrosis	-	64	B
in	-	74	O
rats	-	77	O
.	-	81	O

We	18541230	83	O
investigated	-	86	O
the	-	99	O
effects	-	103	O
of	-	111	O
antithrombin	-	114	O
,	-	126	O
a	-	128	O
plasma	-	130	O
inhibitor	-	137	O
of	-	147	O
coagulation	-	150	O
factors	-	162	O
,	-	169	O
in	-	171	O
rats	-	174	O
with	-	179	O
puromycin	-	184	O
aminonucleoside	-	194	O
-	-	209	O
induced	-	210	O
nephrosis	-	218	B
,	-	227	O
which	-	229	O
is	-	235	O
an	-	238	O
experimental	-	241	O
model	-	254	O
of	-	260	O
human	-	263	O
nephrotic	-	269	B
syndrome	-	279	I
.	-	287	O

Antithrombin	18541230	289	O
(	-	302	O
50	-	303	O
or	-	306	O
500	-	309	O
IU	-	313	O
/	-	315	O
kg	-	316	O
/	-	318	O
i	-	319	O
.	-	320	O
v	-	321	O
.	-	322	O
)	-	323	O
was	-	325	O
administered	-	329	O
to	-	342	O
rats	-	345	O
once	-	350	O
a	-	355	O
day	-	357	O
for	-	361	O
10	-	365	O
days	-	368	O
immediately	-	373	O
after	-	385	O
the	-	391	O
injection	-	395	O
of	-	405	O
puromycin	-	408	O
aminonucleoside	-	418	O
(	-	434	O
50	-	435	O
mg	-	438	O
/	-	440	O
kg	-	441	O
/	-	443	O
i	-	444	O
.	-	445	O
v	-	446	O
.	-	447	O
)	-	448	O
.	-	449	O

Treatment	18541230	451	O
with	-	461	O
antithrombin	-	466	O
attenuated	-	479	O
the	-	490	O
puromycin	-	494	O
aminonucleoside	-	504	O
-	-	519	O
induced	-	520	O
hematological	-	528	B
abnormalities	-	542	I
.	-	555	O

Puromycin	18541230	557	O
aminonucleoside	-	567	O
-	-	582	O
induced	-	583	O
renal	-	591	B
dysfunction	-	597	I
and	-	609	O
hyperlipidemia	-	613	B
were	-	628	O
also	-	633	O
suppressed	-	638	O
.	-	648	O

Histopathological	18541230	650	O
examination	-	668	O
revealed	-	680	O
severe	-	689	O
renal	-	696	B
damage	-	702	I
such	-	709	O
as	-	714	O
proteinaceous	-	717	O
casts	-	731	O
in	-	737	O
tubuli	-	740	O
and	-	747	O
tubular	-	751	O
expansion	-	759	O
in	-	769	O
the	-	772	O
kidney	-	776	O
of	-	783	O
control	-	786	O
rats	-	794	O
,	-	798	O
while	-	800	O
an	-	806	O
improvement	-	809	O
of	-	821	O
the	-	824	O
damage	-	828	O
was	-	835	O
seen	-	839	O
in	-	844	O
antithrombin	-	847	O
-	-	859	O
treated	-	860	O
rats	-	868	O
.	-	872	O

In	18541230	874	O
addition	-	877	O
,	-	885	O
antithrombin	-	887	O
treatment	-	900	O
markedly	-	910	O
suppressed	-	919	O
puromycin	-	930	O
aminonucleoside	-	940	O
-	-	955	O
induced	-	956	O
apoptosis	-	964	O
of	-	974	O
renal	-	977	O
tubular	-	983	O
epithelial	-	991	O
cells	-	1002	O
.	-	1007	O

Furthermore	18541230	1009	O
,	-	1020	O
puromycin	-	1022	O
aminonucleoside	-	1032	O
-	-	1047	O
induced	-	1048	O
increases	-	1056	O
in	-	1066	O
renal	-	1069	O
cytokine	-	1075	O
content	-	1084	O
were	-	1092	O
also	-	1097	O
decreased	-	1102	O
.	-	1111	O

These	18541230	1113	O
findings	-	1119	O
suggest	-	1128	O
that	-	1136	O
thrombin	-	1141	O
plays	-	1150	O
an	-	1156	O
important	-	1159	O
role	-	1169	O
in	-	1174	O
the	-	1177	O
pathogenesis	-	1181	O
of	-	1194	O
puromycin	-	1197	O
aminonucleoside	-	1207	O
-	-	1222	O
induced	-	1223	O
nephrotic	-	1231	B
syndrome	-	1241	I
.	-	1249	O

Treatment	18541230	1251	O
with	-	1261	O
antithrombin	-	1266	O
may	-	1279	O
be	-	1283	O
clinically	-	1286	O
effective	-	1297	O
in	-	1307	O
patients	-	1310	O
with	-	1319	O
nephrotic	-	1324	B
syndrome	-	1334	I
.	-	1342	O

Reverse	18177388	0	O
or	-	8	O
inverted	-	11	O
left	-	20	B
ventricular	-	25	I
apical	-	37	I
ballooning	-	44	I
syndrome	-	55	I
(	-	64	O
reverse	-	65	O
Takotsubo	-	73	B
cardiomyopathy	-	83	I
)	-	97	O
in	-	99	O
a	-	102	O
young	-	104	O
woman	-	110	O
in	-	116	O
the	-	119	O
setting	-	123	O
of	-	131	O
amphetamine	-	134	O
use	-	146	O
.	-	149	O

Transient	18177388	151	O
left	-	161	B
ventricular	-	166	I
apical	-	178	I
ballooning	-	185	I
syndrome	-	196	I
was	-	205	O
first	-	209	O
described	-	215	O
in	-	225	O
Japan	-	228	O
as	-	234	O
""""	-	237	O
Takotsubo	-	238	B
cardiomyopathy	-	248	I
.	-	262	O
""""	-	263	O

This	18177388	265	O
syndrome	-	270	O
has	-	279	O
been	-	283	O
identified	-	288	O
in	-	299	O
many	-	302	O
other	-	307	O
countries	-	313	O
.	-	322	O

Many	18177388	324	O
variations	-	329	O
of	-	340	O
this	-	343	O
syndrome	-	348	O
have	-	357	O
been	-	362	O
recently	-	367	O
described	-	376	O
in	-	386	O
the	-	389	O
literature	-	393	O
.	-	403	O

One	18177388	405	O
of	-	409	O
the	-	412	O
rarest	-	416	O
is	-	423	O
the	-	426	O
reverse	-	430	O
type	-	438	O
of	-	443	O
this	-	446	O
syndrome	-	451	O
,	-	459	O
with	-	461	O
hyperdynamic	-	466	O
apex	-	479	O
and	-	484	O
complete	-	488	O
akinesia	-	497	B
of	-	506	O
the	-	509	O
base	-	513	O
(	-	518	O
as	-	519	O
opposed	-	522	O
to	-	530	O
the	-	533	O
classic	-	537	O
apical	-	545	B
ballooning	-	552	I
)	-	562	O
.	-	563	O

In	18177388	565	O
this	-	568	O
article	-	573	O
,	-	580	O
we	-	582	O
report	-	585	O
an	-	592	O
interesting	-	595	O
case	-	607	O
of	-	612	O
a	-	615	O
young	-	617	O
woman	-	623	O
who	-	629	O
presented	-	633	O
with	-	643	O
this	-	648	O
rare	-	653	O
type	-	658	O
of	-	663	O
reverse	-	666	O
apical	-	674	B
ballooning	-	681	I
syndrome	-	692	I
occurring	-	701	O
after	-	711	O
amphetamine	-	717	O
use	-	729	O
.	-	732	O

This	18177388	734	O
report	-	739	O
is	-	746	O
followed	-	749	O
by	-	758	O
review	-	761	O
of	-	768	O
the	-	771	O
literature	-	775	O
.	-	785	O

Attenuated	17490864	0	O
disruption	-	11	O
of	-	22	O
prepulse	-	25	O
inhibition	-	34	O
by	-	45	O
dopaminergic	-	48	O
stimulation	-	61	O
after	-	73	O
maternal	-	79	O
deprivation	-	88	O
and	-	100	O
adolescent	-	104	O
corticosterone	-	115	O
treatment	-	130	O
in	-	140	O
rats	-	143	O
.	-	147	O

The	17490864	149	O
development	-	153	O
of	-	165	O
schizophrenia	-	168	B
may	-	182	O
include	-	186	O
an	-	194	O
early	-	197	O
neurodevelopmental	-	203	O
stress	-	222	O
component	-	229	O
which	-	239	O
increases	-	245	O
vulnerability	-	255	O
to	-	269	O
later	-	272	O
stressful	-	278	O
life	-	288	O
events	-	293	O
,	-	299	O
in	-	301	O
combination	-	304	O
leading	-	316	O
to	-	324	O
overt	-	327	O
disease	-	333	O
.	-	340	O

We	17490864	342	O
investigated	-	345	O
the	-	358	O
effect	-	362	O
of	-	369	O
an	-	372	O
early	-	375	O
stress	-	381	O
,	-	387	O
in	-	389	O
the	-	392	O
form	-	396	O
of	-	401	O
maternal	-	404	O
deprivation	-	413	O
,	-	424	O
combined	-	426	O
with	-	435	O
a	-	440	O
later	-	442	O
stress	-	448	O
,	-	454	O
simulated	-	456	O
by	-	466	O
chronic	-	469	O
periadolescent	-	477	O
corticosterone	-	492	O
treatment	-	507	O
,	-	516	O
on	-	518	O
behaviour	-	521	O
in	-	531	O
rats	-	534	O
.	-	538	O

Acute	17490864	540	O
treatment	-	546	O
with	-	556	O
apomorphine	-	561	O
caused	-	573	O
disruption	-	580	O
of	-	591	O
prepulse	-	594	O
inhibition	-	603	O
(	-	614	O
PPI	-	615	O
)	-	618	O
in	-	620	O
controls	-	623	O
and	-	632	O
in	-	636	O
rats	-	639	O
that	-	644	O
had	-	649	O
undergone	-	653	O
either	-	663	O
maternal	-	670	O
deprivation	-	679	O
or	-	691	O
corticosterone	-	694	O
treatment	-	709	O
,	-	718	O
but	-	720	O
was	-	724	O
surprisingly	-	728	O
absent	-	741	O
in	-	748	O
rats	-	751	O
that	-	756	O
had	-	761	O
undergone	-	765	O
the	-	775	O
combined	-	779	O
early	-	788	O
and	-	794	O
late	-	798	O
stress	-	803	O
.	-	809	O

Amphetamine	17490864	811	O
treatment	-	823	O
significantly	-	833	O
disrupted	-	847	O
PPI	-	857	O
in	-	861	O
both	-	864	O
non	-	869	O
-	-	872	O
deprived	-	873	O
groups	-	882	O
,	-	888	O
but	-	890	O
was	-	894	O
absent	-	898	O
in	-	905	O
both	-	908	O
maternally	-	913	O
deprived	-	924	O
groups	-	933	O
.	-	939	O

The	17490864	941	O
serotonin	-	945	O
-	-	954	O
1A	-	955	O
receptor	-	958	O
agonist	-	967	O
,	-	974	O
8	-	976	O
-	-	977	O
OH	-	978	O
-	-	980	O
DPAT	-	981	O
,	-	985	O
induced	-	987	O
a	-	995	O
significant	-	997	O
disruption	-	1009	O
of	-	1020	O
PPI	-	1023	O
in	-	1027	O
all	-	1030	O
groups	-	1034	O
.	-	1040	O

Amphetamine	17490864	1042	O
-	-	1053	O
induced	-	1054	O
locomotor	-	1062	B
hyperactivity	-	1072	I
was	-	1086	O
similar	-	1090	O
in	-	1098	O
all	-	1101	O
groups	-	1105	O
.	-	1111	O

These	17490864	1113	O
results	-	1119	O
show	-	1127	O
an	-	1132	O
inhibitory	-	1135	O
interaction	-	1146	O
of	-	1158	O
early	-	1161	O
stress	-	1167	O
,	-	1173	O
caused	-	1175	O
by	-	1182	O
maternal	-	1185	O
deprivation	-	1194	O
,	-	1205	O
combined	-	1207	O
with	-	1216	O
'	-	1221	O
adolescent	-	1222	O
'	-	1232	O
stress	-	1234	O
,	-	1240	O
simulated	-	1242	O
by	-	1252	O
corticosterone	-	1255	O
treatment	-	1270	O
,	-	1279	O
on	-	1281	O
dopaminergic	-	1284	O
regulation	-	1297	O
of	-	1308	O
PPI	-	1311	O
.	-	1314	O

The	17490864	1316	O
altered	-	1320	O
effects	-	1328	O
of	-	1336	O
apomorphine	-	1339	O
and	-	1351	O
amphetamine	-	1355	O
could	-	1367	O
indicate	-	1373	O
differential	-	1382	O
changes	-	1395	O
in	-	1403	O
dopamine	-	1406	O
receptor	-	1415	O
signalling	-	1424	O
leading	-	1435	O
to	-	1443	O
functional	-	1446	O
desensitisation	-	1457	O
,	-	1472	O
or	-	1474	O
altered	-	1477	O
modulation	-	1485	O
of	-	1496	O
sensory	-	1499	O
gating	-	1507	O
in	-	1514	O
the	-	1517	O
nucleus	-	1521	O
accumbens	-	1529	O
by	-	1539	O
limbic	-	1542	O
structures	-	1549	O
such	-	1560	O
as	-	1565	O
the	-	1568	O
hippocampus	-	1572	O
.	-	1583	O

Peripheral	17490790	0	O
iron	-	11	O
dextran	-	16	O
induced	-	24	O
degeneration	-	32	B
of	-	45	I
dopaminergic	-	48	I
neurons	-	61	I
in	-	69	O
rat	-	72	O
substantia	-	76	O
nigra	-	87	O
.	-	92	O

Iron	17490790	94	O
accumulation	-	99	O
is	-	112	O
considered	-	115	O
to	-	126	O
be	-	129	O
involved	-	132	O
in	-	141	O
the	-	144	O
pathogenesis	-	148	O
of	-	161	O
Parkinson	-	164	B
's	-	173	I
disease	-	176	I
.	-	183	O

To	17490790	185	O
demonstrate	-	188	O
the	-	200	O
relationship	-	204	O
between	-	217	O
peripheral	-	225	O
iron	-	236	O
overload	-	241	O
and	-	250	O
dopaminergic	-	254	O
neuron	-	267	O
loss	-	274	O
in	-	279	O
rat	-	282	O
substantia	-	286	O
nigra	-	297	O
(	-	303	O
SN	-	304	O
)	-	306	O
,	-	307	O
in	-	309	O
the	-	312	O
present	-	316	O
study	-	324	O
we	-	330	O
used	-	333	O
fast	-	338	O
cyclic	-	343	O
voltammetry	-	350	O
,	-	361	O
tyrosine	-	363	O
hydroxylase	-	372	O
(	-	384	O
TH	-	385	O
)	-	387	O
immunohistochemistry	-	389	O
,	-	409	O
Perls	-	411	O
'	-	416	O
iron	-	418	O
staining	-	423	O
,	-	431	O
and	-	433	O
high	-	437	O
performance	-	442	O
liquid	-	454	O
chromatography	-	461	O
-	-	475	O
electrochemical	-	476	O
detection	-	492	O
to	-	502	O
study	-	505	O
the	-	511	O
degeneration	-	515	B
of	-	528	I
dopaminergic	-	531	I
neurons	-	544	I
and	-	552	O
increased	-	556	O
iron	-	566	O
content	-	571	O
in	-	579	O
the	-	582	O
SN	-	586	O
of	-	589	O
iron	-	592	O
dextran	-	597	O
overloaded	-	605	O
animals	-	616	O
.	-	623	O

The	17490790	625	O
findings	-	629	O
showed	-	638	O
that	-	645	O
peripheral	-	650	O
iron	-	661	O
dextran	-	666	O
overload	-	674	O
increased	-	683	O
the	-	693	O
iron	-	697	O
staining	-	702	O
positive	-	711	O
cells	-	720	O
and	-	726	O
reduced	-	730	O
the	-	738	O
number	-	742	O
of	-	749	O
TH	-	752	O
-	-	754	O
immunoreactive	-	755	O
neurons	-	770	O
in	-	778	O
the	-	781	O
SN	-	785	O
.	-	787	O

As	17490790	789	O
a	-	792	O
result	-	794	O
,	-	800	O
dopamine	-	802	O
release	-	811	O
and	-	819	O
content	-	823	O
,	-	830	O
as	-	832	O
well	-	835	O
as	-	840	O
its	-	843	O
metabolites	-	847	O
contents	-	859	O
were	-	868	O
decreased	-	873	O
in	-	883	O
caudate	-	886	O
putamen	-	894	O
.	-	901	O

Even	17490790	903	O
more	-	908	O
dramatic	-	913	O
changes	-	922	O
were	-	930	O
found	-	935	O
in	-	941	O
chronic	-	944	O
overload	-	952	O
group	-	961	O
.	-	966	O

These	17490790	968	O
results	-	974	O
suggest	-	982	O
that	-	990	O
peripheral	-	995	O
iron	-	1006	O
dextran	-	1011	O
can	-	1019	O
increase	-	1023	O
the	-	1032	O
iron	-	1036	O
level	-	1041	O
in	-	1047	O
the	-	1050	O
SN	-	1054	O
,	-	1056	O
where	-	1058	O
excessive	-	1064	O
iron	-	1074	O
causes	-	1079	O
the	-	1086	O
degeneration	-	1090	B
of	-	1103	I
dopaminergic	-	1106	I
neurons	-	1119	I
.	-	1126	O

The	17490790	1128	O
chronic	-	1132	O
iron	-	1140	O
overload	-	1145	O
may	-	1154	O
be	-	1158	O
more	-	1161	O
destructive	-	1166	O
to	-	1178	O
dopaminergic	-	1181	O
neurons	-	1194	O
than	-	1202	O
the	-	1207	O
acute	-	1211	O
iron	-	1217	O
overload	-	1222	O
.	-	1230	O

Warfarin	16047871	0	O
-	-	8	O
induced	-	9	O
leukocytoclastic	-	17	B
vasculitis	-	34	I
.	-	44	O

Skin	16047871	46	O
reactions	-	51	O
associated	-	61	O
with	-	72	O
oral	-	77	O
coumarin	-	82	O
-	-	90	O
derived	-	91	O
anticoagulants	-	99	O
are	-	114	O
an	-	118	O
uncommon	-	121	O
occurrence	-	130	O
.	-	140	O

Leukocytoclastic	16047871	142	B
vasculitis	-	159	I
(	-	170	O
LV	-	171	B
)	-	173	O
is	-	175	O
primarily	-	178	O
a	-	188	O
cutaneous	-	190	B
small	-	200	I
vessel	-	206	I
vasculitis	-	213	I
,	-	223	O
though	-	225	O
systemic	-	232	O
involvement	-	241	O
may	-	253	O
be	-	257	O
encountered	-	260	O
.	-	271	O

We	16047871	273	O
report	-	276	O
4	-	283	O
patients	-	285	O
with	-	294	O
late	-	299	O
-	-	303	O
onset	-	304	O
LV	-	310	B
probably	-	313	O
due	-	322	O
to	-	326	O
warfarin	-	329	O
.	-	337	O

All	16047871	339	O
4	-	343	O
patients	-	345	O
presented	-	354	O
with	-	364	O
skin	-	369	B
eruptions	-	374	I
that	-	384	O
developed	-	389	O
after	-	399	O
receiving	-	405	O
warfarin	-	415	O
for	-	424	O
several	-	428	O
years	-	436	O
.	-	441	O

The	16047871	443	O
results	-	447	O
of	-	455	O
skin	-	458	B
lesion	-	463	I
biopsies	-	470	O
were	-	479	O
available	-	484	O
in	-	494	O
3	-	497	O
patients	-	499	O
,	-	507	O
confirming	-	509	O
LV	-	520	B
Cutaneous	-	523	I
lesions	-	533	I
resolved	-	541	O
in	-	550	O
all	-	553	O
patients	-	557	O
after	-	566	O
warfarin	-	572	O
was	-	581	O
discontinued	-	585	O
.	-	597	O

In	16047871	599	O
2	-	602	O
of	-	604	O
the	-	607	O
4	-	611	O
patients	-	613	O
,	-	621	O
rechallenge	-	623	O
with	-	635	O
warfarin	-	640	O
led	-	649	O
to	-	653	O
recurrence	-	656	O
of	-	667	O
the	-	670	O
lesions	-	674	O
.	-	681	O

LV	16047871	683	B
may	-	686	O
be	-	690	O
a	-	693	O
late	-	695	O
-	-	699	O
onset	-	700	O
adverse	-	706	O
reaction	-	714	O
associated	-	723	O
with	-	734	O
warfarin	-	739	O
therapy	-	748	O
.	-	755	O

The	15673851	0	O
activation	-	4	O
of	-	15	O
spinal	-	18	O
N	-	25	O
-	-	26	O
methyl	-	27	O
-	-	33	O
D	-	34	O
-	-	35	O
aspartate	-	36	O
receptors	-	46	O
may	-	56	O
contribute	-	60	O
to	-	71	O
degeneration	-	74	O
of	-	87	O
spinal	-	90	O
motor	-	97	O
neurons	-	103	O
induced	-	111	O
by	-	119	O
neuraxial	-	122	O
morphine	-	132	O
after	-	141	O
a	-	147	O
noninjurious	-	149	O
interval	-	162	O
of	-	171	O
spinal	-	174	B
cord	-	181	I
ischemia	-	186	I
.	-	194	O

We	15673851	196	O
investigated	-	199	O
the	-	212	O
relationship	-	216	O
between	-	229	O
the	-	237	O
degeneration	-	241	O
of	-	254	O
spinal	-	257	O
motor	-	264	O
neurons	-	270	O
and	-	278	O
activation	-	282	O
of	-	293	O
N	-	296	O
-	-	297	O
methyl	-	298	O
-	-	304	O
d	-	305	O
-	-	306	O
aspartate	-	307	O
(	-	317	O
NMDA	-	318	O
)	-	322	O
receptors	-	324	O
after	-	334	O
neuraxial	-	340	O
morphine	-	350	O
following	-	359	O
a	-	369	O
noninjurious	-	371	O
interval	-	384	O
of	-	393	O
aortic	-	396	B
occlusion	-	403	I
in	-	413	O
rats	-	416	O
.	-	420	O

Spinal	15673851	422	B
cord	-	429	I
ischemia	-	434	I
was	-	443	O
induced	-	447	O
by	-	455	O
aortic	-	458	B
occlusion	-	465	I
for	-	475	O
6	-	479	O
min	-	481	O
with	-	485	O
a	-	490	O
balloon	-	492	O
catheter	-	500	O
.	-	508	O

In	15673851	510	O
a	-	513	O
microdialysis	-	515	O
study	-	529	O
,	-	534	O
10	-	536	O
muL	-	539	O
of	-	543	O
saline	-	546	O
(	-	553	O
group	-	554	O
C	-	560	O
;	-	561	O
n	-	563	O
=	-	565	O
8	-	567	O
)	-	568	O
or	-	570	O
30	-	573	O
mug	-	576	O
of	-	580	O
morphine	-	583	O
(	-	592	O
group	-	593	O
M	-	599	O
;	-	600	O
n	-	602	O
=	-	604	O
8	-	606	O
)	-	607	O
was	-	609	O
injected	-	613	O
intrathecally	-	622	O
(	-	636	O
IT	-	637	O
)	-	639	O
0	-	641	O
.	-	642	O
5	-	643	O
h	-	645	O
after	-	647	O
reflow	-	653	O
,	-	659	O
and	-	661	O
30	-	665	O
mug	-	668	O
of	-	672	O
morphine	-	675	O
(	-	684	O
group	-	685	O
SM	-	691	O
;	-	693	O
n	-	695	O
=	-	697	O
8	-	699	O
)	-	700	O
or	-	702	O
10	-	705	O
muL	-	708	O
of	-	712	O
saline	-	715	O
(	-	722	O
group	-	723	O
SC	-	729	O
;	-	731	O
n	-	733	O
=	-	735	O
8	-	737	O
)	-	738	O
was	-	740	O
injected	-	744	O
IT	-	753	O
0	-	756	O
.	-	757	O
5	-	758	O
h	-	760	O
after	-	762	O
sham	-	768	O
operation	-	773	O
.	-	782	O

Microdialysis	15673851	784	O
samples	-	798	O
were	-	806	O
collected	-	811	O
preischemia	-	821	O
,	-	832	O
before	-	834	O
IT	-	841	O
injection	-	844	O
,	-	853	O
and	-	855	O
at	-	859	O
2	-	862	O
,	-	863	O
4	-	865	O
,	-	866	O
8	-	868	O
,	-	869	O
24	-	871	O
,	-	873	O
and	-	875	O
48	-	879	O
h	-	882	O
of	-	884	O
reperfusion	-	887	O
(	-	899	O
after	-	900	O
IT	-	906	O
injection	-	909	O
)	-	918	O
.	-	919	O

Second	15673851	921	O
,	-	927	O
we	-	929	O
investigated	-	932	O
the	-	945	O
effect	-	949	O
of	-	956	O
IT	-	959	O
MK	-	962	O
-	-	964	O
801	-	965	O
(	-	969	O
30	-	970	O
mug	-	973	O
)	-	976	O
on	-	978	O
the	-	981	O
histopathologic	-	985	O
changes	-	1001	O
in	-	1009	O
the	-	1012	O
spinal	-	1016	O
cord	-	1023	O
after	-	1028	O
morphine	-	1034	O
-	-	1042	O
induced	-	1043	O
spastic	-	1051	B
paraparesis	-	1059	I
.	-	1070	O

After	15673851	1072	O
IT	-	1078	O
morphine	-	1081	O
,	-	1089	O
the	-	1091	O
cerebrospinal	-	1095	O
fluid	-	1109	O
(	-	1115	O
CSF	-	1116	O
)	-	1119	O
glutamate	-	1121	O
concentration	-	1131	O
was	-	1145	O
increased	-	1149	O
in	-	1159	O
group	-	1162	O
M	-	1168	O
relative	-	1170	O
to	-	1179	O
both	-	1182	O
baseline	-	1187	O
and	-	1196	O
group	-	1200	O
C	-	1206	O
(	-	1208	O
P	-	1209	O
<	-	1211	O
0	-	1213	O
.	-	1214	O
05	-	1215	O
)	-	1217	O
.	-	1218	O

This	15673851	1220	O
increase	-	1225	O
persisted	-	1234	O
for	-	1244	O
8	-	1248	O
hrs	-	1250	O
.	-	1253	O

IT	15673851	1255	O
MK	-	1258	O
-	-	1260	O
801	-	1261	O
significantly	-	1265	O
reduced	-	1279	O
the	-	1287	O
number	-	1291	O
of	-	1298	O
dark	-	1301	O
-	-	1305	O
stained	-	1306	O
alpha	-	1314	O
-	-	1319	O
motoneurons	-	1320	O
after	-	1332	O
morphine	-	1338	O
-	-	1346	O
induced	-	1347	O
spastic	-	1355	B
paraparesis	-	1363	I
compared	-	1375	O
with	-	1384	O
the	-	1389	O
saline	-	1393	O
group	-	1400	O
.	-	1405	O

These	15673851	1407	O
data	-	1413	O
indicate	-	1418	O
that	-	1427	O
IT	-	1432	O
morphine	-	1435	O
induces	-	1444	O
spastic	-	1452	B
paraparesis	-	1460	I
with	-	1472	O
a	-	1477	O
concomitant	-	1479	O
increase	-	1491	O
in	-	1500	O
CSF	-	1503	O
glutamate	-	1507	O
,	-	1516	O
which	-	1518	O
is	-	1524	O
involved	-	1527	O
in	-	1536	O
NMDA	-	1539	O
receptor	-	1544	O
activation	-	1553	O
.	-	1563	O

We	15673851	1565	O
suggest	-	1568	O
that	-	1576	O
opioids	-	1581	O
may	-	1589	O
be	-	1593	O
neurotoxic	-	1596	B
in	-	1607	O
the	-	1610	O
setting	-	1614	O
of	-	1622	O
spinal	-	1625	B
cord	-	1632	I
ischemia	-	1637	I
via	-	1646	O
NMDA	-	1650	O
receptor	-	1655	O
activation	-	1664	O
.	-	1674	O

Reduced	12481039	0	O
sodium	-	8	O
channel	-	15	O
density	-	23	O
,	-	30	O
altered	-	32	O
voltage	-	40	O
dependence	-	48	O
of	-	59	O
inactivation	-	62	O
,	-	74	O
and	-	76	O
increased	-	80	O
susceptibility	-	90	O
to	-	105	O
seizures	-	108	B
in	-	117	O
mice	-	120	O
lacking	-	125	O
sodium	-	133	O
channel	-	140	O
beta	-	148	O
2	-	153	O
-	-	154	O
subunits	-	155	O
.	-	163	O

Sodium	12481039	165	O
channel	-	172	O
beta	-	180	O
-	-	184	O
subunits	-	185	O
modulate	-	194	O
channel	-	203	O
gating	-	211	O
,	-	217	O
assembly	-	219	O
,	-	227	O
and	-	229	O
cell	-	233	O
surface	-	238	O
expression	-	246	O
in	-	257	O
heterologous	-	260	O
cell	-	273	O
systems	-	278	O
.	-	285	O

We	12481039	287	O
generated	-	290	O
beta2	-	300	O
(	-	305	O
-	-	306	O
/	-	307	O
-	-	308	O
)	-	309	O
mice	-	311	O
to	-	316	O
investigate	-	319	O
the	-	331	O
role	-	335	O
of	-	340	O
beta2	-	343	O
in	-	349	O
control	-	352	O
of	-	360	O
sodium	-	363	O
channel	-	370	O
density	-	378	O
,	-	385	O
localization	-	387	O
,	-	399	O
and	-	401	O
function	-	405	O
in	-	414	O
neurons	-	417	O
in	-	425	O
vivo	-	428	O
.	-	432	O

Measurements	12481039	434	O
of	-	447	O
[	-	450	O
(	-	451	O
3	-	452	O
)	-	453	O
H	-	454	O
]	-	455	O
saxitoxin	-	456	O
(	-	466	O
STX	-	467	O
)	-	470	O
binding	-	472	O
showed	-	480	O
a	-	487	O
significant	-	489	O
reduction	-	501	O
in	-	511	O
the	-	514	O
level	-	518	O
of	-	524	O
plasma	-	527	O
membrane	-	534	O
sodium	-	543	O
channels	-	550	O
in	-	559	O
beta2	-	562	O
(	-	567	O
-	-	568	O
/	-	569	O
-	-	570	O
)	-	571	O
neurons	-	573	O
.	-	580	O

The	12481039	582	O
loss	-	586	O
of	-	591	O
beta2	-	594	O
resulted	-	600	O
in	-	609	O
negative	-	612	O
shifts	-	621	O
in	-	628	O
the	-	631	O
voltage	-	635	O
dependence	-	643	O
of	-	654	O
inactivation	-	657	O
as	-	670	O
well	-	673	O
as	-	678	O
significant	-	681	O
decreases	-	693	O
in	-	703	O
sodium	-	706	O
current	-	713	O
density	-	721	O
in	-	729	O
acutely	-	732	O
dissociated	-	740	O
hippocampal	-	752	O
neurons	-	764	O
.	-	771	O

The	12481039	773	O
integral	-	777	O
of	-	786	O
the	-	789	O
compound	-	793	O
action	-	802	O
potential	-	809	O
in	-	819	O
optic	-	822	O
nerve	-	828	O
was	-	834	O
significantly	-	838	O
reduced	-	852	O
,	-	859	O
and	-	861	O
the	-	865	O
threshold	-	869	O
for	-	879	O
action	-	883	O
potential	-	890	O
generation	-	900	O
was	-	911	O
increased	-	915	O
,	-	924	O
indicating	-	926	O
a	-	937	O
reduction	-	939	O
in	-	949	O
the	-	952	O
level	-	956	O
of	-	962	O
functional	-	965	O
plasma	-	976	O
membrane	-	983	O
sodium	-	992	O
channels	-	999	O
.	-	1007	O

In	12481039	1009	O
contrast	-	1012	O
,	-	1020	O
the	-	1022	O
conduction	-	1026	O
velocity	-	1037	O
,	-	1045	O
the	-	1047	O
number	-	1051	O
and	-	1058	O
size	-	1062	O
of	-	1067	O
axons	-	1070	O
in	-	1076	O
the	-	1079	O
optic	-	1083	O
nerve	-	1089	O
,	-	1094	O
and	-	1096	O
the	-	1100	O
specific	-	1104	O
localization	-	1113	O
of	-	1126	O
Na	-	1129	O
(	-	1131	O
v	-	1132	O
)	-	1133	O
1	-	1134	O
.	-	1135	O
6	-	1136	O
channels	-	1138	O
in	-	1147	O
the	-	1150	O
nodes	-	1154	O
of	-	1160	O
Ranvier	-	1163	O
were	-	1171	O
unchanged	-	1176	O
.	-	1185	O

beta2	12481039	1187	O
(	-	1192	O
-	-	1193	O
/	-	1194	O
-	-	1195	O
)	-	1196	O

mice	12481039	1198	O
displayed	-	1203	O
increased	-	1213	O
susceptibility	-	1223	O
to	-	1238	O
seizures	-	1241	B
,	-	1249	O
as	-	1251	O
indicated	-	1254	O
by	-	1264	O
reduced	-	1267	O
latency	-	1275	O
and	-	1283	O
threshold	-	1287	O
for	-	1297	O
pilocarpine	-	1301	O
-	-	1312	O
induced	-	1313	O
seizures	-	1321	B
,	-	1329	O
but	-	1331	O
seemed	-	1335	O
normal	-	1342	O
in	-	1349	O
other	-	1352	O
neurological	-	1358	O
tests	-	1371	O
.	-	1376	O

Our	12481039	1378	O
observations	-	1382	O
show	-	1395	O
that	-	1400	O
beta2	-	1405	O
-	-	1410	O
subunits	-	1411	O
play	-	1420	O
an	-	1425	O
important	-	1428	O
role	-	1438	O
in	-	1443	O
the	-	1446	O
regulation	-	1450	O
of	-	1461	O
sodium	-	1464	O
channel	-	1471	O
density	-	1479	O
and	-	1487	O
function	-	1491	O
in	-	1500	O
neurons	-	1503	O
in	-	1511	O
vivo	-	1514	O
and	-	1519	O
are	-	1523	O
required	-	1527	O
for	-	1536	O
normal	-	1540	O
action	-	1547	O
potential	-	1554	O
generation	-	1564	O
and	-	1575	O
control	-	1579	O
of	-	1587	O
excitability	-	1590	O
.	-	1602	O

Screening	11185967	0	O
for	-	10	O
stimulant	-	14	O
use	-	24	O
in	-	28	O
adult	-	31	O
emergency	-	37	O
department	-	47	O
seizure	-	58	B
patients	-	66	O
.	-	74	O

OBJECTIVE	11185967	76	O
:	-	85	O
The	-	87	O
objective	-	91	O
of	-	101	O
this	-	104	O
study	-	109	O
was	-	115	O
to	-	119	O
determine	-	122	O
the	-	132	O
prevalence	-	136	O
of	-	147	O
positive	-	150	O
plasma	-	159	O
drug	-	166	O
screening	-	171	O
for	-	181	O
cocaine	-	185	O
or	-	193	O
amphetamine	-	196	O
in	-	208	O
adult	-	211	O
emergency	-	217	O
department	-	227	O
seizure	-	238	B
patients	-	246	O
.	-	254	O

METHODS	11185967	256	O
:	-	263	O

This	11185967	265	O
prospective	-	270	O
study	-	282	O
evaluated	-	288	O
consecutive	-	298	O
eligible	-	310	O
seizure	-	319	B
patients	-	327	O
who	-	336	O
had	-	340	O
a	-	344	O
plasma	-	346	O
sample	-	353	O
collected	-	360	O
as	-	370	O
part	-	373	O
of	-	378	O
their	-	381	O
clinical	-	387	O
evaluation	-	396	O
.	-	406	O

Plasma	11185967	408	O
was	-	415	O
tested	-	419	O
for	-	426	O
amphetamine	-	430	O
and	-	442	O
the	-	446	O
cocaine	-	450	O
metabolite	-	458	O
benzoylecgonine	-	469	O
using	-	485	O
enzyme	-	491	O
-	-	497	O
mediated	-	498	O
immunoassay	-	507	O
methodology	-	519	O
.	-	530	O

Plasma	11185967	532	O
samples	-	539	O
with	-	547	O
benzoylecgonine	-	552	O
greater	-	568	O
than	-	576	O
150	-	581	O
ng	-	585	O
/	-	587	O
mL	-	588	O
or	-	591	O
an	-	594	O
amphetamine	-	597	O
greater	-	609	O
than	-	617	O
500	-	622	O
ng	-	626	O
/	-	628	O
mL	-	629	O
were	-	632	O
defined	-	637	O
as	-	645	O
positive	-	648	O
.	-	656	O

Patient	11185967	658	O
demographics	-	666	O
,	-	678	O
history	-	680	O
of	-	688	O
underlying	-	691	O
drug	-	702	O
or	-	707	O
alcohol	-	710	O
-	-	717	O
related	-	718	O
seizure	-	726	B
disorder	-	734	O
,	-	742	O
estimated	-	744	O
time	-	754	O
from	-	759	O
seizure	-	764	B
to	-	772	O
sample	-	775	O
collection	-	782	O
,	-	792	O
history	-	794	O
or	-	802	O
suspicion	-	805	O
of	-	815	O
cocaine	-	818	B
or	-	826	I
amphetamine	-	829	I
abuse	-	841	I
,	-	846	O
results	-	848	O
of	-	856	O
clinical	-	859	O
urine	-	868	O
testing	-	874	O
for	-	882	O
drugs	-	886	O
of	-	892	O
abuse	-	895	O
,	-	900	O
and	-	902	O
assay	-	906	O
results	-	912	O
were	-	920	O
recorded	-	925	O
without	-	934	O
patient	-	942	O
identifiers	-	950	O
.	-	961	O

RESULTS	11185967	963	O
:	-	970	O

Fourteen	11185967	972	O
of	-	981	O
248	-	984	O
(	-	988	O
5	-	989	O
.	-	990	O
6	-	991	O
%	-	992	O
,	-	993	O
95	-	995	O
%	-	997	O
CI	-	999	O
2	-	1002	O
.	-	1003	O
7	-	1004	O
%	-	1005	O
-	-	1006	O
8	-	1007	O
.	-	1008	O
5	-	1009	O
%	-	1010	O
)	-	1011	O
plasma	-	1013	O
samples	-	1020	O
were	-	1028	O
positive	-	1033	O
by	-	1042	O
immunoassay	-	1045	O
testing	-	1057	O
for	-	1065	O
benzoylecgonine	-	1069	O
and	-	1085	O
no	-	1089	O
samples	-	1092	O
(	-	1100	O
0	-	1101	O
%	-	1102	O
,	-	1103	O
95	-	1105	O
%	-	1107	O
CI	-	1109	O
0	-	1112	O
-	-	1113	O
1	-	1114	O
.	-	1115	O
2	-	1116	O
%	-	1117	O
)	-	1118	O
were	-	1120	O
positive	-	1125	O
for	-	1134	O
amphetamine	-	1138	O
.	-	1149	O

Positive	11185967	1151	O
test	-	1160	O
results	-	1165	O
were	-	1173	O
more	-	1178	O
common	-	1183	O
in	-	1190	O
patient	-	1193	O
visits	-	1201	O
where	-	1208	O
there	-	1214	O
was	-	1220	O
a	-	1224	O
history	-	1226	O
or	-	1234	O
suspicion	-	1237	O
of	-	1247	O
cocaine	-	1250	B
or	-	1258	I
amphetamine	-	1261	I
abuse	-	1273	I
(	-	1279	O
p	-	1280	O
<	-	1282	O
0	-	1284	O
.	-	1285	O
0005	-	1286	O
)	-	1290	O
.	-	1291	O

CONCLUSIONS	11185967	1293	O
:	-	1304	O

During	11185967	1306	O
this	-	1313	O
study	-	1318	O
period	-	1324	O
,	-	1330	O
routine	-	1332	O
plasma	-	1340	O
screening	-	1347	O
for	-	1357	O
cocaine	-	1361	O
and	-	1369	O
amphetamines	-	1373	O
in	-	1386	O
adult	-	1389	O
seizure	-	1395	B
patients	-	1403	O
had	-	1412	O
a	-	1416	O
low	-	1418	O
yield	-	1422	O
.	-	1427	O

As	11185967	1429	O
a	-	1432	O
result	-	1434	O
,	-	1440	O
routine	-	1442	O
plasma	-	1450	O
screening	-	1457	O
would	-	1467	O
yield	-	1473	O
few	-	1479	O
cases	-	1483	O
of	-	1489	O
stimulant	-	1492	O
drug	-	1502	O
in	-	1507	O
which	-	1510	O
there	-	1516	O
was	-	1522	O
neither	-	1526	O
a	-	1534	O
history	-	1536	O
nor	-	1544	O
suspicion	-	1548	O
of	-	1558	O
drug	-	1561	B
abuse	-	1566	I
in	-	1572	O
this	-	1575	O
population	-	1580	O
.	-	1590	O

Evidence	11099450	0	O
of	-	9	O
functional	-	12	O
somatotopy	-	23	O
in	-	34	O
GPi	-	37	O
from	-	41	O
results	-	46	O
of	-	54	O
pallidotomy	-	57	O
.	-	68	O

The	11099450	70	O
objective	-	74	O
of	-	84	O
this	-	87	O
study	-	92	O
was	-	98	O
to	-	102	O
explore	-	105	O
the	-	113	O
functional	-	117	O
anatomy	-	128	O
of	-	136	O
the	-	139	O
globus	-	143	O
pallidus	-	150	O
internus	-	159	O
(	-	168	O
GPi	-	169	O
)	-	172	O
by	-	174	O
studying	-	177	O
the	-	186	O
effects	-	190	O
of	-	198	O
unilateral	-	201	O
pallidotomy	-	212	O
on	-	224	O
parkinsonian	-	227	B
'	-	240	O
off	-	241	O
'	-	244	O
signs	-	246	O
and	-	252	O
levodopa	-	256	O
-	-	264	O
induced	-	265	O
dyskinesias	-	273	B
(	-	285	O
LID	-	286	B
)	-	289	O
.	-	290	O

We	11099450	292	O
found	-	295	O
significant	-	301	O
positive	-	313	O
correlations	-	322	O
between	-	335	O
the	-	343	O
preoperative	-	347	O
levodopa	-	360	O
responsiveness	-	369	O
of	-	384	O
motor	-	387	O
signs	-	393	O
and	-	399	O
the	-	403	O
levodopa	-	407	O
responsiveness	-	416	O
of	-	431	O
scores	-	434	O
in	-	441	O
timed	-	444	O
tests	-	450	O
(	-	456	O
Core	-	457	O
Assessment	-	462	O
Program	-	473	O
for	-	481	O
Intracerebral	-	485	O
Transplantations	-	499	O
)	-	515	O
in	-	517	O
the	-	520	O
contralateral	-	524	O
limbs	-	538	O
and	-	544	O
the	-	548	O
improvement	-	552	O
in	-	564	O
these	-	567	O
scores	-	573	O
after	-	580	O
surgery	-	586	O
,	-	593	O
whereas	-	595	O
there	-	603	O
was	-	609	O
no	-	613	O
correlation	-	616	O
with	-	628	O
the	-	633	O
improvement	-	637	O
in	-	649	O
LID	-	652	B
.	-	655	O

We	11099450	657	O
also	-	660	O
found	-	665	O
a	-	671	O
highly	-	673	O
significant	-	680	O
correlation	-	692	O
(	-	704	O
P	-	705	O
:	-	706	O
<	-	708	O
0	-	710	O
.	-	711	O
0001	-	712	O
,	-	716	O
r	-	718	O
=	-	720	O
0	-	722	O
.	-	723	O
8	-	724	O
)	-	725	O
between	-	727	O
the	-	735	O
volume	-	739	O
of	-	746	O
the	-	749	O
ventral	-	753	O
lesion	-	761	O
in	-	768	O
the	-	771	O
GPi	-	775	O
and	-	779	O
the	-	783	O
improvement	-	787	O
in	-	799	O
LID	-	802	B
in	-	806	O
the	-	809	O
contralateral	-	813	O
limbs	-	827	O
,	-	832	O
whereas	-	834	O
there	-	842	O
was	-	848	O
no	-	852	O
correlation	-	855	O
between	-	867	O
the	-	875	O
ventral	-	879	O
volume	-	887	O
and	-	894	O
the	-	898	O
improvement	-	902	O
in	-	914	O
parkinsonian	-	917	B
'	-	930	O
off	-	931	O
'	-	934	O
signs	-	936	O
.	-	941	O

The	11099450	943	O
volumes	-	947	O
of	-	955	O
the	-	958	O
total	-	962	O
lesion	-	968	O
cylinder	-	975	O
and	-	984	O
the	-	988	O
dorsal	-	992	O
lesion	-	999	O
did	-	1006	O
not	-	1010	O
correlate	-	1014	O
with	-	1024	O
the	-	1029	O
outcome	-	1033	O
of	-	1041	O
either	-	1044	O
dyskinesias	-	1051	B
or	-	1063	O
parkinsonian	-	1066	B
'	-	1079	O
off	-	1080	O
'	-	1083	O
signs	-	1085	O
.	-	1090	O

The	11099450	1092	O
differential	-	1096	O
predictive	-	1109	O
value	-	1120	O
of	-	1126	O
levodopa	-	1129	O
responsiveness	-	1138	O
for	-	1153	O
the	-	1157	O
outcome	-	1161	O
of	-	1169	O
parkinsonian	-	1172	B
'	-	1185	O
off	-	1186	O
'	-	1189	O
signs	-	1191	O
and	-	1197	O
LID	-	1201	B
and	-	1205	O
the	-	1209	O
different	-	1213	O
correlations	-	1223	O
of	-	1236	O
ventral	-	1239	O
lesion	-	1247	O
volume	-	1254	O
with	-	1261	O
dyskinesias	-	1266	B
and	-	1278	O
parkinsonian	-	1282	B
'	-	1295	O
off	-	1296	O
'	-	1299	O
signs	-	1301	O
indicate	-	1307	O
that	-	1316	O
different	-	1321	O
anatomical	-	1331	O
or	-	1342	O
pathophysiological	-	1345	O
substrates	-	1364	O
may	-	1375	O
be	-	1379	O
responsible	-	1382	O
for	-	1394	O
the	-	1398	O
generation	-	1402	O
of	-	1413	O
parkinsonian	-	1416	B
'	-	1429	O
off	-	1430	O
'	-	1433	O
signs	-	1435	O
and	-	1441	O
dyskinesias	-	1445	B
.	-	1456	O

Whereas	11099450	1458	O
cells	-	1466	O
in	-	1472	O
a	-	1475	O
wider	-	1477	O
area	-	1483	O
of	-	1488	O
the	-	1491	O
GPi	-	1495	O
may	-	1499	O
be	-	1503	O
implicated	-	1506	O
in	-	1517	O
parkinsonism	-	1520	B
,	-	1532	O
the	-	1534	O
ventral	-	1538	O
GPi	-	1546	O
seems	-	1550	O
to	-	1556	O
be	-	1559	O
crucial	-	1562	O
for	-	1570	O
the	-	1574	O
manifestation	-	1578	O
of	-	1592	O
LID	-	1595	B
.	-	1598	O

We	11099450	1600	O
suggest	-	1603	O
that	-	1611	O
our	-	1616	O
observations	-	1620	O
are	-	1633	O
additional	-	1637	O
proof	-	1648	O
of	-	1654	O
the	-	1657	O
functional	-	1661	O
somatotopy	-	1672	O
of	-	1683	O
the	-	1686	O
systems	-	1690	O
within	-	1698	O
the	-	1705	O
GPi	-	1709	O
that	-	1713	O
mediate	-	1718	O
parkinsonism	-	1726	B
and	-	1739	O
dyskinesias	-	1743	B
,	-	1754	O
especially	-	1756	O
along	-	1767	O
the	-	1773	O
dorsoventral	-	1777	O
trajectory	-	1790	O
used	-	1801	O
in	-	1806	O
pallidotomy	-	1809	O
.	-	1820	O

The	11099450	1822	O
outcome	-	1826	O
of	-	1834	O
pallidotomy	-	1837	O
in	-	1849	O
which	-	1852	O
the	-	1858	O
lesion	-	1862	O
involves	-	1869	O
the	-	1878	O
ventral	-	1882	O
and	-	1890	O
dorsal	-	1894	O
GPi	-	1901	O
could	-	1905	O
be	-	1911	O
the	-	1914	O
net	-	1918	O
effect	-	1922	O
of	-	1929	O
alteration	-	1932	O
in	-	1943	O
the	-	1946	O
activity	-	1950	O
of	-	1959	O
pathways	-	1962	O
which	-	1971	O
mediate	-	1977	O
different	-	1985	O
symptoms	-	1995	O
,	-	2003	O
and	-	2005	O
hence	-	2009	O
could	-	2015	O
be	-	2021	O
variable	-	2024	O
.	-	2032	O

Pain	11027904	0	B
responses	-	5	O
in	-	15	O
methadone	-	18	O
-	-	27	O
maintained	-	28	O
opioid	-	39	O
abusers	-	46	O
.	-	53	O

Providing	11027904	55	O
pain	-	65	B
management	-	70	O
for	-	81	O
known	-	85	O
opioid	-	91	O
abusers	-	98	O
is	-	106	O
a	-	109	O
challenging	-	111	O
clinical	-	123	O
task	-	132	O
,	-	136	O
in	-	138	O
part	-	141	O
because	-	146	O
little	-	154	O
is	-	161	O
known	-	164	O
about	-	170	O
their	-	176	O
pain	-	182	B
experience	-	187	O
and	-	198	O
analgesic	-	202	O
requirements	-	212	O
.	-	224	O

This	11027904	226	O
study	-	231	O
was	-	237	O
designed	-	241	O
to	-	250	O
describe	-	253	O
pain	-	262	B
tolerance	-	267	O
and	-	277	O
analgesic	-	281	O
response	-	291	O
in	-	300	O
a	-	303	O
sample	-	305	O
of	-	312	O
opioid	-	315	B
addicts	-	322	I
stabilized	-	330	O
in	-	341	O
methadone	-	344	O
-	-	353	O
maintenance	-	354	O
(	-	366	O
MM	-	367	O
)	-	369	O
treatment	-	371	O
(	-	381	O
n	-	382	O
=	-	384	O
60	-	386	O
)	-	388	O
in	-	390	O
comparison	-	393	O
to	-	404	O
matched	-	407	O
nondependent	-	415	O
control	-	428	O
subjects	-	436	O
(	-	445	O
n	-	446	O
=	-	448	O
60	-	450	O
)	-	452	O
.	-	453	O

By	11027904	455	O
using	-	458	O
a	-	464	O
placebo	-	466	O
-	-	473	O
controlled	-	474	O
,	-	484	O
two	-	486	O
-	-	489	O
way	-	490	O
factorial	-	494	O
design	-	504	O
,	-	510	O
tolerance	-	512	O
to	-	522	O
cold	-	525	O
-	-	529	O
pressor	-	530	O
(	-	538	O
CP	-	539	O
)	-	541	O
pain	-	543	B
was	-	548	O
examined	-	552	O
,	-	560	O
both	-	562	O
before	-	567	O
and	-	574	O
after	-	578	O
oral	-	584	O
administration	-	589	O
of	-	604	O
therapeutic	-	607	O
doses	-	619	O
of	-	625	O
common	-	628	O
opioid	-	635	O
(	-	642	O
hydromorphone	-	643	O
2	-	657	O
mg	-	659	O
)	-	661	O
and	-	663	O
nonsteroidal	-	667	O
anti	-	680	O
-	-	684	O
inflammatory	-	685	O
(	-	698	O
ketorolac	-	699	O
10	-	709	O
mg	-	712	O
)	-	714	O
analgesic	-	716	O
agents	-	726	O
.	-	732	O

Results	11027904	734	O
showed	-	742	O
that	-	749	O
MM	-	754	O
individuals	-	757	O
were	-	769	O
significantly	-	774	O
less	-	788	O
tolerant	-	793	O
of	-	802	O
CP	-	805	O
pain	-	808	B
than	-	813	O
control	-	818	O
subjects	-	826	O
,	-	834	O
replicating	-	836	O
previous	-	848	O
work	-	857	O
.	-	861	O

Analgesic	11027904	863	O
effects	-	873	O
were	-	881	O
significant	-	886	O
neither	-	898	O
for	-	906	O
medication	-	910	O
nor	-	921	O
group	-	925	O
.	-	930	O

These	11027904	932	O
data	-	938	O
indicate	-	943	O
that	-	952	O
MM	-	957	O
opioid	-	960	O
abusers	-	967	O
represent	-	975	O
a	-	985	O
pain	-	987	B
-	-	991	I
intolerant	-	992	I
subset	-	1003	O
of	-	1010	O
clinical	-	1013	O
patients	-	1022	O
.	-	1030	O

Their	11027904	1032	O
complaints	-	1038	O
of	-	1049	O
pain	-	1052	B
should	-	1057	O
be	-	1064	O
evaluated	-	1067	O
seriously	-	1077	O
and	-	1087	O
managed	-	1091	O
aggressively	-	1099	O
.	-	1111	O

Urine	10193809	0	O
N	-	6	O
-	-	7	O
acetyl	-	8	O
-	-	14	O
beta	-	15	O
-	-	19	O
D	-	20	O
-	-	21	O
glucosaminidase	-	22	O
-	-	37	O
-	-	38	O
a	-	39	O
marker	-	41	O
of	-	48	O
tubular	-	51	O
damage	-	59	O
?	-	65	O

BACKGROUND	10193809	67	O
:	-	77	O

Although	10193809	79	O
an	-	88	O
indicator	-	91	O
of	-	101	O
renal	-	104	B
tubular	-	110	I
dysfunction	-	118	I
,	-	129	O
an	-	131	O
increased	-	134	O
urinary	-	144	O
N	-	152	O
-	-	153	O
acetyl	-	154	O
-	-	160	O
beta	-	161	O
-	-	165	O
D	-	166	O
-	-	167	O
glucosaminidase	-	168	O
(	-	184	O
NAG	-	185	O
)	-	188	O
activity	-	190	O
might	-	199	O
reflect	-	205	O
increased	-	213	O
lysosomal	-	223	O
activity	-	233	O
in	-	242	O
renal	-	245	O
tubular	-	251	O
cells	-	259	O
.	-	264	O

METHODS	10193809	266	O
:	-	273	O

Puromycin	10193809	275	O
aminonucleoside	-	285	O
(	-	301	O
PAN	-	302	O
)	-	305	O
was	-	307	O
administered	-	311	O
to	-	324	O
Sprague	-	327	O
Dawley	-	335	O
rats	-	342	O
to	-	347	O
induce	-	350	O
proteinuria	-	357	B
.	-	368	O

Total	10193809	370	O
protein	-	376	O
,	-	383	O
albumin	-	385	O
,	-	392	O
NAG	-	394	O
activity	-	398	O
and	-	407	O
protein	-	411	O
electrophoretic	-	419	O
pattern	-	435	O
were	-	443	O
assessed	-	448	O
in	-	457	O
daily	-	460	O
urine	-	466	O
samples	-	472	O
for	-	480	O
33	-	484	O
days	-	487	O
.	-	491	O

The	10193809	493	O
morphological	-	497	O
appearance	-	511	O
of	-	522	O
the	-	525	O
kidneys	-	529	O
was	-	537	O
examined	-	541	O
on	-	550	O
days	-	553	O
three	-	558	O
,	-	563	O
four	-	565	O
,	-	569	O
six	-	571	O
,	-	574	O
eight	-	576	O
and	-	582	O
thirty	-	586	O
three	-	593	O
and	-	599	O
the	-	603	O
NAG	-	607	O
isoenzyme	-	611	O
patterns	-	621	O
on	-	630	O
days	-	633	O
zero	-	638	O
,	-	642	O
four	-	644	O
,	-	648	O
eight	-	650	O
and	-	656	O
thirty	-	660	O
three	-	667	O
.	-	672	O

RESULTS	10193809	674	O
:	-	681	O

Following	10193809	683	O
intravenous	-	693	O
PAN	-	705	O
urine	-	709	O
volume	-	715	O
and	-	722	O
urine	-	726	O
NAG	-	732	O
activity	-	736	O
increased	-	745	O
significantly	-	755	O
by	-	769	O
day	-	772	O
two	-	776	O
,	-	779	O
but	-	781	O
returned	-	785	O
to	-	794	O
normal	-	797	O
by	-	804	O
day	-	807	O
four	-	811	O
.	-	815	O

After	10193809	817	O
day	-	823	O
four	-	827	O
all	-	832	O
treated	-	836	O
animals	-	844	O
exhibited	-	852	O
a	-	862	O
marked	-	864	O
rise	-	871	O
in	-	876	O
urine	-	879	O
albumin	-	885	O
,	-	892	O
total	-	894	O
protein	-	900	O
excretion	-	908	O
and	-	918	O
NAG	-	922	O
activity	-	926	O
.	-	934	O

Electrophoresis	10193809	936	O
showed	-	952	O
a	-	959	O
generalised	-	961	O
increase	-	973	O
in	-	982	O
middle	-	985	O
and	-	992	O
high	-	996	O
molecular	-	1001	O
weight	-	1011	O
urine	-	1018	O
proteins	-	1024	O
from	-	1033	O
day	-	1038	O
four	-	1042	O
onwards	-	1047	O
.	-	1054	O

Protein	10193809	1056	O
droplets	-	1064	O
first	-	1073	O
appeared	-	1079	O
prominent	-	1088	O
in	-	1098	O
tubular	-	1101	O
cells	-	1109	O
on	-	1115	O
day	-	1118	O
four	-	1122	O
.	-	1126	O

Peak	10193809	1128	O
urine	-	1133	O
NAG	-	1139	O
activity	-	1143	O
and	-	1152	O
a	-	1156	O
change	-	1158	O
in	-	1165	O
NAG	-	1168	O
isoenzyme	-	1172	O
pattern	-	1182	O
coincided	-	1190	O
with	-	1200	O
both	-	1205	O
the	-	1210	O
peak	-	1214	O
proteinuria	-	1219	B
and	-	1231	O
the	-	1235	O
reduction	-	1239	O
in	-	1249	O
intracellular	-	1252	O
protein	-	1266	O
and	-	1274	O
NAG	-	1278	O
droplets	-	1282	O
(	-	1291	O
day	-	1292	O
six	-	1296	O
onwards	-	1300	O
)	-	1307	O
.	-	1308	O

CONCLUSIONS	10193809	1310	O
:	-	1321	O

This	10193809	1323	O
animal	-	1328	O
model	-	1335	O
demonstrates	-	1341	O
that	-	1354	O
an	-	1359	O
increase	-	1362	O
in	-	1371	O
lysosomal	-	1374	O
turnover	-	1384	O
and	-	1393	O
hence	-	1397	O
urine	-	1403	O
NAG	-	1409	O
activity	-	1413	O
,	-	1421	O
occurs	-	1423	O
when	-	1430	O
increased	-	1435	O
protein	-	1445	O
is	-	1453	O
presented	-	1456	O
to	-	1466	O
the	-	1469	O
tubular	-	1473	O
cells	-	1481	O
.	-	1486	O

Urine	10193809	1488	O
NAG	-	1494	O
activity	-	1498	O
is	-	1507	O
thus	-	1510	O
a	-	1515	O
measure	-	1517	O
of	-	1525	O
altered	-	1528	O
function	-	1536	O
in	-	1545	O
the	-	1548	O
renal	-	1552	O
tubules	-	1558	O
and	-	1566	O
not	-	1570	O
simply	-	1574	O
an	-	1581	O
indicator	-	1584	O
of	-	1594	O
damage	-	1597	O
.	-	1603	O

Over	9214597	0	O
expression	-	5	O
of	-	16	O
vascular	-	19	O
endothelial	-	28	O
growth	-	40	O
factor	-	47	O
and	-	54	O
its	-	58	O
receptor	-	62	O
during	-	71	O
the	-	78	O
development	-	82	O
of	-	94	O
estrogen	-	97	O
-	-	105	O
induced	-	106	O
rat	-	114	O
pituitary	-	118	B
tumors	-	128	I
may	-	135	O
mediate	-	139	O
estrogen	-	147	O
-	-	155	O
initiated	-	156	O
tumor	-	166	B
angiogenesis	-	172	O
.	-	184	O

Estrogens	9214597	186	O
,	-	195	O
which	-	197	O
have	-	203	O
been	-	208	O
associated	-	213	O
with	-	224	O
several	-	229	O
types	-	237	O
of	-	243	O
human	-	246	O
and	-	252	O
animal	-	256	O
cancers	-	263	B
,	-	270	O
can	-	272	O
induce	-	276	O
tumor	-	283	B
angiogenesis	-	289	O
in	-	302	O
the	-	305	O
pituitary	-	309	O
of	-	319	O
Fischer	-	322	O
344	-	330	O
rats	-	334	O
.	-	338	O

The	9214597	340	O
mechanistic	-	344	O
details	-	356	O
of	-	364	O
tumor	-	367	B
angiogenesis	-	373	O
induction	-	386	O
,	-	395	O
during	-	397	O
estrogen	-	404	O
carcinogenesis	-	413	B
,	-	427	O
are	-	429	O
still	-	433	O
unknown	-	439	O
.	-	446	O

To	9214597	448	O
elucidate	-	451	O
the	-	461	O
role	-	465	O
of	-	470	O
estrogen	-	473	O
in	-	482	O
the	-	485	O
regulation	-	489	O
of	-	500	O
tumor	-	503	B
angiogenesis	-	509	O
in	-	522	O
the	-	525	O
pituitary	-	529	O
of	-	539	O
female	-	542	O
rats	-	549	O
,	-	553	O
the	-	555	O
density	-	559	O
of	-	567	O
blood	-	570	O
vessels	-	576	O
was	-	584	O
analysed	-	588	O
using	-	597	O
factor	-	603	O
VIII	-	610	O
related	-	615	O
antigen	-	623	O
(	-	631	O
FVIIIRAg	-	632	O
)	-	640	O
immunohistochemistry	-	642	O
and	-	663	O
the	-	667	O
expression	-	671	O
of	-	682	O
vascular	-	685	O
endothelial	-	694	O
growth	-	706	O
factor	-	713	O
/	-	719	O
vascular	-	720	O
permeability	-	729	O
factor	-	742	O
(	-	749	O
VEGF	-	750	O
/	-	754	O
VPF	-	755	O
)	-	758	O
was	-	760	O
examined	-	764	O
by	-	773	O
Western	-	776	O
blot	-	784	O
and	-	789	O
immunohistochemical	-	793	O
analysis	-	813	O
.	-	821	O

The	9214597	823	O
expression	-	827	O
of	-	838	O
VEGF	-	841	O
receptor	-	846	O
(	-	855	O
VEGFR	-	856	O
-	-	861	O
2	-	862	O
/	-	863	O
Flk	-	864	O
-	-	867	O
1	-	868	O
/	-	869	O
KDR	-	870	O
)	-	873	O
was	-	875	O
also	-	879	O
examined	-	884	O
by	-	893	O
immunohistochemistry	-	896	O
.	-	916	O

The	9214597	918	O
results	-	922	O
demonstrated	-	930	O
that	-	943	O
17beta	-	948	O
-	-	954	O
estradiol	-	955	O
(	-	965	O
E2	-	966	O
)	-	968	O
induces	-	970	O
neovascularization	-	978	O
,	-	996	O
as	-	998	O
well	-	1001	O
as	-	1006	O
the	-	1009	O
growth	-	1013	O
and	-	1020	O
enlargement	-	1024	O
of	-	1036	O
blood	-	1039	O
vessels	-	1045	O
after	-	1053	O
7	-	1059	O
days	-	1061	O
of	-	1066	O
exposure	-	1069	O
.	-	1077	O

The	9214597	1079	O
high	-	1083	O
tumor	-	1088	B
angiogenic	-	1094	O
potential	-	1105	O
was	-	1115	O
associated	-	1119	O
with	-	1130	O
an	-	1135	O
elevated	-	1138	O
VEGF	-	1147	O
/	-	1151	O
VPF	-	1152	O
protein	-	1156	O
expression	-	1164	O
in	-	1175	O
the	-	1178	O
E2	-	1182	O
exposed	-	1185	O
pituitary	-	1193	O
of	-	1203	O
ovariectomized	-	1206	O
(	-	1221	O
OVEX	-	1222	O
)	-	1226	O
rats	-	1228	O
.	-	1232	O

VEGF	9214597	1234	O
/	-	1238	O
VPF	-	1239	O
and	-	1243	O
FVIIIRAg	-	1247	O
immunohistochemistry	-	1256	O
and	-	1277	O
endothelial	-	1281	O
specific	-	1293	O
lectin	-	1302	O
(	-	1309	O
UEA1	-	1310	O
)	-	1314	O
binding	-	1316	O
studies	-	1324	O
,	-	1331	O
indicate	-	1333	O
that	-	1342	O
the	-	1347	O
elevation	-	1351	O
of	-	1361	O
VEGF	-	1364	O
protein	-	1369	O
expression	-	1377	O
initially	-	1388	O
occurred	-	1398	O
in	-	1407	O
both	-	1410	O
blood	-	1415	O
vessels	-	1421	O
and	-	1429	O
non	-	1433	O
-	-	1436	O
endothelial	-	1437	O
cells	-	1449	O
.	-	1454	O

After	9214597	1456	O
15	-	1462	O
days	-	1465	O
of	-	1470	O
E2	-	1473	O
exposure	-	1476	O
,	-	1484	O
VEGF	-	1486	O
/	-	1490	O
VPF	-	1491	O
protein	-	1495	O
expression	-	1503	O
,	-	1513	O
in	-	1515	O
the	-	1518	O
non	-	1522	O
-	-	1525	O
endothelial	-	1526	O
cell	-	1538	O
population	-	1543	O
,	-	1553	O
sharply	-	1555	O
declined	-	1563	O
and	-	1572	O
was	-	1576	O
restricted	-	1580	O
to	-	1591	O
the	-	1594	O
blood	-	1598	O
vessels	-	1604	O
.	-	1611	O

The	9214597	1613	O
function	-	1617	O
of	-	1626	O
non	-	1629	O
-	-	1632	O
endothelial	-	1633	O
-	-	1644	O
derived	-	1645	O
VEGF	-	1653	O
is	-	1658	O
not	-	1661	O
clear	-	1665	O
.	-	1670	O

Furthermore	9214597	1672	O
,	-	1683	O
immunohistochemical	-	1685	O
studies	-	1705	O
demonstrated	-	1713	O
that	-	1726	O
VEGFR	-	1731	O
-	-	1736	O
2	-	1737	O
(	-	1739	O
flk	-	1740	O
-	-	1743	O
1	-	1744	O
/	-	1745	O
KDR	-	1746	O
)	-	1749	O
,	-	1750	O
expression	-	1752	O
was	-	1763	O
elevated	-	1767	O
significantly	-	1776	O
in	-	1790	O
the	-	1793	O
endothelial	-	1797	O
cells	-	1809	O
of	-	1815	O
microblood	-	1818	O
vessels	-	1829	O
after	-	1837	O
7	-	1843	O
days	-	1845	O
of	-	1850	O
E2	-	1853	O
exposure	-	1856	O
.	-	1864	O

These	9214597	1866	O
findings	-	1872	O
suggest	-	1881	O
that	-	1889	O
over	-	1894	O
expression	-	1899	O
of	-	1910	O
VEGF	-	1913	O
and	-	1918	O
its	-	1922	O
receptor	-	1926	O
(	-	1935	O
VEGFR	-	1936	O
-	-	1941	O
2	-	1942	O
)	-	1943	O
may	-	1945	O
play	-	1949	O
an	-	1954	O
important	-	1957	O
role	-	1967	O
in	-	1972	O
the	-	1975	O
initial	-	1979	O
step	-	1987	O
of	-	1992	O
the	-	1995	O
regulation	-	1999	O
of	-	2010	O
estrogen	-	2013	O
induced	-	2022	O
tumor	-	2030	B
angiogenesis	-	2036	O
in	-	2049	O
the	-	2052	O
rat	-	2056	O
pituitary	-	2060	O
.	-	2069	O

Pravastatin	7604176	0	O
-	-	11	O
associated	-	12	O
myopathy	-	23	B
.	-	31	O

Report	7604176	33	O
of	-	40	O
a	-	43	O
case	-	45	O
.	-	49	O

A	7604176	51	O
case	-	53	O
of	-	58	O
acute	-	61	O
inflammatory	-	67	B
myopathy	-	80	I
associated	-	89	O
with	-	100	O
the	-	105	O
use	-	109	O
of	-	113	O
pravastatin	-	116	O
,	-	127	O
a	-	129	O
new	-	131	O
hydrophilic	-	135	O
3	-	147	O
-	-	148	O
hydroxy	-	149	O
-	-	156	O
3	-	157	O
methylglutaril	-	159	O
coenzyme	-	174	O
A	-	183	O
reductase	-	185	O
inhibitor	-	195	O
,	-	204	O
is	-	206	O
reported	-	209	O
.	-	217	O

The	7604176	219	O
patient	-	223	O
,	-	230	O
a	-	232	O
69	-	234	O
-	-	236	O
year	-	237	O
-	-	241	O
old	-	242	O
man	-	246	O
was	-	250	O
affected	-	254	O
by	-	263	O
non	-	266	B
-	-	269	I
insulin	-	270	I
-	-	277	I
dependent	-	278	I
diabetes	-	288	I
mellitus	-	297	I
and	-	306	O
hypertension	-	310	B
.	-	322	O

He	7604176	324	O
assumed	-	327	O
pravastatin	-	335	O
(	-	347	O
20	-	348	O
mg	-	351	O
/	-	353	O
day	-	354	O
)	-	357	O
because	-	359	O
of	-	367	O
hypercholesterolemia	-	370	B
.	-	390	O

He	7604176	392	O
was	-	395	O
admitted	-	399	O
with	-	408	O
acute	-	413	O
myopathy	-	419	B
of	-	428	O
the	-	431	O
lower	-	435	O
limbs	-	441	O
which	-	447	O
resolved	-	453	O
in	-	462	O
a	-	465	O
few	-	467	O
days	-	471	O
after	-	476	O
pravastatin	-	482	O
discontinuation	-	494	O
.	-	509	O

A	7604176	511	O
previously	-	513	O
unknown	-	524	O
hypothyroidism	-	532	B
,	-	546	O
probably	-	548	O
due	-	557	O
to	-	561	O
chronic	-	564	O
autoimmune	-	572	B
thyroiditis	-	583	I
,	-	594	O
was	-	596	O
evidenced	-	600	O
.	-	609	O

Muscle	7604176	611	O
biopsy	-	618	O
(	-	625	O
left	-	626	O
gastrocnemius	-	631	O
)	-	644	O
revealed	-	646	O
a	-	655	O
perimysial	-	657	O
and	-	668	O
endomysial	-	672	O
inflammatory	-	683	O
infiltrate	-	696	O
with	-	707	O
a	-	712	O
prevalence	-	714	O
of	-	725	O
CD4	-	728	O
+	-	731	O
lymphocytes	-	733	O
.	-	744	O

While	7604176	746	O
lovastatin	-	752	O
and	-	763	O
simvastatin	-	767	O
have	-	779	O
been	-	784	O
associated	-	789	O
with	-	800	O
toxic	-	805	O
myopathy	-	811	B
,	-	819	O
pravastatin	-	821	O
-	-	832	O
associated	-	833	O
myopathy	-	844	B
could	-	853	O
represent	-	859	O
a	-	869	O
distinct	-	871	O
,	-	879	O
inflammatory	-	881	O
entity	-	894	O
.	-	900	O

Dose	7282516	0	O
-	-	4	O
effect	-	5	O
and	-	12	O
structure	-	16	O
-	-	25	O
function	-	26	O
relationships	-	35	O
in	-	49	O
doxorubicin	-	52	O
cardiomyopathy	-	64	B
.	-	78	O

The	7282516	80	O
cardiomyopathy	-	84	B
(	-	99	O
CM	-	100	B
)	-	102	O
produced	-	104	O
by	-	113	O
the	-	116	O
anticancer	-	120	O
drug	-	131	O
doxorubicin	-	136	O
(	-	148	O
DXR	-	149	O
)	-	152	O
(	-	154	O
Adriamycin	-	155	O
)	-	165	O
provides	-	167	O
a	-	176	O
unique	-	178	O
opportunity	-	185	O
to	-	197	O
analyze	-	200	O
dose	-	208	O
-	-	212	O
effect	-	213	O
and	-	220	O
structure	-	224	O
-	-	233	O
function	-	234	O
relationships	-	243	O
during	-	257	O
development	-	264	O
of	-	276	O
myocardial	-	279	B
disease	-	290	I
.	-	297	O

We	7282516	299	O
measured	-	302	O
the	-	311	O
degree	-	315	O
of	-	322	O
morphologic	-	325	O
damage	-	337	O
by	-	344	O
ultrastructural	-	347	O
examination	-	363	O
of	-	375	O
endomyocardial	-	378	O
biopsy	-	393	O
and	-	400	O
the	-	404	O
degree	-	408	O
of	-	415	O
performance	-	418	O
abnormally	-	430	O
by	-	441	O
right	-	444	O
heart	-	450	O
catheterization	-	456	O
in	-	472	O
patients	-	475	O
receiving	-	484	O
DXR	-	494	O
.	-	497	O

Morphologic	7282516	499	O
damage	-	511	O
was	-	518	O
variable	-	522	O
but	-	531	O
was	-	535	O
proportional	-	539	O
to	-	552	O
the	-	555	O
total	-	559	O
cumulative	-	565	O
DXR	-	576	O
dose	-	580	O
between	-	585	O
100	-	593	O
and	-	597	O
600	-	601	O
mg	-	605	O
/	-	607	O
m2	-	608	O
.	-	610	O

Performance	7282516	612	O
abnormalities	-	624	O
correlated	-	638	O
weakly	-	649	O
with	-	656	O
dose	-	661	O
,	-	665	O
exhibited	-	667	O
a	-	677	O
curvilinear	-	679	O
relationship	-	691	O
,	-	703	O
and	-	705	O
had	-	709	O
a	-	713	O
""""	-	715	O
threshold	-	716	O
""""	-	725	O
for	-	727	O
expression	-	731	O
.	-	741	O

Catheterization	7282516	743	O
abnormalities	-	759	O
correlated	-	773	O
well	-	784	O
with	-	789	O
morphologic	-	794	O
damage	-	806	O
(	-	813	O
r	-	814	O
=	-	816	O
0	-	818	O
.	-	819	O
57	-	820	O
to	-	823	O
0	-	826	O
.	-	827	O
78	-	828	O
)	-	830	O
in	-	832	O
a	-	835	O
subgroup	-	837	O
of	-	846	O
patients	-	849	O
in	-	858	O
whom	-	861	O
exercise	-	866	O
hemodynamics	-	875	O
were	-	888	O
measured	-	893	O
,	-	901	O
and	-	903	O
this	-	907	O
relationship	-	912	O
also	-	925	O
exhibited	-	930	O
a	-	940	O
curvilinear	-	942	O
,	-	953	O
threshold	-	955	O
configuration	-	965	O
.	-	978	O

In	7282516	980	O
DXR	-	983	O
-	-	986	O
CM	-	987	B
myocardial	-	990	B
damage	-	1001	I
is	-	1008	O
proportional	-	1011	O
to	-	1024	O
the	-	1027	O
degree	-	1031	O
of	-	1038	O
cytotoxic	-	1041	O
insult	-	1051	O
(	-	1058	O
DXR	-	1059	O
dose	-	1063	O
)	-	1067	O
while	-	1069	O
myocardial	-	1075	O
function	-	1086	O
is	-	1095	O
preserved	-	1098	O
until	-	1108	O
a	-	1114	O
critical	-	1116	O
dose	-	1125	O
or	-	1130	O
degree	-	1133	O
of	-	1140	O
damage	-	1143	O
is	-	1150	O
reached	-	1153	O
,	-	1160	O
after	-	1162	O
which	-	1168	O
myocardial	-	1174	O
performance	-	1185	O
deteriorates	-	1197	O
rapidly	-	1210	O
.	-	1217	O

Fatal	7072798	0	O
aplastic	-	6	B
anemia	-	15	I
following	-	22	O
topical	-	32	O
administration	-	40	O
of	-	55	O
ophthalmic	-	58	O
chloramphenicol	-	69	O
.	-	84	O

A	7072798	86	O
73	-	88	O
-	-	90	O
year	-	91	O
-	-	95	O
old	-	96	O
woman	-	100	O
died	-	106	O
of	-	111	O
aplastic	-	114	B
anemia	-	123	I
less	-	130	O
than	-	135	O
two	-	140	O
months	-	144	O
after	-	151	O
undergoing	-	157	O
cataract	-	168	B
extraction	-	177	O
and	-	188	O
beginning	-	192	O
topical	-	202	O
therapy	-	210	O
with	-	218	O
chloramphenicol	-	223	O
.	-	238	O

The	7072798	240	O
first	-	244	O
signs	-	250	O
of	-	256	O
pancytopenia	-	259	B
began	-	272	O
within	-	278	O
one	-	285	O
month	-	289	O
of	-	295	O
the	-	298	O
surgery	-	302	O
.	-	309	O

The	7072798	311	O
pattern	-	315	O
of	-	323	O
the	-	326	O
aplastic	-	330	B
anemia	-	339	I
was	-	346	O
associated	-	350	O
with	-	361	O
an	-	366	O
idiosyncratic	-	369	O
response	-	383	O
to	-	392	O
chloramphenicol	-	395	O
.	-	410	O

This	7072798	412	O
was	-	417	O
the	-	421	O
second	-	425	O
report	-	432	O
of	-	439	O
fatal	-	442	O
aplastic	-	448	B
anemia	-	457	I
after	-	464	O
topical	-	470	O
treatment	-	478	O
with	-	488	O
chloramphenicol	-	493	O
for	-	509	O
ocular	-	513	O
conditions	-	520	O
,	-	530	O
although	-	532	O
two	-	541	O
cases	-	545	O
of	-	551	O
reversible	-	554	O
bone	-	565	B
marrow	-	570	I
hypoplasia	-	577	I
have	-	588	O
also	-	593	O
been	-	598	O
reported	-	603	O
.	-	611	O

Any	7072798	613	O
other	-	617	O
suspected	-	623	O
cases	-	633	O
of	-	639	O
ocular	-	642	B
toxicity	-	649	I
associated	-	658	O
with	-	669	O
topically	-	674	O
applied	-	684	O
chloramphenicol	-	692	O
should	-	708	O
be	-	715	O
reported	-	718	O
to	-	727	O
the	-	730	O
National	-	734	O
Registry	-	743	O
of	-	752	O
Drug	-	755	O
-	-	759	O
Induced	-	760	O
Ocular	-	768	O
Side	-	775	O
Effects	-	780	O
,	-	787	O
Oregon	-	789	O
Health	-	796	O
Sciences	-	803	O
University	-	812	O
,	-	822	O
Portland	-	824	O
,	-	832	O
OR	-	834	O
97201	-	837	O
.	-	842	O

Bradycardia	3769769	0	B
due	-	12	O
to	-	16	O
trihexyphenidyl	-	19	O
hydrochloride	-	35	O
.	-	48	O

A	3769769	50	O
chronic	-	52	O
schizophrenic	-	60	B
patient	-	74	O
was	-	82	O
treated	-	86	O
with	-	94	O
an	-	99	O
anticholinergic	-	102	O
drug	-	118	O
,	-	122	O
trihexyphenidyl	-	124	O
hydrochloride	-	140	O
.	-	153	O

The	3769769	155	O
patient	-	159	O
developed	-	167	O
,	-	176	O
paradoxically	-	178	O
,	-	191	O
sinus	-	193	O
bradycardia	-	199	B
.	-	210	O

The	3769769	212	O
reaction	-	216	O
was	-	225	O
specific	-	229	O
to	-	238	O
trihexyphenidyl	-	241	O
and	-	257	O
not	-	261	O
to	-	265	O
other	-	268	O
anticholinergic	-	274	O
drugs	-	290	O
.	-	295	O

This	3769769	297	O
antidyskinetic	-	302	O
drug	-	317	O
is	-	322	O
widely	-	325	O
used	-	332	O
in	-	337	O
clinical	-	340	O
psychiatric	-	349	B
practice	-	361	O
and	-	370	O
physicians	-	374	O
should	-	385	O
be	-	392	O
aware	-	395	O
of	-	401	O
this	-	404	O
side	-	409	O
effect	-	414	O
.	-	420	O

Experimental	3708922	0	O
cyclosporine	-	13	O
nephrotoxicity	-	26	B
:	-	40	O
risk	-	42	O
of	-	47	O
concomitant	-	50	O
chemotherapy	-	62	O
.	-	74	O

The	3708922	76	O
role	-	80	O
of	-	85	O
cyclosporine	-	88	O
(	-	101	O
CSA	-	102	O
)	-	105	O
alone	-	107	O
or	-	113	O
in	-	116	O
combination	-	119	O
with	-	131	O
various	-	136	O
chemotherapeutics	-	144	O
in	-	162	O
the	-	165	O
development	-	169	O
of	-	181	O
renal	-	184	B
toxicity	-	190	I
was	-	199	O
evaluated	-	203	O
in	-	213	O
rats	-	216	O
.	-	220	O

Administration	3708922	222	O
of	-	237	O
20	-	240	O
mg	-	243	O
/	-	245	O
kg	-	246	O
/	-	248	O
day	-	249	O
CSA	-	253	O
for	-	257	O
4	-	261	O
weeks	-	263	O
caused	-	269	O
renal	-	276	O
functional	-	282	O
and	-	293	O
structural	-	297	O
changes	-	308	O
similar	-	316	O
to	-	324	O
those	-	327	O
reported	-	333	O
in	-	342	O
man	-	345	O
.	-	348	O

The	3708922	350	O
combined	-	354	O
administration	-	363	O
of	-	378	O
CSA	-	381	O
and	-	385	O
various	-	389	O
chemotherapeutic	-	397	O
drugs	-	414	O
with	-	420	O
a	-	425	O
nephrotoxic	-	427	B
potential	-	439	O
,	-	448	O
such	-	450	O
as	-	455	O
gentamicin	-	458	O
(	-	469	O
at	-	470	O
therapeutic	-	473	O
doses	-	485	O
)	-	490	O
,	-	491	O
amphothericin	-	493	O
B	-	507	O
and	-	509	O
ketoconazole	-	513	O
,	-	525	O
which	-	527	O
are	-	533	O
frequently	-	537	O
used	-	548	O
in	-	553	O
immunosuppressed	-	556	O
patients	-	573	O
,	-	581	O
did	-	583	O
not	-	587	O
aggravate	-	591	O
the	-	601	O
CSA	-	605	O
induced	-	609	O
toxicity	-	617	B
in	-	626	O
the	-	629	O
rat	-	633	O
model	-	637	O
.	-	642	O

Gentamicin	3708922	644	O
at	-	655	O
toxic	-	658	O
doses	-	664	O
,	-	669	O
however	-	671	O
,	-	678	O
increased	-	680	O
CSA	-	690	O
nephrotoxicity	-	694	B
.	-	708	O

Thus	3708922	710	O
,	-	714	O
the	-	716	O
nephrotoxicity	-	720	B
induced	-	735	O
by	-	743	O
CSA	-	746	O
has	-	750	O
a	-	754	O
different	-	756	O
pathogenetic	-	766	O
mechanism	-	779	O
.	-	788	O

Receptor	3220106	0	O
mechanisms	-	9	O
of	-	20	O
nicotine	-	23	O
-	-	31	O
induced	-	32	O
locomotor	-	40	B
hyperactivity	-	50	I
in	-	64	O
chronic	-	67	O
nicotine	-	75	O
-	-	83	O
treated	-	84	O
rats	-	92	O
.	-	96	O

Rats	3220106	98	O
were	-	103	O
pretreated	-	108	O
with	-	119	O
saline	-	124	O
or	-	131	O
nicotine	-	134	O
(	-	143	O
1	-	144	O
.	-	145	O
5	-	146	O
mg	-	148	O
/	-	150	O
kg	-	151	O
per	-	154	O
day	-	158	O
)	-	161	O
by	-	163	O
subcutaneously	-	166	O
implanting	-	181	O
each	-	192	O
animal	-	197	O
with	-	204	O
an	-	209	O
Alzet	-	212	O
osmotic	-	218	O
mini	-	226	O
-	-	230	O
pump	-	231	O
which	-	236	O
continuously	-	242	O
released	-	255	O
saline	-	264	O
or	-	271	O
nicotine	-	274	O
for	-	283	O
1	-	287	O
,	-	288	O
5	-	290	O
and	-	292	O
14	-	296	O
days	-	299	O
.	-	303	O

At	3220106	305	O
the	-	308	O
end	-	312	O
of	-	316	O
each	-	319	O
pretreatment	-	324	O
period	-	337	O
,	-	343	O
animals	-	345	O
were	-	353	O
used	-	358	O
for	-	363	O
(	-	367	O
i	-	368	O
)	-	369	O
determining	-	371	O
their	-	383	O
locomotor	-	389	O
response	-	399	O
to	-	408	O
acutely	-	411	O
injected	-	419	O
nicotine	-	428	O
(	-	437	O
0	-	438	O
.	-	439	O
2	-	440	O
mg	-	442	O
/	-	444	O
kg	-	445	O
,	-	447	O
s	-	449	O
.	-	450	O
c	-	451	O
.	-	452	O
)	-	453	O
and	-	455	O
(	-	459	O
ii	-	460	O
)	-	462	O
measuring	-	464	O
the	-	474	O
density	-	478	O
of	-	486	O
L	-	489	O
-	-	490	O
[	-	491	O
3H	-	492	O
]	-	494	O
nicotine	-	495	O
and	-	504	O
[	-	508	O
3H	-	509	O
]	-	511	O
spiperone	-	512	O
binding	-	522	O
sites	-	530	O
in	-	536	O
the	-	539	O
striatum	-	543	O
.	-	551	O

We	3220106	553	O
observed	-	556	O
no	-	565	O
changes	-	568	O
in	-	576	O
nicotine	-	579	O
-	-	587	O
induced	-	588	O
locomotor	-	596	O
response	-	606	O
,	-	614	O
striatal	-	616	O
L	-	625	O
-	-	626	O
[	-	627	O
3H	-	628	O
]	-	630	O
nicotine	-	631	O
and	-	640	O
[	-	644	O
3H	-	645	O
]	-	647	O
spiperone	-	648	O
binding	-	658	O
in	-	666	O
the	-	669	O
animals	-	673	O
pretreated	-	681	O
with	-	692	O
nicotine	-	697	O
for	-	706	O
1	-	710	O
day	-	712	O
.	-	715	O

In	3220106	717	O
rats	-	720	O
which	-	725	O
were	-	731	O
pretreated	-	736	O
with	-	747	O
nicotine	-	752	O
for	-	761	O
5	-	765	O
days	-	767	O
,	-	771	O
there	-	773	O
was	-	779	O
a	-	783	O
significant	-	785	O
increase	-	797	O
in	-	806	O
the	-	809	O
nicotine	-	813	O
-	-	821	O
stimulated	-	822	O
locomotor	-	833	O
response	-	843	O
which	-	852	O
was	-	858	O
associated	-	862	O
with	-	873	O
an	-	878	O
increase	-	881	O
in	-	890	O
the	-	893	O
number	-	897	O
of	-	904	O
L	-	907	O
-	-	908	O
[	-	909	O
3H	-	910	O
]	-	912	O
nicotine	-	913	O
binding	-	922	O
sites	-	930	O
and	-	936	O
also	-	940	O
with	-	945	O
an	-	950	O
elevated	-	953	O
dopamine	-	962	O
(	-	971	O
DA	-	972	O
)	-	974	O
level	-	976	O
in	-	982	O
the	-	985	O
striatum	-	989	O
.	-	997	O

The	3220106	999	O
number	-	1003	O
of	-	1010	O
striatal	-	1013	O
[	-	1022	O
3H	-	1023	O
]	-	1025	O
spiperone	-	1026	O
binding	-	1036	O
sites	-	1044	O
was	-	1050	O
not	-	1054	O
affected	-	1058	O
.	-	1066	O

In	3220106	1068	O
animals	-	1071	O
pretreated	-	1079	O
with	-	1090	O
nicotine	-	1095	O
for	-	1104	O
14	-	1108	O
days	-	1111	O
,	-	1115	O
the	-	1117	O
nicotine	-	1121	O
-	-	1129	O
induced	-	1130	O
locomotor	-	1138	O
response	-	1148	O
remained	-	1157	O
to	-	1166	O
be	-	1169	O
potentiated	-	1172	O
.	-	1183	O

However	3220106	1185	O
,	-	1192	O
this	-	1194	O
response	-	1199	O
was	-	1208	O
correlated	-	1212	O
with	-	1223	O
an	-	1228	O
elevated	-	1231	O
number	-	1240	O
of	-	1247	O
striatal	-	1250	O
[	-	1259	O
3H	-	1260	O
]	-	1262	O
spiperone	-	1263	O
binding	-	1273	O
sites	-	1281	O
,	-	1286	O
whereas	-	1288	O
the	-	1296	O
number	-	1300	O
of	-	1307	O
striatal	-	1310	O
L	-	1319	O
-	-	1320	O
[	-	1321	O
3H	-	1322	O
]	-	1324	O
nicotine	-	1325	O
binding	-	1334	O
sites	-	1342	O
and	-	1348	O
the	-	1352	O
striatal	-	1356	O
DA	-	1365	O
level	-	1368	O
were	-	1374	O
normal	-	1379	O
.	-	1385	O

These	3220106	1387	O
results	-	1393	O
suggest	-	1401	O
that	-	1409	O
chronic	-	1414	O
nicotine	-	1422	O
-	-	1430	O
treated	-	1431	O
rats	-	1439	O
develop	-	1444	O
locomotor	-	1452	B
hyperactivity	-	1462	I
in	-	1476	O
response	-	1479	O
to	-	1488	O
nicotine	-	1491	O
initially	-	1500	O
due	-	1510	O
to	-	1514	O
increases	-	1517	O
of	-	1527	O
both	-	1530	O
the	-	1535	O
density	-	1539	O
of	-	1547	O
nicotinic	-	1550	O
receptors	-	1560	O
and	-	1570	O
DA	-	1574	O
concentration	-	1577	O
,	-	1590	O
followed	-	1592	O
by	-	1601	O
inducing	-	1604	O
DA	-	1613	O
receptor	-	1616	O
supersensitivity	-	1625	O
in	-	1642	O
the	-	1645	O
striatum	-	1649	O
.	-	1657	O

Hydrocortisone	2722224	0	O
-	-	14	O
induced	-	15	O
hypertension	-	23	B
in	-	36	O
humans	-	39	O
:	-	45	O
pressor	-	47	O
responsiveness	-	55	O
and	-	70	O
sympathetic	-	74	O
function	-	86	O
.	-	94	O

Oral	2722224	96	O
hydrocortisone	-	101	O
increases	-	116	O
blood	-	126	O
pressure	-	132	O
and	-	141	O
enhances	-	145	O
pressor	-	154	O
responsiveness	-	162	O
in	-	177	O
normal	-	180	O
human	-	187	O
subjects	-	193	O
.	-	201	O

We	2722224	203	O
studied	-	206	O
the	-	214	O
effects	-	218	O
of	-	226	O
1	-	229	O
week	-	231	O
of	-	236	O
oral	-	239	O
hydrocortisone	-	244	O
(	-	259	O
200	-	260	O
mg	-	264	O
/	-	266	O
day	-	267	O
)	-	270	O
on	-	272	O
blood	-	275	O
pressure	-	281	O
,	-	289	O
cardiac	-	291	O
output	-	299	O
,	-	305	O
total	-	307	O
peripheral	-	313	O
resistance	-	324	O
,	-	334	O
forearm	-	336	O
vascular	-	344	O
resistance	-	353	O
,	-	363	O
and	-	365	O
norepinephrine	-	369	O
spillover	-	384	O
to	-	394	O
plasma	-	397	O
in	-	404	O
eight	-	407	O
healthy	-	413	O
male	-	421	O
volunteers	-	426	O
.	-	436	O

Although	2722224	438	O
diastolic	-	447	O
blood	-	457	O
pressure	-	463	O
remained	-	472	O
unchanged	-	481	O
,	-	490	O
systolic	-	492	O
blood	-	501	O
pressure	-	507	O
increased	-	516	O
from	-	526	O
119	-	531	O
to	-	535	O
135	-	538	O
mm	-	542	O
Hg	-	545	O
(	-	548	O
SED	-	549	O
+	-	553	O
/	-	554	O
-	-	555	O

3	2722224	557	O
.	-	558	O
4	-	559	O
,	-	560	O
p	-	562	O
less	-	564	O
than	-	569	O
0	-	574	O
.	-	575	O
01	-	576	O
)	-	578	O
,	-	579	O
associated	-	581	O
with	-	592	O
an	-	597	O
increased	-	600	B
cardiac	-	610	I
output	-	618	I
(	-	625	O
5	-	626	O
.	-	627	O
85	-	628	O
-	-	630	O
7	-	631	O
.	-	632	O
73	-	633	O
l	-	636	O
/	-	637	O
min	-	638	O
,	-	641	O
SED	-	643	O
+	-	647	O
/	-	648	O
-	-	649	O

0	2722224	651	O
.	-	652	O
46	-	653	O
,	-	655	O
p	-	657	O
less	-	659	O
than	-	664	O
0	-	669	O
.	-	670	O
01	-	671	O
)	-	673	O
.	-	674	O

Total	2722224	676	O
peripheral	-	682	O
vascular	-	693	O
resistance	-	702	O
fell	-	713	O
from	-	718	O
15	-	723	O
.	-	725	O
1	-	726	O
to	-	728	O
12	-	731	O
.	-	733	O
2	-	734	O
mm	-	736	O
Hg	-	739	O
/	-	741	O
l	-	742	O
/	-	743	O
min	-	744	O
(	-	748	O
SED	-	749	O
+	-	753	O
/	-	754	O
-	-	755	O

1	2722224	757	O
.	-	758	O
03	-	759	O
,	-	761	O
p	-	763	O
less	-	765	O
than	-	770	O
0	-	775	O
.	-	776	O
05	-	777	O
)	-	779	O
.	-	780	O

Resting	2722224	782	O
forearm	-	790	O
vascular	-	798	O
resistance	-	807	O
remained	-	818	O
unchanged	-	827	O
,	-	836	O
but	-	838	O
the	-	842	O
reflex	-	846	O
response	-	853	O
to	-	862	O
the	-	865	O
cold	-	869	O
pressor	-	874	O
test	-	882	O
was	-	887	O
accentuated	-	891	O
,	-	902	O
the	-	904	O
rise	-	908	O
in	-	913	O
resistance	-	916	O
increasing	-	927	O
from	-	938	O
10	-	943	O
.	-	945	O
5	-	946	O
mm	-	948	O
Hg	-	951	O
/	-	953	O
ml	-	954	O
/	-	956	O
100	-	957	O
ml	-	961	O
/	-	963	O
min	-	964	O
(	-	968	O
R	-	969	O
units	-	971	O
)	-	976	O
before	-	978	O
treatment	-	985	O
to	-	995	O
32	-	998	O
.	-	1000	O
6	-	1001	O
R	-	1003	O
units	-	1005	O
after	-	1011	O
treatment	-	1017	O
(	-	1027	O
SED	-	1028	O
+	-	1032	O
/	-	1033	O
-	-	1034	O

6	2722224	1036	O
.	-	1037	O
4	-	1038	O
,	-	1039	O
p	-	1041	O
less	-	1043	O
than	-	1048	O
0	-	1053	O
.	-	1054	O
025	-	1055	O
)	-	1058	O
.	-	1059	O

The	2722224	1061	O
rise	-	1065	O
in	-	1070	O
forearm	-	1073	O
vascular	-	1081	O
resistance	-	1090	O
accompanying	-	1101	O
intra	-	1114	O
-	-	1119	O
arterial	-	1120	O
norepinephrine	-	1129	O
(	-	1144	O
25	-	1145	O
,	-	1147	O
50	-	1149	O
,	-	1151	O
and	-	1153	O
100	-	1157	O
ng	-	1161	O
/	-	1163	O
min	-	1164	O
)	-	1167	O
was	-	1169	O
also	-	1173	O
significantly	-	1178	O
greater	-	1192	O
after	-	1200	O
hydrocortisone	-	1206	O
,	-	1220	O
increasing	-	1222	O
from	-	1233	O
an	-	1238	O
average	-	1241	O
of	-	1249	O
14	-	1252	O
.	-	1254	O
9	-	1255	O
+	-	1257	O
/	-	1258	O
-	-	1259	O

2	2722224	1261	O
.	-	1262	O
4	-	1263	O
R	-	1265	O
units	-	1267	O
before	-	1273	O
treatment	-	1280	O
to	-	1290	O
35	-	1293	O
.	-	1295	O
1	-	1296	O
+	-	1298	O
/	-	1299	O
-	-	1300	O

5	2722224	1302	O
.	-	1303	O
5	-	1304	O
R	-	1306	O
units	-	1308	O
after	-	1314	O
hydrocortisone	-	1320	O
(	-	1335	O
SED	-	1336	O
+	-	1340	O
/	-	1341	O
-	-	1342	O

6	2722224	1344	O
.	-	1345	O
0	-	1346	O
,	-	1347	O
p	-	1349	O
less	-	1351	O
than	-	1356	O
0	-	1361	O
.	-	1362	O
05	-	1363	O
)	-	1365	O
.	-	1366	O

A	2722224	1368	O
shift	-	1370	O
to	-	1376	O
the	-	1379	O
left	-	1383	O
in	-	1388	O
the	-	1391	O
dose	-	1395	O
-	-	1399	O
response	-	1400	O
relation	-	1409	O
and	-	1418	O
fall	-	1422	O
in	-	1427	O
threshold	-	1430	O
suggested	-	1440	O
increased	-	1450	O
sensitivity	-	1460	O
to	-	1472	O
norepinephrine	-	1475	O
after	-	1490	O
treatment	-	1496	O
.	-	1505	O

Measurement	2722224	1507	O
of	-	1519	O
resting	-	1522	O
norepinephrine	-	1530	O
spillover	-	1545	O
rate	-	1555	O
to	-	1560	O
plasma	-	1563	O
and	-	1570	O
norepinephrine	-	1574	O
uptake	-	1589	O
indicated	-	1596	O
that	-	1606	O
overall	-	1611	O
resting	-	1619	O
sympathetic	-	1627	O
nervous	-	1639	O
system	-	1647	O
activity	-	1654	O
was	-	1663	O
not	-	1667	O
increased	-	1671	O
.	-	1680	O

The	2722224	1682	O
rise	-	1686	B
in	-	1691	I
resting	-	1694	I
blood	-	1702	I
pressure	-	1708	I
with	-	1717	O
hydrocortisone	-	1722	O
is	-	1737	O
associated	-	1740	O
with	-	1751	O
an	-	1756	O
increased	-	1759	B
cardiac	-	1769	I
output	-	1777	I
(	-	1784	O
presumably	-	1785	O
due	-	1796	O
to	-	1800	O
increased	-	1803	O
blood	-	1813	O
volume	-	1819	O
)	-	1825	O
.	-	1826	O
(	-	1827	O
ABSTRACT	-	1828	O
TRUNCATED	-	1837	O
AT	-	1847	O
250	-	1850	O
WORDS	-	1854	O
)	-	1859	O

Effects	1636026	0	O
of	-	8	O
suprofen	-	11	O
on	-	20	O
the	-	23	O
isolated	-	27	O
perfused	-	36	O
rat	-	45	O
kidney	-	49	O
.	-	55	O

Although	1636026	57	O
suprofen	-	66	O
has	-	75	O
been	-	79	O
associated	-	84	O
with	-	95	O
the	-	100	O
development	-	104	O
of	-	116	O
acute	-	119	B
renal	-	125	I
failure	-	131	I
in	-	139	O
greater	-	142	O
than	-	150	O
100	-	155	O
subjects	-	159	O
,	-	167	O
the	-	169	O
mechanism	-	173	O
of	-	183	O
damage	-	186	O
remains	-	193	O
unclear	-	201	O
.	-	208	O

The	1636026	210	O
direct	-	214	O
nephrotoxic	-	221	B
effects	-	233	O
of	-	241	O
a	-	244	O
single	-	246	O
dose	-	253	O
of	-	258	O
15	-	261	O
mg	-	264	O
of	-	267	O
suprofen	-	270	O
were	-	279	O
compared	-	284	O
in	-	293	O
the	-	296	O
recirculating	-	300	O
isolated	-	314	O
rat	-	323	O
kidney	-	327	O
perfused	-	334	O
with	-	343	O
cell	-	348	O
-	-	352	O
free	-	353	O
buffer	-	358	O
with	-	365	O
or	-	370	O
without	-	373	O
the	-	381	O
addition	-	385	O
of	-	394	O
5	-	397	O
mg	-	399	O
/	-	401	O
dL	-	402	O
of	-	405	O
uric	-	408	O
acid	-	413	O
.	-	417	O

There	1636026	419	O
were	-	425	O
no	-	430	O
significant	-	433	O
differences	-	445	O
in	-	457	O
renal	-	460	O
sodium	-	466	O
excretion	-	473	O
,	-	482	O
oxygen	-	484	O
consumption	-	491	O
,	-	502	O
or	-	504	O
urinary	-	507	O
flow	-	515	O
rates	-	520	O
in	-	526	O
kidneys	-	529	O
perfused	-	537	O
with	-	546	O
suprofen	-	551	O
compared	-	560	O
with	-	569	O
the	-	574	O
drug	-	578	O
-	-	582	O
free	-	583	O
control	-	588	O
groups	-	596	O
.	-	602	O

In	1636026	604	O
contrast	-	607	O
,	-	615	O
a	-	617	O
significant	-	619	O
decline	-	631	O
in	-	639	O
glomerular	-	642	O
filtration	-	653	O
rate	-	664	O
was	-	669	O
found	-	673	O
after	-	679	O
the	-	685	O
introduction	-	689	O
of	-	702	O
suprofen	-	705	O
to	-	714	O
the	-	717	O
kidney	-	721	O
perfused	-	728	O
with	-	737	O
uric	-	742	O
acid	-	747	O
;	-	751	O
no	-	753	O
changes	-	756	O
were	-	764	O
found	-	769	O
with	-	775	O
suprofen	-	780	O
in	-	789	O
the	-	792	O
absence	-	796	O
of	-	804	O
uric	-	807	O
acid	-	812	O
.	-	816	O

A	1636026	818	O
significant	-	820	O
decrease	-	832	O
in	-	841	O
the	-	844	O
baseline	-	848	O
excretion	-	857	O
rate	-	867	O
of	-	872	O
uric	-	875	O
acid	-	880	O
was	-	885	O
found	-	889	O
in	-	895	O
rats	-	898	O
given	-	903	O
suprofen	-	909	O
,	-	917	O
compared	-	919	O
with	-	928	O
drug	-	933	O
-	-	937	O
free	-	938	O
controls	-	943	O
.	-	951	O

However	1636026	953	O
,	-	960	O
the	-	962	O
fractional	-	966	O
excretion	-	977	O
of	-	987	O
uric	-	990	O
acid	-	995	O
was	-	1000	O
unchanged	-	1004	O
between	-	1014	O
the	-	1022	O
groups	-	1026	O
over	-	1033	O
the	-	1038	O
experimental	-	1042	O
period	-	1055	O
.	-	1061	O

In	1636026	1063	O
summary	-	1066	O
,	-	1073	O
suprofen	-	1075	O
causes	-	1084	O
acute	-	1091	B
declines	-	1097	I
in	-	1106	I
renal	-	1109	I
function	-	1115	I
,	-	1123	O
most	-	1125	O
likely	-	1130	O
by	-	1137	O
directly	-	1140	O
altering	-	1149	O
the	-	1158	O
intrarenal	-	1162	O
distribution	-	1173	O
of	-	1186	O
uric	-	1189	O
acid	-	1194	O
.	-	1198	O

Cocaine	1610717	0	O
-	-	7	O
induced	-	8	O
brainstem	-	16	O
seizures	-	26	B
and	-	35	O
behavior	-	39	O
.	-	47	O

A	1610717	49	O
variety	-	51	O
of	-	59	O
abnormal	-	62	O
sensory	-	71	O
/	-	78	O
motor	-	79	O
behaviors	-	85	O
associated	-	95	O
with	-	106	O
electrical	-	111	O
discharges	-	122	O
recorded	-	133	O
from	-	142	O
the	-	147	O
bilateral	-	151	O
brainstem	-	161	O
were	-	171	O
induced	-	176	O
in	-	184	O
adult	-	187	O
WKY	-	193	O
rats	-	197	O
by	-	202	O
mechanical	-	205	O
(	-	216	O
electrode	-	217	O
implants	-	227	O
)	-	235	O
and	-	237	O
DC	-	241	O
electrical	-	244	O
current	-	255	O
stimulations	-	263	O
and	-	276	O
by	-	280	O
acute	-	283	O
and	-	289	O
chronic	-	293	O
administration	-	301	O
of	-	316	O
cocaine	-	319	O
.	-	326	O

The	1610717	328	O
electrode	-	332	O
implant	-	342	O
implicated	-	350	O
one	-	361	O
side	-	365	O
or	-	370	O
the	-	373	O
other	-	377	O
of	-	383	O
the	-	386	O
reticular	-	390	O
system	-	400	O
of	-	407	O
the	-	410	O
brainstem	-	414	O
but	-	424	O
subjects	-	428	O
were	-	437	O
not	-	442	O
incapacitated	-	446	O
by	-	460	O
the	-	463	O
stimulations	-	467	O
.	-	479	O

Cocaine	1610717	481	O
(	-	489	O
40	-	490	O
mg	-	493	O
/	-	495	O
kg	-	496	O
)	-	498	O
was	-	500	O
injected	-	504	O
subcutaneously	-	513	O
for	-	528	O
an	-	532	O
acute	-	535	O
experiment	-	541	O
and	-	552	O
subsequent	-	556	O
20	-	567	O
mg	-	570	O
/	-	572	O
kg	-	573	O
doses	-	576	O
twice	-	582	O
daily	-	588	O
for	-	594	O
3	-	598	O
days	-	600	O
in	-	605	O
a	-	608	O
chronic	-	610	O
study	-	618	O
.	-	623	O

Cocaine	1610717	625	O
generated	-	633	O
more	-	643	O
abnormal	-	648	O
behaviors	-	657	O
in	-	667	O
the	-	670	O
brainstem	-	674	O
perturbation	-	684	O
group	-	697	O
,	-	702	O
especially	-	704	O
the	-	715	O
electrically	-	719	O
perturbated	-	732	O
subjects	-	744	O
.	-	752	O

The	1610717	754	O
abnormal	-	758	O
behaviors	-	767	O
were	-	777	O
yawning	-	782	O
,	-	789	O
retrocollis	-	791	O
,	-	802	O
hyperactivity	-	804	B
,	-	817	O
hypersensitivity	-	819	B
,	-	835	O
""""	-	837	O
beating	-	838	O
drum	-	846	O
""""	-	850	O
behavior	-	852	O
,	-	860	O
squealing	-	862	O
,	-	871	O
head	-	873	O
bobbing	-	878	O
,	-	885	O
circling	-	887	O
,	-	895	O
sniffing	-	897	O
,	-	905	O
abnormal	-	907	O
posturing	-	916	O
,	-	925	O
and	-	927	O
facial	-	931	O
twitching	-	938	O
.	-	947	O

Shifts	1610717	949	O
in	-	956	O
the	-	959	O
power	-	963	O
frequency	-	969	O
spectra	-	979	O
of	-	987	O
the	-	990	O
discharge	-	994	O
patterns	-	1004	O
were	-	1013	O
noted	-	1018	O
between	-	1024	O
quiet	-	1032	O
and	-	1038	O
pacing	-	1042	O
behavioral	-	1049	O
states	-	1060	O
.	-	1066	O

Hypersensitivity	1610717	1068	B
to	-	1085	O
various	-	1088	O
auditory	-	1096	O
,	-	1104	O
tactile	-	1106	O
,	-	1113	O
and	-	1115	O
visual	-	1119	O
stimulation	-	1126	O
was	-	1138	O
present	-	1142	O
and	-	1150	O
shifts	-	1154	O
in	-	1161	O
the	-	1164	O
brainstem	-	1168	O
ambient	-	1178	O
power	-	1186	O
spectral	-	1192	O
frequency	-	1201	O
occurred	-	1211	O
in	-	1220	O
response	-	1223	O
to	-	1232	O
tactile	-	1235	O
stimulation	-	1243	O
.	-	1254	O

These	1610717	1256	O
findings	-	1262	O
suggest	-	1271	O
that	-	1279	O
the	-	1284	O
brainstem	-	1288	O
generates	-	1298	O
and	-	1308	O
propagates	-	1312	O
pathological	-	1323	O
discharges	-	1336	O
that	-	1347	O
can	-	1352	O
be	-	1356	O
elicited	-	1359	O
by	-	1368	O
mechanical	-	1371	O
and	-	1382	O
DC	-	1386	O
electrical	-	1389	O
perturbation	-	1400	O
.	-	1412	O

Cocaine	1610717	1414	O
was	-	1422	O
found	-	1426	O
to	-	1432	O
activate	-	1435	O
the	-	1444	O
discharge	-	1448	O
system	-	1458	O
and	-	1465	O
thus	-	1469	O
induce	-	1474	O
abnormal	-	1481	O
behaviors	-	1490	O
that	-	1500	O
are	-	1505	O
generated	-	1509	O
at	-	1519	O
the	-	1522	O
discharge	-	1526	O
site	-	1536	O
and	-	1541	O
at	-	1545	O
distant	-	1548	O
sites	-	1556	O
to	-	1562	O
which	-	1565	O
the	-	1571	O
discharge	-	1575	O
propagates	-	1585	O
.	-	1595	O

Cognitive	1610717	1597	O
functions	-	1607	O
may	-	1617	O
also	-	1621	O
be	-	1626	O
involved	-	1629	O
since	-	1638	O
dopaminergic	-	1644	O
and	-	1657	O
serotonergic	-	1661	O
cellular	-	1674	O
elements	-	1683	O
at	-	1692	O
the	-	1695	O
brainstem	-	1699	O
level	-	1709	O
are	-	1715	O
also	-	1719	O
implicated	-	1724	O
.	-	1734	O

Increased	873132	0	O
sulfation	-	10	O
and	-	20	O
decreased	-	24	O
7alpha	-	34	O
-	-	40	O
hydroxylation	-	41	O
of	-	55	O
deoxycholic	-	58	O
acid	-	70	O
in	-	75	O
ethinyl	-	78	O
estradiol	-	86	O
-	-	95	O
induced	-	96	O
cholestasis	-	104	B
in	-	116	O
rats	-	119	O
.	-	123	O

Deoxycholic	873132	125	O
acid	-	137	O
conjugation	-	142	O
,	-	153	O
transport	-	155	O
capacity	-	165	O
,	-	173	O
and	-	175	O
metabolism	-	179	O
were	-	190	O
compared	-	195	O
in	-	204	O
control	-	207	O
and	-	215	O
ethinyl	-	219	O
estradiol	-	227	O
-	-	236	O
treated	-	237	O
rats	-	245	O
.	-	249	O

Control	873132	251	O
rats	-	259	O
were	-	264	O
found	-	269	O
to	-	275	O
have	-	278	O
a	-	283	O
lower	-	285	O
capacity	-	291	O
to	-	300	O
transport	-	303	O
deoxycholic	-	313	O
acid	-	325	O
than	-	330	O
taurodeoxycholic	-	335	O
acid	-	352	O
,	-	356	O
and	-	358	O
both	-	362	O
were	-	367	O
decreased	-	372	O
by	-	382	O
ethinyl	-	385	O
estradiol	-	393	O
treatment	-	403	O
.	-	412	O

During	873132	414	O
[	-	421	O
24	-	422	O
-	-	424	O
14C	-	425	O
]	-	428	O
sodium	-	429	O
deoxycholate	-	436	O
infusion	-	449	O
,	-	457	O
[	-	459	O
14C	-	460	O
]	-	463	O
biliary	-	464	O
bile	-	472	O
acid	-	477	O
secretion	-	482	O
increased	-	492	O
,	-	501	O
but	-	503	O
bile	-	507	O
flow	-	512	O
did	-	517	O
not	-	521	O
change	-	525	O
significantly	-	532	O
in	-	546	O
either	-	549	O
control	-	556	O
or	-	564	O
ethinyl	-	567	O
estradiol	-	575	O
-	-	584	O
treated	-	585	O
rats	-	593	O
.	-	597	O

Ethinyl	873132	599	O
estradiol	-	607	O
-	-	616	O
treated	-	617	O
animals	-	625	O
excreted	-	633	O
significantly	-	642	O
less	-	656	O
14C	-	661	O
as	-	665	O
taurocholic	-	668	O
acid	-	680	O
than	-	685	O
did	-	690	O
control	-	694	O
animals	-	702	O
,	-	709	O
consistent	-	711	O
with	-	722	O
an	-	727	O
impairment	-	730	O
of	-	741	O
7alpha	-	744	O
-	-	750	O
hydroxylation	-	751	O
of	-	765	O
taurodeoxycholic	-	768	O
acid	-	785	O
.	-	789	O

Ethinyl	873132	791	O
estradiol	-	799	O
treatment	-	809	O
did	-	819	O
not	-	823	O
impair	-	827	O
conjugation	-	834	O
of	-	846	O
deoxycholic	-	849	O
acid	-	861	O
,	-	865	O
but	-	867	O
did	-	871	O
result	-	875	O
in	-	882	O
an	-	885	O
increase	-	888	O
in	-	897	O
sulfation	-	900	O
of	-	910	O
taurodeoxycholic	-	913	O
acid	-	930	O
from	-	935	O
1	-	940	O
.	-	941	O
5	-	942	O
%	-	943	O
in	-	945	O
controls	-	948	O
to	-	957	O
nearly	-	960	O
4	-	967	O
.	-	968	O
0	-	969	O
%	-	970	O
(	-	972	O
P	-	973	O
less	-	975	O
than	-	980	O
0	-	985	O
.	-	986	O
01	-	987	O
)	-	989	O
.	-	990	O

These	873132	992	O
results	-	998	O
are	-	1006	O
consistent	-	1010	O
with	-	1021	O
the	-	1026	O
hypothesis	-	1030	O
that	-	1041	O
the	-	1046	O
rat	-	1050	O
has	-	1054	O
a	-	1058	O
poorer	-	1060	O
tolerance	-	1067	O
for	-	1077	O
deoxycholic	-	1081	O
acid	-	1093	O
than	-	1098	O
do	-	1103	O
certain	-	1106	O
other	-	1114	O
species	-	1120	O
.	-	1127	O

Furthermore	873132	1129	O
,	-	1140	O
the	-	1142	O
rat	-	1146	O
converts	-	1150	O
deoxycholic	-	1159	O
acid	-	1171	O
,	-	1175	O
a	-	1177	O
poor	-	1179	O
choleretic	-	1184	O
,	-	1194	O
to	-	1196	O
taurocholic	-	1199	O
acid	-	1211	O
,	-	1215	O
a	-	1217	O
good	-	1219	O
choleretic	-	1224	O
.	-	1234	O

When	873132	1236	O
this	-	1241	O
conversion	-	1246	O
is	-	1257	O
impaired	-	1260	O
with	-	1269	O
ethinyl	-	1274	O
estradiol	-	1282	O
treatment	-	1292	O
,	-	1301	O
sulfation	-	1303	O
may	-	1313	O
be	-	1317	O
an	-	1320	O
important	-	1323	O
alternate	-	1333	O
pathway	-	1343	O
for	-	1351	O
excretion	-	1355	O
of	-	1365	O
this	-	1368	O
potentially	-	1373	O
harmful	-	1385	O
bile	-	1393	O
acid	-	1398	O
.	-	1402	O

Effects	783197	0	O
of	-	8	O
ouabain	-	11	O
on	-	19	O
myocardial	-	22	O
oxygen	-	33	O
supply	-	40	O
and	-	47	O
demand	-	51	O
in	-	58	O
patients	-	61	O
with	-	70	O
chronic	-	75	O
coronary	-	83	B
artery	-	92	I
disease	-	99	I
.	-	106	O

A	783197	108	O
hemodynamic	-	110	O
,	-	121	O
volumetric	-	123	O
,	-	133	O
and	-	135	O
metabolic	-	139	O
study	-	149	O
in	-	155	O
patients	-	158	O
without	-	167	O
heart	-	175	B
failure	-	181	I
.	-	188	O

The	783197	190	O
effects	-	194	O
of	-	202	O
digitalis	-	205	O
glycosides	-	215	O
on	-	226	O
myocardial	-	229	O
oxygen	-	240	O
supply	-	247	O
and	-	254	O
demand	-	258	O
are	-	265	O
of	-	269	O
particular	-	272	O
interest	-	283	O
in	-	292	O
the	-	295	O
presence	-	299	O
of	-	308	O
obstructive	-	311	O
coronary	-	323	B
artery	-	332	I
disease	-	339	I
,	-	346	O
but	-	348	O
have	-	352	O
not	-	357	O
been	-	361	O
measured	-	366	O
previously	-	375	O
in	-	386	O
man	-	389	O
.	-	392	O

We	783197	394	O
assessed	-	397	O
the	-	406	O
effects	-	410	O
of	-	418	O
ouabain	-	421	O
(	-	429	O
0	-	430	O
.	-	431	O
015	-	432	O
mg	-	436	O
/	-	438	O
kg	-	439	O
body	-	442	O
weight	-	447	O
)	-	453	O
on	-	455	O
hemodynamic	-	458	O
,	-	469	O
volumetric	-	471	O
,	-	481	O
and	-	483	O
metabolic	-	487	O
parameters	-	497	O
in	-	508	O
11	-	511	O
patients	-	514	O
with	-	523	O
severe	-	528	O
chronic	-	535	O
coronary	-	543	B
artery	-	552	I
disease	-	559	I
without	-	567	O
clinical	-	575	O
congestive	-	584	B
heart	-	595	I
failure	-	601	I
.	-	608	O

Because	783197	610	O
the	-	618	O
protocol	-	622	O
was	-	631	O
long	-	635	O
and	-	640	O
involved	-	644	O
interventions	-	653	O
which	-	667	O
might	-	673	O
affect	-	679	O
the	-	686	O
determinations	-	690	O
,	-	704	O
we	-	706	O
also	-	709	O
studied	-	714	O
in	-	722	O
nine	-	725	O
patients	-	730	O
using	-	739	O
an	-	745	O
identical	-	748	O
protocol	-	758	O
except	-	767	O
that	-	774	O
ouabain	-	779	O
administration	-	787	O
was	-	802	O
omitted	-	806	O
.	-	813	O

Left	783197	815	O
ventricular	-	820	O
end	-	832	O
-	-	835	O
diastolic	-	836	O
pressure	-	846	O
and	-	855	O
left	-	859	O
ventricular	-	864	O
end	-	876	O
-	-	879	O
diastolic	-	880	O
volume	-	890	O
fell	-	897	O
in	-	902	O
each	-	905	O
patient	-	910	O
given	-	918	O
ouabain	-	924	O
,	-	931	O
even	-	933	O
though	-	938	O
they	-	945	O
were	-	950	O
initially	-	955	O
elevated	-	965	O
in	-	974	O
only	-	977	O
two	-	982	O
patients	-	986	O
.	-	994	O

Left	783197	996	O
ventricular	-	1001	O
end	-	1013	O
-	-	1016	O
diastolic	-	1017	O
pressure	-	1027	O
fell	-	1036	O
from	-	1041	O
11	-	1046	O
.	-	1048	O
5	-	1049	O
+	-	1050	O
/	-	1051	O
-	-	1052	O
1	-	1053	O
.	-	1054	O
4	-	1055	O
(	-	1057	O
mean	-	1058	O
+	-	1062	O
/	-	1063	O
-	-	1064	O
SE	-	1065	O
)	-	1067	O
to	-	1069	O
5	-	1072	O
.	-	1073	O
6	-	1074	O
+	-	1075	O
/	-	1076	O
-	-	1077	O
0	-	1078	O
.	-	1079	O
9	-	1080	O
mm	-	1082	O
Hg	-	1085	O
(	-	1088	O
P	-	1089	O
less	-	1091	O
than	-	1096	O
0	-	1101	O
.	-	1102	O
001	-	1103	O
)	-	1106	O
and	-	1108	O
left	-	1112	O
ventricular	-	1117	O
end	-	1129	O
-	-	1132	O
diastolic	-	1133	O
volume	-	1143	O
fell	-	1150	O
from	-	1155	O
100	-	1160	O
+	-	1163	O
/	-	1164	O
-	-	1165	O
17	-	1166	O
to	-	1169	O
82	-	1172	O
+	-	1174	O
/	-	1175	O
-	-	1176	O
12	-	1177	O
ml	-	1180	O
/	-	1182	O
m2	-	1183	O
(	-	1186	O
P	-	1187	O
less	-	1189	O
than	-	1194	O
0	-	1199	O
.	-	1200	O
01	-	1201	O
)	-	1203	O
1	-	1205	O
h	-	1207	O
after	-	1209	O
ouabain	-	1215	O
infusion	-	1223	O
was	-	1232	O
completed	-	1236	O
.	-	1245	O

The	783197	1247	O
maximum	-	1251	O
velocity	-	1259	O
of	-	1268	O
contractile	-	1271	O
element	-	1283	O
shortening	-	1291	O
increased	-	1302	O
from	-	1312	O
1	-	1317	O
.	-	1318	O
68	-	1319	O
+	-	1321	O
/	-	1322	O
-	-	1323	O
0	-	1324	O
.	-	1325	O
11	-	1326	O
ml	-	1329	O
/	-	1331	O
s	-	1332	O
to	-	1334	O
2	-	1337	O
.	-	1338	O
18	-	1339	O
+	-	1341	O
/	-	1342	O
-	-	1343	O
0	-	1344	O
.	-	1345	O
21	-	1346	O
muscle	-	1349	O
-	-	1355	O
lengths	-	1356	O
/	-	1363	O
s	-	1364	O
(	-	1366	O
P	-	1367	O
less	-	1369	O
than	-	1374	O
0	-	1379	O
.	-	1380	O
05	-	1381	O
)	-	1383	O
and	-	1385	O
is	-	1389	O
consistent	-	1392	O
with	-	1403	O
an	-	1408	O
increase	-	1411	O
in	-	1420	O
contractility	-	1423	O
.	-	1436	O

No	783197	1438	O
significant	-	1441	O
change	-	1453	O
in	-	1460	O
these	-	1463	O
parameters	-	1469	O
occurred	-	1480	O
in	-	1489	O
the	-	1492	O
control	-	1496	O
patients	-	1504	O
.	-	1512	O

No	783197	1514	O
significant	-	1517	O
change	-	1529	O
in	-	1536	O
myocardial	-	1539	O
oxygen	-	1550	O
consumption	-	1557	O
occurred	-	1569	O
after	-	1578	O
ouabain	-	1584	O
administration	-	1592	O
but	-	1607	O
this	-	1611	O
may	-	1616	O
be	-	1620	O
related	-	1623	O
to	-	1631	O
a	-	1634	O
greater	-	1636	O
decrease	-	1644	O
in	-	1653	O
mean	-	1656	O
arterial	-	1661	O
pressure	-	1670	O
in	-	1679	O
the	-	1682	O
ouabain	-	1686	O
patients	-	1694	O
than	-	1703	O
in	-	1708	O
the	-	1711	O
control	-	1715	O
patients	-	1723	O
.	-	1731	O

We	783197	1733	O
conclude	-	1736	O
that	-	1745	O
in	-	1750	O
patients	-	1753	O
with	-	1762	O
chronic	-	1767	O
coronary	-	1775	B
artery	-	1784	I
disease	-	1791	I
who	-	1799	O
are	-	1803	O
not	-	1807	O
in	-	1811	O
clinical	-	1814	O
congestive	-	1823	B
heart	-	1834	I
failure	-	1840	I
left	-	1848	B
ventricular	-	1853	I
end	-	1865	I
-	-	1868	I
diastolic	-	1869	I
volume	-	1879	I
falls	-	1886	I
after	-	1892	O
ouabain	-	1898	O
administration	-	1906	O
even	-	1921	O
when	-	1926	O
it	-	1931	O
is	-	1934	O
initially	-	1937	O
normal	-	1947	O
.	-	1953	O

Though	783197	1955	O
this	-	1962	O
fall	-	1967	O
would	-	1972	O
be	-	1978	O
associated	-	1981	O
with	-	1992	O
a	-	1997	O
decrease	-	1999	O
in	-	2008	O
wall	-	2011	O
tension	-	2016	O
,	-	2023	O
and	-	2025	O
,	-	2028	O
therefore	-	2030	O
,	-	2039	O
of	-	2041	O
myocardial	-	2044	O
oxygen	-	2055	O
consumption	-	2062	O
,	-	2073	O
it	-	2075	O
may	-	2078	O
not	-	2082	O
be	-	2086	O
of	-	2089	O
sufficient	-	2092	O
magnitude	-	2103	O
to	-	2113	O
prevent	-	2116	O
a	-	2124	O
net	-	2126	O
increase	-	2130	O
in	-	2139	O
myocardial	-	2142	O
oxygen	-	2153	O
consumption	-	2160	O
.	-	2171	O

Nevertheless	783197	2173	O
,	-	2185	O
compensatory	-	2187	O
mechanisms	-	2200	O
prevent	-	2211	O
a	-	2219	O
deterioration	-	2221	O
of	-	2235	O
resting	-	2238	O
myocardial	-	2246	O
metabolism	-	2257	O
.	-	2267	O

Prolongation	9545159	0	B
of	-	13	I
the	-	16	I
QT	-	20	I
interval	-	23	I
related	-	32	O
to	-	40	O
cisapride	-	43	O
-	-	52	O
diltiazem	-	53	O
interaction	-	63	O
.	-	74	O

Cisapride	9545159	76	O
,	-	85	O
a	-	87	O
cytochrome	-	89	O
P450	-	100	O
3A4	-	105	O
(	-	109	O
CYP3A4	-	110	O
)	-	116	O
substrate	-	118	O
,	-	127	O
is	-	129	O
widely	-	132	O
prescribed	-	139	O
for	-	150	O
the	-	154	O
treatment	-	158	O
of	-	168	O
gastrointestinal	-	171	B
motility	-	188	I
disorders	-	197	I
.	-	206	O

Prolongation	9545159	208	B
of	-	221	I
QT	-	224	I
interval	-	227	I
,	-	235	O
torsades	-	237	B
de	-	246	I
pointes	-	249	I
,	-	256	O
and	-	258	O
sudden	-	262	B
cardiac	-	269	I
death	-	277	I
have	-	283	O
been	-	288	O
reported	-	293	O
after	-	302	O
concomitant	-	308	O
administration	-	320	O
with	-	335	O
erythromycin	-	340	O
or	-	353	O
azole	-	356	O
antifungal	-	362	O
agents	-	373	O
,	-	379	O
but	-	381	O
not	-	385	O
with	-	389	O
other	-	394	O
CYP3A4	-	400	O
inhibitors	-	407	O
.	-	417	O

A	9545159	419	O
possible	-	421	O
drug	-	430	O
interaction	-	435	O
occurred	-	447	O
in	-	456	O
a	-	459	O
45	-	461	O
-	-	463	O
year	-	464	O
-	-	468	O
old	-	469	O
woman	-	473	O
who	-	479	O
was	-	483	O
taking	-	487	O
cisapride	-	494	O
for	-	504	O
gastroesophageal	-	508	B
reflux	-	525	I
disorder	-	532	I
and	-	541	O
diltiazem	-	545	O
,	-	554	O
an	-	556	O
agent	-	559	O
that	-	565	O
has	-	570	O
inhibitory	-	574	O
effect	-	585	O
on	-	592	O
CYP3A4	-	595	O
,	-	601	O
for	-	603	O
hypertension	-	607	B
.	-	619	O

The	9545159	621	O
patient	-	625	O
was	-	633	O
in	-	637	O
near	-	640	O
syncope	-	645	B
and	-	653	O
had	-	657	O
QT	-	661	B
-	-	663	I
interval	-	664	I
prolongation	-	673	I
.	-	685	O

After	9545159	687	O
discontinuing	-	693	O
cisapride	-	707	O
,	-	716	O
the	-	718	O
QT	-	722	O
interval	-	725	O
returned	-	734	O
to	-	743	O
normal	-	746	O
and	-	753	O
symptoms	-	757	O
did	-	766	O
not	-	770	O
recur	-	774	O
.	-	779	O

We	9545159	781	O
suggest	-	784	O
that	-	792	O
caution	-	797	O
be	-	805	O
taken	-	808	O
when	-	814	O
cisapride	-	819	O
is	-	829	O
prescribed	-	832	O
with	-	843	O
any	-	848	O
potent	-	852	O
inhibitor	-	859	O
of	-	869	O
CYP3A4	-	872	O
,	-	878	O
including	-	880	O
diltiazem	-	890	O
.	-	899	O

Paclitaxel	8643973	0	O
combined	-	11	O
with	-	20	O
carboplatin	-	25	O
in	-	37	O
the	-	40	O
first	-	44	O
-	-	49	O
line	-	50	O
treatment	-	55	O
of	-	65	O
advanced	-	68	O
ovarian	-	77	B
cancer	-	85	I
.	-	91	O

In	8643973	93	O
a	-	96	O
phase	-	98	O
I	-	104	O
study	-	106	O
to	-	112	O
determine	-	115	O
the	-	125	O
maximum	-	129	O
tolerated	-	137	O
dose	-	147	O
of	-	152	O
paclitaxel	-	155	O
(	-	166	O
Taxol	-	167	O
;	-	172	O
Bristol	-	174	O
-	-	181	O
Myers	-	182	O
Squibb	-	188	O
Company	-	195	O
,	-	202	O
Princeton	-	204	O
,	-	213	O
NJ	-	215	O
)	-	217	O
given	-	219	O
as	-	225	O
a	-	228	O
3	-	230	O
-	-	231	O
hour	-	232	O
infusion	-	237	O
in	-	246	O
combination	-	249	O
with	-	261	O
carboplatin	-	266	O
administered	-	278	O
every	-	291	O
21	-	297	O
days	-	300	O
to	-	305	O
women	-	308	O
with	-	314	O
advanced	-	319	O
ovarian	-	328	B
cancer	-	336	I
,	-	342	O
paclitaxel	-	344	O
doses	-	355	O
were	-	361	O
escalated	-	366	O
as	-	376	O
follows	-	379	O
:	-	386	O

level	8643973	388	O
1	-	394	O
,	-	395	O
135	-	397	O
mg	-	401	O
/	-	403	O
m2	-	404	O
;	-	406	O
level	-	408	O
2	-	414	O
,	-	415	O
160	-	417	O
mg	-	421	O
/	-	423	O
m2	-	424	O
;	-	426	O
level	-	428	O
3	-	434	O
,	-	435	O
185	-	437	O
mg	-	441	O
/	-	443	O
m2	-	444	O
;	-	446	O
and	-	448	O
level	-	452	O
4	-	458	O
,	-	459	O
210	-	460	O
mg	-	464	O
/	-	466	O
m2	-	467	O
.	-	469	O

The	8643973	471	O
fixed	-	475	O
dose	-	481	O
of	-	486	O
carboplatin	-	489	O
at	-	501	O
levels	-	504	O
1	-	511	O
through	-	513	O
4	-	521	O
was	-	523	O
given	-	527	O
to	-	533	O
achieve	-	536	O
an	-	544	O
area	-	547	O
under	-	552	O
the	-	558	O
concentration	-	562	O
-	-	575	O
time	-	576	O
curve	-	581	O
(	-	587	O
AUC	-	588	O
)	-	591	O
of	-	593	O
5	-	596	O
using	-	598	O
the	-	604	O
Calvert	-	608	O
formula	-	616	O
.	-	623	O

In	8643973	625	O
levels	-	628	O
5	-	635	O
and	-	637	O
6	-	641	O
the	-	643	O
carboplatin	-	647	O
dose	-	659	O
was	-	664	O
targeted	-	668	O
at	-	677	O
AUCs	-	680	O
of	-	685	O
6	-	688	O
and	-	690	O
7	-	694	O
.	-	695	O
5	-	696	O
,	-	697	O
respectively	-	699	O
,	-	711	O
combined	-	713	O
with	-	722	O
a	-	727	O
fixed	-	729	O
paclitaxel	-	735	O
dose	-	746	O
of	-	751	O
185	-	754	O
mg	-	758	O
/	-	760	O
m2	-	761	O
.	-	763	O

To	8643973	765	O
date	-	768	O
,	-	772	O
30	-	774	O
previously	-	777	O
untreated	-	788	O
patients	-	798	O
,	-	806	O
all	-	808	O
with	-	812	O
a	-	817	O
good	-	819	O
performance	-	824	O
status	-	836	O
(	-	843	O
Eastern	-	844	O
Cooperative	-	852	O
Oncology	-	864	O
Group	-	873	O
0	-	879	O
to	-	881	O
2	-	884	O
)	-	885	O
have	-	887	O
been	-	892	O
entered	-	897	O
into	-	905	O
this	-	910	O
ongoing	-	915	O
study	-	923	O
.	-	928	O

The	8643973	930	O
dose	-	934	O
-	-	938	O
limiting	-	939	O
toxicity	-	948	B
of	-	957	O
the	-	960	O
combination	-	964	O
was	-	976	O
myelosuppression	-	980	B
(	-	997	O
leukopenia	-	998	B
,	-	1008	O
granulocytopenia	-	1010	B
,	-	1026	O
and	-	1028	O
thrombocytopenia	-	1032	B
)	-	1048	O
.	-	1049	O

Neurotoxicity	8643973	1051	B
was	-	1065	O
largely	-	1069	O
moderate	-	1077	O
.	-	1085	O

So	8643973	1087	O
far	-	1090	O
,	-	1093	O
14	-	1095	O
patients	-	1098	O
are	-	1107	O
evaluable	-	1111	O
for	-	1121	O
response	-	1125	O
;	-	1133	O
of	-	1135	O
these	-	1138	O
,	-	1143	O
eight	-	1145	O
(	-	1151	O
57	-	1152	O
%	-	1154	O
)	-	1155	O
showed	-	1157	O
objective	-	1164	O
(	-	1174	O
complete	-	1175	O
or	-	1184	O
partial	-	1187	O
)	-	1194	O
response	-	1196	O
and	-	1205	O
disease	-	1209	O
stabilized	-	1217	O
in	-	1228	O
six	-	1231	O
patients	-	1235	O
.	-	1243	O

No	8643973	1245	O
patient	-	1248	O
had	-	1256	O
disease	-	1260	O
progression	-	1268	O
.	-	1279	O

We	8643973	1281	O
conclude	-	1284	O
that	-	1293	O
the	-	1298	O
combination	-	1302	O
of	-	1314	O
paclitaxel	-	1317	O
185	-	1328	O
mg	-	1332	O
/	-	1334	O
m2	-	1335	O
administered	-	1338	O
as	-	1351	O
a	-	1354	O
3	-	1356	O
-	-	1357	O
hour	-	1358	O
infusion	-	1363	O
followed	-	1372	O
immediately	-	1381	O
by	-	1393	O
a	-	1396	O
1	-	1398	O
-	-	1399	O
hour	-	1400	O
infusion	-	1405	O
of	-	1414	O
carboplatin	-	1417	O
at	-	1429	O
an	-	1432	O
AUC	-	1435	O
of	-	1439	O
6	-	1442	O
can	-	1444	O
be	-	1448	O
administered	-	1451	O
safely	-	1464	O
in	-	1471	O
a	-	1474	O
21	-	1476	O
-	-	1478	O
day	-	1479	O
schedule	-	1483	O
in	-	1492	O
the	-	1495	O
outpatient	-	1499	O
setting	-	1510	O
.	-	1517	O

The	8643973	1519	O
recommended	-	1523	O
dose	-	1535	O
for	-	1540	O
phase	-	1544	O
III	-	1550	O
studies	-	1554	O
is	-	1562	O
paclitaxel	-	1565	O
185	-	1576	O
mg	-	1580	O
/	-	1582	O
m2	-	1583	O
and	-	1586	O
carboplatin	-	1590	O
AUC	-	1602	O
6	-	1606	O
.	-	1607	O

Treatment	10743694	0	O
of	-	10	O
tacrolimus	-	13	O
-	-	23	O
related	-	24	O
adverse	-	32	O
effects	-	40	O
by	-	48	O
conversion	-	51	O
to	-	62	O
cyclosporine	-	65	O
in	-	78	O
liver	-	81	O
transplant	-	87	O
recipients	-	98	O
.	-	108	O

When	10743694	110	O
tacrolimus	-	115	O
side	-	126	O
effects	-	131	O
persist	-	139	O
despite	-	147	O
dose	-	155	O
reduction	-	160	O
,	-	169	O
conversion	-	171	O
to	-	182	O
cyclosporine	-	185	O
-	-	197	O
based	-	198	O
immunosuppression	-	204	O
(	-	222	O
CyA	-	223	O
)	-	226	O
is	-	228	O
necessary	-	231	O
.	-	240	O

We	10743694	242	O
characterized	-	245	O
tacrolimus	-	259	O
side	-	270	O
effects	-	275	O
that	-	283	O
warranted	-	288	O
discontinuation	-	298	O
of	-	314	O
the	-	317	O
drug	-	321	O
,	-	325	O
and	-	327	O
outcomes	-	331	O
after	-	340	O
conversion	-	346	O
.	-	356	O

Of	10743694	358	O
388	-	361	O
liver	-	365	O
recipients	-	371	O
who	-	382	O
received	-	386	O
tacrolimus	-	395	O
as	-	406	O
primary	-	409	O
immunosuppression	-	417	O
,	-	434	O
70	-	436	O
required	-	439	O
conversion	-	448	O
to	-	459	O
CyA	-	462	O
.	-	465	O

We	10743694	467	O
recorded	-	470	O
indication	-	479	O
for	-	490	O
conversion	-	494	O
,	-	504	O
whether	-	506	O
conversion	-	514	O
was	-	525	O
early	-	529	O
or	-	535	O
late	-	538	O
after	-	543	O
transplantation	-	549	O
,	-	564	O
tacrolimus	-	566	O
dose	-	577	O
and	-	582	O
trough	-	586	O
blood	-	593	O
level	-	599	O
at	-	605	O
conversion	-	608	O
,	-	618	O
and	-	620	O
incidence	-	624	O
of	-	634	O
rejection	-	637	O
after	-	647	O
conversion	-	653	O
.	-	663	O

Conversion	10743694	665	O
was	-	676	O
early	-	680	O
in	-	686	O
29	-	689	O
patients	-	692	O
(	-	701	O
41	-	702	O
.	-	704	O
4	-	705	O
%	-	706	O
)	-	707	O
and	-	709	O
late	-	713	O
in	-	718	O
41	-	721	O
(	-	724	O
58	-	725	O
.	-	727	O
6	-	728	O
%	-	729	O
)	-	730	O
.	-	731	O

Indications	10743694	733	O
for	-	745	O
early	-	749	O
conversion	-	755	O
were	-	766	O
neurotoxicity	-	771	B
(	-	785	O
20	-	786	O
)	-	788	O
,	-	789	O
(	-	791	B
insulin	-	792	I
-	-	799	I
dependent	-	800	I
)	-	809	I
diabetes	-	811	I
mellitus	-	820	I
(	-	829	O
IDDM	-	830	B
)	-	834	O
(	-	836	O
5	-	837	O
)	-	838	O
,	-	839	O
nephrotoxicity	-	841	B
(	-	856	O
3	-	857	O
)	-	858	O
,	-	859	O
gastrointestinal	-	861	B
(	-	878	I
GI	-	879	I
)	-	881	I
toxicity	-	883	I
(	-	892	O
6	-	893	O
)	-	894	O
,	-	895	O
and	-	897	O
cardiomyopathy	-	901	B
(	-	916	O
1	-	917	O
)	-	918	O
,	-	919	O
and	-	921	O
for	-	925	O
late	-	929	O
conversion	-	934	O
were	-	945	O
neurotoxicity	-	950	B
(	-	964	O
15	-	965	O
)	-	967	O
,	-	968	O
IDDM	-	970	B
(	-	975	O
12	-	976	O
)	-	978	O
,	-	979	O
nephrotoxicity	-	981	B
(	-	996	O
3	-	997	O
)	-	998	O
,	-	999	O
GI	-	1001	B
toxicity	-	1004	I
(	-	1013	O
5	-	1014	O
)	-	1015	O
,	-	1016	O
hepatotoxicity	-	1018	B
(	-	1033	O
6	-	1034	O
)	-	1035	O
,	-	1036	O
post	-	1038	B
-	-	1042	I
transplant	-	1043	I
lmphoproliferate	-	1054	I
disease	-	1071	I
(	-	1079	O
PTLD	-	1080	B
)	-	1084	O
(	-	1086	O
2	-	1087	O
)	-	1088	O
,	-	1089	O
cardiomyopathy	-	1091	B
(	-	1106	O
1	-	1107	O
)	-	1108	O
,	-	1109	O
hemolytic	-	1111	B
anemia	-	1121	I
(	-	1128	O
1	-	1129	O
)	-	1130	O
,	-	1131	O
and	-	1133	O
pruritus	-	1137	B
(	-	1146	O
1	-	1147	O
)	-	1148	O
.	-	1149	O

All	10743694	1151	O
early	-	1155	O
-	-	1160	O
conversion	-	1161	O
patients	-	1172	O
showed	-	1181	O
improvement	-	1188	O
/	-	1199	O
resolution	-	1200	O
of	-	1211	O
symptoms	-	1214	O
.	-	1222	O

Among	10743694	1224	O
late	-	1230	O
-	-	1234	O
conversion	-	1235	O
patients	-	1246	O
,	-	1254	O
37	-	1256	O
(	-	1259	O
90	-	1260	O
.	-	1262	O
2	-	1263	O
%	-	1264	O
)	-	1265	O
had	-	1267	O
improvement	-	1271	O
/	-	1282	O
resolution	-	1283	O
;	-	1293	O
in	-	1295	O
4	-	1298	O
(	-	1300	O
9	-	1301	O
.	-	1302	O
8	-	1303	O
%	-	1304	O
)	-	1305	O
,	-	1306	O
adverse	-	1308	O
effects	-	1316	O
persisted	-	1324	O
.	-	1333	O

The	10743694	1335	O
overall	-	1339	O
rejection	-	1347	O
rate	-	1357	O
was	-	1362	O
30	-	1366	O
%	-	1368	O
.	-	1369	O

Sixty	10743694	1371	O
-	-	1376	O
two	-	1377	O
patients	-	1381	O
(	-	1390	O
88	-	1391	O
.	-	1393	O
6	-	1394	O
%	-	1395	O
)	-	1396	O
are	-	1398	O
alive	-	1402	O
with	-	1408	O
functioning	-	1413	O
grafts	-	1425	O
686	-	1432	O
+	-	1436	O
/	-	1437	O
-	-	1438	O

362	10743694	1440	O
days	-	1444	O
(	-	1449	O
range	-	1450	O
,	-	1455	O
154	-	1457	O
-	-	1460	O
1433	-	1461	O
days	-	1466	O
)	-	1470	O
after	-	1472	O
conversion	-	1478	O
.	-	1488	O

When	10743694	1490	O
tacrolimus	-	1495	O
side	-	1506	O
effects	-	1511	O
are	-	1519	O
unresponsive	-	1523	O
to	-	1536	O
dose	-	1539	O
reduction	-	1544	O
,	-	1553	O
conversion	-	1555	O
to	-	1566	O
CyA	-	1569	O
can	-	1573	O
be	-	1577	O
accomplished	-	1580	O
safely	-	1593	O
,	-	1599	O
with	-	1601	O
no	-	1606	O
increased	-	1609	O
risk	-	1619	O
of	-	1624	O
rejection	-	1627	O
and	-	1637	O
excellent	-	1641	O
long	-	1651	O
-	-	1655	O
term	-	1656	O
outcome	-	1661	O
.	-	1668	O

Relative	3535719	0	O
efficacy	-	9	O
and	-	18	O
toxicity	-	22	B
of	-	31	O
netilmicin	-	34	O
and	-	45	O
tobramycin	-	49	O
in	-	60	O
oncology	-	63	O
patients	-	72	O
.	-	80	O

We	3535719	82	O
prospectively	-	85	O
compared	-	99	O
the	-	108	O
efficacy	-	112	O
and	-	121	O
safety	-	125	O
of	-	132	O
netilmicin	-	135	O
sulfate	-	146	O
or	-	154	O
tobramycin	-	157	O
sulfate	-	168	O
in	-	176	O
conjunction	-	179	O
with	-	191	O
piperacillin	-	196	O
sodium	-	209	O
in	-	216	O
118	-	219	O
immunocompromised	-	223	O
patients	-	241	O
with	-	250	O
presumed	-	255	O
severe	-	264	O
infections	-	271	B
.	-	281	O

The	3535719	283	O
two	-	287	O
treatment	-	291	O
regimens	-	301	O
were	-	310	O
equally	-	315	O
efficacious	-	323	O
.	-	334	O

Nephrotoxicity	3535719	336	B
occurred	-	351	O
in	-	360	O
a	-	363	O
similar	-	365	O
proportion	-	373	O
in	-	384	O
patients	-	387	O
treated	-	396	O
with	-	404	O
netilmicin	-	409	O
and	-	420	O
tobramycin	-	424	O
(	-	435	O
17	-	436	O
%	-	438	O
vs	-	440	O
11	-	443	O
%	-	445	O
)	-	446	O
.	-	447	O

Ototoxicity	3535719	449	B
occurred	-	461	O
in	-	470	O
four	-	473	O
(	-	478	O
9	-	479	O
.	-	480	O
5	-	481	O
%	-	482	O
)	-	483	O
of	-	485	O
42	-	488	O
netilmicin	-	491	O
and	-	502	O
piperacillin	-	506	O
and	-	519	O
in	-	523	O
12	-	526	O
(	-	529	O
22	-	530	O
%	-	532	O
)	-	533	O
of	-	535	O
54	-	538	O
tobramycin	-	541	O
and	-	552	O
piperacillin	-	556	O
-	-	568	O
treated	-	569	O
patients	-	577	O
.	-	585	O

Of	3535719	587	O
those	-	590	O
evaluated	-	596	O
with	-	606	O
posttherapy	-	611	O
audiograms	-	623	O
,	-	633	O
three	-	635	O
of	-	641	O
four	-	644	O
netilmicin	-	649	O
and	-	660	O
piperacillin	-	664	O
-	-	676	O
treated	-	677	O
patients	-	685	O
had	-	694	O
auditory	-	698	O
thresholds	-	707	O
return	-	718	O
to	-	725	O
baseline	-	728	O
compared	-	737	O
with	-	746	O
one	-	751	O
of	-	755	O
nine	-	758	O
tobramycin	-	763	O
and	-	774	O
piperacillin	-	778	O
-	-	790	O
treated	-	791	O
patients	-	799	O
.	-	807	O

The	3535719	809	O
number	-	813	O
of	-	820	O
greater	-	823	O
than	-	831	O
or	-	836	O
equal	-	839	O
to	-	845	O
15	-	848	O
-	-	850	O
dB	-	851	O
increases	-	854	O
in	-	864	O
auditory	-	867	O
threshold	-	876	O
as	-	886	O
a	-	889	O
proportion	-	891	O
of	-	902	O
total	-	905	O
greater	-	911	O
than	-	919	O
or	-	924	O
equal	-	927	O
to	-	933	O
15	-	936	O
-	-	938	O
dB	-	939	O
changes	-	942	O
(	-	950	O
increases	-	951	O
and	-	961	O
decreases	-	965	O
)	-	974	O
was	-	976	O
significantly	-	980	O
lower	-	994	O
in	-	1000	O
netilmicin	-	1003	O
and	-	1014	O
piperacillin	-	1018	O
-	-	1030	O
vs	-	1032	O
tobramycin	-	1035	O
and	-	1046	O
piperacillin	-	1050	O
-	-	1062	O
treated	-	1063	O
patients	-	1071	O
(	-	1080	O
18	-	1081	O
of	-	1084	O
78	-	1087	O
vs	-	1090	O
67	-	1093	O
of	-	1096	O
115	-	1099	O
)	-	1102	O
.	-	1103	O

We	3535719	1105	O
conclude	-	1108	O
that	-	1117	O
aminoglycoside	-	1122	O
-	-	1136	O
associated	-	1137	O
ototoxicity	-	1148	B
was	-	1160	O
less	-	1164	O
severe	-	1169	O
and	-	1176	O
more	-	1180	O
often	-	1185	O
reversible	-	1191	O
with	-	1202	O
netilmicin	-	1207	O
than	-	1218	O
with	-	1223	O
tobramycin	-	1228	O
.	-	1238	O

Effect	6433367	0	O
of	-	7	O
prostaglandin	-	10	O
synthetase	-	24	O
inhibitors	-	35	O
on	-	46	O
experimentally	-	49	O
induced	-	64	O
convulsions	-	72	B
in	-	84	O
rats	-	87	O
.	-	91	O

To	6433367	93	O
investigate	-	96	O
the	-	108	O
relationship	-	112	O
of	-	125	O
prostaglandins	-	128	O
(	-	143	O
PGs	-	144	O
)	-	147	O
to	-	149	O
seizure	-	152	B
induction	-	160	O
,	-	169	O
the	-	171	O
effects	-	175	O
of	-	183	O
six	-	186	O
PG	-	190	O
synthetase	-	193	O
inhibitors	-	204	O
on	-	215	O
convulsions	-	218	B
induced	-	230	O
by	-	238	O
flurothyl	-	241	O
,	-	250	O
picrotoxin	-	252	O
,	-	262	O
pentetrazol	-	264	O
(	-	276	O
PTZ	-	277	O
)	-	280	O
,	-	281	O
electroshock	-	283	O
or	-	296	O
bicuculline	-	299	O
were	-	311	O
evaluated	-	316	O
.	-	325	O

Ibuprofen	6433367	327	O
,	-	336	O
sulindac	-	338	O
,	-	346	O
mefenamic	-	348	O
acid	-	358	O
,	-	362	O
and	-	364	O
low	-	368	O
dose	-	372	O
meclofenamic	-	377	O
acid	-	390	O
increased	-	395	O
the	-	405	O
latency	-	409	O
-	-	416	O
to	-	417	O
-	-	419	O
onset	-	420	O
in	-	426	O
the	-	429	O
flurothyl	-	433	O
and	-	443	O
/	-	446	O
or	-	447	O
PTZ	-	450	O
models	-	454	O
;	-	460	O
the	-	462	O
electroshock	-	466	O
,	-	478	O
picrotoxin	-	480	O
and	-	491	O
bicuculline	-	495	O
models	-	507	O
were	-	514	O
not	-	519	O
significantly	-	523	O
affected	-	537	O
by	-	546	O
any	-	549	O
of	-	553	O
the	-	556	O
pretreatment	-	560	O
agents	-	573	O
.	-	579	O

These	6433367	581	O
results	-	587	O
suggest	-	595	O
that	-	603	O
PGs	-	608	O
are	-	612	O
involved	-	616	O
in	-	625	O
the	-	628	O
mechanism	-	632	O
(	-	641	O
s	-	642	O
)	-	643	O
underlying	-	645	O
fluorthyl	-	656	O
-	-	665	O
and	-	667	O
PTZ	-	671	O
-	-	674	O
induced	-	675	O
convulsions	-	683	B
,	-	694	O
but	-	696	O
not	-	700	O
picrotoxin	-	704	O
-	-	714	O
,	-	715	O
electroshock	-	717	O
-	-	729	O
,	-	730	O
or	-	732	O
bicuculline	-	735	O
-	-	746	O
induced	-	747	O
convulsions	-	755	B
.	-	766	O

Angiotensin	17285209	0	O
-	-	11	O
converting	-	12	O
enzyme	-	23	O
(	-	30	O
ACE	-	31	O
)	-	34	O
inhibitor	-	36	O
-	-	45	O
associated	-	46	O
angioedema	-	57	B
of	-	68	O
the	-	71	O
stomach	-	75	O
and	-	83	O
small	-	87	O
intestine	-	93	O
:	-	102	O
a	-	104	O
case	-	106	O
report	-	111	O
.	-	117	O

This	17285209	119	O
is	-	124	O
a	-	127	O
case	-	129	O
report	-	134	O
on	-	141	O
a	-	144	O
45	-	146	O
-	-	148	O
year	-	149	O
old	-	154	O
African	-	158	O
-	-	165	O
American	-	166	O
female	-	175	O
with	-	182	O
newly	-	187	O
diagnosed	-	193	O
hypertension	-	203	B
,	-	215	O
who	-	217	O
was	-	221	O
started	-	225	O
on	-	233	O
a	-	236	O
combination	-	238	O
pill	-	250	O
of	-	255	O
amlodipine	-	258	O
/	-	268	O
benazapril	-	269	O
10	-	280	O
/	-	282	O
5	-	283	O
mg	-	285	O
.	-	287	O

The	17285209	289	O
very	-	293	O
next	-	298	O
day	-	303	O
,	-	306	O
she	-	308	O
presented	-	312	O
at	-	322	O
the	-	325	O
emergency	-	329	O
room	-	339	O
(	-	344	O
ER	-	345	O
)	-	347	O
with	-	349	O
abdominal	-	354	B
pain	-	364	I
,	-	368	O
nausea	-	370	B
and	-	377	O
vomiting	-	381	B
.	-	389	O

Physical	17285209	391	O
exam	-	400	O
,	-	404	O
complete	-	406	O
metabolic	-	415	O
panel	-	425	O
,	-	430	O
and	-	432	O
hemogram	-	436	O
were	-	445	O
in	-	450	O
the	-	453	O
normal	-	457	O
range	-	464	O
.	-	469	O

She	17285209	471	O
was	-	475	O
discharged	-	479	O
from	-	490	O
the	-	495	O
ER	-	499	O
after	-	502	O
a	-	508	O
few	-	510	O
hours	-	514	O
of	-	520	O
treatment	-	523	O
with	-	533	O
fluid	-	538	O
and	-	544	O
analgesics	-	548	O
.	-	558	O

However	17285209	560	O
,	-	567	O
she	-	569	O
returned	-	573	O
to	-	582	O
the	-	585	O
ER	-	589	O
the	-	592	O
next	-	596	O
day	-	601	O
with	-	605	O
the	-	610	O
same	-	614	O
complaints	-	619	O
.	-	629	O

This	17285209	631	O
time	-	636	O
the	-	641	O
physical	-	645	O
exam	-	654	O
was	-	659	O
significant	-	663	O
for	-	675	O
a	-	679	O
distended	-	681	O
abdomen	-	691	O
with	-	699	O
dullness	-	704	O
to	-	713	O
percussion	-	716	O
.	-	726	O

CT	17285209	728	O
scan	-	731	O
of	-	736	O
the	-	739	O
abdomen	-	743	O
revealed	-	751	O
markedly	-	760	O
thickened	-	769	O
antrum	-	779	O
of	-	786	O
the	-	789	O
stomach	-	793	O
,	-	800	O
duodenum	-	802	O
and	-	811	O
jejunum	-	815	O
,	-	822	O
along	-	824	O
with	-	830	O
fluid	-	835	O
in	-	841	O
the	-	844	O
abdominal	-	848	O
and	-	858	O
pelvic	-	862	O
cavity	-	869	O
.	-	875	O

Angiotensin	17285209	877	O
-	-	888	O
converting	-	889	O
enzyme	-	900	O
inhibitor	-	907	O
(	-	917	O
ACEI	-	918	O
)	-	922	O
-	-	923	O
induced	-	924	O
angioedema	-	932	B
was	-	943	O
suspected	-	947	O
,	-	956	O
and	-	958	O
anti	-	962	O
-	-	966	O
hypertensive	-	967	B
medications	-	980	O
were	-	992	O
discontinued	-	997	O
.	-	1009	O

Her	17285209	1011	O
symptoms	-	1015	O
improved	-	1024	O
within	-	1033	O
the	-	1040	O
next	-	1044	O
24	-	1049	O
hours	-	1052	O
,	-	1057	O
and	-	1059	O
repeat	-	1063	O
CT	-	1070	O
after	-	1073	O
72	-	1079	O
hours	-	1082	O
revealed	-	1088	O
marked	-	1097	O
improvement	-	1104	O
in	-	1116	O
stomach	-	1119	O
and	-	1127	O
small	-	1131	O
bowel	-	1137	O
thickening	-	1143	O
and	-	1154	O
resolution	-	1158	O
of	-	1169	O
ascites	-	1172	B
.	-	1179	O

The	17285209	1181	O
recognition	-	1185	O
of	-	1197	O
angiotensin	-	1200	O
-	-	1211	O
converting	-	1212	O
enzyme	-	1223	O
(	-	1230	O
ACE	-	1231	O
)	-	1234	O
and	-	1236	O
angiotensin	-	1240	O
receptor	-	1252	O
blocker	-	1261	O
(	-	1269	O
ARB	-	1270	O
)	-	1273	O
intestinal	-	1275	B
angioedema	-	1286	I
constitutes	-	1297	O
a	-	1309	O
challenge	-	1311	O
to	-	1321	O
primary	-	1324	O
care	-	1332	O
physicians	-	1337	O
,	-	1347	O
internists	-	1349	O
,	-	1359	O
emergency	-	1361	O
room	-	1371	O
personal	-	1376	O
and	-	1385	O
surgeons	-	1389	O
.	-	1397	O

Valproic	15858223	0	O
acid	-	9	O

I	15858223	14	O
:	-	15	O
time	-	17	O
course	-	22	O
of	-	29	O
lipid	-	32	O
peroxidation	-	38	O
biomarkers	-	51	O
,	-	61	O
liver	-	63	B
toxicity	-	69	I
,	-	77	O
and	-	79	O
valproic	-	83	O
acid	-	92	O
metabolite	-	97	O
levels	-	108	O
in	-	115	O
rats	-	118	O
.	-	122	O

A	15858223	124	O
single	-	126	O
dose	-	133	O
of	-	138	O
valproic	-	141	O
acid	-	150	O
(	-	155	O
VPA	-	156	O
)	-	159	O
,	-	160	O
which	-	162	O
is	-	168	O
a	-	171	O
widely	-	173	O
used	-	180	O
antiepileptic	-	185	O
drug	-	199	O
,	-	203	O
is	-	205	O
associated	-	208	O
with	-	219	O
oxidative	-	224	O
stress	-	234	O
in	-	241	O
rats	-	244	O
,	-	248	O
as	-	250	O
recently	-	253	O
demonstrated	-	262	O
by	-	275	O
elevated	-	278	O
levels	-	287	O
of	-	294	O
15	-	297	O
-	-	299	O
F	-	300	O
(	-	301	O
2t	-	302	O
)	-	304	O
-	-	305	O
isoprostane	-	306	O
(	-	318	O
15	-	319	O
-	-	321	O
F	-	322	O
(	-	323	O
2t	-	324	O
)	-	326	O
-	-	327	O
IsoP	-	328	O
)	-	332	O
.	-	333	O

To	15858223	335	O
determine	-	338	O
whether	-	348	O
there	-	356	O
was	-	362	O
a	-	366	O
temporal	-	368	O
relationship	-	377	O
between	-	390	O
VPA	-	398	O
-	-	401	O
associated	-	402	O
oxidative	-	413	O
stress	-	423	O
and	-	430	O
hepatotoxicity	-	434	B
,	-	448	O
adult	-	450	O
male	-	456	O
Sprague	-	461	O
-	-	468	O
Dawley	-	469	O
rats	-	476	O
were	-	481	O
treated	-	486	O
ip	-	494	O
with	-	497	O
VPA	-	502	O
(	-	506	O
500	-	507	O
mg	-	511	O
/	-	513	O
kg	-	514	O
)	-	516	O
or	-	518	O
0	-	521	O
.	-	522	O
9	-	523	O
%	-	524	O
saline	-	526	O
(	-	533	O
vehicle	-	534	O
)	-	541	O
once	-	543	O
daily	-	548	O
for	-	554	O
2	-	558	O
,	-	559	O
4	-	561	O
,	-	562	O
7	-	564	O
,	-	565	O
10	-	567	O
,	-	569	O
or	-	571	O
14	-	574	O
days	-	577	O
.	-	581	O

Oxidative	15858223	583	O
stress	-	593	O
was	-	600	O
assessed	-	604	O
by	-	613	O
determining	-	616	O
plasma	-	628	O
and	-	635	O
liver	-	639	O
levels	-	645	O
of	-	652	O
15	-	655	O
-	-	657	O
F	-	658	O
(	-	659	O
2t	-	660	O
)	-	662	O
-	-	663	O
IsoP	-	664	O
,	-	668	O
lipid	-	670	O
hydroperoxides	-	676	O
(	-	691	O
LPO	-	692	O
)	-	695	O
,	-	696	O
and	-	698	O
thiobarbituric	-	702	O
acid	-	717	O
reactive	-	722	O
substances	-	731	O
(	-	742	O
TBARs	-	743	O
)	-	748	O
.	-	749	O

Plasma	15858223	751	O
and	-	758	O
liver	-	762	O
15	-	768	O
-	-	770	O
F	-	771	O
(	-	772	O
2t	-	773	O
)	-	775	O
-	-	776	O
IsoP	-	777	O
were	-	782	O
elevated	-	787	O
and	-	796	O
reached	-	800	O
a	-	808	O
plateau	-	810	O
after	-	818	O
day	-	824	O
2	-	828	O
of	-	830	O
VPA	-	833	O
treatment	-	837	O
compared	-	847	O
to	-	856	O
control	-	859	O
.	-	866	O

Liver	15858223	868	O
LPO	-	874	O
levels	-	878	O
were	-	885	O
not	-	890	O
elevated	-	894	O
until	-	903	O
day	-	909	O
7	-	913	O
of	-	915	O
treatment	-	918	O
(	-	928	O
1	-	929	O
.	-	930	O
8	-	931	O
-	-	932	O
fold	-	933	O
versus	-	938	O
control	-	945	O
,	-	952	O
p	-	954	O
<	-	956	O
0	-	958	O
.	-	959	O
05	-	960	O
)	-	962	O
.	-	963	O

Liver	15858223	965	O
and	-	971	O
plasma	-	975	O
TBARs	-	982	O
were	-	988	O
not	-	993	O
increased	-	997	O
until	-	1007	O
14	-	1013	O
days	-	1016	O
(	-	1021	O
2	-	1022	O
-	-	1023	O
fold	-	1024	O
vs	-	1029	O
.	-	1031	O
control	-	1033	O
,	-	1040	O
p	-	1042	O
<	-	1044	O
0	-	1046	O
.	-	1047	O
05	-	1048	O
)	-	1050	O
.	-	1051	O

Liver	15858223	1053	B
toxicity	-	1059	I
was	-	1068	O
evaluated	-	1072	O
based	-	1082	O
on	-	1088	O
serum	-	1091	O
levels	-	1097	O
of	-	1104	O
alpha	-	1107	O
-	-	1112	O
glutathione	-	1113	O
S	-	1125	O
-	-	1126	O
transferase	-	1127	O
(	-	1139	O
alpha	-	1140	O
-	-	1145	O
GST	-	1146	O
)	-	1149	O
and	-	1151	O
by	-	1155	O
histology	-	1158	O
.	-	1167	O

Serum	15858223	1169	O
alpha	-	1175	O
-	-	1180	O
GST	-	1181	O
levels	-	1185	O
were	-	1192	O
significantly	-	1197	O
elevated	-	1211	O
by	-	1220	O
day	-	1223	O
4	-	1227	O
,	-	1228	O
which	-	1230	O
corresponded	-	1236	O
to	-	1249	O
hepatotoxicity	-	1252	B
as	-	1267	O
shown	-	1270	O
by	-	1276	O
the	-	1279	O
increasing	-	1283	O
incidence	-	1294	O
of	-	1304	O
inflammation	-	1307	B
of	-	1320	O
the	-	1323	O
liver	-	1327	O
capsule	-	1333	O
,	-	1340	O
necrosis	-	1342	B
,	-	1350	O
and	-	1352	O
steatosis	-	1356	B
throughout	-	1366	O
the	-	1377	O
study	-	1381	O
.	-	1386	O

The	15858223	1388	O
liver	-	1392	O
levels	-	1398	O
of	-	1405	O
beta	-	1408	O
-	-	1412	O
oxidation	-	1413	O
metabolites	-	1423	O
of	-	1435	O
VPA	-	1438	O
were	-	1442	O
decreased	-	1447	O
by	-	1457	O
day	-	1460	O
14	-	1464	O
,	-	1466	O
while	-	1468	O
the	-	1474	O
levels	-	1478	O
of	-	1485	O
4	-	1488	O
-	-	1489	O
ene	-	1490	O
-	-	1493	O
VPA	-	1494	O
and	-	1498	O
(	-	1502	O
E	-	1503	O
)	-	1504	O
-	-	1505	O
2	-	1506	O
,	-	1507	O
4	-	1508	O
-	-	1509	O
diene	-	1510	O
-	-	1515	O
VPA	-	1516	O
were	-	1520	O
not	-	1525	O
elevated	-	1529	O
throughout	-	1538	O
the	-	1549	O
study	-	1553	O
.	-	1558	O

Overall	15858223	1560	O
,	-	1567	O
these	-	1569	O
findings	-	1575	O
indicate	-	1584	O
that	-	1593	O
VPA	-	1598	O
treatment	-	1602	O
results	-	1612	O
in	-	1620	O
oxidative	-	1623	O
stress	-	1633	O
,	-	1639	O
as	-	1641	O
measured	-	1644	O
by	-	1653	O
levels	-	1656	O
of	-	1663	O
15	-	1666	O
-	-	1668	O
F	-	1669	O
(	-	1670	O
2t	-	1671	O
)	-	1673	O
-	-	1674	O
IsoP	-	1675	O
,	-	1679	O
which	-	1681	O
precedes	-	1687	O
the	-	1696	O
onset	-	1700	O
of	-	1706	O
necrosis	-	1709	B
,	-	1717	O
steatosis	-	1719	B
,	-	1728	O
and	-	1730	O
elevated	-	1734	O
levels	-	1743	O
of	-	1750	O
serum	-	1753	O
alpha	-	1759	O
-	-	1764	O
GST	-	1765	O
.	-	1768	O

Pheochromocytoma	15811908	0	B
unmasked	-	17	O
by	-	26	O
amisulpride	-	29	O
and	-	41	O
tiapride	-	45	O
.	-	53	O

OBJECTIVE	15811908	55	O
:	-	64	O

To	15811908	66	O
describe	-	69	O
the	-	78	O
unmasking	-	82	O
of	-	92	O
pheochromocytoma	-	95	B
in	-	112	O
a	-	115	O
patient	-	117	O
treated	-	125	O
with	-	133	O
amisulpride	-	138	O
and	-	150	O
tiapride	-	154	O
.	-	162	O

CASE	15811908	164	O
SUMMARY	-	169	O
:	-	176	O

A	15811908	178	O
42	-	180	O
-	-	182	O
year	-	183	O
-	-	187	O
old	-	188	O
white	-	192	O
man	-	198	O
developed	-	202	O
acute	-	212	O
hypertension	-	218	B
with	-	231	O
severe	-	236	O
headache	-	243	B
and	-	252	O
vomiting	-	256	B
2	-	265	O
hours	-	267	O
after	-	273	O
the	-	279	O
first	-	283	O
doses	-	289	O
of	-	295	O
amisulpride	-	298	O
100	-	310	O
mg	-	314	O
and	-	317	O
tiapride	-	321	O
100	-	330	O
mg	-	334	O
.	-	336	O

Both	15811908	338	O
drugs	-	343	O
were	-	349	O
immediately	-	354	O
discontinued	-	366	O
,	-	378	O
and	-	380	O
the	-	384	O
patient	-	388	O
recovered	-	396	O
after	-	406	O
subsequent	-	412	O
nicardipine	-	423	O
and	-	435	O
verapamil	-	439	O
treatment	-	449	O
.	-	458	O

Abdominal	15811908	460	O
ultrasound	-	470	O
showed	-	481	O
an	-	488	O
adrenal	-	491	O
mass	-	499	O
,	-	503	O
and	-	505	O
postoperative	-	509	O
histologic	-	523	O
examination	-	534	O
confirmed	-	546	O
the	-	556	O
diagnosis	-	560	O
of	-	570	O
pheochromocytoma	-	573	B
.	-	589	O

DISCUSSION	15811908	591	O
:	-	601	O

Drug	15811908	603	O
-	-	607	O
induced	-	608	O
symptoms	-	616	O
of	-	625	O
pheochromocytoma	-	628	B
are	-	645	O
often	-	649	O
associated	-	655	O
with	-	666	O
the	-	671	O
use	-	675	O
of	-	679	O
substituted	-	682	O
benzamide	-	694	O
drugs	-	704	O
,	-	709	O
but	-	711	O
the	-	715	O
underlying	-	719	O
mechanism	-	730	O
is	-	740	O
unknown	-	743	O
.	-	750	O

In	15811908	752	O
our	-	755	O
case	-	759	O
,	-	763	O
use	-	765	O
of	-	769	O
the	-	772	O
Naranjo	-	776	O
probability	-	784	O
scale	-	796	O
indicated	-	802	O
a	-	812	O
possible	-	814	O
relationship	-	823	O
between	-	836	O
the	-	844	O
hypertensive	-	848	B
crisis	-	861	O
and	-	868	O
amisulpride	-	872	O
and	-	884	O
tiapride	-	888	O
therapy	-	897	O
.	-	904	O

CONCLUSIONS	15811908	906	O
:	-	917	O

As	15811908	919	O
of	-	922	O
March	-	925	O
24	-	931	O
,	-	933	O
2005	-	935	O
,	-	939	O
this	-	941	O
is	-	946	O
the	-	949	O
first	-	953	O
reported	-	959	O
case	-	968	O
of	-	973	O
amisulpride	-	976	O
-	-	987	O
and	-	989	O
tiapride	-	993	O
-	-	1001	O
induced	-	1002	O
hypertensive	-	1010	B
crisis	-	1023	O
in	-	1030	O
a	-	1033	O
patient	-	1035	O
with	-	1043	O
pheochromocytoma	-	1048	B
.	-	1064	O

Physicians	15811908	1066	O
and	-	1077	O
other	-	1081	O
healthcare	-	1087	O
professionals	-	1098	O
should	-	1112	O
be	-	1119	O
aware	-	1122	O
of	-	1128	O
this	-	1131	O
potential	-	1136	O
adverse	-	1146	O
effect	-	1154	O
of	-	1161	O
tiapride	-	1164	O
and	-	1173	O
amisulpride	-	1177	O
.	-	1188	O

Quantitative	15764424	0	O
drug	-	13	O
levels	-	18	O
in	-	25	O
stimulant	-	28	O
psychosis	-	38	B
:	-	47	O
relationship	-	49	O
to	-	62	O
symptom	-	65	O
severity	-	73	O
,	-	81	O
catecholamines	-	83	O
and	-	98	O
hyperkinesia	-	102	B
.	-	114	O

To	15764424	116	O
examine	-	119	O
the	-	127	O
relationship	-	131	O
between	-	144	O
quantitative	-	152	O
stimulant	-	165	O
drug	-	175	O
levels	-	180	O
,	-	186	O
catecholamines	-	188	O
,	-	202	O
and	-	204	O
psychotic	-	208	B
symptoms	-	218	I
,	-	226	O
nineteen	-	228	O
patients	-	237	O
in	-	246	O
a	-	249	O
psychiatric	-	251	B
emergency	-	263	O
service	-	273	O
with	-	281	O
a	-	286	O
diagnosis	-	288	O
of	-	298	O
amphetamine	-	301	O
-	-	312	O
or	-	314	O
cocaine	-	317	O
-	-	324	O
induced	-	325	O
psychosis	-	333	B
were	-	343	O
interviewed	-	348	O
,	-	359	O
and	-	361	O
plasma	-	365	O
and	-	372	O
urine	-	376	O
were	-	382	O
collected	-	387	O
for	-	397	O
quantitative	-	401	O
assays	-	414	O
of	-	421	O
stimulant	-	424	O
drug	-	434	O
and	-	439	O
catecholamine	-	443	O
metabolite	-	457	O
levels	-	468	O
.	-	474	O

Methamphetamine	15764424	476	O
or	-	492	O
amphetamine	-	495	O
levels	-	507	O
were	-	514	O
related	-	519	O
to	-	527	O
several	-	530	O
psychopathology	-	538	O
scores	-	554	O
and	-	561	O
the	-	565	O
global	-	569	O
hyperkinesia	-	576	B
rating	-	589	O
.	-	595	O

HVA	15764424	597	O
levels	-	601	O
were	-	608	O
related	-	613	O
to	-	621	O
global	-	624	O
hyperkinesia	-	631	B
but	-	644	O
not	-	648	O
to	-	652	O
psychopathology	-	655	O
ratings	-	671	O
.	-	678	O

Although	15764424	680	O
many	-	689	O
other	-	694	O
factors	-	700	O
such	-	708	O
as	-	713	O
sensitization	-	716	O
may	-	730	O
play	-	734	O
a	-	739	O
role	-	741	O
,	-	745	O
intensity	-	747	O
of	-	757	O
stimulant	-	760	O
-	-	769	O
induced	-	770	O
psychotic	-	778	B
symptoms	-	788	I
and	-	797	O
stereotypies	-	801	B
appears	-	814	O
to	-	822	O
be	-	825	O
at	-	828	O
least	-	831	O
in	-	837	O
part	-	840	O
dose	-	845	O
-	-	849	O
related	-	850	O
.	-	857	O

Delayed	12101159	0	O
asystolic	-	8	B
cardiac	-	18	B
arrest	-	26	I
after	-	33	O
diltiazem	-	39	O
overdose	-	49	B
;	-	57	O
resuscitation	-	59	O
with	-	73	O
high	-	78	O
dose	-	83	O
intravenous	-	88	O
calcium	-	100	O
.	-	107	O

A	12101159	109	O
51	-	111	O
year	-	114	O
old	-	119	O
man	-	123	O
took	-	127	O
a	-	132	O
mixed	-	134	O
overdose	-	140	B
including	-	149	O
1	-	159	O
.	-	160	O
8	-	161	O
-	-	162	O
3	-	163	O
.	-	164	O
6	-	165	O
g	-	167	O
of	-	169	O
diltiazem	-	172	O
,	-	181	O
paracetamol	-	183	O
,	-	194	O
aspirin	-	196	O
,	-	203	O
isosorbide	-	205	O
nitrate	-	216	O
,	-	223	O
and	-	225	O
alcohol	-	229	O
.	-	236	O

He	12101159	238	O
initially	-	241	O
presented	-	251	O
to	-	261	O
hospital	-	264	O
after	-	273	O
six	-	279	O
hours	-	283	O
with	-	289	O
mild	-	294	O
hypotension	-	299	B
and	-	311	O
was	-	315	O
treated	-	319	O
with	-	327	O
activated	-	332	O
charcoal	-	342	O
and	-	351	O
intravenous	-	355	O
fluids	-	367	O
.	-	373	O

Eighteen	12101159	375	O
hours	-	384	O
after	-	390	O
the	-	396	O
overdose	-	400	B
he	-	409	O
had	-	412	O
two	-	416	O
generalised	-	420	O
tonic	-	432	B
-	-	437	I
clonic	-	438	I
seizures	-	445	I
.	-	453	O

The	12101159	455	O
patient	-	459	O
remained	-	467	O
unresponsive	-	476	O
with	-	489	O
junctional	-	494	O
bradycardia	-	505	B
,	-	516	O
unrecordable	-	518	O
blood	-	531	O
pressure	-	537	O
,	-	545	O
and	-	547	O
then	-	551	O
became	-	556	O
asystolic	-	563	B
.	-	572	O

He	12101159	574	O
was	-	577	O
resuscitated	-	581	O
with	-	594	O
high	-	599	O
dose	-	604	O
(	-	609	O
13	-	610	O
.	-	612	O
5	-	613	O
g	-	615	O
)	-	616	O
intravenous	-	618	O
calcium	-	630	O
and	-	638	O
adrenaline	-	642	O
(	-	653	O
epinephrine	-	654	O
)	-	665	O
.	-	666	O

He	12101159	668	O
required	-	671	O
inotropic	-	680	O
support	-	690	O
and	-	698	O
temporary	-	702	O
pacing	-	712	O
over	-	719	O
the	-	724	O
next	-	728	O
48	-	733	O
hours	-	736	O
.	-	741	O

This	12101159	743	O
case	-	748	O
suggests	-	753	O
there	-	762	O
is	-	768	O
a	-	771	O
role	-	773	O
for	-	778	O
aggressive	-	782	O
high	-	793	O
dose	-	798	O
intravenous	-	803	O
calcium	-	815	O
therapy	-	823	O
in	-	831	O
severe	-	834	O
diltiazem	-	841	O
overdose	-	851	B
,	-	859	O
particularly	-	861	O
with	-	874	O
the	-	879	O
onset	-	883	O
of	-	889	O
asystole	-	892	B
.	-	900	O

It	12101159	902	O
should	-	905	O
be	-	912	O
considered	-	915	O
early	-	926	O
in	-	932	O
cases	-	935	O
of	-	941	O
cardiac	-	944	B
arrest	-	952	I
after	-	959	O
diltiazem	-	965	O
overdose	-	975	B
.	-	983	O

The	12101159	985	O
case	-	989	O
also	-	994	O
highlights	-	999	O
the	-	1010	O
problems	-	1014	O
with	-	1023	O
delayed	-	1028	O
toxicity	-	1036	B
when	-	1045	O
whole	-	1050	O
bowel	-	1056	O
irrigation	-	1062	O
is	-	1073	O
not	-	1076	O
administered	-	1080	O
.	-	1092	O

Renal	6699841	0	B
papillary	-	6	I
necrosis	-	16	I
due	-	25	O
to	-	29	O
naproxen	-	32	O
.	-	40	O

A	6699841	42	O
31	-	44	O
-	-	46	O
year	-	47	O
-	-	51	O
old	-	52	O
man	-	56	O
with	-	60	O
rheumatoid	-	65	B
arthritis	-	76	I
,	-	85	O
who	-	87	O
had	-	91	O
previously	-	95	O
been	-	106	O
treated	-	111	O
with	-	119	O
sulindac	-	124	O
,	-	132	O
fenoprofen	-	134	O
calcium	-	145	O
,	-	152	O
high	-	154	O
dose	-	159	O
salicylates	-	164	O
and	-	176	O
gold	-	180	O
salts	-	185	O
,	-	190	O
developed	-	192	O
renal	-	202	B
papillary	-	208	I
necrosis	-	218	I
(	-	227	O
RPN	-	228	B
)	-	231	O
4	-	233	O
months	-	235	O
after	-	242	O
institution	-	248	O
of	-	260	O
naproxen	-	263	O
therapy	-	272	O
.	-	279	O

No	6699841	281	O
other	-	284	O
factor	-	290	O
predisposing	-	297	O
to	-	310	O
RPN	-	313	B
could	-	317	O
be	-	323	O
discovered	-	326	O
.	-	336	O

Sulindac	6699841	338	O
was	-	347	O
substituted	-	351	O
for	-	363	O
naproxen	-	367	O
and	-	376	O
no	-	380	O
further	-	383	O
adverse	-	391	O
renal	-	399	O
effects	-	405	O
occurred	-	413	O
over	-	422	O
the	-	427	O
next	-	431	O
12	-	436	O
months	-	439	O
.	-	445	O

We	6699841	447	O
review	-	450	O
previous	-	457	O
reports	-	466	O
linking	-	474	O
RPN	-	482	B
to	-	486	O
antiinflammatory	-	489	O
drug	-	506	O
use	-	511	O
and	-	515	O
discuss	-	519	O
possible	-	527	O
advantages	-	536	O
of	-	547	O
sulindac	-	550	O
in	-	559	O
patients	-	562	O
who	-	571	O
have	-	575	O
experienced	-	580	O
renal	-	592	B
toxicity	-	598	I
from	-	607	O
other	-	612	O
antiinflammatory	-	618	O
agents	-	635	O
.	-	641	O

Adverse	6127992	0	O
interaction	-	8	O
between	-	20	O
beta	-	28	O
-	-	32	O
adrenergic	-	33	O
blocking	-	44	O
drugs	-	53	O
and	-	59	O
verapamil	-	63	O
-	-	72	O
-	-	73	O
report	-	74	O
of	-	81	O
three	-	84	O
cases	-	90	O
.	-	95	O

Three	6127992	97	O
patients	-	103	O
with	-	112	O
ischaemic	-	117	B
heart	-	127	I
disease	-	133	I
developed	-	141	O
profound	-	151	O
cardiac	-	160	B
failure	-	168	I
,	-	175	O
hypotension	-	177	B
and	-	189	O
bradycardia	-	193	B
during	-	205	O
combined	-	212	O
therapy	-	221	O
with	-	229	O
verapamil	-	234	O
and	-	244	O
beta	-	248	O
-	-	252	O
adrenergic	-	253	O
blocking	-	264	O
drugs	-	273	O
.	-	278	O

This	6127992	280	O
clinical	-	285	O
picture	-	294	O
resolved	-	302	O
completely	-	311	O
with	-	322	O
cessation	-	327	O
of	-	337	O
the	-	340	O
combined	-	344	O
therapy	-	353	O
.	-	360	O

Baseline	6127992	362	O
left	-	371	O
ventricular	-	376	O
function	-	388	O
,	-	396	O
assessed	-	398	O
by	-	407	O
cardiac	-	410	O
catheterisation	-	418	O
or	-	434	O
nuclear	-	437	O
angiography	-	445	O
,	-	456	O
was	-	458	O
normal	-	462	O
in	-	469	O
two	-	472	O
patients	-	476	O
and	-	485	O
only	-	489	O
mildly	-	494	O
reduced	-	501	O
in	-	509	O
the	-	512	O
other	-	516	O
.	-	521	O

Simultaneously	6127992	523	O
administration	-	538	O
of	-	553	O
beta	-	556	O
-	-	560	O
adrenergic	-	561	O
blocking	-	572	O
drugs	-	581	O
and	-	587	O
verapamil	-	591	O
may	-	601	O
result	-	605	O
in	-	612	O
profound	-	615	O
adverse	-	624	O
interactions	-	632	O
and	-	645	O
should	-	649	O
only	-	656	O
be	-	661	O
administered	-	664	O
with	-	677	O
great	-	682	O
caution	-	688	O
.	-	695	O

Adverse	6115999	0	O
reactions	-	8	O
to	-	18	O
bendrofluazide	-	21	O
and	-	36	O
propranolol	-	40	O
for	-	52	O
the	-	56	O
treatment	-	60	O
of	-	70	O
mild	-	73	O
hypertension	-	78	B
.	-	90	O

Report	6115999	92	O
of	-	99	O
Medical	-	102	O
Research	-	110	O
Council	-	119	O
Working	-	127	O
Party	-	135	O
on	-	141	O
Mild	-	144	O
to	-	149	O
Moderate	-	152	O
Hypertension	-	161	B
.	-	173	O

Participants	6115999	175	O
in	-	188	O
the	-	191	O
Medical	-	195	O
Research	-	203	O
Council	-	212	O
treatment	-	220	O
trial	-	230	O
for	-	236	O
mild	-	240	O
hypertension	-	245	B
are	-	258	O
randomly	-	262	O
allocated	-	271	O
to	-	281	O
one	-	284	O
of	-	288	O
four	-	291	O
treatment	-	296	O
groups	-	306	O
:	-	312	O
bendrofluazide	-	314	O
,	-	328	O
propranolol	-	330	O
,	-	341	O
or	-	343	O
a	-	346	O
placebo	-	348	O
for	-	356	O
either	-	360	O
of	-	367	O
these	-	370	O
drugs	-	376	O
.	-	381	O

The	6115999	383	O
trial	-	387	O
is	-	393	O
single	-	396	O
-	-	402	O
blind	-	403	O
.	-	408	O

23	6115999	410	O
582	-	413	O
patient	-	417	O
-	-	424	O
years	-	425	O
of	-	431	O
observation	-	434	O
have	-	446	O
been	-	451	O
completed	-	456	O
so	-	466	O
far	-	469	O
,	-	472	O
10	-	474	O
684	-	477	O
on	-	481	O
active	-	484	O
drugs	-	491	O
and	-	497	O
12	-	501	O
898	-	504	O
on	-	508	O
placebos	-	511	O
.	-	519	O

The	6115999	521	O
results	-	525	O
show	-	533	O
an	-	538	O
association	-	541	O
between	-	553	O
bendrofluazide	-	561	O
treatment	-	576	O
and	-	586	O
impotence	-	590	B
,	-	599	O
and	-	601	O
impotence	-	605	B
also	-	615	O
occurred	-	620	O
more	-	629	O
frequently	-	634	O
in	-	645	O
patients	-	648	O
taking	-	657	O
propranolol	-	664	O
than	-	676	O
in	-	681	O
those	-	684	O
taking	-	690	O
placebos	-	697	O
.	-	705	O

Other	6115999	707	O
adverse	-	713	O
reactions	-	721	O
significantly	-	731	O
linked	-	745	O
with	-	752	O
active	-	757	O
drugs	-	764	O
include	-	770	O
impaired	-	778	B
glucose	-	787	I
tolerance	-	795	I
in	-	805	O
men	-	808	O
and	-	812	O
women	-	816	O
and	-	822	O
gout	-	826	B
in	-	831	O
men	-	834	O
,	-	837	O
associated	-	839	O
with	-	850	O
bendrofluazide	-	855	O
treatment	-	870	O
,	-	879	O
and	-	881	O
Raynaud	-	885	B
's	-	892	I
phenomenon	-	895	I
and	-	906	O
dyspnoea	-	910	B
in	-	919	O
men	-	922	O
and	-	926	O
women	-	930	O
taking	-	936	O
propranolol	-	943	O
.	-	954	O

No	6115999	956	O
corneal	-	959	B
disease	-	967	I
is	-	975	O
known	-	978	O
to	-	984	O
have	-	987	O
occurred	-	992	O
in	-	1001	O
the	-	1004	O
propranolol	-	1008	O
group	-	1020	O
.	-	1025	O

Mean	6115999	1027	O
serum	-	1032	O
potassium	-	1038	O
level	-	1048	O
fell	-	1054	O
,	-	1058	O
and	-	1060	O
urea	-	1064	O
and	-	1069	O
uric	-	1073	O
acid	-	1078	O
levels	-	1083	O
rose	-	1090	O
,	-	1094	O
in	-	1096	O
men	-	1099	O
and	-	1103	O
women	-	1107	O
taking	-	1113	O
bendrofluazide	-	1120	O
.	-	1134	O

In	6115999	1136	O
the	-	1139	O
propranolol	-	1143	O
group	-	1155	O
,	-	1160	O
serum	-	1162	O
potassium	-	1168	O
and	-	1178	O
uric	-	1182	O
acid	-	1187	O
levels	-	1192	O
rose	-	1199	O
in	-	1204	O
both	-	1207	O
sexes	-	1212	O
,	-	1217	O
but	-	1219	O
the	-	1223	O
urea	-	1227	O
level	-	1232	O
rose	-	1238	O
significantly	-	1243	O
in	-	1257	O
women	-	1260	O
only	-	1266	O
.	-	1270	O

Dexmedetomidine	18086064	0	O
and	-	16	O
cardiac	-	20	O
protection	-	28	O
for	-	39	O
non	-	43	O
-	-	46	O
cardiac	-	47	O
surgery	-	55	O
:	-	62	O
a	-	64	O
meta	-	66	O
-	-	70	O
analysis	-	71	O
of	-	80	O
randomised	-	83	O
controlled	-	94	O
trials	-	105	O
.	-	111	O

We	18086064	113	O
conducted	-	116	O
a	-	126	O
systematic	-	128	O
review	-	139	O
of	-	146	O
the	-	149	O
effects	-	153	O
of	-	161	O
dexmedetomidine	-	164	O
on	-	180	O
cardiac	-	183	O
outcomes	-	191	O
following	-	200	O
non	-	210	O
-	-	213	O
cardiac	-	214	O
surgery	-	222	O
.	-	229	O

We	18086064	231	O
included	-	234	O
prospective	-	243	O
,	-	254	O
randomised	-	256	O
peri	-	267	O
-	-	271	O
operative	-	272	O
studies	-	282	O
of	-	290	O
dexmedetomidine	-	293	O
that	-	309	O
reported	-	314	O
mortality	-	323	O
,	-	332	O
cardiac	-	334	O
morbidity	-	342	O
or	-	352	O
adverse	-	355	O
drug	-	363	O
events	-	368	O
.	-	374	O

A	18086064	376	O
PubMed	-	378	O
Central	-	385	O
and	-	393	O
EMBASE	-	397	O
search	-	404	O
was	-	411	O
conducted	-	415	O
up	-	425	O
to	-	428	O
July	-	431	O
2007	-	436	O
.	-	440	O

The	18086064	442	O
reference	-	446	O
lists	-	456	O
of	-	462	O
identified	-	465	O
papers	-	476	O
were	-	483	O
examined	-	488	O
for	-	497	O
further	-	501	O
trials	-	509	O
.	-	515	O

Of	18086064	517	O
425	-	520	O
studies	-	524	O
identified	-	532	O
,	-	542	O
20	-	544	O
were	-	547	O
included	-	552	O
in	-	561	O
the	-	564	O
meta	-	568	O
-	-	572	O
analysis	-	573	O
(	-	582	O
840	-	583	O
patients	-	587	O
)	-	595	O
.	-	596	O

Dexmedetomidine	18086064	598	O
was	-	614	O
associated	-	618	O
with	-	629	O
a	-	634	O
trend	-	636	O
towards	-	642	O
improved	-	650	O
cardiac	-	659	O
outcomes	-	667	O
;	-	675	O
all	-	677	O
-	-	680	O
cause	-	681	O
mortality	-	687	O
(	-	697	O
OR	-	698	O
0	-	701	O
.	-	702	O
27	-	703	O
,	-	705	O
95	-	707	O
%	-	709	O
CI	-	711	O
0	-	714	O
.	-	715	O
01	-	716	O
-	-	718	O
7	-	719	O
.	-	720	O
13	-	721	O
,	-	723	O
p	-	725	O
=	-	727	O
0	-	729	O
.	-	730	O
44	-	731	O
)	-	733	O
,	-	734	O
non	-	736	O
-	-	739	O
fatal	-	740	O
myocardial	-	746	B
infarction	-	757	I
(	-	768	O
OR	-	769	O
0	-	772	O
.	-	773	O
26	-	774	O
,	-	776	O
95	-	778	O
%	-	780	O
CI	-	782	O
0	-	785	O
.	-	786	O
04	-	787	O
-	-	789	O
1	-	790	O
.	-	791	O
60	-	792	O
,	-	794	O
p	-	796	O
=	-	798	O
0	-	800	O
.	-	801	O
14	-	802	O
)	-	804	O
,	-	805	O
and	-	807	O
myocardial	-	811	B
ischaemia	-	822	I
(	-	832	O
OR	-	833	O
0	-	836	O
.	-	837	O
65	-	838	O
,	-	840	O
95	-	842	O
%	-	844	O
CI	-	846	O
0	-	849	O
.	-	850	O
26	-	851	O
-	-	853	O
1	-	854	O
.	-	855	O
63	-	856	O
,	-	858	O
p	-	860	O
=	-	862	O
0	-	864	O
.	-	865	O
36	-	866	O
)	-	868	O
.	-	869	O

Peri	18086064	871	O
-	-	875	O
operative	-	876	O
hypotension	-	886	B
(	-	898	O
26	-	899	O
%	-	901	O
,	-	902	O
OR	-	904	O
3	-	907	O
.	-	908	O
80	-	909	O
,	-	911	O
95	-	913	O
%	-	915	O
CI	-	917	O
1	-	920	O
.	-	921	O
91	-	922	O
-	-	924	O
7	-	925	O
.	-	926	O
54	-	927	O
,	-	929	O
p	-	931	O
=	-	933	O
0	-	935	O
.	-	936	O
0001	-	937	O
)	-	941	O
and	-	943	O
bradycardia	-	947	B
(	-	959	O
17	-	960	O
%	-	962	O
,	-	963	O
OR	-	965	O
5	-	968	O
.	-	969	O
45	-	970	O
,	-	972	O
95	-	974	O
%	-	976	O
CI	-	978	O
2	-	981	O
.	-	982	O
98	-	983	O
-	-	985	O
9	-	986	O
.	-	987	O
95	-	988	O
,	-	990	O
p	-	992	O
<	-	994	O
0	-	996	O
.	-	997	O
00001	-	998	O
)	-	1003	O
were	-	1005	O
significantly	-	1010	O
increased	-	1024	O
.	-	1033	O

An	18086064	1035	O
anticholinergic	-	1038	O
did	-	1054	O
not	-	1058	O
reduce	-	1062	O
the	-	1069	O
incidence	-	1073	O
of	-	1083	O
bradycardia	-	1086	B
(	-	1098	O
p	-	1099	O
=	-	1101	O
0	-	1103	O
.	-	1104	O
43	-	1105	O
)	-	1107	O
.	-	1108	O

A	18086064	1110	O
randomised	-	1112	O
placebo	-	1123	O
-	-	1130	O
controlled	-	1131	O
trial	-	1142	O
of	-	1148	O
dexmedetomidine	-	1151	O
is	-	1167	O
warranted	-	1170	O
.	-	1179	O

Differential	12739036	0	O
diagnosis	-	13	O
of	-	23	O
high	-	26	O
serum	-	31	O
creatine	-	37	O
kinase	-	46	O
levels	-	53	O
in	-	60	O
systemic	-	63	B
lupus	-	72	I
erythematosus	-	78	I
.	-	91	O

We	12739036	93	O
report	-	96	O
the	-	103	O
clinical	-	107	O
and	-	116	O
bioptic	-	120	O
findings	-	128	O
for	-	137	O
a	-	141	O
57	-	143	O
-	-	145	O
year	-	146	O
-	-	150	O
old	-	151	O
woman	-	155	O
with	-	161	O
severe	-	166	O
chloroquine	-	173	O
-	-	184	O
induced	-	185	O
myopathy	-	193	B
.	-	201	O

Since	12739036	203	O
1989	-	209	O
,	-	213	O
she	-	215	O
had	-	219	O
been	-	223	O
suffering	-	228	O
from	-	238	O
systemic	-	243	B
lupus	-	252	I
erythematosus	-	258	I
(	-	272	O
SLE	-	273	B
)	-	276	O
with	-	278	O
renal	-	283	B
involvement	-	289	I
and	-	301	O
undergone	-	305	O
periods	-	315	O
of	-	323	O
treatment	-	326	O
with	-	336	O
azathioprine	-	341	O
and	-	354	O
cyclophosphamide	-	358	O
.	-	374	O

Additional	12739036	376	O
therapy	-	387	O
with	-	395	O
chloroquine	-	400	O
(	-	412	O
CQ	-	413	O
)	-	415	O
was	-	417	O
started	-	421	O
because	-	429	O
of	-	437	O
arthralgia	-	440	B
.	-	450	O

At	12739036	452	O
the	-	455	O
same	-	459	O
time	-	464	O
,	-	468	O
slightly	-	470	O
increased	-	479	O
creatine	-	489	O
kinase	-	498	O
(	-	505	O
CK	-	506	O
)	-	508	O
levels	-	510	O
were	-	517	O
noted	-	522	O
.	-	527	O

Myositis	12739036	529	B
was	-	538	O
suspected	-	542	O
,	-	551	O
and	-	553	O
the	-	557	O
patient	-	561	O
was	-	569	O
treated	-	573	O
with	-	581	O
steroids	-	586	O
.	-	594	O

The	12739036	596	O
CK	-	600	O
increase	-	603	O
persisted	-	612	O
,	-	621	O
however	-	623	O
,	-	630	O
and	-	632	O
she	-	636	O
developed	-	640	O
progressive	-	650	O
muscular	-	662	B
weakness	-	671	I
and	-	680	O
muscular	-	684	B
atrophy	-	693	I
.	-	700	O

Routine	12739036	702	O
controls	-	710	O
revealed	-	719	O
markedly	-	728	O
elevated	-	737	O
CK	-	746	O
levels	-	749	O
of	-	756	O
1	-	759	O
,	-	760	O
700	-	761	O
U	-	765	O
/	-	766	O
l	-	767	O
.	-	768	O

The	12739036	770	O
neurological	-	774	O
and	-	787	O
electrophysiological	-	791	O
findings	-	812	O
were	-	821	O
not	-	826	O
typical	-	830	O
of	-	838	O
myositis	-	841	B
.	-	849	O

Thus	12739036	851	O
,	-	855	O
muscle	-	857	O
biopsy	-	864	O
of	-	871	O
the	-	874	O
deltoid	-	878	O
muscle	-	886	O
was	-	893	O
performed	-	897	O
in	-	907	O
order	-	910	O
to	-	916	O
exclude	-	919	O
polymyositis	-	927	B
or	-	940	O
toxic	-	943	O
myopathy	-	949	B
.	-	957	O

As	12739036	959	O
it	-	962	O
revealed	-	965	O
chloroquine	-	974	O
-	-	985	O
induced	-	986	O
myopathy	-	994	B
,	-	1002	O
medication	-	1004	O
was	-	1015	O
stopped	-	1019	O
.	-	1026	O

Discriminating	12739036	1028	O
between	-	1043	O
primary	-	1051	O
SLE	-	1059	B
-	-	1062	O
induced	-	1063	O
affection	-	1071	B
of	-	1081	I
the	-	1084	I
musculoskeletal	-	1088	I
system	-	1104	I
and	-	1111	O
drug	-	1115	O
-	-	1119	O
induced	-	1120	O
side	-	1128	O
effects	-	1133	O
is	-	1141	O
important	-	1144	O
for	-	1154	O
appropriate	-	1158	O
treatment	-	1170	O
of	-	1180	O
SLE	-	1183	B
patients	-	1187	O
.	-	1195	O

Intravenous	12093990	0	O
ribavirin	-	12	O
treatment	-	22	O
for	-	32	O
severe	-	36	O
adenovirus	-	43	B
disease	-	54	I
in	-	62	O
immunocompromised	-	65	O
children	-	83	O
.	-	91	O

BACKGROUND	12093990	93	O
:	-	103	O
Adenovirus	-	105	O
is	-	116	O
an	-	119	O
important	-	122	O
cause	-	132	O
of	-	138	O
morbidity	-	141	O
and	-	151	O
mortality	-	155	O
in	-	165	O
the	-	168	O
immunocompromised	-	172	O
host	-	190	O
.	-	194	O

The	12093990	196	O
incidence	-	200	O
of	-	210	O
severe	-	213	O
adenovirus	-	220	B
disease	-	231	I
in	-	239	O
pediatrics	-	242	O
is	-	253	O
increasing	-	256	O
in	-	267	O
association	-	270	O
with	-	282	O
growing	-	287	O
numbers	-	295	O
of	-	303	O
immunocompromised	-	306	O
children	-	324	O
,	-	332	O
where	-	334	O
case	-	340	O
fatality	-	345	O
rates	-	354	O
as	-	360	O
high	-	363	O
as	-	368	O
50	-	371	O
%	-	373	O
to	-	375	O
80	-	378	O
%	-	380	O
have	-	382	O
been	-	387	O
reported	-	392	O
.	-	400	O

There	12093990	402	O
are	-	408	O
no	-	412	O
approved	-	415	O
antiviral	-	424	O
agents	-	434	O
with	-	441	O
proven	-	446	O
efficacy	-	453	O
for	-	462	O
the	-	466	O
treatment	-	470	O
of	-	480	O
severe	-	483	O
adenovirus	-	490	B
disease	-	501	I
,	-	508	O
nor	-	510	O
are	-	514	O
there	-	518	O
any	-	524	O
prospective	-	528	O
randomized	-	540	O
,	-	550	O
controlled	-	552	O
trials	-	563	O
of	-	570	O
potentially	-	573	O
useful	-	585	O
anti	-	592	O
-	-	596	O
adenovirus	-	597	O
therapies	-	608	O
.	-	617	O

Apparent	12093990	619	O
clinical	-	628	O
success	-	637	O
in	-	645	O
the	-	648	O
treatment	-	652	O
of	-	662	O
severe	-	665	O
adenovirus	-	672	B
disease	-	683	I
is	-	691	O
limited	-	694	O
to	-	702	O
a	-	705	O
few	-	707	O
case	-	711	O
reports	-	716	O
and	-	724	O
small	-	728	O
series	-	734	O
.	-	740	O

Experience	12093990	742	O
is	-	753	O
greatest	-	756	O
with	-	765	O
intravenous	-	770	O
ribavirin	-	782	O
and	-	792	O
cidofovir	-	796	O
.	-	805	O

Ribavirin	12093990	807	O
,	-	816	O
a	-	818	O
guanosine	-	820	O
analogue	-	830	O
,	-	838	O
has	-	840	O
broad	-	844	O
antiviral	-	850	O
activity	-	860	O
against	-	869	O
both	-	877	O
RNA	-	882	O
and	-	886	O
DNA	-	890	O
viruses	-	894	O
,	-	901	O
including	-	903	O
documented	-	913	O
activity	-	924	O
against	-	933	O
adenovirus	-	941	O
in	-	952	O
vitro	-	955	O
.	-	960	O

Ribavirin	12093990	962	O
is	-	972	O
licensed	-	975	O
in	-	984	O
aerosol	-	987	O
form	-	995	O
for	-	1000	O
the	-	1004	O
treatment	-	1008	O
of	-	1018	O
respiratory	-	1021	B
syncytial	-	1033	I
virus	-	1043	I
infection	-	1049	I
,	-	1058	O
and	-	1060	O
orally	-	1064	O
in	-	1071	O
combination	-	1074	O
with	-	1086	O
interferon	-	1091	O
to	-	1102	O
treat	-	1105	O
hepatitis	-	1111	B
C	-	1121	I
.	-	1122	O
Intravenous	-	1124	O
ribavirin	-	1136	O
is	-	1146	O
the	-	1149	O
treatment	-	1153	O
of	-	1163	O
choice	-	1166	O
for	-	1173	O
infection	-	1177	B
with	-	1187	I
hemorrhagic	-	1192	I
fever	-	1204	I
viruses	-	1210	I
.	-	1217	O

The	12093990	1219	O
most	-	1223	O
common	-	1228	O
adverse	-	1235	O
effect	-	1243	O
of	-	1250	O
intravenous	-	1253	O
ribavirin	-	1265	O
is	-	1275	O
reversible	-	1278	O
mild	-	1289	O
anemia	-	1294	B
.	-	1300	O

The	12093990	1302	O
use	-	1306	O
of	-	1310	O
cidofovir	-	1313	O
in	-	1323	O
severe	-	1326	O
adenovirus	-	1333	B
infection	-	1344	I
has	-	1354	O
been	-	1358	O
limited	-	1363	O
by	-	1371	O
adverse	-	1374	O
effects	-	1382	O
,	-	1389	O
the	-	1391	O
most	-	1395	O
significant	-	1400	O
of	-	1412	O
which	-	1415	O
is	-	1421	O
nephrotoxicity	-	1424	B
.	-	1438	O

OBJECTIVE	12093990	1440	O
:	-	1449	O

We	12093990	1451	O
report	-	1454	O
our	-	1461	O
experience	-	1465	O
with	-	1476	O
intravenous	-	1481	O
ribavirin	-	1493	O
therapy	-	1503	O
for	-	1511	O
severe	-	1515	O
adenovirus	-	1522	B
disease	-	1533	I
in	-	1541	O
a	-	1544	O
series	-	1546	O
of	-	1553	O
immunocompromised	-	1556	O
children	-	1574	O
and	-	1583	O
review	-	1587	O
the	-	1594	O
literature	-	1598	O
.	-	1608	O

DESIGN	12093990	1610	O
/	-	1616	O
METHODS	-	1617	O
:	-	1624	O

We	12093990	1626	O
retrospectively	-	1629	O
reviewed	-	1645	O
the	-	1654	O
medical	-	1658	O
records	-	1666	O
of	-	1674	O
5	-	1677	O
children	-	1679	O
treated	-	1688	O
with	-	1696	O
intravenous	-	1701	O
ribavirin	-	1713	O
for	-	1723	O
documented	-	1727	O
severe	-	1738	O
adenovirus	-	1745	B
disease	-	1756	I
.	-	1763	O

Two	12093990	1765	O
patients	-	1769	O
developed	-	1778	O
adenovirus	-	1788	O
hemorrhagic	-	1799	B
cystitis	-	1811	I
after	-	1820	O
cardiac	-	1826	O
and	-	1834	O
bone	-	1838	O
marrow	-	1843	O
transplants	-	1850	O
,	-	1861	O
respectively	-	1863	O
.	-	1875	O

The	12093990	1877	O
bone	-	1881	O
marrow	-	1886	O
transplant	-	1893	O
patient	-	1904	O
also	-	1912	O
received	-	1917	O
intravenous	-	1926	O
cidofovir	-	1938	O
for	-	1948	O
progressive	-	1952	O
disseminated	-	1964	O
disease	-	1977	O
.	-	1984	O

An	12093990	1986	O
additional	-	1989	O
3	-	2000	O
children	-	2002	O
developed	-	2011	O
adenovirus	-	2021	B
pneumonia	-	2032	I
;	-	2041	O
2	-	2043	O
were	-	2045	O
neonates	-	2050	O
,	-	2058	O
1	-	2060	O
of	-	2062	O
whom	-	2065	O
had	-	2070	O
partial	-	2074	O
DiGeorge	-	2082	B
syndrome	-	2091	I
.	-	2099	O

The	12093990	2101	O
remaining	-	2105	O
infant	-	2115	O
had	-	2122	O
recently	-	2126	O
undergone	-	2135	O
a	-	2145	O
cardiac	-	2147	O
transplant	-	2155	O
.	-	2165	O

Intravenous	12093990	2167	O
ribavirin	-	2179	O
was	-	2189	O
administered	-	2193	O
on	-	2206	O
a	-	2209	O
compassionate	-	2211	O
-	-	2224	O
use	-	2225	O
protocol	-	2229	O
.	-	2237	O

RESULTS	12093990	2239	O
:	-	2246	O

Complete	12093990	2248	O
clinical	-	2257	O
recovery	-	2266	O
followed	-	2275	O
later	-	2284	O
by	-	2290	O
viral	-	2293	O
clearance	-	2299	O
was	-	2309	O
observed	-	2313	O
in	-	2322	O
2	-	2325	O
children	-	2327	O
:	-	2335	O
the	-	2337	O
cardiac	-	2341	O
transplant	-	2349	O
recipient	-	2360	O
with	-	2370	O
adenovirus	-	2375	O
hemorrhagic	-	2386	B
cystitis	-	2398	I
and	-	2407	O
the	-	2411	O
immunocompetent	-	2415	O
neonate	-	2431	O
with	-	2439	O
adenovirus	-	2444	B
pneumonia	-	2455	I
.	-	2464	O

The	12093990	2466	O
remaining	-	2470	O
3	-	2480	O
children	-	2482	O
died	-	2491	O
of	-	2496	O
adenovirus	-	2499	B
disease	-	2510	I
.	-	2517	O

Intravenous	12093990	2519	O
ribavirin	-	2531	O
therapy	-	2541	O
was	-	2549	O
well	-	2553	O
tolerated	-	2558	O
.	-	2567	O

Use	12093990	2569	O
of	-	2573	O
cidofovir	-	2576	O
in	-	2586	O
1	-	2589	O
child	-	2591	O
was	-	2597	O
associated	-	2601	O
with	-	2612	O
progressive	-	2617	B
renal	-	2629	I
failure	-	2635	I
and	-	2643	O
neutropenia	-	2647	B
.	-	2658	O

DISCUSSION	12093990	2660	O
:	-	2670	O

Our	12093990	2672	O
series	-	2676	O
of	-	2683	O
patients	-	2686	O
is	-	2695	O
representative	-	2698	O
of	-	2713	O
the	-	2716	O
spectrum	-	2720	O
of	-	2729	O
immunocompromised	-	2732	O
children	-	2750	O
at	-	2759	O
greatest	-	2762	O
risk	-	2771	O
for	-	2776	O
severe	-	2780	O
adenovirus	-	2787	B
disease	-	2798	I
,	-	2805	O
namely	-	2807	O
solid	-	2814	O
-	-	2819	O
organ	-	2820	O
and	-	2826	O
bone	-	2830	O
marrow	-	2835	O
transplant	-	2842	O
recipients	-	2853	O
,	-	2863	O
neonates	-	2865	O
,	-	2873	O
and	-	2875	O
children	-	2879	O
with	-	2888	O
immunodeficiency	-	2893	B
.	-	2909	O

Although	12093990	2911	O
intravenous	-	2920	O
ribavirin	-	2932	O
was	-	2942	O
not	-	2946	O
effective	-	2950	O
for	-	2960	O
all	-	2964	O
children	-	2968	O
with	-	2977	O
severe	-	2982	O
adenovirus	-	2989	B
disease	-	3000	I
in	-	3008	O
this	-	3011	O
series	-	3016	O
or	-	3023	O
in	-	3026	O
the	-	3029	O
literature	-	3033	O
,	-	3043	O
therapy	-	3045	O
is	-	3053	O
unlikely	-	3056	O
to	-	3065	O
be	-	3068	O
of	-	3071	O
benefit	-	3074	O
if	-	3082	O
begun	-	3085	O
late	-	3091	O
in	-	3096	O
the	-	3099	O
course	-	3103	O
of	-	3110	O
the	-	3113	O
infection	-	3117	B
.	-	3126	O

Early	12093990	3128	O
identification	-	3134	O
,	-	3148	O
eg	-	3150	O
by	-	3153	O
polymerase	-	3156	O
chain	-	3167	O
reaction	-	3173	O
of	-	3182	O
those	-	3185	O
patients	-	3191	O
at	-	3200	O
risk	-	3203	O
of	-	3208	O
disseminated	-	3211	O
adenovirus	-	3224	B
disease	-	3235	I
may	-	3243	O
permit	-	3247	O
earlier	-	3254	O
antiviral	-	3262	O
treatment	-	3272	O
and	-	3282	O
better	-	3286	O
evaluation	-	3293	O
of	-	3304	O
therapeutic	-	3307	O
response	-	3319	O
.	-	3327	O

CONCLUSIONS	12093990	3329	O
:	-	3340	O

Two	12093990	3342	O
of	-	3346	O
5	-	3349	O
children	-	3351	O
with	-	3360	O
severe	-	3365	O
adenovirus	-	3372	B
disease	-	3383	I
treated	-	3391	O
with	-	3399	O
intravenous	-	3404	O
ribavirin	-	3416	O
recovered	-	3426	O
.	-	3435	O

The	12093990	3437	O
availability	-	3441	O
of	-	3454	O
newer	-	3457	O
rapid	-	3463	O
diagnostic	-	3469	O
techniques	-	3480	O
,	-	3490	O
such	-	3492	O
as	-	3497	O
polymerase	-	3500	O
chain	-	3511	O
reaction	-	3517	O
,	-	3525	O
may	-	3527	O
make	-	3531	O
earlier	-	3536	O
,	-	3543	O
more	-	3545	O
effective	-	3550	O
treatment	-	3560	O
of	-	3570	O
adenovirus	-	3573	B
infection	-	3584	I
possible	-	3594	O
.	-	3602	O

Given	12093990	3604	O
the	-	3610	O
seriousness	-	3614	O
and	-	3626	O
increasing	-	3630	O
prevalence	-	3641	O
of	-	3652	O
adenovirus	-	3655	B
disease	-	3666	I
in	-	3674	O
certain	-	3677	O
hosts	-	3685	O
,	-	3690	O
especially	-	3692	O
children	-	3703	O
,	-	3711	O
a	-	3713	O
large	-	3715	O
,	-	3720	O
multicenter	-	3722	O
clinical	-	3734	O
trial	-	3743	O
of	-	3749	O
potentially	-	3752	O
useful	-	3764	O
anti	-	3771	O
-	-	3775	O
adenoviral	-	3776	O
therapies	-	3787	O
,	-	3796	O
such	-	3798	O
as	-	3803	O
intravenous	-	3806	O
ribavirin	-	3818	O
,	-	3827	O
is	-	3829	O
clearly	-	3832	O
required	-	3840	O
to	-	3849	O
demonstrate	-	3852	O
the	-	3864	O
most	-	3868	O
effective	-	3873	O
and	-	3883	O
least	-	3887	O
toxic	-	3893	O
therapy	-	3899	O
.	-	3906	O

Hepatotoxicity	3962737	0	B
of	-	15	O
amiodarone	-	18	O
.	-	28	O

Amiodarone	3962737	30	O
has	-	41	O
proved	-	45	O
very	-	52	O
effective	-	57	O
in	-	67	O
the	-	70	O
treatment	-	74	O
of	-	84	O
otherwise	-	87	O
resistant	-	97	O
cardiac	-	107	O
tachyarrhythmias	-	115	B
.	-	131	O

The	3962737	133	O
use	-	137	O
of	-	141	O
amiodarone	-	144	O
has	-	155	O
,	-	158	O
however	-	160	O
,	-	167	O
been	-	169	O
limited	-	174	O
due	-	182	O
to	-	186	O
its	-	189	O
serious	-	193	O
side	-	201	O
-	-	205	O
effects	-	206	O
.	-	213	O

A	3962737	215	O
patient	-	217	O
with	-	225	O
cholestatic	-	230	B
hepatitis	-	242	I
due	-	252	O
to	-	256	O
amiodarone	-	259	O
treatment	-	270	O
is	-	280	O
presented	-	283	O
below	-	293	O
and	-	299	O
a	-	303	O
review	-	305	O
of	-	312	O
the	-	315	O
hepatotoxicity	-	319	B
of	-	334	O
amiodarone	-	337	O
is	-	348	O
given	-	351	O
.	-	356	O

It	3962737	358	O
is	-	361	O
concluded	-	364	O
that	-	374	O
solid	-	379	O
evidence	-	385	O
exists	-	394	O
of	-	401	O
hepatic	-	404	B
injury	-	412	I
due	-	419	O
to	-	423	O
amiodarone	-	426	O
treatment	-	437	O
,	-	446	O
including	-	448	O
steatosis	-	458	B
,	-	467	O
alterations	-	469	O
resembling	-	481	O
alcoholic	-	492	B
hepatitis	-	502	I
,	-	511	O
cholestatic	-	513	B
hepatitis	-	525	I
and	-	535	O
micronodular	-	539	O
cirrhosis	-	552	B
of	-	562	I
the	-	565	I
liver	-	569	I
.	-	574	O

Patients	3962737	576	O
receiving	-	585	O
amiodarone	-	595	O
should	-	606	O
be	-	613	O
regularly	-	616	O
screened	-	626	O
with	-	635	O
respect	-	640	O
to	-	648	O
hepatic	-	651	O
enzyme	-	659	O
levels	-	666	O
.	-	672	O

Therapy	3962737	674	O
should	-	682	O
be	-	689	O
discontinued	-	692	O
on	-	705	O
the	-	708	O
suspicion	-	712	O
of	-	722	O
cholestatic	-	725	B
injury	-	737	I
or	-	744	O
hepatomegaly	-	747	B
.	-	759	O

Catalepsy	2716967	0	B
induced	-	10	O
by	-	18	O
combinations	-	21	O
of	-	34	O
ketamine	-	37	O
and	-	46	O
morphine	-	50	O
:	-	58	O
potentiation	-	60	O
,	-	72	O
antagonism	-	74	O
,	-	84	O
tolerance	-	86	O
and	-	96	O
cross	-	100	O
-	-	105	O
tolerance	-	106	O
in	-	116	O
the	-	119	O
rat	-	123	O
.	-	126	O

Previous	2716967	128	O
studies	-	137	O
demonstrated	-	145	O
that	-	158	O
both	-	163	O
ketamine	-	168	O
and	-	177	O
morphine	-	181	O
induced	-	190	O
analgesia	-	198	B
and	-	208	O
catalepsy	-	212	B
in	-	222	O
the	-	225	O
rat	-	229	O
.	-	232	O
Pre	-	234	O
-	-	237	O
treatment	-	238	O
with	-	248	O
ketamine	-	253	O
produced	-	262	O
cross	-	271	O
-	-	276	O
tolerance	-	277	O
to	-	287	O
morphine	-	290	O
,	-	298	O
whereas	-	300	O
pretreatment	-	308	O
with	-	321	O
morphine	-	326	O
did	-	335	O
not	-	339	O
induce	-	343	O
cross	-	350	O
-	-	355	O
tolerance	-	356	O
to	-	366	O
ketamine	-	369	O
but	-	378	O
rather	-	382	O
augmented	-	389	O
the	-	399	O
cataleptic	-	403	B
response	-	414	O
;	-	422	O
this	-	424	O
augmentation	-	429	O
was	-	442	O
attributed	-	446	O
to	-	457	O
residual	-	460	O
morphine	-	469	O
in	-	478	O
the	-	481	O
brain	-	485	O
.	-	490	O

The	2716967	492	O
present	-	496	O
studies	-	504	O
explored	-	512	O
the	-	521	O
duration	-	525	O
of	-	534	O
the	-	537	O
loss	-	541	O
of	-	546	O
righting	-	549	O
reflex	-	558	O
induced	-	565	O
by	-	573	O
sub	-	576	O
-	-	579	O
effective	-	580	O
doses	-	590	O
of	-	596	O
ketamine	-	599	O
and	-	608	O
morphine	-	612	O
,	-	620	O
administered	-	622	O
simultaneously	-	635	O
.	-	649	O

There	2716967	651	O
was	-	657	O
mutual	-	661	O
potentiation	-	668	O
between	-	681	O
sub	-	689	O
-	-	692	O
effective	-	693	O
doses	-	703	O
of	-	709	O
ketamine	-	712	O
and	-	721	O
morphine	-	725	O
,	-	733	O
but	-	735	O
sub	-	739	O
-	-	742	O
effective	-	743	O
doses	-	753	O
of	-	759	O
ketamine	-	762	O
partly	-	771	O
antagonized	-	778	O
fully	-	790	O
-	-	795	O
effective	-	796	O
doses	-	806	O
of	-	812	O
morphine	-	815	O
.	-	823	O

Latency	2716967	825	O
to	-	833	O
the	-	836	O
loss	-	840	O
of	-	845	O
righting	-	848	O
reflex	-	857	O
,	-	863	O
rigidity	-	865	B
and	-	874	O
behavior	-	878	O
on	-	887	O
recovery	-	890	O
,	-	898	O
reflected	-	900	O
the	-	910	O
relative	-	914	O
predominance	-	923	O
of	-	936	O
ketamine	-	939	O
or	-	948	O
morphine	-	951	O
in	-	960	O
each	-	963	O
combination	-	968	O
.	-	979	O

Naloxone	2716967	981	O
inhibited	-	990	O
the	-	1000	O
induced	-	1004	O
cataleptic	-	1012	B
effects	-	1023	O
.	-	1030	O

The	2716967	1032	O
degree	-	1036	O
and	-	1043	O
time	-	1047	O
course	-	1052	O
of	-	1059	O
development	-	1062	O
of	-	1074	O
tolerance	-	1077	O
to	-	1087	O
daily	-	1090	O
administration	-	1096	O
of	-	1111	O
sub	-	1114	O
-	-	1117	O
effective	-	1118	O
dose	-	1128	O
combinations	-	1133	O
of	-	1146	O
ketamine	-	1149	O
and	-	1158	O
morphine	-	1162	O
were	-	1171	O
similar	-	1176	O
.	-	1183	O

Rats	2716967	1185	O
,	-	1189	O
tolerant	-	1191	O
to	-	1200	O
ketamine	-	1203	O
-	-	1211	O
dominant	-	1212	O
combinations	-	1221	O
,	-	1233	O
were	-	1235	O
cross	-	1240	O
-	-	1245	O
tolerant	-	1246	O
to	-	1255	O
both	-	1258	O
drugs	-	1263	O
,	-	1268	O
while	-	1270	O
those	-	1276	O
tolerant	-	1282	O
to	-	1291	O
morphine	-	1294	O
-	-	1302	O
dominant	-	1303	O
combinations	-	1312	O
were	-	1325	O
cross	-	1330	O
-	-	1335	O
tolerant	-	1336	O
to	-	1345	O
morphine	-	1348	O
but	-	1357	O
showed	-	1361	O
either	-	1368	O
no	-	1375	O
cross	-	1378	O
-	-	1383	O
tolerance	-	1384	O
or	-	1394	O
an	-	1397	O
augmented	-	1400	O
response	-	1410	O
to	-	1419	O
ketamine	-	1422	O
.	-	1430	O

While	2716967	1432	O
the	-	1438	O
mutual	-	1442	O
potentiation	-	1449	O
,	-	1461	O
antagonism	-	1463	O
and	-	1474	O
tolerance	-	1478	O
suggest	-	1488	O
common	-	1496	O
mechanisms	-	1503	O
for	-	1514	O
the	-	1518	O
induced	-	1522	O
catalepsy	-	1530	B
,	-	1539	O
differences	-	1541	O
in	-	1553	O
latency	-	1556	O
,	-	1563	O
rigidity	-	1565	B
and	-	1574	O
behavior	-	1578	O
,	-	1586	O
asymmetry	-	1588	O
of	-	1598	O
cross	-	1601	O
-	-	1606	O
tolerance	-	1607	O
and	-	1617	O
a	-	1621	O
widely	-	1623	O
-	-	1629	O
different	-	1630	O
ID50	-	1640	O
for	-	1645	O
naloxone	-	1649	O
would	-	1658	O
argue	-	1664	O
against	-	1670	O
an	-	1678	O
action	-	1681	O
at	-	1688	O
a	-	1691	O
single	-	1693	O
opioid	-	1700	O
site	-	1707	O
.	-	1711	O

Acute	19642243	0	B
renal	-	6	I
failure	-	12	I
in	-	20	O
patients	-	23	O
with	-	32	O
AIDS	-	37	B
on	-	42	O
tenofovir	-	45	O
while	-	55	O
receiving	-	61	O
prolonged	-	71	O
vancomycin	-	81	O
course	-	92	O
for	-	99	O
osteomyelitis	-	103	B
.	-	116	O

Renal	19642243	118	B
failure	-	124	I
developed	-	132	O
after	-	142	O
a	-	148	O
prolonged	-	150	O
course	-	160	O
of	-	167	O
vancomycin	-	170	O
therapy	-	181	O
in	-	189	O
2	-	192	O
patients	-	194	O
who	-	203	O
were	-	207	O
receiving	-	212	O
tenofovir	-	222	O
disoproxil	-	232	O
fumarate	-	243	O
as	-	252	O
part	-	255	O
of	-	260	O
an	-	263	O
antiretroviral	-	266	O
regimen	-	281	O
.	-	288	O

Tenofovir	19642243	290	O
has	-	300	O
been	-	304	O
implicated	-	309	O
in	-	320	O
the	-	323	O
development	-	327	O
of	-	339	O
Fanconi	-	342	B
syndrome	-	350	I
and	-	359	O
renal	-	363	B
insufficiency	-	369	I
because	-	383	O
of	-	391	O
its	-	394	O
effects	-	398	O
on	-	406	O
the	-	409	O
proximal	-	413	O
renal	-	422	O
tubule	-	428	O
.	-	434	O

Vancomycin	19642243	436	O
nephrotoxicity	-	447	B
is	-	462	O
infrequent	-	465	O
but	-	476	O
may	-	480	O
result	-	484	O
from	-	491	O
coadministration	-	496	O
with	-	513	O
a	-	518	O
nephrotoxic	-	520	B
agent	-	532	O
.	-	537	O

Clinicians	19642243	539	O
should	-	550	O
be	-	557	O
aware	-	560	O
that	-	566	O
tenofovir	-	571	O
may	-	581	O
raise	-	585	O
the	-	591	O
risk	-	595	O
of	-	600	O
renal	-	603	B
failure	-	609	I
during	-	617	O
prolonged	-	624	O
administration	-	634	O
of	-	649	O
vancomycin	-	652	O
.	-	662	O

Delayed	17682013	0	O
leukoencephalopathy	-	8	B
with	-	28	O
stroke	-	33	B
-	-	39	O
like	-	40	O
presentation	-	45	O
in	-	58	O
chemotherapy	-	61	O
recipients	-	74	O
.	-	84	O

BACKGROUND	17682013	86	O
:	-	96	O

A	17682013	98	O
transient	-	100	O
leukoencephalopathy	-	110	B
mimicking	-	130	O
cerebrovascular	-	140	B
accident	-	156	I
has	-	165	O
been	-	169	O
described	-	174	O
as	-	184	O
a	-	187	O
complication	-	189	O
of	-	202	O
chemotherapy	-	205	O
,	-	217	O
most	-	219	O
commonly	-	224	O
in	-	233	O
recipients	-	236	O
of	-	247	O
intrathecal	-	250	O
methotrexate	-	262	O
for	-	275	O
childhood	-	279	O
leukaemia	-	289	B
.	-	298	O

Recently	17682013	300	O
published	-	309	O
neuroimaging	-	319	O
data	-	332	O
suggest	-	337	O
a	-	345	O
common	-	347	O
pathophysiology	-	354	O
associated	-	370	O
with	-	381	O
a	-	386	O
variety	-	388	O
of	-	396	O
chemotherapy	-	399	O
agents	-	412	O
and	-	419	O
modes	-	423	O
of	-	429	O
administration	-	432	O
.	-	446	O

METHODS	17682013	448	O
:	-	455	O

We	17682013	457	O
reviewed	-	460	O
the	-	469	O
medical	-	473	O
literature	-	481	O
for	-	492	O
single	-	496	O
reports	-	503	O
and	-	511	O
case	-	515	O
series	-	520	O
of	-	527	O
patients	-	530	O
presenting	-	539	O
with	-	550	O
stroke	-	555	B
-	-	561	O
like	-	562	O
episodes	-	567	O
while	-	576	O
receiving	-	582	O
systemic	-	592	O
or	-	601	O
intrathecal	-	604	O
chemotherapy	-	616	O
.	-	628	O

We	17682013	630	O
only	-	633	O
included	-	638	O
studies	-	647	O
providing	-	655	O
detailed	-	665	O
neuroimaging	-	674	O
data	-	687	O
.	-	691	O

Patients	17682013	693	O
with	-	702	O
cerebrovascular	-	707	B
accidents	-	723	I
were	-	733	O
excluded	-	738	O
.	-	746	O

RESULTS	17682013	748	O
:	-	755	O

We	17682013	757	O
identified	-	760	O
27	-	771	O
reports	-	774	O
of	-	782	O
toxic	-	785	O
leukoencephalopathy	-	791	B
in	-	811	O
patients	-	814	O
treated	-	823	O
with	-	831	O
methotrexate	-	836	O
(	-	849	O
intrathecal	-	850	O
,	-	861	O
systemic	-	863	O
)	-	871	O
,	-	872	O
5	-	874	O
-	-	875	O
fluorouracil	-	876	O
and	-	889	O
its	-	893	O
derivative	-	897	O
carmofur	-	908	O
,	-	916	O
and	-	918	O
capecitabine	-	922	O
.	-	934	O

Diffusion	17682013	936	O
weighted	-	946	O
imaging	-	955	O
(	-	963	O
DWI	-	964	O
)	-	967	O
of	-	969	O
all	-	972	O
patients	-	976	O
revealed	-	985	O
well	-	994	O
demarcated	-	999	O
hyperintense	-	1010	O
lesions	-	1023	B
within	-	1031	I
the	-	1038	I
subcortical	-	1042	I
white	-	1054	I
matter	-	1060	I
of	-	1067	O
the	-	1070	O
cerebral	-	1074	O
hemispheres	-	1083	O
and	-	1095	O
the	-	1099	O
corpus	-	1103	O
callosum	-	1110	O
,	-	1118	O
corresponding	-	1120	O
to	-	1134	O
areas	-	1137	O
of	-	1143	O
decreased	-	1146	O
proton	-	1156	O
diffusion	-	1163	O
on	-	1173	O
apparent	-	1176	O
diffusion	-	1185	O
coefficient	-	1195	O
(	-	1207	O
ADC	-	1208	O
)	-	1211	O
maps	-	1213	O
(	-	1218	O
available	-	1219	O
in	-	1229	O
21	-	1232	O
/	-	1234	O
27	-	1235	O
patients	-	1238	O
)	-	1246	O
.	-	1247	O

Lesions	17682013	1249	O
exceeded	-	1257	O
the	-	1266	O
confines	-	1270	O
of	-	1279	O
adjacent	-	1282	O
vascular	-	1291	O
territories	-	1300	O
.	-	1311	O

Complete	17682013	1313	O
resolution	-	1322	O
of	-	1333	O
symptoms	-	1336	O
within	-	1345	O
1	-	1352	O
-	-	1353	O
4	-	1354	O
days	-	1356	O
was	-	1361	O
accompanied	-	1365	O
by	-	1377	O
normalisation	-	1380	O
of	-	1394	O
ADC	-	1397	O
abnormalities	-	1401	O
.	-	1414	O

However	17682013	1416	O
,	-	1423	O
fluid	-	1425	O
attenuated	-	1431	O
inversion	-	1442	O
recovery	-	1452	O
(	-	1461	O
FLAIR	-	1462	O
)	-	1467	O
sequences	-	1469	O
frequently	-	1479	O
revealed	-	1490	O
persistent	-	1499	O
white	-	1510	B
matter	-	1516	I
abnormalities	-	1523	I
.	-	1536	O

CONCLUSIONS	17682013	1538	O
:	-	1549	O

Several	17682013	1551	O
pathophysiological	-	1559	O
models	-	1578	O
of	-	1585	O
delayed	-	1588	O
leukoencephalopathy	-	1596	B
after	-	1616	O
exposure	-	1622	O
to	-	1631	O
intrathecal	-	1634	O
or	-	1646	O
systemic	-	1649	O
chemotherapy	-	1658	O
have	-	1671	O
been	-	1676	O
proposed	-	1681	O
.	-	1689	O

DWI	17682013	1691	O
findings	-	1695	O
in	-	1704	O
this	-	1707	O
cohort	-	1712	O
are	-	1719	O
indicative	-	1723	O
of	-	1734	O
cytotoxic	-	1737	B
oedema	-	1747	I
within	-	1754	I
cerebral	-	1761	I
white	-	1770	I
matter	-	1776	I
and	-	1783	O
lend	-	1787	O
support	-	1792	O
to	-	1800	O
an	-	1803	O
at	-	1806	O
least	-	1809	O
partially	-	1815	O
reversible	-	1825	O
metabolic	-	1836	O
derangement	-	1846	O
as	-	1858	O
the	-	1861	O
basis	-	1865	O
for	-	1871	O
this	-	1875	O
syndrome	-	1880	O
.	-	1888	O

Down	16725121	0	O
-	-	4	O
regulation	-	5	O
of	-	16	O
norepinephrine	-	19	O
transporter	-	34	O
function	-	46	O
induced	-	55	O
by	-	63	O
chronic	-	66	O
administration	-	74	O
of	-	89	O
desipramine	-	92	O
linking	-	104	O
to	-	112	O
the	-	115	O
alteration	-	119	O
of	-	130	O
sensitivity	-	133	O
of	-	145	O
local	-	148	O
-	-	153	O
anesthetics	-	154	O
-	-	165	O
induced	-	166	O
convulsions	-	174	B
and	-	186	O
the	-	190	O
counteraction	-	194	O
by	-	208	O
co	-	211	O
-	-	213	O
administration	-	214	O
with	-	229	O
local	-	234	O
anesthetics	-	240	O
.	-	251	O

Alterations	16725121	253	O
of	-	265	O
norepinephrine	-	268	O
transporter	-	283	O
(	-	295	O
NET	-	296	O
)	-	299	O
function	-	301	O
by	-	310	O
chronic	-	313	O
inhibition	-	321	O
of	-	332	O
NET	-	335	O
in	-	339	O
relation	-	342	O
to	-	351	O
sensitization	-	354	O
to	-	368	O
seizures	-	371	B
induce	-	380	O
by	-	387	O
cocaine	-	390	O
and	-	398	O
local	-	402	O
anesthetics	-	408	O
were	-	420	O
studied	-	425	O
in	-	433	O
mice	-	436	O
.	-	440	O

Daily	16725121	442	O
administration	-	448	O
of	-	463	O
desipramine	-	466	O
,	-	477	O
an	-	479	O
inhibitor	-	482	O
of	-	492	O
the	-	495	O
NET	-	499	O
,	-	502	O
for	-	504	O
5	-	508	O
days	-	510	O
decreased	-	515	O
[	-	525	O
(	-	526	O
3	-	527	O
)	-	528	O
H	-	529	O
]	-	530	O
norepinephrine	-	531	O
uptake	-	546	O
in	-	553	O
the	-	556	O
P2	-	560	O
fractions	-	563	O
of	-	573	O
hippocampus	-	576	O
but	-	588	O
not	-	592	O
cortex	-	596	O
,	-	602	O
striatum	-	604	O
or	-	613	O
amygdalae	-	616	O
.	-	625	O

Co	16725121	627	O
-	-	629	O

administration	16725121	630	O
of	-	645	O
lidocaine	-	648	O
,	-	657	O
bupivacaine	-	659	O
or	-	671	O
tricaine	-	674	O
with	-	683	O
desipramine	-	688	O
reversed	-	700	O
this	-	709	O
effect	-	714	O
.	-	720	O

Daily	16725121	722	O
treatment	-	728	O
of	-	738	O
cocaine	-	741	O
increased	-	749	O
[	-	759	O
(	-	760	O
3	-	761	O
)	-	762	O
H	-	763	O
]	-	764	O
norepinephrine	-	765	O
uptake	-	780	O
into	-	787	O
the	-	792	O
hippocampus	-	796	O
.	-	807	O

Daily	16725121	809	O
administration	-	815	O
of	-	830	O
desipramine	-	833	O
increased	-	845	O
the	-	855	O
incidence	-	859	O
of	-	869	O
appearance	-	872	O
of	-	883	O
lidocaine	-	886	O
-	-	895	O
induced	-	896	O
convulsions	-	904	B
and	-	916	O
decreased	-	920	O
that	-	930	O
of	-	935	O
cocaine	-	938	O
-	-	945	O
induced	-	946	O
convulsions	-	954	B
.	-	965	O

Co	16725121	967	O
-	-	969	O

administration	16725121	970	O
of	-	985	O
lidocaine	-	988	O
with	-	998	O
desipramine	-	1003	O
reversed	-	1015	O
the	-	1024	O
changes	-	1028	O
of	-	1036	O
convulsive	-	1039	B
activity	-	1050	O
of	-	1059	O
lidocaine	-	1062	O
and	-	1072	O
cocaine	-	1076	O
induced	-	1084	O
by	-	1092	O
repeated	-	1095	O
administration	-	1104	O
of	-	1119	O
desipramine	-	1122	O
.	-	1133	O

These	16725121	1135	O
results	-	1141	O
suggest	-	1149	O
that	-	1157	O
down	-	1162	O
-	-	1166	O
regulation	-	1167	O
of	-	1178	O
hippocampal	-	1181	O
NET	-	1193	O
induced	-	1197	O
by	-	1205	O
chronic	-	1208	O
administration	-	1216	O
of	-	1231	O
desipramine	-	1234	O
may	-	1246	O
be	-	1250	O
relevant	-	1253	O
to	-	1262	O
desipramine	-	1265	O
-	-	1276	O
induced	-	1277	O
sensitization	-	1285	O
of	-	1299	O
lidocaine	-	1302	O
convulsions	-	1312	B
.	-	1323	O

Inhibition	16725121	1325	O
of	-	1336	O
Na	-	1339	O
(	-	1341	O
+	-	1342	O
)	-	1343	O
channels	-	1345	O
by	-	1354	O
local	-	1357	O
anesthetics	-	1363	O
may	-	1375	O
regulate	-	1379	O
desipramine	-	1388	O
-	-	1399	O
induced	-	1400	O
down	-	1408	O
-	-	1412	O
regulation	-	1413	O
of	-	1424	O
NET	-	1427	O
function	-	1431	O
.	-	1439	O

Repeated	16725121	1441	O
administration	-	1450	O
of	-	1465	O
cocaine	-	1468	O
induces	-	1476	O
up	-	1484	O
-	-	1486	O
regulation	-	1487	O
of	-	1498	O
hippocampal	-	1501	O
NET	-	1513	O
function	-	1517	O
.	-	1525	O

Desipramine	16725121	1527	O
-	-	1538	O
induced	-	1539	O
sensitization	-	1547	O
of	-	1561	O
lidocaine	-	1564	O
seizures	-	1574	B
may	-	1583	O
have	-	1587	O
a	-	1592	O
mechanism	-	1594	O
distinct	-	1604	O
from	-	1613	O
kindling	-	1618	O
resulting	-	1627	O
from	-	1637	O
repeated	-	1642	O
administration	-	1651	O
of	-	1666	O
cocaine	-	1669	O
.	-	1676	O

Definition	16629641	0	O
and	-	11	O
management	-	15	O
of	-	26	O
anemia	-	29	B
in	-	36	O
patients	-	39	O
infected	-	48	B
with	-	57	I
hepatitis	-	62	I
C	-	72	I
virus	-	74	I
.	-	79	O

Chronic	16629641	81	B
infection	-	89	I
with	-	99	I
hepatitis	-	104	I
C	-	114	I
virus	-	116	I
(	-	122	O
HCV	-	123	O
)	-	126	O
can	-	128	O
progress	-	132	O
to	-	141	O
cirrhosis	-	144	B
,	-	153	O
hepatocellular	-	155	B
carcinoma	-	170	I
,	-	179	O
and	-	181	O
end	-	185	B
-	-	188	I
stage	-	189	I
liver	-	195	I
disease	-	201	I
.	-	208	O

The	16629641	210	O
current	-	214	O
best	-	222	O
treatment	-	227	O
for	-	237	O
HCV	-	241	B
infection	-	245	I
is	-	255	O
combination	-	258	O
therapy	-	270	O
with	-	278	O
pegylated	-	283	O
interferon	-	293	O
and	-	304	O
ribavirin	-	308	O
.	-	317	O

Although	16629641	319	O
this	-	328	O
regimen	-	333	O
produces	-	341	O
sustained	-	350	O
virologic	-	360	O
responses	-	370	O
(	-	380	O
SVRs	-	381	O
)	-	385	O
in	-	387	O
approximately	-	390	O
50	-	404	O
%	-	406	O
of	-	408	O
patients	-	411	O
,	-	419	O
it	-	421	O
can	-	424	O
be	-	428	O
associated	-	431	O
with	-	442	O
a	-	447	O
potentially	-	449	O
dose	-	461	O
-	-	465	O
limiting	-	466	O
hemolytic	-	475	B
anemia	-	485	I
.	-	491	O

Hemoglobin	16629641	493	O
concentrations	-	504	O
decrease	-	519	O
mainly	-	528	O
as	-	535	O
a	-	538	O
result	-	540	O
of	-	547	O
ribavirin	-	550	O
-	-	559	O
induced	-	560	O
hemolysis	-	568	B
,	-	577	O
and	-	579	O
this	-	583	O
anemia	-	588	B
can	-	595	O
be	-	599	O
problematic	-	602	O
in	-	614	O
patients	-	617	O
with	-	626	O
HCV	-	631	B
infection	-	635	I
,	-	644	O
especially	-	646	O
those	-	657	O
who	-	663	O
have	-	667	O
comorbid	-	672	O
renal	-	681	B
or	-	687	I
cardiovascular	-	690	I
disorders	-	705	I
.	-	714	O

In	16629641	716	O
general	-	719	O
,	-	726	O
anemia	-	728	B
can	-	735	O
increase	-	739	O
the	-	748	O
risk	-	752	O
of	-	757	O
morbidity	-	760	O
and	-	770	O
mortality	-	774	O
,	-	783	O
and	-	785	O
may	-	789	O
have	-	793	O
negative	-	798	O
effects	-	807	O
on	-	815	O
cerebral	-	818	O
function	-	827	O
and	-	836	O
quality	-	840	O
of	-	848	O
life	-	851	O
.	-	855	O

Although	16629641	857	O
ribavirin	-	866	O
-	-	875	O
associated	-	876	O
anemia	-	887	B
can	-	894	O
be	-	898	O
reversed	-	901	O
by	-	910	O
dose	-	913	O
reduction	-	918	O
or	-	928	O
discontinuation	-	931	O
,	-	946	O
this	-	948	O
approach	-	953	O
compromises	-	962	O
outcomes	-	974	O
by	-	983	O
significantly	-	986	O
decreasing	-	1000	O
SVR	-	1011	O
rates	-	1015	O
.	-	1020	O

Recombinant	16629641	1022	O
human	-	1034	O
erythropoietin	-	1040	O
has	-	1055	O
been	-	1059	O
used	-	1064	O
to	-	1069	O
manage	-	1072	O
ribavirin	-	1079	O
-	-	1088	O
associated	-	1089	O
anemia	-	1100	B
but	-	1107	O
has	-	1111	O
other	-	1115	O
potential	-	1121	O
disadvantages	-	1131	O
.	-	1144	O

Viramidine	16629641	1146	O
,	-	1156	O
a	-	1158	O
liver	-	1160	O
-	-	1165	O
targeting	-	1166	O
prodrug	-	1176	O
of	-	1184	O
ribavirin	-	1187	O
,	-	1196	O
has	-	1198	O
the	-	1202	O
potential	-	1206	O
to	-	1216	O
maintain	-	1219	O
the	-	1228	O
virologic	-	1232	O
efficacy	-	1242	O
of	-	1251	O
ribavirin	-	1254	O
while	-	1264	O
decreasing	-	1270	O
the	-	1281	O
risk	-	1285	O
of	-	1290	O
hemolytic	-	1293	B
anemia	-	1303	I
in	-	1310	O
patients	-	1313	O
with	-	1322	O
chronic	-	1327	B
hepatitis	-	1335	I
C	-	1345	I
.	-	1346	O

Calcium	16006300	0	O
carbonate	-	8	O
toxicity	-	18	B
:	-	26	O
the	-	28	O
updated	-	32	O
milk	-	40	B
-	-	44	I
alkali	-	45	I
syndrome	-	52	I
;	-	60	O
report	-	62	O
of	-	69	O
3	-	72	O
cases	-	74	O
and	-	80	O
review	-	84	O
of	-	91	O
the	-	94	O
literature	-	98	O
.	-	108	O

OBJECTIVE	16006300	110	O
:	-	119	O

To	16006300	121	O
describe	-	124	O
3	-	133	O
patients	-	135	O
with	-	144	O
calcium	-	149	O
carbonate	-	157	O
-	-	166	O
induced	-	167	O
hypercalcemia	-	175	B
and	-	189	O
gain	-	193	O
insights	-	198	O
into	-	207	O
the	-	212	O
cause	-	216	O
and	-	222	O
management	-	226	O
of	-	237	O
the	-	240	O
milk	-	244	B
-	-	248	I
alkali	-	249	I
syndrome	-	256	I
.	-	264	O

METHODS	16006300	266	O
:	-	273	O

We	16006300	275	O
report	-	278	O
the	-	285	O
clinical	-	289	O
and	-	298	O
laboratory	-	302	O
data	-	313	O
in	-	318	O
3	-	321	O
patients	-	323	O
who	-	332	O
presented	-	336	O
with	-	346	O
severe	-	351	O
hypercalcemia	-	358	B
(	-	372	O
corrected	-	373	O
serum	-	383	O
calcium	-	389	O
>	-	397	O
or	-	399	O
=	-	402	O
14	-	404	O
mg	-	407	O
/	-	409	O
dL	-	410	O
)	-	412	O
and	-	414	O
review	-	418	O
the	-	425	O
pertinent	-	429	O
literature	-	439	O
on	-	450	O
milk	-	453	B
-	-	457	I
alkali	-	458	I
syndrome	-	465	I
.	-	473	O

RESULTS	16006300	475	O
:	-	482	O

The	16006300	484	O
3	-	488	O
patients	-	490	O
had	-	499	O
acute	-	503	B
renal	-	509	I
insufficiency	-	515	I
,	-	528	O
relative	-	530	O
metabolic	-	539	B
alkalosis	-	549	I
,	-	558	O
and	-	560	O
low	-	564	O
parathyroid	-	568	O
hormone	-	580	O
(	-	588	O
PTH	-	589	O
)	-	592	O
,	-	593	O
PTH	-	595	O
-	-	598	O
related	-	599	O
peptide	-	607	O
,	-	614	O
and	-	616	O
1	-	620	O
,	-	621	O
25	-	622	O
-	-	624	O
dihydroxyvitamin	-	625	O
D	-	642	O
concentrations	-	644	O
.	-	658	O

No	16006300	660	O
malignant	-	663	O
lesion	-	673	O
was	-	680	O
found	-	684	O
.	-	689	O

Treatment	16006300	691	O
included	-	701	O
aggressive	-	710	O
hydration	-	721	O
and	-	731	O
varied	-	735	O
amounts	-	742	O
of	-	750	O
furosemide	-	753	O
.	-	763	O

The	16006300	765	O
2	-	769	O
patients	-	771	O
with	-	780	O
the	-	785	O
higher	-	789	O
serum	-	796	O
calcium	-	802	O
concentrations	-	810	O
received	-	825	O
pamidronate	-	834	O
intravenously	-	846	O
(	-	860	O
60	-	861	O
and	-	864	O
30	-	868	O
mg	-	871	O
,	-	873	O
respectively	-	875	O
)	-	887	O
,	-	888	O
which	-	890	O
caused	-	896	O
severe	-	903	O
hypocalcemia	-	910	B
.	-	922	O

Of	16006300	924	O
the	-	927	O
3	-	931	O
patients	-	933	O
,	-	941	O
2	-	943	O
were	-	945	O
ingesting	-	950	O
acceptable	-	960	O
doses	-	971	O
of	-	977	O
elemental	-	980	O
calcium	-	990	O
(	-	998	O
1	-	999	O
g	-	1001	O
and	-	1003	O
2	-	1007	O
g	-	1009	O
daily	-	1011	O
,	-	1016	O
respectively	-	1018	O
)	-	1030	O
in	-	1032	O
the	-	1035	O
form	-	1039	O
of	-	1044	O
calcium	-	1047	O
carbonate	-	1055	O
.	-	1064	O

In	16006300	1066	O
addition	-	1069	O
to	-	1078	O
our	-	1081	O
highlighted	-	1085	O
cases	-	1097	O
,	-	1102	O
we	-	1104	O
review	-	1107	O
the	-	1114	O
history	-	1118	O
,	-	1125	O
classification	-	1127	O
,	-	1141	O
pathophysiologic	-	1143	O
features	-	1160	O
,	-	1168	O
and	-	1170	O
treatment	-	1174	O
of	-	1184	O
milk	-	1187	B
-	-	1191	I
alkali	-	1192	I
syndrome	-	1199	I
and	-	1208	O
summarize	-	1212	O
the	-	1222	O
cases	-	1226	O
reported	-	1232	O
from	-	1241	O
early	-	1246	O
1995	-	1252	O
to	-	1257	O
November	-	1260	O
2003	-	1269	O
.	-	1273	O

CONCLUSION	16006300	1275	O
:	-	1285	O

Milk	16006300	1287	B
-	-	1291	I
alkali	-	1292	I
syndrome	-	1299	I
may	-	1308	O
be	-	1312	O
a	-	1315	O
common	-	1317	O
cause	-	1324	O
of	-	1330	O
unexplained	-	1333	O
hypercalcemia	-	1345	B
and	-	1359	O
can	-	1363	O
be	-	1367	O
precipitated	-	1370	O
by	-	1383	O
small	-	1386	O
amounts	-	1392	O
of	-	1400	O
orally	-	1403	O
ingested	-	1410	O
calcium	-	1419	O
carbonate	-	1427	O
in	-	1437	O
susceptible	-	1440	O
persons	-	1452	O
.	-	1459	O

Treatment	16006300	1461	O
with	-	1471	O
hydration	-	1476	O
,	-	1485	O
furosemide	-	1487	O
,	-	1497	O
and	-	1499	O
discontinuation	-	1503	O
of	-	1519	O
the	-	1522	O
calcium	-	1526	O
and	-	1534	O
vitamin	-	1538	O
D	-	1546	O
source	-	1548	O
is	-	1555	O
adequate	-	1558	O
.	-	1566	O

Pamidronate	16006300	1568	O
treatment	-	1580	O
is	-	1590	O
associated	-	1593	O
with	-	1604	O
considerable	-	1609	O
risk	-	1622	O
for	-	1627	O
hypocalcemia	-	1631	B
,	-	1643	O
even	-	1645	O
in	-	1650	O
cases	-	1653	O
of	-	1659	O
initially	-	1662	O
severe	-	1672	O
hypercalcemia	-	1679	B
.	-	1692	O

Management	11705128	0	O
strategies	-	11	O
for	-	22	O
ribavirin	-	26	O
-	-	35	O
induced	-	36	O
hemolytic	-	44	B
anemia	-	54	I
in	-	61	O
the	-	64	O
treatment	-	68	O
of	-	78	O
hepatitis	-	81	B
C	-	91	I
:	-	92	O
clinical	-	94	O
and	-	103	O
economic	-	107	O
implications	-	116	O
.	-	128	O

OBJECTIVES	11705128	130	O
:	-	140	O

Recently	11705128	142	O
published	-	151	O
studies	-	161	O
have	-	169	O
demonstrated	-	174	O
increased	-	187	O
efficacy	-	197	O
and	-	206	O
cost	-	210	O
-	-	214	O
effectiveness	-	215	O
of	-	229	O
combination	-	232	O
therapy	-	244	O
with	-	252	O
interferon	-	257	O
and	-	268	O
alpha	-	272	O
-	-	277	O
2b	-	278	O
/	-	280	O
ribavirin	-	281	O
compared	-	291	O
with	-	300	O
interferon	-	305	O
-	-	315	O
alpha	-	316	O
monotherapy	-	322	O
in	-	334	O
the	-	337	O
treatment	-	341	O
of	-	351	O
chronic	-	354	B
hepatitis	-	362	I
C	-	372	I
(	-	374	O
CHC	-	375	B
)	-	378	O
.	-	379	O

Combination	11705128	381	O
therapy	-	393	O
is	-	401	O
associated	-	404	O
with	-	415	O
a	-	420	O
clinically	-	422	O
important	-	433	O
adverse	-	443	O
effect	-	451	O
:	-	457	O
ribavirin	-	459	O
-	-	468	O
induced	-	469	O
hemolytic	-	477	B
anemia	-	487	I
(	-	494	O
RIHA	-	495	B
)	-	499	O
.	-	500	O

The	11705128	502	O
objective	-	506	O
of	-	516	O
this	-	519	O
study	-	524	O
was	-	530	O
to	-	534	O
evaluate	-	537	O
the	-	546	O
direct	-	550	O
health	-	557	O
-	-	563	O
care	-	564	O
costs	-	569	O
and	-	575	O
management	-	579	O
of	-	590	O
RIHA	-	593	B
during	-	598	O
treatment	-	605	O
of	-	615	O
CHC	-	618	B
in	-	622	O
a	-	625	O
clinical	-	627	O
trial	-	636	O
setting	-	642	O
.	-	649	O

METHODS	11705128	651	O
:	-	658	O

A	11705128	660	O
systematic	-	662	O
literature	-	673	O
review	-	684	O
was	-	691	O
conducted	-	695	O
to	-	705	O
synthesize	-	708	O
information	-	719	O
on	-	731	O
the	-	734	O
incidence	-	738	O
and	-	748	O
management	-	752	O
of	-	763	O
RIHA	-	766	B
.	-	770	O

Decision	11705128	772	O
-	-	780	O
analytic	-	781	O
techniques	-	790	O
were	-	801	O
used	-	806	O
to	-	811	O
estimate	-	814	O
the	-	823	O
cost	-	827	O
of	-	832	O
treating	-	835	O
RIHA	-	844	B
.	-	848	O

Uncertainty	11705128	850	O
was	-	862	O
evaluated	-	866	O
using	-	876	O
sensitivity	-	882	O
analyses	-	894	O
.	-	902	O

RESULTS	11705128	904	O
:	-	911	O
RIHA	-	913	B
,	-	917	O
defined	-	919	O
as	-	927	O
a	-	930	O
reduction	-	932	O
in	-	942	O
hemoglobin	-	945	O
to	-	956	O
less	-	959	O
than	-	964	O
100	-	969	O
g	-	973	O
/	-	974	O
L	-	975	O
,	-	976	O
occurs	-	978	O
in	-	985	O
approximately	-	988	O
7	-	1002	O
%	-	1003	O
to	-	1005	O
9	-	1008	O
%	-	1009	O
of	-	1011	O
patients	-	1014	O
treated	-	1023	O
with	-	1031	O
combination	-	1036	O
therapy	-	1048	O
.	-	1055	O

The	11705128	1057	O
standard	-	1061	O
of	-	1070	O
care	-	1073	O
for	-	1078	O
management	-	1082	O
of	-	1093	O
RIHA	-	1096	B
is	-	1101	O
reduction	-	1104	O
or	-	1114	O
discontinuation	-	1117	O
of	-	1133	O
the	-	1136	O
ribavirin	-	1140	O
dosage	-	1150	O
.	-	1156	O

We	11705128	1158	O
estimated	-	1161	O
the	-	1171	O
direct	-	1175	O
cost	-	1182	O
of	-	1187	O
treating	-	1190	O
clinically	-	1199	O
significant	-	1210	O
RIHA	-	1222	B
to	-	1227	O
be	-	1230	O
170	-	1234	O
per	-	1238	O
patient	-	1242	O
receiving	-	1250	O
combination	-	1260	O
therapy	-	1272	O
per	-	1280	O
48	-	1284	O
-	-	1286	O
week	-	1287	O
treatment	-	1292	O
course	-	1302	O
(	-	1309	O
range	-	1310	O

68	11705128	1317	O
-	-	1319	O
692	-	1321	O
)	-	1324	O
.	-	1325	O

The	11705128	1327	O
results	-	1331	O
of	-	1339	O
the	-	1342	O
one	-	1346	O
-	-	1349	O
way	-	1350	O
sensitivity	-	1354	O
analyses	-	1366	O
ranged	-	1375	O
from	-	1382	O
57	-	1388	O
to	-	1391	O
317	-	1395	O
.	-	1398	O

In	11705128	1400	O
comparison	-	1403	O
,	-	1413	O
the	-	1415	O
cost	-	1419	O
of	-	1424	O
48	-	1427	O
weeks	-	1430	O
of	-	1436	O
combination	-	1439	O
therapy	-	1451	O
is	-	1459	O
16	-	1463	O
,	-	1465	O
459	-	1466	O
.	-	1469	O

CONCLUSIONS	11705128	1471	O
:	-	1482	O

The	11705128	1484	O
direct	-	1488	O
cost	-	1495	O
of	-	1500	O
treating	-	1503	O
clinically	-	1512	O
significant	-	1523	O
RIHA	-	1535	B
is	-	1540	O
1	-	1543	O
%	-	1544	O
(	-	1546	O
170	-	1548	O
/	-	1551	O
16	-	1553	O
,	-	1555	O
459	-	1556	O
)	-	1559	O
of	-	1561	O
drug	-	1564	O
treatment	-	1569	O
costs	-	1579	O
.	-	1584	O

Questions	11705128	1586	O
remain	-	1596	O
about	-	1603	O
the	-	1609	O
optimal	-	1613	O
dose	-	1621	O
of	-	1626	O
ribavirin	-	1629	O
and	-	1639	O
the	-	1643	O
incidence	-	1647	O
of	-	1657	O
RIHA	-	1660	B
in	-	1665	O
a	-	1668	O
real	-	1670	O
-	-	1674	O
world	-	1675	O
population	-	1681	O
.	-	1691	O

Despite	11705128	1693	O
these	-	1701	O
uncertainties	-	1707	O
,	-	1720	O
this	-	1722	O
initial	-	1727	O
evaluation	-	1735	O
of	-	1746	O
the	-	1749	O
direct	-	1753	O
cost	-	1760	O
of	-	1765	O
treating	-	1768	O
RIHA	-	1777	B
provides	-	1782	O
an	-	1791	O
estimate	-	1794	O
of	-	1803	O
the	-	1806	O
cost	-	1810	O
and	-	1815	O
management	-	1819	O
implications	-	1830	O
of	-	1843	O
this	-	1846	O
clinically	-	1851	O
important	-	1862	O
adverse	-	1872	O
effect	-	1880	O
.	-	1886	O

Effects	6540303	0	O
of	-	8	O
amine	-	11	O
pretreatment	-	17	O
on	-	30	O
ketamine	-	33	O
catatonia	-	42	B
in	-	52	O
pinealectomized	-	55	O
or	-	71	O
hypophysectomized	-	74	O
animals	-	92	O
.	-	99	O

The	6540303	101	O
present	-	105	O
studies	-	113	O
were	-	121	O
designed	-	126	O
to	-	135	O
clarify	-	138	O
the	-	146	O
role	-	150	O
of	-	155	O
catecholamines	-	158	O
and	-	173	O
pineal	-	177	O
idolamines	-	184	O
on	-	195	O
ketamine	-	198	O
-	-	206	O
induced	-	207	O
catatonia	-	215	B
in	-	225	O
the	-	228	O
intact	-	232	O
,	-	238	O
pinealectomized	-	240	O
or	-	256	O
hypophysectomized	-	259	O
chick	-	277	O
and	-	283	O
rat	-	287	O
.	-	290	O

In	6540303	292	O
the	-	295	O
pinealectomized	-	299	O
chick	-	315	O
,	-	320	O
pretreatment	-	322	O
with	-	335	O
dopamine	-	340	O
increased	-	349	O
the	-	359	O
duration	-	363	O
of	-	372	O
catatonia	-	375	B
(	-	385	O
DOC	-	386	O
)	-	389	O
after	-	391	O
ketamine	-	397	O
,	-	405	O
but	-	407	O
pretreatment	-	411	O
with	-	424	O
norepinephrine	-	429	O
did	-	444	O
not	-	448	O
.	-	451	O

The	6540303	453	O
pineal	-	457	O
indolamines	-	464	O
exhibited	-	476	O
mixed	-	486	O
actions	-	492	O
.	-	499	O

Serotonin	6540303	501	O
and	-	511	O
N	-	515	O
-	-	516	O
acetyl	-	517	O
serotonin	-	524	O
which	-	534	O
augmented	-	540	O
ketamine	-	550	O
DOC	-	559	O
,	-	562	O
did	-	564	O
not	-	568	O
do	-	572	O
so	-	575	O
in	-	578	O
the	-	581	O
absence	-	585	O
of	-	593	O
the	-	596	O
pineal	-	600	O
gland	-	607	O
,	-	612	O
whereas	-	614	O
melatonin	-	622	O
potentiated	-	632	O
the	-	644	O
ketamine	-	648	O
DOC	-	657	O
in	-	661	O
both	-	664	O
the	-	669	O
intact	-	673	O
and	-	680	O
pinealectomized	-	684	O
chick	-	700	O
.	-	705	O

Ketamine	6540303	707	O
was	-	716	O
more	-	720	O
potent	-	725	O
in	-	732	O
the	-	735	O
hypophysectomized	-	739	O
chick	-	757	O
and	-	763	O
the	-	767	O
circadian	-	771	O
rhythm	-	781	O
noted	-	788	O
in	-	794	O
the	-	797	O
intact	-	801	O
chick	-	808	O
was	-	814	O
absent	-	818	O
;	-	824	O
furthermore	-	826	O
,	-	837	O
melatonin	-	839	O
did	-	849	O
not	-	853	O
augment	-	857	O
the	-	865	O
ketamine	-	869	O
DOC	-	878	O
whereas	-	882	O
dopamine	-	890	O
continued	-	899	O
to	-	909	O
do	-	912	O
so	-	915	O
.	-	917	O

This	6540303	919	O
study	-	924	O
did	-	930	O
not	-	934	O
demonstrate	-	938	O
a	-	950	O
species	-	952	O
difference	-	960	O
regarding	-	971	O
the	-	981	O
role	-	985	O
of	-	990	O
the	-	993	O
amines	-	997	O
on	-	1004	O
the	-	1007	O
pineal	-	1011	O
in	-	1018	O
spite	-	1021	O
of	-	1027	O
the	-	1030	O
immature	-	1034	O
blood	-	1043	O
-	-	1048	O
brain	-	1049	O
barrier	-	1055	O
in	-	1063	O
the	-	1066	O
young	-	1070	O
chick	-	1076	O
and	-	1082	O
the	-	1086	O
intact	-	1090	O
barrier	-	1097	O
in	-	1105	O
the	-	1108	O
rat	-	1112	O
.	-	1115	O

In	6540303	1117	O
addition	-	1120	O
,	-	1128	O
these	-	1130	O
data	-	1136	O
indicate	-	1141	O
a	-	1150	O
direct	-	1152	O
role	-	1159	O
of	-	1164	O
the	-	1167	O
pituitary	-	1171	O
in	-	1181	O
the	-	1184	O
augmentation	-	1188	O
of	-	1201	O
ketamine	-	1204	O
DOC	-	1213	O
induced	-	1217	O
by	-	1225	O
melatonin	-	1228	O
.	-	1237	O

Furthermore	6540303	1239	O
,	-	1250	O
dopamine	-	1252	O
appeared	-	1261	O
to	-	1270	O
act	-	1273	O
on	-	1277	O
systems	-	1280	O
more	-	1288	O
closely	-	1293	O
involved	-	1301	O
with	-	1310	O
the	-	1315	O
induction	-	1319	O
of	-	1329	O
ketamine	-	1332	O
catatonia	-	1341	B
rather	-	1351	O
than	-	1358	O
directly	-	1363	O
on	-	1372	O
the	-	1375	O
pituitary	-	1379	O
.	-	1388	O

Multicenter	3057041	0	O
,	-	11	O
double	-	13	O
-	-	19	O
blind	-	20	O
,	-	25	O
multiple	-	27	O
-	-	35	O
dose	-	36	O
,	-	40	O
parallel	-	42	O
-	-	50	O
groups	-	51	O
efficacy	-	58	O
and	-	67	O
safety	-	71	O
trial	-	78	O
of	-	84	O
azelastine	-	87	O
,	-	97	O
chlorpheniramine	-	99	O
,	-	115	O
and	-	117	O
placebo	-	121	O
in	-	129	O
the	-	132	O
treatment	-	136	O
of	-	146	O
spring	-	149	B
allergic	-	156	I
rhinitis	-	165	I
.	-	173	O

Azelastine	3057041	175	O
,	-	185	O
a	-	187	O
novel	-	189	O
antiallergic	-	195	O
medication	-	208	O
,	-	218	O
was	-	220	O
compared	-	224	O
with	-	233	O
chlorpheniramine	-	238	O
maleate	-	255	O
and	-	263	O
placebo	-	267	O
for	-	275	O
efficacy	-	279	O
and	-	288	O
safety	-	292	O
in	-	299	O
the	-	302	O
treatment	-	306	O
of	-	316	O
spring	-	319	B
allergic	-	326	I
rhinitis	-	335	I
in	-	344	O
a	-	347	O
multicenter	-	349	O
,	-	360	O
double	-	362	O
-	-	368	O
blind	-	369	O
,	-	374	O
multiple	-	376	O
-	-	384	O
dose	-	385	O
,	-	389	O
parallel	-	391	O
-	-	399	O
groups	-	400	O
study	-	407	O
.	-	412	O

One	3057041	414	O
hundred	-	418	O
fifty	-	426	O
-	-	431	O
five	-	432	O
subjects	-	437	O
participated	-	446	O
.	-	458	O

Subjects	3057041	460	O
ranged	-	469	O
in	-	476	O
age	-	479	O
from	-	483	O
18	-	488	O
to	-	491	O
60	-	494	O
years	-	497	O
of	-	503	O
age	-	506	O
and	-	510	O
had	-	514	O
at	-	518	O
least	-	521	O
a	-	527	O
2	-	529	O
-	-	530	O
year	-	531	O
history	-	536	O
of	-	544	O
spring	-	547	B
allergic	-	554	I
rhinitis	-	563	I
,	-	571	O
confirmed	-	573	O
by	-	583	O
positive	-	586	O
skin	-	595	O
test	-	600	O
to	-	605	O
spring	-	608	O
aeroallergens	-	615	O
.	-	628	O

Medications	3057041	630	O
were	-	642	O
given	-	647	O
four	-	653	O
times	-	658	O
daily	-	664	O
;	-	669	O
the	-	671	O
azelastine	-	675	O
groups	-	686	O
received	-	693	O
0	-	702	O
.	-	703	O
5	-	704	O
,	-	705	O
1	-	707	O
.	-	708	O
0	-	709	O
,	-	710	O
or	-	712	O
2	-	715	O
.	-	716	O
0	-	717	O
mg	-	719	O
in	-	722	O
the	-	725	O
morning	-	729	O
and	-	737	O
evening	-	741	O
with	-	749	O
placebo	-	754	O
in	-	762	O
the	-	765	O
early	-	769	O
and	-	775	O
late	-	779	O
afternoon	-	784	O
;	-	793	O
the	-	795	O
chlorpheniramine	-	799	O
group	-	816	O
received	-	822	O
4	-	831	O
.	-	832	O
0	-	833	O
mg	-	835	O
four	-	838	O
times	-	843	O
daily	-	849	O
.	-	854	O

Daily	3057041	856	O
subject	-	862	O
symptom	-	870	O
cards	-	878	O
were	-	884	O
completed	-	889	O
during	-	899	O
a	-	906	O
screening	-	908	O
period	-	918	O
to	-	925	O
assess	-	928	O
pretreatment	-	935	O
symptoms	-	948	O
and	-	957	O
during	-	961	O
a	-	968	O
4	-	970	O
-	-	971	O
week	-	972	O
treatment	-	977	O
period	-	987	O
while	-	994	O
subjects	-	1000	O
received	-	1009	O
study	-	1018	O
medications	-	1024	O
.	-	1035	O

Individual	3057041	1037	O
symptoms	-	1048	O
,	-	1056	O
total	-	1058	O
symptoms	-	1064	O
,	-	1072	O
and	-	1074	O
major	-	1078	O
symptoms	-	1084	O
were	-	1093	O
compared	-	1098	O
to	-	1107	O
determine	-	1110	O
efficacy	-	1120	O
of	-	1129	O
medication	-	1132	O
.	-	1142	O

Elicited	3057041	1144	O
,	-	1152	O
volunteered	-	1154	O
,	-	1165	O
and	-	1167	O
observed	-	1171	O
adverse	-	1180	O
experiences	-	1188	O
were	-	1200	O
recorded	-	1205	O
for	-	1214	O
each	-	1218	O
subject	-	1223	O
and	-	1231	O
compared	-	1235	O
among	-	1244	O
groups	-	1250	O
.	-	1256	O

Vital	3057041	1258	O
signs	-	1264	O
,	-	1269	O
body	-	1271	O
weights	-	1276	O
,	-	1283	O
serum	-	1285	O
chemistry	-	1291	O
values	-	1301	O
,	-	1307	O
complete	-	1309	O
blood	-	1318	O
cell	-	1324	O
counts	-	1329	O
,	-	1335	O
urine	-	1337	O
studies	-	1343	O
,	-	1350	O
and	-	1352	O
electrocardiograms	-	1356	O
were	-	1375	O
obtained	-	1380	O
for	-	1389	O
each	-	1393	O
subject	-	1398	O
and	-	1406	O
compared	-	1410	O
among	-	1419	O
groups	-	1425	O
.	-	1431	O

Symptoms	3057041	1433	O
relief	-	1442	O
in	-	1449	O
the	-	1452	O
group	-	1456	O
receiving	-	1462	O
the	-	1472	O
highest	-	1476	O
concentration	-	1484	O
of	-	1498	O
azelastine	-	1501	O
(	-	1512	O
2	-	1513	O
.	-	1514	O
0	-	1515	O
mg	-	1517	O
twice	-	1520	O
daily	-	1526	O
)	-	1531	O
was	-	1533	O
statistically	-	1537	O
greater	-	1551	O
than	-	1559	O
in	-	1564	O
the	-	1567	O
placebo	-	1571	O
group	-	1579	O
during	-	1585	O
all	-	1592	O
weeks	-	1596	O
of	-	1602	O
the	-	1605	O
study	-	1609	O
.	-	1614	O

Lower	3057041	1616	O
doses	-	1622	O
of	-	1628	O
azelastine	-	1631	O
were	-	1642	O
statistically	-	1647	O
more	-	1661	O
effective	-	1666	O
than	-	1676	O
placebo	-	1681	O
only	-	1689	O
during	-	1694	O
portions	-	1701	O
of	-	1710	O
the	-	1713	O
first	-	1717	O
3	-	1723	O
weeks	-	1725	O
of	-	1731	O
the	-	1734	O
study	-	1738	O
.	-	1743	O

In	3057041	1745	O
contrast	-	1748	O
,	-	1756	O
although	-	1758	O
the	-	1767	O
chlorpheniramine	-	1771	O
group	-	1788	O
did	-	1794	O
have	-	1798	O
fewer	-	1803	O
symptoms	-	1809	O
than	-	1818	O
the	-	1823	O
placebo	-	1827	O
group	-	1835	O
during	-	1841	O
the	-	1848	O
study	-	1852	O
,	-	1857	O
the	-	1859	O
difference	-	1863	O
never	-	1874	O
reached	-	1880	O
statistical	-	1888	O
significance	-	1900	O
during	-	1913	O
any	-	1920	O
week	-	1924	O
of	-	1929	O
the	-	1932	O
study	-	1936	O
.	-	1941	O

There	3057041	1943	O
were	-	1949	O
no	-	1954	O
serious	-	1957	O
side	-	1965	O
effects	-	1970	O
in	-	1978	O
any	-	1981	O
of	-	1985	O
the	-	1988	O
treatment	-	1992	O
groups	-	2002	O
.	-	2008	O

Drowsiness	3057041	2010	B
and	-	2021	O
altered	-	2025	B
taste	-	2033	I
perception	-	2039	I
were	-	2050	O
increased	-	2055	O
significantly	-	2065	O
over	-	2079	O
placebo	-	2084	O
only	-	2092	O
in	-	2097	O
the	-	2100	O
high	-	2104	O
-	-	2108	O
dose	-	2109	O
azelastine	-	2114	O
group	-	2125	O
.	-	2130	O

Azelastine	3057041	2132	O
appears	-	2143	O
to	-	2151	O
be	-	2154	O
a	-	2157	O
safe	-	2159	O
,	-	2163	O
efficacious	-	2165	O
medication	-	2177	O
for	-	2188	O
seasonal	-	2192	B
allergic	-	2201	I
rhinitis	-	2210	I
.	-	2218	O

Obsolete	625456	0	O
but	-	9	O
dangerous	-	13	O
antacid	-	23	O
preparations	-	31	O
.	-	43	O

One	625456	45	O
case	-	49	O
of	-	54	O
acute	-	57	O
hypercalcaemia	-	63	B
and	-	78	O
two	-	82	O
of	-	86	O
recurrent	-	89	O
nephrolithiasis	-	99	B
are	-	115	O
reported	-	119	O
in	-	128	O
patients	-	131	O
who	-	140	O
had	-	144	O
regularly	-	148	O
consumed	-	158	O
large	-	167	O
amounts	-	173	O
of	-	181	O
calcium	-	184	O
carbon	-	192	O
-	-	198	O
ate	-	199	O
-	-	202	O
sodium	-	203	O
bicarbonate	-	210	O
powders	-	222	O
for	-	230	O
more	-	234	O
than	-	239	O
20	-	244	O
years	-	247	O
.	-	252	O

The	625456	254	O
powders	-	258	O
had	-	266	O
been	-	270	O
obtained	-	275	O
from	-	284	O
pharmacists	-	289	O
unknown	-	301	O
to	-	309	O
the	-	312	O
patients	-	316	O
'	-	324	O
medical	-	326	O
practitioners	-	334	O
.	-	347	O

It	625456	349	O
is	-	352	O
suggested	-	355	O
that	-	365	O
these	-	370	O
preparations	-	376	O
were	-	389	O
responsible	-	394	O
for	-	406	O
the	-	410	O
patient	-	414	O
's	-	421	O
problems	-	424	O
,	-	432	O
and	-	434	O
that	-	438	O
such	-	443	O
powders	-	448	O
should	-	456	O
no	-	463	O
longer	-	466	O
be	-	473	O
freely	-	476	O
obtainable	-	483	O
.	-	493	O

Prolonged	7910951	0	O
paralysis	-	10	B
due	-	20	O
to	-	24	O
nondepolarizing	-	27	O
neuromuscular	-	43	O
blocking	-	57	O
agents	-	66	O
and	-	73	O
corticosteroids	-	77	O
.	-	92	O

The	7910951	94	O
long	-	98	O
-	-	102	O
term	-	103	O
use	-	108	O
of	-	112	O
nondepolarizing	-	115	O
neuromuscular	-	131	O
blocking	-	145	O
agents	-	154	O
(	-	161	O
ND	-	162	O
-	-	164	O
NMBA	-	165	O
)	-	169	O
has	-	171	O
recently	-	175	O
been	-	184	O
implicated	-	189	O
as	-	200	O
a	-	203	O
cause	-	205	O
of	-	211	O
prolonged	-	214	O
muscle	-	224	B
weakness	-	231	I
,	-	239	O
although	-	241	O
the	-	250	O
site	-	254	O
of	-	259	O
the	-	262	O
lesion	-	266	O
and	-	273	O
the	-	277	O
predisposing	-	281	O
factors	-	294	O
have	-	302	O
been	-	307	O
unclear	-	312	O
.	-	319	O

We	7910951	321	O
report	-	324	O
3	-	331	O
patients	-	333	O
(	-	342	O
age	-	343	O
37	-	347	O
-	-	349	O
52	-	350	O
years	-	353	O
)	-	358	O
with	-	360	O
acute	-	365	O
respiratory	-	371	B
insufficiency	-	383	I
who	-	397	O
developed	-	401	O
prolonged	-	411	O
weakness	-	421	B
following	-	430	O
the	-	440	O
discontinuation	-	444	O
of	-	460	O
ND	-	463	O
-	-	465	O
NMBAs	-	466	O
.	-	471	O

Two	7910951	473	O
patients	-	477	O
also	-	486	O
received	-	491	O
intravenous	-	500	O
corticosteroids	-	512	O
.	-	527	O

Renal	7910951	529	O
function	-	535	O
was	-	544	O
normal	-	548	O
but	-	555	O
hepatic	-	559	O
function	-	567	O
was	-	576	O
impaired	-	580	O
in	-	589	O
all	-	592	O
patients	-	596	O
,	-	604	O
and	-	606	O
all	-	610	O
had	-	614	O
acidosis	-	618	B
.	-	626	O

Electrophysiologic	7910951	628	O
studies	-	647	O
revealed	-	655	O
low	-	664	O
amplitude	-	668	O
compound	-	678	O
motor	-	687	O
action	-	693	O
potentials	-	700	O
,	-	710	O
normal	-	712	O
sensory	-	719	O
studies	-	727	O
,	-	734	O
and	-	736	O
fibrillations	-	740	O
.	-	753	O

Repetitive	7910951	755	O
stimulation	-	766	O
at	-	778	O
2	-	781	O
Hz	-	783	O
showed	-	786	O
a	-	793	O
decremental	-	795	O
response	-	807	O
in	-	816	O
2	-	819	O
patients	-	821	O
.	-	829	O

The	7910951	831	O
serum	-	835	O
vecuronium	-	841	O
level	-	852	O
measured	-	858	O
in	-	867	O
1	-	870	O
patient	-	872	O
14	-	880	O
days	-	883	O
after	-	888	O
the	-	894	O
drug	-	898	O
had	-	903	O
been	-	907	O
discontinued	-	912	O
was	-	925	O
172	-	929	O
ng	-	933	O
/	-	935	O
mL	-	936	O
.	-	938	O
A	-	940	O
muscle	-	942	O
biopsy	-	949	O
in	-	956	O
this	-	959	O
patient	-	964	O
showed	-	972	O
loss	-	979	B
of	-	984	I
thick	-	987	I
,	-	992	I
myosin	-	994	I
filaments	-	1001	I
.	-	1010	O

The	7910951	1012	O
weakness	-	1016	B
in	-	1025	O
these	-	1028	O
patients	-	1034	O
is	-	1043	O
due	-	1046	O
to	-	1050	O
pathology	-	1053	B
at	-	1063	I
both	-	1066	I
the	-	1071	I
neuromuscular	-	1075	I
junction	-	1089	I
(	-	1098	O
most	-	1099	O
likely	-	1104	O
due	-	1111	O
to	-	1115	O
ND	-	1118	O
-	-	1120	O
NMBA	-	1121	O
)	-	1125	O
and	-	1127	O
muscle	-	1131	O
(	-	1138	O
most	-	1139	O
likely	-	1144	O
due	-	1151	O
to	-	1155	O
corticosteroids	-	1158	O
)	-	1173	O
.	-	1174	O

Hepatic	7910951	1176	B
dysfunction	-	1184	I
and	-	1196	O
acidosis	-	1200	B
are	-	1209	O
contributing	-	1213	O
risk	-	1226	O
factors	-	1231	O
.	-	1238	O

Prostaglandin	7752389	0	O
E2	-	14	O
-	-	16	O
induced	-	17	O
bladder	-	25	B
hyperactivity	-	33	I
in	-	47	O
normal	-	50	O
,	-	56	O
conscious	-	58	O
rats	-	68	O
:	-	72	O
involvement	-	74	O
of	-	86	O
tachykinins	-	89	O
?	-	100	O

In	7752389	102	O
normal	-	105	O
conscious	-	112	O
rats	-	122	O
investigated	-	127	O
by	-	140	O
continuous	-	143	O
cystometry	-	154	O
,	-	164	O
intravesically	-	166	O
instilled	-	181	O
prostaglandin	-	191	O
(	-	205	O
PG	-	206	O
)	-	208	O
E2	-	210	O
facilitated	-	213	O
micturition	-	225	O
and	-	237	O
increased	-	241	O
basal	-	251	O
intravesical	-	257	O
pressure	-	270	O
.	-	278	O

The	7752389	280	O
effect	-	284	O
was	-	291	O
attenuated	-	295	O
by	-	306	O
both	-	309	O
the	-	314	O
NK1	-	318	O
receptor	-	322	O
selective	-	331	O
antagonist	-	341	O
RP	-	352	O
67	-	355	O
,	-	357	O
580	-	358	O
and	-	362	O
the	-	366	O
NK2	-	370	O
receptor	-	374	O
selective	-	383	O
antagonist	-	393	O
SR	-	404	O
48	-	407	O
,	-	409	O
968	-	410	O
,	-	413	O
given	-	415	O
intra	-	421	O
-	-	426	O
arterially	-	427	O
,	-	437	O
suggesting	-	439	O
that	-	450	O
it	-	455	O
was	-	458	O
mediated	-	462	O
by	-	471	O
stimulation	-	474	O
of	-	486	O
both	-	489	O
NK1	-	494	O
and	-	498	O
NK2	-	502	O
receptors	-	506	O
.	-	515	O

Intra	7752389	517	O
-	-	522	O
arterially	-	523	O
given	-	534	O
PGE2	-	540	O
produced	-	545	O
a	-	554	O
distinct	-	556	O
increase	-	565	O
in	-	574	O
bladder	-	577	O
pressure	-	585	O
before	-	594	O
initiating	-	601	O
a	-	612	O
micturition	-	614	O
reflex	-	626	O
,	-	632	O
indicating	-	634	O
that	-	645	O
the	-	650	O
PG	-	654	O
had	-	657	O
a	-	661	O
direct	-	663	O
contractant	-	670	O
effect	-	682	O
on	-	689	O
the	-	692	O
detrusor	-	696	O
smooth	-	705	O
muscle	-	712	O
.	-	718	O

The	7752389	720	O
effect	-	724	O
of	-	731	O
intra	-	734	O
-	-	739	O
arterial	-	740	O
PGE2	-	749	O
could	-	754	O
not	-	760	O
be	-	764	O
blocked	-	767	O
by	-	775	O
intra	-	778	O
-	-	783	O
arterial	-	784	O
RP	-	793	O
67	-	796	O
,	-	798	O
580	-	799	O
or	-	803	O
SR	-	806	O
48	-	809	O
,	-	811	O
968	-	812	O
,	-	815	O
which	-	817	O
opens	-	823	O
the	-	829	O
possibility	-	833	O
that	-	845	O
the	-	850	O
micturition	-	854	O
reflex	-	866	O
elicited	-	873	O
by	-	882	O
intra	-	885	O
-	-	890	O
arterial	-	891	O
PGE2	-	900	O
was	-	905	O
mediated	-	909	O
by	-	918	O
pathways	-	921	O
other	-	930	O
than	-	936	O
the	-	941	O
reflex	-	945	O
initiated	-	952	O
when	-	962	O
the	-	967	O
PG	-	971	O
was	-	974	O
given	-	978	O
intravesically	-	984	O
.	-	998	O

The	7752389	1000	O
present	-	1004	O
results	-	1012	O
thus	-	1020	O
suggest	-	1025	O
that	-	1033	O
intra	-	1038	O
-	-	1043	O
arterial	-	1044	O
PGE2	-	1053	O
,	-	1057	O
given	-	1059	O
near	-	1065	O
the	-	1070	O
bladder	-	1074	O
,	-	1081	O
may	-	1083	O
initiate	-	1087	O
micturition	-	1096	O
in	-	1108	O
the	-	1111	O
normal	-	1115	O
rat	-	1122	O
chiefly	-	1126	O
by	-	1134	O
directly	-	1137	O
contracting	-	1146	O
the	-	1158	O
smooth	-	1162	O
muscle	-	1169	O
of	-	1176	O
the	-	1179	O
detrusor	-	1183	O
.	-	1191	O

However	7752389	1193	O
,	-	1200	O
when	-	1202	O
given	-	1207	O
intravesically	-	1213	O
,	-	1227	O
PGE2	-	1229	O
may	-	1234	O
stimulate	-	1238	O
micturition	-	1248	O
by	-	1260	O
releasing	-	1263	O
tachykinins	-	1273	O
from	-	1285	O
nerves	-	1290	O
in	-	1297	O
and	-	1300	O
/	-	1303	O
or	-	1304	O
immediately	-	1307	O
below	-	1319	O
the	-	1325	O
urothelium	-	1329	O
.	-	1339	O

These	7752389	1341	O
tachykinins	-	1347	O
,	-	1358	O
in	-	1360	O
turn	-	1363	O
,	-	1367	O
initiate	-	1369	O
a	-	1378	O
micturition	-	1380	O
reflex	-	1392	O
by	-	1399	O
stimulating	-	1402	O
NK1	-	1414	O
and	-	1418	O
NK2	-	1422	O
receptors	-	1426	O
.	-	1435	O

Prostanoids	7752389	1437	O
may	-	1449	O
,	-	1452	O
via	-	1454	O
release	-	1458	O
of	-	1466	O
tachykinins	-	1469	O
,	-	1480	O
contribute	-	1482	O
to	-	1493	O
both	-	1496	O
urge	-	1501	O
and	-	1506	O
bladder	-	1510	B
hyperactivity	-	1518	I
seen	-	1532	O
in	-	1537	O
inflammatory	-	1540	O
conditions	-	1553	O
of	-	1564	O
the	-	1567	O
lower	-	1571	O
urinary	-	1577	O
tract	-	1585	O
.	-	1590	O

Thiazide	6942642	0	O
diuretics	-	9	O
,	-	18	O
hypokalemia	-	20	B
and	-	32	O
cardiac	-	36	B
arrhythmias	-	44	I
.	-	55	O

Thiazide	6942642	57	O
diuretics	-	66	O
are	-	76	O
widely	-	80	O
accepted	-	87	O
as	-	96	O
the	-	99	O
cornerstone	-	103	O
of	-	115	O
antihypertensive	-	118	O
treatment	-	135	O
programs	-	145	O
.	-	153	O

Hypokalemia	6942642	155	B
is	-	167	O
a	-	170	O
commonly	-	172	O
encountered	-	181	O
metabolic	-	193	O
consequence	-	203	O
of	-	215	O
chronic	-	218	O
thiazide	-	226	O
therapy	-	235	O
.	-	242	O

We	6942642	244	O
treated	-	247	O
38	-	255	O
patients	-	258	O
(	-	267	O
22	-	268	O
low	-	271	O
renin	-	275	O
,	-	280	O
16	-	282	O
normal	-	285	O
renin	-	292	O
)	-	297	O
with	-	299	O
moderate	-	304	O
diastolic	-	313	B
hypertension	-	323	I
with	-	336	O
hydrochlorothiazide	-	341	O
(	-	361	O
HCTC	-	362	O
)	-	366	O
administered	-	368	O
on	-	381	O
a	-	384	O
twice	-	386	O
daily	-	392	O
schedule	-	398	O
.	-	406	O

Initial	6942642	408	O
dose	-	416	O
was	-	421	O
50	-	425	O
mg	-	428	O
and	-	431	O
the	-	435	O
dose	-	439	O
was	-	444	O
increased	-	448	O
at	-	458	O
monthly	-	461	O
intervals	-	469	O
to	-	479	O
100	-	482	O
mg	-	486	O
,	-	488	O
150	-	490	O
mg	-	494	O
and	-	497	O
200	-	501	O
mg	-	505	O
daily	-	508	O
until	-	514	O
blood	-	520	O
pressure	-	526	O
normalized	-	535	O
.	-	545	O

The	6942642	547	O
serum	-	551	O
K	-	557	O
during	-	559	O
the	-	566	O
control	-	570	O
period	-	578	O
was	-	585	O
4	-	589	O
.	-	590	O
5	-	591	O
+	-	593	O
/	-	594	O
-	-	595	O

0	6942642	597	O
.	-	598	O
2	-	599	O
mEq	-	601	O
/	-	604	O
l	-	605	O
an	-	607	O
on	-	610	O
50	-	613	O
,	-	615	O
100	-	617	O
,	-	620	O
150	-	622	O
and	-	626	O
200	-	630	O
mg	-	634	O
HCTZ	-	637	O
daily	-	642	O
3	-	648	O
.	-	649	O
9	-	650	O
+	-	652	O
/	-	653	O
-	-	654	O

0	6942642	656	O
.	-	657	O
3	-	658	O
,	-	659	O
3	-	661	O
.	-	662	O
4	-	663	O
+	-	665	O
/	-	666	O
-	-	667	O

0	6942642	669	O
.	-	670	O
2	-	671	O
,	-	672	O
2	-	674	O
.	-	675	O
9	-	676	O
+	-	678	O
/	-	679	O
-	-	680	O

0	6942642	682	O
.	-	683	O
2	-	684	O
,	-	685	O
and	-	687	O
2	-	691	O
.	-	692	O
4	-	693	O
+	-	695	O
/	-	696	O
-	-	697	O
0	-	699	O
.	-	700	O
3	-	701	O
mEq	-	703	O
/	-	706	O
l	-	707	O
,	-	708	O
respectively	-	710	O
.	-	722	O

Corresponding	6942642	724	O
figures	-	738	O
for	-	746	O
whole	-	750	O
body	-	756	O
K	-	761	O
were	-	763	O
4107	-	768	O
+	-	773	O
/	-	774	O
-	-	775	O

208	6942642	777	O
,	-	780	O
3722	-	782	O
+	-	787	O
/	-	788	O
-	-	789	O

319	6942642	791	O
,	-	794	O
3628	-	796	O
+	-	801	O
/	-	802	O
-	-	803	O

257	6942642	805	O
,	-	808	O
3551	-	810	O
+	-	815	O
/	-	816	O
-	-	817	O

336	6942642	819	O
,	-	822	O
and	-	824	O
3269	-	828	O
+	-	833	O
/	-	834	O
-	-	835	O

380	6942642	837	O
mEq	-	841	O
,	-	844	O
respectively	-	846	O
.	-	858	O

In	6942642	860	O
13	-	863	O
patients	-	866	O
we	-	875	O
observed	-	878	O
the	-	887	O
effects	-	891	O
of	-	899	O
HCTZ	-	902	O
therapy	-	907	O
(	-	915	O
100	-	916	O
mg	-	920	O
daily	-	923	O
)	-	928	O
on	-	930	O
the	-	933	O
occurrence	-	937	O
of	-	948	O
PVC	-	951	O
's	-	954	O
during	-	957	O
rest	-	964	O
as	-	969	O
well	-	972	O
as	-	977	O
during	-	980	O
static	-	987	O
and	-	994	O
dynamic	-	998	O
exercise	-	1006	O
.	-	1014	O

During	6942642	1016	O
rest	-	1023	O
we	-	1028	O
observed	-	1031	O
0	-	1040	O
.	-	1041	O
6	-	1042	O
+	-	1044	O
/	-	1045	O
-	-	1046	O

0	6942642	1048	O
.	-	1049	O
08	-	1050	O
PVC	-	1053	O
beats	-	1057	O
/	-	1062	O
min	-	1063	O
+	-	1067	O
/	-	1068	O
-	-	1069	O

SEM	6942642	1071	O
and	-	1075	O
during	-	1079	O
static	-	1086	O
and	-	1093	O
dynamic	-	1097	O
exercise	-	1105	O
0	-	1114	O
.	-	1115	O
6	-	1116	O
+	-	1118	O
/	-	1119	O
-	-	1120	O

0	6942642	1122	O
.	-	1123	O
06	-	1124	O
and	-	1127	O
0	-	1131	O
.	-	1132	O
8	-	1133	O
+	-	1135	O
/	-	1136	O
-	-	1137	O
0	-	1139	O
.	-	1140	O
15	-	1141	O
,	-	1143	O
respectively	-	1145	O
.	-	1157	O

Corresponding	6942642	1159	O
figures	-	1173	O
during	-	1181	O
HCTZ	-	1188	O
therapy	-	1193	O

100	6942642	1201	O
mg	-	1205	O
daily	-	1208	O
were	-	1214	O
1	-	1219	O
.	-	1220	O
4	-	1221	O
+	-	1223	O
/	-	1224	O
-	-	1225	O

0	6942642	1227	O
.	-	1228	O
1	-	1229	O
,	-	1230	O
3	-	1232	O
.	-	1233	O
6	-	1234	O
+	-	1236	O
/	-	1237	O
-	-	1238	O

0	6942642	1240	O
.	-	1241	O
7	-	1242	O
and	-	1244	O
5	-	1248	O
.	-	1249	O
7	-	1250	O
4	-	1252	O
/	-	1253	O
-	-	1254	O
0	-	1256	O
.	-	1257	O
8	-	1258	O
,	-	1259	O
respectively	-	1261	O
.	-	1273	O

The	6942642	1275	O
occurrence	-	1279	O
of	-	1290	O
PVC	-	1293	O
's	-	1296	O
correlated	-	1299	O
significantly	-	1310	O
with	-	1324	O
the	-	1329	O
fall	-	1333	O
in	-	1338	O
serum	-	1341	O

K	6942642	1347	O
+	-	1348	O
observed	-	1350	O
r	-	1359	O
=	-	1361	O
0	-	1363	O
.	-	1364	O
72	-	1365	O
,	-	1367	O
p	-	1369	O
less	-	1371	O
than	-	1376	O
0	-	1381	O
.	-	1382	O
001	-	1383	O
.	-	1386	O

In	6942642	1388	O
conclusion	-	1391	O
we	-	1402	O
found	-	1405	O
that	-	1411	O
thiazide	-	1416	O
diuretics	-	1425	O
cause	-	1435	O
hypokalemia	-	1441	B
and	-	1453	O
depletion	-	1457	O
of	-	1467	O
body	-	1470	O
potassium	-	1475	O
.	-	1484	O

The	6942642	1486	O
more	-	1490	O
profound	-	1495	O
hypokalemia	-	1504	B
,	-	1515	O
the	-	1517	O
greater	-	1521	O
the	-	1529	O
propensity	-	1533	O
for	-	1544	O
the	-	1548	O
occurrence	-	1552	O
of	-	1563	O
PVC	-	1566	O
's	-	1569	O
.	-	1571	O

Diuretics	3732088	0	O
,	-	9	O
potassium	-	11	O
and	-	21	O
arrhythmias	-	25	B
in	-	37	O
hypertensive	-	40	B
coronary	-	53	B
disease	-	62	I
.	-	69	O

It	3732088	71	O
has	-	74	O
been	-	78	O
proposed	-	83	O
that	-	92	O
modest	-	97	O
changes	-	104	O
in	-	112	O
plasma	-	115	O
potassium	-	122	O
can	-	132	O
alter	-	136	O
the	-	142	O
tendency	-	146	O
towards	-	155	O
cardiac	-	163	B
arrhythmias	-	171	I
.	-	182	O

If	3732088	184	O
this	-	187	O
were	-	192	O
so	-	197	O
,	-	199	O
patients	-	201	O
with	-	210	O
coronary	-	215	B
artery	-	224	I
disease	-	231	I
might	-	239	O
be	-	245	O
especially	-	248	O
susceptible	-	259	O
.	-	270	O

Thus	3732088	272	O
,	-	276	O
myocardial	-	278	O
electrical	-	289	O
excitability	-	300	O
was	-	313	O
measured	-	317	O
in	-	326	O
patients	-	329	O
with	-	338	O
mild	-	343	O
essential	-	348	O
hypertension	-	358	B
and	-	371	O
known	-	375	O
coronary	-	381	B
artery	-	390	I
disease	-	397	I
after	-	405	O
8	-	411	O
weeks	-	413	O
of	-	419	O
treatment	-	422	O
with	-	432	O
a	-	437	O
potassium	-	439	O
-	-	448	O
conserving	-	449	O
diuretic	-	460	O
(	-	469	O
amiloride	-	470	O
)	-	479	O
and	-	481	O
a	-	485	O
similar	-	487	O
period	-	495	O
on	-	502	O
a	-	505	O
potassium	-	507	O
-	-	516	O
losing	-	517	O
diuretic	-	524	O
(	-	533	O
chlorthalidone	-	534	O
)	-	548	O
in	-	550	O
a	-	553	O
randomised	-	555	O
study	-	566	O
.	-	571	O

Plasma	3732088	573	O
potassium	-	580	O
concentrations	-	590	O
were	-	605	O
on	-	610	O
average	-	613	O
1	-	621	O
mmol	-	623	O
/	-	627	O
L	-	628	O
lower	-	630	O
during	-	636	O
the	-	643	O
chlorthalidone	-	647	O
phase	-	662	O
compared	-	668	O
to	-	677	O
amiloride	-	680	O
therapy	-	690	O
.	-	697	O

Blood	3732088	699	O
pressure	-	705	O
and	-	714	O
volume	-	718	O
states	-	725	O
as	-	732	O
assessed	-	735	O
by	-	744	O
bodyweight	-	747	O
,	-	757	O
plasma	-	759	O
renin	-	766	O
and	-	772	O
noradrenaline	-	776	O
(	-	790	O
norepinephrine	-	791	O
)	-	805	O
concentrations	-	807	O
were	-	822	O
similar	-	827	O
on	-	835	O
the	-	838	O
2	-	842	O
regimens	-	844	O
.	-	852	O

Compared	3732088	854	O
to	-	863	O
amiloride	-	866	O
treatment	-	876	O
,	-	885	O
the	-	887	O
chlorthalidone	-	891	O
phase	-	906	O
was	-	912	O
associated	-	916	O
with	-	927	O
an	-	932	O
increased	-	935	O
frequency	-	945	O
of	-	955	O
ventricular	-	958	B
ectopic	-	970	I
beats	-	978	I
(	-	984	O
24	-	985	O
-	-	987	O
hour	-	988	O
Holter	-	993	O
monitoring	-	1000	O
)	-	1010	O
and	-	1012	O
a	-	1016	O
higher	-	1018	O
Lown	-	1025	O
grading	-	1030	O
,	-	1037	O
increased	-	1039	O
upslope	-	1049	O
and	-	1057	O
duration	-	1061	O
of	-	1070	O
the	-	1073	O
monophasic	-	1077	O
action	-	1088	O
potential	-	1095	O
,	-	1104	O
prolonged	-	1106	O
ventricular	-	1116	O
effective	-	1128	O
refractory	-	1138	O
period	-	1149	O
,	-	1155	O
and	-	1157	O
increased	-	1161	O
electrical	-	1171	O
instability	-	1182	O
during	-	1194	O
programmed	-	1201	O
ventricular	-	1212	O
stimulation	-	1224	O
.	-	1235	O

The	3732088	1237	O
above	-	1241	O
results	-	1247	O
indicate	-	1255	O
that	-	1264	O
because	-	1269	O
potassium	-	1277	O
-	-	1286	O
losing	-	1287	O
diuretic	-	1294	O
therapy	-	1303	O
can	-	1311	O
increase	-	1315	O
myocardial	-	1324	O
electrical	-	1335	O
excitability	-	1346	O
in	-	1359	O
patients	-	1362	O
with	-	1371	O
ischaemic	-	1376	B
heart	-	1386	I
disease	-	1392	I
,	-	1399	O
even	-	1401	O
minor	-	1406	O
falls	-	1412	O
in	-	1418	O
plasma	-	1421	O
potassium	-	1428	O
concentrations	-	1438	O
are	-	1453	O
probably	-	1457	O
best	-	1466	O
avoided	-	1471	O
in	-	1479	O
such	-	1482	O
patients	-	1487	O
.	-	1495	O

GABA	2893236	0	O
involvement	-	5	O
in	-	17	O
naloxone	-	20	O
induced	-	29	O
reversal	-	37	O
of	-	46	O
respiratory	-	49	B
paralysis	-	61	I
produced	-	71	O
by	-	80	O
thiopental	-	83	O
.	-	93	O

No	2893236	95	O
agent	-	98	O
is	-	104	O
yet	-	107	O
available	-	111	O
to	-	121	O
reverse	-	124	O
respiratory	-	132	B
paralysis	-	144	I
produced	-	154	O
by	-	163	O
CNS	-	166	O
depressants	-	170	O
,	-	181	O
such	-	183	O
as	-	188	O
general	-	191	O
anesthetics	-	199	O
.	-	210	O

In	2893236	212	O
this	-	215	O
study	-	220	O
naloxone	-	226	O
reversed	-	235	O
respiratory	-	244	B
paralysis	-	256	I
induced	-	266	O
by	-	274	O
thiopental	-	277	O
in	-	288	O
rats	-	291	O
.	-	295	O

25	2893236	297	O
mg	-	300	O
/	-	302	O
kg	-	303	O
,	-	305	O
i	-	307	O
.	-	308	O
v	-	309	O
.	-	310	O

thiopental	2893236	312	O
produced	-	323	O
anesthesia	-	332	O
without	-	343	O
altering	-	351	O
respiratory	-	360	O
rate	-	372	O
,	-	376	O
increased	-	378	O
GABA	-	388	O
,	-	392	O
decreased	-	394	O
glutamate	-	404	O
,	-	413	O
and	-	415	O
had	-	419	O
no	-	423	O
effect	-	426	O
on	-	433	O
aspartate	-	436	O
or	-	446	O
glycine	-	449	O
levels	-	457	O
compared	-	464	O
to	-	473	O
controls	-	476	O
in	-	485	O
rat	-	488	O
cortex	-	492	O
and	-	499	O
brain	-	503	O
stem	-	509	O
.	-	513	O

Pretreatment	2893236	515	O
of	-	528	O
rats	-	531	O
with	-	536	O
thiosemicarbazide	-	541	O
for	-	559	O
30	-	563	O
minutes	-	566	O
abolished	-	574	O
the	-	584	O
anesthetic	-	588	O
action	-	599	O
as	-	606	O
well	-	609	O
as	-	614	O
the	-	617	O
respiratory	-	621	O
depressant	-	633	O
action	-	644	O
of	-	651	O
thiopental	-	654	O
.	-	664	O

50	2893236	666	O
mg	-	669	O
/	-	671	O
kg	-	672	O
,	-	674	O
i	-	676	O
.	-	677	O
v	-	678	O
.	-	679	O

thiopental	2893236	681	O
produced	-	692	O
respiratory	-	701	B
arrest	-	713	I
with	-	720	O
further	-	725	O
increase	-	733	O
in	-	742	O
GABA	-	745	O
and	-	750	O
decrease	-	754	O
in	-	763	O
glutamate	-	766	O
again	-	776	O
in	-	782	O
cortex	-	785	O
and	-	792	O
brain	-	796	O
stem	-	802	O
without	-	807	O
affecting	-	815	O
any	-	825	O
of	-	829	O
the	-	832	O
amino	-	836	O
acids	-	842	O
studied	-	848	O
in	-	856	O
four	-	859	O
regions	-	864	O
of	-	872	O
rat	-	875	O
brain	-	879	O
.	-	884	O

Naloxone	2893236	886	O
(	-	895	O
2	-	896	O
.	-	897	O
5	-	898	O
mg	-	900	O
/	-	902	O
kg	-	903	O
,	-	905	O
i	-	907	O
.	-	908	O
v	-	909	O
.	-	910	O
)	-	911	O
reversed	-	913	O
respiratory	-	922	B
paralysis	-	934	I
,	-	943	O
glutamate	-	945	O
and	-	955	O
GABA	-	959	O
levels	-	964	O
to	-	971	O
control	-	974	O
values	-	982	O
in	-	989	O
brain	-	992	O
stem	-	998	O
and	-	1003	O
cortex	-	1007	O
with	-	1014	O
no	-	1019	O
changes	-	1022	O
in	-	1030	O
caudate	-	1033	O
or	-	1041	O
cerebellum	-	1044	O
.	-	1054	O

These	2893236	1056	O
data	-	1062	O
suggest	-	1067	O
naloxone	-	1075	O
reverses	-	1084	O
respiratory	-	1093	B
paralysis	-	1105	I
produced	-	1115	O
by	-	1124	O
thiopental	-	1127	O
and	-	1138	O
involves	-	1142	O
GABA	-	1151	O
in	-	1156	O
its	-	1159	O
action	-	1163	O
.	-	1169	O

National	2533791	0	O
project	-	9	O
on	-	17	O
the	-	20	O
prevention	-	24	O
of	-	35	O
mother	-	38	O
-	-	44	O
to	-	45	O
-	-	47	O
infant	-	48	O
infection	-	55	B
by	-	65	I
hepatitis	-	68	I
B	-	78	I
virus	-	80	I
in	-	86	O
Japan	-	89	O
.	-	94	O

In	2533791	96	O
Japan	-	99	O
,	-	104	O
a	-	106	O
nationwide	-	108	O
prevention	-	119	O
program	-	130	O
against	-	138	O
mother	-	146	O
-	-	152	O
to	-	153	O
-	-	155	O
infant	-	156	O
infection	-	163	B
by	-	173	I
hepatitis	-	176	I
B	-	186	I
virus	-	188	I
(	-	194	O
HBV	-	195	O
)	-	198	O
started	-	200	O
in	-	208	O
1985	-	211	O
.	-	215	O

This	2533791	217	O
program	-	222	O
consists	-	230	O
of	-	239	O
double	-	242	O
screenings	-	249	O
of	-	260	O
pregnant	-	263	O
women	-	272	O
and	-	278	O
prophylactic	-	282	O
treatment	-	295	O
to	-	305	O
the	-	308	O
infants	-	312	O
born	-	320	O
to	-	325	O
both	-	328	O
hepatitis	-	333	O
B	-	343	O
surface	-	345	O
antigen	-	353	O
(	-	361	O
HBsAg	-	362	O
)	-	367	O
and	-	369	O
hepatitis	-	373	O
B	-	383	O
e	-	385	O
antigen	-	387	O
(	-	395	O
HBeAg	-	396	O
)	-	401	O
positive	-	403	O
mothers	-	412	O
.	-	419	O

These	2533791	421	O
infants	-	427	O
are	-	435	O
treated	-	439	O
with	-	447	O
two	-	452	O
injections	-	456	O
of	-	467	O
hepatitis	-	470	B
B	-	480	I
immune	-	482	O
globulin	-	489	O
(	-	498	O
HBIG	-	499	O
)	-	503	O
and	-	505	O
at	-	509	O
least	-	512	O
three	-	518	O
injections	-	524	O
of	-	535	O
plasma	-	538	O
derived	-	545	O
hepatitis	-	553	O
B	-	563	O
vaccine	-	565	O
.	-	572	O

We	2533791	574	O
sent	-	577	O
questionnaires	-	582	O
about	-	597	O
the	-	603	O
numbers	-	607	O
of	-	615	O
each	-	618	O
procedure	-	623	O
or	-	633	O
examination	-	636	O
during	-	648	O
nine	-	655	O
months	-	660	O
of	-	667	O
investigation	-	670	O
period	-	684	O
to	-	691	O
each	-	694	O
local	-	699	O
government	-	705	O
in	-	716	O
1986	-	719	O
and	-	724	O
1987	-	728	O
.	-	732	O

93	2533791	734	O
.	-	736	O
4	-	737	O
%	-	738	O
pregnant	-	740	O
women	-	749	O
had	-	755	O
the	-	759	O
chance	-	763	O
to	-	770	O
be	-	773	O
examined	-	776	O
for	-	785	O
HBsAg	-	789	O
,	-	794	O
and	-	796	O
the	-	800	O
positive	-	804	O
rate	-	813	O
was	-	818	O
1	-	822	O
.	-	823	O
4	-	824	O
to	-	826	O
1	-	829	O
.	-	830	O
5	-	831	O
%	-	832	O
.	-	833	O

The	2533791	835	O
HBeAg	-	839	O
positive	-	845	O
rate	-	854	O
in	-	859	O
HBsAg	-	862	O
positive	-	868	O
was	-	877	O
23	-	881	O
to	-	884	O
26	-	887	O
%	-	889	O
.	-	890	O

The	2533791	892	O
HBsAg	-	896	O
positive	-	902	O
rate	-	911	O
in	-	916	O
neonates	-	919	O
and	-	928	O
in	-	932	O
infants	-	935	O
before	-	943	O
two	-	950	O
months	-	954	O
were	-	961	O
3	-	966	O
%	-	967	O
and	-	969	O
2	-	973	O
%	-	974	O
respectively	-	976	O
.	-	988	O

Some	2533791	990	O
problems	-	995	O
may	-	1004	O
arise	-	1008	O
,	-	1013	O
because	-	1015	O
27	-	1023	O
to	-	1026	O
30	-	1029	O
%	-	1031	O
of	-	1033	O
infants	-	1036	O
need	-	1044	O
the	-	1049	O
fourth	-	1053	O
vaccination	-	1060	O
in	-	1072	O
some	-	1075	O
restricted	-	1080	O
areas	-	1091	O
.	-	1096	O

Nociceptive	2322844	0	O
effects	-	12	O
induced	-	20	O
by	-	28	O
intrathecal	-	31	O
administration	-	43	O
of	-	58	O
prostaglandin	-	61	O
D2	-	75	O
,	-	77	O
E2	-	79	O
,	-	81	O
or	-	83	O
F2	-	86	O
alpha	-	89	O
to	-	95	O
conscious	-	98	O
mice	-	108	O
.	-	112	O

The	2322844	114	O
effects	-	118	O
of	-	126	O
intrathecal	-	129	O
administration	-	141	O
of	-	156	O
prostaglandins	-	159	O
on	-	174	O
pain	-	177	B
responses	-	182	O
in	-	192	O
conscious	-	195	O
mice	-	205	O
were	-	210	O
evaluated	-	215	O
by	-	225	O
using	-	228	O
hot	-	234	O
plate	-	238	O
and	-	244	O
acetic	-	248	O
acid	-	255	O
writhing	-	260	O
tests	-	269	O
.	-	274	O

Prostaglandin	2322844	276	O
D2	-	290	O
(	-	293	O
0	-	294	O
.	-	295	O
5	-	296	O
-	-	297	O
3	-	298	O
ng	-	300	O
/	-	302	O
mouse	-	303	O
)	-	308	O
had	-	310	O
a	-	314	O
hyperalgesic	-	316	B
action	-	329	O
on	-	336	O
the	-	339	O
response	-	343	O
to	-	352	O
a	-	355	O
hot	-	357	O
plate	-	361	O
during	-	367	O
a	-	374	O
3	-	376	O
-	-	377	O
60	-	378	O
min	-	381	O
period	-	385	O
after	-	392	O
injection	-	398	O
.	-	407	O

Prostaglandin	2322844	409	O
E2	-	423	O
showed	-	426	O
a	-	433	O
hyperalgesic	-	435	B
effect	-	448	O
at	-	455	O
doses	-	458	O
of	-	464	O
1	-	467	O
pg	-	469	O
to	-	472	O
10	-	475	O
ng	-	478	O
/	-	480	O
mouse	-	481	O
,	-	486	O
but	-	488	O
the	-	492	O
effect	-	496	O
lasted	-	503	O
shorter	-	510	O
(	-	518	O
3	-	519	O
-	-	520	O
30	-	521	O
min	-	524	O
)	-	527	O
than	-	529	O
that	-	534	O
of	-	539	O
prostaglandin	-	542	O
D2	-	556	O
.	-	558	O

Similar	2322844	560	O
results	-	568	O
were	-	576	O
obtained	-	581	O
by	-	590	O
acetic	-	593	O
acid	-	600	O
writhing	-	605	O
tests	-	614	O
.	-	619	O

The	2322844	621	O
hyperalgesic	-	625	B
effect	-	638	O
of	-	645	O
prostaglandin	-	648	O
D2	-	662	O
was	-	665	O
blocked	-	669	O
by	-	677	O
simultaneous	-	680	O
injection	-	693	O
of	-	703	O
a	-	706	O
substance	-	708	O
P	-	718	O
antagonist	-	720	O
(	-	731	O
greater	-	732	O
than	-	740	O
or	-	745	O
equal	-	748	O
to	-	754	O
100	-	757	O
ng	-	761	O
)	-	763	O
but	-	765	O
not	-	769	O
by	-	773	O
AH6809	-	776	O
,	-	782	O
a	-	784	O
prostanoid	-	786	O
EP1	-	797	O
-	-	800	O
receptor	-	801	O
antagonist	-	810	O
.	-	820	O

Conversely	2322844	822	O
,	-	832	O
prostaglandin	-	834	O
E2	-	848	O
-	-	850	O
induced	-	851	O
hyperalgesia	-	859	B
was	-	872	O
blocked	-	876	O
by	-	884	O
AH6809	-	887	O
(	-	894	O
greater	-	895	O
than	-	903	O
or	-	908	O
equal	-	911	O
to	-	917	O
500	-	920	O
ng	-	924	O
)	-	926	O
but	-	928	O
not	-	932	O
by	-	936	O
the	-	939	O
substance	-	943	O
P	-	953	O
antagonist	-	955	O
.	-	965	O

Prostaglandin	2322844	967	O
F2	-	981	O
alpha	-	984	O
had	-	990	O
little	-	994	O
effect	-	1001	O
on	-	1008	O
pain	-	1011	B
responses	-	1016	O
.	-	1025	O

These	2322844	1027	O
results	-	1033	O
demonstrate	-	1041	O
that	-	1053	O
both	-	1058	O
prostaglandin	-	1063	O
D2	-	1077	O
and	-	1080	O
prostaglandin	-	1084	O
E2	-	1098	O
exert	-	1101	O
hyperalgesia	-	1107	B
in	-	1120	O
the	-	1123	O
spinal	-	1127	O
cord	-	1134	O
,	-	1138	O
but	-	1140	O
in	-	1144	O
different	-	1147	O
ways	-	1157	O
.	-	1161	O

Swallowing	20552622	0	O
-	-	10	O
induced	-	11	O
atrial	-	19	B
tachyarrhythmia	-	26	I
triggered	-	42	O
by	-	52	O
salbutamol	-	55	O
:	-	65	O
case	-	67	O
report	-	72	O
and	-	79	O
review	-	83	O
of	-	90	O
the	-	93	O
literature	-	97	O
.	-	107	O

CASE	20552622	109	O
:	-	113	O

A	20552622	115	O
49	-	117	O
-	-	119	O
year	-	120	O
-	-	124	O
old	-	125	O
patient	-	129	O
experienced	-	137	O
chest	-	149	O
discomfort	-	155	O
while	-	166	O
swallowing	-	172	O
.	-	182	O

On	20552622	184	O
electrocardiogram	-	187	O
,	-	204	O
episodes	-	206	O
of	-	215	O
atrial	-	218	B
tachyarrhythmia	-	225	I
were	-	241	O
recorded	-	246	O
immediately	-	255	O
after	-	267	O
swallowing	-	273	O
;	-	283	O
24	-	285	O
-	-	287	O
hour	-	288	O
Holter	-	293	O
monitoring	-	300	O
recorded	-	311	O
several	-	320	O
events	-	328	O
.	-	334	O

The	20552622	336	O
arrhythmia	-	340	B
resolved	-	351	O
after	-	360	O
therapy	-	366	O
with	-	374	O
atenolol	-	379	O
,	-	387	O
but	-	389	O
recurred	-	393	O
a	-	402	O
year	-	404	O
later	-	409	O
.	-	414	O

The	20552622	416	O
patient	-	420	O
noticed	-	428	O
that	-	436	O
before	-	441	O
these	-	448	O
episodes	-	454	O
he	-	463	O
had	-	466	O
been	-	470	O
using	-	475	O
an	-	481	O
inhalator	-	484	O
of	-	494	O
salbutamol	-	497	O
.	-	507	O

After	20552622	509	O
stopping	-	515	O
the	-	524	O
beta	-	528	O
-	-	532	O
agonist	-	533	O
,	-	540	O
and	-	542	O
after	-	546	O
a	-	552	O
week	-	554	O
with	-	559	O
the	-	564	O
atenolol	-	568	O
,	-	576	O
the	-	578	O
arrhythmia	-	582	B
disappeared	-	593	O
.	-	604	O

DISCUSSION	20552622	606	O
:	-	616	O

Swallowing	20552622	618	O
-	-	628	O
induced	-	629	O
atrial	-	637	B
tachyarrhythmia	-	644	I
(	-	660	O
SIAT	-	661	B
)	-	665	O
is	-	667	O
a	-	670	O
rare	-	672	O
phenomenon	-	677	O
.	-	687	O

Fewer	20552622	689	O
than	-	695	O
50	-	700	O
cases	-	703	O
of	-	709	O
SIAT	-	712	B
have	-	717	O
been	-	722	O
described	-	727	O
in	-	737	O
the	-	740	O
literature	-	744	O
.	-	754	O

This	20552622	756	O
article	-	761	O
summarizes	-	769	O
all	-	780	O
the	-	784	O
cases	-	788	O
published	-	794	O
,	-	803	O
creating	-	805	O
a	-	814	O
comprehensive	-	816	O
review	-	830	O
of	-	837	O
the	-	840	O
current	-	844	O
knowledge	-	852	O
and	-	862	O
approach	-	866	O
to	-	875	O
SIAT	-	878	B
.	-	882	O

It	20552622	884	O
discusses	-	887	O
demographics	-	897	O
,	-	909	O
clinical	-	911	O
characteristics	-	920	O
and	-	936	O
types	-	940	O
of	-	946	O
arrhythmia	-	949	B
,	-	959	O
postulated	-	961	O
mechanisms	-	972	O
of	-	983	O
SIAT	-	986	B
,	-	990	O
and	-	992	O
different	-	996	O
treatment	-	1006	O
possibilities	-	1016	O
such	-	1030	O
as	-	1035	O
medications	-	1038	O
,	-	1049	O
surgery	-	1051	O
,	-	1058	O
and	-	1060	O
radiofrequency	-	1064	O
catheter	-	1079	O
ablation	-	1088	O
(	-	1097	O
RFCA	-	1098	O
)	-	1102	O
.	-	1103	O

CONCLUSION	20552622	1105	O
:	-	1115	O

Salbutamol	20552622	1117	O
is	-	1128	O
presented	-	1131	O
here	-	1141	O
as	-	1146	O
a	-	1149	O
possible	-	1151	O
trigger	-	1160	O
for	-	1168	O
SIAT	-	1172	B
.	-	1176	O

Although	20552622	1178	O
it	-	1187	O
is	-	1190	O
difficult	-	1193	O
to	-	1203	O
define	-	1206	O
causality	-	1213	O
in	-	1223	O
a	-	1226	O
case	-	1228	O
report	-	1233	O
,	-	1239	O
it	-	1241	O
is	-	1244	O
logical	-	1247	O
to	-	1255	O
think	-	1258	O
that	-	1264	O
a	-	1269	O
beta	-	1271	O
-	-	1275	O
agonist	-	1276	O
like	-	1284	O
salbutamol	-	1289	O
(	-	1300	O
known	-	1301	O
to	-	1307	O
induce	-	1310	O
tachycardia	-	1317	B
)	-	1328	O
may	-	1330	O
be	-	1334	O
the	-	1337	O
trigger	-	1341	O
of	-	1349	O
adrenergic	-	1352	O
reflexes	-	1363	O
originating	-	1372	O
in	-	1384	O
the	-	1387	O
esophagus	-	1391	O
while	-	1401	O
swallowing	-	1407	O
and	-	1418	O
that	-	1422	O
a	-	1427	O
beta	-	1429	O
-	-	1433	O
blocker	-	1434	O
such	-	1442	O
as	-	1447	O
atenolol	-	1450	O
(	-	1459	O
that	-	1460	O
blocks	-	1465	O
the	-	1472	O
adrenergic	-	1476	O
activity	-	1487	O
)	-	1495	O
may	-	1497	O
relieve	-	1501	O
it	-	1509	O
.	-	1511	O

Coenzyme	20510337	0	O
Q10	-	9	O
treatment	-	13	O
ameliorates	-	23	O
acute	-	35	O
cisplatin	-	41	O
nephrotoxicity	-	51	B
in	-	66	O
mice	-	69	O
.	-	73	O

The	20510337	75	O
nephroprotective	-	79	O
effect	-	96	O
of	-	103	O
coenzyme	-	106	O
Q10	-	115	O
was	-	119	O
investigated	-	123	O
in	-	136	O
mice	-	139	O
with	-	144	O
acute	-	149	B
renal	-	155	I
injury	-	161	I
induced	-	168	O
by	-	176	O
a	-	179	O
single	-	181	O
i	-	188	O
.	-	189	O
p	-	190	O
.	-	191	O

injection	20510337	193	O
of	-	203	O
cisplatin	-	206	O
(	-	216	O
5	-	217	O
mg	-	219	O
/	-	221	O
kg	-	222	O
)	-	224	O
.	-	225	O

Coenzyme	20510337	227	O
Q10	-	236	O
treatment	-	240	O
(	-	250	O
10	-	251	O
mg	-	254	O
/	-	256	O
kg	-	257	O
/	-	259	O
day	-	260	O
,	-	263	O
i	-	265	O
.	-	266	O
p	-	267	O
.	-	268	O
)	-	269	O
was	-	271	O
applied	-	275	O
for	-	283	O
6	-	287	O
consecutive	-	289	O
days	-	301	O
,	-	305	O
starting	-	307	O
1	-	316	O
day	-	318	O
before	-	322	O
cisplatin	-	329	O
administration	-	339	O
.	-	353	O

Coenzyme	20510337	355	O
Q10	-	364	O
significantly	-	368	O
reduced	-	382	O
blood	-	390	O
urea	-	396	O
nitrogen	-	401	O
and	-	410	O
serum	-	414	O
creatinine	-	420	O
levels	-	431	O
which	-	438	O
were	-	444	O
increased	-	449	O
by	-	459	O
cisplatin	-	462	O
.	-	471	O

Coenzyme	20510337	473	O
Q10	-	482	O
significantly	-	486	O
compensated	-	500	O
deficits	-	512	O
in	-	521	O
the	-	524	O
antioxidant	-	528	O
defense	-	540	O
mechanisms	-	548	O
(	-	559	O
reduced	-	560	O
glutathione	-	568	O
level	-	580	O
and	-	586	O
superoxide	-	590	O
dismutase	-	601	O
activity	-	611	O
)	-	619	O
,	-	620	O
suppressed	-	622	O
lipid	-	633	O
peroxidation	-	639	O
,	-	651	O
decreased	-	653	O
the	-	663	O
elevations	-	667	O
of	-	678	O
tumor	-	681	B
necrosis	-	687	B
factor	-	696	O
-	-	702	O
alpha	-	703	O
,	-	708	O
nitric	-	710	O
oxide	-	717	O
and	-	723	O
platinum	-	727	O
ion	-	736	O
concentration	-	740	O
,	-	753	O
and	-	755	O
attenuated	-	759	O
the	-	770	O
reductions	-	774	O
of	-	785	O
selenium	-	788	O
and	-	797	O
zinc	-	801	O
ions	-	806	O
in	-	811	O
renal	-	814	O
tissue	-	820	O
resulted	-	827	O
from	-	836	O
cisplatin	-	841	O
administration	-	851	O
.	-	865	O

Also	20510337	867	O
,	-	871	O
histopathological	-	873	O
renal	-	891	B
tissue	-	897	I
damage	-	904	I
mediated	-	911	O
by	-	920	O
cisplatin	-	923	O
was	-	933	O
ameliorated	-	937	O
by	-	949	O
coenzyme	-	952	O
Q10	-	961	O
treatment	-	965	O
.	-	974	O

Immunohistochemical	20510337	976	O
analysis	-	996	O
revealed	-	1005	O
that	-	1014	O
coenzyme	-	1019	O
Q10	-	1028	O
significantly	-	1032	O
decreased	-	1046	O
the	-	1056	O
cisplatin	-	1060	O
-	-	1069	O
induced	-	1070	O
overexpression	-	1078	O
of	-	1093	O
inducible	-	1096	O
nitric	-	1106	O
oxide	-	1113	O
synthase	-	1119	O
,	-	1127	O
nuclear	-	1129	O
factor	-	1137	O
-	-	1143	O
kappaB	-	1144	O
,	-	1150	O
caspase	-	1152	O
-	-	1159	O
3	-	1160	O
and	-	1162	O
p53	-	1166	O
in	-	1170	O
renal	-	1173	O
tissue	-	1179	O
.	-	1185	O

It	20510337	1187	O
was	-	1190	O
concluded	-	1194	O
that	-	1204	O
coenzyme	-	1209	O
Q10	-	1218	O
represents	-	1222	O
a	-	1233	O
potential	-	1235	O
therapeutic	-	1245	O
option	-	1257	O
to	-	1264	O
protect	-	1267	O
against	-	1275	O
acute	-	1283	O
cisplatin	-	1289	O
nephrotoxicity	-	1299	B
commonly	-	1314	O
encountered	-	1323	O
in	-	1335	O
clinical	-	1338	O
practice	-	1347	O
.	-	1355	O

Metformin	20164825	0	O
prevents	-	10	O
experimental	-	19	O
gentamicin	-	32	O
-	-	42	O
induced	-	43	O
nephropathy	-	51	B
by	-	63	O
a	-	66	O
mitochondria	-	68	O
-	-	80	O
dependent	-	81	O
pathway	-	91	O
.	-	98	O

The	20164825	100	O
antidiabetic	-	104	O
drug	-	117	O
metformin	-	122	O
can	-	132	O
diminish	-	136	O
apoptosis	-	145	O
induced	-	155	O
by	-	163	O
oxidative	-	166	O
stress	-	176	O
in	-	183	O
endothelial	-	186	O
cells	-	198	O
and	-	204	O
prevent	-	208	O
vascular	-	216	B
dysfunction	-	225	I
even	-	237	O
in	-	242	O
nondiabetic	-	245	O
patients	-	257	O
.	-	265	O

Here	20164825	267	O
we	-	272	O
tested	-	275	O
whether	-	282	O
it	-	290	O
has	-	293	O
a	-	297	O
beneficial	-	299	O
effect	-	310	O
in	-	317	O
a	-	320	O
rat	-	322	O
model	-	326	O
of	-	332	O
gentamicin	-	335	O
toxicity	-	346	B
.	-	354	O

Mitochondrial	20164825	356	O
analysis	-	370	O
,	-	378	O
respiration	-	380	O
intensity	-	392	O
,	-	401	O
levels	-	403	O
of	-	410	O
reactive	-	413	O
oxygen	-	422	O
species	-	429	O
,	-	436	O
permeability	-	438	O
transition	-	451	O
,	-	461	O
and	-	463	O
cytochrome	-	467	O
c	-	478	O
release	-	480	O
were	-	488	O
assessed	-	493	O
3	-	502	O
and	-	504	O
6	-	508	O
days	-	510	O
after	-	515	O
gentamicin	-	521	O
administration	-	532	O
.	-	546	O

Metformin	20164825	548	O
treatment	-	558	O
fully	-	568	O
blocked	-	574	O
gentamicin	-	582	O
-	-	592	O
mediated	-	593	O
acute	-	602	B
renal	-	608	I
failure	-	614	I
.	-	621	O

This	20164825	623	O
was	-	628	O
accompanied	-	632	O
by	-	644	O
a	-	647	O
lower	-	649	O
activity	-	655	O
of	-	664	O
N	-	667	O
-	-	668	O
acetyl	-	669	O
-	-	675	O
beta	-	676	O
-	-	680	O
D	-	681	O
-	-	682	O
glucosaminidase	-	683	O
,	-	698	O
together	-	700	O
with	-	709	O
a	-	714	O
decrease	-	716	O
of	-	725	O
lipid	-	728	O
peroxidation	-	734	O
and	-	747	O
increase	-	751	O
of	-	760	O
antioxidant	-	763	O
systems	-	775	O
.	-	782	O

Metformin	20164825	784	O
also	-	794	O
protected	-	799	O
the	-	809	O
kidney	-	813	O
from	-	820	O
histological	-	825	O
damage	-	838	O
6	-	845	O
days	-	847	O
after	-	852	O
gentamicin	-	858	O
administration	-	869	O
.	-	883	O

These	20164825	885	O
in	-	891	O
vivo	-	894	O
markers	-	899	O
of	-	907	O
kidney	-	910	B
dysfunction	-	917	I
and	-	929	O
their	-	933	O
correction	-	939	O
by	-	950	O
metformin	-	953	O
were	-	963	O
complemented	-	968	O
by	-	981	O
in	-	984	O
vitro	-	987	O
studies	-	993	O
of	-	1001	O
mitochondrial	-	1004	O
function	-	1018	O
.	-	1026	O

We	20164825	1028	O
found	-	1031	O
that	-	1037	O
gentamicin	-	1042	O
treatment	-	1053	O
depleted	-	1063	O
respiratory	-	1072	O
components	-	1084	O
(	-	1095	O
cytochrome	-	1096	O
c	-	1107	O
,	-	1108	O
NADH	-	1110	O
)	-	1114	O
,	-	1115	O
probably	-	1117	O
due	-	1126	O
to	-	1130	O
the	-	1133	O
opening	-	1137	O
of	-	1145	O
mitochondrial	-	1148	O
transition	-	1162	O
pores	-	1173	O
.	-	1178	O

These	20164825	1180	O
injuries	-	1186	O
,	-	1194	O
partly	-	1196	O
mediated	-	1203	O
by	-	1212	O
a	-	1215	O
rise	-	1217	O
in	-	1222	O
reactive	-	1225	O
oxygen	-	1234	O
species	-	1241	O
from	-	1249	O
the	-	1254	O
electron	-	1258	O
transfer	-	1267	O
chain	-	1276	O
,	-	1281	O
were	-	1283	O
significantly	-	1288	O
decreased	-	1302	O
by	-	1312	O
metformin	-	1315	O
.	-	1324	O

Thus	20164825	1326	O
,	-	1330	O
our	-	1332	O
study	-	1336	O
suggests	-	1342	O
that	-	1351	O
pleiotropic	-	1356	O
effects	-	1368	O
of	-	1376	O
metformin	-	1379	O
can	-	1389	O
lessen	-	1393	O
gentamicin	-	1400	O
nephrotoxicity	-	1411	B
and	-	1426	O
improve	-	1430	O
mitochondrial	-	1438	O
homeostasis	-	1452	O
.	-	1463	O

Sedation	20042557	0	O
depth	-	9	O
during	-	15	O
spinal	-	22	O
anesthesia	-	29	O
and	-	40	O
the	-	44	O
development	-	48	O
of	-	60	O
postoperative	-	63	B
delirium	-	77	I
in	-	86	O
elderly	-	89	O
patients	-	97	O
undergoing	-	106	O
hip	-	117	B
fracture	-	121	I
repair	-	130	O
.	-	136	O

OBJECTIVE	20042557	138	O
:	-	147	O

To	20042557	149	O
determine	-	152	O
whether	-	162	O
limiting	-	170	O
intraoperative	-	179	O
sedation	-	194	O
depth	-	203	O
during	-	209	O
spinal	-	216	O
anesthesia	-	223	O
for	-	234	O
hip	-	238	B
fracture	-	242	I
repair	-	251	O
in	-	258	O
elderly	-	261	O
patients	-	269	O
can	-	278	O
decrease	-	282	O
the	-	291	O
prevalence	-	295	O
of	-	306	O
postoperative	-	309	B
delirium	-	323	I
.	-	331	O

PATIENTS	20042557	333	O
AND	-	342	O
METHODS	-	346	O
:	-	353	O

We	20042557	355	O
performed	-	358	O
a	-	368	O
double	-	370	O
-	-	376	O
blind	-	377	O
,	-	382	O
randomized	-	384	O
controlled	-	395	O
trial	-	406	O
at	-	412	O
an	-	415	O
academic	-	418	O
medical	-	427	O
center	-	435	O
of	-	442	O
elderly	-	445	O
patients	-	453	O
(	-	462	O
>	-	463	O
or	-	464	O
=	-	466	O
65	-	467	O
years	-	470	O
)	-	475	O
without	-	477	O
preoperative	-	485	O
delirium	-	498	B
or	-	507	O
severe	-	510	O
dementia	-	517	B
who	-	526	O
underwent	-	530	O
hip	-	540	B
fracture	-	544	I
repair	-	553	O
under	-	560	O
spinal	-	566	O
anesthesia	-	573	O
with	-	584	O
propofol	-	589	O
sedation	-	598	O
.	-	606	O

Sedation	20042557	608	O
depth	-	617	O
was	-	623	O
titrated	-	627	O
using	-	636	O
processed	-	642	O
electroencephalography	-	652	O
with	-	675	O
the	-	680	O
bispectral	-	684	O
index	-	695	O
(	-	701	O
BIS	-	702	O
)	-	705	O
,	-	706	O
and	-	708	O
patients	-	712	O
were	-	721	O
randomized	-	726	O
to	-	737	O
receive	-	740	O
either	-	748	O
deep	-	755	O
(	-	760	O
BIS	-	761	O
,	-	764	O
approximately	-	766	O
50	-	780	O
)	-	782	O
or	-	784	O
light	-	787	O
(	-	793	O
BIS	-	794	O
,	-	797	O
>	-	799	O
or	-	800	O
=	-	802	O
80	-	803	O
)	-	805	O
sedation	-	807	O
.	-	815	O

Postoperative	20042557	817	B
delirium	-	831	I
was	-	840	O
assessed	-	844	O
as	-	853	O
defined	-	856	O
by	-	864	O
Diagnostic	-	867	O
and	-	878	O
Statistical	-	882	O
Manual	-	894	O
of	-	901	O
Mental	-	904	B
Disorders	-	911	I
(	-	921	O
Third	-	922	O
Edition	-	928	O
Revised	-	936	O
)	-	943	O
criteria	-	945	O
using	-	954	O
the	-	960	O
Confusion	-	964	O
Assessment	-	974	O
Method	-	985	O
beginning	-	992	O
at	-	1002	O
any	-	1005	O
time	-	1009	O
from	-	1014	O
the	-	1019	O
second	-	1023	O
day	-	1030	O
after	-	1034	O
surgery	-	1040	O
.	-	1047	O

RESULTS	20042557	1049	O
:	-	1056	O

From	20042557	1058	O
April	-	1063	O
2	-	1069	O
,	-	1070	O
2005	-	1072	O
,	-	1076	O
through	-	1078	O
October	-	1086	O
30	-	1094	O
,	-	1096	O
2008	-	1098	O
,	-	1102	O
a	-	1104	O
total	-	1106	O
of	-	1112	O
114	-	1115	O
patients	-	1119	O
were	-	1128	O
randomized	-	1133	O
.	-	1143	O

The	20042557	1145	O
prevalence	-	1149	O
of	-	1160	O
postoperative	-	1163	B
delirium	-	1177	I
was	-	1186	O
significantly	-	1190	O
lower	-	1204	O
in	-	1210	O
the	-	1213	O
light	-	1217	O
sedation	-	1223	O
group	-	1232	O
(	-	1238	O
11	-	1239	O
/	-	1241	O
57	-	1242	O
[	-	1245	O
19	-	1246	O
%	-	1248	O
]	-	1249	O
vs	-	1251	O
23	-	1254	O
/	-	1256	O
57	-	1257	O
[	-	1260	O
40	-	1261	O
%	-	1263	O
]	-	1264	O
in	-	1266	O
the	-	1269	O
deep	-	1273	O
sedation	-	1278	O
group	-	1287	O
;	-	1292	O
P	-	1294	O
=	-	1295	O
.	-	1296	O
02	-	1297	O
)	-	1299	O
,	-	1300	O
indicating	-	1302	O
that	-	1313	O
1	-	1318	O
incident	-	1320	O
of	-	1329	O
delirium	-	1332	B
will	-	1341	O
be	-	1346	O
prevented	-	1349	O
for	-	1359	O
every	-	1363	O
4	-	1369	O
.	-	1370	O
7	-	1371	O
patients	-	1373	O
treated	-	1382	O
with	-	1390	O
light	-	1395	O
sedation	-	1401	O
.	-	1409	O

The	20042557	1411	O
mean	-	1415	O
+	-	1420	O
/	-	1421	O
-	-	1422	O

SD	20042557	1424	O
number	-	1427	O
of	-	1434	O
days	-	1437	O
of	-	1442	O
delirium	-	1445	B
during	-	1454	O
hospitalization	-	1461	O
was	-	1477	O
lower	-	1481	O
in	-	1487	O
the	-	1490	O
light	-	1494	O
sedation	-	1500	O
group	-	1509	O
than	-	1515	O
in	-	1520	O
the	-	1523	O
deep	-	1527	O
sedation	-	1532	O
group	-	1541	O
(	-	1547	O
0	-	1548	O
.	-	1549	O
5	-	1550	O
+	-	1551	O
/	-	1552	O
-	-	1553	O
1	-	1554	O
.	-	1555	O
5	-	1556	O
days	-	1558	O
vs	-	1563	O
1	-	1566	O
.	-	1567	O
4	-	1568	O
+	-	1569	O
/	-	1570	O
-	-	1571	O
4	-	1572	O
.	-	1573	O
0	-	1574	O
days	-	1576	O
;	-	1580	O
P	-	1582	O
=	-	1583	O
.	-	1584	O
01	-	1585	O
)	-	1587	O
.	-	1588	O

CONCLUSION	20042557	1590	O
:	-	1600	O

The	20042557	1602	O
use	-	1606	O
of	-	1610	O
light	-	1613	O
propofol	-	1619	O
sedation	-	1628	O
decreased	-	1637	O
the	-	1647	O
prevalence	-	1651	O
of	-	1662	O
postoperative	-	1665	B
delirium	-	1679	I
by	-	1688	O
50	-	1691	O
%	-	1693	O
compared	-	1695	O
with	-	1704	O
deep	-	1709	O
sedation	-	1714	O
.	-	1722	O

Limiting	20042557	1724	O
depth	-	1733	O
of	-	1739	O
sedation	-	1742	O
during	-	1751	O
spinal	-	1758	O
anesthesia	-	1765	O
is	-	1776	O
a	-	1779	O
simple	-	1781	O
,	-	1787	O
safe	-	1789	O
,	-	1793	O
and	-	1795	O
cost	-	1799	O
-	-	1803	O
effective	-	1804	O
intervention	-	1814	O
for	-	1827	O
preventing	-	1831	O
postoperative	-	1842	B
delirium	-	1856	I
in	-	1865	O
elderly	-	1868	O
patients	-	1876	O
that	-	1885	O
could	-	1890	O
be	-	1896	O
widely	-	1899	O
and	-	1906	O
readily	-	1910	O
adopted	-	1918	O
.	-	1925	O

Sorafenib	19944333	0	O
-	-	9	O
induced	-	10	O
acute	-	18	O
myocardial	-	24	B
infarction	-	35	I
due	-	46	O
to	-	50	O
coronary	-	53	B
artery	-	62	I
spasm	-	69	I
.	-	74	O

A	19944333	76	O
65	-	78	O
-	-	80	O
year	-	81	O
-	-	85	O
old	-	86	O
man	-	90	O
with	-	94	O
advanced	-	99	O
renal	-	108	B
cell	-	114	I
carcinoma	-	119	I
was	-	129	O
admitted	-	133	O
due	-	142	O
to	-	146	O
continuing	-	149	O
chest	-	160	B
pain	-	166	I
at	-	171	O
rest	-	174	O
.	-	178	O

Two	19944333	180	O
weeks	-	184	O
before	-	190	O
his	-	197	O
admission	-	201	O
,	-	210	O
sorafenib	-	212	O
had	-	222	O
been	-	226	O
started	-	231	O
.	-	238	O

He	19944333	240	O
was	-	243	O
diagnosed	-	247	O
with	-	257	O
non	-	262	O
-	-	265	O
ST	-	266	O
-	-	268	O
elevation	-	269	O
myocardial	-	279	B
infarction	-	290	I
by	-	301	O
laboratory	-	304	O
data	-	315	O
and	-	320	O
electrocardiogram	-	324	O
.	-	341	O

Enhanced	19944333	343	O
heart	-	352	O
magnetic	-	358	O
resonance	-	367	O
imaging	-	377	O
also	-	385	O
showed	-	390	O
subendocardial	-	397	B
infarction	-	412	I
.	-	422	O

However	19944333	424	O
,	-	431	O
there	-	433	O
was	-	439	O
no	-	443	O
stenosis	-	446	O
in	-	455	O
coronary	-	458	O
arteries	-	467	O
on	-	476	O
angiography	-	479	O
.	-	490	O

Coronary	19944333	492	B
artery	-	501	I
spasm	-	508	I
was	-	514	O
induced	-	518	O
by	-	526	O
a	-	529	O
provocative	-	531	O
test	-	543	O
.	-	547	O

Cessation	19944333	549	O
of	-	559	O
sorafenib	-	562	O
and	-	572	O
administration	-	576	O
of	-	591	O
Ca	-	594	O
-	-	596	O
channel	-	597	O
blocker	-	605	O
and	-	613	O
nitrates	-	617	O
ameliorated	-	626	O
his	-	638	O
symptoms	-	642	O
,	-	650	O
but	-	652	O
relapse	-	656	O
occurred	-	664	O
after	-	673	O
resumption	-	679	O
of	-	690	O
sorafenib	-	693	O
.	-	702	O

Addition	19944333	704	O
of	-	713	O
oral	-	716	O
nicorandil	-	721	O
reduced	-	732	O
his	-	740	O
symptoms	-	744	O
and	-	753	O
maintained	-	757	O
stable	-	768	B
angina	-	775	I
status	-	782	O
.	-	788	O

We	19944333	790	O
report	-	793	O
the	-	800	O
first	-	804	O
case	-	810	O
of	-	815	O
sorafenib	-	818	O
-	-	827	O
induced	-	828	O
coronary	-	836	B
artery	-	845	I
spasm	-	852	I
.	-	857	O

Sorafenib	19944333	859	O
is	-	869	O
a	-	872	O
multikinase	-	874	O
inhibitor	-	886	O
that	-	896	O
targets	-	901	O
signaling	-	909	O
pathways	-	919	O
necessary	-	928	O
for	-	938	O
cellular	-	942	O
proliferation	-	951	O
and	-	965	O
survival	-	969	O
.	-	977	O

On	19944333	979	O
the	-	982	O
other	-	986	O
hand	-	992	O
,	-	996	O
the	-	998	O
Rho	-	1002	O
/	-	1005	O
ROCK	-	1006	O
pathway	-	1011	O
has	-	1019	O
an	-	1023	O
important	-	1026	O
role	-	1036	O
in	-	1041	O
the	-	1044	O
pathogenesis	-	1048	O
of	-	1061	O
coronary	-	1064	B
artery	-	1073	I
spasm	-	1080	I
.	-	1085	O

Our	19944333	1087	O
report	-	1091	O
may	-	1098	O
show	-	1102	O
an	-	1107	O
adverse	-	1110	O
effect	-	1118	O
on	-	1125	O
the	-	1128	O
Rho	-	1132	O
/	-	1135	O
ROCK	-	1136	O
pathway	-	1141	O
by	-	1149	O
sorafenib	-	1152	O
use	-	1162	O
.	-	1165	O

Anxiogenic	17975693	0	O
potential	-	11	O
of	-	21	O
ciprofloxacin	-	24	O
and	-	38	O
norfloxacin	-	42	O
in	-	54	O
rats	-	57	O
.	-	61	O

INTRODUCTION	17975693	63	O
:	-	75	O

The	17975693	77	O
possible	-	81	O
anxiogenic	-	90	O
effects	-	101	O
of	-	109	O
fluoroquinolones	-	112	O
,	-	128	O
namely	-	130	O
ciprofloxacin	-	137	O
and	-	151	O
norfloxacin	-	155	O
,	-	166	O
were	-	168	O
investigated	-	173	O
in	-	186	O
adult	-	189	O
Charles	-	195	O
Foster	-	203	O
albino	-	210	O
rats	-	217	O
of	-	222	O
either	-	225	O
sex	-	232	O
,	-	235	O
weighing	-	237	O
150	-	246	O
-	-	249	O
200	-	250	O
g	-	254	O
.	-	255	O
METHODS	-	257	O
:	-	264	O

The	17975693	266	O
drugs	-	270	O
were	-	276	O
given	-	281	O
orally	-	287	O
,	-	293	O
in	-	295	O
doses	-	298	O
of	-	304	O
50	-	307	O
mg	-	310	O
/	-	312	O
kg	-	313	O
for	-	316	O
five	-	320	O
consecutive	-	325	O
days	-	337	O
and	-	342	O
the	-	346	O
experiments	-	350	O
were	-	362	O
performed	-	367	O
on	-	377	O
the	-	380	O
fifth	-	384	O
day	-	390	O
.	-	393	O

The	17975693	395	O
tests	-	399	O
included	-	405	O
open	-	414	O
-	-	418	O
field	-	419	O
exploratory	-	425	O
behaviour	-	437	O
,	-	446	O
elevated	-	448	O
plus	-	457	O
maze	-	462	O
and	-	467	O
elevated	-	471	O
zero	-	480	O
maze	-	485	O
,	-	489	O
social	-	491	O
interaction	-	498	O
and	-	510	O
novelty	-	514	O
-	-	521	O
suppressed	-	522	O
feeding	-	533	O
latency	-	541	O
behaviour	-	549	O
.	-	558	O

RESULTS	17975693	560	O
:	-	567	O

The	17975693	569	O
results	-	573	O
indicate	-	581	O
that	-	590	O
ciprofloxacin	-	595	O
-	-	608	O
and	-	610	O
norfloxacin	-	614	O
-	-	625	O
treated	-	626	O
rats	-	634	O
showed	-	639	O
anxious	-	646	B
behaviour	-	654	I
in	-	664	O
comparison	-	667	O
to	-	678	O
control	-	681	O
rats	-	689	O
in	-	694	O
all	-	697	O
the	-	701	O
parameters	-	705	O
studied	-	716	O
.	-	723	O

However	17975693	725	O
,	-	732	O
ciprofloxacin	-	734	O
-	-	747	O
and	-	749	O
norfloxacin	-	753	O
-	-	764	O
treated	-	765	O
rats	-	773	O
did	-	778	O
not	-	782	O
differ	-	786	O
significantly	-	793	O
from	-	807	O
each	-	812	O
other	-	817	O
in	-	823	O
various	-	826	O
behavioural	-	834	O
parameters	-	846	O
.	-	856	O

CONCLUSION	17975693	858	O
:	-	868	O

The	17975693	870	O
present	-	874	O
experimental	-	882	O
findings	-	895	O
substantiate	-	904	O
the	-	917	O
clinically	-	921	O
observed	-	932	O
anxiogenic	-	941	O
potential	-	952	O
of	-	962	O
ciprofloxacin	-	965	O
and	-	979	O
norfloxacin	-	983	O
.	-	994	O

Myocardial	17943461	0	O
Fas	-	11	O
ligand	-	15	O
expression	-	22	O
increases	-	33	O
susceptibility	-	43	O
to	-	58	O
AZT	-	61	O
-	-	64	O
induced	-	65	O
cardiomyopathy	-	73	B
.	-	87	O

BACKGROUND	17943461	89	O
:	-	99	O

Dilated	17943461	101	B
cardiomyopathy	-	109	I
(	-	124	O
DCM	-	125	B
)	-	128	O
and	-	130	O
myocarditis	-	134	B
occur	-	146	O
in	-	152	O
many	-	155	O
HIV	-	160	B
-	-	163	I
infected	-	164	I
individuals	-	173	O
,	-	184	O
resulting	-	186	O
in	-	196	O
symptomatic	-	199	O
heart	-	211	B
failure	-	217	I
in	-	225	O
up	-	228	O
to	-	231	O
5	-	234	O
%	-	235	O
of	-	237	O
patients	-	240	O
.	-	248	O

Highly	17943461	250	O
active	-	257	O
antiretroviral	-	264	O
therapy	-	279	O
(	-	287	O
HAART	-	288	O
)	-	293	O
has	-	295	O
significantly	-	299	O
reduced	-	313	O
morbidity	-	321	O
and	-	331	O
mortality	-	335	O
of	-	345	O
acquired	-	348	B
immunodeficiency	-	357	I
syndrome	-	374	I
(	-	383	O
AIDS	-	384	B
)	-	388	O
,	-	389	O
but	-	391	O
has	-	395	O
resulted	-	399	O
in	-	408	O
an	-	411	O
increase	-	414	O
in	-	423	O
cardiac	-	426	B
and	-	434	I
skeletal	-	438	I
myopathies	-	447	I
.	-	457	O

METHODS	17943461	459	O
AND	-	467	O
RESULTS	-	471	O
:	-	478	O

In	17943461	480	O
order	-	483	O
to	-	489	O
investigate	-	492	O
whether	-	504	O
the	-	512	O
HAART	-	516	O
component	-	522	O
zidovudine	-	532	O
(	-	543	O
3'	-	544	O
-	-	546	O
azido	-	547	O
-	-	552	O
2'	-	553	O
,	-	555	O
3'	-	556	O
-	-	558	O
deoxythymidine	-	559	O
;	-	573	O
AZT	-	575	O
)	-	578	O
triggers	-	580	O
the	-	589	O
Fas	-	593	O
-	-	596	O
dependent	-	597	O
cell	-	607	O
-	-	611	O
death	-	612	O
pathway	-	618	O
and	-	626	O
cause	-	630	O
cytoskeletal	-	636	O
disruption	-	649	O
in	-	660	O
a	-	663	O
murine	-	665	O
model	-	672	O
of	-	678	O
DCM	-	681	B
,	-	684	O
8	-	686	O
-	-	687	O
week	-	688	O
-	-	692	O
old	-	693	O
transgenic	-	697	O
(	-	708	O
expressing	-	709	O
Fas	-	720	O
ligand	-	724	O
in	-	731	O
the	-	734	O
myocardium	-	738	O
:	-	748	O
FasL	-	750	O
Tg	-	755	O
)	-	757	O
and	-	759	O
non	-	763	O
-	-	766	O
transgenic	-	767	O
(	-	778	O
NTg	-	779	O
)	-	782	O
mice	-	784	O
received	-	789	O
water	-	798	O
ad	-	804	O
libitum	-	807	O
containing	-	815	O
different	-	826	O
concentrations	-	836	O
of	-	851	O
AZT	-	854	O
(	-	858	O
0	-	859	O
,	-	860	O
0	-	862	O
.	-	863	O
07	-	864	O
,	-	866	O
0	-	868	O
.	-	869	O
2	-	870	O
,	-	871	O
and	-	873	O
0	-	877	O
.	-	878	O
7	-	879	O
mg	-	881	O
/	-	883	O
ml	-	884	O
)	-	886	O
.	-	887	O

After	17943461	889	O
6	-	895	O
weeks	-	897	O
,	-	902	O
cardiac	-	904	O
function	-	912	O
was	-	921	O
assessed	-	925	O
by	-	934	O
echocardiography	-	937	O
and	-	954	O
morphology	-	958	O
was	-	969	O
assessed	-	973	O
by	-	982	O
histopathologic	-	985	O
and	-	1001	O
immunohistochemical	-	1005	O
methods	-	1025	O
.	-	1032	O

NTg	17943461	1034	O
and	-	1038	O
untreated	-	1042	O
FasL	-	1052	O

Tg	17943461	1057	O
mice	-	1060	O
showed	-	1065	O
little	-	1072	O
or	-	1079	O
no	-	1082	O
change	-	1085	O
in	-	1092	O
cardiac	-	1095	O
structure	-	1103	O
or	-	1113	O
function	-	1116	O
.	-	1124	O

In	17943461	1126	O
contrast	-	1129	O
,	-	1137	O
AZT	-	1139	O
-	-	1142	O
treated	-	1143	O
FasL	-	1151	O
Tg	-	1156	O
mice	-	1159	O
developed	-	1164	O
cardiac	-	1174	B
dilation	-	1182	I
and	-	1191	O
depressed	-	1195	O
cardiac	-	1205	O
function	-	1213	O
in	-	1222	O
a	-	1225	O
dose	-	1227	O
-	-	1231	O
dependent	-	1232	O
manner	-	1242	O
,	-	1248	O
with	-	1250	O
concomitant	-	1255	O
inflammatory	-	1267	O
infiltration	-	1280	O
of	-	1293	O
both	-	1296	O
ventricles	-	1301	O
.	-	1311	O

These	17943461	1313	O
changes	-	1319	O
were	-	1327	O
associated	-	1332	O
with	-	1343	O
an	-	1348	O
increased	-	1351	O
sarcolemmal	-	1361	O
expression	-	1373	O
of	-	1384	O
Fas	-	1387	O
and	-	1391	O
FasL	-	1395	O
,	-	1399	O
as	-	1401	O
well	-	1404	O
as	-	1409	O
increased	-	1412	O
activation	-	1422	O
of	-	1433	O
caspase	-	1436	O
3	-	1444	O
,	-	1445	O
translocation	-	1447	O
of	-	1461	O
calpain	-	1464	O
1	-	1472	O
to	-	1474	O
the	-	1477	O
sarcolemma	-	1481	O
and	-	1492	O
sarcomere	-	1496	O
,	-	1505	O
and	-	1507	O
increased	-	1511	O
numbers	-	1521	O
of	-	1529	O
cells	-	1532	O
undergoing	-	1538	O
apoptosis	-	1549	O
.	-	1558	O

These	17943461	1560	O
were	-	1566	O
associated	-	1571	O
with	-	1582	O
changes	-	1587	O
in	-	1595	O
dystrophin	-	1598	O
and	-	1609	O
cardiac	-	1613	O
troponin	-	1621	O
I	-	1630	O
localization	-	1632	O
,	-	1644	O
as	-	1646	O
well	-	1649	O
as	-	1654	O
loss	-	1657	O
of	-	1662	O
sarcolemmal	-	1665	O
integrity	-	1677	O
.	-	1686	O

CONCLUSIONS	17943461	1688	O
:	-	1699	O

The	17943461	1701	O
expression	-	1705	O
of	-	1716	O
Fas	-	1719	O
ligand	-	1723	O
in	-	1730	O
the	-	1733	O
myocardium	-	1737	O
,	-	1747	O
as	-	1749	O
identified	-	1752	O
in	-	1763	O
HIV	-	1766	O
-	-	1769	O
positive	-	1770	O
patients	-	1779	O
,	-	1787	O
might	-	1789	O
increase	-	1795	O
the	-	1804	O
susceptibility	-	1808	O
to	-	1823	O
HAART	-	1826	O
-	-	1831	O
induced	-	1832	O
cardiomyopathy	-	1840	B
due	-	1855	O
to	-	1859	O
activation	-	1862	O
of	-	1873	O
apoptotic	-	1876	O
pathways	-	1886	O
,	-	1894	O
resulting	-	1896	O
in	-	1906	O
cardiac	-	1909	B
dilation	-	1917	I
and	-	1926	I
dysfunction	-	1930	I
.	-	1941	O

Valproate	17074608	0	O
-	-	9	O
induced	-	10	O
chorea	-	18	B
and	-	25	O
encephalopathy	-	29	B
in	-	44	O
atypical	-	47	O
nonketotic	-	56	B
hyperglycinemia	-	67	I
.	-	82	O

Nonketotic	17074608	84	B
hyperglycinemia	-	95	I
is	-	111	O
a	-	114	O
disorder	-	116	B
of	-	125	I
amino	-	128	I
acid	-	134	I
metabolism	-	139	I
in	-	150	O
which	-	153	O
a	-	159	O
defect	-	161	O
in	-	168	O
the	-	171	O
glycine	-	175	O
cleavage	-	183	O
system	-	192	O
leads	-	199	O
to	-	205	O
an	-	208	O
accumulation	-	211	O
of	-	224	O
glycine	-	227	O
in	-	235	O
the	-	238	O
brain	-	242	O
and	-	248	O
other	-	252	O
body	-	258	O
compartments	-	263	O
.	-	275	O

In	17074608	277	O
the	-	280	O
classical	-	284	O
form	-	294	O
it	-	299	O
presents	-	302	O
as	-	311	O
neonatal	-	314	O
apnea	-	323	B
,	-	328	O
intractable	-	330	O
seizures	-	342	B
,	-	350	O
and	-	352	O
hypotonia	-	356	B
,	-	365	O
followed	-	367	O
by	-	376	O
significant	-	379	O
psychomotor	-	391	B
retardation	-	403	I
.	-	414	O

An	17074608	416	O
important	-	419	O
subset	-	429	O
of	-	436	O
children	-	439	O
with	-	448	O
nonketotic	-	453	B
hyperglycinemia	-	464	I
are	-	480	O
atypical	-	484	O
variants	-	493	O
who	-	502	O
present	-	506	O
in	-	514	O
a	-	517	O
heterogeneous	-	519	O
manner	-	533	O
.	-	539	O

This	17074608	541	O
report	-	546	O
describes	-	553	O
a	-	563	O
patient	-	565	O
with	-	573	O
mild	-	578	O
language	-	583	B
delay	-	592	I
and	-	598	O
mental	-	602	B
retardation	-	609	I
,	-	620	O
who	-	622	O
was	-	626	O
found	-	630	O
to	-	636	O
have	-	639	O
nonketotic	-	644	B
hyperglycinemia	-	655	I
following	-	671	O
her	-	681	O
presentation	-	685	O
with	-	698	O
acute	-	703	O
encephalopathy	-	709	B
and	-	724	O
chorea	-	728	B
shortly	-	735	O
after	-	743	O
initiation	-	749	O
of	-	760	O
valproate	-	763	O
therapy	-	773	O
.	-	780	O

Microinjection	16364460	0	O
of	-	15	O
ritanserin	-	18	O
into	-	29	O
the	-	34	O
CA1	-	38	O
region	-	42	O
of	-	49	O
hippocampus	-	52	O
improves	-	64	O
scopolamine	-	73	O
-	-	84	O
induced	-	85	O
amnesia	-	93	B
in	-	101	O
adult	-	104	O
male	-	110	O
rats	-	115	O
.	-	119	O

The	16364460	121	O
effect	-	125	O
of	-	132	O
ritanserin	-	135	O
(	-	146	O
5	-	147	O
-	-	148	O
HT2	-	149	O
antagonist	-	153	O
)	-	163	O
on	-	165	O
scopolamine	-	168	O
(	-	180	O
muscarinic	-	181	O
cholinergic	-	192	O
antagonist	-	204	O
)	-	214	O
-	-	215	O
induced	-	216	O
amnesia	-	224	B
in	-	232	O
Morris	-	235	O
water	-	242	O
maze	-	248	O
(	-	253	O
MWM	-	254	O
)	-	257	O
was	-	259	O
investigated	-	263	O
.	-	275	O

Rats	16364460	277	O
were	-	282	O
divided	-	287	O
into	-	295	O
eight	-	300	O
groups	-	306	O
and	-	313	O
bilaterally	-	317	O
cannulated	-	329	O
into	-	340	O
CA1	-	345	O
region	-	349	O
of	-	356	O
the	-	359	O
hippocampus	-	363	O
.	-	374	O

One	16364460	376	O
week	-	380	O
later	-	385	O
,	-	390	O
they	-	392	O
received	-	397	O
repeatedly	-	406	O
vehicles	-	417	O
(	-	426	O
saline	-	427	O
,	-	433	O
DMSO	-	435	O
,	-	439	O
saline	-	441	O
+	-	447	O
DMSO	-	448	O
)	-	452	O
,	-	453	O
scopolamine	-	455	O
(	-	467	O
2	-	468	O
microg	-	470	O
/	-	476	O
0	-	477	O
.	-	478	O
5	-	479	O
microl	-	481	O
saline	-	488	O
/	-	494	O
side	-	495	O
;	-	499	O
30	-	501	O
min	-	504	O
before	-	508	O
training	-	515	O
)	-	523	O
,	-	524	O
ritanserin	-	526	O
(	-	537	O
2	-	538	O
,	-	539	O
4	-	541	O
and	-	543	O
8	-	547	O
microg	-	549	O
/	-	555	O
0	-	556	O
.	-	557	O
5	-	558	O
microl	-	560	O
DMSO	-	567	O
/	-	571	O
side	-	572	O
;	-	576	O
20	-	578	O
min	-	581	O
before	-	585	O
training	-	592	O
)	-	600	O
and	-	602	O
scopolamine	-	606	O
(	-	618	O
2	-	619	O
microg	-	621	O
/	-	627	O
0	-	628	O
.	-	629	O
5	-	630	O
microl	-	632	O
;	-	638	O
30	-	640	O
min	-	643	O
before	-	647	O
ritanserin	-	654	O
injection	-	665	O
)	-	674	O
+	-	675	O
ritanserin	-	676	O
(	-	687	O
4	-	688	O
microg	-	690	O
/	-	696	O
0	-	697	O
.	-	698	O
5	-	699	O
microl	-	701	O
DMSO	-	708	O
)	-	712	O
through	-	714	O
cannulae	-	722	O
each	-	731	O
day	-	736	O
.	-	739	O

Animals	16364460	741	O
were	-	749	O
tested	-	754	O
for	-	761	O
four	-	765	O
consecutive	-	770	O
days	-	782	O
(	-	787	O
4	-	788	O
trial	-	790	O
/	-	795	O
day	-	796	O
)	-	799	O
in	-	801	O
MWM	-	804	O
during	-	808	O
which	-	815	O
the	-	821	O
position	-	825	O
of	-	834	O
hidden	-	837	O
platform	-	844	O
was	-	853	O
unchanged	-	857	O
.	-	866	O

In	16364460	868	O
the	-	871	O
fifth	-	875	O
day	-	881	O
,	-	884	O
the	-	886	O
platform	-	890	O
was	-	899	O
elevated	-	903	O
above	-	912	O
the	-	918	O
water	-	922	O
surface	-	928	O
in	-	936	O
another	-	939	O
position	-	947	O
to	-	956	O
evaluate	-	959	O
the	-	968	O
function	-	972	O
of	-	981	O
motor	-	984	O
,	-	989	O
motivational	-	991	O
and	-	1004	O
visual	-	1008	O
systems	-	1015	O
.	-	1022	O

The	16364460	1024	O
results	-	1028	O
showed	-	1036	O
a	-	1043	O
significant	-	1045	O
increase	-	1057	O
in	-	1066	O
escape	-	1069	O
latencies	-	1076	O
and	-	1086	O
traveled	-	1090	O
distances	-	1099	O
to	-	1109	O
find	-	1112	O
platform	-	1117	O
in	-	1126	O
scopolamine	-	1129	O
-	-	1140	O
treated	-	1141	O
group	-	1149	O
as	-	1155	O
compared	-	1158	O
to	-	1167	O
saline	-	1170	O
group	-	1177	O
.	-	1182	O

Ritanserin	16364460	1184	O
-	-	1194	O
treated	-	1195	O
rats	-	1203	O
(	-	1208	O
4	-	1209	O
microg	-	1211	O
/	-	1217	O
0	-	1218	O
.	-	1219	O
5	-	1220	O
microl	-	1222	O
/	-	1228	O
side	-	1229	O
)	-	1233	O
showed	-	1235	O
a	-	1242	O
significant	-	1244	O
decrease	-	1256	O
in	-	1265	O
the	-	1268	O
mentioned	-	1272	O
parameters	-	1282	O
as	-	1293	O
compared	-	1296	O
to	-	1305	O
DMSO	-	1308	O
-	-	1312	O
treated	-	1313	O
group	-	1321	O
.	-	1326	O

However	16364460	1328	O
,	-	1335	O
scopolamine	-	1337	O
and	-	1349	O
ritanserin	-	1353	O
co	-	1364	O
-	-	1366	O
administration	-	1367	O
resulted	-	1382	O
in	-	1391	O
a	-	1394	O
significant	-	1396	O
decrease	-	1408	O
in	-	1417	O
escape	-	1420	O
latencies	-	1427	O
and	-	1437	O
traveled	-	1441	O
distances	-	1450	O
as	-	1460	O
compared	-	1463	O
to	-	1472	O
the	-	1475	O
scopolamine	-	1479	O
-	-	1490	O
treated	-	1491	O
rats	-	1499	O
.	-	1503	O

Our	16364460	1505	O
findings	-	1509	O
show	-	1518	O
that	-	1523	O
microinjection	-	1528	O
of	-	1543	O
ritanserin	-	1546	O
into	-	1557	O
the	-	1562	O
CA1	-	1566	O
region	-	1570	O
of	-	1577	O
the	-	1580	O
hippocampus	-	1584	O
improves	-	1596	O
the	-	1605	O
scopolamine	-	1609	O
-	-	1620	O
induced	-	1621	O
amnesia	-	1629	B
.	-	1636	O

Hypoxia	15579441	0	B
in	-	8	O
renal	-	11	B
disease	-	17	I
with	-	25	O
proteinuria	-	30	B
and	-	42	O
/	-	45	O
or	-	46	O
glomerular	-	49	O
hypertension	-	60	B
.	-	72	O

Despite	15579441	74	O
the	-	82	O
increasing	-	86	O
need	-	97	O
to	-	102	O
identify	-	105	O
and	-	114	O
quantify	-	118	O
tissue	-	127	O
oxygenation	-	134	O
at	-	146	O
the	-	149	O
cellular	-	153	O
level	-	162	O
,	-	167	O
relatively	-	169	O
few	-	180	O
methods	-	184	O
have	-	192	O
been	-	197	O
available	-	202	O
.	-	211	O

In	15579441	213	O
this	-	216	O
study	-	221	O
,	-	226	O
we	-	228	O
developed	-	231	O
a	-	241	O
new	-	243	O
hypoxia	-	247	B
-	-	254	O
responsive	-	255	O
reporter	-	266	O
vector	-	275	O
using	-	282	O
a	-	288	O
hypoxia	-	290	B
-	-	297	O
responsive	-	298	O
element	-	309	O
of	-	317	O
the	-	320	O
5	-	324	O
'	-	325	O
vascular	-	327	O
endothelial	-	336	O
growth	-	348	O
factor	-	355	O
untranslated	-	362	O
region	-	375	O
and	-	382	O
generated	-	386	O
a	-	396	O
novel	-	398	O
hypoxia	-	404	B
-	-	411	O
sensing	-	412	O
transgenic	-	420	O
rat	-	431	O
.	-	434	O

We	15579441	436	O
then	-	439	O
applied	-	444	O
this	-	452	O
animal	-	457	O
model	-	464	O
to	-	470	O
the	-	473	O
detection	-	477	O
of	-	487	O
tubulointerstitial	-	490	O
hypoxia	-	509	B
in	-	517	O
the	-	520	O
diseased	-	524	B
kidney	-	533	I
.	-	539	O

With	15579441	541	O
this	-	546	O
model	-	551	O
,	-	556	O
we	-	558	O
were	-	561	O
able	-	566	O
to	-	571	O
identify	-	574	O
diffuse	-	583	O
cortical	-	591	O
hypoxia	-	600	B
in	-	608	O
the	-	611	O
puromycin	-	615	O
aminonucleoside	-	625	O
-	-	640	O
induced	-	641	O
nephrotic	-	649	B
syndrome	-	659	I
and	-	668	O
focal	-	672	O
and	-	678	O
segmental	-	682	O
hypoxia	-	692	B
in	-	700	O
the	-	703	O
remnant	-	707	O
kidney	-	715	O
model	-	722	O
.	-	727	O

Expression	15579441	729	O
of	-	740	O
the	-	743	O
hypoxia	-	747	B
-	-	754	O
responsive	-	755	O
transgene	-	766	O
increased	-	776	O
throughout	-	786	O
the	-	797	O
observation	-	801	O
period	-	813	O
,	-	819	O
reaching	-	821	O
2	-	830	O
.	-	831	O
2	-	832	O
-	-	833	O
fold	-	834	O
at	-	839	O
2	-	842	O
weeks	-	844	O
in	-	850	O
the	-	853	O
puromycin	-	857	O
aminonucleoside	-	867	O
model	-	883	O
and	-	889	O
2	-	893	O
.	-	894	O
6	-	895	O
-	-	896	O
fold	-	897	O
at	-	902	O
4	-	905	O
weeks	-	907	O
in	-	913	O
the	-	916	O
remnant	-	920	O
kidney	-	928	O
model	-	935	O
,	-	940	O
whereas	-	942	O
that	-	950	O
of	-	955	O
vascular	-	958	O
endothelial	-	967	O
growth	-	979	O
factor	-	986	O
showed	-	993	O
a	-	1000	O
mild	-	1002	O
decrease	-	1007	O
,	-	1015	O
reflecting	-	1017	O
distinct	-	1028	O
behaviors	-	1037	O
of	-	1047	O
the	-	1050	O
two	-	1054	O
genes	-	1058	O
.	-	1063	O

The	15579441	1065	O
degree	-	1069	O
of	-	1076	O
hypoxia	-	1079	B
showed	-	1087	O
a	-	1094	O
positive	-	1096	O
correlation	-	1105	O
with	-	1117	O
microscopic	-	1122	O
tubulointerstitial	-	1134	B
injury	-	1153	I
in	-	1160	O
both	-	1163	O
models	-	1168	O
.	-	1174	O

Finally	15579441	1176	O
,	-	1183	O
we	-	1185	O
identified	-	1188	O
the	-	1199	O
localization	-	1203	O
of	-	1216	O
proliferating	-	1219	O
cell	-	1233	O
nuclear	-	1238	O
antigen	-	1246	O
-	-	1253	O
positive	-	1254	O
,	-	1262	O
ED	-	1264	O
-	-	1266	O
1	-	1267	O
-	-	1268	O
positive	-	1269	O
,	-	1277	O
and	-	1279	O
terminal	-	1283	O
dUTP	-	1292	O
nick	-	1297	O
-	-	1301	O
end	-	1302	O
labeled	-	1306	O
-	-	1313	O
positive	-	1314	O
cells	-	1323	O
in	-	1329	O
the	-	1332	O
hypoxic	-	1336	B
cortical	-	1344	O
area	-	1353	O
in	-	1358	O
the	-	1361	O
remnant	-	1365	O
kidney	-	1373	O
model	-	1380	O
.	-	1385	O

We	15579441	1387	O
propose	-	1390	O
here	-	1398	O
a	-	1403	O
possible	-	1405	O
pathological	-	1414	O
tie	-	1427	O
between	-	1431	O
chronic	-	1439	O
tubulointerstitial	-	1447	O
hypoxia	-	1466	B
and	-	1474	O
progressive	-	1478	O
glomerular	-	1490	B
diseases	-	1501	I
.	-	1509	O

Consensus	15517007	0	O
statement	-	10	O
concerning	-	20	O
cardiotoxicity	-	31	B
occurring	-	46	O
during	-	56	O
haematopoietic	-	63	O
stem	-	78	O
cell	-	83	O
transplantation	-	88	O
in	-	104	O
the	-	107	O
treatment	-	111	O
of	-	121	O
autoimmune	-	124	B
diseases	-	135	I
,	-	143	O
with	-	145	O
special	-	150	O
reference	-	158	O
to	-	168	O
systemic	-	171	B
sclerosis	-	180	I
and	-	190	O
multiple	-	194	B
sclerosis	-	203	I
.	-	212	O

Autologous	15517007	214	O
haematopoietic	-	225	O
stem	-	240	O
cell	-	245	O
transplantation	-	250	O
is	-	266	O
now	-	269	O
a	-	273	O
feasible	-	275	O
and	-	284	O
effective	-	288	O
treatment	-	298	O
for	-	308	O
selected	-	312	O
patients	-	321	O
with	-	330	O
severe	-	335	O
autoimmune	-	342	B
diseases	-	353	I
.	-	361	O

Worldwide	15517007	363	O
,	-	372	O
over	-	374	O
650	-	379	O
patients	-	383	O
have	-	392	O
been	-	397	O
transplanted	-	402	O
in	-	415	O
the	-	418	O
context	-	422	O
of	-	430	O
phase	-	433	O
I	-	439	O
and	-	441	O
II	-	445	O
clinical	-	448	O
trials	-	457	O
.	-	463	O

The	15517007	465	O
results	-	469	O
are	-	477	O
encouraging	-	481	O
enough	-	493	O
to	-	500	O
begin	-	503	O
randomised	-	509	O
phase	-	520	O
III	-	526	O
trials	-	530	O
.	-	536	O

However	15517007	538	O
,	-	545	O
as	-	547	O
predicted	-	550	O
,	-	559	O
significant	-	561	O
transplant	-	573	O
-	-	583	O
related	-	584	O
morbidity	-	592	O
and	-	602	O
mortality	-	606	O
have	-	616	O
been	-	621	O
observed	-	626	O
.	-	634	O

This	15517007	636	O
is	-	641	O
primarily	-	644	O
due	-	654	O
to	-	658	O
complications	-	661	O
related	-	675	O
to	-	683	O
either	-	686	O
the	-	693	O
stage	-	697	O
of	-	703	O
the	-	706	O
disease	-	710	O
at	-	718	O
transplant	-	721	O
or	-	732	O
due	-	735	O
to	-	739	O
infections	-	742	B
.	-	752	O

The	15517007	754	O
number	-	758	O
of	-	765	O
deaths	-	768	O
related	-	775	O
to	-	783	O
cardiac	-	786	B
toxicity	-	794	I
is	-	803	O
low	-	806	O
.	-	809	O

However	15517007	811	O
,	-	818	O
caution	-	820	O
is	-	828	O
required	-	831	O
when	-	840	O
cyclophosphamide	-	845	O
or	-	862	O
anthracyclines	-	865	O
such	-	880	O
as	-	885	O
mitoxantrone	-	888	O
are	-	901	O
used	-	905	O
in	-	910	O
patients	-	913	O
with	-	922	O
a	-	927	O
possible	-	929	O
underlying	-	938	O
heart	-	949	B
damage	-	955	I
,	-	961	O
for	-	963	O
example	-	967	O
,	-	974	O
systemic	-	976	B
sclerosis	-	985	I
patients	-	995	O
.	-	1003	O

In	15517007	1005	O
November	-	1008	O
2002	-	1017	O
,	-	1021	O
a	-	1023	O
meeting	-	1025	O
was	-	1033	O
held	-	1037	O
in	-	1042	O
Florence	-	1045	O
,	-	1053	O
bringing	-	1055	O
together	-	1064	O
a	-	1073	O
number	-	1075	O
of	-	1082	O
experts	-	1085	O
in	-	1093	O
various	-	1096	O
fields	-	1104	O
,	-	1110	O
including	-	1112	O
rheumatology	-	1122	O
,	-	1134	O
cardiology	-	1136	O
,	-	1146	O
neurology	-	1148	O
,	-	1157	O
pharmacology	-	1159	O
and	-	1172	O
transplantation	-	1176	O
medicine	-	1192	O
.	-	1200	O

The	15517007	1202	O
object	-	1206	O
of	-	1213	O
the	-	1216	O
meeting	-	1220	O
was	-	1228	O
to	-	1232	O
analyse	-	1235	O
existing	-	1243	O
data	-	1252	O
,	-	1256	O
both	-	1258	O
published	-	1263	O
or	-	1273	O
available	-	1276	O
,	-	1285	O
in	-	1287	O
the	-	1290	O
European	-	1294	O
Group	-	1303	O
for	-	1309	O
Blood	-	1313	O
and	-	1319	O
Marrow	-	1323	O
Transplantation	-	1330	O
autoimmune	-	1346	B
disease	-	1357	I
database	-	1365	O
,	-	1373	O
and	-	1375	O
to	-	1379	O
propose	-	1382	O
a	-	1390	O
safe	-	1392	O
approach	-	1397	O
to	-	1406	O
such	-	1409	O
patients	-	1414	O
.	-	1422	O

A	15517007	1424	O
full	-	1426	O
cardiological	-	1431	O
assessment	-	1445	O
before	-	1456	O
and	-	1463	O
during	-	1467	O
the	-	1474	O
transplant	-	1478	O
emerged	-	1489	O
as	-	1497	O
the	-	1500	O
major	-	1504	O
recommendation	-	1510	O
.	-	1524	O

Immunohistochemical	12180796	0	O
study	-	20	O
on	-	26	O
inducible	-	29	O
type	-	39	O
of	-	44	O
nitric	-	47	O
oxide	-	54	O
(	-	60	O
iNOS	-	61	O
)	-	65	O
,	-	66	O
basic	-	68	O
fibroblast	-	74	O
growth	-	85	O
factor	-	92	O
(	-	99	O
bFGF	-	100	O
)	-	104	O
and	-	106	O
tumor	-	110	B
growth	-	116	O
factor	-	123	O
-	-	129	O
beta1	-	130	O
(	-	136	O
TGF	-	137	O
-	-	140	O
beta1	-	141	O
)	-	146	O
in	-	148	O
arteritis	-	151	B
induced	-	161	O
in	-	169	O
rats	-	172	O
by	-	177	O
fenoldopam	-	180	O
and	-	191	O
theophylline	-	195	O
,	-	207	O
vasodilators	-	209	O
.	-	221	O

Arteritis	12180796	223	B
induced	-	233	O
in	-	241	O
rats	-	244	O
by	-	249	O
vasodilators	-	252	O
,	-	264	O
fenoldopam	-	266	O
and	-	277	O
theophylline	-	281	O
,	-	293	O
was	-	295	O
examined	-	299	O
immunohistochemically	-	308	O
for	-	330	O
expressions	-	334	O
of	-	346	O
inducible	-	349	O
type	-	359	O
of	-	364	O
nitric	-	367	O
oxide	-	374	O
synthase	-	380	O
(	-	389	O
iNOS	-	390	O
)	-	394	O
,	-	395	O
basic	-	397	O
fibroblast	-	403	O
growth	-	414	O
factor	-	421	O
(	-	428	O
bFGF	-	429	O
)	-	433	O
and	-	435	O
tumor	-	439	B
growth	-	445	O
factor	-	452	O
-	-	458	O
beta1	-	459	O
(	-	465	O
TGF	-	466	O
-	-	469	O
beta1	-	470	O
)	-	475	O
.	-	476	O

Rats	12180796	478	O
were	-	483	O
administered	-	488	O
fenoldopam	-	501	O
for	-	512	O
24	-	516	O
hours	-	519	O
by	-	525	O
intravenous	-	528	O
infusion	-	540	O
with	-	549	O
or	-	554	O
without	-	557	O
following	-	565	O
repeated	-	575	O
daily	-	584	O
oral	-	590	O
administrations	-	595	O
of	-	611	O
theophylline	-	614	O
.	-	626	O

Irrespective	12180796	628	O
of	-	641	O
theophylline	-	644	O
administration	-	657	O
,	-	671	O
iNOS	-	673	O
antigens	-	678	O
were	-	687	O
remarkably	-	692	O
abundant	-	703	O
in	-	712	O
ED	-	715	O
-	-	717	O
1	-	718	O
-	-	719	O
positive	-	720	O
cells	-	729	O
on	-	735	O
day	-	738	O
5	-	742	O
and	-	744	O
8	-	748	O
post	-	750	O
-	-	754	O
fenoldopam	-	755	O
-	-	765	O
infusion	-	766	O
(	-	775	O
DPI	-	776	O
)	-	779	O
;	-	780	O
bFGF	-	782	O
antigens	-	787	O
were	-	796	O
remarkably	-	801	O
abundant	-	812	O
in	-	821	O
ED	-	824	O
-	-	826	O
1	-	827	O
-	-	828	O
positive	-	829	O
cells	-	838	O
on	-	844	O
1	-	847	O
and	-	849	O
3	-	853	O
DPI	-	855	O
;	-	858	O
TGF	-	860	O
-	-	863	O
beta1	-	864	O
antigens	-	870	O
were	-	879	O
observed	-	884	O
in	-	893	O
ED	-	896	O
-	-	898	O
1	-	899	O
-	-	900	O
positive	-	901	O
cells	-	910	O
on	-	916	O
and	-	919	O
after	-	923	O
5	-	929	O
DPI	-	931	O
.	-	934	O

These	12180796	936	O
results	-	942	O
suggest	-	950	O
that	-	958	O
the	-	963	O
peak	-	967	O
expression	-	972	O
of	-	983	O
iNOS	-	986	O
antigen	-	991	O
was	-	999	O
followed	-	1003	O
by	-	1012	O
that	-	1015	O
of	-	1020	O
bFGF	-	1023	O
antigen	-	1028	O
,	-	1035	O
and	-	1037	O
bFGF	-	1041	O
may	-	1046	O
have	-	1050	O
a	-	1055	O
suppressive	-	1057	O
effect	-	1069	O
on	-	1076	O
iNOS	-	1079	O
expression	-	1084	O
in	-	1095	O
these	-	1098	O
rat	-	1104	O
arteritis	-	1108	B
models	-	1118	O
.	-	1124	O

On	12180796	1126	O
the	-	1129	O
other	-	1133	O
hand	-	1139	O
,	-	1143	O
TGF	-	1145	O
-	-	1148	O
beta1	-	1149	O
was	-	1155	O
not	-	1159	O
considered	-	1163	O
to	-	1174	O
have	-	1177	O
a	-	1182	O
suppressive	-	1184	O
effect	-	1196	O
on	-	1203	O
iNOS	-	1206	O
expression	-	1211	O
in	-	1222	O
these	-	1225	O
models	-	1231	O
.	-	1237	O

Low	12109865	0	O
-	-	3	O
molecular	-	4	O
-	-	13	O
weight	-	14	O
heparin	-	21	O
for	-	29	O
the	-	33	O
treatment	-	37	O
of	-	47	O
patients	-	50	O
with	-	59	O
mechanical	-	64	O
heart	-	75	O
valves	-	81	O
.	-	87	O

BACKGROUND	12109865	89	O
:	-	99	O

The	12109865	101	O
interruption	-	105	O
of	-	118	O
oral	-	121	O
anticoagulant	-	126	O
(	-	140	O
OAC	-	141	O
)	-	144	O
administration	-	146	O
is	-	161	O
sometimes	-	164	O
indicated	-	174	O
in	-	184	O
patients	-	187	O
with	-	196	O
mechanical	-	201	O
heart	-	212	O
valves	-	218	O
,	-	224	O
mainly	-	226	O
before	-	233	O
noncardiac	-	240	O
surgery	-	251	O
,	-	258	O
non	-	260	O
-	-	263	O
surgical	-	264	O
interventions	-	273	O
,	-	286	O
and	-	288	O
pregnancy	-	292	O
.	-	301	O

Unfractionated	12109865	303	O
heparin	-	318	O
(	-	326	O
UH	-	327	O
)	-	329	O
is	-	331	O
currently	-	334	O
the	-	344	O
substitute	-	348	O
for	-	359	O
selected	-	363	O
patients	-	372	O
.	-	380	O

Low	12109865	382	O
-	-	385	O
molecular	-	386	O
-	-	395	O
weight	-	396	O
heparin	-	403	O
(	-	411	O
LMWH	-	412	O
)	-	416	O
offers	-	418	O
theoretical	-	425	O
advantages	-	437	O
over	-	448	O
UH	-	453	O
,	-	455	O
but	-	457	O
is	-	461	O
not	-	464	O
currently	-	468	O
considered	-	478	O
in	-	489	O
clinical	-	492	O
guidelines	-	501	O
as	-	512	O
an	-	515	O
alternative	-	518	O
to	-	530	O
UH	-	533	O
in	-	536	O
patients	-	539	O
with	-	548	O
prosthetic	-	553	O
valves	-	564	O
.	-	570	O

HYPOTHESIS	12109865	572	O
:	-	582	O

The	12109865	584	O
aim	-	588	O
of	-	592	O
the	-	595	O
present	-	599	O
study	-	607	O
was	-	613	O
to	-	617	O
review	-	620	O
the	-	627	O
data	-	631	O
accumulated	-	636	O
so	-	648	O
far	-	651	O
on	-	655	O
the	-	658	O
use	-	662	O
of	-	666	O
LMWH	-	669	O
in	-	674	O
this	-	677	O
patient	-	682	O
population	-	690	O
and	-	701	O
to	-	705	O
discuss	-	708	O
its	-	716	O
applicability	-	720	O
in	-	734	O
common	-	737	O
practice	-	744	O
.	-	752	O

METHODS	12109865	754	O
:	-	761	O

For	12109865	763	O
this	-	767	O
paper	-	772	O
,	-	777	O
the	-	779	O
current	-	783	O
medical	-	791	O
literature	-	799	O
on	-	810	O
LMWH	-	813	O
in	-	818	O
patients	-	821	O
with	-	830	O
mechanical	-	835	O
heart	-	846	O
valves	-	852	O
was	-	859	O
extensively	-	863	O
reviewed	-	875	O
.	-	883	O

RESULTS	12109865	885	O
:	-	892	O

There	12109865	894	O
were	-	900	O
eight	-	905	O
series	-	911	O
and	-	918	O
six	-	922	O
case	-	926	O
reports	-	931	O
.	-	938	O

None	12109865	940	O
of	-	945	O
the	-	948	O
studies	-	952	O
was	-	960	O
randomized	-	964	O
,	-	974	O
and	-	976	O
only	-	980	O
one	-	985	O
was	-	989	O
prospective	-	993	O
.	-	1004	O

Data	12109865	1006	O
to	-	1011	O
establish	-	1014	O
the	-	1024	O
thromboembolic	-	1028	B
risk	-	1043	O
were	-	1048	O
incomplete	-	1053	O
.	-	1063	O

After	12109865	1065	O
excluding	-	1071	O
case	-	1081	O
reports	-	1086	O
,	-	1093	O
the	-	1095	O
following	-	1099	O
groups	-	1109	O
were	-	1116	O
constructed	-	1121	O
:	-	1132	O
(	-	1134	O
a	-	1135	O
)	-	1136	O
short	-	1138	O
-	-	1143	O
term	-	1144	O
administration	-	1149	O
,	-	1163	O
after	-	1165	O
valve	-	1171	O
insertion	-	1177	O
(	-	1187	O
n	-	1188	O
=	-	1190	O
212	-	1192	O
)	-	1195	O
;	-	1196	O
(	-	1198	O
b	-	1199	O
)	-	1200	O
short	-	1202	O
-	-	1207	O
term	-	1208	O
,	-	1212	O
perioperative	-	1214	O
(	-	1228	O
noncardiac	-	1229	O
)	-	1239	O
/	-	1240	O
periprocedural	-	1241	O
(	-	1256	O
n	-	1257	O
=	-	1259	O
114	-	1261	O
)	-	1264	O
;	-	1265	O
(	-	1267	O
c	-	1268	O
)	-	1269	O
long	-	1271	O
-	-	1275	O
term	-	1276	O
,	-	1280	O
due	-	1282	O
to	-	1286	O
intolerance	-	1289	O
to	-	1301	O
OAC	-	1304	O
(	-	1308	O
n	-	1309	O
=	-	1311	O
16	-	1313	O
)	-	1315	O
;	-	1316	O
(	-	1318	O
d	-	1319	O
)	-	1320	O
long	-	1322	O
-	-	1326	O
term	-	1327	O
,	-	1331	O
in	-	1333	O
pregnancy	-	1336	O
(	-	1346	O
n	-	1347	O
=	-	1349	O
10	-	1351	O
)	-	1353	O
.	-	1354	O

The	12109865	1356	O
incidence	-	1360	O
rate	-	1370	O
of	-	1375	O
thromboembolism	-	1378	B
was	-	1394	O
0	-	1398	O
.	-	1399	O
9	-	1400	O
%	-	1401	O
for	-	1403	O
all	-	1407	O
the	-	1411	O
studies	-	1415	O
and	-	1423	O
0	-	1427	O
.	-	1428	O
5	-	1429	O
,	-	1430	O
0	-	1432	O
,	-	1433	O
20	-	1435	O
,	-	1437	O
and	-	1439	O
0	-	1443	O
%	-	1444	O
in	-	1446	O
groups	-	1449	O
a	-	1456	O
,	-	1457	O
b	-	1459	O
,	-	1460	O
c	-	1462	O
,	-	1463	O
and	-	1465	O
d	-	1469	O
,	-	1470	O
respectively	-	1472	O
;	-	1484	O
for	-	1486	O
hemorrhage	-	1490	B
,	-	1500	O
the	-	1502	O
overall	-	1506	O
rate	-	1514	O
was	-	1519	O
3	-	1523	O
.	-	1524	O
4	-	1525	O
%	-	1526	O
(	-	1528	O
3	-	1529	O
.	-	1530	O
8	-	1531	O
,	-	1532	O
2	-	1534	O
.	-	1535	O
6	-	1536	O
,	-	1537	O
10	-	1539	O
,	-	1541	O
and	-	1543	O
0	-	1547	O
%	-	1548	O
for	-	1550	O
the	-	1554	O
respective	-	1558	O
groups	-	1569	O
)	-	1575	O
.	-	1576	O

CONCLUSIONS	12109865	1578	O
:	-	1589	O

In	12109865	1591	O
patients	-	1594	O
with	-	1603	O
mechanical	-	1608	O
heart	-	1619	O
valves	-	1625	O
,	-	1631	O
short	-	1633	O
-	-	1638	O
term	-	1639	O
LMWH	-	1644	O
therapy	-	1649	O
compares	-	1657	O
favorably	-	1666	O
with	-	1676	O
UH	-	1681	O
.	-	1683	O

Data	12109865	1685	O
on	-	1690	O
mid	-	1693	O
-	-	1696	O
and	-	1698	O
long	-	1702	O
-	-	1706	O
term	-	1707	O
LMWH	-	1712	O
administration	-	1717	O
in	-	1732	O
these	-	1735	O
patients	-	1741	O
are	-	1750	O
sparse	-	1754	O
.	-	1760	O

Further	12109865	1762	O
randomized	-	1770	O
studies	-	1781	O
are	-	1789	O
needed	-	1793	O
to	-	1800	O
confirm	-	1803	O
the	-	1811	O
safety	-	1815	O
and	-	1822	O
precise	-	1826	O
indications	-	1834	O
for	-	1846	O
the	-	1850	O
use	-	1854	O
of	-	1858	O
LMWH	-	1861	O
in	-	1866	O
patients	-	1869	O
with	-	1878	O
mechanical	-	1883	O
heart	-	1894	O
valves	-	1900	O
.	-	1906	O

Topiramate	12042105	0	O
-	-	10	O
induced	-	11	O
nephrolithiasis	-	19	B
.	-	34	O

Topiramate	12042105	36	O
is	-	47	O
a	-	50	O
recently	-	52	O
developed	-	61	O
antiepileptic	-	71	O
medication	-	85	O
that	-	96	O
is	-	101	O
becoming	-	104	O
more	-	113	O
widely	-	118	O
prescribed	-	125	O
because	-	136	O
of	-	144	O
its	-	147	O
efficacy	-	151	O
in	-	160	O
treating	-	163	O
refractory	-	172	B
seizures	-	183	I
.	-	191	O

Urologists	12042105	193	O
should	-	204	O
be	-	211	O
aware	-	214	O
that	-	220	O
this	-	225	O
medication	-	230	O
can	-	241	O
cause	-	245	O
metabolic	-	251	B
acidosis	-	261	I
in	-	270	O
patients	-	273	O
secondary	-	282	O
to	-	292	O
inhibition	-	295	O
of	-	306	O
carbonic	-	309	O
anhydrase	-	318	O
.	-	327	O

In	12042105	329	O
addition	-	332	O
,	-	340	O
a	-	342	O
distal	-	344	O
tubular	-	351	O
acidification	-	359	O
defect	-	373	O
may	-	380	O
result	-	384	O
,	-	390	O
thus	-	392	O
impairing	-	397	O
the	-	407	O
normal	-	411	O
compensatory	-	418	O
drop	-	431	O
in	-	436	O
urine	-	439	O
pH	-	445	O
.	-	447	O
These	-	449	O
factors	-	455	O
can	-	463	O
lead	-	467	O
to	-	472	O
the	-	475	O
development	-	479	O
of	-	491	O
calcium	-	494	O
phosphate	-	502	O
nephrolithiasis	-	512	B
.	-	527	O

We	12042105	529	O
report	-	532	O
the	-	539	O
first	-	543	O
two	-	549	O
cases	-	553	O
of	-	559	O
topiramate	-	562	O
-	-	572	O
induced	-	573	O
nephrolithiasis	-	581	B
in	-	597	O
the	-	600	O
urologic	-	604	O
literature	-	613	O
.	-	623	O

Spironolactone	11868798	0	O
:	-	14	O
is	-	16	O
it	-	19	O
a	-	22	O
novel	-	24	O
drug	-	30	O
for	-	35	O
the	-	39	O
prevention	-	43	O
of	-	54	O
amphotericin	-	57	O
B	-	70	O
-	-	71	O
related	-	72	O
hypokalemia	-	80	B
in	-	92	O
cancer	-	95	B
patients	-	102	O
?	-	110	O

OBJECTIVE	11868798	112	O
:	-	121	O
Nephrotoxicity	-	123	B
is	-	138	O
the	-	141	O
major	-	145	O
adverse	-	151	O
effect	-	159	O
of	-	166	O
amphotericin	-	169	O
B	-	182	O
(	-	184	O
AmB	-	185	O
)	-	188	O
,	-	189	O
often	-	191	O
limiting	-	197	O
administration	-	206	O
of	-	221	O
full	-	224	O
dosage	-	229	O
.	-	235	O

Selective	11868798	237	O
distal	-	247	O
tubular	-	254	O
epithelial	-	262	O
toxicity	-	273	B
seems	-	282	O
to	-	288	O
be	-	291	O
responsible	-	294	O
for	-	306	O
the	-	310	O
profound	-	314	O
potassium	-	323	O
wasting	-	333	O
that	-	341	O
is	-	346	O
a	-	349	O
major	-	351	O
clinical	-	357	O
side	-	366	O
effect	-	371	O
of	-	378	O
treatment	-	381	O
with	-	391	O
AmB	-	396	O
.	-	399	O
Potassium	-	401	O
depletion	-	411	O
also	-	421	O
potentiates	-	426	O
the	-	438	O
tubular	-	442	O
toxicity	-	450	B
of	-	459	O
AmB	-	462	O
.	-	465	O

This	11868798	467	O
study	-	472	O
was	-	478	O
designed	-	482	O
to	-	491	O
assess	-	494	O
the	-	501	O
ability	-	505	O
of	-	513	O
spironolactone	-	516	O
to	-	531	O
reduce	-	534	O
potassium	-	541	O
requirements	-	551	O
and	-	564	O
to	-	568	O
prevent	-	571	O
hypokalemia	-	579	B
in	-	591	O
neutropenic	-	594	B
patients	-	606	O
on	-	615	O
AmB	-	618	O
treatment	-	622	O
.	-	631	O

METHODS	11868798	633	O
:	-	640	O

In	11868798	642	O
this	-	645	O
study	-	650	O
26	-	656	O
patients	-	659	O
with	-	668	O
various	-	673	O
hematological	-	681	B
disorders	-	695	I
were	-	705	O
randomized	-	710	O
to	-	721	O
receive	-	724	O
either	-	732	O
intravenous	-	739	O
AmB	-	751	O
alone	-	755	O
or	-	761	O
AmB	-	764	O
and	-	768	O
oral	-	772	O
spironolactone	-	777	O
100	-	792	O
mg	-	796	O
twice	-	799	O
daily	-	805	O
when	-	811	O
developing	-	816	O
a	-	827	O
proven	-	829	O
or	-	836	O
suspected	-	839	O
fungal	-	849	B
infection	-	856	I
.	-	865	O

RESULTS	11868798	867	O
:	-	874	O

Patients	11868798	876	O
receiving	-	885	O
concomitant	-	895	O
AmB	-	907	O
and	-	911	O
spironolactone	-	915	O
had	-	930	O
significantly	-	934	O
higher	-	948	O
plasma	-	955	O
potassium	-	962	O
levels	-	972	O
than	-	979	O
those	-	984	O
receiving	-	990	O
AmB	-	1000	O
alone	-	1004	O
(	-	1010	O
P	-	1011	O
=	-	1013	O
0	-	1015	O
.	-	1016	O
0027	-	1017	O
)	-	1021	O
.	-	1022	O

Those	11868798	1024	O
patients	-	1030	O
receiving	-	1039	O
AmB	-	1049	O
and	-	1053	O
spironolactone	-	1057	O
required	-	1072	O
significantly	-	1081	O
less	-	1095	O
potassium	-	1100	O
supplementation	-	1110	O
to	-	1126	O
maintain	-	1129	O
their	-	1138	O
plasma	-	1144	O
potassium	-	1151	O
within	-	1161	O
the	-	1168	O
normal	-	1172	O
range	-	1179	O
(	-	1185	O
P	-	1186	O
=	-	1188	O
0	-	1190	O
.	-	1191	O
022	-	1192	O
)	-	1195	O
.	-	1196	O

Moreover	11868798	1198	O
,	-	1206	O
urinary	-	1208	O
potassium	-	1216	O
losses	-	1226	O
were	-	1233	O
significantly	-	1238	O
less	-	1252	O
in	-	1257	O
patients	-	1260	O
receiving	-	1269	O
AmB	-	1279	O
and	-	1283	O
spironolactone	-	1287	O
than	-	1302	O
those	-	1307	O
receiving	-	1313	O
AmB	-	1323	O
alone	-	1327	O
(	-	1333	O
P	-	1334	O
=	-	1336	O
0	-	1338	O
.	-	1339	O
040	-	1340	O
)	-	1343	O
.	-	1344	O

CONCLUSION	11868798	1346	O
:	-	1356	O

This	11868798	1358	O
study	-	1363	O
showed	-	1369	O
that	-	1376	O
spironolactone	-	1381	O
can	-	1396	O
reduce	-	1400	O
potassium	-	1407	O
requirements	-	1417	O
and	-	1430	O
prevent	-	1434	O
hypokalemia	-	1442	B
by	-	1454	O
reducing	-	1457	O
urinary	-	1466	O
potassium	-	1474	O
loss	-	1484	O
in	-	1489	O
neutropenic	-	1492	B
patients	-	1504	O
on	-	1513	O
AmB	-	1516	O
treatment	-	1520	O
.	-	1529	O

Dopamine	11860278	0	O
D2	-	9	O
receptor	-	12	O
signaling	-	21	O
controls	-	31	O
neuronal	-	40	O
cell	-	49	O
death	-	54	O
induced	-	60	O
by	-	68	O
muscarinic	-	71	O
and	-	82	O
glutamatergic	-	86	O
drugs	-	100	O
.	-	105	O

Dopamine	11860278	107	O
(	-	116	O
DA	-	117	O
)	-	119	O
,	-	120	O
through	-	122	O
D1	-	130	O
/	-	132	O
D2	-	133	O
receptor	-	136	O
-	-	144	O
mediated	-	145	O
signaling	-	154	O
,	-	163	O
plays	-	165	O
a	-	171	O
major	-	173	O
role	-	179	O
in	-	184	O
the	-	187	O
control	-	191	O
of	-	199	O
epileptic	-	202	B
seizures	-	212	I
arising	-	221	O
in	-	229	O
the	-	232	O
limbic	-	236	O
system	-	243	O
.	-	249	O

Excitotoxicity	11860278	251	B
leading	-	266	O
to	-	274	O
neuronal	-	277	O
cell	-	286	O
death	-	291	O
in	-	297	O
the	-	300	O
affected	-	304	O
areas	-	313	O
is	-	319	O
a	-	322	O
major	-	324	O
consequence	-	330	O
of	-	342	O
seizures	-	345	B
at	-	354	O
the	-	357	O
cellular	-	361	O
level	-	370	O
.	-	375	O

In	11860278	377	O
this	-	380	O
respect	-	385	O
,	-	392	O
little	-	394	O
is	-	401	O
known	-	404	O
about	-	410	O
the	-	416	O
role	-	420	O
of	-	425	O
DA	-	428	O
receptors	-	431	O
in	-	441	O
the	-	444	O
occurrence	-	448	O
of	-	459	O
epilepsy	-	462	B
-	-	470	O
induced	-	471	O
neuronal	-	479	O
cell	-	488	O
death	-	493	O
.	-	498	O

Here	11860278	500	O
we	-	505	O
analyze	-	508	O
the	-	516	O
occurrence	-	520	O
of	-	531	O
seizures	-	534	B
and	-	543	O
neurotoxicity	-	547	B
in	-	561	O
D2R	-	564	O
-	-	568	O
/	-	569	O
-	-	570	O
mice	-	572	O
treated	-	577	O
with	-	585	O
the	-	590	O
cholinergic	-	594	O
agonist	-	606	O
pilocarpine	-	614	O
.	-	625	O

We	11860278	627	O
compared	-	630	O
these	-	639	O
results	-	645	O
with	-	653	O
those	-	658	O
previously	-	664	O
obtained	-	675	O
with	-	684	O
kainic	-	689	O
acid	-	696	O
(	-	701	O
KA	-	702	O
)	-	704	O
,	-	705	O
a	-	707	O
potent	-	709	O
glutamate	-	716	O
agonist	-	726	O
.	-	733	O

Importantly	11860278	735	O
,	-	746	O
D2R	-	748	O
-	-	752	O
/	-	753	O
-	-	754	O
mice	-	756	O
develop	-	761	O
seizures	-	769	B
at	-	778	O
doses	-	781	O
of	-	787	O
both	-	790	O
drugs	-	795	O
that	-	801	O
are	-	806	O
not	-	810	O
epileptogenic	-	814	O
for	-	828	O
WT	-	832	O
littermates	-	835	O
and	-	847	O
show	-	851	O
greater	-	856	O
neurotoxicity	-	864	B
.	-	877	O

However	11860278	879	O
,	-	886	O
pilocarpine	-	888	O
-	-	899	O
induced	-	900	O
seizures	-	908	B
result	-	917	O
in	-	924	O
a	-	927	O
more	-	929	O
widespread	-	934	O
neuronal	-	945	O
death	-	954	O
in	-	960	O
both	-	963	O
WT	-	968	O
and	-	971	O
D2R	-	975	O
-	-	979	O
/	-	980	O
-	-	981	O
brains	-	983	O
in	-	990	O
comparison	-	993	O
to	-	1004	O
KA	-	1007	O
.	-	1009	O

Thus	11860278	1011	O
,	-	1015	O
the	-	1017	O
absence	-	1021	O
of	-	1029	O
D2R	-	1032	O
lowers	-	1036	O
the	-	1043	O
threshold	-	1047	O
for	-	1057	O
seizures	-	1061	B
induced	-	1070	O
by	-	1078	O
both	-	1081	O
glutamate	-	1086	O
and	-	1096	O
acetylcholine	-	1100	O
.	-	1113	O

Moreover	11860278	1115	O
,	-	1123	O
the	-	1125	O
dopaminergic	-	1129	O
control	-	1142	O
of	-	1150	O
epilepsy	-	1153	B
-	-	1161	O
induced	-	1162	O
neurodegeneration	-	1170	B
seems	-	1188	O
to	-	1194	O
be	-	1197	O
mediated	-	1200	O
by	-	1209	O
distinct	-	1212	O
interactions	-	1221	O
of	-	1234	O
D2R	-	1237	O
signaling	-	1241	O
with	-	1251	O
these	-	1256	O
two	-	1262	O
neurotransmitters	-	1266	O
.	-	1283	O

Treatment	11838826	0	O
of	-	10	O
risperidone	-	13	O
-	-	24	O
induced	-	25	O
hyperprolactinemia	-	33	B
with	-	52	O
a	-	57	O
dopamine	-	59	O
agonist	-	68	O
in	-	76	O
children	-	79	O
.	-	87	O

BACKGROUND	11838826	89	O
:	-	99	O

Risperidone	11838826	101	O
,	-	112	O
a	-	114	O
potent	-	116	O
antagonist	-	123	O
of	-	134	O
both	-	137	O
serotonergic	-	142	O
(	-	155	O
5HT2A	-	156	O
)	-	161	O
and	-	163	O
dopaminergic	-	167	O
D2	-	180	O
receptors	-	183	O
is	-	193	O
associated	-	196	O
with	-	207	O
hyperprolactinemia	-	212	B
in	-	231	O
adults	-	234	O
and	-	241	O
children	-	245	O
.	-	253	O

Chronically	11838826	255	O
elevated	-	267	O
prolactin	-	276	O
levels	-	286	O
in	-	293	O
children	-	296	O
with	-	305	O
prolactinomas	-	310	B
may	-	324	O
be	-	328	O
associated	-	331	O
with	-	342	O
arrested	-	347	O
growth	-	356	O
and	-	363	O
development	-	367	O
resulting	-	379	O
in	-	389	O
either	-	392	O
delayed	-	399	B
puberty	-	407	I
or	-	415	O
short	-	418	O
stature	-	424	O
.	-	431	O

These	11838826	433	O
possibilities	-	439	O
stress	-	453	O
the	-	460	O
importance	-	464	O
of	-	475	O
developing	-	478	O
a	-	489	O
safe	-	491	O
and	-	496	O
effective	-	500	O
approach	-	510	O
to	-	519	O
drug	-	522	O
-	-	526	O
induced	-	527	O
hyperprolactinemia	-	535	B
in	-	554	O
youth	-	557	O
.	-	562	O

We	11838826	564	O
report	-	567	O
the	-	574	O
successful	-	578	O
treatment	-	589	O
of	-	599	O
risperidone	-	602	O
-	-	613	O
induced	-	614	O
hyperprolactinemia	-	622	B
with	-	641	O
cabergoline	-	646	O
in	-	658	O
youth	-	661	O
.	-	666	O

METHODS	11838826	668	O
:	-	675	O

We	11838826	677	O
undertook	-	680	O
a	-	690	O
retrospective	-	692	O
case	-	706	O
review	-	711	O
of	-	718	O
four	-	721	O
children	-	726	O
with	-	735	O
risperidone	-	740	O
-	-	751	O
induced	-	752	O
hyperprolactinemia	-	760	B
treated	-	779	O
with	-	787	O
cabergoline	-	792	O
.	-	803	O

RESULTS	11838826	805	O
:	-	812	O

Four	11838826	814	O
males	-	819	O
(	-	825	O
age	-	826	O
6	-	830	O
-	-	831	O
11	-	832	O
years	-	835	O
)	-	840	O
with	-	842	O
Diagnostic	-	847	O
and	-	858	O
Statistical	-	862	O
Manual	-	874	O
of	-	881	O
Mental	-	884	B
Disorders	-	891	I
(	-	901	O
fourth	-	902	O
edition	-	909	O
)	-	916	O
bipolar	-	918	B
disorder	-	926	I
or	-	935	O
psychoses	-	938	B
,	-	947	O
with	-	949	O
risperidone	-	954	O
-	-	965	O
induced	-	966	O
elevations	-	974	O
in	-	985	O
serum	-	988	O
prolactin	-	994	O
levels	-	1004	O
(	-	1011	O
57	-	1012	O
.	-	1014	O
5	-	1015	O
-	-	1016	O
129	-	1017	O
ng	-	1021	O
/	-	1023	O
mL	-	1024	O
,	-	1026	O
normal	-	1028	O
5	-	1035	O
-	-	1036	O
15	-	1037	O
ng	-	1040	O
/	-	1042	O
mL	-	1043	O
)	-	1045	O
,	-	1046	O
were	-	1048	O
treated	-	1053	O
with	-	1061	O
cabergoline	-	1066	O
(	-	1078	O
mean	-	1079	O
dose	-	1084	O
2	-	1089	O
.	-	1090	O
13	-	1091	O
+	-	1094	O
/	-	1095	O
-	-	1096	O

0	11838826	1098	O
.	-	1099	O
09	-	1100	O
mg	-	1103	O
/	-	1105	O
week	-	1106	O
)	-	1110	O
.	-	1111	O

When	11838826	1113	O
serum	-	1118	O
prolactin	-	1124	O
levels	-	1134	O
normalized	-	1141	O
in	-	1152	O
all	-	1155	O
four	-	1159	O
subjects	-	1164	O
(	-	1173	O
mean	-	1174	O
11	-	1179	O
.	-	1181	O
2	-	1182	O
+	-	1184	O
/	-	1185	O
-	-	1186	O

10	11838826	1188	O
.	-	1190	O
9	-	1191	O
ng	-	1193	O
/	-	1195	O
mL	-	1196	O
)	-	1198	O
,	-	1199	O
the	-	1201	O
cabergoline	-	1205	O
dose	-	1217	O
was	-	1222	O
reduced	-	1226	O
to	-	1234	O
1	-	1237	O
mg	-	1239	O
/	-	1241	O
week	-	1242	O
in	-	1247	O
three	-	1250	O
of	-	1256	O
four	-	1259	O
subjects	-	1264	O
.	-	1272	O

The	11838826	1274	O
mean	-	1278	O
duration	-	1283	O
of	-	1292	O
therapy	-	1295	O
with	-	1303	O
cabergoline	-	1308	O
was	-	1320	O
523	-	1324	O
.	-	1327	O
5	-	1328	O
+	-	1330	O
/	-	1331	O
-	-	1332	O

129	11838826	1334	O
.	-	1337	O
7	-	1338	O
days	-	1340	O
,	-	1344	O
and	-	1346	O
the	-	1350	O
mean	-	1354	O
duration	-	1359	O
of	-	1368	O
therapy	-	1371	O
with	-	1379	O
risperidone	-	1384	O
was	-	1396	O
788	-	1400	O
.	-	1403	O
5	-	1404	O
+	-	1406	O
/	-	1407	O
-	-	1408	O

162	11838826	1410	O
.	-	1413	O
5	-	1414	O
days	-	1416	O
.	-	1420	O

Cabergoline	11838826	1422	O
was	-	1434	O
well	-	1438	O
tolerated	-	1443	O
without	-	1453	O
adverse	-	1461	O
effects	-	1469	O
.	-	1476	O

CONCLUSIONS	11838826	1478	O
:	-	1489	O

Cabergoline	11838826	1491	O
may	-	1503	O
be	-	1507	O
useful	-	1510	O
for	-	1517	O
the	-	1521	O
treatment	-	1525	O
of	-	1535	O
risperidone	-	1538	O
-	-	1549	O
induced	-	1550	O
hyperprolactinemia	-	1558	B
in	-	1577	O
youth	-	1580	O
;	-	1585	O
however	-	1587	O
,	-	1594	O
further	-	1596	O
research	-	1604	O
is	-	1613	O
needed	-	1616	O
.	-	1622	O

Cholestatic	11467664	0	B
jaundice	-	12	I
associated	-	21	O
with	-	32	O
the	-	37	O
use	-	41	O
of	-	45	O
metformin	-	48	O
.	-	57	O

We	11467664	59	O
report	-	62	O
a	-	69	O
patient	-	71	O
who	-	79	O
developed	-	83	O
cholestatic	-	93	B
jaundice	-	105	I
shortly	-	114	O
after	-	122	O
initiation	-	128	O
of	-	139	O
treatment	-	142	O
with	-	152	O
metformin	-	157	O
hydrochloride	-	167	O
.	-	180	O

Ultrasound	11467664	182	O
of	-	193	O
the	-	196	O
liver	-	200	O
and	-	206	O
abdominal	-	210	O
CT	-	220	O
were	-	223	O
normal	-	228	O
.	-	234	O

An	11467664	236	O
ERCP	-	239	O
showed	-	244	O
normal	-	251	O
biliary	-	258	O
anatomy	-	266	O
.	-	273	O

A	11467664	275	O
percutaneous	-	277	O
liver	-	290	O
biopsy	-	296	O
was	-	303	O
obtained	-	307	O
showing	-	316	O
marked	-	324	O
cholestasis	-	331	B
,	-	342	O
with	-	344	O
portal	-	349	O
edema	-	356	B
,	-	361	O
ductular	-	363	O
proliferation	-	372	O
,	-	385	O
and	-	387	O
acute	-	391	O
inflammation	-	397	B
.	-	409	O

Metformin	11467664	411	O
hydrochloride	-	421	O
was	-	435	O
discontinued	-	439	O
,	-	451	O
and	-	453	O
the	-	457	O
patient	-	461	O
's	-	468	O
jaundice	-	471	B
resolved	-	480	O
slowly	-	489	O
over	-	496	O
a	-	501	O
period	-	503	O
of	-	510	O
several	-	513	O
months	-	521	O
.	-	527	O

Given	11467664	529	O
the	-	535	O
onset	-	539	O
of	-	545	O
his	-	548	O
jaundice	-	552	B
2	-	561	O
wk	-	563	O
after	-	566	O
the	-	572	O
initiation	-	576	O
of	-	587	O
metformin	-	590	O
,	-	599	O
we	-	601	O
believe	-	604	O
that	-	612	O
this	-	617	O
case	-	622	O
represents	-	627	O
an	-	638	O
example	-	641	O
of	-	649	O
metformin	-	652	O
-	-	661	O
associated	-	662	O
hepatotoxicity	-	673	B
,	-	687	O
the	-	689	O
first	-	693	O
such	-	699	O
case	-	704	O
reported	-	709	O
.	-	717	O

Electro	11077455	0	O
-	-	7	O
oculography	-	8	O
,	-	19	O
electroretinography	-	21	O
,	-	40	O
visual	-	42	O
evoked	-	49	O
potentials	-	56	O
,	-	66	O
and	-	68	O
multifocal	-	72	O
electroretinography	-	83	O
in	-	103	O
patients	-	106	O
with	-	115	O
vigabatrin	-	120	O
-	-	130	O
attributed	-	131	O
visual	-	142	B
field	-	149	I
constriction	-	155	I
.	-	167	O

PURPOSE	11077455	169	O
:	-	176	O

Symptomatic	11077455	178	O
visual	-	190	B
field	-	197	I
constriction	-	203	I
thought	-	216	O
to	-	224	O
be	-	227	O
associated	-	230	O
with	-	241	O
vigabatrin	-	246	O
has	-	257	O
been	-	261	O
reported	-	266	O
.	-	274	O

The	11077455	276	O
current	-	280	O
study	-	288	O
investigated	-	294	O
the	-	307	O
visual	-	311	O
fields	-	318	O
and	-	325	O
visual	-	329	O
electrophysiology	-	336	O
of	-	354	O
eight	-	357	O
patients	-	363	O
with	-	372	O
known	-	377	O
vigabatrin	-	383	O
-	-	393	O
attributed	-	394	O
visual	-	405	B
field	-	412	I
loss	-	418	I
,	-	422	O
three	-	424	O
of	-	430	O
whom	-	433	O
were	-	438	O
reported	-	443	O
previously	-	452	O
.	-	462	O

Six	11077455	464	O
of	-	468	O
the	-	471	O
patients	-	475	O
were	-	484	O
no	-	489	O
longer	-	492	O
receiving	-	499	O
vigabatrin	-	509	O
.	-	519	O

METHODS	11077455	521	O
:	-	528	O

The	11077455	530	O
central	-	534	O
and	-	542	O
peripheral	-	546	O
fields	-	557	O
were	-	564	O
examined	-	569	O
with	-	578	O
the	-	583	O
Humphrey	-	587	O
Visual	-	596	O
Field	-	603	O
Analyzer	-	609	O
.	-	617	O

Full	11077455	619	O
visual	-	624	O
electrophysiology	-	631	O
,	-	648	O
including	-	650	O
flash	-	660	O
electroretinography	-	666	O
(	-	686	O
ERG	-	687	O
)	-	690	O
,	-	691	O
pattern	-	693	O
electroretinography	-	701	O
,	-	720	O
multifocal	-	722	O
ERG	-	733	O
using	-	737	O
the	-	743	O
VERIS	-	747	O
system	-	753	O
,	-	759	O
electro	-	761	O
-	-	768	O
oculography	-	769	O
,	-	780	O
and	-	782	O
flash	-	786	O
and	-	792	O
pattern	-	796	O
visual	-	804	O
evoked	-	811	O
potentials	-	818	O
,	-	828	O
was	-	830	O
undertaken	-	834	O
.	-	844	O

RESULTS	11077455	846	O
:	-	853	O

Seven	11077455	855	O
patients	-	861	O
showed	-	870	O
marked	-	877	O
visual	-	884	B
field	-	891	I
constriction	-	897	I
with	-	910	O
some	-	915	O
sparing	-	920	O
of	-	928	O
the	-	931	O
temporal	-	935	O
visual	-	944	O
field	-	951	O
.	-	956	O

The	11077455	958	O
eighth	-	962	O
exhibited	-	969	O
concentric	-	979	O
constriction	-	990	O
.	-	1002	O

Most	11077455	1004	O
electrophysiological	-	1009	O
responses	-	1030	O
were	-	1040	O
usually	-	1045	O
just	-	1053	O
within	-	1058	O
normal	-	1065	O
limits	-	1072	O
;	-	1078	O
two	-	1080	O
patients	-	1084	O
had	-	1093	O
subnormal	-	1097	O
Arden	-	1107	O
electro	-	1113	O
-	-	1120	O
oculography	-	1121	O
indices	-	1133	O
;	-	1140	O
and	-	1142	O
one	-	1146	O
patient	-	1150	O
showed	-	1158	O
an	-	1165	O
abnormally	-	1168	O
delayed	-	1179	O
photopic	-	1187	O
b	-	1196	O
wave	-	1198	O
.	-	1202	O

However	11077455	1204	O
,	-	1211	O
five	-	1213	O
patients	-	1218	O
showed	-	1227	O
delayed	-	1234	O
30	-	1242	O
-	-	1244	O
Hz	-	1245	O
flicker	-	1248	O
b	-	1256	O
waves	-	1258	O
,	-	1263	O
and	-	1265	O
seven	-	1269	O
patients	-	1275	O
showed	-	1284	O
delayed	-	1291	O
oscillatory	-	1299	O
potentials	-	1311	O
.	-	1321	O

Multifocal	11077455	1323	O
ERG	-	1334	O
showed	-	1338	O
abnormalities	-	1345	O
that	-	1359	O
sometimes	-	1364	O
correlated	-	1374	O
with	-	1385	O
the	-	1390	O
visual	-	1394	O
field	-	1401	O
appearance	-	1407	O
and	-	1418	O
confirmed	-	1422	O
that	-	1432	O
the	-	1437	O
deficit	-	1441	O
occurs	-	1449	O
at	-	1456	O
the	-	1459	O
retinal	-	1463	O
level	-	1471	O
.	-	1476	O

CONCLUSION	11077455	1478	O
:	-	1488	O

Marked	11077455	1490	O
visual	-	1497	B
field	-	1504	I
constriction	-	1510	I
appears	-	1523	O
to	-	1531	O
be	-	1534	O
associated	-	1537	O
with	-	1548	O
vigabatrin	-	1553	O
therapy	-	1564	O
.	-	1571	O

The	11077455	1573	O
field	-	1577	O
defects	-	1583	O
and	-	1591	O
some	-	1595	O
electrophysiological	-	1600	O
abnormalities	-	1621	O
persist	-	1635	O
when	-	1643	O
vigabatrin	-	1648	O
therapy	-	1659	O
is	-	1667	O
withdrawn	-	1670	O
.	-	1679	O

Conversion	11063349	0	O
to	-	11	O
rapamycin	-	14	O
immunosuppression	-	24	O
in	-	42	O
renal	-	45	O
transplant	-	51	O
recipients	-	62	O
:	-	72	O
report	-	74	O
of	-	81	O
an	-	84	O
initial	-	87	O
experience	-	95	O
.	-	105	O

BACKGROUND	11063349	107	O
:	-	117	O

The	11063349	119	O
aim	-	123	O
of	-	127	O
this	-	130	O
study	-	135	O
is	-	141	O
to	-	144	O
evaluate	-	147	O
the	-	156	O
effects	-	160	O
of	-	168	O
RAPA	-	171	O
conversion	-	176	O
in	-	187	O
patients	-	190	O
undergoing	-	199	O
cyclosporine	-	210	O
(	-	223	O
CsA	-	224	O
)	-	227	O
or	-	229	O
tacrolimus	-	232	O
(	-	243	O
Tac	-	244	O
)	-	247	O
toxicity	-	249	B
.	-	257	O

METHODS	11063349	259	O
:	-	266	O

Twenty	11063349	268	O
renal	-	275	O
transplant	-	281	O
recipients	-	292	O
were	-	303	O
switched	-	308	O
to	-	317	O
fixed	-	320	O
dose	-	326	O
rapamycin	-	331	O
(	-	341	O
RAPA	-	342	O
)	-	346	O
(	-	348	O
5	-	349	O
mg	-	351	O
/	-	353	O
day	-	354	O
)	-	357	O
0	-	359	O
to	-	361	O
204	-	364	O
months	-	368	O
posttransplant	-	375	O
.	-	389	O

Drug	11063349	391	O
monitoring	-	396	O
was	-	407	O
not	-	411	O
initially	-	415	O
used	-	425	O
to	-	430	O
adjust	-	433	O
doses	-	440	O
.	-	445	O

The	11063349	447	O
indications	-	451	O
for	-	463	O
switch	-	467	O
were	-	474	O
chronic	-	479	O
CsA	-	487	O
or	-	491	O
Tac	-	494	O
nephrotoxicity	-	498	B
(	-	513	O
12	-	514	O
)	-	516	O
,	-	517	O
acute	-	519	O
CsA	-	525	O
or	-	529	O
Tac	-	532	O
toxicity	-	536	B
(	-	545	O
3	-	546	O
)	-	547	O
,	-	548	O
severe	-	550	O
facial	-	557	B
dysmorphism	-	564	I
(	-	576	O
2	-	577	O
)	-	578	O
,	-	579	O
posttransplant	-	581	B
lymphoproliferative	-	596	I
disorder	-	616	I
(	-	625	O
PTLD	-	626	B
)	-	630	O
in	-	632	O
remission	-	635	O
(	-	645	O
2	-	646	O
)	-	647	O
,	-	648	O
and	-	650	O
hepatotoxicity	-	654	B
in	-	669	O
1	-	672	O
.	-	673	O

Follow	11063349	675	O
-	-	681	O
up	-	682	O
is	-	685	O
7	-	688	O
to	-	690	O
24	-	693	O
months	-	696	O
.	-	702	O

RESULTS	11063349	704	O
:	-	711	O

In	11063349	713	O
the	-	716	O
12	-	720	O
patients	-	723	O
switched	-	732	O
because	-	741	O
of	-	749	O
chronic	-	752	O
nephrotoxicity	-	760	B
there	-	775	O
was	-	781	O
a	-	785	O
significant	-	787	O
decrease	-	799	O
in	-	808	O
serum	-	811	O
creatinine	-	817	O

[	11063349	828	O
233	-	829	O
+	-	832	O
/	-	833	O
-	-	834	O
34	-	835	O
to	-	838	O
210	-	841	O
+	-	844	O
/	-	845	O
-	-	846	O
56	-	847	O
micromol	-	850	O
/	-	858	O
liter	-	859	O
(	-	865	O
P	-	866	O
<	-	867	O
0	-	868	O
.	-	869	O
05	-	870	O
)	-	872	O
at	-	874	O
6	-	877	O
months	-	879	O
]	-	885	O
.	-	886	O

Facial	11063349	888	B
dysmorphism	-	895	I
improved	-	907	O
in	-	916	O
two	-	919	O
patients	-	923	O
.	-	931	O

No	11063349	933	O
relapse	-	936	O
of	-	944	O
PTLD	-	947	B
was	-	952	O
observed	-	956	O
.	-	964	O

Five	11063349	966	O
patients	-	971	O
developed	-	980	O
pneumonia	-	990	B
(	-	1000	O
two	-	1001	O
Pneumocystis	-	1005	B
carinii	-	1018	I
pneumonia	-	1026	I
,	-	1035	O
one	-	1037	O
infectious	-	1041	B
mononucleosis	-	1052	I
with	-	1066	O
polyclonal	-	1071	O
PTLD	-	1082	B
lung	-	1087	O
infiltrate	-	1092	O
)	-	1102	O
and	-	1104	O
two	-	1108	O
had	-	1112	O
bronchiolitis	-	1116	B
obliterans	-	1130	I
.	-	1140	O

There	11063349	1142	O
were	-	1148	O
no	-	1153	O
deaths	-	1156	O
.	-	1162	O

RAPA	11063349	1164	O
was	-	1169	O
discontinued	-	1173	O
in	-	1186	O
four	-	1189	O
patients	-	1194	O
,	-	1202	O
because	-	1204	O
of	-	1212	O
pneumonia	-	1215	B
in	-	1225	O
two	-	1228	O
,	-	1231	O
PTLD	-	1233	B
in	-	1238	O
one	-	1241	O
,	-	1244	O
and	-	1246	O
oral	-	1250	O
aphtous	-	1255	B
ulcers	-	1263	I
in	-	1270	O
one	-	1273	O
.	-	1276	O

RAPA	11063349	1278	O
levels	-	1283	O
were	-	1290	O
high	-	1295	O
(	-	1300	O
>	-	1301	O
15	-	1302	O
ng	-	1305	O
/	-	1307	O
ml	-	1308	O
)	-	1310	O
in	-	1312	O
7	-	1315	O
of	-	1317	O
13	-	1320	O
(	-	1323	O
54	-	1324	O
%	-	1326	O
)	-	1327	O
patients	-	1329	O
.	-	1337	O

CONCLUSIONS	11063349	1339	O
:	-	1350	O

RAPA	11063349	1352	O
conversion	-	1357	O
provides	-	1368	O
adequate	-	1377	O
immunosuppression	-	1386	O
to	-	1404	O
enable	-	1407	O
CsA	-	1414	O
withdrawal	-	1418	O
.	-	1428	O

However	11063349	1430	O
,	-	1437	O
when	-	1439	O
converting	-	1444	O
patients	-	1455	O
to	-	1464	O
RAPA	-	1467	O
drug	-	1472	O
levels	-	1477	O
should	-	1484	O
be	-	1491	O
monitored	-	1494	O
to	-	1504	O
avoid	-	1507	O
over	-	1513	O
-	-	1517	O
immunosuppression	-	1518	O
and	-	1536	O
adequate	-	1540	O
antiviral	-	1549	O
and	-	1559	O
Pneumocystis	-	1563	B
carinii	-	1576	I
pneumonia	-	1584	I
prophylaxis	-	1594	O
should	-	1606	O
be	-	1613	O
given	-	1616	O
.	-	1621	O

Worsening	10091616	0	O
of	-	10	O
levodopa	-	13	O
-	-	21	O
induced	-	22	O
dyskinesias	-	30	B
by	-	42	O
motor	-	45	O
and	-	51	O
mental	-	55	O
tasks	-	62	O
.	-	67	O

Ten	10091616	69	O
patients	-	73	O
who	-	82	O
had	-	86	O
Parkinson	-	90	B
's	-	99	I
disease	-	102	I
with	-	110	O
disabling	-	115	O
dyskinesia	-	125	B
were	-	136	O
included	-	141	O
in	-	150	O
this	-	153	O
study	-	158	O
to	-	164	O
evaluate	-	167	O
the	-	176	O
role	-	180	O
of	-	185	O
mental	-	188	O
(	-	195	O
mental	-	196	O
calculation	-	203	O
)	-	214	O
and	-	216	O
motor	-	220	O
(	-	226	O
flexion	-	227	O
/	-	234	O
extension	-	235	O
of	-	245	O
right	-	248	O
fingers	-	254	O
,	-	261	O
flexion	-	263	O
/	-	270	O
extension	-	271	O
of	-	281	O
left	-	284	O
fingers	-	289	O
,	-	296	O
flexion	-	298	O
/	-	305	O
extension	-	306	O
of	-	316	O
the	-	319	O
neck	-	323	O
,	-	327	O
speaking	-	329	O
aloud	-	338	O
)	-	343	O
tasks	-	345	O
on	-	351	O
the	-	354	O
worsening	-	358	O
of	-	368	O
peak	-	371	O
-	-	375	O
dose	-	376	O
dyskinesia	-	381	B
following	-	392	O
administration	-	402	O
of	-	417	O
an	-	420	O
effective	-	423	O
single	-	433	O
dose	-	440	O
of	-	445	O
apomorphine	-	448	O
.	-	459	O

Compared	10091616	461	O
with	-	470	O
the	-	475	O
score	-	479	O
at	-	485	O
rest	-	488	O
(	-	493	O
1	-	494	O
.	-	495	O
3	-	496	O
+	-	497	O
/	-	498	O
-	-	499	O
0	-	500	O
.	-	501	O
3	-	502	O
)	-	503	O
,	-	504	O
a	-	506	O
significant	-	508	O
aggravation	-	520	O
of	-	532	O
the	-	535	O
dyskinesia	-	539	B
score	-	550	O
was	-	556	O
observed	-	560	O
during	-	569	O
speaking	-	576	O
aloud	-	585	O
(	-	591	O
5	-	592	O
.	-	593	O
2	-	594	O
+	-	595	O
/	-	596	O
-	-	597	O
1	-	598	O
.	-	599	O
1	-	600	O
,	-	601	O
p	-	603	O
<	-	604	O
0	-	605	O
.	-	606	O
05	-	607	O
)	-	609	O
,	-	610	O
movements	-	612	O
of	-	622	O
right	-	625	O
(	-	631	O
4	-	632	O
.	-	633	O
5	-	634	O
+	-	635	O
/	-	636	O
-	-	637	O
1	-	638	O
.	-	639	O
0	-	640	O
,	-	641	O
p	-	643	O
<	-	644	O
0	-	645	O
.	-	646	O
05	-	647	O
)	-	649	O
and	-	651	O
left	-	655	O
(	-	660	O
3	-	661	O
.	-	662	O
7	-	663	O
+	-	664	O
/	-	665	O
-	-	666	O
0	-	667	O
.	-	668	O
8	-	669	O
,	-	670	O
p	-	672	O
<	-	673	O
0	-	674	O
.	-	675	O
05	-	676	O
)	-	678	O
fingers	-	680	O
,	-	687	O
movements	-	689	O
of	-	699	O
the	-	702	O
neck	-	706	O
(	-	711	O
5	-	712	O
.	-	713	O
1	-	714	O
+	-	715	O
/	-	716	O
-	-	717	O
1	-	718	O
.	-	719	O
0	-	720	O
,	-	721	O
p	-	723	O
<	-	724	O
0	-	725	O
.	-	726	O
05	-	727	O
)	-	729	O
,	-	730	O
and	-	732	O
mental	-	736	O
calculation	-	743	O
(	-	755	O
3	-	756	O
.	-	757	O
1	-	758	O
+	-	759	O
/	-	760	O
-	-	761	O
1	-	762	O
.	-	763	O
0	-	764	O
,	-	765	O
p	-	767	O
<	-	768	O
0	-	769	O
.	-	770	O
05	-	771	O
)	-	773	O
.	-	774	O

These	10091616	776	O
results	-	782	O
suggest	-	790	O
that	-	798	O
activation	-	803	O
tasks	-	814	O
such	-	820	O
as	-	825	O
""""	-	828	O
speaking	-	829	O
aloud	-	838	O
""""	-	843	O
could	-	845	O
be	-	851	O
used	-	854	O
for	-	859	O
objective	-	863	O
assessment	-	873	O
of	-	884	O
dyskinesia	-	887	B
severity	-	898	O
.	-	906	O

Structural	9952311	0	B
and	-	11	I
functional	-	15	I
impairment	-	26	I
of	-	37	I
mitochondria	-	40	I
in	-	53	O
adriamycin	-	56	O
-	-	66	O
induced	-	67	O
cardiomyopathy	-	75	B
in	-	90	O
mice	-	93	O
:	-	97	O
suppression	-	99	O
of	-	111	O
cytochrome	-	114	O
c	-	125	O
oxidase	-	127	O
II	-	135	O
gene	-	138	O
expression	-	143	O
.	-	153	O

The	9952311	155	O
use	-	159	O
of	-	163	O
adriamycin	-	166	O
(	-	177	O
ADR	-	178	O
)	-	181	O
in	-	183	O
cancer	-	186	B
chemotherapy	-	193	O
has	-	206	O
been	-	210	O
limited	-	215	O
due	-	223	O
to	-	227	O
its	-	230	O
cumulative	-	234	O
cardiovascular	-	245	B
toxicity	-	260	I
.	-	268	O

Earlier	9952311	270	O
observations	-	278	O
that	-	291	O
ADR	-	296	O
interacts	-	300	O
with	-	310	O
mitochondrial	-	315	O
cytochrome	-	329	O
c	-	340	O
oxidase	-	342	O
(	-	350	O
COX	-	351	O
)	-	354	O
and	-	356	O
suppresses	-	360	O
its	-	371	O
enzyme	-	375	O
activity	-	382	O
led	-	391	O
us	-	395	O
to	-	398	O
investigate	-	401	O
ADR	-	413	O
's	-	416	O
action	-	419	O
on	-	426	O
the	-	429	O
cardiovascular	-	433	O
functions	-	448	O
and	-	458	O
heart	-	462	O
mitochondrial	-	468	O
morphology	-	482	O
in	-	493	O
Balb	-	496	O
-	-	500	O
c	-	501	O
mice	-	503	O
i	-	508	O
.	-	509	O
p	-	510	O
.	-	511	O

treated	9952311	513	O
with	-	521	O
ADR	-	526	O
for	-	530	O
several	-	534	O
weeks	-	542	O
.	-	547	O

At	9952311	549	O
various	-	552	O
times	-	560	O
during	-	566	O
treatment	-	573	O
,	-	582	O
the	-	584	O
animals	-	588	O
were	-	596	O
assessed	-	601	O
for	-	610	O
cardiovascular	-	614	O
functions	-	629	O
by	-	639	O
electrocardiography	-	642	O
and	-	662	O
for	-	666	O
heart	-	670	O
tissue	-	676	O
damage	-	683	O
by	-	690	O
electron	-	693	O
microscopy	-	702	O
.	-	712	O

In	9952311	714	O
parallel	-	717	O
,	-	725	O
total	-	727	O
RNA	-	733	O
was	-	737	O
extracted	-	741	O
from	-	751	O
samples	-	756	O
of	-	764	O
dissected	-	767	O
heart	-	777	O
and	-	783	O
analyzed	-	787	O
by	-	796	O
Northern	-	799	O
blot	-	808	O
hybridization	-	813	O
to	-	827	O
determine	-	830	O
the	-	840	O
steady	-	844	O
-	-	850	O
state	-	851	O
level	-	857	O
of	-	863	O
three	-	866	O
RNA	-	872	O
transcripts	-	876	O
encoded	-	888	O
by	-	896	O
the	-	899	O
COXII	-	903	O
,	-	908	O
COXIII	-	910	O
,	-	916	O
and	-	918	O
COXIV	-	922	O
genes	-	928	O
.	-	933	O

Similarly	9952311	935	O
,	-	944	O
samples	-	946	O
obtained	-	954	O
from	-	963	O
the	-	968	O
liver	-	972	O
of	-	978	O
the	-	981	O
same	-	985	O
animals	-	990	O
were	-	998	O
analyzed	-	1003	O
for	-	1012	O
comparative	-	1016	O
studies	-	1028	O
.	-	1035	O

Our	9952311	1037	O
results	-	1041	O
indicated	-	1049	O
that	-	1059	O
1	-	1064	O
)	-	1065	O
treatment	-	1067	O
of	-	1077	O
mice	-	1080	O
with	-	1085	O
ADR	-	1090	O
caused	-	1094	O
cardiovascular	-	1101	B
arrhythmias	-	1116	I
characterized	-	1128	O
by	-	1142	O
bradycardia	-	1145	B
,	-	1156	O
extension	-	1158	O
of	-	1168	O
ventricular	-	1171	O
depolarization	-	1183	O
time	-	1198	O
(	-	1203	O
tQRS	-	1204	O
)	-	1208	O
,	-	1209	O
and	-	1211	O
failure	-	1215	O
of	-	1223	O
QRS	-	1226	O
at	-	1230	O
high	-	1233	O
concentrations	-	1238	O
(	-	1253	O
10	-	1254	O
-	-	1256	O
14	-	1257	O
mg	-	1260	O
/	-	1262	O
kg	-	1263	O
body	-	1266	O
weight	-	1271	O
cumulative	-	1278	O
dose	-	1289	O
)	-	1293	O
;	-	1294	O
2	-	1296	O
)	-	1297	O
the	-	1299	O
heart	-	1303	O
mitochondria	-	1309	O
underwent	-	1322	O
swelling	-	1332	B
,	-	1340	O
fusion	-	1342	O
,	-	1348	O
dissolution	-	1350	O
,	-	1361	O
and	-	1363	O
/	-	1366	O
or	-	1367	O
disruption	-	1370	O
of	-	1381	O
mitochondrial	-	1384	O
cristae	-	1398	O
after	-	1406	O
several	-	1412	O
weeks	-	1420	O
of	-	1426	O
treatment	-	1429	O
.	-	1438	O

Such	9952311	1440	O
abnormalities	-	1445	O
were	-	1459	O
not	-	1464	O
observed	-	1468	O
in	-	1477	O
the	-	1480	O
mitochondria	-	1484	O
of	-	1497	O
liver	-	1500	O
tissue	-	1506	O
;	-	1512	O
and	-	1514	O
3	-	1518	O
)	-	1519	O
among	-	1521	O
the	-	1527	O
three	-	1531	O
genes	-	1537	O
of	-	1543	O
COX	-	1546	O
enzyme	-	1550	O
examined	-	1557	O
,	-	1565	O
only	-	1567	O
COXII	-	1572	O
gene	-	1578	O
expression	-	1583	O
was	-	1594	O
suppressed	-	1598	O
by	-	1609	O
ADR	-	1612	O
treatment	-	1616	O
,	-	1625	O
mainly	-	1627	O
after	-	1634	O
8	-	1640	O
weeks	-	1642	O
in	-	1648	O
both	-	1651	O
heart	-	1656	O
and	-	1662	O
liver	-	1666	O
.	-	1671	O

Knowing	9952311	1673	O
that	-	1681	O
heart	-	1686	O
mitochondria	-	1692	O
represent	-	1705	O
almost	-	1715	O
40	-	1722	O
%	-	1724	O
of	-	1726	O
heart	-	1729	O
muscle	-	1735	O
by	-	1742	O
weight	-	1745	O
,	-	1751	O
we	-	1753	O
conclude	-	1756	O
that	-	1765	O
the	-	1770	O
deteriorating	-	1774	O
effects	-	1788	O
of	-	1796	O
ADR	-	1799	O
on	-	1803	O
cardiovascular	-	1806	O
function	-	1821	O
involve	-	1830	O
mitochondrial	-	1838	B
structural	-	1852	I
and	-	1863	I
functional	-	1867	I
impairment	-	1878	I
.	-	1888	O

Enhanced	9915601	0	O
bradycardia	-	9	B
induced	-	21	O
by	-	29	O
beta	-	32	O
-	-	36	O
adrenoceptor	-	37	O
antagonists	-	50	O
in	-	62	O
rats	-	65	O
pretreated	-	70	O
with	-	81	O
isoniazid	-	86	O
.	-	95	O

High	9915601	97	O
doses	-	102	O
of	-	108	O
isoniazid	-	111	O
increase	-	121	O
hypotension	-	130	B
induced	-	142	O
by	-	150	O
vasodilators	-	153	O
and	-	166	O
change	-	170	O
the	-	177	O
accompanying	-	181	O
reflex	-	194	O
tachycardia	-	201	B
to	-	213	O
bradycardia	-	216	B
,	-	227	O
an	-	229	O
interaction	-	232	O
attributed	-	244	O
to	-	255	O
decreased	-	258	O
synthesis	-	268	O
of	-	278	O
brain	-	281	O
gamma	-	287	O
-	-	292	O
aminobutyric	-	293	O
acid	-	306	O
(	-	311	O
GABA	-	312	O
)	-	316	O
.	-	317	O

In	9915601	319	O
the	-	322	O
present	-	326	O
study	-	334	O
,	-	339	O
the	-	341	O
possible	-	345	O
enhancement	-	354	O
by	-	366	O
isoniazid	-	369	O
of	-	379	O
bradycardia	-	382	B
induced	-	394	O
by	-	402	O
beta	-	405	O
-	-	409	O
adrenoceptor	-	410	O
antagonists	-	423	O
was	-	435	O
determined	-	439	O
in	-	450	O
rats	-	453	O
anaesthetised	-	458	O
with	-	472	O
chloralose	-	477	O
-	-	487	O
urethane	-	488	O
.	-	496	O

Isoniazid	9915601	498	O
significantly	-	508	O
increased	-	522	O
bradycardia	-	532	B
after	-	544	O
propranolol	-	550	O
,	-	561	O
pindolol	-	563	O
,	-	571	O
labetalol	-	573	O
and	-	583	O
atenolol	-	587	O
,	-	595	O
as	-	597	O
well	-	600	O
as	-	605	O
after	-	608	O
clonidine	-	614	O
,	-	623	O
but	-	625	O
not	-	629	O
after	-	633	O
hexamethonium	-	639	O
or	-	653	O
carbachol	-	656	O
.	-	665	O

Enhancement	9915601	667	O
was	-	679	O
not	-	683	O
observed	-	687	O
in	-	696	O
rats	-	699	O
pretreated	-	704	O
with	-	715	O
methylatropine	-	720	O
or	-	735	O
previously	-	738	O
vagotomised	-	749	O
.	-	760	O

These	9915601	762	O
results	-	768	O
are	-	776	O
compatible	-	780	O
with	-	791	O
interference	-	796	O
by	-	809	O
isoniazid	-	812	O
with	-	822	O
GABAergic	-	827	O
inhibition	-	837	O
of	-	848	O
cardiac	-	851	O
parasympathetic	-	859	O
tone	-	875	O
.	-	879	O

Such	9915601	881	O
interference	-	886	O
could	-	899	O
be	-	905	O
exerted	-	908	O
centrally	-	916	O
,	-	925	O
possibly	-	927	O
at	-	936	O
the	-	939	O
nucleus	-	943	O
ambiguus	-	951	O
,	-	959	O
or	-	961	O
peripherally	-	964	O
at	-	977	O
the	-	980	O
sinus	-	984	O
node	-	990	O
.	-	994	O

Epileptogenic	9758264	0	O
activity	-	14	O
of	-	23	O
folic	-	26	O
acid	-	32	O
after	-	37	O
drug	-	43	O
induces	-	48	O
SLE	-	56	B
(	-	60	O
folic	-	61	O
acid	-	67	O
and	-	72	O
epilepsy	-	76	B
)	-	84	O
OBJECTIVE	-	86	O
:	-	95	O

To	9758264	97	O
study	-	100	O
the	-	106	O
effect	-	110	O
of	-	117	O
folic	-	120	O
acid	-	126	O
-	-	130	O
containing	-	131	O
multivitamin	-	142	O
supplementation	-	155	O
in	-	171	O
epileptic	-	174	B
women	-	184	O
before	-	190	O
and	-	197	O
during	-	201	O
pregnancy	-	208	O
in	-	218	O
order	-	221	O
to	-	227	O
determine	-	230	O
the	-	240	O
rate	-	244	O
of	-	249	O
structural	-	252	O
birth	-	263	B
defects	-	269	I
and	-	277	O
epilepsy	-	281	B
-	-	289	O
related	-	290	O
side	-	298	O
effects	-	303	O
.	-	310	O

STUDY	9758264	312	O
DESIGN	-	318	O
:	-	324	O

First	9758264	326	O
a	-	332	O
randomised	-	334	O
trial	-	345	O
,	-	350	O
later	-	352	O
periconception	-	358	O
care	-	373	O
including	-	378	O
in	-	388	O
total	-	391	O
12225	-	397	O
females	-	403	O
.	-	410	O

RESULTS	9758264	412	O
:	-	419	O

Of	9758264	421	O
60	-	424	O
epileptic	-	427	B
women	-	437	O
with	-	443	O
periconceptional	-	448	O
folic	-	465	O
acid	-	471	O
(	-	476	O
0	-	477	O
.	-	478	O
8	-	479	O
mg	-	481	O
)	-	483	O
-	-	484	O
containing	-	485	O
multivitamin	-	496	O
supplementation	-	509	O
,	-	524	O
no	-	526	O
one	-	529	O
developed	-	533	O
epilepsy	-	543	B
-	-	551	O
related	-	552	O
side	-	560	O
effects	-	565	O
during	-	573	O
the	-	580	O
periconception	-	584	O
period	-	599	O
.	-	605	O

One	9758264	607	O
epileptic	-	611	B
woman	-	621	O
delivered	-	627	O
a	-	637	O
newborn	-	639	O
with	-	647	O
cleft	-	652	B
lip	-	658	I
and	-	662	I
palate	-	666	I
.	-	672	O

Another	9758264	674	O
patient	-	682	O
exhibited	-	690	O
with	-	700	O
a	-	705	O
cluster	-	707	O
of	-	715	O
seizures	-	718	B
after	-	727	O
the	-	733	O
periconception	-	737	O
period	-	752	O
using	-	759	O
another	-	765	O
multivitamin	-	773	O
.	-	785	O

This	9758264	787	O
22	-	792	O
-	-	794	O
year	-	795	O
-	-	799	O
old	-	800	O
epileptic	-	804	B
woman	-	814	O
was	-	820	O
treated	-	824	O
continuously	-	832	O
by	-	845	O
carbamazepine	-	848	O
and	-	862	O
a	-	866	O
folic	-	868	O
acid	-	874	O
(	-	879	O
1	-	880	O
mg	-	882	O
)	-	884	O
-	-	885	O
containing	-	886	O
multivitamin	-	897	O
from	-	910	O
the	-	915	O
20th	-	919	O
week	-	924	O
of	-	929	O
gestation	-	932	O
.	-	941	O

She	9758264	943	O
developed	-	947	O
status	-	957	B
epilepticus	-	964	I
and	-	976	O
later	-	980	O
symptoms	-	986	O
of	-	995	O
systemic	-	998	B
lupus	-	1007	I
erythematodes	-	1013	I
.	-	1026	O

Her	9758264	1028	O
pregnancy	-	1032	O
ended	-	1042	O
with	-	1048	O
stillbirth	-	1053	B
.	-	1063	O

CONCLUSIONS	9758264	1065	O
:	-	1076	O

The	9758264	1078	O
epileptic	-	1082	B
pregnant	-	1092	O
patient	-	1101	O
's	-	1108	O
autoimmune	-	1111	B
disease	-	1122	I
(	-	1130	O
probably	-	1131	O
drug	-	1140	O
-	-	1144	O
induced	-	1145	O
lupus	-	1153	B
)	-	1158	O
could	-	1160	O
damage	-	1166	O
the	-	1173	O
blood	-	1177	O
-	-	1182	O
brain	-	1183	O
barrier	-	1189	O
,	-	1196	O
therefore	-	1198	O
the	-	1208	O
therapeutic	-	1212	O
dose	-	1224	O
(	-	1229	O
>	-	1230	O
or	-	1232	O
=	-	1235	O
1	-	1236	O
mg	-	1238	O
)	-	1240	O
of	-	1242	O
folic	-	1245	O
acid	-	1251	O
triggered	-	1256	O
a	-	1266	O
cluster	-	1268	O
of	-	1276	O
seizures	-	1279	B
.	-	1287	O

Physiological	9758264	1289	O
dose	-	1303	O
(	-	1308	O
<	-	1309	O
1	-	1310	O
mg	-	1312	O
)	-	1314	O
of	-	1316	O
folic	-	1319	O
acid	-	1325	O
both	-	1330	O
in	-	1335	O
healthy	-	1338	O
and	-	1346	O
60	-	1350	O
epileptic	-	1353	B
women	-	1363	O
,	-	1368	O
all	-	1370	O
without	-	1374	O
any	-	1382	O
autoimmune	-	1386	B
disease	-	1397	I
,	-	1404	O
did	-	1406	O
not	-	1410	O
increase	-	1414	O
the	-	1423	O
risk	-	1427	O
for	-	1432	O
epileptic	-	1436	B
seizures	-	1446	I
.	-	1454	O

Effects	9669632	0	O
of	-	8	O
cisapride	-	11	O
on	-	21	O
symptoms	-	24	O
and	-	33	O
postcibal	-	37	O
small	-	47	O
-	-	52	O
bowel	-	53	O
motor	-	59	O
function	-	65	O
in	-	74	O
patients	-	77	O
with	-	86	O
irritable	-	91	B
bowel	-	101	I
syndrome	-	107	I
.	-	115	O

BACKGROUND	9669632	117	O
:	-	127	O

Irritable	9669632	129	B
bowel	-	139	I
syndrome	-	145	I
is	-	154	O
a	-	157	O
common	-	159	O
cause	-	166	O
of	-	172	O
abdominal	-	175	B
pain	-	185	I
and	-	190	O
discomfort	-	194	O
and	-	205	O
may	-	209	O
be	-	213	O
related	-	216	O
to	-	224	O
disordered	-	227	B
gastrointestinal	-	238	I
motility	-	255	I
.	-	263	O

Our	9669632	265	O
aim	-	269	O
was	-	273	O
to	-	277	O
assess	-	280	O
the	-	287	O
effects	-	291	O
of	-	299	O
long	-	302	O
-	-	306	O
term	-	307	O
treatment	-	312	O
with	-	322	O
a	-	327	O
prokinetic	-	329	O
agent	-	340	O
,	-	345	O
cisapride	-	347	O
,	-	356	O
on	-	358	O
postprandial	-	361	O
jejunal	-	374	O
motility	-	382	O
and	-	391	O
symptoms	-	395	O
in	-	404	O
the	-	407	O
irritable	-	411	B
bowel	-	421	I
syndrome	-	427	I
(	-	436	O
IBS	-	437	B
)	-	440	O
.	-	441	O

METHODS	9669632	443	O
:	-	450	O

Thirty	9669632	452	O
-	-	458	O
eight	-	459	O
patients	-	465	O
with	-	474	O
IBS	-	479	B
(	-	483	O
constipation	-	484	B
-	-	496	O
predominant	-	497	O
,	-	508	O
n	-	510	O
=	-	512	O
17	-	514	O
;	-	516	O
diarrhoea	-	518	B
-	-	527	O
predominant	-	528	O
,	-	539	O
n	-	541	O
=	-	543	O
21	-	545	O
)	-	547	O
underwent	-	549	O
24	-	559	O
-	-	561	O
h	-	562	O
ambulatory	-	564	O
jejunal	-	575	O
manometry	-	583	O
before	-	593	O
and	-	600	O
after	-	604	O
12	-	610	O
week	-	613	O
's	-	617	O
treatment	-	620	O

[	9669632	630	O
cisapride	-	631	O
,	-	640	O
5	-	642	O
mg	-	644	O
three	-	647	O
times	-	653	O
daily	-	659	O
(	-	665	O
n	-	666	O
=	-	668	O
19	-	670	O
)	-	672	O
or	-	674	O
placebo	-	677	O
(	-	685	O
n	-	686	O
=	-	688	O
19	-	690	O
)	-	692	O
]	-	693	O
.	-	694	O

RESULTS	9669632	696	O
:	-	703	O

In	9669632	705	O
diarrhoea	-	708	B
-	-	717	O
predominant	-	718	O
patients	-	730	O
significant	-	739	O
differences	-	751	O
in	-	763	O
contraction	-	766	O
characteristics	-	778	O
were	-	794	O
observed	-	799	O
between	-	808	O
the	-	816	O
cisapride	-	820	O
and	-	830	O
placebo	-	834	O
groups	-	842	O
.	-	848	O

In	9669632	850	O
cisapride	-	853	O
-	-	862	O
treated	-	863	O
diarrhoea	-	871	B
-	-	880	O
predominant	-	881	O
patients	-	893	O
the	-	902	O
mean	-	906	O
contraction	-	911	O
amplitude	-	923	O
was	-	933	O
higher	-	937	O
(	-	944	O
29	-	945	O
.	-	947	O
3	-	948	O
+	-	950	O
/	-	951	O
-	-	952	O

3	9669632	954	O
.	-	955	O
2	-	956	O
versus	-	958	O
24	-	965	O
.	-	967	O
9	-	968	O
+	-	970	O
/	-	971	O
-	-	972	O

2	9669632	974	O
.	-	975	O
6	-	976	O
mm	-	978	O
Hg	-	981	O
,	-	983	O
cisapride	-	985	O
versus	-	995	O
placebo	-	1002	O
(	-	1010	O
P	-	1011	O
<	-	1013	O
0	-	1015	O
.	-	1016	O
001	-	1017	O
)	-	1020	O
;	-	1021	O
pretreatment	-	1023	O
,	-	1035	O
25	-	1037	O
.	-	1039	O
7	-	1040	O
+	-	1042	O
/	-	1043	O
-	-	1044	O

6	9669632	1046	O
.	-	1047	O
0	-	1048	O
mm	-	1050	O
Hg	-	1053	O
)	-	1055	O
,	-	1056	O
the	-	1058	O
mean	-	1062	O
contraction	-	1067	O
duration	-	1079	O
longer	-	1088	O
(	-	1095	O
3	-	1096	O
.	-	1097	O
4	-	1098	O
+	-	1100	O
/	-	1101	O
-	-	1102	O
0	-	1104	O
.	-	1105	O
2	-	1106	O
versus	-	1108	O
3	-	1115	O
.	-	1116	O
0	-	1117	O
+	-	1119	O
/	-	1120	O
-	-	1121	O

0	9669632	1123	O
.	-	1124	O
2	-	1125	O
sec	-	1127	O
,	-	1130	O
cisapride	-	1132	O
versus	-	1142	O
placebo	-	1149	O
(	-	1157	O
P	-	1158	O
<	-	1160	O
0	-	1162	O
.	-	1163	O
001	-	1164	O
)	-	1167	O
;	-	1168	O
pretreatment	-	1170	O
,	-	1182	O
3	-	1184	O
.	-	1185	O
1	-	1186	O
+	-	1188	O
/	-	1189	O
-	-	1190	O

0	9669632	1192	O
.	-	1193	O
5	-	1194	O
sec	-	1196	O
)	-	1199	O
,	-	1200	O
and	-	1202	O
the	-	1206	O
mean	-	1210	O
contraction	-	1215	O
frequency	-	1227	O
lower	-	1237	O
(	-	1243	O
2	-	1244	O
.	-	1245	O
0	-	1246	O
+	-	1248	O
/	-	1249	O
-	-	1250	O

0	9669632	1252	O
.	-	1253	O
2	-	1254	O
versus	-	1256	O
2	-	1263	O
.	-	1264	O
5	-	1265	O
+	-	1267	O
/	-	1268	O
-	-	1269	O

0	9669632	1271	O
.	-	1272	O
4	-	1273	O
cont	-	1275	O
.	-	1279	O
/	-	1280	O
min	-	1281	O
,	-	1284	O
cisapride	-	1286	O
versus	-	1296	O
placebo	-	1303	O
(	-	1311	O
P	-	1312	O
<	-	1314	O
0	-	1316	O
.	-	1317	O
001	-	1318	O
)	-	1321	O
;	-	1322	O
pretreatment	-	1324	O
,	-	1336	O
2	-	1338	O
.	-	1339	O
5	-	1340	O
+	-	1342	O
/	-	1343	O
-	-	1344	O

1	9669632	1346	O
.	-	1347	O
1	-	1348	O
cont	-	1350	O
.	-	1354	O
/	-	1355	O
min	-	1356	O
]	-	1359	O
than	-	1361	O
patients	-	1366	O
treated	-	1375	O
with	-	1383	O
placebo	-	1388	O
.	-	1395	O

No	9669632	1397	O
significant	-	1400	O
differences	-	1412	O
in	-	1424	O
jejunal	-	1427	O
motility	-	1435	O
were	-	1444	O
found	-	1449	O
in	-	1455	O
the	-	1458	O
constipation	-	1462	B
-	-	1474	O
predominant	-	1475	O
IBS	-	1487	B
group	-	1491	O
.	-	1496	O

Symptoms	9669632	1498	O
were	-	1507	O
assessed	-	1512	O
by	-	1521	O
using	-	1524	O
a	-	1530	O
visual	-	1532	O
analogue	-	1539	O
scale	-	1548	O
before	-	1554	O
and	-	1561	O
after	-	1565	O
treatment	-	1571	O
.	-	1580	O

Symptom	9669632	1582	O
scores	-	1590	O
relating	-	1597	O
to	-	1606	O
the	-	1609	O
severity	-	1613	O
of	-	1622	O
constipation	-	1625	B
were	-	1638	O
lower	-	1643	O
in	-	1649	O
cisapride	-	1652	O
-	-	1661	O
treated	-	1662	O
constipation	-	1670	B
-	-	1682	O
predominant	-	1683	O
IBS	-	1695	B
patients	-	1699	O
[	-	1708	O
score	-	1709	O
,	-	1714	O
54	-	1716	O
+	-	1719	O
/	-	1720	O
-	-	1721	O

5	9669632	1723	O
versus	-	1725	O
67	-	1732	O
+	-	1735	O
/	-	1736	O
-	-	1737	O

14	9669632	1739	O
mm	-	1742	O
,	-	1744	O
cisapride	-	1746	O
versus	-	1756	O
placebo	-	1763	O
(	-	1771	O
P	-	1772	O
<	-	1774	O
0	-	1776	O
.	-	1777	O
05	-	1778	O
)	-	1780	O
;	-	1781	O
pretreatment	-	1783	O
,	-	1795	O
62	-	1797	O
+	-	1800	O
/	-	1801	O
-	-	1802	O

19	9669632	1804	O
mm	-	1807	O
]	-	1809	O
.	-	1810	O

Diarrhoea	9669632	1812	B
-	-	1821	O
predominant	-	1822	O
IBS	-	1834	B
patients	-	1838	O
had	-	1847	O
a	-	1851	O
higher	-	1853	O
pain	-	1860	B
score	-	1865	O
after	-	1871	O
cisapride	-	1877	O
therapy	-	1887	O
[	-	1895	O
score	-	1896	O
,	-	1901	O
55	-	1903	O
+	-	1906	O
/	-	1907	O
-	-	1908	O

15	9669632	1910	O
versus	-	1913	O
34	-	1920	O
+	-	1923	O
/	-	1924	O
-	-	1925	O
12	-	1927	O
mm	-	1930	O
,	-	1932	O
cisapride	-	1934	O
versus	-	1944	O
placebo	-	1951	O
(	-	1959	O
P	-	1960	O
<	-	1962	O
0	-	1964	O
.	-	1965	O
05	-	1966	O
)	-	1968	O
;	-	1969	O
pretreatment	-	1971	O
,	-	1983	O
67	-	1985	O
+	-	1988	O
/	-	1989	O
-	-	1990	O
19	-	1992	O
mm	-	1995	O
]	-	1997	O
.	-	1998	O

CONCLUSION	9669632	2000	O
:	-	2010	O

Cisapride	9669632	2012	O
affects	-	2022	O
jejunal	-	2030	O
contraction	-	2038	O
characteristics	-	2050	O
and	-	2066	O
some	-	2070	O
symptoms	-	2075	O
in	-	2084	O
IBS	-	2087	B
.	-	2090	O

Clarithromycin	9326871	0	O
-	-	14	O
induced	-	15	O
ventricular	-	23	B
tachycardia	-	35	I
.	-	46	O

Clarithromycin	9326871	48	O
is	-	63	O
a	-	66	O
relatively	-	68	O
new	-	79	O
macrolide	-	83	O
antibiotic	-	93	O
that	-	104	O
offers	-	109	O
twice	-	116	O
-	-	121	O
daily	-	122	O
dosing	-	128	O
.	-	134	O

It	9326871	136	O
differs	-	139	O
from	-	147	O
erythromycin	-	152	O
only	-	165	O
in	-	170	O
the	-	173	O
methylation	-	177	O
of	-	189	O
the	-	192	O
hydroxyl	-	196	O
group	-	205	O
at	-	211	O
position	-	214	O
6	-	223	O
.	-	224	O

Although	9326871	226	O
the	-	235	O
side	-	239	O
-	-	243	O
effect	-	244	O
profile	-	251	O
of	-	259	O
erythromycin	-	262	O
is	-	275	O
established	-	278	O
,	-	289	O
including	-	291	O
gastroenteritis	-	301	B
and	-	317	O
interactions	-	321	O
with	-	334	O
other	-	339	O
drugs	-	345	O
subject	-	351	O
to	-	359	O
hepatic	-	362	O
mixed	-	370	O
-	-	375	O
function	-	376	O
oxidase	-	385	O
metabolism	-	393	O
,	-	403	O
experience	-	405	O
with	-	416	O
the	-	421	O
newer	-	425	O
macrolides	-	431	O
is	-	442	O
still	-	445	O
being	-	451	O
recorded	-	457	O
.	-	465	O

Cardiotoxicity	9326871	467	B
has	-	482	O
been	-	486	O
demonstrated	-	491	O
after	-	504	O
both	-	510	O
intravenous	-	515	O
and	-	527	O
oral	-	531	O
administration	-	536	O
of	-	551	O
erythromycin	-	554	O
but	-	567	O
has	-	571	O
never	-	575	O
been	-	581	O
reported	-	586	O
with	-	595	O
the	-	600	O
newer	-	604	O
macrolides	-	610	O
.	-	620	O

We	9326871	622	O
report	-	625	O
a	-	632	O
case	-	634	O
of	-	639	O
ventricular	-	642	B
dysrhythmias	-	654	I
that	-	667	O
occurred	-	672	O
after	-	681	O
six	-	687	O
therapeutic	-	691	O
doses	-	703	O
of	-	709	O
clarithromycin	-	712	O
.	-	726	O

The	9326871	728	O
dysrhythmias	-	732	B
resolved	-	745	O
after	-	754	O
discontinuation	-	760	O
of	-	776	O
the	-	779	O
drug	-	783	O
.	-	787	O

Persistent	9226773	0	O
nephrogenic	-	11	B
diabetes	-	23	I
insipidus	-	32	I
following	-	42	O
lithium	-	52	O
therapy	-	60	O
.	-	67	O

We	9226773	69	O
report	-	72	O
the	-	79	O
case	-	83	O
of	-	88	O
a	-	91	O
patient	-	93	O
who	-	101	O
developed	-	105	O
severe	-	115	O
hypernatraemic	-	122	O
dehydration	-	137	B
following	-	149	O
a	-	159	O
head	-	161	B
injury	-	166	I
.	-	172	O

Ten	9226773	174	O
years	-	178	O
previously	-	184	O
he	-	195	O
had	-	198	O
been	-	202	O
diagnosed	-	207	O
to	-	217	O
have	-	220	O
lithium	-	225	O
-	-	232	O
induced	-	233	O
nephrogenic	-	241	B
diabetes	-	253	I
insipidus	-	262	I
,	-	271	O
and	-	273	O
lithium	-	277	O
therapy	-	285	O
had	-	293	O
been	-	297	O
discontinued	-	302	O
.	-	314	O

He	9226773	316	O
remained	-	319	O
thirsty	-	328	O
and	-	336	O
polyuric	-	340	B
despite	-	349	O
cessation	-	357	O
of	-	367	O
lithium	-	370	O
and	-	378	O
investigations	-	382	O
on	-	397	O
admission	-	400	O
showed	-	410	O
him	-	417	O
to	-	421	O
have	-	424	O
normal	-	429	O
osmoregulated	-	436	O
thirst	-	450	O
and	-	457	O
vasopressin	-	461	O
secretion	-	473	O
,	-	482	O
with	-	484	O
clear	-	489	O
evidence	-	495	O
of	-	504	O
nephrogenic	-	507	B
diabetes	-	519	I
insipidus	-	528	I
.	-	537	O

Lithium	9226773	539	O
induced	-	547	O
nephrogenic	-	555	B
diabetes	-	567	I
insipidus	-	576	I
is	-	586	O
considered	-	589	O
to	-	600	O
be	-	603	O
reversible	-	606	O
on	-	617	O
cessation	-	620	O
of	-	630	O
therapy	-	633	O
but	-	641	O
polyuria	-	645	B
persisted	-	654	O
in	-	664	O
this	-	667	O
patient	-	672	O
for	-	680	O
ten	-	684	O
years	-	688	O
after	-	694	O
lithium	-	700	O
was	-	708	O
stopped	-	712	O
.	-	719	O

We	9226773	721	O
discuss	-	724	O
the	-	732	O
possible	-	736	O
renal	-	745	O
mechanisms	-	751	O
and	-	762	O
the	-	766	O
implications	-	770	O
for	-	783	O
management	-	787	O
of	-	798	O
patients	-	801	O
with	-	810	O
lithium	-	815	O
-	-	822	O
induced	-	823	O
nephrogenic	-	831	B
diabetes	-	843	I
insipidus	-	852	I
.	-	861	O

Late	8600333	0	O
cardiotoxicity	-	5	B
after	-	20	O
treatment	-	26	O
for	-	36	O
a	-	40	O
malignant	-	42	O
bone	-	52	B
tumor	-	57	I
.	-	62	O

Cardiac	8600333	64	O
function	-	72	O
was	-	81	O
assessed	-	85	O
in	-	94	O
long	-	97	O
-	-	101	O
term	-	102	O
survivors	-	107	O
of	-	117	O
malignant	-	120	O
bone	-	130	B
tumors	-	135	I
who	-	142	O
were	-	146	O
treated	-	151	O
according	-	159	O
to	-	169	O
Rosen	-	172	O
's	-	177	O
T5	-	180	O
or	-	183	O
T10	-	186	O
protocol	-	190	O
,	-	198	O
both	-	200	O
including	-	205	O
doxorubicin	-	215	O
.	-	226	O

Thirty	8600333	228	O
-	-	234	O
one	-	235	O
patients	-	239	O
,	-	247	O
age	-	249	O
10	-	253	O
-	-	255	O
45	-	256	O
years	-	259	O
(	-	265	O
median	-	266	O
age	-	273	O
17	-	277	O
.	-	279	O
8	-	280	O
years	-	282	O
)	-	287	O
were	-	289	O
evaluated	-	294	O
2	-	304	O
.	-	305	O
3	-	306	O
-	-	307	O
14	-	308	O
.	-	310	O
1	-	311	O
years	-	313	O
(	-	319	O
median	-	320	O
8	-	327	O
.	-	328	O
9	-	329	O
years	-	331	O
)	-	336	O
following	-	338	O
completion	-	348	O
of	-	359	O
treatment	-	362	O
.	-	371	O

Cumulative	8600333	373	O
doses	-	384	O
of	-	390	O
doxorubicin	-	393	O
were	-	405	O
225	-	410	O
-	-	413	O
550	-	414	O
mg	-	418	O
/	-	420	O
m2	-	421	O
(	-	424	O
median	-	425	O
dose	-	432	O
360	-	437	O
)	-	440	O
.	-	441	O

The	8600333	443	O
evaluation	-	447	O
consisted	-	458	O
of	-	468	O
a	-	471	O
history	-	473	O
,	-	480	O
physical	-	482	O
examination	-	491	O
,	-	502	O
electrocardiogram	-	504	O
(	-	522	O
ECG	-	523	O
)	-	526	O
,	-	527	O
signal	-	529	O
averaged	-	536	O
ECG	-	545	O
,	-	548	O
24	-	550	O
-	-	552	O
hour	-	553	O
ambulatory	-	558	O
ECG	-	569	O
,	-	572	O
echocardiography	-	574	O
and	-	591	O
radionuclide	-	595	O
angiography	-	608	O
.	-	619	O

Eighteen	8600333	621	O
of	-	630	O
31	-	633	O
(	-	636	O
58	-	637	O
%	-	639	O
)	-	640	O
patients	-	642	O
showed	-	651	O
cardiac	-	658	B
toxicity	-	666	I
,	-	674	O
defined	-	676	O
as	-	684	O
having	-	687	O
one	-	694	O
or	-	698	O
more	-	701	O
of	-	706	O
the	-	709	O
following	-	713	O
abnormalities	-	723	O
:	-	736	O
late	-	738	O
potentials	-	743	O
,	-	753	O
complex	-	755	O
ventricular	-	763	B
arrhythmias	-	775	I
,	-	786	O
left	-	788	O
ventricular	-	793	B
dilation	-	805	I
,	-	813	O
decreased	-	815	O
shortening	-	825	O
fraction	-	836	O
,	-	844	O
or	-	846	O
decreased	-	849	O
ejection	-	859	O
fraction	-	868	O
.	-	876	O

The	8600333	878	O
incidence	-	882	O
of	-	892	O
cardiac	-	895	B
abnormalities	-	903	I
increased	-	917	O
with	-	927	O
length	-	932	O
of	-	939	O
follow	-	942	O
-	-	948	O
up	-	949	O
(	-	952	O
P	-	953	O
<	-	954	O
or	-	956	O
=	-	959	O
.	-	961	O
05	-	962	O
)	-	964	O
.	-	965	O

No	8600333	967	O
correlation	-	970	O
could	-	982	O
be	-	988	O
demonstrated	-	991	O
between	-	1004	O
cumulative	-	1012	O
dose	-	1023	O
of	-	1028	O
doxorubicin	-	1031	O
and	-	1043	O
cardiac	-	1047	O
status	-	1055	O
,	-	1061	O
except	-	1063	O
for	-	1070	O
heart	-	1074	O
rate	-	1080	O
variability	-	1085	O
.	-	1096	O

When	8600333	1098	O
adjusted	-	1103	O
to	-	1112	O
body	-	1115	O
surface	-	1120	O
area	-	1128	O
,	-	1132	O
the	-	1134	O
left	-	1138	O
ventricular	-	1143	O
posterior	-	1155	O
wall	-	1165	O
thickness	-	1170	O
(	-	1180	O
LVPW	-	1181	O
index	-	1186	O
)	-	1191	O
was	-	1193	O
decreased	-	1197	O
in	-	1207	O
all	-	1210	O
patients	-	1214	O
.	-	1222	O

The	8600333	1224	O
incidence	-	1228	O
of	-	1238	O
doxorubicin	-	1241	O
-	-	1252	O
induced	-	1253	O
cardiotoxicity	-	1261	B
is	-	1276	O
high	-	1279	O
and	-	1284	O
increases	-	1288	O
with	-	1298	O
follow	-	1303	O
-	-	1309	O
up	-	1310	O
,	-	1312	O
irrespective	-	1314	O
of	-	1327	O
cumulative	-	1330	O
dose	-	1341	O
.	-	1345	O

Life	8600333	1347	O
-	-	1351	O
long	-	1352	O
cardiac	-	1357	O
follow	-	1365	O
-	-	1371	O
up	-	1372	O
in	-	1375	O
these	-	1378	O
patients	-	1384	O
is	-	1393	O
warranted	-	1396	O
.	-	1405	O

The	8600333	1407	O
results	-	1411	O
of	-	1419	O
our	-	1422	O
study	-	1426	O
suggest	-	1432	O
that	-	1440	O
heart	-	1445	O
rate	-	1451	O
variability	-	1456	O
and	-	1468	O
LVPW	-	1472	O
index	-	1477	O
could	-	1483	O
be	-	1489	O
sensitive	-	1492	O
indicators	-	1502	O
for	-	1513	O
cardiotoxicity	-	1517	B
.	-	1531	O

Venous	8514073	0	B
complications	-	7	I
of	-	21	O
midazolam	-	24	O
versus	-	34	O
diazepam	-	41	O
.	-	49	O

Although	8514073	51	O
some	-	60	O
studies	-	65	O
have	-	73	O
suggested	-	78	O
fewer	-	88	O
venous	-	94	B
complications	-	101	I
are	-	115	O
associated	-	119	O
with	-	130	O
midazolam	-	135	O
than	-	145	O
with	-	150	O
diazepam	-	155	O
for	-	164	O
endoscopic	-	168	O
procedures	-	179	O
,	-	189	O
this	-	191	O
variable	-	196	O
has	-	205	O
not	-	209	O
been	-	213	O
well	-	218	O
documented	-	223	O
.	-	233	O

We	8514073	235	O
prospectively	-	238	O
evaluated	-	252	O
the	-	262	O
incidence	-	266	O
of	-	276	O
venous	-	279	B
complications	-	286	I
after	-	300	O
intravenous	-	306	O
injection	-	318	O
of	-	328	O
diazepam	-	331	O
or	-	340	O
midazolam	-	343	O
in	-	353	O
122	-	356	O
consecutive	-	360	O
patients	-	372	O
undergoing	-	381	O
colonoscopy	-	392	O
and	-	404	O
esophagogastroduodenoscopy	-	408	O
.	-	434	O

Overall	8514073	436	O
,	-	443	O
venous	-	445	B
complications	-	452	I
were	-	466	O
more	-	471	O
frequent	-	476	O
with	-	485	O
diazepam	-	490	O
(	-	499	O
22	-	500	O
of	-	503	O
62	-	506	O
patients	-	509	O
)	-	517	O
than	-	519	O
with	-	524	O
midazolam	-	529	O
(	-	539	O
4	-	540	O
of	-	542	O
60	-	545	O
patients	-	548	O
)	-	556	O
(	-	558	O
p	-	559	O
<	-	561	O
0	-	563	O
.	-	564	O
001	-	565	O
)	-	568	O
.	-	569	O

A	8514073	571	O
palpable	-	573	O
venous	-	582	O
cord	-	589	O
was	-	594	O
present	-	598	O
in	-	606	O
23	-	609	O
%	-	611	O
(	-	613	O
14	-	614	O
of	-	617	O
62	-	620	O
)	-	622	O
of	-	624	O
patients	-	627	O
in	-	636	O
the	-	639	O
diazepam	-	643	O
group	-	652	O
,	-	657	O
compared	-	659	O
with	-	668	O
2	-	673	O
%	-	674	O
(	-	676	O
1	-	677	O
of	-	679	O
60	-	682	O
patients	-	685	O
)	-	693	O
in	-	695	O
the	-	698	O
midazolam	-	702	O
group	-	712	O
(	-	718	O
p	-	719	O
<	-	721	O
0	-	723	O
.	-	724	O
002	-	725	O
)	-	728	O
.	-	729	O

Pain	8514073	731	B
at	-	736	O
the	-	739	O
injection	-	743	O
site	-	753	O
occurred	-	758	O
in	-	767	O
35	-	770	O
%	-	772	O
(	-	774	O
22	-	775	O
of	-	778	O
62	-	781	O
)	-	783	O
of	-	785	O
patients	-	788	O
in	-	797	O
the	-	800	O
diazepam	-	804	O
group	-	813	O
compared	-	819	O
with	-	828	O
7	-	833	O
%	-	834	O
(	-	836	O
4	-	837	O
of	-	839	O
60	-	842	O
patients	-	845	O
)	-	853	O
in	-	855	O
the	-	858	O
midazolam	-	862	O
group	-	872	O
(	-	878	O
p	-	879	O
<	-	881	O
0	-	883	O
.	-	884	O
001	-	885	O
)	-	888	O
.	-	889	O

Swelling	8514073	891	B
and	-	900	O
warmth	-	904	O
at	-	911	O
the	-	914	O
injection	-	918	O
site	-	928	O
were	-	933	O
not	-	938	O
significantly	-	942	O
different	-	956	O
between	-	966	O
the	-	974	O
two	-	978	O
groups	-	982	O
.	-	988	O

Smoking	8514073	990	O
,	-	997	O
nonsteroidal	-	999	O
anti	-	1012	O
-	-	1016	O
inflammatory	-	1017	O
drug	-	1030	O
use	-	1035	O
,	-	1038	O
intravenous	-	1040	O
catheter	-	1052	O
site	-	1061	O
,	-	1065	O
dwell	-	1067	O
time	-	1073	O
of	-	1078	O
the	-	1081	O
needle	-	1085	O
,	-	1091	O
alcohol	-	1093	O
use	-	1101	O
,	-	1104	O
and	-	1106	O
pain	-	1110	B
during	-	1115	O
the	-	1122	O
injection	-	1126	O
had	-	1136	O
no	-	1140	O
effect	-	1143	O
on	-	1150	O
the	-	1153	O
incidence	-	1157	O
of	-	1167	O
venous	-	1170	B
complications	-	1177	I
.	-	1190	O

Tetany	8492347	0	B
and	-	7	O
rhabdomyolysis	-	11	B
due	-	26	O
to	-	30	O
surreptitious	-	33	O
furosemide	-	47	O
-	-	57	O
-	-	58	O
importance	-	59	O
of	-	70	O
magnesium	-	73	O
supplementation	-	83	O
.	-	98	O

Diuretics	8492347	100	O
may	-	110	O
induce	-	114	O
hypokalemia	-	121	B
,	-	132	O
hypocalcemia	-	134	B
and	-	147	O
hypomagnesemia	-	151	B
.	-	165	O

While	8492347	167	O
severe	-	173	O
hypokalemia	-	180	B
may	-	192	O
cause	-	196	O
muscle	-	202	B
weakness	-	209	I
,	-	217	O
severe	-	219	O
hypomagnesemia	-	226	B
is	-	241	O
associated	-	244	O
with	-	255	O
muscle	-	260	B
spasms	-	267	I
and	-	274	O
tetany	-	278	B
which	-	285	O
can	-	291	O
not	-	294	O
be	-	298	O
corrected	-	301	O
by	-	311	O
potassium	-	314	O
and	-	324	O
calcium	-	328	O
supplementation	-	336	O
alone	-	352	O
(	-	358	O
1	-	359	O
,	-	360	O
2	-	361	O
)	-	362	O
.	-	363	O

Surreptitious	8492347	365	O
diuretic	-	379	O
ingestion	-	388	O
has	-	398	O
been	-	402	O
described	-	407	O
,	-	416	O
mainly	-	418	O
in	-	425	O
women	-	428	O
who	-	434	O
are	-	438	O
concerned	-	442	O
that	-	452	O
they	-	457	O
are	-	462	O
obese	-	466	B
or	-	472	O
edematous	-	475	B
.	-	484	O

Symptomatic	8492347	486	O
hypokalemia	-	498	B
has	-	510	O
been	-	514	O
reported	-	519	O
in	-	528	O
such	-	531	O
patients	-	536	O
(	-	545	O
3	-	546	O
-	-	547	O
7	-	548	O
)	-	549	O
and	-	551	O
in	-	555	O
one	-	558	O
case	-	562	O
hypocalcemia	-	567	B
was	-	580	O
observed	-	584	O
(	-	593	O
8	-	594	O
)	-	595	O
,	-	596	O
but	-	598	O
the	-	602	O
effects	-	606	O
of	-	614	O
magnesium	-	617	O
depletion	-	627	O
were	-	637	O
not	-	642	O
noted	-	646	O
in	-	652	O
these	-	655	O
patients	-	661	O
.	-	669	O

Loss	8410199	0	O
of	-	5	O
glutamate	-	8	O
decarboxylase	-	18	O
mRNA	-	32	O
-	-	36	O
containing	-	37	O
neurons	-	48	O
in	-	56	O
the	-	59	O
rat	-	63	O
dentate	-	67	O
gyrus	-	75	O
following	-	81	O
pilocarpine	-	91	O
-	-	102	O
induced	-	103	O
seizures	-	111	B
.	-	119	O

In	8410199	121	O
situ	-	124	O
hybridization	-	129	O
methods	-	143	O
were	-	151	O
used	-	156	O
to	-	161	O
determine	-	164	O
if	-	174	O
glutamic	-	177	O
acid	-	186	O
decarboxylase	-	191	O
(	-	205	O
GAD	-	206	O
)	-	209	O
mRNA	-	211	O
-	-	215	O
containing	-	216	O
neurons	-	227	O
within	-	235	O
the	-	242	O
hilus	-	246	O
of	-	252	O
the	-	255	O
dentate	-	259	O
gyrus	-	267	O
are	-	273	O
vulnerable	-	277	O
to	-	288	O
seizure	-	291	B
-	-	298	O
induced	-	299	O
damage	-	307	O
in	-	314	O
a	-	317	O
model	-	319	O
of	-	325	O
chronic	-	328	O
seizures	-	336	B
.	-	344	O

Sprague	8410199	346	O
-	-	353	O
Dawley	-	354	O
rats	-	361	O
were	-	366	O
injected	-	371	O
intraperitoneally	-	380	O
with	-	398	O
pilocarpine	-	403	O
,	-	414	O
and	-	416	O
the	-	420	O
hippocampal	-	424	O
formation	-	436	O
was	-	446	O
studied	-	450	O
histologically	-	458	O
at	-	473	O
1	-	476	O
,	-	477	O
2	-	479	O
,	-	480	O
4	-	482	O
,	-	483	O
and	-	485	O
8	-	489	O
week	-	491	O
intervals	-	496	O
after	-	506	O
pilocarpine	-	512	O
-	-	523	O
induced	-	524	O
seizures	-	532	B
.	-	540	O

In	8410199	542	O
situ	-	545	O
hybridization	-	550	O
histochemistry	-	564	O
,	-	578	O
using	-	580	O
a	-	586	O
digoxigenin	-	588	O
-	-	599	O
labeled	-	600	O
GAD	-	608	O
cRNA	-	612	O
probe	-	617	O
,	-	622	O
demonstrated	-	624	O
a	-	637	O
substantial	-	639	O
decrease	-	651	O
in	-	660	O
the	-	663	O
number	-	667	O
of	-	674	O
GAD	-	677	O
mRNA	-	681	O
-	-	685	O
containing	-	686	O
neurons	-	697	O
in	-	705	O
the	-	708	O
hilus	-	712	O
of	-	718	O
the	-	721	O
dentate	-	725	O
gyrus	-	733	O
in	-	739	O
the	-	742	O
pilocarpine	-	746	O
-	-	757	O
treated	-	758	O
rats	-	766	O
as	-	771	O
compared	-	774	O
to	-	783	O
controls	-	786	O
at	-	795	O
all	-	798	O
time	-	802	O
intervals	-	807	O
.	-	816	O

Additional	8410199	818	O
neuronanatomical	-	829	O
studies	-	846	O
,	-	853	O
including	-	855	O
cresyl	-	865	O
violet	-	872	O
staining	-	879	O
,	-	887	O
neuronal	-	889	B
degeneration	-	898	I
methods	-	911	O
,	-	918	O
and	-	920	O
histochemical	-	924	O
localization	-	938	O
of	-	951	O
glial	-	954	O
fibrillary	-	960	O
acidic	-	971	O
protein	-	978	O
,	-	985	O
suggested	-	987	O
that	-	997	O
the	-	1002	O
decrease	-	1006	O
in	-	1015	O
the	-	1018	O
number	-	1022	O
of	-	1029	O
GAD	-	1032	O
mRNA	-	1036	O
-	-	1040	O
containing	-	1041	O
neurons	-	1052	O
was	-	1060	O
related	-	1064	O
to	-	1072	O
neuronal	-	1075	B
loss	-	1084	I
rather	-	1089	O
than	-	1096	O
to	-	1101	O
a	-	1104	O
decrease	-	1106	O
in	-	1115	O
GAD	-	1118	O
mRNA	-	1122	O
levels	-	1127	O
.	-	1133	O

The	8410199	1135	O
loss	-	1139	O
of	-	1144	O
GAD	-	1147	O
mRNA	-	1151	O
-	-	1155	O
containing	-	1156	O
neurons	-	1167	O
in	-	1175	O
the	-	1178	O
hilus	-	1182	O
contrasted	-	1188	O
with	-	1199	O
the	-	1204	O
relative	-	1208	O
preservation	-	1217	O
of	-	1230	O
labeled	-	1233	O
putative	-	1241	O
basket	-	1250	O
cells	-	1257	O
along	-	1263	O
the	-	1269	O
inner	-	1273	O
margin	-	1279	O
of	-	1286	O
the	-	1289	O
granule	-	1293	O
cell	-	1301	O
layer	-	1306	O
.	-	1311	O

Quantitative	8410199	1313	O
analyses	-	1326	O
of	-	1335	O
labeled	-	1338	O
neurons	-	1346	O
in	-	1354	O
three	-	1357	O
regions	-	1363	O
of	-	1371	O
the	-	1374	O
dentate	-	1378	O
gyrus	-	1386	O
in	-	1392	O
the	-	1395	O
1	-	1399	O
and	-	1401	O
2	-	1405	O
week	-	1407	O
groups	-	1412	O
showed	-	1419	O
statistically	-	1426	O
significant	-	1440	O
decreases	-	1452	O
in	-	1462	O
the	-	1465	O
mean	-	1469	O
number	-	1474	O
of	-	1481	O
GAD	-	1484	O
mRNA	-	1488	O
-	-	1492	O
containing	-	1493	O
neurons	-	1504	O
in	-	1512	O
the	-	1515	O
hilus	-	1519	O
of	-	1525	O
both	-	1528	O
groups	-	1533	O
of	-	1540	O
experimental	-	1543	O
animals	-	1556	O
.	-	1563	O

No	8410199	1565	O
significant	-	1568	O
differences	-	1580	O
were	-	1592	O
found	-	1597	O
in	-	1603	O
the	-	1606	O
molecular	-	1610	O
layer	-	1620	O
or	-	1626	O
the	-	1629	O
granule	-	1633	O
cell	-	1641	O
layer	-	1646	O
,	-	1651	O
which	-	1653	O
included	-	1659	O
labeled	-	1668	O
neurons	-	1676	O
along	-	1684	O
the	-	1690	O
lower	-	1694	O
margin	-	1700	O
of	-	1707	O
the	-	1710	O
granule	-	1714	O
cell	-	1722	O
layer	-	1727	O
.	-	1732	O

The	8410199	1734	O
results	-	1738	O
indicate	-	1746	O
that	-	1755	O
,	-	1759	O
in	-	1761	O
this	-	1764	O
model	-	1769	O
,	-	1774	O
a	-	1776	O
subpopulation	-	1778	O
of	-	1792	O
GAD	-	1795	O
mRNA	-	1799	O
-	-	1803	O
containing	-	1804	O
neurons	-	1815	O
within	-	1823	O
the	-	1830	O
dentate	-	1834	O
gyrus	-	1842	O
is	-	1848	O
selectively	-	1851	O
vulnerable	-	1863	O
to	-	1874	O
seizure	-	1877	B
-	-	1884	O
induced	-	1885	O
damage	-	1893	O
.	-	1899	O

Such	8410199	1901	O
differential	-	1906	O
vulnerability	-	1919	O
appears	-	1933	O
to	-	1941	O
be	-	1944	O
another	-	1947	O
indication	-	1955	O
of	-	1966	O
the	-	1969	O
heterogeneity	-	1973	O
of	-	1987	O
GABA	-	1990	O
neurons	-	1995	O
.	-	2002	O

Protective	7791169	0	O
effect	-	11	O
of	-	18	O
misoprostol	-	21	O
on	-	33	O
indomethacin	-	36	O
induced	-	49	O
renal	-	57	B
dysfunction	-	63	I
in	-	75	O
elderly	-	78	O
patients	-	86	O
.	-	94	O

OBJECTIVE	7791169	96	O
:	-	105	O

To	7791169	107	O
evaluate	-	110	O
the	-	119	O
possible	-	123	O
protective	-	132	O
effects	-	143	O
of	-	151	O
misoprostol	-	154	O
on	-	166	O
renal	-	169	O
function	-	175	O
in	-	184	O
hospitalized	-	187	O
elderly	-	200	O
patients	-	208	O
treated	-	217	O
with	-	225	O
indomethacin	-	230	O
.	-	242	O

METHODS	7791169	244	O
:	-	251	O

Forty	7791169	253	O
-	-	258	O
five	-	259	O
hospitalized	-	264	O
elderly	-	277	O
patients	-	285	O
(	-	294	O
>	-	295	O
65	-	297	O
years	-	300	O
old	-	306	O
)	-	309	O
who	-	311	O
required	-	315	O
therapy	-	324	O
with	-	332	O
nonsteroidal	-	337	O
antiinflammatory	-	350	O
drugs	-	367	O
(	-	373	O
NSAID	-	374	O
)	-	379	O
were	-	381	O
randomly	-	386	O
assigned	-	395	O
to	-	404	O
receive	-	407	O
either	-	415	O
indomethacin	-	422	O
,	-	434	O
150	-	436	O
mg	-	440	O
/	-	442	O
day	-	443	O
(	-	447	O
Group	-	448	O
A	-	454	O
)	-	455	O
,	-	456	O
or	-	458	O
indomethacin	-	461	O
150	-	474	O
mg	-	478	O
/	-	480	O
day	-	481	O
plus	-	485	O
misoprostol	-	490	O
at	-	502	O
0	-	505	O
.	-	506	O
6	-	507	O
mg	-	509	O
/	-	511	O
day	-	512	O
(	-	516	O
Group	-	517	O
B	-	523	O
)	-	524	O
.	-	525	O

Laboratory	7791169	527	O
variables	-	538	O
of	-	548	O
renal	-	551	O
function	-	557	O
[	-	566	O
serum	-	567	O
creatinine	-	573	O
,	-	583	O
blood	-	585	O
urea	-	591	O
nitrogen	-	596	O
(	-	605	O
BUN	-	606	O
)	-	609	O
and	-	611	O
electrolytes	-	615	O
]	-	627	O
were	-	629	O
evaluated	-	634	O
before	-	644	O
initiation	-	651	O
of	-	662	O
therapy	-	665	O
and	-	673	O
every	-	677	O
2	-	683	O
days	-	685	O
,	-	689	O
until	-	691	O
termination	-	697	O
of	-	709	O
the	-	712	O
study	-	716	O
(	-	722	O
a	-	723	O
period	-	725	O
of	-	732	O
at	-	735	O
least	-	738	O
6	-	744	O
days	-	746	O
)	-	750	O
.	-	751	O

Response	7791169	753	O
to	-	762	O
treatment	-	765	O
was	-	775	O
estimated	-	779	O
by	-	789	O
the	-	792	O
visual	-	796	O
analog	-	803	O
scale	-	810	O
for	-	816	O
severity	-	820	O
of	-	829	O
pain	-	832	B
.	-	836	O

RESULTS	7791169	838	O
:	-	845	O

Forty	7791169	847	O
-	-	852	O
two	-	853	O
patients	-	857	O
completed	-	866	O
the	-	876	O
study	-	880	O
,	-	885	O
22	-	887	O
in	-	890	O
Group	-	893	O
A	-	899	O
and	-	901	O
20	-	905	O
in	-	908	O
Group	-	911	O
B	-	917	O
.	-	918	O
BUN	-	920	O
and	-	924	O
creatinine	-	928	O
increased	-	939	O
by	-	949	O
>	-	952	O
50	-	954	O
%	-	956	O
of	-	958	O
baseline	-	961	O
levels	-	970	O
in	-	977	O
54	-	980	O
and	-	983	O
45	-	987	O
%	-	989	O
of	-	991	O
Group	-	994	O
A	-	1000	O
patients	-	1002	O
,	-	1010	O
respectively	-	1012	O
,	-	1024	O
compared	-	1026	O
to	-	1035	O
only	-	1038	O
20	-	1043	O
and	-	1046	O
10	-	1050	O
%	-	1052	O
of	-	1054	O
Group	-	1057	O
B	-	1063	O
patients	-	1065	O
(	-	1074	O
p	-	1075	O
<	-	1077	O
0	-	1079	O
.	-	1080	O
05	-	1081	O
)	-	1083	O
.	-	1084	O

Potassium	7791169	1086	O
(	-	1096	O
K	-	1097	O
)	-	1098	O
increment	-	1100	O
of	-	1110	O
0	-	1113	O
.	-	1114	O
6	-	1115	O
mEq	-	1117	O
/	-	1120	O

l	7791169	1121	O
or	-	1123	O
more	-	1126	O
was	-	1131	O
observed	-	1135	O
in	-	1144	O
50	-	1147	O
%	-	1149	O
of	-	1151	O
Group	-	1154	O
A	-	1160	O
,	-	1161	O
but	-	1163	O
in	-	1167	O
only	-	1170	O
15	-	1175	O
%	-	1177	O
of	-	1179	O
Group	-	1182	O
B	-	1188	O
patients	-	1190	O
(	-	1199	O
p	-	1200	O
<	-	1202	O
0	-	1204	O
.	-	1205	O
05	-	1206	O
)	-	1208	O
.	-	1209	O

The	7791169	1211	O
mean	-	1215	O
increments	-	1220	O
in	-	1231	O
BUN	-	1234	O
,	-	1237	O
creatinine	-	1239	O
,	-	1249	O
and	-	1251	O
K	-	1255	O
were	-	1257	O
reduced	-	1262	O
by	-	1270	O
63	-	1273	O
,	-	1275	O
80	-	1277	O
,	-	1279	O
and	-	1281	O
42	-	1285	O
%	-	1287	O
,	-	1288	O
respectively	-	1290	O
,	-	1302	O
in	-	1304	O
Group	-	1307	O
B	-	1313	O
patients	-	1315	O
compared	-	1324	O
to	-	1333	O
Group	-	1336	O
A	-	1342	O
.	-	1343	O
Response	-	1345	O
to	-	1354	O
treatment	-	1357	O
did	-	1367	O
not	-	1371	O
differ	-	1375	O
significantly	-	1382	O
between	-	1396	O
the	-	1404	O
2	-	1408	O
groups	-	1410	O
.	-	1416	O

CONCLUSION	7791169	1418	O
:	-	1428	O

Hospitalized	7791169	1430	O
elderly	-	1443	O
patients	-	1451	O
are	-	1460	O
at	-	1464	O
risk	-	1467	O
for	-	1472	O
developing	-	1476	O
indomethacin	-	1487	O
related	-	1500	O
renal	-	1508	B
dysfunction	-	1514	I
.	-	1525	O

Addition	7791169	1527	O
of	-	1536	O
misoprostol	-	1539	O
can	-	1551	O
minimize	-	1555	O
this	-	1564	O
renal	-	1569	B
impairment	-	1575	I
without	-	1586	O
affecting	-	1594	O
pain	-	1604	B
control	-	1609	O
.	-	1616	O

Nephrotoxic	6728084	0	B
effects	-	12	O
of	-	20	O
aminoglycoside	-	23	O
treatment	-	38	O
on	-	48	O
renal	-	51	O
protein	-	57	O
reabsorption	-	65	O
and	-	78	O
accumulation	-	82	O
.	-	94	O

To	6728084	96	O
quantify	-	99	O
the	-	108	O
effects	-	112	O
of	-	120	O
gentamicin	-	123	O
,	-	133	O
kanamycin	-	135	O
and	-	145	O
netilmicin	-	149	O
on	-	160	O
renal	-	163	O
protein	-	169	O
reabsorption	-	177	O
and	-	190	O
accumulation	-	194	O
,	-	206	O
these	-	208	O
drugs	-	214	O
were	-	220	O
administered	-	225	O
to	-	238	O
rats	-	241	O
intraperitoneally	-	246	O
(	-	264	O
30	-	265	O
mg	-	268	O
/	-	270	O
kg	-	271	O
/	-	273	O
day	-	274	O
)	-	277	O
for	-	279	O
7	-	283	O
,	-	284	O
14	-	286	O
or	-	289	O
21	-	292	O
days	-	295	O
.	-	299	O

Scanning	6728084	301	O
electron	-	310	O
microscopy	-	319	O
of	-	330	O
the	-	333	O
glomerular	-	337	O
endothelia	-	348	O
,	-	358	O
urinary	-	360	O
measurements	-	368	O
of	-	381	O
sodium	-	384	O
,	-	390	O
potassium	-	392	O
,	-	401	O
endogenous	-	403	O
lysozyme	-	414	O
,	-	422	O
N	-	424	O
-	-	425	O
acetyl	-	426	O
-	-	432	O
beta	-	433	O
-	-	437	O
D	-	438	O
-	-	439	O
glucosaminidase	-	440	O
(	-	456	O
NAG	-	457	O
)	-	460	O
as	-	462	O
well	-	465	O
as	-	470	O
clearance	-	473	O
and	-	483	O
accumulation	-	487	O
experiments	-	500	O
after	-	512	O
i	-	518	O
.	-	519	O
v	-	520	O
.	-	521	O

administration	6728084	523	O
of	-	538	O
egg	-	541	O
-	-	544	O
white	-	545	O
lysozyme	-	551	O
and	-	560	O
measurements	-	564	O
of	-	577	O
inulin	-	580	O
clearance	-	587	O
(	-	597	O
GFR	-	598	O
)	-	601	O
were	-	603	O
done	-	608	O
in	-	613	O
each	-	616	O
treatment	-	621	O
group	-	631	O
.	-	636	O

Gentamicin	6728084	638	O
administration	-	649	O
decreased	-	664	O
diameter	-	674	O
,	-	682	O
density	-	684	O
and	-	692	O
shape	-	696	O
of	-	702	O
endothelial	-	705	O
fenestrae	-	717	O
.	-	726	O

Kanamycin	6728084	728	O
and	-	738	O
netilmicin	-	742	O
appeared	-	753	O
to	-	762	O
have	-	765	O
no	-	770	O
effect	-	773	O
at	-	780	O
the	-	783	O
dose	-	787	O
used	-	792	O
.	-	796	O

All	6728084	798	O
three	-	802	O
aminoglycosides	-	808	O
decreased	-	824	O
GFR	-	834	O
and	-	838	O
increased	-	842	O
urinary	-	852	O
excretion	-	860	O
of	-	870	O
sodium	-	873	O
and	-	880	O
potassium	-	884	O
.	-	893	O

While	6728084	895	O
gentamicin	-	901	O
and	-	912	O
kanamycin	-	916	O
decreased	-	926	O
the	-	936	O
percentage	-	940	O
reabsorption	-	951	O
and	-	964	O
accumulation	-	968	O
of	-	981	O
lysozyme	-	984	O
after	-	993	O
i	-	999	O
.	-	1000	O
v	-	1001	O
.	-	1002	O

administration	6728084	1004	O
of	-	1019	O
egg	-	1022	O
-	-	1025	O
white	-	1026	O
lysozyme	-	1032	O
netilmicin	-	1041	O
had	-	1052	O
no	-	1056	O
effect	-	1059	O
.	-	1065	O

Daily	6728084	1067	O
excretion	-	1073	O
of	-	1083	O
total	-	1086	O
protein	-	1092	O
,	-	1099	O
endogenous	-	1101	O
lysozyme	-	1112	O
and	-	1121	O
NAG	-	1125	O
increased	-	1129	O
only	-	1139	O
after	-	1144	O
treatment	-	1150	O
with	-	1160	O
kanamycin	-	1165	O
and	-	1175	O
gentamicin	-	1179	O
.	-	1189	O

Thus	6728084	1191	O
,	-	1195	O
aminoglycosides	-	1197	O
may	-	1213	O
act	-	1217	O
as	-	1221	O
nephrotoxicants	-	1224	O
at	-	1240	O
glomerular	-	1243	O
and	-	1254	O
/	-	1257	O
or	-	1258	O
tubular	-	1261	O
level	-	1269	O
inducing	-	1275	O
impairment	-	1284	B
of	-	1295	I
renal	-	1298	I
reabsorption	-	1304	I
and	-	1317	O
accumulation	-	1321	O
of	-	1334	O
proteins	-	1337	O
.	-	1345	O

Pharmacology	6111982	0	O
of	-	13	O
GYKI	-	16	O
-	-	20	O
41	-	21	O
099	-	24	O
(	-	28	O
chlorpropanol	-	29	O
,	-	42	O
Tobanum	-	44	O
)	-	51	O
a	-	53	O
new	-	55	O
potent	-	59	O
beta	-	66	O
-	-	70	O
adrenergic	-	71	O
antagonist	-	82	O
.	-	92	O

The	6111982	94	O
compound	-	98	O
GYKI	-	107	O
-	-	111	O
41	-	112	O
099	-	115	O
,	-	118	O
as	-	120	O
a	-	123	O
beta	-	125	O
-	-	129	O
adrenergic	-	130	O
antagonist	-	141	O
,	-	151	O
is	-	153	O
3	-	156	O
-	-	157	O
8	-	158	O
times	-	160	O
more	-	166	O
potent	-	171	O
than	-	178	O
propranolol	-	183	O
in	-	195	O
vitro	-	198	O
and	-	204	O
in	-	208	O
vivo	-	211	O
.	-	215	O

Its	6111982	217	O
antiarrhythmic	-	221	O
effectiveness	-	236	O
surpasses	-	250	O
that	-	260	O
of	-	265	O
propranolol	-	268	O
and	-	280	O
pindolol	-	284	O
inhibiting	-	293	O
the	-	304	O
ouabain	-	308	O
arrhythmia	-	316	B
in	-	327	O
dogs	-	330	O
and	-	335	O
cats	-	339	O
.	-	343	O

GYKI	6111982	345	O
-	-	349	O
41	-	350	O
900	-	353	O
has	-	357	O
a	-	361	O
negligible	-	363	O
cardiodepressant	-	374	O
activity	-	391	O
;	-	399	O
it	-	401	O
is	-	404	O
not	-	407	O
cardioselective	-	411	O
.	-	426	O

The	6111982	428	O
compound	-	432	O
shows	-	441	O
a	-	447	O
rapid	-	449	O
and	-	455	O
long	-	459	O
lasting	-	464	O
effect	-	472	O
.	-	478	O

There	6111982	480	O
was	-	486	O
a	-	490	O
prolonged	-	492	O
elimination	-	502	O
of	-	514	O
the	-	517	O
radioactivity	-	521	O
after	-	535	O
the	-	541	O
injection	-	545	O
of	-	555	O
14C	-	558	O
-	-	561	O
41	-	562	O
099	-	565	O
to	-	569	O
rats	-	572	O
and	-	577	O
dogs	-	581	O
.	-	585	O

The	6111982	587	O
half	-	591	O
life	-	596	O
of	-	601	O
the	-	604	O
unlabeled	-	608	O
substance	-	618	O
in	-	628	O
humans	-	631	O
was	-	638	O
more	-	642	O
than	-	647	O
10	-	652	O
hours	-	655	O
.	-	660	O

Chorea	3123611	0	B
associated	-	7	O
with	-	18	O
oral	-	23	O
contraception	-	28	O
.	-	41	O

Three	3123611	43	O
patients	-	49	O
developed	-	58	O
chorea	-	68	B
while	-	75	O
receiving	-	81	O
oral	-	91	O
contraceptives	-	96	O
.	-	110	O

Two	3123611	112	O
were	-	116	O
young	-	121	O
patients	-	127	O
whose	-	136	O
chorea	-	142	B
developed	-	149	O
long	-	159	O
after	-	164	O
treatment	-	170	O
had	-	180	O
been	-	184	O
started	-	189	O
and	-	197	O
disappeared	-	201	O
soon	-	213	O
after	-	218	O
it	-	224	O
had	-	227	O
been	-	231	O
discontinued	-	236	O
.	-	248	O

The	3123611	250	O
third	-	254	O
patient	-	260	O
had	-	268	O
acute	-	272	O
amphetamine	-	278	O
-	-	289	O
induced	-	290	O
chorea	-	298	B
after	-	305	O
prolonged	-	311	O
oral	-	321	O
contraception	-	326	O
.	-	339	O

Prolonged	3123611	341	O
administration	-	351	O
of	-	366	O
female	-	369	O
sex	-	376	O
hormones	-	380	O
is	-	389	O
a	-	392	O
possible	-	394	O
cause	-	403	O
of	-	409	O
chorea	-	412	B
in	-	419	O
women	-	422	O
who	-	428	O
have	-	432	O
not	-	437	O
previously	-	441	O
had	-	452	O
chorea	-	456	B
or	-	463	O
rheumatic	-	466	B
fever	-	476	I
.	-	481	O

Reversal	761833	0	O
of	-	9	O
ammonia	-	12	O
coma	-	20	B
in	-	25	O
rats	-	28	O
by	-	33	O
L	-	36	O
-	-	37	O
dopa	-	38	O
:	-	42	O
a	-	44	O
peripheral	-	46	O
effect	-	57	O
.	-	63	O

Ammonia	761833	65	O
coma	-	73	B
was	-	78	O
produced	-	82	O
in	-	91	O
rats	-	94	O
within	-	99	O
10	-	106	O
to	-	109	O
15	-	112	O
minutes	-	115	O
of	-	123	O
an	-	126	O
intraperitonealinjection	-	129	O
of	-	154	O
1	-	157	O
.	-	158	O
7	-	159	O
mmol	-	161	O
NH4CL	-	166	O
.	-	171	O

This	761833	173	O
coma	-	178	B
was	-	183	O
prevented	-	187	O
with	-	197	O
1	-	202	O
.	-	203	O
68	-	204	O
mmol	-	207	O
L	-	212	O
-	-	213	O
dopa	-	214	O
given	-	219	O
by	-	225	O
gastric	-	228	O
intubation	-	236	O
15	-	247	O
minutes	-	250	O
before	-	258	O
the	-	265	O
ammonium	-	269	O
salt	-	278	O
injection	-	283	O
.	-	292	O

The	761833	294	O
effect	-	298	O
of	-	305	O
L	-	308	O
-	-	309	O
dopa	-	310	O
was	-	315	O
correlated	-	319	O
with	-	330	O
a	-	335	O
decrease	-	337	O
in	-	346	O
blood	-	349	O
and	-	355	O
brain	-	359	O
ammonia	-	365	O
,	-	372	O
an	-	374	O
increase	-	377	O
in	-	386	O
brain	-	389	O
dopamine	-	395	O
,	-	403	O
and	-	405	O
an	-	409	O
increase	-	412	O
in	-	421	O
renal	-	424	O
excretion	-	430	O
of	-	440	O
ammonia	-	443	O
and	-	451	O
urea	-	455	O
.	-	459	O

Intraventricular	761833	461	O
infusion	-	478	O
of	-	487	O
dopamine	-	490	O
sufficient	-	499	O
to	-	510	O
raise	-	513	O
the	-	519	O
brain	-	523	O
dopamine	-	529	O
to	-	538	O
the	-	541	O
same	-	545	O
extent	-	550	O
did	-	557	O
not	-	561	O
prevent	-	565	O
the	-	573	O
ammonia	-	577	O
coma	-	585	B
nor	-	590	O
affect	-	594	O
the	-	601	O
blood	-	605	O
and	-	611	O
brain	-	615	O
ammonia	-	621	O
concentrations	-	629	O
.	-	643	O

Bilateral	761833	645	O
nephrectomy	-	655	O
eliminated	-	667	O
the	-	678	O
beneficial	-	682	O
effect	-	693	O
of	-	700	O
L	-	703	O
-	-	704	O
dopa	-	705	O
on	-	710	O
blood	-	713	O
and	-	719	O
brain	-	723	O
ammonia	-	729	O
and	-	737	O
the	-	741	O
ammonia	-	745	O
coma	-	753	B
was	-	758	O
not	-	762	O
prevented	-	766	O
.	-	775	O

Thus	761833	777	O
,	-	781	O
the	-	783	O
reduction	-	787	O
in	-	797	O
blood	-	800	O
and	-	806	O
brain	-	810	O
ammonia	-	816	O
and	-	824	O
the	-	828	O
prevention	-	832	O
of	-	843	O
ammonia	-	846	O
coma	-	854	B
after	-	859	O
L	-	865	O
-	-	866	O
dopa	-	867	O
,	-	871	O
can	-	873	O
be	-	877	O
accounted	-	880	O
for	-	890	O
by	-	894	O
the	-	897	O
peripheral	-	901	O
effect	-	912	O
of	-	919	O
dopamine	-	922	O
on	-	931	O
renal	-	934	O
function	-	940	O
rather	-	949	O
than	-	956	O
its	-	961	O
central	-	965	O
action	-	973	O
.	-	979	O

These	761833	981	O
results	-	987	O
provide	-	995	O
a	-	1003	O
reasonable	-	1005	O
explanation	-	1016	O
for	-	1028	O
the	-	1032	O
beneficial	-	1036	O
effects	-	1047	O
observed	-	1055	O
in	-	1064	O
some	-	1067	O
encephalopathic	-	1072	B
patients	-	1088	O
receiving	-	1097	O
L	-	1107	O
-	-	1108	O
dopa	-	1109	O
.	-	1113	O

Heparin	18589141	0	O
-	-	7	O
induced	-	8	O
thrombocytopenia	-	16	B
after	-	33	O
liver	-	39	O
transplantation	-	45	O
.	-	60	O

BACKGROUND	18589141	62	O
:	-	72	O

Unfractionated	18589141	74	O
heparin	-	89	O
sodium	-	97	O
(	-	104	O
UFH	-	105	O
)	-	108	O
or	-	110	O
low	-	113	O
-	-	116	O
molecular	-	117	O
weight	-	127	O
heparin	-	134	O
(	-	142	O
LMWH	-	143	O
)	-	147	O
is	-	149	O
used	-	152	O
in	-	157	O
anticoagulant	-	160	O
protocols	-	174	O
at	-	184	O
several	-	187	O
institutions	-	195	O
to	-	208	O
prevent	-	211	O
thrombosis	-	219	B
after	-	230	O
liver	-	236	O
transplantation	-	242	O
.	-	257	O

Heparin	18589141	259	O
-	-	266	O
induced	-	267	O
thrombocytopenia	-	275	B
(	-	292	O
HIT	-	293	B
)	-	296	O
is	-	298	O
an	-	301	O
adverse	-	304	O
immune	-	312	O
-	-	318	O
mediated	-	319	O
reaction	-	328	O
to	-	337	O
heparin	-	340	O
,	-	347	O
resulting	-	349	O
in	-	359	O
platelet	-	362	O
count	-	371	O
decreases	-	377	O
of	-	387	O
more	-	390	O
than	-	395	O
50	-	400	O
%	-	402	O
.	-	403	O

The	18589141	405	O
frequencies	-	409	O
of	-	421	O
HIT	-	424	B
after	-	428	O
liver	-	434	O
transplantation	-	440	O
and	-	456	O
platelet	-	460	O
factor	-	469	O
4	-	476	O
/	-	477	O
heparin	-	478	O
-	-	485	O
reactive	-	486	O
antibody	-	495	O
(	-	504	O
HIT	-	505	B
antibody	-	509	O
)	-	517	O
positivity	-	519	O
in	-	530	O
liver	-	533	O
transplantation	-	539	O
patients	-	555	O
,	-	563	O
however	-	565	O
,	-	572	O
are	-	574	O
unknown	-	578	O
.	-	585	O

PATIENTS	18589141	587	O
AND	-	596	O
METHODS	-	600	O
:	-	607	O

The	18589141	609	O
32	-	613	O
men	-	616	O
and	-	620	O
20	-	624	O
women	-	627	O
underwent	-	633	O
living	-	643	O
donor	-	650	O
liver	-	656	O
transplantation	-	662	O
.	-	677	O

We	18589141	679	O
started	-	682	O
LMWH	-	690	O
(	-	695	O
25	-	696	O
IU	-	699	O
/	-	701	O
kg	-	702	O
/	-	704	O
h	-	705	O
)	-	706	O
on	-	708	O
postoperative	-	711	O
day	-	725	O
(	-	729	O
POD	-	730	O
)	-	733	O
1	-	735	O
,	-	736	O
switching	-	738	O
to	-	748	O
UFH	-	751	O
(	-	755	O
5000	-	756	O
U	-	761	O
/	-	762	O
d	-	763	O
)	-	764	O
on	-	766	O
POD	-	769	O
2	-	773	O
or	-	775	O
3	-	778	O
.	-	779	O

The	18589141	781	O
dose	-	785	O
of	-	790	O
UFH	-	793	O
was	-	797	O
changed	-	801	O
according	-	809	O
to	-	819	O
the	-	822	O
activated	-	826	O
clotting	-	836	O
time	-	845	O
level	-	850	O
.	-	855	O

HIT	18589141	857	B
antibody	-	861	O
levels	-	870	O
were	-	877	O
measured	-	882	O
the	-	891	O
day	-	895	O
before	-	899	O
surgery	-	906	O
and	-	914	O
on	-	918	O
POD	-	921	O
7	-	925	O
and	-	927	O
14	-	931	O
.	-	933	O

Platelet	18589141	935	O
count	-	944	O
was	-	950	O
measured	-	954	O
daily	-	963	O
for	-	969	O
3	-	973	O
weeks	-	975	O
.	-	980	O

RESULTS	18589141	982	O
:	-	989	O

The	18589141	991	O
average	-	995	O
platelet	-	1003	O
counts	-	1012	O
preoperatively	-	1019	O
,	-	1033	O
and	-	1035	O
on	-	1039	O
POD	-	1042	O
7	-	1046	O
,	-	1047	O
14	-	1049	O
,	-	1051	O
and	-	1053	O
21	-	1057	O
were	-	1060	O
65	-	1065	O
,	-	1067	O
88	-	1069	O
,	-	1071	O
149	-	1073	O
,	-	1076	O
and	-	1078	O
169	-	1082	O
x	-	1086	O
10	-	1088	O
(	-	1090	O
9	-	1091	O
)	-	1092	O
/	-	1093	O
L	-	1094	O
,	-	1095	O
respectively	-	1097	O
.	-	1109	O

Two	18589141	1111	O
patients	-	1115	O
developed	-	1124	O
hepatic	-	1134	O
artery	-	1142	O
thrombosis	-	1149	B
on	-	1160	O
POD	-	1163	O
11	-	1167	O
and	-	1170	O
19	-	1174	O
,	-	1176	O
respectively	-	1178	O
,	-	1190	O
although	-	1192	O
they	-	1201	O
were	-	1206	O
HIT	-	1211	B
antibody	-	1215	O
-	-	1223	O
negative	-	1224	O
and	-	1233	O
their	-	1237	O
platelet	-	1243	O
counts	-	1252	O
were	-	1259	O
stable	-	1264	O
.	-	1270	O

In	18589141	1272	O
2	-	1275	O
other	-	1277	O
patients	-	1283	O
,	-	1291	O
the	-	1293	O
platelet	-	1297	O
count	-	1306	O
decreased	-	1312	O
suddenly	-	1322	O
from	-	1331	O
107	-	1336	O
x	-	1340	O
10	-	1342	O
(	-	1344	O
9	-	1345	O
)	-	1346	O
/	-	1347	O
L	-	1348	O
on	-	1350	O
POD	-	1353	O
4	-	1357	O
to	-	1359	O
65	-	1362	O
x	-	1365	O
10	-	1367	O
(	-	1369	O
9	-	1370	O
)	-	1371	O
/	-	1372	O
L	-	1373	O
on	-	1375	O
POD	-	1378	O
6	-	1382	O
and	-	1384	O
from	-	1388	O
76	-	1393	O
x	-	1396	O
10	-	1398	O
(	-	1400	O
9	-	1401	O
)	-	1402	O
/	-	1403	O
L	-	1404	O
on	-	1406	O
POD	-	1409	O
7	-	1413	O
to	-	1415	O
33	-	1418	O
x	-	1421	O
10	-	1423	O
(	-	1425	O
9	-	1426	O
)	-	1427	O
/	-	1428	O
L	-	1429	O
on	-	1431	O
POD	-	1434	O
9	-	1438	O
,	-	1439	O
respectively	-	1441	O
.	-	1453	O

The	18589141	1455	O
heparin	-	1459	O
-	-	1466	O
induced	-	1467	O
platelet	-	1475	B
aggregation	-	1484	I
test	-	1496	O
was	-	1501	O
negative	-	1505	O
in	-	1514	O
these	-	1517	O
patients	-	1523	O
.	-	1531	O

The	18589141	1533	O
percentage	-	1537	O
of	-	1548	O
HIT	-	1551	B
antibody	-	1555	O
-	-	1563	O
positive	-	1564	O
patients	-	1573	O
was	-	1582	O
0	-	1586	O
.	-	1587	O
5	-	1588	O
%	-	1589	O
preoperatively	-	1591	O
,	-	1605	O
5	-	1607	O
.	-	1608	O
6	-	1609	O
%	-	1610	O
on	-	1612	O
POD	-	1615	O
7	-	1619	O
,	-	1620	O
and	-	1622	O
5	-	1626	O
.	-	1627	O
6	-	1628	O
%	-	1629	O
on	-	1631	O
POD	-	1634	O
14	-	1638	O
.	-	1640	O

None	18589141	1642	O
of	-	1647	O
the	-	1650	O
subjects	-	1654	O
/	-	1662	O
patients	-	1663	O
developed	-	1672	O
UFH	-	1682	O
-	-	1685	O
related	-	1686	O
HIT	-	1694	B
.	-	1697	O

CONCLUSIONS	18589141	1699	O
:	-	1710	O

In	18589141	1712	O
our	-	1715	O
series	-	1719	O
,	-	1725	O
the	-	1727	O
occurrence	-	1731	O
of	-	1742	O
HIT	-	1745	B
after	-	1749	O
liver	-	1755	O
transplantation	-	1761	O
was	-	1777	O
uncommon	-	1781	O
.	-	1789	O

PTU	16418614	0	O
-	-	3	O
associated	-	4	O
vasculitis	-	15	B
in	-	26	O
a	-	29	O
girl	-	31	O
with	-	36	O
Turner	-	41	B
Syndrome	-	48	I
and	-	57	O
Graves	-	61	B
'	-	67	I
disease	-	69	I
.	-	76	O

Palpable	16418614	78	O
purpura	-	87	B
is	-	95	O
a	-	98	O
concerning	-	100	O
clinical	-	111	O
finding	-	120	O
in	-	128	O
pediatric	-	131	O
patients	-	141	O
and	-	150	O
can	-	154	O
have	-	158	O
many	-	163	O
causes	-	168	O
,	-	174	O
including	-	176	O
infectious	-	186	O
and	-	197	O
autoimmune	-	201	O
processes	-	212	O
.	-	221	O

A	16418614	223	O
rare	-	225	O
cause	-	230	O
,	-	235	O
drug	-	237	O
-	-	241	O
induced	-	242	O
vasculitis	-	250	B
,	-	260	O
may	-	262	O
result	-	266	O
from	-	273	O
the	-	278	O
production	-	282	O
of	-	293	O
antineutrophil	-	296	O
cytoplasmic	-	311	O
antibodies	-	323	O
(	-	334	O
ANCAs	-	335	O
)	-	340	O
in	-	342	O
response	-	345	O
to	-	354	O
a	-	357	O
medication	-	359	O
.	-	369	O

We	16418614	371	O
report	-	374	O
a	-	381	O
girl	-	383	O
with	-	388	O
Turner	-	393	B
syndrome	-	400	I
and	-	409	O
Graves	-	413	B
'	-	419	I
disease	-	421	I
who	-	429	O
presented	-	433	O
with	-	443	O
palpable	-	448	O
purpuric	-	457	B
lesions	-	466	I
.	-	473	O

The	16418614	475	O
diagnosis	-	479	O
of	-	489	O
propylthiouracil	-	492	O
(	-	509	O
PTU	-	510	O
)	-	513	O
-	-	514	O
associated	-	515	O
vasculitis	-	526	B
was	-	537	O
made	-	541	O
by	-	546	O
observation	-	549	O
of	-	561	O
consistent	-	564	O
clinical	-	575	O
features	-	584	O
,	-	592	O
the	-	594	O
detection	-	598	O
of	-	608	O
elevated	-	611	O
ANA	-	620	O
and	-	624	O
ANCA	-	628	O
in	-	633	O
the	-	636	O
blood	-	640	O
,	-	645	O
and	-	647	O
the	-	651	O
observed	-	655	O
clinical	-	664	O
resolution	-	673	O
of	-	684	O
symptoms	-	687	O
following	-	696	O
withdrawal	-	706	O
of	-	717	O
PTU	-	720	O
.	-	723	O

Subsequent	16418614	725	O
treatment	-	736	O
of	-	746	O
persistent	-	749	O
hyperthyroidism	-	760	B
with	-	776	O
radioablation	-	781	O
did	-	795	O
not	-	799	O
result	-	803	O
in	-	810	O
an	-	813	O
exacerbation	-	816	O
of	-	829	O
the	-	832	O
vasculitis	-	836	B
,	-	846	O
a	-	848	O
complication	-	850	O
described	-	863	O
in	-	873	O
prior	-	876	O
case	-	882	O
reports	-	887	O
.	-	894	O

Succinylcholine	15893386	0	O
-	-	15	O
induced	-	16	O
masseter	-	24	B
muscle	-	33	I
rigidity	-	40	I
during	-	49	O
bronchoscopic	-	56	O
removal	-	70	O
of	-	78	O
a	-	81	O
tracheal	-	83	O
foreign	-	92	O
body	-	100	O
.	-	104	O

Masseter	15893386	106	B
muscle	-	115	I
rigidity	-	122	I
during	-	131	O
general	-	138	O
anesthesia	-	146	O
is	-	157	O
considered	-	160	O
an	-	171	O
early	-	174	O
warning	-	180	O
sign	-	188	O
of	-	193	O
a	-	196	O
possible	-	198	O
episode	-	207	O
of	-	215	O
malignant	-	218	B
hyperthermia	-	228	I
.	-	240	O

The	15893386	242	O
decision	-	246	O
whether	-	255	O
to	-	263	O
continue	-	266	O
or	-	275	O
discontinue	-	278	O
the	-	290	O
procedure	-	294	O
depends	-	304	O
on	-	312	O
the	-	315	O
urgency	-	319	O
of	-	327	O
the	-	330	O
surgery	-	334	O
and	-	342	O
severity	-	346	O
of	-	355	O
masseter	-	358	B
muscle	-	367	I
rigidity	-	374	I
.	-	382	O

Here	15893386	384	O
,	-	388	O
we	-	390	O
describe	-	393	O
a	-	402	O
case	-	404	O
of	-	409	O
severe	-	412	O
masseter	-	419	B
muscle	-	428	I
rigidity	-	435	I
(	-	444	O
jaw	-	445	B
of	-	449	I
steel	-	452	I
)	-	457	O
after	-	459	O
succinylcholine	-	465	O
(	-	481	O
Sch	-	482	O
)	-	485	O
administration	-	487	O
during	-	502	O
general	-	509	O
anesthetic	-	517	O
management	-	528	O
for	-	539	O
rigid	-	543	O
bronchoscopic	-	549	O
removal	-	563	O
of	-	571	O
a	-	574	O
tracheal	-	576	O
foreign	-	585	O
body	-	593	O
.	-	597	O

Anesthesia	15893386	599	O
was	-	610	O
continued	-	614	O
uneventfully	-	624	O
with	-	637	O
propofol	-	642	O
infusion	-	651	O
while	-	660	O
all	-	666	O
facilities	-	670	O
were	-	681	O
available	-	686	O
to	-	696	O
detect	-	699	O
and	-	706	O
treat	-	710	O
malignant	-	716	B
hyperthermia	-	726	I
.	-	738	O

Minor	15814210	0	O
neurological	-	6	B
dysfunction	-	19	I
,	-	30	O
cognitive	-	32	O
development	-	42	O
,	-	53	O
and	-	55	O
somatic	-	59	O
development	-	67	O
at	-	79	O
the	-	82	O
age	-	86	O
of	-	90	O
3	-	93	O
to	-	95	O
7	-	98	O
years	-	100	O
after	-	106	O
dexamethasone	-	112	O
treatment	-	126	O
in	-	136	O
very	-	139	O
-	-	143	O
low	-	144	O
birth	-	148	O
-	-	153	O
weight	-	154	O
infants	-	161	O
.	-	168	O

The	15814210	170	O
objective	-	174	O
of	-	184	O
this	-	187	O
study	-	192	O
was	-	198	O
to	-	202	O
assess	-	205	O
minor	-	212	O
neurological	-	218	B
dysfunction	-	231	I
,	-	242	O
cognitive	-	244	O
development	-	254	O
,	-	265	O
and	-	267	O
somatic	-	271	O
development	-	279	O
after	-	291	O
dexamethasone	-	297	O
therapy	-	311	O
in	-	319	O
very	-	322	O
-	-	326	O
low	-	327	O
-	-	330	O
birthweight	-	331	O
infants	-	343	O
.	-	350	O

Thirty	15814210	352	O
-	-	358	O
three	-	359	O
children	-	365	O
after	-	374	O
dexamethasone	-	380	O
treatment	-	394	O
were	-	404	O
matched	-	409	O
to	-	417	O
33	-	420	O
children	-	423	O
without	-	432	O
dexamethasone	-	440	O
treatment	-	454	O
.	-	463	O

Data	15814210	465	O
were	-	470	O
assessed	-	475	O
at	-	484	O
the	-	487	O
age	-	491	O
of	-	495	O
3	-	498	O
-	-	499	O
7	-	500	O
years	-	502	O
.	-	507	O

Dexamethasone	15814210	509	O
was	-	523	O
started	-	527	O
between	-	535	O
the	-	543	O
7th	-	547	O
and	-	551	O
the	-	555	O
28th	-	559	O
day	-	564	O
of	-	568	O
life	-	571	O
over	-	576	O
7	-	581	O
days	-	583	O
with	-	588	O
a	-	593	O
total	-	595	O
dose	-	601	O
of	-	606	O
2	-	609	O
.	-	610	O
35	-	611	O
mg	-	614	O
/	-	616	O
kg	-	617	O
/	-	619	O
day	-	620	O
.	-	623	O

Exclusion	15814210	625	O
criteria	-	635	O
were	-	644	O
asphyxia	-	649	B
,	-	657	O
malformations	-	659	B
,	-	672	O
major	-	674	O
surgical	-	680	O
interventions	-	689	O
,	-	702	O
small	-	704	O
for	-	710	O
gestational	-	714	O
age	-	726	O
,	-	729	O
intraventricular	-	731	O
haemorrhage	-	748	B
grades	-	760	O
III	-	767	O
and	-	771	O
IV	-	775	O
,	-	777	O
periventricular	-	779	B
leukomalacia	-	795	I
,	-	807	O
and	-	809	O
severe	-	813	O
psychomotor	-	820	B
retardation	-	832	I
.	-	843	O

Each	15814210	845	O
child	-	850	O
was	-	856	O
examined	-	860	O
by	-	869	O
a	-	872	O
neuropediatrician	-	874	O
for	-	892	O
minor	-	896	O
neurological	-	902	B
dysfunctions	-	915	I
and	-	928	O
tested	-	932	O
by	-	939	O
a	-	942	O
psychologist	-	944	O
for	-	957	O
cognitive	-	961	O
development	-	971	O
with	-	983	O
a	-	988	O
Kaufman	-	990	O
Assessment	-	998	O
Battery	-	1009	O
for	-	1017	O
Children	-	1021	O
and	-	1030	O
a	-	1034	O
Draw	-	1036	O
-	-	1040	O
a	-	1041	O
-	-	1042	O
Man	-	1043	O
Test	-	1047	O
.	-	1051	O

There	15814210	1053	O
were	-	1059	O
no	-	1064	O
differences	-	1067	O
in	-	1079	O
demographic	-	1082	O
data	-	1094	O
,	-	1098	O
growth	-	1100	O
,	-	1106	O
and	-	1108	O
socio	-	1112	O
-	-	1117	O
economic	-	1118	O
status	-	1127	O
between	-	1134	O
the	-	1142	O
two	-	1146	O
groups	-	1150	O
.	-	1156	O

Fine	15814210	1158	O
motor	-	1163	O
skills	-	1169	O
and	-	1176	O
gross	-	1180	O
motor	-	1186	O
function	-	1192	O
were	-	1201	O
significantly	-	1206	O
better	-	1220	O
in	-	1227	O
the	-	1230	O
control	-	1234	O
group	-	1242	O
(	-	1248	O
p	-	1249	O
<	-	1250	O
0	-	1251	O
.	-	1252	O
01	-	1253	O
)	-	1255	O
.	-	1256	O

In	15814210	1258	O
the	-	1261	O
Draw	-	1265	O
-	-	1269	O
a	-	1270	O
-	-	1271	O
Man	-	1272	O
Test	-	1276	O
,	-	1280	O
the	-	1282	O
control	-	1286	O
group	-	1294	O
showed	-	1300	O
better	-	1307	O
results	-	1314	O
(	-	1322	O
p	-	1323	O
<	-	1324	O
0	-	1325	O
.	-	1326	O
001	-	1327	O
)	-	1330	O
.	-	1331	O

There	15814210	1333	O
were	-	1339	O
no	-	1344	O
differences	-	1347	O
in	-	1359	O
development	-	1362	O
of	-	1374	O
speech	-	1377	O
,	-	1383	O
social	-	1385	O
development	-	1392	O
,	-	1403	O
and	-	1405	O
the	-	1409	O
Kaufman	-	1413	O
Assessment	-	1421	O
Battery	-	1432	O
for	-	1440	O
Children	-	1444	O
.	-	1452	O

After	15814210	1454	O
dexamethasone	-	1460	O
treatment	-	1474	O
,	-	1483	O
children	-	1485	O
showed	-	1494	O
a	-	1501	O
higher	-	1503	O
rate	-	1510	O
of	-	1515	O
minor	-	1518	O
neurological	-	1524	B
dysfunctions	-	1537	I
.	-	1549	O

Neurological	15814210	1551	O
development	-	1564	O
was	-	1576	O
affected	-	1580	O
even	-	1589	O
without	-	1594	O
neurological	-	1602	O
diagnosis	-	1615	O
.	-	1624	O

Further	15814210	1626	O
long	-	1634	O
-	-	1638	O
term	-	1639	O
follow	-	1644	O
-	-	1650	O
up	-	1651	O
studies	-	1654	O
will	-	1662	O
be	-	1667	O
necessary	-	1670	O
to	-	1680	O
fully	-	1683	O
evaluate	-	1689	O
the	-	1698	O
impact	-	1702	O
of	-	1709	O
dexamethasone	-	1712	O
on	-	1726	O
neurological	-	1729	O
and	-	1742	O
cognitive	-	1746	O
development	-	1756	O
.	-	1767	O

Force	11912119	0	O
overflow	-	6	O
and	-	15	O
levodopa	-	19	O
-	-	27	O
induced	-	28	O
dyskinesias	-	36	B
in	-	48	O
Parkinson	-	51	B
's	-	60	I
disease	-	63	I
.	-	70	O

We	11912119	72	O
assessed	-	75	O
force	-	84	O
coordination	-	90	O
of	-	103	O
the	-	106	O
hand	-	110	O
in	-	115	O
Parkinson	-	118	B
's	-	127	I
disease	-	130	I
and	-	138	O
its	-	142	O
relationship	-	146	O
to	-	159	O
motor	-	162	O
complications	-	168	O
of	-	182	O
levodopa	-	185	O
therapy	-	194	O
,	-	201	O
particularly	-	203	O
to	-	216	O
levodopa	-	219	O
-	-	227	O
induced	-	228	O
dyskinesias	-	236	B
(	-	248	O
LID	-	249	B
)	-	252	O
.	-	253	O

We	11912119	255	O
studied	-	258	O
two	-	266	O
groups	-	270	O
of	-	277	O
Parkinson	-	280	B
's	-	289	I
disease	-	292	I
patients	-	300	O
with	-	309	O
(	-	314	O
Parkinson	-	315	B
's	-	324	I
disease	-	327	I
+	-	335	O
LID	-	337	B
,	-	340	O
n	-	342	O
=	-	344	O
23	-	346	O
)	-	348	O
and	-	350	O
without	-	354	O
levodopa	-	362	O
-	-	370	O
induced	-	371	O
dyskinesias	-	379	B
(	-	391	O
Parkinson	-	392	B
's	-	401	I
disease	-	404	I
-	-	412	O
LID	-	414	B
,	-	417	O
n	-	419	O
=	-	421	O
10	-	423	O
)	-	425	O
,	-	426	O
and	-	428	O
age	-	432	O
-	-	435	O
matched	-	436	O
healthy	-	444	O
controls	-	452	O
.	-	460	O

The	11912119	462	O
motor	-	466	O
score	-	472	O
of	-	478	O
the	-	481	O
Unified	-	485	O
Parkinson	-	493	B
's	-	502	I
Disease	-	505	I
Rating	-	513	O
Scale	-	520	O
,	-	525	O
a	-	527	O
dyskinesia	-	529	B
score	-	540	O
and	-	546	O
force	-	550	O
in	-	556	O
a	-	559	O
grip	-	561	O
-	-	565	O
lift	-	566	O
paradigm	-	571	O
were	-	580	O
assessed	-	585	O
ON	-	594	O
and	-	597	O
OFF	-	601	O
levodopa	-	605	O
.	-	613	O

A	11912119	615	O
pathological	-	617	O
increase	-	630	O
of	-	639	O
forces	-	642	O
was	-	649	O
seen	-	653	O
in	-	658	O
ON	-	661	O
-	-	663	O
state	-	664	O
in	-	670	O
Parkinson	-	673	B
's	-	682	I
disease	-	685	I
+	-	693	O
LID	-	695	B
only	-	699	O
.	-	703	O

In	11912119	705	O
Parkinson	-	708	B
's	-	717	I
disease	-	720	I
+	-	728	O
LID	-	730	B
,	-	733	O
the	-	735	O
force	-	739	O
involved	-	745	O
in	-	754	O
pressing	-	757	O
down	-	766	O
the	-	771	O
object	-	775	O
before	-	782	O
lifting	-	789	O
was	-	797	O
significantly	-	801	O
increased	-	815	O
by	-	825	O
levodopa	-	828	O
(	-	837	O
by	-	838	O
61	-	841	O
%	-	843	O
,	-	844	O
P	-	846	O
<	-	848	O
0	-	850	O
.	-	851	O
05	-	852	O
)	-	854	O
.	-	855	O

An	11912119	857	O
overshooting	-	860	O
of	-	873	O
peak	-	876	O
grip	-	881	O
force	-	886	O
by	-	892	O
51	-	895	O
%	-	897	O
(	-	899	O
P	-	900	O
<	-	902	O
0	-	904	O
.	-	905	O
05	-	906	O
)	-	908	O
and	-	910	O
of	-	914	O
static	-	917	O
grip	-	924	O
force	-	929	O
by	-	935	O
45	-	938	O
%	-	940	O
(	-	942	O
P	-	943	O
<	-	945	O
0	-	947	O
.	-	948	O
01	-	949	O
)	-	951	O
was	-	953	O
observed	-	957	O
in	-	966	O
the	-	969	O
ON	-	973	O
-	-	975	O
compared	-	977	O
with	-	986	O
the	-	991	O
OFF	-	995	O
-	-	998	O
drug	-	999	O
condition	-	1004	O
.	-	1013	O

In	11912119	1015	O
contrast	-	1018	O
,	-	1026	O
no	-	1028	O
excessive	-	1031	O
force	-	1041	O
was	-	1047	O
found	-	1051	O
in	-	1057	O
Parkinson	-	1060	B
's	-	1069	I
disease	-	1072	I
-	-	1080	O
LID	-	1082	B
.	-	1085	O

Peak	11912119	1087	O
grip	-	1092	O
force	-	1097	O
in	-	1103	O
ON	-	1106	O
-	-	1108	O
state	-	1109	O
was	-	1115	O
140	-	1119	O
%	-	1122	O
(	-	1124	O
P	-	1125	O
<	-	1127	O
0	-	1129	O
.	-	1130	O
05	-	1131	O
)	-	1133	O
higher	-	1135	O
in	-	1142	O
Parkinson	-	1145	B
's	-	1154	I
disease	-	1157	I
+	-	1165	O
LID	-	1167	B
than	-	1171	O
in	-	1176	O
Parkinson	-	1179	B
's	-	1188	I
disease	-	1191	I
-	-	1199	O
LID	-	1201	B
,	-	1204	O
while	-	1206	O
static	-	1212	O
grip	-	1219	O
force	-	1224	O
was	-	1230	O
increased	-	1234	O
by	-	1244	O
138	-	1247	O
%	-	1250	O
(	-	1252	O
P	-	1253	O
<	-	1255	O
0	-	1257	O
.	-	1258	O
01	-	1259	O
)	-	1261	O
between	-	1263	O
groups	-	1271	O
.	-	1277	O

Severity	11912119	1279	O
of	-	1288	O
peak	-	1291	O
-	-	1295	O
dose	-	1296	O
dyskinesias	-	1301	B
was	-	1313	O
strongly	-	1317	O
correlated	-	1326	O
with	-	1337	O
grip	-	1342	O
force	-	1347	O
in	-	1353	O
ON	-	1356	O
-	-	1358	O
state	-	1359	O
(	-	1365	O
r	-	1366	O
=	-	1368	O
0	-	1370	O
.	-	1371	O
79	-	1372	O
with	-	1375	O
peak	-	1380	O
force	-	1385	O
,	-	1390	O
P	-	1392	O
<	-	1394	O
0	-	1396	O
.	-	1397	O
01	-	1398	O
)	-	1400	O
.	-	1401	O

No	11912119	1403	O
correlation	-	1406	O
was	-	1418	O
observed	-	1422	O
between	-	1431	O
forces	-	1439	O
and	-	1446	O
the	-	1450	O
motor	-	1454	O
score	-	1460	O
as	-	1466	O
well	-	1469	O
as	-	1474	O
with	-	1477	O
the	-	1482	O
daily	-	1486	O
dose	-	1492	O
of	-	1497	O
dopaminergic	-	1500	O
medication	-	1513	O
.	-	1523	O

Force	11912119	1525	O
excess	-	1531	O
was	-	1538	O
only	-	1542	O
observed	-	1547	O
in	-	1556	O
patients	-	1559	O
with	-	1568	O
LID	-	1573	B
and	-	1577	O
motor	-	1581	O
fluctuations	-	1587	O
.	-	1599	O

A	11912119	1601	O
close	-	1603	O
relationship	-	1609	O
was	-	1622	O
seen	-	1626	O
between	-	1631	O
the	-	1639	O
overshooting	-	1643	O
of	-	1656	O
forces	-	1659	O
and	-	1666	O
dyskinesias	-	1670	B
in	-	1682	O
the	-	1685	O
ON	-	1689	O
-	-	1691	O
drug	-	1692	O
condition	-	1697	O
.	-	1706	O

We	11912119	1708	O
postulate	-	1711	O
that	-	1721	O
both	-	1726	O
LID	-	1731	B
and	-	1735	O
grip	-	1739	O
force	-	1744	O
excess	-	1750	O
share	-	1757	O
common	-	1763	O
pathophysiological	-	1770	O
mechanisms	-	1789	O
related	-	1800	O
to	-	1808	O
motor	-	1811	O
fluctuations	-	1817	O
.	-	1829	O

Postinfarction	9105126	0	O
ventricular	-	15	B
septal	-	27	I
defect	-	34	I
associated	-	41	O
with	-	52	O
long	-	57	O
-	-	61	O
term	-	62	O
steroid	-	67	O
therapy	-	75	O
.	-	82	O

Two	9105126	84	O
cases	-	88	O
of	-	94	O
postinfarction	-	97	O
ventricular	-	112	B
septal	-	124	I
rupture	-	131	I
in	-	139	O
patients	-	142	O
on	-	151	O
long	-	154	O
-	-	158	O
term	-	159	O
steroid	-	164	O
therapy	-	172	O
are	-	180	O
presented	-	184	O
and	-	194	O
the	-	198	O
favourable	-	202	O
outcome	-	213	O
in	-	221	O
both	-	224	O
cases	-	229	O
described	-	235	O
.	-	244	O

A	9105126	246	O
possible	-	248	O
association	-	257	O
between	-	269	O
steroid	-	277	O
therapy	-	285	O
and	-	293	O
subsequent	-	297	O
postinfarction	-	308	O
septal	-	323	B
rupture	-	330	I
is	-	338	O
discussed	-	341	O
.	-	350	O

Angioedema	8599504	0	B
associated	-	11	O
with	-	22	O
droperidol	-	27	O
administration	-	38	O
.	-	52	O

Angioedema	8599504	54	B
,	-	64	O
also	-	66	O
known	-	71	O
as	-	77	O
angioneurotic	-	80	B
edema	-	94	I
or	-	100	O
Quincke	-	103	B
's	-	110	I
disease	-	113	I
,	-	120	O
is	-	122	O
a	-	125	O
well	-	127	O
-	-	131	O
demarcated	-	132	O
,	-	142	O
localized	-	144	O
edema	-	154	B
involving	-	160	O
the	-	170	O
subcutaneous	-	174	O
tissues	-	187	O
that	-	195	O
may	-	200	O
cause	-	204	O
upper	-	210	B
-	-	215	I
airway	-	216	I
obstruction	-	223	I
.	-	234	O

We	8599504	236	O
report	-	239	O
the	-	246	O
case	-	250	O
of	-	255	O
a	-	258	O
previously	-	260	O
healthy	-	271	O
19	-	279	O
-	-	281	O
year	-	282	O
-	-	286	O
old	-	287	O
man	-	291	O
with	-	295	O
no	-	300	O
known	-	303	O
drug	-	309	B
allergies	-	314	I
in	-	324	O
whom	-	327	O
angioedema	-	332	B
with	-	343	O
significant	-	348	O
tongue	-	360	B
swelling	-	367	I
and	-	376	O
protrusion	-	380	O
developed	-	391	O
within	-	401	O
10	-	408	O
minutes	-	411	O
of	-	419	O
the	-	422	O
administration	-	426	O
of	-	441	O
a	-	444	O
single	-	446	O
IV	-	453	O
dose	-	456	O
of	-	461	O
droperidol	-	464	O
.	-	474	O

Clarithromycin	8546130	0	O
-	-	14	O
associated	-	15	O
visual	-	26	B
hallucinations	-	33	I
in	-	48	O
a	-	51	O
patient	-	53	O
with	-	61	O
chronic	-	66	B
renal	-	74	I
failure	-	80	I
on	-	88	O
continuous	-	91	O
ambulatory	-	102	O
peritoneal	-	113	O
dialysis	-	124	O
.	-	132	O

Visual	8546130	134	B
hallucinations	-	141	I
are	-	156	O
a	-	160	O
rare	-	162	O
event	-	167	O
in	-	173	O
chronic	-	176	B
renal	-	184	I
failure	-	190	I
and	-	198	O
not	-	202	O
related	-	206	O
to	-	214	O
uremia	-	217	B
per	-	224	O
se	-	228	O
.	-	230	O

Unreported	8546130	232	O
in	-	243	O
the	-	246	O
literature	-	250	O
is	-	261	O
visual	-	264	B
hallucinations	-	271	I
occurring	-	286	O
in	-	296	O
association	-	299	O
with	-	311	O
the	-	316	O
new	-	320	O
macrolide	-	324	O
antibiotic	-	334	O
,	-	344	O
clarithromycin	-	346	O
.	-	360	O

We	8546130	362	O
describe	-	365	O
such	-	374	O
a	-	379	O
case	-	381	O
in	-	386	O
a	-	389	O
patient	-	391	O
with	-	399	O
end	-	404	B
-	-	407	I
stage	-	408	I
renal	-	414	I
disease	-	420	I
(	-	428	O
ESRD	-	429	B
)	-	433	O
maintained	-	435	O
on	-	446	O
continuous	-	449	O
ambulatory	-	460	O
peritoneal	-	471	O
dialysis	-	482	O
(	-	491	O
CAPD	-	492	O
)	-	496	O
.	-	497	O

The	8546130	499	O
combination	-	503	O
of	-	515	O
a	-	518	O
relatively	-	520	O
high	-	531	O
dose	-	536	O
of	-	541	O
clarithromycin	-	544	O
in	-	559	O
face	-	562	O
of	-	567	O
chronic	-	570	B
renal	-	578	I
failure	-	584	I
in	-	592	O
a	-	595	O
functionally	-	597	O
anephric	-	610	O
patient	-	619	O
,	-	626	O
with	-	628	O
underlying	-	633	O
aluminum	-	644	O
intoxication	-	653	O
,	-	665	O
may	-	667	O
have	-	671	O
facilitated	-	676	O
the	-	688	O
appearance	-	692	O
of	-	703	O
this	-	706	O
neurotoxic	-	711	B
side	-	722	O
effect	-	727	O
.	-	733	O

It	8546130	735	O
is	-	738	O
important	-	741	O
to	-	751	O
understand	-	754	O
the	-	765	O
pharmacokinetics	-	769	O
of	-	786	O
medications	-	789	O
in	-	801	O
face	-	804	O
of	-	809	O
chronic	-	812	B
renal	-	820	I
failure	-	826	I
,	-	833	O
the	-	835	O
possibility	-	839	O
of	-	851	O
drug	-	854	O
interactions	-	859	O
,	-	871	O
and	-	873	O
how	-	877	O
these	-	881	O
factors	-	887	O
should	-	895	O
help	-	902	O
guide	-	907	O
medication	-	913	O
therapy	-	924	O
in	-	932	O
the	-	935	O
ESRD	-	939	B
patient	-	944	O
.	-	951	O

Acute	7724492	0	O
renal	-	6	B
toxicity	-	12	I
of	-	21	O
doxorubicin	-	24	O
(	-	36	O
adriamycin	-	37	O
)	-	47	O
-	-	48	O
loaded	-	49	O
cyanoacrylate	-	56	O
nanoparticles	-	70	O
.	-	83	O

Acute	7724492	85	O
doxorubicin	-	91	O
-	-	102	O
loaded	-	103	O
nanoparticle	-	110	O
(	-	123	O
DXNP	-	124	O
)	-	128	O
renal	-	130	B
toxicity	-	136	I
was	-	145	O
explored	-	149	O
in	-	158	O
both	-	161	O
normal	-	166	O
rats	-	173	O
and	-	178	O
rats	-	182	O
with	-	187	O
experimental	-	192	O
glomerulonephritis	-	205	B
.	-	223	O

In	7724492	225	O
normal	-	228	O
rats	-	235	O
,	-	239	O
2	-	241	O
/	-	242	O
6	-	243	O
rats	-	245	O
given	-	250	O
free	-	256	O
doxorubicin	-	261	O
(	-	273	O
DX	-	274	O
)	-	276	O
(	-	278	O
5	-	279	O
mg	-	281	O
/	-	283	O
kg	-	284	O
)	-	286	O
died	-	288	O
within	-	293	O
one	-	300	O
week	-	304	O
,	-	308	O
whereas	-	310	O
all	-	318	O
control	-	322	O
animals	-	330	O
and	-	338	O
all	-	342	O
rats	-	346	O
having	-	351	O
received	-	358	O
free	-	367	O
NP	-	372	O
or	-	375	O
DXNP	-	378	O
survived	-	383	O
.	-	391	O

A	7724492	393	O
3	-	395	O
times	-	397	O
higher	-	403	O
proteinuria	-	410	B
appeared	-	422	O
in	-	431	O
animals	-	434	O
treated	-	442	O
with	-	450	O
DXNP	-	455	O
than	-	460	O
in	-	465	O
those	-	468	O
treated	-	474	O
with	-	482	O
DX	-	487	O
.	-	489	O

Free	7724492	491	O
NP	-	496	O
did	-	499	O
not	-	503	O
provoke	-	507	O
any	-	515	O
proteinuria	-	519	B
.	-	530	O

Two	7724492	532	O
hr	-	536	O
post	-	539	O
-	-	543	O
injection	-	544	O
,	-	553	O
DXNP	-	555	O
was	-	560	O
2	-	564	O
.	-	565	O
7	-	566	O
times	-	568	O
more	-	574	O
concentrated	-	579	O
in	-	592	O
kidneys	-	595	O
than	-	603	O
free	-	608	O
DX	-	613	O
(	-	616	O
p	-	617	O
<	-	619	O
0	-	621	O
.	-	622	O
025	-	623	O
)	-	626	O
.	-	627	O

In	7724492	629	O
rats	-	632	O
with	-	637	O
immune	-	642	O
experimental	-	649	O
glomerulonephritis	-	662	B
,	-	680	O
5	-	682	O
/	-	683	O
6	-	684	O
rats	-	686	O
given	-	691	O
DX	-	697	O
died	-	700	O
within	-	705	O
7	-	712	O
days	-	714	O
,	-	718	O
in	-	720	O
contrast	-	723	O
to	-	732	O
animals	-	735	O
treated	-	743	O
by	-	751	O
DXNP	-	754	O
,	-	758	O
NP	-	760	O
,	-	762	O
or	-	764	O
untreated	-	767	O
,	-	776	O
which	-	778	O
all	-	784	O
survived	-	788	O
.	-	796	O

Proteinuria	7724492	798	B
appeared	-	810	O
in	-	819	O
all	-	822	O
series	-	826	O
,	-	832	O
but	-	834	O
was	-	838	O
2	-	842	O
-	-	843	O
5	-	844	O
times	-	846	O
more	-	852	O
intense	-	857	O
(	-	865	O
p	-	866	O
>	-	868	O
0	-	870	O
.	-	871	O
001	-	872	O
)	-	875	O
and	-	877	O
prolonged	-	881	O
after	-	891	O
doxorubicin	-	897	O
treatment	-	909	O
(	-	919	O
400	-	920	O
-	-	923	O
700	-	924	O
mg	-	928	O
/	-	930	O
day	-	931	O
)	-	934	O
,	-	935	O
without	-	937	O
significant	-	945	O
difference	-	957	O
between	-	968	O
DXNP	-	976	O
and	-	981	O
DX	-	985	O
.	-	987	O

Rats	7724492	989	O
treated	-	994	O
by	-	1002	O
unloaded	-	1005	O
NP	-	1014	O
behaved	-	1017	O
as	-	1025	O
controls	-	1028	O
.	-	1036	O

These	7724492	1038	O
results	-	1044	O
demonstrate	-	1052	O
that	-	1064	O
,	-	1068	O
in	-	1070	O
these	-	1073	O
experimental	-	1079	O
conditions	-	1092	O
,	-	1102	O
DXNP	-	1104	O
killed	-	1109	O
less	-	1116	O
animals	-	1121	O
than	-	1129	O
free	-	1134	O
DX	-	1139	O
,	-	1141	O
despite	-	1143	O
of	-	1151	O
an	-	1154	O
enhanced	-	1157	O
renal	-	1166	B
toxicity	-	1172	I
of	-	1181	O
the	-	1184	O
former	-	1188	O
.	-	1194	O

Both	7724492	1196	O
effects	-	1201	O
(	-	1209	O
better	-	1210	O
survival	-	1217	O
and	-	1226	O
nephrosis	-	1230	B
)	-	1239	O
are	-	1241	O
most	-	1245	O
probably	-	1250	O
related	-	1259	O
to	-	1267	O
an	-	1270	O
enhanced	-	1273	O
capture	-	1282	O
of	-	1290	O
DXNP	-	1293	O
by	-	1298	O
cells	-	1301	O
of	-	1307	O
the	-	1310	O
mononuclear	-	1314	O
phagocyte	-	1326	O
system	-	1336	O
,	-	1342	O
including	-	1344	O
mesangial	-	1354	O
cells	-	1364	O
.	-	1369	O

Etoposide	7619765	0	O
-	-	9	O
related	-	10	O
myocardial	-	18	B
infarction	-	29	I
.	-	39	O

The	7619765	41	O
occurrence	-	45	O
of	-	56	O
a	-	59	O
myocardial	-	61	B
infarction	-	72	I
is	-	83	O
reported	-	86	O
after	-	95	O
chemotherapy	-	101	O
containing	-	114	O
etoposide	-	125	O
,	-	134	O
in	-	136	O
a	-	139	O
man	-	141	O
with	-	145	O
no	-	150	O
risk	-	153	O
factors	-	158	O
for	-	166	O
coronary	-	170	B
heart	-	179	I
disease	-	185	I
.	-	192	O

Possible	7619765	194	O
causal	-	203	O
mechanisms	-	210	O
are	-	221	O
discussed	-	225	O
.	-	234	O

Subjective	7416947	0	O
assessment	-	11	O
of	-	22	O
sexual	-	25	B
dysfunction	-	32	I
of	-	44	O
patients	-	47	O
on	-	56	O
long	-	59	O
-	-	63	O
term	-	64	O
administration	-	69	O
of	-	84	O
digoxin	-	87	O
.	-	94	O

Various	7416947	96	O
data	-	104	O
suggest	-	109	O
that	-	117	O
male	-	122	O
patients	-	127	O
who	-	136	O
have	-	140	O
received	-	145	O
digoxin	-	154	O
on	-	162	O
a	-	165	O
longterm	-	167	O
basis	-	176	O
have	-	182	O
increased	-	187	O
levels	-	197	O
of	-	204	O
serum	-	207	O
estrogen	-	213	O
and	-	222	O
decreased	-	226	O
levels	-	236	O
of	-	243	O
plasma	-	246	O
testosterone	-	253	O
and	-	266	O
luteinizing	-	270	O
hormone	-	282	O
(	-	290	O
LH	-	291	O
)	-	293	O
.	-	294	O

This	7416947	296	O
study	-	301	O
was	-	307	O
undertaken	-	311	O
to	-	322	O
investigate	-	325	O
the	-	337	O
links	-	341	O
between	-	347	O
the	-	355	O
long	-	359	O
-	-	363	O
term	-	364	O
administration	-	369	O
of	-	384	O
digoxin	-	387	O
therapy	-	395	O
and	-	403	O
sexual	-	407	O
behavior	-	414	O
,	-	422	O
and	-	424	O
the	-	428	O
effect	-	432	O
of	-	439	O
digoxin	-	442	O
on	-	450	O
plasma	-	453	O
levels	-	460	O
of	-	467	O
estradiol	-	470	O
,	-	479	O
testosterone	-	481	O
,	-	493	O
and	-	495	O
LH	-	499	O
.	-	501	O

The	7416947	503	O
patients	-	507	O
of	-	516	O
the	-	519	O
study	-	523	O
and	-	529	O
control	-	533	O
group	-	541	O
(	-	547	O
without	-	548	O
digoxin	-	556	O
)	-	563	O
were	-	565	O
of	-	570	O
similar	-	573	O
cardiac	-	581	O
functional	-	589	O
capacity	-	600	O
and	-	609	O
age	-	613	O
(	-	617	O
25	-	618	O
-	-	620	O
40	-	621	O
years	-	624	O
)	-	629	O
and	-	631	O
were	-	635	O
randomly	-	640	O
selected	-	649	O
from	-	658	O
the	-	663	O
rheumatic	-	667	B
heart	-	677	I
disease	-	683	I
patients	-	691	O
.	-	699	O

A	7416947	701	O
subjective	-	703	O
assessment	-	714	O
of	-	725	O
sexual	-	728	O
behavior	-	735	O
in	-	744	O
the	-	747	O
study	-	751	O
and	-	757	O
control	-	761	O
groups	-	769	O
was	-	776	O
carried	-	780	O
out	-	788	O
,	-	791	O
using	-	793	O
parameters	-	799	O
such	-	810	O
as	-	815	O
sexual	-	818	O
desire	-	825	O
,	-	831	O
sexual	-	833	O
excitement	-	840	O
,	-	850	O
and	-	852	O
frequency	-	856	O
of	-	866	O
sexual	-	869	O
relations	-	876	O
.	-	885	O

Personal	7416947	887	O
interviews	-	896	O
and	-	907	O
a	-	911	O
questionnaire	-	913	O
were	-	927	O
also	-	932	O
used	-	937	O
for	-	942	O
the	-	946	O
evaluation	-	950	O
of	-	961	O
sexual	-	964	O
behavior	-	971	O
.	-	979	O

The	7416947	981	O
findings	-	985	O
support	-	994	O
the	-	1002	O
reports	-	1006	O
concerning	-	1014	O
digoxin	-	1025	O
effect	-	1033	O
on	-	1040	O
plasma	-	1043	O
estradiol	-	1050	O
,	-	1059	O
testosterone	-	1061	O
,	-	1073	O
and	-	1075	O
LH	-	1079	O
.	-	1081	O

The	7416947	1083	O
differences	-	1087	O
in	-	1099	O
the	-	1102	O
means	-	1106	O
were	-	1112	O
significant	-	1117	O
.	-	1128	O

Tests	7416947	1130	O
used	-	1136	O
to	-	1141	O
evaluate	-	1144	O
the	-	1153	O
changes	-	1157	O
in	-	1165	O
sexual	-	1168	O
behavior	-	1175	O
showed	-	1184	O
a	-	1191	O
significant	-	1193	O
decrease	-	1205	B
in	-	1214	I
sexual	-	1217	I
desire	-	1224	I
,	-	1230	O
sexual	-	1232	O
excitement	-	1239	O
phase	-	1250	O
(	-	1256	O
erection	-	1257	O
)	-	1265	O
,	-	1266	O
and	-	1268	O
frequency	-	1272	O
of	-	1282	O
sexual	-	1285	O
relations	-	1292	O
in	-	1302	O
the	-	1305	O
study	-	1309	O
group	-	1315	O
.	-	1320	O

Fatal	7263204	0	O
aplastic	-	6	B
anemia	-	15	I
due	-	22	O
to	-	26	O
indomethacin	-	29	O
-	-	41	O
-	-	42	O
lymphocyte	-	43	O
transformation	-	54	O
tests	-	69	O
in	-	75	O
vitro	-	78	O
.	-	83	O

Although	7263204	85	O
indomethacin	-	94	O
has	-	107	O
been	-	111	O
implicated	-	116	O
as	-	127	O
a	-	130	O
possible	-	132	O
cause	-	141	O
of	-	147	O
aplastic	-	150	B
anemia	-	159	I
on	-	166	O
the	-	169	O
basis	-	173	O
of	-	179	O
a	-	182	O
few	-	184	O
clinical	-	188	O
observations	-	197	O
,	-	209	O
its	-	211	O
role	-	215	O
has	-	220	O
not	-	224	O
been	-	228	O
definitely	-	233	O
established	-	244	O
.	-	255	O

A	7263204	257	O
case	-	259	O
of	-	264	O
fatal	-	267	O
aplastic	-	273	B
anemia	-	282	I
is	-	289	O
described	-	292	O
in	-	302	O
which	-	305	O
no	-	311	O
drugs	-	314	O
other	-	320	O
than	-	326	O
allopurinol	-	331	O
and	-	343	O
indomethacin	-	347	O
were	-	360	O
given	-	365	O
.	-	370	O

Indomethacin	7263204	372	O
was	-	385	O
first	-	389	O
given	-	395	O
four	-	401	O
weeks	-	406	O
prior	-	412	O
to	-	418	O
the	-	421	O
onset	-	425	O
of	-	431	O
symptoms	-	434	O
.	-	442	O

A	7263204	444	O
positive	-	446	O
lymphocyte	-	455	O
transformation	-	466	O
test	-	481	O
with	-	486	O
indomethacin	-	491	O
in	-	504	O
vitro	-	507	O
further	-	513	O
substantiates	-	521	O
the	-	535	O
potential	-	539	O
role	-	549	O
of	-	554	O
this	-	557	O
drug	-	562	O
in	-	567	O
causing	-	570	O
aplastic	-	578	B
anemia	-	587	I
in	-	594	O
a	-	597	O
susceptible	-	599	O
patient	-	611	O
.	-	618	O

Fortunately	7263204	620	O
,	-	631	O
this	-	633	O
seems	-	638	O
to	-	644	O
be	-	647	O
a	-	650	O
very	-	652	O
rare	-	657	O
complication	-	662	O
.	-	674	O

Plasma	7066357	0	O
and	-	7	O
urinary	-	11	O
lipids	-	19	O
and	-	26	O
lipoproteins	-	30	O
during	-	43	O
the	-	50	O
development	-	54	O
of	-	66	O
nephrotic	-	69	B
syndrome	-	79	I
induced	-	88	O
in	-	96	O
the	-	99	O
rat	-	103	O
by	-	107	O
puromycin	-	110	O
aminonucleoside	-	120	O
.	-	135	O

This	7066357	137	O
study	-	142	O
was	-	148	O
undertaken	-	152	O
to	-	163	O
ascertain	-	166	O
whether	-	176	O
the	-	184	O
alterations	-	188	O
of	-	200	O
plasma	-	203	O
lipoproteins	-	210	O
found	-	223	O
in	-	229	O
nephrotic	-	232	B
syndrome	-	242	I
induced	-	251	O
by	-	259	O
puromycin	-	262	O
aminonucleoside	-	272	O
were	-	288	O
due	-	293	O
to	-	297	O
nephrotic	-	300	B
syndrome	-	310	I
per	-	319	O
se	-	323	O
,	-	325	O
or	-	327	O
,	-	329	O
at	-	331	O
least	-	334	O
in	-	340	O
part	-	343	O
,	-	347	O
to	-	349	O
the	-	352	O
aminonucleoside	-	356	O
.	-	371	O

The	7066357	373	O
purpose	-	377	O
of	-	385	O
the	-	388	O
present	-	392	O
study	-	400	O
was	-	406	O
to	-	410	O
investigate	-	413	O
the	-	425	O
changes	-	429	O
in	-	437	O
plasma	-	440	O
and	-	447	O
urinary	-	451	O
lipoproteins	-	459	O
during	-	472	O
the	-	479	O
administration	-	483	O
of	-	498	O
puromycin	-	501	O
aminonucleoside	-	511	O
(	-	527	O
20	-	528	O
mg	-	531	O
/	-	533	O
kg	-	534	O
for	-	537	O
7	-	541	O
days	-	543	O
)	-	547	O
and	-	549	O
the	-	553	O
subsequent	-	557	O
development	-	568	O
of	-	580	O
nephrotic	-	583	B
syndrome	-	593	I
.	-	601	O

Since	7066357	603	O
massive	-	609	O
albuminuria	-	617	B
occurred	-	629	O
after	-	638	O
6	-	644	O
days	-	646	O
of	-	651	O
treatment	-	654	O
,	-	663	O
the	-	665	O
time	-	669	O
-	-	673	O
course	-	674	O
study	-	681	O
was	-	687	O
divided	-	691	O
into	-	699	O
two	-	704	O
stages	-	708	O
:	-	714	O
pre	-	716	O
-	-	719	O
nephrotic	-	720	B
stage	-	730	O

(	7066357	736	O
day	-	737	O
1	-	741	O
-	-	742	O
5	-	743	O
)	-	744	O
and	-	746	O
nephrotic	-	750	B
stage	-	760	O
(	-	766	O
day	-	767	O
6	-	771	O
-	-	772	O
11	-	773	O
)	-	775	O
.	-	776	O

In	7066357	778	O
pre	-	781	O
-	-	784	O
nephrotic	-	785	B
stage	-	795	O
the	-	801	O
plasma	-	805	O
level	-	812	O
of	-	818	O
fatty	-	821	O
acids	-	827	O
,	-	832	O
triacylglycerol	-	834	O
and	-	850	O
VLDL	-	854	O
decreased	-	859	O
while	-	869	O
that	-	875	O
of	-	880	O
phospholipid	-	883	O
,	-	895	O
cholesteryl	-	897	O
esters	-	909	O
and	-	916	O
HDL	-	920	O
remained	-	924	O
constant	-	933	O
.	-	941	O

Plasma	7066357	943	O
apolipoprotein	-	950	O
A	-	965	O

-	7066357	966	O
I	-	967	O
tended	-	969	O
to	-	976	O
increase	-	979	O
(	-	988	O
40	-	989	O
%	-	991	O
increase	-	993	O
at	-	1002	O
day	-	1005	O
5	-	1009	O
)	-	1010	O
.	-	1011	O

At	7066357	1013	O
the	-	1016	O
beginning	-	1020	O
of	-	1030	O
nephrotic	-	1033	B
stage	-	1043	O
(	-	1049	O
day	-	1050	O
6	-	1054	O
)	-	1055	O
the	-	1057	O
concentration	-	1061	O
of	-	1075	O
plasma	-	1078	O
albumin	-	1085	O
dropped	-	1093	O
to	-	1101	O
a	-	1104	O
very	-	1106	O
low	-	1111	O
level	-	1115	O
,	-	1120	O
while	-	1122	O
that	-	1128	O
of	-	1133	O
apolipoprotein	-	1136	O
A	-	1151	O
-	-	1152	O
I	-	1153	O
increased	-	1155	O
abruptly	-	1165	O
(	-	1174	O
4	-	1175	O
-	-	1176	O
fold	-	1177	O
increase	-	1182	O
)	-	1190	O
and	-	1192	O
continued	-	1196	O
to	-	1206	O
rise	-	1209	O
,	-	1213	O
although	-	1215	O
less	-	1224	O
steeply	-	1229	O
,	-	1236	O
in	-	1238	O
the	-	1241	O
following	-	1245	O
days	-	1255	O
.	-	1259	O

The	7066357	1261	O
plasma	-	1265	O
concentration	-	1272	O
of	-	1286	O
HDL	-	1289	O
followed	-	1293	O
the	-	1302	O
same	-	1306	O
pattern	-	1311	O
.	-	1318	O

Plasma	7066357	1320	O
VLDL	-	1327	O
and	-	1332	O
LDL	-	1336	O
increased	-	1340	O
at	-	1350	O
a	-	1353	O
later	-	1355	O
stage	-	1361	O
(	-	1367	O
day	-	1368	O
9	-	1372	O
)	-	1373	O
.	-	1374	O

Plasma	7066357	1376	O
apolipoprotein	-	1383	O
A	-	1398	O
-	-	1399	O
I	-	1400	O
was	-	1402	O
found	-	1406	O
not	-	1412	O
only	-	1416	O
in	-	1421	O
HDL	-	1424	O
(	-	1428	O
1	-	1429	O
.	-	1430	O
063	-	1431	O
-	-	1434	O
1	-	1435	O
.	-	1436	O
210	-	1437	O
g	-	1441	O
/	-	1442	O
ml	-	1443	O
)	-	1445	O
but	-	1447	O
also	-	1451	O
in	-	1456	O
the	-	1459	O
LDL	-	1463	O
density	-	1467	O
class	-	1475	O
(	-	1481	O
1	-	1482	O
.	-	1483	O
025	-	1484	O
-	-	1487	O
1	-	1488	O
.	-	1489	O
050	-	1490	O
g	-	1494	O
/	-	1495	O
ml	-	1496	O
)	-	1498	O
.	-	1499	O

In	7066357	1501	O
the	-	1504	O
pre	-	1508	O
-	-	1511	O
nephrotic	-	1512	B
stage	-	1522	O
lipoproteinuria	-	1528	O
was	-	1544	O
negligible	-	1548	O
,	-	1558	O
while	-	1560	O
in	-	1566	O
the	-	1569	O
early	-	1573	O
nephrotic	-	1579	B
stage	-	1589	O
the	-	1595	O
urinary	-	1599	O
loss	-	1607	O
of	-	1612	O
plasma	-	1615	O
lipoproteins	-	1622	O
consisted	-	1635	O
mainly	-	1645	O
of	-	1652	O
HDL	-	1655	O
.	-	1658	O

These	7066357	1660	O
observations	-	1666	O
indicate	-	1679	O
that	-	1688	O
puromycin	-	1693	O
aminonucleoside	-	1703	O
alters	-	1719	O
plasma	-	1726	O
lipoproteins	-	1733	O
by	-	1746	O
lowering	-	1749	O
VLDL	-	1758	O
and	-	1763	O
increasing	-	1767	O
HDL	-	1778	O
.	-	1781	O

It	7066357	1783	O
is	-	1786	O
likely	-	1789	O
that	-	1796	O
the	-	1801	O
early	-	1805	O
and	-	1811	O
striking	-	1815	O
increase	-	1824	O
of	-	1833	O
plasma	-	1836	O
HDL	-	1843	O
found	-	1847	O
in	-	1853	O
nephrotic	-	1856	B
rats	-	1866	O
is	-	1871	O
related	-	1874	O
to	-	1882	O
a	-	1885	O
direct	-	1887	O
effect	-	1894	O
of	-	1901	O
the	-	1904	O
drug	-	1908	O
on	-	1913	O
HDL	-	1916	O
metabolism	-	1920	O
.	-	1930	O

Circulating	7007443	0	O
lysosomal	-	12	O
enzymes	-	22	O
and	-	30	O
acute	-	34	B
hepatic	-	40	I
necrosis	-	48	I
.	-	56	O

The	7007443	58	O
activities	-	62	O
of	-	73	O
the	-	76	O
lysosomal	-	80	O
enzymes	-	90	O
acid	-	98	O
and	-	103	O
neutral	-	107	O
protease	-	115	O
,	-	123	O
N	-	125	O
-	-	126	O
acetylglucosaminidase	-	127	O
,	-	148	O
and	-	150	O
acid	-	154	O
phosphatase	-	159	O
were	-	171	O
measured	-	176	O
in	-	185	O
the	-	188	O
serum	-	192	O
of	-	198	O
patients	-	201	O
with	-	210	O
fulminant	-	215	B
hepatic	-	225	I
failure	-	233	I
.	-	240	O

Acid	7007443	242	O
protease	-	247	O
(	-	256	O
cathepsin	-	257	O
D	-	267	O
)	-	268	O
activity	-	270	O
was	-	279	O
increased	-	283	O
about	-	293	O
tenfold	-	299	O
in	-	307	O
patients	-	310	O
who	-	319	O
died	-	323	O
and	-	328	O
nearly	-	332	O
fourfold	-	339	O
in	-	348	O
those	-	351	O
who	-	357	O
survived	-	361	O
fulminant	-	370	B
hepatic	-	380	I
failure	-	388	I
after	-	396	O
paracetamol	-	402	O
overdose	-	414	B
,	-	422	O
whereas	-	424	O
activities	-	432	O
were	-	443	O
increased	-	448	O
equally	-	458	O
in	-	466	O
patients	-	469	O
with	-	478	O
fulminant	-	483	B
hepatic	-	493	I
failure	-	501	I
due	-	509	O
to	-	513	O
viral	-	516	B
hepatitis	-	522	I
whether	-	532	O
or	-	540	O
not	-	543	O
they	-	547	O
survived	-	552	O
.	-	560	O

A	7007443	562	O
correlation	-	564	O
was	-	576	O
found	-	580	O
between	-	586	O
serum	-	594	O
acid	-	600	O
protease	-	605	O
activity	-	614	O
and	-	623	O
prothrombin	-	627	O
time	-	639	O
,	-	643	O
and	-	645	O
the	-	649	O
increase	-	653	O
in	-	662	O
cathepsin	-	665	O
D	-	675	O
activity	-	677	O
was	-	686	O
sustained	-	690	O
over	-	700	O
several	-	705	O
days	-	713	O
compared	-	718	O
with	-	727	O
aspartate	-	732	O
aminotransferase	-	742	O
,	-	758	O
which	-	760	O
showed	-	766	O
a	-	773	O
sharp	-	775	O
early	-	781	O
peak	-	787	O
and	-	792	O
then	-	796	O
a	-	801	O
fall	-	803	O
.	-	807	O

Circulating	7007443	809	O
lysosomal	-	821	O
proteases	-	831	O
can	-	841	O
damage	-	845	O
other	-	852	O
organs	-	858	O
,	-	864	O
and	-	866	O
measurement	-	870	O
of	-	882	O
their	-	885	O
activity	-	891	O
may	-	900	O
therefore	-	904	O
be	-	914	O
of	-	917	O
added	-	920	O
value	-	926	O
in	-	932	O
assessing	-	935	O
prognosis	-	945	O
in	-	955	O
this	-	958	O
condition	-	963	O
.	-	972	O

Transketolase	3762968	0	O
abnormality	-	14	O
in	-	26	O
tolazamide	-	29	O
-	-	39	O
induced	-	40	O
Wernicke	-	48	B
's	-	56	I
encephalopathy	-	59	I
.	-	73	O

We	3762968	75	O
studied	-	78	O
a	-	86	O
thiamine	-	88	O
-	-	96	O
dependent	-	97	O
enzyme	-	107	O
,	-	113	O
transketolase	-	115	O
,	-	128	O
from	-	130	O
fibroblasts	-	135	O
of	-	147	O
a	-	150	O
diabetic	-	152	B
patient	-	161	O
who	-	169	O
developed	-	173	O
Wernicke	-	183	B
's	-	191	I
encephalopathy	-	194	I
when	-	209	O
treated	-	214	O
with	-	222	O
tolazamide	-	227	O
,	-	237	O
in	-	239	O
order	-	242	O
to	-	248	O
delineate	-	251	O
if	-	261	O
this	-	264	O
patient	-	269	O
also	-	277	O
had	-	282	O
transketolase	-	286	O
abnormality	-	300	O
[	-	312	O
high	-	313	O
Km	-	318	O
for	-	321	O
thiamine	-	325	O
pyrophosphate	-	334	O
(	-	348	O
TPP	-	349	O
)	-	352	O
]	-	353	O
,	-	354	O
as	-	356	O
previously	-	359	O
reported	-	370	O
in	-	379	O
postalcoholic	-	382	O
Wernicke	-	396	B
-	-	404	I
Korsakoff	-	405	I
syndrome	-	415	I
.	-	423	O

In	3762968	425	O
addition	-	428	O
to	-	437	O
this	-	440	O
patient	-	445	O
,	-	452	O
we	-	454	O
also	-	457	O
studied	-	462	O
this	-	470	O
enzyme	-	475	O
from	-	482	O
three	-	487	O
diabetic	-	493	B
kindreds	-	502	O
without	-	511	O
any	-	519	O
history	-	523	O
of	-	531	O
Wernicke	-	534	B
's	-	542	I
encephalopathy	-	545	I
and	-	560	O
from	-	564	O
four	-	569	O
normal	-	574	O
controls	-	581	O
.	-	589	O

We	3762968	591	O
found	-	594	O
that	-	600	O
the	-	605	O
above	-	609	O
-	-	614	O
mentioned	-	615	O
patient	-	625	O
and	-	633	O
one	-	637	O
of	-	641	O
the	-	644	O
diabetic	-	648	B
kindreds	-	657	O
with	-	666	O
no	-	671	O
history	-	674	O
of	-	682	O
Wernicke	-	685	B
's	-	693	I
encephalopathy	-	696	I
had	-	711	O
abnormal	-	715	O
transketolase	-	724	O
as	-	738	O
determined	-	741	O
by	-	752	O
its	-	755	O
Km	-	759	O
for	-	762	O
TPP	-	766	O
.	-	769	O

These	3762968	771	O
data	-	777	O
suggest	-	782	O
a	-	790	O
similarity	-	792	O
between	-	803	O
postalcoholic	-	811	O
Wernicke	-	825	B
-	-	833	I
Korsakoff	-	834	I
syndrome	-	844	I
and	-	853	O
the	-	857	O
patient	-	861	O
with	-	869	O
tolazamide	-	874	O
-	-	884	O
induced	-	885	O
Wernicke	-	893	B
's	-	901	I
encephalopathy	-	904	I
from	-	919	O
the	-	924	O
standpoint	-	928	O
of	-	939	O
transketolase	-	942	O
abnormality	-	956	O
.	-	967	O

Mechanisms	3413271	0	O
of	-	11	O
myocardial	-	14	B
ischemia	-	25	I
induced	-	34	O
by	-	42	O
epinephrine	-	45	O
:	-	56	O
comparison	-	58	O
with	-	69	O
exercise	-	74	O
-	-	82	O
induced	-	83	O
ischemia	-	91	B
.	-	99	O

The	3413271	101	O
role	-	105	O
of	-	110	O
epinephrine	-	113	O
in	-	125	O
eliciting	-	128	O
myocardial	-	138	B
ischemia	-	149	I
was	-	158	O
examined	-	162	O
in	-	171	O
patients	-	174	O
with	-	183	O
coronary	-	188	B
artery	-	197	I
disease	-	204	I
.	-	211	O

Objective	3413271	213	O
signs	-	223	O
of	-	229	O
ischemia	-	232	B
and	-	241	O
factors	-	245	O
increasing	-	253	O
myocardial	-	264	O
oxygen	-	275	O
consumption	-	282	O
were	-	294	O
compared	-	299	O
during	-	308	O
epinephrine	-	315	O
infusion	-	327	O
and	-	336	O
supine	-	340	O
bicycle	-	347	O
exercise	-	355	O
.	-	363	O

Both	3413271	365	O
epinephrine	-	370	O
and	-	382	O
exercise	-	386	O
produced	-	395	O
myocardial	-	404	B
ischemia	-	415	I
as	-	424	O
evidenced	-	427	O
by	-	437	O
ST	-	440	O
segment	-	443	O
depression	-	451	B
and	-	462	O
angina	-	466	B
.	-	472	O

However	3413271	474	O
,	-	481	O
the	-	483	O
mechanisms	-	487	O
of	-	498	O
myocardial	-	501	B
ischemia	-	512	I
induced	-	521	O
by	-	529	O
epinephrine	-	532	O
were	-	544	O
significantly	-	549	O
different	-	563	O
from	-	573	O
those	-	578	O
of	-	584	O
exercise	-	587	O
.	-	595	O

Exercise	3413271	597	O
-	-	605	O
induced	-	606	O
myocardial	-	614	B
ischemia	-	625	I
was	-	634	O
marked	-	638	O
predominantly	-	645	O
by	-	659	O
increased	-	662	O
heart	-	672	O
rate	-	678	O
and	-	683	O
rate	-	687	O
-	-	691	O
pressure	-	692	O
product	-	701	O
with	-	709	O
a	-	714	O
minor	-	716	O
contribution	-	722	O
of	-	735	O
end	-	738	O
-	-	741	O
diastolic	-	742	O
volume	-	752	O
,	-	758	O
while	-	760	O
epinephrine	-	766	O
-	-	777	O
induced	-	778	O
ischemia	-	786	B
was	-	795	O
characterized	-	799	O
by	-	813	O
a	-	816	O
marked	-	818	O
increase	-	825	O
in	-	834	O
contractility	-	837	O
and	-	851	O
a	-	855	O
less	-	857	O
pronounced	-	862	O
increase	-	873	O
in	-	882	O
heart	-	885	O
rate	-	891	O
and	-	896	O
rate	-	900	O
-	-	904	O
pressure	-	905	O
product	-	914	O
.	-	921	O

These	3413271	923	O
findings	-	929	O
indicate	-	938	O
that	-	947	O
ischemia	-	952	B
produced	-	961	O
by	-	970	O
epinephrine	-	973	O
,	-	984	O
as	-	986	O
may	-	989	O
occur	-	993	O
during	-	999	O
states	-	1006	O
of	-	1013	O
emotional	-	1016	O
distress	-	1026	O
,	-	1034	O
has	-	1036	O
a	-	1040	O
mechanism	-	1042	O
distinct	-	1052	O
from	-	1061	O
that	-	1066	O
due	-	1071	O
to	-	1075	O
physical	-	1078	O
exertion	-	1087	O
.	-	1095	O

Transient	3088349	0	O
contralateral	-	10	B
rotation	-	24	I
following	-	33	O
unilateral	-	43	O
substantia	-	54	B
nigra	-	65	I
lesion	-	71	I
reflects	-	78	O
susceptibility	-	87	O
of	-	102	O
the	-	105	O
nigrostriatal	-	109	O
system	-	123	O
to	-	130	O
exhaustion	-	133	O
by	-	144	O
amphetamine	-	147	O
.	-	158	O

Following	3088349	160	O
unilateral	-	170	O
6	-	181	O
-	-	182	O
OHDA	-	183	O
induced	-	188	O
SN	-	196	B
lesion	-	199	I
,	-	205	O
a	-	207	O
transient	-	209	O
period	-	219	O
of	-	226	O
contralateral	-	229	B
rotation	-	243	I
has	-	252	O
been	-	256	O
reported	-	261	O
to	-	270	O
precede	-	273	O
the	-	281	O
predominant	-	285	O
ipsilateral	-	297	B
circling	-	309	I
.	-	317	O

In	3088349	319	O
order	-	322	O
to	-	328	O
clarify	-	331	O
the	-	339	O
nature	-	343	O
of	-	350	O
this	-	353	O
initial	-	358	O
contralateral	-	366	B
rotation	-	380	I
we	-	389	O
examined	-	392	O
the	-	401	O
effect	-	405	O
of	-	412	O
the	-	415	O
duration	-	419	O
of	-	428	O
recovery	-	431	O
period	-	440	O
after	-	447	O
the	-	453	O
lesion	-	457	O
,	-	463	O
on	-	465	O
amphetamine	-	468	O
-	-	479	O
induced	-	480	O
rotational	-	488	B
behavior	-	499	I
.	-	507	O

Three	3088349	509	O
days	-	515	O
post	-	520	O
lesion	-	525	O
,	-	531	O
most	-	533	O
rats	-	538	O
circled	-	543	O
predominantly	-	551	O
contralaterally	-	565	O
to	-	581	O
the	-	584	O
lesion	-	588	O
.	-	594	O

Such	3088349	596	O
contralateral	-	601	B
rotation	-	615	I
may	-	624	O
result	-	628	O
from	-	635	O
either	-	640	O
degeneration	-	647	O
-	-	659	O
induced	-	660	O
breakdown	-	668	O
of	-	678	O
the	-	681	O
DA	-	685	O
pool	-	688	O
,	-	692	O
or	-	694	O
lesion	-	697	O
-	-	703	O
induced	-	704	O
increase	-	712	O
of	-	721	O
DA	-	724	O
turnover	-	727	O
in	-	736	O
the	-	739	O
spared	-	743	O
neurons	-	750	O
.	-	757	O

A	3088349	759	O
substantial	-	761	O
degree	-	773	O
of	-	780	O
contralateral	-	783	O
preference	-	797	O
was	-	808	O
still	-	812	O
evident	-	818	O
when	-	826	O
amphetamine	-	831	O
was	-	843	O
administered	-	847	O
for	-	860	O
the	-	864	O
first	-	868	O
time	-	874	O
24	-	879	O
days	-	882	O
after	-	887	O
lesioning	-	893	O
,	-	902	O
indicating	-	904	O
involvement	-	915	O
of	-	927	O
spared	-	930	O
cells	-	937	O
in	-	943	O
the	-	946	O
contralateral	-	950	B
rotation	-	964	I
.	-	972	O

However	3088349	974	O
,	-	981	O
regardless	-	983	O
of	-	994	O
the	-	997	O
duration	-	1001	O
of	-	1010	O
recovery	-	1013	O
(	-	1022	O
and	-	1023	O
irrespective	-	1027	O
of	-	1040	O
either	-	1043	O
lesion	-	1050	O
volume	-	1057	O
,	-	1063	O
amphetamine	-	1065	O
dose	-	1077	O
,	-	1081	O
or	-	1083	O
post	-	1086	O
-	-	1090	O
lesion	-	1091	O
motor	-	1098	O
exercise	-	1104	O
)	-	1112	O
,	-	1113	O
amphetamine	-	1115	O
-	-	1126	O
induced	-	1127	O
rotation	-	1135	B
tended	-	1144	O
to	-	1151	O
become	-	1154	O
gradually	-	1161	O
more	-	1171	O
ipsilateral	-	1176	O
as	-	1188	O
the	-	1191	O
observation	-	1195	O
session	-	1207	O
progressed	-	1215	O
,	-	1225	O
and	-	1227	O
all	-	1231	O
rats	-	1235	O
circled	-	1240	O
ipsilaterally	-	1248	O
to	-	1262	O
the	-	1265	O
lesion	-	1269	O
in	-	1276	O
response	-	1279	O
to	-	1288	O
further	-	1291	O
amphetamine	-	1299	O
injections	-	1311	O
.	-	1321	O

These	3088349	1323	O
findings	-	1329	O
suggest	-	1338	O
that	-	1346	O
amphetamine	-	1351	O
has	-	1363	O
an	-	1367	O
irreversible	-	1370	O
effect	-	1383	O
on	-	1390	O
the	-	1393	O
post	-	1397	O
-	-	1401	O
lesion	-	1402	O
DA	-	1409	O
pool	-	1412	O
contributing	-	1417	O
to	-	1430	O
contralateral	-	1433	B
rotation	-	1447	I
.	-	1455	O

Thyroid	3001299	0	O
function	-	8	O
and	-	17	O
urine	-	21	O
-	-	26	O
concentrating	-	27	O
ability	-	41	O
during	-	49	O
lithium	-	56	O
treatment	-	64	O
.	-	73	O

It	3001299	75	O
has	-	78	O
been	-	82	O
suggested	-	87	O
that	-	97	O
adenylate	-	102	O
cyclase	-	112	O
inhibition	-	120	O
may	-	131	O
be	-	135	O
important	-	138	O
in	-	148	O
the	-	151	O
development	-	155	O
of	-	167	O
both	-	170	O
nephrogenic	-	175	B
diabetes	-	187	I
insipidus	-	196	I
and	-	206	O
hypothyroidism	-	210	B
during	-	225	O
lithium	-	232	O
treatment	-	240	O
.	-	249	O

We	3001299	251	O
measured	-	254	O
serum	-	263	O
thyroxine	-	269	O
and	-	279	O
urine	-	283	O
-	-	288	O
concentrating	-	289	O
ability	-	303	O
(	-	311	O
Umax	-	312	O
)	-	316	O
in	-	318	O
response	-	321	O
to	-	330	O
desmopressin	-	333	O
(	-	346	O
DDAVP	-	347	O
)	-	352	O
in	-	354	O
85	-	357	O
patients	-	360	O
receiving	-	369	O
lithium	-	379	O
.	-	386	O

Hypothyroidism	3001299	388	B
developed	-	403	O
in	-	413	O
eight	-	416	O
patients	-	422	O
while	-	431	O
they	-	437	O
were	-	442	O
taking	-	447	O
lithium	-	454	O
.	-	461	O

Impaired	3001299	463	O
Umax	-	472	O
was	-	477	O
found	-	481	O
in	-	487	O
both	-	490	O
euthyroid	-	495	O
and	-	505	O
hypothyroid	-	509	B
patients	-	521	O
while	-	530	O
some	-	536	O
hypothyroid	-	541	B
patients	-	553	O
concentrated	-	562	O
their	-	575	O
urine	-	581	O
well	-	587	O
.	-	591	O

It	3001299	593	O
is	-	596	O
concluded	-	599	O
that	-	609	O
the	-	614	O
dominant	-	618	O
mechanisms	-	627	O
by	-	638	O
which	-	641	O
lithium	-	647	O
exerts	-	655	O
these	-	662	O
two	-	668	O
effects	-	672	O
are	-	680	O
different	-	684	O
.	-	693	O

Sensitivity	2004015	0	O
of	-	12	O
erythroid	-	15	O
progenitor	-	25	O
colonies	-	36	O
to	-	45	O
erythropoietin	-	48	O
in	-	63	O
azidothymidine	-	66	O
treated	-	81	O
immunodeficient	-	89	B
mice	-	105	O
.	-	109	O

The	2004015	111	O
anaemia	-	115	B
induced	-	123	O
by	-	131	O
3'	-	134	O
-	-	136	O
azido	-	137	O
-	-	142	O
3'dideoxythymidine	-	143	O
(	-	162	O
AZT	-	163	O
)	-	166	O
is	-	168	O
poorly	-	171	O
understood	-	178	O
.	-	188	O

We	2004015	190	O
have	-	193	O
used	-	198	O
a	-	203	O
murine	-	205	O
model	-	212	O
of	-	218	O
AIDS	-	221	B
,	-	225	O
infection	-	227	B
of	-	237	O
female	-	240	O
C57BL	-	247	O
/	-	252	O
6	-	253	O
mice	-	255	O
with	-	260	O
LP	-	265	O
-	-	267	O
BM5	-	268	O
murine	-	272	O
leukaemia	-	279	B
(	-	289	O
MuLV	-	290	O
)	-	294	O
virus	-	296	O
,	-	301	O
to	-	303	O
determine	-	306	O
if	-	316	O
AZT	-	319	O
-	-	322	O
induced	-	323	O
anaemia	-	331	B
is	-	339	O
due	-	342	O
,	-	345	O
in	-	347	O
part	-	350	O
,	-	354	O
to	-	356	O
decreased	-	359	O
responsiveness	-	369	O
of	-	384	O
erythropoietic	-	387	O
precursors	-	402	O
(	-	413	O
BFU	-	414	O
-	-	417	O
e	-	418	O
)	-	419	O
to	-	421	O
erythropoietin	-	424	O
(	-	439	O
EPO	-	440	O
)	-	443	O
.	-	444	O

Mice	2004015	446	O
in	-	451	O
the	-	454	O
early	-	458	O
stage	-	464	O
of	-	470	O
LP	-	473	O
-	-	475	O
BM5	-	476	O
MuLV	-	480	O
disease	-	485	O
were	-	493	O
given	-	498	O
AZT	-	504	O
in	-	508	O
their	-	511	O
drinking	-	517	O
water	-	526	O
at	-	532	O
1	-	535	O
.	-	536	O
0	-	537	O
and	-	539	O
2	-	543	O
.	-	544	O
5	-	545	O
mg	-	547	O
/	-	549	O
ml	-	550	O
.	-	552	O

AZT	2004015	554	O
produced	-	558	O
anaemia	-	567	B
in	-	575	O
both	-	578	O
groups	-	583	O
,	-	589	O
in	-	591	O
a	-	594	O
dose	-	596	O
-	-	600	O
dependent	-	601	O
fashion	-	611	O
.	-	618	O

Despite	2004015	620	O
the	-	628	O
anaemia	-	632	B
,	-	639	O
the	-	641	O
number	-	645	O
of	-	652	O
splenic	-	655	O
and	-	663	O
bone	-	667	O
marrow	-	672	O
BFU	-	679	O
-	-	682	O
e	-	683	O
in	-	685	O
AZT	-	688	O
treated	-	692	O
mice	-	700	O
increased	-	705	O
up	-	715	O
to	-	718	O
five	-	721	O
-	-	725	O
fold	-	726	O
over	-	731	O
levels	-	736	O
observed	-	743	O
in	-	752	O
infected	-	755	O
untreated	-	764	O
animals	-	774	O
after	-	782	O
15	-	788	O
d	-	791	O
of	-	793	O
treatment	-	796	O
.	-	805	O

Colony	2004015	807	O
formation	-	814	O
by	-	824	O
splenic	-	827	O
and	-	835	O
bone	-	839	O
marrow	-	844	O
BFUe	-	851	O
was	-	856	O
stimulated	-	860	O
at	-	871	O
lower	-	874	O
concentrations	-	880	O
of	-	895	O
EPO	-	898	O
in	-	902	O
mice	-	905	O
receiving	-	910	O
AZT	-	920	O
for	-	924	O
15	-	928	O
d	-	931	O
than	-	933	O
for	-	938	O
infected	-	942	O
,	-	950	O
untreated	-	952	O
mice	-	962	O
.	-	966	O

By	2004015	968	O
day	-	971	O
30	-	975	O
,	-	977	O
sensitivity	-	979	O
of	-	991	O
both	-	994	O
splenic	-	999	O
and	-	1007	O
bone	-	1011	O
marrow	-	1016	O
BFU	-	1023	O
-	-	1026	O
e	-	1027	O
of	-	1029	O
treated	-	1032	O
animals	-	1040	O
returned	-	1048	O
to	-	1057	O
that	-	1060	O
observed	-	1065	O
from	-	1074	O
cells	-	1079	O
of	-	1085	O
infected	-	1088	O
untreated	-	1097	O
animals	-	1107	O
.	-	1114	O

The	2004015	1116	O
mean	-	1120	O
plasma	-	1125	O
levels	-	1132	O
of	-	1139	O
EPO	-	1142	O
observed	-	1146	O
in	-	1155	O
AZT	-	1158	O
treated	-	1162	O
mice	-	1170	O
were	-	1175	O
appropriate	-	1180	O
for	-	1192	O
the	-	1196	O
degree	-	1200	O
of	-	1207	O
anaemia	-	1210	B
observed	-	1218	O
when	-	1227	O
compared	-	1232	O
with	-	1241	O
phenylhydrazine	-	1246	O
(	-	1262	O
PHZ	-	1263	O
)	-	1266	O
treated	-	1268	O
mice	-	1276	O
.	-	1280	O

The	2004015	1282	O
numbers	-	1286	O
of	-	1294	O
BFU	-	1297	O
-	-	1300	O
e	-	1301	O
and	-	1303	O
the	-	1307	O
percentage	-	1311	O
of	-	1322	O
bone	-	1325	O
marrow	-	1330	O
erythroblasts	-	1337	O
observed	-	1351	O
were	-	1360	O
comparable	-	1365	O
in	-	1376	O
AZT	-	1379	O
and	-	1383	O
PHZ	-	1387	O
treated	-	1391	O
mice	-	1399	O
with	-	1404	O
similar	-	1409	O
degrees	-	1417	O
of	-	1425	O
anaemia	-	1428	B
.	-	1435	O

However	2004015	1437	O
,	-	1444	O
reticulocytosis	-	1446	B
was	-	1462	O
inappropriate	-	1466	O
for	-	1480	O
the	-	1484	O
degree	-	1488	O
of	-	1495	O
anaemia	-	1498	B
observed	-	1506	O
in	-	1515	O
AZT	-	1518	O
treated	-	1522	O
infected	-	1530	O
mice	-	1539	O
.	-	1543	O

AZT	2004015	1545	O
-	-	1548	O
induced	-	1549	O
peripheral	-	1557	O
anaemia	-	1568	B
in	-	1576	O
the	-	1579	O
face	-	1583	O
of	-	1588	O
increased	-	1591	O
numbers	-	1601	O
of	-	1609	O
BFU	-	1612	O
-	-	1615	O
e	-	1616	O
and	-	1618	O
increased	-	1622	O
levels	-	1632	O
of	-	1639	O
plasma	-	1642	O
EPO	-	1649	O
suggest	-	1653	O
a	-	1661	O
lesion	-	1663	O
in	-	1670	O
terminal	-	1673	O
differentiation	-	1682	O
.	-	1697	O

Detection	1732442	0	O
of	-	10	O
abnormal	-	13	O
cardiac	-	22	O
adrenergic	-	30	O
neuron	-	41	O
activity	-	48	O
in	-	57	O
adriamycin	-	60	O
-	-	70	O
induced	-	71	O
cardiomyopathy	-	79	B
with	-	94	O
iodine	-	99	O
-	-	105	O
125	-	106	O
-	-	109	O
metaiodobenzylguanidine	-	110	O
.	-	133	O

Radiolabeled	1732442	135	O
metaiodobenzylguanidine	-	148	O
(	-	172	O
MIBG	-	173	O
)	-	177	O
,	-	178	O
an	-	180	O
analog	-	183	O
of	-	190	O
norepinephrine	-	193	O
(	-	208	O
NE	-	209	O
)	-	211	O
,	-	212	O
serves	-	214	O
as	-	221	O
an	-	224	O
index	-	227	O
of	-	233	O
adrenergic	-	236	O
neuron	-	247	O
integrity	-	254	O
and	-	264	O
function	-	268	O
.	-	276	O

Using	1732442	278	O
a	-	284	O
rat	-	286	O
model	-	290	O
of	-	296	O
adriamycin	-	299	O
-	-	309	O
induced	-	310	O
cardiomyopathy	-	318	B
,	-	332	O
we	-	334	O
tested	-	337	O
the	-	344	O
hypothesis	-	348	O
that	-	359	O
abnormal	-	364	O
cardiac	-	373	O
adrenergic	-	381	O
neuron	-	392	O
activity	-	399	O
may	-	408	O
appear	-	412	O
and	-	419	O
be	-	423	O
exacerbated	-	426	O
dose	-	438	O
-	-	442	O
dependently	-	443	O
in	-	455	O
adriamycin	-	458	O
cardiomyopathy	-	469	B
.	-	483	O

The	1732442	485	O
degree	-	489	O
of	-	496	O
vacuolar	-	499	B
degeneration	-	508	I
of	-	521	I
myocardial	-	524	I
cells	-	535	I
was	-	541	O
analyzed	-	545	O
in	-	554	O
relation	-	557	O
to	-	566	O
the	-	569	O
duration	-	573	O
of	-	582	O
adriamycin	-	585	O
treatment	-	596	O
(	-	606	O
2	-	607	O
mg	-	609	O
/	-	611	O
kg	-	612	O
,	-	614	O
once	-	616	O
a	-	621	O
week	-	623	O
)	-	627	O
.	-	628	O

There	1732442	630	O
were	-	636	O
no	-	641	O
abnormalities	-	644	O
or	-	658	O
only	-	661	O
isolated	-	666	O
degeneration	-	675	O
in	-	688	O
the	-	691	O
1	-	695	O
-	-	696	O
or	-	698	O
2	-	701	O
-	-	702	O
wk	-	703	O
treatment	-	706	O
groups	-	716	O
,	-	722	O
isolated	-	724	O
or	-	733	O
scattered	-	736	O
degeneration	-	746	O
in	-	759	O
half	-	762	O
of	-	767	O
the	-	770	O
3	-	774	O
-	-	775	O
wk	-	776	O
group	-	779	O
,	-	784	O
frequent	-	786	O
scattered	-	795	O
degeneration	-	805	O
in	-	818	O
the	-	821	O
4	-	825	O
-	-	826	O
wk	-	827	O
group	-	830	O
,	-	835	O
scattered	-	837	O
or	-	847	O
focal	-	850	O
degeneration	-	856	O
in	-	869	O
the	-	872	O
5	-	876	O
-	-	877	O
wk	-	878	O
group	-	881	O
,	-	886	O
and	-	888	O
extensive	-	892	O
degeneration	-	902	O
in	-	915	O
the	-	918	O
8	-	922	O
-	-	923	O
wk	-	924	O
group	-	927	O
.	-	932	O

Myocardial	1732442	934	O
accumulation	-	945	O
of	-	958	O
[	-	961	O
125I	-	962	O
]	-	966	O
MIBG	-	967	O
4	-	972	O
hr	-	974	O
after	-	977	O
intravenous	-	983	O
injection	-	995	O
did	-	1005	O
not	-	1009	O
differ	-	1013	O
between	-	1020	O
the	-	1028	O
controls	-	1032	O
and	-	1041	O
the	-	1045	O
groups	-	1049	O
treated	-	1056	O
3	-	1064	O
wk	-	1066	O
or	-	1069	O
less	-	1072	O
.	-	1076	O

However	1732442	1078	O
,	-	1085	O
the	-	1087	O
4	-	1091	O
-	-	1092	O
wk	-	1093	O
group	-	1096	O
had	-	1102	O
a	-	1106	O
slightly	-	1108	O
lower	-	1117	O
accumulation	-	1123	O
in	-	1136	O
the	-	1139	O
right	-	1143	O
ventricular	-	1149	O
wall	-	1161	O
(	-	1166	O
82	-	1167	O
%	-	1169	O
of	-	1171	O
the	-	1174	O
control	-	1178	O
)	-	1185	O
and	-	1187	O
significantly	-	1191	O
lower	-	1205	O
accumulation	-	1211	O
in	-	1224	O
the	-	1227	O
left	-	1231	O
ventricular	-	1236	O
wall	-	1248	O
(	-	1253	O
about	-	1254	O
66	-	1260	O
%	-	1262	O
of	-	1264	O
the	-	1267	O
control	-	1271	O
:	-	1278	O
p	-	1280	O
less	-	1282	O
than	-	1287	O
0	-	1292	O
.	-	1293	O
05	-	1294	O
)	-	1296	O
.	-	1297	O

In	1732442	1299	O
the	-	1302	O
5	-	1306	O
-	-	1307	O
wk	-	1308	O
group	-	1311	O
,	-	1316	O
MIBG	-	1318	O
accumulation	-	1323	O
in	-	1336	O
the	-	1339	O
right	-	1343	O
and	-	1349	O
left	-	1353	O
ventricular	-	1358	O
wall	-	1370	O
was	-	1375	O
35	-	1379	O
%	-	1381	O
and	-	1383	O
27	-	1387	O
%	-	1389	O
of	-	1391	O
that	-	1394	O
in	-	1399	O
controls	-	1402	O
,	-	1410	O
respectively	-	1412	O
(	-	1425	O
p	-	1426	O
less	-	1428	O
than	-	1433	O
0	-	1438	O
.	-	1439	O
001	-	1440	O
)	-	1443	O
.	-	1444	O

In	1732442	1446	O
the	-	1449	O
8	-	1453	O
-	-	1454	O
wk	-	1455	O
group	-	1458	O
,	-	1463	O
MIBG	-	1465	O
accumulation	-	1470	O
in	-	1483	O
the	-	1486	O
right	-	1490	O
and	-	1496	O
left	-	1500	O
ventricular	-	1505	O
wall	-	1517	O
was	-	1522	O
18	-	1526	O
%	-	1528	O
and	-	1530	O
14	-	1534	O
%	-	1536	O
of	-	1538	O
that	-	1541	O
in	-	1546	O
controls	-	1549	O
,	-	1557	O
respectively	-	1559	O
(	-	1572	O
p	-	1573	O
less	-	1575	O
than	-	1580	O
0	-	1585	O
.	-	1586	O
001	-	1587	O
)	-	1590	O
.	-	1591	O

Thus	1732442	1593	O
,	-	1597	O
MIBG	-	1599	O
accumulation	-	1604	O
in	-	1617	O
the	-	1620	O
myocardium	-	1624	O
decreased	-	1635	O
in	-	1645	O
an	-	1648	O
adriamycin	-	1651	O
dose	-	1662	O
-	-	1666	O
dependent	-	1667	O
manner	-	1677	O
.	-	1683	O

The	1732442	1685	O
appearance	-	1689	O
of	-	1700	O
impaired	-	1703	O
cardiac	-	1712	O
adrenergic	-	1720	O
neuron	-	1731	O
activity	-	1738	O
in	-	1747	O
the	-	1750	O
presence	-	1754	O
of	-	1763	O
slight	-	1766	O
myocardial	-	1773	B
impairment	-	1784	I
(	-	1795	O
scattered	-	1796	O
or	-	1806	O
focal	-	1809	O
vacuolar	-	1815	B
degeneration	-	1824	I
)	-	1836	O
indicates	-	1838	O
that	-	1848	O
MIBG	-	1853	O
scintigraphy	-	1858	O
may	-	1871	O
be	-	1875	O
a	-	1878	O
useful	-	1880	O
method	-	1887	O
for	-	1894	O
detection	-	1898	O
of	-	1908	O
adriamycin	-	1911	O
-	-	1921	O
induced	-	1922	O
cardiomyopathy	-	1930	B
.	-	1944	O

Amnestic	1423339	0	B
syndrome	-	9	I
associated	-	18	O
with	-	29	O
propranolol	-	34	O
toxicity	-	46	B
:	-	54	O
a	-	56	O
case	-	58	O
report	-	63	O
.	-	69	O

An	1423339	71	O
elderly	-	74	O
woman	-	82	O
developed	-	88	O
an	-	98	O
Alzheimer	-	101	B
-	-	110	O
like	-	111	O
subacute	-	116	O
dementia	-	125	B
as	-	134	O
a	-	137	O
result	-	139	O
of	-	146	O
propranolol	-	149	O
toxicity	-	161	B
.	-	169	O

Analysis	1423339	171	O
of	-	180	O
the	-	183	O
manifestations	-	187	O
showed	-	202	O
that	-	209	O
severe	-	214	O
impairment	-	221	O
of	-	232	O
memory	-	235	O
accounted	-	242	O
for	-	252	O
virtually	-	256	O
all	-	266	O
of	-	270	O
the	-	273	O
abnormalities	-	277	O
.	-	290	O

There	1423339	292	O
is	-	298	O
evidence	-	301	O
that	-	310	O
cerebral	-	315	O
reactions	-	324	O
to	-	334	O
drug	-	337	O
toxicity	-	342	B
can	-	351	O
exhibit	-	355	O
patterns	-	363	O
that	-	372	O
suggest	-	377	O
highly	-	385	O
selective	-	392	O
involvement	-	402	O
of	-	414	O
functional	-	417	O
subdivisions	-	428	O
of	-	441	O
the	-	444	O
brain	-	448	O
.	-	453	O

Biphasic	921394	0	O
response	-	9	O
of	-	18	O
the	-	21	O
SA	-	25	O
node	-	28	O
of	-	33	O
the	-	36	O
dog	-	40	O
heart	-	44	O
in	-	50	O
vivo	-	53	O
to	-	58	O
selective	-	61	O
administration	-	71	O
of	-	86	O
ketamine	-	89	O
.	-	97	O

Effect	921394	99	O
of	-	106	O
ketamine	-	109	O
on	-	118	O
the	-	121	O
SA	-	125	O
node	-	128	O
of	-	133	O
the	-	136	O
dog	-	140	O
heart	-	144	O
was	-	150	O
studied	-	154	O
in	-	162	O
vivo	-	165	O
using	-	170	O
a	-	176	O
selective	-	178	O
perfusion	-	188	O
technique	-	198	O
of	-	208	O
the	-	211	O
SA	-	215	O
node	-	218	O
artery	-	223	O
.	-	229	O

Injections	921394	231	O
of	-	242	O
ketamine	-	245	O
in	-	254	O
doses	-	257	O
from	-	263	O
100	-	268	O
microgram	-	272	O
to	-	282	O
3	-	285	O
mg	-	287	O
into	-	290	O
the	-	295	O
artery	-	299	O
produced	-	306	O
a	-	315	O
depression	-	317	B
of	-	328	O
the	-	331	O
SA	-	335	O
nodal	-	338	O
activity	-	344	O
by	-	353	O
a	-	356	O
direct	-	358	O
action	-	365	O
.	-	371	O

This	921394	373	O
depression	-	378	B
was	-	389	O
followed	-	393	O
by	-	402	O
the	-	405	O
sudden	-	409	O
appearance	-	416	O
of	-	427	O
a	-	430	O
stimulatory	-	432	O
phase	-	444	O
.	-	449	O

Bilateral	921394	451	O
vagotomy	-	461	O
and	-	470	O
sympathectomy	-	474	O
or	-	488	O
prior	-	491	O
administration	-	497	O
of	-	512	O
a	-	515	O
ganglion	-	517	O
blocker	-	526	O
failed	-	534	O
to	-	541	O
inhibit	-	544	O
the	-	552	O
occurrence	-	556	O
of	-	567	O
the	-	570	O
ketamine	-	574	O
-	-	582	O
induced	-	583	O
tachycardia	-	591	B
,	-	602	O
while	-	604	O
it	-	610	O
was	-	613	O
completely	-	617	O
abolished	-	628	O
in	-	638	O
the	-	641	O
reserpinized	-	645	O
dogs	-	658	O
or	-	663	O
by	-	666	O
a	-	669	O
prior	-	671	O
injection	-	677	O
of	-	687	O
a	-	690	O
beta	-	692	O
-	-	696	O
blocking	-	697	O
agent	-	706	O
into	-	712	O
the	-	717	O
SA	-	721	O
node	-	724	O
artery	-	729	O
.	-	735	O

This	921394	737	O
may	-	742	O
indicate	-	746	O
that	-	755	O
an	-	760	O
activation	-	763	O
of	-	774	O
the	-	777	O
peripheral	-	781	O
adrenergic	-	792	O
mechanism	-	803	O
plays	-	813	O
an	-	819	O
important	-	822	O
role	-	832	O
in	-	837	O
the	-	840	O
induction	-	844	O
of	-	854	O
the	-	857	O
excitatory	-	861	O
effect	-	872	O
of	-	879	O
ketamine	-	882	O
injected	-	891	O
in	-	900	O
the	-	903	O
SA	-	907	O
node	-	910	O
artery	-	915	O
.	-	921	O

The	871943	0	O
use	-	4	O
of	-	8	O
serum	-	11	O
cholinesterase	-	17	O
in	-	32	O
succinylcholine	-	35	O
apnoea	-	51	B
.	-	57	O

Fifteen	871943	59	O
patients	-	67	O
demonstrating	-	76	O
unexpected	-	90	O
prolonged	-	101	O
apnoea	-	111	B
lasting	-	118	O
several	-	126	O
hours	-	134	O
after	-	140	O
succinylcholine	-	146	O
have	-	162	O
been	-	167	O
treated	-	172	O
by	-	180	O
a	-	183	O
new	-	185	O
preparation	-	189	O
of	-	201	O
human	-	204	O
serum	-	210	O
cholinesterase	-	216	O
.	-	230	O

Adequate	871943	232	O
spontaneous	-	241	O
respiration	-	253	O
was	-	265	O
re	-	269	O
-	-	271	O
established	-	272	O
in	-	284	O
an	-	287	O
average	-	290	O
period	-	298	O
of	-	305	O
ten	-	308	O
minutes	-	312	O
after	-	320	O
the	-	326	O
injection	-	330	O
.	-	339	O

In	871943	341	O
12	-	344	O
patients	-	347	O
biochemical	-	356	O
genetic	-	368	O
examinations	-	376	O
confirmed	-	389	O
the	-	399	O
presence	-	403	O
of	-	412	O
an	-	415	O
atypical	-	418	O
serum	-	427	O
cholinesterase	-	433	O
.	-	447	O

In	871943	449	O
three	-	452	O
patients	-	458	O
none	-	467	O
of	-	472	O
the	-	475	O
usual	-	479	O
variants	-	485	O
were	-	494	O
found	-	499	O
.	-	504	O

It	871943	506	O
is	-	509	O
therefore	-	512	O
supposed	-	522	O
that	-	531	O
other	-	536	O
unknown	-	542	O
variants	-	550	O
of	-	559	O
serum	-	562	O
cholinesterase	-	568	O
exist	-	583	O
which	-	589	O
can	-	595	O
not	-	598	O
hydrolyze	-	602	O
succinylcholine	-	612	O
.	-	627	O

The	871943	629	O
use	-	633	O
of	-	637	O
serum	-	640	O
cholinesterase	-	646	O
in	-	661	O
succinylcholine	-	664	O
apnoea	-	680	B
provided	-	687	O
considerable	-	696	O
relief	-	709	O
to	-	716	O
both	-	719	O
patient	-	724	O
and	-	732	O
anaesthetist	-	736	O
.	-	748	O

Orthostatic	1355091	0	B
hypotension	-	12	I
occurs	-	24	O
following	-	31	O
alpha	-	41	O
2	-	47	O
-	-	48	O
adrenoceptor	-	49	O
blockade	-	62	O
in	-	71	O
chronic	-	74	O
prazosin	-	82	O
-	-	90	O
pretreated	-	91	O
conscious	-	102	O
spontaneously	-	112	O
hypertensive	-	126	B
rats	-	139	O
.	-	143	O

1	1355091	145	O
.	-	146	O

Studies	1355091	148	O
were	-	156	O
performed	-	161	O
to	-	171	O
evaluate	-	174	O
whether	-	183	O
chronic	-	191	O
prazosin	-	199	O
treatment	-	208	O
alters	-	218	O
the	-	225	O
alpha	-	229	O
2	-	235	O
-	-	236	O
adrenoceptor	-	237	O
function	-	250	O
for	-	259	O
orthostatic	-	263	O
control	-	275	O
of	-	283	O
arterial	-	286	O
blood	-	295	O
pressure	-	301	O
in	-	310	O
conscious	-	313	O
spontaneously	-	323	O
hypertensive	-	337	B
rats	-	350	O
(	-	355	O
SHR	-	356	O
)	-	359	O
.	-	360	O

2	1355091	362	O
.	-	363	O

Conscious	1355091	365	O
SHR	-	375	O
(	-	379	O
male	-	380	O
300	-	385	O
-	-	388	O
350	-	389	O
g	-	393	O
)	-	394	O
were	-	396	O
subjected	-	401	O
to	-	411	O
90	-	414	O
degrees	-	417	O
head	-	425	O
-	-	429	O
up	-	430	O
tilts	-	433	O
for	-	439	O
60	-	443	O
s	-	446	O
following	-	448	O
acute	-	458	O
administration	-	464	O
of	-	479	O
prazosin	-	482	O
(	-	491	O
0	-	492	O
.	-	493	O
1	-	494	O
mg	-	496	O
kg	-	499	O
-	-	501	O
1	-	502	O
i	-	504	O
.	-	505	O
p	-	506	O
.	-	507	O
)	-	508	O
or	-	510	O
rauwolscine	-	513	O
(	-	525	O
3	-	526	O
mg	-	528	O
kg	-	531	O
-	-	533	O
1	-	534	O
i	-	536	O
.	-	537	O
v	-	538	O
.	-	539	O
)	-	540	O
.	-	541	O

Orthostatic	1355091	543	B
hypotension	-	555	I
was	-	567	O
determined	-	571	O
by	-	582	O
the	-	585	O
average	-	589	O
decrease	-	597	O
(	-	606	O
%	-	607	O
)	-	608	O
in	-	610	O
mean	-	613	O
arterial	-	618	O
pressure	-	627	O
(	-	636	O
MAP	-	637	O
femoral	-	641	O
)	-	648	O
over	-	650	O
the	-	655	O
60	-	659	O
-	-	661	O
s	-	662	O
tilt	-	664	O
period	-	669	O
.	-	675	O

The	1355091	677	O
basal	-	681	O
MAP	-	687	O
of	-	691	O
conscious	-	694	O
SHR	-	704	O
was	-	708	O
reduced	-	712	O
to	-	720	O
a	-	723	O
similar	-	725	O
extent	-	733	O
by	-	740	O
prazosin	-	743	O
(	-	752	O
-	-	753	O
23	-	754	O
%	-	756	O
(	-	757	O
-	-	758	O
)	-	759	O
-	-	760	O
26	-	761	O
%	-	763	O
MAP	-	765	O
)	-	768	O
and	-	770	O
rauwolscine	-	774	O
(	-	786	O
-	-	787	O
16	-	788	O
%	-	790	O
(	-	791	O
-	-	792	O
)	-	793	O
-	-	794	O
33	-	795	O
%	-	797	O
MAP	-	799	O
)	-	802	O
.	-	803	O

However	1355091	805	O
,	-	812	O
the	-	814	O
head	-	818	O
-	-	822	O
up	-	823	O
tilt	-	826	O
induced	-	831	O
orthostatic	-	839	B
hypotension	-	851	I
in	-	863	O
the	-	866	O
SHR	-	870	O
treated	-	874	O
with	-	882	O
prazosin	-	887	O
(	-	896	O
-	-	897	O
16	-	898	O
%	-	900	O
MAP	-	902	O
,	-	905	O
n	-	907	O
=	-	909	O
6	-	911	O
)	-	912	O
,	-	913	O
but	-	915	O
not	-	919	O
in	-	923	O
the	-	926	O
SHR	-	930	O
treated	-	934	O
with	-	942	O
rauwolscine	-	947	O
(	-	959	O
less	-	960	O
than	-	965	O
+	-	970	O
2	-	971	O
%	-	972	O
MAP	-	974	O
,	-	977	O
n	-	979	O
=	-	981	O
6	-	983	O
)	-	984	O
.	-	985	O

3	1355091	987	O
.	-	988	O

Conscious	1355091	990	O
SHR	-	1000	O
were	-	1004	O
treated	-	1009	O
for	-	1017	O
4	-	1021	O
days	-	1023	O
with	-	1028	O
prazosin	-	1033	O
at	-	1042	O
2	-	1045	O
mg	-	1047	O
kg	-	1050	O
-	-	1052	O
1	-	1053	O
day	-	1055	O
-	-	1058	O
1	-	1059	O

i	1355091	1061	O
.	-	1062	O
p	-	1063	O
.	-	1064	O

for	1355091	1066	O
chronic	-	1070	O
alpha	-	1078	O
1	-	1084	O
-	-	1085	O
adrenoceptor	-	1086	O
blockade	-	1099	O
.	-	1107	O

MAP	1355091	1109	O
in	-	1113	O
conscious	-	1116	O
SHR	-	1126	O
after	-	1130	O
chronic	-	1136	O
prazosin	-	1144	O
treatment	-	1153	O
was	-	1163	O
14	-	1167	O
%	-	1169	O
lower	-	1171	O
than	-	1177	O
in	-	1182	O
the	-	1185	O
untreated	-	1189	O
SHR	-	1199	O
(	-	1203	O
n	-	1204	O
=	-	1206	O
8	-	1208	O
)	-	1209	O
.	-	1210	O

Head	1355091	1212	O
-	-	1216	O
up	-	1217	O
tilts	-	1220	O
in	-	1226	O
these	-	1229	O
rats	-	1235	O
did	-	1240	O
not	-	1244	O
produce	-	1248	O
orthostatic	-	1256	B
hypotension	-	1268	I
when	-	1280	O
performed	-	1285	O
either	-	1295	O
prior	-	1302	O
to	-	1308	O
or	-	1311	O
after	-	1314	O
acute	-	1320	O
dosing	-	1326	O
of	-	1333	O
prazosin	-	1336	O
(	-	1345	O
0	-	1346	O
.	-	1347	O
1	-	1348	O
mg	-	1350	O
kg	-	1353	O
-	-	1355	O
1	-	1356	O
i	-	1358	O
.	-	1359	O
p	-	1360	O
.	-	1361	O
)	-	1362	O
.	-	1363	O

Conversely	1355091	1365	O
,	-	1375	O
administration	-	1377	O
of	-	1392	O
rauwolscine	-	1395	O
(	-	1407	O
3	-	1408	O
mg	-	1410	O
kg	-	1413	O
-	-	1415	O
1	-	1416	O
i	-	1418	O
.	-	1419	O
v	-	1420	O
.	-	1421	O
)	-	1422	O
in	-	1424	O
chronic	-	1427	O
prazosin	-	1435	O
treated	-	1444	O
SHR	-	1452	O
decreased	-	1456	O
the	-	1466	O
basal	-	1470	O
MAP	-	1476	O
by	-	1480	O
12	-	1483	O
-	-	1485	O
31	-	1486	O
%	-	1488	O
(	-	1490	O
n	-	1491	O
=	-	1493	O
4	-	1495	O
)	-	1496	O
,	-	1497	O
and	-	1499	O
subsequent	-	1503	O
tilts	-	1514	O
induced	-	1520	O
further	-	1528	O
drops	-	1536	O
of	-	1542	O
MAP	-	1545	O
by	-	1549	O
19	-	1552	O
-	-	1554	O
23	-	1555	O
%	-	1557	O
in	-	1559	O
these	-	1562	O
rats	-	1568	O
.	-	1572	O

4	1355091	1574	O
.	-	1575	O

The	1355091	1577	O
pressor	-	1581	O
responses	-	1589	O
and	-	1599	O
bradycardia	-	1603	B
to	-	1615	O
the	-	1618	O
alpha	-	1622	O
1	-	1628	O
-	-	1629	O
agonist	-	1630	O
cirazoline	-	1638	O
(	-	1649	O
0	-	1650	O
.	-	1651	O
6	-	1652	O
and	-	1654	O
2	-	1658	O
micrograms	-	1660	O
kg	-	1671	O
-	-	1673	O
1	-	1674	O
i	-	1676	O
.	-	1677	O
v	-	1678	O
.	-	1679	O
)	-	1680	O
,	-	1681	O
the	-	1683	O
alpha	-	1687	O
2	-	1693	O
-	-	1694	O
agonist	-	1695	O
Abbott	-	1703	O
-	-	1709	O
53693	-	1710	O
(	-	1716	O
1	-	1717	O
and	-	1719	O
3	-	1723	O
micrograms	-	1725	O
kg	-	1736	O
-	-	1738	O
1	-	1739	O
i	-	1741	O
.	-	1742	O
v	-	1743	O
.	-	1744	O
)	-	1745	O
,	-	1746	O
and	-	1748	O
noradrenaline	-	1752	O
(	-	1766	O
0	-	1767	O
.	-	1768	O
1	-	1769	O
and	-	1771	O
1	-	1775	O
.	-	1776	O
0	-	1777	O
micrograms	-	1779	O
kg	-	1790	O
-	-	1792	O
1	-	1793	O
i	-	1795	O
.	-	1796	O
v	-	1797	O
.	-	1798	O
)	-	1799	O
were	-	1801	O
determined	-	1806	O
in	-	1817	O
conscious	-	1820	O
SHR	-	1830	O
with	-	1834	O
and	-	1839	O
without	-	1843	O
chronic	-	1851	O
prazosin	-	1859	O
pretreatment	-	1868	O
.	-	1880	O

Both	1355091	1882	O
the	-	1887	O
pressor	-	1891	O
and	-	1899	O
bradycardia	-	1903	B
effects	-	1915	O
of	-	1923	O
cirazoline	-	1926	O
were	-	1937	O
abolished	-	1942	O
in	-	1952	O
chronic	-	1955	O
prazosin	-	1963	O
treated	-	1972	O
SHR	-	1980	O
(	-	1984	O
n	-	1985	O
=	-	1987	O
4	-	1989	O
)	-	1990	O
as	-	1992	O
compared	-	1995	O
to	-	2004	O
the	-	2007	O
untreated	-	2011	O
SHR	-	2021	O
(	-	2025	O
n	-	2026	O
=	-	2028	O
4	-	2030	O
)	-	2031	O
.	-	2032	O

On	1355091	2034	O
the	-	2037	O
other	-	2041	O
hand	-	2047	O
,	-	2051	O
the	-	2053	O
pressor	-	2057	O
effects	-	2065	O
of	-	2073	O
Abbott	-	2076	O
-	-	2082	O
53693	-	2083	O
were	-	2089	O
similar	-	2094	O
in	-	2102	O
both	-	2105	O
groups	-	2110	O
of	-	2117	O
SHR	-	2120	O
,	-	2123	O
but	-	2125	O
the	-	2129	O
accompanying	-	2133	O
bradycardia	-	2146	B
was	-	2158	O
greater	-	2162	O
in	-	2170	O
SHR	-	2173	O
with	-	2177	O
chronic	-	2182	O
prazosin	-	2190	O
treatment	-	2199	O
than	-	2209	O
without	-	2214	O
such	-	2222	O
treatment	-	2227	O
.	-	2236	O

Furthermore	1355091	2238	O
,	-	2249	O
the	-	2251	O
bradycardia	-	2255	B
that	-	2267	O
accompanied	-	2272	O
the	-	2284	O
noradrenaline	-	2288	O
-	-	2301	O
induced	-	2302	O
pressor	-	2310	O
effect	-	2318	O
in	-	2325	O
SHR	-	2328	O
was	-	2332	O
similar	-	2336	O
with	-	2344	O
and	-	2349	O
without	-	2353	O
chronic	-	2361	O
prazosin	-	2369	O
treatment	-	2378	O
despite	-	2388	O
a	-	2396	O
47	-	2398	O
-	-	2400	O
71	-	2401	O
%	-	2403	O
reduction	-	2405	O
of	-	2415	O
the	-	2418	O
pressor	-	2422	O
effect	-	2430	O
in	-	2437	O
chronic	-	2440	O
alpha	-	2448	O
1	-	2454	O
-	-	2455	O
receptor	-	2456	O
blocked	-	2465	O
SHR	-	2473	O
.	-	2476	O
(	-	2477	O
ABSTRACT	-	2478	O
TRUNCATED	-	2487	O
AT	-	2497	O
400	-	2500	O
WORDS	-	2504	O
)	-	2509	O

Coexistence	8638876	0	O
of	-	12	O
cerebral	-	15	B
venous	-	24	I
sinus	-	31	I
and	-	37	I
internal	-	41	I
carotid	-	50	I
artery	-	58	I
thrombosis	-	65	I
associated	-	76	O
with	-	87	O
exogenous	-	92	O
sex	-	102	O
hormones	-	106	O
.	-	114	O

A	8638876	116	O
case	-	118	O
report	-	123	O
.	-	129	O

A	8638876	131	O
forty	-	133	O
-	-	138	O
six	-	139	O
year	-	143	O
-	-	147	O
old	-	148	O
premenopausal	-	152	O
woman	-	166	O
developed	-	172	O
headache	-	182	B
,	-	190	O
nausea	-	192	B
and	-	199	O
vomiting	-	203	B
,	-	211	O
left	-	213	O
hemiparesis	-	218	B
and	-	230	O
seizure	-	234	B
two	-	242	O
days	-	246	O
after	-	251	O
parenteral	-	257	O
use	-	268	O
of	-	272	O
progesterone	-	275	O
and	-	288	O
estradiol	-	292	O
.	-	301	O

Diabetes	8638876	303	B
mellitus	-	312	I
(	-	321	O
DM	-	322	B
)	-	324	O
was	-	326	O
found	-	330	O
during	-	336	O
admission	-	343	O
.	-	352	O

Computed	8638876	354	O
tomography	-	363	O
showed	-	374	O
a	-	381	O
hemorrhagic	-	383	B
infarct	-	395	I
in	-	403	O
the	-	406	O
right	-	410	O
frontal	-	416	O
lobe	-	424	O
and	-	429	O
increased	-	433	O
density	-	443	O
in	-	451	O
the	-	454	O
superior	-	458	O
sagittal	-	467	O
sinus	-	476	O
(	-	482	O
SSS	-	483	O
)	-	486	O
.	-	487	O

Left	8638876	489	O
carotid	-	494	O
angiography	-	502	O
found	-	514	O
occlusion	-	520	B
of	-	530	I
the	-	533	I
left	-	537	I
internal	-	542	I
carotid	-	551	I
artery	-	559	I
(	-	566	O
ICA	-	567	O
)	-	570	O
.	-	571	O

Right	8638876	573	O
carotid	-	579	O
angiograms	-	587	O
failed	-	598	O
to	-	605	O
show	-	608	O
the	-	613	O
SSS	-	617	O
and	-	621	O
inferior	-	625	O
sagittal	-	634	O
sinus	-	643	O
,	-	648	O
suggestive	-	650	O
of	-	661	O
venous	-	664	B
sinus	-	671	I
thrombosis	-	677	I
.	-	687	O

Coexistence	8638876	689	O
of	-	701	O
the	-	704	O
cerebral	-	708	B
artery	-	717	I
and	-	724	I
the	-	728	I
venous	-	732	I
sinus	-	739	I
occlusion	-	745	I
has	-	755	O
been	-	759	O
described	-	764	O
infrequently	-	774	O
.	-	786	O

In	8638876	788	O
this	-	791	O
case	-	796	O
,	-	800	O
the	-	802	O
authors	-	806	O
postulate	-	814	O
that	-	824	O
the	-	829	O
use	-	833	O
of	-	837	O
estradiol	-	840	O
and	-	850	O
progesterone	-	854	O
and	-	867	O
the	-	871	O
underlying	-	875	O
DM	-	886	B
increased	-	889	O
vascular	-	899	O
thrombogenicity	-	908	O
,	-	923	O
which	-	925	O
provided	-	931	O
a	-	940	O
common	-	942	O
denominator	-	949	O
for	-	961	O
thrombosis	-	965	B
of	-	976	I
both	-	979	I
the	-	984	I
ICA	-	988	I
and	-	992	I
the	-	996	I
venous	-	1000	I
sinus	-	1007	I
.	-	1012	O

Chloroquine	1628552	0	O
related	-	12	O
complete	-	20	O
heart	-	29	B
block	-	35	I
with	-	41	O
blindness	-	46	B
:	-	55	O
case	-	57	O
report	-	62	O
.	-	68	O

A	1628552	70	O
27	-	72	O
-	-	74	O
year	-	75	O
old	-	80	O
African	-	84	O
woman	-	92	O
with	-	98	O
history	-	103	O
of	-	111	O
regular	-	114	O
chloroquine	-	122	O
ingestion	-	134	O
presented	-	144	O
with	-	154	O
progressive	-	159	O
deterioration	-	171	B
of	-	185	I
vision	-	188	I
,	-	194	O
easy	-	196	O
fatiguability	-	201	B
,	-	214	O
dyspnoea	-	216	B
,	-	224	O
dizziness	-	226	B
progressing	-	236	O
to	-	248	O
syncopal	-	251	B
attacks	-	260	I
.	-	267	O

Ophthalmological	1628552	269	O
assessment	-	286	O
revealed	-	297	O
features	-	306	O
of	-	315	O
chloroquine	-	318	O
retinopathy	-	330	B
,	-	341	O
cardiac	-	343	O
assessment	-	351	O
revealed	-	362	O
features	-	371	O
of	-	380	O
heart	-	383	B
failure	-	389	I
and	-	397	O
a	-	401	O
complete	-	403	O
heart	-	412	B
block	-	418	I
with	-	424	O
right	-	429	B
bundle	-	435	I
branch	-	442	I
block	-	449	I
pattern	-	455	O
.	-	462	O

The	1628552	464	O
heart	-	468	B
block	-	474	I
was	-	480	O
treated	-	484	O
by	-	492	O
pacemaker	-	495	O
insertion	-	505	O
and	-	515	O
the	-	519	O
heart	-	523	B
failure	-	529	I
resolved	-	537	O
spontaneously	-	546	O
following	-	560	O
chloroquine	-	570	O
discontinuation	-	582	O
.	-	597	O

She	1628552	599	O
however	-	603	O
remains	-	611	O
blind	-	619	B
.	-	624	O

Systemic	11524350	0	O
toxicity	-	9	B
and	-	18	O
resuscitation	-	22	O
in	-	36	O
bupivacaine	-	39	O
-	-	50	O
,	-	51	O
levobupivacaine	-	53	O
-	-	68	O
,	-	69	O
or	-	71	O
ropivacaine	-	74	O
-	-	85	O
infused	-	86	O
rats	-	94	O
.	-	98	O

We	11524350	100	O
compared	-	103	O
the	-	112	O
systemic	-	116	O
toxicity	-	125	B
of	-	134	O
bupivacaine	-	137	O
,	-	148	O
levobupivacaine	-	150	O
,	-	165	O
and	-	167	O
ropivacaine	-	171	O
in	-	183	O
anesthetized	-	186	O
rats	-	199	O
.	-	203	O

We	11524350	205	O
also	-	208	O
compared	-	213	O
the	-	222	O
ability	-	226	O
to	-	234	O
resuscitate	-	237	O
rats	-	249	O
after	-	254	O
lethal	-	260	O
doses	-	267	O
of	-	273	O
these	-	276	O
local	-	282	O
anesthetics	-	288	O
.	-	299	O

Bupivacaine	11524350	301	O
,	-	312	O
levobupivacaine	-	314	O
,	-	329	O
or	-	331	O
ropivacaine	-	334	O
was	-	346	O
infused	-	350	O
at	-	358	O
a	-	361	O
rate	-	363	O
of	-	368	O
2	-	371	O
mg	-	373	O
.	-	375	O

kg	11524350	377	O
(	-	379	O
-	-	380	O
1	-	381	O
)	-	382	O
.	-	383	O

min	11524350	385	O
(	-	388	O
-	-	389	O
1	-	390	O
)	-	391	O
while	-	393	O
electrocardiogram	-	399	O
,	-	416	O
electroencephalogram	-	418	O
,	-	438	O
and	-	440	O
arterial	-	444	O
pressure	-	453	O
were	-	462	O
continuously	-	467	O
monitored	-	480	O
.	-	489	O

When	11524350	491	O
asystole	-	496	B
was	-	505	O
recorded	-	509	O
,	-	517	O
drug	-	519	O
infusion	-	524	O
was	-	533	O
stopped	-	537	O
and	-	545	O
a	-	549	O
resuscitation	-	551	O
sequence	-	565	O
was	-	574	O
begun	-	578	O
.	-	583	O

Epinephrine	11524350	585	O
0	-	597	O
.	-	598	O
01	-	599	O

mg	11524350	602	O
/	-	604	O
kg	-	605	O
was	-	608	O
administered	-	612	O
at	-	625	O
1	-	628	O
-	-	629	O
min	-	630	O
intervals	-	634	O
while	-	644	O
external	-	650	O
cardiac	-	659	O
compressions	-	667	O
were	-	680	O
applied	-	685	O
.	-	692	O

Resuscitation	11524350	694	O
was	-	708	O
considered	-	712	O
successful	-	723	O
when	-	734	O
a	-	739	O
systolic	-	741	O
arterial	-	750	O
pressure	-	759	O
>	-	768	O
or	-	770	O
=	-	773	O
100	-	774	O
mm	-	778	O
Hg	-	781	O
was	-	784	O
achieved	-	788	O
within	-	797	O
5	-	804	O
min	-	806	O
.	-	809	O

The	11524350	811	O
cumulative	-	815	O
doses	-	826	O
of	-	832	O
levobupivacaine	-	835	O
and	-	851	O
ropivacaine	-	855	O
that	-	867	O
produced	-	872	O
seizures	-	881	B
were	-	890	O
similar	-	895	O
and	-	903	O
were	-	907	O
larger	-	912	O
than	-	919	O
those	-	924	O
of	-	930	O
bupivacaine	-	933	O
.	-	944	O

The	11524350	946	O
cumulative	-	950	O
doses	-	961	O
of	-	967	O
levobupivacaine	-	970	O
that	-	986	O
produced	-	991	O
dysrhythmias	-	1000	B
and	-	1013	O
asystole	-	1017	B
were	-	1026	O
smaller	-	1031	O
than	-	1039	O
the	-	1044	O
corresponding	-	1048	O
doses	-	1062	O
of	-	1068	O
ropivacaine	-	1071	O
,	-	1082	O
but	-	1084	O
they	-	1088	O
were	-	1093	O
larger	-	1098	O
than	-	1105	O
those	-	1110	O
of	-	1116	O
bupivacaine	-	1119	O
.	-	1130	O

The	11524350	1132	O
number	-	1136	O
of	-	1143	O
successful	-	1146	O
resuscitations	-	1157	O
did	-	1172	O
not	-	1176	O
differ	-	1180	O
among	-	1187	O
groups	-	1193	O
.	-	1199	O

However	11524350	1201	O
,	-	1208	O
a	-	1210	O
smaller	-	1212	O
dose	-	1220	O
of	-	1225	O
epinephrine	-	1228	O
was	-	1240	O
required	-	1244	O
in	-	1253	O
the	-	1256	O
Ropivacaine	-	1260	O
group	-	1272	O
than	-	1278	O
in	-	1283	O
the	-	1286	O
other	-	1290	O
groups	-	1296	O
.	-	1302	O

We	11524350	1304	O
conclude	-	1307	O
that	-	1316	O
the	-	1321	O
systemic	-	1325	O
toxicity	-	1334	B
of	-	1343	O
levobupivacaine	-	1346	O
is	-	1362	O
intermediate	-	1365	O
between	-	1378	O
that	-	1386	O
of	-	1391	O
ropivacaine	-	1394	O
and	-	1406	O
bupivacaine	-	1410	O
when	-	1422	O
administered	-	1427	O
at	-	1440	O
the	-	1443	O
same	-	1447	O
rate	-	1452	O
and	-	1457	O
that	-	1461	O
ropivacaine	-	1466	O
-	-	1477	O
induced	-	1478	O
cardiac	-	1486	B
arrest	-	1494	I
appears	-	1501	O
to	-	1509	O
be	-	1512	O
more	-	1515	O
susceptible	-	1520	O
to	-	1532	O
treatment	-	1535	O
than	-	1545	O
that	-	1550	O
induced	-	1555	O
by	-	1563	O
bupivacaine	-	1566	O
or	-	1578	O
levobupivacaine	-	1581	O
.	-	1596	O

22	10027919	0	O
-	-	2	O
oxacalcitriol	-	3	O
suppresses	-	17	O
secondary	-	28	B
hyperparathyroidism	-	38	I
without	-	58	O
inducing	-	66	O
low	-	75	B
bone	-	79	I
turnover	-	84	I
in	-	93	O
dogs	-	96	O
with	-	101	O
renal	-	106	B
failure	-	112	I
.	-	119	O

BACKGROUND	10027919	121	O
:	-	131	O

Calcitriol	10027919	133	O
therapy	-	144	O
suppresses	-	152	O
serum	-	163	O
levels	-	169	O
of	-	176	O
parathyroid	-	179	O
hormone	-	191	O
(	-	199	O
PTH	-	200	O
)	-	203	O
in	-	205	O
patients	-	208	O
with	-	217	O
renal	-	222	B
failure	-	228	I
but	-	236	O
has	-	240	O
several	-	244	O
drawbacks	-	252	O
,	-	261	O
including	-	263	O
hypercalcemia	-	273	B
and	-	287	O
/	-	290	O
or	-	291	O
marked	-	294	O
suppression	-	301	B
of	-	313	I
bone	-	316	I
turnover	-	321	I
,	-	329	O
which	-	331	O
may	-	337	O
lead	-	341	O
to	-	346	O
adynamic	-	349	B
bone	-	358	I
disease	-	363	I
.	-	370	O

A	10027919	372	O
new	-	374	O
vitamin	-	378	O
D	-	386	O
analogue	-	388	O
,	-	396	O
22	-	398	O
-	-	400	O
oxacalcitriol	-	401	O
(	-	415	O
OCT	-	416	O
)	-	419	O
,	-	420	O
has	-	422	O
been	-	426	O
shown	-	431	O
to	-	437	O
have	-	440	O
promising	-	445	O
characteristics	-	455	O
.	-	470	O

This	10027919	472	O
study	-	477	O
was	-	483	O
undertaken	-	487	O
to	-	498	O
determine	-	501	O
the	-	511	O
effects	-	515	O
of	-	523	O
OCT	-	526	O
on	-	530	O
serum	-	533	O
PTH	-	539	O
levels	-	543	O
and	-	550	O
bone	-	554	O
turnover	-	559	O
in	-	568	O
states	-	571	O
of	-	578	O
normal	-	581	O
or	-	588	O
impaired	-	591	B
renal	-	600	I
function	-	606	I
.	-	614	O

METHODS	10027919	616	O
:	-	623	O

Sixty	10027919	625	O
dogs	-	631	O
were	-	636	O
either	-	641	O
nephrectomized	-	648	O
(	-	663	O
Nx	-	664	O
,	-	666	O
N	-	668	O
=	-	670	O
38	-	672	O
)	-	674	O
or	-	676	O
sham	-	679	O
-	-	683	O
operated	-	684	O
(	-	693	O
Sham	-	694	O
,	-	698	O
N	-	700	O
=	-	702	O
22	-	704	O
)	-	706	O
.	-	707	O

The	10027919	709	O
animals	-	713	O
received	-	721	O
supplemental	-	730	O
phosphate	-	743	O
to	-	753	O
enhance	-	756	O
PTH	-	764	O
secretion	-	768	O
.	-	777	O

Fourteen	10027919	779	O
weeks	-	788	O
after	-	794	O
the	-	800	O
start	-	804	O
of	-	810	O
phosphate	-	813	O
supplementation	-	823	O
,	-	838	O
half	-	840	O
of	-	845	O
the	-	848	O
Nx	-	852	O
and	-	855	O
Sham	-	859	O
dogs	-	864	O
received	-	869	O
doses	-	878	O
of	-	884	O
OCT	-	887	O
(	-	891	O
three	-	892	O
times	-	898	O
per	-	904	O
week	-	908	O
)	-	912	O
;	-	913	O
the	-	915	O
other	-	919	O
half	-	925	O
were	-	930	O
given	-	935	O
vehicle	-	941	O
for	-	949	O
60	-	953	O
weeks	-	956	O
.	-	961	O

Thereafter	10027919	963	O
,	-	973	O
the	-	975	O
treatment	-	979	O
modalities	-	989	O
for	-	1000	O
a	-	1004	O
subset	-	1006	O
of	-	1013	O
animals	-	1016	O
were	-	1024	O
crossed	-	1029	O
over	-	1037	O
for	-	1042	O
an	-	1046	O
additional	-	1049	O
eight	-	1060	O
months	-	1066	O
.	-	1072	O

Biochemical	10027919	1074	O
and	-	1086	O
hormonal	-	1090	O
indices	-	1099	O
of	-	1107	O
calcium	-	1110	O
and	-	1118	O
bone	-	1122	O
metabolism	-	1127	O
were	-	1138	O
measured	-	1143	O
throughout	-	1152	O
the	-	1163	O
study	-	1167	O
,	-	1172	O
and	-	1174	O
bone	-	1178	O
biopsies	-	1183	O
were	-	1192	O
done	-	1197	O
at	-	1202	O
baseline	-	1205	O
,	-	1213	O
60	-	1215	O
weeks	-	1218	O
after	-	1224	O
OCT	-	1230	O
or	-	1234	O
vehicle	-	1237	O
treatment	-	1245	O
,	-	1254	O
and	-	1256	O
at	-	1260	O
the	-	1263	O
end	-	1267	O
of	-	1271	O
the	-	1274	O
crossover	-	1278	O
period	-	1288	O
.	-	1294	O

RESULTS	10027919	1296	O
:	-	1303	O

In	10027919	1305	O
Nx	-	1308	O
dogs	-	1311	O
,	-	1315	O
OCT	-	1317	O
significantly	-	1321	O
decreased	-	1335	O
serum	-	1345	O
PTH	-	1351	O
levels	-	1355	O
soon	-	1362	O
after	-	1367	O
the	-	1373	O
induction	-	1377	O
of	-	1387	O
renal	-	1390	B
insufficiency	-	1396	I
.	-	1409	O

In	10027919	1411	O
long	-	1414	O
-	-	1418	O
standing	-	1419	O
secondary	-	1428	B
hyperparathyroidism	-	1438	I
,	-	1457	O
OCT	-	1459	O
(	-	1463	O
0	-	1464	O
.	-	1465	O
03	-	1466	O
microg	-	1469	O
/	-	1475	O
kg	-	1476	O
)	-	1478	O
stabilized	-	1480	O
serum	-	1491	O
PTH	-	1497	O
levels	-	1501	O
during	-	1508	O
the	-	1515	O
first	-	1519	O
months	-	1525	O
.	-	1531	O

Serum	10027919	1533	O
PTH	-	1539	O
levels	-	1543	O
rose	-	1550	O
thereafter	-	1555	O
,	-	1565	O
but	-	1567	O
the	-	1571	O
rise	-	1575	O
was	-	1580	O
less	-	1584	O
pronounced	-	1589	O
compared	-	1600	O
with	-	1609	O
baseline	-	1614	O
than	-	1623	O
the	-	1628	O
rise	-	1632	O
seen	-	1637	O
in	-	1642	O
Nx	-	1645	O
control	-	1648	O
.	-	1655	O

These	10027919	1657	O
effects	-	1663	O
were	-	1671	O
accompanied	-	1676	O
by	-	1688	O
episodes	-	1691	O
of	-	1700	O
hypercalcemia	-	1703	B
and	-	1717	O
hyperphosphatemia	-	1721	B
.	-	1738	O

In	10027919	1740	O
animals	-	1743	O
with	-	1751	O
normal	-	1756	O
renal	-	1763	O
function	-	1769	O
,	-	1777	O
OCT	-	1779	O
induced	-	1783	O
a	-	1791	O
transient	-	1793	O
decrease	-	1803	O
in	-	1812	O
serum	-	1815	O
PTH	-	1821	O
levels	-	1825	O
at	-	1832	O
a	-	1835	O
dose	-	1837	O
of	-	1842	O
0	-	1845	O
.	-	1846	O
1	-	1847	O
microg	-	1849	O
/	-	1855	O
kg	-	1856	O
,	-	1858	O
which	-	1860	O
was	-	1866	O
not	-	1870	O
sustained	-	1874	O
with	-	1884	O
lowering	-	1889	O
of	-	1898	O
the	-	1901	O
doses	-	1905	O
.	-	1910	O

In	10027919	1912	O
Nx	-	1915	O
dogs	-	1918	O
,	-	1922	O
OCT	-	1924	O
reversed	-	1928	O
abnormal	-	1937	O
bone	-	1946	O
formation	-	1951	O
,	-	1960	O
such	-	1962	O
as	-	1967	O
woven	-	1970	B
osteoid	-	1976	I
and	-	1984	O
fibrosis	-	1988	B
,	-	1996	O
but	-	1998	O
did	-	2002	O
not	-	2006	O
significantly	-	2010	O
alter	-	2024	O
the	-	2030	O
level	-	2034	O
of	-	2040	O
bone	-	2043	O
turnover	-	2048	O
.	-	2056	O

In	10027919	2058	O
addition	-	2061	O
,	-	2069	O
OCT	-	2071	O
improved	-	2075	O
mineralization	-	2084	O
lag	-	2099	O
time	-	2103	O
,	-	2107	O
(	-	2109	O
that	-	2110	O
is	-	2115	O
,	-	2117	O
the	-	2119	O
rate	-	2123	O
at	-	2128	O
which	-	2131	O
osteoid	-	2137	O
mineralizes	-	2145	O
)	-	2156	O
in	-	2158	O
both	-	2161	O
Nx	-	2166	O
and	-	2169	O
Sham	-	2173	O
dogs	-	2178	O
.	-	2182	O

CONCLUSIONS	10027919	2184	O
:	-	2195	O

These	10027919	2197	O
results	-	2203	O
indicate	-	2211	O
that	-	2220	O
even	-	2225	O
though	-	2230	O
OCT	-	2237	O
does	-	2241	O
not	-	2246	O
completely	-	2250	O
prevent	-	2261	O
the	-	2269	O
occurrence	-	2273	O
of	-	2284	O
hypercalcemia	-	2287	B
in	-	2301	O
experimental	-	2304	O
dogs	-	2317	O
with	-	2322	O
renal	-	2327	B
insufficiency	-	2333	I
,	-	2346	O
it	-	2348	O
may	-	2351	O
be	-	2355	O
of	-	2358	O
use	-	2361	O
in	-	2365	O
the	-	2368	O
management	-	2372	O
of	-	2383	O
secondary	-	2386	B
hyperparathyroidism	-	2396	I
because	-	2416	O
it	-	2424	O
does	-	2427	O
not	-	2432	O
induce	-	2436	O
low	-	2443	B
bone	-	2447	I
turnover	-	2452	I
and	-	2461	O
,	-	2464	O
therefore	-	2466	O
,	-	2475	O
does	-	2477	O
not	-	2482	O
increase	-	2486	O
the	-	2495	O
risk	-	2499	O
of	-	2504	O
adynamic	-	2507	B
bone	-	2516	I
disease	-	2521	I
.	-	2528	O

Chemotherapy	8643966	0	O
of	-	13	O
advanced	-	16	O
inoperable	-	25	O
non	-	36	B
-	-	39	I
small	-	40	I
cell	-	46	I
lung	-	51	I
cancer	-	56	I
with	-	63	O
paclitaxel	-	68	O
:	-	78	O
a	-	80	O
phase	-	82	O
II	-	88	O
trial	-	91	O
.	-	96	O

Paclitaxel	8643966	98	O

(	8643966	109	O
Taxol	-	110	O
;	-	115	O
Bristol	-	117	O
-	-	124	O
Myers	-	125	O
Squibb	-	131	O
Company	-	138	O
,	-	145	O
Princeton	-	147	O
,	-	156	O
NJ	-	158	O
)	-	160	O
has	-	162	O
demonstrated	-	166	O
significant	-	179	O
antineoplastic	-	191	O
activity	-	206	O
against	-	215	O
different	-	223	O
tumor	-	233	B
types	-	239	O
,	-	244	O
notably	-	246	O
ovarian	-	254	B
and	-	262	I
breast	-	266	I
carcinoma	-	273	I
.	-	282	O

Two	8643966	284	O
phase	-	288	O
II	-	294	O
trials	-	297	O
of	-	304	O
24	-	307	O
-	-	309	O
hour	-	310	O
paclitaxel	-	315	O
infusions	-	326	O
in	-	336	O
chemotherapy	-	339	O
-	-	351	O
naive	-	352	O
patients	-	358	O
with	-	367	O
stage	-	372	O
IIIB	-	378	O
or	-	383	O
IV	-	386	O
non	-	389	B
-	-	392	I
small	-	393	I
cell	-	399	I
lung	-	404	I
cancer	-	409	I
(	-	416	O
NSCLC	-	417	B
)	-	422	O
reported	-	424	O
response	-	433	O
rates	-	442	O
of	-	448	O
21	-	451	O
%	-	453	O
and	-	455	O
24	-	459	O
%	-	461	O
.	-	462	O

Leukopenia	8643966	464	B
was	-	475	O
dose	-	479	O
limiting	-	484	O
:	-	492	O
as	-	494	O
many	-	497	O
as	-	502	O
62	-	505	O
.	-	507	O
5	-	508	O
%	-	509	O
of	-	511	O
patients	-	514	O
experienced	-	523	O
grade	-	535	O
4	-	541	O
leukopenia	-	543	B
.	-	553	O

We	8643966	555	O
investigated	-	558	O
the	-	571	O
efficacy	-	575	O
and	-	584	O
toxicity	-	588	B
of	-	597	O
a	-	600	O
3	-	602	O
-	-	603	O
hour	-	604	O
paclitaxel	-	609	O
infusion	-	620	O
in	-	629	O
a	-	632	O
phase	-	634	O
II	-	640	O
trial	-	643	O
in	-	649	O
patients	-	652	O
with	-	661	O
inoperable	-	666	O
stage	-	677	O
IIIB	-	683	O
or	-	688	O
IV	-	691	O
NSCLC	-	694	B
.	-	699	O

The	8643966	701	O
58	-	705	O
patients	-	708	O
treated	-	717	O
(	-	725	O
41	-	726	O
men	-	729	O
and	-	733	O
17	-	737	O
women	-	740	O
)	-	745	O
had	-	747	O
a	-	751	O
median	-	753	O
age	-	760	O
of	-	764	O
59	-	767	O
years	-	770	O
(	-	776	O
age	-	777	O
range	-	781	O
,	-	786	O
25	-	788	O
to	-	791	O
75	-	794	O
)	-	796	O
and	-	798	O
a	-	802	O
performance	-	804	O
status	-	816	O
of	-	823	O
0	-	826	O
through	-	828	O
2	-	836	O
.	-	837	O

Most	8643966	839	O
patients	-	844	O
(	-	853	O
72	-	854	O
.	-	856	O
4	-	857	O
%	-	858	O
)	-	859	O
had	-	861	O
stage	-	865	O
IV	-	871	O
NSCLC	-	874	B
.	-	879	O

Paclitaxel	8643966	881	O
225	-	892	O
mg	-	896	O
/	-	898	O
m2	-	899	O
was	-	902	O
infused	-	906	O
over	-	914	O
3	-	919	O
hours	-	921	O
every	-	927	O
3	-	933	O
weeks	-	935	O
with	-	941	O
standard	-	946	O
prophylactic	-	955	O
premedication	-	968	O
.	-	981	O

Of	8643966	983	O
50	-	986	O
patients	-	989	O
evaluable	-	998	O
for	-	1008	O
response	-	1012	O
,	-	1020	O
12	-	1022	O
(	-	1025	O
24	-	1026	O
%	-	1028	O
)	-	1029	O
had	-	1031	O
partial	-	1035	O
remission	-	1043	O
,	-	1052	O
26	-	1054	O
(	-	1057	O
52	-	1058	O
%	-	1060	O
)	-	1061	O
had	-	1063	O
no	-	1067	O
change	-	1070	O
,	-	1076	O
and	-	1078	O
12	-	1082	O
had	-	1085	O
disease	-	1089	O
progression	-	1097	O
(	-	1109	O
24	-	1110	O
%	-	1112	O
)	-	1113	O
.	-	1114	O

Hematologic	8643966	1116	O
toxicities	-	1128	B
were	-	1139	O
mild	-	1144	O
:	-	1148	O
only	-	1150	O
one	-	1155	O
patient	-	1159	O
(	-	1167	O
2	-	1168	O
%	-	1169	O
)	-	1170	O
developed	-	1172	O
grade	-	1182	O
3	-	1188	O
or	-	1190	O
4	-	1193	O
neutropenia	-	1195	B
,	-	1206	O
while	-	1208	O
29	-	1214	O
%	-	1216	O
had	-	1218	O
grade	-	1222	O
1	-	1228	O
or	-	1230	O
2	-	1233	O
.	-	1234	O

Grade	8643966	1236	O
1	-	1242	O
or	-	1244	O
2	-	1247	O
polyneuropathy	-	1249	B
affected	-	1264	O
56	-	1273	O
%	-	1275	O
of	-	1277	O
patients	-	1280	O
while	-	1289	O
only	-	1295	O
one	-	1300	O
(	-	1304	O
2	-	1305	O
%	-	1306	O
)	-	1307	O
experienced	-	1309	O
severe	-	1321	O
polyneuropathy	-	1328	B
.	-	1342	O

Similarly	8643966	1344	O
,	-	1353	O
grade	-	1355	O
1	-	1361	O
or	-	1363	O
2	-	1366	O
myalgia	-	1368	B
/	-	1375	O
arthralgia	-	1376	B
was	-	1387	O
observed	-	1391	O
in	-	1400	O
63	-	1403	O
.	-	1405	O
2	-	1406	O
%	-	1407	O
of	-	1409	O
patients	-	1412	O
,	-	1420	O
but	-	1422	O
only	-	1426	O
14	-	1431	O
.	-	1433	O
3	-	1434	O
%	-	1435	O
experienced	-	1437	O
grade	-	1449	O
3	-	1455	O
or	-	1457	O
4	-	1460	O
.	-	1461	O

Nausea	8643966	1463	B
and	-	1470	O
vomiting	-	1474	B
were	-	1483	O
infrequent	-	1488	O
,	-	1498	O
with	-	1500	O
14	-	1505	O
%	-	1507	O
of	-	1509	O
patients	-	1512	O
experiencing	-	1521	O
grade	-	1534	O
1	-	1540	O
or	-	1542	O
2	-	1545	O
and	-	1547	O
only	-	1551	O
2	-	1556	O
%	-	1557	O
experiencing	-	1559	O
grade	-	1572	O
3	-	1578	O
or	-	1580	O
4	-	1583	O
.	-	1584	O

Paclitaxel	8643966	1586	O
is	-	1597	O
thus	-	1600	O
an	-	1605	O
active	-	1608	O
single	-	1615	O
agent	-	1622	O
in	-	1628	O
this	-	1631	O
patient	-	1636	O
population	-	1644	O
,	-	1654	O
with	-	1656	O
a	-	1661	O
3	-	1663	O
-	-	1664	O
hour	-	1665	O
infusion	-	1670	O
proving	-	1679	O
comparably	-	1687	O
effective	-	1698	O
to	-	1708	O
a	-	1711	O
24	-	1713	O
-	-	1715	O
hour	-	1716	O
infusion	-	1721	O
and	-	1730	O
superior	-	1734	O
in	-	1743	O
terms	-	1746	O
of	-	1752	O
the	-	1755	O
incidence	-	1759	O
of	-	1769	O
hematologic	-	1772	O
and	-	1784	O
nonhematologic	-	1788	O
toxicity	-	1803	B
.	-	1811	O

Further	8643966	1813	O
phase	-	1821	O
II	-	1827	O
studies	-	1830	O
with	-	1838	O
paclitaxel	-	1843	O
combined	-	1854	O
with	-	1863	O
other	-	1868	O
drugs	-	1874	O
active	-	1880	O
against	-	1887	O
NSCLC	-	1895	B
are	-	1901	O
indicated	-	1905	O
,	-	1914	O
and	-	1916	O
phase	-	1920	O
III	-	1926	O
studies	-	1930	O
comparing	-	1938	O
paclitaxel	-	1948	O
with	-	1959	O
standard	-	1964	O
chemotherapy	-	1973	O
remain	-	1986	O
to	-	1993	O
be	-	1996	O
completed	-	1999	O
.	-	2008	O

Cerebral	6695415	0	B
hemorrhage	-	9	I
associated	-	20	O
with	-	31	O
phenylpropanolamine	-	36	O
in	-	56	O
combination	-	59	O
with	-	71	O
caffeine	-	76	O
.	-	84	O

Phenylpropanolamine	6695415	86	O
(	-	106	O
PPA	-	107	O
)	-	110	O
is	-	112	O
a	-	115	O
drug	-	117	O
that	-	122	O
has	-	127	O
been	-	131	O
associated	-	136	O
with	-	147	O
serious	-	152	O
side	-	160	O
effects	-	165	O
including	-	173	O
stroke	-	183	B
.	-	189	O

It	6695415	191	O
is	-	194	O
often	-	197	O
combined	-	203	O
with	-	212	O
caffeine	-	217	O
in	-	226	O
diet	-	229	O
preparations	-	234	O
and	-	247	O
""""	-	251	O
look	-	252	O
-	-	256	O
alike	-	257	O
""""	-	262	O
pills	-	264	O
.	-	269	O

In	6695415	271	O
order	-	274	O
to	-	280	O
determine	-	283	O
if	-	293	O
PPA	-	296	O
/	-	299	O
caffeine	-	300	O
can	-	309	O
lead	-	313	O
to	-	318	O
stroke	-	321	B
in	-	328	O
normotensive	-	331	O
and	-	344	O
/	-	347	O
or	-	348	O
hypertensive	-	351	B
rats	-	364	O
,	-	368	O
we	-	370	O
administered	-	373	O
the	-	386	O
combination	-	390	O
in	-	402	O
six	-	405	O
times	-	409	O
the	-	415	O
allowed	-	419	O
human	-	427	O
dose	-	433	O
calculated	-	438	O
on	-	449	O
a	-	452	O
per	-	454	O
weight	-	458	O
basis	-	465	O
for	-	471	O
the	-	475	O
rats	-	479	O
two	-	484	O
times	-	488	O
per	-	494	O
day	-	498	O
for	-	502	O
five	-	506	O
days	-	511	O
.	-	515	O

Subarachnoid	6695415	517	B
and	-	530	I
cerebral	-	534	I
hemorrhage	-	543	I
was	-	554	O
noted	-	558	O
in	-	564	O
18	-	567	O
%	-	569	O
of	-	571	O
the	-	574	O
hypertensive	-	578	B
rats	-	591	O
.	-	595	O

A	6695415	597	O
single	-	599	O
PPA	-	606	O
/	-	609	O
caffeine	-	610	O
administration	-	619	O
(	-	634	O
same	-	635	O
dose	-	640	O
)	-	644	O
lead	-	646	O
to	-	651	O
acute	-	654	O
hypertension	-	660	B
in	-	673	O
both	-	676	O
the	-	681	O
normotensive	-	685	O
and	-	698	O
hypertensive	-	702	B
animals	-	715	O
.	-	722	O

These	6695415	724	O
results	-	730	O
suggest	-	738	O
that	-	746	O
PPA	-	751	O
/	-	754	O
caffeine	-	755	O
can	-	764	O
lead	-	768	O
to	-	773	O
cerebral	-	776	B
hemorrhage	-	785	I
in	-	796	O
previously	-	799	O
hypertensive	-	810	B
animals	-	823	O
when	-	831	O
administered	-	836	O
in	-	849	O
greater	-	852	O
than	-	860	O
the	-	865	O
allowed	-	869	O
dosage	-	877	O
.	-	883	O

An	6695415	885	O
acute	-	888	O
elevation	-	894	O
in	-	904	O
blood	-	907	O
pressure	-	913	O
may	-	922	O
be	-	926	O
a	-	929	O
contributing	-	931	O
factor	-	944	O
.	-	950	O

Long	6637851	0	O
-	-	4	O
term	-	5	O
efficacy	-	10	O
and	-	19	O
toxicity	-	23	B
of	-	32	O
high	-	35	O
-	-	39	O
dose	-	40	O
amiodarone	-	45	O
therapy	-	56	O
for	-	64	O
ventricular	-	68	B
tachycardia	-	80	I
or	-	92	O
ventricular	-	95	B
fibrillation	-	107	I
.	-	119	O

Amiodarone	6637851	121	O
was	-	132	O
administered	-	136	O
to	-	149	O
154	-	152	O
patients	-	156	O
who	-	165	O
had	-	169	O
sustained	-	173	O
,	-	182	O
symptomatic	-	184	O
ventricular	-	196	B
tachycardia	-	208	I
(	-	220	O
VT	-	221	B
)	-	223	O
(	-	225	O
n	-	226	O
=	-	228	O
118	-	230	O
)	-	233	O
or	-	235	O
a	-	238	O
cardiac	-	240	B
arrest	-	248	I
(	-	255	O
n	-	256	O
=	-	258	O
36	-	260	O
)	-	262	O
and	-	264	O
who	-	268	O
were	-	272	O
refractory	-	277	O
to	-	288	O
conventional	-	291	O
antiarrhythmic	-	304	O
drugs	-	319	O
.	-	324	O

The	6637851	326	O
loading	-	330	O
dose	-	338	O
was	-	343	O
800	-	347	O
mg	-	351	O
/	-	353	O
day	-	354	O
for	-	358	O
6	-	362	O
weeks	-	364	O
and	-	370	O
the	-	374	O
maintenance	-	378	O
dose	-	390	O
was	-	395	O
600	-	399	O
mg	-	403	O
/	-	405	O
day	-	406	O
.	-	409	O

Sixty	6637851	411	O
-	-	416	O
nine	-	417	O
percent	-	422	O
of	-	430	O
patients	-	433	O
continued	-	442	O
treatment	-	452	O
with	-	462	O
amiodarone	-	467	O
and	-	478	O
had	-	482	O
no	-	486	O
recurrence	-	489	O
of	-	500	O
symptomatic	-	503	O
VT	-	515	B
or	-	518	O
ventricular	-	521	B
fibrillation	-	533	I
(	-	546	O
VF	-	547	B
)	-	549	O
over	-	551	O
a	-	556	O
follow	-	558	O
-	-	564	O
up	-	565	O
of	-	568	O
6	-	571	O
to	-	573	O
52	-	576	O
months	-	579	O
(	-	586	O
mean	-	587	O
+	-	592	O
/	-	593	O
-	-	594	O

standard	6637851	596	O
deviation	-	605	O
14	-	615	O
.	-	617	O
2	-	618	O
+	-	620	O
/	-	621	O
-	-	622	O

8	6637851	624	O
.	-	625	O
2	-	626	O
)	-	627	O
.	-	628	O

Six	6637851	630	O
percent	-	634	O
of	-	642	O
the	-	645	O
patients	-	649	O
had	-	658	O
a	-	662	O
nonfatal	-	664	O
recurrence	-	673	O
of	-	684	O
VT	-	687	B
and	-	690	O
were	-	694	O
successfully	-	699	O
managed	-	712	O
by	-	720	O
continuing	-	723	O
amiodarone	-	734	O
at	-	745	O
a	-	748	O
higher	-	750	O
dose	-	757	O
or	-	762	O
by	-	765	O
the	-	768	O
addition	-	772	O
of	-	781	O
a	-	784	O
conventional	-	786	O
antiarrhythmic	-	799	O
drug	-	814	O
.	-	818	O

One	6637851	820	O
or	-	824	O
more	-	827	O
adverse	-	832	O
drug	-	840	O
reactions	-	845	O
occurred	-	855	O
in	-	864	O
51	-	867	O
%	-	869	O
of	-	871	O
patients	-	874	O
.	-	882	O

Adverse	6637851	884	O
effects	-	892	O
forced	-	900	O
a	-	907	O
reduction	-	909	O
in	-	919	O
the	-	922	O
dose	-	926	O
of	-	931	O
amiodarone	-	934	O
in	-	945	O
41	-	948	O
%	-	950	O
and	-	952	O
discontinuation	-	956	O
of	-	972	O
amiodarone	-	975	O
in	-	986	O
10	-	989	O
%	-	991	O
of	-	993	O
patients	-	996	O
.	-	1004	O

The	6637851	1006	O
most	-	1010	O
common	-	1015	O
symptomatic	-	1022	O
adverse	-	1034	O
reactions	-	1042	O
were	-	1052	O
tremor	-	1057	B
or	-	1064	O
ataxia	-	1067	B
(	-	1074	O
35	-	1075	O
%	-	1077	O
)	-	1078	O
,	-	1079	O
nausea	-	1081	B
and	-	1088	O
anorexia	-	1092	B
(	-	1101	O
8	-	1102	O
%	-	1103	O
)	-	1104	O
,	-	1105	O
visual	-	1107	B
halos	-	1114	I
or	-	1120	I
blurring	-	1123	I
(	-	1132	O
6	-	1133	O
%	-	1134	O
)	-	1135	O
,	-	1136	O
thyroid	-	1138	B
function	-	1146	I
abnormalities	-	1155	I
(	-	1169	O
6	-	1170	O
%	-	1171	O
)	-	1172	O
and	-	1174	O
pulmonary	-	1178	B
interstitial	-	1188	I
infiltrates	-	1201	I
(	-	1213	O
5	-	1214	O
%	-	1215	O
)	-	1216	O
.	-	1217	O

Although	6637851	1219	O
large	-	1228	O
-	-	1233	O
dose	-	1234	O
amiodarone	-	1239	O
is	-	1250	O
highly	-	1253	O
effective	-	1260	O
in	-	1270	O
the	-	1273	O
long	-	1277	O
-	-	1281	O
term	-	1282	O
treatment	-	1287	O
of	-	1297	O
VT	-	1300	B
or	-	1303	O
VF	-	1306	B
refractory	-	1309	O
to	-	1320	O
conventional	-	1323	O
antiarrhythmic	-	1336	O
drugs	-	1351	O
,	-	1356	O
it	-	1358	O
causes	-	1361	O
significant	-	1368	O
toxicity	-	1380	B
in	-	1389	O
approximately	-	1392	O
50	-	1406	O
%	-	1408	O
of	-	1410	O
patients	-	1413	O
.	-	1421	O

However	6637851	1423	O
,	-	1430	O
when	-	1432	O
the	-	1437	O
dose	-	1441	O
is	-	1446	O
adjusted	-	1449	O
based	-	1458	O
on	-	1464	O
clinical	-	1467	O
response	-	1476	O
or	-	1485	O
the	-	1488	O
development	-	1492	O
of	-	1504	O
adverse	-	1507	O
effects	-	1515	O
,	-	1522	O
75	-	1524	O
%	-	1526	O
of	-	1528	O
patients	-	1531	O
with	-	1540	O
VT	-	1545	B
or	-	1548	O
VF	-	1551	B
can	-	1554	O
be	-	1558	O
successfully	-	1561	O
managed	-	1574	O
with	-	1582	O
amiodarone	-	1587	O
.	-	1597	O

Effect	8800187	0	O
of	-	7	O
calcium	-	10	O
chloride	-	18	O
and	-	27	O
4	-	31	O
-	-	32	O
aminopyridine	-	33	O
therapy	-	47	O
on	-	55	O
desipramine	-	58	O
toxicity	-	70	B
in	-	79	O
rats	-	82	O
.	-	86	O

BACKGROUND	8800187	88	O
:	-	98	O
Hypotension	-	100	B
is	-	112	O
a	-	115	O
major	-	117	O
contributor	-	123	O
to	-	135	O
mortality	-	138	O
in	-	148	O
tricyclic	-	151	O
antidepressant	-	161	O
overdose	-	176	B
.	-	184	O

Recent	8800187	186	O
data	-	193	O
suggest	-	198	O
that	-	206	O
tricyclic	-	211	O
antidepressants	-	221	O
inhibit	-	237	O
calcium	-	245	O
influx	-	253	O
in	-	260	O
some	-	263	O
tissues	-	268	O
.	-	275	O

This	8800187	277	O
study	-	282	O
addressed	-	288	O
the	-	298	O
potential	-	302	O
role	-	312	O
of	-	317	O
calcium	-	320	O
channel	-	328	O
blockade	-	336	O
in	-	345	O
tricyclic	-	348	O
antidepressant	-	358	O
-	-	372	O
induced	-	373	O
hypotension	-	381	B
.	-	392	O

METHODS	8800187	394	O
:	-	401	O

Two	8800187	403	O
interventions	-	407	O
were	-	421	O
studied	-	426	O
that	-	434	O
have	-	439	O
been	-	444	O
shown	-	449	O
previously	-	455	O
to	-	466	O
improve	-	469	O
blood	-	477	O
pressure	-	483	O
with	-	492	O
calcium	-	497	O
channel	-	505	O
blocker	-	513	O
overdose	-	521	B
.	-	529	O

CaCl2	8800187	531	O
and	-	537	O
4	-	541	O
-	-	542	O
aminopyridine	-	543	O
.	-	556	O

Anesthetized	8800187	558	O
rats	-	571	O
received	-	576	O
the	-	585	O
tricyclic	-	589	O
antidepressant	-	599	O
desipramine	-	614	O
IP	-	626	O
to	-	629	O
produce	-	632	O
hypotension	-	640	B
,	-	651	O
QRS	-	653	O
prolongation	-	657	O
,	-	669	O
and	-	671	O
bradycardia	-	675	B
.	-	686	O

Fifteen	8800187	688	O
min	-	696	O
later	-	700	O
,	-	705	O
animals	-	707	O
received	-	715	O
CaCl2	-	724	O
,	-	729	O
NaHCO3	-	731	O
,	-	737	O
or	-	739	O
saline	-	742	O
.	-	748	O

In	8800187	750	O
a	-	753	O
second	-	755	O
experiment	-	762	O
,	-	772	O
rats	-	774	O
received	-	779	O
tricyclic	-	788	O
antidepressant	-	798	O
desipramine	-	813	O
IP	-	825	O
followed	-	828	O
in	-	837	O
15	-	840	O
min	-	843	O
by	-	847	O
4	-	850	O
-	-	851	O
aminopyridine	-	852	O
or	-	866	O
saline	-	869	O
.	-	875	O

RESULTS	8800187	877	O
:	-	884	O

NaHCO3	8800187	886	O
briefly	-	893	O
(	-	901	O
5	-	902	O
min	-	904	O
)	-	907	O
reversed	-	909	O
hypotension	-	918	B
and	-	930	O
QRS	-	934	O
prolongation	-	938	O
.	-	950	O

CaCl2	8800187	952	O
and	-	958	O
4	-	962	O
-	-	963	O
aminopyridine	-	964	O
failed	-	978	O
to	-	985	O
improve	-	988	O
blood	-	996	O
pressure	-	1002	O
.	-	1010	O

The	8800187	1012	O
incidence	-	1016	O
of	-	1026	O
ventricular	-	1029	B
arrhythmias	-	1041	I
(	-	1053	O
p	-	1054	O
=	-	1056	O
0	-	1058	O
.	-	1059	O
004	-	1060	O
)	-	1063	O
and	-	1065	O
seizures	-	1069	B
(	-	1078	O
p	-	1079	O
=	-	1081	O
0	-	1083	O
.	-	1084	O
03	-	1085	O
)	-	1087	O
in	-	1089	O
the	-	1092	O
CaCl2	-	1096	O
group	-	1102	O
was	-	1108	O
higher	-	1112	O
than	-	1119	O
the	-	1124	O
other	-	1128	O
groups	-	1134	O
.	-	1140	O

CONCLUSION	8800187	1142	O
:	-	1152	O

The	8800187	1154	O
administration	-	1158	O
of	-	1173	O
CaCl2	-	1176	O
or	-	1182	O
4	-	1185	O
-	-	1186	O
aminopyridine	-	1187	O
did	-	1201	O
not	-	1205	O
reverse	-	1209	O
tricyclic	-	1217	O
antidepressant	-	1227	O
-	-	1241	O
induced	-	1242	O
hypotension	-	1250	B
in	-	1262	O
rats	-	1265	O
.	-	1269	O

CaCl2	8800187	1271	O
therapy	-	1277	O
may	-	1285	O
possibly	-	1289	O
worsen	-	1298	O
both	-	1305	O
cardiovascular	-	1310	B
and	-	1325	I
central	-	1329	I
nervous	-	1337	I
system	-	1345	I
toxicity	-	1352	I
.	-	1360	O

These	8800187	1362	O
findings	-	1368	O
do	-	1377	O
not	-	1380	O
support	-	1384	O
a	-	1392	O
role	-	1394	O
for	-	1399	O
calcium	-	1403	O
channel	-	1411	O
inhibition	-	1419	O
in	-	1430	O
the	-	1433	O
pathogenesis	-	1437	O
of	-	1450	O
tricyclic	-	1453	O
antidepressant	-	1463	O
-	-	1477	O
induced	-	1478	O
hypotension	-	1486	B
.	-	1497	O

Phase	7707116	0	O
I	-	6	O
trial	-	8	O
of	-	14	O
13	-	17	O
-	-	19	O
cis	-	20	O
-	-	23	O
retinoic	-	24	O
acid	-	33	O
in	-	38	O
children	-	41	O
with	-	50	O
neuroblastoma	-	55	B
following	-	69	O
bone	-	79	O
marrow	-	84	O
transplantation	-	91	O
.	-	106	O

PURPOSE	7707116	108	O
:	-	115	O

Treatment	7707116	117	O
of	-	127	O
neuroblastoma	-	130	B
cell	-	144	O
lines	-	149	O
with	-	155	O
13	-	160	O
-	-	162	O
cis	-	163	O
-	-	166	O
retinoic	-	167	O
acid	-	176	O
(	-	181	O
cis	-	182	O
-	-	185	O
RA	-	186	O
)	-	188	O
can	-	190	O
cause	-	194	O
sustained	-	200	O
inhibition	-	210	O
of	-	221	O
proliferation	-	224	O
.	-	237	O

Since	7707116	239	O
cis	-	245	O
-	-	248	O
RA	-	249	O
has	-	252	O
demonstrated	-	256	O
clinical	-	269	O
responses	-	278	O
in	-	288	O
neuroblastoma	-	291	B
patients	-	305	O
,	-	313	O
it	-	315	O
may	-	318	O
be	-	322	O
effective	-	325	O
in	-	335	O
preventing	-	338	O
relapse	-	349	O
after	-	357	O
cytotoxic	-	363	O
therapy	-	373	O
.	-	380	O

This	7707116	382	O
phase	-	387	O
I	-	393	O
trial	-	395	O
was	-	401	O
designed	-	405	O
to	-	414	O
determine	-	417	O
the	-	427	O
maximal	-	431	O
-	-	438	O
tolerated	-	439	O
dosage	-	449	O
(	-	456	O
MTD	-	457	O
)	-	460	O
,	-	461	O
toxicities	-	463	B
,	-	473	O
and	-	475	O
pharmacokinetics	-	479	O
of	-	496	O
cis	-	499	O
-	-	502	O
RA	-	503	O
administered	-	506	O
on	-	519	O
an	-	522	O
intermittent	-	525	O
schedule	-	538	O
in	-	547	O
children	-	550	O
with	-	559	O
neuroblastoma	-	564	B
following	-	578	O
bone	-	588	O
marrow	-	593	O
transplantation	-	600	O
(	-	616	O
BMT	-	617	O
)	-	620	O
.	-	621	O

PATIENTS	7707116	623	O
AND	-	632	O
METHODS	-	636	O
:	-	643	O

Fifty	7707116	645	O
-	-	650	O
one	-	651	O
assessable	-	655	O
patients	-	666	O
,	-	674	O
2	-	676	O
to	-	678	O
12	-	681	O
years	-	684	O
of	-	690	O
age	-	693	O
,	-	696	O
were	-	698	O
treated	-	703	O
with	-	711	O
oral	-	716	O
cis	-	721	O
-	-	724	O
RA	-	725	O
administered	-	728	O
in	-	741	O
two	-	744	O
equally	-	748	O
divided	-	756	O
doses	-	764	O
daily	-	770	O
for	-	776	O
2	-	780	O
weeks	-	782	O
,	-	787	O
followed	-	789	O
by	-	798	O
a	-	801	O
2	-	803	O
-	-	804	O
week	-	805	O
rest	-	810	O
period	-	815	O
,	-	821	O
for	-	823	O
up	-	827	O
to	-	830	O
12	-	833	O
courses	-	836	O
.	-	843	O

The	7707116	845	O
dose	-	849	O
was	-	854	O
escalated	-	858	O
from	-	868	O
100	-	873	O
to	-	877	O
200	-	880	O
mg	-	884	O
/	-	886	O
m2	-	887	O
/	-	889	O
d	-	890	O
until	-	892	O
dose	-	898	O
-	-	902	O
limiting	-	903	O
toxicity	-	912	B
(	-	921	O
DLT	-	922	O
)	-	925	O
was	-	927	O
observed	-	931	O
.	-	939	O

A	7707116	941	O
single	-	943	O
intrapatient	-	950	O
dose	-	963	O
escalation	-	968	O
was	-	979	O
permitted	-	983	O
.	-	992	O

RESULTS	7707116	994	O
:	-	1001	O

The	7707116	1003	O
MTD	-	1007	O
of	-	1011	O
cis	-	1014	O
-	-	1017	O
RA	-	1018	O
was	-	1021	O
160	-	1025	O
mg	-	1029	O
/	-	1031	O
m2	-	1032	O
/	-	1034	O
d	-	1035	O
.	-	1036	O

Dose	7707116	1038	O
-	-	1042	O
limiting	-	1043	O
toxicities	-	1052	B
in	-	1063	O
six	-	1066	O
of	-	1070	O
nine	-	1073	O
patients	-	1078	O
at	-	1087	O
200	-	1090	O
mg	-	1094	O
/	-	1096	O
m2	-	1097	O
/	-	1099	O
d	-	1100	O
included	-	1102	O
hypercalcemia	-	1111	B
(	-	1125	O
n	-	1126	O
=	-	1128	O
3	-	1130	O
)	-	1131	O
,	-	1132	O
rash	-	1134	B
(	-	1139	O
n	-	1140	O
=	-	1142	O
2	-	1144	O
)	-	1145	O
,	-	1146	O
and	-	1148	O
anemia	-	1152	B
/	-	1158	O
thrombocytopenia	-	1159	B
/	-	1175	O
emesis	-	1176	B
/	-	1182	O
rash	-	1183	B
(	-	1188	O
n	-	1189	O
=	-	1191	O
1	-	1193	O
)	-	1194	O
.	-	1195	O

All	7707116	1197	O
toxicities	-	1201	B
resolved	-	1212	O
after	-	1221	O
cis	-	1227	O
-	-	1230	O
RA	-	1231	O
was	-	1234	O
discontinued	-	1238	O
.	-	1250	O

Three	7707116	1252	O
complete	-	1258	O
responses	-	1267	O
were	-	1277	O
observed	-	1282	O
in	-	1291	O
marrow	-	1294	O
metastases	-	1301	B
.	-	1311	O

Serum	7707116	1313	O
levels	-	1319	O
of	-	1326	O
7	-	1329	O
.	-	1330	O
4	-	1331	O
+	-	1333	O
/	-	1334	O
-	-	1335	O

3	7707116	1337	O
.	-	1338	O
0	-	1339	O
mumol	-	1341	O
/	-	1346	O
L	-	1347	O
(	-	1349	O
peak	-	1350	O
)	-	1354	O
and	-	1356	O
4	-	1360	O
.	-	1361	O
0	-	1362	O
+	-	1364	O
/	-	1365	O
-	-	1366	O

2	7707116	1368	O
.	-	1369	O
8	-	1370	O
mumol	-	1372	O
/	-	1377	O
L	-	1378	O
(	-	1380	O
trough	-	1381	O
)	-	1387	O
at	-	1389	O
the	-	1392	O
MTD	-	1396	O
were	-	1400	O
maintained	-	1405	O
during	-	1416	O
14	-	1423	O
days	-	1426	O
of	-	1431	O
therapy	-	1434	O
.	-	1441	O

The	7707116	1443	O
DLT	-	1447	O
correlated	-	1451	O
with	-	1462	O
serum	-	1467	O
levels	-	1473	O
>	-	1480	O
or	-	1482	O
=	-	1485	O
10	-	1487	O
mumol	-	1490	O
/	-	1495	O
L	-	1496	O
.	-	1497	O
CONCLUSION	-	1499	O
:	-	1509	O

The	7707116	1511	O
MTD	-	1515	O
of	-	1519	O
cis	-	1522	O
-	-	1525	O
RA	-	1526	O
given	-	1529	O
on	-	1535	O
this	-	1538	O
intermittent	-	1543	O
schedule	-	1556	O
was	-	1565	O
160	-	1569	O
mg	-	1573	O
/	-	1575	O
m2	-	1576	O
/	-	1578	O
d	-	1579	O
.	-	1580	O

Serum	7707116	1582	O
levels	-	1588	O
known	-	1595	O
to	-	1601	O
be	-	1604	O
effective	-	1607	O
against	-	1617	O
neuroblastoma	-	1625	B
in	-	1639	O
vitro	-	1642	O
were	-	1648	O
achieved	-	1653	O
at	-	1662	O
this	-	1665	O
dose	-	1670	O
.	-	1674	O

The	7707116	1676	O
DLT	-	1680	O
included	-	1684	O
hypercalcemia	-	1693	B
,	-	1706	O
and	-	1708	O
may	-	1712	O
be	-	1716	O
predicted	-	1719	O
by	-	1729	O
serum	-	1732	O
cis	-	1738	O
-	-	1741	O
RA	-	1742	O
levels	-	1745	O
.	-	1751	O

Monitoring	7707116	1753	O
of	-	1764	O
serum	-	1767	O
calcium	-	1773	O
and	-	1781	O
cis	-	1785	O
-	-	1788	O
RA	-	1789	O
levels	-	1792	O
is	-	1799	O
indicated	-	1802	O
in	-	1812	O
future	-	1815	O
trials	-	1822	O
.	-	1828	O

Effect	6892185	0	O
of	-	7	O
calcium	-	10	O
chloride	-	18	O
on	-	27	O
gross	-	30	O
behavioural	-	36	O
changes	-	48	O
produced	-	56	O
by	-	65	O
carbachol	-	68	O
and	-	78	O
eserine	-	82	O
in	-	90	O
cats	-	93	O
.	-	97	O

The	6892185	99	O
effect	-	103	O
of	-	110	O
calcium	-	113	O
chloride	-	121	O
injected	-	130	O
into	-	139	O
the	-	144	O
cerebral	-	148	O
ventricles	-	157	O
of	-	168	O
group	-	171	O
-	-	176	O
housed	-	177	O
unanaesthetized	-	184	O
cats	-	200	O
upon	-	205	O
vocalization	-	210	O
(	-	223	O
rage	-	224	O
,	-	228	O
hissing	-	230	O
and	-	238	O
snarling	-	242	O
)	-	250	O
,	-	251	O
fighting	-	253	O
(	-	262	O
attack	-	263	O
with	-	270	O
paws	-	275	O
and	-	280	O
claws	-	284	O
,	-	289	O
defense	-	291	O
with	-	299	O
paws	-	304	O
and	-	309	O
claws	-	313	O
and	-	319	O
biting	-	323	O
)	-	329	O
,	-	330	O
mydriasis	-	332	B
,	-	341	O
tremor	-	343	B
and	-	350	O
clonic	-	354	B
-	-	360	I
tonic	-	361	I
convulsions	-	367	I
produced	-	379	O
by	-	388	O
carbachol	-	391	O
and	-	401	O
eserine	-	405	O
injected	-	413	O
similarly	-	422	O
was	-	432	O
investigated	-	436	O
.	-	448	O

Calcium	6892185	450	O
chloride	-	458	O
depressed	-	467	O
or	-	477	O
almost	-	480	O
completely	-	487	O
abolished	-	498	O
the	-	508	O
vocalization	-	512	O
and	-	525	O
fighting	-	529	O
due	-	538	O
to	-	542	O
carbachol	-	545	O
and	-	555	O
eserine	-	559	O
.	-	566	O

On	6892185	568	O
the	-	571	O
other	-	575	O
hand	-	581	O
,	-	585	O
mydriasis	-	587	B
,	-	596	O
tremor	-	598	B
and	-	605	O
clonic	-	609	B
-	-	615	I
tonic	-	616	I
convulsions	-	622	I
evoked	-	634	O
by	-	641	O
carbachol	-	644	O
and	-	654	O
eserine	-	658	O
were	-	666	O
not	-	671	O
significantly	-	675	O
changed	-	689	O
by	-	697	O
calcium	-	700	O
chloride	-	708	O
.	-	716	O

It	6892185	718	O
is	-	721	O
apparent	-	724	O
that	-	733	O
calcium	-	738	O
chloride	-	746	O
can	-	755	O
""""	-	759	O
dissociate	-	760	O
""""	-	770	O
vocalization	-	772	O
and	-	785	O
fighting	-	789	O
from	-	798	O
autonomic	-	803	O
and	-	813	O
motor	-	817	O
phenomena	-	823	O
such	-	833	O
as	-	838	O
mydriasis	-	841	B
,	-	850	O
tremor	-	852	B
and	-	859	O
clonic	-	863	B
-	-	869	I
tonic	-	870	I
convulsions	-	876	I
caused	-	888	O
by	-	895	O
carbachol	-	898	O
and	-	908	O
eserine	-	912	O
.	-	919	O

Calcium	6892185	921	O
chloride	-	929	O
inhibited	-	938	O
the	-	948	O
vocalization	-	952	O
and	-	965	O
fighting	-	969	O
produced	-	978	O
by	-	987	O
carbachol	-	990	O
and	-	1000	O
eserine	-	1004	O
most	-	1012	O
probably	-	1017	O
by	-	1026	O
a	-	1029	O
nonspecific	-	1031	O
stabilizing	-	1043	O
action	-	1055	O
on	-	1062	O
central	-	1065	O
muscarinic	-	1073	O
cholinoceptive	-	1084	O
sites	-	1099	O
.	-	1104	O

These	6892185	1106	O
results	-	1112	O
further	-	1120	O
support	-	1128	O
the	-	1136	O
view	-	1140	O
that	-	1145	O
calcium	-	1150	O
ions	-	1158	O
in	-	1163	O
excess	-	1166	O
have	-	1173	O
an	-	1178	O
atropine	-	1181	O
-	-	1189	O
like	-	1190	O
action	-	1195	O
also	-	1202	O
in	-	1207	O
the	-	1210	O
central	-	1214	O
nervous	-	1222	O
system	-	1230	O
.	-	1236	O

Multiple	6216862	0	O
side	-	9	O
effects	-	14	O
of	-	22	O
penicillamine	-	25	O
therapy	-	39	O
in	-	47	O
one	-	50	O
patient	-	54	O
with	-	62	O
rheumatoid	-	67	B
arthritis	-	78	I
.	-	87	O

Skin	6216862	89	B
rashes	-	94	I
,	-	100	O
proteinuria	-	102	B
,	-	113	O
systemic	-	115	B
lupus	-	124	I
erythematosus	-	130	I
,	-	143	O
polymyositis	-	145	B
and	-	158	O
myasthenia	-	162	B
gravis	-	173	I
have	-	180	O
all	-	185	O
been	-	189	O
recorded	-	194	O
as	-	203	O
complications	-	206	O
of	-	220	O
penicillamine	-	223	O
therapy	-	237	O
in	-	245	O
patients	-	248	O
with	-	257	O
rheumatoid	-	262	B
arthritis	-	273	I
.	-	282	O

A	6216862	284	O
patient	-	286	O
who	-	294	O
had	-	298	O
developed	-	302	O
all	-	312	O
5	-	316	O
is	-	318	O
now	-	321	O
described	-	325	O
.	-	334	O

The	6216862	336	O
skin	-	340	B
lesion	-	345	I
resembled	-	352	O
elastosis	-	362	B
perforans	-	372	I
serpiginosa	-	382	I
,	-	393	O
which	-	395	O
has	-	401	O
been	-	405	O
reported	-	410	O
as	-	419	O
a	-	422	O
rare	-	424	O
side	-	429	O
effect	-	434	O
in	-	441	O
patients	-	444	O
with	-	453	O
Wilson	-	458	B
's	-	464	I
disease	-	467	I
but	-	475	O
not	-	479	O
in	-	483	O
patients	-	486	O
with	-	495	O
rheumatoid	-	500	B
arthritis	-	511	I
treated	-	521	O
with	-	529	O
penicillamine	-	534	O
.	-	547	O

Electrocardiographic	2004	0	O
changes	-	21	O
and	-	29	O
cardiac	-	33	B
arrhythmias	-	41	I
in	-	53	O
patients	-	56	O
receiving	-	65	O
psychotropic	-	75	O
drugs	-	88	O
.	-	93	O

Eight	2004	95	O
patients	-	101	O
had	-	110	O
cardiac	-	114	O
manifestations	-	122	O
that	-	137	O
were	-	142	O
life	-	147	O
-	-	151	O
threatening	-	152	O
in	-	164	O
five	-	167	O
while	-	172	O
taking	-	178	O
psychotropic	-	185	O
drugs	-	198	O
,	-	203	O
either	-	205	O
phenothiazines	-	212	O
or	-	227	O
tricyclic	-	230	O
antidepressants	-	240	O
.	-	255	O

Although	2004	257	O
most	-	266	O
patients	-	271	O
were	-	280	O
receiving	-	285	O
several	-	295	O
drugs	-	303	O
,	-	308	O
Mellaril	-	310	O
(	-	319	O
thioridazine	-	320	O
)	-	332	O
appeared	-	334	O
to	-	343	O
be	-	346	O
responsible	-	349	O
for	-	361	O
five	-	365	O
cases	-	370	O
of	-	376	O
ventricular	-	379	B
tachycardia	-	391	I
,	-	402	O
one	-	404	O
of	-	408	O
which	-	411	O
was	-	417	O
fatal	-	421	O
in	-	427	O
a	-	430	O
35	-	432	O
year	-	435	O
old	-	440	O
woman	-	444	O
.	-	449	O

Supraventricular	2004	451	B
tachycardia	-	468	I
developed	-	480	O
in	-	490	O
one	-	493	O
patient	-	497	O
receiving	-	505	O
Thorazine	-	515	O
(	-	525	O
chlorpromazine	-	526	O
)	-	540	O
.	-	541	O

Aventyl	2004	543	O
(	-	551	O
nortriptyline	-	552	O
)	-	565	O
and	-	567	O
Elavil	-	571	O
(	-	578	O
amitriptyline	-	579	O
)	-	592	O
each	-	594	O
produced	-	599	O
left	-	608	B
bundle	-	613	I
branch	-	620	I
block	-	627	I
in	-	633	O
a	-	636	O
73	-	638	O
year	-	641	O
old	-	646	O
woman	-	650	O
.	-	655	O

Electrocardiographic	2004	657	O
T	-	678	O
and	-	680	O
U	-	684	O
wave	-	686	O
abnormalities	-	691	O
were	-	705	O
present	-	710	O
in	-	718	O
most	-	721	O
patients	-	726	O
.	-	734	O

The	2004	736	O
ventricular	-	740	B
arrhythmias	-	752	I
responded	-	764	O
to	-	774	O
intravenous	-	777	O
administration	-	789	O
of	-	804	O
lidocaine	-	807	O
and	-	817	O
to	-	821	O
direct	-	824	O
current	-	831	O
electric	-	839	O
shock	-	848	O
;	-	853	O
ventricular	-	855	O
pacing	-	867	O
was	-	874	O
required	-	878	O
in	-	887	O
some	-	890	O
instances	-	895	O
and	-	905	O
intravenous	-	909	O
administration	-	921	O
of	-	936	O
propranolol	-	939	O
combined	-	951	O
with	-	960	O
ventricular	-	965	O
pacing	-	977	O
in	-	984	O
one	-	987	O
.	-	990	O

The	2004	992	O
tachyarrhythmias	-	996	B
generally	-	1013	O
subsided	-	1023	O
within	-	1032	O
48	-	1039	O
hours	-	1042	O
after	-	1048	O
administration	-	1054	O
of	-	1069	O
the	-	1072	O
drugs	-	1076	O
was	-	1082	O
stopped	-	1086	O
.	-	1093	O

Five	2004	1095	O
of	-	1100	O
the	-	1103	O
eight	-	1107	O
patients	-	1113	O
were	-	1122	O
50	-	1127	O
years	-	1130	O
of	-	1136	O
age	-	1139	O
or	-	1143	O
younger	-	1146	O
;	-	1153	O
only	-	1155	O
one	-	1160	O
clearly	-	1164	O
had	-	1172	O
antecedent	-	1176	O
heart	-	1187	B
disease	-	1193	I
.	-	1200	O

Major	2004	1202	O
cardiac	-	1208	B
arrhythmias	-	1216	I
are	-	1228	O
a	-	1232	O
potential	-	1234	O
hazard	-	1244	O
in	-	1251	O
patients	-	1254	O
without	-	1263	O
heart	-	1271	B
disease	-	1277	I
who	-	1285	O
are	-	1289	O
receiving	-	1293	O
customary	-	1303	O
therapeutic	-	1313	O
doses	-	1325	O
of	-	1331	O
psychotropic	-	1334	O
drugs	-	1347	O
.	-	1352	O

A	2004	1354	O
prospective	-	1356	O
clinical	-	1368	O
trial	-	1377	O
is	-	1383	O
suggested	-	1386	O
to	-	1396	O
quantify	-	1399	O
the	-	1408	O
risk	-	1412	O
of	-	1417	O
cardiac	-	1420	B
complications	-	1428	I
to	-	1442	O
patients	-	1445	O
receiving	-	1454	O
phenothiazines	-	1464	O
or	-	1479	O
tricyclic	-	1482	O
antidepressant	-	1492	O
drugs	-	1507	O
.	-	1512	O

Serotonergic	6118280	0	O
drugs	-	13	O
,	-	18	O
benzodiazepines	-	20	O
and	-	36	O
baclofen	-	40	O
block	-	49	O
muscimol	-	55	O
-	-	63	O
induced	-	64	O
myoclonic	-	72	B
jerks	-	82	I
in	-	88	O
a	-	91	O
strain	-	93	O
of	-	100	O
mice	-	103	O
.	-	107	O

In	6118280	109	O
male	-	112	O
Swiss	-	117	O
mice	-	123	O
,	-	127	O
muscimol	-	129	O
produced	-	138	O
myoclonic	-	147	B
jerks	-	157	I
.	-	162	O

A	6118280	164	O
3	-	166	O
mg	-	168	O
/	-	170	O
kg	-	171	O
(	-	174	O
i	-	175	O
.	-	176	O
p	-	177	O
.	-	178	O
)	-	179	O

dose	6118280	181	O
induced	-	186	O
this	-	194	O
response	-	199	O
in	-	208	O
all	-	211	O
of	-	215	O
the	-	218	O
mice	-	222	O
tested	-	227	O
and	-	234	O
the	-	238	O
peak	-	242	O
response	-	247	O
of	-	256	O
73	-	259	O
jerks	-	262	O
per	-	268	O
min	-	272	O
was	-	276	O
observed	-	280	O
between	-	289	O
27	-	297	O
and	-	300	O
45	-	304	O
min	-	307	O
.	-	310	O

Increasing	6118280	312	O
the	-	323	O
brain	-	327	O
serotonin	-	333	O
levels	-	343	O
by	-	350	O
the	-	353	O
administration	-	357	O
of	-	372	O
5	-	375	O
-	-	376	O
hydroxytryptophan	-	377	O
(	-	395	O
80	-	396	O
-	-	398	O
160	-	399	O
mg	-	403	O
/	-	405	O
kg	-	406	O
)	-	408	O
in	-	410	O
combination	-	413	O
with	-	425	O
a	-	430	O
peripheral	-	432	O
decarboxylase	-	443	O
inhibitor	-	457	O
resulted	-	467	O
in	-	476	O
an	-	479	O
inhibition	-	482	O
of	-	493	O
the	-	496	O
muscimol	-	500	O
effect	-	509	O
.	-	515	O

However	6118280	517	O
,	-	524	O
in	-	526	O
a	-	529	O
similar	-	531	O
experiment	-	539	O
l	-	550	O
-	-	551	O
dopa	-	552	O
(	-	557	O
80	-	558	O
-	-	560	O
160	-	561	O
mg	-	565	O
/	-	567	O
kg	-	568	O
)	-	570	O
was	-	572	O
without	-	576	O
effect	-	584	O
.	-	590	O

In	6118280	592	O
doses	-	595	O
of	-	601	O
3	-	604	O
-	-	605	O
10	-	606	O
mg	-	609	O
/	-	611	O
kg	-	612	O
,	-	614	O
the	-	616	O
serotonin	-	620	O
receptor	-	630	O
agonist	-	639	O
MK	-	647	O
-	-	649	O
212	-	650	O
caused	-	654	O
a	-	661	O
dose	-	663	O
-	-	667	O
dependent	-	668	O
blockade	-	678	O
of	-	687	O
the	-	690	O
response	-	694	O
of	-	703	O
muscimol	-	706	O
.	-	714	O

Of	6118280	716	O
the	-	719	O
benzodiazepines	-	723	O
,	-	738	O
clonazepam	-	740	O
(	-	751	O
0	-	752	O
.	-	753	O
1	-	754	O
-	-	755	O
0	-	756	O
.	-	757	O
3	-	758	O
mg	-	760	O
/	-	762	O
kg	-	763	O
)	-	765	O
was	-	767	O
found	-	771	O
to	-	777	O
be	-	780	O
several	-	783	O
fold	-	791	O
more	-	796	O
potent	-	801	O
than	-	808	O
diazepam	-	813	O
(	-	822	O
0	-	823	O
.	-	824	O
3	-	825	O
-	-	826	O
3	-	827	O
mg	-	829	O
/	-	831	O
kg	-	832	O
)	-	834	O
in	-	836	O
blocking	-	839	O
the	-	848	O
myoclonic	-	852	B
jerks	-	862	I
.	-	867	O

While	6118280	869	O
(	-	875	O
-	-	876	O
)	-	877	O
-	-	878	O
baclofen	-	879	O
(	-	888	O
1	-	889	O
-	-	890	O
3	-	891	O
mg	-	893	O
/	-	895	O
kg	-	896	O
)	-	898	O
proved	-	900	O
to	-	907	O
be	-	910	O
an	-	913	O
effective	-	916	O
antagonist	-	926	O
of	-	937	O
muscimol	-	940	O
,	-	948	O
its	-	950	O
(	-	954	O
+	-	955	O
)	-	956	O
-	-	957	O
isomer	-	958	O
(	-	965	O
5	-	966	O
-	-	967	O
20	-	968	O
mg	-	971	O
/	-	973	O
kg	-	974	O
)	-	976	O
lacked	-	978	O
this	-	985	O
property	-	990	O
.	-	998	O

Considering	6118280	1000	O
the	-	1012	O
fact	-	1016	O
that	-	1021	O
5	-	1026	O
-	-	1027	O
HTP	-	1028	O
and	-	1032	O
the	-	1036	O
benzodiazepines	-	1040	O
have	-	1056	O
been	-	1061	O
found	-	1066	O
to	-	1072	O
be	-	1075	O
beneficial	-	1078	O
in	-	1089	O
the	-	1092	O
management	-	1096	O
of	-	1107	O
clinical	-	1110	O
myoclonus	-	1119	B
,	-	1128	O
the	-	1130	O
muscimol	-	1134	O
-	-	1142	O
induced	-	1143	O
myoclonus	-	1151	B
seems	-	1161	O
to	-	1167	O
be	-	1170	O
a	-	1173	O
satisfactory	-	1175	O
animal	-	1188	O
model	-	1195	O
that	-	1201	O
may	-	1206	O
prove	-	1210	O
useful	-	1216	O
for	-	1223	O
the	-	1227	O
development	-	1231	O
of	-	1243	O
new	-	1246	O
drug	-	1250	O
treatments	-	1255	O
for	-	1266	O
this	-	1270	O
condition	-	1275	O
.	-	1284	O

Our	6118280	1286	O
present	-	1290	O
study	-	1298	O
indicated	-	1304	O
the	-	1314	O
possible	-	1318	O
value	-	1327	O
of	-	1333	O
MK	-	1336	O
-	-	1338	O
212	-	1339	O
and	-	1343	O
(	-	1347	O
-	-	1348	O
)	-	1349	O
-	-	1350	O
baclofen	-	1351	O
in	-	1360	O
the	-	1363	O
management	-	1367	O
of	-	1378	O
clinical	-	1381	O
myoclonus	-	1390	B
.	-	1399	O

Hyperglycemic	3703509	0	B
acidotic	-	14	I
coma	-	23	I
and	-	28	O
death	-	32	O
in	-	38	O
Kearns	-	41	B
-	-	47	I
Sayre	-	48	I
syndrome	-	54	I
.	-	62	O

This	3703509	64	O
paper	-	69	O
presents	-	75	O
the	-	84	O
clinical	-	88	O
and	-	97	O
metabolic	-	101	O
findings	-	111	O
in	-	120	O
two	-	123	O
young	-	127	O
boys	-	133	O
with	-	138	O
long	-	143	O
-	-	147	O
standing	-	148	O
Kearns	-	157	B
-	-	163	I
Sayre	-	164	I
syndrome	-	170	I
.	-	178	O

Following	3703509	180	O
short	-	190	O
exposure	-	196	O
to	-	205	O
oral	-	208	O
prednisone	-	213	O
,	-	223	O
both	-	225	O
boys	-	230	O
developed	-	235	O
lethargy	-	245	B
,	-	253	O
increasing	-	255	O
somnolence	-	266	B
,	-	276	O
polydipsia	-	278	B
,	-	288	O
polyphagia	-	290	B
,	-	300	O
and	-	302	O
polyuria	-	306	B
.	-	314	O

Both	3703509	316	O
presented	-	321	O
in	-	331	O
the	-	334	O
emergency	-	338	O
room	-	348	O
with	-	353	O
profound	-	358	O
coma	-	367	B
,	-	371	O
hypotension	-	373	B
,	-	384	O
severe	-	386	O
hyperglycemia	-	393	B
,	-	406	O
and	-	408	O
acidosis	-	412	B
.	-	420	O

Nonketotic	3703509	422	O
lactic	-	433	B
acidosis	-	440	I
was	-	449	O
present	-	453	O
in	-	461	O
one	-	464	O
and	-	468	O
ketosis	-	472	B
without	-	480	O
a	-	488	O
known	-	490	O
serum	-	496	O
lactate	-	502	O
level	-	510	O
was	-	516	O
present	-	520	O
in	-	528	O
the	-	531	O
other	-	535	O
.	-	540	O

Respiratory	3703509	542	B
failure	-	554	I
rapidly	-	562	O
ensued	-	570	O
and	-	577	O
both	-	581	O
patients	-	586	O
expired	-	595	O
in	-	603	O
spite	-	606	O
of	-	612	O
efforts	-	615	O
at	-	623	O
resuscitation	-	626	O
.	-	639	O

We	3703509	641	O
believe	-	644	O
these	-	652	O
two	-	658	O
cases	-	662	O
represent	-	668	O
a	-	678	O
newly	-	680	O
described	-	686	O
and	-	696	O
catastrophic	-	700	O
metabolic	-	713	B
-	-	722	I
endocrine	-	723	I
failure	-	733	I
in	-	741	O
the	-	744	O
Kearns	-	748	B
-	-	754	I
Sayre	-	755	I
syndrome	-	761	I
.	-	769	O

Effects	20683499	0	O
of	-	8	O
active	-	11	O
constituents	-	18	O
of	-	31	O
Crocus	-	34	O
sativus	-	41	O
L	-	49	O
.	-	50	O
,	-	51	O
crocin	-	53	O
on	-	60	O
streptozocin	-	63	O
-	-	75	O
induced	-	76	O
model	-	84	O
of	-	90	O
sporadic	-	93	O
Alzheimer	-	102	B
's	-	111	I
disease	-	114	I
in	-	122	O
male	-	125	O
rats	-	130	O
.	-	134	O

BACKGROUND	20683499	136	O
:	-	146	O

The	20683499	148	O
involvement	-	152	O
of	-	164	O
water	-	167	O
-	-	172	O
soluble	-	173	O
carotenoids	-	181	O
,	-	192	O
crocins	-	194	O
,	-	201	O
as	-	203	O
the	-	206	O
main	-	210	O
and	-	215	O
active	-	219	O
components	-	226	O
of	-	237	O
Crocus	-	240	O
sativus	-	247	O
L	-	255	O
.	-	256	O
extract	-	258	O
in	-	266	O
learning	-	269	O
and	-	278	O
memory	-	282	O
processes	-	289	O
has	-	299	O
been	-	303	O
proposed	-	308	O
.	-	316	O

In	20683499	318	O
the	-	321	O
present	-	325	O
study	-	333	O
,	-	338	O
the	-	340	O
effect	-	344	O
of	-	351	O
crocins	-	354	O
on	-	362	O
sporadic	-	365	O
Alzheimer	-	374	B
's	-	383	I
disease	-	386	I
induced	-	394	O
by	-	402	O
intracerebroventricular	-	405	O
(	-	429	O
icv	-	430	O
)	-	433	O
streptozocin	-	435	O
(	-	448	O
STZ	-	449	O
)	-	452	O
in	-	454	O
male	-	457	O
rats	-	462	O
was	-	467	O
investigated	-	471	O
.	-	483	O

METHODS	20683499	485	O
:	-	492	O

Male	20683499	494	O
adult	-	499	O
Wistar	-	505	O
rats	-	512	O
(	-	517	O
n	-	518	O
=	-	520	O
90	-	522	O
and	-	525	O
260	-	529	O
-	-	532	O
290	-	533	O
g	-	537	O
)	-	538	O
were	-	540	O
divided	-	545	O
into	-	553	O
1	-	558	O
,	-	559	O
control	-	561	O
;	-	568	O
2	-	570	O
and	-	572	O
3	-	576	O
,	-	577	O
crocins	-	579	O
(	-	587	O
15	-	588	O
and	-	591	O
30	-	595	O
mg	-	598	O
/	-	600	O
kg	-	601	O
)	-	603	O
;	-	604	O
4	-	606	O
,	-	607	O
STZ	-	609	O
;	-	612	O
5	-	614	O
and	-	616	O
6	-	620	O
,	-	621	O
STZ	-	623	O
+	-	627	O
crocins	-	629	O
(	-	637	O
15	-	638	O
and	-	641	O
30	-	645	O
mg	-	648	O
/	-	650	O
kg	-	651	O
)	-	653	O
groups	-	655	O
.	-	661	O

In	20683499	663	O
Alzheimer	-	666	B
's	-	675	I
disease	-	678	I
groups	-	686	O
,	-	692	O
rats	-	694	O
were	-	699	O
injected	-	704	O
with	-	713	O
STZ	-	718	O
-	-	721	O
icv	-	722	O
bilaterally	-	726	O
(	-	738	O
3	-	739	O
mg	-	741	O
/	-	743	O
kg	-	744	O
)	-	746	O
in	-	748	O
first	-	751	O
day	-	757	O
and	-	761	O
3	-	765	O
days	-	767	O
later	-	772	O
,	-	777	O
a	-	779	O
similar	-	781	O
STZ	-	789	O
-	-	792	O
icv	-	793	O
application	-	797	O
was	-	809	O
repeated	-	813	O
.	-	821	O

In	20683499	823	O
STZ	-	826	O
+	-	830	O
crocin	-	832	O
animal	-	839	O
groups	-	846	O
,	-	852	O
crocin	-	854	O
was	-	861	O
applied	-	865	O
in	-	873	O
doses	-	876	O
of	-	882	O
15	-	885	O
and	-	888	O
30	-	892	O
mg	-	895	O
/	-	897	O
kg	-	898	O
,	-	900	O
i	-	902	O
.	-	903	O
p	-	904	O
.	-	905	O

,	20683499	906	O
one	-	908	O
day	-	912	O
pre	-	916	O
-	-	919	O
surgery	-	920	O
and	-	928	O
continued	-	932	O
for	-	942	O
three	-	946	O
weeks	-	952	O
.	-	957	O

Prescription	20683499	959	O
of	-	972	O
crocin	-	975	O
in	-	982	O
each	-	985	O
dose	-	990	O
was	-	995	O
repeated	-	999	O
once	-	1008	O
for	-	1013	O
two	-	1017	O
days	-	1021	O
.	-	1025	O

However	20683499	1027	O
,	-	1034	O
the	-	1036	O
learning	-	1040	O
and	-	1049	O
memory	-	1053	O
performance	-	1060	O
was	-	1072	O
assessed	-	1076	O
using	-	1085	O
passive	-	1091	O
avoidance	-	1099	O
paradigm	-	1109	O
,	-	1117	O
and	-	1119	O
for	-	1123	O
spatial	-	1127	O
cognition	-	1135	O
evaluation	-	1145	O
,	-	1155	O
Y	-	1157	O
-	-	1158	O
maze	-	1159	O
task	-	1164	O
was	-	1169	O
used	-	1173	O
.	-	1177	O

RESULTS	20683499	1179	O
:	-	1186	O

It	20683499	1188	O
was	-	1191	O
found	-	1195	O
out	-	1201	O
that	-	1205	O
crocin	-	1210	O
(	-	1217	O
30	-	1218	O
mg	-	1221	O
/	-	1223	O
kg	-	1224	O
)	-	1226	O
-	-	1227	O
treated	-	1228	O
STZ	-	1236	O
-	-	1239	O
injected	-	1240	O
rats	-	1249	O
show	-	1254	O
higher	-	1259	O
correct	-	1266	O
choices	-	1274	O
and	-	1282	O
lower	-	1286	O
errors	-	1292	O
in	-	1299	O
Y	-	1302	O
-	-	1303	O
maze	-	1304	O
than	-	1309	O
vehicle	-	1314	O
-	-	1321	O
treated	-	1322	O
STZ	-	1330	O
-	-	1333	O
injected	-	1334	O
rats	-	1343	O
.	-	1347	O

In	20683499	1349	O
addition	-	1352	O
,	-	1360	O
crocin	-	1362	O
in	-	1369	O
the	-	1372	O
mentioned	-	1376	O
dose	-	1386	O
could	-	1391	O
significantly	-	1397	O
attenuated	-	1411	O
learning	-	1422	B
and	-	1431	I
memory	-	1435	I
impairment	-	1442	I
in	-	1453	O
treated	-	1456	O
STZ	-	1464	O
-	-	1467	O
injected	-	1468	O
group	-	1477	O
in	-	1483	O
passive	-	1486	O
avoidance	-	1494	O
test	-	1504	O
.	-	1508	O

CONCLUSION	20683499	1510	O
:	-	1520	O

Therefore	20683499	1522	O
,	-	1531	O
these	-	1533	O
results	-	1539	O
demonstrate	-	1547	O
the	-	1559	O
effectiveness	-	1563	O
of	-	1577	O
crocin	-	1580	O
(	-	1587	O
30	-	1588	O
mg	-	1591	O
/	-	1593	O
kg	-	1594	O
)	-	1596	O
in	-	1598	O
antagonizing	-	1601	O
the	-	1614	O
cognitive	-	1618	B
deficits	-	1628	I
caused	-	1637	O
by	-	1644	O
STZ	-	1647	O
-	-	1650	O
icv	-	1651	O
in	-	1655	O
rats	-	1658	O
and	-	1663	O
its	-	1667	O
potential	-	1671	O
in	-	1681	O
the	-	1684	O
treatment	-	1688	O
of	-	1698	O
neurodegenerative	-	1701	B
diseases	-	1719	I
such	-	1728	O
as	-	1733	O
Alzheimer	-	1736	B
's	-	1745	I
disease	-	1748	I
.	-	1755	O

Rosaceiform	20466178	0	O
dermatitis	-	12	B
associated	-	23	O
with	-	34	O
topical	-	39	O
tacrolimus	-	47	O
treatment	-	58	O
.	-	67	O

We	20466178	69	O
describe	-	72	O
herein	-	81	O
3	-	88	O
patients	-	90	O
who	-	99	O
developed	-	103	O
rosacea	-	113	B
-	-	120	O
like	-	121	O
dermatitis	-	126	B
eruptions	-	137	B
while	-	147	O
using	-	153	O
0	-	159	O
.	-	160	O
03	-	161	O
%	-	163	O
or	-	165	O
0	-	168	O
.	-	169	O
1	-	170	O
%	-	171	O
tacrolimus	-	173	O
ointment	-	184	O
for	-	193	O
facial	-	197	B
dermatitis	-	204	I
.	-	214	O

Skin	20466178	216	O
biopsy	-	221	O
specimens	-	228	O
showed	-	238	O
telangiectasia	-	245	B
and	-	260	O
noncaseating	-	264	O
epithelioid	-	277	O
granulomatous	-	289	O
tissue	-	303	O
formation	-	310	O
in	-	320	O
the	-	323	O
papillary	-	327	O
to	-	337	O
mid	-	340	O
dermis	-	344	O
.	-	350	O

Continuous	20466178	352	O
topical	-	363	O
use	-	371	O
of	-	375	O
immunomodulators	-	378	O
such	-	395	O
as	-	400	O
tacrolimus	-	403	O
or	-	414	O
pimecrolimus	-	417	O
should	-	430	O
be	-	437	O
regarded	-	440	O
as	-	449	O
a	-	452	O
potential	-	454	O
cause	-	464	O
of	-	470	O
rosaceiform	-	473	O
dermatitis	-	485	B
,	-	495	O
although	-	497	O
many	-	506	O
cases	-	511	O
have	-	517	O
not	-	522	O
been	-	526	O
reported	-	531	O
.	-	539	O

A	19944736	0	O
novel	-	2	O
animal	-	8	O
model	-	15	O
to	-	21	O
evaluate	-	24	O
the	-	33	O
ability	-	37	O
of	-	45	O
a	-	48	O
drug	-	50	O
delivery	-	55	O
system	-	64	O
to	-	71	O
promote	-	74	O
the	-	82	O
passage	-	86	O
through	-	94	O
the	-	102	O
BBB	-	106	O
.	-	109	O

The	19944736	111	O
purpose	-	115	O
of	-	123	O
this	-	126	O
investigation	-	131	O
was	-	145	O
to	-	149	O
explore	-	152	O
the	-	160	O
potentiality	-	164	O
of	-	177	O
a	-	180	O
novel	-	182	O
animal	-	188	O
model	-	195	O
to	-	201	O
be	-	204	O
used	-	207	O
for	-	212	O
the	-	216	O
in	-	220	O
vivo	-	223	O
evaluation	-	228	O
of	-	239	O
the	-	242	O
ability	-	246	O
of	-	254	O
a	-	257	O
drug	-	259	O
delivery	-	264	O
system	-	273	O
to	-	280	O
promote	-	283	O
the	-	291	O
passage	-	295	O
through	-	303	O
the	-	311	O
blood	-	315	O
-	-	320	O
brain	-	321	O
barrier	-	327	O
(	-	335	O
BBB	-	336	O
)	-	339	O
and	-	341	O
/	-	344	O
or	-	345	O
to	-	348	O
improve	-	351	O
the	-	359	O
brain	-	363	O
localization	-	369	O
of	-	382	O
a	-	385	O
bioactive	-	387	O
compound	-	397	O
.	-	405	O

A	19944736	407	O

Tween	19944736	409	O
80	-	415	O
-	-	417	O
coated	-	418	O
poly	-	425	O
-	-	429	O
L	-	430	O
-	-	431	O
lactid	-	432	O
acid	-	439	O
nanoparticles	-	444	O
was	-	458	O
used	-	462	O
as	-	467	O
a	-	470	O
model	-	472	O
of	-	478	O
colloidal	-	481	O
drug	-	491	O
delivery	-	496	O
system	-	505	O
,	-	511	O
able	-	513	O
to	-	518	O
trespass	-	521	O
the	-	530	O
BBB	-	534	O
.	-	537	O

Tacrine	19944736	539	O
,	-	546	O
administered	-	548	O
in	-	561	O
LiCl	-	564	O
pre	-	569	O
-	-	572	O
treated	-	573	O
rats	-	581	O
,	-	585	O
induces	-	587	O
electrocorticographic	-	595	O
seizures	-	617	B
and	-	626	O
delayed	-	630	O
hippocampal	-	638	B
damage	-	650	I
.	-	656	O

The	19944736	658	O
toxic	-	662	O
effects	-	668	O
of	-	676	O
tacrine	-	679	O
-	-	686	O
loaded	-	687	O
poly	-	694	O
-	-	698	O
L	-	699	O
-	-	700	O
lactid	-	701	O
acid	-	708	O
nanoparticles	-	713	O
(	-	727	O
5mg	-	728	O
/	-	731	O
kg	-	732	O
)	-	734	O
,	-	735	O
a	-	737	O
saline	-	739	O
solution	-	746	O
of	-	755	O
tacrine	-	758	O
(	-	766	O
5mg	-	767	O
/	-	770	O
kg	-	771	O
)	-	773	O
and	-	775	O
an	-	779	O
empty	-	782	O
colloidal	-	788	O
nanoparticle	-	798	O
suspension	-	811	O
were	-	822	O
compared	-	827	O
following	-	836	O
i	-	846	O
.	-	847	O
p	-	848	O
.	-	849	O

administration	19944736	851	O
in	-	866	O
LiCl	-	869	O
-	-	873	O
pre	-	874	O
-	-	877	O
treated	-	878	O
Wistar	-	886	O
rats	-	893	O
.	-	897	O

All	19944736	899	O
the	-	903	O
animals	-	907	O
treated	-	915	O
with	-	923	O
tacrine	-	928	O
-	-	935	O
loaded	-	936	O
nanoparticles	-	943	O
showed	-	957	O
an	-	964	O
earlier	-	967	O
outcome	-	975	O
of	-	983	O
CNS	-	986	O
adverse	-	990	O
symptoms	-	998	O
,	-	1006	O
i	-	1008	O
.	-	1009	O
e	-	1010	O
.	-	1011	O
epileptic	-	1013	B
onset	-	1023	O
,	-	1028	O
with	-	1030	O
respect	-	1035	O
to	-	1043	O
those	-	1046	O
animals	-	1052	O
treated	-	1060	O
with	-	1068	O
the	-	1073	O
free	-	1077	O
compound	-	1082	O
(	-	1091	O
10	-	1092	O
min	-	1095	O
vs	-	1099	O
.	-	1101	O
22	-	1103	O
min	-	1106	O
respectively	-	1110	O
)	-	1122	O
.	-	1123	O

In	19944736	1125	O
addition	-	1128	O
,	-	1136	O
tacrine	-	1138	O
-	-	1145	O
loaded	-	1146	O
nanoparticles	-	1153	O
administration	-	1167	O
induced	-	1182	O
damage	-	1190	B
of	-	1197	I
neuronal	-	1200	I
cells	-	1209	I
in	-	1215	O
CA1	-	1218	O
field	-	1222	O
of	-	1228	O
the	-	1231	O
hippocampus	-	1235	O
in	-	1247	O
all	-	1250	O
treated	-	1254	O
animals	-	1262	O
,	-	1269	O
while	-	1271	O
the	-	1277	O
saline	-	1281	O
solution	-	1288	O
of	-	1297	O
tacrine	-	1300	O
only	-	1308	O
in	-	1313	O
60	-	1316	O
%	-	1318	O
of	-	1320	O
animals	-	1323	O
.	-	1330	O

Empty	19944736	1332	O
nanoparticles	-	1338	O
provided	-	1352	O
similar	-	1361	O
results	-	1369	O
to	-	1377	O
control	-	1380	O
(	-	1388	O
saline	-	1389	O
-	-	1395	O
treated	-	1396	O
)	-	1403	O
group	-	1405	O
of	-	1411	O
animals	-	1414	O
.	-	1421	O

In	19944736	1423	O
conclusion	-	1426	O
,	-	1436	O
the	-	1438	O
evaluation	-	1442	O
of	-	1453	O
time	-	1456	O
-	-	1460	O
to	-	1461	O
-	-	1463	O
onset	-	1464	O
of	-	1470	O
symptoms	-	1473	O
and	-	1482	O
the	-	1486	O
severity	-	1490	O
of	-	1499	O
neurodegenerative	-	1502	O
processes	-	1520	O
induced	-	1530	O
by	-	1538	O
the	-	1541	O
tacrine	-	1545	O
-	-	1552	O
lithium	-	1553	O
model	-	1561	O
of	-	1567	O
epilepsy	-	1570	B
in	-	1579	O
the	-	1582	O
rat	-	1586	O
,	-	1589	O
could	-	1591	O
be	-	1597	O
used	-	1600	O
to	-	1605	O
evaluate	-	1608	O
preliminarily	-	1617	O
the	-	1631	O
capability	-	1635	O
of	-	1646	O
a	-	1649	O
drug	-	1651	O
delivery	-	1656	O
system	-	1665	O
to	-	1672	O
trespass	-	1675	O
(	-	1684	O
or	-	1685	O
not	-	1688	O
)	-	1691	O
the	-	1693	O
BBB	-	1697	O
in	-	1701	O
vivo	-	1704	O
.	-	1708	O

The	19721134	0	O
antiarrhythmic	-	4	O
effect	-	19	O
and	-	26	O
possible	-	30	O
ionic	-	39	O
mechanisms	-	45	O
of	-	56	O
pilocarpine	-	59	O
on	-	71	O
animal	-	74	O
models	-	81	O
.	-	87	O

This	19721134	89	O
study	-	94	O
was	-	100	O
designed	-	104	O
to	-	113	O
evaluate	-	116	O
the	-	125	O
effects	-	129	O
of	-	137	O
pilocarpine	-	140	O
and	-	152	O
explore	-	156	O
the	-	164	O
underlying	-	168	O
ionic	-	179	O
mechanism	-	185	O
,	-	194	O
using	-	196	O
both	-	202	O
aconitine	-	207	O
-	-	216	O
induced	-	217	O
rat	-	225	O
and	-	229	O
ouabain	-	233	O
-	-	240	O
induced	-	241	O
guinea	-	249	O
pig	-	256	O
arrhythmia	-	260	B
models	-	271	O
.	-	277	O

Confocal	19721134	279	O
microscopy	-	288	O
was	-	299	O
used	-	303	O
to	-	308	O
measure	-	311	O
intracellular	-	319	O
free	-	333	O
-	-	337	O
calcium	-	338	O
concentrations	-	346	O
(	-	361	O
[	-	362	O
Ca	-	363	O
(	-	365	O
2	-	366	O
+	-	367	O
)	-	368	O
]	-	369	O
(	-	370	O
i	-	371	O
)	-	372	O
)	-	373	O
in	-	375	O
isolated	-	378	O
myocytes	-	387	O
.	-	395	O

The	19721134	397	O
current	-	401	O
data	-	409	O
showed	-	414	O
that	-	421	O
pilocarpine	-	426	O
significantly	-	438	O
delayed	-	452	O
onset	-	460	O
of	-	466	O
arrhythmias	-	469	B
,	-	480	O
decreased	-	482	O
the	-	492	O
time	-	496	O
course	-	501	O
of	-	508	O
ventricular	-	511	B
tachycardia	-	523	I
and	-	535	I
fibrillation	-	539	I
,	-	551	O
reduced	-	553	O
arrhythmia	-	561	B
score	-	572	O
,	-	577	O
and	-	579	O
increased	-	583	O
the	-	593	O
survival	-	597	O
time	-	606	O
of	-	611	O
arrhythmic	-	614	B
rats	-	625	O
and	-	630	O
guinea	-	634	O
pigs	-	641	O
.	-	645	O

[	19721134	647	O
Ca	-	648	O
(	-	650	O
2	-	651	O
+	-	652	O
)	-	653	O
]	-	654	O
(	-	655	O
i	-	656	O
)	-	657	O
overload	-	659	O
induced	-	668	O
by	-	676	O
aconitine	-	679	O
or	-	689	O
ouabain	-	692	O
was	-	700	O
reduced	-	704	O
in	-	712	O
isolated	-	715	O
myocytes	-	724	O
pretreated	-	733	O
with	-	744	O
pilocarpine	-	749	O
.	-	760	O

Moreover	19721134	762	O
,	-	770	O
M	-	772	O
(	-	773	O
3	-	774	O
)	-	775	O
-	-	776	O
muscarinic	-	777	O
acetylcholine	-	788	O
receptor	-	802	O
(	-	811	O
mAChR	-	812	O
)	-	817	O
antagonist	-	819	O
4	-	830	O
-	-	831	O
DAMP	-	832	O
(	-	837	O
4	-	838	O
-	-	839	O
diphenylacetoxy	-	840	O
-	-	855	O
N	-	856	O
-	-	857	O
methylpiperidine	-	858	O
-	-	874	O
methiodide	-	875	O
)	-	885	O
partially	-	887	O
abolished	-	897	O
the	-	907	O
beneficial	-	911	O
effects	-	922	O
of	-	930	O
pilocarpine	-	933	O
.	-	944	O

These	19721134	946	O
data	-	952	O
suggest	-	957	O
that	-	965	O
pilocarpine	-	970	O
produced	-	982	O
antiarrhythmic	-	991	O
actions	-	1006	O
on	-	1014	O
arrhythmic	-	1017	B
rat	-	1028	O
and	-	1032	O
guinea	-	1036	O
pig	-	1043	O
models	-	1047	O
induced	-	1054	O
by	-	1062	O
aconitine	-	1065	O
or	-	1075	O
ouabain	-	1078	O
via	-	1086	O
stimulating	-	1090	O
the	-	1102	O
cardiac	-	1106	O
M	-	1114	O
(	-	1115	O
3	-	1116	O
)	-	1117	O
-	-	1118	O
mAChR	-	1119	O
.	-	1124	O
The	-	1126	O
mechanism	-	1130	O
may	-	1140	O
be	-	1144	O
related	-	1147	O
to	-	1155	O
the	-	1158	O
improvement	-	1162	O
of	-	1174	O
Ca	-	1177	O
(	-	1179	O
2	-	1180	O
+	-	1181	O
)	-	1182	O
handling	-	1184	O
.	-	1192	O

Disulfiram	17786501	0	O
-	-	10	O
induced	-	11	O
transient	-	19	O
optic	-	29	B
and	-	35	I
peripheral	-	39	I
neuropathy	-	50	I
:	-	60	O
a	-	62	O
case	-	64	O
report	-	69	O
.	-	75	O

AIM	17786501	77	O
:	-	80	O

To	17786501	82	O
report	-	85	O
a	-	92	O
case	-	94	O
of	-	99	O
optic	-	102	B
and	-	108	I
peripheral	-	112	I
neuropathy	-	123	I
after	-	134	O
chronic	-	140	O
use	-	148	O
of	-	152	O
disulfiram	-	155	O
for	-	166	O
alcohol	-	170	B
dependence	-	178	I
management	-	189	O
.	-	199	O

MATERIALS	17786501	201	O
AND	-	211	O
METHODS	-	215	O
:	-	222	O

A	17786501	224	O
case	-	226	O
report	-	231	O
.	-	237	O

RESULTS	17786501	239	O
:	-	246	O

A	17786501	248	O
57	-	250	O
-	-	252	O
year	-	253	O
-	-	257	O
old	-	258	O
male	-	262	O
presented	-	267	O
with	-	277	O
gradual	-	282	O
loss	-	290	B
of	-	295	I
vision	-	298	I
in	-	305	O
both	-	308	O
eyes	-	313	O
with	-	318	O
intermittent	-	323	O
headaches	-	336	B
for	-	346	O
2	-	350	O
months	-	352	O
.	-	358	O

He	17786501	360	O
also	-	363	O
complained	-	368	O
of	-	379	O
paraesthesia	-	382	B
with	-	395	O
numbness	-	400	B
in	-	409	O
both	-	412	O
feet	-	417	O
.	-	421	O

His	17786501	423	O
vision	-	427	O
was	-	434	O
6	-	438	O
/	-	439	O
15	-	440	O
and	-	443	O
2	-	447	O
/	-	448	O
60	-	449	O
in	-	452	O
the	-	455	O
right	-	459	O
and	-	465	O
left	-	469	O
eyes	-	474	O
,	-	478	O
respectively	-	480	O
.	-	492	O

Fundoscopy	17786501	494	O
revealed	-	505	O
bilaterally	-	514	O
swollen	-	526	O
optic	-	534	O
nerve	-	540	O
heads	-	546	O
.	-	551	O

Visual	17786501	553	O
field	-	560	O
testing	-	566	O
confirmed	-	574	O
bilateral	-	584	O
central	-	594	O
-	-	601	O
caecal	-	602	O
scotomata	-	609	B
.	-	618	O

He	17786501	620	O
had	-	623	O
been	-	627	O
taking	-	632	O
disulfiram	-	639	O
for	-	650	O
alcohol	-	654	B
dependence	-	662	I
for	-	673	O
the	-	677	O
preceding	-	681	O
3	-	691	O
years	-	693	O
.	-	698	O

Disulfiram	17786501	700	O
discontinuation	-	711	O
lead	-	727	O
to	-	732	O
an	-	735	O
immediate	-	738	O
symptomatic	-	748	O
improvement	-	760	O
.	-	771	O

CONCLUSION	17786501	773	O
:	-	783	O

Physicians	17786501	785	O
initiating	-	796	O
long	-	807	O
-	-	811	O
term	-	812	O
disulfiram	-	817	O
therapy	-	828	O
should	-	836	O
be	-	843	O
aware	-	846	O
of	-	852	O
these	-	855	O
adverse	-	861	O
effects	-	869	O
.	-	876	O

They	17786501	878	O
should	-	883	O
recommend	-	890	O
annual	-	900	O
ophthalmic	-	907	O
reviews	-	918	O
with	-	926	O
visual	-	931	O
field	-	938	O
testing	-	944	O
.	-	951	O

Patients	17786501	953	O
should	-	962	O
be	-	969	O
reassured	-	972	O
with	-	982	O
respect	-	987	O
to	-	995	O
the	-	998	O
reversibility	-	1002	O
of	-	1016	O
these	-	1019	O
adverse	-	1025	O
effects	-	1033	O
.	-	1040	O

Sustained	16960342	0	O
clinical	-	10	O
improvement	-	19	O
of	-	31	O
a	-	34	O
patient	-	36	O
with	-	44	O
decompensated	-	49	O
hepatitis	-	63	B
B	-	73	I
virus	-	75	O
-	-	80	O
related	-	81	O
cirrhosis	-	89	B
after	-	99	O
treatment	-	105	O
with	-	115	O
lamivudine	-	120	O
monotherapy	-	131	O
.	-	142	O

Hepatitis	16960342	144	B
B	-	154	I
virus	-	156	I
(	-	162	I
HBV	-	163	I
)	-	166	I
infection	-	168	I
,	-	177	O
which	-	179	O
causes	-	185	O
liver	-	192	B
cirrhosis	-	198	I
and	-	208	O
hepatocellular	-	212	B
carcinoma	-	227	I
,	-	236	O
remains	-	238	O
a	-	246	O
major	-	248	O
health	-	254	O
problem	-	261	O
in	-	269	O
Asian	-	272	O
countries	-	278	O
.	-	287	O

Recent	16960342	289	O
development	-	296	O
of	-	308	O
vaccine	-	311	O
for	-	319	O
prevention	-	323	O
is	-	334	O
reported	-	337	O
to	-	346	O
be	-	349	O
successful	-	352	O
in	-	363	O
reducing	-	366	O
the	-	375	O
size	-	379	O
of	-	384	O
chronically	-	387	O
infected	-	399	O
carriers	-	408	O
,	-	416	O
although	-	418	O
the	-	427	O
standard	-	431	O
medical	-	440	O
therapies	-	448	O
have	-	458	O
not	-	463	O
been	-	467	O
established	-	472	O
up	-	484	O
to	-	487	O
now	-	490	O
.	-	493	O

In	16960342	495	O
this	-	498	O
report	-	503	O
,	-	509	O
we	-	511	O
encountered	-	514	O
a	-	526	O
patient	-	528	O
with	-	536	O
decompensated	-	541	O
HBV	-	555	O
-	-	558	O
related	-	559	O
cirrhosis	-	567	B
who	-	577	O
exhibited	-	581	O
the	-	591	O
dramatic	-	595	O
improvements	-	604	O
after	-	617	O
antiviral	-	623	O
therapy	-	633	O
.	-	640	O

The	16960342	642	O
patient	-	646	O
was	-	654	O
a	-	658	O
50	-	660	O
-	-	662	O
year	-	663	O
-	-	667	O
old	-	668	O
woman	-	672	O
.	-	677	O

Previous	16960342	679	O
conventional	-	688	O
medical	-	701	O
treatments	-	709	O
were	-	720	O
not	-	725	O
effective	-	729	O
for	-	739	O
this	-	743	O
patient	-	748	O
,	-	755	O
thus	-	757	O
this	-	762	O
patient	-	767	O
had	-	775	O
been	-	779	O
referred	-	784	O
to	-	793	O
our	-	796	O
hospital	-	800	O
.	-	808	O

However	16960342	810	O
,	-	817	O
the	-	819	O
administration	-	823	O
of	-	838	O
lamivudine	-	841	O
,	-	851	O
a	-	853	O
reverse	-	855	O
transcriptase	-	863	O
inhibitor	-	877	O
,	-	886	O
for	-	888	O
23	-	892	O
months	-	895	O
dramatically	-	902	O
improved	-	915	O
her	-	924	O
liver	-	928	O
severity	-	934	O
.	-	942	O

During	16960342	944	O
this	-	951	O
period	-	956	O
,	-	962	O
no	-	964	O
drug	-	967	O
resistant	-	972	O
mutant	-	982	O
HBV	-	989	O
emerged	-	993	O
,	-	1000	O
and	-	1002	O
the	-	1006	O
serum	-	1010	O
HBV	-	1016	O
-	-	1019	O
DNA	-	1020	O
level	-	1024	O
was	-	1030	O
continuously	-	1034	O
suppressed	-	1047	O
.	-	1057	O

These	16960342	1059	O
virological	-	1065	O
responses	-	1077	O
were	-	1087	O
also	-	1092	O
maintained	-	1097	O
even	-	1108	O
after	-	1113	O
the	-	1119	O
antiviral	-	1123	O
therapy	-	1133	O
was	-	1141	O
discontinued	-	1145	O
.	-	1157	O

Moreover	16960342	1159	O
,	-	1167	O
both	-	1169	O
hepatitis	-	1174	O
B	-	1184	O
surface	-	1186	O
antigen	-	1194	O
and	-	1202	O
e	-	1206	O
antigen	-	1208	O
were	-	1216	O
observed	-	1221	O
to	-	1230	O
have	-	1233	O
disappeared	-	1238	O
in	-	1250	O
this	-	1253	O
patient	-	1258	O
.	-	1265	O

The	16960342	1267	O
administration	-	1271	O
of	-	1286	O
lamivudine	-	1289	O
to	-	1300	O
patients	-	1303	O
with	-	1312	O
HBV	-	1317	O
-	-	1320	O
related	-	1321	O
cirrhosis	-	1329	B
,	-	1338	O
like	-	1340	O
our	-	1345	O
present	-	1349	O
case	-	1357	O
,	-	1361	O
should	-	1363	O
be	-	1370	O
considered	-	1373	O
as	-	1384	O
an	-	1387	O
initial	-	1390	O
medical	-	1398	O
therapeutic	-	1406	O
option	-	1418	O
,	-	1424	O
especially	-	1426	O
in	-	1437	O
countries	-	1440	O
where	-	1450	O
liver	-	1456	O
transplantation	-	1462	O
is	-	1478	O
not	-	1481	O
reliably	-	1485	O
available	-	1494	O
.	-	1503	O

Dual	11226639	0	O
effects	-	5	O
of	-	13	O
melatonin	-	16	O
on	-	26	O
barbiturate	-	29	O
-	-	40	O
induced	-	41	O
narcosis	-	49	B
in	-	58	O
rats	-	61	O
.	-	65	O

Melatonin	11226639	67	O
affects	-	77	O
the	-	85	O
circadian	-	89	O
sleep	-	99	O
/	-	104	O
wake	-	105	O
cycle	-	110	O
,	-	115	O
but	-	117	O
it	-	121	O
is	-	124	O
not	-	127	O
clear	-	131	O
whether	-	137	O
it	-	145	O
may	-	148	O
influence	-	152	O
drug	-	162	O
-	-	166	O
induced	-	167	O
narcosis	-	175	B
.	-	183	O

Sodium	11226639	185	O
thiopenthal	-	192	O
was	-	204	O
administered	-	208	O
intraperitoneally	-	221	O
into	-	239	O
male	-	244	O
rats	-	249	O
pre	-	254	O
-	-	257	O
treated	-	258	O
with	-	266	O
melatonin	-	271	O
(	-	281	O
0	-	282	O
.	-	283	O
05	-	284	O
,	-	286	O
0	-	288	O
.	-	289	O
5	-	290	O
,	-	291	O
5	-	293	O
and	-	295	O
50	-	299	O
mg	-	302	O
/	-	304	O
kg	-	305	O
)	-	307	O
.	-	308	O

Melatonin	11226639	310	O
pre	-	320	O
-	-	323	O
treatment	-	324	O
affected	-	334	O
in	-	343	O
a	-	346	O
dual	-	348	O
manner	-	353	O
barbiturate	-	360	O
narcosis	-	372	B
,	-	380	O
however	-	382	O
,	-	389	O
no	-	391	O
dose	-	394	O
-	-	398	O
effect	-	399	O
correlation	-	406	O
was	-	418	O
found	-	422	O
.	-	427	O

In	11226639	429	O
particular	-	432	O
,	-	442	O
low	-	444	O
doses	-	448	O
reduced	-	454	O
the	-	462	O
latency	-	466	O
to	-	474	O
and	-	477	O
prolonged	-	481	O
the	-	491	O
duration	-	495	O
of	-	504	O
barbiturate	-	507	O
narcosis	-	519	B
.	-	527	O

In	11226639	529	O
contrast	-	532	O
,	-	540	O
the	-	542	O
highest	-	546	O
dose	-	554	O
of	-	559	O
melatonin	-	562	O
(	-	572	O
50	-	573	O
mg	-	576	O
/	-	578	O
kg	-	579	O
)	-	581	O
caused	-	583	O
a	-	590	O
paradoxical	-	592	O
increase	-	604	O
in	-	613	O
the	-	616	O
latency	-	620	O
and	-	628	O
produced	-	632	O
a	-	641	O
sustained	-	643	O
reduction	-	653	O
of	-	663	O
the	-	666	O
duration	-	670	O
of	-	679	O
narcosis	-	682	B
,	-	690	O
and	-	692	O
a	-	696	O
reduction	-	698	O
in	-	708	O
mortality	-	711	O
rate	-	721	O
.	-	725	O

Melatonin	11226639	727	O
0	-	737	O
.	-	738	O
5	-	739	O
and	-	741	O
5	-	745	O
mg	-	747	O
/	-	749	O
kg	-	750	O
influenced	-	753	O
the	-	764	O
duration	-	768	O
but	-	777	O
not	-	781	O
the	-	785	O
latency	-	789	O
of	-	797	O
ketamine	-	800	O
-	-	808	O
or	-	810	O
diazepam	-	813	O
-	-	821	O
induced	-	822	O
narcosis	-	830	B
.	-	838	O

Thus	11226639	840	O
,	-	844	O
the	-	846	O
dual	-	850	O
action	-	855	O
of	-	862	O
melatonin	-	865	O
on	-	875	O
pharmacological	-	878	O
narcosis	-	894	B
seems	-	903	O
to	-	909	O
be	-	912	O
specific	-	915	O
for	-	924	O
the	-	928	O
barbiturate	-	932	O
mechanism	-	944	O
of	-	954	O
action	-	957	O
.	-	963	O

Effects	9228650	0	O
of	-	8	O
NIK	-	11	O
-	-	14	O
247	-	15	O
on	-	19	O
cholinesterase	-	22	O
and	-	37	O
scopolamine	-	41	O
-	-	52	O
induced	-	53	O
amnesia	-	61	B
.	-	68	O

The	9228650	70	O
effects	-	74	O
of	-	82	O
NIK	-	85	O
-	-	88	O
247	-	89	O
on	-	93	O
cholinesterase	-	96	O
,	-	110	O
scopolamine	-	112	O
-	-	123	O
induced	-	124	O
amnesia	-	132	B
and	-	140	O
spontaneous	-	144	O
movement	-	156	O
were	-	165	O
examined	-	170	O
and	-	179	O
compared	-	183	O
with	-	192	O
those	-	197	O
of	-	203	O
the	-	206	O
well	-	210	O
-	-	214	O
known	-	215	O
cholinesterase	-	221	O
inhibitors	-	236	O
tacrine	-	247	O
and	-	255	O
E	-	259	O
-	-	260	O
2020	-	261	O
.	-	265	O

NIK	9228650	267	O
-	-	270	O
247	-	271	O
,	-	274	O
tacrine	-	276	O
and	-	284	O
E	-	288	O
-	-	289	O
2020	-	290	O
all	-	295	O
strongly	-	299	O
inhibited	-	308	O
acetylcholinesterase	-	318	O
(	-	339	O
AChE	-	340	O
)	-	344	O
in	-	346	O
human	-	349	O
red	-	355	O
blood	-	359	O
cells	-	365	O
(	-	371	O
IC50s	-	372	O
=	-	378	O
1	-	380	O
.	-	381	O
0	-	382	O
x	-	384	O
10	-	386	O
(	-	388	O
-	-	389	O
6	-	390	O
)	-	391	O
,	-	392	O
2	-	394	O
.	-	395	O
9	-	396	O
x	-	398	O
10	-	400	O
(	-	402	O
-	-	403	O
7	-	404	O
)	-	405	O
and	-	407	O
3	-	411	O
.	-	412	O
7	-	413	O
x	-	415	O
10	-	417	O
(	-	419	O
-	-	420	O
8	-	421	O
)	-	422	O
M	-	424	O
,	-	425	O
respectively	-	427	O
)	-	439	O
.	-	440	O

In	9228650	442	O
addition	-	445	O
,	-	453	O
NIK	-	455	O
-	-	458	O
247	-	459	O
and	-	463	O
tacrine	-	467	O
,	-	474	O
but	-	476	O
not	-	480	O
E	-	484	O
-	-	485	O
2020	-	486	O
,	-	490	O
strongly	-	492	O
inhibited	-	501	O
butyrylcholinestrase	-	511	O
(	-	532	O
BuChE	-	533	O
)	-	538	O
in	-	540	O
human	-	543	O
serum	-	549	O
.	-	554	O

All	9228650	556	O
three	-	560	O
drugs	-	566	O
produced	-	572	O
mixed	-	581	O
inhibition	-	587	O
of	-	598	O
AChE	-	601	O
activity	-	606	O
.	-	614	O

Moreover	9228650	616	O
,	-	624	O
the	-	626	O
inhibitory	-	630	O
effect	-	641	O
of	-	648	O
NIK	-	651	O
-	-	654	O
247	-	655	O
on	-	659	O
AChE	-	662	O
was	-	667	O
reversible	-	671	O
.	-	681	O

All	9228650	683	O
compounds	-	687	O
at	-	697	O
0	-	700	O
.	-	701	O
1	-	702	O
-	-	703	O
1	-	704	O
mg	-	706	O
/	-	708	O
kg	-	709	O
p	-	712	O
.	-	713	O
o	-	714	O
.	-	715	O

significantly	9228650	717	O
improved	-	731	O
the	-	740	O
amnesia	-	744	B
induced	-	752	O
by	-	760	O
scopolamine	-	763	O
(	-	775	O
0	-	776	O
.	-	777	O
5	-	778	O
mg	-	780	O
/	-	782	O
kg	-	783	O
s	-	786	O
.	-	787	O
c	-	788	O
.	-	789	O
)	-	790	O

in	9228650	792	O
rats	-	795	O
performing	-	800	O
a	-	811	O
passive	-	813	O
avoidance	-	821	O
task	-	831	O
.	-	835	O

The	9228650	837	O
three	-	841	O
compounds	-	847	O
at	-	857	O
1	-	860	O
and	-	862	O
3	-	866	O
mg	-	868	O
/	-	870	O
kg	-	871	O
p	-	874	O
.	-	875	O
o	-	876	O
.	-	877	O

did	9228650	879	O
not	-	883	O
significantly	-	887	O
decrease	-	901	O
spontaneous	-	910	O
movement	-	922	O
by	-	931	O
rats	-	934	O
.	-	938	O

These	9228650	940	O
findings	-	946	O
suggest	-	955	O
that	-	963	O
NIK	-	968	O
-	-	971	O
247	-	972	O
at	-	976	O
a	-	979	O
low	-	981	O
dose	-	985	O
(	-	990	O
0	-	991	O
.	-	992	O
1	-	993	O
-	-	994	O
1	-	995	O
mg	-	997	O
/	-	999	O
kg	-	1000	O
p	-	1003	O
.	-	1004	O
o	-	1005	O
.	-	1006	O
)	-	1007	O
improves	-	1009	O
scopolamine	-	1018	O
-	-	1029	O
induced	-	1030	O
amnesia	-	1038	B
but	-	1046	O
does	-	1050	O
not	-	1055	O
affect	-	1059	O
spontaneous	-	1066	O
movement	-	1078	O
.	-	1086	O

The	9228650	1088	O
findings	-	1092	O
suggest	-	1101	O
that	-	1109	O
NIK	-	1114	O
-	-	1117	O
247	-	1118	O
may	-	1122	O
be	-	1126	O
a	-	1129	O
useful	-	1131	O
drug	-	1138	O
for	-	1143	O
the	-	1147	O
treatment	-	1151	O
of	-	1161	O
Alzheimer	-	1164	B
's	-	1173	I
disease	-	1176	I
.	-	1183	O

Nightmares	8766220	0	O
and	-	11	O
hallucinations	-	15	B
after	-	30	O
long	-	36	O
-	-	40	O
term	-	41	O
intake	-	46	O
of	-	53	O
tramadol	-	56	O
combined	-	65	O
with	-	74	O
antidepressants	-	79	O
.	-	94	O

Tramadol	8766220	96	O
is	-	105	O
a	-	108	O
weak	-	110	O
opioid	-	115	O
with	-	122	O
effects	-	127	O
on	-	135	O
adrenergic	-	138	O
and	-	149	O
serotonergic	-	153	O
neurotransmission	-	166	O
that	-	184	O
is	-	189	O
used	-	192	O
to	-	197	O
treat	-	200	O
cancer	-	206	B
pain	-	213	B
and	-	218	O
chronic	-	222	O
non	-	230	O
malignant	-	234	O
pain	-	244	B
.	-	248	O

This	8766220	250	O
drug	-	255	O
was	-	260	O
initiated	-	264	O
in	-	274	O
association	-	277	O
with	-	289	O
paroxetine	-	294	O
and	-	305	O
dosulepine	-	309	O
hydrochloride	-	320	O
in	-	334	O
a	-	337	O
tetraparetic	-	339	B
patient	-	352	O
with	-	360	O
chronic	-	365	B
pain	-	373	I
.	-	377	O

Fifty	8766220	379	O
-	-	384	O
six	-	385	O
days	-	389	O
after	-	394	O
initiation	-	400	O
of	-	411	O
the	-	414	O
treatment	-	418	O
the	-	428	O
patient	-	432	O
presented	-	440	O
hallucinations	-	450	B
that	-	465	O
only	-	470	O
stopped	-	475	O
after	-	483	O
the	-	489	O
withdrawal	-	493	O
of	-	504	O
psycho	-	507	O
-	-	513	O
active	-	514	O
drugs	-	521	O
and	-	527	O
tramadol	-	531	O
.	-	539	O

The	8766220	541	O
case	-	545	O
report	-	550	O
questions	-	557	O
the	-	567	O
long	-	571	O
term	-	576	O
use	-	581	O
of	-	585	O
pain	-	588	B
killers	-	593	O
combined	-	601	O
with	-	610	O
psycho	-	615	O
-	-	621	O
active	-	622	O
drugs	-	629	O
in	-	635	O
chronic	-	638	O
non	-	646	O
malignant	-	650	O
pain	-	660	B
,	-	664	O
especially	-	666	O
if	-	677	O
pain	-	680	B
is	-	685	O
under	-	688	O
control	-	694	O
.	-	701	O

Apparent	8441146	0	O
cure	-	9	O
of	-	14	O
rheumatoid	-	17	B
arthritis	-	28	I
by	-	38	O
bone	-	41	O
marrow	-	46	O
transplantation	-	53	O
.	-	68	O

We	8441146	70	O
describe	-	73	O
the	-	82	O
induction	-	86	O
of	-	96	O
sustained	-	99	O
remissions	-	109	O
and	-	120	O
possible	-	124	O
cure	-	133	O
of	-	138	O
severe	-	141	O
erosive	-	148	O
rheumatoid	-	156	B
arthritis	-	167	I
(	-	177	O
RA	-	178	B
)	-	180	O
by	-	182	O
bone	-	185	O
marrow	-	190	O
transplantation	-	197	O
(	-	213	O
BMT	-	214	O
)	-	217	O
in	-	219	O
2	-	222	O
patients	-	224	O
.	-	232	O

BMT	8441146	234	O
was	-	238	O
used	-	242	O
to	-	247	O
treat	-	250	O
severe	-	256	O
aplastic	-	263	B
anemia	-	272	I
which	-	279	O
was	-	285	O
caused	-	289	O
by	-	296	O
gold	-	299	O
in	-	304	O
one	-	307	O
case	-	311	O
and	-	316	O
D	-	320	O
-	-	321	O
penicillamine	-	322	O
in	-	336	O
the	-	339	O
other	-	343	O
.	-	348	O

In	8441146	350	O
the	-	353	O
8	-	357	O
and	-	359	O
6	-	363	O
years	-	365	O
since	-	371	O
the	-	377	O
transplants	-	381	O
(	-	393	O
representing	-	394	O
8	-	407	O
and	-	409	O
4	-	413	O
years	-	415	O
since	-	421	O
cessation	-	427	O
of	-	437	O
all	-	440	O
immunosuppressive	-	444	O
therapy	-	462	O
,	-	469	O
respectively	-	471	O
)	-	483	O
,	-	484	O
the	-	486	O
RA	-	490	B
in	-	493	O
each	-	496	O
case	-	501	O
has	-	506	O
been	-	510	O
completely	-	515	O
quiescent	-	526	O
.	-	535	O

Although	8441146	537	O
short	-	546	O
term	-	552	O
remission	-	557	O
of	-	567	O
severe	-	570	O
RA	-	577	B
following	-	580	O
BMT	-	590	O
has	-	594	O
been	-	598	O
reported	-	603	O
,	-	611	O
these	-	613	O
are	-	619	O
the	-	623	O
first	-	627	O
cases	-	633	O
for	-	639	O
which	-	643	O
prolonged	-	649	O
followup	-	659	O
has	-	668	O
been	-	672	O
available	-	677	O
.	-	686	O

This	8441146	688	O
experience	-	693	O
raises	-	704	O
the	-	711	O
question	-	715	O
of	-	724	O
the	-	727	O
role	-	731	O
of	-	736	O
BMT	-	739	O
itself	-	743	O
as	-	750	O
a	-	753	O
therapeutic	-	755	O
option	-	767	O
for	-	774	O
patients	-	778	O
with	-	787	O
uncontrolled	-	792	O
destructive	-	805	O
synovitis	-	817	B
.	-	826	O

Urinary	3653576	0	O
enzymes	-	8	O
and	-	16	O
protein	-	20	O
patterns	-	28	O
as	-	37	O
indicators	-	40	O
of	-	51	O
injury	-	54	B
to	-	61	I
different	-	64	I
regions	-	74	I
of	-	82	I
the	-	85	I
kidney	-	89	I
.	-	95	O

Acute	3653576	97	B
experimental	-	103	I
models	-	116	I
of	-	123	I
renal	-	126	I
damage	-	132	I
to	-	139	O
the	-	142	O
proximal	-	146	O
tubular	-	155	O
,	-	162	O
glomerular	-	164	O
,	-	174	O
and	-	176	O
papillary	-	180	O
regions	-	190	O
of	-	198	O
the	-	201	O
rat	-	205	O
were	-	209	O
produced	-	214	O
by	-	223	O
administration	-	226	O
of	-	241	O
hexachloro	-	244	O
-	-	254	O
1	-	255	O
:	-	256	O
3	-	257	O
-	-	258	O
butadiene	-	259	O
(	-	269	O
HCBD	-	270	O
)	-	274	O
,	-	275	O
puromycin	-	277	O
aminonucleoside	-	287	O
(	-	303	O
PAN	-	304	O
)	-	307	O
,	-	308	O
and	-	310	O
2	-	314	O
-	-	315	O
bromoethylamine	-	316	O
(	-	332	O
BEA	-	333	O
)	-	336	O
,	-	337	O
respectively	-	339	O
.	-	351	O

Several	3653576	353	O
routine	-	361	O
indicators	-	369	O
of	-	380	O
nephrotoxicity	-	383	B
,	-	397	O
the	-	399	O
enzymes	-	403	O
alkaline	-	411	O
phosphatase	-	420	O
and	-	432	O
N	-	436	O
-	-	437	O
acetyl	-	438	O
-	-	444	O
beta	-	445	O
-	-	449	O
glucosaminidase	-	450	O
,	-	465	O
and	-	467	O
the	-	471	O
molecular	-	475	O
weight	-	485	O
of	-	492	O
protein	-	495	B
excretion	-	503	I
were	-	513	O
determined	-	518	O
on	-	529	O
urine	-	532	O
samples	-	538	O
.	-	545	O

Tubular	3653576	547	O
damage	-	555	O
produced	-	562	O
by	-	571	O
HCBD	-	574	O
or	-	579	O
BEA	-	582	O
was	-	586	O
discriminated	-	590	O
both	-	604	O
quantitatively	-	609	O
and	-	624	O
qualitatively	-	628	O
from	-	642	O
glomerular	-	647	B
damage	-	658	I
produced	-	665	O
by	-	674	O
PAN	-	677	O
.	-	680	O

The	3653576	682	O
latter	-	686	O
was	-	693	O
characterized	-	697	O
by	-	711	O
a	-	714	O
pronounced	-	716	O
increase	-	727	O
in	-	736	O
protein	-	739	B
excretion	-	747	I
,	-	756	O
especially	-	758	O
proteins	-	769	O
with	-	778	O
molecular	-	783	O
weight	-	793	O
greater	-	800	O
than	-	808	O
40	-	813	O
,	-	815	O
000	-	816	O
Da	-	820	O
.	-	822	O

In	3653576	824	O
contrast	-	827	O
,	-	835	O
protein	-	837	B
excretion	-	845	I
in	-	855	O
tubular	-	858	O
damage	-	866	O
was	-	873	O
raised	-	877	O
only	-	884	O
slightly	-	889	O
and	-	898	O
characterized	-	902	O
by	-	916	O
excretion	-	919	B
of	-	929	I
proteins	-	932	I
of	-	941	O
a	-	944	O
wide	-	946	O
range	-	951	O
of	-	957	O
molecular	-	960	O
weights	-	970	O
.	-	977	O

Proximal	3653576	979	O
tubular	-	988	O
damage	-	996	O
caused	-	1003	O
by	-	1010	O
HCBD	-	1013	O
and	-	1018	O
papillary	-	1022	O
damage	-	1032	O
caused	-	1039	O
by	-	1046	O
BEA	-	1049	O
were	-	1053	O
distinguished	-	1058	O
both	-	1072	O
by	-	1077	O
conventional	-	1080	O
urinalysis	-	1093	O
(	-	1104	O
volume	-	1105	O
and	-	1112	O
specific	-	1116	O
gravity	-	1125	O
)	-	1132	O
and	-	1134	O
by	-	1138	O
measurement	-	1141	O
of	-	1153	O
the	-	1156	O
two	-	1160	O
urinary	-	1164	O
enzymes	-	1172	O
.	-	1179	O

Alkaline	3653576	1181	O
phosphatase	-	1190	O
and	-	1202	O
glucose	-	1206	O
were	-	1214	O
markedly	-	1219	O
and	-	1228	O
transiently	-	1232	O
elevated	-	1244	O
in	-	1253	O
proximal	-	1256	O
tubular	-	1265	O
damage	-	1273	O
and	-	1280	O
N	-	1284	O
-	-	1285	O
acetyl	-	1286	O
-	-	1292	O
beta	-	1293	O
-	-	1297	O
glucosaminidase	-	1298	O
showed	-	1314	O
a	-	1321	O
sustained	-	1323	O
elevation	-	1333	O
in	-	1343	O
papillary	-	1346	O
damage	-	1356	O
.	-	1362	O

It	3653576	1364	O
is	-	1367	O
concluded	-	1370	O
that	-	1380	O
both	-	1385	O
selective	-	1390	O
urinary	-	1400	O
enzymes	-	1408	O
and	-	1416	O
the	-	1420	O
molecular	-	1424	O
weight	-	1434	O
pattern	-	1441	O
of	-	1449	O
urinary	-	1452	O
proteins	-	1460	O
can	-	1469	O
be	-	1473	O
used	-	1476	O
to	-	1481	O
provide	-	1484	O
diagnostic	-	1492	O
information	-	1503	O
about	-	1515	O
the	-	1521	O
possible	-	1525	O
site	-	1534	O
of	-	1539	O
renal	-	1542	B
damage	-	1548	I
.	-	1554	O

Neuromuscular	2750819	0	B
blockade	-	14	I
with	-	23	O
magnesium	-	28	O
sulfate	-	38	O
and	-	46	O
nifedipine	-	50	O
.	-	60	O

A	2750819	62	O
patient	-	64	O
who	-	72	O
received	-	76	O
tocolysis	-	85	O
with	-	95	O
nifedipine	-	100	O
developed	-	111	O
neuromuscular	-	121	B
blockade	-	135	I
after	-	144	O
500	-	150	O
mg	-	154	O
of	-	157	O
magnesium	-	160	O
sulfate	-	170	O
was	-	178	O
administered	-	182	O
.	-	194	O

This	2750819	196	O
reaction	-	201	O
demonstrates	-	210	O
that	-	223	O
nifedipine	-	228	O
can	-	239	O
seriously	-	243	O
potentiate	-	253	O
the	-	264	O
toxicity	-	268	B
of	-	277	O
magnesium	-	280	O
.	-	289	O

Caution	2750819	291	O
should	-	299	O
be	-	306	O
exercised	-	309	O
when	-	319	O
these	-	324	O
two	-	330	O
tocolytics	-	334	O
are	-	345	O
combined	-	349	O
.	-	357	O

Ifosfamide	1899352	0	O
continuous	-	11	O
infusion	-	22	O
without	-	31	O
mesna	-	39	O
.	-	44	O

A	1899352	46	O
phase	-	48	O
I	-	54	O
trial	-	56	O
of	-	62	O
a	-	65	O
14	-	67	O
-	-	69	O
day	-	70	O
cycle	-	74	O
.	-	79	O

Twenty	1899352	81	O
patients	-	88	O
received	-	97	O
27	-	106	O
courses	-	109	O
of	-	117	O
ifosfamide	-	120	O
administered	-	131	O
as	-	144	O
a	-	147	O
24	-	149	O
-	-	151	O
hour	-	152	O
continuous	-	157	O
infusion	-	168	O
for	-	177	O
14	-	181	O
days	-	184	O
without	-	189	O
Mesna	-	197	O
.	-	202	O

The	1899352	204	O
goal	-	208	O
of	-	213	O
the	-	216	O
study	-	220	O
was	-	226	O
to	-	230	O
deliver	-	233	O
a	-	241	O
dose	-	243	O
rate	-	248	O
and	-	253	O
total	-	257	O
cumulative	-	263	O
dose	-	274	O
of	-	279	O
ifosfamide	-	282	O
that	-	293	O
would	-	298	O
be	-	304	O
comparable	-	307	O
to	-	318	O
standard	-	321	O
bolus	-	330	O
or	-	336	O
short	-	339	O
-	-	344	O
term	-	345	O
infusions	-	350	O
administered	-	360	O
with	-	373	O
Mesna	-	378	O
.	-	383	O

Dose	1899352	385	O
escalations	-	390	O
proceeded	-	402	O
from	-	412	O
200	-	417	O
to	-	421	O
300	-	424	O
,	-	427	O
400	-	429	O
,	-	432	O
450	-	434	O
,	-	437	O
500	-	439	O
,	-	442	O
and	-	444	O
550	-	448	O
mg	-	452	O
/	-	454	O
m2	-	455	O
/	-	457	O
d	-	458	O
.	-	459	O

Four	1899352	461	O
patients	-	466	O
developed	-	475	O
transient	-	485	O
microscopic	-	495	O
hematuria	-	507	B
at	-	517	O
400	-	520	O
,	-	523	O
450	-	525	O
,	-	528	O
and	-	530	O
500	-	534	O
mg	-	538	O
/	-	540	O
m2	-	541	O
/	-	543	O
d	-	544	O
.	-	545	O

There	1899352	547	O
were	-	553	O
no	-	558	O
instances	-	561	O
of	-	571	O
macroscopic	-	574	O
hematuria	-	586	B
.	-	595	O

At	1899352	597	O
550	-	600	O
mg	-	604	O
/	-	606	O
m2	-	607	O
/	-	609	O
d	-	610	O
,	-	611	O
three	-	613	O
patients	-	619	O
experienced	-	628	O
nonurologic	-	640	O
toxicity	-	652	B
;	-	660	O
confusion	-	662	B
(	-	672	O
1	-	673	O
)	-	674	O
,	-	675	O
nausea	-	677	B
(	-	684	O
1	-	685	O
)	-	686	O
,	-	687	O
and	-	689	O
Grade	-	693	O
2	-	699	O
leukopenia	-	701	B
(	-	712	O
1	-	713	O
)	-	714	O
.	-	715	O

The	1899352	717	O
recommended	-	721	O
dose	-	733	O
of	-	738	O
500	-	741	O
mg	-	745	O
/	-	747	O
m2	-	748	O
/	-	750	O
d	-	751	O
delivers	-	753	O
a	-	762	O
total	-	764	O
dose	-	770	O
of	-	775	O
7	-	778	O
g	-	780	O
/	-	781	O
m2	-	782	O
per	-	785	O
cycle	-	789	O
,	-	794	O
which	-	796	O
is	-	802	O
comparable	-	805	O
to	-	816	O
that	-	819	O
delivered	-	824	O
in	-	834	O
clinical	-	837	O
practice	-	846	O
for	-	855	O
bolus	-	859	O
or	-	865	O
short	-	868	O
-	-	873	O
term	-	874	O
infusion	-	879	O
.	-	887	O

Because	1899352	889	O
few	-	897	O
patients	-	901	O
received	-	910	O
multiple	-	919	O
courses	-	928	O
over	-	936	O
time	-	941	O
,	-	945	O
the	-	947	O
cumulative	-	951	O
effects	-	962	O
are	-	970	O
indeterminate	-	974	O
in	-	988	O
the	-	991	O
present	-	995	O
trial	-	1003	O
.	-	1008	O

The	1899352	1010	O
frequency	-	1014	O
and	-	1024	O
predictability	-	1028	O
of	-	1043	O
hematuria	-	1046	B
are	-	1056	O
not	-	1060	O
precise	-	1064	O
,	-	1071	O
and	-	1073	O
at	-	1077	O
least	-	1080	O
daily	-	1086	O
monitoring	-	1092	O
by	-	1103	O
urine	-	1106	O
Hematest	-	1112	O
is	-	1121	O
essential	-	1124	O
,	-	1133	O
adding	-	1135	O
Mesna	-	1142	O
to	-	1148	O
the	-	1151	O
infusate	-	1155	O
in	-	1164	O
patients	-	1167	O
with	-	1176	O
persistent	-	1181	O
hematuria	-	1192	B
.	-	1201	O

The	1899352	1203	O
protracted	-	1207	O
infusion	-	1218	O
schedule	-	1227	O
for	-	1236	O
ifosfamide	-	1240	O
permits	-	1251	O
convenient	-	1259	O
outpatient	-	1270	O
administration	-	1281	O
without	-	1296	O
Mesna	-	1304	O
and	-	1310	O
reduces	-	1314	O
the	-	1322	O
drug	-	1326	O
cost	-	1331	O
of	-	1336	O
clinical	-	1339	O
usage	-	1348	O
of	-	1354	O
this	-	1357	O
agent	-	1362	O
by	-	1368	O
up	-	1371	O
to	-	1374	O
890	-	1378	O
per	-	1382	O
cycle	-	1386	O
.	-	1391	O

Clinical	1899352	1393	O
activity	-	1402	O
was	-	1411	O
demonstrated	-	1415	O
in	-	1428	O
a	-	1431	O
single	-	1433	O
patient	-	1440	O
,	-	1447	O
but	-	1449	O
a	-	1453	O
comparative	-	1455	O
trial	-	1467	O
of	-	1473	O
standard	-	1476	O
bolus	-	1485	O
schedules	-	1491	O
with	-	1501	O
the	-	1506	O
protracted	-	1510	O
infusion	-	1521	O
schedule	-	1530	O
will	-	1539	O
be	-	1544	O
necessary	-	1547	O
to	-	1557	O
determine	-	1560	O
if	-	1570	O
the	-	1573	O
clinical	-	1577	O
effectiveness	-	1586	O
of	-	1600	O
the	-	1603	O
drug	-	1607	O
is	-	1612	O
maintained	-	1615	O
.	-	1625	O

Myocardial	18161408	0	B
infarction	-	11	I
in	-	22	O
pregnancy	-	25	O
associated	-	35	O
with	-	46	O
clomiphene	-	51	O
citrate	-	62	O
for	-	70	O
ovulation	-	74	O
induction	-	84	O
:	-	93	O
a	-	95	O
case	-	97	O
report	-	102	O
.	-	108	O

BACKGROUND	18161408	110	O
:	-	120	O

Clomiphene	18161408	122	O
citrate	-	133	O
(	-	141	O
CC	-	142	O
)	-	144	O
is	-	146	O
commonly	-	149	O
prescribed	-	158	O
for	-	169	O
ovulation	-	173	O
induction	-	183	O
.	-	192	O

It	18161408	194	O
is	-	197	O
considered	-	200	O
safe	-	211	O
,	-	215	O
with	-	217	O
minimal	-	222	O
side	-	230	O
effects	-	235	O
.	-	242	O

Thromboembolism	18161408	244	B
is	-	260	O
a	-	263	O
rare	-	265	O
but	-	270	O
life	-	274	O
-	-	278	O
threatening	-	279	O
complication	-	291	O
that	-	304	O
has	-	309	O
been	-	313	O
reported	-	318	O
after	-	327	O
ovulation	-	333	O
induction	-	343	O
with	-	353	O
CC	-	358	O
.	-	360	O

Spontaneous	18161408	362	O
coronary	-	374	B
thrombosis	-	383	I
or	-	394	O
thromboembolism	-	397	B
with	-	413	O
subsequent	-	418	O
clot	-	429	O
lysis	-	434	O
has	-	440	O
been	-	444	O
suggested	-	449	O
as	-	459	O
one	-	462	O
of	-	466	O
the	-	469	O
most	-	473	O
common	-	478	O
causes	-	485	O
of	-	492	O
myocardial	-	495	B
infarction	-	506	I
(	-	517	O
MI	-	518	B
)	-	520	O
during	-	522	O
pregnancy	-	529	O
,	-	538	O
with	-	540	O
a	-	545	O
subsequently	-	547	O
normal	-	560	O
coronary	-	567	O
angiogram	-	576	O
.	-	585	O

CASE	18161408	587	O
:	-	591	O

A	18161408	593	O
33	-	595	O
-	-	597	O
year	-	598	O
-	-	602	O
old	-	603	O
woman	-	607	O
with	-	613	O
a	-	618	O
5	-	620	O
-	-	621	O
week	-	622	O
gestation	-	627	O
had	-	637	O
recently	-	641	O
received	-	650	O
CC	-	659	O
for	-	662	O
ovulation	-	666	O
induction	-	676	O
and	-	686	O
presented	-	690	O
with	-	700	O
chest	-	705	B
pain	-	711	I
.	-	715	O

An	18161408	717	O
electrocardiogram	-	720	O
showed	-	738	O
a	-	745	O
lateral	-	747	O
and	-	755	O
anterior	-	759	O
wall	-	768	O
myocardial	-	773	B
infarction	-	784	I
.	-	794	O

Cardiac	18161408	796	O
enzymes	-	804	O
showed	-	812	O
a	-	819	O
peak	-	821	O
rise	-	826	O
in	-	831	O
troponin	-	834	O
I	-	843	O
to	-	845	O
9	-	848	O
.	-	849	O
10	-	850	O
ng	-	853	O
/	-	855	O
mL	-	856	O
.	-	858	O

An	18161408	860	O
initial	-	863	O
exercise	-	871	O
stress	-	880	O
test	-	887	O
was	-	892	O
normal	-	896	O
.	-	902	O

At	18161408	904	O
the	-	907	O
time	-	911	O
of	-	916	O
admission	-	919	O
,	-	928	O
the	-	930	O
patient	-	934	O
was	-	942	O
at	-	946	O
high	-	949	O
risk	-	954	O
of	-	959	O
radiation	-	962	B
injury	-	972	I
to	-	979	O
the	-	982	O
fetus	-	986	O
,	-	991	O
so	-	993	O
a	-	996	O
coronary	-	998	O
angiogram	-	1007	O
was	-	1017	O
postponed	-	1021	O
until	-	1031	O
the	-	1037	O
second	-	1041	O
trimester	-	1048	O
.	-	1057	O

It	18161408	1059	O
showed	-	1062	O
normal	-	1069	O
coronary	-	1076	O
vessels	-	1085	O
.	-	1092	O

CONCLUSION	18161408	1094	O
:	-	1104	O

This	18161408	1106	O
appears	-	1111	O
to	-	1119	O
be	-	1122	O
the	-	1125	O
first	-	1129	O
reported	-	1135	O
case	-	1144	O
documenting	-	1149	O
a	-	1161	O
possible	-	1163	O
association	-	1172	O
between	-	1184	O
CC	-	1192	O
and	-	1195	O
myocardial	-	1199	B
infarction	-	1210	I
.	-	1220	O

Thrombosis	18161408	1222	B
might	-	1233	O
be	-	1239	O
a	-	1242	O
rare	-	1244	O
but	-	1249	O
hazardous	-	1253	O
complication	-	1263	O
of	-	1276	O
CC	-	1279	O
.	-	1281	O

Given	18161408	1283	O
this	-	1289	O
life	-	1294	O
-	-	1298	O
threatening	-	1299	O
complication	-	1311	O
,	-	1323	O
appropriate	-	1325	O
prophylactic	-	1337	O
measures	-	1350	O
should	-	1359	O
be	-	1366	O
used	-	1369	O
in	-	1374	O
high	-	1377	O
-	-	1381	O
risk	-	1382	O
woman	-	1387	O
undergoing	-	1393	O
ovarian	-	1404	O
stimulation	-	1412	O
.	-	1423	O

Hepatonecrosis	17574447	0	B
and	-	15	O
cholangitis	-	19	B
related	-	31	O
to	-	39	O
long	-	42	O
-	-	46	O
term	-	47	O
phenobarbital	-	52	O
therapy	-	66	O
:	-	73	O
an	-	75	O
autopsy	-	78	O
report	-	86	O
of	-	93	O
two	-	96	O
patients	-	100	O
.	-	108	O

Phenobarbital	17574447	110	O
(	-	124	O
PB	-	125	O
)	-	127	O
has	-	129	O
a	-	133	O
reputation	-	135	O
for	-	146	O
safety	-	150	O
,	-	156	O
and	-	158	O
it	-	162	O
is	-	165	O
commonly	-	168	O
believed	-	177	O
that	-	186	O
PB	-	191	O
-	-	193	O
related	-	194	O
increases	-	202	O
in	-	212	O
serum	-	215	O
aminotransferase	-	221	O
levels	-	238	O
do	-	245	O
not	-	248	O
indicate	-	252	O
or	-	261	O
predict	-	264	O
the	-	272	O
development	-	276	O
of	-	288	O
significant	-	291	O
chronic	-	303	O
liver	-	311	B
disease	-	317	I
.	-	324	O

Here	17574447	326	O
we	-	331	O
report	-	334	O
of	-	341	O
two	-	344	O
adult	-	348	O
patients	-	354	O
with	-	363	O
a	-	368	O
long	-	370	O
history	-	375	O
of	-	383	O
epilepsy	-	386	B
treated	-	395	O
with	-	403	O
PB	-	408	O
who	-	411	O
died	-	415	O
suddenly	-	420	O
:	-	428	O
one	-	430	O
as	-	434	O
consequence	-	437	O
of	-	449	O
cardiac	-	452	B
arrest	-	460	I
,	-	466	O
the	-	468	O
other	-	472	O
of	-	478	O
acute	-	481	O
bronchopneumonia	-	487	B
.	-	503	O

At	17574447	505	O
autopsy	-	508	O
,	-	515	O
analysis	-	517	O
of	-	526	O
liver	-	529	O
parenchyma	-	535	O
revealed	-	546	O
rich	-	555	O
portal	-	560	O
inflammatory	-	567	O
infiltrate	-	580	O
,	-	590	O
which	-	592	O
consisted	-	598	O
of	-	608	O
mixed	-	611	O
eosinophil	-	617	O
and	-	628	O
monocyte	-	632	O
cells	-	641	O
,	-	646	O
associated	-	648	O
with	-	659	O
several	-	664	O
foci	-	672	O
of	-	677	O
necrosis	-	680	B
surrounded	-	689	O
by	-	700	O
a	-	703	O
hard	-	705	O
ring	-	710	O
of	-	715	O
non	-	718	O
-	-	721	O
specific	-	722	O
granulomatous	-	731	O
tissue	-	745	O
.	-	751	O

Inflammatory	17574447	753	O
reactions	-	766	O
of	-	776	O
internal	-	779	O
and	-	788	O
external	-	792	O
hepatic	-	801	O
biliary	-	809	O
ducts	-	817	O
were	-	823	O
also	-	828	O
seen	-	833	O
.	-	837	O

Our	17574447	839	O
findings	-	843	O
illustrate	-	852	O
that	-	863	O
PB	-	868	O
may	-	871	O
be	-	875	O
associated	-	878	O
with	-	889	O
chronic	-	894	O
liver	-	902	B
damage	-	908	I
,	-	914	O
which	-	916	O
may	-	922	O
lead	-	926	O
to	-	931	O
more	-	934	O
serious	-	939	O
and	-	947	O
deleterious	-	951	O
consequences	-	963	O
.	-	975	O

For	17574447	977	O
this	-	981	O
reason	-	986	O
,	-	992	O
each	-	994	O
clinician	-	999	O
should	-	1009	O
recognize	-	1016	O
this	-	1026	O
entity	-	1031	O
in	-	1038	O
the	-	1041	O
differential	-	1045	O
diagnosis	-	1058	O
of	-	1068	O
PB	-	1071	O
-	-	1073	O
related	-	1074	O
asymptomatic	-	1082	O
chronic	-	1095	B
hepatic	-	1103	I
enzyme	-	1111	I
dysfunction	-	1118	I
.	-	1129	O

Ethambutol	16710500	0	O
-	-	10	O
associated	-	11	O
optic	-	22	B
neuropathy	-	28	I
.	-	38	O

INTRODUCTION	16710500	40	O
:	-	52	O

Ethambutol	16710500	54	O
is	-	65	O
used	-	68	O
in	-	73	O
the	-	76	O
treatment	-	80	O
of	-	90	O
tuberculosis	-	93	B
,	-	105	O
which	-	107	O
is	-	113	O
still	-	116	O
prevalent	-	122	O
in	-	132	O
Southeast	-	135	O
Asia	-	145	O
,	-	149	O
and	-	151	O
can	-	155	O
be	-	159	O
associated	-	162	O
with	-	173	O
permanent	-	178	O
visual	-	188	B
loss	-	195	I
.	-	199	O

We	16710500	201	O
report	-	204	O
3	-	211	O
cases	-	213	O
which	-	219	O
presented	-	225	O
with	-	235	O
bitemporal	-	240	B
hemianopia	-	251	I
.	-	261	O

CLINICAL	16710500	263	O
PICTURE	-	272	O
:	-	279	O

Three	16710500	281	O
patients	-	287	O
with	-	296	O
ethambutol	-	301	O
-	-	311	O
associated	-	312	O
toxic	-	323	O
optic	-	329	B
neuropathy	-	335	I
are	-	346	O
described	-	350	O
.	-	359	O

All	16710500	361	O
3	-	365	O
patients	-	367	O
had	-	376	O
loss	-	380	B
of	-	385	I
central	-	388	I
visual	-	396	I
acuity	-	403	I
,	-	409	I
colour	-	411	I
vision	-	418	I
(	-	425	I
Ishihara	-	426	I
)	-	434	I
and	-	436	I
visual	-	440	I
field	-	447	I
.	-	452	O

The	16710500	454	O
visual	-	458	B
field	-	465	I
loss	-	471	I
had	-	476	O
a	-	480	O
bitemporal	-	482	O
flavour	-	493	O
,	-	500	O
suggesting	-	502	O
involvement	-	513	O
of	-	525	O
the	-	528	O
optic	-	532	O
chiasm	-	538	O
.	-	544	O

TREATMENT	16710500	546	O
:	-	555	O

Despite	16710500	557	O
stopping	-	565	O
ethambutol	-	574	O
on	-	585	O
diagnosis	-	588	O
,	-	597	O
visual	-	599	O
function	-	606	O
continued	-	615	O
to	-	625	O
deteriorate	-	628	O
for	-	640	O
a	-	644	O
few	-	646	O
months	-	650	O
.	-	656	O

Subsequent	16710500	658	O
improvement	-	669	O
was	-	681	O
mild	-	685	O
in	-	690	O
2	-	693	O
cases	-	695	O
.	-	700	O

In	16710500	702	O
the	-	705	O
third	-	709	O
case	-	715	O
,	-	719	O
visual	-	721	O
acuity	-	728	O
and	-	735	O
colour	-	739	O
vision	-	746	O
normalised	-	753	O
but	-	764	O
the	-	768	O
optic	-	772	O
discs	-	778	O
were	-	784	O
pale	-	789	O
.	-	793	O

OUTCOME	16710500	795	O
:	-	802	O

All	16710500	804	O
3	-	808	O
patients	-	810	O
had	-	819	O
some	-	823	O
permanent	-	828	O
loss	-	838	B
of	-	843	I
visual	-	846	I
function	-	853	I
.	-	861	O

CONCLUSIONS	16710500	863	O
:	-	874	O

Ethambutol	16710500	876	O
usage	-	887	O
is	-	893	O
associated	-	896	O
with	-	907	O
permanent	-	912	O
visual	-	922	B
loss	-	929	I
and	-	934	O
should	-	938	O
be	-	945	O
avoided	-	948	O
if	-	956	O
possible	-	959	O
or	-	968	O
used	-	971	O
with	-	976	O
caution	-	981	O
and	-	989	O
proper	-	993	O
ophthalmological	-	1000	O
follow	-	1017	O
-	-	1023	O
up	-	1024	O
.	-	1026	O

The	16710500	1028	O
author	-	1032	O
postulates	-	1039	O
that	-	1050	O
in	-	1055	O
cases	-	1058	O
of	-	1064	O
ethambutol	-	1067	O
associated	-	1078	O
chiasmopathy	-	1089	O
,	-	1101	O
ethambutol	-	1103	O
may	-	1114	O
initially	-	1118	O
affect	-	1128	O
the	-	1135	O
optic	-	1139	O
nerves	-	1145	O
and	-	1152	O
subsequently	-	1156	O
progress	-	1169	O
to	-	1178	O
involve	-	1181	O
the	-	1189	O
optic	-	1193	O
chiasm	-	1199	O
.	-	1205	O

Tolerability	11694026	0	O
of	-	13	O
nimesulide	-	16	O
and	-	27	O
paracetamol	-	31	O
in	-	43	O
patients	-	46	O
with	-	55	O
NSAID	-	60	O
-	-	65	O
induced	-	66	O
urticaria	-	74	B
/	-	83	O
angioedema	-	84	B
.	-	94	O

Previous	11694026	96	O
studies	-	105	O
evaluated	-	113	O
the	-	123	O
tolerance	-	127	O
of	-	137	O
nimesulide	-	140	O
and	-	151	O
paracetamol	-	155	O
in	-	167	O
subjects	-	170	O
with	-	179	O
cutaneous	-	184	O
,	-	193	O
respiratory	-	195	O
and	-	207	O
anaphylactoid	-	211	O
reactions	-	225	O
induced	-	235	O
by	-	243	O
nonsteroidal	-	246	O
anti	-	259	O
-	-	263	O
inflammatory	-	264	O
drugs	-	277	O
(	-	283	O
NSAIDs	-	284	O
)	-	290	O
.	-	291	O

In	11694026	293	O
this	-	296	O
study	-	301	O
we	-	307	O
investigated	-	310	O
tolerability	-	323	O
and	-	336	O
reliability	-	340	O
of	-	352	O
nimesulide	-	355	O
and	-	366	O
paracetamol	-	370	O
in	-	382	O
a	-	385	O
very	-	387	O
large	-	392	O
number	-	398	O
of	-	405	O
patients	-	408	O
with	-	417	O
an	-	422	O
exclusive	-	425	O
well	-	435	O
-	-	439	O
documented	-	440	O
history	-	451	O
of	-	459	O
NSAID	-	462	O
-	-	467	O
induced	-	468	O
urticaria	-	476	B
/	-	485	O
angioedema	-	486	B
.	-	496	O

Furthermore	11694026	498	O
,	-	509	O
we	-	511	O
evaluated	-	514	O
whether	-	524	O
some	-	532	O
factors	-	537	O
have	-	545	O
the	-	550	O
potential	-	554	O
to	-	564	O
increase	-	567	O
the	-	576	O
risk	-	580	O
of	-	585	O
reaction	-	588	O
to	-	597	O
paracetamol	-	600	O
and	-	612	O
nimesulide	-	616	O
.	-	626	O

A	11694026	628	O
single	-	630	O
-	-	636	O
placebo	-	637	O
-	-	644	O
controlled	-	645	O
oral	-	656	O
challenge	-	661	O
procedure	-	671	O
with	-	681	O
nimesulide	-	686	O
or	-	697	O
paracetamol	-	700	O
was	-	712	O
applied	-	716	O
to	-	724	O
829	-	727	O
patients	-	731	O
with	-	740	O
a	-	745	O
history	-	747	O
of	-	755	O
NSAID	-	758	O
-	-	763	O
induced	-	764	O
urticaria	-	772	B
/	-	781	O
angioedema	-	782	B
.	-	792	O

A	11694026	794	O
total	-	796	O
of	-	802	O
75	-	805	O
/	-	807	O
829	-	808	O
(	-	812	O
9	-	813	O
.	-	814	O
4	-	815	O
%	-	816	O
)	-	817	O
patients	-	819	O
experienced	-	828	O
reactions	-	840	O
to	-	850	O
nimesulide	-	853	O
or	-	864	O
paracetamol	-	867	O
.	-	878	O

Of	11694026	880	O
the	-	883	O
715	-	887	O
patients	-	891	O
tested	-	900	O
with	-	907	O
nimesulide	-	912	O
62	-	923	O
(	-	926	O
8	-	927	O
.	-	928	O
6	-	929	O
%	-	930	O
)	-	931	O
showed	-	933	O
a	-	940	O
positive	-	942	O
test	-	951	O
,	-	955	O
while	-	957	O
of	-	963	O
114	-	966	O
subjects	-	970	O
submitted	-	979	O
to	-	989	O
the	-	992	O
challenge	-	996	O
with	-	1006	O
paracetamol	-	1011	O
,	-	1022	O
13	-	1024	O
(	-	1027	O
9	-	1028	O
.	-	1029	O
6	-	1030	O
%	-	1031	O
)	-	1032	O
did	-	1034	O
not	-	1038	O
tolerate	-	1042	O
this	-	1051	O
drug	-	1056	O
.	-	1060	O

Furthermore	11694026	1062	O
,	-	1073	O
18	-	1075	O
.	-	1077	O
28	-	1078	O
%	-	1080	O
of	-	1082	O
patients	-	1085	O
with	-	1094	O
a	-	1099	O
history	-	1101	O
of	-	1109	O
chronic	-	1112	O
urticaria	-	1120	B
and	-	1130	O
11	-	1134	O
.	-	1136	O
8	-	1137	O
%	-	1138	O
of	-	1140	O
subjects	-	1143	O
with	-	1152	O
an	-	1157	O
history	-	1160	O
of	-	1168	O
NSAID	-	1171	O
-	-	1176	O
induced	-	1177	O
urticaria	-	1185	B
/	-	1194	O
angioedema	-	1195	B
or	-	1206	O
angioedema	-	1209	B
alone	-	1220	O
(	-	1226	O
with	-	1227	O
or	-	1232	O
without	-	1235	O
chronic	-	1243	O
urticaria	-	1251	B
)	-	1260	O
resulted	-	1262	O
to	-	1271	O
be	-	1274	O
intolerant	-	1277	O
to	-	1288	O
alternative	-	1291	O
drugs	-	1303	O
.	-	1308	O

Taken	11694026	1310	O
together	-	1316	O
,	-	1324	O
our	-	1326	O
results	-	1330	O
confirm	-	1338	O
the	-	1346	O
good	-	1350	O
tolerability	-	1355	O
of	-	1368	O
nimesulide	-	1371	O
and	-	1382	O
paracetamol	-	1386	O
in	-	1398	O
patients	-	1401	O
who	-	1410	O
experienced	-	1414	O
urticaria	-	1426	B
/	-	1435	O
angioedema	-	1436	B
caused	-	1447	O
by	-	1454	O
NSAIDs	-	1457	O
.	-	1463	O

However	11694026	1465	O
,	-	1472	O
the	-	1474	O
risk	-	1478	O
of	-	1483	O
reaction	-	1486	O
to	-	1495	O
these	-	1498	O
alternative	-	1504	O
study	-	1516	O
drugs	-	1522	O
is	-	1528	O
statistically	-	1531	O
increased	-	1545	O
by	-	1555	O
a	-	1558	O
history	-	1560	O
of	-	1568	O
chronic	-	1571	O
urticaria	-	1579	B
and	-	1589	O
,	-	1592	O
above	-	1594	O
all	-	1600	O
,	-	1603	O
by	-	1605	O
a	-	1608	O
history	-	1610	O
of	-	1618	O
NSAID	-	1621	O
-	-	1626	O
induced	-	1627	O
angioedema	-	1635	B
.	-	1645	O

Effects	11282081	0	O
of	-	8	O
verapamil	-	11	O
on	-	21	O
atrial	-	24	B
fibrillation	-	31	I
and	-	44	O
its	-	48	O
electrophysiological	-	52	O
determinants	-	73	O
in	-	86	O
dogs	-	89	O
.	-	93	O

BACKGROUND	11282081	95	O
:	-	105	O

Atrial	11282081	107	B
tachycardia	-	114	I
-	-	125	O
induced	-	126	O
remodeling	-	134	O
promotes	-	145	O
the	-	154	O
occurrence	-	158	O
and	-	169	O
maintenance	-	173	O
of	-	185	O
atrial	-	188	B
fibrillation	-	195	I
(	-	208	O
AF	-	209	B
)	-	211	O
and	-	213	O
decreases	-	217	O
L	-	227	O
-	-	228	O
type	-	229	O
Ca	-	234	O
(	-	236	O
2	-	237	O
+	-	238	O
)	-	239	O
current	-	241	O
.	-	248	O

There	11282081	250	O
is	-	256	O
also	-	259	O
a	-	264	O
clinical	-	266	O
suggestion	-	275	O
that	-	286	O
acute	-	291	O
L	-	297	O
-	-	298	O
type	-	299	O
Ca	-	304	O
(	-	306	O
2	-	307	O
)	-	308	O
channel	-	310	O
blockade	-	318	O
can	-	327	O
promote	-	331	O
AF	-	339	B
,	-	341	O
consistent	-	343	O
with	-	354	O
an	-	359	O
AF	-	362	B
promoting	-	365	O
effect	-	375	O
of	-	382	O
Ca	-	385	O
(	-	387	O
2	-	388	O
+	-	389	O
)	-	390	O
channel	-	392	O
inhibition	-	400	O
.	-	410	O

METHODS	11282081	412	O
:	-	419	O

To	11282081	421	O
evaluate	-	424	O
the	-	433	O
potential	-	437	O
mechanisms	-	447	O
of	-	458	O
AF	-	461	B
promotion	-	464	O
by	-	474	O
Ca	-	477	O
(	-	479	O
2	-	480	O
+	-	481	O
)	-	482	O
channel	-	484	O
blockers	-	492	O
,	-	500	O
we	-	502	O
administered	-	505	O
verapamil	-	518	O
to	-	528	O
morphine	-	531	O
-	-	539	O
chloralose	-	540	O
anesthetized	-	551	O
dogs	-	564	O
.	-	568	O

Diltiazem	11282081	570	O
was	-	580	O
used	-	584	O
as	-	589	O
a	-	592	O
comparison	-	594	O
drug	-	605	O
and	-	610	O
autonomic	-	614	O
blockade	-	624	O
with	-	633	O
atropine	-	638	O
and	-	647	O
nadolol	-	651	O
was	-	659	O
applied	-	663	O
in	-	671	O
some	-	674	O
experiments	-	679	O
.	-	690	O

Epicardial	11282081	692	O
mapping	-	703	O
with	-	711	O
240	-	716	O
epicardial	-	720	O
electrodes	-	731	O
was	-	742	O
used	-	746	O
to	-	751	O
evaluate	-	754	O
activation	-	763	O
during	-	774	O
AF	-	781	B
.	-	783	O

RESULTS	11282081	785	O
:	-	792	O

Verapamil	11282081	794	O
caused	-	804	O
AF	-	811	B
promotion	-	814	O
in	-	824	O
six	-	827	O
dogs	-	831	O
,	-	835	O
increasing	-	837	O
mean	-	848	O
duration	-	853	O
of	-	862	O
AF	-	865	B
induced	-	868	O
by	-	876	O
burst	-	879	O
pacing	-	885	O
,	-	891	O
from	-	893	O
8	-	898	O
+	-	899	O
/	-	900	O
-	-	901	O
4	-	902	O
s	-	904	O
(	-	906	O
mean	-	907	O
+	-	911	O
/	-	912	O
-	-	913	O
S	-	914	O
.	-	915	O
E	-	916	O
.	-	917	O
)	-	918	O
to	-	920	O
95	-	923	O
+	-	925	O
/	-	926	O
-	-	927	O
39	-	928	O
s	-	931	O
(	-	933	O
P	-	934	O
<	-	935	O
0	-	936	O
.	-	937	O
01	-	938	O
vs	-	941	O
.	-	943	O
control	-	945	O
)	-	952	O
at	-	954	O
a	-	957	O
loading	-	959	O
dose	-	967	O
of	-	972	O
0	-	975	O
.	-	976	O
1	-	977	O
mg	-	979	O
/	-	981	O
kg	-	982	O
and	-	985	O
228	-	989	O
+	-	992	O
/	-	993	O
-	-	994	O
101	-	995	O
s	-	999	O
(	-	1001	O
P	-	1002	O
<	-	1003	O
0	-	1004	O
.	-	1005	O
0005	-	1006	O
vs	-	1011	O
.	-	1013	O
control	-	1015	O
)	-	1022	O
at	-	1024	O
a	-	1027	O
dose	-	1029	O
of	-	1034	O
0	-	1037	O
.	-	1038	O
2	-	1039	O
mg	-	1041	O
/	-	1043	O
kg	-	1044	O
.	-	1046	O

Underlying	11282081	1048	O
electrophysiological	-	1059	O
mechanisms	-	1080	O
were	-	1091	O
studied	-	1096	O
in	-	1104	O
detail	-	1107	O
in	-	1114	O
five	-	1117	O
additional	-	1122	O
dogs	-	1133	O
under	-	1138	O
control	-	1144	O
conditions	-	1152	O
and	-	1163	O
in	-	1167	O
the	-	1170	O
presence	-	1174	O
of	-	1183	O
the	-	1186	O
higher	-	1190	O
dose	-	1197	O
of	-	1202	O
verapamil	-	1205	O
.	-	1214	O

In	11282081	1216	O
these	-	1219	O
experiments	-	1225	O
,	-	1236	O
verapamil	-	1238	O
shortened	-	1248	O
mean	-	1258	O
effective	-	1263	O
refractory	-	1273	O
period	-	1284	O
(	-	1291	O
ERP	-	1292	O
)	-	1295	O
from	-	1297	O
122	-	1302	O
+	-	1305	O
/	-	1306	O
-	-	1307	O
5	-	1308	O
to	-	1310	O
114	-	1313	O
+	-	1316	O
/	-	1317	O
-	-	1318	O
4	-	1319	O
ms	-	1321	O
(	-	1324	O
P	-	1325	O
<	-	1326	O
0	-	1327	O
.	-	1328	O
02	-	1329	O
)	-	1331	O
at	-	1333	O
a	-	1336	O
cycle	-	1338	O
length	-	1344	O
of	-	1351	O
300	-	1354	O
ms	-	1358	O
,	-	1360	O
decreased	-	1362	O
ERP	-	1372	O
heterogeneity	-	1376	O
(	-	1390	O
from	-	1391	O
15	-	1396	O
+	-	1398	O
/	-	1399	O
-	-	1400	O
1	-	1401	O
to	-	1403	O
10	-	1406	O
+	-	1408	O
/	-	1409	O
-	-	1410	O
1	-	1411	O
%	-	1412	O
,	-	1413	O
P	-	1415	O
<	-	1416	O
0	-	1417	O
.	-	1418	O
05	-	1419	O
)	-	1421	O
,	-	1422	O
heterogeneously	-	1424	O
accelerated	-	1440	O
atrial	-	1452	O
conduction	-	1459	O
and	-	1470	O
decreased	-	1474	O
the	-	1484	O
cycle	-	1488	O
length	-	1494	O
of	-	1501	O
AF	-	1504	B
(	-	1507	O
94	-	1508	O
+	-	1510	O
/	-	1511	O
-	-	1512	O
4	-	1513	O
to	-	1515	O
84	-	1518	O
+	-	1520	O
/	-	1521	O
-	-	1522	O
3	-	1523	O
ms	-	1525	O
,	-	1527	O
P	-	1529	O
<	-	1530	O
0	-	1531	O
.	-	1532	O
005	-	1533	O
)	-	1536	O
.	-	1537	O

Diltiazem	11282081	1539	O
did	-	1549	O
not	-	1553	O
affect	-	1557	O
ERP	-	1564	O
,	-	1567	O
AF	-	1569	B
cycle	-	1572	O
length	-	1578	O
or	-	1585	O
AF	-	1588	B
duration	-	1591	O
,	-	1599	O
but	-	1601	O
produced	-	1605	O
conduction	-	1614	O
acceleration	-	1625	O
similar	-	1638	O
to	-	1646	O
that	-	1649	O
caused	-	1654	O
by	-	1661	O
verapamil	-	1664	O
(	-	1674	O
n	-	1675	O
=	-	1676	O
5	-	1677	O
)	-	1678	O
.	-	1679	O

In	11282081	1681	O
the	-	1684	O
presence	-	1688	O
of	-	1697	O
autonomic	-	1700	O
blockade	-	1710	O
,	-	1718	O
verapamil	-	1720	O
failed	-	1730	O
to	-	1737	O
promote	-	1740	O
AF	-	1748	B
and	-	1751	O
increased	-	1755	O
,	-	1764	O
rather	-	1766	O
than	-	1773	O
decreasing	-	1778	O
,	-	1788	O
refractoriness	-	1790	O
.	-	1804	O

Neither	11282081	1806	O
verapamil	-	1814	O
nor	-	1824	O
diltiazem	-	1828	O
affected	-	1838	O
atrial	-	1847	O
conduction	-	1854	O
in	-	1865	O
the	-	1868	O
presence	-	1872	O
of	-	1881	O
autonomic	-	1884	O
blockade	-	1894	O
.	-	1902	O

Epicardial	11282081	1904	O
mapping	-	1915	O
suggested	-	1923	O
that	-	1933	O
verapamil	-	1938	O
promoted	-	1948	O
AF	-	1957	B
by	-	1960	O
increasing	-	1963	O
the	-	1974	O
number	-	1978	O
of	-	1985	O
simultaneous	-	1988	O
wavefronts	-	2001	O
reflected	-	2012	O
by	-	2022	O
separate	-	2025	O
zones	-	2034	O
of	-	2040	O
reactivation	-	2043	O
in	-	2056	O
each	-	2059	O
cycle	-	2064	O
.	-	2069	O

CONCLUSIONS	11282081	2071	O
:	-	2082	O

Verapamil	11282081	2084	O
promotes	-	2094	O
AF	-	2103	B
in	-	2106	O
normal	-	2109	O
dogs	-	2116	O
by	-	2121	O
promoting	-	2124	O
multiple	-	2134	O
circuit	-	2143	O
reentry	-	2151	O
,	-	2158	O
an	-	2160	O
effect	-	2163	O
dependent	-	2170	O
on	-	2180	O
intact	-	2183	O
autonomic	-	2190	O
tone	-	2200	O
and	-	2205	O
not	-	2209	O
shared	-	2213	O
by	-	2220	O
diltiazem	-	2223	O
.	-	2232	O

Hypotension	10074612	0	B
,	-	11	O
bradycardia	-	13	B
,	-	24	O
and	-	26	O
asystole	-	30	B
after	-	39	O
high	-	45	O
-	-	49	O
dose	-	50	O
intravenous	-	55	O
methylprednisolone	-	67	O
in	-	86	O
a	-	89	O
monitored	-	91	O
patient	-	101	O
.	-	108	O

We	10074612	110	O
report	-	113	O
a	-	120	O
case	-	122	O
of	-	127	O
hypotension	-	130	B
,	-	141	O
bradycardia	-	143	B
,	-	154	O
and	-	156	O
asystole	-	160	B
after	-	169	O
intravenous	-	175	O
administration	-	187	O
of	-	202	O
high	-	205	O
-	-	209	O
dose	-	210	O
methylprednisolone	-	215	O
in	-	234	O
a	-	237	O
73	-	239	O
-	-	241	O
year	-	242	O
-	-	246	O
old	-	247	O
patient	-	251	O
who	-	259	O
underwent	-	263	O
electrocardiographic	-	273	O
(	-	294	O
ECG	-	295	O
)	-	298	O
monitoring	-	300	O
throughout	-	311	O
the	-	322	O
episode	-	326	O
.	-	333	O

There	10074612	335	O
was	-	341	O
a	-	345	O
history	-	347	O
of	-	355	O
ischemic	-	358	B
cardiac	-	367	B
disease	-	375	I
9	-	383	O
years	-	385	O
earlier	-	391	O
.	-	398	O

The	10074612	400	O
patient	-	404	O
was	-	412	O
admitted	-	416	O
with	-	425	O
a	-	430	O
pulmonary	-	432	B
-	-	441	I
renal	-	442	I
syndrome	-	448	I
with	-	457	O
hemoptysis	-	462	B
,	-	472	O
rapidly	-	474	O
progressive	-	482	O
renal	-	494	B
failure	-	500	I
,	-	507	O
and	-	509	O
hypoxemia	-	513	B
that	-	523	O
required	-	528	O
mechanical	-	537	O
ventilation	-	548	O
in	-	560	O
the	-	563	O
intensive	-	567	O
care	-	577	O
unit	-	582	O
.	-	586	O

After	10074612	588	O
receiving	-	594	O
advanced	-	604	O
cardiopulmonary	-	613	O
resuscitation	-	629	O
,	-	642	O
the	-	644	O
patient	-	648	O
recovered	-	656	O
cardiac	-	666	O
rhythm	-	674	O
.	-	680	O

The	10074612	682	O
ECG	-	686	O
showed	-	690	O
a	-	697	O
junctional	-	699	O
rhythm	-	710	O
without	-	717	O
ventricular	-	725	B
arrhythmia	-	737	I
.	-	747	O

This	10074612	749	O
study	-	754	O
reviews	-	760	O
the	-	768	O
current	-	772	O
proposed	-	780	O
mechanisms	-	789	O
of	-	800	O
sudden	-	803	B
death	-	810	I
after	-	816	O
a	-	822	O
high	-	824	O
dose	-	829	O
of	-	834	O
intravenous	-	837	O
methylprednisolone	-	849	O
(	-	868	O
IVMP	-	869	O
)	-	873	O
.	-	874	O

These	10074612	876	O
mechanisms	-	882	O
are	-	893	O
not	-	897	O
well	-	901	O
understood	-	906	O
because	-	917	O
,	-	924	O
in	-	926	O
most	-	929	O
cases	-	934	O
,	-	939	O
the	-	941	O
patients	-	945	O
were	-	954	O
not	-	959	O
monitored	-	963	O
at	-	973	O
the	-	976	O
moment	-	980	O
of	-	987	O
the	-	990	O
event	-	994	O
.	-	999	O

Rapid	10074612	1001	O
infusion	-	1007	O
and	-	1016	O
underlying	-	1020	O
cardiac	-	1031	B
disease	-	1039	I
were	-	1047	O
important	-	1052	O
risk	-	1062	O
factors	-	1067	O
in	-	1075	O
the	-	1078	O
case	-	1082	O
reported	-	1087	O
here	-	1096	O
,	-	1100	O
and	-	1102	O
the	-	1106	O
authors	-	1110	O
discount	-	1118	O
ventricular	-	1127	B
arrhythmia	-	1139	I
as	-	1150	O
the	-	1153	O
main	-	1157	O
mechanism	-	1162	O
.	-	1171	O

Lifetime	9209318	0	O
treatment	-	9	O
of	-	19	O
mice	-	22	O
with	-	27	O
azidothymidine	-	32	O
(	-	47	O
AZT	-	48	O
)	-	51	O
produces	-	53	O
myelodysplasia	-	62	B
.	-	76	O

AZT	9209318	78	O
has	-	82	O
induced	-	86	O
a	-	94	O
macrocytic	-	96	B
anemia	-	107	I
in	-	114	O
AIDS	-	117	B
patients	-	122	O
on	-	131	O
long	-	134	O
term	-	139	O
AZT	-	144	O
therapy	-	148	O
.	-	155	O

It	9209318	157	O
is	-	160	O
generally	-	163	O
assumed	-	173	O
that	-	181	O
DNA	-	186	O
elongation	-	190	O
is	-	201	O
stopped	-	204	O
by	-	212	O
the	-	215	O
insertion	-	219	O
of	-	229	O
AZT	-	232	O
into	-	236	O
the	-	241	O
chain	-	245	O
in	-	251	O
place	-	254	O
of	-	260	O
thymidine	-	263	O
thus	-	273	O
preventing	-	278	O
the	-	289	O
phosphate	-	293	O
hydroxyl	-	303	O
linkages	-	312	O
and	-	321	O
therefore	-	325	O
suppresses	-	335	O
hemopoietic	-	346	O
progenitor	-	358	O
cell	-	369	O
proliferation	-	374	O
in	-	388	O
an	-	391	O
early	-	394	O
stage	-	400	O
of	-	406	O
differentiation	-	409	O
.	-	424	O

CBA	9209318	426	O
/	-	429	O
Ca	-	430	O
male	-	433	O
mice	-	438	O
started	-	443	O
on	-	451	O
AZT	-	454	O
0	-	458	O
.	-	459	O
75	-	460	O
mg	-	463	O
/	-	465	O
ml	-	466	O
H2O	-	469	O
at	-	473	O
84	-	476	O
days	-	479	O
of	-	484	O
age	-	487	O
and	-	491	O
kept	-	495	O
on	-	500	O
it	-	503	O
for	-	506	O
687	-	510	O
days	-	514	O
when	-	519	O
dosage	-	524	O
reduced	-	531	O
to	-	539	O
0	-	542	O
.	-	543	O
5	-	544	O
mg	-	546	O
/	-	548	O
ml	-	549	O
H2O	-	552	O
for	-	556	O
a	-	560	O
group	-	562	O
,	-	567	O
another	-	569	O
group	-	577	O
removed	-	583	O
from	-	591	O
AZT	-	596	O
to	-	600	O
see	-	603	O
recovery	-	607	O
,	-	615	O
and	-	617	O
third	-	621	O
group	-	627	O
remained	-	633	O
on	-	642	O
0	-	645	O
.	-	646	O
75	-	647	O
mg	-	650	O
.	-	652	O

At	9209318	654	O
687	-	657	O
days	-	661	O
mice	-	666	O
that	-	671	O
had	-	676	O
been	-	680	O
on	-	685	O
0	-	688	O
.	-	689	O
75	-	690	O
mg	-	693	O
had	-	696	O
average	-	700	O
platelet	-	708	O
counts	-	717	O
of	-	724	O
2	-	727	O
.	-	728	O
5	-	729	O
x	-	731	O
10	-	733	O
(	-	735	O
6	-	736	O
)	-	737	O
.	-	738	O

Histological	9209318	740	O
examination	-	753	O
on	-	765	O
9	-	768	O
of	-	770	O
10	-	773	O
mice	-	776	O
with	-	781	O
such	-	786	O
thrombocytopenia	-	791	B
showed	-	808	O
changes	-	815	O
compatible	-	823	O
with	-	834	O
myelodysplastic	-	839	B
syndrome	-	855	I
(	-	864	O
MDS	-	865	B
)	-	868	O
.	-	869	O

A	9209318	871	O
variety	-	873	O
of	-	881	O
histological	-	884	O
patterns	-	897	O
was	-	906	O
observed	-	910	O
.	-	918	O

There	9209318	920	O
were	-	926	O
two	-	931	O
cases	-	935	O
of	-	941	O
hypocellular	-	944	O
myelodysplasia	-	957	B
,	-	971	O
two	-	973	O
cases	-	977	O
of	-	983	O
hypersegmented	-	986	O
myelodysplastic	-	1001	B
granulocytosis	-	1017	O
,	-	1031	O
two	-	1033	O
cases	-	1037	O
of	-	1043	O
hypercellular	-	1046	O
marrow	-	1060	O
with	-	1067	O
abnormal	-	1072	O
megakaryocytes	-	1081	O
with	-	1096	O
bizarre	-	1101	O
nuclei	-	1109	O
,	-	1115	O
one	-	1117	O
case	-	1121	O
of	-	1126	O
megakaryocytic	-	1129	O
myelosis	-	1144	O
associated	-	1153	O
with	-	1164	O
a	-	1169	O
hyperplastic	-	1171	B
marrow	-	1184	I
,	-	1190	O
dysmyelopoiesis	-	1192	B
and	-	1208	O
a	-	1212	O
hypocellular	-	1214	B
marrow	-	1227	I
and	-	1234	O
two	-	1238	O
cases	-	1242	O
of	-	1248	O
myelodysplasia	-	1251	B
with	-	1266	O
dyserythropoiesis	-	1271	B
,	-	1288	O
hemosiderosis	-	1290	B
and	-	1304	O
a	-	1308	O
hypocellular	-	1310	B
marrow	-	1323	I
.	-	1329	O

Above	9209318	1331	O
mentioned	-	1337	O
AZT	-	1347	O
incorporation	-	1351	O
may	-	1365	O
have	-	1369	O
induced	-	1374	O
an	-	1382	O
ineffective	-	1385	O
hemopoiesis	-	1397	O
in	-	1409	O
the	-	1412	O
primitive	-	1416	O
hemopoietic	-	1426	O
progenitor	-	1438	O
cells	-	1449	O
,	-	1454	O
which	-	1456	O
is	-	1462	O
known	-	1465	O
to	-	1471	O
be	-	1474	O
seen	-	1477	O
commonly	-	1482	O
in	-	1491	O
the	-	1494	O
myelodysplastic	-	1498	B
syndrome	-	1514	I
.	-	1522	O

Influence	8742498	0	O
of	-	10	O
diet	-	13	O
free	-	18	O
of	-	23	O
NAD	-	26	O
-	-	29	O
precursors	-	30	O
on	-	41	O
acetaminophen	-	44	O
hepatotoxicity	-	58	B
in	-	73	O
mice	-	76	O
.	-	80	O

Recently	8742498	82	O
,	-	90	O
we	-	92	O
demonstrated	-	95	O
the	-	108	O
hepatoprotective	-	112	O
effects	-	129	O
of	-	137	O
nicotinic	-	140	O
acid	-	150	O
amide	-	155	O
,	-	160	O
a	-	162	O
selective	-	164	O
inhibitor	-	174	O
of	-	184	O
poly	-	187	O
(	-	191	O
ADP	-	192	O
-	-	195	O
ribose	-	196	O
)	-	202	O
polymerase	-	204	O
(	-	215	O
PARP	-	216	O
;	-	220	O
EC	-	222	O
2	-	225	O
.	-	226	O
4	-	227	O
.	-	228	O
2	-	229	O
.	-	230	O
30	-	231	O
)	-	233	O
on	-	235	O
mice	-	238	O
suffering	-	243	O
from	-	253	O
acetaminophen	-	258	O
(	-	272	O
AAP	-	273	O
)	-	276	O
-	-	277	O
hepatitis	-	278	B
,	-	287	O
suggesting	-	289	O
that	-	300	O
the	-	305	O
AAP	-	309	O
-	-	312	O
induced	-	313	O
liver	-	321	B
injury	-	327	I
involves	-	334	O
a	-	343	O
step	-	345	O
which	-	350	O
depends	-	356	O
on	-	364	O
adenoribosylation	-	367	O
.	-	384	O

The	8742498	386	O
present	-	390	O
study	-	398	O
investigates	-	404	O
the	-	417	O
effects	-	421	O
of	-	429	O
a	-	432	O
diet	-	434	O
free	-	439	O
of	-	444	O
precursors	-	447	O
of	-	458	O
NAD	-	461	O
,	-	464	O
the	-	466	O
substrate	-	470	O
on	-	480	O
which	-	483	O
PARP	-	489	O
acts	-	494	O
,	-	498	O
in	-	500	O
female	-	503	O
NMRI	-	510	O
mice	-	515	O
with	-	520	O
AAP	-	525	O
hepatitis	-	529	B
and	-	539	O
evaluates	-	543	O
the	-	553	O
influence	-	557	O
of	-	567	O
simultaneous	-	570	O
ethanol	-	583	O
consumption	-	591	O
in	-	603	O
these	-	606	O
animals	-	612	O
.	-	619	O

Liver	8742498	621	B
injuries	-	627	I
were	-	636	O
quantified	-	641	O
as	-	652	O
serum	-	655	O
activities	-	661	O
of	-	672	O
glutamate	-	675	O
-	-	684	O
oxaloacetate	-	685	O
transaminase	-	698	O
(	-	711	O
GOT	-	712	O
)	-	715	O
and	-	717	O
glutamate	-	721	O
-	-	730	O
pyruvate	-	731	O
transaminase	-	740	O
(	-	753	O
GPT	-	754	O
)	-	757	O
.	-	758	O

While	8742498	760	O
AAP	-	766	O
caused	-	770	O
a	-	777	O
117	-	779	O
-	-	782	O
fold	-	783	O
elevation	-	788	O
of	-	798	O
serum	-	801	O
transaminase	-	807	O
activities	-	820	O
in	-	831	O
mice	-	834	O
kept	-	839	O
on	-	844	O
a	-	847	O
standard	-	849	O
laboratory	-	858	O
diet	-	869	O
,	-	873	O
which	-	875	O
was	-	881	O
significantly	-	885	O
exacerbated	-	899	O
by	-	911	O
ethanol	-	914	O
and	-	922	O
inhibited	-	926	O
by	-	936	O
nicotinic	-	939	O
acid	-	949	O
amide	-	954	O
(	-	960	O
NAA	-	961	O
)	-	964	O
,	-	965	O
adverse	-	967	O
effects	-	975	O
were	-	983	O
noted	-	988	O
in	-	994	O
animals	-	997	O
fed	-	1005	O
a	-	1009	O
diet	-	1011	O
free	-	1016	O
of	-	1021	O
precursors	-	1024	O
of	-	1035	O
NAD	-	1038	O
.	-	1041	O

In	8742498	1043	O
these	-	1046	O
animals	-	1052	O
,	-	1059	O
only	-	1061	O
minor	-	1066	O
increases	-	1072	O
of	-	1082	O
serum	-	1085	O
transaminase	-	1091	O
activities	-	1104	O
were	-	1115	O
measured	-	1120	O
in	-	1129	O
the	-	1132	O
presence	-	1136	O
of	-	1145	O
AAP	-	1148	O
,	-	1151	O
and	-	1153	O
unlike	-	1157	O
the	-	1164	O
exacerbation	-	1168	O
caused	-	1181	O
by	-	1188	O
ethanol	-	1191	O
in	-	1199	O
mice	-	1202	O
on	-	1207	O
a	-	1210	O
standard	-	1212	O
diet	-	1221	O
,	-	1225	O
the	-	1227	O
liver	-	1231	B
damage	-	1237	I
was	-	1244	O
inhibited	-	1248	O
by	-	1258	O
50	-	1261	O
%	-	1263	O
by	-	1265	O
ethanol	-	1268	O
.	-	1275	O

A	8742498	1277	O
further	-	1279	O
64	-	1287	O
%	-	1289	O
reduction	-	1291	O
of	-	1301	O
hepatitis	-	1304	B
was	-	1314	O
observed	-	1318	O
,	-	1326	O
when	-	1328	O
NAA	-	1333	O
was	-	1337	O
given	-	1341	O
to	-	1347	O
ethanol	-	1350	O
/	-	1357	O
AAP	-	1358	O
-	-	1361	O
mice	-	1362	O
.	-	1366	O

Our	8742498	1368	O
results	-	1372	O
provide	-	1380	O
evidence	-	1388	O
that	-	1397	O
the	-	1402	O
AAP	-	1406	O
-	-	1409	O
induced	-	1410	O
hepatitis	-	1418	B
and	-	1428	O
its	-	1432	O
exacerbation	-	1436	O
by	-	1449	O
ethanol	-	1452	O
can	-	1460	O
either	-	1464	O
be	-	1471	O
reduced	-	1474	O
by	-	1482	O
end	-	1485	O
-	-	1488	O
product	-	1489	O
inhibition	-	1497	O
of	-	1508	O
PARP	-	1511	O
by	-	1516	O
NAA	-	1519	O
or	-	1523	O
by	-	1526	O
dietary	-	1529	O
depletion	-	1537	O
of	-	1547	O
the	-	1550	O
enzyme	-	1554	O
's	-	1560	O
substrate	-	1563	O
NAD	-	1573	O
.	-	1576	O

We	8742498	1578	O
see	-	1581	O
the	-	1585	O
main	-	1589	O
application	-	1594	O
of	-	1606	O
NAA	-	1609	O
as	-	1613	O
for	-	1616	O
the	-	1620	O
combinational	-	1624	O
use	-	1638	O
in	-	1642	O
pharmaceutical	-	1645	O
preparations	-	1660	O
of	-	1673	O
acetaminophen	-	1676	O
in	-	1690	O
order	-	1693	O
to	-	1699	O
avoid	-	1702	O
hepatic	-	1708	B
damage	-	1716	I
in	-	1723	O
patients	-	1726	O
treated	-	1735	O
with	-	1743	O
this	-	1748	O
widely	-	1753	O
used	-	1760	O
analgesic	-	1765	O
.	-	1774	O

Antiarrhythmic	2435991	0	O
plasma	-	15	O
concentrations	-	22	O
of	-	37	O
cibenzoline	-	40	O
on	-	52	O
canine	-	55	O
ventricular	-	62	B
arrhythmias	-	74	I
.	-	85	O

Using	2435991	87	O
two	-	93	O
-	-	96	O
stage	-	97	O
coronary	-	103	O
ligation	-	112	O
-	-	120	O
,	-	121	O
digitalis	-	123	O
-	-	132	O
,	-	133	O
and	-	135	O
adrenaline	-	139	O
-	-	149	O
induced	-	150	O
canine	-	158	O
ventricular	-	165	B
arrhythmias	-	177	I
,	-	188	O
antiarrhythmic	-	190	O
effects	-	205	O
of	-	213	O
cibenzoline	-	216	O
were	-	228	O
examined	-	233	O
and	-	242	O
the	-	246	O
minimum	-	250	O
effective	-	258	O
plasma	-	268	O
concentration	-	275	O
for	-	289	O
each	-	293	O
arrhythmia	-	298	B
model	-	309	O
was	-	315	O
determined	-	319	O
.	-	329	O

Cibenzoline	2435991	331	O
suppressed	-	343	O
all	-	354	O
the	-	358	O
arrhythmias	-	362	B
,	-	373	O
and	-	375	O
the	-	379	O
minimum	-	383	O
effective	-	391	O
plasma	-	401	O
concentrations	-	408	O
for	-	423	O
arrhythmias	-	427	B
induced	-	439	O
by	-	447	O
24	-	450	O
-	-	452	O
h	-	453	O
coronary	-	455	O
ligation	-	464	O
,	-	472	O
48	-	474	O
-	-	476	O
h	-	477	O
coronary	-	479	O
ligation	-	488	O
,	-	496	O
digitalis	-	498	O
,	-	507	O
and	-	509	O
adrenaline	-	513	O
were	-	524	O
1	-	529	O
.	-	530	O
9	-	531	O
+	-	533	O
/	-	534	O
-	-	535	O

0	2435991	537	O
.	-	538	O
9	-	539	O
(	-	541	O
by	-	542	O
8	-	545	O
mg	-	547	O
/	-	549	O
kg	-	550	O
i	-	553	O
.	-	554	O
v	-	555	O
.	-	556	O
)	-	557	O
,	-	558	O
1	-	560	O
.	-	561	O
6	-	562	O
+	-	564	O
/	-	565	O
-	-	566	O
0	-	568	O
.	-	569	O
5	-	570	O
(	-	572	O
by	-	573	O
8	-	576	O
mg	-	578	O
/	-	580	O
kg	-	581	O
i	-	584	O
.	-	585	O
v	-	586	O
.	-	587	O
)	-	588	O
,	-	589	O
0	-	591	O
.	-	592	O
6	-	593	O
+	-	595	O
/	-	596	O
-	-	597	O

0	2435991	599	O
.	-	600	O
2	-	601	O
(	-	603	O
by	-	604	O
2	-	607	O
mg	-	609	O
/	-	611	O
kg	-	612	O
i	-	615	O
.	-	616	O
v	-	617	O
.	-	618	O
)	-	619	O
,	-	620	O
and	-	622	O
3	-	626	O
.	-	627	O
5	-	628	O
+	-	630	O
/	-	631	O
-	-	632	O

1	2435991	634	O
.	-	635	O
3	-	636	O
(	-	638	O
by	-	639	O
5	-	642	O
mg	-	644	O
/	-	646	O
kg	-	647	O
i	-	650	O
.	-	651	O
v	-	652	O
.	-	653	O
)	-	654	O

micrograms	2435991	656	O
/	-	666	O
ml	-	667	O
,	-	669	O
respectively	-	671	O
(	-	684	O
mean	-	685	O
+	-	690	O
/	-	691	O
-	-	692	O

SDM	2435991	694	O
,	-	697	O
n	-	699	O
=	-	701	O
6	-	703	O
-	-	704	O
7	-	705	O
)	-	706	O
.	-	707	O

The	2435991	709	O
concentration	-	713	O
for	-	727	O
adrenaline	-	731	O
-	-	741	O
induced	-	742	O
arrhythmia	-	750	B
was	-	761	O
significantly	-	765	O
higher	-	779	O
than	-	786	O
those	-	791	O
for	-	797	O
the	-	801	O
other	-	805	O
types	-	811	O
of	-	817	O
arrhythmias	-	820	B
.	-	831	O

This	2435991	833	O
pharmacological	-	838	O
profile	-	854	O
is	-	862	O
similar	-	865	O
to	-	873	O
those	-	876	O
of	-	882	O
mexiletine	-	885	O
and	-	896	O
tocainide	-	900	O
,	-	909	O
and	-	911	O
all	-	915	O
three	-	919	O
drugs	-	925	O
have	-	931	O
central	-	936	O
nervous	-	944	O
system	-	952	O
(	-	959	O
CNS	-	960	O
)	-	963	O
stimulant	-	965	O
action	-	975	O
.	-	981	O

Because	2435991	983	O
cibenzoline	-	991	O
had	-	1003	O
only	-	1007	O
weak	-	1012	O
hypotensive	-	1017	B
and	-	1029	O
sinus	-	1033	O
node	-	1039	O
depressive	-	1044	B
effects	-	1055	O
and	-	1063	O
was	-	1067	O
found	-	1071	O
to	-	1077	O
be	-	1080	O
orally	-	1083	O
active	-	1090	O
when	-	1097	O
given	-	1102	O
to	-	1108	O
coronary	-	1111	O
ligation	-	1120	O
arrhythmia	-	1129	B
dogs	-	1140	O
,	-	1144	O
its	-	1146	O
clinical	-	1150	O
usefulness	-	1159	O
is	-	1170	O
expected	-	1173	O
.	-	1181	O

Immunopathology	950631	0	O
of	-	16	O
penicillamine	-	19	O
-	-	32	O
induced	-	33	O
glomerular	-	41	B
disease	-	52	I
.	-	59	O

Four	950631	61	O
patients	-	66	O
with	-	75	O
rheumatoid	-	80	B
arthritis	-	91	I
developed	-	101	O
heavy	-	111	O
proteinuria	-	117	B
after	-	129	O
five	-	135	O
to	-	140	O
12	-	143	O
months	-	146	O
of	-	153	O
treatment	-	156	O
with	-	166	O
D	-	171	O
-	-	172	O
penicillamine	-	173	O
.	-	186	O

Light	950631	188	O
microscopy	-	194	O
of	-	205	O
renal	-	208	O
biopsy	-	214	O
samples	-	221	O
showed	-	229	O
minimal	-	236	O
glomerular	-	244	O
capillary	-	255	O
wall	-	265	O
thickening	-	270	O
and	-	281	O
mesangial	-	285	O
matrix	-	295	O
increase	-	302	O
,	-	310	O
or	-	312	O
no	-	315	O
departure	-	318	O
from	-	328	O
normal	-	333	O
.	-	339	O

Electron	950631	341	O
microscopy	-	350	O
,	-	360	O
however	-	362	O
,	-	369	O
revealed	-	371	O
subepithelial	-	380	O
electron	-	394	O
-	-	402	O
dense	-	403	O
deposits	-	409	O
,	-	417	O
fusion	-	419	O
of	-	426	O
epithelial	-	429	O
cell	-	440	O
foot	-	445	O
processes	-	450	O
,	-	459	O
and	-	461	O
evidence	-	465	O
of	-	474	O
mesangial	-	477	O
cell	-	487	O
hyperactivity	-	492	O
.	-	505	O

Immunofluorescence	950631	507	O
microscopy	-	526	O
demonstrated	-	537	O
granular	-	550	O
capillary	-	559	O
wall	-	569	O
deposits	-	574	O
of	-	583	O
IgG	-	586	O
and	-	590	O
C3	-	594	O
.	-	596	O

The	950631	598	O
findings	-	602	O
were	-	611	O
similar	-	616	O
to	-	624	O
those	-	627	O
in	-	633	O
early	-	636	O
membranous	-	642	B
glomerulonephritis	-	653	I
,	-	671	O
differences	-	673	O
being	-	685	O
observed	-	691	O
however	-	700	O
in	-	708	O
the	-	711	O
results	-	715	O
of	-	723	O
staining	-	726	O
for	-	735	O
the	-	739	O
early	-	743	O
-	-	748	O
acting	-	749	O
complement	-	756	O
components	-	767	O
C1q	-	778	O
and	-	782	O
C4	-	786	O
.	-	788	O

It	950631	790	O
is	-	793	O
tentatively	-	796	O
concluded	-	808	O
that	-	818	O
complement	-	823	O
was	-	834	O
activated	-	838	O
by	-	848	O
the	-	851	O
classical	-	855	O
pathway	-	865	O
.	-	872	O

Ventricular	663266	0	B
fibrillation	-	12	I
from	-	25	O
diatrizoate	-	30	O
with	-	42	O
and	-	47	O
without	-	51	O
chelating	-	59	O
agents	-	69	O
.	-	75	O

The	663266	77	O
toxicity	-	81	B
of	-	90	O
Renografin	-	93	O
76	-	104	O
%	-	106	O
was	-	108	O
compared	-	112	O
with	-	121	O
that	-	126	O
of	-	131	O
Hypaque	-	134	O
76	-	142	O
%	-	144	O
by	-	146	O
selective	-	149	O
injection	-	159	O
of	-	169	O
each	-	172	O
into	-	177	O
the	-	182	O
right	-	186	O
coronary	-	192	O
artery	-	201	O
of	-	208	O
dogs	-	211	O
.	-	215	O

Renografin	663266	217	O
contains	-	228	O
the	-	237	O
chelating	-	241	O
agents	-	251	O
sodium	-	258	O
citrate	-	265	O
and	-	273	O
disodium	-	277	O
edetate	-	286	O
,	-	293	O
while	-	295	O
Hypaque	-	301	O
contains	-	309	O
calcium	-	318	O
disodium	-	326	O
edetate	-	335	O
and	-	343	O
no	-	347	O
sodium	-	350	O
citrate	-	357	O
.	-	364	O

Ventricular	663266	366	B
fibrillation	-	378	I
occurred	-	391	O
significantly	-	400	O
more	-	414	O
often	-	419	O
with	-	425	O
Renografin	-	430	O
,	-	440	O
suggesting	-	442	O
that	-	453	O
chelating	-	458	O
agents	-	468	O
contribute	-	475	O
to	-	486	O
toxicity	-	489	B
in	-	498	O
coronary	-	501	O
angiography	-	510	O
.	-	521	O

Rapid	19319147	0	O
reversal	-	6	O
of	-	15	O
anticoagulation	-	18	O
reduces	-	34	O
hemorrhage	-	42	B
volume	-	53	O
in	-	60	O
a	-	63	O
mouse	-	65	O
model	-	71	O
of	-	77	O
warfarin	-	80	O
-	-	88	O
associated	-	89	O
intracerebral	-	100	B
hemorrhage	-	114	I
.	-	124	O

Warfarin	19319147	126	O
-	-	134	O
associated	-	135	O
intracerebral	-	146	B
hemorrhage	-	160	I
(	-	171	O
W	-	172	O
-	-	173	O
ICH	-	174	B
)	-	177	O
is	-	179	O
a	-	182	O
severe	-	184	O
type	-	191	O
of	-	196	O
stroke	-	199	B
.	-	205	O

There	19319147	207	O
is	-	213	O
no	-	216	O
consensus	-	219	O
on	-	229	O
the	-	232	O
optimal	-	236	O
treatment	-	244	O
for	-	254	O
W	-	258	O
-	-	259	O
ICH	-	260	B
.	-	263	O

Using	19319147	265	O
a	-	271	O
mouse	-	273	O
model	-	279	O
,	-	284	O
we	-	286	O
tested	-	289	O
whether	-	296	O
the	-	304	O
rapid	-	308	O
reversal	-	314	O
of	-	323	O
anticoagulation	-	326	O
using	-	342	O
human	-	348	O
prothrombin	-	354	O
complex	-	366	O
concentrate	-	374	O
(	-	386	O
PCC	-	387	O
)	-	390	O
can	-	392	O
reduce	-	396	O
hemorrhagic	-	403	O
blood	-	415	O
volume	-	421	O
.	-	427	O

Male	19319147	429	O
CD	-	434	O
-	-	436	O
1	-	437	O
mice	-	439	O
were	-	444	O
treated	-	449	O
with	-	457	O
warfarin	-	462	O
(	-	471	O
2	-	472	O
mg	-	474	O
/	-	476	O
kg	-	477	O
over	-	480	O
24	-	485	O
h	-	488	O
)	-	489	O
,	-	490	O
resulting	-	492	O
in	-	502	O
a	-	505	O
mean	-	507	O
(	-	512	O
+	-	513	O
/	-	514	O
-	-	515	O
s	-	516	O
.	-	517	O
d	-	518	O
.	-	519	O
)	-	520	O

International	19319147	522	O
Normalized	-	536	O
Ratio	-	547	O
of	-	553	O
3	-	556	O
.	-	557	O
5	-	558	O
+	-	559	O
/	-	560	O
-	-	561	O
0	-	562	O
.	-	563	O
9	-	564	O
.	-	565	O

First	19319147	567	O
,	-	572	O
we	-	574	O
showed	-	577	O
that	-	584	O
an	-	589	O
intravenous	-	592	O
administration	-	604	O
of	-	619	O
human	-	622	O
PCC	-	628	O
rapidly	-	632	O
reversed	-	640	O
anticoagulation	-	649	O
in	-	665	O
mice	-	668	O
.	-	672	O

Second	19319147	674	O
,	-	680	O
a	-	682	O
stereotactic	-	684	O
injection	-	697	O
of	-	707	O
collagenase	-	710	O
was	-	722	O
administered	-	726	O
to	-	739	O
induce	-	742	O
hemorrhage	-	749	B
in	-	760	O
the	-	763	O
right	-	767	O
striatum	-	773	O
.	-	781	O

Forty	19319147	783	O
-	-	788	O
five	-	789	O
minutes	-	794	O
later	-	802	O
,	-	807	O
the	-	809	O
animals	-	813	O
were	-	821	O
randomly	-	826	O
treated	-	835	O
with	-	843	O
PCC	-	848	O
(	-	852	O
100	-	853	O
U	-	857	O
/	-	858	O
kg	-	859	O
)	-	861	O
or	-	863	O
saline	-	866	O
i	-	873	O
.	-	874	O
v	-	875	O
.	-	876	O

(	19319147	878	O
n	-	879	O
=	-	880	O
12	-	881	O
per	-	884	O
group	-	888	O
)	-	893	O
.	-	894	O

Twenty	19319147	896	O
-	-	902	O
four	-	903	O
hours	-	908	O
after	-	914	O
hemorrhage	-	920	B
induction	-	931	O
,	-	940	O
hemorrhagic	-	942	O
blood	-	954	O
volume	-	960	O
was	-	967	O
quantified	-	971	O
using	-	982	O
a	-	988	O
photometric	-	990	O
hemoglobin	-	1002	O
assay	-	1013	O
.	-	1018	O

The	19319147	1020	O
mean	-	1024	O
hemorrhagic	-	1029	O
blood	-	1041	O
volume	-	1047	O
was	-	1054	O
reduced	-	1058	O
in	-	1066	O
PCC	-	1069	O
-	-	1072	O
treated	-	1073	O
animals	-	1081	O
(	-	1089	O
6	-	1090	O
.	-	1091	O
5	-	1092	O
+	-	1093	O
/	-	1094	O
-	-	1095	O
3	-	1096	O
.	-	1097	O
1	-	1098	O
microL	-	1100	O
)	-	1106	O
compared	-	1108	O
with	-	1117	O
saline	-	1122	O
controls	-	1129	O
(	-	1138	O
15	-	1139	O
.	-	1141	O
3	-	1142	O
+	-	1143	O
/	-	1144	O
-	-	1145	O
11	-	1146	O
.	-	1148	O
2	-	1149	O
microL	-	1151	O
,	-	1157	O
P	-	1159	O
=	-	1160	O
0	-	1161	O
.	-	1162	O
015	-	1163	O
)	-	1166	O
.	-	1167	O

In	19319147	1169	O
the	-	1172	O
saline	-	1176	O
group	-	1183	O
,	-	1188	O
45	-	1190	O
%	-	1192	O
of	-	1194	O
the	-	1197	O
mice	-	1201	O
developed	-	1206	O
large	-	1216	O
hematomas	-	1222	B
(	-	1232	O
i	-	1233	O
.	-	1234	O
e	-	1235	O
.	-	1236	O
,	-	1237	O
>	-	1239	O
15	-	1240	O
microL	-	1243	O
)	-	1249	O
.	-	1250	O

In	19319147	1252	O
contrast	-	1255	O
,	-	1263	O
such	-	1265	O
extensive	-	1270	O
lesions	-	1280	O
were	-	1288	O
never	-	1293	O
found	-	1299	O
in	-	1305	O
the	-	1308	O
PCC	-	1312	O
group	-	1316	O
.	-	1321	O

We	19319147	1323	O
provide	-	1326	O
experimental	-	1334	O
data	-	1347	O
suggesting	-	1352	O
PCC	-	1363	O
to	-	1367	O
be	-	1370	O
an	-	1373	O
effective	-	1376	O
acute	-	1386	O
treatment	-	1392	O
for	-	1402	O
W	-	1406	O
-	-	1407	O
ICH	-	1408	B
in	-	1412	O
terms	-	1415	O
of	-	1421	O
reducing	-	1424	O
hemorrhagic	-	1433	O
blood	-	1445	O
volume	-	1451	O
.	-	1457	O

Future	19319147	1459	O
studies	-	1466	O
are	-	1474	O
needed	-	1478	O
to	-	1485	O
assess	-	1488	O
the	-	1495	O
therapeutic	-	1499	O
potential	-	1511	O
emerging	-	1521	O
from	-	1530	O
our	-	1535	O
finding	-	1539	O
for	-	1547	O
human	-	1551	O
W	-	1557	O
-	-	1558	O
ICH	-	1559	B
.	-	1562	O

Impact	16634859	0	O
of	-	7	O
alcohol	-	10	O
exposure	-	18	O
after	-	27	O
pregnancy	-	33	O
recognition	-	43	O
on	-	55	O
ultrasonographic	-	58	O
fetal	-	75	O
growth	-	81	O
measures	-	88	O
.	-	96	O

BACKGROUND	16634859	98	O
:	-	108	O
More	-	110	O
than	-	115	O
3	-	120	O
decades	-	122	O
after	-	130	O
Jones	-	136	O
and	-	142	O
Smith	-	146	O
(	-	152	O
1973	-	153	O
)	-	157	O
reported	-	159	O
on	-	168	O
the	-	171	O
devastation	-	175	O
caused	-	187	O
by	-	194	O
alcohol	-	197	O
exposure	-	205	O
on	-	214	O
fetal	-	217	O
development	-	223	O
,	-	234	O
the	-	236	O
rates	-	240	O
of	-	246	O
heavy	-	249	O
drinking	-	255	O
during	-	264	O
pregnancy	-	271	O
remain	-	281	O
relatively	-	288	O
unchanged	-	299	O
.	-	308	O

Early	16634859	310	O
identification	-	316	O
of	-	331	O
fetal	-	334	O
alcohol	-	340	O
exposure	-	348	O
and	-	357	O
maternal	-	361	O
abstinence	-	370	O
led	-	381	O
to	-	385	O
better	-	388	O
infant	-	395	O
outcomes	-	402	O
.	-	410	O

This	16634859	412	O
study	-	417	O
examined	-	423	O
the	-	432	O
utility	-	436	O
of	-	444	O
biometry	-	447	O
for	-	456	O
detecting	-	460	O
alcohol	-	470	O
-	-	477	O
related	-	478	O
fetal	-	486	O
growth	-	492	B
impairment	-	499	I
.	-	509	O

METHODS	16634859	511	O
:	-	518	O

We	16634859	520	O
obtained	-	523	O
fetal	-	532	O
ultrasound	-	538	O
measures	-	549	O
from	-	558	O
routine	-	563	O
ultrasound	-	571	O
examinations	-	582	O
for	-	595	O
167	-	599	O
pregnant	-	603	O
hazardous	-	612	O
drinkers	-	622	O
who	-	631	O
were	-	635	O
enrolled	-	640	O
in	-	649	O
a	-	652	O
brief	-	654	O
alcohol	-	660	O
intervention	-	668	O
study	-	681	O
.	-	686	O

The	16634859	688	O
fetal	-	692	O
measures	-	698	O
for	-	707	O
women	-	711	O
who	-	717	O
quit	-	721	O
after	-	726	O
learning	-	732	O
of	-	741	O
their	-	744	O
pregnancies	-	750	O
were	-	762	O
compared	-	767	O
with	-	776	O
measures	-	781	O
for	-	790	O
women	-	794	O
who	-	800	O
continued	-	804	O
some	-	814	O
drinking	-	819	O
throughout	-	828	O
the	-	839	O
course	-	843	O
of	-	850	O
their	-	853	O
pregnancies	-	859	O
.	-	870	O

Because	16634859	872	O
intensity	-	880	O
of	-	890	O
alcohol	-	893	O
consumption	-	901	O
is	-	913	O
associated	-	916	O
with	-	927	O
poorer	-	932	O
fetal	-	939	O
outcomes	-	945	O
,	-	953	O
separate	-	955	O
analyses	-	964	O
were	-	973	O
conducted	-	978	O
for	-	988	O
the	-	992	O
heavy	-	996	O
(	-	1002	O
average	-	1003	O
of	-	1011	O
>	-	1014	O
or	-	1015	O
=	-	1017	O
5	-	1018	O
drinks	-	1020	O
per	-	1027	O
drinking	-	1031	O
day	-	1040	O
)	-	1043	O
alcohol	-	1045	O
consumers	-	1053	O
.	-	1062	O

Fetal	16634859	1064	O
measures	-	1070	O
from	-	1079	O
the	-	1084	O
heavy	-	1088	O
-	-	1093	O
exposed	-	1094	O
fetuses	-	1102	O
were	-	1110	O
also	-	1115	O
compared	-	1120	O
with	-	1129	O
measures	-	1134	O
from	-	1143	O
a	-	1148	O
nondrinking	-	1150	O
group	-	1162	O
that	-	1168	O
was	-	1173	O
representative	-	1177	O
of	-	1192	O
normal	-	1195	O
,	-	1201	O
uncomplicated	-	1203	O
pregnancies	-	1217	O
from	-	1229	O
our	-	1234	O
clinics	-	1238	O
.	-	1245	O

Analyses	16634859	1247	O
of	-	1256	O
covariance	-	1259	O
were	-	1270	O
used	-	1275	O
to	-	1280	O
determine	-	1283	O
whether	-	1293	O
there	-	1301	O
were	-	1307	O
differences	-	1312	O
between	-	1324	O
groups	-	1332	O
after	-	1339	O
controlling	-	1345	O
for	-	1357	O
influences	-	1361	O
of	-	1372	O
gestational	-	1375	O
age	-	1387	O
and	-	1391	O
drug	-	1395	B
abuse	-	1400	I
.	-	1405	O

RESULTS	16634859	1407	O
:	-	1414	O

Nearly	16634859	1416	O
half	-	1423	O
of	-	1428	O
the	-	1431	O
pregnant	-	1435	O
drinkers	-	1444	O
abstained	-	1453	O
after	-	1463	O
learning	-	1469	O
of	-	1478	O
their	-	1481	O
pregnancies	-	1487	O
.	-	1498	O

When	16634859	1500	O
women	-	1505	O
reportedly	-	1511	O
quit	-	1522	O
drinking	-	1527	O
early	-	1536	O
in	-	1542	O
their	-	1545	O
pregnancies	-	1551	O
,	-	1562	O
fetal	-	1564	O
growth	-	1570	O
measures	-	1577	O
were	-	1586	O
not	-	1591	O
significantly	-	1595	O
different	-	1609	O
from	-	1619	O
a	-	1624	O
non	-	1626	O
-	-	1629	O
alcohol	-	1630	O
-	-	1637	O
exposed	-	1638	O
group	-	1646	O
,	-	1651	O
regardless	-	1653	O
of	-	1664	O
prior	-	1667	O
drinking	-	1673	O
patterns	-	1682	O
.	-	1690	O

Any	16634859	1692	O
alcohol	-	1696	O
consumption	-	1704	O
postpregnancy	-	1716	O
recognition	-	1730	O
among	-	1742	O
the	-	1748	O
heavy	-	1752	O
drinkers	-	1758	O
resulted	-	1767	O
in	-	1776	O
reduced	-	1779	B
cerebellar	-	1787	I
growth	-	1798	I
as	-	1805	O
well	-	1808	O
as	-	1813	O
decreased	-	1816	B
cranial	-	1826	I
to	-	1834	I
body	-	1837	I
growth	-	1842	I
in	-	1849	O
comparison	-	1852	O
with	-	1863	O
women	-	1868	O
who	-	1874	O
either	-	1878	O
quit	-	1885	O
drinking	-	1890	O
or	-	1899	O
who	-	1902	O
were	-	1906	O
nondrinkers	-	1911	O
.	-	1922	O

Amphetamine	16634859	1924	O
abuse	-	1936	O
was	-	1942	O
predictive	-	1946	O
of	-	1957	O
larger	-	1960	O
cranial	-	1967	O
to	-	1975	O
body	-	1978	O
growth	-	1983	O
ratios	-	1990	O
.	-	1996	O

CONCLUSIONS	16634859	1998	O
:	-	2009	O

Alterations	16634859	2011	O
in	-	2023	O
fetal	-	2026	O
biometric	-	2032	O
measurements	-	2042	O
were	-	2055	O
observed	-	2060	O
among	-	2069	O
the	-	2075	O
heavy	-	2079	O
drinkers	-	2085	O
only	-	2094	O
when	-	2099	O
they	-	2104	O
continued	-	2109	O
drinking	-	2119	O
after	-	2128	O
becoming	-	2134	O
aware	-	2143	O
of	-	2149	O
their	-	2152	O
pregnancies	-	2158	O
.	-	2169	O

Although	16634859	2171	O
the	-	2180	O
reliance	-	2184	O
on	-	2193	O
self	-	2196	O
-	-	2200	O
reported	-	2201	O
drinking	-	2210	O
is	-	2219	O
a	-	2222	O
limitation	-	2224	O
in	-	2235	O
this	-	2238	O
study	-	2243	O
,	-	2248	O
these	-	2250	O
findings	-	2256	O
support	-	2265	O
the	-	2273	O
benefits	-	2277	O
of	-	2286	O
early	-	2289	O
abstinence	-	2295	O
and	-	2306	O
the	-	2310	O
potential	-	2314	O
for	-	2324	O
ultrasound	-	2328	O
examinations	-	2339	O
in	-	2352	O
the	-	2355	O
detection	-	2359	O
of	-	2369	O
fetal	-	2372	O
alcohol	-	2378	O
effects	-	2386	O
.	-	2393	O

Urinary	16471092	0	O
symptoms	-	8	O
and	-	17	O
quality	-	21	O
of	-	29	O
life	-	32	O
changes	-	37	O
in	-	45	O
Thai	-	48	O
women	-	53	O
with	-	59	O
overactive	-	64	B
bladder	-	75	I
after	-	83	O
tolterodine	-	89	O
treatment	-	101	O
.	-	110	O

OBJECTIVES	16471092	112	O
:	-	122	O

To	16471092	124	O
study	-	127	O
the	-	133	O
urinary	-	137	O
symptoms	-	145	O
and	-	154	O
quality	-	158	O
of	-	166	O
life	-	169	O
changes	-	174	O
in	-	182	O
Thai	-	185	O
women	-	190	O
with	-	196	O
overactive	-	201	B
bladder	-	212	I
(	-	220	O
OAB	-	221	B
)	-	224	O
after	-	226	O
tolterodine	-	232	O
treatment	-	244	O
.	-	253	O

MATERIAL	16471092	255	O
AND	-	264	O
METHOD	-	268	O
:	-	274	O

Thirty	16471092	276	O
women	-	283	O
(	-	289	O
aged	-	290	O
30	-	295	O
-	-	297	O
77	-	298	O
years	-	301	O
)	-	306	O
diagnosed	-	308	O
as	-	318	O
having	-	321	O
OAB	-	328	B
at	-	332	O
the	-	335	O
Gynecology	-	339	O
Clinic	-	350	O
,	-	356	O
King	-	358	O
Chulalongkorn	-	363	O
Memorial	-	377	O
Hospital	-	386	O
from	-	395	O
January	-	400	O
to	-	408	O
April	-	411	O
2004	-	417	O
were	-	422	O
included	-	427	O
in	-	436	O
the	-	439	O
present	-	443	O
study	-	451	O
.	-	456	O

Tolterodine	16471092	458	O
2	-	470	O
mg	-	472	O
,	-	474	O
twice	-	476	O
daily	-	482	O
was	-	488	O
given	-	492	O
.	-	497	O

After	16471092	499	O
8	-	505	O
weeks	-	507	O
treatment	-	513	O
,	-	522	O
changes	-	524	O
in	-	532	O
micturition	-	535	O
diary	-	547	O
variables	-	553	O
and	-	563	O
tolerability	-	567	O
were	-	580	O
determined	-	585	O
.	-	595	O

Short	16471092	597	O
form	-	603	O
36	-	608	O
(	-	611	O
SF36	-	612	O
)	-	616	O
questionaires	-	618	O
(	-	632	O
Thai	-	633	O
version	-	638	O
)	-	645	O
were	-	647	O
given	-	652	O
before	-	658	O
and	-	665	O
after	-	669	O
8	-	675	O
weeks	-	677	O
of	-	683	O
treatment	-	686	O
.	-	695	O

RESULTS	16471092	697	O
:	-	704	O

At	16471092	706	O
8	-	709	O
weeks	-	711	O
,	-	716	O
all	-	718	O
micturition	-	722	O
per	-	734	O
day	-	738	O
decreased	-	742	O
from	-	752	O
16	-	757	O
.	-	759	O

7	16471092	761	O
+	-	763	O
/	-	764	O
-	-	765	O
5	-	767	O
.	-	768	O

3	16471092	770	O
to	-	772	O
6	-	775	O
.	-	776	O
7	-	778	O
+	-	780	O
/	-	781	O
-	-	782	O

2	16471092	784	O
.	-	785	O
4	-	786	O
times	-	788	O
per	-	794	O
day	-	798	O
.	-	801	O

The	16471092	803	O
number	-	807	O
of	-	814	O
nocturia	-	817	B
episodes	-	826	O
decreased	-	835	O
from	-	845	O
5	-	850	O
.	-	851	O
4	-	852	O
+	-	854	O
/	-	855	O
-	-	856	O

4	16471092	858	O
.	-	859	O
2	-	860	O
to	-	862	O
1	-	865	O
.	-	866	O
1	-	867	O
+	-	869	O
/	-	870	O
-	-	871	O

1	16471092	873	O
.	-	874	O
0	-	875	O
times	-	877	O
per	-	883	O
night	-	887	O
.	-	892	O

The	16471092	894	O
most	-	898	O
common	-	903	O
side	-	910	O
effect	-	915	O
was	-	922	O
dry	-	926	B
month	-	930	I
in	-	936	O
5	-	939	O
cases	-	941	O
(	-	947	O
16	-	948	O
.	-	950	O
7	-	951	O
%	-	952	O
)	-	953	O
with	-	955	O
2	-	960	O
cases	-	962	O
reporting	-	968	O
a	-	978	O
moderate	-	980	O
degree	-	989	O
and	-	996	O
1	-	1000	O
case	-	1002	O
with	-	1007	O
severe	-	1012	O
degree	-	1019	O
.	-	1025	O

Only	16471092	1027	O
one	-	1032	O
case	-	1036	O
(	-	1041	O
3	-	1042	O
.	-	1043	O
3	-	1044	O
%	-	1045	O
)	-	1046	O
withdrew	-	1048	O
from	-	1057	O
the	-	1062	O
present	-	1066	O
study	-	1074	O
due	-	1080	O
to	-	1084	O
a	-	1087	O
severe	-	1089	O
dry	-	1096	B
mouth	-	1100	I
.	-	1105	O

The	16471092	1107	O
SF	-	1111	O
-	-	1113	O
36	-	1114	O
scores	-	1117	O
changed	-	1124	O
significantly	-	1132	O
in	-	1146	O
the	-	1149	O
domains	-	1153	O
of	-	1161	O
physical	-	1164	O
functioning	-	1173	O
,	-	1184	O
role	-	1186	O
function	-	1191	O
emotional	-	1200	O
,	-	1209	O
social	-	1211	O
function	-	1218	O
and	-	1227	O
mental	-	1231	O
heath	-	1238	O
.	-	1243	O

CONCLUSION	16471092	1245	O
:	-	1255	O

Tolterodine	16471092	1257	O
was	-	1269	O
well	-	1273	O
tolerated	-	1278	O
and	-	1288	O
its	-	1292	O
effects	-	1296	O
improved	-	1304	O
the	-	1313	O
quality	-	1317	O
of	-	1325	O
life	-	1328	O
in	-	1333	O
Thai	-	1336	O
women	-	1341	O
with	-	1347	O
OAB	-	1352	B
.	-	1355	O

Absence	16174948	0	O
of	-	8	O
acute	-	11	O
cerebral	-	17	O
vasoconstriction	-	26	O
after	-	43	O
cocaine	-	49	O
-	-	56	O
associated	-	57	O
subarachnoid	-	68	B
hemorrhage	-	81	I
.	-	91	O

INTRODUCTION	16174948	93	O
:	-	105	O

Cocaine	16174948	107	O
use	-	115	O
has	-	119	O
been	-	123	O
associated	-	128	O
with	-	139	O
neurovascular	-	144	B
complications	-	158	I
,	-	171	O
including	-	173	O
arterial	-	183	O
vasoconstriction	-	192	O
and	-	209	O
vasculitis	-	213	B
.	-	223	O

However	16174948	225	O
,	-	232	O
there	-	234	O
are	-	240	O
few	-	244	O
studies	-	248	O
of	-	256	O
angiographic	-	259	O
effects	-	272	O
of	-	280	O
cocaine	-	283	O
on	-	291	O
human	-	294	O
cerebral	-	300	O
arteries	-	309	O
.	-	317	O

Information	16174948	319	O
on	-	331	O
these	-	334	O
effects	-	340	O
could	-	348	O
be	-	354	O
obtained	-	357	O
from	-	366	O
angiograms	-	371	O
of	-	382	O
patients	-	385	O
with	-	394	O
cocaine	-	399	O
-	-	406	O
associated	-	407	O
subarachnoid	-	418	B
hemorrhage	-	431	I
(	-	442	O
SAH	-	443	B
)	-	446	O
who	-	448	O
underwent	-	452	O
angiography	-	462	O
shortly	-	474	O
after	-	482	O
cocaine	-	488	O
use	-	496	O
.	-	499	O

METHODS	16174948	501	O
:	-	508	O

We	16174948	510	O
screened	-	513	O
patients	-	522	O
with	-	531	O
SAH	-	536	B
retrospectively	-	540	O
and	-	556	O
identified	-	560	O
those	-	571	O
with	-	577	O
positive	-	582	O
urine	-	591	O
toxicology	-	597	O
for	-	608	O
cocaine	-	612	O
or	-	620	O
its	-	623	O
metabolites	-	627	O
.	-	638	O

Quantitative	16174948	640	O
arterial	-	653	O
diameter	-	662	O
measurements	-	671	O
from	-	684	O
angiograms	-	689	O
of	-	700	O
these	-	703	O
patients	-	709	O
were	-	718	O
compared	-	723	O
to	-	732	O
measurements	-	735	O
from	-	748	O
control	-	753	O
patients	-	761	O
with	-	770	O
SAH	-	775	B
who	-	779	O
were	-	783	O
matched	-	788	O
for	-	796	O
factors	-	800	O
known	-	808	O
to	-	814	O
influence	-	817	O
arterial	-	827	O
diameter	-	836	O
.	-	844	O

Qualitative	16174948	846	O
comparisons	-	858	O
of	-	870	O
small	-	873	O
artery	-	879	O
changes	-	886	O
also	-	894	O
were	-	899	O
made	-	904	O
.	-	908	O

RESULTS	16174948	910	O
:	-	917	O

Thirteen	16174948	919	O
patients	-	928	O
with	-	937	O
positive	-	942	O
cocaine	-	951	O
toxicology	-	959	O
were	-	970	O
compared	-	975	O
to	-	984	O
26	-	987	O
controls	-	990	O
.	-	998	O

There	16174948	1000	O
were	-	1006	O
no	-	1011	O
significant	-	1014	O
differences	-	1026	O
between	-	1038	O
groups	-	1046	O
in	-	1053	O
the	-	1056	O
mean	-	1060	O
diameters	-	1065	O
of	-	1075	O
the	-	1078	O
intradural	-	1082	O
internal	-	1093	O
carotid	-	1102	O
,	-	1109	O
sphenoidal	-	1111	O
segment	-	1122	O
of	-	1130	O
the	-	1133	O
middle	-	1137	O
cerebral	-	1144	O
,	-	1152	O
precommunicating	-	1154	O
segment	-	1171	O
of	-	1179	O
the	-	1182	O
anterior	-	1186	O
cerebral	-	1195	O
,	-	1203	O
or	-	1205	O
basilar	-	1208	O
arteries	-	1216	O
(	-	1225	O
p	-	1226	O
greater	-	1228	O
than	-	1236	O
0	-	1241	O
.	-	1242	O
05	-	1243	O
for	-	1246	O
all	-	1250	O
comparisons	-	1254	O
,	-	1265	O
unpaired	-	1267	O
t	-	1276	O
-	-	1277	O
tests	-	1278	O
)	-	1283	O
.	-	1284	O

There	16174948	1286	O
also	-	1292	O
were	-	1297	O
no	-	1302	O
significant	-	1305	O
differences	-	1317	O
between	-	1329	O
groups	-	1337	O
when	-	1344	O
expressing	-	1349	O
diameters	-	1360	O
as	-	1370	O
the	-	1373	O
sum	-	1377	O
of	-	1381	O
the	-	1384	O
precommunicating	-	1388	O
segment	-	1405	O
of	-	1413	O
the	-	1416	O
anterior	-	1420	O
cerebral	-	1429	O
+	-	1438	O
sphenoidal	-	1440	O
segment	-	1451	O
of	-	1459	O
the	-	1462	O
middle	-	1466	O
cerebral	-	1473	O
+	-	1482	O
supraclinoid	-	1484	O
internal	-	1497	O
carotid	-	1506	O
artery	-	1514	O
+	-	1521	O
basilar	-	1523	O
artery	-	1531	O
divided	-	1538	O
by	-	1546	O
the	-	1549	O
diameter	-	1553	O
of	-	1562	O
the	-	1565	O
petrous	-	1569	O
internal	-	1577	O
carotid	-	1586	O
artery	-	1594	O
(	-	1601	O
p	-	1602	O
greater	-	1604	O
than	-	1612	O
0	-	1617	O
.	-	1618	O
05	-	1619	O
,	-	1621	O
unpaired	-	1623	O
t	-	1632	O
-	-	1633	O
tests	-	1634	O
)	-	1639	O
.	-	1640	O

Qualitative	16174948	1642	O
assessments	-	1654	O
showed	-	1666	O
two	-	1673	O
arterial	-	1677	O
irregularities	-	1686	O
in	-	1701	O
the	-	1704	O
distal	-	1708	O
vasculature	-	1715	O
in	-	1727	O
each	-	1730	O
group	-	1735	O
.	-	1740	O

CONCLUSION	16174948	1742	O
:	-	1752	O

No	16174948	1754	O
quantitative	-	1757	O
evidence	-	1770	O
for	-	1779	O
narrowing	-	1783	O
of	-	1793	O
large	-	1796	O
cerebral	-	1802	O
arteries	-	1811	O
or	-	1820	O
qualitative	-	1823	O
angiographic	-	1835	O
evidence	-	1848	O
for	-	1857	O
distal	-	1861	O
narrowing	-	1868	O
or	-	1878	O
vasculitis	-	1881	B
could	-	1892	O
be	-	1898	O
found	-	1901	O
in	-	1907	O
patients	-	1910	O
who	-	1919	O
underwent	-	1923	O
angiography	-	1933	O
after	-	1945	O
aneurysmal	-	1951	B
SAH	-	1962	B
associated	-	1966	O
with	-	1977	O
cocaine	-	1982	O
use	-	1990	O
.	-	1993	O

Atrial	15042318	0	B
fibrillation	-	7	I
following	-	20	O
chemotherapy	-	30	O
for	-	43	O
stage	-	47	O
IIIE	-	53	O
diffuse	-	58	O
large	-	66	O
B	-	72	O
-	-	73	O
cell	-	74	O
gastric	-	79	B
lymphoma	-	87	I
in	-	96	O
a	-	99	O
patient	-	101	O
with	-	109	O
myotonic	-	114	B
dystrophy	-	123	I
(	-	133	O
Steinert	-	134	B
's	-	142	I
disease	-	145	I
)	-	152	O
.	-	153	O

The	15042318	155	O
authors	-	159	O
describe	-	167	O
the	-	176	O
unusual	-	180	O
association	-	188	O
between	-	200	O
diffuse	-	208	O
B	-	216	O
-	-	217	O
cell	-	218	O
gastric	-	223	B
lymphoma	-	231	I
and	-	240	O
myotonic	-	244	B
dystrophy	-	253	I
,	-	262	O
the	-	264	O
most	-	268	O
common	-	273	O
form	-	280	O
of	-	285	O
adult	-	288	O
muscular	-	294	B
dystrophy	-	303	I
,	-	312	O
and	-	314	O
sudden	-	318	O
atrial	-	325	B
fibrillation	-	332	I
following	-	345	O
one	-	355	O
cycle	-	359	O
of	-	365	O
doxorubicin	-	368	O
-	-	379	O
based	-	380	O
chemotherapy	-	386	O
in	-	399	O
the	-	402	O
same	-	406	O
patient	-	411	O
.	-	418	O

Atrial	15042318	420	B
fibrillation	-	427	I
or	-	440	O
other	-	443	O
cardiac	-	449	B
arrhythmias	-	457	I
are	-	469	O
unusual	-	473	O
complications	-	481	O
in	-	495	O
patients	-	498	O
treated	-	507	O
with	-	515	O
chemotherapy	-	520	O
.	-	532	O

The	15042318	534	O
cardiac	-	538	B
toxicity	-	546	I
intrinsically	-	555	O
associated	-	569	O
with	-	580	O
the	-	585	O
aggressive	-	589	O
chemotherapy	-	600	O
employed	-	613	O
could	-	622	O
function	-	628	O
as	-	637	O
a	-	640	O
triggering	-	642	O
factor	-	653	O
for	-	660	O
the	-	664	O
arrhythmia	-	668	B
in	-	679	O
the	-	682	O
predisposed	-	686	O
myocardium	-	698	O
of	-	709	O
this	-	712	O
patient	-	717	O
.	-	724	O

A	12448656	0	O
phase	-	2	O
II	-	8	O
study	-	11	O
of	-	17	O
thalidomide	-	20	O
in	-	32	O
advanced	-	35	O
metastatic	-	44	O
renal	-	55	B
cell	-	61	I
carcinoma	-	66	I
.	-	75	O

OBJECTIVES	12448656	77	O
:	-	87	O

To	12448656	89	O
evaluate	-	92	O
the	-	101	O
toxicity	-	105	B
and	-	114	O
activity	-	118	O
of	-	127	O
thalidomide	-	130	O
in	-	142	O
patients	-	145	O
with	-	154	O
advanced	-	159	O
metastatic	-	168	O
renal	-	179	B
cell	-	185	I
cancer	-	190	I
and	-	197	O
to	-	201	O
measure	-	204	O
changes	-	212	O
of	-	220	O
one	-	223	O
angiogenic	-	227	O
factor	-	238	O
,	-	244	O
vascular	-	246	O
endothelial	-	255	O
growth	-	267	O
factor	-	274	O
(	-	281	O
VEGF	-	282	O
)	-	286	O
165	-	287	O
,	-	290	O
with	-	292	O
therapy	-	297	O
.	-	304	O

PATIENTS	12448656	306	O
AND	-	315	O
METHODS	-	319	O
:	-	326	O

29	12448656	328	O
patients	-	331	O
were	-	340	O
enrolled	-	345	O
on	-	354	O
a	-	357	O
study	-	359	O
of	-	365	O
thalidomide	-	368	O
using	-	380	O
an	-	386	O
intra	-	389	O
-	-	394	O
patient	-	395	O
dose	-	403	O
escalation	-	408	O
schedule	-	419	O
.	-	427	O

Patients	12448656	429	O
began	-	438	O
thalidomide	-	444	O
at	-	456	O
400	-	459	O
mg	-	463	O
/	-	465	O
d	-	466	O
and	-	468	O
escalated	-	472	O
as	-	482	O
tolerated	-	485	O
to	-	495	O
1200	-	498	O
mg	-	503	O
/	-	505	O
d	-	506	O
by	-	508	O
day	-	511	O
54	-	515	O
.	-	517	O

Fifty	12448656	519	O
-	-	524	O
nine	-	525	O
per	-	530	O
cent	-	534	O
of	-	539	O
patients	-	542	O
had	-	551	O
had	-	555	O
previous	-	559	O
therapy	-	568	O
with	-	576	O
IL	-	581	O
-	-	583	O
2	-	584	O
and	-	586	O
52	-	590	O
%	-	592	O
were	-	594	O
performance	-	599	O
status	-	611	O
2	-	618	O
or	-	620	O
3	-	623	O
.	-	624	O

Systemic	12448656	626	O
plasma	-	635	O
VEGF165	-	642	O
levels	-	650	O
were	-	657	O
measured	-	662	O
by	-	671	O
dual	-	674	O
monoclonal	-	679	O
ELISA	-	690	O
in	-	696	O
8	-	699	O
patients	-	701	O
.	-	709	O

RESULTS	12448656	711	O
:	-	718	O

24	12448656	720	O
patients	-	723	O
were	-	732	O
evaluable	-	737	O
for	-	747	O
response	-	751	O
with	-	760	O
one	-	765	O
partial	-	769	O
response	-	777	O
of	-	786	O
11	-	789	O
months	-	792	O
duration	-	799	O
of	-	808	O
a	-	811	O
patient	-	813	O
with	-	821	O
hepatic	-	826	O
and	-	834	O
pulmonary	-	838	O
metastases	-	848	B
(	-	859	O
4	-	860	O
%	-	861	O
)	-	862	O
,	-	863	O
one	-	865	O
minor	-	869	O
response	-	875	O
,	-	883	O
and	-	885	O
2	-	889	O
patients	-	891	O
stable	-	900	O
for	-	907	O
over	-	911	O
6	-	916	O
months	-	918	O
.	-	924	O

Somnolence	12448656	926	B
and	-	937	O
constipation	-	941	B
were	-	954	O
prominent	-	959	O
toxicities	-	969	B
and	-	980	O
most	-	984	O
patients	-	989	O
could	-	998	O
not	-	1004	O
tolerate	-	1008	O
the	-	1017	O
1200	-	1021	O
mg	-	1026	O
/	-	1028	O
day	-	1029	O
dose	-	1033	O
level	-	1038	O
.	-	1043	O

Systemic	12448656	1045	O
plasma	-	1054	O
VEGF165	-	1061	O
levels	-	1069	O
did	-	1076	O
not	-	1080	O
change	-	1084	O
with	-	1091	O
therapy	-	1096	O
.	-	1103	O

CONCLUSION	12448656	1105	O
:	-	1115	O

These	12448656	1117	O
results	-	1123	O
are	-	1131	O
consistent	-	1135	O
with	-	1146	O
a	-	1151	O
low	-	1153	O
level	-	1157	O
of	-	1163	O
activity	-	1166	O
of	-	1175	O
thalidomide	-	1178	O
in	-	1190	O
renal	-	1193	B
cell	-	1199	I
carcinoma	-	1204	I
.	-	1213	O

Administration	12448656	1215	O
of	-	1230	O
doses	-	1233	O
over	-	1239	O
800	-	1244	O
mg	-	1248	O
/	-	1250	O
day	-	1251	O
was	-	1255	O
difficult	-	1259	O
to	-	1269	O
achieve	-	1272	O
in	-	1280	O
this	-	1283	O
patient	-	1288	O
population	-	1296	O
,	-	1306	O
however	-	1308	O
lower	-	1316	O
doses	-	1322	O
were	-	1328	O
practical	-	1333	O
.	-	1342	O

The	12448656	1344	O
dose	-	1348	O
-	-	1352	O
response	-	1353	O
relationship	-	1362	O
,	-	1374	O
if	-	1376	O
any	-	1379	O
,	-	1382	O
of	-	1384	O
thalidomide	-	1387	O
for	-	1399	O
renal	-	1403	B
cell	-	1409	I
carcinoma	-	1414	I
is	-	1424	O
unclear	-	1427	O
.	-	1434	O

The	12231232	0	O
striatum	-	4	O
as	-	13	O
a	-	16	O
target	-	18	O
for	-	25	O
anti	-	29	O
-	-	33	O
rigor	-	34	O
effects	-	40	O
of	-	48	O
an	-	51	O
antagonist	-	54	O
of	-	65	O
mGluR1	-	68	O
,	-	74	O
but	-	76	O
not	-	80	O
an	-	84	O
agonist	-	87	O
of	-	95	O
group	-	98	O
II	-	104	O
metabotropic	-	107	O
glutamate	-	120	O
receptors	-	130	O
.	-	139	O

The	12231232	141	O
aim	-	145	O
of	-	149	O
the	-	152	O
present	-	156	O
study	-	164	O
was	-	170	O
to	-	174	O
find	-	177	O
out	-	182	O
whether	-	186	O
the	-	194	O
metabotropic	-	198	O
receptor	-	211	O
1	-	220	O
(	-	222	O
mGluR1	-	223	O
)	-	229	O
and	-	231	O
group	-	235	O
II	-	241	O
mGluRs	-	244	O
,	-	250	O
localized	-	252	O
in	-	262	O
the	-	265	O
striatum	-	269	O
,	-	277	O
are	-	279	O
involved	-	283	O
in	-	292	O
antiparkinsonian	-	295	O
-	-	311	O
like	-	312	O
effects	-	317	O
in	-	325	O
rats	-	328	O
.	-	332	O

Haloperidol	12231232	334	O
(	-	346	O
1	-	347	O
mg	-	349	O
/	-	351	O
kg	-	352	O
ip	-	355	O
)	-	357	O
induced	-	359	O
parkinsonian	-	367	B
-	-	379	O
like	-	380	O
muscle	-	385	B
rigidity	-	392	I
,	-	400	O
measured	-	402	O
as	-	411	O
an	-	414	O
increased	-	417	O
resistance	-	427	O
of	-	438	O
a	-	441	O
rat	-	443	O
's	-	446	O
hind	-	449	O
foot	-	454	O
to	-	459	O
passive	-	462	O
flexion	-	470	O
and	-	478	O
extension	-	482	O
at	-	492	O
the	-	495	O
ankle	-	499	O
joint	-	505	O
.	-	510	O

(	12231232	512	O
RS	-	513	O
)	-	515	O
-	-	516	O
1	-	517	O
-	-	518	O
aminoindan	-	519	O
-	-	529	O
1	-	530	O
,	-	531	O
5	-	532	O
-	-	533	O
dicarboxylic	-	534	O
acid	-	547	O
(	-	552	O
AIDA	-	553	O
;	-	557	O
0	-	559	O
.	-	560	O
5	-	561	O
-	-	562	O
15	-	563	O
microg	-	566	O
/	-	572	O
0	-	573	O
.	-	574	O
5	-	575	O
microl	-	577	O
)	-	583	O
,	-	584	O
a	-	586	O
potent	-	588	O
and	-	595	O
selective	-	599	O
mGluR1	-	609	O
antagonist	-	616	O
,	-	626	O
or	-	628	O
(	-	631	O
2R	-	632	O
,	-	634	O
4R	-	635	O
)	-	637	O
-	-	638	O
4	-	639	O
-	-	640	O
aminopyrrolidine	-	641	O
-	-	657	O
2	-	658	O
,	-	659	O
4	-	660	O
-	-	661	O
dicarboxylate	-	662	O
(	-	676	O
2R	-	677	O
,	-	679	O
4R	-	680	O
-	-	682	O
APDC	-	683	O
;	-	687	O
7	-	689	O
.	-	690	O
5	-	691	O
-	-	692	O
15	-	693	O
microg	-	696	O
/	-	702	O
0	-	703	O
.	-	704	O
5	-	705	O
microl	-	707	O
)	-	713	O
,	-	714	O
a	-	716	O
selective	-	718	O
group	-	728	O
II	-	734	O
agonist	-	737	O
,	-	744	O
was	-	746	O
injected	-	750	O
bilaterally	-	759	O
into	-	771	O
the	-	776	O
striatum	-	780	O
of	-	789	O
haloperidol	-	792	O
-	-	803	O
treated	-	804	O
animals	-	812	O
.	-	819	O

AIDA	12231232	821	O
in	-	826	O
doses	-	829	O
of	-	835	O
7	-	838	O
.	-	839	O
5	-	840	O
-	-	841	O
15	-	842	O
microg	-	845	O
/	-	851	O
0	-	852	O
.	-	853	O
5	-	854	O
microl	-	856	O
diminished	-	863	O
the	-	874	O
haloperidol	-	878	O
-	-	889	O
induced	-	890	O
muscle	-	898	B
rigidity	-	905	I
.	-	913	O

In	12231232	915	O
contrast	-	918	O
,	-	926	O
2R	-	928	O
,	-	930	O
4R	-	931	O
-	-	933	O
APDC	-	934	O
injections	-	939	O
were	-	950	O
ineffective	-	955	O
.	-	966	O

The	12231232	968	O
present	-	972	O
results	-	980	O
may	-	988	O
suggest	-	992	O
that	-	1000	O
the	-	1005	O
blockade	-	1009	O
of	-	1018	O
striatal	-	1021	O
mGluR1	-	1030	O
,	-	1036	O
but	-	1038	O
not	-	1042	O
the	-	1046	O
stimulation	-	1050	O
of	-	1062	O
group	-	1065	O
II	-	1071	O
mGluRs	-	1074	O
,	-	1080	O
may	-	1082	O
ameliorate	-	1086	O
parkinsonian	-	1097	B
muscle	-	1110	B
rigidity	-	1117	I
.	-	1125	O

Acute	11847945	0	O
cholestatic	-	6	B
hepatitis	-	18	I
after	-	28	O
exposure	-	34	O
to	-	43	O
isoflurane	-	46	O
.	-	56	O

OBJECTIVE	11847945	58	O
:	-	67	O

To	11847945	69	O
report	-	72	O
a	-	79	O
case	-	81	O
of	-	86	O
acute	-	89	O
cholestatic	-	95	B
hepatitis	-	107	I
following	-	117	O
exposure	-	127	O
to	-	136	O
the	-	139	O
inhalational	-	143	O
anesthetic	-	156	O
isoflurane	-	167	O
.	-	177	O

CASE	11847945	179	O
SUMMARY	-	184	O
:	-	191	O

A	11847945	193	O
70	-	195	O
-	-	197	O
year	-	198	O
-	-	202	O
old	-	203	O
healthy	-	207	O
woman	-	215	O
from	-	221	O
Iraq	-	226	O
developed	-	231	O
acute	-	241	O
cholestatic	-	247	B
hepatitis	-	259	I
3	-	269	O
weeks	-	271	O
following	-	277	O
repair	-	287	O
of	-	294	O
the	-	297	O
right	-	301	O
rotator	-	307	O
cuff	-	315	O
under	-	320	O
general	-	326	O
anesthesia	-	334	O
.	-	344	O

There	11847945	346	O
was	-	352	O
no	-	356	O
evidence	-	359	O
for	-	368	O
viral	-	372	O
,	-	377	O
autoimmune	-	379	O
,	-	389	O
or	-	391	O
metabolic	-	394	O
causes	-	404	O
of	-	411	O
hepatitis	-	414	B
.	-	423	O

No	11847945	425	O
other	-	428	O
medications	-	434	O
were	-	446	O
involved	-	451	O
except	-	460	O
for	-	467	O
dipyrone	-	471	O
for	-	480	O
analgesia	-	484	B
.	-	493	O

The	11847945	495	O
alanine	-	499	O
aminotransferase	-	507	O
was	-	524	O
elevated	-	528	O
to	-	537	O
a	-	540	O
peak	-	542	O
concentration	-	547	O
of	-	561	O
1533	-	564	O
U	-	569	O
/	-	570	O
L	-	571	O
and	-	573	O
the	-	577	O
serum	-	581	O
bilirubin	-	587	O
reached	-	597	O
a	-	605	O
peak	-	607	O
of	-	612	O
17	-	615	O
.	-	617	O
0	-	618	O
mg	-	620	O
/	-	622	O
dL	-	623	O
.	-	625	O
There	-	627	O
was	-	633	O
slow	-	637	O
improvement	-	642	O
over	-	654	O
4	-	659	O
months	-	661	O
.	-	667	O

Accidental	11847945	669	O
reexposure	-	680	O
by	-	691	O
the	-	694	O
patient	-	698	O
to	-	706	O
dipyrone	-	709	O
was	-	718	O
uneventful	-	722	O
.	-	732	O

DISCUSSION	11847945	734	O
:	-	744	O

The	11847945	746	O
clinical	-	750	O
and	-	759	O
histologic	-	763	O
picture	-	774	O
of	-	782	O
this	-	785	O
case	-	790	O
resembles	-	795	O
halothane	-	805	B
hepatitis	-	815	I
,	-	824	O
which	-	826	O
has	-	832	O
a	-	836	O
significant	-	838	O
mortality	-	850	O
rate	-	860	O
.	-	864	O

CONCLUSIONS	11847945	866	O
:	-	877	O

Isoflurane	11847945	879	O
,	-	889	O
a	-	891	O
common	-	893	O
anesthetic	-	900	O
agent	-	911	O
,	-	916	O
can	-	918	O
cause	-	922	O
severe	-	928	O
cholestatic	-	935	B
hepatitis	-	947	I
.	-	956	O

Calcitonin	11284996	0	O
gene	-	11	O
-	-	15	O
related	-	16	O
peptide	-	24	O
levels	-	32	O
during	-	39	O
nitric	-	46	O
oxide	-	53	O
-	-	58	O
induced	-	59	O
headache	-	67	B
in	-	76	O
patients	-	79	O
with	-	88	O
chronic	-	93	O
tension	-	101	B
-	-	108	I
type	-	109	I
headache	-	114	I
.	-	122	O

It	11284996	124	O
has	-	127	O
been	-	131	O
proposed	-	136	O
that	-	145	O
nitric	-	150	O
oxide	-	157	O
(	-	163	O
NO	-	164	O
)	-	166	O
induced	-	168	O
headache	-	176	B
in	-	185	O
primary	-	188	B
headaches	-	196	I
may	-	206	O
be	-	210	O
associated	-	213	O
with	-	224	O
release	-	229	O
of	-	237	O
calcitonin	-	240	O
gene	-	251	O
-	-	255	O
related	-	256	O
peptide	-	264	O
(	-	272	O
CGRP	-	273	O
)	-	277	O
.	-	278	O

In	11284996	280	O
the	-	283	O
present	-	287	O
study	-	295	O
we	-	301	O
aimed	-	304	O
to	-	310	O
investigate	-	313	O
plasma	-	325	O
levels	-	332	O
of	-	339	O
CGRP	-	342	O
during	-	347	O
headache	-	354	B
induced	-	363	O
by	-	371	O
the	-	374	O
NO	-	378	O
donor	-	381	O
glyceryl	-	387	O
trinitrate	-	396	O
(	-	407	O
GTN	-	408	O
)	-	411	O
in	-	413	O
16	-	416	O
patients	-	419	O
with	-	428	O
chronic	-	433	O
tension	-	441	B
-	-	448	I
type	-	449	I
headache	-	454	I
and	-	463	O
16	-	467	O
healthy	-	470	O
controls	-	478	O
.	-	486	O

The	11284996	488	O
subjects	-	492	O
were	-	501	O
randomly	-	506	O
allocated	-	515	O
to	-	525	O
receive	-	528	O
0	-	536	O
.	-	537	O
5	-	538	O
microg	-	540	O
/	-	546	O
kg	-	547	O
/	-	549	O
min	-	550	O
GTN	-	554	O
or	-	558	O
placebo	-	561	O
over	-	569	O
20	-	574	O
min	-	577	O
on	-	581	O
two	-	584	O
headache	-	588	B
-	-	596	O
free	-	597	O
days	-	602	O
.	-	606	O

Blood	11284996	608	O
samples	-	614	O
were	-	622	O
collected	-	627	O
at	-	637	O
baseline	-	640	O
,	-	648	O
10	-	650	O
,	-	652	O
20	-	654	O
and	-	657	O
60	-	661	O
min	-	664	O
after	-	668	O
start	-	674	O
of	-	680	O
infusion	-	683	O
.	-	691	O

Both	11284996	693	O
patients	-	698	O
and	-	707	O
controls	-	711	O
developed	-	720	O
significantly	-	730	O
stronger	-	744	O
immediate	-	753	O
headache	-	763	B
on	-	772	O
the	-	775	O
GTN	-	779	O
day	-	783	O
than	-	787	O
on	-	792	O
the	-	795	O
placebo	-	799	O
day	-	807	O
and	-	811	O
the	-	815	O
headache	-	819	B
was	-	828	O
significantly	-	832	O
more	-	846	O
pronounced	-	851	O
in	-	862	O
patients	-	865	O
than	-	874	O
in	-	879	O
controls	-	882	O
.	-	890	O

There	11284996	892	O
was	-	898	O
no	-	902	O
difference	-	905	O
between	-	916	O
the	-	924	O
area	-	928	O
under	-	933	O
the	-	939	O
CGRP	-	943	O
curve	-	948	O
(	-	954	O
AUCCGRP	-	955	O
)	-	962	O
on	-	964	O
GTN	-	967	O
vs	-	971	O
.	-	973	O
placebo	-	975	O
day	-	983	O
in	-	987	O
either	-	990	O
patients	-	997	O
(	-	1006	O
P	-	1007	O
=	-	1008	O
0	-	1009	O
.	-	1010	O
65	-	1011	O
)	-	1013	O
or	-	1015	O
controls	-	1018	O
(	-	1027	O
P	-	1028	O
=	-	1029	O
0	-	1030	O
.	-	1031	O
48	-	1032	O
)	-	1034	O
.	-	1035	O

The	11284996	1037	O
AUCCGRP	-	1041	O
recorded	-	1049	O
on	-	1058	O
the	-	1061	O
GTN	-	1065	O
day	-	1069	O
did	-	1073	O
not	-	1077	O
differ	-	1081	O
between	-	1088	O
patients	-	1096	O
and	-	1105	O
controls	-	1109	O
(	-	1118	O
P	-	1119	O
=	-	1120	O
0	-	1121	O
.	-	1122	O
36	-	1123	O
)	-	1125	O
.	-	1126	O

Both	11284996	1128	O
in	-	1133	O
patients	-	1136	O
and	-	1145	O
controls	-	1149	O
,	-	1157	O
CGRP	-	1159	O
levels	-	1164	O
changed	-	1171	O
significantly	-	1179	O
over	-	1193	O
time	-	1198	O
,	-	1202	O
on	-	1204	O
both	-	1207	O
the	-	1212	O
GTN	-	1216	O
and	-	1220	O
placebo	-	1224	O
days	-	1232	O
(	-	1237	O
P	-	1238	O
<	-	1240	O
0	-	1242	O
.	-	1243	O
05	-	1244	O
)	-	1246	O
.	-	1247	O

The	11284996	1249	O
present	-	1253	O
study	-	1261	O
indicates	-	1267	O
that	-	1277	O
NO	-	1282	O
-	-	1284	O
induced	-	1285	O
immediate	-	1293	O
headache	-	1303	B
is	-	1312	O
not	-	1315	O
associated	-	1319	O
with	-	1330	O
release	-	1335	O
of	-	1343	O
CGRP	-	1346	O
.	-	1350	O

Myocardial	11078231	0	B
ischemia	-	11	I
due	-	20	O
to	-	24	O
coronary	-	27	B
artery	-	36	I
spasm	-	43	I
during	-	49	O
dobutamine	-	56	O
stress	-	67	O
echocardiography	-	74	O
.	-	90	O

Dobutamine	11078231	92	O
stress	-	103	O
echocardiography	-	110	O
(	-	127	O
DSE	-	128	O
)	-	131	O
is	-	133	O
a	-	136	O
useful	-	138	O
and	-	145	O
safe	-	149	O
provocation	-	154	O
test	-	166	O
for	-	171	O
myocardial	-	175	B
ischemia	-	186	I
.	-	194	O

Until	11078231	196	O
now	-	202	O
,	-	205	O
the	-	207	O
test	-	211	O
has	-	216	O
been	-	220	O
focused	-	225	O
only	-	233	O
on	-	238	O
the	-	241	O
organic	-	245	O
lesion	-	253	O
in	-	260	O
the	-	263	O
coronary	-	267	O
artery	-	276	O
,	-	282	O
and	-	284	O
positive	-	288	O
DSE	-	297	O
has	-	301	O
indicated	-	305	O
the	-	315	O
presence	-	319	O
of	-	328	O
significant	-	331	O
fixed	-	343	O
coronary	-	349	B
artery	-	358	I
stenosis	-	365	I
.	-	373	O

The	11078231	375	O
aim	-	379	O
of	-	383	O
the	-	386	O
present	-	390	O
study	-	398	O
is	-	404	O
to	-	407	O
examine	-	410	O
whether	-	418	O
myocardial	-	426	B
ischemia	-	437	I
due	-	446	O
to	-	450	O
coronary	-	453	B
spasm	-	462	I
is	-	468	O
induced	-	471	O
by	-	479	O
dobutamine	-	482	O
.	-	492	O

We	11078231	494	O
performed	-	497	O
DSE	-	507	O
on	-	511	O
51	-	514	O
patients	-	517	O
with	-	526	O
coronary	-	531	B
spastic	-	540	I
angina	-	548	I
but	-	555	O
without	-	559	O
significant	-	567	O
fixed	-	579	O
coronary	-	585	B
artery	-	594	I
stenosis	-	601	I
.	-	609	O

All	11078231	611	O
patients	-	615	O
had	-	624	O
anginal	-	628	B
attacks	-	636	O
at	-	644	O
rest	-	647	O
with	-	652	O
ST	-	657	O
elevation	-	660	O
on	-	670	O
the	-	673	O
electrocardiogram	-	677	O
(	-	695	O
variant	-	696	B
angina	-	704	I
)	-	710	O
.	-	711	O

Coronary	11078231	713	O
spasm	-	722	O
was	-	728	O
induced	-	732	O
by	-	740	O
intracoronary	-	743	O
injection	-	757	O
of	-	767	O
acetylcholine	-	770	O
,	-	783	O
and	-	785	O
no	-	789	O
fixed	-	792	O
coronary	-	798	B
artery	-	807	I
stenosis	-	814	I
was	-	823	O
documented	-	827	O
on	-	838	O
angiograms	-	841	O
in	-	852	O
all	-	855	O
patients	-	859	O
.	-	867	O

DSE	11078231	869	O
was	-	873	O
performed	-	877	O
with	-	887	O
intravenous	-	892	O
dobutamine	-	904	O
infusion	-	915	O
with	-	924	O
an	-	929	O
incremental	-	932	O
doses	-	944	O
of	-	950	O
5	-	953	O
,	-	954	O
10	-	956	O
,	-	958	O
20	-	960	O
,	-	962	O
30	-	964	O
,	-	966	O
and	-	968	O
40	-	972	O
microg	-	975	O
/	-	981	O
kg	-	982	O
/	-	984	O
min	-	985	O
every	-	989	O
5	-	995	O
minutes	-	997	O
.	-	1004	O

Of	11078231	1006	O
the	-	1009	O
51	-	1013	O
patients	-	1016	O
,	-	1024	O
7	-	1026	O
patients	-	1028	O
showed	-	1037	O
asynergy	-	1044	O
with	-	1053	O
ST	-	1058	O
elevation	-	1061	O
.	-	1070	O

All	11078231	1072	O
7	-	1076	O
patients	-	1078	O
(	-	1087	O
13	-	1088	O
.	-	1090	O
7	-	1091	O
%	-	1092	O
)	-	1093	O
had	-	1095	O
chest	-	1099	B
pain	-	1105	I
during	-	1110	O
asynergy	-	1117	O
,	-	1125	O
and	-	1127	O
both	-	1131	O
chest	-	1136	B
pain	-	1142	I
and	-	1147	O
electrocardiographic	-	1151	O
changes	-	1172	O
were	-	1180	O
preceded	-	1185	O
by	-	1194	O
asynergy	-	1197	O
.	-	1205	O

These	11078231	1207	O
findings	-	1213	O
indicate	-	1222	O
that	-	1231	O
dobutamine	-	1236	O
can	-	1247	O
provoke	-	1251	O
coronary	-	1259	B
spasm	-	1268	I
in	-	1274	O
some	-	1277	O
patients	-	1282	O
with	-	1291	O
coronary	-	1296	B
spastic	-	1305	I
angina	-	1313	I
.	-	1319	O

When	11078231	1321	O
DSE	-	1326	O
is	-	1330	O
performed	-	1333	O
to	-	1343	O
evaluate	-	1346	O
coronary	-	1355	B
artery	-	1364	I
disease	-	1371	I
,	-	1378	O
not	-	1380	O
only	-	1384	O
fixed	-	1389	O
coronary	-	1395	B
stenosis	-	1404	I
,	-	1412	O
but	-	1414	O
also	-	1418	O
coronary	-	1423	B
spasm	-	1432	I
should	-	1438	O
be	-	1445	O
considered	-	1448	O
as	-	1459	O
a	-	1462	O
genesis	-	1464	O
of	-	1472	O
asynergy	-	1475	O
.	-	1483	O

Nitric	10523326	0	O
oxide	-	7	O
synthase	-	13	O
expression	-	22	O
in	-	33	O
the	-	36	O
course	-	40	O
of	-	47	O
lead	-	50	O
-	-	54	O
induced	-	55	O
hypertension	-	63	B
.	-	75	O

We	10523326	77	O
recently	-	80	O
showed	-	89	O
elevated	-	96	O
reactive	-	105	O
oxygen	-	114	O
species	-	121	O
(	-	129	O
ROS	-	130	O
)	-	133	O
,	-	134	O
reduced	-	136	O
urinary	-	144	O
excretion	-	152	O
of	-	162	O
NO	-	165	O
metabolites	-	168	O
(	-	180	O
NOx	-	181	O
)	-	184	O
,	-	185	O
and	-	187	O
increased	-	191	O
NO	-	201	O
sequestration	-	204	O
as	-	218	O
nitrotyrosine	-	221	O
in	-	235	O
various	-	238	O
tissues	-	246	O
in	-	254	O
rats	-	257	O
with	-	262	O
lead	-	267	O
-	-	271	O
induced	-	272	O
hypertension	-	280	B
.	-	292	O

This	10523326	294	O
study	-	299	O
was	-	305	O
designed	-	309	O
to	-	318	O
discern	-	321	O
whether	-	329	O
the	-	337	O
reduction	-	341	O
in	-	351	O
urinary	-	354	O
NOx	-	362	O
in	-	366	O
lead	-	369	O
-	-	373	O
induced	-	374	O
hypertension	-	382	B
is	-	395	O
,	-	397	O
in	-	399	O
part	-	402	O
,	-	406	O
due	-	408	O
to	-	412	O
depressed	-	415	O
NO	-	425	O
synthase	-	428	O
(	-	437	O
NOS	-	438	O
)	-	441	O
expression	-	443	O
.	-	453	O

Male	10523326	455	O
Sprague	-	460	O
-	-	467	O
Dawley	-	468	O
rats	-	475	O
were	-	480	O
randomly	-	485	O
assigned	-	494	O
to	-	503	O
a	-	506	O
lead	-	508	O
-	-	512	O
treated	-	513	O
group	-	521	O
(	-	527	O
given	-	528	O
lead	-	534	O
acetate	-	539	O
,	-	546	O
100	-	548	O
ppm	-	552	O
,	-	555	O
in	-	557	O
drinking	-	560	O
water	-	569	O
and	-	575	O
regular	-	579	O
rat	-	587	O
chow	-	591	O
)	-	595	O
,	-	596	O
a	-	598	O
group	-	600	O
given	-	606	O
lead	-	612	O
and	-	617	O
vitamin	-	621	O
E	-	629	O
-	-	630	O
fortified	-	631	O
chow	-	641	O
,	-	645	O
or	-	647	O
a	-	650	O
normal	-	652	O
control	-	659	O
group	-	667	O
given	-	673	O
either	-	679	O
regular	-	686	O
food	-	694	O
and	-	699	O
water	-	703	O
or	-	709	O
vitamin	-	712	O
E	-	720	O
-	-	721	O
fortified	-	722	O
food	-	732	O
for	-	737	O
12	-	741	O
weeks	-	744	O
.	-	749	O

Tail	10523326	751	O
blood	-	756	O
pressure	-	762	O
,	-	770	O
urinary	-	772	O
NOx	-	780	O
excretion	-	784	O
,	-	793	O
plasma	-	795	O
malondialdehyde	-	802	O
(	-	818	O
MDA	-	819	O
)	-	822	O
,	-	823	O
and	-	825	O
endothelial	-	829	O
and	-	841	O
inducible	-	845	O
NOS	-	855	O
(	-	859	O
eNOS	-	860	O
and	-	865	O
iNOS	-	869	O
)	-	873	O
isotypes	-	875	O
in	-	884	O
the	-	887	O
aorta	-	891	O
and	-	897	O
kidney	-	901	O
were	-	908	O
measured	-	913	O
.	-	921	O

The	10523326	923	O
lead	-	927	O
-	-	931	O
treated	-	932	O
group	-	940	O
exhibited	-	946	O
a	-	956	O
rise	-	958	O
in	-	963	O
blood	-	966	O
pressure	-	972	O
and	-	981	O
plasma	-	985	O
MDA	-	992	O
concentration	-	996	O
,	-	1009	O
a	-	1011	O
fall	-	1013	O
in	-	1018	O
urinary	-	1021	O
NOx	-	1029	O
excretion	-	1033	O
,	-	1042	O
and	-	1044	O
a	-	1048	O
paradoxical	-	1050	O
rise	-	1062	O
in	-	1067	O
vascular	-	1070	O
and	-	1079	O
renal	-	1083	O
tissue	-	1089	O
eNOS	-	1096	O
and	-	1101	O
iNOS	-	1105	O
expression	-	1110	O
.	-	1120	O

Vitamin	10523326	1122	O
E	-	1130	O
supplementation	-	1132	O
ameliorated	-	1148	O
hypertension	-	1160	B
,	-	1172	O
lowered	-	1174	O
plasma	-	1182	O
MDA	-	1189	O
concentration	-	1193	O
,	-	1206	O
and	-	1208	O
raised	-	1212	O
urinary	-	1219	O
NOx	-	1227	O
excretion	-	1231	O
while	-	1241	O
significantly	-	1247	O
lowering	-	1261	O
vascular	-	1270	O
,	-	1278	O
but	-	1280	O
not	-	1284	O
renal	-	1288	O
,	-	1293	O
tissue	-	1295	O
eNOS	-	1302	O
and	-	1307	O
iNOS	-	1311	O
expression	-	1316	O
.	-	1326	O

Vitamin	10523326	1328	O
E	-	1336	O
supplementation	-	1338	O
had	-	1354	O
no	-	1358	O
effect	-	1361	O
on	-	1368	O
either	-	1371	O
blood	-	1378	O
pressure	-	1384	O
,	-	1392	O
plasma	-	1394	O
MDA	-	1401	O
,	-	1404	O
or	-	1406	O
NOS	-	1409	O
expression	-	1413	O
in	-	1424	O
the	-	1427	O
control	-	1431	O
group	-	1439	O
.	-	1444	O

The	10523326	1446	O
study	-	1450	O
also	-	1456	O
revealed	-	1461	O
significant	-	1470	O
inhibition	-	1482	O
of	-	1493	O
NOS	-	1496	O
enzymatic	-	1500	O
activity	-	1510	O
by	-	1519	O
lead	-	1522	O
in	-	1527	O
cell	-	1530	O
-	-	1534	O
free	-	1535	O
preparations	-	1540	O
.	-	1552	O

In	10523326	1554	O
conclusion	-	1557	O
,	-	1567	O
lead	-	1569	O
-	-	1573	O
induced	-	1574	O
hypertension	-	1582	B
in	-	1595	O
this	-	1598	O
model	-	1603	O
was	-	1609	O
associated	-	1613	O
with	-	1624	O
a	-	1629	O
compensatory	-	1631	O
upregulation	-	1644	O
of	-	1657	O
renal	-	1660	O
and	-	1666	O
vascular	-	1670	O
eNOS	-	1679	O
and	-	1684	O
iNOS	-	1688	O
expression	-	1693	O
.	-	1703	O

This	10523326	1705	O
is	-	1710	O
,	-	1712	O
in	-	1714	O
part	-	1717	O
,	-	1721	O
due	-	1723	O
to	-	1727	O
ROS	-	1730	O
-	-	1733	O
mediated	-	1734	O
NO	-	1743	O
inactivation	-	1746	O
,	-	1758	O
lead	-	1760	O
-	-	1764	O
associated	-	1765	O
inhibition	-	1776	O
of	-	1787	O
NOS	-	1790	O
activity	-	1794	O
,	-	1802	O
and	-	1804	O
perhaps	-	1808	O
stimulatory	-	1816	O
actions	-	1828	O
of	-	1836	O
increased	-	1839	O
shear	-	1849	O
stress	-	1855	O
associated	-	1862	O
with	-	1873	O
hypertension	-	1878	B
.	-	1890	O

Risk	9867728	0	O
for	-	5	O
valvular	-	9	B
heart	-	18	I
disease	-	24	I
among	-	32	O
users	-	38	O
of	-	44	O
fenfluramine	-	47	O
and	-	60	O
dexfenfluramine	-	64	O
who	-	80	O
underwent	-	84	O
echocardiography	-	94	O
before	-	111	O
use	-	118	O
of	-	122	O
medication	-	125	O
.	-	135	O

BACKGROUND	9867728	137	O
:	-	147	O

Because	9867728	149	O
uncontrolled	-	157	O
echocardiographic	-	170	O
surveys	-	188	O
suggested	-	196	O
that	-	206	O
up	-	211	O
to	-	214	O
30	-	217	O
%	-	219	O
to	-	221	O
38	-	224	O
%	-	226	O
of	-	228	O
users	-	231	O
of	-	237	O
fenfluramine	-	240	O
and	-	253	O
dexfenfluramine	-	257	O
had	-	273	O
valvular	-	277	B
disease	-	286	I
,	-	293	O
these	-	295	O
drugs	-	301	O
were	-	307	O
withdrawn	-	312	O
from	-	322	O
the	-	327	O
market	-	331	O
.	-	337	O

OBJECTIVE	9867728	339	O
:	-	348	O

To	9867728	350	O
determine	-	353	O
the	-	363	O
risk	-	367	O
for	-	372	O
new	-	376	O
or	-	380	O
worsening	-	383	O
valvular	-	393	B
abnormalities	-	402	I
among	-	416	O
users	-	422	O
of	-	428	O
fenfluramine	-	431	O
or	-	444	O
dexfenfluramine	-	447	O
who	-	463	O
underwent	-	467	O
echocardiography	-	477	O
before	-	494	O
they	-	501	O
began	-	506	O
to	-	512	O
take	-	515	O
these	-	520	O
medications	-	526	O
.	-	537	O

DESIGN	9867728	539	O
:	-	545	O

Cohort	9867728	547	O
study	-	554	O
.	-	559	O

SETTING	9867728	561	O
:	-	568	O

Academic	9867728	570	O
primary	-	579	O
care	-	587	O
practices	-	592	O
.	-	601	O

PATIENTS	9867728	603	O
:	-	611	O
46	-	613	O
patients	-	616	O
who	-	625	O
used	-	629	O
fenfluramine	-	634	O
or	-	647	O
dexfenfluramine	-	650	O
for	-	666	O
14	-	670	O
days	-	673	O
or	-	678	O
more	-	681	O
and	-	686	O
had	-	690	O
echocardiograms	-	694	O
obtained	-	710	O
before	-	719	O
therapy	-	726	O
.	-	733	O

MEASUREMENTS	9867728	735	O
:	-	747	O
Follow	-	749	O
-	-	755	O
up	-	756	O
echocardiography	-	759	O
.	-	775	O

The	9867728	777	O
primary	-	781	O
outcome	-	789	O
was	-	797	O
new	-	801	O
or	-	805	O
worsening	-	808	O
valvulopathy	-	818	B
,	-	830	O
defined	-	832	O
as	-	840	O
progression	-	843	O
of	-	855	O
either	-	858	O
aortic	-	865	B
or	-	872	I
mitral	-	875	I
regurgitation	-	882	I
by	-	896	O
at	-	899	O
least	-	902	O
one	-	908	O
degree	-	912	O
of	-	919	O
severity	-	922	O
and	-	931	O
disease	-	935	O
that	-	943	O
met	-	948	O
U	-	952	O
.	-	953	O
S	-	954	O
.	-	955	O
Food	-	957	O
and	-	962	O
Drug	-	966	O
Administration	-	971	O
criteria	-	986	O
(	-	995	O
at	-	996	O
least	-	999	O
mild	-	1005	O
aortic	-	1010	B
regurgitation	-	1017	I
or	-	1031	O
moderate	-	1034	O
mitral	-	1043	B
regurgitation	-	1050	I
)	-	1063	O
.	-	1064	O

RESULTS	9867728	1066	O
:	-	1073	O

Two	9867728	1075	O
patients	-	1079	O
(	-	1088	O
4	-	1089	O
.	-	1090	O
3	-	1091	O
%	-	1092	O
[	-	1094	O
95	-	1095	O
%	-	1097	O
CI	-	1099	O
,	-	1101	O
0	-	1103	O
.	-	1104	O
6	-	1105	O
%	-	1106	O
to	-	1108	O
14	-	1111	O
.	-	1113	O
8	-	1114	O
%	-	1115	O
]	-	1116	O
)	-	1117	O
receiving	-	1119	O
fenfluramine	-	1129	O
-	-	1141	O
phentermine	-	1142	O
developed	-	1154	O
valvular	-	1164	B
heart	-	1173	I
disease	-	1179	I
.	-	1186	O

One	9867728	1188	O
had	-	1192	O
baseline	-	1196	O
bicuspid	-	1205	B
aortic	-	1214	I
valve	-	1221	I
and	-	1227	O
mild	-	1231	O
aortic	-	1236	B
regurgitation	-	1243	I
that	-	1257	O
progressed	-	1262	O
to	-	1273	O
moderate	-	1276	O
regurgitation	-	1285	O
.	-	1298	O

The	9867728	1300	O
second	-	1304	O
patient	-	1311	O
developed	-	1319	O
new	-	1329	O
moderate	-	1333	O
aortic	-	1342	B
insufficiency	-	1349	I
.	-	1362	O

CONCLUSION	9867728	1364	O
:	-	1374	O

Users	9867728	1376	O
of	-	1382	O
diet	-	1385	O
medications	-	1390	O
are	-	1402	O
at	-	1406	O
risk	-	1409	O
for	-	1414	O
valvular	-	1418	B
heart	-	1427	I
disease	-	1433	I
.	-	1440	O

However	9867728	1442	O
,	-	1449	O
the	-	1451	O
incidence	-	1455	O
may	-	1465	O
be	-	1469	O
lower	-	1472	O
than	-	1478	O
that	-	1483	O
reported	-	1488	O
previously	-	1497	O
.	-	1507	O

Carboplatin	9636837	0	O
toxic	-	12	O
effects	-	18	O
on	-	26	O
the	-	29	O
peripheral	-	33	O
nervous	-	44	O
system	-	52	O
of	-	59	O
the	-	62	O
rat	-	66	O
.	-	69	O

BACKGROUND	9636837	71	O
:	-	81	O

The	9636837	83	O
most	-	87	O
striking	-	92	O
of	-	101	O
carboplatin	-	104	O
's	-	115	O
advantages	-	118	O
(	-	129	O
CBDCA	-	130	O
)	-	135	O
over	-	137	O
cisplatin	-	142	O
(	-	152	O
CDDP	-	153	O
)	-	157	O
is	-	159	O
its	-	162	O
markedly	-	166	O
reduced	-	175	O
rate	-	183	O
of	-	188	O
neurotoxic	-	191	B
effects	-	202	O
.	-	209	O

However	9636837	211	O
,	-	218	O
the	-	220	O
use	-	224	O
of	-	228	O
CBDCA	-	231	O
higher	-	237	O
-	-	243	O
intensity	-	244	O
schedules	-	254	O
and	-	264	O
the	-	268	O
association	-	272	O
with	-	284	O
other	-	289	O
neurotoxic	-	295	B
drugs	-	306	O
in	-	312	O
polychemotherapy	-	315	O
may	-	332	O
cause	-	336	O
some	-	342	O
concern	-	347	O
about	-	355	O
its	-	361	O
safety	-	365	O
with	-	372	O
respect	-	377	O
to	-	385	O
peripheral	-	388	B
nervous	-	399	I
system	-	407	I
damage	-	414	I
.	-	420	O

MATERIALS	9636837	422	O
AND	-	432	O
METHODS	-	436	O
:	-	443	O

Two	9636837	445	O
different	-	449	O
schedules	-	459	O
of	-	469	O
CBDCA	-	472	O
administration	-	478	O
(	-	493	O
10	-	494	O
mg	-	497	O
/	-	499	O
kg	-	500	O
and	-	503	O
15	-	507	O
mg	-	510	O
/	-	512	O
kg	-	513	O
i	-	516	O
.	-	517	O
p	-	518	O
.	-	519	O

twice	9636837	521	O
a	-	527	O
week	-	529	O
for	-	534	O
nine	-	538	O
times	-	543	O
)	-	548	O
were	-	550	O
evaluated	-	555	O
in	-	565	O
Wistar	-	568	O
rats	-	575	O
.	-	579	O

Neurotoxicity	9636837	581	B
was	-	595	O
assessed	-	599	O
for	-	608	O
behavioral	-	612	O
(	-	623	O
tail	-	624	O
-	-	628	O
flick	-	629	O
test	-	635	O
)	-	639	O
,	-	640	O
neurophysiological	-	642	O
(	-	661	O
nerve	-	662	O
conduction	-	668	O
velocity	-	679	O
in	-	688	O
the	-	691	O
tail	-	695	O
nerve	-	700	O
)	-	705	O
,	-	706	O
morphological	-	708	O
,	-	721	O
morphometrical	-	723	O
and	-	738	O
analytical	-	742	O
effects	-	753	O
.	-	760	O

RESULTS	9636837	762	O
:	-	769	O

CBDCA	9636837	771	O
administration	-	777	O
induced	-	792	O
dose	-	800	O
-	-	804	O
dependent	-	805	O
peripheral	-	815	B
neurotoxicity	-	826	I
.	-	839	O

Pain	9636837	841	B
perception	-	846	O
and	-	857	O
nerve	-	861	O
conduction	-	867	O
velocity	-	878	O
in	-	887	O
the	-	890	O
tail	-	894	O
were	-	899	O
significantly	-	904	O
impaired	-	918	O
,	-	926	O
particularly	-	928	O
after	-	941	O
the	-	947	O
high	-	951	O
-	-	955	O
dose	-	956	O
treatment	-	961	O
.	-	970	O

The	9636837	972	O
dorsal	-	976	O
root	-	983	O
ganglia	-	988	O
sensory	-	996	O
neurons	-	1004	O
and	-	1012	O
,	-	1015	O
to	-	1017	O
a	-	1020	O
lesser	-	1022	O
extent	-	1029	O
,	-	1035	O
satellite	-	1037	O
cells	-	1047	O
showed	-	1053	O
the	-	1060	O
same	-	1064	O
changes	-	1069	O
as	-	1077	O
those	-	1080	O
induced	-	1086	O
by	-	1094	O
CDDP	-	1097	O
,	-	1101	O
mainly	-	1103	O
affecting	-	1110	O
the	-	1120	O
nucleus	-	1124	O
and	-	1132	O
nucleolus	-	1136	O
of	-	1146	O
ganglionic	-	1149	O
sensory	-	1160	O
neurons	-	1168	O
.	-	1175	O

Moreover	9636837	1177	O
,	-	1185	O
significant	-	1187	O
amounts	-	1199	O
of	-	1207	O
platinum	-	1210	O
were	-	1219	O
detected	-	1224	O
in	-	1233	O
the	-	1236	O
dorsal	-	1240	O
root	-	1247	O
ganglia	-	1252	O
and	-	1260	O
kidney	-	1264	O
after	-	1271	O
CBDCA	-	1277	O
treatment	-	1283	O
.	-	1292	O

CONCLUSIONS	9636837	1294	O
:	-	1305	O

CBDCA	9636837	1307	O
is	-	1313	O
neurotoxic	-	1316	B
in	-	1327	O
our	-	1330	O
model	-	1334	O
,	-	1339	O
and	-	1341	O
the	-	1345	O
type	-	1349	O
of	-	1354	O
pathological	-	1357	O
changes	-	1370	O
it	-	1378	O
induces	-	1381	O
are	-	1389	O
so	-	1393	O
closely	-	1396	O
similar	-	1404	O
to	-	1412	O
those	-	1415	O
caused	-	1421	O
by	-	1428	O
CDDP	-	1431	O
that	-	1436	O
it	-	1441	O
is	-	1444	O
probable	-	1447	O
that	-	1456	O
neurotoxicity	-	1461	B
is	-	1475	O
induced	-	1478	O
in	-	1486	O
the	-	1489	O
two	-	1493	O
drugs	-	1497	O
by	-	1503	O
the	-	1506	O
same	-	1510	O
mechanism	-	1515	O
.	-	1524	O

This	9636837	1526	O
model	-	1531	O
can	-	1537	O
be	-	1541	O
used	-	1544	O
alone	-	1549	O
or	-	1555	O
in	-	1558	O
combination	-	1561	O
with	-	1573	O
other	-	1578	O
drugs	-	1584	O
to	-	1590	O
explore	-	1593	O
the	-	1601	O
effect	-	1605	O
of	-	1612	O
CBDCA	-	1615	O
on	-	1621	O
the	-	1624	O
peripheral	-	1628	O
nervous	-	1639	O
system	-	1647	O
.	-	1653	O

Iatrogenic	9579567	0	O
risks	-	11	O
of	-	17	O
endometrial	-	20	B
carcinoma	-	32	I
after	-	42	O
treatment	-	48	O
for	-	58	O
breast	-	62	B
cancer	-	69	I
in	-	76	O
a	-	79	O
large	-	81	O
French	-	87	O
case	-	94	O
-	-	98	O
control	-	99	O
study	-	107	O
.	-	112	O

F	9579567	114	O
d	-	117	O
ration	-	120	O
Nationale	-	127	O
des	-	137	O
Centres	-	141	O
de	-	149	O
Lutte	-	152	O
Contre	-	158	O
le	-	165	O
Cancer	-	168	O
(	-	175	O
FNCLCC	-	176	O
)	-	182	O
.	-	183	O

Since	9579567	185	O
tamoxifen	-	191	O
is	-	201	O
widely	-	204	O
used	-	211	O
in	-	216	O
breast	-	219	B
cancer	-	226	I
treatment	-	233	O
and	-	243	O
has	-	247	O
been	-	251	O
proposed	-	256	O
for	-	265	O
the	-	269	O
prevention	-	273	O
of	-	284	O
breast	-	287	B
cancer	-	294	I
,	-	300	O
its	-	302	O
endometrial	-	306	O
iatrogenic	-	318	O
effects	-	329	O
must	-	337	O
be	-	342	O
carefully	-	345	O
examined	-	355	O
.	-	363	O

We	9579567	365	O
have	-	368	O
investigated	-	373	O
the	-	386	O
association	-	390	O
between	-	402	O
endometrial	-	410	B
cancer	-	422	I
and	-	429	O
tamoxifen	-	433	O
use	-	443	O
or	-	447	O
other	-	450	O
treatments	-	456	O
in	-	467	O
women	-	470	O
treated	-	476	O
for	-	484	O
breast	-	488	B
cancer	-	495	I
in	-	502	O
a	-	505	O
case	-	507	O
-	-	511	O
control	-	512	O
study	-	520	O
.	-	525	O

Cases	9579567	527	O
of	-	533	O
endometrial	-	536	B
cancer	-	548	I
diagnosed	-	555	O
after	-	565	O
breast	-	571	B
cancer	-	578	I
(	-	585	O
n	-	586	O
=	-	588	O
135	-	590	O
)	-	593	O
and	-	595	O
467	-	599	O
controls	-	603	O
matched	-	612	O
for	-	620	O
age	-	624	O
,	-	627	O
year	-	629	O
of	-	634	O
diagnosis	-	637	O
of	-	647	O
breast	-	650	B
cancer	-	657	I
and	-	664	O
hospital	-	668	O
and	-	677	O
survival	-	681	O
time	-	690	O
with	-	695	O
an	-	700	O
intact	-	703	O
uterus	-	710	O
were	-	717	O
included	-	722	O
.	-	730	O

Women	9579567	732	O
who	-	738	O
had	-	742	O
received	-	746	O
tamoxifen	-	755	O
were	-	765	O
significantly	-	770	O
more	-	784	O
likely	-	789	O
to	-	796	O
have	-	799	O
endometrial	-	804	B
cancer	-	816	I
diagnosed	-	823	O
than	-	833	O
those	-	838	O
who	-	844	O
had	-	848	O
not	-	852	O
(	-	856	O
crude	-	857	O
relative	-	863	O
risk	-	872	O
=	-	877	O
4	-	879	O
.	-	880	O
9	-	881	O
,	-	882	O
p	-	884	O
=	-	886	O
0	-	888	O
.	-	889	O
0001	-	890	O
)	-	894	O
.	-	895	O

Univariate	9579567	897	O
and	-	908	O
adjusted	-	912	O
analyses	-	921	O
showed	-	930	O
that	-	937	O
the	-	942	O
risk	-	946	O
increased	-	951	O
with	-	961	O
the	-	966	O
length	-	970	O
of	-	977	O
treatment	-	980	O
(	-	990	O
p	-	991	O
=	-	993	O
0	-	995	O
.	-	996	O
0001	-	997	O
)	-	1001	O
or	-	1003	O
the	-	1006	O
cumulative	-	1010	O
dose	-	1021	O
of	-	1026	O
tamoxifen	-	1029	O
received	-	1039	O
(	-	1048	O
p	-	1049	O
=	-	1051	O
0	-	1053	O
.	-	1054	O
0001	-	1055	O
)	-	1059	O
,	-	1060	O
irrespective	-	1062	O
of	-	1075	O
the	-	1078	O
daily	-	1082	O
dose	-	1088	O
.	-	1092	O

Women	9579567	1094	O
who	-	1100	O
had	-	1104	O
undergone	-	1108	O
pelvic	-	1118	O
radiotherapy	-	1125	O
also	-	1138	O
had	-	1143	O
a	-	1147	O
higher	-	1149	O
risk	-	1156	O
(	-	1161	O
crude	-	1162	O
relative	-	1168	O
risk	-	1177	O
=	-	1182	O
7	-	1184	O
.	-	1185	O
8	-	1186	O
,	-	1187	O
p	-	1189	O
=	-	1191	O
0	-	1193	O
.	-	1194	O
0001	-	1195	O
)	-	1199	O
.	-	1200	O

After	9579567	1202	O
adjusting	-	1208	O
for	-	1218	O
confounding	-	1222	O
factors	-	1234	O
,	-	1241	O
the	-	1243	O
risk	-	1247	O
was	-	1252	O
higher	-	1256	O
for	-	1263	O
tamoxifen	-	1267	O
users	-	1277	O
(	-	1283	O
p	-	1284	O
=	-	1286	O
0	-	1288	O
.	-	1289	O
0012	-	1290	O
)	-	1294	O
,	-	1295	O
treatment	-	1297	O
for	-	1307	O
more	-	1311	O
than	-	1316	O
3	-	1321	O
years	-	1323	O
(	-	1329	O
all	-	1330	O
p	-	1334	O
<	-	1336	O
0	-	1338	O
.	-	1339	O
03	-	1340	O
)	-	1342	O
and	-	1344	O
pelvic	-	1348	O
radiotherapy	-	1355	O
(	-	1368	O
p	-	1369	O
=	-	1371	O
0	-	1373	O
.	-	1374	O
012	-	1375	O
)	-	1378	O
.	-	1379	O

Women	9579567	1381	O
who	-	1387	O
had	-	1391	O
endometrial	-	1395	B
cancer	-	1407	I
and	-	1414	O
had	-	1418	O
received	-	1422	O
tamoxifen	-	1431	O
had	-	1441	O
more	-	1445	O
advanced	-	1450	B
disease	-	1459	I
and	-	1467	O
poorer	-	1471	O
prognosis	-	1478	O
than	-	1488	O
those	-	1493	O
with	-	1499	O
endometrial	-	1504	B
cancer	-	1516	I
who	-	1523	O
had	-	1527	O
not	-	1531	O
received	-	1535	O
this	-	1544	O
treatment	-	1549	O
.	-	1558	O

Our	9579567	1560	O
results	-	1564	O
suggest	-	1572	O
a	-	1580	O
causal	-	1582	O
role	-	1589	O
of	-	1594	O
tamoxifen	-	1597	O
in	-	1607	O
endometrial	-	1610	B
cancer	-	1622	I
,	-	1628	O
particularly	-	1630	O
when	-	1643	O
used	-	1648	O
as	-	1653	O
currently	-	1656	O
proposed	-	1666	O
for	-	1675	O
breast	-	1679	B
cancer	-	1686	I
prevention	-	1693	O
.	-	1703	O

Pelvic	9579567	1705	O
radiotherapy	-	1712	O
may	-	1725	O
be	-	1729	O
an	-	1732	O
additional	-	1735	O
iatrogenic	-	1746	O
factor	-	1757	O
for	-	1764	O
women	-	1768	O
with	-	1774	O
breast	-	1779	B
cancer	-	1786	I
.	-	1792	O

Endometrial	9579567	1794	B
cancers	-	1806	I
diagnosed	-	1814	O
in	-	1824	O
women	-	1827	O
treated	-	1833	O
with	-	1841	O
tamoxifen	-	1846	O
have	-	1856	O
poorer	-	1861	O
prognosis	-	1868	O
.	-	1877	O

Women	9579567	1879	O
who	-	1885	O
receive	-	1889	O
tamoxifen	-	1897	O
for	-	1907	O
breast	-	1911	B
cancer	-	1918	I
should	-	1925	O
be	-	1932	O
offered	-	1935	O
gynaecological	-	1943	O
surveillance	-	1958	O
during	-	1971	O
and	-	1978	O
after	-	1982	O
treatment	-	1988	O
.	-	1997	O

A	9579567	1999	O
long	-	2001	O
-	-	2005	O
term	-	2006	O
evaluation	-	2011	O
of	-	2022	O
the	-	2025	O
risk	-	2029	O
-	-	2033	O
benefit	-	2034	O
ratio	-	2042	O
of	-	2048	O
tamoxifen	-	2051	O
as	-	2061	O
a	-	2064	O
preventive	-	2066	O
treatment	-	2077	O
for	-	2087	O
breast	-	2091	B
cancer	-	2098	I
is	-	2105	O
clearly	-	2108	O
warranted	-	2116	O
.	-	2125	O

Granulosa	9205462	0	B
cell	-	10	I
tumor	-	15	I
of	-	21	I
the	-	24	I
ovary	-	28	I
associated	-	34	O
with	-	45	O
antecedent	-	50	O
tamoxifen	-	61	O
use	-	71	O
.	-	74	O

BACKGROUND	9205462	76	O
:	-	86	O
Increased	-	88	O
attention	-	98	O
has	-	108	O
been	-	112	O
focused	-	117	O
recently	-	125	O
on	-	134	O
the	-	137	O
estrogenic	-	141	O
effects	-	152	O
of	-	160	O
tamoxifen	-	163	O
.	-	172	O

Review	9205462	174	O
of	-	181	O
the	-	184	O
literature	-	188	O
reveals	-	199	O
an	-	207	O
association	-	210	O
between	-	222	O
tamoxifen	-	230	O
use	-	240	O
and	-	244	O
gynecologic	-	248	O
tumors	-	260	B
.	-	266	O

CASE	9205462	268	O
:	-	272	O

A	9205462	274	O
52	-	276	O
-	-	278	O
year	-	279	O
-	-	283	O
old	-	284	O
postmenopausal	-	288	O
woman	-	303	O
was	-	309	O
treated	-	313	O
with	-	321	O
tamoxifen	-	326	O
for	-	336	O
stage	-	340	O
II	-	346	O
estrogen	-	349	O
receptor	-	358	O
-	-	366	O
positive	-	367	O
breast	-	376	B
carcinoma	-	383	I
.	-	392	O

Her	9205462	394	O
aspartate	-	398	O
transaminase	-	408	O
and	-	421	O
alanine	-	425	O
transaminase	-	433	O
levels	-	446	O
increase	-	453	O
markedly	-	462	O
after	-	471	O
6	-	477	O
months	-	479	O
of	-	486	O
tamoxifen	-	489	O
use	-	499	O
.	-	502	O

After	9205462	504	O
an	-	510	O
additional	-	513	O
17	-	524	O
months	-	527	O
of	-	534	O
elevated	-	537	O
serum	-	546	O
transaminases	-	552	O
,	-	565	O
the	-	567	O
patient	-	571	O
was	-	579	O
found	-	583	O
to	-	589	O
have	-	592	O
a	-	597	O
stage	-	599	O
Ic	-	605	O
granulosa	-	608	B
cell	-	618	I
tumor	-	623	I
of	-	629	I
the	-	632	I
ovary	-	636	I
.	-	641	O

CONCLUSION	9205462	643	O
:	-	653	O

Patients	9205462	655	O
with	-	664	O
tamoxifen	-	669	O
-	-	678	O
induced	-	679	O
liver	-	687	B
dysfunction	-	693	I
may	-	705	O
be	-	709	O
at	-	712	O
increased	-	715	O
risk	-	725	O
for	-	730	O
granulosa	-	734	B
cell	-	744	I
tumors	-	749	I
because	-	756	O
of	-	764	O
alterations	-	767	O
in	-	779	O
tamoxifen	-	782	O
metabolism	-	792	O
.	-	802	O

A	9098464	0	O
murine	-	2	O
model	-	9	O
of	-	15	O
adenomyosis	-	18	B
:	-	29	O
the	-	31	O
effects	-	35	O
of	-	43	O
hyperprolactinemia	-	46	B
induced	-	65	O
by	-	73	O
fluoxetine	-	76	O
hydrochloride	-	87	O
,	-	100	O
a	-	102	O
selective	-	104	O
serotonin	-	114	O
reuptake	-	124	O
inhibitor	-	133	O
,	-	142	O
on	-	144	O
adenomyosis	-	147	B
induction	-	159	O
in	-	169	O
Wistar	-	172	O
albino	-	179	O
rats	-	186	O
.	-	190	O

OBJECTIVE	9098464	192	O
:	-	201	O
The	-	203	O
aim	-	207	O
of	-	211	O
this	-	214	O
study	-	219	O
was	-	225	O
to	-	229	O
investigate	-	232	O
whether	-	244	O
fluoxetine	-	252	O
given	-	263	O
to	-	269	O
castrated	-	272	O
and	-	282	O
noncastrated	-	286	O
rats	-	299	O
caused	-	304	O
hyperprolactinemia	-	311	B
and	-	330	O
its	-	334	O
effects	-	338	O
with	-	346	O
respect	-	351	O
to	-	359	O
adenomyosis	-	362	B
.	-	373	O

DESIGN	9098464	375	O
:	-	381	O

Fluoxetine	9098464	383	O
,	-	393	O
a	-	395	O
serotonin	-	397	O
reuptake	-	407	O
inhibitor	-	416	O
,	-	425	O
was	-	427	O
given	-	431	O
to	-	437	O
Wistar	-	440	O
Albino	-	447	O
rats	-	454	O
for	-	459	O
98	-	463	O
days	-	466	O
to	-	471	O
produce	-	474	O
hyperprolactinemia	-	482	B
.	-	500	O

The	9098464	502	O
drug	-	506	O
was	-	511	O
given	-	515	O
to	-	521	O
two	-	524	O
groups	-	528	O
consisting	-	535	O
of	-	546	O
castrated	-	549	O
and	-	559	O
noncastrated	-	563	O
rats	-	576	O
and	-	581	O
compared	-	585	O
to	-	594	O
two	-	597	O
groups	-	601	O
of	-	608	O
castrated	-	611	O
and	-	621	O
noncastrated	-	625	O
controls	-	638	O
.	-	646	O

Prolactin	9098464	648	O
levels	-	658	O
were	-	665	O
measured	-	670	O
and	-	679	O
the	-	683	O
uteri	-	687	O
of	-	693	O
the	-	696	O
rats	-	700	O
were	-	705	O
removed	-	710	O
for	-	718	O
histopathological	-	722	O
analysis	-	740	O
at	-	749	O
the	-	752	O
end	-	756	O
of	-	760	O
98	-	763	O
days	-	766	O
.	-	770	O

SETTING	9098464	772	O
:	-	779	O

Marmara	9098464	781	O
University	-	789	O
School	-	800	O
of	-	807	O
Medicine	-	810	O
,	-	818	O
Department	-	820	O
of	-	831	O
Histology	-	834	O
and	-	844	O
Embryology	-	848	O
,	-	858	O
Zeynep	-	860	O
Kamil	-	867	O
Women	-	873	O
and	-	879	O
Children	-	883	O
's	-	891	O
Hospital	-	894	O
.	-	902	O

MAIN	9098464	904	O
OUTCOME	-	909	O
MEASURES	-	917	O
:	-	925	O

Serum	9098464	927	O
prolactin	-	933	O
levels	-	943	O
,	-	949	O
uterine	-	951	O
histopathology	-	959	O
.	-	973	O

RESULTS	9098464	975	O
:	-	982	O

The	9098464	984	O
prolactin	-	988	O
levels	-	998	O
of	-	1005	O
castrated	-	1008	O
and	-	1018	O
noncastrated	-	1022	O
groups	-	1035	O
treated	-	1042	O
with	-	1050	O
fluoxetine	-	1055	O
were	-	1066	O
statistically	-	1071	O
significantly	-	1085	O
higher	-	1099	O
when	-	1106	O
compared	-	1111	O
to	-	1120	O
their	-	1123	O
respective	-	1129	O
control	-	1140	O
groups	-	1148	O
.	-	1154	O

Histological	9098464	1156	O
studies	-	1169	O
revealed	-	1177	O
11	-	1186	O
cases	-	1189	O
of	-	1195	O
adenomyosis	-	1198	B
,	-	1209	O
all	-	1211	O
within	-	1215	O
the	-	1222	O
noncastrated	-	1226	O
group	-	1239	O
receiving	-	1245	O
fluoxetine	-	1255	O
.	-	1265	O

CONCLUSION	9098464	1267	O
:	-	1277	O

It	9098464	1279	O
was	-	1282	O
suggested	-	1286	O
that	-	1296	O
high	-	1301	O
serum	-	1306	O
prolactin	-	1312	O
levels	-	1322	O
cause	-	1329	O
degeneration	-	1335	O
of	-	1348	O
myometrial	-	1351	O
cells	-	1362	O
in	-	1368	O
the	-	1371	O
presence	-	1375	O
of	-	1384	O
ovarian	-	1387	O
steroids	-	1395	O
that	-	1404	O
results	-	1409	O
in	-	1417	O
a	-	1420	O
myometrial	-	1422	O
invasion	-	1433	O
by	-	1442	O
endometrial	-	1445	O
stroma	-	1457	O
.	-	1463	O

This	9098464	1465	O
invasion	-	1470	O
eventually	-	1479	O
progresses	-	1490	O
to	-	1501	O
adenomyosis	-	1504	B
.	-	1515	O

Effects	8424298	0	O
of	-	8	O
deliberate	-	11	O
hypotension	-	22	B
induced	-	34	O
by	-	42	O
labetalol	-	45	O
with	-	55	O
isoflurane	-	60	O
on	-	71	O
neuropsychological	-	74	O
function	-	93	O
.	-	101	O

The	8424298	103	O
effect	-	107	O
of	-	114	O
deliberate	-	117	O
hypotension	-	128	B
on	-	140	O
brain	-	143	O
function	-	149	O
measured	-	158	O
by	-	167	O
neuropsychological	-	170	O
tests	-	189	O
was	-	195	O
studied	-	199	O
in	-	207	O
41	-	210	O
adult	-	213	O
patients	-	219	O
.	-	227	O

Twenty	8424298	229	O
-	-	235	O
four	-	236	O
patients	-	241	O
were	-	250	O
anaesthetized	-	255	O
for	-	269	O
middle	-	273	O
-	-	279	O
ear	-	280	O
surgery	-	284	O
with	-	292	O
deliberate	-	297	O
hypotension	-	308	B
induced	-	320	O
by	-	328	O
labetalol	-	331	O
with	-	341	O
isoflurane	-	346	O
(	-	357	O
hypotensive	-	358	B
group	-	370	O
)	-	375	O
.	-	376	O

Seventeen	8424298	378	O
patients	-	388	O
without	-	397	O
hypotension	-	405	B
served	-	417	O
as	-	424	O
a	-	427	O
control	-	429	O
group	-	437	O
.	-	442	O

The	8424298	444	O
mean	-	448	O
arterial	-	453	O
pressure	-	462	O
was	-	471	O
77	-	475	O
+	-	478	O
/	-	479	O
-	-	480	O

2	8424298	482	O
mmHg	-	484	O
(	-	489	O
10	-	490	O
.	-	492	O
3	-	493	O
+	-	495	O
/	-	496	O
-	-	497	O

0	8424298	499	O
.	-	500	O
3	-	501	O
kPa	-	503	O
)	-	506	O
before	-	508	O
hypotension	-	515	B
and	-	527	O
50	-	531	O

+	8424298	534	O
/	-	535	O
-	-	536	O
0	-	538	O

mmHg	8424298	540	O
(	-	545	O
6	-	546	O
.	-	547	O
7	-	548	O
+	-	550	O
/	-	551	O
-	-	552	O
0	-	554	O
.	-	555	O
0	-	556	O
kPa	-	558	O
)	-	561	O
during	-	563	O
hypotension	-	570	B
in	-	582	O
the	-	585	O
hypotensive	-	589	B
group	-	601	O
,	-	606	O
and	-	608	O
86	-	612	O
+	-	615	O
/	-	616	O
-	-	617	O
2	-	619	O
mmHg	-	621	O
(	-	626	O
11	-	627	O
.	-	629	O
5	-	630	O
+	-	632	O
/	-	633	O
-	-	634	O
0	-	636	O
.	-	637	O
3	-	638	O
kPa	-	640	O
)	-	643	O
during	-	645	O
anaesthesia	-	652	O
in	-	664	O
the	-	667	O
control	-	671	O
group	-	679	O
.	-	684	O

The	8424298	686	O
following	-	690	O
psychological	-	700	O
tests	-	714	O
were	-	720	O
performed	-	725	O
:	-	734	O
four	-	736	O
subtests	-	741	O
of	-	750	O
the	-	753	O
Wechsler	-	757	O
Adult	-	766	O
Intelligence	-	772	O
Scale	-	785	O
(	-	791	O
similarities	-	792	O
,	-	804	O
digit	-	806	O
span	-	812	O
,	-	816	O
vocabulary	-	818	O
and	-	829	O
digit	-	833	O
symbol	-	839	O
)	-	845	O
,	-	846	O
Trail	-	848	O
-	-	853	O
Making	-	854	O
tests	-	861	O
A	-	867	O
and	-	869	O
B	-	873	O
,	-	874	O
Zung	-	876	O
tests	-	881	O
(	-	887	O
self	-	888	O
-	-	892	O
rating	-	893	O
anxiety	-	900	B
scale	-	908	O
and	-	914	O
self	-	918	O
-	-	922	O
rating	-	923	O
depression	-	930	B
scale	-	941	O
)	-	946	O
and	-	948	O
two	-	952	O
-	-	955	O
part	-	956	O
memory	-	961	O
test	-	968	O
battery	-	973	O
with	-	981	O
immediate	-	986	O
and	-	996	O
delayed	-	1000	O
recall	-	1008	O
.	-	1014	O

The	8424298	1016	O
tests	-	1020	O
were	-	1026	O
performed	-	1031	O
preoperatively	-	1041	O
and	-	1056	O
2	-	1060	O
days	-	1062	O
postoperatively	-	1067	O
.	-	1082	O

There	8424298	1084	O
were	-	1090	O
no	-	1095	O
statistically	-	1098	O
significant	-	1112	O
differences	-	1124	O
between	-	1136	O
the	-	1144	O
groups	-	1148	O
in	-	1155	O
any	-	1158	O
of	-	1162	O
the	-	1165	O
tests	-	1169	O
in	-	1175	O
the	-	1178	O
changes	-	1182	O
from	-	1190	O
preoperative	-	1195	O
value	-	1208	O
to	-	1214	O
postoperative	-	1217	O
value	-	1231	O
.	-	1236	O

The	8424298	1238	O
results	-	1242	O
indicate	-	1250	O
that	-	1259	O
hypotension	-	1264	B
induced	-	1276	O
by	-	1284	O
labetalol	-	1287	O
with	-	1297	O
isoflurane	-	1302	O
has	-	1313	O
no	-	1317	O
significant	-	1320	O
harmful	-	1332	O
effects	-	1340	O
on	-	1348	O
mental	-	1351	O
functions	-	1358	O
compared	-	1368	O
to	-	1377	O
normotensive	-	1380	O
anaesthesia	-	1393	O
.	-	1404	O

Auditory	7880714	0	O
disturbance	-	9	O
associated	-	21	O
with	-	32	O
interscalene	-	37	O
brachial	-	50	O
plexus	-	59	O
block	-	66	O
.	-	71	O

We	7880714	73	O
performed	-	76	O
an	-	86	O
audiometric	-	89	O
study	-	101	O
in	-	107	O
20	-	110	O
patients	-	113	O
who	-	122	O
underwent	-	126	O
surgery	-	136	O
of	-	144	O
the	-	147	O
shoulder	-	151	O
region	-	160	O
under	-	167	O
an	-	173	O
interscalene	-	176	O
brachial	-	189	O
plexus	-	198	O
block	-	205	O
(	-	211	O
IBPB	-	212	O
)	-	216	O
.	-	217	O

Bupivacaine	7880714	219	O
0	-	231	O
.	-	232	O
75	-	233	O
%	-	235	O
with	-	237	O
adrenaline	-	242	O
was	-	253	O
given	-	257	O
followed	-	263	O
by	-	272	O
a	-	275	O
24	-	277	O
-	-	279	O
hr	-	280	O
continuous	-	283	O
infusion	-	294	O
of	-	303	O
0	-	306	O
.	-	307	O
25	-	308	O
%	-	310	O
bupivacaine	-	312	O
.	-	323	O

Three	7880714	325	O
audiometric	-	331	O
threshold	-	343	O
measurements	-	353	O
(	-	366	O
0	-	367	O
.	-	368	O
25	-	369	O
-	-	371	O
18	-	372	O
kHz	-	375	O
)	-	378	O
were	-	380	O
made	-	385	O
:	-	389	O
the	-	391	O
first	-	395	O
before	-	401	O
IBPB	-	408	O
,	-	412	O
the	-	414	O
second	-	418	O
2	-	425	O
-	-	426	O
6	-	427	O
h	-	429	O
after	-	431	O
surgery	-	437	O
and	-	445	O
the	-	449	O
third	-	453	O
on	-	459	O
the	-	462	O
first	-	466	O
day	-	472	O
after	-	476	O
operation	-	482	O
.	-	491	O

In	7880714	493	O
four	-	496	O
patients	-	501	O
hearing	-	510	B
impairment	-	518	I
on	-	529	O
the	-	532	O
side	-	536	O
of	-	541	O
the	-	544	O
block	-	548	O
was	-	554	O
demonstrated	-	558	O
after	-	571	O
operation	-	577	O
,	-	586	O
in	-	588	O
three	-	591	O
measurements	-	597	O
on	-	610	O
the	-	613	O
day	-	617	O
of	-	621	O
surgery	-	624	O
and	-	632	O
in	-	636	O
one	-	639	O
on	-	643	O
the	-	646	O
following	-	650	O
day	-	660	O
.	-	663	O

The	7880714	665	O
frequencies	-	669	O
at	-	681	O
which	-	684	O
the	-	690	O
impairment	-	694	O
occurred	-	705	O
varied	-	714	O
between	-	721	O
patients	-	729	O
;	-	737	O
in	-	739	O
one	-	742	O
only	-	746	O
low	-	751	O
frequencies	-	755	O
(	-	767	O
0	-	768	O
.	-	769	O
25	-	770	O
-	-	772	O
0	-	773	O
.	-	774	O
5	-	775	O
kHz	-	777	O
)	-	780	O
were	-	782	O
involved	-	787	O
.	-	795	O

The	7880714	797	O
maximum	-	801	O
change	-	809	O
in	-	816	O
threshold	-	819	O
was	-	829	O
35	-	833	O
dB	-	836	O
at	-	839	O
6	-	842	O
kHz	-	844	O
measured	-	848	O
at	-	857	O
the	-	860	O
end	-	864	O
of	-	868	O
the	-	871	O
continuous	-	875	O
infusion	-	886	O
of	-	895	O
bupivacaine	-	898	O
.	-	909	O

This	7880714	911	O
patient	-	916	O
had	-	924	O
hearing	-	928	O
threshold	-	936	O
changes	-	946	O
(	-	954	O
15	-	955	O
-	-	957	O
20	-	958	O
dB	-	961	O
)	-	963	O
at	-	965	O
6	-	968	O
-	-	969	O
10	-	970	O
kHz	-	973	O
on	-	977	O
the	-	980	O
opposite	-	984	O
side	-	993	O
also	-	998	O
.	-	1002	O

IBPB	7880714	1004	O
may	-	1009	O
cause	-	1013	O
transient	-	1019	O
auditory	-	1029	B
dysfunction	-	1038	I
in	-	1050	O
the	-	1053	O
ipsilateral	-	1057	O
ear	-	1069	O
,	-	1072	O
possibly	-	1074	O
via	-	1083	O
an	-	1087	O
effect	-	1090	O
on	-	1097	O
sympathetic	-	1100	O
innervation	-	1112	O
.	-	1123	O

Midazolam	7102237	0	O
compared	-	10	O
with	-	19	O
thiopentone	-	24	O
as	-	36	O
an	-	39	O
induction	-	42	O
agent	-	52	O
.	-	57	O

In	7102237	59	O
patients	-	62	O
premedicated	-	71	O
with	-	84	O
scopolamine	-	89	O
+	-	101	O
morphine	-	103	O
(	-	112	O
+	-	113	O
5	-	114	O
mg	-	116	O
nitrazepam	-	119	O
the	-	130	O
evening	-	134	O
before	-	142	O
surgery	-	149	O
)	-	156	O
,	-	157	O
the	-	159	O
sleep	-	163	O
-	-	168	O
inducing	-	169	O
effect	-	178	O
of	-	185	O
midazolam	-	188	O
0	-	198	O
.	-	199	O
15	-	200	O
mg	-	203	O
/	-	205	O
kg	-	206	O
i	-	209	O
.	-	210	O
v	-	211	O
.	-	212	O

was	7102237	214	O
clearly	-	218	O
slower	-	226	O
in	-	233	O
onset	-	236	O
than	-	242	O
that	-	247	O
of	-	252	O
thiopentone	-	255	O
4	-	267	O
.	-	268	O
67	-	269	O
mg	-	272	O
/	-	274	O
kg	-	275	O
i	-	278	O
.	-	279	O
v	-	280	O
.	-	281	O

Somewhat	7102237	283	O
fewer	-	292	O
cardiovascular	-	298	O
and	-	313	O
local	-	317	O
sequelae	-	323	O
were	-	332	O
found	-	337	O
in	-	343	O
the	-	346	O
midazolam	-	350	O
group	-	360	O
,	-	365	O
but	-	367	O
,	-	370	O
although	-	372	O
apnoea	-	381	B
occurred	-	388	O
less	-	397	O
often	-	402	O
in	-	408	O
the	-	411	O
midazolam	-	415	O
group	-	425	O
it	-	431	O
lasted	-	434	O
longer	-	441	O
.	-	447	O

On	7102237	449	O
the	-	452	O
whole	-	456	O
,	-	461	O
the	-	463	O
differences	-	467	O
between	-	479	O
midazolam	-	487	O
and	-	497	O
thiopentone	-	501	O
had	-	513	O
no	-	517	O
apparent	-	520	O
clinical	-	529	O
consequences	-	538	O
.	-	550	O

Midazolam	7102237	552	O
is	-	562	O
a	-	565	O
new	-	567	O
alternative	-	571	O
agent	-	583	O
for	-	589	O
induction	-	593	O
in	-	603	O
combination	-	606	O
anaesthesia	-	618	O
.	-	629	O

Cardiotoxic	6769133	0	B
and	-	12	O
possible	-	16	O
leukemogenic	-	25	O
effects	-	38	O
of	-	46	O
adriamycin	-	49	O
in	-	60	O
nonhuman	-	63	O
primates	-	72	O
.	-	80	O

10	6769133	82	O
monkeys	-	85	O
(	-	93	O
macaques	-	94	O
)	-	102	O
received	-	104	O
adriamycin	-	113	O
by	-	124	O
monthly	-	127	O
intravenous	-	135	O
injections	-	147	O
at	-	158	O
12	-	161	O
mg	-	164	O
/	-	166	O
m2	-	167	O
(	-	170	O
1	-	171	O
mg	-	173	O
/	-	175	O
kg	-	176	O
)	-	178	O
.	-	179	O

8	6769133	181	O
of	-	183	O
the	-	186	O
10	-	190	O
monkeys	-	193	O
developed	-	201	O
congestive	-	211	B
heart	-	222	I
failure	-	228	I
at	-	236	O
an	-	239	O
average	-	242	O
cumulative	-	250	O
adriamycin	-	261	O
dose	-	272	O
(	-	277	O
310	-	278	O
mg	-	282	O
/	-	284	O
m2	-	285	O
)	-	287	O
well	-	289	O
below	-	294	O
that	-	300	O
considered	-	305	O
the	-	316	O
safe	-	320	O
upper	-	325	O
limit	-	331	O
(	-	337	O
550	-	338	O
mg	-	342	O
/	-	344	O
m2	-	345	O
)	-	347	O
in	-	349	O
man	-	352	O
.	-	355	O

Histologically	6769133	357	O
,	-	371	O
the	-	373	O
myocardial	-	377	B
lesions	-	388	I
resembled	-	396	O
those	-	406	O
found	-	412	O
in	-	418	O
human	-	421	O
anthracycline	-	427	O
-	-	440	O
induced	-	441	O
cardiomyopathy	-	449	B
.	-	463	O

1	6769133	465	O
of	-	467	O
the	-	470	O
10	-	474	O
monkeys	-	477	O
developed	-	485	O
acute	-	495	B
myeloblastic	-	501	I
leukemia	-	514	I
after	-	523	O
receiving	-	529	O
324	-	539	O
mg	-	543	O
/	-	545	O
m2	-	546	O
of	-	549	O
adriamycin	-	552	O
;	-	562	O
the	-	564	O
10th	-	568	O
monkey	-	573	O
is	-	580	O
alive	-	583	O
and	-	589	O
well	-	593	O
26	-	598	O
months	-	601	O
after	-	608	O
the	-	614	O
last	-	618	O
dose	-	623	O
of	-	628	O
drug	-	631	O
.	-	635	O

Our	6769133	637	O
results	-	641	O
suggest	-	649	O
that	-	657	O
adriamycin	-	662	O
is	-	673	O
a	-	676	O
more	-	678	O
potent	-	683	O
cardiotoxin	-	690	O
in	-	702	O
monkeys	-	705	O
than	-	713	O
in	-	718	O
man	-	721	O
,	-	724	O
and	-	726	O
that	-	730	O
leukemia	-	735	B
may	-	744	O
be	-	748	O
a	-	751	O
consequence	-	753	O
of	-	765	O
prolonged	-	768	O
treatment	-	778	O
with	-	788	O
this	-	793	O
drug	-	798	O
.	-	802	O

Doxorubicin	6292680	0	O
cardiomyopathy	-	12	B
in	-	27	O
children	-	30	O
with	-	39	O
left	-	44	O
-	-	48	O
sided	-	49	O
Wilms	-	55	B
tumor	-	61	I
.	-	66	O

Two	6292680	68	O
children	-	72	O
with	-	81	O
Wilms	-	86	B
tumor	-	92	I
of	-	98	O
the	-	101	O
left	-	105	O
kidney	-	110	O
experienced	-	117	O
severe	-	129	O
anthracycline	-	136	O
cardiomyopathy	-	150	B
after	-	165	O
irradiation	-	171	O
to	-	183	O
the	-	186	O
tumor	-	190	B
bed	-	196	O
and	-	200	O
conventional	-	204	O
dosage	-	217	O
of	-	224	O
doxorubicin	-	227	O
.	-	238	O

The	6292680	240	O
cardiomyopathy	-	244	B
is	-	259	O
attributed	-	262	O
1	-	273	O
)	-	274	O
to	-	276	O
the	-	279	O
fact	-	283	O
that	-	288	O
radiation	-	293	O
fields	-	303	O
for	-	310	O
left	-	314	O
Wilms	-	319	B
tumor	-	325	I
include	-	331	O
the	-	339	O
lower	-	343	O
portion	-	349	O
of	-	357	O
the	-	360	O
heart	-	364	O
and	-	370	O
2	-	374	O
)	-	375	O
to	-	377	O
the	-	380	O
interaction	-	384	O
of	-	396	O
doxorubicin	-	399	O
and	-	411	O
irradiation	-	415	O
on	-	427	O
cardiac	-	430	O
muscle	-	438	O
.	-	444	O

It	6292680	446	O
is	-	449	O
recommended	-	452	O
that	-	464	O
doxorubicin	-	469	O
dosage	-	481	O
be	-	488	O
sharply	-	491	O
restricted	-	499	O
in	-	510	O
children	-	513	O
with	-	522	O
Wilms	-	527	B
tumor	-	533	I
of	-	539	O
the	-	542	O
left	-	546	O
kidney	-	551	O
who	-	558	O
receive	-	562	O
postoperative	-	570	O
irradiation	-	584	O
.	-	595	O

Promotional	3969369	0	O
effects	-	12	O
of	-	20	O
testosterone	-	23	O
and	-	36	O
dietary	-	40	O
fat	-	48	O
on	-	52	O
prostate	-	55	O
carcinogenesis	-	64	B
in	-	79	O
genetically	-	82	O
susceptible	-	94	O
rats	-	106	O
.	-	110	O

Germfree	3969369	112	O
(	-	121	O
GF	-	122	O
)	-	124	O

Lobund	3969369	126	O
strain	-	133	O
Wistar	-	140	O
(	-	147	O
LW	-	148	O
)	-	150	O
rats	-	152	O
,	-	156	O
fed	-	158	O
vegetable	-	162	O
diet	-	172	O
L	-	177	O
-	-	178	O
485	-	179	O
,	-	182	O
have	-	184	O
developed	-	189	O
prostate	-	199	B
adenocarcinomas	-	208	I
spontaneously	-	224	O
(	-	238	O
10	-	239	O
%	-	241	O
incidence	-	243	O
)	-	252	O
at	-	254	O
average	-	257	O
age	-	265	O
34	-	269	O
months	-	272	O
.	-	278	O

Conventional	3969369	280	O
LW	-	293	O
rats	-	296	O
,	-	300	O
implanted	-	302	O
with	-	312	O
testosterone	-	317	O
at	-	330	O
age	-	333	O
4	-	337	O
months	-	339	O
,	-	345	O
developed	-	347	O
a	-	357	O
higher	-	359	O
incidence	-	366	O
of	-	376	O
prostate	-	379	B
cancer	-	388	I
after	-	395	O
an	-	401	O
average	-	404	O
interval	-	412	O
of	-	421	O
14	-	424	O
months	-	427	O
:	-	433	O
24	-	435	O
%	-	437	O
had	-	439	O
developed	-	443	O
gross	-	453	O
tumors	-	459	B
,	-	465	O
and	-	467	O
40	-	471	O
%	-	473	O
when	-	475	O
it	-	480	O
included	-	483	O
microscopic	-	492	O
tumors	-	504	B
.	-	510	O

Preliminary	3969369	512	O
results	-	524	O
indicate	-	532	O
that	-	541	O
testosterone	-	546	O
-	-	558	O
treated	-	559	O
LW	-	567	O
rats	-	570	O
that	-	575	O
were	-	580	O
fed	-	585	O
the	-	589	O
same	-	593	O
diet	-	598	O
,	-	602	O
which	-	604	O
was	-	610	O
supplemented	-	614	O
with	-	627	O
corn	-	632	O
oil	-	637	O
up	-	641	O
to	-	644	O
20	-	647	O
%	-	649	O
fat	-	651	O
,	-	654	O
developed	-	656	O
prostate	-	666	B
cancer	-	675	I
after	-	682	O
intervals	-	688	O
of	-	698	O
6	-	701	O
-	-	702	O
12	-	703	O
months	-	706	O
.	-	712	O

Aged	3969369	714	O
GF	-	719	O
Sprague	-	722	O
-	-	729	O
Dawley	-	730	O
(	-	737	O
SD	-	738	O
)	-	740	O
rats	-	742	O
have	-	747	O
not	-	752	O
developed	-	756	O
prostate	-	766	B
cancer	-	775	I
spontaneously	-	782	O
.	-	795	O

Conventional	3969369	797	O
SD	-	810	O
rats	-	813	O
fed	-	818	O
diet	-	822	O
L	-	827	O
-	-	828	O
485	-	829	O
and	-	833	O
treated	-	837	O
with	-	845	O
testosterone	-	850	O
developed	-	863	O
only	-	873	O
prostatitis	-	878	B
.	-	889	O

Experimental	3969369	891	O
designs	-	904	O
should	-	912	O
consider	-	919	O
genetic	-	928	O
susceptibility	-	936	O
as	-	951	O
a	-	954	O
basic	-	956	O
prerequisite	-	962	O
for	-	975	O
studies	-	979	O
on	-	987	O
experimental	-	990	O
prostate	-	1003	B
cancer	-	1012	I
.	-	1018	O

Mitomycin	3108839	0	O
C	-	10	O
associated	-	12	O
hemolytic	-	23	B
uremic	-	33	I
syndrome	-	40	I
.	-	48	O

Mitomycin	3108839	50	O
C	-	60	O
associated	-	62	O
Hemolytic	-	73	B
Uremic	-	83	I
Syndrome	-	90	I
(	-	99	O
HUS	-	100	B
)	-	103	O
is	-	105	O
a	-	108	O
potentially	-	110	O
fatal	-	122	O
but	-	128	O
uncommon	-	132	O
condition	-	141	O
that	-	151	O
is	-	156	O
not	-	159	O
yet	-	163	O
widely	-	167	O
recognised	-	174	O
.	-	184	O

It	3108839	186	O
consists	-	189	O
of	-	198	O
microangiopathic	-	201	O
hemolytic	-	218	B
anemia	-	228	I
,	-	234	O
thrombocytopenia	-	236	B
and	-	253	O
progressive	-	257	O
renal	-	269	B
failure	-	275	I
associated	-	283	O
with	-	294	O
mitomycin	-	299	O
C	-	309	O
treatment	-	311	O
and	-	321	O
affects	-	325	O
about	-	333	O
10	-	339	O
%	-	341	O
of	-	343	O
patients	-	346	O
treated	-	355	O
with	-	363	O
this	-	368	O
agent	-	373	O
.	-	378	O

The	3108839	380	O
renal	-	384	B
failure	-	390	I
usually	-	398	O
develops	-	406	O
about	-	415	O
8	-	421	O
-	-	422	O
10	-	423	O
mth	-	426	O
after	-	430	O
start	-	436	O
of	-	442	O
mitomycin	-	445	O
C	-	455	O
treatment	-	457	O
and	-	467	O
the	-	471	O
mortality	-	475	O
is	-	485	O
approximately	-	488	O
60	-	502	O
%	-	504	O
from	-	506	O
renal	-	511	B
failure	-	517	I
or	-	525	O
pulmonary	-	528	B
edema	-	538	I
.	-	543	O

Renal	3108839	545	B
lesions	-	551	I
are	-	559	O
similar	-	563	O
to	-	571	O
those	-	574	O
seen	-	580	O
in	-	585	O
idiopathic	-	588	O
HUS	-	599	B
and	-	603	O
include	-	607	O
arteriolar	-	615	O
fibrin	-	626	O
thrombi	-	633	B
,	-	640	O
expanded	-	642	O
subendothelial	-	651	O
zones	-	666	O
in	-	672	O
glomerular	-	675	O
capillary	-	686	O
walls	-	696	O
,	-	701	O
ischemic	-	703	B
wrinkling	-	712	O
of	-	722	O
glomerular	-	725	O
basement	-	736	O
membranes	-	745	O
and	-	755	O
mesangiolysis	-	759	O
.	-	772	O

The	3108839	774	O
mechanism	-	778	O
of	-	788	O
action	-	791	O
is	-	798	O
postulated	-	801	O
as	-	812	O
mitomycin	-	815	O
C	-	825	O
-	-	826	O
induced	-	827	O
endothelial	-	835	O
cell	-	847	O
damage	-	852	O
.	-	858	O

We	3108839	860	O
describe	-	863	O
the	-	872	O
clinical	-	876	O
course	-	885	O
and	-	892	O
pathological	-	896	O
findings	-	909	O
in	-	918	O
a	-	921	O
65	-	923	O
yr	-	926	O
-	-	928	O
old	-	929	O
man	-	933	O
with	-	937	O
gastric	-	942	B
adenocarcinoma	-	950	I
who	-	965	O
developed	-	969	O
renal	-	979	B
failure	-	985	I
and	-	993	O
thrombocytopenia	-	997	B
while	-	1014	O
on	-	1020	O
treatment	-	1023	O
with	-	1033	O
mitomycin	-	1038	O
C	-	1048	O
and	-	1050	O
died	-	1054	O
in	-	1059	O
pulmonary	-	1062	B
edema	-	1072	I
.	-	1077	O

Continuous	2466960	0	O
ambulatory	-	11	O
ECG	-	22	O
monitoring	-	26	O
during	-	37	O
fluorouracil	-	44	O
therapy	-	57	O
:	-	64	O
a	-	66	O
prospective	-	68	O
study	-	80	O
.	-	85	O

Although	2466960	87	O
there	-	96	O
have	-	102	O
been	-	107	O
anecdotal	-	112	O
reports	-	122	O
of	-	130	O
cardiac	-	133	B
toxicity	-	141	I
associated	-	150	O
with	-	161	O
fluorouracil	-	166	O
(	-	179	O
5	-	180	O
-	-	181	O
FU	-	182	O
)	-	184	O
therapy	-	186	O
,	-	193	O
this	-	195	O
phenomenon	-	200	O
has	-	211	O
not	-	215	O
been	-	219	O
studied	-	224	O
in	-	232	O
a	-	235	O
systematic	-	237	O
fashion	-	248	O
.	-	255	O

We	2466960	257	O
prospectively	-	260	O
performed	-	274	O
continuous	-	284	O
ambulatory	-	295	O
ECG	-	306	O
monitoring	-	310	O
on	-	321	O
25	-	324	O
patients	-	327	O
undergoing	-	336	O
5	-	347	O
-	-	348	O
FU	-	349	O
infusion	-	352	O
for	-	361	O
treatment	-	365	O
of	-	375	O
solid	-	378	O
tumors	-	384	B
in	-	391	O
order	-	394	O
to	-	400	O
assess	-	403	O
the	-	410	O
incidence	-	414	O
of	-	424	O
ischemic	-	427	B
ST	-	436	O
changes	-	439	O
.	-	446	O

Patients	2466960	448	O
were	-	457	O
monitored	-	462	O
for	-	472	O
23	-	476	O
+	-	479	O
/	-	480	O
-	-	481	O

4	2466960	483	O
hours	-	485	O
before	-	491	O
5	-	498	O
-	-	499	O
FU	-	500	O
infusion	-	503	O
,	-	511	O
and	-	513	O
98	-	517	O
+	-	520	O
/	-	521	O
-	-	522	O

9	2466960	524	O
hours	-	526	O
during	-	532	O
5	-	539	O
-	-	540	O
FU	-	541	O
infusion	-	544	O
.	-	552	O

Anginal	2466960	554	B
episodes	-	562	O
were	-	571	O
rare	-	576	O
:	-	580	O
only	-	582	O
one	-	587	O
patient	-	591	O
had	-	599	O
angina	-	603	B
(	-	610	O
during	-	611	O
5	-	618	O
-	-	619	O
FU	-	620	O
infusion	-	623	O
)	-	631	O
.	-	632	O

However	2466960	634	O
,	-	641	O
asymptomatic	-	643	O
ST	-	656	O
changes	-	659	O
(	-	667	O
greater	-	668	O
than	-	676	O
or	-	681	O
equal	-	684	O
to	-	690	O
1	-	693	O
mm	-	695	O
ST	-	698	O
deviation	-	701	O
)	-	710	O
were	-	712	O
common	-	717	O
:	-	723	O
six	-	725	O
of	-	729	O
25	-	732	O
patients	-	735	O
(	-	744	O
24	-	745	O
%	-	747	O
)	-	748	O
had	-	750	O
ST	-	754	O
changes	-	757	O
before	-	765	O
5	-	772	O
-	-	773	O
FU	-	774	O
infusion	-	777	O
v	-	786	O
17	-	788	O
(	-	791	O
68	-	792	O
%	-	794	O
)	-	795	O
during	-	797	O
5	-	804	O
-	-	805	O
FU	-	806	O
infusion	-	809	O
(	-	818	O
P	-	819	O
less	-	821	O
than	-	826	O
.	-	831	O
002	-	832	O
)	-	835	O
.	-	836	O

The	2466960	838	O
incidence	-	842	O
of	-	852	O
ischemic	-	855	B
episodes	-	864	O
per	-	873	O
patient	-	877	O
per	-	885	O
hour	-	889	O
was	-	894	O
0	-	898	O
.	-	899	O
05	-	900	O
+	-	903	O
/	-	904	O
-	-	905	O

0	2466960	907	O
.	-	908	O
02	-	909	O

prior	2466960	912	O
to	-	918	O
5	-	921	O
-	-	922	O
FU	-	923	O
infusion	-	926	O
v	-	935	O
0	-	937	O
.	-	938	O
13	-	939	O
+	-	942	O
/	-	943	O
-	-	944	O
0	-	946	O
.	-	947	O
03	-	948	O
during	-	951	O
5	-	958	O
-	-	959	O
FU	-	960	O
infusion	-	963	O
(	-	972	O
P	-	973	O
less	-	975	O
than	-	980	O
.	-	985	O
001	-	986	O
)	-	989	O
;	-	990	O
the	-	992	O
duration	-	996	O
of	-	1005	O
ECG	-	1008	O
changes	-	1012	O
was	-	1020	O
0	-	1024	O
.	-	1025	O
6	-	1026	O
+	-	1028	O
/	-	1029	O
-	-	1030	O
0	-	1032	O
.	-	1033	O
3	-	1034	O
minutes	-	1036	O
per	-	1044	O
patient	-	1048	O
per	-	1056	O
hour	-	1060	O
before	-	1065	O
5	-	1072	O
-	-	1073	O
FU	-	1074	O
v	-	1077	O
1	-	1079	O
.	-	1080	O
9	-	1081	O
+	-	1083	O
/	-	1084	O
-	-	1085	O

0	2466960	1087	O
.	-	1088	O
5	-	1089	O
minutes	-	1091	O
per	-	1099	O
patient	-	1103	O
per	-	1111	O
hour	-	1115	O
during	-	1120	O
5	-	1127	O
-	-	1128	O
FU	-	1129	O
(	-	1132	O
P	-	1133	O
less	-	1135	O
than	-	1140	O
.	-	1145	O
01	-	1146	O
)	-	1148	O
.	-	1149	O

ECG	2466960	1151	O
changes	-	1155	O
were	-	1163	O
more	-	1168	O
common	-	1173	O
among	-	1180	O
patients	-	1186	O
with	-	1195	O
known	-	1200	O
coronary	-	1206	B
artery	-	1215	I
disease	-	1222	I
.	-	1229	O

There	2466960	1231	O
were	-	1237	O
two	-	1242	O
cases	-	1246	O
of	-	1252	O
sudden	-	1255	B
death	-	1262	I
,	-	1267	O
both	-	1269	O
of	-	1274	O
which	-	1277	O
occurred	-	1283	O
at	-	1292	O
the	-	1295	O
end	-	1299	O
of	-	1303	O
the	-	1306	O
chemotherapy	-	1310	O
course	-	1323	O
.	-	1329	O

We	2466960	1331	O
conclude	-	1334	O
that	-	1343	O
5	-	1348	O
-	-	1349	O
FU	-	1350	O
infusion	-	1353	O
is	-	1362	O
associated	-	1365	O
with	-	1376	O
a	-	1381	O
significant	-	1383	O
increase	-	1395	O
in	-	1404	O
silent	-	1407	O
ST	-	1414	O
segment	-	1417	O
deviation	-	1425	O
suggestive	-	1435	O
of	-	1446	O
ischemia	-	1449	B
,	-	1457	O
particularly	-	1459	O
among	-	1472	O
patients	-	1478	O
with	-	1487	O
coronary	-	1492	B
artery	-	1501	I
disease	-	1508	I
.	-	1515	O

The	2466960	1517	O
mechanism	-	1521	O
and	-	1531	O
clinical	-	1535	O
significance	-	1544	O
of	-	1557	O
these	-	1560	O
ECG	-	1566	O
changes	-	1570	O
remain	-	1578	O
to	-	1585	O
be	-	1588	O
determined	-	1591	O
.	-	1601	O

Lethal	2320800	0	O
anuria	-	7	B
complicating	-	14	O
high	-	27	O
dose	-	32	O
ifosfamide	-	37	O
chemotherapy	-	48	O
in	-	61	O
a	-	64	O
breast	-	66	B
cancer	-	73	I
patient	-	80	O
with	-	88	O
an	-	93	O
impaired	-	96	B
renal	-	105	I
function	-	111	I
.	-	119	O

A	2320800	121	O
sixty	-	123	O
-	-	128	O
year	-	129	O
-	-	133	O
old	-	134	O
woman	-	138	O
with	-	144	O
advanced	-	149	O
breast	-	158	B
cancer	-	165	I
,	-	171	O
previously	-	173	O
treated	-	184	O
with	-	192	O
cisplatin	-	197	O
,	-	206	O
developed	-	208	O
an	-	218	O
irreversible	-	221	O
lethal	-	234	O
renal	-	241	B
failure	-	247	I
with	-	255	O
anuria	-	260	B
,	-	266	O
the	-	268	O
day	-	272	O
after	-	276	O
5	-	282	O
g	-	284	O
/	-	285	O
m2	-	286	O
bolus	-	289	O
ifosfamide	-	295	O
.	-	305	O

Postrenal	2320800	307	B
failure	-	317	I
was	-	325	O
excluded	-	329	O
by	-	338	O
echography	-	341	O
.	-	351	O

A	2320800	353	O
prerenal	-	355	O
component	-	364	O
could	-	374	O
have	-	380	O
contributed	-	385	O
to	-	397	O
renal	-	400	B
failure	-	406	I
because	-	414	O
of	-	422	O
a	-	425	O
transient	-	427	O
hypotension	-	437	B
,	-	448	O
due	-	450	O
to	-	454	O
an	-	457	O
increasing	-	460	O
ascitis	-	471	O
,	-	478	O
occurring	-	480	O
just	-	490	O
before	-	495	O
anuria	-	502	B
.	-	508	O

However	2320800	510	O
,	-	517	O
correction	-	519	O
of	-	530	O
the	-	533	O
hemodynamic	-	537	O
parameters	-	549	O
did	-	560	O
not	-	564	O
improve	-	568	O
renal	-	576	O
function	-	582	O
.	-	590	O

Ifosfamide	2320800	592	O
is	-	603	O
a	-	606	O
known	-	608	O
nephrotoxic	-	614	B
drug	-	626	O
with	-	631	O
demonstrated	-	636	O
tubulopathies	-	649	B
.	-	662	O

We	2320800	664	O
strongly	-	667	O
suspect	-	676	O
that	-	684	O
this	-	689	O
lethal	-	694	O
anuria	-	701	B
was	-	708	O
mainly	-	712	O
due	-	719	O
to	-	723	O
ifosfamide	-	726	O
,	-	736	O
occurring	-	738	O
in	-	748	O
a	-	751	O
patient	-	753	O
having	-	761	O
received	-	768	O
previous	-	777	O
cisplatin	-	786	O
chemotherapy	-	796	O
and	-	809	O
with	-	813	O
poor	-	818	O
kidney	-	823	O
perfusion	-	830	O
due	-	840	O
to	-	844	O
transient	-	847	O
hypotension	-	857	B
.	-	868	O

We	2320800	870	O
recommend	-	873	O
careful	-	883	O
use	-	891	O
of	-	895	O
ifosfamide	-	898	O
in	-	909	O
patients	-	912	O
pretreated	-	921	O
with	-	932	O
nephrotoxic	-	937	B
chemotherapy	-	949	O
and	-	962	O
inadequate	-	966	O
renal	-	977	O
perfusion	-	983	O
.	-	992	O

Central	2220369	0	O
vein	-	8	B
thrombosis	-	13	I
and	-	24	O
topical	-	28	O
dipivalyl	-	36	O
epinephrine	-	46	O
.	-	57	O

A	2220369	59	O
report	-	61	O
is	-	68	O
given	-	71	O
on	-	77	O
an	-	80	O
83	-	83	O
-	-	85	O
year	-	86	O
-	-	90	O
old	-	91	O
female	-	95	O
who	-	102	O
acquired	-	106	O
central	-	115	O
vein	-	123	B
thrombosis	-	128	I
in	-	139	O
her	-	142	O
seeing	-	146	O
eye	-	153	O
one	-	157	O
day	-	161	O
after	-	165	O
having	-	171	O
started	-	178	O
topical	-	186	O
medication	-	194	O
with	-	205	O
dipivalyl	-	210	O
epinephrine	-	220	O
for	-	232	O
advanced	-	236	O
glaucoma	-	245	B
discovered	-	254	O
in	-	265	O
the	-	268	O
other	-	272	O
eye	-	278	O
.	-	281	O

From	2220369	283	O
present	-	288	O
knowledge	-	296	O
about	-	306	O
the	-	312	O
effects	-	316	O
of	-	324	O
adrenergic	-	327	O
eye	-	338	O
drops	-	342	O
on	-	348	O
ocular	-	351	O
blood	-	358	O
circulation	-	364	O
,	-	375	O
it	-	377	O
is	-	380	O
difficult	-	383	O
to	-	393	O
suggest	-	396	O
an	-	404	O
association	-	407	O
between	-	419	O
the	-	427	O
two	-	431	O
events	-	435	O
,	-	441	O
which	-	443	O
may	-	449	O
be	-	453	O
coincidental	-	456	O
only	-	469	O
.	-	473	O

Amelioration	326460	0	O
of	-	13	O
bendrofluazide	-	16	O
-	-	30	O
induced	-	31	O
hypokalemia	-	39	B
by	-	51	O
timolol	-	54	O
.	-	61	O

The	326460	63	O
beta	-	67	O
adrenergic	-	72	O
blocking	-	83	O
drug	-	92	O
,	-	96	O
timolol	-	98	O
,	-	105	O
tended	-	107	O
to	-	114	O
correct	-	117	O
the	-	125	O
hypokalemia	-	129	B
of	-	141	O
short	-	144	O
-	-	149	O
term	-	150	O
bendrofluazide	-	155	O
treatment	-	170	O
in	-	180	O
6	-	183	O
healthy	-	185	O
male	-	193	O
subjects	-	198	O
and	-	207	O
although	-	211	O
the	-	220	O
effect	-	224	O
was	-	231	O
small	-	235	O
it	-	241	O
was	-	244	O
significant	-	248	O
.	-	259	O

Timolol	326460	261	O
also	-	269	O
reduced	-	274	O
the	-	282	O
rise	-	286	O
in	-	291	O
plasma	-	294	O
aldosterone	-	301	O
and	-	313	O
urine	-	317	O
potassium	-	323	O
excretion	-	333	O
following	-	343	O
bendrofluazide	-	353	O
and	-	368	O
increased	-	372	O
the	-	382	O
urine	-	386	O
sodium	-	392	O
/	-	398	O
potassium	-	399	O
ratio	-	409	O
.	-	414	O

There	326460	416	O
was	-	422	O
no	-	426	O
evidence	-	429	O
of	-	438	O
a	-	441	O
shift	-	443	O
of	-	449	O
potassium	-	452	O
from	-	462	O
the	-	467	O
intracellular	-	471	O
to	-	485	O
the	-	488	O
extracellular	-	492	O
space	-	506	O
.	-	511	O

A	20331935	0	O
cross	-	2	O
-	-	7	O
sectional	-	8	O
evaluation	-	18	O
of	-	29	O
the	-	32	O
effect	-	36	O
of	-	43	O
risperidone	-	46	O
and	-	58	O
selective	-	62	O
serotonin	-	72	O
reuptake	-	82	O
inhibitors	-	91	O
on	-	102	O
bone	-	105	O
mineral	-	110	O
density	-	118	O
in	-	126	O
boys	-	129	O
.	-	133	O

OBJECTIVE	20331935	135	O
:	-	144	O
The	-	146	O
aim	-	150	O
of	-	154	O
the	-	157	O
present	-	161	O
study	-	169	O
was	-	175	O
to	-	179	O
investigate	-	182	O
the	-	194	O
effect	-	198	O
of	-	205	O
risperidone	-	208	O
-	-	219	O
induced	-	220	O
hyperprolactinemia	-	228	B
on	-	247	O
trabecular	-	250	O
bone	-	261	O
mineral	-	266	O
density	-	274	O
(	-	282	O
BMD	-	283	O
)	-	286	O
in	-	288	O
children	-	291	O
and	-	300	O
adolescents	-	304	O
.	-	315	O

METHOD	20331935	317	O
:	-	323	O

Medically	20331935	325	O
healthy	-	335	O
7	-	343	O
-	-	344	O
to	-	346	O
17	-	349	O
-	-	351	O
year	-	352	O
-	-	356	O
old	-	357	O
males	-	361	O
chronically	-	367	O
treated	-	379	O
,	-	386	O
in	-	388	O
a	-	391	O
naturalistic	-	393	O
setting	-	406	O
,	-	413	O
with	-	415	O
risperidone	-	420	O
were	-	432	O
recruited	-	437	O
for	-	447	O
this	-	451	O
cross	-	456	O
-	-	461	O
sectional	-	462	O
study	-	472	O
through	-	478	O
child	-	486	O
psychiatry	-	492	O
outpatient	-	503	O
clinics	-	514	O
between	-	522	O
November	-	530	O
2005	-	539	O
and	-	544	O
June	-	548	O
2007	-	553	O
.	-	557	O

Anthropometric	20331935	559	O
measurements	-	574	O
and	-	587	O
laboratory	-	591	O
testing	-	602	O
were	-	610	O
conducted	-	615	O
.	-	624	O

The	20331935	626	O
clinical	-	630	O
diagnoses	-	639	O
were	-	649	O
based	-	654	O
on	-	660	O
chart	-	663	O
review	-	669	O
,	-	675	O
and	-	677	O
developmental	-	681	O
and	-	695	O
treatment	-	699	O
history	-	709	O
was	-	717	O
obtained	-	721	O
from	-	730	O
the	-	735	O
medical	-	739	O
record	-	747	O
.	-	753	O

Volumetric	20331935	755	O
BMD	-	766	O
of	-	770	O
the	-	773	O
ultradistal	-	777	O
radius	-	789	O
was	-	796	O
measured	-	800	O
using	-	809	O
peripheral	-	815	O
quantitative	-	826	O
computed	-	839	O
tomography	-	848	O
,	-	858	O
and	-	860	O
areal	-	864	O
BMD	-	870	O
of	-	874	O
the	-	877	O
lumbar	-	881	O
spine	-	888	O
was	-	894	O
estimated	-	898	O
using	-	908	O
dual	-	914	O
-	-	918	O
energy	-	919	O
x	-	926	O
-	-	927	O
ray	-	928	O
absorptiometry	-	932	O
.	-	946	O

RESULTS	20331935	948	O
:	-	955	O

Hyperprolactinemia	20331935	957	B
was	-	976	O
present	-	980	O
in	-	988	O
49	-	991	O
%	-	993	O
of	-	995	O
83	-	998	O
boys	-	1001	O
(	-	1006	O
n	-	1007	O
=	-	1009	O
41	-	1011	O
)	-	1013	O
treated	-	1015	O
with	-	1023	O
risperidone	-	1028	O
for	-	1040	O
a	-	1044	O
mean	-	1046	O
of	-	1051	O
2	-	1054	O
.	-	1055	O
9	-	1056	O
years	-	1058	O
.	-	1063	O

Serum	20331935	1065	O
testosterone	-	1071	O
concentration	-	1084	O
increased	-	1098	O
with	-	1108	O
pubertal	-	1113	O
status	-	1122	O
but	-	1129	O
was	-	1133	O
not	-	1137	O
affected	-	1141	O
by	-	1150	O
hyperprolactinemia	-	1153	B
.	-	1171	O

As	20331935	1173	O
expected	-	1176	O
,	-	1184	O
bone	-	1186	O
mineral	-	1191	O
content	-	1199	O
and	-	1207	O
BMD	-	1211	O
increased	-	1215	O
with	-	1225	O
sexual	-	1230	O
maturity	-	1237	O
.	-	1245	O

After	20331935	1247	O
adjusting	-	1253	O
for	-	1263	O
the	-	1267	O
stage	-	1271	O
of	-	1277	O
sexual	-	1280	O
development	-	1287	O
and	-	1299	O
height	-	1303	O
and	-	1310	O
BMI	-	1314	O
z	-	1318	O
scores	-	1320	O
,	-	1326	O
serum	-	1328	O
prolactin	-	1334	O
was	-	1344	O
negatively	-	1348	O
associated	-	1359	O
with	-	1370	O
trabecular	-	1375	O
volumetric	-	1386	O
BMD	-	1397	O
at	-	1401	O
the	-	1404	O
ultradistal	-	1408	O
radius	-	1420	O
(	-	1427	O
P	-	1428	O
<	-	1430	O
.	-	1432	O
03	-	1433	O
)	-	1435	O
.	-	1436	O

Controlling	20331935	1438	O
for	-	1450	O
relevant	-	1454	O
covariates	-	1463	O
,	-	1473	O
we	-	1475	O
also	-	1478	O
found	-	1483	O
treatment	-	1489	O
with	-	1499	O
selective	-	1504	O
serotonin	-	1514	O
reuptake	-	1524	O
inhibitors	-	1533	O
(	-	1544	O
SSRIs	-	1545	O
)	-	1550	O
to	-	1552	O
be	-	1555	O
associated	-	1558	O
with	-	1569	O
lower	-	1574	O
trabecular	-	1580	O
BMD	-	1591	O
at	-	1595	O
the	-	1598	O
radius	-	1602	O
(	-	1609	O
P	-	1610	O
=	-	1612	O
.	-	1614	O
03	-	1615	O
)	-	1617	O
and	-	1619	O
BMD	-	1623	O
z	-	1627	O
score	-	1629	O
at	-	1635	O
the	-	1638	O
lumbar	-	1642	O
spine	-	1649	O
(	-	1655	O
P	-	1656	O
<	-	1658	O
.	-	1660	O
05	-	1661	O
)	-	1663	O
.	-	1664	O

These	20331935	1666	O
findings	-	1672	O
became	-	1681	O
more	-	1688	O
marked	-	1693	O
when	-	1700	O
the	-	1705	O
analysis	-	1709	O
was	-	1718	O
restricted	-	1722	O
to	-	1733	O
non	-	1736	O
-	-	1739	O
Hispanic	-	1740	O
white	-	1749	O
patients	-	1755	O
.	-	1763	O

Of	20331935	1765	O
13	-	1768	O
documented	-	1771	O
fractures	-	1782	B
,	-	1791	O
3	-	1793	O
occurred	-	1795	O
after	-	1804	O
risperidone	-	1810	O
and	-	1822	O
SSRIs	-	1826	O
were	-	1832	O
started	-	1837	O
,	-	1844	O
and	-	1846	O
none	-	1850	O
occurred	-	1855	O
in	-	1864	O
patients	-	1867	O
with	-	1876	O
hyperprolactinemia	-	1881	B
.	-	1899	O

CONCLUSIONS	20331935	1901	O
:	-	1912	O

This	20331935	1914	O
is	-	1919	O
the	-	1922	O
first	-	1926	O
study	-	1932	O
to	-	1938	O
link	-	1941	O
risperidone	-	1946	O
-	-	1957	O
induced	-	1958	O
hyperprolactinemia	-	1966	B
and	-	1985	O
SSRI	-	1989	O
treatment	-	1994	O
to	-	2004	O
lower	-	2007	O
BMD	-	2013	O
in	-	2017	O
children	-	2020	O
and	-	2029	O
adolescents	-	2033	O
.	-	2044	O

Future	20331935	2046	O
research	-	2053	O
should	-	2062	O
evaluate	-	2069	O
the	-	2078	O
longitudinal	-	2082	O
course	-	2095	O
of	-	2102	O
this	-	2105	O
adverse	-	2110	O
event	-	2118	O
to	-	2124	O
determine	-	2127	O
its	-	2137	O
temporal	-	2141	O
stability	-	2150	O
and	-	2160	O
whether	-	2164	O
a	-	2172	O
higher	-	2174	O
fracture	-	2181	O
rate	-	2190	O
ensues	-	2195	O
.	-	2201	O

Seizures	19707748	0	B
associated	-	9	O
with	-	20	O
levofloxacin	-	25	O
:	-	37	O
case	-	39	O
presentation	-	44	O
and	-	57	O
literature	-	61	O
review	-	72	O
.	-	78	O

PURPOSE	19707748	80	O
:	-	87	O

We	19707748	89	O
present	-	92	O
a	-	100	O
case	-	102	O
of	-	107	O
a	-	110	O
patient	-	112	O
who	-	120	O
developed	-	124	O
seizures	-	134	B
shortly	-	143	O
after	-	151	O
initiating	-	157	O
treatment	-	168	O
with	-	178	O
levofloxacin	-	183	O
and	-	196	O
to	-	200	O
discuss	-	203	O
the	-	211	O
potential	-	215	O
drug	-	225	O
-	-	229	O
drug	-	230	O
interactions	-	235	O
related	-	248	O
to	-	256	O
the	-	259	O
inhibition	-	263	O
of	-	274	O
cytochrome	-	277	O
P450	-	288	O
(	-	293	O
CYP	-	294	O
)	-	297	O

1A2	19707748	299	O
in	-	303	O
this	-	306	O
case	-	311	O
,	-	315	O
as	-	317	O
well	-	320	O
as	-	325	O
in	-	328	O
other	-	331	O
cases	-	337	O
,	-	342	O
of	-	344	O
levofloxacin	-	347	O
-	-	359	O
induced	-	360	O
seizures	-	368	B
.	-	376	O

METHODS	19707748	378	O
:	-	385	O

Several	19707748	387	O
biomedical	-	395	O
databases	-	406	O
were	-	416	O
searched	-	421	O
including	-	430	O
MEDLINE	-	440	O
,	-	447	O
Cochrane	-	449	O
and	-	458	O
Ovid	-	462	O
.	-	466	O

The	19707748	468	O
main	-	472	O
search	-	477	O
terms	-	484	O
utilized	-	490	O
were	-	499	O
case	-	504	O
report	-	509	O
and	-	516	O
levofloxacin	-	520	O
.	-	532	O

The	19707748	534	O
search	-	538	O
was	-	545	O
limited	-	549	O
to	-	557	O
studies	-	560	O
published	-	568	O
in	-	578	O
English	-	581	O
.	-	588	O

RESULTS	19707748	590	O
:	-	597	O

Six	19707748	599	O
cases	-	603	O
of	-	609	O
levofloxacin	-	612	O
-	-	624	O
induced	-	625	O
seizures	-	633	B
have	-	642	O
been	-	647	O
reported	-	652	O
in	-	661	O
the	-	664	O
literature	-	668	O
.	-	678	O

Drug	19707748	680	O
-	-	684	O
drug	-	685	O
interactions	-	690	O
related	-	703	O
to	-	711	O
the	-	714	O
inhibition	-	718	O
of	-	729	O
CYP1A2	-	732	O
by	-	739	O
levofloxacin	-	742	O
are	-	755	O
likely	-	759	O
involved	-	766	O
in	-	775	O
the	-	778	O
clinical	-	782	O
outcome	-	791	O
of	-	799	O
these	-	802	O
cases	-	808	O
.	-	813	O

CONCLUSIONS	19707748	815	O
:	-	826	O

Clinicians	19707748	828	O
are	-	839	O
exhorted	-	843	O
to	-	852	O
pay	-	855	O
close	-	859	O
attention	-	865	O
when	-	875	O
initiating	-	880	O
levofloxacin	-	891	O
therapy	-	904	O
in	-	912	O
patients	-	915	O
taking	-	924	O
medications	-	931	O
with	-	943	O
epileptogenic	-	948	O
properties	-	962	O
that	-	973	O
are	-	978	O
CYP1A2	-	982	O
substrates	-	989	O
.	-	999	O

Mice	19692487	0	O
lacking	-	5	O
mPGES	-	13	O
-	-	18	O
1	-	19	O
are	-	21	O
resistant	-	25	O
to	-	35	O
lithium	-	38	O
-	-	45	O
induced	-	46	O
polyuria	-	54	B
.	-	62	O

Cyclooxygenase	19692487	64	O
-	-	78	O
2	-	79	O
activity	-	81	O
is	-	90	O
required	-	93	O
for	-	102	O
the	-	106	O
development	-	110	O
of	-	122	O
lithium	-	125	O
-	-	132	O
induced	-	133	O
polyuria	-	141	B
.	-	149	O

However	19692487	151	O
,	-	158	O
the	-	160	O
involvement	-	164	O
of	-	176	O
a	-	179	O
specific	-	181	O
,	-	189	O
terminal	-	191	O
prostaglandin	-	200	O
(	-	214	O
PG	-	215	O
)	-	217	O
isomerase	-	219	O
has	-	229	O
not	-	233	O
been	-	237	O
evaluated	-	242	O
.	-	251	O

The	19692487	253	O
present	-	257	O
study	-	265	O
was	-	271	O
undertaken	-	275	O
to	-	286	O
assess	-	289	O
lithium	-	296	O
-	-	303	O
induced	-	304	O
polyuria	-	312	B
in	-	321	O
mice	-	324	O
deficient	-	329	O
in	-	339	O
microsomal	-	342	O
prostaglandin	-	353	O
E	-	367	O
synthase	-	369	O
-	-	377	O
1	-	378	O
(	-	380	O
mPGES	-	381	O
-	-	386	O
1	-	387	O
)	-	388	O
.	-	389	O

A	19692487	391	O
2	-	393	O
-	-	394	O
wk	-	395	O
administration	-	398	O
of	-	413	O
LiCl	-	416	O
(	-	421	O
4	-	422	O
mmol	-	424	O
.	-	428	O
kg	-	429	O
(	-	431	O
-	-	432	O
1	-	433	O
)	-	434	O
.	-	435	O
day	-	436	O
(	-	439	O
-	-	440	O
1	-	441	O
)	-	442	O
ip	-	444	O
)	-	446	O
in	-	448	O
mPGES	-	451	O
-	-	456	O
1	-	457	O
+	-	459	O
/	-	460	O
+	-	461	O
mice	-	463	O
led	-	468	O
to	-	472	O
a	-	475	O
marked	-	477	O
polyuria	-	484	B
with	-	493	O
hyposmotic	-	498	O
urine	-	509	O
.	-	514	O

This	19692487	516	O
was	-	521	O
associated	-	525	O
with	-	536	O
elevated	-	541	O
renal	-	550	O
mPGES	-	556	O
-	-	561	O
1	-	562	O
protein	-	564	O
expression	-	572	O
and	-	583	O
increased	-	587	O
urine	-	597	O
PGE	-	603	O
(	-	606	O
2	-	607	O
)	-	608	O
excretion	-	610	O
.	-	619	O

In	19692487	621	O
contrast	-	624	O
,	-	632	O
mPGES	-	634	O
-	-	639	O
1	-	640	O
-	-	642	O
/	-	643	O
-	-	644	O
mice	-	646	O
were	-	651	O
largely	-	656	O
resistant	-	664	O
to	-	674	O
lithium	-	677	O
-	-	684	O
induced	-	685	O
polyuria	-	693	B
and	-	702	O
a	-	706	O
urine	-	708	O
concentrating	-	714	O
defect	-	728	O
,	-	734	O
accompanied	-	736	O
by	-	748	O
nearly	-	751	O
complete	-	758	O
blockade	-	767	O
of	-	776	O
high	-	779	O
urine	-	784	O
PGE	-	790	O
(	-	793	O
2	-	794	O
)	-	795	O
and	-	797	O
cAMP	-	801	O
output	-	806	O
.	-	812	O

Immunoblotting	19692487	814	O
,	-	828	O
immunohistochemistry	-	830	O
,	-	850	O
and	-	852	O
quantitative	-	856	O
(	-	869	O
q	-	870	O
)	-	871	O
RT	-	873	O
-	-	875	O
PCR	-	876	O
consistently	-	880	O
detected	-	893	O
a	-	902	O
significant	-	904	O
decrease	-	916	O
in	-	925	O
aquaporin	-	928	O
-	-	937	O
2	-	938	O
(	-	940	O
AQP2	-	941	O
)	-	945	O
protein	-	947	O
expression	-	955	O
in	-	966	O
both	-	969	O
the	-	974	O
renal	-	978	O
cortex	-	984	O
and	-	991	O
medulla	-	995	O
of	-	1003	O
lithium	-	1006	O
-	-	1013	O
treated	-	1014	O
+	-	1022	O
/	-	1023	O
+	-	1024	O
mice	-	1026	O
.	-	1030	O

This	19692487	1032	O
decrease	-	1037	O
was	-	1046	O
significantly	-	1050	O
attenuated	-	1064	O
in	-	1075	O
the	-	1078	O
-	-	1082	O
/	-	1083	O
-	-	1084	O
mice	-	1086	O
.	-	1090	O
qRT	-	1092	O
-	-	1095	O
PCR	-	1096	O
detected	-	1100	O
similar	-	1109	O
patterns	-	1117	O
of	-	1126	O
changes	-	1129	O
in	-	1137	O
AQP2	-	1140	O
mRNA	-	1145	O
in	-	1150	O
the	-	1153	O
medulla	-	1157	O
but	-	1165	O
not	-	1169	O
in	-	1173	O
the	-	1176	O
cortex	-	1180	O
.	-	1186	O

Similarly	19692487	1188	O
,	-	1197	O
the	-	1199	O
total	-	1203	O
protein	-	1209	O
abundance	-	1217	O
of	-	1227	O
the	-	1230	O
Na	-	1234	O
-	-	1236	O
K	-	1237	O
-	-	1238	O
2Cl	-	1239	O
cotransporter	-	1243	O
(	-	1257	O
NKCC2	-	1258	O
)	-	1263	O
in	-	1265	O
the	-	1268	O
medulla	-	1272	O
but	-	1280	O
not	-	1284	O
in	-	1288	O
the	-	1291	O
cortex	-	1295	O
of	-	1302	O
the	-	1305	O
+	-	1309	O
/	-	1310	O
+	-	1311	O
mice	-	1313	O
was	-	1318	O
significantly	-	1322	O
reduced	-	1336	O
by	-	1344	O
lithium	-	1347	O
treatment	-	1355	O
.	-	1364	O

In	19692487	1366	O
contrast	-	1369	O
,	-	1377	O
the	-	1379	O
dowregulation	-	1383	O
of	-	1397	O
renal	-	1400	O
medullary	-	1406	O
NKCC2	-	1416	O
expression	-	1422	O
was	-	1433	O
significantly	-	1437	O
attenuated	-	1451	O
in	-	1462	O
the	-	1465	O
-	-	1469	O
/	-	1470	O
-	-	1471	O
mice	-	1473	O
.	-	1477	O

We	19692487	1479	O
conclude	-	1482	O
that	-	1491	O
mPGES	-	1496	O
-	-	1501	O
1	-	1502	O
-	-	1503	O
derived	-	1504	O
PGE	-	1512	O
(	-	1515	O
2	-	1516	O
)	-	1517	O
mediates	-	1519	O
lithium	-	1528	O
-	-	1535	O
induced	-	1536	O
polyuria	-	1544	B
likely	-	1553	O
via	-	1560	O
inhibition	-	1564	O
of	-	1575	O
AQP2	-	1578	O
and	-	1583	O
NKCC2	-	1587	O
expression	-	1593	O
.	-	1603	O

Identification	19289093	0	O
of	-	15	O
a	-	18	O
simple	-	20	O
and	-	27	O
sensitive	-	31	O
microplate	-	41	O
method	-	52	O
for	-	59	O
the	-	63	O
detection	-	67	O
of	-	77	O
oversulfated	-	80	O
chondroitin	-	93	O
sulfate	-	105	O
in	-	113	O
heparin	-	116	O
products	-	124	O
.	-	132	O

Heparin	19289093	134	O
is	-	142	O
a	-	145	O
commonly	-	147	O
implemented	-	156	O
anticoagulant	-	168	O
used	-	182	O
to	-	187	O
treat	-	190	O
critically	-	196	O
ill	-	207	O
patients	-	211	O
.	-	219	O

Recently	19289093	221	O
,	-	229	O
a	-	231	O
number	-	233	O
of	-	240	O
commercial	-	243	O
lots	-	254	O
of	-	259	O
heparin	-	262	O
products	-	270	O
were	-	279	O
found	-	284	O
to	-	290	O
be	-	293	O
contaminated	-	296	O
with	-	309	O
an	-	314	O
oversulfated	-	317	O
chondroitin	-	330	O
sulfate	-	342	O
(	-	350	O
OSCS	-	351	O
)	-	355	O
derivative	-	357	O
that	-	368	O
could	-	373	O
elicit	-	379	O
a	-	386	O
hypotensive	-	388	B
response	-	400	O
in	-	409	O
pigs	-	412	O
following	-	417	O
a	-	427	O
single	-	429	O
high	-	436	O
-	-	440	O
dose	-	441	O
infusion	-	446	O
.	-	454	O

Using	19289093	456	O
both	-	462	O
contaminated	-	467	O
heparin	-	480	O
products	-	488	O
and	-	497	O
the	-	501	O
synthetically	-	505	O
produced	-	519	O
derivative	-	528	O
,	-	538	O
we	-	540	O
showed	-	543	O
that	-	550	O
the	-	555	O
OSCS	-	559	O
produces	-	564	O
dose	-	573	O
-	-	577	O
dependent	-	578	O
hypotension	-	588	B
in	-	600	O
pigs	-	603	O
.	-	607	O

The	19289093	609	O
no	-	613	O
observed	-	616	O
effect	-	625	O
level	-	632	O
(	-	638	O
NOEL	-	639	O
)	-	643	O
for	-	645	O
this	-	649	O
contaminant	-	654	O
appears	-	666	O
to	-	674	O
be	-	677	O
approximately	-	680	O
1mg	-	694	O
/	-	697	O
kg	-	698	O
,	-	700	O
corresponding	-	702	O
to	-	716	O
a	-	719	O
contamination	-	721	O
level	-	735	O
of	-	741	O
approximately	-	744	O
3	-	758	O
%	-	759	O
.	-	760	O

We	19289093	762	O
also	-	765	O
demonstrated	-	770	O
that	-	783	O
OSCS	-	788	O
can	-	793	O
be	-	797	O
identified	-	800	O
in	-	811	O
heparin	-	814	O
products	-	822	O
using	-	831	O
a	-	837	O
simple	-	839	O
,	-	845	O
inexpensive	-	847	O
,	-	858	O
commercially	-	860	O
available	-	873	O
heparin	-	883	O
enzyme	-	891	O
immunoassay	-	898	O
(	-	910	O
EIA	-	911	O
)	-	914	O
kit	-	916	O
that	-	920	O
has	-	925	O
a	-	929	O
limit	-	931	O
of	-	937	O
detection	-	940	O
of	-	950	O
approximately	-	953	O
0	-	967	O
.	-	968	O
1	-	969	O
%	-	970	O
,	-	971	O
well	-	973	O
below	-	978	O
the	-	984	O
NOEL	-	988	O
.	-	992	O

This	19289093	994	O
kit	-	999	O
may	-	1003	O
provide	-	1007	O
a	-	1015	O
useful	-	1017	O
method	-	1024	O
to	-	1031	O
test	-	1034	O
heparin	-	1039	O
products	-	1047	O
for	-	1056	O
contamination	-	1060	O
with	-	1074	O
oversulfated	-	1079	O
GAG	-	1092	O
derivatives	-	1096	O
.	-	1107	O

Doxorubicin	18627295	0	O
cardiomyopathy	-	12	B
-	-	26	O
induced	-	27	O
inflammation	-	35	B
and	-	48	O
apoptosis	-	52	O
are	-	62	O
attenuated	-	66	O
by	-	77	O
gene	-	80	O
deletion	-	85	O
of	-	94	O
the	-	97	O
kinin	-	101	O
B1	-	107	O
receptor	-	110	O
.	-	118	O

Clinical	18627295	120	O
use	-	129	O
of	-	133	O
the	-	136	O
anthracycline	-	140	O
doxorubicin	-	154	O
(	-	166	O
DOX	-	167	O
)	-	170	O
is	-	172	O
limited	-	175	O
by	-	183	O
its	-	186	O
cardiotoxic	-	190	B
effects	-	202	O
,	-	209	O
which	-	211	O
are	-	217	O
attributed	-	221	O
to	-	232	O
the	-	235	O
induction	-	239	O
of	-	249	O
apoptosis	-	252	O
.	-	261	O

To	18627295	263	O
elucidate	-	266	O
the	-	276	O
possible	-	280	O
role	-	289	O
of	-	294	O
the	-	297	O
kinin	-	301	O
B1	-	307	O
receptor	-	310	O
(	-	319	O
B1R	-	320	O
)	-	323	O
during	-	325	O
the	-	332	O
development	-	336	O
of	-	348	O
DOX	-	351	O
cardiomyopathy	-	355	B
,	-	369	O
we	-	371	O
studied	-	374	O
B1R	-	382	O
knockout	-	386	O
mice	-	395	O
(	-	400	O
B1R	-	401	O
(	-	404	O
-	-	405	O
/	-	406	O
-	-	407	O
)	-	408	O
)	-	409	O
by	-	411	O
investigating	-	414	O
cardiac	-	428	O
inflammation	-	436	B
and	-	449	O
apoptosis	-	453	O
after	-	463	O
induction	-	469	O
of	-	479	O
DOX	-	482	O
-	-	485	O
induced	-	486	O
cardiomyopathy	-	494	B
.	-	508	O

DOX	18627295	510	O
control	-	514	O
mice	-	522	O
showed	-	527	O
cardiac	-	534	B
dysfunction	-	542	I
measured	-	554	O
by	-	563	O
pressure	-	566	O
-	-	574	O
volume	-	575	O
loops	-	582	O
in	-	588	O
vivo	-	591	O
.	-	595	O

This	18627295	597	O
was	-	602	O
associated	-	606	O
with	-	617	O
a	-	622	O
reduced	-	624	O
activation	-	632	O
state	-	643	O
of	-	649	O
AKT	-	652	O
,	-	655	O
as	-	657	O
well	-	660	O
as	-	665	O
an	-	668	O
increased	-	671	O
bax	-	681	O
/	-	684	O
bcl2	-	685	O
ratio	-	690	O
in	-	696	O
Western	-	699	O
blots	-	707	O
,	-	712	O
indicating	-	714	O
cardiac	-	725	B
apoptosis	-	733	I
.	-	742	O

Furthermore	18627295	744	O
,	-	755	O
mRNA	-	757	O
levels	-	762	O
of	-	769	O
the	-	772	O
proinflammatory	-	776	O
cytokine	-	792	O
interleukin	-	801	O
6	-	813	O
were	-	815	O
increased	-	820	O
in	-	830	O
the	-	833	O
cardiac	-	837	O
tissue	-	845	O
.	-	851	O

In	18627295	853	O
DOX	-	856	O
B1R	-	860	O
(	-	863	O
-	-	864	O
/	-	865	O
-	-	866	O
)	-	867	O
mice	-	869	O
,	-	873	O
cardiac	-	875	B
dysfunction	-	883	I
was	-	895	O
improved	-	899	O
compared	-	908	O
to	-	917	O
DOX	-	920	O
control	-	924	O
mice	-	932	O
,	-	936	O
which	-	938	O
was	-	944	O
associated	-	948	O
with	-	959	O
normalization	-	964	O
of	-	978	O
the	-	981	O
bax	-	985	O
/	-	988	O
bcl	-	989	O
-	-	992	O
2	-	993	O
ratio	-	995	O
and	-	1001	O
interleukin	-	1005	O
6	-	1017	O
,	-	1018	O
as	-	1020	O
well	-	1023	O
as	-	1028	O
AKT	-	1031	O
activation	-	1035	O
state	-	1046	O
.	-	1051	O

These	18627295	1053	O
findings	-	1059	O
suggest	-	1068	O
that	-	1076	O
B1R	-	1081	O
is	-	1085	O
detrimental	-	1088	O
in	-	1100	O
DOX	-	1103	O
cardiomyopathy	-	1107	B
in	-	1122	O
that	-	1125	O
it	-	1130	O
mediates	-	1133	O
the	-	1142	O
inflammatory	-	1146	O
response	-	1159	O
and	-	1168	O
apoptosis	-	1172	O
.	-	1181	O

These	18627295	1183	O
insights	-	1189	O
might	-	1198	O
have	-	1204	O
useful	-	1209	O
implications	-	1216	O
for	-	1229	O
future	-	1233	O
studies	-	1240	O
utilizing	-	1248	O
B1R	-	1258	O
antagonists	-	1262	O
for	-	1274	O
treatment	-	1278	O
of	-	1288	O
human	-	1291	O
DOX	-	1297	O
cardiomyopathy	-	1301	B
.	-	1315	O

Hepatotoxicity	18405372	0	B
associated	-	15	O
with	-	26	O
sulfasalazine	-	31	O
in	-	45	O
inflammatory	-	48	O
arthritis	-	61	B
:	-	70	O

A	18405372	72	O
case	-	74	O
series	-	79	O
from	-	86	O
a	-	91	O
local	-	93	O
surveillance	-	99	O
of	-	112	O
serious	-	115	O
adverse	-	123	O
events	-	131	O
.	-	137	O

BACKGROUND	18405372	139	O
:	-	149	O

Spontaneous	18405372	151	O
reporting	-	163	O
systems	-	173	O
for	-	181	O
adverse	-	185	O
drug	-	193	O
reactions	-	198	O
(	-	208	O
ADRs	-	209	O
)	-	213	O
are	-	215	O
handicapped	-	219	O
by	-	231	O
under	-	234	O
-	-	239	O
reporting	-	240	O
and	-	250	O
limited	-	254	O
detail	-	262	O
on	-	269	O
individual	-	272	O
cases	-	283	O
.	-	288	O

We	18405372	290	O
report	-	293	O
an	-	300	O
investigation	-	303	O
from	-	317	O
a	-	322	O
local	-	324	O
surveillance	-	330	O
for	-	343	O
serious	-	347	O
adverse	-	355	O
drug	-	363	O
reactions	-	368	O
associated	-	378	O
with	-	389	O
disease	-	394	O
modifying	-	402	O
anti	-	412	O
-	-	416	O
rheumatic	-	417	O
drugs	-	427	O
that	-	433	O
was	-	438	O
triggered	-	442	O
by	-	452	O
the	-	455	O
occurrence	-	459	O
of	-	470	O
liver	-	473	B
failure	-	479	I
in	-	487	O
two	-	490	O
of	-	494	O
our	-	497	O
patients	-	501	O
.	-	509	O

METHODS	18405372	511	O
:	-	518	O

Serious	18405372	520	O
ADR	-	528	O
reports	-	532	O
have	-	540	O
been	-	545	O
solicited	-	550	O
from	-	560	O
local	-	565	O
clinicians	-	571	O
by	-	582	O
regular	-	585	O
postcards	-	593	O
over	-	603	O
the	-	608	O
past	-	612	O
seven	-	617	O
years	-	623	O
.	-	628	O

Patients	18405372	630	O
'	-	638	O
,	-	639	O
who	-	641	O
had	-	645	O
hepatotoxicity	-	649	B
on	-	664	O
sulfasalazine	-	667	O
and	-	681	O
met	-	685	O
a	-	689	O
definition	-	691	O
of	-	702	O
a	-	705	O
serious	-	707	O
ADR	-	715	O
,	-	718	O
were	-	720	O
identified	-	725	O
.	-	735	O

Two	18405372	737	O
clinicians	-	741	O
reviewed	-	752	O
structured	-	761	O
case	-	772	O
reports	-	777	O
and	-	785	O
assessed	-	789	O
causality	-	798	O
by	-	808	O
consensus	-	811	O
and	-	821	O
by	-	825	O
using	-	828	O
a	-	834	O
causality	-	836	O
assessment	-	846	O
instrument	-	857	O
.	-	867	O

The	18405372	869	O
likely	-	873	O
frequency	-	880	O
of	-	890	O
hepatotoxicity	-	893	B
with	-	908	O
sulfasalazine	-	913	O
was	-	927	O
estimated	-	931	O
by	-	941	O
making	-	944	O
a	-	951	O
series	-	953	O
of	-	960	O
conservative	-	963	O
assumptions	-	976	O
.	-	987	O

RESULTS	18405372	989	O
:	-	996	O

Ten	18405372	998	O
cases	-	1002	O
were	-	1008	O
identified	-	1013	O
:	-	1023	O
eight	-	1025	O
occurred	-	1031	O
during	-	1040	O
surveillance	-	1047	O
.	-	1059	O

Eight	18405372	1061	O
patients	-	1067	O
were	-	1076	O
hospitalised	-	1081	O
,	-	1093	O
two	-	1095	O
in	-	1099	O
hepatic	-	1102	B
failure	-	1110	I
-	-	1118	O
one	-	1120	O
died	-	1124	O
after	-	1129	O
a	-	1135	O
liver	-	1137	O
transplant	-	1143	O
.	-	1153	O

All	18405372	1155	O
but	-	1159	O
one	-	1163	O
event	-	1167	O
occurred	-	1173	O
within	-	1182	O
6	-	1189	O
weeks	-	1191	O
of	-	1197	O
treatment	-	1200	O
.	-	1209	O

Seven	18405372	1211	O
patients	-	1217	O
had	-	1226	O
a	-	1230	O
skin	-	1232	B
rash	-	1237	I
,	-	1241	O
three	-	1243	O
eosinophilia	-	1249	B
and	-	1262	O
one	-	1266	O
interstitial	-	1270	B
nephritis	-	1283	I
.	-	1292	O

Five	18405372	1294	O
patients	-	1299	O
were	-	1308	O
of	-	1313	O
Black	-	1316	O
British	-	1322	O
of	-	1330	O
African	-	1333	O
or	-	1341	O
Caribbean	-	1344	O
descent	-	1354	O
.	-	1361	O

Liver	18405372	1363	O
enzymes	-	1369	O
showed	-	1377	O
a	-	1384	O
hepatocellular	-	1386	O
pattern	-	1401	O
in	-	1409	O
four	-	1412	O
cases	-	1417	O
and	-	1423	O
a	-	1427	O
mixed	-	1429	O
pattern	-	1435	O
in	-	1443	O
six	-	1446	O
.	-	1449	O

Drug	18405372	1451	O
-	-	1455	O
related	-	1456	O
hepatotoxicity	-	1464	B
was	-	1479	O
judged	-	1483	O
probable	-	1490	O
or	-	1499	O
highly	-	1502	O
probable	-	1509	O
in	-	1518	O
8	-	1521	O
patients	-	1523	O
.	-	1531	O

The	18405372	1533	O
likely	-	1537	O
frequency	-	1544	O
of	-	1554	O
serious	-	1557	O
hepatotoxicity	-	1565	B
with	-	1580	O
sulfasalazine	-	1585	O
was	-	1599	O
estimated	-	1603	O
at	-	1613	O
0	-	1616	O
.	-	1617	O
4	-	1618	O
%	-	1619	O
of	-	1621	O
treated	-	1624	O
patients	-	1632	O
.	-	1640	O

CONCLUSION	18405372	1642	O
:	-	1652	O

Serious	18405372	1654	O
hepatotoxicity	-	1662	B
associated	-	1677	O
with	-	1688	O
sulfasalazine	-	1693	O
appears	-	1707	O
to	-	1715	O
be	-	1718	O
under	-	1721	O
-	-	1726	O
appreciated	-	1727	O
and	-	1739	O
intensive	-	1743	O
monitoring	-	1753	O
and	-	1764	O
vigilance	-	1768	O
in	-	1778	O
the	-	1781	O
first	-	1785	O
6	-	1791	O
weeks	-	1793	O
of	-	1799	O
treatment	-	1802	O
is	-	1812	O
especially	-	1815	O
important	-	1826	O
.	-	1835	O

An	18356633	0	O
evaluation	-	3	O
of	-	14	O
amikacin	-	17	O
nephrotoxicity	-	26	B
in	-	41	O
the	-	44	O
hematology	-	48	O
/	-	58	O
oncology	-	59	O
population	-	68	O
.	-	78	O

Amikacin	18356633	80	O
is	-	89	O
an	-	92	O
aminoglycoside	-	95	O
commonly	-	110	O
used	-	119	O
to	-	124	O
provide	-	127	O
empirical	-	135	O
double	-	145	O
gram	-	152	O
-	-	156	O
negative	-	157	O
treatment	-	166	O
for	-	176	O
febrile	-	180	B
neutropenia	-	188	I
and	-	200	O
other	-	204	O
suspected	-	210	O
infections	-	220	B
.	-	230	O

Strategies	18356633	232	O
of	-	243	O
extended	-	246	O
-	-	254	O
interval	-	255	O
and	-	264	O
conventional	-	268	O
dosing	-	281	O
have	-	288	O
been	-	293	O
utilized	-	298	O
extensively	-	307	O
in	-	319	O
the	-	322	O
general	-	326	O
medical	-	334	O
population	-	342	O
;	-	352	O
however	-	354	O
,	-	361	O
data	-	363	O
are	-	368	O
lacking	-	372	O
to	-	380	O
support	-	383	O
a	-	391	O
dosing	-	393	O
strategy	-	400	O
in	-	409	O
the	-	412	O
hematology	-	416	O
/	-	426	O
oncology	-	427	O
population	-	436	O
.	-	446	O

To	18356633	448	O
evaluate	-	451	O
amikacin	-	460	O
-	-	468	O
associated	-	469	O
nephrotoxicity	-	480	B
in	-	495	O
an	-	498	O
adult	-	501	O
hematology	-	507	O
/	-	517	O
oncology	-	518	O
population	-	527	O
,	-	537	O
a	-	539	O
prospective	-	541	O
,	-	552	O
randomized	-	554	O
,	-	564	O
open	-	566	O
-	-	570	O
label	-	571	O
trial	-	577	O
was	-	583	O
conducted	-	587	O
at	-	597	O
a	-	600	O
university	-	602	O
-	-	612	O
affiliated	-	613	O
medical	-	624	O
center	-	632	O
.	-	638	O

Forty	18356633	640	O
patients	-	646	O
with	-	655	O
a	-	660	O
diagnosis	-	662	O
consistent	-	672	O
with	-	683	O
a	-	688	O
hematologic	-	690	B
/	-	701	I
oncologic	-	702	I
disorder	-	712	I
that	-	721	O
required	-	726	O
treatment	-	735	O
with	-	745	O
an	-	750	O
aminoglycoside	-	753	O
were	-	768	O
randomized	-	773	O
to	-	784	O
either	-	787	O
conventional	-	794	O
or	-	807	O
extended	-	810	O
-	-	818	O
interval	-	819	O
amikacin	-	828	O
.	-	836	O

The	18356633	838	O
occurrence	-	842	O
of	-	853	O
nephrotoxicity	-	856	B
by	-	871	O
means	-	874	O
of	-	880	O
an	-	883	O
increase	-	886	O
in	-	895	O
serum	-	898	O
creatinine	-	904	O
and	-	915	O
evaluation	-	919	O
of	-	930	O
efficacy	-	933	O
via	-	942	O
amikacin	-	946	O
serum	-	955	O
concentrations	-	961	O
with	-	976	O
respective	-	981	O
pathogens	-	992	O
were	-	1002	O
assessed	-	1007	O
.	-	1015	O

The	18356633	1017	O
occurrence	-	1021	O
of	-	1032	O
nephrotoxicity	-	1035	B
was	-	1050	O
similar	-	1054	O
between	-	1062	O
the	-	1070	O
conventional	-	1074	O
and	-	1087	O
extended	-	1091	O
-	-	1099	O
interval	-	1100	O
groups	-	1109	O
,	-	1115	O
at	-	1117	O
10	-	1120	O
%	-	1122	O
and	-	1124	O
5	-	1128	O
%	-	1129	O
,	-	1130	O
respectively	-	1132	O
(	-	1145	O
P	-	1146	O
=	-	1148	O
1	-	1150	O
.	-	1151	O
00	-	1152	O
)	-	1154	O
.	-	1155	O

Six	18356633	1157	O
patients	-	1161	O
in	-	1170	O
the	-	1173	O
conventional	-	1177	O
group	-	1190	O
had	-	1196	O
a	-	1200	O
positive	-	1202	O
culture	-	1211	O
,	-	1218	O
compared	-	1220	O
with	-	1229	O
none	-	1234	O
in	-	1239	O
the	-	1242	O
extended	-	1246	O
-	-	1254	O
interval	-	1255	O
group	-	1264	O
(	-	1270	O
P	-	1271	O
=	-	1273	O
0	-	1275	O
.	-	1276	O
002	-	1277	O
)	-	1280	O
.	-	1281	O

The	18356633	1283	O
occurrence	-	1287	O
of	-	1298	O
nephrotoxicity	-	1301	B
was	-	1316	O
similar	-	1320	O
between	-	1328	O
the	-	1336	O
two	-	1340	O
dosing	-	1344	O
regimens	-	1351	O
,	-	1359	O
but	-	1361	O
the	-	1365	O
distribution	-	1369	O
of	-	1382	O
risk	-	1385	O
factors	-	1390	O
was	-	1398	O
variable	-	1402	O
between	-	1411	O
the	-	1419	O
two	-	1423	O
groups	-	1427	O
.	-	1433	O

Efficacy	18356633	1435	O
could	-	1444	O
not	-	1450	O
be	-	1454	O
assessed	-	1457	O
.	-	1465	O

Memory	16574713	0	O
function	-	7	O
and	-	16	O
serotonin	-	20	O
transporter	-	30	O
promoter	-	42	O
gene	-	51	O
polymorphism	-	56	O
in	-	69	O
ecstasy	-	72	O
(	-	80	O
MDMA	-	81	O
)	-	85	O
users	-	87	O
.	-	92	O

Although	16574713	94	O
3	-	103	O
,	-	104	O
4	-	105	O
-	-	106	O
methylenedioxymethamphetamine	-	107	O
(	-	137	O
MDMA	-	138	O
or	-	143	O
ecstasy	-	146	O
)	-	153	O
has	-	155	O
been	-	159	O
shown	-	164	O
to	-	170	O
damage	-	173	O
brain	-	180	O
serotonin	-	186	O
(	-	196	O
5	-	197	O
-	-	198	O
HT	-	199	O
)	-	201	O
neurons	-	203	O
in	-	211	O
animals	-	214	O
and	-	222	O
possibly	-	226	O
humans	-	235	O
,	-	241	O
little	-	243	O
is	-	250	O
known	-	253	O
about	-	259	O
the	-	265	O
long	-	269	O
-	-	273	O
term	-	274	O
consequences	-	279	O
of	-	292	O
MDMA	-	295	O
-	-	299	O
induced	-	300	O
5	-	308	O
-	-	309	O
HT	-	310	O
neurotoxic	-	313	B
lesions	-	324	I
on	-	332	O
functions	-	335	O
in	-	345	O
which	-	348	O
5	-	354	O
-	-	355	O
HT	-	356	O
is	-	359	O
involved	-	362	O
,	-	370	O
such	-	372	O
as	-	377	O
cognitive	-	380	O
function	-	390	O
.	-	398	O

Because	16574713	400	O
5	-	408	O
-	-	409	O
HT	-	410	O
transporters	-	413	O
play	-	426	O
a	-	431	O
key	-	433	O
element	-	437	O
in	-	445	O
the	-	448	O
regulation	-	452	O
of	-	463	O
synaptic	-	466	O
5	-	475	O
-	-	476	O
HT	-	477	O
transmission	-	480	O
it	-	493	O
may	-	496	O
be	-	500	O
important	-	503	O
to	-	513	O
control	-	516	O
for	-	524	O
the	-	528	O
potential	-	532	O
covariance	-	542	O
effect	-	553	O
of	-	560	O
a	-	563	O
polymorphism	-	565	O
in	-	578	O
the	-	581	O
5	-	585	O
-	-	586	O
HT	-	587	O
transporter	-	590	O
promoter	-	602	O
gene	-	611	O
region	-	616	O
(	-	623	O
5	-	624	O
-	-	625	O
HTTLPR	-	626	O
)	-	632	O
when	-	634	O
studying	-	639	O
the	-	648	O
effects	-	652	O
of	-	660	O
MDMA	-	663	O
as	-	668	O
well	-	671	O
as	-	676	O
cognitive	-	679	O
functioning	-	689	O
.	-	700	O

The	16574713	702	O
aim	-	706	O
of	-	710	O
the	-	713	O
study	-	717	O
was	-	723	O
to	-	727	O
investigate	-	730	O
the	-	742	O
effects	-	746	O
of	-	754	O
moderate	-	757	O
and	-	766	O
heavy	-	770	O
MDMA	-	776	O
use	-	781	O
on	-	785	O
cognitive	-	788	O
function	-	798	O
,	-	806	O
as	-	808	O
well	-	811	O
as	-	816	O
the	-	819	O
effects	-	823	O
of	-	831	O
long	-	834	O
-	-	838	O
term	-	839	O
abstention	-	844	O
from	-	855	O
MDMA	-	860	O
,	-	864	O
in	-	866	O
subjects	-	869	O
genotyped	-	878	O
for	-	888	O
5	-	892	O
-	-	893	O
HTTLPR	-	894	O
.	-	900	O

A	16574713	902	O
second	-	904	O
aim	-	911	O
of	-	915	O
the	-	918	O
study	-	922	O
was	-	928	O
to	-	932	O
determine	-	935	O
whether	-	945	O
these	-	953	O
effects	-	959	O
differ	-	967	O
for	-	974	O
females	-	978	O
and	-	986	O
males	-	990	O
.	-	995	O

Fifteen	16574713	997	O
moderate	-	1005	O
MDMA	-	1014	O
users	-	1019	O
(	-	1025	O
<	-	1026	O
55	-	1027	O
lifetime	-	1030	O
tablets	-	1039	O
)	-	1046	O
,	-	1047	O
22	-	1049	O
heavy	-	1052	O
MDMA	-	1058	O
+	-	1062	O
users	-	1064	O
(	-	1070	O
>	-	1071	O
55	-	1072	O
lifetime	-	1075	O
tablets	-	1084	O
)	-	1091	O
,	-	1092	O
16	-	1094	O
ex	-	1097	O
-	-	1099	O
MDMA	-	1100	O
+	-	1104	O
users	-	1106	O
(	-	1112	O
last	-	1113	O
tablet	-	1118	O
>	-	1125	O
1	-	1127	O
year	-	1129	O
ago	-	1134	O
)	-	1137	O
and	-	1139	O
13	-	1143	O
controls	-	1146	O
were	-	1155	O
compared	-	1160	O
on	-	1169	O
a	-	1172	O
battery	-	1174	O
of	-	1182	O
neuropsychological	-	1185	O
tests	-	1204	O
.	-	1209	O

DNA	16574713	1211	O
from	-	1215	O
peripheral	-	1220	O
nuclear	-	1231	O
blood	-	1239	O
cells	-	1245	O
was	-	1251	O
genotyped	-	1255	O
for	-	1265	O
5	-	1269	O
-	-	1270	O
HTTLPR	-	1271	O
using	-	1278	O
standard	-	1284	O
polymerase	-	1293	O
chain	-	1304	O
reaction	-	1310	O
methods	-	1319	O
.	-	1326	O

A	16574713	1327	O
significant	-	1329	O
group	-	1341	O
effect	-	1347	O
was	-	1354	O
observed	-	1358	O
only	-	1367	O
on	-	1372	O
memory	-	1375	O
function	-	1382	O
tasks	-	1391	O
(	-	1397	O
p	-	1398	O
=	-	1400	O
0	-	1402	O
.	-	1403	O
04	-	1404	O
)	-	1406	O
but	-	1408	O
not	-	1412	O
on	-	1416	O
reaction	-	1419	O
times	-	1428	O
(	-	1434	O
p	-	1435	O
=	-	1437	O
0	-	1439	O
.	-	1440	O
61	-	1441	O
)	-	1443	O
or	-	1445	O
attention	-	1448	O
/	-	1457	O
executive	-	1458	O
functioning	-	1468	O
(	-	1480	O
p	-	1481	O
=	-	1483	O
0	-	1485	O
.	-	1486	O
59	-	1487	O
)	-	1489	O
.	-	1490	O

Heavy	16574713	1492	O
and	-	1498	O
ex	-	1502	O
-	-	1504	O
MDMA	-	1505	O
+	-	1509	O
users	-	1511	O
performed	-	1517	O
significantly	-	1527	O
poorer	-	1541	O
on	-	1548	O
memory	-	1551	O
tasks	-	1558	O
than	-	1564	O
controls	-	1569	O
.	-	1577	O

In	16574713	1579	O
contrast	-	1582	O
,	-	1590	O
no	-	1592	O
evidence	-	1595	O
of	-	1604	O
memory	-	1607	B
impairment	-	1614	I
was	-	1625	O
observed	-	1629	O
in	-	1638	O
moderate	-	1641	O
MDMA	-	1650	O
users	-	1655	O
.	-	1660	O

No	16574713	1662	O
significant	-	1665	O
effect	-	1677	O
of	-	1684	O
5	-	1687	O
-	-	1688	O
HTTLPR	-	1689	O
or	-	1696	O
gender	-	1699	O
was	-	1706	O
observed	-	1710	O
.	-	1718	O

While	16574713	1720	O
the	-	1726	O
use	-	1730	O
of	-	1734	O
MDMA	-	1737	O
in	-	1742	O
quantities	-	1745	O
that	-	1756	O
may	-	1761	O
be	-	1765	O
considered	-	1768	O
""""	-	1779	O
moderate	-	1780	O
""""	-	1788	O
is	-	1790	O
not	-	1793	O
associated	-	1797	O
with	-	1808	O
impaired	-	1813	B
memory	-	1822	I
functioning	-	1829	I
,	-	1840	O
heavy	-	1842	O
use	-	1848	O
of	-	1852	O
MDMA	-	1855	O
use	-	1860	O
may	-	1864	O
lead	-	1868	O
to	-	1873	O
long	-	1876	O
lasting	-	1881	O
memory	-	1889	B
impairments	-	1896	I
.	-	1907	O

No	16574713	1909	O
effect	-	1912	O
of	-	1919	O
5	-	1922	O
-	-	1923	O
HTTLPR	-	1924	O
or	-	1931	O
gender	-	1934	O
on	-	1941	O
memory	-	1944	O
function	-	1951	O
or	-	1960	O
MDMA	-	1963	O
use	-	1968	O
was	-	1972	O
observed	-	1976	O
.	-	1984	O

Aging	15638391	0	O
process	-	6	O
of	-	14	O
epithelial	-	17	O
cells	-	28	O
of	-	34	O
the	-	37	O
rat	-	41	O
prostate	-	45	O
lateral	-	54	O
lobe	-	62	O
in	-	67	O
experimental	-	70	O
hyperprolactinemia	-	83	B
induced	-	102	O
by	-	110	O
haloperidol	-	113	O
.	-	124	O

The	15638391	126	O
aim	-	130	O
of	-	134	O
the	-	137	O
study	-	141	O
was	-	147	O
to	-	151	O
examine	-	154	O
the	-	162	O
influence	-	166	O
of	-	176	O
hyperprolactinemia	-	179	B
,	-	197	O
induced	-	199	O
by	-	207	O
haloperidol	-	210	O
(	-	222	O
HAL	-	223	O
)	-	226	O
on	-	228	O
age	-	231	O
related	-	235	O
morphology	-	243	O
and	-	254	O
function	-	258	O
changes	-	267	O
of	-	275	O
epithelial	-	278	O
cells	-	289	O
in	-	295	O
rat	-	298	O
prostate	-	302	O
lateral	-	311	O
lobe	-	319	O
.	-	323	O

The	15638391	325	O
study	-	329	O
was	-	335	O
performed	-	339	O
on	-	349	O
sexually	-	352	O
mature	-	361	O
male	-	368	O
rats	-	373	O
.	-	377	O

Serum	15638391	379	O
concentrations	-	385	O
of	-	400	O
prolactin	-	403	O
(	-	413	O
PRL	-	414	O
)	-	417	O
and	-	419	O
testosterone	-	423	O
(	-	436	O
T	-	437	O
)	-	438	O
were	-	440	O
measured	-	445	O
.	-	453	O

Tissue	15638391	455	O
sections	-	462	O
were	-	471	O
evaluated	-	476	O
with	-	486	O
light	-	491	O
and	-	497	O
electron	-	501	O
microscopy	-	510	O
.	-	520	O

Immunohistochemical	15638391	522	O
reactions	-	542	O
for	-	552	O
Anti	-	556	O
-	-	560	O
Proliferating	-	561	O
Cell	-	575	O
Nuclear	-	580	O
Antigen	-	588	O
(	-	596	O
PCNA	-	597	O
)	-	601	O
were	-	603	O
performed	-	608	O
.	-	617	O

In	15638391	619	O
rats	-	622	O
of	-	627	O
the	-	630	O
experimental	-	634	O
group	-	647	O
,	-	652	O
the	-	654	O
mean	-	658	O
concentration	-	663	O
of	-	677	O
:	-	679	O
PRL	-	681	O
was	-	685	O
more	-	689	O
than	-	694	O
twice	-	699	O
higher	-	705	O
,	-	711	O
whereas	-	713	O
T	-	721	O
concentration	-	723	O
was	-	737	O
almost	-	741	O
twice	-	748	O
lower	-	754	O
than	-	760	O
that	-	765	O
in	-	770	O
the	-	773	O
control	-	777	O
group	-	785	O
.	-	790	O

Light	15638391	792	O
microscopy	-	798	O
visualized	-	809	O
the	-	820	O
following	-	824	O
:	-	833	O
hypertrophy	-	835	B
and	-	847	O
epithelium	-	851	O
hyperplasia	-	862	B
of	-	874	O
the	-	877	O
glandular	-	881	O
ducts	-	891	O
,	-	896	O
associated	-	898	O
with	-	909	O
increased	-	914	O
PCNA	-	924	O
expression	-	929	O
.	-	939	O

Electron	15638391	941	O
microscopy	-	950	O
revealed	-	961	O
changes	-	970	O
in	-	978	O
columnar	-	981	O
epithelial	-	990	O
cells	-	1001	O
,	-	1006	O
concerning	-	1008	O
organelles	-	1019	O
,	-	1029	O
engaged	-	1031	O
in	-	1039	O
protein	-	1042	O
synthesis	-	1050	O
and	-	1060	O
secretion	-	1064	O
.	-	1073	O

Does	15531665	0	O
supplemental	-	5	O
vitamin	-	18	O
C	-	26	O
increase	-	28	O
cardiovascular	-	37	B
disease	-	52	I
risk	-	60	O
in	-	65	O
women	-	68	O
with	-	74	O
diabetes	-	79	B
?	-	87	O

BACKGROUND	15531665	89	O
:	-	99	O

Vitamin	15531665	101	O
C	-	109	O
acts	-	111	O
as	-	116	O
a	-	119	O
potent	-	121	O
antioxidant	-	128	O
;	-	139	O
however	-	141	O
,	-	148	O
it	-	150	O
can	-	153	O
also	-	157	O
be	-	162	O
a	-	165	O
prooxidant	-	167	O
and	-	178	O
glycate	-	182	O
protein	-	190	O
under	-	198	O
certain	-	204	O
circumstances	-	212	O
in	-	226	O
vitro	-	229	O
.	-	234	O

These	15531665	236	O
observations	-	242	O
led	-	255	O
us	-	259	O
to	-	262	O
hypothesize	-	265	O
that	-	277	O
a	-	282	O
high	-	284	O
intake	-	289	O
of	-	296	O
vitamin	-	299	O
C	-	307	O
in	-	309	O
diabetic	-	312	B
persons	-	321	O
might	-	329	O
promote	-	335	O
atherosclerosis	-	343	B
.	-	358	O

OBJECTIVE	15531665	360	O
:	-	369	O
The	-	371	O
objective	-	375	O
was	-	385	O
to	-	389	O
examine	-	392	O
the	-	400	O
relation	-	404	O
between	-	413	O
vitamin	-	421	O
C	-	429	O
intake	-	431	O
and	-	438	O
mortality	-	442	O
from	-	452	O
cardiovascular	-	457	B
disease	-	472	I
.	-	479	O

DESIGN	15531665	481	O
:	-	487	O

We	15531665	489	O
studied	-	492	O
the	-	500	O
relation	-	504	O
between	-	513	O
vitamin	-	521	O
C	-	529	O
intake	-	531	O
and	-	538	O
mortality	-	542	O
from	-	552	O
total	-	557	O
cardiovascular	-	563	B
disease	-	578	I
(	-	586	O
n	-	587	O
=	-	589	O
281	-	591	O
)	-	594	O
,	-	595	O
coronary	-	597	B
artery	-	606	I
disease	-	613	I
(	-	621	O
n	-	622	O
=	-	624	O
175	-	626	O
)	-	629	O
,	-	630	O
and	-	632	O
stroke	-	636	B
(	-	643	O
n	-	644	O
=	-	646	O
57	-	648	O
)	-	650	O
in	-	652	O
1923	-	655	O
postmenopausal	-	660	O
women	-	675	O
who	-	681	O
reported	-	685	O
being	-	694	O
diabetic	-	700	B
at	-	709	O
baseline	-	712	O
.	-	720	O

Diet	15531665	722	O
was	-	727	O
assessed	-	731	O
with	-	740	O
a	-	745	O
food	-	747	O
-	-	751	O
frequency	-	752	O
questionnaire	-	762	O
at	-	776	O
baseline	-	779	O
,	-	787	O
and	-	789	O
subjects	-	793	O
initially	-	802	O
free	-	812	O
of	-	817	O
coronary	-	820	B
artery	-	829	I
disease	-	836	I
were	-	844	O
prospectively	-	849	O
followed	-	863	O
for	-	872	O
15	-	876	O
y	-	879	O
.	-	880	O
RESULTS	-	882	O
:	-	889	O

After	15531665	891	O
adjustment	-	897	O
for	-	908	O
cardiovascular	-	912	B
disease	-	927	I
risk	-	935	O
factors	-	940	O
,	-	947	O
type	-	949	O
of	-	954	O
diabetes	-	957	B
medication	-	966	O
used	-	977	O
,	-	981	O
duration	-	983	O
of	-	992	O
diabetes	-	995	B
,	-	1003	O
and	-	1005	O
intakes	-	1009	O
of	-	1017	O
folate	-	1020	O
,	-	1026	O
vitamin	-	1028	O
E	-	1036	O
,	-	1037	O
and	-	1039	O
beta	-	1043	O
-	-	1047	O
carotene	-	1048	O
,	-	1056	O
the	-	1058	O
adjusted	-	1062	O
relative	-	1071	O
risks	-	1080	O
of	-	1086	O
total	-	1089	O
cardiovascular	-	1095	B
disease	-	1110	I
mortality	-	1118	O
were	-	1128	O
1	-	1133	O
.	-	1134	O
0	-	1135	O
,	-	1136	O
0	-	1138	O
.	-	1139	O
97	-	1140	O
,	-	1142	O
1	-	1144	O
.	-	1145	O
11	-	1146	O
,	-	1148	O
1	-	1150	O
.	-	1151	O
47	-	1152	O
,	-	1154	O
and	-	1156	O
1	-	1160	O
.	-	1161	O
84	-	1162	O

(	15531665	1165	O
P	-	1166	O
for	-	1168	O
trend	-	1172	O
<	-	1178	O
0	-	1180	O
.	-	1181	O
01	-	1182	O
)	-	1184	O
across	-	1186	O
quintiles	-	1193	O
of	-	1203	O
total	-	1206	O
vitamin	-	1212	O
C	-	1220	O
intake	-	1222	O
from	-	1229	O
food	-	1234	O
and	-	1239	O
supplements	-	1243	O
.	-	1254	O

Adjusted	15531665	1256	O
relative	-	1265	O
risks	-	1274	O
of	-	1280	O
coronary	-	1283	B
artery	-	1292	I
disease	-	1299	I
were	-	1307	O
1	-	1312	O
.	-	1313	O
0	-	1314	O
,	-	1315	O
0	-	1317	O
.	-	1318	O
81	-	1319	O
,	-	1321	O
0	-	1323	O
.	-	1324	O
99	-	1325	O
,	-	1327	O
1	-	1329	O
.	-	1330	O
26	-	1331	O
,	-	1333	O
and	-	1335	O
1	-	1339	O
.	-	1340	O
91	-	1341	O
(	-	1344	O
P	-	1345	O
for	-	1347	O
trend	-	1351	O
=	-	1357	O
0	-	1359	O
.	-	1360	O
01	-	1361	O
)	-	1363	O
and	-	1365	O
of	-	1369	O
stroke	-	1372	B
were	-	1379	O
1	-	1384	O
.	-	1385	O
0	-	1386	O
,	-	1387	O
0	-	1389	O
.	-	1390	O
52	-	1391	O
,	-	1393	O
1	-	1395	O
.	-	1396	O
23	-	1397	O
,	-	1399	O
2	-	1401	O
.	-	1402	O
22	-	1403	O
,	-	1405	O
and	-	1407	O
2	-	1411	O
.	-	1412	O
57	-	1413	O
(	-	1416	O
P	-	1417	O
for	-	1419	O
trend	-	1423	O
<	-	1429	O
0	-	1431	O
.	-	1432	O
01	-	1433	O
)	-	1435	O
.	-	1436	O

When	15531665	1438	O
dietary	-	1443	O
and	-	1451	O
supplemental	-	1455	O
vitamin	-	1468	O
C	-	1476	O
were	-	1478	O
analyzed	-	1483	O
separately	-	1492	O
,	-	1502	O
only	-	1504	O
supplemental	-	1509	O
vitamin	-	1522	O
C	-	1530	O
showed	-	1532	O
a	-	1539	O
positive	-	1541	O
association	-	1550	O
with	-	1562	O
mortality	-	1567	O
endpoints	-	1577	O
.	-	1586	O

Vitamin	15531665	1588	O
C	-	1596	O
intake	-	1598	O
was	-	1605	O
unrelated	-	1609	O
to	-	1619	O
mortality	-	1622	O
from	-	1632	O
cardiovascular	-	1637	B
disease	-	1652	I
in	-	1660	O
the	-	1663	O
nondiabetic	-	1667	O
subjects	-	1679	O
at	-	1688	O
baseline	-	1691	O
.	-	1699	O

CONCLUSION	15531665	1701	O
:	-	1711	O

A	15531665	1713	O
high	-	1715	O
vitamin	-	1720	O
C	-	1728	O
intake	-	1730	O
from	-	1737	O
supplements	-	1742	O
is	-	1754	O
associated	-	1757	O
with	-	1768	O
an	-	1773	O
increased	-	1776	O
risk	-	1786	O
of	-	1791	O
cardiovascular	-	1794	B
disease	-	1809	I
mortality	-	1817	O
in	-	1827	O
postmenopausal	-	1830	O
women	-	1845	O
with	-	1851	O
diabetes	-	1856	B
.	-	1864	O

Absolute	12851669	0	O
and	-	9	O
attributable	-	13	O
risk	-	26	O
of	-	31	O
venous	-	34	B
thromboembolism	-	41	I
in	-	57	O
women	-	60	O
on	-	66	O
combined	-	69	O
cyproterone	-	78	O
acetate	-	90	O
and	-	98	O
ethinylestradiol	-	102	O
.	-	118	O

OBJECTIVE	12851669	120	O
:	-	129	O

To	12851669	131	O
achieve	-	134	O
absolute	-	142	O
risk	-	151	O
estimates	-	156	O
of	-	166	O
venous	-	169	B
thromboembolism	-	176	I
(	-	192	O
VTE	-	193	B
)	-	196	O
among	-	198	O
women	-	204	O
on	-	210	O
cyproterone	-	213	O
acetate	-	225	O
plus	-	233	O
ethinylestradiol	-	238	O
(	-	255	O
CPA	-	256	O
/	-	259	O
EE	-	260	O
)	-	262	O
,	-	263	O
and	-	265	O
among	-	269	O
women	-	275	O
on	-	281	O
combined	-	284	O
oral	-	293	O
contraceptives	-	298	O
(	-	313	O
COCs	-	314	O
)	-	318	O
.	-	319	O

METHODS	12851669	321	O
:	-	328	O

From	12851669	330	O
the	-	335	O
Danish	-	339	O
National	-	346	O
Register	-	355	O
of	-	364	O
Patients	-	367	O
(	-	376	O
NRP	-	377	O
)	-	380	O
,	-	381	O
1996	-	383	O
to	-	388	O
1998	-	391	O
,	-	395	O
the	-	397	O
records	-	401	O
of	-	409	O
1	-	412	O
.	-	413	O
1	-	414	O
million	-	416	O
Danish	-	424	O
women	-	431	O
,	-	436	O
ages	-	438	O
15	-	443	O
to	-	446	O
44	-	449	O
years	-	452	O
,	-	457	O
were	-	459	O
searched	-	464	O
for	-	473	O
evidence	-	477	O
of	-	486	O
VTE	-	489	B
.	-	492	O

COC	12851669	494	O
use	-	498	O
was	-	502	O
ascertained	-	506	O
through	-	518	O
mailed	-	526	O
questionnaires	-	533	O
.	-	547	O

Sales	12851669	549	O
statistics	-	555	O
of	-	566	O
COCs	-	569	O
and	-	574	O
CPA	-	578	O
/	-	581	O
EE	-	582	O
were	-	585	O
provided	-	590	O
through	-	599	O
Danish	-	607	O
Drug	-	614	O
Statistics	-	619	O
.	-	629	O

RESULTS	12851669	631	O
:	-	638	O

During	12851669	640	O
the	-	647	O
time	-	651	O
frame	-	656	O
of	-	662	O
the	-	665	O
study	-	669	O
,	-	674	O
330	-	676	O
women	-	680	O
were	-	686	O
found	-	691	O
to	-	697	O
have	-	700	O
had	-	705	O
VTE	-	709	B
while	-	713	O
on	-	719	O
COCs	-	722	O
.	-	726	O

Of	12851669	728	O
these	-	731	O
women	-	737	O
,	-	742	O
67	-	744	O
were	-	747	O
on	-	752	O
levonorgestrel	-	755	O
-	-	769	O
containing	-	770	O
COCs	-	781	O
.	-	785	O

Eleven	12851669	787	O
were	-	794	O
on	-	799	O
CPA	-	802	O
/	-	805	O
EE	-	806	O
.	-	808	O

The	12851669	810	O
corresponding	-	814	O
absolute	-	828	O
risk	-	837	O
of	-	842	O
VTE	-	845	B
was	-	849	O
3	-	853	O
.	-	854	O
4	-	855	O
(	-	857	O
range	-	858	O
,	-	863	O
3	-	865	O
.	-	866	O
1	-	867	O
-	-	868	O
3	-	869	O
.	-	870	O
8	-	871	O
)	-	872	O
per	-	874	O
10	-	878	O
000	-	881	O
women	-	885	O
years	-	891	O
among	-	897	O
the	-	903	O
women	-	907	O
on	-	913	O
COCs	-	916	O
,	-	920	O
4	-	922	O
.	-	923	O
2	-	924	O
(	-	926	O
range	-	927	O
,	-	932	O
3	-	934	O
.	-	935	O
2	-	936	O
-	-	937	O
5	-	938	O
.	-	939	O
2	-	940	O
)	-	941	O
per	-	943	O
10	-	947	O
000	-	950	O
women	-	954	O
years	-	960	O
among	-	966	O
women	-	972	O
on	-	978	O
levonorgestrel	-	981	O
-	-	995	O
containing	-	996	O
COCs	-	1007	O
,	-	1011	O
and	-	1013	O
3	-	1017	O
.	-	1018	O
1	-	1019	O
(	-	1021	O
range	-	1022	O
,	-	1027	O
1	-	1029	O
.	-	1030	O
3	-	1031	O
-	-	1032	O
4	-	1033	O
.	-	1034	O
9	-	1035	O
)	-	1036	O
per	-	1038	O
10	-	1042	O
000	-	1045	O
women	-	1049	O
years	-	1055	O
among	-	1061	O
the	-	1067	O
women	-	1071	O
on	-	1077	O
CPA	-	1080	O
/	-	1083	O
EE	-	1084	O
.	-	1086	O

CONCLUSION	12851669	1088	O
:	-	1098	O

Our	12851669	1100	O
results	-	1104	O
suggest	-	1112	O
the	-	1120	O
absolute	-	1124	O
risk	-	1133	O
of	-	1138	O
VTE	-	1141	B
among	-	1145	O
Danish	-	1151	O
women	-	1158	O
on	-	1164	O
COCs	-	1167	O
is	-	1172	O
similar	-	1175	O
to	-	1183	O
that	-	1186	O
among	-	1191	O
women	-	1197	O
taking	-	1203	O
CPA	-	1210	O
/	-	1213	O
EE	-	1214	O
.	-	1216	O

Effect	12842176	0	O
of	-	7	O
lindane	-	10	O
on	-	18	O
hepatic	-	21	O
and	-	29	O
brain	-	33	O
cytochrome	-	39	O
P450s	-	50	O
and	-	56	O
influence	-	60	O
of	-	70	O
P450	-	73	O
modulation	-	78	O
in	-	89	O
lindane	-	92	O
induced	-	100	O
neurotoxicity	-	108	B
.	-	121	O

Oral	12842176	123	O
administration	-	128	O
of	-	143	O
lindane	-	146	O
(	-	154	O
2	-	155	O
.	-	156	O
5	-	157	O
,	-	158	O
5	-	160	O
,	-	161	O
10	-	163	O
and	-	166	O
15	-	170	O
mg	-	173	O
/	-	175	O
kg	-	176	O
,	-	178	O
body	-	180	O
weight	-	185	O
)	-	191	O
for	-	193	O
5	-	197	O
days	-	199	O
was	-	204	O
found	-	208	O
to	-	214	O
produce	-	217	O
a	-	225	O
dose	-	227	O
-	-	231	O
dependent	-	232	O
increase	-	242	O
in	-	251	O
the	-	254	O
activity	-	258	O
of	-	267	O
P450	-	270	O
dependent	-	275	O
7	-	285	O
-	-	286	O
ethoxyresorufin	-	287	O
-	-	302	O
O	-	303	O
-	-	304	O
deethylase	-	305	O
(	-	316	O
EROD	-	317	O
)	-	321	O
,	-	322	O
7	-	324	O
-	-	325	O
pentoxyresorufin	-	326	O
-	-	342	O
O	-	343	O
-	-	344	O
dealkylase	-	345	O
(	-	356	O
PROD	-	357	O
)	-	361	O
and	-	363	O
N	-	367	O
-	-	368	O
nitrosodimethylamine	-	369	O
demethylase	-	390	O
(	-	402	O
NDMA	-	403	O
-	-	407	O
d	-	408	O
)	-	409	O
in	-	411	O
rat	-	414	O
brain	-	418	O
and	-	424	O
liver	-	428	O
.	-	433	O

A	12842176	435	O
significant	-	437	O
increase	-	449	O
in	-	458	O
the	-	461	O
hepatic	-	465	O
and	-	473	O
brain	-	477	O
P450	-	483	O
monooxygenases	-	488	O
was	-	503	O
also	-	507	O
observed	-	512	O
when	-	521	O
the	-	526	O
duration	-	530	O
of	-	539	O
exposure	-	542	O
of	-	551	O
low	-	554	O
dose	-	558	O
(	-	563	O
2	-	564	O
.	-	565	O
5	-	566	O
mg	-	568	O
/	-	570	O
kg	-	571	O
)	-	573	O
of	-	575	O
lindane	-	578	O
was	-	586	O
increased	-	590	O
from	-	600	O
5	-	605	O
days	-	607	O
to	-	612	O
15	-	615	O
or	-	618	O
21	-	621	O
days	-	624	O
.	-	628	O

As	12842176	630	O
observed	-	633	O
with	-	642	O
different	-	647	O
doses	-	657	O
,	-	662	O
the	-	664	O
magnitude	-	668	O
of	-	678	O
induction	-	681	O
in	-	691	O
the	-	694	O
activity	-	698	O
of	-	707	O
P450	-	710	O
monooxygenases	-	715	O
was	-	730	O
several	-	734	O
fold	-	742	O
higher	-	747	O
in	-	754	O
liver	-	757	O
microsomes	-	763	O
when	-	774	O
compared	-	779	O
with	-	788	O
the	-	793	O
brain	-	797	O
.	-	802	O

Western	12842176	804	O
blotting	-	812	O
studies	-	821	O
have	-	829	O
indicated	-	834	O
that	-	844	O
the	-	849	O
increase	-	853	O
in	-	862	O
the	-	865	O
P450	-	869	O
enzymes	-	874	O
could	-	882	O
be	-	888	O
due	-	891	O
to	-	895	O
the	-	898	O
increase	-	902	O
in	-	911	O
the	-	914	O
expression	-	918	O
of	-	929	O
P450	-	932	O
1A1	-	937	O
/	-	940	O
1A2	-	941	O
,	-	944	O
2B1	-	946	O
/	-	949	O
2B2	-	950	O
and	-	954	O
2E1	-	958	O
isoenzymes	-	962	O
.	-	972	O

In	12842176	974	O
vitro	-	977	O
studies	-	983	O
using	-	991	O
organic	-	997	O
inhibitors	-	1005	O
specific	-	1016	O
for	-	1025	O
individual	-	1029	O
P450	-	1040	O
isoenzymes	-	1045	O
and	-	1056	O
antibody	-	1060	O
inhibition	-	1069	O
experiments	-	1080	O
have	-	1092	O
further	-	1097	O
demonstrated	-	1105	O
that	-	1118	O
the	-	1123	O
increase	-	1127	O
in	-	1136	O
the	-	1139	O
activity	-	1143	O
of	-	1152	O
PROD	-	1155	O
,	-	1159	O
EROD	-	1161	O
and	-	1166	O
NDMA	-	1170	O
-	-	1174	O
d	-	1175	O
are	-	1177	O
due	-	1181	O
to	-	1185	O
the	-	1188	O
increase	-	1192	O
in	-	1201	O
the	-	1204	O
levels	-	1208	O
of	-	1215	O
P450	-	1218	O
2B1	-	1223	O
/	-	1226	O
2B2	-	1227	O
,	-	1230	O
1A1	-	1232	O
/	-	1235	O
1A2	-	1236	O
and	-	1240	O
2E1	-	1244	O
isoenzymes	-	1248	O
,	-	1258	O
respectively	-	1260	O
.	-	1272	O

Induction	12842176	1274	O
studies	-	1284	O
have	-	1292	O
further	-	1297	O
shown	-	1305	O
that	-	1311	O
while	-	1316	O
pretreatment	-	1322	O
of	-	1335	O
3	-	1338	O
-	-	1339	O
methylcholanthrene	-	1340	O
(	-	1359	O
MC	-	1360	O
)	-	1362	O
,	-	1363	O
an	-	1365	O
inducer	-	1368	O
of	-	1376	O
P4501A1	-	1379	O
/	-	1386	O
1A2	-	1387	O
,	-	1390	O
did	-	1392	O
not	-	1396	O
produce	-	1400	O
any	-	1408	O
significant	-	1412	O
effect	-	1424	O
in	-	1431	O
the	-	1434	O
incidence	-	1438	O
of	-	1448	O
lindane	-	1451	O
induced	-	1459	O
convulsions	-	1467	B
,	-	1478	O
pretreatment	-	1480	O
with	-	1493	O
phenobarbital	-	1498	O
(	-	1512	O
PB	-	1513	O
)	-	1515	O
,	-	1516	O
an	-	1518	O
inducer	-	1521	O
of	-	1529	O
P450	-	1532	O
2B1	-	1537	O
/	-	1540	O
2B2	-	1541	O
or	-	1545	O
ethanol	-	1548	O
,	-	1555	O
an	-	1557	O
inducer	-	1560	O
of	-	1568	O
P450	-	1571	O
2E1	-	1576	O
catalysed	-	1580	O
reactions	-	1590	O
,	-	1599	O
significantly	-	1601	O
increased	-	1615	O
the	-	1625	O
incidence	-	1629	O
of	-	1639	O
lindane	-	1642	O
induced	-	1650	O
convulsions	-	1658	B
.	-	1669	O

Similarly	12842176	1671	O
,	-	1680	O
when	-	1682	O
the	-	1687	O
P450	-	1691	O
-	-	1695	O
mediated	-	1696	O
metabolism	-	1705	O
of	-	1716	O
lindane	-	1719	O
was	-	1727	O
blocked	-	1731	O
by	-	1739	O
cobalt	-	1742	O
chloride	-	1749	O
incidence	-	1758	O
of	-	1768	O
convulsions	-	1771	B
was	-	1783	O
increased	-	1787	O
in	-	1797	O
animals	-	1800	O
treated	-	1808	O
with	-	1816	O
lindane	-	1821	O
indicating	-	1829	O
that	-	1840	O
lindane	-	1845	O
per	-	1853	O
se	-	1857	O
or	-	1860	O
its	-	1863	O
metabolites	-	1867	O
formed	-	1879	O
by	-	1886	O
PB	-	1889	O
or	-	1892	O
ethanol	-	1895	O
inducible	-	1903	O
P450	-	1913	O
isoenzymes	-	1918	O
are	-	1929	O
involved	-	1933	O
in	-	1942	O
its	-	1945	O
neurobehavioral	-	1949	O
toxicity	-	1965	B
.	-	1973	O

Seizure	12745515	0	B
associated	-	8	O
with	-	19	O
sleep	-	24	B
deprivation	-	30	I
and	-	42	O
sustained	-	46	O
-	-	55	O
release	-	56	O
bupropion	-	64	O
.	-	73	O

This	12745515	75	O
case	-	80	O
report	-	85	O
describes	-	92	O
a	-	102	O
generalized	-	104	O
seizure	-	116	B
associated	-	124	O
with	-	135	O
sustained	-	140	O
-	-	149	O
release	-	150	O
bupropion	-	158	O
use	-	168	O
and	-	172	O
sleep	-	176	B
deprivation	-	182	I
.	-	193	O

The	12745515	195	O
subject	-	199	O
,	-	206	O
a	-	208	O
31	-	210	O
-	-	212	O
year	-	213	O
-	-	217	O
old	-	218	O
female	-	222	O
smoker	-	229	O
,	-	235	O
was	-	237	O
participating	-	241	O
in	-	255	O
a	-	258	O
clinical	-	260	O
trial	-	269	O
evaluating	-	275	O
an	-	286	O
investigational	-	289	O
medication	-	305	O
for	-	316	O
smoking	-	320	O
cessation	-	328	O
that	-	338	O
used	-	343	O
sustained	-	348	O
-	-	357	O
release	-	358	O
bupropion	-	366	O
as	-	376	O
an	-	379	O
active	-	382	O
control	-	389	O
.	-	396	O

After	12745515	398	O
5	-	404	O
weeks	-	406	O
of	-	412	O
bupropion	-	415	O
use	-	425	O
,	-	428	O
the	-	430	O
subject	-	434	O
experienced	-	442	O
a	-	454	O
generalized	-	456	O
tonic	-	468	O
clonic	-	474	O
seizure	-	481	B
after	-	489	O
staying	-	495	O
up	-	503	O
nearly	-	506	O
all	-	513	O
night	-	517	O
packing	-	523	O
and	-	531	O
moving	-	535	O
to	-	542	O
a	-	545	O
new	-	547	O
residence	-	551	O
.	-	560	O

The	12745515	562	O
patient	-	566	O
had	-	574	O
no	-	578	O
other	-	581	O
risk	-	587	O
factors	-	592	O
for	-	600	O
seizures	-	604	B
.	-	612	O

We	12745515	614	O
suggest	-	617	O
that	-	625	O
sleep	-	630	B
deprivation	-	636	I
may	-	648	O
add	-	652	O
to	-	656	O
the	-	659	O
risk	-	663	O
of	-	668	O
bupropion	-	671	O
-	-	680	O
associated	-	681	O
seizures	-	692	B
.	-	700	O

Nephrotoxic	12571256	0	B
effects	-	12	O
in	-	20	O
high	-	23	O
-	-	27	O
risk	-	28	O
patients	-	33	O
undergoing	-	42	O
angiography	-	53	O
.	-	64	O

BACKGROUND	12571256	66	O
:	-	76	O

The	12571256	78	O
use	-	82	O
of	-	86	O
iodinated	-	89	O
contrast	-	99	O
medium	-	108	O
can	-	115	O
result	-	119	O
in	-	126	O
nephropathy	-	129	B
.	-	140	O

Whether	12571256	142	O
iso	-	150	O
-	-	153	O
osmolar	-	154	O
contrast	-	162	O
medium	-	171	O
is	-	178	O
less	-	181	O
nephrotoxic	-	186	B
than	-	198	O
low	-	203	O
-	-	206	O
osmolar	-	207	O
contrast	-	215	O
medium	-	224	O
in	-	231	O
high	-	234	O
-	-	238	O
risk	-	239	O
patients	-	244	O
is	-	253	O
uncertain	-	256	O
.	-	265	O

METHODS	12571256	267	O
:	-	274	O

We	12571256	276	O
conducted	-	279	O
a	-	289	O
randomized	-	291	O
,	-	301	O
double	-	303	O
-	-	309	O
blind	-	310	O
,	-	315	O
prospective	-	317	O
,	-	328	O
multicenter	-	330	O
study	-	342	O
comparing	-	348	O
the	-	358	O
nephrotoxic	-	362	B
effects	-	374	O
of	-	382	O
an	-	385	O
iso	-	388	O
-	-	391	O
osmolar	-	392	O
,	-	399	O
dimeric	-	401	O
,	-	408	O
nonionic	-	410	O
contrast	-	419	O
medium	-	428	O
,	-	434	O
iodixanol	-	436	O
,	-	445	O
with	-	447	O
those	-	452	O
of	-	458	O
a	-	461	O
low	-	463	O
-	-	466	O
osmolar	-	467	O
,	-	474	O
nonionic	-	476	O
,	-	484	O
monomeric	-	486	O
contrast	-	496	O
medium	-	505	O
,	-	511	O
iohexol	-	513	O
.	-	520	O

The	12571256	522	O
study	-	526	O
involved	-	532	O
129	-	541	O
patients	-	545	O
with	-	554	O
diabetes	-	559	B
with	-	568	O
serum	-	573	O
creatinine	-	579	O
concentrations	-	590	O
of	-	605	O
1	-	608	O
.	-	609	O
5	-	610	O
to	-	612	O
3	-	615	O
.	-	616	O
5	-	617	O
mg	-	619	O
per	-	622	O
deciliter	-	626	O
who	-	636	O
underwent	-	640	O
coronary	-	650	O
or	-	659	O
aortofemoral	-	662	O
angiography	-	675	O
.	-	686	O

The	12571256	688	O
primary	-	692	O
end	-	700	O
point	-	704	O
was	-	710	O
the	-	714	O
peak	-	718	O
increase	-	723	O
from	-	732	O
base	-	737	O
line	-	742	O
in	-	747	O
the	-	750	O
creatinine	-	754	O
concentration	-	765	O
during	-	779	O
the	-	786	O
three	-	790	O
days	-	796	O
after	-	801	O
angiography	-	807	O
.	-	818	O

Other	12571256	820	O
end	-	826	O
points	-	830	O
were	-	837	O
an	-	842	O
increase	-	845	O
in	-	854	O
the	-	857	O
creatinine	-	861	O
concentration	-	872	O
of	-	886	O
0	-	889	O
.	-	890	O
5	-	891	O
mg	-	893	O
per	-	896	O
deciliter	-	900	O
or	-	910	O
more	-	913	O
,	-	917	O
an	-	919	O
increase	-	922	O
of	-	931	O
1	-	934	O
.	-	935	O
0	-	936	O
mg	-	938	O
per	-	941	O
deciliter	-	945	O
or	-	955	O
more	-	958	O
,	-	962	O
and	-	964	O
a	-	968	O
change	-	970	O
in	-	977	O
the	-	980	O
creatinine	-	984	O
concentration	-	995	O
from	-	1009	O
day	-	1014	O
0	-	1018	O
to	-	1020	O
day	-	1023	O
7	-	1027	O
.	-	1028	O

RESULTS	12571256	1030	O
:	-	1037	O

The	12571256	1039	O
creatinine	-	1043	O
concentration	-	1054	O
increased	-	1068	O
significantly	-	1078	O
less	-	1092	O
in	-	1097	O
patients	-	1100	O
who	-	1109	O
received	-	1113	O
iodixanol	-	1122	O
.	-	1131	O

From	12571256	1133	O
day	-	1138	O
0	-	1142	O
to	-	1144	O
day	-	1147	O
3	-	1151	O
,	-	1152	O
the	-	1154	O
mean	-	1158	O
peak	-	1163	O
increase	-	1168	O
in	-	1177	O
creatinine	-	1180	O
was	-	1191	O
0	-	1195	O
.	-	1196	O
13	-	1197	O
mg	-	1200	O
per	-	1203	O
deciliter	-	1207	O
in	-	1217	O
the	-	1220	O
iodixanol	-	1224	O
group	-	1234	O
and	-	1240	O
0	-	1244	O
.	-	1245	O
55	-	1246	O
mg	-	1249	O
per	-	1252	O
deciliter	-	1256	O
in	-	1266	O
the	-	1269	O
iohexol	-	1273	O
group	-	1281	O
(	-	1287	O
P	-	1288	O
=	-	1289	O
0	-	1290	O
.	-	1291	O
001	-	1292	O
;	-	1295	O
the	-	1297	O
increase	-	1301	O
with	-	1310	O
iodixanol	-	1315	O
minus	-	1325	O
the	-	1331	O
increase	-	1335	O
with	-	1344	O
iohexol	-	1349	O
,	-	1356	O
-	-	1358	O
0	-	1359	O
.	-	1360	O
42	-	1361	O
mg	-	1364	O
per	-	1367	O
deciliter	-	1371	O
[	-	1381	O
95	-	1382	O
percent	-	1385	O
confidence	-	1393	O
interval	-	1404	O
,	-	1412	O
-	-	1414	O
0	-	1415	O
.	-	1416	O
73	-	1417	O
to	-	1420	O
-	-	1423	O
0	-	1424	O
.	-	1425	O
22	-	1426	O
]	-	1428	O
)	-	1429	O
.	-	1430	O

Two	12571256	1432	O
of	-	1436	O
the	-	1439	O
64	-	1443	O
patients	-	1446	O
in	-	1455	O
the	-	1458	O
iodixanol	-	1462	O
group	-	1472	O
(	-	1478	O
3	-	1479	O
percent	-	1481	O
)	-	1488	O
had	-	1490	O
an	-	1494	O
increase	-	1497	O
in	-	1506	O
the	-	1509	O
creatinine	-	1513	O
concentration	-	1524	O
of	-	1538	O
0	-	1541	O
.	-	1542	O
5	-	1543	O
mg	-	1545	O
per	-	1548	O
deciliter	-	1552	O
or	-	1562	O
more	-	1565	O
,	-	1569	O
as	-	1571	O
compared	-	1574	O
with	-	1583	O
17	-	1588	O
of	-	1591	O
the	-	1594	O
65	-	1598	O
patients	-	1601	O
in	-	1610	O
the	-	1613	O
iohexol	-	1617	O
group	-	1625	O
(	-	1631	O
26	-	1632	O
percent	-	1635	O
)	-	1642	O
(	-	1644	O
P	-	1645	O
=	-	1646	O
0	-	1647	O
.	-	1648	O
002	-	1649	O
;	-	1652	O
odds	-	1654	O
ratio	-	1659	O
for	-	1665	O
such	-	1669	O
an	-	1674	O
increase	-	1677	O
in	-	1686	O
the	-	1689	O
iodixanol	-	1693	O
group	-	1703	O
,	-	1708	O
0	-	1710	O
.	-	1711	O
09	-	1712	O

[	12571256	1715	O
95	-	1716	O
percent	-	1719	O
confidence	-	1727	O
interval	-	1738	O
,	-	1746	O
0	-	1748	O
.	-	1749	O
02	-	1750	O
to	-	1753	O
0	-	1756	O
.	-	1757	O
41	-	1758	O
]	-	1760	O
)	-	1761	O
.	-	1762	O

No	12571256	1764	O
patient	-	1767	O
receiving	-	1775	O
iodixanol	-	1785	O
had	-	1795	O
an	-	1799	O
increase	-	1802	O
of	-	1811	O
1	-	1814	O
.	-	1815	O
0	-	1816	O
mg	-	1818	O
per	-	1821	O
deciliter	-	1825	O
or	-	1835	O
more	-	1838	O
,	-	1842	O
but	-	1844	O
10	-	1848	O
patients	-	1851	O
in	-	1860	O
the	-	1863	O
iohexol	-	1867	O
group	-	1875	O
(	-	1881	O
15	-	1882	O
percent	-	1885	O
)	-	1892	O
did	-	1894	O
.	-	1897	O

The	12571256	1899	O
mean	-	1903	O
change	-	1908	O
in	-	1915	O
the	-	1918	O
creatinine	-	1922	O
concentration	-	1933	O
from	-	1947	O
day	-	1952	O
0	-	1956	O
to	-	1958	O
day	-	1961	O
7	-	1965	O
was	-	1967	O
0	-	1971	O
.	-	1972	O
07	-	1973	O
mg	-	1976	O
per	-	1979	O
deciliter	-	1983	O
in	-	1993	O
the	-	1996	O
iodixanol	-	2000	O
group	-	2010	O
and	-	2016	O
0	-	2020	O
.	-	2021	O
24	-	2022	O
mg	-	2025	O
per	-	2028	O
deciliter	-	2032	O
in	-	2042	O
the	-	2045	O
iohexol	-	2049	O
group	-	2057	O
(	-	2063	O
P	-	2064	O
=	-	2065	O
0	-	2066	O
.	-	2067	O
003	-	2068	O
;	-	2071	O
value	-	2073	O
in	-	2079	O
the	-	2082	O
iodixanol	-	2086	O
group	-	2096	O
minus	-	2102	O
the	-	2108	O
value	-	2112	O
in	-	2118	O
the	-	2121	O
iohexol	-	2125	O
group	-	2133	O
,	-	2138	O
-	-	2140	O
0	-	2141	O
.	-	2142	O
17	-	2143	O
mg	-	2146	O
per	-	2149	O
deciliter	-	2153	O
[	-	2163	O
95	-	2164	O
percent	-	2167	O
confidence	-	2175	O
interval	-	2186	O
,	-	2194	O
-	-	2196	O
0	-	2197	O
.	-	2198	O
34	-	2199	O
to	-	2202	O
-	-	2205	O
0	-	2206	O
.	-	2207	O
07	-	2208	O
]	-	2210	O
)	-	2211	O
.	-	2212	O

CONCLUSIONS	12571256	2214	O
:	-	2225	O

Nephropathy	12571256	2227	B
induced	-	2239	O
by	-	2247	O
contrast	-	2250	O
medium	-	2259	O
may	-	2266	O
be	-	2270	O
less	-	2273	O
likely	-	2278	O
to	-	2285	O
develop	-	2288	O
in	-	2296	O
high	-	2299	O
-	-	2303	O
risk	-	2304	O
patients	-	2309	O
when	-	2318	O
iodixanol	-	2323	O
is	-	2333	O
used	-	2336	O
rather	-	2341	O
than	-	2348	O
a	-	2353	O
low	-	2355	O
-	-	2358	O
osmolar	-	2359	O
,	-	2366	O
nonionic	-	2368	O
contrast	-	2377	O
medium	-	2386	O
.	-	2392	O

Experimental	9514561	0	O
cranial	-	13	O
pain	-	21	B
elicited	-	26	O
by	-	35	O
capsaicin	-	38	O
:	-	47	O
a	-	49	O
PET	-	51	O
study	-	55	O
.	-	60	O

Using	9514561	62	O
a	-	68	O
positron	-	70	O
emission	-	79	O
tomography	-	88	O
(	-	99	O
PET	-	100	O
)	-	103	O
study	-	105	O
it	-	111	O
was	-	114	O
shown	-	118	O
recently	-	124	O
that	-	133	O
in	-	138	O
migraine	-	141	B
without	-	150	O
aura	-	158	O
certain	-	163	O
areas	-	171	O
in	-	177	O
the	-	180	O
brain	-	184	O
stem	-	190	O
were	-	195	O
activated	-	200	O
during	-	210	O
the	-	217	O
headache	-	221	B
state	-	230	O
,	-	235	O
but	-	237	O
not	-	241	O
in	-	245	O
the	-	248	O
headache	-	252	B
free	-	261	O
interval	-	266	O
.	-	274	O

It	9514561	276	O
was	-	279	O
suggested	-	283	O
that	-	293	O
this	-	298	O
brain	-	303	O
stem	-	309	O
activation	-	314	O
is	-	325	O
inherent	-	328	O
to	-	337	O
the	-	340	O
migraine	-	344	B
attack	-	353	O
itself	-	360	O
and	-	367	O
represents	-	371	O
the	-	382	O
so	-	386	O
called	-	389	O
'	-	396	O
migraine	-	397	B
generator	-	406	O
'	-	415	O
.	-	416	O

To	9514561	418	O
test	-	421	O
this	-	426	O
hypothesis	-	431	O
we	-	442	O
performed	-	445	O
an	-	455	O
experimental	-	458	O
pain	-	471	B
study	-	476	O
in	-	482	O
seven	-	485	O
healthy	-	491	O
volunteers	-	499	O
,	-	509	O
using	-	511	O
the	-	517	O
same	-	521	O
positioning	-	526	O
in	-	538	O
the	-	541	O
PET	-	545	O
scanner	-	549	O
as	-	557	O
in	-	560	O
the	-	563	O
migraine	-	567	B
patients	-	576	O
.	-	584	O

A	9514561	586	O
small	-	588	O
amount	-	594	O
of	-	601	O
capsaicin	-	604	O
was	-	614	O
administered	-	618	O
subcutaneously	-	631	O
in	-	646	O
the	-	649	O
right	-	653	O
forehead	-	659	O
to	-	668	O
evoke	-	671	O
a	-	677	O
burning	-	679	O
painful	-	687	B
sensation	-	695	O
in	-	705	O
the	-	708	O
first	-	712	O
division	-	718	O
of	-	727	O
the	-	730	O
trigeminal	-	734	O
nerve	-	745	O
.	-	750	O

Increases	9514561	752	O
of	-	762	O
regional	-	765	O
cerebral	-	774	O
blood	-	783	O
flow	-	789	O
(	-	794	O
rCBF	-	795	O
)	-	799	O
were	-	801	O
found	-	806	O
bilaterally	-	812	O
in	-	824	O
the	-	827	O
insula	-	831	O
,	-	837	O
in	-	839	O
the	-	842	O
anterior	-	846	O
cingulate	-	855	O
cortex	-	865	O
,	-	871	O
the	-	873	O
cavernous	-	877	O
sinus	-	887	O
and	-	893	O
the	-	897	O
cerebellum	-	901	O
.	-	911	O

Using	9514561	913	O
the	-	919	O
same	-	923	O
stereotactic	-	928	O
space	-	941	O
limits	-	947	O
as	-	954	O
in	-	957	O
the	-	960	O
above	-	964	O
mentioned	-	970	O
migraine	-	980	B
study	-	989	O
no	-	995	O
brain	-	998	O
stem	-	1004	O
activation	-	1009	O
was	-	1020	O
found	-	1024	O
in	-	1030	O
the	-	1033	O
acute	-	1037	O
pain	-	1043	B
state	-	1048	O
compared	-	1054	O
to	-	1063	O
the	-	1066	O
pain	-	1070	B
free	-	1075	O
state	-	1080	O
.	-	1085	O

The	9514561	1087	O
increase	-	1091	O
of	-	1100	O
activation	-	1103	O
in	-	1114	O
the	-	1117	O
region	-	1121	O
of	-	1128	O
the	-	1131	O
cavernous	-	1135	O
sinus	-	1145	O
however	-	1151	O
,	-	1158	O
suggests	-	1160	O
that	-	1169	O
this	-	1174	O
structure	-	1179	O
is	-	1189	O
more	-	1192	O
likely	-	1197	O
to	-	1204	O
be	-	1207	O
involved	-	1210	O
in	-	1219	O
trigeminal	-	1222	O
transmitted	-	1233	O
pain	-	1245	B
as	-	1250	O
such	-	1253	O
,	-	1257	O
rather	-	1259	O
than	-	1266	O
in	-	1271	O
a	-	1274	O
specific	-	1276	O
type	-	1285	O
of	-	1290	O
headache	-	1293	B
as	-	1302	O
was	-	1305	O
suggested	-	1309	O
for	-	1319	O
cluster	-	1323	B
headache	-	1331	I
.	-	1339	O

Neuroleptic	9165568	0	B
malignant	-	12	I
syndrome	-	22	I
with	-	31	O
risperidone	-	36	O
.	-	47	O

Neuroleptic	9165568	49	B
malignant	-	61	I
syndrome	-	71	I
is	-	80	O
thought	-	83	O
to	-	91	O
be	-	94	O
a	-	97	O
result	-	99	O
of	-	106	O
dopamine	-	109	O
D2	-	118	O
receptor	-	121	O
blockade	-	130	O
in	-	139	O
the	-	142	O
striatum	-	146	O
of	-	155	O
the	-	158	O
basal	-	162	O
ganglia	-	168	O
.	-	175	O

Risperidone	9165568	177	O
,	-	188	O
a	-	190	O
benzisoxazole	-	192	O
derivative	-	206	O
antipsychotic	-	217	O
,	-	230	O
has	-	232	O
high	-	236	O
serotonin	-	241	O
5	-	251	O
-	-	252	O
HT2	-	253	O
receptor	-	257	O
blockade	-	266	O
and	-	275	O
dose	-	279	O
-	-	283	O
related	-	284	O
D2	-	292	O
receptor	-	295	O
blockade	-	304	O
.	-	312	O

The	9165568	314	O
high	-	318	O
ratio	-	323	O
is	-	329	O
believed	-	332	O
to	-	341	O
impart	-	344	O
the	-	351	O
low	-	355	O
frequency	-	359	O
of	-	369	O
extrapyramidal	-	372	B
symptoms	-	387	I
with	-	396	O
risperidone	-	401	O
at	-	413	O
low	-	416	O
dosages	-	420	O
.	-	427	O

With	9165568	429	O
this	-	434	O
low	-	439	O
frequency	-	443	O
of	-	453	O
extrapyramidal	-	456	B
symptoms	-	471	I
,	-	479	O
it	-	481	O
was	-	484	O
thought	-	488	O
the	-	496	O
frequency	-	500	O
of	-	510	O
neuroleptic	-	513	B
malignant	-	525	I
syndrome	-	535	I
might	-	544	O
also	-	550	O
be	-	555	O
lowered	-	558	O
.	-	565	O

A	9165568	567	O
73	-	569	O
-	-	571	O
year	-	572	O
-	-	576	O
old	-	577	O
woman	-	581	O
developed	-	587	O
neuroleptic	-	597	B
malignant	-	609	I
syndrome	-	619	I
after	-	628	O
monotherapy	-	634	O
with	-	646	O
risperidone	-	651	O
.	-	662	O

The	9165568	664	O
syndrome	-	668	O
reversed	-	677	O
after	-	686	O
discontinuing	-	692	O
risperidone	-	706	O
and	-	718	O
starting	-	722	O
treatment	-	731	O
with	-	741	O
dantrolene	-	746	O
and	-	757	O
bromocriptine	-	761	O
.	-	774	O

It	9165568	776	O
appears	-	779	O
that	-	787	O
the	-	792	O
protection	-	796	O
from	-	807	O
extrapyramidal	-	812	O
side	-	827	O
effects	-	832	O
observed	-	840	O
with	-	849	O
risperidone	-	854	O
does	-	866	O
not	-	871	O
ensure	-	875	O
protection	-	882	O
from	-	893	O
neuroleptic	-	898	B
malignant	-	910	I
syndrome	-	920	I
.	-	928	O

Hepatic	9154656	0	O
and	-	8	O
extrahepatic	-	12	O
angiotensinogen	-	25	O
gene	-	41	O
expression	-	46	O
in	-	57	O
rats	-	60	O
with	-	65	O
acute	-	70	O
nephrotic	-	76	B
syndrome	-	86	I
.	-	94	O

Plasma	9154656	96	O
concentration	-	103	O
and	-	117	O
urine	-	121	O
excretion	-	127	O
of	-	137	O
the	-	140	O
renin	-	144	O
-	-	149	O
angiotensin	-	150	O
system	-	162	O
proteins	-	169	O
are	-	178	O
altered	-	182	O
in	-	190	O
rats	-	193	O
with	-	198	O
nephrotic	-	203	B
syndrome	-	213	I
(	-	222	O
NS	-	223	B
)	-	225	O
.	-	226	O

In	9154656	228	O
this	-	231	O
work	-	236	O
the	-	241	O
messenger	-	245	O
ribonucleic	-	255	O
acid	-	267	O
(	-	272	O
mRNA	-	273	O
)	-	277	O
levels	-	279	O
of	-	286	O
angiotensinogen	-	289	O
(	-	305	O
Ao	-	306	O
)	-	308	O
were	-	310	O
analyzed	-	315	O
with	-	324	O
the	-	329	O
slot	-	333	O
-	-	337	O
blot	-	338	O
hybridization	-	343	O
technique	-	357	O
in	-	367	O
liver	-	370	O
and	-	376	O
other	-	380	O
extrahepatic	-	386	O
tissues	-	399	O
:	-	406	O
kidney	-	408	O
,	-	414	O
heart	-	416	O
,	-	421	O
brain	-	423	O
,	-	428	O
and	-	430	O
adrenal	-	434	O
gland	-	442	O
from	-	448	O
control	-	453	O
,	-	460	O
nephrotic	-	462	B
,	-	471	O
and	-	473	O
pair	-	477	O
-	-	481	O
fed	-	482	O
(	-	486	O
PF	-	487	O
)	-	489	O
rats	-	491	O
.	-	495	O

NS	9154656	497	B
was	-	500	O
induced	-	504	O
by	-	512	O
a	-	515	O
single	-	517	O
injection	-	524	O
of	-	534	O
puromycin	-	537	O
amino	-	547	O
-	-	552	O
nucleoside	-	553	O
(	-	564	O
PAN	-	565	O
)	-	568	O
.	-	569	O

Although	9154656	571	O
a	-	580	O
great	-	582	O
urinary	-	588	O
excretion	-	596	O
and	-	606	O
half	-	610	O
-	-	614	O
normal	-	615	O
plasma	-	622	O
levels	-	629	O
of	-	636	O
Ao	-	639	O
were	-	642	O
observed	-	647	O
on	-	656	O
day	-	659	O
6	-	663	O
after	-	665	O
PAN	-	671	O
injection	-	675	O
,	-	684	O
when	-	686	O
NS	-	691	B
was	-	694	O
clearly	-	698	O
established	-	706	O
,	-	717	O
hepatic	-	719	O
Ao	-	727	O
mRNA	-	730	O
levels	-	735	O
did	-	742	O
not	-	746	O
change	-	750	O
.	-	756	O

Furthermore	9154656	758	O
,	-	769	O
the	-	771	O
Ao	-	775	O
mRNA	-	778	O
levels	-	783	O
did	-	790	O
not	-	794	O
change	-	798	O
in	-	805	O
any	-	808	O
of	-	812	O
the	-	815	O
extrahepatic	-	819	O
tissues	-	832	O
studied	-	840	O
on	-	848	O
day	-	851	O
6	-	855	O
,	-	856	O
nor	-	858	O
did	-	862	O
its	-	866	O
hepatic	-	870	O
levels	-	878	O
at	-	885	O
days	-	888	O
1	-	893	O
,	-	894	O
3	-	896	O
,	-	897	O
5	-	899	O
,	-	900	O
or	-	902	O
7	-	905	O
after	-	907	O
PAN	-	913	O
injection	-	917	O
.	-	926	O

These	9154656	928	O
data	-	934	O
suggest	-	939	O
that	-	947	O
the	-	952	O
hepatic	-	956	O
and	-	964	O
extrahepatic	-	968	O
Ao	-	981	O
mRNA	-	984	O
levels	-	989	O
are	-	996	O
unaltered	-	1000	O
during	-	1010	O
the	-	1017	O
development	-	1021	O
of	-	1033	O
the	-	1036	O
acute	-	1040	O
NS	-	1046	B
induced	-	1049	O
by	-	1057	O
PAN	-	1060	O
.	-	1063	O

Cyclophosphamide	8911359	0	O
associated	-	17	O
bladder	-	28	B
cancer	-	36	I
-	-	42	O
-	-	43	O
a	-	44	O
highly	-	46	O
aggressive	-	53	O
disease	-	64	O
:	-	71	O
analysis	-	73	O
of	-	82	O
12	-	85	O
cases	-	88	O
.	-	93	O

PURPOSE	8911359	95	O
:	-	102	O

We	8911359	104	O
gained	-	107	O
knowledge	-	114	O
of	-	124	O
the	-	127	O
etiology	-	131	O
,	-	139	O
treatment	-	141	O
and	-	151	O
prevention	-	155	O
of	-	166	O
cyclophosphamide	-	169	O
associated	-	186	O
urothelial	-	197	B
cancer	-	208	I
.	-	214	O

MATERIALS	8911359	216	O
AND	-	226	O
METHODS	-	230	O
:	-	237	O

The	8911359	239	O
medical	-	243	O
records	-	251	O
of	-	259	O
6	-	262	O
men	-	264	O
and	-	268	O
6	-	272	O
women	-	274	O
(	-	280	O
mean	-	281	O
age	-	286	O
55	-	290	O
years	-	293	O
)	-	298	O
with	-	300	O
cyclophosphamide	-	305	O
associated	-	322	O
bladder	-	333	B
cancer	-	341	I
were	-	348	O
reviewed	-	353	O
.	-	361	O

RESULTS	8911359	363	O
:	-	370	O

All	8911359	372	O
tumors	-	376	B
were	-	383	O
grade	-	388	O
3	-	394	O
or	-	396	O
4	-	399	O
transitional	-	401	O
cell	-	414	O
carcinoma	-	419	B
.	-	428	O

Of	8911359	430	O
the	-	433	O
5	-	437	O
patients	-	439	O
initially	-	448	O
treated	-	458	O
with	-	466	O
endoscopic	-	471	O
resection	-	482	O
alone	-	492	O
only	-	498	O
1	-	503	O
is	-	505	O
alive	-	508	O
without	-	514	O
disease	-	522	O
.	-	529	O

Of	8911359	531	O
the	-	534	O
6	-	538	O
patients	-	540	O
who	-	549	O
underwent	-	553	O
early	-	563	O
cystectomy	-	569	O
4	-	580	O
were	-	582	O
alive	-	587	O
at	-	593	O
24	-	596	O
to	-	599	O
111	-	602	O
months	-	606	O
.	-	612	O

The	8911359	614	O
remaining	-	618	O
patient	-	628	O
with	-	636	O
extensive	-	641	O
cancer	-	651	B
underwent	-	658	O
partial	-	668	O
cystectomy	-	676	O
for	-	687	O
palliation	-	691	O
and	-	702	O
died	-	706	O
3	-	711	O
months	-	713	O
later	-	720	O
.	-	725	O

CONCLUSIONS	8911359	727	O
:	-	738	O

Cyclophosphamide	8911359	740	O
associated	-	757	O
bladder	-	768	B
tumor	-	776	I
is	-	782	O
an	-	785	O
aggressive	-	788	O
disease	-	799	O
.	-	806	O

However	8911359	808	O
,	-	815	O
long	-	817	O
-	-	821	O
term	-	822	O
survival	-	827	O
is	-	836	O
possible	-	839	O
when	-	848	O
radical	-	853	O
cystectomy	-	861	O
is	-	872	O
performed	-	875	O
for	-	885	O
bladder	-	889	B
tumors	-	897	I
with	-	904	O
any	-	909	O
sign	-	913	O
of	-	918	O
invasion	-	921	O
and	-	930	O
for	-	934	O
recurrent	-	938	O
high	-	948	O
grade	-	953	O
disease	-	959	O
,	-	966	O
even	-	968	O
when	-	973	O
noninvasive	-	978	O
.	-	989	O

Leg	8686832	0	B
and	-	4	I
back	-	8	I
pain	-	13	I
after	-	18	O
spinal	-	24	O
anaesthesia	-	31	O
involving	-	43	O
hyperbaric	-	53	O
5	-	64	O
%	-	65	O
lignocaine	-	67	O
.	-	77	O

Fifty	8686832	79	O
-	-	84	O
four	-	85	O
patients	-	90	O
,	-	98	O
aged	-	100	O
27	-	105	O
-	-	107	O
90	-	108	O
years	-	111	O
,	-	116	O
who	-	118	O
were	-	122	O
given	-	127	O
lignocaine	-	133	O
5	-	144	O
%	-	145	O
in	-	147	O
6	-	150	O
.	-	151	O
8	-	152	O
%	-	153	O
glucose	-	155	O
solution	-	163	O
for	-	172	O
spinal	-	176	O
anaesthesia	-	183	O
were	-	195	O
studied	-	200	O
.	-	207	O

Thirteen	8686832	209	O
of	-	218	O
these	-	221	O
patients	-	227	O
experienced	-	236	O
pain	-	248	B
in	-	253	I
the	-	256	I
legs	-	260	I
and	-	265	I
/	-	268	I
or	-	269	I
back	-	272	I
after	-	277	O
recovery	-	283	O
from	-	292	O
anaesthesia	-	297	O
.	-	308	O

The	8686832	310	O
patients	-	314	O
affected	-	323	O
were	-	332	O
younger	-	337	O
(	-	345	O
p	-	346	O
<	-	348	O
0	-	350	O
.	-	351	O
05	-	352	O
)	-	354	O
and	-	356	O
the	-	360	O
site	-	364	O
of	-	369	O
the	-	372	O
dural	-	376	O
puncture	-	382	O
was	-	391	O
higher	-	395	O
(	-	402	O
p	-	403	O
<	-	405	O
0	-	407	O
.	-	408	O
01	-	409	O
)	-	411	O
than	-	413	O
those	-	418	O
individuals	-	424	O
without	-	436	O
pain	-	444	B
.	-	448	O

Five	8686832	450	O
of	-	455	O
the	-	458	O
13	-	462	O
patients	-	465	O
(	-	474	O
38	-	475	O
%	-	477	O
)	-	478	O
with	-	480	O
pain	-	485	B
and	-	490	O
seven	-	494	O
of	-	500	O
the	-	503	O
41	-	507	O
patients	-	510	O
(	-	519	O
17	-	520	O
%	-	522	O
)	-	523	O
without	-	525	O
pain	-	533	B
admitted	-	538	O
to	-	547	O
a	-	550	O
high	-	552	O
alcohol	-	557	O
intake	-	565	O
,	-	571	O
which	-	573	O
might	-	579	O
be	-	585	O
a	-	588	O
contributing	-	590	O
factor	-	603	O
.	-	609	O

Leg	8686832	611	B
and	-	615	I
/	-	618	I
or	-	619	I
back	-	622	I
pain	-	627	I
is	-	632	O
associated	-	635	O
with	-	646	O
the	-	651	O
intrathecal	-	655	O
use	-	667	O
of	-	671	O
hyperbaric	-	674	O
5	-	685	O
%	-	686	O
lignocaine	-	688	O
.	-	698	O

Acute	8607407	0	O
blood	-	6	O
pressure	-	12	O
elevations	-	21	O
with	-	32	O
caffeine	-	37	O
in	-	46	O
men	-	49	O
with	-	53	O
borderline	-	58	O
systemic	-	69	O
hypertension	-	78	B
.	-	90	O

Whether	8607407	92	O
the	-	100	O
vasoconstrictive	-	104	O
actions	-	121	O
of	-	129	O
caffeine	-	132	O
are	-	141	O
enhanced	-	145	O
in	-	154	O
hypertensive	-	157	B
persons	-	170	O
has	-	178	O
not	-	182	O
been	-	186	O
demonstrated	-	191	O
.	-	203	O

Thus	8607407	205	O
,	-	209	O
caffeine	-	211	O
(	-	220	O
3	-	221	O
.	-	222	O
3	-	223	O
mg	-	225	O
/	-	227	O
kg	-	228	O
)	-	230	O
versus	-	232	O
placebo	-	239	O
was	-	247	O
tested	-	251	O
in	-	258	O
48	-	261	O
healthy	-	264	O
men	-	272	O
(	-	276	O
aged	-	277	O
20	-	282	O
to	-	285	O
35	-	288	O
years	-	291	O
)	-	296	O
selected	-	298	O
after	-	307	O
screening	-	313	O
on	-	323	O
2	-	326	O
separate	-	328	O
occasions	-	337	O
.	-	346	O

Borderline	8607407	348	O
hypertensive	-	359	B
men	-	372	O
(	-	376	O
n	-	377	O
=	-	379	O
24	-	381	O
)	-	383	O
were	-	385	O
selected	-	390	O
with	-	399	O
screening	-	404	O
systolic	-	414	O
blood	-	423	O
pressure	-	429	O
(	-	438	O
BP	-	439	O
)	-	441	O
of	-	443	O
140	-	446	O
to	-	450	O
160	-	453	O
mm	-	457	O
Hg	-	460	O
and	-	463	O
/	-	466	O
or	-	467	O
diastolic	-	470	O
BP	-	480	O
90	-	483	O
to	-	486	O
99	-	489	O
mm	-	492	O
Hg	-	495	O
.	-	497	O

Low	8607407	499	O
-	-	502	O
risk	-	503	O
controls	-	508	O
(	-	517	O
n	-	518	O
=	-	520	O
24	-	522	O
)	-	524	O
reported	-	526	O
no	-	535	O
parental	-	538	O
history	-	547	O
of	-	555	O
hypertension	-	558	B
and	-	571	O
had	-	575	O
screening	-	579	O
BP	-	589	O
<	-	592	O
130	-	594	O
/	-	597	O
85	-	598	O
mm	-	601	O
Hg	-	604	O
.	-	606	O

Participants	8607407	608	O
were	-	621	O
then	-	626	O
tested	-	631	O
on	-	638	O
2	-	641	O
occasions	-	643	O
after	-	653	O
12	-	659	O
-	-	661	O
hour	-	662	O
abstinence	-	667	O
from	-	678	O
caffeine	-	683	O
in	-	692	O
each	-	695	O
of	-	700	O
2	-	703	O
protocols	-	705	O
;	-	714	O
this	-	716	O
required	-	721	O
a	-	730	O
total	-	732	O
of	-	738	O
4	-	741	O
laboratory	-	743	O
visits	-	754	O
.	-	760	O

Caffeine	8607407	762	O
-	-	770	O
induced	-	771	O
changes	-	779	O
in	-	787	O
diastolic	-	790	O
BP	-	800	O
were	-	803	O
2	-	808	O
to	-	810	O
3	-	813	O
times	-	815	O
larger	-	821	O
in	-	828	O
borderline	-	831	O
subjects	-	842	O
than	-	851	O
in	-	856	O
controls	-	859	O
(	-	868	O
+	-	869	O
8	-	870	O
.	-	871	O
4	-	872	O
vs	-	874	O
+	-	877	O
3	-	878	O
.	-	879	O
8	-	880	O
mm	-	882	O
Hg	-	885	O
,	-	887	O
p	-	889	O
<	-	891	O
0	-	893	O
.	-	894	O
0001	-	895	O
)	-	899	O
,	-	900	O
and	-	902	O
were	-	906	O
attributable	-	911	O
to	-	924	O
larger	-	927	O
changes	-	934	O
in	-	942	O
impedance	-	945	O
-	-	954	O
derived	-	955	O
measures	-	963	O
of	-	972	O
systemic	-	975	O
vascular	-	984	O
resistance	-	993	O
(	-	1004	O
+	-	1005	O
135	-	1006	O
vs	-	1010	O
+	-	1013	O
45	-	1014	O
dynes	-	1017	O
.	-	1022	O
s	-	1023	O
.	-	1024	O
cm	-	1025	O
-	-	1027	O
5	-	1028	O
,	-	1029	O
p	-	1031	O
<	-	1033	O
0	-	1035	O
.	-	1036	O
004	-	1037	O
)	-	1040	O
.	-	1041	O

These	8607407	1043	O
findings	-	1049	O
were	-	1058	O
consistent	-	1063	O
and	-	1074	O
reached	-	1078	O
significance	-	1086	O
in	-	1099	O
both	-	1102	O
protocols	-	1107	O
.	-	1116	O

The	8607407	1118	O
percentage	-	1122	O
of	-	1133	O
borderline	-	1136	O
subjects	-	1147	O
in	-	1156	O
whom	-	1159	O
diastolic	-	1164	O
BP	-	1174	O
changes	-	1177	O
exceeded	-	1185	O
the	-	1194	O
median	-	1198	O
control	-	1205	O
response	-	1213	O
was	-	1222	O
96	-	1226	O
%	-	1228	O
.	-	1229	O

Consequently	8607407	1231	O
,	-	1243	O
whereas	-	1245	O
all	-	1253	O
participants	-	1257	O
exhibited	-	1270	O
normotensive	-	1280	O
levels	-	1293	O
during	-	1300	O
the	-	1307	O
resting	-	1311	O
predrug	-	1319	O
baseline	-	1327	O
,	-	1335	O
33	-	1337	O
%	-	1339	O
of	-	1341	O
borderline	-	1344	O
subjects	-	1355	O
achieved	-	1364	O
hypertensive	-	1373	B
BP	-	1386	O
levels	-	1389	O
after	-	1396	O
caffeine	-	1402	O
ingestion	-	1411	O
.	-	1420	O

Thus	8607407	1422	O
,	-	1426	O
in	-	1428	O
borderline	-	1431	O
hypertensive	-	1442	B
men	-	1455	O
,	-	1458	O
exaggerated	-	1460	O
responses	-	1472	O
to	-	1482	O
caffeine	-	1485	O
were	-	1494	O
:	-	1498	O
selective	-	1500	O
for	-	1510	O
diastolic	-	1514	O
BP	-	1524	O
,	-	1526	O
consistent	-	1528	O
with	-	1539	O
greater	-	1544	O
vasoconstriction	-	1552	O
,	-	1568	O
replicated	-	1570	O
in	-	1581	O
2	-	1584	O
protocols	-	1586	O
,	-	1595	O
and	-	1597	O
representative	-	1601	O
of	-	1616	O
nearly	-	1619	O
all	-	1626	O
borderline	-	1630	O
hypertensives	-	1641	B
.	-	1654	O

We	8607407	1656	O
suspect	-	1659	O
that	-	1667	O
the	-	1672	O
potential	-	1676	O
for	-	1686	O
caffeine	-	1690	O
to	-	1699	O
stabilize	-	1702	O
high	-	1712	O
resistance	-	1717	O
states	-	1728	O
in	-	1735	O
susceptible	-	1738	O
persons	-	1750	O
suggests	-	1758	O
that	-	1767	O
its	-	1772	O
use	-	1776	O
may	-	1780	O
facilitate	-	1784	O
their	-	1795	O
disease	-	1801	O
progression	-	1809	O
,	-	1820	O
as	-	1822	O
well	-	1825	O
as	-	1830	O
hinder	-	1833	O
accurate	-	1840	O
diagnosis	-	1849	O
and	-	1859	O
treatment	-	1863	O
.	-	1872	O

Hallucinations	8111719	0	B
and	-	15	O
ifosfamide	-	19	O
-	-	29	O
induced	-	30	O
neurotoxicity	-	38	B
.	-	51	O

BACKGROUND	8111719	53	O
:	-	63	O

Hallucinations	8111719	65	B
as	-	80	O
a	-	83	O
symptom	-	85	O
of	-	93	O
central	-	96	O
neurotoxicity	-	104	B
are	-	118	O
a	-	122	O
known	-	124	O
but	-	130	O
poorly	-	134	O
described	-	141	O
side	-	151	O
effect	-	156	O
of	-	163	O
ifosfamide	-	166	O
.	-	176	O

Most	8111719	178	O
cases	-	183	O
of	-	189	O
ifosfamide	-	192	O
-	-	202	O
induced	-	203	O
hallucinations	-	211	B
have	-	226	O
been	-	231	O
reported	-	236	O
with	-	245	O
other	-	250	O
mental	-	256	O
status	-	263	O
changes	-	270	O
.	-	277	O

METHODS	8111719	279	O
:	-	286	O

The	8111719	288	O
authors	-	292	O
interviewed	-	300	O
six	-	312	O
persons	-	316	O
with	-	324	O
ifosfamide	-	329	O
-	-	339	O
induced	-	340	O
hallucinations	-	348	B
in	-	363	O
the	-	366	O
presence	-	370	O
of	-	379	O
a	-	382	O
clear	-	384	O
sensorium	-	390	O
.	-	399	O

All	8111719	401	O
patients	-	405	O
were	-	414	O
receiving	-	419	O
high	-	429	O
-	-	433	O
dose	-	434	O
ifosfamide	-	439	O
as	-	450	O
part	-	453	O
of	-	458	O
their	-	461	O
bone	-	467	O
marrow	-	472	O
transplant	-	479	O
procedure	-	490	O
.	-	499	O

RESULTS	8111719	501	O
:	-	508	O

Hallucinations	8111719	510	B
occurred	-	525	O
only	-	534	O
when	-	539	O
the	-	544	O
patient	-	548	O
's	-	555	O
eyes	-	558	O
were	-	563	O
closed	-	568	O
and	-	575	O
,	-	578	O
in	-	580	O
all	-	583	O
but	-	587	O
one	-	591	O
case	-	595	O
,	-	599	O
were	-	601	O
reported	-	606	O
as	-	615	O
disturbing	-	618	O
or	-	629	O
frightening	-	632	O
.	-	643	O

Underreporting	8111719	645	O
of	-	660	O
these	-	663	O
hallucinations	-	669	B
by	-	684	O
patients	-	687	O
is	-	696	O
likely	-	699	O
.	-	705	O

CONCLUSIONS	8111719	707	O
:	-	718	O

Hallucinations	8111719	720	B
may	-	735	O
be	-	739	O
the	-	742	O
sole	-	746	O
or	-	751	O
first	-	754	O
manifestation	-	760	O
of	-	774	O
neurotoxicity	-	777	B
.	-	790	O

The	8111719	792	O
incidence	-	796	O
may	-	806	O
be	-	810	O
dose	-	813	O
and	-	818	O
infusion	-	822	O
-	-	830	O
time	-	831	O
related	-	836	O
.	-	843	O

The	8111719	845	O
clinician	-	849	O
should	-	859	O
be	-	866	O
alerted	-	869	O
for	-	877	O
possible	-	881	O
ifosfamide	-	890	O
-	-	900	O
induced	-	901	O
hallucinations	-	909	B
,	-	923	O
which	-	925	O
may	-	931	O
occur	-	935	O
without	-	941	O
other	-	949	O
signs	-	955	O
of	-	961	O
neurotoxicity	-	964	B
.	-	977	O

""""	8111719	979	O
Eyes	-	980	O
-	-	984	O
closed	-	985	O
""""	-	991	O
hallucinatory	-	993	B
experiences	-	1007	O
appear	-	1019	O
to	-	1026	O
be	-	1029	O
an	-	1032	O
unusual	-	1035	O
feature	-	1043	O
of	-	1051	O
this	-	1054	O
presentation	-	1059	O
.	-	1071	O

Patients	8111719	1073	O
anxious	-	1082	O
about	-	1090	O
this	-	1096	O
experience	-	1101	O
respond	-	1112	O
well	-	1120	O
to	-	1125	O
support	-	1128	O
and	-	1136	O
education	-	1140	O
about	-	1150	O
this	-	1156	O
occurrence	-	1161	O
.	-	1171	O

Optimal	8111719	1173	O
pharmacologic	-	1181	O
management	-	1195	O
of	-	1206	O
disturbed	-	1209	O
patients	-	1219	O
is	-	1228	O
unclear	-	1231	O
.	-	1238	O

If	8111719	1240	O
agitation	-	1243	B
becomes	-	1253	O
marked	-	1261	O
,	-	1267	O
high	-	1269	O
-	-	1273	O
potency	-	1274	O
neuroleptics	-	1282	O
(	-	1295	O
i	-	1296	O
.	-	1297	O
e	-	1298	O
.	-	1299	O
,	-	1300	O
haloperidol	-	1302	O
)	-	1313	O
may	-	1315	O
be	-	1319	O
effective	-	1322	O
.	-	1331	O

Chlorpropamide	7059267	0	O
-	-	14	O
induced	-	15	O
optic	-	23	B
neuropathy	-	29	I
.	-	39	O

A	7059267	41	O
65	-	43	O
-	-	45	O
year	-	46	O
-	-	50	O
old	-	51	O
woman	-	55	O
with	-	61	O
adult	-	66	B
-	-	71	I
onset	-	72	I
diabetes	-	78	I
treated	-	87	O
with	-	95	O
chlorpropamide	-	100	O
(	-	115	O
Diabenese	-	116	O
)	-	125	O
had	-	127	O
a	-	131	O
toxic	-	133	B
optic	-	139	I
neuropathy	-	145	I
that	-	156	O
resolved	-	161	O
with	-	170	O
discontinuation	-	175	O
of	-	191	O
chlorpropamide	-	194	O
therapy	-	209	O
.	-	216	O

Visual	7059267	218	B
loss	-	225	I
occurs	-	230	O
in	-	237	O
diabetics	-	240	B
for	-	250	O
a	-	254	O
variety	-	256	O
of	-	264	O
reasons	-	267	O
,	-	274	O
and	-	276	O
accurate	-	280	O
diagnosis	-	289	O
is	-	299	O
necessary	-	302	O
to	-	312	O
institute	-	315	O
appropriate	-	325	O
therapy	-	337	O
.	-	344	O

The	7059267	346	O
possibility	-	350	O
of	-	362	O
a	-	365	O
drug	-	367	O
-	-	371	O
induced	-	372	O
optic	-	380	B
neuropathy	-	386	I
should	-	397	O
be	-	404	O
considered	-	407	O
in	-	418	O
the	-	421	O
differential	-	425	O
diagnosis	-	438	O
of	-	448	O
visual	-	451	B
loss	-	458	I
in	-	463	O
diabetics	-	466	B
.	-	475	O

Levodopa	6381653	0	O
-	-	8	O
induced	-	9	O
dyskinesia	-	17	B
and	-	28	O
thalamotomy	-	32	O
.	-	43	O

Levodopa	6381653	45	O
-	-	53	O
induced	-	54	O
dyskinesia	-	62	B
of	-	73	O
the	-	76	O
limbs	-	80	O
in	-	86	O
thirteen	-	89	O
cases	-	98	O
of	-	104	O
Parkinsonism	-	107	B
,	-	119	O
which	-	121	O
was	-	127	O
choreic	-	131	O
,	-	138	O
ballistic	-	140	O
or	-	150	O
dystonic	-	153	B
in	-	162	O
type	-	165	O
,	-	169	O
was	-	171	O
alleviated	-	175	O
almost	-	186	O
completely	-	193	O
by	-	204	O
stereotaxic	-	207	O
surgery	-	219	O
using	-	227	O
a	-	233	O
microelectrode	-	235	O
technique	-	250	O
for	-	260	O
the	-	264	O
ventralis	-	268	O
oralis	-	278	O
anterior	-	285	O
and	-	294	O
posterior	-	298	O
nuclei	-	308	O
of	-	315	O
the	-	318	O
thalamus	-	322	O
,	-	330	O
but	-	332	O
much	-	336	O
less	-	341	O
by	-	346	O
the	-	349	O
ventralis	-	353	O
intermedius	-	363	O
nucleus	-	375	O
.	-	382	O

Control	6381653	384	O
of	-	392	O
levodopa	-	395	O
-	-	403	O
induced	-	404	O
dyskinesias	-	412	B
by	-	424	O
thalamic	-	427	B
lesions	-	436	I
in	-	444	O
the	-	447	O
course	-	451	O
of	-	458	O
routine	-	461	O
treatment	-	469	O
of	-	479	O
Parkinsonism	-	482	B
is	-	495	O
discussed	-	498	O
.	-	507	O

Factors	3950060	0	O
associated	-	8	O
with	-	19	O
nephrotoxicity	-	24	B
and	-	39	O
clinical	-	43	O
outcome	-	52	O
in	-	60	O
patients	-	63	O
receiving	-	72	O
amikacin	-	82	O
.	-	90	O

Data	3950060	92	O
from	-	97	O
60	-	102	O
patients	-	105	O
treated	-	114	O
with	-	122	O
amikacin	-	127	O
were	-	136	O
analyzed	-	141	O
for	-	150	O
factors	-	154	O
associated	-	162	O
with	-	173	O
nephrotoxicity	-	178	B
.	-	192	O

In	3950060	194	O
42	-	197	O
of	-	200	O
these	-	203	O
patients	-	209	O
,	-	217	O
data	-	219	O
were	-	224	O
examined	-	229	O
for	-	238	O
factors	-	242	O
associated	-	250	O
with	-	261	O
clinical	-	266	O
outcome	-	275	O
.	-	282	O

Variables	3950060	284	O
evaluated	-	294	O
included	-	304	O
patient	-	313	O
weight	-	321	O
,	-	327	O
age	-	329	O
,	-	332	O
sex	-	334	O
,	-	337	O
serum	-	339	O
creatinine	-	345	O
level	-	356	O
,	-	361	O
creatinine	-	363	O
clearance	-	374	O
,	-	383	O
duration	-	385	O
of	-	394	O
therapy	-	397	O
,	-	404	O
total	-	406	O
dose	-	412	O
,	-	416	O
mean	-	418	O
daily	-	423	O
dose	-	429	O
,	-	433	O
organism	-	435	O
minimum	-	444	O
inhibitory	-	452	O
concentration	-	463	O
(	-	477	O
MIC	-	478	O
)	-	481	O
,	-	482	O
mean	-	484	O
peak	-	489	O
levels	-	494	O
,	-	500	O
mean	-	502	O
trough	-	507	O
levels	-	514	O
,	-	520	O
mean	-	522	O

area	3950060	527	O
under	-	532	O
the	-	538	O
serum	-	542	O
concentration	-	548	O
-	-	561	O
time	-	562	O
curve	-	567	O
(	-	573	O
AUC	-	574	O
)	-	577	O
,	-	578	O
total	-	580	O
AUC	-	586	O
,	-	589	O
mean	-	591	O
AUC	-	596	O
greater	-	600	O
than	-	608	O
MIC	-	613	O
,	-	616	O
total	-	618	O
AUC	-	624	O
greater	-	628	O
than	-	636	O
MIC	-	641	O
,	-	644	O
mean	-	646	O
Schumacher	-	651	O
's	-	661	O
intensity	-	664	O
factor	-	674	O
(	-	681	O
IF	-	682	O
)	-	684	O
,	-	685	O
total	-	687	O
IF	-	693	O
,	-	695	O
In	-	697	O
(	-	700	O
mean	-	701	O
maximum	-	706	O
concentration	-	714	O
[	-	728	O
Cmax	-	729	O
]	-	733	O
/	-	734	O
MIC	-	735	O
)	-	738	O
.	-	739	O

Model	3950060	741	O
-	-	746	O
dependent	-	747	O
pharmacokinetic	-	757	O
parameters	-	773	O
were	-	784	O
calculated	-	789	O
by	-	800	O
computer	-	803	O
based	-	812	O
on	-	818	O
a	-	821	O
one	-	823	O
-	-	826	O
compartment	-	827	O
model	-	839	O
.	-	844	O

When	3950060	846	O
the	-	851	O
parameters	-	855	O
were	-	866	O
examined	-	871	O
individually	-	880	O
,	-	892	O
duration	-	894	O
of	-	903	O
therapy	-	906	O
and	-	914	O
total	-	918	O
AUC	-	924	O
correlated	-	928	O
significantly	-	939	O
(	-	953	O
P	-	954	O
less	-	956	O
than	-	961	O
.	-	966	O
05	-	967	O
)	-	969	O
with	-	971	O
nephrotoxicity	-	976	B
.	-	990	O

In	3950060	992	O
contrast	-	995	O
,	-	1003	O
a	-	1005	O
stepwise	-	1007	O
discriminant	-	1016	O
function	-	1029	O
analysis	-	1038	O
identified	-	1047	O
only	-	1058	O
duration	-	1063	O
of	-	1072	O
therapy	-	1075	O
(	-	1083	O
P	-	1084	O
less	-	1086	O
than	-	1091	O
.	-	1096	O
001	-	1097	O
)	-	1100	O
as	-	1102	O
an	-	1105	O
important	-	1108	O
factor	-	1118	O
.	-	1124	O

Based	3950060	1126	O
on	-	1132	O
this	-	1135	O
model	-	1140	O
and	-	1146	O
on	-	1150	O
Bayes	-	1153	O
'	-	1158	O
theorem	-	1160	O
,	-	1167	O
the	-	1169	O
predictive	-	1173	O
accuracy	-	1184	O
of	-	1193	O
identifying	-	1196	O
""""	-	1208	O
nephrotoxic	-	1209	B
""""	-	1220	O
patients	-	1222	O
increased	-	1231	O
from	-	1241	O
0	-	1246	O
.	-	1247	O
17	-	1248	O
to	-	1251	O
0	-	1254	O
.	-	1255	O
39	-	1256	O
.	-	1258	O

When	3950060	1260	O
examined	-	1265	O
individually	-	1274	O
,	-	1286	O
mean	-	1288	O
IF	-	1293	O
,	-	1295	O
MIC	-	1297	O
,	-	1300	O
total	-	1302	O
dose	-	1308	O
,	-	1312	O
mean	-	1314	O
daily	-	1319	O
dose	-	1325	O
,	-	1329	O
and	-	1331	O
ln	-	1335	O
(	-	1338	O
mean	-	1339	O
Cmax	-	1344	O
/	-	1348	O
MIC	-	1349	O
)	-	1352	O
correlated	-	1354	O
significantly	-	1365	O
(	-	1379	O
P	-	1380	O
less	-	1382	O
than	-	1387	O
.	-	1392	O
05	-	1393	O
)	-	1395	O
with	-	1397	O
cure	-	1402	O
.	-	1406	O

In	3950060	1408	O
contrast	-	1411	O
,	-	1419	O
a	-	1421	O
simultaneous	-	1423	O
multivariable	-	1436	O
analysis	-	1450	O
identified	-	1459	O
IF	-	1470	O
,	-	1472	O
MIC	-	1474	O
,	-	1477	O
and	-	1479	O
total	-	1483	O
dose	-	1489	O
according	-	1494	O
to	-	1504	O
one	-	1507	O
model	-	1511	O
and	-	1517	O
ln	-	1521	O
(	-	1524	O
mean	-	1525	O
Cmax	-	1530	O
/	-	1534	O
MIC	-	1535	O
)	-	1538	O
according	-	1540	O
to	-	1550	O
a	-	1553	O
second	-	1555	O
statistical	-	1562	O
model	-	1574	O
of	-	1580	O
parameters	-	1583	O
selected	-	1594	O
to	-	1603	O
have	-	1606	O
the	-	1611	O
greatest	-	1615	O
prospective	-	1624	O
value	-	1636	O
.	-	1641	O

Based	3950060	1643	O
on	-	1649	O
Bayes	-	1652	O
'	-	1657	O
theorem	-	1659	O
and	-	1667	O
the	-	1671	O
first	-	1675	O
model	-	1681	O
,	-	1686	O
the	-	1688	O
predictive	-	1692	O
accuracy	-	1703	O
of	-	1712	O
identifying	-	1715	O
patients	-	1727	O
not	-	1736	O
cured	-	1740	O
increased	-	1746	O
from	-	1756	O
0	-	1761	O
.	-	1762	O
19	-	1763	O
to	-	1766	O
0	-	1769	O
.	-	1770	O
83	-	1771	O
.	-	1773	O

For	3950060	1775	O
the	-	1779	O
second	-	1783	O
model	-	1790	O
,	-	1795	O
the	-	1797	O
predictive	-	1801	O
accuracy	-	1812	O
increased	-	1821	O
from	-	1831	O
0	-	1836	O
.	-	1837	O
19	-	1838	O
to	-	1841	O
0	-	1844	O
.	-	1845	O
50	-	1846	O
.	-	1848	O
(	-	1849	O
ABSTRACT	-	1850	O

TRUNCATED	3950060	1859	O
AT	-	1869	O
250	-	1872	O
WORDS	-	1876	O
)	-	1881	O

Cardiac	3311455	0	O
transplantation	-	8	O
:	-	23	O
improved	-	25	O
quality	-	34	O
of	-	42	O
survival	-	45	O
with	-	54	O
a	-	59	O
modified	-	61	O
immunosuppressive	-	70	O
protocol	-	88	O
.	-	96	O

The	3311455	98	O
effects	-	102	O
on	-	110	O
renal	-	113	O
function	-	119	O
on	-	128	O
two	-	131	O
different	-	135	O
immunosuppressive	-	145	O
protocols	-	163	O
were	-	173	O
evaluated	-	178	O
retrospectively	-	188	O
in	-	204	O
two	-	207	O
subsequent	-	211	O
groups	-	222	O
of	-	229	O
heart	-	232	O
transplant	-	238	O
recipients	-	249	O
.	-	259	O

In	3311455	261	O
group	-	264	O
I	-	270	O
,	-	271	O
cyclosporine	-	273	O
was	-	286	O
given	-	290	O
before	-	296	O
the	-	303	O
procedure	-	307	O
at	-	317	O
a	-	320	O
loading	-	322	O
dose	-	330	O
of	-	335	O
17	-	338	O
.	-	340	O
5	-	341	O
mg	-	343	O
/	-	345	O
kg	-	346	O
and	-	349	O
then	-	353	O
continued	-	358	O
after	-	368	O
the	-	374	O
procedure	-	378	O
to	-	388	O
keep	-	391	O
a	-	396	O
whole	-	398	O
blood	-	404	O
level	-	410	O
about	-	416	O
1000	-	422	O
ng	-	427	O
/	-	429	O
ml	-	430	O
.	-	432	O

In	3311455	434	O
group	-	437	O
II	-	443	O
,	-	445	O
cyclosporine	-	447	O
was	-	460	O
started	-	464	O
only	-	472	O
after	-	477	O
the	-	483	O
procedure	-	487	O
at	-	497	O
a	-	500	O
lower	-	502	O
dosage	-	508	O
and	-	515	O
was	-	519	O
complemented	-	523	O
by	-	536	O
azathioprine	-	539	O
,	-	551	O
which	-	553	O
was	-	559	O
used	-	563	O
for	-	568	O
the	-	572	O
first	-	576	O
postoperative	-	582	O
week	-	596	O
.	-	600	O

Group	3311455	602	O
II	-	608	O
showed	-	611	O
a	-	618	O
better	-	620	O
perioperative	-	627	O
renal	-	641	O
function	-	647	O
as	-	656	O
determined	-	659	O
by	-	670	O
serum	-	673	O
blood	-	679	O
urea	-	685	O
nitrogen	-	690	O
and	-	699	O
serum	-	703	O
creatinine	-	709	O
levels	-	720	O
.	-	726	O

Group	3311455	728	O
II	-	734	O
also	-	737	O
showed	-	742	O
a	-	749	O
significant	-	751	O
decrease	-	763	O
of	-	772	O
chronic	-	775	O
nephrotoxicity	-	783	B
secondary	-	798	O
to	-	808	O
long	-	811	O
-	-	815	O
term	-	816	O
therapy	-	821	O
with	-	829	O
cyclosporine	-	834	O
.	-	846	O

Despite	3311455	848	O
this	-	856	O
improvement	-	861	O
in	-	873	O
late	-	876	O
renal	-	881	O
function	-	887	O
,	-	895	O
group	-	897	O
II	-	903	O
still	-	906	O
shows	-	912	O
a	-	918	O
slow	-	920	O
rise	-	925	O
in	-	930	O
serum	-	933	O
creatinine	-	939	O
.	-	949	O

We	3311455	951	O
think	-	954	O
that	-	960	O
even	-	965	O
these	-	970	O
lower	-	976	O
dosages	-	982	O
of	-	990	O
cyclosporine	-	993	O
can	-	1006	O
cause	-	1010	O
chronic	-	1016	O
nephrotoxicity	-	1024	B
and	-	1039	O
that	-	1043	O
further	-	1048	O
modification	-	1056	O
of	-	1069	O
the	-	1072	O
immunosuppressive	-	1076	O
regimen	-	1094	O
is	-	1102	O
required	-	1105	O
to	-	1114	O
completely	-	1117	O
abolish	-	1128	O
this	-	1136	O
toxic	-	1141	O
side	-	1147	O
effect	-	1152	O
.	-	1158	O

Reversible	2051906	0	O
cholestasis	-	11	B
with	-	23	O
bile	-	28	B
duct	-	33	I
injury	-	38	I
following	-	45	O
azathioprine	-	55	O
therapy	-	68	O
.	-	75	O

A	2051906	77	O
case	-	79	O
report	-	84	O
.	-	90	O

A	2051906	92	O
67	-	94	O
-	-	96	O
year	-	97	O
-	-	101	O
old	-	102	O
patient	-	106	O
,	-	113	O
with	-	115	O
primary	-	120	O
polymyositis	-	128	B
and	-	141	O
without	-	145	O
previous	-	153	O
evidence	-	162	O
of	-	171	O
liver	-	174	B
disease	-	180	I
,	-	187	O
developed	-	189	O
clinical	-	199	O
and	-	208	O
biochemical	-	212	O
features	-	224	O
of	-	233	O
severe	-	236	O
cholestasis	-	243	B
3	-	255	O
months	-	257	O
after	-	264	O
initiation	-	270	O
of	-	281	O
azathioprine	-	284	O
therapy	-	297	O
.	-	304	O

Liver	2051906	306	O
biopsy	-	312	O
showed	-	319	O
cholestasis	-	326	B
with	-	338	O
both	-	343	O
cytological	-	348	O
and	-	360	O
architectural	-	364	O
alterations	-	378	O
of	-	390	O
interlobular	-	393	O
bile	-	406	O
ducts	-	411	O
.	-	416	O

Azathioprine	2051906	418	O
withdrawal	-	431	O
resulted	-	442	O
after	-	451	O
7	-	457	O
weeks	-	459	O
in	-	465	O
the	-	468	O
resolution	-	472	O
of	-	483	O
clinical	-	486	O
and	-	495	O
biochemical	-	499	O
abnormalities	-	511	O
.	-	524	O

It	2051906	526	O
is	-	529	O
believed	-	532	O
that	-	541	O
this	-	546	O
is	-	551	O
the	-	554	O
first	-	558	O
reported	-	564	O
case	-	573	O
of	-	578	O
reversible	-	581	O
azathioprine	-	592	O
-	-	604	O
induced	-	605	O
cholestasis	-	613	B
associated	-	625	O
with	-	636	O
histological	-	641	O
evidence	-	654	O
of	-	663	O
bile	-	666	B
duct	-	671	I
injury	-	676	I
.	-	682	O

Renal	2021202	0	O
function	-	6	O
and	-	15	O
hemodynamics	-	19	O
during	-	32	O
prolonged	-	39	O
isoflurane	-	49	O
-	-	59	O
induced	-	60	O
hypotension	-	68	B
in	-	80	O
humans	-	83	O
.	-	89	O

The	2021202	91	O
effect	-	95	O
of	-	102	O
isoflurane	-	105	O
-	-	115	O
induced	-	116	O
hypotension	-	124	B
on	-	136	O
glomerular	-	139	O
function	-	150	O
and	-	159	O
renal	-	163	O
blood	-	169	O
flow	-	175	O
was	-	180	O
investigated	-	184	O
in	-	197	O
20	-	200	O
human	-	203	O
subjects	-	209	O
.	-	217	O

Glomerular	2021202	219	O
filtration	-	230	O
rate	-	241	O
(	-	246	O
GFR	-	247	O
)	-	250	O
and	-	252	O
effective	-	256	O
renal	-	266	O
plasma	-	272	O
flow	-	279	O
(	-	284	O
ERPF	-	285	O
)	-	289	O
were	-	291	O
measured	-	296	O
by	-	305	O
inulin	-	308	O
and	-	315	O
para	-	319	O
-	-	323	O
aminohippurate	-	324	O
(	-	339	O
PAH	-	340	O
)	-	343	O
clearance	-	345	O
,	-	354	O
respectively	-	356	O
.	-	368	O

Anesthesia	2021202	370	O
was	-	381	O
maintained	-	385	O
with	-	396	O
fentanyl	-	401	O
,	-	409	O
nitrous	-	411	O
oxide	-	419	O
,	-	424	O
oxygen	-	426	O
,	-	432	O
and	-	434	O
isoflurane	-	438	O
.	-	448	O

Hypotension	2021202	450	B
was	-	462	O
induced	-	466	O
for	-	474	O
236	-	478	O
.	-	481	O
9	-	482	O
+	-	484	O
/	-	485	O
-	-	486	O

15	2021202	488	O
.	-	490	O
1	-	491	O
min	-	493	O
by	-	497	O
increasing	-	500	O
the	-	511	O
isoflurane	-	515	O
inspired	-	526	O
concentration	-	535	O
to	-	549	O
maintain	-	552	O
a	-	561	O
mean	-	563	O
arterial	-	568	O
pressure	-	577	O
of	-	586	O
59	-	589	O
.	-	591	O
8	-	592	O
+	-	594	O
/	-	595	O
-	-	596	O

0	2021202	598	O
.	-	599	O
4	-	600	O
mmHg	-	602	O
.	-	606	O

GFR	2021202	608	O
and	-	612	O
ERPF	-	616	O
decreased	-	621	O
with	-	631	O
the	-	636	O
induction	-	640	O
of	-	650	O
anesthesia	-	653	O
but	-	664	O
not	-	668	O
significantly	-	672	O
more	-	686	O
during	-	691	O
hypotension	-	698	B
.	-	709	O

Postoperatively	2021202	711	O
,	-	726	O
ERPF	-	728	O
returned	-	733	O
to	-	742	O
preoperative	-	745	O
values	-	758	O
,	-	764	O
whereas	-	766	O
GFR	-	774	O
was	-	778	O
higher	-	782	O
than	-	789	O
preoperative	-	794	O
values	-	807	O
.	-	813	O

Renal	2021202	815	O
vascular	-	821	O
resistance	-	830	O
increased	-	841	O
during	-	851	O
anesthesia	-	858	O
but	-	869	O
decreased	-	873	O
when	-	883	O
hypotension	-	888	B
was	-	900	O
induced	-	904	O
,	-	911	O
allowing	-	913	O
the	-	922	O
maintenance	-	926	O
of	-	938	O
renal	-	941	O
blood	-	947	O
flow	-	953	O
.	-	957	O

We	2021202	959	O
conclude	-	962	O
that	-	971	O
renal	-	976	O
compensatory	-	982	O
mechanisms	-	995	O
are	-	1006	O
preserved	-	1010	O
during	-	1020	O
isoflurane	-	1027	O
-	-	1037	O
induced	-	1038	O
hypotension	-	1046	B
and	-	1058	O
that	-	1062	O
renal	-	1067	O
function	-	1073	O
and	-	1082	O
hemodynamics	-	1086	O
quickly	-	1099	O
return	-	1107	O
to	-	1114	O
normal	-	1117	O
when	-	1124	O
normotension	-	1129	O
is	-	1142	O
resumed	-	1145	O
.	-	1152	O

Debrisoquine	1848636	0	O
phenotype	-	13	O
and	-	23	O
the	-	27	O
pharmacokinetics	-	31	O
and	-	48	O
beta	-	52	O
-	-	56	O
2	-	57	O
receptor	-	59	O
pharmacodynamics	-	68	O
of	-	85	O
metoprolol	-	88	O
and	-	99	O
its	-	103	O
enantiomers	-	107	O
.	-	118	O

The	1848636	120	O
metabolism	-	124	O
of	-	135	O
the	-	138	O
cardioselective	-	142	O
beta	-	158	O
-	-	162	O
blocker	-	163	O
metoprolol	-	171	O
is	-	182	O
under	-	185	O
genetic	-	191	O
control	-	199	O
of	-	207	O
the	-	210	O
debrisoquine	-	214	O
/	-	226	O
sparteine	-	227	O
type	-	237	O
.	-	241	O

The	1848636	243	O
two	-	247	O
metabolic	-	251	O
phenotypes	-	261	O
,	-	271	O
extensive	-	273	O
(	-	283	O
EM	-	284	O
)	-	286	O
and	-	288	O
poor	-	292	O
metabolizers	-	297	O
(	-	310	O
PM	-	311	O
)	-	313	O
,	-	314	O
show	-	316	O
different	-	321	O
stereoselective	-	331	O
metabolism	-	347	O
,	-	357	O
resulting	-	359	O
in	-	369	O
apparently	-	372	O
higher	-	383	O
beta	-	390	O
-	-	394	O
1	-	395	O
adrenoceptor	-	397	O
antagonistic	-	410	O
potency	-	423	O
of	-	431	O
racemic	-	434	O
metoprolol	-	442	O
in	-	453	O
EMs	-	456	O
.	-	459	O

We	1848636	461	O
investigated	-	464	O
if	-	477	O
the	-	480	O
latter	-	484	O
also	-	491	O
applies	-	496	O
to	-	504	O
the	-	507	O
beta	-	511	O
-	-	515	O
2	-	516	O
adrenoceptor	-	518	O
antagonism	-	531	O
by	-	542	O
metoprolol	-	545	O
.	-	555	O

The	1848636	557	O
drug	-	561	O
effect	-	566	O
studied	-	573	O
was	-	581	O
the	-	585	O
antagonism	-	589	O
by	-	600	O
metoprolol	-	603	O
of	-	614	O
terbutaline	-	617	O
-	-	628	O
induced	-	629	O
hypokalemia	-	637	B
.	-	648	O

By	1848636	650	O
using	-	653	O
pharmacokinetic	-	659	O
pharmacodynamic	-	675	O
modeling	-	691	O
the	-	700	O
pharmacodynamics	-	704	O
of	-	721	O
racemic	-	724	O
metoprolol	-	732	O
and	-	743	O
the	-	747	O
active	-	751	O
S	-	758	O
-	-	759	O
isomer	-	760	O
,	-	766	O
were	-	768	O
quantitated	-	773	O
in	-	785	O
EMs	-	788	O
and	-	792	O
PMs	-	796	O
in	-	800	O
terms	-	803	O
of	-	809	O
IC50	-	812	O
values	-	817	O
,	-	823	O
representing	-	825	O
metoprolol	-	838	O
plasma	-	849	O
concentrations	-	856	O
resulting	-	871	O
in	-	881	O
half	-	884	O
-	-	888	O
maximum	-	889	O
receptor	-	897	O
occupancy	-	906	O
.	-	915	O

Six	1848636	917	O
EMs	-	921	O
received	-	925	O
0	-	934	O
.	-	935	O
5	-	936	O
mg	-	938	O
of	-	941	O
terbutaline	-	944	O
s	-	956	O
.	-	957	O
c	-	958	O
.	-	959	O

on	1848636	961	O
two	-	964	O
different	-	968	O
occasions	-	978	O
:	-	987	O
1	-	989	O
)	-	990	O
1	-	992	O
hr	-	994	O
after	-	997	O
administration	-	1003	O
of	-	1018	O
a	-	1021	O
placebo	-	1023	O
and	-	1031	O
2	-	1035	O
)	-	1036	O
1	-	1038	O
hr	-	1040	O
after	-	1043	O
150	-	1049	O
mg	-	1053	O
of	-	1056	O
metoprolol	-	1059	O
p	-	1070	O
.	-	1071	O
o	-	1072	O
.	-	1073	O

Five	1848636	1075	O
PMs	-	1080	O
were	-	1084	O
studied	-	1089	O
according	-	1097	O
to	-	1107	O
the	-	1110	O
same	-	1114	O
protocol	-	1119	O
,	-	1127	O
except	-	1129	O
for	-	1136	O
a	-	1140	O
higher	-	1142	O
terbutaline	-	1149	O
dose	-	1161	O
(	-	1166	O
0	-	1167	O
.	-	1168	O
75	-	1169	O
mg	-	1172	O
)	-	1174	O
on	-	1176	O
day	-	1179	O
2	-	1183	O
.	-	1184	O

Blood	1848636	1186	O
samples	-	1192	O
for	-	1200	O
the	-	1204	O
analysis	-	1208	O
of	-	1217	O
plasma	-	1220	O
potassium	-	1227	O
,	-	1236	O
terbutaline	-	1238	O
,	-	1249	O
metoprolol	-	1251	O
(	-	1262	O
racemic	-	1263	O
,	-	1270	O
R	-	1272	O
-	-	1273	O
and	-	1275	O
S	-	1279	O
-	-	1280	O
isomer	-	1281	O
)	-	1287	O
,	-	1288	O
and	-	1290	O
alpha	-	1294	O
-	-	1299	O
hydroxymetoprolol	-	1300	O
concentrations	-	1318	O
were	-	1333	O
taken	-	1338	O
at	-	1344	O
regular	-	1347	O
time	-	1355	O
intervals	-	1360	O
,	-	1369	O
during	-	1371	O
8	-	1378	O
hr	-	1380	O
after	-	1383	O
metoprolol	-	1389	O
.	-	1399	O

In	1848636	1401	O
PMs	-	1404	O
,	-	1407	O
metoprolol	-	1409	O
increased	-	1420	O
the	-	1430	O
terbutaline	-	1434	O
area	-	1446	O
under	-	1451	O
the	-	1457	O
plasma	-	1461	O
concentration	-	1468	O
vs	-	1482	O
.	-	1484	O
time	-	1486	O
curve	-	1491	O
(	-	1497	O
+	-	1498	O
67	-	1499	O
%	-	1501	O
)	-	1502	O
.	-	1503	O

Higher	1848636	1505	O
metoprolol	-	1512	O
/	-	1522	O
alpha	-	1523	O
-	-	1528	O
hydroxymetoprolol	-	1529	O
ratios	-	1547	O
in	-	1554	O
PMs	-	1557	O
were	-	1561	O
predictive	-	1566	O
for	-	1577	O
higher	-	1581	O
R	-	1588	O
-	-	1589	O
/	-	1590	O
S	-	1591	O
-	-	1592	O
isomer	-	1593	O
ratios	-	1600	O
of	-	1607	O
unchanged	-	1610	O
drug	-	1620	O
.	-	1624	O

There	1848636	1626	O
was	-	1632	O
a	-	1636	O
difference	-	1638	O
in	-	1649	O
metoprolol	-	1652	O
potency	-	1663	O
with	-	1671	O
higher	-	1676	O
racemic	-	1683	O
metoprolol	-	1691	O
IC50	-	1702	O
values	-	1707	O
in	-	1714	O
PMs	-	1717	O
(	-	1721	O
72	-	1722	O
+	-	1725	O
/	-	1726	O
-	-	1727	O

7	1848636	1729	O
ng	-	1731	O
.	-	1733	O
ml	-	1734	O
-	-	1736	O
1	-	1737	O
)	-	1738	O
than	-	1740	O
EMs	-	1745	O
(	-	1749	O
42	-	1750	O
+	-	1753	O
/	-	1754	O
-	-	1755	O

8	1848636	1757	O
ng	-	1759	O
.	-	1761	O
ml	-	1762	O
-	-	1764	O
1	-	1765	O
,	-	1766	O
P	-	1768	O
less	-	1770	O
than	-	1775	O
.	-	1780	O
001	-	1781	O
)	-	1784	O
.	-	1785	O
(	-	1786	O
ABSTRACT	-	1787	O

TRUNCATED	1848636	1796	O
AT	-	1806	O
250	-	1809	O
WORDS	-	1813	O
)	-	1818	O

Cefotetan	1445986	0	O
-	-	9	O
induced	-	10	O
immune	-	18	O
hemolytic	-	25	B
anemia	-	35	I
.	-	41	O

Immune	1445986	43	O
hemolytic	-	50	B
anemia	-	60	I
due	-	67	O
to	-	71	O
a	-	74	O
drug	-	76	O
-	-	80	O
adsorption	-	81	O
mechanism	-	92	O
has	-	102	O
been	-	106	O
described	-	111	O
primarily	-	121	O
in	-	131	O
patients	-	134	O
receiving	-	143	O
penicillins	-	153	O
and	-	165	O
first	-	169	O
-	-	174	O
generation	-	175	O
cephalosporins	-	186	O
.	-	200	O

We	1445986	202	O
describe	-	205	O
a	-	214	O
patient	-	216	O
who	-	224	O
developed	-	228	O
anemia	-	238	B
while	-	245	O
receiving	-	251	O
intravenous	-	261	O
cefotetan	-	273	O
.	-	282	O

Cefotetan	1445986	284	O
-	-	293	O
dependent	-	294	O
antibodies	-	304	O
were	-	315	O
detected	-	320	O
in	-	329	O
the	-	332	O
patient	-	336	O
's	-	343	O
serum	-	346	O
and	-	352	O
in	-	356	O
an	-	359	O
eluate	-	362	O
prepared	-	369	O
from	-	378	O
his	-	383	O
red	-	387	O
blood	-	391	O
cells	-	397	O
.	-	402	O

The	1445986	404	O
eluate	-	408	O
also	-	415	O
reacted	-	420	O
weakly	-	428	O
with	-	435	O
red	-	440	O
blood	-	444	O
cells	-	450	O
in	-	456	O
the	-	459	O
absence	-	463	O
of	-	471	O
cefotetan	-	474	O
,	-	483	O
suggesting	-	485	O
the	-	496	O
concomitant	-	500	O
formation	-	512	O
of	-	522	O
warm	-	525	O
-	-	529	O
reactive	-	530	O
autoantibodies	-	539	O
.	-	553	O

These	1445986	555	O
observations	-	561	O
,	-	573	O
in	-	575	O
conjunction	-	578	O
with	-	590	O
clinical	-	595	O
and	-	604	O
laboratory	-	608	O
evidence	-	619	O
of	-	628	O
extravascular	-	631	O
hemolysis	-	645	B
,	-	654	O
are	-	656	O
consistent	-	660	O
with	-	671	O
drug	-	676	O
-	-	680	O
induced	-	681	O
hemolytic	-	689	B
anemia	-	699	I
,	-	705	O
possibly	-	707	O
involving	-	716	O
both	-	726	O
drug	-	731	O
-	-	735	O
adsorption	-	736	O
and	-	747	O
autoantibody	-	751	O
formation	-	764	O
mechanisms	-	774	O
.	-	784	O

This	1445986	786	O
case	-	791	O
emphasizes	-	796	O
the	-	807	O
need	-	811	O
for	-	816	O
increased	-	820	O
awareness	-	830	O
of	-	840	O
hemolytic	-	843	O
reactions	-	853	O
to	-	863	O
all	-	866	O
cephalosporins	-	870	O
.	-	884	O

Acute	982002	0	B
renal	-	6	I
failure	-	12	I
subsequent	-	20	O
to	-	31	O
the	-	34	O
administration	-	38	O
of	-	53	O
rifampicin	-	56	O
.	-	66	O

A	982002	68	O
follow	-	70	O
-	-	76	O
up	-	77	O
study	-	80	O
of	-	86	O
cases	-	89	O
reported	-	95	O
earlier	-	104	O
.	-	111	O

A	982002	113	O
clinical	-	115	O
presentation	-	124	O
is	-	137	O
made	-	140	O
of	-	145	O
a	-	148	O
2	-	150	O
-	-	151	O
3	-	152	O
year	-	154	O
follow	-	159	O
-	-	165	O
up	-	166	O
of	-	169	O
six	-	172	O
cases	-	176	O
of	-	182	O
acute	-	185	B
renal	-	191	I
failure	-	197	I
that	-	205	O
have	-	210	O
been	-	215	O
reported	-	220	O
earlier	-	229	O
.	-	236	O

The	982002	238	O
patients	-	242	O
had	-	251	O
developed	-	255	O
transient	-	265	O
renal	-	275	B
failure	-	281	I
after	-	289	O
the	-	295	O
intermittent	-	299	O
administration	-	312	O
of	-	327	O
rifampicin	-	330	O
.	-	340	O

The	982002	342	O
stage	-	346	O
of	-	352	O
olig	-	355	O
-	-	359	O
anuria	-	360	B
lasted	-	367	O
for	-	374	O
1	-	378	O
-	-	379	O
3	-	380	O
weeks	-	382	O
,	-	387	O
and	-	389	O
five	-	393	O
of	-	398	O
the	-	401	O
patients	-	405	O
were	-	414	O
treated	-	419	O
by	-	427	O
hemodialysis	-	430	O
.	-	442	O

Two	982002	444	O
of	-	448	O
the	-	451	O
patients	-	455	O
died	-	464	O
due	-	469	O
to	-	473	O
unrelated	-	476	O
causes	-	486	O
during	-	493	O
the	-	500	O
follow	-	504	O
-	-	510	O
up	-	511	O
period	-	514	O
.	-	520	O

The	982002	522	O
four	-	526	O
patients	-	531	O
re	-	540	O
-	-	542	O
examined	-	543	O
were	-	552	O
clinically	-	557	O
cured	-	568	O
.	-	573	O

Pathologic	982002	575	O
findings	-	586	O
by	-	595	O
light	-	598	O
microscopy	-	604	O
and	-	615	O
immunofluorescence	-	619	O
at	-	638	O
biopsy	-	641	O
were	-	648	O
scarce	-	653	O
.	-	659	O

Nothing	982002	661	O
abnormal	-	669	O
was	-	678	O
seen	-	682	O
by	-	687	O
electron	-	690	O
microscopy	-	699	O
in	-	710	O
two	-	713	O
of	-	717	O
the	-	720	O
cases	-	724	O
studied	-	730	O
.	-	737	O

Renal	982002	739	O
function	-	745	O
was	-	754	O
normal	-	758	O
.	-	764	O

In	982002	766	O
three	-	769	O
cases	-	775	O
the	-	781	O
excretion	-	785	O
at	-	795	O
131I	-	798	O
-	-	802	O
hippuran	-	803	O
renography	-	812	O
was	-	823	O
slightly	-	827	O
slowed	-	836	O
.	-	842	O

Although	982002	844	O
in	-	853	O
the	-	856	O
acute	-	860	O
stage	-	866	O
the	-	872	O
renal	-	876	B
lesions	-	882	I
histologically	-	890	O
appeared	-	905	O
toxic	-	914	O
,	-	919	O
evidence	-	921	O
suggestive	-	930	O
of	-	941	O
an	-	944	O
immunological	-	947	O
mechanism	-	961	O
can	-	971	O
not	-	974	O
be	-	978	O
excluded	-	981	O
.	-	989	O

Type	343678	0	B
B	-	5	I
hepatitis	-	7	I
after	-	17	O
needle	-	23	O
-	-	29	O
stick	-	30	O
exposure	-	36	O
:	-	44	O
prevention	-	46	O
with	-	57	O
hepatitis	-	62	B
B	-	72	I
immune	-	74	O
globulin	-	81	O
.	-	89	O

Final	343678	91	O
report	-	97	O
of	-	104	O
the	-	107	O
Veterans	-	111	O
Administration	-	120	O
Cooperative	-	135	O
Study	-	147	O
.	-	152	O

Hepatitis	343678	154	B
B	-	164	I
immune	-	166	O
globulin	-	173	O
(	-	182	O
HBIG	-	183	O
)	-	187	O
and	-	189	O
immune	-	193	O
serum	-	200	O
globulin	-	206	O
(	-	215	O
ISG	-	216	O
)	-	219	O
were	-	221	O
examined	-	226	O
in	-	235	O
a	-	238	O
randomized	-	240	O
,	-	250	O
double	-	252	O
-	-	258	O
blind	-	259	O
trial	-	265	O
to	-	271	O
assess	-	274	O
their	-	281	O
relative	-	287	O
efficacies	-	296	O
in	-	307	O
preventing	-	310	O
type	-	321	B
B	-	326	I
hepatitis	-	328	I
after	-	338	O
needle	-	344	O
-	-	350	O
stick	-	351	O
exposure	-	357	O
to	-	366	O
hepatitis	-	369	O
B	-	379	O
surface	-	381	O
antigen	-	389	O
(	-	397	O
HBsAG	-	398	O
)	-	403	O
-	-	404	O
positive	-	405	O
donors	-	414	O
.	-	420	O

Clinical	343678	422	O
hepatitis	-	431	B
developed	-	441	O
in	-	451	O
1	-	454	O
.	-	455	O
4	-	456	O
%	-	457	O
of	-	459	O
HBIG	-	462	O
and	-	467	O
in	-	471	O
5	-	474	O
.	-	475	O
9	-	476	O
%	-	477	O
of	-	479	O
ISG	-	482	O
recipients	-	486	O
(	-	497	O
P	-	498	O
=	-	500	O
0	-	502	O
.	-	503	O
016	-	504	O
)	-	507	O
,	-	508	O
and	-	510	O
seroconversion	-	514	O
(	-	529	O
anti	-	530	O
-	-	534	O
HBs	-	535	O
)	-	538	O
occurred	-	540	O
in	-	549	O
5	-	552	O
.	-	553	O
6	-	554	O
%	-	555	O
and	-	557	O
20	-	561	O
.	-	563	O
7	-	564	O
%	-	565	O
of	-	567	O
them	-	570	O
respectively	-	575	O
(	-	588	O
P	-	589	O
less	-	591	O
than	-	596	O
0	-	601	O
.	-	602	O
001	-	603	O
)	-	606	O
.	-	607	O

Mild	343678	609	O
and	-	614	O
transient	-	618	O
side	-	628	O
-	-	632	O
effects	-	633	O
were	-	641	O
noted	-	646	O
in	-	652	O
3	-	655	O
.	-	656	O
0	-	657	O
%	-	658	O
of	-	660	O
ISG	-	663	O
and	-	667	O
in	-	671	O
3	-	674	O
.	-	675	O
2	-	676	O
%	-	677	O
of	-	679	O
HBIG	-	682	O
recipients	-	687	O
.	-	697	O

Available	343678	699	O
donor	-	709	O
sera	-	715	O
were	-	720	O
examined	-	725	O
for	-	734	O
DNA	-	738	O
polymerase	-	742	O
(	-	753	O
DNAP	-	754	O
)	-	758	O
and	-	760	O
e	-	764	O
antigen	-	766	O
and	-	774	O
antibody	-	778	O
(	-	787	O
HBeAg	-	788	O
;	-	793	O
anti	-	795	O
-	-	799	O
HBE	-	800	O
)	-	803	O
.	-	804	O

Both	343678	806	O
DNAP	-	811	O
and	-	816	O
HBeAg	-	820	O
showed	-	826	O
a	-	833	O
highly	-	835	O
statistically	-	842	O
significant	-	856	O
correlation	-	868	O
with	-	880	O
the	-	885	O
infectivity	-	889	O
of	-	901	O
HBsAg	-	904	O
-	-	909	O
positive	-	910	O
donors	-	919	O
.	-	925	O

Hepatitis	343678	927	B
B	-	937	I
immune	-	939	O
globulin	-	946	O
remained	-	955	O
significantly	-	964	O
superior	-	978	O
to	-	987	O
ISG	-	990	O
in	-	994	O
preventing	-	997	O
type	-	1008	B
B	-	1013	I
hepatitis	-	1015	I
even	-	1025	O
when	-	1030	O
the	-	1035	O
analysis	-	1039	O
was	-	1048	O
confined	-	1052	O
to	-	1061	O
these	-	1064	O
two	-	1070	O
high	-	1074	O
-	-	1078	O
risk	-	1079	O
subgroups	-	1084	O
.	-	1093	O

The	343678	1095	O
efficacy	-	1099	O
of	-	1108	O
ISG	-	1111	O
in	-	1115	O
preventing	-	1118	O
type	-	1129	B
B	-	1134	I
hepatitis	-	1136	I
can	-	1146	O
not	-	1149	O
be	-	1153	O
ascertained	-	1156	O
because	-	1168	O
a	-	1176	O
true	-	1178	O
placebo	-	1183	O
group	-	1191	O
was	-	1197	O
not	-	1201	O
included	-	1205	O
.	-	1213	O

Serotonin	8888541	0	B
syndrome	-	10	I
from	-	19	O
venlafaxine	-	24	O
-	-	35	O
tranylcypromine	-	36	O
interaction	-	52	O
.	-	63	O

Excessive	8888541	65	O
stimulation	-	75	O
of	-	87	O
serotonin	-	90	O
5HT1A	-	100	O
receptors	-	106	O
causes	-	116	O
a	-	123	O
syndrome	-	125	O
of	-	134	O
serotonin	-	137	O
excess	-	147	O
that	-	154	O
consists	-	159	O
of	-	168	O
shivering	-	171	O
,	-	180	O
muscle	-	182	B
rigidity	-	189	I
,	-	197	O
salivation	-	199	B
,	-	209	O
confusion	-	211	B
,	-	220	O
agitation	-	222	B
and	-	232	O
hyperthermia	-	236	B
.	-	248	O

The	8888541	250	O
most	-	254	O
common	-	259	O
cause	-	266	O
of	-	272	O
this	-	275	O
syndrome	-	280	O
is	-	289	O
an	-	292	O
interaction	-	295	O
between	-	307	O
a	-	315	O
monoamine	-	317	O
oxidase	-	327	O
inhibitor	-	335	O
(	-	345	O
MAOI	-	346	O
)	-	350	O
and	-	352	O
a	-	356	O
specific	-	358	O
serotonin	-	367	O
reuptake	-	377	O
inhibitor	-	386	O
.	-	395	O

Venlafaxine	8888541	397	O
is	-	409	O
a	-	412	O
new	-	414	O
antidepressant	-	418	O
agent	-	433	O
that	-	439	O
inhibits	-	444	O
the	-	453	O
reuptake	-	457	O
of	-	466	O
serotonin	-	469	O
and	-	479	O
norepinephrine	-	483	O
.	-	497	O

We	8888541	499	O
report	-	502	O
a	-	509	O
venlafaxine	-	511	O
-	-	522	O
MAOI	-	523	O
interaction	-	528	O
that	-	540	O
resulted	-	545	O
in	-	554	O
the	-	557	O
serotonin	-	561	B
syndrome	-	571	I
in	-	580	O
a	-	583	O
23	-	585	O
-	-	587	O
y	-	588	O
-	-	589	O
old	-	590	O
male	-	594	O
who	-	599	O
was	-	603	O
taking	-	607	O
tranylcypromine	-	614	O
for	-	630	O
depression	-	634	B
.	-	644	O

He	8888541	646	O
had	-	649	O
been	-	653	O
well	-	658	O
until	-	663	O
the	-	669	O
morning	-	673	O
of	-	681	O
presentation	-	684	O
when	-	697	O
he	-	702	O
took	-	705	O
1	-	710	O
/	-	711	O
2	-	712	O
tab	-	714	O
of	-	718	O
venlafaxine	-	721	O
.	-	732	O

Within	8888541	734	O
2	-	741	O
h	-	743	O
he	-	745	O
became	-	748	O
confused	-	755	O
with	-	764	O
jerking	-	769	O
movements	-	777	O
of	-	787	O
his	-	790	O
extremities	-	794	O
,	-	805	O
tremors	-	807	B
and	-	815	O
rigidity	-	819	B
.	-	827	O

He	8888541	829	O
was	-	832	O
brought	-	836	O
directly	-	844	O
to	-	853	O
a	-	856	O
hospital	-	858	O
where	-	867	O
he	-	873	O
was	-	876	O
found	-	880	O
to	-	886	O
be	-	889	O
agitated	-	892	O
and	-	901	O
confused	-	905	O
with	-	914	O
shivering	-	919	O
,	-	928	O
myoclonic	-	930	B
jerks	-	940	I
,	-	945	O
rigidity	-	947	B
,	-	955	O
salivation	-	957	B
and	-	968	O
diaphoresis	-	972	O
.	-	983	O

His	8888541	985	O
pupils	-	989	O
were	-	996	O
7	-	1001	O
mm	-	1003	O
and	-	1006	O
sluggishly	-	1010	O
reactive	-	1021	O
to	-	1030	O
light	-	1033	O
.	-	1038	O

Vital	8888541	1040	O
signs	-	1046	O
were	-	1052	O
:	-	1056	O
blood	-	1058	O
pressure	-	1064	O
120	-	1073	O
/	-	1076	O
67	-	1077	O
mm	-	1080	O
Hg	-	1083	O
,	-	1085	O
heart	-	1087	O
rate	-	1093	O
127	-	1098	O
/	-	1101	O
min	-	1102	O
,	-	1105	O
respiratory	-	1107	O
rate	-	1119	O
28	-	1124	O
/	-	1126	O
min	-	1127	O
,	-	1130	O
and	-	1132	O
temperature	-	1136	O
97	-	1148	O
F	-	1151	O
.	-	1152	O

After	8888541	1154	O
180	-	1160	O
mg	-	1164	O
of	-	1167	O
diazepam	-	1170	O
i	-	1179	O
.	-	1180	O
v	-	1181	O
.	-	1182	O

he	8888541	1184	O
remained	-	1187	O
tremulous	-	1196	O
with	-	1206	O
muscle	-	1211	B
rigidity	-	1218	I
and	-	1227	O
clenched	-	1231	O
jaws	-	1240	O
.	-	1244	O

He	8888541	1246	O
was	-	1249	O
intubated	-	1253	O
for	-	1263	O
airway	-	1267	O
protection	-	1274	O
and	-	1285	O
because	-	1289	O
of	-	1297	O
hypoventilation	-	1300	B
,	-	1315	O
and	-	1317	O
was	-	1321	O
paralyzed	-	1325	B
to	-	1335	O
control	-	1338	O
muscle	-	1346	B
rigidity	-	1353	I
.	-	1361	O

His	8888541	1363	O
subsequent	-	1367	O
course	-	1378	O
was	-	1385	O
remarkable	-	1389	O
for	-	1400	O
non	-	1404	O
-	-	1407	O
immune	-	1408	O
thrombocytopenia	-	1415	B
which	-	1432	O
resolved	-	1438	O
.	-	1446	O

The	8888541	1448	O
patient	-	1452	O
's	-	1459	O
maximal	-	1462	O
temperature	-	1470	O
was	-	1482	O
101	-	1486	O
.	-	1489	O
2	-	1490	O
F	-	1492	O
and	-	1494	O
his	-	1498	O
CPK	-	1502	O
remained	-	1506	O
<	-	1515	O
500	-	1517	O
units	-	1521	O
/	-	1526	O
L	-	1527	O
with	-	1529	O
no	-	1534	O
other	-	1537	O
evidence	-	1543	O
of	-	1552	O
rhabdomyolysis	-	1555	B
.	-	1569	O

His	8888541	1571	O
mental	-	1575	O
status	-	1582	O
normalized	-	1589	O
and	-	1600	O
he	-	1604	O
was	-	1607	O
transferred	-	1611	O
to	-	1623	O
a	-	1626	O
psychiatry	-	1628	O
ward	-	1639	O
.	-	1643	O

This	8888541	1645	O
patient	-	1650	O
survived	-	1658	O
without	-	1667	O
sequelae	-	1675	O
due	-	1684	O
to	-	1688	O
the	-	1691	O
aggressive	-	1695	O
sedation	-	1706	O
and	-	1715	O
neuromuscular	-	1719	O
paralysis	-	1733	B
.	-	1742	O

Effect	8106150	0	O
of	-	7	O
nondopaminergic	-	10	O
drugs	-	26	O
on	-	32	O
L	-	35	O
-	-	36	O
dopa	-	37	O
-	-	41	O
induced	-	42	O
dyskinesias	-	50	B
in	-	62	O
MPTP	-	65	O
-	-	69	O
treated	-	70	O
monkeys	-	78	O
.	-	85	O

A	8106150	87	O
group	-	89	O
of	-	95	O
four	-	98	O
monkeys	-	103	O
was	-	111	O
rendered	-	115	O
parkinsonian	-	124	B
with	-	137	O
the	-	142	O
toxin	-	146	O
MPTP	-	152	O
.	-	156	O

They	8106150	158	O
were	-	163	O
then	-	168	O
treated	-	173	O
chronically	-	181	O
with	-	193	O
L	-	198	O
-	-	199	O
DOPA	-	200	O
/	-	204	O
benserazide	-	205	O
50	-	217	O
/	-	219	O
12	-	220	O
.	-	222	O
5	-	223	O
mg	-	225	O
/	-	227	O
kg	-	228	O
given	-	231	O
orally	-	237	O
daily	-	244	O
for	-	250	O
2	-	254	O
months	-	256	O
.	-	262	O

This	8106150	264	O
dose	-	269	O
produced	-	274	O
a	-	283	O
striking	-	285	O
antiparkinsonian	-	294	O
effect	-	311	O
,	-	317	O
but	-	319	O
all	-	323	O
animals	-	327	O
manifested	-	335	O
dyskinesia	-	346	B
.	-	356	O

A	8106150	358	O
series	-	360	O
of	-	367	O
agents	-	370	O
acting	-	377	O
primarily	-	384	O
on	-	394	O
neurotransmitters	-	397	O
other	-	415	O
than	-	421	O
dopamine	-	426	O
were	-	435	O
then	-	440	O
tested	-	445	O
in	-	452	O
combination	-	455	O
with	-	467	O
L	-	472	O
-	-	473	O
DOPA	-	474	O
to	-	479	O
see	-	482	O
if	-	486	O
the	-	489	O
dyskinetic	-	493	B
movements	-	504	O
would	-	514	O
be	-	520	O
modified	-	523	O
.	-	531	O

Several	8106150	533	O
drugs	-	541	O
,	-	546	O
including	-	548	O
clonidine	-	558	O
,	-	567	O
physostigmine	-	569	O
,	-	582	O
methysergide	-	584	O
,	-	596	O
5	-	598	O
-	-	599	O
MDOT	-	600	O
,	-	604	O
propranolol	-	606	O
,	-	617	O
and	-	619	O
MK	-	623	O
-	-	625	O
801	-	626	O
,	-	629	O
markedly	-	631	O
reduced	-	640	O
the	-	648	O
dyskinetic	-	652	B
movements	-	663	O
but	-	673	O
at	-	677	O
the	-	680	O
cost	-	684	O
of	-	689	O
a	-	692	O
return	-	694	O
of	-	701	O
parkinsonian	-	704	B
symptomatology	-	717	O
.	-	731	O

However	8106150	733	O
,	-	740	O
yohimbine	-	742	O
and	-	752	O
meperidine	-	756	O
reduced	-	767	O
predominantly	-	775	O
the	-	789	O
dyskinetic	-	793	B
movements	-	804	O
.	-	813	O

Baclofen	8106150	815	O
was	-	824	O
also	-	828	O
useful	-	833	O
in	-	840	O
one	-	843	O
monkey	-	847	O
against	-	854	O
a	-	862	O
more	-	864	O
dystonic	-	869	B
form	-	878	O
of	-	883	O
dyskinesia	-	886	B
.	-	896	O

Atropine	8106150	898	O
converted	-	907	O
the	-	917	O
dystonic	-	921	B
movements	-	930	O
into	-	940	O
chorea	-	945	B
.	-	951	O

CCNU	21418164	0	O
(	-	5	O
lomustine	-	6	O
)	-	15	O
toxicity	-	17	B
in	-	26	O
dogs	-	29	O
:	-	33	O
a	-	35	O
retrospective	-	37	O
study	-	51	O
(	-	57	O
2002	-	58	O
-	-	62	O
07	-	63	O
)	-	65	O
.	-	66	O

OBJECTIVE	21418164	68	O
:	-	77	O

To	21418164	79	O
describe	-	82	O
the	-	91	O
incidence	-	95	O
of	-	105	O
haematological	-	108	B
,	-	122	I
renal	-	124	I
,	-	129	I
hepatic	-	131	I
and	-	139	I
gastrointestinal	-	143	I
toxicities	-	160	I
in	-	171	O
tumour	-	174	O
-	-	180	O
bearing	-	181	O
dogs	-	189	O
receiving	-	194	O
1	-	204	O
-	-	205	O
(	-	206	O
2	-	207	O
-	-	208	O
chloroethyl	-	209	O
)	-	220	O
-	-	221	O
3	-	222	O
-	-	223	O
cyclohexyl	-	224	O
-	-	234	O
1	-	235	O
-	-	236	O
nitrosourea	-	237	O
(	-	249	O
CCNU	-	250	O
)	-	254	O
.	-	255	O

DESIGN	21418164	257	O
:	-	263	O

The	21418164	265	O
medical	-	269	O
records	-	277	O
of	-	285	O
206	-	288	O
dogs	-	292	O
that	-	297	O
were	-	302	O
treated	-	307	O
with	-	315	O
CCNU	-	320	O
at	-	325	O
the	-	328	O
Melbourne	-	332	O
Veterinary	-	342	O
Specialist	-	353	O
Centre	-	364	O
between	-	371	O
February	-	379	O
2002	-	388	O
and	-	393	O
December	-	397	O
2007	-	406	O
were	-	411	O
retrospectively	-	416	O
evaluated	-	432	O
.	-	441	O

RESULTS	21418164	443	O
:	-	450	O

Of	21418164	452	O
the	-	455	O
206	-	459	O
dogs	-	463	O
treated	-	468	O
with	-	476	O
CCNU	-	481	O
,	-	485	O
185	-	487	O
met	-	491	O
the	-	495	O
inclusion	-	499	O
criteria	-	509	O
for	-	518	O
at	-	522	O
least	-	525	O
one	-	531	O
class	-	535	O
of	-	541	O
toxicity	-	544	B
.	-	552	O

CCNU	21418164	554	O
was	-	559	O
used	-	563	O
most	-	568	O
commonly	-	573	O
in	-	582	O
the	-	585	O
treatment	-	589	O
of	-	599	O
lymphoma	-	602	B
,	-	610	O
mast	-	612	B
cell	-	617	I
tumour	-	622	I
,	-	628	O
brain	-	630	B
tumour	-	636	I
,	-	642	O
histiocytic	-	644	B
tumours	-	656	I
and	-	664	O
epitheliotropic	-	668	B
lymphoma	-	684	I
.	-	692	O

Throughout	21418164	694	O
treatment	-	705	O
,	-	714	O
56	-	716	O
.	-	718	O
9	-	719	O
%	-	720	O
of	-	722	O
dogs	-	725	O
experienced	-	730	O
neutropenia	-	742	B
,	-	753	O
34	-	755	O
.	-	757	O
2	-	758	O
%	-	759	O
experienced	-	761	O
anaemia	-	773	B
and	-	781	O
14	-	785	O
.	-	787	O
2	-	788	O
%	-	789	O
experienced	-	791	O
thrombocytopenia	-	803	B
.	-	819	O

Gastrointestinal	21418164	821	B
toxicosis	-	838	I
was	-	848	O
detected	-	852	O
in	-	861	O
37	-	864	O
.	-	866	O
8	-	867	O
%	-	868	O
of	-	870	O
dogs	-	873	O
,	-	877	O
the	-	879	O
most	-	883	O
common	-	888	O
sign	-	895	O
of	-	900	O
which	-	903	O
was	-	909	O
vomiting	-	913	B
(	-	922	O
24	-	923	O
.	-	925	O
3	-	926	O
%	-	927	O
)	-	928	O
.	-	929	O

Potential	21418164	931	O
renal	-	941	O
toxicity	-	947	B
and	-	956	O
elevated	-	960	O
alanine	-	969	O
transaminase	-	977	O
(	-	990	O
ALT	-	991	O
)	-	994	O
concentration	-	996	O
were	-	1010	O
reported	-	1015	O
in	-	1024	O
12	-	1027	O
.	-	1029	O
2	-	1030	O
%	-	1031	O
and	-	1033	O
48	-	1037	O
.	-	1039	O
8	-	1040	O
%	-	1041	O
of	-	1043	O
dogs	-	1046	O
,	-	1050	O
respectively	-	1052	O
.	-	1064	O

The	21418164	1066	O
incidence	-	1070	O
of	-	1080	O
hepatic	-	1083	B
failure	-	1091	I
was	-	1099	O
1	-	1103	O
.	-	1104	O
2	-	1105	O
%	-	1106	O
.	-	1107	O

CONCLUSIONS	21418164	1109	O
:	-	1120	O

CCNU	21418164	1122	O
-	-	1126	O
associated	-	1127	O
toxicity	-	1138	B
in	-	1147	O
dogs	-	1150	O
is	-	1155	O
common	-	1158	O
,	-	1164	O
but	-	1166	O
is	-	1170	O
usually	-	1173	O
not	-	1181	O
life	-	1185	O
threatening	-	1190	O
.	-	1201	O

Neuroactive	9121607	0	O
steroids	-	12	O
protect	-	21	O
against	-	29	O
pilocarpine	-	37	O
-	-	48	O
and	-	50	O
kainic	-	54	O
acid	-	61	O
-	-	65	O
induced	-	66	O
limbic	-	74	O
seizures	-	81	B
and	-	90	O
status	-	94	B
epilepticus	-	101	I
in	-	113	O
mice	-	116	O
.	-	120	O

Several	9121607	122	O
structurally	-	130	O
related	-	143	O
metabolites	-	151	O
of	-	163	O
progesterone	-	166	O
(	-	179	O
3	-	180	O
alpha	-	182	O
-	-	187	O
hydroxy	-	188	O
pregnane	-	196	O
-	-	204	O
20	-	205	O
-	-	207	O
ones	-	208	O
)	-	212	O
and	-	214	O
deoxycorticosterone	-	218	O
(	-	238	O
3	-	239	O
alpha	-	241	O
-	-	246	O
hydroxy	-	247	O
pregnane	-	255	O
-	-	263	O
21	-	264	O
-	-	266	O
diol	-	267	O
-	-	271	O
20	-	272	O
-	-	274	O
ones	-	275	O
)	-	279	O
and	-	281	O
their	-	285	O
3	-	291	O
beta	-	293	O
-	-	297	O
epimers	-	298	O
were	-	306	O
evaluated	-	311	O
for	-	321	O
protective	-	325	O
activity	-	336	O
against	-	345	O
pilocarpine	-	353	O
-	-	364	O
,	-	365	O
kainic	-	367	O
acid	-	374	O
-	-	378	O
and	-	380	O
N	-	384	O
-	-	385	O
methyl	-	386	O
-	-	392	O
D	-	393	O
-	-	394	O
aspartate	-	395	O
(	-	405	O
NMDA	-	406	O
)	-	410	O
-	-	411	O
induced	-	412	O
seizures	-	420	B
in	-	429	O
mice	-	432	O
.	-	436	O

Steroids	9121607	438	O
with	-	447	O
the	-	452	O
3	-	456	O
-	-	457	O
hydroxy	-	458	O
group	-	466	O
in	-	472	O
the	-	475	O
alpha	-	479	O
-	-	484	O
position	-	485	O
and	-	494	O
5	-	498	O
-	-	499	O
H	-	500	O
in	-	502	O
the	-	505	O
alpha	-	509	O
-	-	514	O
or	-	516	O
beta	-	519	O
-	-	523	O
configurations	-	524	O
were	-	539	O
highly	-	544	O
effective	-	551	O
in	-	561	O
protecting	-	564	O
against	-	575	O
pilocarpine	-	583	O
(	-	595	O
416	-	596	O
mg	-	600	O
/	-	602	O
kg	-	603	O
,	-	605	O
s	-	607	O
.	-	608	O
c	-	609	O
.	-	610	O
)	-	611	O
-	-	612	O
induced	-	613	O
limbic	-	621	O
motor	-	628	O
seizures	-	634	B
and	-	643	O
status	-	647	B
epilepticus	-	654	I
(	-	666	O
ED50	-	667	O
values	-	672	O
,	-	678	O
7	-	680	O
.	-	681	O
0	-	682	O
-	-	683	O
18	-	684	O
.	-	686	O
7	-	687	O
mg	-	689	O
/	-	691	O
kg	-	692	O
,	-	694	O
i	-	696	O
.	-	697	O
p	-	698	O
.	-	699	O
)	-	700	O
.	-	701	O

The	9121607	703	O
corresponding	-	707	O
epimers	-	721	O
with	-	729	O
the	-	734	O
3	-	738	O
-	-	739	O
hydroxy	-	740	O
group	-	748	O
in	-	754	O
the	-	757	O
beta	-	761	O
-	-	765	O
position	-	766	O
were	-	775	O
also	-	780	O
effective	-	785	O
but	-	795	O
less	-	799	O
potent	-	804	O
(	-	811	O
ED50	-	812	O
values	-	817	O
,	-	823	O
33	-	825	O
.	-	827	O
8	-	828	O
-	-	829	O
63	-	830	O
.	-	832	O
5	-	833	O
,	-	834	O
i	-	836	O
.	-	837	O
p	-	838	O
.	-	839	O
)	-	840	O
.	-	841	O

Although	9121607	843	O
the	-	852	O
neuroactive	-	856	O
steroids	-	868	O
were	-	877	O
considerably	-	882	O
less	-	895	O
potent	-	900	O
than	-	907	O
the	-	912	O
benzodiazepine	-	916	O
clonazepam	-	931	O
in	-	942	O
protecting	-	945	O
against	-	956	O
pilocarpine	-	964	O
seizures	-	976	B
,	-	984	O
steroids	-	986	O
with	-	995	O
the	-	1000	O
5	-	1004	O
alpha	-	1006	O
,	-	1011	O
3	-	1012	O
alpha	-	1014	O
-	-	1019	O
configuration	-	1020	O
had	-	1034	O
comparable	-	1038	O
or	-	1049	O
higher	-	1052	O
protective	-	1059	O
index	-	1070	O
values	-	1076	O
(	-	1083	O
TD50	-	1084	O
for	-	1089	O
motor	-	1093	O
impairment	-	1099	O
divided	-	1110	O
by	-	1118	O
ED50	-	1121	O
for	-	1126	O
seizure	-	1130	B
protection	-	1138	O
)	-	1148	O
than	-	1150	O
clonazepam	-	1155	O
,	-	1165	O
indicating	-	1167	O
that	-	1178	O
some	-	1183	O
neuroactive	-	1188	O
steroids	-	1200	O
may	-	1209	O
have	-	1213	O
lower	-	1218	O
relative	-	1224	O
toxicity	-	1233	B
.	-	1241	O

Steroids	9121607	1243	O
with	-	1252	O
the	-	1257	O
5	-	1261	O
alpha	-	1263	O
,	-	1268	O
3	-	1269	O
alpha	-	1271	O
-	-	1276	O
or	-	1278	O
5	-	1281	O
beta	-	1283	O
,	-	1287	O
3	-	1288	O
alpha	-	1290	O
-	-	1295	O
configurations	-	1296	O
also	-	1311	O
produced	-	1316	O
a	-	1325	O
dose	-	1327	O
-	-	1331	O
dependent	-	1332	O
delay	-	1342	O
in	-	1348	O
the	-	1351	O
onset	-	1355	O
of	-	1361	O
limbic	-	1364	O
seizures	-	1371	B
induced	-	1380	O
by	-	1388	O
kainic	-	1391	O
acid	-	1398	O
(	-	1403	O
32	-	1404	O
mg	-	1407	O
/	-	1409	O
kg	-	1410	O
,	-	1412	O
s	-	1414	O
.	-	1415	O
c	-	1416	O
.	-	1417	O
)	-	1418	O
,	-	1419	O
but	-	1421	O
did	-	1425	O
not	-	1429	O
completely	-	1433	O
protect	-	1444	O
against	-	1452	O
the	-	1460	O
seizures	-	1464	B
.	-	1472	O

However	9121607	1474	O
,	-	1481	O
when	-	1483	O
a	-	1488	O
second	-	1490	O
dose	-	1497	O
of	-	1502	O
the	-	1505	O
steroid	-	1509	O
was	-	1517	O
administered	-	1521	O
1	-	1534	O
hr	-	1536	O
after	-	1539	O
the	-	1545	O
first	-	1549	O
dose	-	1555	O
,	-	1559	O
complete	-	1561	O
protection	-	1570	O
from	-	1581	O
the	-	1586	O
kainic	-	1590	O
acid	-	1597	O
-	-	1601	O
induced	-	1602	O
limbic	-	1610	O
seizures	-	1617	B
and	-	1626	O
status	-	1630	B
epilepticus	-	1637	I
was	-	1649	O
obtained	-	1653	O
.	-	1661	O

The	9121607	1663	O
steroids	-	1667	O
also	-	1676	O
caused	-	1681	O
a	-	1688	O
dose	-	1690	O
-	-	1694	O
dependent	-	1695	O
delay	-	1705	O
in	-	1711	O
NMDA	-	1714	O
(	-	1719	O
257	-	1720	O
mg	-	1724	O
/	-	1726	O
kg	-	1727	O
,	-	1729	O
s	-	1731	O
.	-	1732	O
c	-	1733	O
.	-	1734	O
)	-	1735	O
-	-	1736	O
induced	-	1737	O
lethality	-	1745	O
,	-	1754	O
but	-	1756	O
did	-	1760	O
not	-	1764	O
completely	-	1768	O
protect	-	1779	O
against	-	1787	O
NMDA	-	1795	O
seizures	-	1800	B
or	-	1809	O
lethality	-	1812	O
.	-	1821	O

We	9121607	1823	O
conclude	-	1826	O
that	-	1835	O
neuroactive	-	1840	O
steroids	-	1852	O
are	-	1861	O
highly	-	1865	O
effective	-	1872	O
in	-	1882	O
protecting	-	1885	O
against	-	1896	O
pilocarpine	-	1904	O
-	-	1915	O
and	-	1917	O
kainic	-	1921	O
acid	-	1928	O
-	-	1932	O
induced	-	1933	O
seizures	-	1941	B
and	-	1950	O
status	-	1954	B
epilepticus	-	1961	I
in	-	1973	O
mice	-	1976	O
,	-	1980	O
and	-	1982	O
may	-	1986	O
be	-	1990	O
of	-	1993	O
utility	-	1996	O
in	-	2004	O
the	-	2007	O
treatment	-	2011	O
of	-	2021	O
some	-	2024	O
forms	-	2029	O
of	-	2035	O
status	-	2038	B
epilepticus	-	2045	I
in	-	2057	O
humans	-	2060	O
.	-	2066	O

The	7905523	0	O
safety	-	4	O
and	-	11	O
efficacy	-	15	O
of	-	24	O
combination	-	27	O
N	-	39	O
-	-	40	O
butyl	-	41	O
-	-	46	O
deoxynojirimycin	-	47	O
(	-	64	O
SC	-	65	O
-	-	67	O
48334	-	68	O
)	-	73	O
and	-	75	O
zidovudine	-	79	O
in	-	90	O
patients	-	93	O
with	-	102	O
HIV	-	107	B
-	-	110	I
1	-	111	I
infection	-	113	I
and	-	123	O
200	-	127	O
-	-	130	O
500	-	131	O
CD4	-	135	O
cells	-	139	O
/	-	144	O
mm3	-	145	O
.	-	148	O

We	7905523	150	O
conducted	-	153	O
a	-	163	O
double	-	165	O
-	-	171	O
blind	-	172	O
,	-	177	O
randomized	-	179	O
phase	-	190	O
II	-	196	O
study	-	199	O
to	-	205	O
evaluate	-	208	O
the	-	217	O
safety	-	221	O
and	-	228	O
activity	-	232	O
of	-	241	O
combination	-	244	O
therapy	-	256	O
with	-	264	O
N	-	269	O
-	-	270	O
butyl	-	271	O
-	-	276	O
deoxynojirimycin	-	277	O
(	-	294	O
SC	-	295	O
-	-	297	O
48334	-	298	O
)	-	303	O
(	-	305	O
an	-	306	O
alpha	-	309	O
-	-	314	O
glucosidase	-	315	O
I	-	327	O
inhibitor	-	329	O
)	-	338	O
and	-	340	O
zidovudine	-	344	O
versus	-	355	O
zidovudine	-	362	O
alone	-	373	O
.	-	378	O

Patients	7905523	380	O
with	-	389	O
200	-	394	O
to	-	398	O
500	-	401	O
CD4	-	405	O
cells	-	409	O
/	-	414	O
mm3	-	415	O
who	-	419	O
tolerated	-	423	O
<	-	433	O
or	-	435	O
=	-	438	O
12	-	440	O
weeks	-	443	O
of	-	449	O
prior	-	452	O
zidovudine	-	458	O
therapy	-	469	O
received	-	477	O
SC	-	486	O
-	-	488	O
48334	-	489	O
(	-	495	O
1000	-	496	O
mg	-	501	O
every	-	504	O
8	-	510	O
h	-	512	O
)	-	513	O
and	-	515	O
zidovudine	-	519	O
(	-	530	O
100	-	531	O
mg	-	535	O
every	-	538	O
8	-	544	O
h	-	546	O
)	-	547	O
or	-	549	O
zidovudine	-	552	O
and	-	563	O
placebo	-	567	O
.	-	574	O

Sixty	7905523	576	O
patients	-	582	O
received	-	591	O
combination	-	600	O
therapy	-	612	O
and	-	620	O
58	-	624	O
,	-	626	O
zidovudine	-	628	O
and	-	639	O
placebo	-	643	O
.	-	650	O

Twenty	7905523	652	O
-	-	658	O
three	-	659	O
patients	-	665	O
(	-	674	O
38	-	675	O
%	-	677	O
)	-	678	O
and	-	680	O
15	-	684	O
(	-	687	O
26	-	688	O
%	-	690	O
)	-	691	O
,	-	692	O
in	-	694	O
the	-	697	O
combination	-	701	O
and	-	713	O
zidovudine	-	717	O
groups	-	728	O
,	-	734	O
respectively	-	736	O
,	-	748	O
discontinued	-	750	O
therapy	-	763	O
(	-	771	O
p	-	772	O
=	-	774	O
0	-	776	O
.	-	777	O
15	-	778	O
)	-	780	O
.	-	781	O

The	7905523	783	O
mean	-	787	O
SC	-	792	O
-	-	794	O
48334	-	795	O
steady	-	801	O
-	-	807	O
state	-	808	O
trough	-	814	O
level	-	821	O
(	-	827	O
4	-	828	O
.	-	829	O
04	-	830	O
+	-	833	O
/	-	834	O
-	-	835	O

0	7905523	837	O
.	-	838	O
99	-	839	O
micrograms	-	842	O
/	-	852	O
ml	-	853	O
)	-	855	O
was	-	857	O
below	-	861	O
the	-	867	O
in	-	871	O
vitro	-	874	O
inhibitory	-	880	O
concentration	-	891	O
for	-	905	O
human	-	909	O
immunodeficiency	-	915	B
virus	-	932	O
(	-	938	O
HIV	-	939	O
)	-	942	O
.	-	943	O

The	7905523	945	O
mean	-	949	O
increase	-	954	O
in	-	963	O
CD4	-	966	O
cells	-	970	O
at	-	976	O
week	-	979	O
4	-	984	O
was	-	986	O
73	-	990	O
.	-	992	O
8	-	993	O
cells	-	995	O
/	-	1000	O
mm3	-	1001	O
and	-	1005	O
52	-	1009	O
.	-	1011	O
4	-	1012	O
cells	-	1014	O
/	-	1019	O
mm3	-	1020	O
for	-	1024	O
the	-	1028	O
combination	-	1032	O
and	-	1044	O
zidovudine	-	1048	O
groups	-	1059	O
,	-	1065	O
respectively	-	1067	O
(	-	1080	O
p	-	1081	O
>	-	1083	O
0	-	1085	O
.	-	1086	O
36	-	1087	O
)	-	1089	O
.	-	1090	O

For	7905523	1092	O
patients	-	1096	O
with	-	1105	O
prior	-	1110	O
zidovudine	-	1116	O
therapy	-	1127	O
,	-	1134	O
the	-	1136	O
mean	-	1140	O
change	-	1145	O
in	-	1152	O
CD4	-	1155	O
cells	-	1159	O
in	-	1165	O
the	-	1168	O
combination	-	1172	O
and	-	1184	O
zidovudine	-	1188	O
groups	-	1199	O
was	-	1206	O
63	-	1210	O
.	-	1212	O
7	-	1213	O
cells	-	1215	O
/	-	1220	O
mm3	-	1221	O
and	-	1225	O
4	-	1229	O
.	-	1230	O
9	-	1231	O
cells	-	1233	O
/	-	1238	O
mm3	-	1239	O
at	-	1243	O
week	-	1246	O
8	-	1251	O
and	-	1253	O
6	-	1257	O
.	-	1258	O
8	-	1259	O
cells	-	1261	O
/	-	1266	O
mm3	-	1267	O
and	-	1271	O
-	-	1275	O
45	-	1276	O
.	-	1278	O
1	-	1279	O
cells	-	1281	O
/	-	1286	O
mm3	-	1287	O
at	-	1291	O
week	-	1294	O
16	-	1299	O
,	-	1301	O
respectively	-	1303	O
.	-	1315	O

The	7905523	1317	O
number	-	1321	O
of	-	1328	O
patients	-	1331	O
with	-	1340	O
suppression	-	1345	O
of	-	1357	O
HIV	-	1360	O
p24	-	1364	O
antigenemia	-	1368	O
in	-	1380	O
the	-	1383	O
combination	-	1387	O
and	-	1399	O
zidovudine	-	1403	O
groups	-	1414	O
was	-	1421	O
six	-	1425	O
(	-	1429	O
40	-	1430	O
%	-	1432	O
)	-	1433	O
and	-	1435	O
two	-	1439	O
(	-	1443	O
11	-	1444	O
%	-	1446	O
)	-	1447	O
at	-	1449	O
week	-	1452	O
4	-	1457	O
(	-	1459	O
p	-	1460	O
=	-	1462	O
0	-	1464	O
.	-	1465	O
10	-	1466	O
)	-	1468	O
and	-	1470	O
five	-	1474	O
(	-	1479	O
45	-	1480	O
%	-	1482	O
)	-	1483	O
and	-	1485	O
two	-	1489	O
(	-	1493	O
14	-	1494	O
%	-	1496	O
)	-	1497	O
at	-	1499	O
week	-	1502	O
24	-	1507	O
(	-	1510	O
p	-	1511	O
=	-	1513	O
0	-	1515	O
.	-	1516	O
08	-	1517	O
)	-	1519	O
,	-	1520	O
respectively	-	1522	O
.	-	1534	O

Diarrhea	7905523	1536	B
,	-	1544	O
flatulence	-	1546	B
,	-	1556	O
abdominal	-	1558	B
pain	-	1568	I
,	-	1572	O
and	-	1574	O
weight	-	1578	B
loss	-	1585	I
were	-	1590	O
common	-	1595	O
for	-	1602	O
combination	-	1606	O
recipients	-	1618	O
.	-	1628	O
(	-	1629	O
ABSTRACT	-	1630	O

TRUNCATED	7905523	1639	O
AT	-	1649	O
250	-	1652	O
WORDS	-	1656	O
)	-	1661	O

Recent	3431591	0	O
preclinical	-	7	O
and	-	19	O
clinical	-	23	O
studies	-	32	O
with	-	40	O
the	-	45	O
thymidylate	-	49	O
synthase	-	61	O
inhibitor	-	70	O
N10	-	80	O
-	-	83	O
propargyl	-	84	O
-	-	93	O
5	-	94	O
,	-	95	O
8	-	96	O
-	-	97	O
dideazafolic	-	98	O
acid	-	111	O
(	-	116	O
CB	-	117	O
3717	-	120	O
)	-	124	O
.	-	125	O

CB	3431591	127	O
3717	-	130	O
,	-	134	O
N10	-	136	O
-	-	139	O
propargyl	-	140	O
-	-	149	O
5	-	150	O
,	-	151	O
8	-	152	O
-	-	153	O
dideazafolic	-	154	O
acid	-	167	O
,	-	171	O
is	-	173	O
a	-	176	O
tight	-	178	O
-	-	183	O
binding	-	184	O
inhibitor	-	192	O
of	-	202	O
thymidylate	-	205	O
synthase	-	217	O
(	-	226	O
TS	-	227	O
)	-	229	O
whose	-	231	O
cytotoxicity	-	237	B
is	-	250	O
mediated	-	253	O
solely	-	262	O
through	-	269	O
the	-	277	O
inhibition	-	281	O
of	-	292	O
this	-	295	O
enzyme	-	300	O
.	-	306	O

Recent	3431591	308	O
preclinical	-	315	O
studies	-	327	O
have	-	335	O
focused	-	340	O
on	-	348	O
the	-	351	O
intracellular	-	355	O
formation	-	369	O
of	-	379	O
CB	-	382	O
3717	-	385	O
polyglutamates	-	390	O
.	-	404	O

Following	3431591	406	O
a	-	416	O
12	-	418	O
-	-	420	O
hour	-	421	O
exposure	-	426	O
of	-	435	O
L1210	-	438	O
cells	-	444	O
to	-	450	O
50	-	453	O
microM	-	456	O
[	-	463	O
3H	-	464	O
]	-	466	O
CB	-	467	O
3717	-	470	O
,	-	474	O
30	-	476	O
%	-	478	O
of	-	480	O
the	-	483	O
extractable	-	487	O
radioactivity	-	499	O
could	-	513	O
be	-	519	O
accounted	-	522	O
for	-	532	O
as	-	536	O
CB	-	539	O
3717	-	542	O
tetra	-	547	O
-	-	552	O
and	-	554	O
pentaglutamate	-	558	O
,	-	572	O
as	-	574	O
determined	-	577	O
by	-	588	O
high	-	591	O
-	-	595	O
pressure	-	596	O
liquid	-	605	O
chromatography	-	612	O
(	-	627	O
HPLC	-	628	O
)	-	632	O
analyses	-	634	O
.	-	642	O

As	3431591	644	O
inhibitors	-	647	O
of	-	658	O
isolated	-	661	O
L1210	-	670	O
TS	-	676	O
,	-	678	O
CB	-	680	O
3717	-	683	O
di	-	688	O
-	-	690	O
,	-	691	O
tri	-	693	O
-	-	696	O
,	-	697	O
tetra	-	699	O
-	-	704	O
and	-	706	O
pentaglutamate	-	710	O
are	-	725	O
26	-	729	O
-	-	731	O
,	-	732	O
87	-	734	O
-	-	736	O
,	-	737	O
119	-	739	O
-	-	742	O
and	-	744	O
114	-	748	O
-	-	751	O
fold	-	752	O
more	-	757	O
potent	-	762	O
than	-	769	O
CB	-	774	O
3717	-	777	O
,	-	781	O
respectively	-	783	O
,	-	795	O
and	-	797	O
their	-	801	O
formation	-	807	O
may	-	817	O
,	-	820	O
therefore	-	822	O
,	-	831	O
be	-	833	O
an	-	836	O
important	-	839	O
determinant	-	849	O
of	-	861	O
CB	-	864	O
3717	-	867	O
cytotoxicity	-	872	B
.	-	884	O

In	3431591	886	O
early	-	889	O
clinical	-	895	O
studies	-	904	O
with	-	912	O
CB	-	917	O
3717	-	920	O
,	-	924	O
activity	-	926	O
has	-	935	O
been	-	939	O
seen	-	944	O
in	-	949	O
breast	-	952	B
cancer	-	959	I
,	-	965	O
ovarian	-	967	B
cancer	-	975	I
,	-	981	O
hepatoma	-	983	B
,	-	991	O
and	-	993	O
mesothelioma	-	997	B
.	-	1009	O

Toxicities	3431591	1011	B
included	-	1022	O
hepatotoxicity	-	1031	B
,	-	1045	O
malaise	-	1047	B
,	-	1054	O
and	-	1056	O
dose	-	1060	O
-	-	1064	O
limiting	-	1065	O
nephrotoxicity	-	1074	B
.	-	1088	O

This	3431591	1090	O
latter	-	1095	O
effect	-	1102	O
is	-	1109	O
thought	-	1112	O
to	-	1120	O
be	-	1123	O
due	-	1126	O
to	-	1130	O
drug	-	1133	O
precipitation	-	1138	O
within	-	1152	O
the	-	1159	O
renal	-	1163	O
tubule	-	1169	O
as	-	1176	O
a	-	1179	O
result	-	1181	O
of	-	1188	O
the	-	1191	O
poor	-	1195	O
solubility	-	1200	O
of	-	1211	O
CB	-	1214	O
3717	-	1217	O
under	-	1222	O
acidic	-	1228	O
conditions	-	1235	O
.	-	1245	O

In	3431591	1247	O
an	-	1250	O
attempt	-	1253	O
to	-	1261	O
overcome	-	1264	O
this	-	1273	O
problem	-	1278	O
,	-	1285	O
a	-	1287	O
clinical	-	1289	O
trial	-	1298	O
of	-	1304	O
CB	-	1307	O
3717	-	1310	O
administered	-	1315	O
with	-	1328	O
alkaline	-	1333	O
diuresis	-	1342	O
is	-	1351	O
under	-	1354	O
way	-	1360	O
.	-	1363	O

Preliminary	3431591	1365	O
results	-	1377	O
at	-	1385	O
400	-	1388	O
and	-	1392	O
500	-	1396	O
mg	-	1400	O
/	-	1402	O
m2	-	1403	O
suggest	-	1406	O
that	-	1414	O
a	-	1419	O
reduction	-	1421	O
in	-	1431	O
nephrotoxicity	-	1434	B
may	-	1449	O
have	-	1453	O
been	-	1458	O
achieved	-	1463	O
with	-	1472	O
only	-	1477	O
1	-	1482	O
instance	-	1484	O
of	-	1493	O
renal	-	1496	B
toxicity	-	1502	I
in	-	1511	O
10	-	1514	O
patients	-	1517	O
.	-	1525	O

Hepatotoxicity	3431591	1527	B
and	-	1542	O
malaise	-	1546	B
are	-	1554	O
again	-	1558	O
the	-	1564	O
most	-	1568	O
frequent	-	1573	O
side	-	1582	O
effects	-	1587	O
.	-	1594	O

Evidence	3431591	1596	O
of	-	1605	O
antitumor	-	1608	O
activity	-	1618	O
has	-	1627	O
been	-	1631	O
seen	-	1636	O
in	-	1641	O
3	-	1644	O
patients	-	1646	O
.	-	1654	O

Pharmacokinetic	3431591	1656	O
investigations	-	1672	O
have	-	1687	O
shown	-	1692	O
that	-	1698	O
alkaline	-	1703	O
diuresis	-	1712	O
does	-	1721	O
not	-	1726	O
alter	-	1730	O
CB	-	1736	O
3717	-	1739	O
plasma	-	1744	O
levels	-	1751	O
or	-	1758	O
urinary	-	1761	O
excretion	-	1769	O
and	-	1779	O
that	-	1783	O
satisfactory	-	1788	O
urinary	-	1801	O
alkalinization	-	1809	O
can	-	1824	O
be	-	1828	O
readily	-	1831	O
achieved	-	1839	O
.	-	1847	O

Ethopropazine	33969	0	O
and	-	14	O
benztropine	-	18	O
in	-	30	O
neuroleptic	-	33	O
-	-	44	O
induced	-	45	O
parkinsonism	-	53	B
.	-	65	O

In	33969	67	O
a	-	70	O
12	-	72	O
-	-	74	O
week	-	75	O
controlled	-	80	O
study	-	91	O
ethopropazine	-	97	O
was	-	111	O
compared	-	115	O
to	-	124	O
benztropine	-	127	O
in	-	139	O
the	-	142	O
treatment	-	146	O
of	-	156	O
parkinsonism	-	159	B
induced	-	172	O
by	-	180	O
fluphenazine	-	183	O
enanthate	-	196	O
in	-	206	O
60	-	209	O
schizophrenic	-	212	B
outpatients	-	226	O
.	-	237	O

Ethopropazine	33969	239	O
and	-	253	O
benztropine	-	257	O
were	-	269	O
found	-	274	O
to	-	280	O
be	-	283	O
equally	-	286	O
effective	-	294	O
in	-	304	O
controlling	-	307	O
parkinsonian	-	319	B
symptoms	-	332	I
and	-	341	O
were	-	345	O
as	-	350	O
efficacious	-	353	O
as	-	365	O
procyclidine	-	368	O
,	-	380	O
their	-	382	O
previous	-	388	O
antiparkinsonian	-	397	O
drug	-	414	O
.	-	418	O

However	33969	420	O
,	-	427	O
benztropine	-	429	O
treated	-	441	O
patients	-	449	O
had	-	458	O
a	-	462	O
significant	-	464	O
increase	-	476	O
in	-	485	O
tardive	-	488	B
dyskinesia	-	496	I
compared	-	507	O
to	-	516	O
their	-	519	O
condition	-	525	O
during	-	535	O
procyclindine	-	542	O
treatment	-	556	O
,	-	565	O
and	-	567	O
significantly	-	571	O
more	-	585	O
anxiety	-	590	B
and	-	598	O
depression	-	602	B
than	-	613	O
ethopropazine	-	618	O
treated	-	632	O
patients	-	640	O
.	-	648	O

This	33969	650	O
suggests	-	655	O
that	-	664	O
benztropine	-	669	O
is	-	681	O
not	-	684	O
the	-	688	O
anticholinergic	-	692	O
drug	-	708	O
of	-	713	O
choice	-	716	O
in	-	723	O
the	-	726	O
treatment	-	730	O
of	-	740	O
neuroleptic	-	743	O
-	-	754	O
induced	-	755	O
parkinsonian	-	763	B
symptoms	-	776	I
,	-	784	O
because	-	786	O
of	-	794	O
its	-	797	O
more	-	801	O
toxic	-	806	O
central	-	812	O
and	-	820	O
peripheral	-	824	O
atropinic	-	835	O
effect	-	845	O
.	-	851	O

Effect	16844102	0	O
of	-	7	O
alpha	-	10	O
-	-	15	O
tocopherol	-	16	O
and	-	27	O
deferoxamine	-	31	O
on	-	44	O
methamphetamine	-	47	O
-	-	62	O
induced	-	63	O
neurotoxicity	-	71	B
.	-	84	O

Methamphetamine	16844102	86	O
(	-	102	O
MA	-	103	O
)	-	105	O
-	-	106	O
induced	-	107	O
dopaminergic	-	115	O
neurotoxicity	-	128	B
is	-	142	O
believed	-	145	O
to	-	154	O
be	-	157	O
associated	-	160	O
with	-	171	O
the	-	176	O
increased	-	180	O
formation	-	190	O
of	-	200	O
free	-	203	O
radicals	-	208	O
.	-	216	O

This	16844102	218	O
study	-	223	O
examined	-	229	O
the	-	238	O
effect	-	242	O
of	-	249	O
alpha	-	252	O
-	-	257	O
tocopherol	-	258	O
(	-	269	O
alpha	-	270	O
-	-	275	O
TC	-	276	O
)	-	278	O
,	-	279	O
a	-	281	O
scavenger	-	283	O
of	-	293	O
reactive	-	296	O
oxygen	-	305	O
species	-	312	O
,	-	319	O
and	-	321	O
deferoxamine	-	325	O
(	-	338	O
DFO	-	339	O
)	-	342	O
,	-	343	O
an	-	345	O
iron	-	348	O
chelator	-	353	O
,	-	361	O
on	-	363	O
the	-	366	O
MA	-	370	O
-	-	372	O
induced	-	373	O
neurotoxicity	-	381	B
.	-	394	O

Male	16844102	396	O
rats	-	401	O
were	-	406	O
treated	-	411	O
with	-	419	O
MA	-	424	O
(	-	427	O
10	-	428	O
mg	-	431	O
/	-	433	O
kg	-	434	O
,	-	436	O
every	-	438	O
2	-	444	O
h	-	446	O
for	-	448	O
four	-	452	O
injections	-	457	O
)	-	467	O
.	-	468	O

The	16844102	470	O
rat	-	474	O
received	-	478	O
either	-	487	O
alpha	-	494	O
-	-	499	O
TC	-	500	O
(	-	503	O
20	-	504	O
mg	-	507	O
/	-	509	O
kg	-	510	O
)	-	512	O
intraperitoneally	-	514	O
for	-	532	O
3	-	536	O
days	-	538	O
and	-	543	O
30	-	547	O
min	-	550	O
prior	-	554	O
to	-	560	O
MA	-	563	O
administration	-	566	O
or	-	581	O
DFO	-	584	O
(	-	588	O
50	-	589	O
mg	-	592	O
/	-	594	O
kg	-	595	O
)	-	597	O
subcutaneously	-	599	O
30	-	614	O
min	-	617	O
before	-	621	O
MA	-	628	O
administration	-	631	O
.	-	645	O

The	16844102	647	O
concentrations	-	651	O
of	-	666	O
dopamine	-	669	O
(	-	678	O
DA	-	679	O
)	-	681	O
,	-	682	O
serotonin	-	684	O
and	-	694	O
their	-	698	O
metabolites	-	704	O
decreased	-	716	O
significantly	-	726	O
after	-	740	O
MA	-	746	O
administration	-	749	O
,	-	763	O
which	-	765	O
was	-	771	O
inhibited	-	775	O
by	-	785	O
the	-	788	O
alpha	-	792	O
-	-	797	O
TC	-	798	O
and	-	801	O
DFO	-	805	O
pretreatment	-	809	O
.	-	821	O

alpha	16844102	823	O
-	-	828	O
TC	-	829	O
and	-	832	O
DFO	-	836	O
attenuated	-	840	O
the	-	851	O
MA	-	855	O
-	-	857	O
induced	-	858	O
hyperthermia	-	866	B
as	-	879	O
well	-	882	O
as	-	887	O
the	-	890	O
alterations	-	894	O
in	-	906	O
the	-	909	O
locomotor	-	913	O
activity	-	923	O
.	-	931	O

The	16844102	933	O
level	-	937	O
of	-	943	O
lipid	-	946	O
peroxidation	-	952	O
was	-	965	O
higher	-	969	O
and	-	976	O
the	-	980	O
reduced	-	984	O
glutathione	-	992	O
concentration	-	1004	O
was	-	1018	O
lower	-	1022	O
in	-	1028	O
the	-	1031	O
MA	-	1035	O
-	-	1037	O
treated	-	1038	O
rats	-	1046	O
.	-	1050	O

These	16844102	1052	O
changes	-	1058	O
were	-	1066	O
significantly	-	1071	O
attenuated	-	1085	O
by	-	1096	O
alpha	-	1099	O
-	-	1104	O
TC	-	1105	O
and	-	1108	O
DFO	-	1112	O
.	-	1115	O

This	16844102	1117	O
suggests	-	1122	O
that	-	1131	O
alpha	-	1136	O
-	-	1141	O
TC	-	1142	O
and	-	1145	O
DFO	-	1149	O
ameliorate	-	1153	O
the	-	1164	O
MA	-	1168	O
-	-	1170	O
induced	-	1171	O
neuronal	-	1179	B
damage	-	1188	I
by	-	1195	O
decreasing	-	1198	O
the	-	1209	O
level	-	1213	O
of	-	1219	O
oxidative	-	1222	O
stress	-	1232	O
.	-	1238	O

Use	14633084	0	O
of	-	4	O
dexamethasone	-	7	O
with	-	21	O
mesna	-	26	O
for	-	32	O
the	-	36	O
prevention	-	40	O
of	-	51	O
ifosfamide	-	54	O
-	-	64	O
induced	-	65	O
hemorrhagic	-	73	B
cystitis	-	85	I
.	-	93	O

AIM	14633084	95	O
:	-	98	O
Hemorrhagic	-	100	B
cystitis	-	112	I
(	-	121	O
HC	-	122	B
)	-	124	O
is	-	126	O
a	-	129	O
limiting	-	131	O
side	-	140	O
-	-	144	O
effect	-	145	O
of	-	152	O
chemotherapy	-	155	O
with	-	168	O
ifosfamide	-	173	O
(	-	184	O
IFS	-	185	O
)	-	188	O
.	-	189	O

In	14633084	191	O
the	-	194	O
study	-	198	O
presented	-	204	O
here	-	214	O
,	-	218	O
we	-	220	O
investigated	-	223	O
the	-	236	O
use	-	240	O
of	-	244	O
dexamethasone	-	247	O
in	-	261	O
combination	-	264	O
with	-	276	O
mesna	-	281	O
for	-	287	O
the	-	291	O
prevention	-	295	O
of	-	306	O
IFS	-	309	O
-	-	312	O
induced	-	313	O
HC	-	321	B
.	-	323	O

METHODS	14633084	325	O
:	-	332	O

Male	14633084	334	O
Wistar	-	339	O
rats	-	346	O
(	-	351	O
150	-	352	O
-	-	355	O
200	-	356	O
g	-	360	O
;	-	361	O
6	-	363	O
rats	-	365	O
per	-	370	O
group	-	374	O
)	-	379	O
were	-	381	O
treated	-	386	O
with	-	394	O
saline	-	399	O
or	-	406	O
mesna	-	409	O
5	-	415	O
min	-	417	O
(	-	421	O
i	-	422	O
.	-	423	O
p	-	424	O
.	-	425	O
)	-	426	O

before	14633084	428	O
and	-	435	O
2	-	439	O
and	-	441	O
6	-	445	O
h	-	447	O
after	-	449	O
(	-	455	O
v	-	456	O
.	-	457	O
o	-	458	O
.	-	459	O
)	-	460	O
administration	-	462	O
of	-	477	O
IFS	-	480	O
.	-	483	O

One	14633084	485	O
,	-	488	O
two	-	490	O
or	-	494	O
three	-	497	O
doses	-	503	O
of	-	509	O
mesna	-	512	O
were	-	518	O
replaced	-	523	O
with	-	532	O
dexamethasone	-	537	O
alone	-	551	O
or	-	557	O
with	-	560	O
dexamethasone	-	565	O
plus	-	579	O
mesna	-	584	O
.	-	589	O

Cystitis	14633084	591	B
was	-	600	O
evaluated	-	604	O
24	-	614	O
h	-	617	O
after	-	619	O
its	-	625	O
induction	-	629	O
by	-	639	O
the	-	642	O
changes	-	646	O
in	-	654	O
bladder	-	657	O
wet	-	665	O
weight	-	669	O
and	-	676	O
by	-	680	O
macroscopic	-	683	O
and	-	695	O
microscopic	-	699	O
analysis	-	711	O
.	-	719	O

RESULTS	14633084	721	O
:	-	728	O

The	14633084	730	O
replacement	-	734	O
of	-	746	O
the	-	749	O
last	-	753	O
dose	-	758	O
or	-	763	O
the	-	766	O
last	-	770	O
two	-	775	O
doses	-	779	O
of	-	785	O
mesna	-	788	O
with	-	794	O
dexamethasone	-	799	O
reduced	-	813	O
the	-	821	O
increase	-	825	O
in	-	834	O
bladder	-	837	O
wet	-	845	O
weight	-	849	O
induced	-	856	O
by	-	864	O
IFS	-	867	O
by	-	871	O
84	-	874	O
.	-	876	O
79	-	877	O
%	-	879	O
and	-	881	O
89	-	885	O
.	-	887	O
13	-	888	O
%	-	890	O
,	-	891	O
respectively	-	893	O
.	-	905	O

In	14633084	907	O
addition	-	910	O
,	-	918	O
it	-	920	O
almost	-	923	O
abolished	-	930	O
the	-	940	O
macroscopic	-	944	O
and	-	956	O
microscopic	-	960	O
alterations	-	972	O
induced	-	984	O
by	-	992	O
IFS	-	995	O
.	-	998	O

Moreover	14633084	1000	O
,	-	1008	O
the	-	1010	O
addition	-	1014	O
of	-	1023	O
dexamethasone	-	1026	O
to	-	1040	O
the	-	1043	O
last	-	1047	O
two	-	1052	O
doses	-	1056	O
of	-	1062	O
mesna	-	1065	O
was	-	1071	O
more	-	1075	O
efficient	-	1080	O
than	-	1090	O
three	-	1095	O
doses	-	1101	O
of	-	1107	O
mesna	-	1110	O
alone	-	1116	O
when	-	1122	O
evaluated	-	1127	O
microscopically	-	1137	O
.	-	1152	O

CONCLUSION	14633084	1154	O
:	-	1164	O

Dexamethasone	14633084	1166	O
in	-	1180	O
combination	-	1183	O
with	-	1195	O
mesna	-	1200	O
was	-	1206	O
efficient	-	1210	O
in	-	1220	O
blocking	-	1223	O
IFS	-	1232	O
-	-	1235	O
induced	-	1236	O
HC	-	1244	B
.	-	1246	O

However	14633084	1248	O
,	-	1255	O
the	-	1257	O
replacement	-	1261	O
of	-	1273	O
last	-	1276	O
two	-	1281	O
doses	-	1285	O
of	-	1291	O
mesna	-	1294	O
with	-	1300	O
saline	-	1305	O
or	-	1312	O
all	-	1315	O
of	-	1319	O
the	-	1322	O
mesna	-	1326	O
doses	-	1332	O
with	-	1338	O
dexamethasone	-	1343	O
did	-	1357	O
not	-	1361	O
prevent	-	1365	O
HC	-	1373	B
.	-	1375	O

Behavioral	11999899	0	O
effects	-	11	O
of	-	19	O
MK	-	22	O
-	-	24	O
801	-	25	O
on	-	29	O
reserpine	-	32	O
-	-	41	O
treated	-	42	O
mice	-	50	O
.	-	54	O

The	11999899	56	O
effects	-	60	O
of	-	68	O
dizocilpine	-	71	O
(	-	83	O
MK	-	84	O
-	-	86	O
801	-	87	O
)	-	90	O
,	-	91	O
a	-	93	O
noncompetitive	-	95	O
N	-	110	O
-	-	111	O
methyl	-	112	O
-	-	118	O
D	-	119	O
-	-	120	O
aspartate	-	121	O
(	-	131	O
NMDA	-	132	O
)	-	136	O
receptor	-	138	O
antagonist	-	147	O
,	-	157	O
were	-	159	O
studied	-	164	O
on	-	172	O
dopamine	-	175	O
-	-	183	O
related	-	184	O
behaviors	-	192	O
induced	-	202	O
by	-	210	O
reserpine	-	213	O
treatments	-	223	O
.	-	233	O

This	11999899	235	O
study	-	240	O
focuses	-	246	O
on	-	254	O
behavioral	-	257	O
syndromes	-	268	O
that	-	278	O
may	-	283	O
used	-	287	O
as	-	292	O
models	-	295	O
for	-	302	O
Parkinson	-	306	B
's	-	315	I
disease	-	318	I
,	-	325	O
or	-	327	O
tardive	-	330	B
dyskinesia	-	338	I
,	-	348	O
and	-	350	O
its	-	354	O
response	-	358	O
after	-	367	O
glutamatergic	-	373	O
blockage	-	387	O
.	-	395	O

Reserpine	11999899	397	O
(	-	407	O
1	-	408	O
mg	-	410	O
/	-	412	O
kg	-	413	O
)	-	415	O
,	-	416	O
administered	-	418	O
once	-	431	O
every	-	436	O
other	-	442	O
day	-	448	O
for	-	452	O
4	-	456	O
days	-	458	O
,	-	462	O
produced	-	464	O
increases	-	473	O
in	-	483	O
orofacial	-	486	B
dyskinesia	-	496	I
,	-	506	O
tongue	-	508	O
protrusion	-	515	O
and	-	526	O
vacuous	-	530	O
chewing	-	538	O
in	-	546	O
mice	-	549	O
,	-	553	O
which	-	555	O
are	-	561	O
signs	-	565	O
indicative	-	571	O
of	-	582	O
tardive	-	585	B
dyskinesia	-	593	I
.	-	603	O

Reserpine	11999899	605	O
also	-	615	O
produced	-	620	O
tremor	-	629	B
and	-	636	O
catalepsy	-	640	B
,	-	649	O
which	-	651	O
are	-	657	O
signs	-	661	O
suggestive	-	667	O
of	-	678	O
Parkinson	-	681	B
's	-	690	I
disease	-	693	I
.	-	700	O
MK	-	702	O
-	-	704	O
801	-	705	O

(	11999899	709	O
0	-	710	O
.	-	711	O
1	-	712	O
mg	-	714	O
/	-	716	O
kg	-	717	O
)	-	719	O
,	-	720	O
administered	-	722	O
30	-	735	O
min	-	738	O
before	-	742	O
the	-	749	O
observation	-	753	O
test	-	765	O
,	-	769	O
prevented	-	771	O
the	-	781	O
vacuous	-	785	O
chewing	-	793	O
movements	-	801	O
,	-	810	O
tongue	-	812	O
protrusions	-	819	O
and	-	831	O
catalepsy	-	835	B
induced	-	845	O
by	-	853	O
reserpine	-	856	O
.	-	865	O

However	11999899	867	O
,	-	874	O
MK	-	876	O
-	-	878	O
801	-	879	O
injection	-	883	O
produced	-	893	O
a	-	902	O
significant	-	904	O
increase	-	916	O
of	-	925	O
tremor	-	928	B
in	-	935	O
reserpine	-	938	O
-	-	947	O
treated	-	948	O
mice	-	956	O
.	-	960	O

Reserpine	11999899	962	O
(	-	972	O
1	-	973	O
mg	-	975	O
/	-	977	O
kg	-	978	O
)	-	980	O
,	-	981	O
administered	-	983	O
90	-	996	O
min	-	999	O
before	-	1003	O
the	-	1010	O
test	-	1014	O
and	-	1019	O
followed	-	1023	O
by	-	1032	O
apomophine	-	1035	O
injection	-	1046	O
(	-	1056	O
0	-	1057	O
.	-	1058	O
1	-	1059	O
mg	-	1061	O
/	-	1063	O
kg	-	1064	O
)	-	1066	O
5	-	1068	O
min	-	1070	O
before	-	1074	O
the	-	1081	O
test	-	1085	O
,	-	1089	O
did	-	1091	O
not	-	1095	O
produce	-	1099	O
oral	-	1107	B
dyskinesia	-	1112	I
in	-	1123	O
mice	-	1126	O
.	-	1130	O

On	11999899	1132	O
the	-	1135	O
other	-	1139	O
hand	-	1145	O
,	-	1149	O
reserpine	-	1151	O
induced	-	1161	O
increases	-	1169	O
in	-	1179	O
tremor	-	1182	B
and	-	1189	O
catalepsy	-	1193	B
compared	-	1203	O
to	-	1212	O
control	-	1215	O
mice	-	1223	O
.	-	1227	O
MK	-	1229	O
-	-	1231	O
801	-	1232	O

(	11999899	1236	O
0	-	1237	O
.	-	1238	O
1	-	1239	O
mg	-	1241	O
/	-	1243	O
kg	-	1244	O
)	-	1246	O
administration	-	1248	O
attenuated	-	1263	O
the	-	1274	O
catalepsy	-	1278	B
and	-	1288	O
tremor	-	1292	B
induced	-	1299	O
by	-	1307	O
reserpine	-	1310	O
.	-	1319	O

Pretreatment	11999899	1321	O
with	-	1334	O
reserpine	-	1339	O
(	-	1349	O
1	-	1350	O
mg	-	1352	O
/	-	1354	O
kg	-	1355	O
)	-	1357	O
24	-	1359	O
h	-	1362	O
before	-	1364	O
the	-	1371	O
observation	-	1375	O
test	-	1387	O
produced	-	1392	O
increases	-	1401	O
in	-	1411	O
vacuous	-	1414	O
chewing	-	1422	O
movements	-	1430	O
and	-	1440	O
tongue	-	1444	O
protrusion	-	1451	O
,	-	1461	O
as	-	1463	O
well	-	1466	O
as	-	1471	O
increases	-	1474	O
in	-	1484	O
tremor	-	1487	B
and	-	1494	O
catalepsy	-	1498	B
,	-	1507	O
whereas	-	1509	O
MK	-	1517	O
-	-	1519	O
801	-	1520	O
(	-	1524	O
0	-	1525	O
.	-	1526	O
1	-	1527	O
mg	-	1529	O
/	-	1531	O
kg	-	1532	O
)	-	1534	O
injection	-	1536	O
90	-	1546	O
min	-	1549	O
before	-	1553	O
the	-	1560	O
test	-	1564	O
reversed	-	1569	O
the	-	1578	O
effects	-	1582	O
of	-	1590	O
reserpine	-	1593	O
.	-	1602	O

These	11999899	1604	O
results	-	1610	O
show	-	1618	O
that	-	1623	O
reserpine	-	1628	O
produces	-	1638	O
different	-	1647	O
and	-	1657	O
abnormal	-	1661	B
movements	-	1670	I
,	-	1679	O
which	-	1681	O
are	-	1687	O
related	-	1691	O
to	-	1699	O
dose	-	1702	O
and	-	1707	O
schedule	-	1711	O
employed	-	1720	O
and	-	1729	O
can	-	1733	O
be	-	1737	O
considered	-	1740	O
as	-	1751	O
parkinsonian	-	1754	B
-	-	1766	O
like	-	1767	O
and	-	1772	O
tardive	-	1776	B
dsykinesia	-	1784	I
signs	-	1795	O
.	-	1800	O

The	11999899	1802	O
glutamatergic	-	1806	O
blockage	-	1820	O
produced	-	1829	O
by	-	1838	O
NMDA	-	1841	O
can	-	1846	O
restore	-	1850	O
these	-	1858	O
signs	-	1864	O
,	-	1869	O
such	-	1871	O
as	-	1876	O
vacuous	-	1879	O
chewing	-	1887	O
movements	-	1895	O
,	-	1904	O
tongue	-	1906	O
protrusions	-	1913	O
,	-	1924	O
catalepsy	-	1926	B
and	-	1936	O
tremor	-	1940	B
according	-	1947	O
to	-	1957	O
the	-	1960	O
employed	-	1964	O
model	-	1973	O
.	-	1978	O

Effect	9431903	0	O
of	-	7	O
glyceryl	-	10	O
trinitrate	-	19	O
on	-	30	O
the	-	33	O
sphincter	-	37	B
of	-	47	I
Oddi	-	50	I
spasm	-	55	I
evoked	-	61	O
by	-	68	O
prostigmine	-	71	O
-	-	82	O
morphine	-	83	O
administration	-	92	O
.	-	106	O

OBJECTIVE	9431903	108	O
:	-	117	O
In	-	119	O
this	-	122	O
study	-	127	O
the	-	133	O
effect	-	137	O
of	-	144	O
glyceryl	-	147	O
trinitrate	-	156	O
on	-	167	O
the	-	170	O
prostigmine	-	174	O
-	-	185	O
morphine	-	186	O
-	-	194	O
induced	-	195	O
sphincter	-	203	B
of	-	213	I
Oddi	-	216	I
spasm	-	221	I
was	-	227	O
evaluated	-	231	O
in	-	241	O
nine	-	244	O
female	-	249	O
patients	-	256	O
with	-	265	O
sphincter	-	270	B
of	-	280	I
Oddi	-	283	I
dyskinesia	-	288	I
.	-	298	O

METHOD	9431903	300	O
:	-	306	O

Sphincter	9431903	308	B
of	-	318	I
Oddi	-	321	I
spasm	-	326	I
was	-	332	O
induced	-	336	O
by	-	344	O
prostigmine	-	347	O
-	-	358	O
morphine	-	359	O
administration	-	368	O
(	-	383	O
0	-	384	O
.	-	385	O
5	-	386	O
mg	-	388	O
prostigmine	-	391	O
intramuscularly	-	403	O
and	-	419	O
10	-	423	O
mg	-	426	O
morphine	-	429	O
subcutaneously	-	438	O
)	-	452	O
and	-	454	O
visualized	-	458	O
by	-	469	O
quantitative	-	472	O
hepatobiliary	-	485	O
scintigraphy	-	499	O
.	-	511	O

The	9431903	513	O
entire	-	517	O
procedure	-	524	O
was	-	534	O
repeated	-	538	O
during	-	547	O
glyceryl	-	554	O
trinitrate	-	563	O
infusion	-	574	O
(	-	583	O
Nitrolingual	-	584	O
1	-	597	O
microg	-	599	O
/	-	605	O
kg	-	606	O
/	-	608	O
min	-	609	O
for	-	613	O
120	-	617	O
min	-	621	O
)	-	624	O
.	-	625	O

RESULTS	9431903	627	O
:	-	634	O

Prostigmine	9431903	636	O
-	-	647	O
morphine	-	648	O
provocation	-	657	O
caused	-	669	O
significant	-	676	O
increases	-	688	O
in	-	698	O
the	-	701	O
time	-	705	O
to	-	710	O
peak	-	713	O
activity	-	718	O
(	-	727	O
Tmax	-	728	O
)	-	732	O
over	-	734	O
the	-	739	O
hepatic	-	743	O
hilum	-	751	O
(	-	757	O
HH	-	758	O
:	-	760	O
34	-	762	O
.	-	764	O
33	-	765	O
+	-	768	O
/	-	769	O
-	-	770	O

5	9431903	772	O
.	-	773	O
05	-	774	O
vs	-	777	O
.	-	779	O
22	-	781	O
.	-	783	O
77	-	784	O
+	-	787	O
/	-	788	O
-	-	789	O

3	9431903	791	O
.	-	792	O
26	-	793	O
)	-	795	O
and	-	797	O
the	-	801	O
common	-	805	O
bile	-	812	O
duct	-	817	O

(	9431903	822	O
CBD	-	823	O
:	-	826	O
60	-	828	O
.	-	830	O
44	-	831	O
+	-	834	O
/	-	835	O
-	-	836	O

5	9431903	838	O
.	-	839	O
99	-	840	O
vs	-	843	O
.	-	845	O
40	-	847	O
.	-	849	O
0	-	850	O
+	-	852	O
/	-	853	O
-	-	854	O

2	9431903	856	O
.	-	857	O
88	-	858	O
)	-	860	O
and	-	862	O
in	-	866	O
the	-	869	O
half	-	873	O
-	-	877	O
time	-	878	O
of	-	883	O
excretion	-	886	O
(	-	896	O
T1	-	897	O
/	-	899	O
2	-	900	O
)	-	901	O
over	-	903	O
the	-	908	O
liver	-	912	O
parenchyma	-	918	O
(	-	929	O
LP	-	930	O
:	-	932	O
120	-	934	O
.	-	937	O
04	-	938	O
+	-	941	O
/	-	942	O
-	-	943	O

16	9431903	945	O
.	-	947	O
01	-	948	O
vs	-	951	O
.	-	953	O
27	-	955	O
.	-	957	O
37	-	958	O
+	-	961	O
/	-	962	O
-	-	963	O

2	9431903	965	O
.	-	966	O
19	-	967	O
)	-	969	O
,	-	970	O
HH	-	972	O
(	-	975	O
117	-	976	O
.	-	979	O
61	-	980	O
+	-	983	O
/	-	984	O
-	-	985	O

14	9431903	987	O
.	-	989	O
71	-	990	O
vs	-	993	O
.	-	995	O
31	-	997	O
.	-	999	O
85	-	1000	O
+	-	1003	O
/	-	1004	O
-	-	1005	O

3	9431903	1007	O
.	-	1008	O
99	-	1009	O
)	-	1011	O
and	-	1013	O
CBD	-	1017	O
(	-	1021	O
158	-	1022	O
.	-	1025	O
11	-	1026	O
+	-	1029	O
/	-	1030	O
-	-	1031	O

9	9431903	1033	O
.	-	1034	O
18	-	1035	O
vs	-	1038	O
.	-	1040	O
40	-	1042	O
.	-	1044	O
1	-	1045	O
+	-	1047	O
/	-	1048	O
-	-	1049	O

6	9431903	1051	O
.	-	1052	O
24	-	1053	O
)	-	1055	O
,	-	1056	O
indicating	-	1058	O
a	-	1069	O
complete	-	1071	O
spasm	-	1080	B
at	-	1086	O
the	-	1089	O
level	-	1093	O
of	-	1099	O
the	-	1102	O
sphincter	-	1106	O
of	-	1116	O
Oddi	-	1119	O
.	-	1123	O

Glyceryl	9431903	1125	O
trinitrate	-	1134	O
infusion	-	1145	O
completely	-	1154	O
normalized	-	1165	O
the	-	1176	O
prostigmine	-	1180	O
-	-	1191	O
morphine	-	1192	O
-	-	1200	O
induced	-	1201	O
alterations	-	1209	O
in	-	1221	O
these	-	1224	O
quantitative	-	1230	O
parameters	-	1243	O
(	-	1254	O
TmaX	-	1255	O
over	-	1260	O
the	-	1265	O
LP	-	1269	O
:	-	1271	O
11	-	1273	O
.	-	1275	O
33	-	1276	O
+	-	1279	O
/	-	1280	O
-	-	1281	O

1	9431903	1283	O
.	-	1284	O
13	-	1285	O
;	-	1287	O
over	-	1289	O
the	-	1294	O
HH	-	1298	O
:	-	1300	O
18	-	1302	O
.	-	1304	O
88	-	1305	O
+	-	1308	O
/	-	1309	O
-	-	1310	O

1	9431903	1312	O
.	-	1313	O
48	-	1314	O
;	-	1316	O
and	-	1318	O
over	-	1322	O
the	-	1327	O
CBD	-	1331	O
:	-	1334	O
36	-	1336	O
.	-	1338	O
22	-	1339	O
+	-	1342	O
/	-	1343	O
-	-	1344	O

1	9431903	1346	O
.	-	1347	O
92	-	1348	O
;	-	1350	O
and	-	1352	O
T1	-	1356	O
/	-	1358	O
2	-	1359	O
over	-	1361	O
the	-	1366	O
LP	-	1370	O
:	-	1372	O
28	-	1374	O
.	-	1376	O
21	-	1377	O
+	-	1380	O
/	-	1381	O
-	-	1382	O

1	9431903	1384	O
.	-	1385	O
83	-	1386	O
;	-	1388	O
over	-	1390	O
the	-	1395	O
HH	-	1399	O
:	-	1401	O
33	-	1403	O
.	-	1405	O
42	-	1406	O
+	-	1409	O
/	-	1410	O
-	-	1411	O

3	9431903	1413	O
.	-	1414	O
10	-	1415	O
;	-	1417	O
and	-	1419	O
over	-	1423	O
the	-	1428	O
CBD	-	1432	O
:	-	1435	O
41	-	1437	O
.	-	1439	O
66	-	1440	O
+	-	1443	O
/	-	1444	O
-	-	1445	O

6	9431903	1447	O
.	-	1448	O
33	-	1449	O
)	-	1451	O
,	-	1452	O
suggesting	-	1454	O
an	-	1465	O
effective	-	1468	O
sphincter	-	1478	O
-	-	1487	O
relaxing	-	1488	O
effect	-	1497	O
of	-	1504	O
glyceryl	-	1507	O
trinitrate	-	1516	O
.	-	1526	O

CONCLUSION	9431903	1528	O
:	-	1538	O

These	9431903	1540	O
results	-	1546	O
provide	-	1554	O
the	-	1562	O
first	-	1566	O
evidence	-	1572	O
of	-	1581	O
the	-	1584	O
effectiveness	-	1588	O
of	-	1602	O
glyceryl	-	1605	O
trinitrate	-	1614	O
on	-	1625	O
the	-	1628	O
morphine	-	1632	O
-	-	1640	O
induced	-	1641	O
sphincter	-	1649	B
of	-	1659	I
Oddi	-	1662	I
spasm	-	1667	I
in	-	1673	O
humans	-	1676	O
.	-	1682	O

Since	9431903	1684	O
glyceryl	-	1690	O
trinitrate	-	1699	O
is	-	1710	O
able	-	1713	O
to	-	1718	O
overcome	-	1721	O
even	-	1730	O
the	-	1735	O
drastic	-	1739	O
effect	-	1747	O
of	-	1754	O
morphine	-	1757	O
,	-	1765	O
it	-	1767	O
might	-	1770	O
be	-	1776	O
of	-	1779	O
relevance	-	1782	O
in	-	1792	O
the	-	1795	O
treatment	-	1799	O
of	-	1809	O
sphincter	-	1812	B
of	-	1822	I
Oddi	-	1825	I
dyskinesia	-	1830	I
.	-	1840	O

Effects	8665051	0	O
of	-	8	O
acute	-	11	O
steroid	-	17	O
administration	-	25	O
on	-	40	O
ventilatory	-	43	O
and	-	55	O
peripheral	-	59	O
muscles	-	70	O
in	-	78	O
rats	-	81	O
.	-	85	O

Occasional	8665051	87	O
case	-	98	O
reports	-	103	O
have	-	111	O
shown	-	116	O
that	-	122	O
acute	-	127	O
myopathy	-	133	B
may	-	142	O
occur	-	146	O
in	-	152	O
patients	-	155	O
treated	-	164	O
with	-	172	O
massive	-	177	O
doses	-	185	O
of	-	191	O
corticosteroids	-	194	O
.	-	209	O

The	8665051	211	O
mechanism	-	215	O
of	-	225	O
this	-	228	O
myopathy	-	233	B
is	-	242	O
poorly	-	245	O
understood	-	252	O
.	-	262	O

Therefore	8665051	264	O
,	-	273	O
60	-	275	O
male	-	278	O
rats	-	283	O
were	-	288	O
randomly	-	293	O
assigned	-	302	O
to	-	311	O
receive	-	314	O
daily	-	322	O
injection	-	328	O
of	-	338	O
saline	-	341	O
(	-	348	O
C	-	349	O
)	-	350	O
,	-	351	O
methylprednisolone	-	353	O
(	-	372	O
M	-	373	O
)	-	374	O
,	-	375	O
or	-	377	O
triamcinolone	-	380	O
(	-	394	O
T	-	395	O
)	-	396	O
80	-	398	O
mg	-	401	O
/	-	403	O
kg	-	404	O
/	-	406	O
d	-	407	O
for	-	409	O
5	-	413	O
d	-	415	O
.	-	416	O
Nutritional	-	418	O
intake	-	430	O
,	-	436	O
measured	-	438	O
daily	-	447	O
in	-	453	O
15	-	456	O
animals	-	459	O
,	-	466	O
showed	-	468	O
a	-	475	O
significant	-	477	O
reduction	-	489	B
of	-	499	I
food	-	502	I
intake	-	507	I
in	-	514	O
the	-	517	O
steroid	-	521	O
-	-	528	O
treated	-	529	O
groups	-	537	O
(	-	544	O
-	-	545	O
50	-	546	O
and	-	549	O
-	-	553	O
79	-	554	O
%	-	556	O
in	-	558	O
M	-	561	O
and	-	563	O
T	-	567	O
,	-	568	O
respectively	-	570	O
)	-	582	O
.	-	583	O

This	8665051	585	O
was	-	590	O
associated	-	594	O
with	-	605	O
a	-	610	O
similar	-	612	O
loss	-	620	B
in	-	625	I
body	-	628	I
weight	-	633	I
.	-	639	O

In	8665051	641	O
the	-	644	O
45	-	648	O
remaining	-	651	O
animals	-	661	O
,	-	668	O
diaphragm	-	670	O
contractility	-	680	O
and	-	694	O
histopathologic	-	698	O
features	-	714	O
of	-	723	O
several	-	726	O
muscles	-	734	O
were	-	742	O
studied	-	747	O
.	-	754	O

Weights	8665051	756	O
of	-	764	O
respiratory	-	767	O
and	-	779	O
peripheral	-	783	O
muscles	-	794	O
were	-	802	O
similarly	-	807	O
decreased	-	817	O
after	-	827	O
steroid	-	833	O
treatment	-	841	O
.	-	850	O

Maximal	8665051	852	O
twitches	-	860	O
of	-	869	O
the	-	872	O
diaphragm	-	876	O
were	-	886	O
lower	-	891	O
in	-	897	O
the	-	900	O
C	-	904	O
group	-	906	O
(	-	912	O
653	-	913	O
+	-	917	O
/	-	918	O
-	-	919	O

174	8665051	921	O
g	-	925	O
/	-	926	O
cm	-	927	O
(	-	929	O
2	-	930	O
)	-	931	O
)	-	932	O
than	-	934	O
in	-	939	O
the	-	942	O
M	-	946	O
group	-	948	O
(	-	954	O
837	-	955	O
+	-	959	O
/	-	960	O
-	-	961	O

171	8665051	963	O
g	-	967	O
/	-	968	O
cm	-	969	O
(	-	971	O
2	-	972	O
)	-	973	O
;	-	974	O
p	-	976	O
<	-	978	O
0	-	980	O
.	-	981	O
05	-	982	O
)	-	984	O
and	-	986	O
the	-	990	O
T	-	994	O
group	-	996	O
(	-	1002	O
765	-	1003	O
+	-	1007	O
/	-	1008	O
-	-	1009	O

145	8665051	1011	O
g	-	1015	O
/	-	1016	O
cm	-	1017	O
(	-	1019	O
2	-	1020	O
)	-	1021	O
,	-	1022	O
NS	-	1024	O
)	-	1026	O
.	-	1027	O

Half	8665051	1029	O
-	-	1033	O
relaxation	-	1034	O
time	-	1045	O
was	-	1050	O
prolonged	-	1054	O
in	-	1064	O
both	-	1067	O
steroid	-	1072	O
groups	-	1080	O
,	-	1086	O
and	-	1088	O
time	-	1092	O
to	-	1097	O
peak	-	1100	O
tension	-	1105	O
was	-	1113	O
longer	-	1117	O
with	-	1124	O
M	-	1129	O
,	-	1130	O
whereas	-	1132	O
tetanic	-	1140	B
tensions	-	1148	O
were	-	1157	O
similar	-	1162	O
.	-	1169	O

Steroid	8665051	1171	O
treatment	-	1179	O
also	-	1189	O
induced	-	1194	O
a	-	1202	O
leftward	-	1204	O
shift	-	1213	O
of	-	1219	O
the	-	1222	O
force	-	1226	O
-	-	1231	O
frequency	-	1232	O
curve	-	1242	O
at	-	1248	O
25	-	1251	O
and	-	1254	O
50	-	1258	O
Hz	-	1261	O
when	-	1264	O
compared	-	1269	O
with	-	1278	O
saline	-	1283	O
treatment	-	1290	O
(	-	1300	O
p	-	1301	O
<	-	1303	O
0	-	1305	O
.	-	1306	O
05	-	1307	O
)	-	1309	O
.	-	1310	O

ATPase	8665051	1312	O
staining	-	1319	O
of	-	1328	O
the	-	1331	O
diaphragm	-	1335	O
,	-	1344	O
scalenus	-	1346	O
medius	-	1355	O
,	-	1361	O
and	-	1363	O
gastrocnemius	-	1367	O
showed	-	1381	O
type	-	1388	O
IIb	-	1393	O
fiber	-	1397	O
atrophy	-	1403	B
in	-	1411	O
the	-	1414	O
steroid	-	1418	O
groups	-	1426	O
and	-	1433	O
also	-	1437	O
diaphragmatic	-	1442	O
type	-	1456	O
IIa	-	1461	O

atrophy	8665051	1465	B
with	-	1473	O
T	-	1478	O
,	-	1479	O
whereas	-	1481	O
histologic	-	1489	O
examinations	-	1500	O
revealed	-	1513	O
a	-	1522	O
normal	-	1524	O
muscular	-	1531	O
pattern	-	1540	O
with	-	1548	O
absence	-	1553	O
of	-	1561	O
necrosis	-	1564	B
.	-	1572	O

Finally	8665051	1574	O
,	-	1581	O
a	-	1583	O
pair	-	1585	O
-	-	1589	O
fed	-	1590	O
(	-	1594	O
PF	-	1595	O
)	-	1597	O
study	-	1599	O
,	-	1604	O
performed	-	1606	O
in	-	1616	O
18	-	1619	O
rats	-	1622	O
(	-	1627	O
C	-	1628	O
,	-	1629	O
T	-	1631	O
,	-	1632	O
and	-	1634	O
PF	-	1638	O
)	-	1640	O
,	-	1641	O
showed	-	1643	O
that	-	1650	O
muscle	-	1655	B
atrophy	-	1662	I
was	-	1670	O
considerably	-	1674	O
less	-	1687	O
pronounced	-	1692	O
in	-	1703	O
PF	-	1706	O
animals	-	1709	O
than	-	1717	O
in	-	1722	O
T	-	1725	O
-	-	1726	O
treated	-	1727	O
animals	-	1735	O
.	-	1742	O

We	8665051	1744	O
conclude	-	1747	O
that	-	1756	O
(	-	1761	O
1	-	1762	O
)	-	1763	O
short	-	1765	O
-	-	1770	O
term	-	1771	O
treatment	-	1776	O
with	-	1786	O
massive	-	1791	O
doses	-	1799	O
of	-	1805	O
steroids	-	1808	O
induced	-	1817	O
severe	-	1825	O
respiratory	-	1832	O
and	-	1844	O
limb	-	1848	O
muscle	-	1853	O
wasting	-	1860	O
;	-	1867	O
(	-	1869	O
2	-	1870	O
)	-	1871	O
both	-	1873	O
types	-	1878	O
of	-	1884	O
steroids	-	1887	O
induced	-	1896	O
predominantly	-	1904	O
type	-	1918	O
IIb	-	1923	O
atrophy	-	1927	B
,	-	1934	O
resulting	-	1936	O
in	-	1946	O
the	-	1949	O
expected	-	1953	O
alterations	-	1962	O
in	-	1974	O
diaphragm	-	1977	O
contractile	-	1987	O
properties	-	1999	O
;	-	2009	O
(	-	2011	O
3	-	2012	O
)	-	2013	O
neither	-	2015	O
steroid	-	2023	O
caused	-	2031	O
muscle	-	2038	O
necrosis	-	2045	B
;	-	2053	O
(	-	2055	O
4	-	2056	O
)	-	2057	O
type	-	2059	O
IIb	-	2064	O
atrophy	-	2068	B
was	-	2076	O
not	-	2080	O
caused	-	2084	O
by	-	2091	O
acute	-	2094	O
nutritional	-	2100	O
deprivation	-	2112	O
alone	-	2124	O
.	-	2129	O

Refractory	7785794	0	O
cardiogenic	-	11	B
shock	-	23	I
and	-	29	O
complete	-	33	O
heart	-	42	B
block	-	48	I
after	-	54	O
verapamil	-	60	O
SR	-	70	O
and	-	73	O
metoprolol	-	77	O
treatment	-	88	O
.	-	97	O

A	7785794	99	O
case	-	101	O
report	-	106	O
.	-	112	O

A	7785794	114	O
seventy	-	116	O
-	-	123	O
eight	-	124	O
-	-	129	O
year	-	130	O
-	-	134	O
old	-	135	O
woman	-	139	O
presented	-	145	O
with	-	155	O
complete	-	160	O
heart	-	169	B
block	-	175	I
and	-	181	O
refractory	-	185	O
hypotension	-	196	B
two	-	208	O
days	-	212	O
after	-	217	O
a	-	223	O
therapeutic	-	225	O
dose	-	237	O
of	-	242	O
sustained	-	245	O
-	-	254	O
release	-	255	O
verapamil	-	263	O
with	-	273	O
concomitant	-	278	O
use	-	290	O
of	-	294	O
metoprolol	-	297	O
.	-	307	O

The	7785794	309	O
patient	-	313	O
continued	-	321	O
to	-	331	O
remain	-	334	O
hypotensive	-	341	B
with	-	353	O
complete	-	358	O
heart	-	367	B
block	-	373	I
,	-	378	O
even	-	380	O
with	-	385	O
multiple	-	390	O
uses	-	399	O
of	-	404	O
intravenous	-	407	O
atropine	-	419	O
as	-	428	O
well	-	431	O
as	-	436	O
high	-	439	O
doses	-	444	O
of	-	450	O
pressor	-	453	O
agents	-	461	O
such	-	468	O
as	-	473	O
dopamine	-	476	O
and	-	485	O
dobutamine	-	489	O
.	-	499	O

However	7785794	501	O
,	-	508	O
shortly	-	510	O
after	-	518	O
the	-	524	O
use	-	528	O
of	-	532	O
intravenous	-	535	O
calcium	-	547	O
chloride	-	555	O
,	-	563	O
the	-	565	O
refractory	-	569	O
hypotension	-	580	B
and	-	592	O
complete	-	596	O
heart	-	605	B
block	-	611	I
resolved	-	617	O
.	-	625	O

A	8958188	0	O
phase	-	2	O
I	-	8	O
clinical	-	10	O
study	-	19	O
of	-	25	O
the	-	28	O
antipurine	-	32	O
antifolate	-	43	O
lometrexol	-	54	O
(	-	65	O
DDATHF	-	66	O
)	-	72	O
given	-	74	O
with	-	80	O
oral	-	85	O
folic	-	90	O
acid	-	96	O
.	-	100	O

Lometrexol	8958188	102	O
is	-	113	O
an	-	116	O
antifolate	-	119	O
which	-	130	O
inhibits	-	136	O
glycinamide	-	145	O
ribonucleotide	-	157	O
formyltransferase	-	172	O
(	-	190	O
GARFT	-	191	O
)	-	196	O
,	-	197	O
an	-	199	O
enzyme	-	202	O
essential	-	209	O
for	-	219	O
de	-	223	O
novo	-	226	O
purine	-	231	O
synthesis	-	238	O
.	-	247	O

Extensive	8958188	249	O
experimental	-	259	O
and	-	272	O
limited	-	276	O
clinical	-	284	O
data	-	293	O
have	-	298	O
shown	-	303	O
that	-	309	O
lometrexol	-	314	O
has	-	325	O
activity	-	329	O
against	-	338	O
tumours	-	346	B
which	-	354	O
are	-	360	O
refractory	-	364	O
to	-	375	O
other	-	378	O
drugs	-	384	O
,	-	389	O
notably	-	391	O
methotrexate	-	399	O
.	-	411	O

However	8958188	413	O
,	-	420	O
the	-	422	O
initial	-	426	O
clinical	-	434	O
development	-	443	O
of	-	455	O
lometrexol	-	458	O
was	-	469	O
curtailed	-	473	O
because	-	483	O
of	-	491	O
severe	-	494	O
and	-	501	O
cumulative	-	505	O
antiproliferative	-	516	O
toxicities	-	534	B
.	-	544	O

Preclinical	8958188	546	O
murine	-	558	O
studies	-	565	O
demonstrated	-	573	O
that	-	586	O
the	-	591	O
toxicity	-	595	B
of	-	604	O
lometrexol	-	607	O
can	-	618	O
be	-	622	O
prevented	-	625	O
by	-	635	O
low	-	638	O
dose	-	642	O
folic	-	647	O
acid	-	653	O
administration	-	658	O
,	-	672	O
i	-	674	O
.	-	675	O
e	-	676	O
.	-	677	O
for	-	679	O
7	-	683	O
days	-	685	O
prior	-	690	O
to	-	696	O
and	-	699	O
7	-	703	O
days	-	705	O
following	-	710	O
a	-	720	O
single	-	722	O
bolus	-	729	O
dose	-	735	O
.	-	739	O

This	8958188	741	O
observation	-	746	O
prompted	-	758	O
a	-	767	O
Phase	-	769	O
I	-	775	O
clinical	-	777	O
study	-	786	O
of	-	792	O
lometrexol	-	795	O
given	-	806	O
with	-	812	O
folic	-	817	O
acid	-	823	O
supplementation	-	828	O
which	-	844	O
has	-	850	O
confirmed	-	854	O
that	-	864	O
the	-	869	O
toxicity	-	873	B
of	-	882	O
lometrexol	-	885	O
can	-	896	O
be	-	900	O
markedly	-	903	O
reduced	-	912	O
by	-	920	O
folic	-	923	O
acid	-	929	O
supplementation	-	934	O
.	-	949	O

Thrombocytopenia	8958188	951	B
and	-	968	O
mucositis	-	972	B
were	-	982	O
the	-	987	O
major	-	991	O
toxicities	-	997	B
.	-	1007	O

There	8958188	1009	O
was	-	1015	O
no	-	1019	O
clear	-	1022	O
relationship	-	1028	O
between	-	1041	O
clinical	-	1049	O
toxicity	-	1058	B
and	-	1067	O
the	-	1071	O
extent	-	1075	O
of	-	1082	O
plasma	-	1085	O
folate	-	1092	O
elevation	-	1099	O
.	-	1108	O

Associated	8958188	1110	O
studies	-	1121	O
demonstrated	-	1129	O
that	-	1142	O
lometrexol	-	1147	O
plasma	-	1158	O
pharmacokinetics	-	1165	O
were	-	1182	O
not	-	1187	O
altered	-	1191	O
by	-	1199	O
folic	-	1202	O
acid	-	1208	O
administration	-	1213	O
indicating	-	1228	O
that	-	1239	O
supplementation	-	1244	O
is	-	1260	O
unlikely	-	1263	O
to	-	1272	O
reduce	-	1275	O
toxicity	-	1282	B
by	-	1291	O
enhancing	-	1294	O
lometrexol	-	1304	O
plasma	-	1315	O
clearance	-	1322	O
.	-	1331	O

The	8958188	1333	O
work	-	1337	O
described	-	1342	O
in	-	1352	O
this	-	1355	O
report	-	1360	O
has	-	1367	O
identified	-	1371	O
for	-	1382	O
the	-	1386	O
first	-	1390	O
time	-	1396	O
a	-	1401	O
clinically	-	1403	O
acceptable	-	1414	O
schedule	-	1425	O
for	-	1434	O
the	-	1438	O
administration	-	1442	O
of	-	1457	O
a	-	1460	O
GARFT	-	1462	O
inhibitor	-	1468	O
.	-	1477	O

This	8958188	1479	O
information	-	1484	O
will	-	1496	O
facilitate	-	1501	O
the	-	1512	O
future	-	1516	O
evaluation	-	1523	O
of	-	1534	O
this	-	1537	O
class	-	1542	O
of	-	1548	O
compounds	-	1551	O
in	-	1561	O
cancer	-	1564	B
therapy	-	1571	O
.	-	1578	O

Involvement	2557556	0	O
of	-	12	O
the	-	15	O
mu	-	19	O
-	-	21	O
opiate	-	22	O
receptor	-	29	O
in	-	38	O
peripheral	-	41	O
analgesia	-	52	B
.	-	61	O

The	2557556	63	O
intradermal	-	67	O
injection	-	79	O
of	-	89	O
mu	-	92	O
(	-	95	O
morphine	-	96	O
,	-	104	O
Tyr	-	106	O
-	-	109	O
D	-	110	O
-	-	111	O
Ala	-	112	O
-	-	115	O
Gly	-	116	O
-	-	119	O
NMe	-	120	O
-	-	123	O
Phe	-	124	O
-	-	127	O
Gly	-	128	O
-	-	131	O
ol	-	132	O
and	-	135	O
morphiceptin	-	139	O
)	-	151	O
,	-	152	O
kappa	-	154	O
(	-	160	O
trans	-	161	O
-	-	166	O
3	-	167	O
,	-	168	O
4	-	169	O
-	-	170	O
dichloro	-	171	O
-	-	179	O
N	-	180	O
-	-	181	O
methyl	-	182	O
-	-	188	O
N	-	189	O
[	-	190	O
2	-	191	O
-	-	192	O
(	-	193	O
1	-	194	O
-	-	195	O
pyrrolidinyl	-	196	O
)	-	208	O
cyclohexyl	-	210	O
]	-	220	O
benzeneactemide	-	221	O
)	-	236	O
and	-	238	O
delta	-	242	O
(	-	248	O
[	-	249	O
D	-	250	O
-	-	251	O
Pen2	-	252	O
.	-	256	O
5	-	257	O
]	-	258	O
-	-	259	O
enkephalin	-	260	O
and	-	271	O
[	-	275	O
D	-	276	O
-	-	277	O
Ser2	-	278	O
]	-	282	O
-	-	283	O
[	-	284	O
Leu	-	285	O
]	-	288	O
enkephalin	-	289	O
-	-	299	O
Thr	-	300	O
)	-	303	O
selective	-	305	O
opioid	-	315	O
-	-	321	O
agonists	-	322	O
,	-	330	O
by	-	332	O
themselves	-	335	O
,	-	345	O
did	-	347	O
not	-	351	O
significantly	-	355	O
affect	-	369	O
the	-	376	O
mechanical	-	380	O
nociceptive	-	391	O
threshold	-	403	O
in	-	413	O
the	-	416	O
hindpaw	-	420	O
of	-	428	O
the	-	431	O
rat	-	435	O
.	-	438	O

Intradermal	2557556	440	O
injection	-	452	O
of	-	462	O
mu	-	465	O
,	-	467	O
but	-	469	O
not	-	473	O
delta	-	477	O
or	-	483	O
kappa	-	486	O
opioid	-	492	O
-	-	498	O
agonists	-	499	O
,	-	507	O
however	-	509	O
,	-	516	O
produced	-	518	O
dose	-	527	O
-	-	531	O
dependent	-	532	O
inhibition	-	542	O
of	-	553	O
prostaglandin	-	556	O
E2	-	570	O
-	-	572	O
induced	-	573	O
hyperalgesia	-	581	B
.	-	593	O

The	2557556	595	O
analgesic	-	599	O
effect	-	609	O
of	-	616	O
the	-	619	O
mu	-	623	O
-	-	625	O
agonist	-	626	O
morphine	-	634	O
was	-	643	O
dose	-	647	O
-	-	651	O
dependently	-	652	O
antagonized	-	664	O
by	-	676	O
naloxone	-	679	O
and	-	688	O
prevented	-	692	O
by	-	702	O
co	-	705	O
-	-	707	O
injection	-	708	O
of	-	718	O
pertussis	-	721	O
toxin	-	731	O
.	-	736	O

Morphine	2557556	738	O
did	-	747	O
not	-	751	O
,	-	754	O
however	-	756	O
,	-	763	O
alter	-	765	O
the	-	771	O
hyperalgesia	-	775	B
induced	-	788	O
by	-	796	O
8	-	799	O
-	-	800	O
bromo	-	801	O
cyclic	-	807	O
adenosine	-	814	O
monophosphate	-	824	O
.	-	837	O

We	2557556	839	O
conclude	-	842	O
that	-	851	O
the	-	856	O
analgesic	-	860	O
action	-	870	O
of	-	877	O
opioids	-	880	O
on	-	888	O
the	-	891	O
peripheral	-	895	O
terminals	-	906	O
of	-	916	O
primary	-	919	O
afferents	-	927	O
is	-	937	O
via	-	940	O
a	-	944	O
binding	-	946	O
site	-	954	O
with	-	959	O
characteristics	-	964	O
of	-	980	O
the	-	983	O
mu	-	987	O
-	-	989	O
opioid	-	990	O
receptor	-	997	O
and	-	1006	O
that	-	1010	O
this	-	1015	O
action	-	1020	O
is	-	1027	O
mediated	-	1030	O
by	-	1039	O
inhibition	-	1042	O
of	-	1053	O
the	-	1056	O
cyclic	-	1060	O
adenosine	-	1067	O
monophosphate	-	1077	O
second	-	1091	O
messenger	-	1098	O
system	-	1108	O
.	-	1114	O

Adequate	15580403	0	O
timing	-	9	O
of	-	16	O
ribavirin	-	19	O
reduction	-	29	O
in	-	39	O
patients	-	42	O
with	-	51	O
hemolysis	-	56	B
during	-	66	O
combination	-	73	O
therapy	-	85	O
of	-	93	O
interferon	-	96	O
and	-	107	O
ribavirin	-	111	O
for	-	121	O
chronic	-	125	B
hepatitis	-	133	I
C	-	143	I
.	-	144	O
BACKGROUND	-	146	O
:	-	156	O
Hemolytic	-	158	B
anemia	-	168	I
is	-	175	O
one	-	178	O
of	-	182	O
the	-	185	O
major	-	189	O
adverse	-	195	O
events	-	203	O
of	-	210	O
the	-	213	O
combination	-	217	O
therapy	-	229	O
of	-	237	O
interferon	-	240	O
and	-	251	O
ribavirin	-	255	O
.	-	264	O

Because	15580403	266	O
of	-	274	O
ribavirin	-	277	O
-	-	286	O
related	-	287	O
hemolytic	-	295	B
anemia	-	305	I
,	-	311	O
dose	-	313	O
reduction	-	318	O
is	-	328	O
a	-	331	O
common	-	333	O
event	-	340	O
in	-	346	O
this	-	349	O
therapy	-	354	O
.	-	361	O

In	15580403	363	O
this	-	366	O
clinical	-	371	O
retrospective	-	380	O
cohort	-	394	O
study	-	401	O
we	-	407	O
have	-	410	O
examined	-	415	O
the	-	424	O
suitable	-	428	O
timing	-	437	O
of	-	444	O
ribavirin	-	447	O
reduction	-	457	O
in	-	467	O
patients	-	470	O
with	-	479	O
hemolysis	-	484	B
during	-	494	O
combination	-	501	O
therapy	-	513	O
.	-	520	O

METHODS	15580403	522	O
:	-	529	O

Thirty	15580403	531	O
-	-	537	O
seven	-	538	O
of	-	544	O
160	-	547	O
patients	-	551	O
who	-	560	O
had	-	564	O
HCV	-	568	O
-	-	571	O
genotype	-	572	O
1b	-	581	O
,	-	583	O
had	-	585	O
high	-	589	O
virus	-	594	O
load	-	600	O
,	-	604	O
and	-	606	O
received	-	610	O
24	-	619	O
-	-	621	O
week	-	622	O
combination	-	627	O
therapy	-	639	O
developed	-	647	O
anemia	-	657	B
with	-	664	O
hemoglobin	-	669	O
level	-	680	O
<	-	686	O
10	-	687	O
g	-	690	O
/	-	691	O
dl	-	692	O
or	-	695	O
anemia	-	698	B
-	-	704	O
related	-	705	O
signs	-	713	O
during	-	719	O
therapy	-	726	O
.	-	733	O

After	15580403	735	O
that	-	741	O
,	-	745	O
these	-	747	O
37	-	753	O
patients	-	756	O
were	-	765	O
reduced	-	770	O
one	-	778	O
tablet	-	782	O
of	-	789	O
ribavirin	-	792	O
(	-	802	O
200	-	803	O
mg	-	807	O
)	-	809	O
per	-	811	O
day	-	815	O
.	-	818	O

After	15580403	820	O
reduction	-	826	O
of	-	836	O
ribavirin	-	839	O
,	-	848	O
27	-	850	O
of	-	853	O
37	-	856	O
patients	-	859	O
could	-	868	O
continue	-	874	O
combination	-	883	O
therapy	-	895	O
for	-	903	O
a	-	907	O
total	-	909	O
of	-	915	O
24	-	918	O
weeks	-	921	O
(	-	927	O
group	-	928	O
A	-	934	O
)	-	935	O
.	-	936	O

However	15580403	938	O
,	-	945	O
10	-	947	O
of	-	950	O
37	-	953	O
patients	-	956	O
with	-	965	O
reduction	-	970	O
of	-	980	O
ribavirin	-	983	O
could	-	993	O
not	-	999	O
continue	-	1003	O
combination	-	1012	O
therapy	-	1024	O
because	-	1032	O
their	-	1040	O
<	-	1046	O
8	-	1047	O
.	-	1048	O
5	-	1049	O
g	-	1051	O
/	-	1052	O
dl	-	1053	O
hemoglobin	-	1056	O
values	-	1067	O
decreased	-	1074	O
to	-	1084	O
or	-	1087	O
anemia	-	1090	B
-	-	1096	O
related	-	1097	O
severe	-	1105	O
side	-	1112	O
effects	-	1117	O
occurred	-	1125	O
(	-	1134	O
group	-	1135	O
B	-	1141	O
)	-	1142	O
.	-	1143	O

We	15580403	1145	O
assessed	-	1148	O
the	-	1157	O
final	-	1161	O
efficacy	-	1167	O
and	-	1176	O
safety	-	1180	O
after	-	1187	O
reduction	-	1193	O
of	-	1203	O
ribavirin	-	1206	O
in	-	1216	O
groups	-	1219	O
A	-	1226	O
and	-	1228	O
B	-	1232	O
.	-	1233	O
RESULTS	-	1235	O
:	-	1242	O

A	15580403	1244	O
sustained	-	1246	O
virological	-	1256	O
response	-	1268	O
(	-	1277	O
SVR	-	1278	O
)	-	1281	O
was	-	1283	O
29	-	1287	O
.	-	1289	O
6	-	1290	O
%	-	1291	O
(	-	1293	O
8	-	1294	O
/	-	1295	O
27	-	1296	O
)	-	1298	O
in	-	1300	O
group	-	1303	O
A	-	1309	O
and	-	1311	O
10	-	1315	O
%	-	1317	O
(	-	1319	O
1	-	1320	O
/	-	1321	O
10	-	1322	O
)	-	1324	O
in	-	1326	O
group	-	1329	O
B	-	1335	O
,	-	1336	O
respectively	-	1338	O
.	-	1350	O

A	15580403	1352	O
34	-	1354	O
.	-	1356	O
4	-	1357	O
%	-	1358	O
(	-	1360	O
12	-	1361	O
/	-	1363	O
27	-	1364	O
)	-	1366	O
of	-	1368	O
SVR	-	1371	O
+	-	1375	O
biological	-	1377	O
response	-	1388	O
in	-	1397	O
group	-	1400	O
A	-	1406	O
was	-	1408	O
higher	-	1412	O
than	-	1419	O
10	-	1424	O
%	-	1426	O
(	-	1428	O
1	-	1429	O
/	-	1430	O
10	-	1431	O
)	-	1433	O
in	-	1435	O
group	-	1438	O
B	-	1444	O
(	-	1446	O
P	-	1448	O
=	-	1450	O
0	-	1452	O
.	-	1453	O
051	-	1454	O
)	-	1457	O
,	-	1458	O
with	-	1460	O
slight	-	1465	O
significance	-	1472	O
.	-	1484	O

With	15580403	1486	O
respect	-	1491	O
to	-	1499	O
hemoglobin	-	1502	O
level	-	1513	O
at	-	1519	O
the	-	1522	O
time	-	1526	O
of	-	1531	O
ribavirin	-	1534	O
reduction	-	1544	O
,	-	1553	O
a	-	1555	O
rate	-	1557	O
of	-	1562	O
continuation	-	1565	O
of	-	1578	O
therapy	-	1581	O
in	-	1589	O
patients	-	1592	O
with	-	1601	O
>	-	1606	O
or	-	1608	O
=	-	1611	O
10	-	1612	O
g	-	1615	O
/	-	1616	O
dl	-	1617	O
hemoglobin	-	1620	O
was	-	1631	O
higher	-	1635	O
than	-	1642	O
that	-	1647	O
in	-	1652	O
patients	-	1655	O
with	-	1664	O
<	-	1669	O
10	-	1670	O
g	-	1673	O
/	-	1674	O
dl	-	1675	O
(	-	1678	O
P	-	1680	O
=	-	1682	O
0	-	1684	O
.	-	1685	O
036	-	1686	O
)	-	1689	O
.	-	1690	O

CONCLUSIONS	15580403	1692	O
:	-	1703	O
Reduction	-	1705	O
of	-	1715	O
ribavirin	-	1718	O
at	-	1728	O
hemoglobin	-	1731	O
level	-	1742	O
>	-	1748	O
or	-	1750	O
=	-	1753	O
10	-	1754	O
g	-	1757	O
/	-	1758	O
dl	-	1759	O

is	15580403	1762	O
suitable	-	1765	O
in	-	1774	O
terms	-	1777	O
of	-	1783	O
efficacy	-	1786	O
and	-	1795	O
side	-	1799	O
effects	-	1804	O
.	-	1811	O

Increased	15075188	0	O
expression	-	10	O
and	-	21	O
apical	-	25	O
targeting	-	32	O
of	-	42	O
renal	-	45	O
ENaC	-	51	O
subunits	-	56	O
in	-	65	O
puromycin	-	68	O
aminonucleoside	-	78	O
-	-	93	O
induced	-	94	O
nephrotic	-	102	B
syndrome	-	112	I
in	-	121	O
rats	-	124	O
.	-	128	O

Nephrotic	15075188	130	B
syndrome	-	140	I
is	-	149	O
often	-	152	O
accompanied	-	158	O
by	-	170	O
sodium	-	173	O
retention	-	180	O
and	-	190	O
generalized	-	194	O
edema	-	206	B
.	-	211	O

However	15075188	213	O
,	-	220	O
the	-	222	O
molecular	-	226	O
basis	-	236	O
for	-	242	O
the	-	246	O
decreased	-	250	O
renal	-	260	O
sodium	-	266	O
excretion	-	273	O
remains	-	283	O
undefined	-	291	O
.	-	300	O

We	15075188	302	O
hypothesized	-	305	O
that	-	318	O
epithelial	-	323	O
Na	-	334	O
channel	-	337	O
(	-	345	O
ENaC	-	346	O
)	-	350	O
subunit	-	352	O
dysregulation	-	360	O
may	-	374	O
be	-	378	O
responsible	-	381	O
for	-	393	O
the	-	397	O
increased	-	401	O
sodium	-	411	O
retention	-	418	O
.	-	427	O

An	15075188	429	O
experimental	-	432	O
group	-	445	O
of	-	451	O
rats	-	454	O
was	-	459	O
treated	-	463	O
with	-	471	O
puromycin	-	476	O
aminonucleoside	-	486	O
(	-	502	O
PAN	-	503	O
;	-	506	O
180	-	508	O
mg	-	512	O
/	-	514	O
kg	-	515	O
iv	-	518	O
)	-	520	O
,	-	521	O
whereas	-	523	O
the	-	531	O
control	-	535	O
group	-	543	O
received	-	549	O
only	-	558	O
vehicle	-	563	O
.	-	570	O

After	15075188	572	O
7	-	578	O
days	-	580	O
,	-	584	O
PAN	-	586	O
treatment	-	590	O
induced	-	600	O
significant	-	608	O
proteinuria	-	620	B
,	-	631	O
hypoalbuminemia	-	633	B
,	-	648	O
decreased	-	650	O
urinary	-	660	O
sodium	-	668	O
excretion	-	675	O
,	-	684	O
and	-	686	O
extensive	-	690	O
ascites	-	700	B
.	-	707	O

The	15075188	709	O
protein	-	713	O
abundance	-	721	O
of	-	731	O
alpha	-	734	O
-	-	739	O
ENaC	-	740	O
and	-	745	O
beta	-	749	O
-	-	753	O
ENaC	-	754	O
was	-	759	O
increased	-	763	O
in	-	773	O
the	-	776	O
inner	-	780	O
stripe	-	786	O
of	-	793	O
the	-	796	O
outer	-	800	O
medulla	-	806	O
(	-	814	O
ISOM	-	815	O
)	-	819	O
and	-	821	O
in	-	825	O
the	-	828	O
inner	-	832	O
medulla	-	838	O
(	-	846	O
IM	-	847	O
)	-	849	O
but	-	851	O
was	-	855	O
not	-	859	O
altered	-	863	O
in	-	871	O
the	-	874	O
cortex	-	878	O
.	-	884	O

gamma	15075188	886	O
-	-	891	O
ENaC	-	892	O
abundance	-	897	O
was	-	907	O
increased	-	911	O
in	-	921	O
the	-	924	O
cortex	-	928	O
,	-	934	O
ISOM	-	936	O
,	-	940	O
and	-	942	O
IM	-	946	O
.	-	948	O

Immunoperoxidase	15075188	950	O
brightfield	-	967	O
-	-	978	O
and	-	980	O
laser	-	984	O
-	-	989	O
scanning	-	990	O
confocal	-	999	O
fluorescence	-	1008	O

microscopy	15075188	1021	O
demonstrated	-	1032	O
increased	-	1045	O
targeting	-	1055	O
of	-	1065	O
alpha	-	1068	O
-	-	1073	O
ENaC	-	1074	O
,	-	1078	O
beta	-	1080	O
-	-	1084	O
ENaC	-	1085	O
,	-	1089	O
and	-	1091	O
gamma	-	1095	O
-	-	1100	O
ENaC	-	1101	O
subunits	-	1106	O
to	-	1115	O
the	-	1118	O
apical	-	1122	O
plasma	-	1129	O
membrane	-	1136	O
in	-	1145	O
the	-	1148	O
distal	-	1152	O
convoluted	-	1159	O
tubule	-	1170	O
(	-	1177	O
DCT2	-	1178	O
)	-	1182	O
,	-	1183	O
connecting	-	1185	O
tubule	-	1196	O
,	-	1202	O
and	-	1204	O
cortical	-	1208	O
and	-	1217	O
medullary	-	1221	O
collecting	-	1231	O
duct	-	1242	O
segments	-	1247	O
.	-	1255	O

Immunoelectron	15075188	1257	O
microscopy	-	1272	O
further	-	1283	O
revealed	-	1291	O
an	-	1300	O
increased	-	1303	O
labeling	-	1313	O
of	-	1322	O
alpha	-	1325	O
-	-	1330	O
ENaC	-	1331	O
in	-	1336	O
the	-	1339	O
apical	-	1343	O
plasma	-	1350	O
membrane	-	1357	O
of	-	1366	O
cortical	-	1369	O
collecting	-	1378	O
duct	-	1389	O
principal	-	1394	O
cells	-	1404	O
of	-	1410	O
PAN	-	1413	O
-	-	1416	O
treated	-	1417	O
rats	-	1425	O
,	-	1429	O
indicating	-	1431	O
enhanced	-	1442	O
apical	-	1451	O
targeting	-	1458	O
of	-	1468	O
alpha	-	1471	O
-	-	1476	O
ENaC	-	1477	O
subunits	-	1482	O
.	-	1490	O

In	15075188	1492	O
contrast	-	1495	O
,	-	1503	O
the	-	1505	O
protein	-	1509	O
abundances	-	1517	O
of	-	1528	O
Na	-	1531	O
(	-	1533	O
+	-	1534	O
)	-	1535	O
/	-	1536	O
H	-	1537	O
(	-	1538	O
+	-	1539	O
)	-	1540	O
exchanger	-	1542	O
type	-	1552	O
3	-	1557	O
(	-	1559	O
NHE3	-	1560	O
)	-	1564	O
,	-	1565	O
Na	-	1567	O
(	-	1569	O
+	-	1570	O
)	-	1571	O
-	-	1572	O
K	-	1573	O
(	-	1574	O
+	-	1575	O
)	-	1576	O
-	-	1577	O
2Cl	-	1578	O
(	-	1581	O
-	-	1582	O
)	-	1583	O
cotransporter	-	1585	O
(	-	1599	O
BSC	-	1600	O
-	-	1603	O
1	-	1604	O
)	-	1605	O
,	-	1606	O
and	-	1608	O
thiazide	-	1612	O
-	-	1620	O
sensitive	-	1621	O
Na	-	1631	O
(	-	1633	O
+	-	1634	O
)	-	1635	O
-	-	1636	O
Cl	-	1637	O
(	-	1639	O
-	-	1640	O
)	-	1641	O
cotransporter	-	1643	O
(	-	1657	O
TSC	-	1658	O
)	-	1661	O
were	-	1663	O
decreased	-	1668	O
.	-	1677	O

Moreover	15075188	1679	O
,	-	1687	O
the	-	1689	O
abundance	-	1693	O
of	-	1703	O
the	-	1706	O
alpha	-	1710	O
(	-	1715	O
1	-	1716	O
)	-	1717	O
-	-	1718	O
subunit	-	1719	O
of	-	1727	O
the	-	1730	O
Na	-	1734	O
-	-	1736	O
K	-	1737	O
-	-	1738	O
ATPase	-	1739	O
was	-	1746	O
decreased	-	1750	O
in	-	1760	O
the	-	1763	O
cortex	-	1767	O
and	-	1774	O
ISOM	-	1778	O
,	-	1782	O
but	-	1784	O
it	-	1788	O
remained	-	1791	O
unchanged	-	1800	O
in	-	1810	O
the	-	1813	O
IM	-	1817	O
.	-	1819	O

In	15075188	1821	O
conclusion	-	1824	O
,	-	1834	O
the	-	1836	O
increased	-	1840	O
or	-	1850	O
sustained	-	1853	O
expression	-	1863	O
of	-	1874	O
ENaC	-	1877	O
subunits	-	1882	O
combined	-	1891	O
with	-	1900	O
increased	-	1905	O
apical	-	1915	O
targeting	-	1922	O
in	-	1932	O
the	-	1935	O
DCT2	-	1939	O
,	-	1943	O
connecting	-	1945	O
tubule	-	1956	O
,	-	1962	O
and	-	1964	O
collecting	-	1968	O
duct	-	1979	O
are	-	1984	O
likely	-	1988	O
to	-	1995	O
play	-	1998	O
a	-	2003	O
role	-	2005	O
in	-	2010	O
the	-	2013	O
sodium	-	2017	O
retention	-	2024	O
associated	-	2034	O
with	-	2045	O
PAN	-	2050	O
-	-	2053	O
induced	-	2054	O
nephrotic	-	2062	B
syndrome	-	2072	I
.	-	2080	O

The	15075188	2082	O
decreased	-	2086	O
abundance	-	2096	O
of	-	2106	O
NHE3	-	2109	O
,	-	2113	O
BSC	-	2115	O
-	-	2118	O
1	-	2119	O
,	-	2120	O
TSC	-	2122	O
,	-	2125	O
and	-	2127	O
Na	-	2131	O
-	-	2133	O
K	-	2134	O
-	-	2135	O
ATPase	-	2136	O
may	-	2143	O
play	-	2147	O
a	-	2152	O
compensatory	-	2154	O
role	-	2167	O
to	-	2172	O
promote	-	2175	O
sodium	-	2183	O
excretion	-	2190	O
.	-	2199	O

Does	14745746	0	O
hormone	-	5	O
therapy	-	13	O
for	-	21	O
the	-	25	O
treatment	-	29	O
of	-	39	O
breast	-	42	B
cancer	-	49	I
have	-	56	O
a	-	61	O
detrimental	-	63	B
effect	-	75	I
on	-	82	I
memory	-	85	I
and	-	92	I
cognition	-	96	I
?	-	105	O

A	14745746	107	O
pilot	-	109	O
study	-	115	O
.	-	120	O

This	14745746	122	O
pilot	-	127	O
study	-	133	O
examines	-	139	O
whether	-	148	O
hormone	-	156	O
therapy	-	164	O
for	-	172	O
breast	-	176	B
cancer	-	183	I
affects	-	190	O
cognition	-	198	O
.	-	207	O

Patients	14745746	209	O
participating	-	218	O
in	-	232	O
a	-	235	O
randomised	-	237	O
trial	-	248	O
of	-	254	O
anastrozole	-	257	O
,	-	268	O
tamoxifen	-	270	O
alone	-	280	O
or	-	286	O
combined	-	289	O
(	-	298	O
ATAC	-	299	O
)	-	303	O
(	-	305	O
n	-	306	O
=	-	307	O
94	-	308	O
)	-	310	O
and	-	312	O
a	-	316	O
group	-	318	O
of	-	324	O
women	-	327	O
without	-	333	O
breast	-	341	B
cancer	-	348	I
(	-	355	O
n	-	356	O
=	-	357	O
35	-	358	O
)	-	360	O
completed	-	362	O
a	-	372	O
battery	-	374	O
of	-	382	O
neuropsychological	-	385	O
measures	-	404	O
.	-	412	O

Compared	14745746	414	O
with	-	423	O
the	-	428	O
control	-	432	O
group	-	440	O
,	-	445	O
the	-	447	O
patients	-	451	O
were	-	460	O
impaired	-	465	O
on	-	474	O
a	-	477	O
processing	-	479	O
speed	-	490	O
task	-	496	O
(	-	501	O
p	-	502	O
=	-	503	O
0	-	504	O
.	-	505	O
032	-	506	O
)	-	509	O
and	-	511	O
on	-	515	O
a	-	518	O
measure	-	520	O
of	-	528	O
immediate	-	531	O
verbal	-	541	O
memory	-	548	O
(	-	555	O
p	-	556	O
=	-	557	O
0	-	558	O
.	-	559	O
026	-	560	O
)	-	563	O
after	-	565	O
controlling	-	571	O
for	-	583	O
the	-	587	O
use	-	591	O
of	-	595	O
hormone	-	598	O
replacement	-	606	O
therapy	-	618	O
in	-	626	O
both	-	629	O
groups	-	634	O
.	-	640	O

Patient	14745746	642	O
group	-	650	O
performance	-	656	O
was	-	668	O
not	-	672	O
significantly	-	676	O
related	-	690	O
to	-	698	O
length	-	701	O
of	-	708	O
treatment	-	711	O
or	-	721	O
measures	-	724	O
of	-	733	O
psychological	-	736	O
morbidity	-	750	O
.	-	759	O

The	14745746	761	O
results	-	765	O
showed	-	773	O
specific	-	780	O
impairments	-	789	O
in	-	801	O
processing	-	804	O
speed	-	815	O
and	-	821	O
verbal	-	825	O
memory	-	832	O
in	-	839	O
women	-	842	O
receiving	-	848	O
hormonal	-	858	O
therapy	-	867	O
for	-	875	O
the	-	879	O
treatment	-	883	O
of	-	893	O
breast	-	896	B
cancer	-	903	I
.	-	909	O

Verbal	14745746	911	O
memory	-	918	O
may	-	925	O
be	-	929	O
especially	-	932	O
sensitive	-	943	O
to	-	953	O
changes	-	956	O
in	-	964	O
oestrogen	-	967	O
levels	-	977	O
,	-	983	O
a	-	985	O
finding	-	987	O
commonly	-	995	O
reported	-	1004	O
in	-	1013	O
studies	-	1016	O
of	-	1024	O
hormone	-	1027	O
replacement	-	1035	O
therapy	-	1047	O
in	-	1055	O
healthy	-	1058	O
women	-	1066	O
.	-	1071	O

In	14745746	1073	O
view	-	1076	O
of	-	1081	O
the	-	1084	O
increased	-	1088	O
use	-	1098	O
of	-	1102	O
hormone	-	1105	O
therapies	-	1113	O
in	-	1123	O
an	-	1126	O
adjuvant	-	1129	O
and	-	1138	O
preventative	-	1142	O
setting	-	1155	O
their	-	1163	O
impact	-	1169	O
on	-	1176	O
cognitive	-	1179	O
functioning	-	1189	O
should	-	1201	O
be	-	1208	O
investigated	-	1211	O
more	-	1224	O
thoroughly	-	1229	O
.	-	1239	O

Association	11208990	0	O
of	-	12	O
nitric	-	15	O
oxide	-	22	O
production	-	28	O
and	-	39	O
apoptosis	-	43	O
in	-	53	O
a	-	56	O
model	-	58	O
of	-	64	O
experimental	-	67	O
nephropathy	-	80	B
.	-	91	O

BACKGROUND	11208990	93	O
:	-	103	O
In	-	105	O
recent	-	108	O
studies	-	115	O
increased	-	123	O
amounts	-	133	O
of	-	141	O
nitric	-	144	O
oxide	-	151	O
(	-	157	O
NO	-	158	O
)	-	160	O
and	-	162	O
apoptosis	-	166	O
have	-	176	O
been	-	181	O
implicated	-	186	O
in	-	197	O
various	-	200	O
pathological	-	208	O
conditions	-	221	O
in	-	232	O
the	-	235	O
kidney	-	239	O
.	-	245	O

We	11208990	247	O
have	-	250	O
studied	-	255	O
the	-	263	O
role	-	267	O
of	-	272	O
NO	-	275	O
and	-	278	O
its	-	282	O
association	-	286	O
with	-	298	O
apoptosis	-	303	O
in	-	313	O
an	-	316	O
experimental	-	319	O
model	-	332	O
of	-	338	O
nephrotic	-	341	B
syndrome	-	351	I
induced	-	360	O
by	-	368	O
a	-	371	O
single	-	373	O
injection	-	380	O
of	-	390	O
adriamycin	-	393	O
(	-	404	O
ADR	-	405	O
)	-	408	O
.	-	409	O

METHODS	11208990	411	O
:	-	418	O

The	11208990	420	O
alteration	-	424	O
in	-	435	O
the	-	438	O
NO	-	442	O
pathway	-	445	O
was	-	453	O
assessed	-	457	O
by	-	466	O
measuring	-	469	O
nitrite	-	479	O
levels	-	487	O
in	-	494	O
serum	-	497	O
/	-	502	O
urine	-	503	O
and	-	509	O
by	-	513	O
evaluating	-	516	O
the	-	527	O
changes	-	531	O
in	-	539	O
vascular	-	542	O
reactivity	-	551	O
of	-	562	O
the	-	565	O
isolated	-	569	O
perfused	-	578	O
rat	-	587	O
kidney	-	591	O
(	-	598	O
IPRK	-	599	O
)	-	603	O
system	-	605	O
.	-	611	O

Rats	11208990	613	O
were	-	618	O
stratified	-	623	O
into	-	634	O
control	-	639	O
groups	-	647	O
and	-	654	O
ADR	-	658	O
-	-	661	O
induced	-	662	O
nephropathy	-	670	B
groups	-	682	O
.	-	688	O

These	11208990	690	O
two	-	696	O
groups	-	700	O
were	-	707	O
then	-	712	O
divided	-	717	O
into	-	725	O
:	-	729	O
group	-	731	O
1	-	737	O
,	-	738	O
animals	-	740	O
receiving	-	748	O
saline	-	758	O
;	-	764	O
and	-	766	O
group	-	770	O
2	-	776	O
,	-	777	O
animals	-	779	O
receiving	-	787	O
aminoguanidine	-	797	O
(	-	812	O
AG	-	813	O
)	-	815	O
which	-	817	O
is	-	823	O
a	-	826	O
specific	-	828	O
inhibitor	-	837	O
of	-	847	O
inducible	-	850	O
-	-	859	O
NO	-	860	O
synthase	-	863	O
.	-	871	O

On	11208990	873	O
day	-	876	O
21	-	880	O
,	-	882	O
rats	-	884	O
were	-	889	O
sacrificed	-	894	O
after	-	905	O
obtaining	-	911	O
material	-	921	O
for	-	930	O
biochemical	-	934	O
analysis	-	946	O
.	-	954	O

RESULTS	11208990	956	O
:	-	963	O

Histopathological	11208990	965	O
examination	-	983	O
of	-	995	O
the	-	998	O
kidneys	-	1002	O
of	-	1010	O
rats	-	1013	O
treated	-	1018	O
with	-	1026	O
ADR	-	1031	O
revealed	-	1035	O
focal	-	1044	O
areas	-	1050	O
of	-	1056	O
mesangial	-	1059	B
proliferation	-	1069	I
and	-	1083	O
mild	-	1087	O
tubulointerstitial	-	1092	B
inflammation	-	1111	I
.	-	1123	O

They	11208990	1125	O
also	-	1130	O
had	-	1135	O
significantly	-	1139	O
higher	-	1153	O
levels	-	1160	O
of	-	1167	O
proteinuria	-	1170	B
compared	-	1182	O
with	-	1191	O
control	-	1196	O
and	-	1204	O
treatment	-	1208	O
groups	-	1218	O
(	-	1225	O
P	-	1226	O
<	-	1228	O
0	-	1230	O
.	-	1231	O
05	-	1232	O
)	-	1234	O
.	-	1235	O

Urine	11208990	1237	O
nitrite	-	1243	O
levels	-	1251	O
were	-	1258	O
significantly	-	1263	O
increased	-	1277	O
in	-	1287	O
the	-	1290	O
ADR	-	1294	O
-	-	1297	O
nephropathy	-	1298	B
group	-	1310	O
(	-	1316	O
P	-	1317	O
<	-	1319	O
0	-	1321	O
.	-	1322	O
05	-	1323	O
)	-	1325	O
.	-	1326	O

In	11208990	1328	O
the	-	1331	O
IPRK	-	1335	O
phenylephrine	-	1340	O
and	-	1354	O
acetylcholine	-	1358	O
related	-	1372	O
responses	-	1380	O
were	-	1390	O
significantly	-	1395	O
impaired	-	1409	O
in	-	1418	O
the	-	1421	O
ADR	-	1425	O
-	-	1428	O
nephropathy	-	1429	B
group	-	1441	O
.	-	1446	O

Apoptosis	11208990	1448	O
was	-	1458	O
not	-	1462	O
detected	-	1466	O
in	-	1475	O
controls	-	1478	O
.	-	1486	O

However	11208990	1488	O
,	-	1495	O
in	-	1497	O
the	-	1500	O
ADR	-	1504	O
-	-	1507	O
nephropathy	-	1508	B
group	-	1520	O
,	-	1525	O
numerous	-	1527	O
apoptotic	-	1536	O
cells	-	1546	O
were	-	1552	O
identified	-	1557	O
in	-	1568	O
the	-	1571	O
tubulointerstitial	-	1575	O
areas	-	1594	O
.	-	1599	O

Double	11208990	1601	O
staining	-	1608	O
revealed	-	1617	O
numerous	-	1626	O
interstitial	-	1635	O
apoptotic	-	1648	O
cells	-	1658	O
to	-	1664	O
stain	-	1667	O
for	-	1673	O
ED1	-	1677	O
,	-	1680	O
a	-	1682	O
marker	-	1684	O
for	-	1691	O
monocytes	-	1695	O
/	-	1704	O
macrophages	-	1705	O
.	-	1716	O

Treatment	11208990	1718	O
with	-	1728	O
AG	-	1733	O
prevented	-	1736	O
the	-	1746	O
impairment	-	1750	O
of	-	1761	O
renal	-	1764	O
vascular	-	1770	O
bed	-	1779	O
responses	-	1783	O
and	-	1793	O
reduced	-	1797	O
both	-	1805	O
urine	-	1810	O
nitrite	-	1816	O
levels	-	1824	O
and	-	1831	O
apoptosis	-	1835	O
to	-	1845	O
control	-	1848	O
levels	-	1856	O
.	-	1862	O

CONCLUSION	11208990	1864	O
:	-	1874	O

We	11208990	1876	O
suggest	-	1879	O
that	-	1887	O
interactions	-	1892	O
between	-	1905	O
NO	-	1913	O
and	-	1916	O
apoptosis	-	1920	O
are	-	1930	O
important	-	1934	O
in	-	1944	O
the	-	1947	O
pathogenesis	-	1951	O
of	-	1964	O
the	-	1967	O
ADR	-	1971	O
-	-	1974	O
induced	-	1975	O
nephrosis	-	1983	B
.	-	1992	O

The	9201797	0	O
attenuating	-	4	O
effect	-	16	O
of	-	23	O
carteolol	-	26	O
hydrochloride	-	36	O
,	-	49	O
a	-	51	O
beta	-	53	O
-	-	57	O
adrenoceptor	-	58	O
antagonist	-	71	O
,	-	81	O
on	-	83	O
neuroleptic	-	86	O
-	-	97	O
induced	-	98	O
catalepsy	-	106	B
in	-	116	O
rats	-	119	O
.	-	123	O

It	9201797	125	O
is	-	128	O
known	-	131	O
that	-	137	O
beta	-	142	O
-	-	146	O
adrenoceptor	-	147	O
antagonists	-	160	O
are	-	172	O
effective	-	176	O
in	-	186	O
the	-	189	O
treatment	-	193	O
of	-	203	O
akathisia	-	206	B
,	-	215	O
one	-	217	O
of	-	221	O
the	-	224	O
extrapyramidal	-	228	O
side	-	243	O
effects	-	248	O
that	-	256	O
occur	-	261	O
during	-	267	O
neuroleptic	-	274	O
treatment	-	286	O
.	-	295	O

Neuroleptic	9201797	297	O
-	-	308	O
induced	-	309	O
catalepsy	-	317	B
,	-	326	O
a	-	328	O
model	-	330	O
of	-	336	O
neuroleptic	-	339	O
-	-	350	O
induced	-	351	O
extrapyramidal	-	359	O
side	-	374	O
effects	-	379	O
,	-	386	O
was	-	388	O
considered	-	392	O
suitable	-	403	O
as	-	412	O
a	-	415	O
model	-	417	O
for	-	423	O
predicting	-	427	O
neuroleptic	-	438	O
-	-	449	O
induced	-	450	O
akathisia	-	458	B
in	-	468	O
humans	-	471	O
,	-	477	O
although	-	479	O
neuroleptic	-	488	O
-	-	499	O
induced	-	500	O
catalepsy	-	508	B
was	-	518	O
not	-	522	O
considered	-	526	O
a	-	537	O
specific	-	539	O
test	-	548	O
for	-	553	O
neuroleptic	-	557	O
-	-	568	O
induced	-	569	O
akathisia	-	577	B
.	-	586	O

Therefore	9201797	588	O
,	-	597	O
the	-	599	O
effects	-	603	O
of	-	611	O
carteolol	-	614	O
,	-	623	O
a	-	625	O
beta	-	627	O
-	-	631	O
adrenoceptor	-	632	O
antagonist	-	645	O
,	-	655	O
on	-	657	O
haloperidol	-	660	O
-	-	671	O
induced	-	672	O
catalepsy	-	680	B
in	-	690	O
rats	-	693	O
were	-	698	O
behaviorally	-	703	O
studied	-	716	O
and	-	724	O
compared	-	728	O
with	-	737	O
those	-	742	O
of	-	748	O
propranolol	-	751	O
and	-	763	O
biperiden	-	767	O
,	-	776	O
a	-	778	O
muscarinic	-	780	O
receptor	-	791	O
antagonist	-	800	O
.	-	810	O

Carteolol	9201797	812	O
,	-	821	O
as	-	823	O
well	-	826	O
as	-	831	O
propranolol	-	834	O
and	-	846	O
biperiden	-	850	O
,	-	859	O
inhibited	-	861	O
the	-	871	O
haloperidol	-	875	O
-	-	886	O
induced	-	887	O
catalepsy	-	895	B
.	-	904	O

The	9201797	906	O
inhibitory	-	910	O
effect	-	921	O
of	-	928	O
carteolol	-	931	O
was	-	941	O
almost	-	945	O
comparable	-	952	O
to	-	963	O
that	-	966	O
of	-	971	O
propranolol	-	974	O
,	-	985	O
but	-	987	O
was	-	991	O
weaker	-	995	O
than	-	1002	O
that	-	1007	O
of	-	1012	O
biperiden	-	1015	O
.	-	1024	O

Carteolol	9201797	1026	O
did	-	1036	O
not	-	1040	O
evoke	-	1044	O
postsynaptic	-	1050	O
dopamine	-	1063	O
receptor	-	1072	O
-	-	1080	O
stimulating	-	1081	O
behavioral	-	1093	O
signs	-	1104	O
such	-	1110	O
as	-	1115	O
stereotypy	-	1118	O
and	-	1129	O
hyperlocomotion	-	1133	B
in	-	1149	O
rats	-	1152	O
.	-	1156	O

Carteolol	9201797	1158	O
did	-	1168	O
not	-	1172	O
antagonize	-	1176	O
the	-	1187	O
inhibitory	-	1191	O
effects	-	1202	O
of	-	1210	O
haloperidol	-	1213	O
on	-	1225	O
apomorphine	-	1228	O
-	-	1239	O
induced	-	1240	O
stereotypy	-	1248	O
and	-	1259	O
locomotor	-	1263	O
activity	-	1273	O
in	-	1282	O
rats	-	1285	O
.	-	1289	O

In	9201797	1291	O
addition	-	1294	O
,	-	1302	O
carteolol	-	1304	O
did	-	1314	O
not	-	1318	O
evoke	-	1322	O
5	-	1328	O
-	-	1329	O
HT1A	-	1330	O
receptor	-	1335	O
-	-	1343	O
stimulating	-	1344	O
behavioral	-	1356	O
signs	-	1367	O
such	-	1373	O
as	-	1378	O
flat	-	1381	O
body	-	1386	O
posture	-	1391	O
and	-	1399	O
forepaw	-	1403	O
treading	-	1411	O
and	-	1420	O
did	-	1424	O
not	-	1428	O
inhibit	-	1432	O
5	-	1440	O
-	-	1441	O
hydroxytryptophan	-	1442	O
-	-	1459	O
induced	-	1460	O
head	-	1468	O
twitch	-	1473	O
in	-	1480	O
rats	-	1483	O
.	-	1487	O

Finally	9201797	1489	O
,	-	1496	O
carteolol	-	1498	O
did	-	1508	O
not	-	1512	O
inhibit	-	1516	O
physostigmine	-	1524	O
-	-	1537	O
induced	-	1538	O
lethality	-	1546	O
in	-	1556	O
rats	-	1559	O
.	-	1563	O

These	9201797	1565	O
results	-	1571	O
strongly	-	1579	O
suggest	-	1588	O
that	-	1596	O
carteolol	-	1601	O
improves	-	1611	O
haloperidol	-	1620	O
-	-	1631	O
induced	-	1632	O
catalepsy	-	1640	B
via	-	1650	O
its	-	1654	O
beta	-	1658	O
-	-	1662	O
adrenoceptor	-	1663	O
antagonistic	-	1676	O
activity	-	1689	O
and	-	1698	O
is	-	1702	O
expected	-	1705	O
to	-	1714	O
be	-	1717	O
effective	-	1720	O
in	-	1730	O
the	-	1733	O
treatment	-	1737	O
of	-	1747	O
akathisia	-	1750	B
without	-	1760	O
attenuating	-	1768	O
neuroleptic	-	1780	O
-	-	1791	O
induced	-	1792	O
antipsychotic	-	1800	O
effects	-	1814	O
due	-	1822	O
to	-	1826	O
its	-	1829	O
postsynaptic	-	1833	O
dopamine	-	1846	O
receptor	-	1855	O
antagonistic	-	1864	O
activity	-	1877	O
.	-	1885	O

Penicillamine	8267029	0	O
-	-	13	O
induced	-	14	O
rapidly	-	22	O
progressive	-	30	O
glomerulonephritis	-	42	B
in	-	61	O
a	-	64	O
patient	-	66	O
with	-	74	O
rheumatoid	-	79	B
arthritis	-	90	I
.	-	99	O

A	8267029	101	O
67	-	103	O
-	-	105	O
year	-	106	O
-	-	110	O
old	-	111	O
woman	-	115	O
with	-	121	O
rheumatoid	-	126	B
arthritis	-	137	I
presented	-	147	O
rapidly	-	157	O
progressive	-	165	O
glomerulonephritis	-	177	B
(	-	196	O
RPGN	-	197	B
)	-	201	O
after	-	203	O
5	-	209	O
months	-	211	O
of	-	218	O
D	-	221	O
-	-	222	O
penicillamine	-	223	O
(	-	237	O
250	-	238	O
mg	-	242	O
/	-	244	O
day	-	245	O
)	-	248	O
treatment	-	250	O
.	-	259	O

Light	8267029	261	O
microscopy	-	267	O
study	-	278	O
showed	-	284	O
severe	-	291	O
glomerulonephritis	-	298	B
with	-	317	O
crescent	-	322	O
formation	-	331	O
in	-	341	O
60	-	344	O
%	-	346	O
of	-	348	O
the	-	351	O
glomeruli	-	355	O
and	-	365	O
infiltration	-	369	O
of	-	382	O
inflammatory	-	385	O
cells	-	398	O
in	-	404	O
the	-	407	O
wall	-	411	O
of	-	416	O
an	-	419	O
arteriole	-	422	O
.	-	431	O

Immunofluorescence	8267029	433	O
revealed	-	452	O
scanty	-	461	O
granular	-	468	O
IgG	-	477	O
,	-	480	O
IgA	-	482	O
and	-	486	O
C3	-	490	O
deposits	-	493	O
along	-	502	O
the	-	508	O
capillary	-	512	O
walls	-	522	O
and	-	528	O
mesangium	-	532	O
.	-	541	O

The	8267029	543	O
patient	-	547	O
was	-	555	O
treated	-	559	O
with	-	567	O
steroid	-	572	O
pulse	-	580	O
,	-	585	O
plasmapheresis	-	587	O
,	-	601	O
cyclophosphamide	-	603	O
and	-	620	O
antiplatelet	-	624	O
agents	-	637	O
.	-	643	O

A	8267029	645	O
complete	-	647	O
recovery	-	656	O
of	-	665	O
renal	-	668	O
function	-	674	O
was	-	683	O
achieved	-	687	O
in	-	696	O
a	-	699	O
few	-	701	O
weeks	-	705	O
.	-	710	O

This	8267029	712	O
new	-	717	O
case	-	721	O
of	-	726	O
RPGN	-	729	B
in	-	734	O
the	-	737	O
course	-	741	O
of	-	748	O
D	-	751	O
-	-	752	O
penicillamine	-	753	O
treatment	-	767	O
emphasizes	-	777	O
the	-	788	O
need	-	792	O
for	-	797	O
frequent	-	801	O
monitoring	-	810	O
of	-	821	O
renal	-	824	O
function	-	830	O
and	-	839	O
evaluation	-	843	O
of	-	854	O
urinary	-	857	O
sediment	-	865	O
and	-	874	O
proteinuria	-	878	B
in	-	890	O
these	-	893	O
patients	-	899	O
.	-	907	O

The	8267029	909	O
prompt	-	913	O
discontinuation	-	920	O
of	-	936	O
D	-	939	O
-	-	940	O
penicillamine	-	941	O
and	-	955	O
vigorous	-	959	O
treatment	-	968	O
measures	-	978	O
could	-	987	O
allow	-	993	O
for	-	999	O
a	-	1003	O
good	-	1005	O
prognosis	-	1010	O
as	-	1020	O
in	-	1023	O
this	-	1026	O
case	-	1031	O
.	-	1035	O

Nature	2528969	0	O
,	-	6	O
time	-	8	O
course	-	13	O
and	-	20	O
dose	-	24	O
dependence	-	29	O
of	-	40	O
zidovudine	-	43	O
-	-	53	O
related	-	54	O
side	-	62	O
effects	-	67	O
:	-	74	O
results	-	76	O
from	-	84	O
the	-	89	O
Multicenter	-	93	O
Canadian	-	105	O
Azidothymidine	-	114	O
Trial	-	129	O
.	-	134	O

To	2528969	136	O
characterize	-	139	O
the	-	152	O
nature	-	156	O
,	-	162	O
time	-	164	O
course	-	169	O
and	-	176	O
dose	-	180	O
dependency	-	185	O
of	-	196	O
zidovudine	-	199	O
-	-	209	O
related	-	210	O
side	-	218	O
effects	-	223	O
,	-	230	O
we	-	232	O
undertook	-	235	O
a	-	245	O
multicenter	-	247	O
,	-	258	O
prospective	-	260	O
,	-	271	O
dose	-	273	O
-	-	277	O
range	-	278	O
finding	-	284	O
study	-	292	O
.	-	297	O

Our	2528969	299	O
study	-	303	O
group	-	309	O
consisted	-	315	O
of	-	325	O
74	-	328	O
HIV	-	331	O
-	-	334	O
positive	-	335	O
homosexual	-	344	O
men	-	355	O
belonging	-	359	O
to	-	369	O
groups	-	372	O
II	-	379	O
B	-	382	O
,	-	383	O
III	-	385	O
and	-	389	O
IV	-	393	O
C2	-	396	O
from	-	399	O
the	-	404	O
Centers	-	408	O
for	-	416	O
Disease	-	420	O
Control	-	428	O
(	-	436	O
CDC	-	437	O
)	-	440	O
classification	-	442	O
of	-	457	O
HIV	-	460	B
disease	-	464	I
.	-	471	O

Following	2528969	473	O
a	-	483	O
3	-	485	O
-	-	486	O
week	-	487	O
observation	-	492	O
period	-	504	O
,	-	510	O
volunteers	-	512	O
were	-	523	O
treated	-	528	O
with	-	536	O
zidovudine	-	541	O
600	-	552	O
mg	-	556	O
/	-	558	O
day	-	559	O
for	-	563	O
18	-	567	O
weeks	-	570	O
,	-	575	O
900	-	577	O
mg	-	581	O
/	-	583	O
day	-	584	O
for	-	588	O
9	-	592	O
weeks	-	594	O
and	-	600	O
1200	-	604	O
mg	-	609	O
/	-	611	O
day	-	612	O
for	-	616	O
9	-	620	O
weeks	-	622	O
,	-	627	O
followed	-	629	O
by	-	638	O
a	-	641	O
washout	-	643	O
period	-	651	O
of	-	658	O
6	-	661	O
weeks	-	663	O
after	-	669	O
which	-	675	O
they	-	681	O
were	-	686	O
re	-	691	O
-	-	693	O
started	-	694	O
on	-	702	O
1200	-	705	O
mg	-	710	O
/	-	712	O
day	-	713	O
or	-	717	O
the	-	720	O
highest	-	724	O
tolerated	-	732	O
dose	-	742	O
at	-	747	O
8	-	750	O
-	-	751	O
hourly	-	752	O
intervals	-	759	O
.	-	768	O

Subjects	2528969	770	O
were	-	779	O
randomly	-	784	O
assigned	-	793	O
to	-	802	O
4	-	805	O
-	-	806	O
hourly	-	807	O
or	-	814	O
8	-	817	O
-	-	818	O
hourly	-	819	O
regimens	-	826	O
within	-	835	O
CDC	-	842	O
groups	-	846	O
while	-	853	O
taking	-	859	O
600	-	866	O
and	-	870	O
1200	-	874	O
mg	-	879	O
/	-	881	O
day	-	882	O
.	-	885	O

Clinical	2528969	887	O
and	-	896	O
laboratory	-	900	O
evaluations	-	911	O
were	-	923	O
performed	-	928	O
at	-	938	O
3	-	941	O
-	-	942	O
week	-	943	O
intervals	-	948	O
.	-	957	O

Symptomatic	2528969	959	O
adverse	-	971	O
effects	-	979	O
were	-	987	O
present	-	992	O
in	-	1000	O
96	-	1003	O
%	-	1005	O
of	-	1007	O
subjects	-	1010	O
,	-	1018	O
most	-	1020	O
commonly	-	1025	O
nausea	-	1034	B
(	-	1041	O
64	-	1042	O
%	-	1044	O
)	-	1045	O
,	-	1046	O
fatigue	-	1048	B
(	-	1056	O
55	-	1057	O
%	-	1059	O
)	-	1060	O
and	-	1062	O
headache	-	1066	B
(	-	1075	O
49	-	1076	O
%	-	1078	O
)	-	1079	O
.	-	1080	O

These	2528969	1082	O
were	-	1088	O
generally	-	1093	O
self	-	1103	O
-	-	1107	O
limited	-	1108	O
,	-	1115	O
reappearing	-	1117	O
briefly	-	1129	O
at	-	1137	O
each	-	1140	O
dose	-	1145	O
increment	-	1150	O
.	-	1159	O

A	2528969	1161	O
decrease	-	1163	O
in	-	1172	O
hemoglobin	-	1175	O
occurred	-	1186	O
shortly	-	1195	O
after	-	1203	O
initiation	-	1209	O
of	-	1220	O
therapy	-	1223	O
.	-	1230	O

This	2528969	1232	O
was	-	1237	O
not	-	1241	O
dose	-	1245	O
dependent	-	1250	O
and	-	1260	O
reversed	-	1264	O
rapidly	-	1273	O
upon	-	1281	O
discontinuation	-	1286	O
of	-	1302	O
treatment	-	1305	O
.	-	1314	O

A	2528969	1316	O
red	-	1318	O
blood	-	1322	O
cell	-	1328	O
count	-	1333	O
decrease	-	1339	O
,	-	1347	O
a	-	1349	O
mean	-	1351	O
cell	-	1356	O
volume	-	1361	O
increase	-	1368	O
and	-	1377	O
a	-	1381	O
granulocyte	-	1383	O
count	-	1395	O
decrease	-	1401	O
developed	-	1410	O
early	-	1420	O
in	-	1426	O
a	-	1429	O
dose	-	1431	O
-	-	1435	O
independent	-	1436	O
fashion	-	1448	O
,	-	1455	O
reverting	-	1457	O
at	-	1467	O
least	-	1470	O
partially	-	1476	O
during	-	1486	O
the	-	1493	O
washout	-	1497	O
phase	-	1505	O
.	-	1510	O

The	2528969	1512	O
decrease	-	1516	O
in	-	1525	O
reticulocyte	-	1528	O
count	-	1541	O
was	-	1547	O
dose	-	1551	O
related	-	1556	O
between	-	1564	O
600	-	1572	O
and	-	1576	O
900	-	1580	O
mg	-	1584	O
/	-	1586	O
day	-	1587	O
with	-	1591	O
no	-	1596	O
further	-	1599	O
change	-	1607	O
when	-	1614	O
the	-	1619	O
dose	-	1623	O
was	-	1628	O
escalated	-	1632	O
to	-	1642	O
1200	-	1645	O
mg	-	1650	O
/	-	1652	O
day	-	1653	O
.	-	1656	O

Bone	2528969	1658	O
marrow	-	1663	O
changes	-	1670	O
occurred	-	1678	O
rapidly	-	1687	O
as	-	1695	O
demonstrated	-	1698	O
by	-	1711	O
megaloblastosis	-	1714	B
in	-	1730	O
95	-	1733	O
%	-	1735	O
of	-	1737	O
65	-	1740	O
specimens	-	1743	O
at	-	1753	O
week	-	1756	O
18	-	1761	O
.	-	1763	O
(	-	1764	O
ABSTRACT	-	1765	O

TRUNCATED	2528969	1774	O
AT	-	1784	O
250	-	1787	O
WORDS	-	1791	O
)	-	1796	O

Bilateral	384871	0	B
optic	-	10	I
neuropathy	-	16	I
due	-	27	O
to	-	31	O
combined	-	34	O
ethambutol	-	43	O
and	-	54	O
isoniazid	-	58	O
treatment	-	68	O
.	-	77	O

The	384871	79	O
case	-	83	O
of	-	88	O
a	-	91	O
40	-	93	O
-	-	95	O
year	-	96	O
-	-	100	O
old	-	101	O
patient	-	105	O
who	-	113	O
underwent	-	117	O
an	-	127	O
unsuccessful	-	130	O
cadaver	-	143	O
kidney	-	151	O
transplantation	-	158	O
and	-	174	O
was	-	178	O
treated	-	182	O
with	-	190	O
ethambutol	-	195	O
and	-	206	O
isoniazid	-	210	O
is	-	220	O
reported	-	223	O
.	-	231	O

A	384871	233	O
bilateral	-	235	B
retrobulbar	-	245	I
neuropathy	-	257	I
with	-	268	O
an	-	273	O
unusual	-	276	O
central	-	284	O
bitemporal	-	292	O
hemianopic	-	303	O
scotoma	-	314	B
was	-	322	O
found	-	326	O
.	-	331	O

Ethambutol	384871	333	O
was	-	344	O
stopped	-	348	O
and	-	356	O
only	-	360	O
small	-	365	O
improvement	-	371	O
of	-	383	O
the	-	386	O
visual	-	390	O
acuity	-	397	O
followed	-	404	O
.	-	412	O

Isoniazid	384871	414	O
was	-	424	O
discontinued	-	428	O
later	-	441	O
,	-	446	O
followed	-	448	O
by	-	457	O
a	-	460	O
dramatic	-	462	O
improvement	-	471	O
in	-	483	O
the	-	486	O
visual	-	490	O
acuity	-	497	O
.	-	503	O

The	384871	505	O
hazards	-	509	O
of	-	517	O
optic	-	520	O
nerve	-	526	O
toxicity	-	532	B
due	-	541	O
to	-	545	O
ethambutol	-	548	O
are	-	559	O
known	-	563	O
.	-	568	O

We	384871	570	O
emphasize	-	573	O
the	-	583	O
potential	-	587	O
danger	-	597	O
in	-	604	O
the	-	607	O
use	-	611	O
of	-	615	O
ethambutol	-	618	O
and	-	629	O
isoniazid	-	633	O
.	-	642	O

Progestational	133615	0	O
agents	-	15	O
and	-	22	O
blood	-	26	B
coagulation	-	32	I
.	-	43	O

VII	133615	45	O
.	-	48	O

Thromboembolic	133615	50	B
and	-	65	O
other	-	69	O
complications	-	75	O
of	-	89	O
oral	-	92	O
contraceptive	-	97	O
therapy	-	111	O
in	-	119	O
relationship	-	122	O
to	-	135	O
pretreatment	-	138	O
levels	-	151	O
of	-	158	O
blood	-	161	B
coagulation	-	167	I
factors	-	179	O
:	-	186	O
summary	-	188	O
report	-	196	O
of	-	203	O
a	-	206	O
ten	-	208	O
-	-	211	O
year	-	212	O
study	-	217	O
.	-	222	O

During	133615	224	O
a	-	231	O
ten	-	233	O
-	-	236	O
year	-	237	O
period	-	242	O
,	-	248	O
348	-	250	O
women	-	254	O
were	-	260	O
studied	-	265	O
for	-	273	O
a	-	277	O
total	-	279	O
of	-	285	O
5	-	288	O
,	-	289	O
877	-	290	O
patient	-	294	O
months	-	302	O
in	-	309	O
four	-	312	O
separate	-	317	O
studies	-	326	O
relating	-	334	O
oral	-	343	O
contraceptives	-	348	O
to	-	363	O
changes	-	366	O
in	-	374	O
hematologic	-	377	O
parameters	-	389	O
.	-	399	O

Significant	133615	401	O
increases	-	413	O
in	-	423	O
certain	-	426	O
factors	-	434	O
of	-	442	O
the	-	445	O
blood	-	449	B
coagulation	-	455	I
and	-	467	O
fibrinolysin	-	471	O
systems	-	484	O
(	-	492	O
factors	-	493	O
I	-	501	O
,	-	502	O
II	-	503	O
,	-	505	O
VII	-	506	O
,	-	509	O
VIII	-	510	O
,	-	514	O
IX	-	515	O
,	-	517	O
and	-	519	O
X	-	523	O
and	-	525	O
plasminogen	-	529	O
)	-	540	O
were	-	542	O
observed	-	547	O
in	-	556	O
the	-	559	O
treated	-	563	O
groups	-	571	O
.	-	577	O

Severe	133615	579	O
complications	-	586	O
developed	-	600	O
in	-	610	O
four	-	613	O
patients	-	618	O
.	-	626	O

All	133615	628	O
four	-	632	O
had	-	637	O
an	-	641	O
abnormal	-	644	O
blood	-	653	B
coagulation	-	659	I
profile	-	671	O
,	-	678	O
suggesting	-	680	O
""""	-	691	O
hypercoagulability	-	692	B
""""	-	710	O
before	-	712	O
initiation	-	719	O
of	-	730	O
therapy	-	733	O
.	-	740	O

Some	133615	742	O
of	-	747	O
these	-	750	O
findings	-	756	O
represented	-	765	O
the	-	777	O
most	-	781	O
extreme	-	786	O
abnormalities	-	794	O
seen	-	808	O
in	-	813	O
the	-	816	O
entire	-	820	O
group	-	827	O
of	-	833	O
patients	-	836	O
;	-	844	O
some	-	846	O
increased	-	851	O
further	-	861	O
during	-	869	O
therapy	-	876	O
.	-	883	O

One	133615	885	O
of	-	889	O
these	-	892	O
patients	-	898	O
developed	-	907	O
a	-	917	O
myocardial	-	919	B
infarction	-	930	I
before	-	941	O
receiving	-	948	O
any	-	958	O
medication	-	962	O
,	-	972	O
shortly	-	974	O
after	-	982	O
the	-	988	O
base	-	992	O
-	-	996	O
line	-	997	O
values	-	1002	O
were	-	1009	O
obtained	-	1014	O
.	-	1022	O

One	133615	1024	O
patient	-	1028	O
developed	-	1036	O
retinopathy	-	1046	B
19	-	1058	O
months	-	1061	O
after	-	1068	O
she	-	1074	O
began	-	1078	O
therapy	-	1084	O
,	-	1091	O
and	-	1093	O
another	-	1097	O
developed	-	1105	O
thrombophlebitis	-	1115	B
after	-	1132	O
27	-	1138	O
months	-	1141	O
of	-	1148	O
therapy	-	1151	O
.	-	1158	O

The	133615	1160	O
fourth	-	1164	O
patient	-	1171	O
developed	-	1179	O
thrombophlebitis	-	1189	B
14	-	1206	O
days	-	1209	O
after	-	1214	O
initiation	-	1220	O
of	-	1231	O
contraceptive	-	1234	O
therapy	-	1248	O
.	-	1255	O

All	133615	1257	O
four	-	1261	O
patients	-	1266	O
were	-	1275	O
of	-	1280	O
the	-	1283	O
A	-	1287	O
or	-	1289	O
AB	-	1292	O
blood	-	1295	O
group	-	1301	O
.	-	1306	O

Previous	133615	1308	O
studies	-	1317	O
suggested	-	1325	O
the	-	1335	O
possiblility	-	1339	O
of	-	1352	O
increased	-	1355	O
propensity	-	1365	O
for	-	1376	O
thromboembolic	-	1380	B
episodes	-	1395	I
in	-	1404	O
patients	-	1407	O
possessing	-	1416	O
the	-	1427	O
A	-	1431	O
antigen	-	1433	O
.	-	1440	O

It	133615	1442	O
appears	-	1445	O
from	-	1453	O
these	-	1458	O
data	-	1464	O
that	-	1469	O
hematologic	-	1474	O
work	-	1486	O
-	-	1490	O
ups	-	1491	O
may	-	1495	O
be	-	1499	O
useful	-	1502	O
in	-	1509	O
women	-	1512	O
who	-	1518	O
are	-	1522	O
about	-	1526	O
to	-	1532	O
start	-	1535	O
long	-	1541	O
-	-	1545	O
term	-	1546	O
oral	-	1551	O
contraceptive	-	1556	O
therapy	-	1570	O
.	-	1577	O

Cardiac	17263743	0	B
arrest	-	8	I
in	-	15	O
a	-	18	O
child	-	20	O
with	-	26	O
cerebral	-	31	B
palsy	-	40	I
undergoing	-	46	O
sevoflurane	-	57	O
induction	-	69	O
of	-	79	O
anesthesia	-	82	O
after	-	93	O
preoperative	-	99	O
clonidine	-	112	O
.	-	121	O

Clonidine	17263743	123	O
is	-	133	O
a	-	136	O
frequently	-	138	O
administered	-	149	O
alpha2	-	162	O
-	-	168	O
adrenergic	-	169	O
agonist	-	180	O
which	-	188	O
can	-	194	O
decrease	-	198	O
heart	-	207	O
rate	-	213	O
and	-	218	O
blood	-	222	O
pressure	-	228	O
.	-	236	O

We	17263743	238	O
present	-	241	O
a	-	249	O
case	-	251	O
of	-	256	O
a	-	259	O
5	-	261	O
-	-	262	O
year	-	263	O
-	-	267	O
old	-	268	O
child	-	272	O
with	-	278	O
cerebral	-	283	B
palsy	-	292	I
and	-	298	O
seizure	-	302	B
disorder	-	310	I
,	-	318	O
receiving	-	320	O
clonidine	-	330	O
for	-	340	O
restlessness	-	344	B
,	-	356	O
who	-	358	O
presented	-	362	O
for	-	372	O
placement	-	376	O
of	-	386	O
a	-	389	O
baclofen	-	391	O
pump	-	400	O
.	-	404	O

Without	17263743	406	O
the	-	414	O
knowledge	-	418	O
of	-	428	O
the	-	431	O
medical	-	435	O
personnel	-	443	O
,	-	452	O
the	-	454	O
patient	-	458	O
's	-	465	O
mother	-	468	O
administered	-	475	O
three	-	488	O
doses	-	494	O
of	-	500	O
clonidine	-	503	O
during	-	513	O
the	-	520	O
evening	-	524	O
before	-	532	O
and	-	539	O
morning	-	543	O
of	-	551	O
surgery	-	554	O
to	-	562	O
reduce	-	565	O
anxiety	-	572	B
.	-	579	O

During	17263743	581	O
induction	-	588	O
of	-	598	O
anesthesia	-	601	O
,	-	611	O
the	-	613	O
patient	-	617	O
developed	-	625	O
bradycardia	-	635	B
and	-	647	O
hypotension	-	651	B
requiring	-	663	O
cardiac	-	673	O
resuscitation	-	681	O
.	-	694	O

There	17263743	696	O
are	-	702	O
no	-	706	O
previous	-	709	O
reports	-	718	O
of	-	726	O
clonidine	-	729	O
-	-	738	O
associated	-	739	O
cardiac	-	750	B
arrest	-	758	I
in	-	765	O
a	-	768	O
child	-	770	O
undergoing	-	776	O
induction	-	787	O
of	-	797	O
anesthesia	-	800	O
.	-	810	O

Effects	17241657	0	O
of	-	8	O
UMB24	-	11	O
and	-	17	O
(	-	21	O
+	-	22	O
/	-	23	O
-	-	24	O
)	-	25	O
-	-	26	O
SM	-	27	O
21	-	30	O
,	-	32	O
putative	-	34	O
sigma2	-	43	O
-	-	49	O
preferring	-	50	O
antagonists	-	61	O
,	-	72	O
on	-	74	O
behavioral	-	77	O
toxic	-	88	O
and	-	94	O
stimulant	-	98	O
effects	-	108	O
of	-	116	O
cocaine	-	119	O
in	-	127	O
mice	-	130	O
.	-	134	O

Earlier	17241657	136	O
studies	-	144	O
have	-	152	O
demonstrated	-	157	O
that	-	170	O
antagonism	-	175	O
of	-	186	O
sigma1	-	189	O
receptors	-	196	O
attenuates	-	206	O
the	-	217	O
convulsive	-	221	B
,	-	231	O
lethal	-	233	O
,	-	239	O
locomotor	-	241	O
stimulatory	-	251	O
and	-	263	O
rewarding	-	267	O
actions	-	277	O
of	-	285	O
cocaine	-	288	O
in	-	296	O
mice	-	299	O
.	-	303	O

In	17241657	305	O
contrast	-	308	O
,	-	316	O
the	-	318	O
contribution	-	322	O
of	-	335	O
sigma2	-	338	O
receptors	-	345	O
is	-	355	O
unclear	-	358	O
because	-	366	O
experimental	-	374	O
tools	-	387	O
to	-	393	O
selectively	-	396	O
target	-	408	O
this	-	415	O
subtype	-	420	O
are	-	428	O
unavailable	-	432	O
.	-	443	O

To	17241657	445	O
begin	-	448	O
addressing	-	454	O
this	-	465	O
need	-	470	O
,	-	474	O
we	-	476	O
characterized	-	479	O
UMB24	-	493	O
(	-	499	O
1	-	500	O
-	-	501	O
(	-	502	O
2	-	503	O
-	-	504	O
phenethyl	-	505	O
)	-	514	O
-	-	515	O
4	-	516	O
-	-	517	O
(	-	518	O
2	-	519	O
-	-	520	O
pyridyl	-	521	O
)	-	528	O
-	-	529	O
piperazine	-	530	O
)	-	540	O
and	-	542	O
(	-	546	O
+	-	547	O
/	-	548	O
-	-	549	O
)	-	550	O
-	-	551	O
SM	-	552	O
21	-	555	O
(	-	558	O
3alpha	-	559	O
-	-	565	O
tropanyl	-	566	O
-	-	574	O
2	-	575	O
-	-	576	O
(	-	577	O
4	-	578	O
-	-	579	O
chorophenoxy	-	580	O
)	-	592	O
butyrate	-	593	O
)	-	601	O
in	-	603	O
receptor	-	606	O
binding	-	615	O
and	-	623	O
behavioral	-	627	O
studies	-	638	O
.	-	645	O

Receptor	17241657	647	O
binding	-	656	O
studies	-	664	O
confirmed	-	672	O
that	-	682	O
UMB24	-	687	O
and	-	693	O
(	-	697	O
+	-	698	O
/	-	699	O
-	-	700	O
)	-	701	O
-	-	702	O
SM	-	703	O
21	-	706	O
display	-	709	O
preferential	-	717	O
affinity	-	730	O
for	-	739	O
sigma2	-	743	O
over	-	750	O
sigma1	-	755	O
receptors	-	762	O
.	-	771	O

In	17241657	773	O
behavioral	-	776	O
studies	-	787	O
,	-	794	O
pretreatment	-	796	O
of	-	809	O
Swiss	-	812	O
Webster	-	818	O
mice	-	826	O
with	-	831	O
UMB24	-	836	O
or	-	842	O
(	-	845	O
+	-	846	O
/	-	847	O
-	-	848	O
)	-	849	O
-	-	850	O
SM	-	851	O
21	-	854	O
significantly	-	857	O
attenuated	-	871	O
cocaine	-	882	O
-	-	889	O
induced	-	890	O
convulsions	-	898	B
and	-	910	O
locomotor	-	914	O
activity	-	924	O
,	-	932	O
but	-	934	O
not	-	938	O
lethality	-	942	O
.	-	951	O

When	17241657	953	O
administered	-	958	O
alone	-	971	O
,	-	976	O
(	-	978	O
+	-	979	O
/	-	980	O
-	-	981	O
)	-	982	O
-	-	983	O
SM	-	984	O
21	-	987	O
produced	-	990	O
no	-	999	O
significant	-	1002	O
effects	-	1014	O
compared	-	1022	O
to	-	1031	O
control	-	1034	O
injections	-	1042	O
of	-	1053	O
saline	-	1056	O
,	-	1062	O
but	-	1064	O
UMB24	-	1068	O
had	-	1074	O
locomotor	-	1078	O
depressant	-	1088	O
actions	-	1099	O
.	-	1106	O

Together	17241657	1108	O
,	-	1116	O
the	-	1118	O
data	-	1122	O
suggest	-	1127	O
that	-	1135	O
sigma2	-	1140	O
receptor	-	1147	O
antagonists	-	1156	O
have	-	1168	O
the	-	1173	O
potential	-	1177	O
to	-	1187	O
attenuate	-	1190	O
some	-	1200	O
of	-	1205	O
the	-	1208	O
behavioral	-	1212	O
effects	-	1223	O
of	-	1231	O
cocaine	-	1234	O
,	-	1241	O
and	-	1243	O
further	-	1247	O
development	-	1255	O
of	-	1267	O
more	-	1270	O
selective	-	1275	O
,	-	1284	O
high	-	1286	O
affinity	-	1291	O
ligands	-	1300	O
are	-	1308	O
warranted	-	1312	O
.	-	1321	O

Methimazole	14982270	0	O
-	-	11	O
induced	-	12	O
cholestatic	-	20	B
jaundice	-	32	I
.	-	40	O

Methimazole	14982270	42	O
is	-	54	O
a	-	57	O
widely	-	59	O
used	-	66	O
and	-	71	O
generally	-	75	O
well	-	85	O
-	-	89	O
tolerated	-	90	O
antithyroid	-	100	O
agent	-	112	O
.	-	117	O

A	14982270	119	O
43	-	121	O
-	-	123	O
year	-	124	O
-	-	128	O
old	-	129	O
woman	-	133	O
had	-	139	O
severe	-	143	O
jaundice	-	150	B
and	-	159	O
itching	-	163	B
1	-	171	O
month	-	173	O
after	-	179	O
receiving	-	185	O
methimazole	-	195	O
(	-	207	O
10	-	208	O
mg	-	211	O
tid	-	214	O
)	-	217	O
and	-	219	O
propranolol	-	223	O
(	-	235	O
20	-	236	O
mg	-	239	O
tid	-	242	O
)	-	245	O
for	-	247	O
treatment	-	251	O
of	-	261	O
hyperthyroidism	-	264	B
.	-	279	O

The	14982270	281	O
patient	-	285	O
continued	-	293	O
treatment	-	303	O
for	-	313	O
another	-	317	O
4	-	325	O
days	-	327	O
after	-	332	O
the	-	338	O
appearance	-	342	O
of	-	353	O
jaundice	-	356	B
until	-	365	O
she	-	371	O
finished	-	375	O
both	-	384	O
medications	-	389	O
.	-	400	O

When	14982270	402	O
seen	-	407	O
at	-	412	O
the	-	415	O
emergency	-	419	O
department	-	429	O
2	-	440	O
weeks	-	442	O
later	-	448	O
,	-	453	O
she	-	455	O
still	-	459	O
had	-	465	O
severe	-	469	O
icterus	-	476	B
,	-	483	O
pruritus	-	485	B
,	-	493	O
and	-	495	O
hyperbilirubinemia	-	499	B
,	-	517	O
formed	-	519	O
mainly	-	526	O
of	-	533	O
the	-	536	O
conjugated	-	540	O
fraction	-	551	O
.	-	559	O

Methimazole	14982270	561	O
-	-	572	O
induced	-	573	O
cholestasis	-	581	B
was	-	593	O
diagnosed	-	597	O
,	-	606	O
and	-	608	O
propranolol	-	612	O
therapy	-	624	O
was	-	632	O
resumed	-	636	O
.	-	643	O

Over	14982270	645	O
the	-	650	O
following	-	654	O
9	-	664	O
days	-	666	O
,	-	670	O
the	-	672	O
symptoms	-	676	O
improved	-	685	O
and	-	694	O
plasma	-	698	O
bilirubin	-	705	O
levels	-	715	O
were	-	722	O
normal	-	727	O
after	-	734	O
12	-	740	O
weeks	-	743	O
without	-	749	O
methimazole	-	757	O
.	-	768	O

In	14982270	770	O
rare	-	773	O
cases	-	778	O
within	-	784	O
the	-	791	O
first	-	795	O
few	-	801	O
weeks	-	805	O
of	-	811	O
therapy	-	814	O
,	-	821	O
this	-	823	O
drug	-	828	O
can	-	833	O
cause	-	837	O
severe	-	843	O
and	-	850	O
reversible	-	854	O
cholestatic	-	865	B
jaundice	-	877	I
.	-	885	O

Physicians	14982270	887	O
and	-	898	O
patients	-	902	O
should	-	911	O
be	-	918	O
aware	-	921	O
of	-	927	O
this	-	930	O
adverse	-	935	O
effect	-	943	O
so	-	950	O
that	-	953	O
,	-	957	O
upon	-	959	O
occurrence	-	964	O
,	-	974	O
they	-	976	O
can	-	981	O
discontinue	-	985	O
methimazole	-	997	O
therapy	-	1009	O
and	-	1017	O
avoid	-	1021	O
unnecessary	-	1027	O
invasive	-	1039	O
procedures	-	1048	O
.	-	1058	O

Ciprofloxacin	12911170	0	O
-	-	13	O
induced	-	14	O
acute	-	22	O
interstitial	-	28	B
nephritis	-	41	I
and	-	51	O
autoimmune	-	55	B
hemolytic	-	66	I
anemia	-	76	I
.	-	82	O

Ciprofloxacin	12911170	84	O
has	-	98	O
been	-	102	O
associated	-	107	O
with	-	118	O
several	-	123	O
side	-	131	O
effects	-	136	O
including	-	144	O
interstitial	-	154	B
nephritis	-	167	I
and	-	177	O
hemolytic	-	181	B
anemia	-	191	I
.	-	197	O

The	12911170	199	O
combination	-	203	O
of	-	215	O
both	-	218	O
side	-	223	O
effects	-	228	O
is	-	236	O
extremely	-	239	O
rare	-	249	O
.	-	253	O

In	12911170	255	O
this	-	258	O
report	-	263	O
,	-	269	O
we	-	271	O
describe	-	274	O
a	-	283	O
case	-	285	O
of	-	290	O
ciprofloxacin	-	293	O
-	-	306	O
induced	-	307	O
interstitial	-	315	B
nephritis	-	328	I
and	-	338	O
autoimmune	-	342	B
hemolytic	-	353	I
anemia	-	363	I
.	-	369	O

Hemolytic	12911170	371	B
anemia	-	381	I
improved	-	388	O
after	-	397	O
stopping	-	403	O
the	-	412	O
drug	-	416	O
and	-	421	O
initiation	-	425	O
of	-	436	O
steroid	-	439	O
therapy	-	447	O
.	-	454	O

Unfortunately	12911170	456	O
,	-	469	O
acute	-	471	O
interstitial	-	477	B
nephritis	-	490	I
was	-	500	O
irreversible	-	504	O
and	-	517	O
the	-	521	O
patient	-	525	O
developed	-	533	O
end	-	543	B
-	-	546	I
stage	-	547	I
renal	-	553	I
disease	-	559	I
.	-	566	O

Contribution	11195262	0	O
of	-	13	O
sodium	-	16	O
valproate	-	23	O
to	-	33	O
the	-	36	O
syndrome	-	40	B
of	-	49	I
inappropriate	-	52	I
secretion	-	66	I
of	-	76	I
antidiuretic	-	79	I
hormone	-	92	I
.	-	99	O

We	11195262	101	O
report	-	104	O
the	-	111	O
case	-	115	O
of	-	120	O
a	-	123	O
62	-	125	O
-	-	127	O
year	-	128	O
-	-	132	O
old	-	133	O
man	-	137	O
who	-	141	O
was	-	145	O
administered	-	149	O
sodium	-	162	O
valproate	-	169	O
(	-	179	O
VPA	-	180	O
)	-	183	O
and	-	185	O
who	-	189	O
subsequently	-	193	O
developed	-	206	O
the	-	216	O
syndrome	-	220	B
of	-	229	I
inappropriate	-	232	I
secretion	-	246	I
of	-	256	I
antidiuretic	-	259	I
hormone	-	272	I
(	-	280	O
SIADH	-	281	B
)	-	286	O
.	-	287	O

He	11195262	289	O
had	-	292	O
been	-	296	O
taking	-	301	O
VPA	-	308	O
for	-	312	O
treatment	-	316	O
of	-	326	O
idiopathic	-	329	O
generalized	-	340	O
tonic	-	352	B
-	-	357	I
clonic	-	358	I
convulsions	-	365	I
since	-	377	O
he	-	383	O
was	-	386	O
56	-	390	O
years	-	393	O
old	-	399	O
.	-	402	O

After	11195262	404	O
substituting	-	410	O
VPA	-	423	O
with	-	427	O
zonisamide	-	432	O
,	-	442	O
the	-	444	O
serum	-	448	O
sodium	-	454	O
level	-	461	O
returned	-	467	O
to	-	476	O
normal	-	479	O
.	-	485	O

We	11195262	487	O
consider	-	490	O
this	-	499	O
episode	-	504	O
of	-	512	O
SIADH	-	515	B
to	-	521	O
be	-	524	O
the	-	527	O
result	-	531	O
of	-	538	O
a	-	541	O
combination	-	543	O
of	-	555	O
factors	-	558	O
including	-	566	O
a	-	576	O
weakness	-	578	B
of	-	587	I
the	-	590	I
central	-	594	I
nervous	-	602	I
system	-	610	I
and	-	617	O
the	-	621	O
long	-	625	O
-	-	629	O
term	-	630	O
administration	-	635	O
of	-	650	O
VPA	-	653	O
.	-	656	O

Vasopressin	10728962	0	O
in	-	12	O
the	-	15	O
treatment	-	19	O
of	-	29	O
milrinone	-	32	O
-	-	41	O
induced	-	42	O
hypotension	-	50	B
in	-	62	O
severe	-	65	O
heart	-	72	B
failure	-	78	I
.	-	85	O

The	10728962	87	O
use	-	91	O
of	-	95	O
phosphodiesterase	-	98	O
inhibitors	-	116	O
such	-	127	O
as	-	132	O
milrinone	-	135	O
in	-	145	O
the	-	148	O
treatment	-	152	O
of	-	162	O
severe	-	165	O
heart	-	172	B
failure	-	178	I
is	-	186	O
frequently	-	189	O
restricted	-	200	O
because	-	211	O
they	-	219	O
cause	-	224	O
vasodilation	-	230	O
and	-	243	O
hypotension	-	247	B
.	-	258	O

In	10728962	260	O
patients	-	263	O
with	-	272	O
decompensated	-	277	O
heart	-	291	B
failure	-	297	I
with	-	305	O
hypotension	-	310	B
after	-	322	O
treatment	-	328	O
with	-	338	O
milrinone	-	343	O
,	-	352	O
low	-	354	O
doses	-	358	O
of	-	364	O
vasopressin	-	367	O
restored	-	379	O
blood	-	388	O
pressure	-	394	O
without	-	403	O
inhibiting	-	411	O
the	-	422	O
inotropic	-	426	O
effect	-	436	O
of	-	443	O
milrinone	-	446	O
.	-	455	O

Halogenated	7647582	0	O
anesthetics	-	12	O
form	-	24	O
liver	-	29	O
adducts	-	35	O
and	-	43	O
antigens	-	47	O
that	-	56	O
cross	-	61	O
-	-	66	O
react	-	67	O
with	-	73	O
halothane	-	78	O
-	-	87	O
induced	-	88	O
antibodies	-	96	O
.	-	106	O

Two	7647582	108	O
halogenated	-	112	O
anesthetics	-	124	O
,	-	135	O
enflurane	-	137	O
and	-	147	O
isoflurane	-	151	O
,	-	161	O
have	-	163	O
been	-	168	O
associated	-	173	O
with	-	184	O
an	-	189	O
allergic	-	192	O
-	-	200	O
type	-	201	O
hepatic	-	206	B
injury	-	214	I
both	-	221	O
alone	-	226	O
and	-	232	O
following	-	236	O
previous	-	246	O
exposure	-	255	O
to	-	264	O
halothane	-	267	O
.	-	276	O

Halothane	7647582	278	O
hepatitis	-	288	B
appears	-	298	O
to	-	306	O
involve	-	309	O
an	-	317	O
aberrant	-	320	O
immune	-	329	O
response	-	336	O
.	-	344	O

An	7647582	346	O
antibody	-	349	O
response	-	358	O
to	-	367	O
a	-	370	O
protein	-	372	O
-	-	379	O
bound	-	380	O
biotransformation	-	386	O
product	-	404	O
(	-	412	O
trifluoroacetyl	-	413	O
adduct	-	429	O
)	-	435	O
has	-	437	O
been	-	441	O
detected	-	446	O
on	-	455	O
halothane	-	458	O
hepatitis	-	468	B
patients	-	478	O
.	-	486	O

This	7647582	488	O
study	-	493	O
was	-	499	O
performed	-	503	O
to	-	513	O
determine	-	516	O
cross	-	526	O
-	-	531	O
reactivity	-	532	O
between	-	543	O
enflurane	-	551	O
and	-	561	O
isoflurane	-	565	O
with	-	576	O
the	-	581	O
hypersensitivity	-	585	B
induced	-	602	O
by	-	610	O
halothane	-	613	O
.	-	622	O

The	7647582	624	O
subcellular	-	628	O
and	-	640	O
lobular	-	644	O
production	-	652	O
of	-	663	O
hepatic	-	666	O
neoantigens	-	674	O
recognized	-	686	O
by	-	697	O
halothane	-	700	O
-	-	709	O
induced	-	710	O
antibodies	-	718	O
following	-	729	O
enflurane	-	739	O
and	-	749	O
isoflurane	-	753	O
,	-	763	O
and	-	765	O
the	-	769	O
biochemical	-	773	O
nature	-	785	O
of	-	792	O
these	-	795	O
neoantigens	-	801	O
was	-	813	O
investigated	-	817	O
in	-	830	O
two	-	833	O
animal	-	837	O
models	-	844	O
.	-	850	O

Enflurane	7647582	852	O
administration	-	862	O
resulted	-	877	O
in	-	886	O
neoantigens	-	889	O
detected	-	901	O
in	-	910	O
both	-	913	O
the	-	918	O
microsomal	-	922	O
and	-	933	O
cytosolic	-	937	O
fraction	-	947	O
of	-	956	O
liver	-	959	O
homogenates	-	965	O
and	-	977	O
in	-	981	O
the	-	984	O
centrilobular	-	988	O
region	-	1002	O
of	-	1009	O
the	-	1012	O
liver	-	1016	O
.	-	1021	O

In	7647582	1023	O
the	-	1026	O
same	-	1030	O
liver	-	1035	O
,	-	1040	O
biochemical	-	1042	O
analysis	-	1054	O
detected	-	1063	O
fluorinated	-	1072	O
liver	-	1084	O
adducts	-	1090	O
that	-	1098	O
were	-	1103	O
up	-	1108	O
to	-	1111	O
20	-	1114	O
-	-	1116	O
fold	-	1117	O
greater	-	1122	O
in	-	1130	O
guinea	-	1133	O
pigs	-	1140	O
than	-	1145	O
in	-	1150	O
rats	-	1153	O
.	-	1157	O

This	7647582	1159	O
supports	-	1164	O
and	-	1173	O
extends	-	1177	O
previous	-	1185	O
evidence	-	1194	O
for	-	1203	O
a	-	1207	O
mechanism	-	1209	O
by	-	1219	O
which	-	1222	O
enflurane	-	1228	O
and	-	1238	O
/	-	1241	O
or	-	1242	O
isoflurane	-	1245	O
could	-	1256	O
produce	-	1262	O
a	-	1270	O
hypersensitivity	-	1272	B
condition	-	1289	O
similar	-	1299	O
to	-	1307	O
that	-	1310	O
of	-	1315	O
halothane	-	1318	O
hepatitis	-	1328	B
either	-	1338	O
alone	-	1345	O
or	-	1351	O
subsequent	-	1354	O
to	-	1365	O
halothane	-	1368	O
administration	-	1378	O
.	-	1392	O

The	7647582	1394	O
guinea	-	1398	O
pig	-	1405	O
would	-	1409	O
appear	-	1415	O
to	-	1422	O
be	-	1425	O
a	-	1428	O
useful	-	1430	O
model	-	1437	O
for	-	1443	O
further	-	1447	O
investigations	-	1455	O
of	-	1470	O
the	-	1473	O
immunological	-	1477	O
response	-	1491	O
to	-	1500	O
these	-	1503	O
antigens	-	1509	O
.	-	1517	O

Induction	4090988	0	O
by	-	10	O
paracetamol	-	13	O
of	-	25	O
bladder	-	28	B
and	-	36	I
liver	-	40	I
tumours	-	46	I
in	-	54	O
the	-	57	O
rat	-	61	O
.	-	64	O

Effects	4090988	66	O
on	-	74	O
hepatocyte	-	77	O
fine	-	88	O
structure	-	93	O
.	-	102	O

Groups	4090988	104	O
of	-	111	O
male	-	114	O
and	-	119	O
female	-	123	O
inbred	-	130	O
Leeds	-	137	O
strain	-	143	O
rats	-	150	O
were	-	155	O
fed	-	160	O
diets	-	164	O
containing	-	170	O
either	-	181	O
0	-	188	O
.	-	189	O
5	-	190	O
%	-	191	O
or	-	193	O
1	-	196	O
.	-	197	O
0	-	198	O
%	-	199	O
paracetamol	-	201	O
by	-	213	O
weight	-	216	O
for	-	223	O
up	-	227	O
to	-	230	O
18	-	233	O
months	-	236	O
.	-	242	O

At	4090988	244	O
the	-	247	O
1	-	251	O
.	-	252	O
0	-	253	O
%	-	254	O
dosage	-	256	O
level	-	263	O
,	-	268	O
20	-	270	O
%	-	272	O
of	-	274	O
rats	-	277	O
of	-	282	O
both	-	285	O
sexes	-	290	O
developed	-	296	O
neoplastic	-	306	O
nodules	-	317	O
of	-	325	O
the	-	328	O
liver	-	332	O
,	-	337	O
a	-	339	O
statistically	-	341	O
significant	-	355	O
incidence	-	367	O
.	-	376	O

These	4090988	378	O
rats	-	384	O
also	-	389	O
showed	-	394	O
gross	-	401	O
enlargement	-	407	O
of	-	419	O
their	-	422	O
livers	-	428	O
and	-	435	O
an	-	439	O
increase	-	442	O
in	-	451	O
foci	-	454	O
of	-	459	O
cellular	-	462	O
alteration	-	471	O
,	-	481	O
the	-	483	O
latter	-	487	O
also	-	494	O
being	-	499	O
observed	-	505	O
in	-	514	O
the	-	517	O
low	-	521	O
dosage	-	525	O
male	-	532	O
rats	-	537	O
.	-	541	O

Papillomas	4090988	543	B
of	-	554	O
the	-	557	O
transitional	-	561	O
epithelium	-	574	O
of	-	585	O
the	-	588	O
bladder	-	592	O
developed	-	600	O
in	-	610	O
all	-	613	O
paracetamol	-	617	O
-	-	628	O
treated	-	629	O
groups	-	637	O
,	-	643	O
and	-	645	O
three	-	649	O
rats	-	655	O
bore	-	660	O
bladder	-	665	B
carcinomas	-	673	I
.	-	683	O

However	4090988	685	O
,	-	692	O
significant	-	694	O
yields	-	706	O
of	-	713	O
bladder	-	716	B
tumours	-	724	I
were	-	732	O
only	-	737	O
obtained	-	742	O
from	-	751	O
low	-	756	O
dosage	-	760	O
females	-	767	O
and	-	775	O
high	-	779	O
dosage	-	784	O
males	-	791	O
.	-	796	O

Additionally	4090988	798	O
,	-	810	O
20	-	812	O
to	-	815	O
25	-	818	O
%	-	820	O
of	-	822	O
paracetamol	-	825	O
-	-	836	O
treated	-	837	O
rats	-	845	O
developed	-	850	O
hyperplasia	-	860	B
of	-	872	O
the	-	875	O
bladder	-	879	O
epithelium	-	887	O
,	-	897	O
which	-	899	O
was	-	905	O
not	-	909	O
coincident	-	913	O
with	-	924	O
the	-	929	O
presence	-	933	O
of	-	942	O
bladder	-	945	B
calculi	-	953	I
.	-	960	O

A	4090988	962	O
low	-	964	O
yield	-	968	O
of	-	974	O
tumours	-	977	B
at	-	985	O
various	-	988	O
other	-	996	O
sites	-	1002	O
also	-	1008	O
arose	-	1013	O
following	-	1019	O
paracetamol	-	1029	O
feeding	-	1041	O
.	-	1048	O

An	4090988	1050	O
electron	-	1053	O
microscope	-	1062	O
study	-	1073	O
of	-	1079	O
the	-	1082	O
livers	-	1086	O
of	-	1093	O
paracetamol	-	1096	O
-	-	1107	O
treated	-	1108	O
rats	-	1116	O
revealed	-	1121	O
ultrastructural	-	1130	O
changes	-	1146	O
in	-	1154	O
the	-	1157	O
hepatocytes	-	1161	O
that	-	1173	O
resemble	-	1178	O
those	-	1187	O
that	-	1193	O
result	-	1198	O
from	-	1205	O
exposure	-	1210	O
to	-	1219	O
a	-	1222	O
variety	-	1224	O
of	-	1232	O
known	-	1235	O
hepatocarcinogens	-	1241	B
.	-	1258	O

Rat	4038130	0	O
extraocular	-	4	O
muscle	-	16	O
regeneration	-	23	O
.	-	35	O

Repair	4038130	37	O
of	-	44	O
local	-	47	O
anesthetic	-	53	O
-	-	63	O
induced	-	64	O
damage	-	72	O
.	-	78	O

Local	4038130	80	O
anesthetics	-	86	O
that	-	98	O
are	-	103	O
commonly	-	107	O
used	-	116	O
in	-	121	O
ophthalmic	-	124	O
surgery	-	135	O
(	-	143	O
0	-	144	O
.	-	145	O
75	-	146	O
%	-	148	O
bupivacaine	-	150	O
hydrochloride	-	162	O
,	-	175	O
2	-	177	O
.	-	178	O
0	-	179	O
%	-	180	O
mepivacaine	-	182	O
hydrochloride	-	194	O
,	-	207	O
and	-	209	O
2	-	213	O
.	-	214	O
0	-	215	O
%	-	216	O
lidocaine	-	218	O
hydrochloride	-	228	O
plus	-	242	O
1	-	247	O
:	-	248	O
100	-	249	O
,	-	252	O
000	-	253	O
epinephrine	-	257	O
)	-	268	O
were	-	270	O
injected	-	275	O
into	-	284	O
the	-	289	O
retrobulbar	-	293	O
area	-	305	O
of	-	310	O
rat	-	313	O
eyes	-	317	O
.	-	321	O

Controls	4038130	323	O
were	-	332	O
injected	-	337	O
with	-	346	O
physiological	-	351	O
saline	-	365	O
.	-	371	O

All	4038130	373	O
three	-	377	O
anesthetics	-	383	O
produced	-	395	O
massive	-	404	O
degeneration	-	412	O
of	-	425	O
the	-	428	O
extraocular	-	432	O
muscles	-	444	O
.	-	451	O

Muscle	4038130	453	B
degeneration	-	460	I
is	-	473	O
followed	-	476	O
by	-	485	O
regeneration	-	488	O
of	-	501	O
the	-	504	O
damaged	-	508	O
muscle	-	516	O
fibers	-	523	O
.	-	529	O

In	4038130	531	O
addition	-	534	O
to	-	543	O
muscle	-	546	B
damage	-	553	I
,	-	559	O
severe	-	561	O
damage	-	568	O
was	-	575	O
also	-	579	O
seen	-	584	O
in	-	589	O
harderian	-	592	O
glands	-	602	O
,	-	608	O
especially	-	610	O
after	-	621	O
exposure	-	627	O
to	-	636	O
mepivacaine	-	639	O
and	-	651	O
lidocaine	-	655	O
plus	-	665	O
epinephrine	-	670	O
.	-	681	O

With	4038130	683	O
these	-	688	O
findings	-	694	O
in	-	703	O
rats	-	706	O
,	-	710	O
it	-	712	O
is	-	715	O
hypothesized	-	718	O
that	-	731	O
the	-	736	O
temporary	-	740	O
diplopia	-	750	B
sometimes	-	759	O
seen	-	769	O
in	-	774	O
patients	-	777	O
after	-	786	O
ophthalmic	-	792	O
surgery	-	803	O
might	-	811	O
be	-	817	O
due	-	820	O
to	-	824	O
anesthetic	-	827	O
-	-	837	O
induced	-	838	O
damage	-	846	O
to	-	853	O
the	-	856	O
extraocular	-	860	O
muscles	-	872	O
.	-	879	O

Reversal	2907585	0	O
of	-	9	O
neuroleptic	-	12	O
-	-	23	O
induced	-	24	O
catalepsy	-	32	B
by	-	42	O
novel	-	45	O
aryl	-	51	O
-	-	55	O
piperazine	-	56	O
anxiolytic	-	67	O
drugs	-	78	O
.	-	83	O

The	2907585	85	O
novel	-	89	O
anxiolytic	-	95	O
drug	-	106	O
,	-	110	O
buspirone	-	112	O
,	-	121	O
reverses	-	123	O
catalepsy	-	132	B
induced	-	142	O
by	-	150	O
haloperidol	-	153	O
.	-	164	O

A	2907585	166	O
series	-	168	O
of	-	175	O
aryl	-	178	O
-	-	182	O
piperazine	-	183	O
analogues	-	194	O
of	-	204	O
buspirone	-	207	O
and	-	217	O
other	-	221	O
5	-	227	O
-	-	228	O
hydroxytryptaminergic	-	229	O
agonists	-	251	O
were	-	260	O
tested	-	265	O
for	-	272	O
their	-	276	O
ability	-	282	O
to	-	290	O
reverse	-	293	O
haloperidol	-	301	O
induced	-	313	O
catalepsy	-	321	B
.	-	330	O

Those	2907585	332	O
drugs	-	338	O
with	-	344	O
strong	-	349	O
affinity	-	356	O
for	-	365	O
5	-	369	O
-	-	370	O
hydroxytryptamine1a	-	371	O
receptors	-	391	O
were	-	401	O
able	-	406	O
to	-	411	O
reverse	-	414	O
catalepsy	-	422	B
.	-	431	O

Drugs	2907585	433	O
with	-	439	O
affinity	-	444	O
for	-	453	O
other	-	457	O
5	-	463	O
-	-	464	O
HT	-	465	O
receptors	-	468	O
or	-	478	O
weak	-	481	O
affinity	-	486	O
were	-	495	O
ineffective	-	500	O
.	-	511	O

However	2907585	513	O
,	-	520	O
inhibition	-	522	O
of	-	533	O
postsynaptic	-	536	O
5	-	549	O
-	-	550	O
HT	-	551	O
receptors	-	554	O
neither	-	564	O
inhibited	-	572	O
nor	-	582	O
potentiated	-	586	O
reversal	-	598	O
of	-	607	O
catalepsy	-	610	B
and	-	620	O
leaves	-	624	O
open	-	631	O
the	-	636	O
question	-	640	O
as	-	649	O
to	-	652	O
the	-	655	O
site	-	659	O
or	-	664	O
mechanism	-	667	O
for	-	677	O
this	-	681	O
effect	-	686	O
.	-	692	O

Diazepam	2894433	0	O
facilitates	-	9	O
reflex	-	21	O
bradycardia	-	28	B
in	-	40	O
conscious	-	43	O
rats	-	53	O
.	-	57	O

The	2894433	59	O
effects	-	63	O
of	-	71	O
diazepam	-	74	O
on	-	83	O
cardiovascular	-	86	O
function	-	101	O
were	-	110	O
assessed	-	115	O
in	-	124	O
conscious	-	127	O
rats	-	137	O
.	-	141	O

Intravenous	2894433	143	O
administration	-	155	O
of	-	170	O
diazepam	-	173	O
(	-	182	O
1	-	183	O
-	-	184	O
30	-	185	O
mg	-	188	O
kg	-	191	O
-	-	193	O
1	-	194	O
)	-	195	O
produced	-	197	O
a	-	206	O
dose	-	208	O
-	-	212	O
dependent	-	213	O
decrease	-	223	O
in	-	232	O
both	-	235	O
the	-	240	O
mean	-	244	O
arterial	-	249	O
pressure	-	258	O
and	-	267	O
the	-	271	O
heart	-	275	O
rate	-	281	O
.	-	285	O

Also	2894433	287	O
,	-	291	O
reflex	-	293	O
bradycardia	-	300	B
was	-	312	O
produced	-	316	O
in	-	325	O
rats	-	328	O
by	-	333	O
intravenous	-	336	O
infusion	-	348	O
of	-	357	O
adrenaline	-	360	O
(	-	371	O
1	-	372	O
.	-	373	O
25	-	374	O
-	-	376	O
2	-	377	O
.	-	378	O
5	-	379	O
micrograms	-	381	O
kg	-	392	O
-	-	394	O
1	-	395	O
)	-	396	O
.	-	397	O

Intravenous	2894433	399	O
pretreatment	-	411	O
of	-	424	O
the	-	427	O
rats	-	431	O
with	-	436	O
diazepam	-	441	O
,	-	449	O
although	-	451	O
causing	-	460	O
no	-	468	O
change	-	471	O
in	-	478	O
the	-	481	O
adrenaline	-	485	O
-	-	495	O
induced	-	496	O
pressor	-	504	O
effect	-	512	O
,	-	518	O
did	-	520	O
enhance	-	524	O
the	-	532	O
adrenaline	-	536	O
-	-	546	O
induced	-	547	O
reflex	-	555	O
bradycardia	-	562	B
.	-	573	O

However	2894433	575	O
,	-	582	O
the	-	584	O
diazepam	-	588	O
enhancement	-	597	O
of	-	609	O
adrenaline	-	612	O
-	-	622	O
induced	-	623	O
reflex	-	631	O
bradycardia	-	638	B
was	-	650	O
antagonized	-	654	O
by	-	666	O
pretreatment	-	669	O
of	-	682	O
rats	-	685	O
with	-	690	O
an	-	695	O
intravenous	-	698	O
dose	-	710	O
of	-	715	O
picrotoxin	-	718	O
(	-	729	O
an	-	730	O
agent	-	733	O
blocks	-	739	O
chloride	-	746	O
channels	-	755	O
by	-	764	O
binding	-	767	O
to	-	775	O
sites	-	778	O
associated	-	784	O
with	-	795	O
the	-	800	O
benzodiazepine	-	804	O
-	-	818	O
GABA	-	819	O
-	-	823	O
chloride	-	824	O
channel	-	833	O
macromolecular	-	841	O
complex	-	856	O
)	-	863	O
.	-	864	O

The	2894433	866	O
data	-	870	O
indicate	-	875	O
that	-	884	O
diazepam	-	889	O
acts	-	898	O
through	-	903	O
the	-	911	O
benzodiazepine	-	915	O
-	-	929	O
GABA	-	930	O
-	-	934	O
chloride	-	935	O
channel	-	944	O
macromolecular	-	952	O
complex	-	967	O
within	-	975	O
the	-	982	O
central	-	986	O
nervous	-	994	O
system	-	1002	O
to	-	1009	O
facilitate	-	1012	O
reflex	-	1023	O
bradycardia	-	1030	B
mediated	-	1042	O
through	-	1051	O
baroreceptor	-	1059	O
reflexes	-	1072	O
in	-	1081	O
response	-	1084	O
to	-	1093	O
an	-	1096	O
acute	-	1099	O
increase	-	1105	O
in	-	1114	O
arterial	-	1117	O
pressure	-	1126	O
.	-	1134	O

Chronic	2790457	0	O
carbamazepine	-	8	O
inhibits	-	22	O
the	-	31	O
development	-	35	O
of	-	47	O
local	-	50	O
anesthetic	-	56	O
seizures	-	67	B
kindled	-	76	O
by	-	84	O
cocaine	-	87	O
and	-	95	O
lidocaine	-	99	O
.	-	108	O

The	2790457	110	O
effects	-	114	O
of	-	122	O
carbamazepine	-	125	O
(	-	139	O
CBZ	-	140	O
)	-	143	O
treatment	-	145	O
on	-	155	O
local	-	158	O
anesthetic	-	164	O
-	-	174	O
kindled	-	175	O
seizures	-	183	B
and	-	192	O
lethality	-	196	O
were	-	206	O
evaluated	-	211	O
in	-	221	O
different	-	224	O
stages	-	234	O
of	-	241	O
the	-	244	O
kindling	-	248	O
process	-	257	O
and	-	265	O
under	-	269	O
different	-	275	O
methods	-	285	O
of	-	293	O
CBZ	-	296	O
administration	-	300	O
.	-	314	O

Chronic	2790457	316	O
oral	-	324	O
CBZ	-	329	O
inhibited	-	333	O
the	-	343	O
development	-	347	O
of	-	359	O
both	-	362	O
lidocaine	-	367	O
-	-	376	O
and	-	378	O
cocaine	-	382	O
-	-	389	O
induced	-	390	O
seizures	-	398	B
,	-	406	O
but	-	408	O
had	-	412	O
little	-	416	O
effect	-	423	O
on	-	430	O
the	-	433	O
fully	-	437	O
developed	-	443	O
local	-	453	O
anesthetic	-	459	O
seizures	-	470	B
.	-	478	O

Chronic	2790457	480	O
CBZ	-	488	O
also	-	492	O
decreased	-	497	O
the	-	507	O
incidence	-	511	O
of	-	521	O
seizure	-	524	B
-	-	531	O
related	-	532	O
mortality	-	540	O
in	-	550	O
the	-	553	O
cocaine	-	557	O
-	-	564	O
injected	-	565	O
rats	-	574	O
.	-	578	O

Acute	2790457	580	O
CBZ	-	586	O
over	-	590	O
a	-	595	O
range	-	597	O
of	-	603	O
doses	-	606	O
(	-	612	O
15	-	613	O
-	-	615	O
50	-	616	O
mg	-	619	O
/	-	621	O
kg	-	622	O
)	-	624	O
had	-	626	O
no	-	630	O
effect	-	633	O
on	-	640	O
completed	-	643	O
lidocaine	-	653	O
-	-	662	O
kindled	-	663	O
or	-	671	O
acute	-	674	O
cocaine	-	680	O
-	-	687	O
induced	-	688	O
seizures	-	696	B
.	-	704	O

Repeated	2790457	706	O
i	-	715	O
.	-	716	O
p	-	717	O
.	-	718	O

injection	2790457	720	O
of	-	730	O
CBZ	-	733	O
(	-	737	O
15	-	738	O
mg	-	741	O
/	-	743	O
kg	-	744	O
)	-	746	O
also	-	748	O
was	-	753	O
without	-	757	O
effect	-	765	O
on	-	772	O
the	-	775	O
development	-	779	O
of	-	791	O
lidocaine	-	794	O
-	-	803	O
or	-	805	O
cocaine	-	808	O
-	-	815	O
kindled	-	816	O
seizures	-	824	B
.	-	832	O

The	2790457	834	O
differential	-	838	O
effects	-	851	O
of	-	859	O
CBZ	-	862	O
depending	-	866	O
upon	-	876	O
stage	-	881	O
of	-	887	O
seizure	-	890	B
development	-	898	O
suggest	-	910	O
that	-	918	O
distinct	-	923	O
mechanisms	-	932	O
underlie	-	943	O
the	-	952	O
development	-	956	O
versus	-	968	O
maintenance	-	975	O
of	-	987	O
local	-	990	O
anesthetic	-	996	O
-	-	1006	O
kindled	-	1007	O
seizures	-	1015	B
.	-	1023	O

The	2790457	1025	O
effectiveness	-	1029	O
of	-	1043	O
chronic	-	1046	O
but	-	1054	O
not	-	1058	O
repeated	-	1062	O
,	-	1070	O
intermittent	-	1072	O
injections	-	1085	O
of	-	1096	O
CBZ	-	1099	O
suggests	-	1103	O
that	-	1112	O
different	-	1117	O
biochemical	-	1127	O
consequences	-	1139	O
result	-	1152	O
from	-	1159	O
the	-	1164	O
different	-	1168	O
treatment	-	1178	O
regimens	-	1188	O
.	-	1196	O

The	2790457	1198	O
possible	-	1202	O
utility	-	1211	O
of	-	1219	O
chronic	-	1222	O
CBZ	-	1230	O
in	-	1234	O
preventing	-	1237	O
the	-	1248	O
development	-	1252	O
of	-	1264	O
toxic	-	1267	O
side	-	1273	O
effects	-	1278	O
in	-	1286	O
human	-	1289	O
cocaine	-	1295	O
users	-	1303	O
is	-	1309	O
suggested	-	1312	O
by	-	1322	O
these	-	1325	O
data	-	1331	O
,	-	1335	O
but	-	1337	O
remains	-	1341	O
to	-	1349	O
be	-	1352	O
directly	-	1355	O
evaluated	-	1364	O
.	-	1373	O

D	2334179	0	O
-	-	1	O
penicillamine	-	2	O
in	-	16	O
the	-	19	O
treatment	-	23	O
of	-	33	O
localized	-	36	B
scleroderma	-	46	I
.	-	57	O

Localized	2334179	59	B
scleroderma	-	69	I
has	-	81	O
no	-	85	O
recognized	-	88	O
internal	-	99	O
organ	-	108	O
involvement	-	114	O
but	-	126	O
may	-	130	O
be	-	134	O
disfiguring	-	137	O
and	-	149	O
disabling	-	153	O
when	-	163	O
the	-	168	O
cutaneous	-	172	O
lesions	-	182	O
are	-	190	O
extensive	-	194	O
or	-	204	O
affect	-	207	O
children	-	214	O
.	-	222	O

There	2334179	224	O
is	-	230	O
no	-	233	O
accepted	-	236	O
or	-	245	O
proven	-	248	O
treatment	-	255	O
for	-	265	O
localized	-	269	B
scleroderma	-	279	I
.	-	290	O

Case	2334179	292	O
reports	-	297	O
of	-	305	O
11	-	308	O
patients	-	311	O
with	-	320	O
severe	-	325	O
,	-	331	O
extensive	-	333	O
localized	-	343	B
scleroderma	-	353	I
who	-	365	O
were	-	369	O
treated	-	374	O
with	-	382	O
D	-	387	O
-	-	388	O
penicillamine	-	389	O
are	-	403	O
summarized	-	407	O
in	-	418	O
this	-	421	O
article	-	426	O
.	-	433	O

This	2334179	435	O
drug	-	440	O
was	-	445	O
judged	-	449	O
to	-	456	O
have	-	459	O
a	-	464	O
favorable	-	466	O
effect	-	476	O
on	-	483	O
the	-	486	O
disease	-	490	O
course	-	498	O
in	-	505	O
7	-	508	O
(	-	510	O
64	-	511	O
%	-	513	O
)	-	514	O
of	-	516	O
11	-	519	O
patients	-	522	O
.	-	530	O

Improvement	2334179	532	O
began	-	544	O
within	-	550	O
3	-	557	O
to	-	559	O
6	-	562	O
months	-	564	O
and	-	571	O
consisted	-	575	O
of	-	585	O
cessation	-	588	O
of	-	598	O
active	-	601	O
cutaneous	-	608	O
lesions	-	618	O
in	-	626	O
all	-	629	O
7	-	633	O
patients	-	635	O
,	-	643	O
skin	-	645	O
softening	-	650	O
in	-	660	O
5	-	663	O
,	-	664	O
and	-	666	O
more	-	670	O
normal	-	675	O
growth	-	682	O
of	-	689	O
the	-	692	O
affected	-	696	O
limb	-	705	O
in	-	710	O
2	-	713	O
of	-	715	O
3	-	718	O
children	-	720	O
.	-	728	O

Joint	2334179	730	O
stiffness	-	736	O
and	-	746	O
contractures	-	750	B
also	-	763	O
improved	-	768	O
.	-	776	O

The	2334179	778	O
dose	-	782	O
of	-	787	O
D	-	790	O
-	-	791	O
penicillamine	-	792	O
associated	-	806	O
with	-	817	O
a	-	822	O
favorable	-	824	O
response	-	834	O
was	-	843	O
as	-	847	O
low	-	850	O
as	-	854	O
2	-	857	O
to	-	859	O
5	-	862	O
mg	-	864	O
/	-	866	O
kg	-	867	O
per	-	870	O
day	-	874	O
given	-	878	O
over	-	884	O
a	-	889	O
period	-	891	O
ranging	-	898	O
from	-	906	O
15	-	911	O
to	-	914	O
53	-	917	O
months	-	920	O
.	-	926	O

D	2334179	928	O
-	-	929	O
Penicillamine	-	930	O
caused	-	944	O
nephrotic	-	951	B
syndrome	-	961	I
in	-	970	O
1	-	973	O
patient	-	975	O
and	-	983	O
milder	-	987	O
reversible	-	994	O
proteinuria	-	1005	B
in	-	1017	O
3	-	1020	O
other	-	1022	O
patients	-	1028	O
;	-	1036	O
none	-	1038	O
developed	-	1043	O
renal	-	1053	B
insufficiency	-	1059	I
.	-	1072	O

These	2334179	1074	O
data	-	1080	O
suggest	-	1085	O
that	-	1093	O
D	-	1098	O
-	-	1099	O
penicillamine	-	1100	O
may	-	1114	O
be	-	1118	O
effective	-	1121	O
in	-	1131	O
severe	-	1134	O
cases	-	1141	O
of	-	1147	O
localized	-	1150	B
scleroderma	-	1160	I
.	-	1171	O

Preservation	1969772	0	O
of	-	13	O
renal	-	16	O
blood	-	22	O
flow	-	28	O
during	-	33	O
hypotension	-	40	B
induced	-	52	O
with	-	60	O
fenoldopam	-	65	O
in	-	76	O
dogs	-	79	O
.	-	83	O

The	1969772	85	O
introduction	-	89	O
of	-	102	O
drugs	-	105	O
that	-	111	O
could	-	116	O
induce	-	122	O
hypotension	-	129	B
with	-	141	O
different	-	146	O
pharmacological	-	156	O
actions	-	172	O
would	-	180	O
be	-	186	O
advantageous	-	189	O
because	-	202	O
side	-	210	O
effects	-	215	O
unique	-	223	O
to	-	230	O
a	-	233	O
specific	-	235	O
drug	-	244	O
could	-	249	O
be	-	255	O
minimized	-	258	O
by	-	268	O
selecting	-	271	O
appropriate	-	281	O
therapy	-	293	O
.	-	300	O

Specific	1969772	302	O
dopamine	-	311	O
-	-	319	O
1	-	320	O
,	-	321	O
(	-	323	O
DA1	-	324	O
)	-	327	O
and	-	329	O
dopamine	-	333	O
-	-	341	O
2	-	342	O
(	-	344	O
DA2	-	345	O
)	-	348	O
receptor	-	350	O
agonists	-	359	O
are	-	368	O
now	-	372	O
under	-	376	O
clinical	-	382	O
investigation	-	391	O
.	-	404	O

Fenoldopam	1969772	406	O
mesylate	-	417	O
is	-	426	O
a	-	429	O
specific	-	431	O
DA1	-	440	O
receptor	-	444	O
agonist	-	453	O
that	-	461	O
lowers	-	466	O
blood	-	473	O
pressure	-	479	O
by	-	488	O
vasodilatation	-	491	O
.	-	505	O

The	1969772	507	O
hypothesis	-	511	O
that	-	522	O
fenoldopam	-	527	O
could	-	538	O
be	-	544	O
used	-	547	O
to	-	552	O
induce	-	555	O
hypotension	-	562	B
and	-	574	O
preserve	-	578	O
blood	-	587	O
flow	-	593	O
to	-	598	O
the	-	601	O
kidney	-	605	O
was	-	612	O
tested	-	616	O
.	-	622	O

Systemic	1969772	624	O
aortic	-	633	O
blood	-	640	O
pressure	-	646	O
and	-	655	O
renal	-	659	O
blood	-	665	O
flow	-	671	O
were	-	676	O
measured	-	681	O
continuously	-	690	O
with	-	703	O
a	-	708	O
carotid	-	710	O
arterial	-	718	O
catheter	-	727	O
and	-	736	O
an	-	740	O
electromagnetic	-	743	O
flow	-	759	O
probe	-	764	O
respectively	-	770	O
,	-	782	O
in	-	784	O
order	-	787	O
to	-	793	O
compare	-	796	O
the	-	804	O
cardiovascular	-	808	O
and	-	823	O
renal	-	827	O
vascular	-	833	O
effects	-	842	O
of	-	850	O
fenoldopam	-	853	O
and	-	864	O
sodium	-	868	O
nitroprusside	-	875	O
in	-	889	O
ten	-	892	O
dogs	-	896	O
under	-	901	O
halothane	-	907	O
general	-	917	O
anaesthesia	-	925	O
.	-	936	O

Mean	1969772	938	O
arterial	-	943	O
pressure	-	952	O
was	-	961	O
decreased	-	965	O
30	-	975	O
+	-	978	O
/	-	979	O
-	-	980	O

8	1969772	982	O
per	-	984	O
cent	-	988	O
from	-	993	O
control	-	998	O
with	-	1006	O
infusion	-	1011	O
of	-	1020	O
fenoldopam	-	1023	O
(	-	1034	O
3	-	1035	O
.	-	1036	O
4	-	1037	O
+	-	1039	O
/	-	1040	O
-	-	1041	O
2	-	1043	O
.	-	1044	O
0	-	1045	O
micrograms	-	1047	O
.	-	1057	O
kg	-	1058	O
-	-	1060	O
1	-	1061	O
.	-	1062	O
min	-	1063	O
-	-	1066	O
1	-	1067	O
)	-	1068	O
and	-	1070	O
34	-	1074	O
+	-	1077	O
/	-	1078	O
-	-	1079	O
4	-	1081	O
per	-	1083	O
cent	-	1087	O
with	-	1092	O
infusion	-	1097	O
of	-	1106	O
sodium	-	1109	O
nitroprusside	-	1116	O
(	-	1130	O
5	-	1131	O
.	-	1132	O
9	-	1133	O
micrograms	-	1135	O
.	-	1145	O
kg	-	1146	O
-	-	1148	O
1	-	1149	O
.	-	1150	O
min	-	1151	O
-	-	1154	O
1	-	1155	O
)	-	1156	O
(	-	1158	O
NS	-	1159	O
)	-	1161	O
.	-	1162	O

Renal	1969772	1164	O
blood	-	1170	O
flow	-	1176	O
(	-	1181	O
RBF	-	1182	O
)	-	1185	O
increased	-	1187	O
during	-	1197	O
fenoldopam	-	1204	O
-	-	1214	O
induced	-	1215	O
hypotension	-	1223	B
11	-	1235	O
+	-	1238	O
/	-	1239	O
-	-	1240	O

7	1969772	1242	O
per	-	1244	O
cent	-	1248	O
and	-	1253	O
decreased	-	1257	O
21	-	1267	O
+	-	1270	O
/	-	1271	O
-	-	1272	O

8	1969772	1274	O
per	-	1276	O
cent	-	1280	O
during	-	1285	O
sodium	-	1292	O
nitroprusside	-	1299	O
-	-	1312	O
induced	-	1313	O
hypotension	-	1321	B
(	-	1333	O
P	-	1334	O
less	-	1336	O
than	-	1341	O
0	-	1346	O
.	-	1347	O
01	-	1348	O
)	-	1350	O
.	-	1351	O

Sodium	1969772	1353	O
nitroprusside	-	1360	O
is	-	1374	O
a	-	1377	O
non	-	1379	O
-	-	1382	O
selective	-	1383	O
arteriolar	-	1393	O
and	-	1404	O
venous	-	1408	O
vasodilator	-	1415	O
that	-	1427	O
can	-	1432	O
produce	-	1436	O
redistribution	-	1444	O
of	-	1459	O
blood	-	1462	O
flow	-	1468	O
away	-	1473	O
from	-	1478	O
the	-	1483	O
kidney	-	1487	O
during	-	1494	O
induced	-	1501	O
hypotension	-	1509	B
.	-	1520	O

Fenoldopam	1969772	1522	O
is	-	1533	O
a	-	1536	O
selective	-	1538	O
dopamine	-	1548	O
-	-	1556	O
1	-	1557	O
(	-	1559	O
DA1	-	1560	O
)	-	1563	O
receptor	-	1565	O
agonist	-	1574	O
that	-	1582	O
causes	-	1587	O
vasodilatation	-	1594	O
to	-	1609	O
the	-	1612	O
kidney	-	1616	O
and	-	1623	O
other	-	1627	O
organs	-	1633	O
with	-	1640	O
DA1	-	1645	O
receptors	-	1649	O
and	-	1659	O
preserves	-	1663	O
blood	-	1673	O
flow	-	1679	O
to	-	1684	O
the	-	1687	O
kidney	-	1691	O
during	-	1698	O
induced	-	1705	O
hypotension	-	1713	B
.	-	1724	O

Antiarrhythmic	1700207	0	O
effects	-	15	O
of	-	23	O
optical	-	26	O
isomers	-	34	O
of	-	42	O
cibenzoline	-	45	O
on	-	57	O
canine	-	60	O
ventricular	-	67	B
arrhythmias	-	79	I
.	-	90	O

Antiarrhythmic	1700207	92	O
effects	-	107	O
of	-	115	O
(	-	118	O
+	-	119	O
)	-	120	O
-	-	121	O
cibenzoline	-	122	O

and	1700207	134	O
(	-	138	O
-	-	139	O
)	-	140	O
-	-	141	O
cibenzoline	-	142	O
were	-	154	O
examined	-	159	O
using	-	168	O
two	-	174	O
canine	-	178	O
ventricular	-	185	B
arrhythmia	-	197	I
models	-	208	O
.	-	214	O

Digitalis	1700207	216	O
arrhythmia	-	226	B
,	-	236	O
which	-	238	O
is	-	244	O
suppressed	-	247	O
by	-	258	O
Na	-	261	O
channel	-	264	O
blockers	-	272	O
,	-	280	O
was	-	282	O
induced	-	286	O
by	-	294	O
intermittent	-	297	O
intravenous	-	310	O
(	-	322	O
i	-	323	O
.	-	324	O
v	-	325	O
.	-	326	O
)	-	327	O

injection	1700207	329	O
of	-	339	O
ouabain	-	342	O
in	-	350	O
pentobarbital	-	353	O
-	-	366	O
anesthetized	-	367	O
dogs	-	380	O
.	-	384	O

Adrenaline	1700207	386	B
arrhythmia	-	397	I
,	-	407	O
which	-	409	O
is	-	415	O
suppressed	-	418	O
by	-	429	O
Ca	-	432	O
channel	-	435	O
blockers	-	443	O
,	-	451	O
was	-	453	O
induced	-	457	O
by	-	465	O
adrenaline	-	468	O
infusion	-	479	O
in	-	488	O
halothane	-	491	O
-	-	500	O
anesthetized	-	501	O
dogs	-	514	O
.	-	518	O

Ten	1700207	520	O
and	-	524	O
5	-	528	O
mg	-	530	O
/	-	532	O
kg	-	533	O
i	-	536	O
.	-	537	O
v	-	538	O
.	-	539	O

(	1700207	541	O
+	-	542	O
)	-	543	O
-	-	544	O
cibenzoline	-	545	O
suppressed	-	557	O
digitalis	-	568	O
-	-	577	O
and	-	579	O
adrenaline	-	583	O
-	-	593	O
induced	-	594	O
arrhythmias	-	602	B
,	-	613	O
respectively	-	615	O
.	-	627	O

The	1700207	629	O
minimum	-	633	O
effective	-	641	O
plasma	-	651	O
concentrations	-	658	O
of	-	673	O
(	-	676	O
+	-	677	O
)	-	678	O
-	-	679	O
cibenzoline	-	680	O
for	-	692	O
digitalis	-	696	O
-	-	705	O
and	-	707	O
adrenaline	-	711	O
-	-	721	O
induced	-	722	O
arrhythmias	-	730	B
were	-	742	O
1	-	747	O
.	-	748	O
4	-	749	O
+	-	751	O
/	-	752	O
-	-	753	O

0	1700207	755	O
.	-	756	O
4	-	757	O
and	-	759	O
2	-	763	O
.	-	764	O
0	-	765	O
+	-	767	O
/	-	768	O
-	-	769	O

0	1700207	771	O
.	-	772	O
6	-	773	O
micrograms	-	775	O
/	-	785	O
ml	-	786	O
,	-	788	O
respectively	-	790	O
(	-	803	O
mean	-	804	O
+	-	809	O
/	-	810	O
-	-	811	O

SD	1700207	813	O
,	-	815	O
n	-	817	O
=	-	819	O
6	-	821	O
)	-	822	O
.	-	823	O

A	1700207	825	O
lower	-	827	O
dose	-	833	O
of	-	838	O
1	-	841	O
mg	-	843	O
/	-	845	O
kg	-	846	O
i	-	849	O
.	-	850	O
v	-	851	O
.	-	852	O

of	1700207	854	O
(	-	857	O
-	-	858	O
)	-	859	O
-	-	860	O
cibenzoline	-	861	O
suppressed	-	873	O
the	-	884	O
digitalis	-	888	O
-	-	897	O
induced	-	898	O
arrhythmia	-	906	B
,	-	916	O
whereas	-	918	O
5	-	926	O
mg	-	928	O
/	-	930	O
kg	-	931	O
i	-	934	O
.	-	935	O
v	-	936	O
.	-	937	O
was	-	939	O
needed	-	943	O
to	-	950	O
suppress	-	953	O
adrenaline	-	962	O
-	-	972	O
induced	-	973	O
arrhythmias	-	981	B
.	-	992	O

The	1700207	994	O
minimum	-	998	O
effective	-	1006	O
plasma	-	1016	O
concentrations	-	1023	O
of	-	1038	O
(	-	1041	O
-	-	1042	O
)	-	1043	O
-	-	1044	O
cibenzoline	-	1045	O
for	-	1057	O
digitalis	-	1061	O
-	-	1070	O
and	-	1072	O
adrenaline	-	1076	O
-	-	1086	O
induced	-	1087	O
arrhythmia	-	1095	B
were	-	1106	O
0	-	1111	O
.	-	1112	O
06	-	1113	O
+	-	1116	O
/	-	1117	O
-	-	1118	O

0	1700207	1120	O
.	-	1121	O
04	-	1122	O
and	-	1125	O
0	-	1129	O
.	-	1130	O
7	-	1131	O
+	-	1133	O
/	-	1134	O
-	-	1135	O
0	-	1137	O
.	-	1138	O
1	-	1139	O
micrograms	-	1141	O
/	-	1151	O
ml	-	1152	O
,	-	1154	O
respectively	-	1156	O
(	-	1169	O
mean	-	1170	O
+	-	1175	O
/	-	1176	O
-	-	1177	O

SD	1700207	1179	O
,	-	1181	O
n	-	1183	O
=	-	1185	O
6	-	1187	O
)	-	1188	O
.	-	1189	O

The	1700207	1191	O
stronger	-	1195	O
antiarrhythmic	-	1204	O
effect	-	1219	O
of	-	1226	O
(	-	1229	O
-	-	1230	O
)	-	1231	O
-	-	1232	O
cibenzoline	-	1233	O
indicates	-	1245	O
that	-	1255	O
(	-	1260	O
-	-	1261	O
)	-	1262	O
-	-	1263	O
isomer	-	1264	O
may	-	1271	O
have	-	1275	O
an	-	1280	O
effect	-	1283	O
nearly	-	1290	O
5	-	1297	O
-	-	1298	O
20	-	1299	O
times	-	1302	O
stronger	-	1308	O
in	-	1317	O
suppressing	-	1320	O
Na	-	1332	O
channels	-	1335	O
,	-	1343	O
but	-	1345	O
effects	-	1349	O
of	-	1357	O
both	-	1360	O
drugs	-	1365	O
on	-	1371	O
Ca	-	1374	O
channels	-	1377	O
may	-	1386	O
be	-	1390	O
almost	-	1393	O
equipotent	-	1400	O
.	-	1410	O

Effect	19761039	0	O
of	-	7	O
Hibiscus	-	10	O
rosa	-	19	O
sinensis	-	24	O
on	-	33	O
reserpine	-	36	O
-	-	45	O
induced	-	46	O
neurobehavioral	-	54	O
and	-	70	O
biochemical	-	74	O
alterations	-	86	O
in	-	98	O
rats	-	101	O
.	-	105	O

Effect	19761039	107	O
of	-	114	O
methanolic	-	117	O
extract	-	128	O
of	-	136	O
Hibiscus	-	139	O
rosa	-	148	O
sinensis	-	153	O
(	-	162	O
100	-	163	O
-	-	166	O
300	-	167	O
mg	-	171	O
/	-	173	O
kg	-	174	O
)	-	176	O
was	-	178	O
studied	-	182	O
on	-	190	O
reserpine	-	193	O
-	-	202	O
induced	-	203	O
orofacial	-	211	O
dyskinesia	-	221	B
and	-	232	O
neurochemical	-	236	O
alterations	-	250	O
.	-	261	O

The	19761039	263	O
rats	-	267	O
were	-	272	O
treated	-	277	O
with	-	285	O
intraperitoneal	-	290	O
reserpine	-	306	O
(	-	316	O
1	-	317	O
mg	-	319	O
/	-	321	O
kg	-	322	O
,	-	324	O
ip	-	326	O
)	-	328	O
for	-	330	O
3	-	334	O
days	-	336	O
every	-	341	O
other	-	347	O
day	-	353	O
.	-	356	O

On	19761039	358	O
day	-	361	O
5	-	365	O
,	-	366	O
vacuous	-	368	O
chewing	-	376	O
movements	-	384	O
and	-	394	O
tongue	-	398	O
protrusions	-	405	O
were	-	417	O
counted	-	422	O
for	-	430	O
5	-	434	O
min	-	436	O
.	-	439	O

Reserpine	19761039	441	O
treated	-	451	O
rats	-	459	O
significantly	-	464	O
developed	-	478	O
vacuous	-	488	O
chewing	-	496	O
movements	-	504	O
and	-	514	O
tongue	-	518	O
protrusions	-	525	O
however	-	537	O
,	-	544	O
coadministration	-	546	O
of	-	563	O
Hibiscus	-	566	O
rosa	-	575	O
sinensis	-	580	O
roots	-	589	O
extract	-	595	O
(	-	603	O
100	-	604	O
,	-	607	O
200	-	609	O
and	-	613	O
300	-	617	O
mg	-	621	O
/	-	623	O
kg	-	624	O
,	-	626	O
per	-	628	O
orally	-	632	O
)	-	638	O
attenuated	-	640	O
the	-	651	O
effects	-	655	O
.	-	662	O

Biochemical	19761039	664	O
analysis	-	676	O
of	-	685	O
brain	-	688	O
revealed	-	694	O
that	-	703	O
the	-	708	O
reserpine	-	712	O
treatment	-	722	O
significantly	-	732	O
increased	-	746	O
lipid	-	756	O
peroxidation	-	762	O
and	-	775	O
decreased	-	779	O
levels	-	789	O
of	-	796	O
superoxide	-	799	O
dismutase	-	810	O
(	-	820	O
SOD	-	821	O
)	-	824	O
,	-	825	O
catalase	-	827	O
(	-	836	O
CAT	-	837	O
)	-	840	O
and	-	842	O
glutathione	-	846	O
reductase	-	858	O
(	-	868	O
GSH	-	869	O
)	-	872	O
,	-	873	O
an	-	875	O
index	-	878	O
of	-	884	O
oxidative	-	887	O
stress	-	897	O
process	-	904	O
.	-	911	O

Coadministration	19761039	913	O
of	-	930	O
extract	-	933	O
significantly	-	941	O
reduced	-	955	O
the	-	963	O
lipid	-	967	O
peroxidation	-	973	O
and	-	986	O
reversed	-	990	O
the	-	999	O
decrease	-	1003	O
in	-	1012	O
brain	-	1015	O
SOD	-	1021	O
,	-	1024	O
CAT	-	1026	O
and	-	1030	O
GSH	-	1034	O
levels	-	1038	O
.	-	1044	O

The	19761039	1046	O
results	-	1050	O
of	-	1058	O
the	-	1061	O
present	-	1065	O
study	-	1073	O
suggested	-	1079	O
that	-	1089	O
Hibiscus	-	1094	O
rosa	-	1103	O
sinensis	-	1108	O
had	-	1117	O
a	-	1121	O
protective	-	1123	O
role	-	1134	O
against	-	1139	O
reserpine	-	1147	O
-	-	1156	O
induced	-	1157	O
orofacial	-	1165	O
dyskinesia	-	1175	B
and	-	1186	O
oxidative	-	1190	O
stress	-	1200	O
.	-	1206	O

Comparison	11704023	0	O
of	-	11	O
aqueous	-	14	O
and	-	22	O
gellan	-	26	O
ophthalmic	-	33	O
timolol	-	44	O
with	-	52	O
placebo	-	57	O
on	-	65	O
the	-	68	O
24	-	72	O
-	-	74	O
hour	-	75	O
heart	-	80	O
rate	-	86	O
response	-	91	O
in	-	100	O
patients	-	103	O
on	-	112	O
treatment	-	115	O
for	-	125	O
glaucoma	-	129	B
.	-	137	O

PURPOSE	11704023	139	O
:	-	146	O

Topical	11704023	148	O
beta	-	156	O
-	-	160	O
blocker	-	161	O
treatment	-	169	O
is	-	179	O
routine	-	182	O
therapy	-	190	O
in	-	198	O
the	-	201	O
management	-	205	O
of	-	216	O
patients	-	219	O
with	-	228	O
glaucoma	-	233	B
.	-	241	O

Therapy	11704023	243	O
results	-	251	O
in	-	259	O
systemic	-	262	O
absorption	-	271	O
,	-	281	O
however	-	283	O
,	-	290	O
the	-	292	O
degree	-	296	O
of	-	303	O
reduction	-	306	O
of	-	316	O
resting	-	319	O
and	-	327	O
peak	-	331	O
heart	-	336	O
rate	-	342	O
has	-	347	O
not	-	351	O
been	-	355	O
quantified	-	360	O
.	-	370	O

DESIGN	11704023	372	O
:	-	378	O

This	11704023	380	O
trial	-	385	O
evaluated	-	391	O
the	-	401	O
effect	-	405	O
of	-	412	O
placebo	-	415	O
,	-	422	O
0	-	424	O
.	-	425	O
5	-	426	O
%	-	427	O
aqueous	-	429	O
timolol	-	437	O
(	-	445	O
timolol	-	446	O
solution	-	454	O
)	-	462	O
and	-	464	O
a	-	468	O
0	-	470	O
.	-	471	O
5	-	472	O
%	-	473	O
timolol	-	475	O
suspension	-	483	O
that	-	494	O
forms	-	499	O
a	-	505	O
gel	-	507	O
on	-	511	O
application	-	514	O
to	-	526	O
the	-	529	O
conjunctiva	-	533	O
(	-	545	O
timolol	-	546	O
gellan	-	554	O
)	-	560	O
on	-	562	O
the	-	565	O
24	-	569	O
-	-	571	O
hour	-	572	O
heart	-	577	O
rate	-	583	O
in	-	588	O
patients	-	591	O
currently	-	600	O
being	-	610	O
treated	-	616	O
for	-	624	O
glaucoma	-	628	B
to	-	637	O
quantify	-	640	O
the	-	649	O
reduction	-	653	O
in	-	663	O
mean	-	666	O
heart	-	671	O
rate	-	677	O
.	-	681	O

METHODS	11704023	683	O
:	-	690	O

Forty	11704023	692	O
-	-	697	O
three	-	698	O
Caucasian	-	704	O
patients	-	714	O
with	-	723	O
primary	-	728	O
open	-	736	B
-	-	740	I
angle	-	741	I
glaucoma	-	747	I
or	-	756	O
ocular	-	759	B
hypertension	-	766	I
with	-	779	O
a	-	784	O
mean	-	786	O
(	-	791	O
+	-	792	O
/	-	793	O
-	-	794	O
SD	-	795	O
)	-	797	O
age	-	799	O
of	-	803	O
63	-	806	O
(	-	809	O
+	-	810	O
/	-	811	O
-	-	812	O
8	-	813	O
)	-	814	O
years	-	816	O
were	-	822	O
randomized	-	827	O
and	-	838	O
crossed	-	842	O
over	-	850	O
in	-	855	O
a	-	858	O
double	-	860	O
-	-	866	O
masked	-	867	O
manner	-	874	O
to	-	881	O
14	-	884	O
days	-	887	O
of	-	892	O
treatment	-	895	O
with	-	905	O
placebo	-	910	O
(	-	918	O
morning	-	919	O
and	-	927	O
evening	-	931	O
in	-	939	O
both	-	942	O
eyes	-	947	O
)	-	951	O
,	-	952	O
timolol	-	954	O
solution	-	962	O
(	-	971	O
morning	-	972	O
and	-	980	O
evening	-	984	O
in	-	992	O
both	-	995	O
eyes	-	1000	O
)	-	1004	O
,	-	1005	O
or	-	1007	O
timolol	-	1010	O
gellan	-	1018	O
(	-	1025	O
morning	-	1026	O
in	-	1034	O
both	-	1037	O
eyes	-	1042	O
with	-	1047	O
placebo	-	1052	O
in	-	1060	O
the	-	1063	O
evening	-	1067	O
)	-	1074	O
.	-	1075	O

On	11704023	1077	O
the	-	1080	O
13th	-	1084	O
day	-	1089	O
of	-	1093	O
each	-	1096	O
period	-	1101	O
,	-	1107	O
heart	-	1109	O
rate	-	1115	O
was	-	1120	O
recorded	-	1124	O
continuously	-	1133	O
during	-	1146	O
a	-	1153	O
typical	-	1155	O
,	-	1162	O
ambulant	-	1164	O
24	-	1173	O
-	-	1175	O
hour	-	1176	O
period	-	1181	O
.	-	1187	O

RESULTS	11704023	1189	O
:	-	1196	O

Both	11704023	1198	O
timolol	-	1203	O
solution	-	1211	O
and	-	1220	O
timolol	-	1224	O
gellan	-	1232	O
reduced	-	1239	O
the	-	1247	O
mean	-	1251	O
24	-	1256	O
-	-	1258	O
hour	-	1259	O
heart	-	1264	O
rate	-	1270	O
compared	-	1275	O
with	-	1284	O
placebo	-	1289	O
(	-	1297	O
P	-	1298	O
<	-	1300	O
or	-	1302	O
=	-	1305	O
.	-	1307	O
001	-	1308	O
)	-	1311	O
,	-	1312	O
and	-	1314	O
this	-	1318	O
reduction	-	1323	O
was	-	1333	O
most	-	1337	O
pronounced	-	1342	O
during	-	1353	O
the	-	1360	O
daytime	-	1364	O
(	-	1372	O
-	-	1373	O
7	-	1374	O
.	-	1375	O
5	-	1376	O
%	-	1377	O
change	-	1379	O
in	-	1386	O
mean	-	1389	O
heart	-	1394	O
rate	-	1400	O
,	-	1404	O
-	-	1406	O
5	-	1407	O
.	-	1408	O
7	-	1409	O
beats	-	1411	O
/	-	1416	O
min	-	1417	O
)	-	1420	O
.	-	1421	O

Timolol	11704023	1423	O
gellan	-	1431	O
showed	-	1438	O
a	-	1445	O
numerically	-	1447	O
but	-	1459	O
not	-	1463	O
significantly	-	1467	O
smaller	-	1481	O
reduction	-	1489	O
in	-	1499	O
24	-	1502	O
-	-	1504	O
hour	-	1505	O
heart	-	1510	O
rate	-	1516	O
,	-	1520	O
compared	-	1522	O
with	-	1531	O
timolol	-	1536	O
solution	-	1544	O
.	-	1552	O

During	11704023	1554	O
the	-	1561	O
night	-	1565	O
,	-	1570	O
the	-	1572	O
mean	-	1576	O
12	-	1581	O
-	-	1583	O
hour	-	1584	O
heart	-	1589	O
rate	-	1595	O
on	-	1600	O
placebo	-	1603	O
and	-	1611	O
timolol	-	1615	O
gellan	-	1623	O
were	-	1630	O
both	-	1635	O
significantly	-	1640	O
less	-	1654	O
than	-	1659	O
on	-	1664	O
timolol	-	1667	O
solution	-	1675	O
;	-	1683	O
the	-	1685	O
difference	-	1689	O
between	-	1700	O
solution	-	1708	O
and	-	1717	O
gellan	-	1721	O
treatments	-	1728	O
was	-	1739	O
statistically	-	1743	O
significant	-	1757	O
(	-	1769	O
P	-	1770	O
=	-	1772	O
.	-	1774	O
01	-	1775	O
)	-	1777	O
.	-	1778	O

CONCLUSIONS	11704023	1780	O
:	-	1791	O

Both	11704023	1793	O
timolol	-	1798	O
solution	-	1806	O
and	-	1815	O
timolol	-	1819	O
gellan	-	1827	O
decrease	-	1834	O
the	-	1843	O
mean	-	1847	O
24	-	1852	O
-	-	1854	O
hour	-	1855	O
heart	-	1860	O
rate	-	1866	O
compared	-	1871	O
with	-	1880	O
placebo	-	1885	O
.	-	1892	O

This	11704023	1894	O
response	-	1899	O
was	-	1908	O
most	-	1912	O
pronounced	-	1917	O
during	-	1928	O
the	-	1935	O
active	-	1939	O
daytime	-	1946	O
period	-	1954	O
.	-	1960	O

These	11704023	1962	O
data	-	1968	O
quantify	-	1973	O
the	-	1982	O
modest	-	1986	O
bradycardia	-	1993	B
associated	-	2005	O
with	-	2016	O
ophthalmic	-	2021	O
beta	-	2032	O
-	-	2036	O
blocker	-	2037	O
therapy	-	2045	O
in	-	2053	O
a	-	2056	O
typical	-	2058	O
patient	-	2066	O
population	-	2074	O
on	-	2085	O
therapy	-	2088	O
for	-	2096	O
glaucoma	-	2100	B
.	-	2108	O

Although	11704023	2110	O
exercise	-	2119	O
performance	-	2128	O
was	-	2140	O
not	-	2144	O
assessed	-	2148	O
in	-	2157	O
this	-	2160	O
trial	-	2165	O
,	-	2170	O
reductions	-	2172	O
of	-	2183	O
this	-	2186	O
magnitude	-	2191	O
should	-	2201	O
not	-	2208	O
have	-	2212	O
substantial	-	2217	O
clinical	-	2229	O
consequences	-	2238	O
.	-	2250	O

5	19300240	0	O
flourouracil	-	2	O
-	-	14	O
induced	-	15	O
apical	-	23	B
ballooning	-	30	I
syndrome	-	41	I
:	-	49	O
a	-	51	O
case	-	53	O
report	-	58	O
.	-	64	O

The	19300240	66	O
apical	-	70	B
ballooning	-	77	I
syndrome	-	88	I
(	-	97	O
ABS	-	98	B
)	-	101	O
is	-	103	O
a	-	106	O
recently	-	108	O
described	-	117	O
stress	-	127	O
-	-	133	O
mediated	-	134	O
acute	-	143	B
cardiac	-	149	I
syndrome	-	157	I
characterized	-	166	O
by	-	180	O
transient	-	183	O
wall	-	193	O
-	-	197	O
motion	-	198	O
abnormalities	-	205	O
involving	-	219	O
the	-	229	O
apex	-	233	O
and	-	238	O
midventricle	-	242	O
with	-	255	O
hyperkinesis	-	260	B
of	-	273	O
the	-	276	O
basal	-	280	O
left	-	286	O
ventricular	-	291	O
(	-	303	O
LV	-	304	O
)	-	306	O
segments	-	308	O
without	-	317	O
obstructive	-	325	O
epicardial	-	337	B
coronary	-	348	I
disease	-	357	I
.	-	364	O

Cardiotoxicity	19300240	366	B
is	-	381	O
not	-	384	O
an	-	388	O
uncommon	-	391	O
adverse	-	400	O
effect	-	408	O
of	-	415	O
chemotherapeutic	-	418	O
agents	-	435	O
.	-	441	O

However	19300240	443	O
,	-	450	O
there	-	452	O
are	-	458	O
no	-	462	O
reports	-	465	O
of	-	473	O
ABS	-	476	B
secondary	-	480	O
to	-	490	O
chemotherapeutic	-	493	O
agents	-	510	O
.	-	516	O

We	19300240	518	O
describe	-	521	O
the	-	530	O
case	-	534	O
of	-	539	O
a	-	542	O
woman	-	544	O
who	-	550	O
developed	-	554	O
the	-	564	O
syndrome	-	568	O
after	-	577	O
chemotherapy	-	583	O
for	-	596	O
metastatic	-	600	O
cancer	-	611	B
.	-	617	O

A	19300240	619	O
79	-	621	O
-	-	623	O
year	-	624	O
-	-	628	O
old	-	629	O
woman	-	633	O
presented	-	639	O
with	-	649	O
typical	-	654	O
ischemic	-	662	B
chest	-	671	B
pain	-	677	I
,	-	681	O
elevated	-	683	O
cardiac	-	692	O
enzymes	-	700	O
with	-	708	O
significant	-	713	O
ST	-	725	O
-	-	727	O
segment	-	728	O
abnormalities	-	736	O
on	-	750	O
her	-	753	O
electrocardiogram	-	757	O
.	-	774	O

She	19300240	776	O
underwent	-	780	O
recent	-	790	O
chemotherapy	-	797	O
with	-	810	O
fluorouracil	-	815	O
for	-	828	O
metastatic	-	832	O
colorectal	-	843	B
cancer	-	854	I
.	-	860	O

Echocardiography	19300240	862	O
revealed	-	879	O
a	-	888	O
wall	-	890	O
-	-	894	O
motion	-	895	O
abnormality	-	902	O
involving	-	914	O
the	-	924	O
apical	-	928	O
and	-	935	O
periapical	-	939	O
segments	-	950	O
which	-	959	O
appeared	-	965	O
akinetic	-	974	B
.	-	982	O

Coronary	19300240	984	O
angiography	-	993	O
revealed	-	1005	O
no	-	1014	O
obstructive	-	1017	O
coronary	-	1029	O
lesions	-	1038	O
.	-	1045	O

The	19300240	1047	O
patient	-	1051	O
was	-	1059	O
stabilized	-	1063	O
with	-	1074	O
medical	-	1079	O
therapy	-	1087	O
.	-	1094	O

Four	19300240	1096	O
weeks	-	1101	O
later	-	1107	O
she	-	1113	O
remained	-	1117	O
completely	-	1126	O
asymptomatic	-	1137	O
.	-	1149	O

Echocardiogram	19300240	1151	O
revealed	-	1166	O
a	-	1175	O
normal	-	1177	O
ejection	-	1184	O
fraction	-	1193	O
and	-	1202	O
a	-	1206	O
resolution	-	1208	O
of	-	1219	O
the	-	1222	O
apical	-	1226	O
akinesis	-	1233	B
.	-	1241	O

Pathogenetic	19300240	1243	O
mechanisms	-	1256	O
of	-	1267	O
cardiac	-	1270	B
complications	-	1278	I
in	-	1292	O
cancer	-	1295	B
patients	-	1302	O
undergoing	-	1311	O
chemotherapy	-	1322	O
include	-	1335	O
coronary	-	1343	B
vasospasm	-	1352	I
,	-	1361	O
endothelial	-	1363	O
damage	-	1375	O
and	-	1382	O
consequent	-	1386	O
thrombus	-	1397	B
formation	-	1406	O
.	-	1415	O

In	19300240	1417	O
our	-	1420	O
patient	-	1424	O
,	-	1431	O
both	-	1433	O
supraphysiologic	-	1438	O
levels	-	1455	O
of	-	1462	O
plasma	-	1465	O
catecholamines	-	1472	O
and	-	1487	O
stress	-	1491	O
related	-	1498	O
neuropeptides	-	1506	O
caused	-	1520	O
by	-	1527	O
cancer	-	1530	B
diagnosis	-	1537	O
as	-	1547	O
well	-	1550	O
as	-	1555	O
chemotherapy	-	1558	O
may	-	1571	O
have	-	1575	O
contributed	-	1580	O
the	-	1592	O
development	-	1596	O
of	-	1608	O
ABS	-	1611	B
.	-	1614	O

Reduction	18006530	0	O
of	-	10	O
pain	-	13	B
during	-	18	O
induction	-	25	O
with	-	35	O
target	-	40	O
-	-	46	O
controlled	-	47	O
propofol	-	58	O
and	-	67	O
remifentanil	-	71	O
.	-	83	O

BACKGROUND	18006530	85	O
:	-	95	O

Pain	18006530	97	B
on	-	102	O
injection	-	105	O
of	-	115	O
propofol	-	118	O
is	-	127	O
unpleasant	-	130	O
.	-	140	O

We	18006530	142	O
hypothesized	-	145	O
that	-	158	O
propofol	-	163	O
infusion	-	172	O
pain	-	181	B
might	-	186	O
be	-	192	O
prevented	-	195	O
by	-	205	O
infusing	-	208	O
remifentanil	-	217	O
before	-	230	O
starting	-	237	O
the	-	246	O
propofol	-	250	O
infusion	-	259	O
in	-	268	O
a	-	271	O
clinical	-	273	O
setting	-	282	O
where	-	290	O
target	-	296	O
-	-	302	O
controlled	-	303	O
infusions	-	314	O
(	-	324	O
TCI	-	325	O
)	-	328	O
of	-	330	O
both	-	333	O
drugs	-	338	O
were	-	344	O
used	-	349	O
.	-	353	O

A	18006530	355	O
prospective	-	357	O
,	-	368	O
randomized	-	370	O
,	-	380	O
double	-	382	O
-	-	388	O
blind	-	389	O
,	-	394	O
placebo	-	396	O
-	-	403	O
controlled	-	404	O
trial	-	415	O
was	-	421	O
performed	-	425	O
to	-	435	O
determine	-	438	O
the	-	448	O
effect	-	452	O
-	-	458	O
site	-	459	O
concentration	-	464	O
(	-	478	O
Ce	-	479	O
)	-	481	O
of	-	483	O
remifentanil	-	486	O
to	-	499	O
prevent	-	502	O
the	-	510	O
pain	-	514	B
without	-	519	O
producing	-	527	O
complications	-	537	O
.	-	550	O

METHODS	18006530	552	O
:	-	559	O

A	18006530	561	O
total	-	563	O
of	-	569	O
128	-	572	O
patients	-	576	O
undergoing	-	585	O
general	-	596	O
surgery	-	604	O
were	-	612	O
randomly	-	617	O
allocated	-	626	O
to	-	636	O
receive	-	639	O
normal	-	647	O
saline	-	654	O
(	-	661	O
control	-	662	O
)	-	669	O
or	-	671	O
remifentanil	-	674	O
to	-	687	O
a	-	690	O
target	-	692	O

Ce	18006530	699	O
of	-	702	O
2	-	705	O
ng	-	707	O
ml	-	710	O
(	-	712	O
-	-	713	O
1	-	714	O
)	-	715	O
(	-	717	O
R2	-	718	O
)	-	720	O

,	18006530	721	O
4	-	723	O
ng	-	725	O
ml	-	728	O
(	-	730	O
-	-	731	O
1	-	732	O
)	-	733	O

(	18006530	735	O
R4	-	736	O
)	-	738	O
,	-	739	O
or	-	741	O
6	-	744	O
ng	-	746	O
ml	-	749	O
(	-	751	O
-	-	752	O
1	-	753	O
)	-	754	O
(	-	756	O
R6	-	757	O
)	-	759	O
administered	-	761	O
via	-	774	O
TCI	-	778	O
.	-	781	O

After	18006530	783	O
the	-	789	O
target	-	793	O
Ce	-	800	O
was	-	803	O
achieved	-	807	O
,	-	815	O
the	-	817	O
infusion	-	821	O
of	-	830	O
propofol	-	833	O
was	-	842	O
started	-	846	O
.	-	853	O

Remifentanil	18006530	855	O
-	-	867	O
related	-	868	O
complications	-	876	O
were	-	890	O
assessed	-	895	O
during	-	904	O
the	-	911	O
remifentanil	-	915	O
infusion	-	928	O
,	-	936	O
and	-	938	O
pain	-	942	B
caused	-	947	O
by	-	954	O
propofol	-	957	O
was	-	966	O
evaluated	-	970	O
using	-	980	O
a	-	986	O
four	-	988	O
-	-	992	O
point	-	993	O
scale	-	999	O
during	-	1005	O
the	-	1012	O
propofol	-	1016	O
infusion	-	1025	O
.	-	1033	O

RESULTS	18006530	1035	O
:	-	1042	O

The	18006530	1044	O
incidence	-	1048	O
of	-	1058	O
pain	-	1061	B
was	-	1066	O
significantly	-	1070	O
lower	-	1084	O
in	-	1090	O
Groups	-	1093	O
R4	-	1100	O
and	-	1103	O
R6	-	1107	O
than	-	1110	O
in	-	1115	O
the	-	1118	O
control	-	1122	O
and	-	1130	O
R2	-	1134	O
groups	-	1137	O
(	-	1144	O
12	-	1145	O
/	-	1147	O
32	-	1148	O
and	-	1151	O
6	-	1155	O
/	-	1156	O
31	-	1157	O
vs	-	1160	O
26	-	1163	O
/	-	1165	O
31	-	1166	O
and	-	1169	O
25	-	1173	O
/	-	1175	O
32	-	1176	O
,	-	1178	O
respectively	-	1180	O
,	-	1192	O
P	-	1194	O
<	-	1195	O
0	-	1196	O
.	-	1197	O
001	-	1198	O
)	-	1201	O
.	-	1202	O

Pain	18006530	1204	B
was	-	1209	O
less	-	1213	O
severe	-	1218	O
in	-	1225	O
Groups	-	1228	O
R4	-	1235	O
and	-	1238	O
R6	-	1242	O
than	-	1245	O
in	-	1250	O
the	-	1253	O
control	-	1257	O
and	-	1265	O
R2	-	1269	O
groups	-	1272	O
(	-	1279	O
P	-	1280	O
<	-	1281	O
0	-	1282	O
.	-	1283	O
001	-	1284	O
)	-	1287	O
.	-	1288	O

However	18006530	1290	O
,	-	1297	O
both	-	1299	O
incidence	-	1304	O
and	-	1314	O
severity	-	1318	O
of	-	1327	O
pain	-	1330	B
were	-	1335	O
not	-	1340	O
different	-	1344	O
between	-	1354	O
Groups	-	1362	O
R4	-	1369	O
and	-	1372	O
R6	-	1376	O
.	-	1378	O

No	18006530	1380	O
significant	-	1383	O
complications	-	1395	O
were	-	1409	O
observed	-	1414	O
during	-	1423	O
the	-	1430	O
study	-	1434	O
.	-	1439	O

CONCLUSIONS	18006530	1441	O
:	-	1452	O

During	18006530	1454	O
induction	-	1461	O
of	-	1471	O
anaesthesia	-	1474	O
with	-	1486	O
TCI	-	1491	O
of	-	1495	O
propofol	-	1498	O
and	-	1507	O
remifentanil	-	1511	O
,	-	1523	O
a	-	1525	O
significant	-	1527	O
reduction	-	1539	O
in	-	1549	O
propofol	-	1552	O
infusion	-	1561	O
pain	-	1570	B
was	-	1575	O
achieved	-	1579	O
without	-	1588	O
significant	-	1596	O
complications	-	1608	O
by	-	1622	O
prior	-	1625	O
administration	-	1631	O
of	-	1646	O
remifentanil	-	1649	O
at	-	1662	O
a	-	1665	O
target	-	1667	O

Ce	18006530	1674	O
of	-	1677	O
4	-	1680	O
ng	-	1682	O
ml	-	1685	O
(	-	1687	O
-	-	1688	O
1	-	1689	O
)	-	1690	O
.	-	1691	O

Prenatal	17702969	0	O
exposure	-	9	O
to	-	18	O
fluoxetine	-	21	O
induces	-	32	O
fetal	-	40	B
pulmonary	-	46	I
hypertension	-	56	I
in	-	69	O
the	-	72	O
rat	-	76	O
.	-	79	O

RATIONALE	17702969	81	O
:	-	90	O
Fluoxetine	-	92	O
is	-	103	O
a	-	106	O
selective	-	108	O
serotonin	-	118	O
reuptake	-	128	O
inhibitor	-	137	O
antidepressant	-	147	O
widely	-	162	O
used	-	169	O
by	-	174	O
pregnant	-	177	O
women	-	186	O
.	-	191	O

Epidemiological	17702969	193	O
data	-	209	O
suggest	-	214	O
that	-	222	O
fluoxetine	-	227	O
exposure	-	238	O
prenatally	-	247	O
increases	-	258	O
the	-	268	O
prevalence	-	272	O
of	-	283	O
persistent	-	286	O
pulmonary	-	297	B
hypertension	-	307	I
syndrome	-	320	I
of	-	329	O
the	-	332	O
newborn	-	336	O
.	-	343	O

The	17702969	345	O
mechanism	-	349	O
responsible	-	359	O
for	-	371	O
this	-	375	O
effect	-	380	O
is	-	387	O
unclear	-	390	O
and	-	398	O
paradoxical	-	402	O
,	-	413	O
considering	-	415	O
the	-	427	O
current	-	431	O
evidence	-	439	O
of	-	448	O
a	-	451	O
pulmonary	-	453	B
hypertension	-	463	I
protective	-	476	O
fluoxetine	-	487	O
effect	-	498	O
in	-	505	O
adult	-	508	O
rodents	-	514	O
.	-	521	O

OBJECTIVES	17702969	523	O
:	-	533	O

To	17702969	535	O
evaluate	-	538	O
the	-	547	O
fluoxetine	-	551	O
effect	-	562	O
on	-	569	O
fetal	-	572	O
rat	-	578	O
pulmonary	-	582	O
vascular	-	592	O
smooth	-	601	O
muscle	-	608	O
mechanical	-	615	O
properties	-	626	O
and	-	637	O
cell	-	641	O
proliferation	-	646	O
rate	-	660	O
.	-	664	O

METHODS	17702969	666	O
:	-	673	O

Pregnant	17702969	675	O
rats	-	684	O
were	-	689	O
treated	-	694	O
with	-	702	O
fluoxetine	-	707	O
(	-	718	O
10	-	719	O
mg	-	722	O
/	-	724	O
kg	-	725	O
)	-	727	O
from	-	729	O
Day	-	734	O
11	-	738	O
through	-	741	O
Day	-	749	O
21	-	753	O
of	-	756	O
gestation	-	759	O
.	-	768	O

MEASUREMENTS	17702969	770	O
AND	-	783	O
MAIN	-	787	O
RESULTS	-	792	O
:	-	799	O

Fetuses	17702969	801	O
were	-	809	O
delivered	-	814	O
by	-	824	O
cesarean	-	827	O
section	-	836	O
.	-	843	O

As	17702969	845	O
compared	-	848	O
with	-	857	O
controls	-	862	O
,	-	870	O
fluoxetine	-	872	O
exposure	-	883	O
resulted	-	892	O
in	-	901	O
fetal	-	904	B
pulmonary	-	910	I
hypertension	-	920	I
as	-	933	O
evidenced	-	936	O
by	-	946	O
an	-	949	O
increase	-	952	O
in	-	961	O
the	-	964	O
weight	-	968	O
ratio	-	975	O
of	-	981	O
the	-	984	O
right	-	988	O
ventricle	-	994	O
to	-	1004	O
the	-	1007	O
left	-	1011	O
ventricle	-	1016	O
plus	-	1026	O
septum	-	1031	O
(	-	1038	O
P	-	1039	O
=	-	1041	O
0	-	1043	O
.	-	1044	O
02	-	1045	O
)	-	1047	O
and	-	1049	O
by	-	1053	O
an	-	1056	O
increase	-	1059	O
in	-	1068	O
pulmonary	-	1071	O
arterial	-	1081	O
medial	-	1090	O
thickness	-	1097	O
(	-	1107	O
P	-	1108	O
<	-	1110	O
0	-	1112	O
.	-	1113	O
01	-	1114	O
)	-	1116	O
.	-	1117	O

Postnatal	17702969	1119	O
mortality	-	1129	O
was	-	1139	O
increased	-	1143	O
among	-	1153	O
experimental	-	1159	O
animals	-	1172	O
,	-	1179	O
and	-	1181	O
arterial	-	1185	O
oxygen	-	1194	O
saturation	-	1201	O
was	-	1212	O
96	-	1216	O
+	-	1219	O
/	-	1220	O
-	-	1221	O

1	17702969	1223	O
%	-	1224	O
in	-	1226	O
1	-	1229	O
-	-	1230	O
day	-	1231	O
-	-	1234	O
old	-	1235	O
control	-	1239	O
animals	-	1247	O
and	-	1255	O
significantly	-	1259	O
lower	-	1273	O
(	-	1279	O
P	-	1280	O
<	-	1282	O
0	-	1284	O
.	-	1285	O
01	-	1286	O
)	-	1288	O
in	-	1290	O
fluoxetine	-	1293	O
-	-	1303	O
exposed	-	1304	O
pups	-	1312	O
(	-	1317	O
79	-	1318	O
+	-	1321	O
/	-	1322	O
-	-	1323	O
2	-	1325	O
%	-	1326	O
)	-	1327	O
.	-	1328	O

In	17702969	1330	O
vitro	-	1333	O
,	-	1338	O
fluoxetine	-	1340	O
induced	-	1351	O
pulmonary	-	1359	O
arterial	-	1369	O
muscle	-	1378	O
contraction	-	1385	O
in	-	1397	O
fetal	-	1400	O
,	-	1405	O
but	-	1407	O
not	-	1411	O
adult	-	1415	O
,	-	1420	O
animals	-	1422	O
(	-	1430	O
P	-	1431	O
<	-	1433	O
0	-	1435	O
.	-	1436	O
01	-	1437	O
)	-	1439	O
and	-	1441	O
reduced	-	1445	O
serotonin	-	1453	O
-	-	1462	O
induced	-	1463	O
contraction	-	1471	O
at	-	1483	O
both	-	1486	O
ages	-	1491	O
(	-	1496	O
P	-	1497	O
<	-	1499	O
0	-	1501	O
.	-	1502	O
01	-	1503	O
)	-	1505	O
.	-	1506	O

After	17702969	1508	O
in	-	1514	O
utero	-	1517	O
exposure	-	1523	O
to	-	1532	O
a	-	1535	O
low	-	1537	O
fluoxetine	-	1541	O
concentration	-	1552	O
the	-	1566	O
pulmonary	-	1570	O
arterial	-	1580	O
smooth	-	1589	O
muscle	-	1596	O
cell	-	1603	O
proliferation	-	1608	O
rate	-	1622	O
was	-	1627	O
significantly	-	1631	O
increased	-	1645	O
in	-	1655	O
fetal	-	1658	O
,	-	1663	O
but	-	1665	O
not	-	1669	O
adult	-	1673	O
,	-	1678	O
cells	-	1680	O
(	-	1686	O
P	-	1687	O
<	-	1689	O
0	-	1691	O
.	-	1692	O
01	-	1693	O
)	-	1695	O
.	-	1696	O

CONCLUSIONS	17702969	1698	O
:	-	1709	O

In	17702969	1711	O
contrast	-	1714	O
to	-	1723	O
the	-	1726	O
adult	-	1730	O
,	-	1735	O
fluoxetine	-	1737	O
exposure	-	1748	O
in	-	1757	O
utero	-	1760	O
induces	-	1766	O
pulmonary	-	1774	B
hypertension	-	1784	I
in	-	1797	O
the	-	1800	O
fetal	-	1804	O
rat	-	1810	O
as	-	1814	O
a	-	1817	O
result	-	1819	O
of	-	1826	O
a	-	1829	O
developmentally	-	1831	O
regulated	-	1847	O
increase	-	1857	O
in	-	1866	O
pulmonary	-	1869	O
vascular	-	1879	O
smooth	-	1888	O
muscle	-	1895	O
proliferation	-	1902	O
.	-	1915	O

Syncope	17344330	0	B
and	-	8	O
QT	-	12	B
prolongation	-	15	I
among	-	28	O
patients	-	34	O
treated	-	43	O
with	-	51	O
methadone	-	56	O
for	-	66	O
heroin	-	70	O
dependence	-	77	O
in	-	88	O
the	-	91	O
city	-	95	O
of	-	100	O
Copenhagen	-	103	O
.	-	113	O

BACKGROUND	17344330	115	O
:	-	125	O

Methadone	17344330	127	O
is	-	137	O
prescribed	-	140	O
to	-	151	O
heroin	-	154	O
addicts	-	161	O
to	-	169	O
decrease	-	172	O
illicit	-	181	O
opioid	-	189	O
use	-	196	O
.	-	199	O

Prolongation	17344330	201	O
of	-	214	O
the	-	217	O
QT	-	221	O
interval	-	224	O
in	-	233	O
the	-	236	O
ECG	-	240	O
of	-	244	O
patients	-	247	O
with	-	256	O
torsade	-	261	B
de	-	269	I
pointes	-	272	I
(	-	280	O
TdP	-	281	B
)	-	284	O
has	-	286	O
been	-	290	O
reported	-	295	O
in	-	304	O
methadone	-	307	O
users	-	317	O
.	-	322	O

As	17344330	324	O
heroin	-	327	O
addicts	-	334	O
sometimes	-	342	O
faint	-	352	O
while	-	358	O
using	-	364	O
illicit	-	370	O
drugs	-	378	O
,	-	383	O
doctors	-	385	O
might	-	393	O
attribute	-	399	O
too	-	409	O
many	-	413	O
episodes	-	418	O
of	-	427	O
syncope	-	430	B
to	-	438	O
illicit	-	441	O
drug	-	449	O
use	-	454	O
and	-	458	O
thereby	-	462	O
underestimate	-	470	O
the	-	484	O
incidence	-	488	O
of	-	498	O
TdP	-	501	B
in	-	505	O
this	-	508	O
special	-	513	O
population	-	521	O
,	-	531	O
and	-	533	O
the	-	537	O
high	-	541	O
mortality	-	546	O
in	-	556	O
this	-	559	O
population	-	564	O
may	-	575	O
,	-	578	O
in	-	580	O
part	-	583	O
,	-	587	O
be	-	589	O
caused	-	592	O
by	-	599	O
the	-	602	O
proarrhythmic	-	606	O
effect	-	620	O
of	-	627	O
methadone	-	630	O
.	-	639	O

METHODS	17344330	641	O
:	-	648	O

In	17344330	650	O
this	-	653	O
cross	-	658	O
-	-	663	O
sectional	-	664	O
study	-	674	O
interview	-	680	O
,	-	689	O
ECGs	-	691	O
and	-	696	O
blood	-	700	O
samples	-	706	O
were	-	714	O
collected	-	719	O
in	-	729	O
a	-	732	O
population	-	734	O
of	-	745	O
adult	-	748	O
heroin	-	754	O
addicts	-	761	O
treated	-	769	O
with	-	777	O
methadone	-	782	O
or	-	792	O
buprenorphine	-	795	O
on	-	809	O
a	-	812	O
daily	-	814	O
basis	-	820	O
.	-	825	O

Of	17344330	827	O
the	-	830	O
patients	-	834	O
at	-	843	O
the	-	846	O
Drug	-	850	O
Addiction	-	855	O
Service	-	865	O
in	-	873	O
the	-	876	O
municipal	-	880	O
of	-	890	O
Copenhagen	-	893	O
,	-	903	O
450	-	905	O
(	-	909	O
approximately	-	910	O
52	-	924	O
%	-	926	O
)	-	927	O
were	-	929	O
included	-	934	O
.	-	942	O

The	17344330	944	O
QT	-	948	O
interval	-	951	O
was	-	960	O
estimated	-	964	O
from	-	974	O
12	-	979	O
lead	-	982	O
ECGs	-	987	O
.	-	991	O

All	17344330	993	O
participants	-	997	O
were	-	1010	O
interviewed	-	1015	O
about	-	1027	O
any	-	1033	O
experience	-	1037	O
of	-	1048	O
syncope	-	1051	B
.	-	1058	O

The	17344330	1060	O
association	-	1064	O
between	-	1076	O
opioid	-	1084	O
dose	-	1091	O
and	-	1096	O
QT	-	1100	O
,	-	1102	O
and	-	1104	O
methadone	-	1108	O
dose	-	1118	O
and	-	1123	O
reporting	-	1127	O
of	-	1137	O
syncope	-	1140	B
was	-	1148	O
assessed	-	1152	O
using	-	1161	O
multivariate	-	1167	O
linear	-	1180	O
regression	-	1187	O
and	-	1198	O
logistic	-	1202	O
regression	-	1211	O
,	-	1221	O
respectively	-	1223	O
.	-	1235	O

RESULTS	17344330	1237	O
:	-	1244	O

Methadone	17344330	1246	O
dose	-	1256	O
was	-	1261	O
associated	-	1265	O
with	-	1276	O
longer	-	1281	O
QT	-	1288	O
interval	-	1291	O
of	-	1300	O
0	-	1303	O
.	-	1304	O
140	-	1305	O
ms	-	1309	O
/	-	1311	O
mg	-	1312	O
(	-	1315	O
p	-	1316	O
=	-	1318	O
0	-	1320	O
.	-	1321	O
002	-	1322	O
)	-	1325	O
.	-	1326	O

No	17344330	1328	O
association	-	1331	O
between	-	1343	O
buprenorphine	-	1351	O
and	-	1365	O
QTc	-	1369	O
was	-	1373	O
found	-	1377	O
.	-	1382	O

Among	17344330	1384	O
the	-	1390	O
subjects	-	1394	O
treated	-	1403	O
with	-	1411	O
methadone	-	1416	O
,	-	1425	O
28	-	1427	O
%	-	1429	O
men	-	1431	O
and	-	1435	O
32	-	1439	O
%	-	1441	O
women	-	1443	O
had	-	1449	O
prolonged	-	1453	B
QTc	-	1463	I
interval	-	1467	I
.	-	1475	O

None	17344330	1477	O
of	-	1482	O
the	-	1485	O
subjects	-	1489	O
treated	-	1498	O
with	-	1506	O
buprenorphine	-	1511	O
had	-	1525	O
QTc	-	1529	O
interval	-	1533	O
>	-	1542	O
0	-	1543	O
.	-	1544	O
440	-	1545	O
s	-	1549	O
(	-	1550	O
(	-	1551	O
1	-	1552	O
/	-	1553	O
2	-	1554	O
)	-	1555	O
)	-	1556	O
.	-	1557	O

A	17344330	1559	O
50	-	1561	O
mg	-	1564	O
higher	-	1567	O
methadone	-	1574	O
dose	-	1584	O
was	-	1589	O
associated	-	1593	O
with	-	1604	O
a	-	1609	O
1	-	1611	O
.	-	1612	O
2	-	1613	O
(	-	1615	O
95	-	1616	O
%	-	1618	O
CI	-	1620	O
1	-	1623	O
.	-	1624	O
1	-	1625	O
to	-	1627	O
1	-	1630	O
.	-	1631	O
4	-	1632	O
)	-	1633	O
times	-	1635	O
higher	-	1641	O
odds	-	1648	O
for	-	1653	O
syncope	-	1657	B
.	-	1664	O

CONCLUSIONS	17344330	1666	O
:	-	1677	O

Methadone	17344330	1679	O
is	-	1689	O
associated	-	1692	O
with	-	1703	O
QT	-	1708	B
prolongation	-	1711	I
and	-	1724	O
higher	-	1728	O
reporting	-	1735	O
of	-	1745	O
syncope	-	1748	B
in	-	1756	O
a	-	1759	O
population	-	1761	O
of	-	1772	O
heroin	-	1775	O
addicts	-	1782	O
.	-	1789	O

Peripheral	16826348	0	B
neuropathy	-	11	I
caused	-	22	O
by	-	29	O
high	-	32	O
-	-	36	O
dose	-	37	O
cytosine	-	42	O
arabinoside	-	51	O
treatment	-	63	O
in	-	73	O
a	-	76	O
patient	-	78	O
with	-	86	O
acute	-	91	B
myeloid	-	97	I
leukemia	-	105	I
.	-	113	O

The	16826348	115	O
central	-	119	O
nervous	-	127	O
system	-	135	O
toxicity	-	142	B
of	-	151	O
high	-	154	O
-	-	158	O
dose	-	159	O
cytosine	-	164	O
arabinoside	-	173	O
is	-	185	O
well	-	188	O
recognized	-	193	O
,	-	203	O
but	-	205	O
the	-	209	O
toxicity	-	213	B
of	-	222	O
cytosine	-	225	O
arabinoside	-	234	O
in	-	246	O
the	-	249	O
peripheral	-	253	O
nervous	-	264	O
system	-	272	O
has	-	279	O
been	-	283	O
infrequently	-	288	O
reported	-	301	O
.	-	309	O

A	16826348	311	O
49	-	313	O
-	-	315	O
year	-	316	O
-	-	320	O
old	-	321	O
Japanese	-	325	O
man	-	334	O
was	-	338	O
diagnosed	-	342	O
with	-	352	O
acute	-	357	B
myeloid	-	363	I
leukemia	-	371	I
.	-	379	O

After	16826348	381	O
he	-	387	O
achieved	-	390	O
complete	-	399	O
remission	-	408	O
,	-	417	O
he	-	419	O
received	-	422	O
high	-	431	O
-	-	435	O
dose	-	436	O
cytosine	-	441	O
arabinoside	-	450	O
treatment	-	462	O
(	-	472	O
2	-	473	O
g	-	475	O

/	16826348	476	O
m2	-	477	O
twice	-	480	O
a	-	486	O
day	-	488	O
for	-	492	O
5	-	496	O
days	-	498	O

;	16826348	502	O
total	-	504	O
,	-	509	O
20	-	511	O
g	-	514	O
/	-	515	O
m2	-	516	O
)	-	518	O
as	-	520	O
consolidation	-	523	O
therapy	-	537	O
.	-	544	O

The	16826348	546	O
first	-	550	O
course	-	556	O
of	-	563	O
high	-	566	O
-	-	570	O
dose	-	571	O
cytosine	-	576	O
arabinoside	-	585	O
resulted	-	597	O
in	-	606	O
no	-	609	O
unusual	-	612	O
symptoms	-	620	O
,	-	628	O
but	-	630	O
on	-	634	O
day	-	637	O
21	-	641	O
of	-	644	O
the	-	647	O
second	-	651	O
course	-	658	O
of	-	665	O
treatment	-	668	O
,	-	677	O
the	-	679	O
patient	-	683	O
complained	-	691	O
of	-	702	O
numbness	-	705	B
in	-	714	O
his	-	717	O
right	-	721	O
foot	-	727	O
.	-	731	O

Electromyogram	16826348	733	O
and	-	748	O
nerve	-	752	O
-	-	757	O
conduction	-	758	O
studies	-	769	O
showed	-	777	O
peripheral	-	784	B
neuropathy	-	795	I
in	-	806	O
both	-	809	O
peroneal	-	814	O
nerves	-	823	O
.	-	829	O

This	16826348	831	O
neuropathy	-	836	B
was	-	847	O
gradually	-	851	O
resolving	-	861	O
;	-	870	O
however	-	872	O
,	-	879	O
after	-	881	O
the	-	887	O
patient	-	891	O
received	-	899	O
allogeneic	-	908	O
bone	-	919	O
marrow	-	924	O
transplantation	-	931	O
,	-	946	O
the	-	948	O
symptoms	-	952	O
worsened	-	961	O
,	-	969	O
with	-	971	O
the	-	976	O
development	-	980	O
of	-	992	O
graft	-	995	B
-	-	1000	I
versus	-	1001	I
-	-	1007	I
host	-	1008	I
disease	-	1013	I
,	-	1020	O
and	-	1022	O
the	-	1026	O
symptoms	-	1030	O
subsequently	-	1039	O
responded	-	1052	O
to	-	1062	O
methylprednisolone	-	1065	O
.	-	1083	O

Although	16826348	1085	O
the	-	1094	O
mechanisms	-	1098	O
of	-	1109	O
peripheral	-	1112	B
neuropathy	-	1123	I
are	-	1134	O
still	-	1138	O
unclear	-	1144	O
,	-	1151	O
high	-	1153	O
-	-	1157	O
dose	-	1158	O
cytosine	-	1163	O
arabinoside	-	1172	O
is	-	1184	O
a	-	1187	O
therapy	-	1189	O
that	-	1197	O
is	-	1202	O
potentially	-	1205	O
toxic	-	1217	O
to	-	1223	O
the	-	1226	O
peripheral	-	1230	O
nervous	-	1241	O
system	-	1249	O
,	-	1255	O
and	-	1257	O
auto	-	1261	O
/	-	1265	O
alloimmunity	-	1266	O
may	-	1279	O
play	-	1283	O
an	-	1288	O
important	-	1291	O
role	-	1301	O
in	-	1306	O
these	-	1309	O
mechanisms	-	1315	O
.	-	1325	O

Atorvastatin	16820346	0	O
prevented	-	13	O
and	-	23	O
reversed	-	27	O
dexamethasone	-	36	O
-	-	49	O
induced	-	50	O
hypertension	-	58	B
in	-	71	O
the	-	74	O
rat	-	78	O
.	-	81	O

To	16820346	83	O
assess	-	86	O
the	-	93	O
antioxidant	-	97	O
effects	-	109	O
of	-	117	O
atorvastatin	-	120	O
(	-	133	O
atorva	-	134	O
)	-	140	O
on	-	142	O
dexamethasone	-	145	O
(	-	159	O
dex	-	160	O
)	-	163	O
-	-	164	O
induced	-	165	O
hypertension	-	173	B
,	-	185	O
60	-	187	O
male	-	190	O
Sprague	-	195	O
-	-	202	O
Dawley	-	203	O
rats	-	210	O
were	-	215	O
treated	-	220	O
with	-	228	O
atorva	-	233	O
30	-	240	O
mg	-	243	O
/	-	245	O
kg	-	246	O
/	-	248	O
day	-	249	O
or	-	253	O
tap	-	256	O
water	-	260	O
for	-	266	O
15	-	270	O
days	-	273	O
.	-	277	O

Dex	16820346	279	O
increased	-	283	O
systolic	-	293	O
blood	-	302	O
pressure	-	308	O
(	-	317	O
SBP	-	318	O
)	-	321	O
from	-	323	O
109	-	328	O
+	-	332	O
/	-	333	O
-	-	334	O

1	16820346	336	O
.	-	337	O
8	-	338	O
to	-	340	O
135	-	343	O
+	-	347	O
/	-	348	O
-	-	349	O

0	16820346	351	O
.	-	352	O
6	-	353	O
mmHg	-	355	O
and	-	360	O
plasma	-	364	O
superoxide	-	371	O
(	-	382	O
5711	-	383	O
+	-	388	O
/	-	389	O
-	-	390	O

284	16820346	392	O
.	-	395	O
9	-	396	O
saline	-	398	O
,	-	404	O
7931	-	406	O
+	-	411	O
/	-	412	O
-	-	413	O

392	16820346	415	O
.	-	418	O
8	-	419	O
U	-	421	O
/	-	422	O
ml	-	423	O
dex	-	426	O
,	-	429	O
P	-	431	O
<	-	433	O
0	-	435	O
.	-	436	O
001	-	437	O
)	-	440	O
.	-	441	O

In	16820346	443	O
this	-	446	O
prevention	-	451	O
study	-	462	O
,	-	467	O
SBP	-	469	O
in	-	473	O
the	-	476	O
atorva	-	480	O
+	-	487	O
dex	-	489	O
group	-	493	O
was	-	499	O
increased	-	503	O
from	-	513	O
115	-	518	O
+	-	522	O
/	-	523	O
-	-	524	O

0	16820346	526	O
.	-	527	O
4	-	528	O
to	-	530	O
124	-	533	O
+	-	537	O
/	-	538	O
-	-	539	O

1	16820346	541	O
.	-	542	O
5	-	543	O
mmHg	-	545	O
,	-	549	O
but	-	551	O
this	-	555	O
was	-	560	O
significantly	-	564	O
lower	-	578	O
than	-	584	O
in	-	589	O
the	-	592	O
dex	-	596	O
-	-	599	O
only	-	600	O
group	-	605	O
(	-	611	O
P	-	612	O
'	-	613	O
<	-	615	O
0	-	617	O
.	-	618	O
05	-	619	O
)	-	621	O
.	-	622	O

Atorva	16820346	624	O
reversed	-	631	O
dex	-	640	O
-	-	643	O
induced	-	644	O
hypertension	-	652	B
(	-	665	O
129	-	666	O
+	-	670	O
/	-	671	O
-	-	672	O
0	-	674	O
.	-	675	O
6	-	676	O
mmHg	-	678	O
,	-	682	O
vs	-	684	O
.	-	686	O
135	-	688	O
+	-	692	O
/	-	693	O
-	-	694	O

0	16820346	696	O
.	-	697	O
6	-	698	O
mmHg	-	700	O
P	-	705	O
'	-	706	O
<	-	708	O
0	-	710	O
.	-	711	O
05	-	712	O
)	-	714	O
and	-	716	O
decreased	-	720	O
plasma	-	730	O
superoxide	-	737	O
(	-	748	O
7931	-	749	O
+	-	754	O
/	-	755	O
-	-	756	O

392	16820346	758	O
.	-	761	O
8	-	762	O
dex	-	764	O
,	-	767	O
1187	-	769	O
+	-	774	O
/	-	775	O
-	-	776	O

441	16820346	778	O
.	-	781	O
2	-	782	O
atorva	-	784	O
+	-	791	O
dex	-	793	O
,	-	796	O
P	-	798	O
<	-	800	O
0	-	802	O
.	-	803	O
0001	-	804	O
)	-	808	O
.	-	809	O

Plasma	16820346	811	O
nitrate	-	818	O
/	-	825	O
nitrite	-	826	O
(	-	834	O
NOx	-	835	O
)	-	838	O
was	-	840	O
decreased	-	844	O
in	-	854	O
dex	-	857	O
-	-	860	O
treated	-	861	O
rats	-	869	O
compared	-	874	O
to	-	883	O
saline	-	886	O
-	-	892	O
treated	-	893	O
rats	-	901	O
(	-	906	O
11	-	907	O
.	-	909	O
2	-	910	O
+	-	912	O
/	-	913	O
-	-	914	O

1	16820346	916	O
.	-	917	O
08	-	918	O
microm	-	921	O
,	-	927	O
15	-	929	O
.	-	931	O
3	-	932	O
+	-	934	O
/	-	935	O
-	-	936	O

1	16820346	938	O
.	-	939	O
17	-	940	O
microm	-	943	O
,	-	949	O
respectively	-	951	O
,	-	963	O
P	-	965	O
<	-	967	O
0	-	969	O
.	-	970	O
05	-	971	O
)	-	973	O
.	-	974	O

Atorva	16820346	976	O
affected	-	983	O
neither	-	992	O
plasma	-	1000	O
NOx	-	1007	O
nor	-	1011	O
thymus	-	1015	O
weight	-	1022	O
.	-	1028	O

Thus	16820346	1030	O
,	-	1034	O
atorvastatin	-	1036	O
prevented	-	1049	O
and	-	1059	O
reversed	-	1063	O
dexamethasone	-	1072	O
-	-	1085	O
induced	-	1086	O
hypertension	-	1094	B
in	-	1107	O
the	-	1110	O
rat	-	1114	O
.	-	1117	O

Two	15974569	0	O
prodrugs	-	4	O
of	-	13	O
potent	-	16	O
and	-	23	O
selective	-	27	O
GluR5	-	37	O
kainate	-	43	O
receptor	-	51	O
antagonists	-	60	O
actives	-	72	O
in	-	80	O
three	-	83	O
animal	-	89	O
models	-	96	O
of	-	103	O
pain	-	106	B
.	-	110	O

Amino	15974569	112	O
acids	-	118	O
5	-	124	O
and	-	126	O
7	-	130	O
,	-	131	O
two	-	133	O
potent	-	137	O
and	-	144	O
selective	-	148	O
competitive	-	158	O
GluR5	-	170	O
KA	-	176	O
receptor	-	179	O
antagonists	-	188	O
,	-	199	O
exhibited	-	201	O
high	-	211	O
GluR5	-	216	O
receptor	-	222	O
affinity	-	231	O
over	-	240	O
other	-	245	O
glutamate	-	251	O
receptors	-	261	O
.	-	270	O

Their	15974569	272	O
ester	-	278	O
prodrugs	-	284	O
6	-	293	O
and	-	295	O
8	-	299	O
were	-	301	O
orally	-	306	O
active	-	313	O
in	-	320	O
three	-	323	O
models	-	329	O
of	-	336	O
pain	-	339	B
:	-	343	O
reversal	-	345	O
of	-	354	O
formalin	-	357	O
-	-	365	O
induced	-	366	O
paw	-	374	O
licking	-	378	O
,	-	385	O
carrageenan	-	387	O
-	-	398	O
induced	-	399	O
thermal	-	407	B
hyperalgesia	-	415	I
,	-	427	O
and	-	429	O
capsaicin	-	433	O
-	-	442	O
induced	-	443	O
mechanical	-	451	B
hyperalgesia	-	462	I
.	-	474	O

Sirolimus	11583940	0	O
and	-	10	O
mycophenolate	-	14	O
mofetil	-	28	O
for	-	36	O
calcineurin	-	40	O
-	-	51	O
free	-	52	O
immunosuppression	-	57	O
in	-	75	O
renal	-	78	O
transplant	-	84	O
recipients	-	95	O
.	-	105	O

Calcineurin	11583940	107	O
inhibitors	-	119	O
,	-	129	O
such	-	131	O
as	-	136	O
cyclosporine	-	139	O
and	-	152	O
tacrolimus	-	156	O
,	-	166	O
have	-	168	O
been	-	173	O
available	-	178	O
for	-	188	O
almost	-	192	O
20	-	199	O
years	-	202	O
.	-	207	O

Although	11583940	209	O
these	-	218	O
drugs	-	224	O
are	-	230	O
highly	-	234	O
effective	-	241	O
and	-	251	O
represent	-	255	O
the	-	265	O
mainstay	-	269	O
of	-	278	O
transplant	-	281	O
immunosuppression	-	292	O
,	-	309	O
they	-	311	O
are	-	316	O
associated	-	320	O
with	-	331	O
acute	-	336	O
and	-	342	O
chronic	-	346	O
nephrotoxicity	-	354	B
.	-	368	O

Acute	11583940	370	O
nephrotoxicity	-	376	B
,	-	390	O
which	-	392	O
occurs	-	398	O
in	-	405	O
the	-	408	O
early	-	412	O
period	-	418	O
after	-	425	O
transplantation	-	431	O
,	-	446	O
leads	-	448	O
to	-	454	O
a	-	457	O
higher	-	459	O
rate	-	466	O
of	-	471	O
dialysis	-	474	O
,	-	482	O
and	-	484	O
chronic	-	488	O
nephrotoxicity	-	496	B
may	-	511	O
eventually	-	515	O
result	-	526	O
in	-	533	O
graft	-	536	O
loss	-	542	O
.	-	546	O

Acute	11583940	548	O
and	-	554	O
chronic	-	558	O
nephrotoxicity	-	566	B
is	-	581	O
becoming	-	584	O
more	-	593	O
common	-	598	O
as	-	605	O
the	-	608	O
use	-	612	O
of	-	616	O
marginal	-	619	O
kidneys	-	628	O
for	-	636	O
transplantation	-	640	O
increases	-	656	O
.	-	665	O

Two	11583940	667	O
recently	-	671	O
available	-	680	O
immunosuppressive	-	690	O
agents	-	708	O
,	-	714	O
mycophenolate	-	716	O
mofetil	-	730	O
and	-	738	O
sirolimus	-	742	O
(	-	752	O
rapamycin	-	753	O
)	-	762	O
,	-	763	O
have	-	765	O
no	-	770	O
nephrotoxicity	-	773	B
.	-	787	O

The	11583940	789	O
use	-	793	O
of	-	797	O
these	-	800	O
drugs	-	806	O
in	-	812	O
combination	-	815	O
with	-	827	O
other	-	832	O
agents	-	838	O
has	-	845	O
led	-	849	O
to	-	853	O
the	-	856	O
development	-	860	O
of	-	872	O
new	-	875	O
paradigms	-	879	O
of	-	889	O
immunosuppressive	-	892	O
therapy	-	910	O
.	-	917	O

This	11583940	919	O
paper	-	924	O
reviews	-	930	O
the	-	938	O
results	-	942	O
of	-	950	O
clinical	-	953	O
trials	-	962	O
that	-	969	O
have	-	974	O
investigated	-	979	O
these	-	992	O
new	-	998	O
approaches	-	1002	O
to	-	1013	O
immunosuppression	-	1016	O
in	-	1034	O
renal	-	1037	O
transplant	-	1043	O
recipients	-	1054	O
.	-	1064	O

Erythropoietin	11245434	0	O
restores	-	15	O
the	-	24	O
anemia	-	28	B
-	-	34	O
induced	-	35	O
reduction	-	43	O
in	-	53	O
cyclophosphamide	-	56	O
cytotoxicity	-	73	B
in	-	86	O
rat	-	89	O
tumors	-	93	B
.	-	99	O

The	11245434	101	O
aim	-	105	O
of	-	109	O
this	-	112	O
study	-	117	O
was	-	123	O
to	-	127	O
examine	-	130	O
the	-	138	O
impact	-	142	O
of	-	149	O
anemia	-	152	B
prevention	-	159	O
by	-	170	O
recombinant	-	173	O
human	-	185	O
erythropoietin	-	191	O
(	-	206	O
rHuEPO	-	207	O
)	-	213	O
treatment	-	215	O
on	-	225	O
the	-	228	O
cytotoxicity	-	232	B
of	-	245	O
cyclophosphamide	-	248	O
in	-	265	O
solid	-	268	O
experimental	-	274	O
tumors	-	287	B
.	-	293	O

Anemia	11245434	295	B
was	-	302	O
induced	-	306	O
using	-	314	O
a	-	320	O
single	-	322	O
dose	-	329	O
of	-	334	O
carboplatin	-	337	O
(	-	349	O
50	-	350	O
mg	-	353	O
/	-	355	O
kg	-	356	O
i	-	359	O
.	-	360	O
v	-	361	O
.	-	362	O
)	-	363	O
resulting	-	365	O
in	-	375	O
a	-	378	O
long	-	380	O
-	-	384	O
lasting	-	385	O
reduction	-	393	O
(	-	403	O
30	-	404	O
%	-	406	O
)	-	407	O
of	-	409	O
the	-	412	O
hemoglobin	-	416	O
concentration	-	427	O
.	-	440	O

In	11245434	442	O
a	-	445	O
second	-	447	O
group	-	454	O
,	-	459	O
the	-	461	O
development	-	465	O
of	-	477	O
anemia	-	480	B
was	-	487	O
prevented	-	491	O
by	-	501	O
rHuEPO	-	504	O
(	-	511	O
1000	-	512	O
IU	-	517	O
/	-	519	O
kg	-	520	O
)	-	522	O
administered	-	524	O
s	-	537	O
.	-	538	O
c	-	539	O
.	-	540	O

three	11245434	542	O
times	-	548	O
/	-	553	O
week	-	554	O
starting	-	559	O
7	-	568	O
days	-	570	O
before	-	575	O
carboplatin	-	582	O
application	-	594	O
.	-	605	O

Four	11245434	607	O
days	-	612	O
after	-	617	O
carboplatin	-	623	O
treatment	-	635	O
,	-	644	O
tumors	-	646	B
(	-	653	O
DS	-	654	O
-	-	656	O
sarcoma	-	657	B
of	-	665	O
the	-	668	O
rat	-	672	O
)	-	675	O
were	-	677	O
implanted	-	682	O
s	-	692	O
.	-	693	O
c	-	694	O
.	-	695	O

onto	11245434	697	O
the	-	702	O
hind	-	706	O
food	-	711	O
dorsum	-	716	O
.	-	722	O

Neither	11245434	724	O
carboplatin	-	732	O
nor	-	744	O
rHuEPO	-	748	O
treatment	-	755	O
influenced	-	765	O
tumor	-	776	B
growth	-	782	O
rate	-	789	O
per	-	794	O
se	-	798	O
.	-	800	O

When	11245434	802	O
tumors	-	807	B
were	-	814	O
treated	-	819	O
with	-	827	O
a	-	832	O
single	-	834	O
dose	-	841	O
of	-	846	O
cyclophosphamide	-	849	O
(	-	866	O
60	-	867	O
mg	-	870	O
/	-	872	O
kg	-	873	O

i	11245434	876	O
.	-	877	O
p	-	878	O
.	-	879	O
)	-	880	O

5	11245434	882	O
days	-	884	O
after	-	889	O
implantation	-	895	O
,	-	907	O
a	-	909	O
growth	-	911	O
delay	-	918	O
with	-	924	O
a	-	929	O
subsequent	-	931	O
regrowth	-	942	O
of	-	951	O
the	-	954	O
tumors	-	958	B
was	-	965	O
observed	-	969	O
.	-	977	O

In	11245434	979	O
the	-	982	O
anemia	-	986	B
group	-	993	O
,	-	998	O
the	-	1000	O
growth	-	1004	O
delay	-	1011	O
was	-	1017	O
significantly	-	1021	O
shorter	-	1035	O
compared	-	1043	O
with	-	1052	O
nonanemic	-	1057	O
controls	-	1067	O
(	-	1076	O
13	-	1077	O
.	-	1079	O
3	-	1080	O
days	-	1082	O
versus	-	1087	O
8	-	1094	O
.	-	1095	O
6	-	1096	O
days	-	1098	O
)	-	1102	O
.	-	1103	O

In	11245434	1105	O
the	-	1108	O
group	-	1112	O
where	-	1118	O
anemia	-	1124	B
was	-	1131	O
prevented	-	1135	O
by	-	1145	O
rHuEPO	-	1148	O
treatment	-	1155	O
,	-	1164	O
growth	-	1166	O
delay	-	1173	O
was	-	1179	O
comparable	-	1183	O
with	-	1194	O
that	-	1199	O
of	-	1204	O
nonanemic	-	1207	O
controls	-	1217	O
(	-	1226	O
13	-	1227	O
.	-	1229	O
3	-	1230	O
days	-	1232	O
)	-	1236	O
.	-	1237	O

These	11245434	1239	O
results	-	1245	O
suggest	-	1253	O
that	-	1261	O
chemotherapy	-	1266	O
-	-	1278	O
induced	-	1279	O
anemia	-	1287	B
reduces	-	1294	O
cytotoxicity	-	1302	B
of	-	1315	O
cyclophosphamide	-	1318	O
in	-	1335	O
tumors	-	1338	B
,	-	1344	O
whereas	-	1346	O
correction	-	1354	O
of	-	1365	O
anemia	-	1368	B
by	-	1375	O
rHuEPO	-	1378	O
treatment	-	1385	O
(	-	1395	O
epoetin	-	1396	O
alpha	-	1404	O
)	-	1409	O
increases	-	1411	O
the	-	1421	O
sensitivity	-	1425	O
,	-	1436	O
probably	-	1438	O
as	-	1447	O
a	-	1450	O
result	-	1452	O
of	-	1459	O
an	-	1462	O
improved	-	1465	O
oxygen	-	1474	O
supply	-	1481	O
to	-	1488	O
tumor	-	1491	B
tissue	-	1497	O
.	-	1503	O

The	11243580	0	O
role	-	4	O
of	-	9	O
nitrergic	-	12	O
system	-	22	O
in	-	29	O
lidocaine	-	32	O
-	-	41	O
induced	-	42	O
convulsion	-	50	B
in	-	61	O
the	-	64	O
mouse	-	68	O
.	-	73	O

The	11243580	75	O
effects	-	79	O
of	-	87	O
N	-	90	O
-	-	91	O
nitro	-	92	O
-	-	97	O
L	-	98	O
-	-	99	O
arginine	-	100	O
-	-	108	O
methyl	-	109	O
ester	-	116	O
(	-	122	O
L	-	123	O
-	-	124	O
NAME	-	125	O
)	-	129	O
a	-	131	O
nitric	-	133	O
oxide	-	140	O
(	-	146	O
NO	-	147	O
)	-	149	O
synthase	-	151	O
inhibitor	-	160	O
and	-	170	O
L	-	174	O
-	-	175	O
arginine	-	176	O
,	-	184	O
a	-	186	O
NO	-	188	O
precursor	-	191	O
,	-	200	O
were	-	202	O
investigated	-	207	O
on	-	220	O
lidocaine	-	223	O
-	-	232	O
induced	-	233	O
convulsions	-	241	B
.	-	252	O

In	11243580	254	O
the	-	257	O
first	-	261	O
experiment	-	267	O
,	-	277	O
four	-	279	O
groups	-	284	O
of	-	291	O
mice	-	294	O
received	-	299	O
physiological	-	308	O
saline	-	322	O
(	-	329	O
0	-	330	O
.	-	331	O
9	-	332	O
%	-	333	O
)	-	334	O
,	-	335	O
L	-	337	O
-	-	338	O
arginine	-	339	O
(	-	348	O
300	-	349	O
mg	-	353	O
/	-	355	O
kg	-	356	O
,	-	358	O
i	-	360	O
.	-	361	O
p	-	362	O
.	-	363	O
)	-	364	O
,	-	365	O
L	-	367	O
-	-	368	O
NAME	-	369	O
(	-	374	O
100	-	375	O
mg	-	379	O
/	-	381	O
kg	-	382	O
,	-	384	O
i	-	386	O
.	-	387	O
p	-	388	O
.	-	389	O
)	-	390	O
and	-	392	O
diazepam	-	396	O
(	-	405	O
2	-	406	O
mg	-	408	O
/	-	410	O
kg	-	411	O
)	-	413	O
,	-	414	O
respectively	-	416	O
.	-	428	O

Thirty	11243580	430	O
minutes	-	437	O
after	-	445	O
these	-	451	O
injections	-	457	O
,	-	467	O
all	-	469	O
mice	-	473	O
received	-	478	O
lidocaine	-	487	O
(	-	497	O
50	-	498	O
mg	-	501	O
/	-	503	O
kg	-	504	O
,	-	506	O
i	-	508	O
.	-	509	O
p	-	510	O
.	-	511	O
)	-	512	O
.	-	513	O

In	11243580	515	O
the	-	518	O
second	-	522	O
experiment	-	529	O
,	-	539	O
four	-	541	O
groups	-	546	O
of	-	553	O
mice	-	556	O
received	-	561	O
similar	-	570	O
treatment	-	578	O
in	-	588	O
the	-	591	O
first	-	595	O
experiment	-	601	O
,	-	611	O
and	-	613	O
30	-	617	O
min	-	620	O
after	-	624	O
these	-	630	O
injections	-	636	O
,	-	646	O
all	-	648	O
mice	-	652	O
received	-	657	O
a	-	666	O
higher	-	668	O
dose	-	675	O
of	-	680	O
lidocaine	-	683	O
(	-	693	O
80	-	694	O
mg	-	697	O
/	-	699	O
kg	-	700	O
)	-	702	O
.	-	703	O

L	11243580	705	O
-	-	706	O
NAME	-	707	O
(	-	712	O
100	-	713	O
mg	-	717	O
/	-	719	O
kg	-	720	O
,	-	722	O
i	-	724	O
.	-	725	O
p	-	726	O
.	-	727	O
)	-	728	O
and	-	730	O
diazepam	-	734	O
(	-	743	O
2	-	744	O
mg	-	746	O
/	-	748	O
kg	-	749	O
)	-	751	O
significantly	-	753	O
decreased	-	767	O
the	-	777	O
incidence	-	781	O
of	-	791	O
lidocaine	-	794	O
(	-	804	O
50	-	805	O
mg	-	808	O
/	-	810	O
kg	-	811	O
)	-	813	O
-	-	814	O
induced	-	815	O
convulsions	-	823	B
.	-	834	O

In	11243580	836	O
contrast	-	839	O
,	-	847	O
the	-	849	O
L	-	853	O
-	-	854	O
arginine	-	855	O
treatment	-	864	O
increased	-	874	O
the	-	884	O
incidence	-	888	O
of	-	898	O
lidocaine	-	901	O
(	-	911	O
80	-	912	O
mg	-	915	O
/	-	917	O
kg	-	918	O
,	-	920	O
i	-	922	O
.	-	923	O
p	-	924	O
.	-	925	O
)	-	926	O
-	-	927	O
induced	-	928	O
convulsions	-	936	B
significantly	-	948	O
.	-	961	O

These	11243580	963	O
results	-	969	O
may	-	977	O
suggest	-	981	O
that	-	989	O
NO	-	994	O
is	-	997	O
a	-	1000	O
proconvulsant	-	1002	O
mediator	-	1016	O
in	-	1025	O
lidocaine	-	1028	O
-	-	1037	O
induced	-	1038	O
convulsions	-	1046	B
.	-	1057	O

Effect	11079278	0	O
of	-	7	O
intravenous	-	10	O
metoprolol	-	22	O
or	-	33	O
intravenous	-	36	O
metoprolol	-	48	O
plus	-	59	O
glucagon	-	64	O
on	-	73	O
dobutamine	-	76	O
-	-	86	O
induced	-	87	O
myocardial	-	95	B
ischemia	-	106	I
.	-	114	O

STUDY	11079278	116	O
OBJECTIVE	-	122	O
:	-	131	O

To	11079278	133	O
determine	-	136	O
the	-	146	O
effect	-	150	O
of	-	157	O
metoprolol	-	160	O
on	-	171	O
dobutamine	-	174	O
stress	-	185	O
testing	-	192	O
with	-	200	O
technetium	-	205	O
-	-	215	O
99	-	216	O
m	-	218	O
sestamibi	-	220	O
single	-	230	O
-	-	236	O
photon	-	237	O
emission	-	244	O
computed	-	253	O
tomography	-	262	O
imaging	-	273	O
and	-	281	O
ST	-	285	O
-	-	287	O
segment	-	288	O
monitoring	-	296	O
,	-	306	O
and	-	308	O
to	-	312	O
assess	-	315	O
the	-	322	O
impact	-	326	O
of	-	333	O
intravenous	-	336	O
glucagon	-	348	O
on	-	357	O
metoprolol	-	360	O
's	-	370	O
effects	-	373	O
.	-	380	O

DESIGN	11079278	382	O
:	-	388	O

Randomized	11079278	390	O
,	-	400	O
double	-	402	O
-	-	408	O
blind	-	409	O
,	-	414	O
placebo	-	416	O
-	-	423	O
controlled	-	424	O
trial	-	435	O
.	-	440	O

SETTING	11079278	442	O
:	-	449	O

Community	11079278	451	O
hospital	-	461	O
.	-	469	O

PATIENTS	11079278	471	O
:	-	479	O

Twenty	11079278	481	O
-	-	487	O
two	-	488	O
patients	-	492	O
with	-	501	O
known	-	506	O
reversible	-	512	O
perfusion	-	523	O
defects	-	533	O
.	-	540	O

INTERVENTION	11079278	542	O
:	-	554	O

Patients	11079278	556	O
underwent	-	565	O
dobutamine	-	575	O
stress	-	586	O
tests	-	593	O
per	-	599	O
standard	-	603	O
protocol	-	612	O
.	-	620	O

Before	11079278	622	O
dobutamine	-	629	O
was	-	640	O
begun	-	644	O
,	-	649	O
no	-	651	O
therapy	-	654	O
was	-	662	O
given	-	666	O
during	-	672	O
the	-	679	O
first	-	683	O
visit	-	689	O
,	-	694	O
and	-	696	O
patients	-	700	O
were	-	709	O
randomized	-	714	O
on	-	725	O
subsequent	-	728	O
visits	-	739	O
to	-	746	O
receive	-	749	O
metoprolol	-	757	O
or	-	768	O
metoprolol	-	771	O
plus	-	782	O
glucagon	-	787	O
1	-	796	O
mg	-	798	O
.	-	800	O

Metoprolol	11079278	802	O
was	-	813	O
dosed	-	817	O
to	-	823	O
achieve	-	826	O
a	-	834	O
resting	-	836	O
predobutamine	-	844	O
heart	-	858	O
rate	-	864	O
below	-	869	O
65	-	875	O
beats	-	878	O
/	-	883	O
minute	-	884	O
or	-	891	O
a	-	894	O
total	-	896	O
intravenous	-	902	O
dose	-	914	O
of	-	919	O
20	-	922	O
mg	-	925	O
.	-	927	O

MEASUREMENTS	11079278	929	O
AND	-	942	O
MAIN	-	946	O
RESULTS	-	951	O
:	-	958	O

Metoprolol	11079278	960	O
reduced	-	971	O
maximum	-	979	O
heart	-	987	O
rate	-	993	O
31	-	998	O
%	-	1000	O
,	-	1001	O
summed	-	1003	O
stress	-	1010	O
scores	-	1017	O
29	-	1024	O
%	-	1026	O
,	-	1027	O
and	-	1029	O
summed	-	1033	O
difference	-	1040	O
scores	-	1051	O
43	-	1058	O
%	-	1060	O
versus	-	1062	O
control	-	1069	O
.	-	1076	O

Metoprolol	11079278	1078	O
plus	-	1089	O
glucagon	-	1094	O
also	-	1103	O
reduced	-	1108	O
the	-	1116	O
maximum	-	1120	O
heart	-	1128	O
rate	-	1134	O
29	-	1139	O
%	-	1141	O
versus	-	1143	O
control	-	1150	O
.	-	1157	O

Summed	11079278	1159	O
stress	-	1166	O
and	-	1173	O
summed	-	1177	O
difference	-	1184	O
scores	-	1195	O
were	-	1202	O
not	-	1207	O
significantly	-	1211	O
reduced	-	1225	O
,	-	1232	O
although	-	1234	O
they	-	1243	O
were	-	1248	O
18	-	1253	O
%	-	1255	O
and	-	1257	O
30	-	1261	O
%	-	1263	O
lower	-	1265	O
,	-	1270	O
respectively	-	1272	O
,	-	1284	O
than	-	1286	O
control	-	1291	O
.	-	1298	O

No	11079278	1300	O
significant	-	1303	O
differences	-	1315	O
were	-	1327	O
found	-	1332	O
in	-	1338	O
any	-	1341	O
parameter	-	1345	O
between	-	1355	O
metoprolol	-	1363	O
and	-	1374	O
metoprolol	-	1378	O
-	-	1388	O
glucagon	-	1389	O
.	-	1397	O

CONCLUSION	11079278	1399	O
:	-	1409	O

During	11079278	1411	O
dobutamine	-	1418	O
stress	-	1429	O
testing	-	1436	O
,	-	1443	O
metoprolol	-	1445	O
attenuates	-	1456	O
or	-	1467	O
eliminates	-	1470	O
evidence	-	1481	O
of	-	1490	O
myocardial	-	1493	B
ischemia	-	1504	I
.	-	1512	O

Glucagon	11079278	1514	O
1	-	1523	O
mg	-	1525	O
,	-	1527	O
although	-	1529	O
somewhat	-	1538	O
effective	-	1547	O
,	-	1556	O
does	-	1558	O
not	-	1563	O
correct	-	1567	O
this	-	1575	O
effect	-	1580	O
to	-	1587	O
the	-	1590	O
extent	-	1594	O
that	-	1601	O
it	-	1606	O
can	-	1609	O
be	-	1613	O
administered	-	1616	O
clinically	-	1629	O
.	-	1639	O

Prednisolone	10910842	0	O
-	-	12	O
induced	-	13	O
muscle	-	21	B
dysfunction	-	28	I
is	-	40	O
caused	-	43	O
more	-	50	O
by	-	55	O
atrophy	-	58	B
than	-	66	O
by	-	71	O
altered	-	74	O
acetylcholine	-	82	O
receptor	-	96	O
expression	-	105	O
.	-	115	O

Large	10910842	117	O
doses	-	123	O
of	-	129	O
glucocorticoids	-	132	O
can	-	148	O
alter	-	152	O
muscle	-	158	O
physiology	-	165	O
and	-	176	O
susceptibility	-	180	O
to	-	195	O
neuromuscular	-	198	O
blocking	-	212	O
drugs	-	221	O
by	-	227	O
mechanisms	-	230	O
not	-	241	O
clearly	-	245	O
understood	-	253	O
.	-	263	O

We	10910842	265	O
investigated	-	268	O
the	-	281	O
effects	-	285	O
of	-	293	O
moderate	-	296	O
and	-	305	O
large	-	309	O
doses	-	315	O
of	-	321	O
prednisolone	-	324	O
on	-	337	O
muscle	-	340	O
function	-	347	O
and	-	356	O
pharmacology	-	360	O
,	-	372	O
and	-	374	O
their	-	378	O
relationship	-	384	O
to	-	397	O
changes	-	400	O
in	-	408	O
muscle	-	411	O
size	-	418	O
and	-	423	O
acetylcholine	-	427	O
receptor	-	441	O
(	-	450	O
AChR	-	451	O
)	-	455	O
expression	-	457	O
.	-	467	O

With	10910842	469	O
institutional	-	474	O
approval	-	488	O
,	-	496	O
35	-	498	O
Sprague	-	501	O
-	-	508	O
Dawley	-	509	O
rats	-	516	O
were	-	521	O
randomly	-	526	O
allocated	-	535	O
to	-	545	O
receive	-	548	O
daily	-	556	O
subcutaneous	-	562	O
doses	-	575	O
of	-	581	O
10	-	584	O
mg	-	587	O
/	-	589	O
kg	-	590	O
prednisolone	-	593	O
(	-	606	O
P10	-	607	O
group	-	611	O
)	-	616	O
,	-	617	O
100	-	619	O
mg	-	623	O
/	-	625	O
kg	-	626	O
prednisolone	-	629	O
(	-	642	O
P100	-	643	O
group	-	648	O
)	-	653	O
,	-	654	O
or	-	656	O
an	-	659	O
equal	-	662	O
volume	-	668	O
of	-	675	O
saline	-	678	O
(	-	685	O
S	-	686	O
group	-	688	O
)	-	693	O
for	-	695	O
7	-	699	O
days	-	701	O
.	-	705	O

A	10910842	707	O
fourth	-	709	O
group	-	716	O
of	-	722	O
rats	-	725	O
was	-	730	O
pair	-	734	O
fed	-	739	O
(	-	743	O
food	-	744	O
restricted	-	749	O
)	-	759	O
with	-	761	O
the	-	766	O
P100	-	770	O
rats	-	775	O
for	-	780	O
7	-	784	O
days	-	786	O
(	-	791	O
FR	-	792	O
group	-	795	O
)	-	800	O
.	-	801	O

On	10910842	803	O
Day	-	806	O
8	-	810	O
,	-	811	O
the	-	813	O
nerve	-	817	O
-	-	822	O
evoked	-	823	O
peak	-	830	O
twitch	-	835	O
tensions	-	842	O
,	-	850	O
tetanic	-	852	B
tensions	-	860	O
,	-	868	O
and	-	870	O
fatigability	-	874	O
,	-	886	O
and	-	888	O
the	-	892	O
dose	-	896	O
-	-	900	O
response	-	901	O
curves	-	910	O
of	-	917	O
d	-	920	O
-	-	921	O
tubocurarine	-	922	O
in	-	935	O
the	-	938	O
tibialis	-	942	O
cranialis	-	951	O
muscle	-	961	O
were	-	968	O
measured	-	973	O
in	-	982	O
vivo	-	985	O
and	-	990	O
related	-	994	O
to	-	1002	O
muscle	-	1005	O
mass	-	1012	O
or	-	1017	O
expression	-	1020	O
of	-	1031	O
AChRs	-	1034	O
.	-	1039	O

Rate	10910842	1041	O
of	-	1046	O
body	-	1049	O
weight	-	1054	O
gain	-	1061	O
was	-	1066	O
depressed	-	1070	O
in	-	1080	O
the	-	1083	O
P100	-	1087	O
,	-	1091	O
FR	-	1093	O
,	-	1095	O
and	-	1097	O
P10	-	1101	O
groups	-	1105	O
compared	-	1112	O
with	-	1121	O
the	-	1126	O
S	-	1130	O
group	-	1132	O
.	-	1137	O

Tibialis	10910842	1139	O
muscle	-	1148	O
mass	-	1155	O
was	-	1160	O
smaller	-	1164	O
in	-	1172	O
the	-	1175	O
P100	-	1179	O
group	-	1184	O
than	-	1190	O
in	-	1195	O
the	-	1198	O
P10	-	1202	O
or	-	1206	O
S	-	1209	O
groups	-	1211	O
.	-	1217	O

The	10910842	1219	O
evoked	-	1223	O
peak	-	1230	O
twitch	-	1235	O
and	-	1242	O
tetanic	-	1246	B
tensions	-	1254	O
were	-	1263	O
less	-	1268	O
in	-	1273	O
the	-	1276	O
P100	-	1280	O
group	-	1285	O
than	-	1291	O
in	-	1296	O
the	-	1299	O
P10	-	1303	O
or	-	1307	O
S	-	1310	O
groups	-	1312	O
,	-	1318	O
however	-	1320	O
,	-	1327	O
tension	-	1329	O
per	-	1337	O
milligram	-	1341	O
of	-	1351	O
muscle	-	1354	O
mass	-	1361	O
was	-	1366	O
greater	-	1370	O
in	-	1378	O
the	-	1381	O
P100	-	1385	O
group	-	1390	O
than	-	1396	O
in	-	1401	O
the	-	1404	O
S	-	1408	O
group	-	1410	O
.	-	1415	O

The	10910842	1417	O
50	-	1421	O
%	-	1423	O
effective	-	1425	O
dose	-	1435	O
of	-	1440	O
d	-	1443	O
-	-	1444	O
tubocurarine	-	1445	O
(	-	1458	O
microg	-	1459	O
/	-	1465	O
kg	-	1466	O
)	-	1468	O
in	-	1470	O
the	-	1473	O
tibialis	-	1477	O
muscle	-	1486	O
was	-	1493	O
smaller	-	1497	O
in	-	1505	O
the	-	1508	O
P10	-	1512	O
(	-	1516	O
33	-	1517	O
.	-	1519	O
6	-	1520	O
+	-	1522	O
/	-	1523	O
-	-	1524	O

5	10910842	1526	O
.	-	1527	O
4	-	1528	O
)	-	1529	O
than	-	1531	O
in	-	1536	O
the	-	1539	O
S	-	1543	O
(	-	1545	O
61	-	1546	O
.	-	1548	O
9	-	1549	O
+	-	1551	O
/	-	1552	O
-	-	1553	O

5	10910842	1555	O
.	-	1556	O
0	-	1557	O
)	-	1558	O
or	-	1560	O
the	-	1563	O
P100	-	1567	O
(	-	1572	O
71	-	1573	O
.	-	1575	O
3	-	1576	O
+	-	1578	O
/	-	1579	O
-	-	1580	O

9	10910842	1582	O
.	-	1583	O
6	-	1584	O
)	-	1585	O
groups	-	1587	O
.	-	1593	O

AChR	10910842	1595	O
expression	-	1600	O
was	-	1611	O
less	-	1615	O
in	-	1620	O
the	-	1623	O
P10	-	1627	O
group	-	1631	O
than	-	1637	O
in	-	1642	O
the	-	1645	O
S	-	1649	O
group	-	1651	O
.	-	1656	O

The	10910842	1658	O
evoked	-	1662	O
tensions	-	1669	O
correlated	-	1678	O
with	-	1689	O
muscle	-	1694	O
mass	-	1701	O
(	-	1706	O
r	-	1707	O
(	-	1708	O
2	-	1709	O
)	-	1710	O
=	-	1712	O
0	-	1714	O
.	-	1715	O
32	-	1716	O
,	-	1718	O
P	-	1720	O
<	-	1722	O
0	-	1724	O
.	-	1725	O
001	-	1726	O
)	-	1729	O
,	-	1730	O
however	-	1732	O
,	-	1739	O
not	-	1741	O
with	-	1745	O
expression	-	1750	O
of	-	1761	O
AChR	-	1764	O
.	-	1768	O

The	10910842	1770	O
50	-	1774	O
%	-	1776	O
effective	-	1778	O
dose	-	1788	O
of	-	1793	O
d	-	1796	O
-	-	1797	O
tubocurarine	-	1798	O
did	-	1811	O
not	-	1815	O
correlate	-	1819	O
with	-	1829	O
muscle	-	1834	O
mass	-	1841	O
or	-	1846	O
AChR	-	1849	O
expression	-	1854	O
.	-	1864	O

Our	10910842	1866	O
results	-	1870	O
suggest	-	1878	O
that	-	1886	O
the	-	1891	O
neuromuscular	-	1895	B
dysfunction	-	1909	I
after	-	1921	O
prednisolone	-	1927	O
is	-	1940	O
dose	-	1943	O
-	-	1947	O
dependent	-	1948	O
,	-	1957	O
and	-	1959	O
derives	-	1963	O
primarily	-	1971	O
from	-	1981	O
muscle	-	1986	B
atrophy	-	1993	I
and	-	2001	O
derives	-	2005	O
less	-	2013	O
so	-	2018	O
from	-	2021	O
changes	-	2026	O
in	-	2034	O
AChR	-	2037	O
expression	-	2042	O
.	-	2052	O

IMPLICATIONS	10910842	2054	O
:	-	2066	O

The	10910842	2068	O
mechanisms	-	2072	O
by	-	2083	O
which	-	2086	O
chronic	-	2092	O
glucocorticoid	-	2100	O
therapy	-	2115	O
alters	-	2123	O
neuromuscular	-	2130	O
physiology	-	2144	O
and	-	2155	O
pharmacology	-	2159	O
are	-	2172	O
unclear	-	2176	O
.	-	2183	O

We	10910842	2185	O
suggest	-	2188	O
that	-	2196	O
the	-	2201	O
observed	-	2205	O
effects	-	2214	O
are	-	2222	O
dose	-	2226	O
-	-	2230	O
dependent	-	2231	O
and	-	2241	O
derive	-	2245	O
primarily	-	2252	O
from	-	2262	O
muscle	-	2267	B
atrophy	-	2274	I
and	-	2282	O
derive	-	2286	O
less	-	2293	O
from	-	2298	O
changes	-	2303	O
in	-	2311	O
acetylcholine	-	2314	O
receptor	-	2328	O
expression	-	2337	O
.	-	2347	O

Rapid	10533019	0	O
reversal	-	6	O
of	-	15	O
life	-	18	O
-	-	22	O
threatening	-	23	O
diltiazem	-	35	O
-	-	44	O
induced	-	45	O
tetany	-	53	B
with	-	60	O
calcium	-	65	O
chloride	-	73	O
.	-	81	O

We	10533019	83	O
describe	-	86	O
a	-	95	O
patient	-	97	O
who	-	105	O
developed	-	109	O
tetany	-	119	B
with	-	126	O
sudden	-	131	O
respiratory	-	138	B
arrest	-	150	I
after	-	157	O
the	-	163	O
infusion	-	167	O
of	-	176	O
intravenous	-	179	O
diltiazem	-	191	O
.	-	200	O

The	10533019	202	O
administration	-	206	O
of	-	221	O
calcium	-	224	O
chloride	-	232	O
rapidly	-	241	O
resolved	-	249	O
the	-	258	O
patient	-	262	O
's	-	269	O
tetany	-	272	B
with	-	279	O
prompt	-	284	O
recovery	-	291	O
of	-	300	O
respiratory	-	303	O
function	-	315	O
,	-	323	O
averting	-	325	O
the	-	334	O
need	-	338	O
for	-	343	O
more	-	347	O
aggressive	-	352	O
airway	-	363	O
management	-	370	O
and	-	381	O
ventilatory	-	385	O
support	-	397	O
.	-	404	O

The	10533019	406	O
emergency	-	410	O
physician	-	420	O
should	-	430	O
be	-	437	O
aware	-	440	O
that	-	446	O
life	-	451	O
-	-	455	O
threatening	-	456	O
tetany	-	468	B
may	-	475	O
accompany	-	479	O
the	-	489	O
administration	-	493	O
of	-	508	O
intravenous	-	511	O
diltiazem	-	523	O
and	-	533	O
that	-	537	O
calcium	-	542	O
chloride	-	550	O
may	-	559	O
be	-	563	O
a	-	566	O
rapid	-	568	O
and	-	574	O
effective	-	578	O
remedy	-	588	O
.	-	594	O

Effects	10414674	0	O
of	-	8	O
nonsteroidal	-	11	O
anti	-	24	O
-	-	28	O
inflammatory	-	29	O
drugs	-	42	O
on	-	48	O
hemostasis	-	51	O
in	-	62	O
patients	-	65	O
with	-	74	O
aneurysmal	-	79	B
subarachnoid	-	90	I
hemorrhage	-	103	I
.	-	113	O

Platelet	10414674	115	O
function	-	124	O
is	-	133	O
impaired	-	136	O
by	-	145	O
nonsteroidal	-	148	O
anti	-	161	O
-	-	165	O
inflammatory	-	166	O
drugs	-	179	O
(	-	185	O
NSAIDs	-	186	O
)	-	192	O
with	-	194	O
prominent	-	199	O
anti	-	209	O
-	-	213	O
inflammatory	-	214	O
properties	-	227	O
.	-	237	O

Their	10414674	239	O
safety	-	245	O
in	-	252	O
patients	-	255	O
undergoing	-	264	O
intracranial	-	275	O
surgery	-	288	O
is	-	296	O
under	-	299	O
debate	-	305	O
.	-	311	O

Patients	10414674	313	O
with	-	322	O
aneurysmal	-	327	B
subarachnoid	-	338	I
hemorrhage	-	351	I
(	-	362	O
SAH	-	363	B
)	-	366	O
were	-	368	O
randomized	-	373	O
to	-	384	O
receive	-	387	O
either	-	395	O
ketoprofen	-	402	O
,	-	412	O
100	-	414	O
mg	-	418	O
,	-	420	O
three	-	422	O
times	-	428	O
a	-	434	O
day	-	436	O
(	-	440	O
ketoprofen	-	441	O
group	-	452	O
,	-	457	O
n	-	459	O
=	-	461	O
9	-	463	O
)	-	464	O
or	-	466	O
a	-	469	O
weak	-	471	O
NSAID	-	476	O
,	-	481	O
acetaminophen	-	483	O
,	-	496	O
1	-	498	O
g	-	500	O
,	-	501	O
three	-	503	O
times	-	509	O
a	-	515	O
day	-	517	O
(	-	521	O
acetaminophen	-	522	O
group	-	536	O
,	-	541	O
n	-	543	O
=	-	545	O
9	-	547	O
)	-	548	O
starting	-	550	O
immediately	-	559	O
after	-	571	O
the	-	577	O
diagnosis	-	581	O
of	-	591	O
aneurysmal	-	594	B
SAH	-	605	B
.	-	608	O

Treatment	10414674	610	O
was	-	620	O
continued	-	624	O
for	-	634	O
3	-	638	O
days	-	640	O
postoperatively	-	645	O
.	-	660	O

Test	10414674	662	O
blood	-	667	O
samples	-	673	O
were	-	681	O
taken	-	686	O
before	-	692	O
treatment	-	699	O
and	-	709	O
surgery	-	713	O
as	-	721	O
well	-	724	O
as	-	729	O
on	-	732	O
the	-	735	O
first	-	739	O
,	-	744	O
third	-	746	O
,	-	751	O
and	-	753	O
fifth	-	757	O
postoperative	-	763	O
mornings	-	777	O
.	-	785	O

Maximal	10414674	787	O
platelet	-	795	B
aggregation	-	804	I
induced	-	816	O
by	-	824	O
6	-	827	O
microM	-	829	O
of	-	836	O
adenosine	-	839	O
diphosphate	-	849	O
decreased	-	861	O
after	-	871	O
administration	-	877	O
of	-	892	O
ketoprofen	-	895	O
.	-	905	O

Aggregation	10414674	907	O
was	-	919	O
lower	-	923	O
(	-	929	O
P	-	930	O
<	-	932	O
.	-	934	O
05	-	935	O
)	-	937	O
in	-	939	O
the	-	942	O
ketoprofen	-	946	O
group	-	957	O
than	-	963	O
in	-	968	O
the	-	971	O
acetaminophen	-	975	O
group	-	989	O
just	-	995	O
before	-	1000	O
surgery	-	1007	O
and	-	1015	O
on	-	1019	O
the	-	1022	O
third	-	1026	O
postoperative	-	1032	O
day	-	1046	O
.	-	1049	O

In	10414674	1051	O
contrast	-	1054	O
,	-	1062	O
maximal	-	1064	O
platelet	-	1072	B
aggregation	-	1081	I
increased	-	1093	O
in	-	1103	O
the	-	1106	O
acetaminophen	-	1110	O
group	-	1124	O
on	-	1130	O
the	-	1133	O
third	-	1137	O
postoperative	-	1143	O
day	-	1157	O
as	-	1161	O
compared	-	1164	O
with	-	1173	O
the	-	1178	O
pretreatment	-	1182	O
platelet	-	1195	B
aggregation	-	1204	I
results	-	1216	O
(	-	1224	O
P	-	1225	O
<	-	1227	O
.	-	1229	O
05	-	1230	O
)	-	1232	O
.	-	1233	O

One	10414674	1235	O
patient	-	1239	O
in	-	1247	O
the	-	1250	O
ketoprofen	-	1254	O
group	-	1265	O
developed	-	1271	O
a	-	1281	O
postoperative	-	1283	O
intracranial	-	1297	O
hematoma	-	1310	B
.	-	1318	O

Coagulation	10414674	1320	O
(	-	1332	O
prothrombin	-	1333	O
time	-	1345	O
[	-	1350	O
PT	-	1351	O
]	-	1353	O
,	-	1354	O
activated	-	1356	O
partial	-	1366	O
thromboplastin	-	1374	O
time	-	1389	O
[	-	1394	O
APPT	-	1395	O
]	-	1399	O
,	-	1400	O
fibrinogen	-	1402	O
concentration	-	1413	O
,	-	1426	O
and	-	1428	O
antithrombin	-	1432	O
III	-	1445	O

[	10414674	1449	O
AT	-	1450	O
III	-	1453	O
]	-	1456	O
)	-	1457	O
was	-	1459	O
comparable	-	1463	O
between	-	1474	O
the	-	1482	O
two	-	1486	O
groups	-	1490	O
.	-	1496	O

Ketoprofen	10414674	1498	O
but	-	1509	O
not	-	1513	O
acetaminophen	-	1517	O
impaired	-	1531	O
platelet	-	1540	O
function	-	1549	O
in	-	1558	O
patients	-	1561	O
with	-	1570	O
SAH	-	1575	B
.	-	1578	O

If	10414674	1580	O
ketoprofen	-	1583	O
is	-	1594	O
used	-	1597	O
before	-	1602	O
surgery	-	1609	O
on	-	1617	O
cerebral	-	1620	O
artery	-	1629	B
aneurysms	-	1636	I
,	-	1645	O
it	-	1647	O
may	-	1650	O
pose	-	1654	O
an	-	1659	O
additional	-	1662	O
risk	-	1673	O
factor	-	1678	O
for	-	1685	O
hemorrhage	-	1689	B
.	-	1699	O

Value	9523850	0	O
of	-	6	O
methylprednisolone	-	9	O
in	-	28	O
prevention	-	31	O
of	-	42	O
the	-	45	O
arthralgia	-	49	B
-	-	59	O
myalgia	-	60	B
syndrome	-	68	O
associated	-	77	O
with	-	88	O
the	-	93	O
total	-	97	O
dose	-	103	O
infusion	-	108	O
of	-	117	O
iron	-	120	O
dextran	-	125	O
:	-	132	O
a	-	134	O
double	-	136	O
blind	-	143	O
randomized	-	149	O
trial	-	160	O
.	-	165	O

The	9523850	167	O
safety	-	171	O
and	-	178	O
efficacy	-	182	O
of	-	191	O
total	-	194	O
dose	-	200	O
infusion	-	205	O
(	-	214	O
TDI	-	215	O
)	-	218	O
of	-	220	O
iron	-	223	O
dextran	-	228	O
has	-	236	O
been	-	240	O
well	-	245	O
documented	-	250	O
.	-	260	O

In	9523850	262	O
40	-	265	O
%	-	267	O
of	-	269	O
treated	-	272	O
patients	-	280	O
,	-	288	O
an	-	290	O
arthralgia	-	293	B
-	-	303	O
myalgia	-	304	B
syndrome	-	312	O
develops	-	321	O
.	-	329	O

The	9523850	331	O
purpose	-	335	O
of	-	343	O
this	-	346	O
randomized	-	351	O
,	-	361	O
double	-	363	O
-	-	369	O
blind	-	370	O
,	-	375	O
prospective	-	377	O
study	-	389	O
was	-	395	O
to	-	399	O
investigate	-	402	O
whether	-	414	O
intravenous	-	422	O
(	-	434	O
i	-	435	O
.	-	436	O
v	-	437	O
.	-	438	O
)	-	439	O
administration	-	441	O
of	-	456	O
methylprednisolone	-	459	O
(	-	478	O
MP	-	479	O
)	-	481	O
prevents	-	483	O
this	-	492	O
complication	-	497	O
.	-	509	O

Sixty	9523850	511	O
-	-	516	O
five	-	517	O
patients	-	522	O
,	-	530	O
34	-	532	O
women	-	535	O
and	-	541	O
31	-	545	O
men	-	548	O
,	-	551	O
ages	-	553	O
36	-	558	O
to	-	561	O
80	-	564	O
years	-	567	O
,	-	572	O
received	-	574	O
either	-	583	O
normal	-	590	O
saline	-	597	O
before	-	604	O
and	-	611	O
after	-	615	O
TDI	-	621	O
(	-	625	O
group	-	626	O
1	-	632	O
)	-	633	O
,	-	634	O
125	-	636	O
mg	-	640	O
i	-	643	O
.	-	644	O
v	-	645	O
.	-	646	O

MP	9523850	648	O
before	-	651	O
and	-	658	O
saline	-	662	O
after	-	669	O
TDI	-	675	O
(	-	679	O
group	-	680	O
2	-	686	O
)	-	687	O
,	-	688	O
or	-	690	O
125	-	693	O
mg	-	697	O
i	-	700	O
.	-	701	O
v	-	702	O
.	-	703	O

MP	9523850	705	O
before	-	708	O
and	-	715	O
after	-	719	O
TDI	-	725	O
(	-	729	O
group	-	730	O
3	-	736	O
)	-	737	O
.	-	738	O

Patients	9523850	740	O
were	-	749	O
observed	-	754	O
for	-	763	O
72	-	767	O
hours	-	770	O
and	-	776	O
reactions	-	780	O
were	-	790	O
recorded	-	795	O
and	-	804	O
graded	-	808	O
according	-	815	O
to	-	825	O
severity	-	828	O
.	-	836	O

Fifty	9523850	838	O
-	-	843	O
eight	-	844	O
percent	-	850	O
of	-	858	O
group	-	861	O
1	-	867	O
patients	-	869	O
,	-	877	O
33	-	879	O
%	-	881	O
of	-	883	O
group	-	886	O
2	-	892	O
,	-	893	O
and	-	895	O
26	-	899	O
%	-	901	O
of	-	903	O
group	-	906	O
3	-	912	O
had	-	914	O
reactions	-	918	O
to	-	928	O
TDI	-	931	O
.	-	934	O

The	9523850	936	O
severity	-	940	O
of	-	949	O
reactions	-	952	O
(	-	962	O
minimal	-	963	O
,	-	970	O
mild	-	972	O
,	-	976	O
and	-	978	O
moderate	-	982	O
,	-	990	O
respectively	-	992	O
)	-	1004	O
was	-	1006	O
as	-	1010	O
follows	-	1013	O
:	-	1020	O
group	-	1022	O
1	-	1028	O
-	-	1029	O
-	-	1030	O
6	-	1031	O
,	-	1032	O
6	-	1034	O
,	-	1035	O
and	-	1037	O
2	-	1041	O
;	-	1042	O
group	-	1044	O
2	-	1050	O
-	-	1051	O
-	-	1052	O
1	-	1053	O
,	-	1054	O
5	-	1056	O
,	-	1057	O
and	-	1059	O
0	-	1063	O
;	-	1064	O
group	-	1066	O
3	-	1072	O
-	-	1073	O
-	-	1074	O
5	-	1075	O
,	-	1076	O
1	-	1078	O
,	-	1079	O
and	-	1081	O
0	-	1085	O
.	-	1086	O

Data	9523850	1088	O
were	-	1093	O
analyzed	-	1098	O
by	-	1107	O
the	-	1110	O
two	-	1114	O
-	-	1117	O
sided	-	1118	O
Fisher	-	1124	O
's	-	1130	O
exact	-	1133	O
test	-	1139	O
using	-	1144	O
95	-	1150	O
%	-	1152	O
confidence	-	1154	O
intervals	-	1165	O
with	-	1175	O
the	-	1180	O
approximation	-	1184	O
of	-	1198	O
Woolf	-	1201	O
.	-	1206	O

These	9523850	1208	O
data	-	1214	O
demonstrate	-	1219	O
that	-	1231	O
administration	-	1236	O
of	-	1251	O
MP	-	1254	O
before	-	1257	O
and	-	1264	O
after	-	1268	O
TDI	-	1274	O
reduces	-	1278	O
the	-	1286	O
frequency	-	1290	O
and	-	1300	O
severity	-	1304	O
of	-	1313	O
the	-	1316	O
arthralgia	-	1320	B
-	-	1330	O
myalgia	-	1331	B
syndrome	-	1339	O
.	-	1347	O

We	9523850	1349	O
conclude	-	1352	O
that	-	1361	O
125	-	1366	O
mg	-	1370	O
i	-	1373	O
.	-	1374	O
v	-	1375	O
.	-	1376	O

MP	9523850	1378	O
should	-	1381	O
be	-	1388	O
given	-	1391	O
routinely	-	1397	O
before	-	1407	O
and	-	1414	O
after	-	1418	O
TDI	-	1424	O
of	-	1428	O
iron	-	1431	O
dextran	-	1436	O
.	-	1443	O

Long	8384253	0	O
-	-	4	O
term	-	5	O
effects	-	10	O
of	-	18	O
vincristine	-	21	O
on	-	33	O
the	-	36	O
peripheral	-	40	O
nervous	-	51	O
system	-	59	O
.	-	65	O

Forty	8384253	67	O
patients	-	73	O
with	-	82	O
Non	-	87	B
-	-	90	I
Hodgkin	-	91	I
's	-	98	I
Lymphoma	-	101	I
treated	-	110	O
with	-	118	O
vincristine	-	123	O
between	-	135	O
1984	-	143	O
and	-	148	O
1990	-	152	O
(	-	157	O
cumulative	-	158	O
dose	-	169	O
12	-	174	O
mg	-	177	O
in	-	180	O
18	-	183	O
-	-	185	O
24	-	186	O
weeks	-	189	O
)	-	194	O
were	-	196	O
investigated	-	201	O
in	-	214	O
order	-	217	O
to	-	223	O
evaluate	-	226	O
the	-	235	O
long	-	239	O
term	-	244	O
effects	-	249	O
of	-	257	O
vincristine	-	260	O
on	-	272	O
the	-	275	O
peripheral	-	279	O
nervous	-	290	O
system	-	298	O
.	-	304	O

The	8384253	306	O
patients	-	310	O
were	-	319	O
interviewed	-	324	O
with	-	336	O
emphasis	-	341	O
on	-	350	O
neuropathic	-	353	B
symptoms	-	365	I
.	-	373	O

Physical	8384253	375	O
and	-	384	O
quantitative	-	388	O
sensory	-	401	O
examination	-	409	O
with	-	421	O
determination	-	426	O
of	-	440	O
vibratory	-	443	O
perception	-	453	O
and	-	464	O
thermal	-	468	O
discrimination	-	476	O
thresholds	-	491	O
were	-	502	O
performed	-	507	O
,	-	516	O
four	-	518	O
to	-	523	O
77	-	526	O
months	-	529	O
(	-	536	O
median	-	537	O
34	-	544	O
months	-	547	O
)	-	553	O
after	-	555	O
vincristine	-	561	O
treatment	-	573	O
.	-	582	O

Twenty	8384253	584	O
-	-	590	O
seven	-	591	O
patients	-	597	O
reported	-	606	O
neuropathic	-	615	B
symptoms	-	627	I
.	-	635	O

In	8384253	637	O
13	-	640	O
of	-	643	O
these	-	646	O
27	-	652	O
patients	-	655	O
symptoms	-	664	O
were	-	673	O
still	-	678	O
present	-	684	O
at	-	692	O
the	-	695	O
time	-	699	O
of	-	704	O
examination	-	707	O
.	-	718	O

In	8384253	720	O
these	-	723	O
patients	-	729	O
sensory	-	738	O
signs	-	746	O
and	-	752	O
symptoms	-	756	O
predominated	-	765	O
.	-	777	O

In	8384253	779	O
the	-	782	O
other	-	786	O
14	-	792	O
patients	-	795	O
symptoms	-	804	O
had	-	813	O
been	-	817	O
present	-	822	O
in	-	830	O
the	-	833	O
past	-	837	O
.	-	841	O

Symptoms	8384253	843	O
persisted	-	852	O
maximally	-	862	O
40	-	872	O
months	-	875	O
since	-	882	O
cessation	-	888	O
of	-	898	O
therapy	-	901	O
.	-	908	O

There	8384253	910	O
was	-	916	O
no	-	920	O
age	-	923	O
difference	-	927	O
between	-	938	O
patients	-	946	O
with	-	955	O
and	-	960	O
without	-	964	O
complaints	-	972	O
at	-	983	O
the	-	986	O
time	-	990	O
of	-	995	O
examination	-	998	O
.	-	1009	O

Normal	8384253	1011	O
reflexes	-	1018	O
were	-	1027	O
found	-	1032	O
in	-	1038	O
two	-	1041	O
third	-	1045	O
of	-	1051	O
patients	-	1054	O
.	-	1062	O

Neuropathic	8384253	1064	O
complaints	-	1076	O
were	-	1087	O
not	-	1092	O
very	-	1096	O
troublesome	-	1101	O
on	-	1113	O
the	-	1116	O
long	-	1120	O
term	-	1125	O
.	-	1129	O

It	8384253	1131	O
is	-	1134	O
concluded	-	1137	O
that	-	1147	O
with	-	1152	O
the	-	1157	O
above	-	1161	O
mentioned	-	1167	O
vincristine	-	1177	O
dose	-	1189	O
schedule	-	1194	O
signs	-	1203	O
and	-	1209	O
symptoms	-	1213	O
of	-	1222	O
vincristine	-	1225	O
neuropathy	-	1237	B
are	-	1248	O
reversible	-	1252	O
for	-	1263	O
a	-	1267	O
great	-	1269	O
deal	-	1275	O
and	-	1280	O
prognosis	-	1284	O
is	-	1294	O
fairly	-	1297	O
good	-	1304	O
.	-	1308	O

A	8268147	0	O
case	-	2	O
of	-	7	O
polymyositis	-	10	B
in	-	23	O
a	-	26	O
patient	-	28	O
with	-	36	O
primary	-	41	B
biliary	-	49	I
cirrhosis	-	57	I
treated	-	67	O
with	-	75	O
D	-	80	O
-	-	81	O
penicillamine	-	82	O
.	-	95	O

Although	8268147	97	O
D	-	106	O
-	-	107	O
penicillamine	-	108	O
has	-	122	O
been	-	126	O
used	-	131	O
for	-	136	O
many	-	140	O
rheumatologic	-	145	B
diseases	-	159	I
,	-	167	O
toxicity	-	169	B
limits	-	178	O
its	-	185	O
usefulness	-	189	O
in	-	200	O
many	-	203	O
patients	-	208	O
.	-	216	O

Polymyositis	8268147	218	B
/	-	230	O
dermatomyositis	-	231	B
can	-	247	O
develop	-	251	O
as	-	259	O
one	-	262	O
of	-	266	O
the	-	269	O
autoimmune	-	273	O
complications	-	284	O
of	-	298	O
D	-	301	O
-	-	302	O
penicillamine	-	303	O
treatment	-	317	O
,	-	326	O
but	-	328	O
its	-	332	O
exact	-	336	O
pathogenesis	-	342	O
remains	-	355	O
unclear	-	363	O
.	-	370	O

We	8268147	372	O
report	-	375	O
a	-	382	O
patient	-	384	O
with	-	392	O
primary	-	397	B
biliary	-	405	I
cirrhosis	-	413	I
,	-	422	O
who	-	424	O
developed	-	428	O
polymyositis	-	438	B
while	-	451	O
receiving	-	457	O
D	-	467	O
-	-	468	O
penicillamine	-	469	O
therapy	-	483	O
.	-	490	O

We	8268147	492	O
described	-	495	O
the	-	505	O
special	-	509	O
clinical	-	517	O
course	-	526	O
of	-	533	O
the	-	536	O
patient	-	540	O
.	-	547	O

Patients	8268147	549	O
receiving	-	558	O
D	-	568	O
-	-	569	O
penicillamine	-	570	O
therapy	-	584	O
should	-	592	O
be	-	599	O
followed	-	602	O
carefully	-	611	O
for	-	621	O
the	-	625	O
development	-	629	O
of	-	641	O
autoimmune	-	644	O
complications	-	655	O
like	-	669	O
polymyositis	-	674	B
/	-	686	O
dermatomyositis	-	687	B
.	-	702	O

Photodistributed	8251368	0	O
nifedipine	-	17	O
-	-	27	O
induced	-	28	O
facial	-	36	O
telangiectasia	-	43	B
.	-	57	O

Five	8251368	59	O
months	-	64	O
after	-	71	O
starting	-	77	O
nifedipine	-	86	O
(	-	97	O
Adalat	-	98	O
)	-	104	O
,	-	105	O
two	-	107	O
patients	-	111	O
developed	-	120	O
photodistributed	-	130	O
facial	-	147	O
telangiectasia	-	154	B
,	-	168	O
which	-	170	O
became	-	176	O
more	-	183	O
noticeable	-	188	O
with	-	199	O
time	-	204	O
.	-	208	O

Neither	8251368	210	O
patient	-	218	O
complained	-	226	O
of	-	237	O
photosensitivity	-	240	O
or	-	257	O
flushing	-	260	B
.	-	268	O

Both	8251368	270	O
patients	-	275	O
reported	-	284	O
a	-	293	O
significant	-	295	O
cosmetic	-	307	O
improvement	-	316	O
after	-	328	O
discontinuing	-	334	O
the	-	348	O
drug	-	352	O
.	-	356	O

One	8251368	358	O
commenced	-	362	O
the	-	372	O
closely	-	376	O
related	-	384	O
drug	-	392	O
amlodipine	-	397	O
3	-	408	O
years	-	410	O
later	-	416	O
,	-	421	O
with	-	423	O
recurrence	-	428	O
of	-	439	O
telangiectasia	-	442	B
.	-	456	O

The	8251368	458	O
photodistribution	-	462	O
of	-	480	O
the	-	483	O
telangiectasia	-	487	B
suggests	-	502	O
a	-	511	O
significant	-	513	O
drug	-	525	O
/	-	529	O
light	-	530	O
interaction	-	536	O
.	-	547	O

Nephrotoxicity	7542793	0	B
of	-	15	O
cyclosporin	-	18	O
A	-	30	O
and	-	32	O
FK506	-	36	O
:	-	41	O
inhibition	-	43	O
of	-	54	O
calcineurin	-	57	O
phosphatase	-	69	O
.	-	80	O

Cyclosporin	7542793	82	O
A	-	94	O
(	-	96	O
CsA	-	97	O
;	-	100	O
50	-	102	O
mg	-	105	O
/	-	107	O
kg	-	108	O
)	-	110	O
and	-	112	O
Fujimycine	-	116	O
(	-	127	O
FK506	-	128	O
;	-	133	O
5	-	135	O
mg	-	137	O
/	-	139	O
kg	-	140	O
)	-	142	O
,	-	143	O
but	-	145	O
not	-	149	O
the	-	153	O
related	-	157	O
macrolide	-	165	O
immunosuppressant	-	175	O
rapamycin	-	193	O
(	-	203	O
5	-	204	O
mg	-	206	O
/	-	208	O
kg	-	209	O
)	-	211	O
,	-	212	O
caused	-	214	O
a	-	221	O
reduction	-	223	O
of	-	233	O
glomerular	-	236	O
filtration	-	247	O
rate	-	258	O
,	-	262	O
degenerative	-	264	O
changes	-	277	O
of	-	285	O
proximal	-	288	O
tubular	-	297	O
epithelium	-	305	O
,	-	315	O
and	-	317	O
hypertrophy	-	321	B
of	-	333	O
the	-	336	O
juxtaglomerular	-	340	O
apparatus	-	356	O
in	-	366	O
male	-	369	O
Wistar	-	374	O
rats	-	381	O
when	-	386	O
given	-	391	O
for	-	397	O
10	-	401	O
days	-	404	O
.	-	408	O

The	7542793	410	O
molecular	-	414	O
mechanisms	-	424	O
of	-	435	O
CsA	-	438	O
and	-	442	O
FK506	-	446	O
toxicity	-	452	B
were	-	461	O
investigated	-	466	O
.	-	478	O

Cyclophilin	7542793	480	O
A	-	492	O
and	-	494	O
FK506	-	498	O
-	-	503	O
binding	-	504	O
protein	-	512	O
,	-	519	O
the	-	521	O
main	-	525	O
intracytoplasmic	-	530	O
receptors	-	547	O
for	-	557	O
CsA	-	561	O
and	-	565	O
FK506	-	569	O
,	-	574	O
respectively	-	576	O
,	-	588	O
were	-	590	O
each	-	595	O
detected	-	600	O
in	-	609	O
renal	-	612	O
tissue	-	618	O
extract	-	625	O
.	-	632	O

In	7542793	634	O
the	-	637	O
kidney	-	641	O
,	-	647	O
high	-	649	O
levels	-	654	O
of	-	661	O
immunoreactive	-	664	O
and	-	679	O
enzymatically	-	683	O
active	-	697	O
calcineurin	-	704	O
were	-	716	O
found	-	721	O
which	-	727	O
were	-	733	O
inhibited	-	738	O
by	-	748	O
the	-	751	O
immunosuppressants	-	755	O
CsA	-	774	O
and	-	778	O
FK506	-	782	O
,	-	787	O
but	-	789	O
not	-	793	O
by	-	797	O
rapamycin	-	800	O
.	-	809	O

Finally	7542793	811	O
,	-	818	O
specific	-	820	O
immunophilin	-	829	O
-	-	841	O
drug	-	842	O
-	-	846	O
calcineurin	-	847	O
complexes	-	859	O
formed	-	869	O
only	-	876	O
in	-	881	O
the	-	884	O
presence	-	888	O
of	-	897	O
CsA	-	900	O
and	-	904	O
FK506	-	908	O
,	-	913	O
but	-	915	O
not	-	919	O
rapamycin	-	923	O
.	-	932	O

These	7542793	934	O
results	-	940	O
suggest	-	948	O
that	-	956	O
the	-	961	O
nephrotoxic	-	965	B
effects	-	977	O
of	-	985	O
CsA	-	988	O
and	-	992	O
FK506	-	996	O
is	-	1002	O
likely	-	1005	O
mediated	-	1012	O
through	-	1021	O
binding	-	1029	O
to	-	1037	O
renal	-	1040	O
immunophilin	-	1046	O
and	-	1059	O
inhibiting	-	1063	O
calcineurin	-	1074	O
phosphatase	-	1086	O
.	-	1097	O

Massive	7337133	0	O
cerebral	-	8	B
edema	-	17	I
associated	-	23	O
with	-	34	O
fulminant	-	39	O
hepatic	-	49	B
failure	-	57	I
in	-	65	O
acetaminophen	-	68	O
overdose	-	82	B
:	-	90	O
possible	-	92	O
role	-	101	O
of	-	106	O
cranial	-	109	O
decompression	-	117	O
.	-	130	O

Cerebral	7337133	132	B
edema	-	141	I
may	-	147	O
complicate	-	151	O
the	-	162	O
course	-	166	O
of	-	173	O
fulminant	-	176	B
hepatic	-	186	I
failure	-	194	I
.	-	201	O

Response	7337133	203	O
to	-	212	O
conventional	-	215	O
therapy	-	228	O
has	-	236	O
been	-	240	O
disappointing	-	245	O
.	-	258	O

We	7337133	260	O
present	-	263	O
a	-	271	O
patient	-	273	O
with	-	281	O
fatal	-	286	O
acetaminophen	-	292	O
-	-	305	O
induced	-	306	O
fulminant	-	314	B
hepatic	-	324	I
failure	-	332	I
,	-	339	O
with	-	341	O
signs	-	346	O
and	-	352	O
symptoms	-	356	O
of	-	365	O
cerebral	-	368	B
edema	-	377	I
,	-	382	O
unresponsive	-	384	O
to	-	397	O
conventional	-	400	O
medical	-	413	O
therapy	-	421	O
.	-	428	O

Cranial	7337133	430	O
decompression	-	438	O
was	-	452	O
carried	-	456	O
out	-	464	O
.	-	467	O

A	7337133	469	O
justification	-	471	O
of	-	485	O
the	-	488	O
need	-	492	O
for	-	497	O
further	-	501	O
evaluation	-	509	O
of	-	520	O
cranial	-	523	O
decompression	-	531	O
in	-	545	O
such	-	548	O
patients	-	553	O
is	-	562	O
presented	-	565	O
.	-	574	O

Gentamicin	4069770	0	O
nephropathy	-	11	B
in	-	23	O
a	-	26	O
neonate	-	28	O
.	-	35	O

The	4069770	37	O
clinical	-	41	O
and	-	50	O
autopsy	-	54	O
findings	-	62	O
in	-	71	O
a	-	74	O
premature	-	76	O
baby	-	86	O
who	-	91	O
died	-	95	O
of	-	100	O
acute	-	103	B
renal	-	109	I
failure	-	115	I
after	-	123	O
therapy	-	129	O
with	-	137	O
gentamicin	-	142	O
(	-	153	O
5	-	154	O
mg	-	156	O
/	-	158	O
kg	-	159	O
/	-	161	O
day	-	162	O
)	-	165	O
and	-	167	O
penicillin	-	171	O
are	-	182	O
presented	-	186	O
.	-	195	O

The	4069770	197	O
serum	-	201	O
gentamicin	-	207	O
concentration	-	218	O
had	-	232	O
reached	-	236	O
toxic	-	244	O
levels	-	250	O
when	-	257	O
anuria	-	262	B
developed	-	269	O
.	-	278	O

Numerous	4069770	280	O
periodic	-	289	O
acid	-	298	O
Schiff	-	303	O
(	-	310	O
PAS	-	311	O
)	-	314	O
positive	-	316	O
,	-	324	O
diastase	-	326	O
resistant	-	335	O
cytoplasmic	-	345	O
inclusion	-	357	O
bodies	-	367	O
which	-	374	O
appeared	-	380	O
as	-	389	O
myelin	-	392	O
figures	-	399	O
in	-	407	O
cytosegresomes	-	410	O
under	-	425	O
the	-	431	O
electron	-	435	O
microscope	-	444	O
were	-	455	O
identified	-	460	O
in	-	471	O
the	-	474	O
proximal	-	478	O
convoluted	-	487	O
tubules	-	498	O
.	-	505	O

The	4069770	507	O
pathological	-	511	O
changes	-	524	O
induced	-	532	O
by	-	540	O
gentamicin	-	543	O
in	-	554	O
the	-	557	O
human	-	561	O
neonatal	-	567	O
kidneys	-	576	O
have	-	584	O
not	-	589	O
been	-	593	O
previously	-	598	O
reported	-	609	O
.	-	617	O

Anti	3780814	0	O
-	-	4	O
carcinogenic	-	5	B
action	-	18	O
of	-	25	O
phenobarbital	-	28	O
given	-	42	O
simultaneously	-	48	O
with	-	63	O
diethylnitrosamine	-	68	O
in	-	87	O
the	-	90	O
rat	-	94	O
.	-	97	O

The	3780814	99	O
present	-	103	O
work	-	111	O
has	-	116	O
been	-	120	O
planned	-	125	O
in	-	133	O
order	-	136	O
to	-	142	O
elucidate	-	145	O
the	-	155	O
effect	-	159	O
of	-	166	O
phenobarbital	-	169	O
(	-	183	O
PB	-	184	O
:	-	186	O
15	-	188	O
mg	-	191	O
per	-	194	O
rat	-	198	O
of	-	202	O
ingested	-	205	O
dose	-	214	O
)	-	218	O
on	-	220	O
carcinogenesis	-	223	B
when	-	238	O
it	-	243	O
is	-	246	O
administered	-	249	O
simultaneously	-	262	O
with	-	277	O
diethylnitrosamine	-	282	O
(	-	301	O
DEN	-	302	O
:	-	305	O
10	-	307	O
mg	-	310	O
/	-	312	O
kg	-	313	O
/	-	315	O
day	-	316	O
)	-	319	O
.	-	320	O

Wistar	3780814	322	O
rats	-	329	O
(	-	334	O
180	-	335	O
g	-	339	O
)	-	340	O
were	-	342	O
treated	-	347	O
by	-	355	O
DEN	-	358	O
alone	-	362	O
or	-	368	O
by	-	371	O
DEN	-	374	O
+	-	378	O
PB	-	380	O
during	-	383	O
2	-	390	O
,	-	391	O
4	-	393	O
and	-	395	O
6	-	399	O
weeks	-	401	O
according	-	407	O
to	-	417	O
our	-	420	O
schedule	-	424	O
for	-	433	O
hepatocarcinogenesis	-	437	B
.	-	457	O

After	3780814	459	O
the	-	465	O
end	-	469	O
of	-	473	O
the	-	476	O
treatment	-	480	O
,	-	489	O
the	-	491	O
number	-	495	O
and	-	502	O
the	-	506	O
size	-	510	O
of	-	515	O
induced	-	518	O
PAS	-	526	O
positive	-	530	O
preneoplastic	-	539	B
foci	-	553	I
was	-	558	O
significantly	-	562	O
reduced	-	576	O
when	-	584	O
PB	-	589	O
was	-	592	O
given	-	596	O
simultaneously	-	602	O
with	-	617	O
DEN	-	622	O
for	-	626	O
4	-	630	O
and	-	632	O
6	-	636	O
weeks	-	638	O
.	-	643	O

The	3780814	645	O
mitotic	-	649	O
inhibition	-	657	O
and	-	668	O
the	-	672	O
production	-	676	O
of	-	687	O
micronuclei	-	690	O
normally	-	702	O
observed	-	711	O
after	-	720	O
partial	-	726	O
hepatectomy	-	734	O
in	-	746	O
DEN	-	749	O
treated	-	753	O
rats	-	761	O
were	-	766	O
also	-	771	O
significantly	-	776	O
decreased	-	790	O
in	-	800	O
DEN	-	803	O
+	-	807	O
PB	-	809	O
treated	-	812	O
rats	-	820	O
.	-	824	O

When	3780814	826	O
the	-	831	O
treatment	-	835	O
last	-	845	O
only	-	850	O
2	-	855	O
weeks	-	857	O
,	-	862	O
the	-	864	O
presence	-	868	O
of	-	877	O
PB	-	880	O
did	-	883	O
not	-	887	O
change	-	891	O
significantly	-	898	O
the	-	912	O
last	-	916	O
parameters	-	921	O
.	-	931	O

In	3780814	933	O
DEN	-	936	O
+	-	940	O
PB	-	942	O
treated	-	945	O
rats	-	953	O
,	-	957	O
the	-	959	O
survival	-	963	O
was	-	972	O
prolonged	-	976	O
and	-	986	O
the	-	990	O
tumor	-	994	B
incidence	-	1000	O
decreased	-	1010	O
as	-	1020	O
compared	-	1023	O
with	-	1032	O
the	-	1037	O
results	-	1041	O
obtained	-	1049	O
by	-	1058	O
DEN	-	1061	O
alone	-	1065	O
.	-	1070	O

It	3780814	1072	O
is	-	1075	O
concluded	-	1078	O
that	-	1088	O
PB	-	1093	O
,	-	1095	O
which	-	1097	O
promotes	-	1103	O
carcinogenesis	-	1112	B
when	-	1127	O
administered	-	1132	O
after	-	1145	O
the	-	1151	O
DEN	-	1155	O
treatment	-	1159	O
,	-	1168	O
reduces	-	1170	O
the	-	1178	O
carcinogen	-	1182	O
effect	-	1193	O
when	-	1200	O
given	-	1205	O
simultaneously	-	1211	O
with	-	1226	O
DEN	-	1231	O
.	-	1234	O

This	3780814	1236	O
'	-	1241	O
anti	-	1242	O
-	-	1246	O
carcinogen	-	1247	O
'	-	1257	O
effect	-	1259	O
acts	-	1266	O
on	-	1271	O
the	-	1274	O
initiation	-	1278	O
as	-	1289	O
well	-	1292	O
as	-	1297	O
on	-	1300	O
the	-	1303	O
promotion	-	1307	O
of	-	1317	O
the	-	1320	O
precancerous	-	1324	B
lesions	-	1337	I
.	-	1344	O

Biochemical	3780814	1346	O
investigations	-	1358	O
are	-	1373	O
in	-	1377	O
progress	-	1380	O
to	-	1389	O
obtain	-	1392	O
more	-	1399	O
information	-	1404	O
about	-	1416	O
this	-	1422	O
'	-	1427	O
paradoxical	-	1428	O
'	-	1439	O
PB	-	1441	O
effect	-	1444	O
.	-	1450	O

Post	3780697	0	O
-	-	4	O
operative	-	5	O
rigidity	-	15	B
after	-	24	O
fentanyl	-	30	O
administration	-	39	O
.	-	53	O

A	3780697	55	O
case	-	57	O
of	-	62	O
thoraco	-	65	O
-	-	72	O
abdominal	-	73	O
rigidity	-	83	B
leading	-	92	O
to	-	100	O
respiratory	-	103	B
failure	-	115	I
is	-	123	O
described	-	126	O
in	-	136	O
the	-	139	O
post	-	143	O
-	-	147	O
operative	-	148	O
period	-	158	O
in	-	165	O
an	-	168	O
elderly	-	171	O
patient	-	179	O
who	-	187	O
received	-	191	O
a	-	200	O
moderate	-	202	O
dose	-	211	O
of	-	216	O
fentanyl	-	219	O
.	-	227	O

This	3780697	229	O
was	-	234	O
successfully	-	238	O
reversed	-	251	O
by	-	260	O
naloxone	-	263	O
.	-	271	O

The	3780697	273	O
mechanisms	-	277	O
possibly	-	288	O
implicated	-	297	O
in	-	308	O
this	-	311	O
accident	-	316	O
are	-	325	O
discussed	-	329	O
.	-	338	O

Postpartum	3686155	0	O
psychosis	-	11	B
induced	-	21	O
by	-	29	O
bromocriptine	-	32	O
.	-	45	O

Two	3686155	47	O
multigravida	-	51	O
patients	-	64	O
with	-	73	O
no	-	78	O
prior	-	81	O
psychiatric	-	87	B
history	-	99	O
were	-	107	O
seen	-	112	O
with	-	117	O
postpartum	-	122	O
psychosis	-	133	B
,	-	142	O
having	-	144	O
received	-	151	O
bromocriptine	-	160	O
for	-	174	O
inhibition	-	178	B
of	-	189	I
lactation	-	192	I
.	-	201	O

Bromocriptine	3686155	203	O
given	-	217	O
in	-	223	O
high	-	226	O
doses	-	231	O
has	-	237	O
been	-	241	O
associated	-	246	O
with	-	257	O
psychosis	-	262	B
in	-	272	O
patients	-	275	O
receiving	-	284	O
the	-	294	O
drug	-	298	O
for	-	303	O
Parkinson	-	307	B
's	-	316	I
disease	-	319	I
.	-	326	O

These	3686155	328	O
cases	-	334	O
demonstrate	-	340	O
that	-	352	O
bromocriptine	-	357	O
may	-	371	O
cause	-	375	O
psychosis	-	381	B
even	-	391	O
when	-	396	O
given	-	401	O
in	-	407	O
low	-	410	O
doses	-	414	O
.	-	419	O

A	3137399	0	O
prospective	-	2	O
study	-	14	O
on	-	20	O
the	-	23	O
dose	-	27	O
dependency	-	32	O
of	-	43	O
cardiotoxicity	-	46	B
induced	-	61	O
by	-	69	O
mitomycin	-	72	O
C	-	82	O
.	-	83	O

Since	3137399	85	O
1975	-	91	O
mitomycin	-	96	O
C	-	106	O
(	-	108	O
MMC	-	109	O
)	-	112	O
has	-	114	O
been	-	118	O
suggested	-	123	O
to	-	133	O
be	-	136	O
cardiotoxic	-	139	B
,	-	150	O
especially	-	152	O
when	-	163	O
combined	-	168	O
with	-	177	O
or	-	182	O
given	-	185	O
following	-	191	O
doxorubicin	-	201	O
.	-	212	O

Data	3137399	214	O
on	-	219	O
dose	-	222	O
dependency	-	227	O
or	-	238	O
incidence	-	241	O
concerning	-	251	O
this	-	262	O
side	-	267	O
effect	-	272	O
were	-	279	O
not	-	284	O
known	-	288	O
.	-	293	O

We	3137399	295	O
have	-	298	O
initiated	-	303	O
a	-	313	O
prospective	-	315	O
study	-	327	O
to	-	333	O
obtain	-	336	O
some	-	343	O
more	-	348	O
data	-	353	O
on	-	358	O
these	-	361	O
subjects	-	367	O
.	-	375	O

Forty	3137399	377	O
-	-	382	O
four	-	383	O
MMC	-	388	O
-	-	391	O
treated	-	392	O
patients	-	400	O
were	-	409	O
studied	-	414	O
,	-	421	O
37	-	423	O
of	-	426	O
them	-	429	O
could	-	434	O
be	-	440	O
evaluated	-	443	O
.	-	452	O

All	3137399	454	O
patients	-	458	O
were	-	467	O
studied	-	472	O
by	-	480	O
repeated	-	483	O
physical	-	492	O
examinations	-	501	O
,	-	513	O
chest	-	515	O
X	-	521	O
-	-	522	O
rays	-	523	O
,	-	527	O
electro	-	529	O
-	-	536	O
and	-	538	O
echocardiography	-	542	O
and	-	559	O
radionuclide	-	563	O
left	-	576	O
ventricular	-	581	O
ejection	-	593	O
fraction	-	602	O
(	-	611	O
EF	-	612	O
)	-	614	O
determinations	-	616	O
.	-	630	O

The	3137399	632	O
results	-	636	O
were	-	644	O
evaluated	-	649	O
per	-	659	O
cumulative	-	663	O
dose	-	674	O
level	-	679	O
.	-	684	O

One	3137399	686	O
of	-	690	O
the	-	693	O
patients	-	697	O
developed	-	706	O
cardiac	-	716	B
failure	-	724	I
after	-	732	O
30	-	738	O
mg	-	741	O
m	-	744	O
-	-	745	O
2	-	746	O
MMC	-	748	O
and	-	752	O
only	-	756	O
150	-	761	O
mg	-	765	O

m	3137399	768	O
-	-	769	O
2	-	770	O
doxorubicin	-	772	O
.	-	783	O

The	3137399	785	O
cardiac	-	789	B
failure	-	797	I
was	-	805	O
predicted	-	809	O
by	-	819	O
a	-	822	O
drop	-	824	O
in	-	829	O
EF	-	832	O
determined	-	835	O
during	-	846	O
a	-	853	O
cold	-	855	O
pressor	-	860	O
test	-	868	O
.	-	872	O

None	3137399	874	O
of	-	879	O
the	-	882	O
other	-	886	O
patients	-	892	O
developed	-	901	O
clinical	-	911	O
cardiotoxicity	-	920	B
,	-	934	O
nor	-	936	O
did	-	940	O
the	-	944	O
studied	-	948	O
parameters	-	956	O
change	-	967	O
.	-	973	O

The	3137399	975	O
literature	-	979	O
on	-	990	O
this	-	993	O
subject	-	998	O
was	-	1006	O
also	-	1010	O
reviewed	-	1015	O
.	-	1023	O

Based	3137399	1025	O
on	-	1031	O
the	-	1034	O
combined	-	1038	O
data	-	1047	O
from	-	1052	O
the	-	1057	O
present	-	1061	O
study	-	1069	O
and	-	1075	O
the	-	1079	O
literature	-	1083	O
,	-	1093	O
we	-	1095	O
suggest	-	1098	O
that	-	1106	O
MMC	-	1111	O
-	-	1114	O
related	-	1115	O
cardiotoxicity	-	1123	B
is	-	1138	O
dose	-	1141	O
dependent	-	1146	O
,	-	1155	O
occurring	-	1157	O
at	-	1167	O
cumulative	-	1170	O
dose	-	1181	O
levels	-	1186	O
of	-	1193	O
30	-	1196	O
mg	-	1199	O
m	-	1202	O
-	-	1203	O
2	-	1204	O
or	-	1206	O
more	-	1209	O
,	-	1213	O
mainly	-	1215	O
in	-	1222	O
patients	-	1225	O
also	-	1234	O
(	-	1239	O
previously	-	1240	O
or	-	1251	O
simultaneously	-	1254	O
)	-	1268	O
treated	-	1270	O
with	-	1278	O
doxorubicin	-	1283	O
.	-	1294	O

The	3137399	1296	O
incidence	-	1300	O
is	-	1310	O
likely	-	1313	O
to	-	1320	O
be	-	1323	O
less	-	1326	O
than	-	1331	O
10	-	1336	O
%	-	1338	O
even	-	1340	O
for	-	1345	O
this	-	1349	O
risk	-	1354	O
group	-	1359	O
.	-	1364	O

Phlorizin	2709684	0	O
-	-	9	O
induced	-	10	O
glycosuria	-	18	B
does	-	29	O
not	-	34	O
prevent	-	38	O
gentamicin	-	46	O
nephrotoxicity	-	57	B
in	-	72	O
rats	-	75	O
.	-	79	O

Because	2709684	81	O
rats	-	89	O
with	-	94	O
streptozotocin	-	99	O
-	-	113	O
induced	-	114	O
diabetes	-	122	B
mellitus	-	131	I
(	-	140	O
DM	-	141	B
)	-	143	O
have	-	145	O
a	-	150	O
high	-	152	O
solute	-	157	O
diuresis	-	164	O
(	-	173	O
glycosuria	-	174	B
of	-	185	O
10	-	188	O
to	-	191	O
12	-	194	O
g	-	197	O
/	-	198	O
day	-	199	O
)	-	202	O
,	-	203	O
we	-	205	O
have	-	208	O
suggested	-	213	O
that	-	223	O
this	-	228	O
may	-	233	O
in	-	237	O
part	-	240	O
be	-	245	O
responsible	-	248	O
for	-	260	O
their	-	264	O
resistance	-	270	O
to	-	281	O
gentamicin	-	284	O
-	-	294	O
induced	-	295	O
acute	-	303	B
renal	-	309	I
failure	-	315	I
(	-	323	O
ARF	-	324	B
)	-	327	O
.	-	328	O

The	2709684	330	O
protection	-	334	O
from	-	345	O
gentamicin	-	350	O
nephrotoxicity	-	361	B
was	-	376	O
studied	-	380	O
in	-	388	O
non	-	391	O
-	-	394	O
diabetic	-	395	B
rats	-	404	O
with	-	409	O
chronic	-	414	O
solute	-	422	O
diuresis	-	429	O
induced	-	438	O
by	-	446	O
blockage	-	449	O
of	-	458	O
tubular	-	461	O
glucose	-	469	O
reabsorption	-	477	O
with	-	490	O
phlorizin	-	495	O
(	-	505	O
P	-	506	O
)	-	507	O
.	-	508	O

DM	2709684	510	B
rats	-	513	O
with	-	518	O
mild	-	523	O
glycosuria	-	528	B
(	-	539	O
similar	-	540	O
in	-	548	O
degree	-	551	O
to	-	558	O
that	-	561	O
of	-	566	O
the	-	569	O
P	-	573	O
treated	-	575	O
animals	-	583	O
)	-	590	O
were	-	592	O
also	-	597	O
studied	-	602	O
.	-	609	O

Unanesthetized	2709684	611	O
adult	-	626	O
female	-	632	O
,	-	638	O
Sprague	-	640	O
-	-	647	O
Dawley	-	648	O
rats	-	655	O
were	-	660	O
divided	-	665	O
in	-	673	O
four	-	676	O
groups	-	681	O
and	-	688	O
studied	-	692	O
for	-	700	O
15	-	704	O
days	-	707	O
.	-	711	O

Group	2709684	713	O
1	-	719	O
(	-	721	O
P	-	722	O
alone	-	724	O
)	-	729	O
received	-	731	O
P	-	740	O
,	-	741	O
360	-	743	O
mg	-	747	O
/	-	749	O
day	-	750	O
,	-	753	O
for	-	755	O
15	-	759	O
days	-	762	O
;	-	766	O
Group	-	768	O
II	-	774	O
(	-	777	O
P	-	778	O
+	-	780	O
gentamicin	-	782	O
)	-	792	O
;	-	793	O
Group	-	795	O
III	-	801	O
(	-	805	O
gentamicin	-	806	O
alone	-	817	O
)	-	822	O
and	-	824	O
Group	-	828	O
IV	-	834	O
(	-	837	O
mild	-	838	O
DM	-	843	B
+	-	846	O
gentamicin	-	848	O
)	-	858	O
.	-	859	O

Nephrotoxic	2709684	861	B
doses	-	873	O
(	-	879	O
40	-	880	O
mg	-	883	O
/	-	885	O
kg	-	886	O
body	-	889	O
wt	-	894	O
/	-	896	O
day	-	897	O
)	-	900	O
of	-	902	O
gentamicin	-	905	O
were	-	916	O
injected	-	921	O
during	-	930	O
the	-	937	O
last	-	941	O
nine	-	946	O
days	-	951	O
of	-	956	O
study	-	959	O
to	-	965	O
the	-	968	O
animals	-	972	O
of	-	980	O
groups	-	983	O
II	-	990	O
to	-	993	O
IV	-	996	O
.	-	998	O

In	2709684	1000	O
Group	-	1003	O
I	-	1009	O
,	-	1010	O
P	-	1012	O
induced	-	1014	O
a	-	1022	O
moderate	-	1024	O
and	-	1033	O
stable	-	1037	O
glycosuria	-	1044	B
(	-	1055	O
3	-	1056	O
.	-	1057	O
9	-	1058	O
+	-	1060	O
/	-	1061	O
-	-	1062	O

0	2709684	1064	O
.	-	1065	O
1	-	1066	O
g	-	1068	O
/	-	1069	O
day	-	1070	O
,	-	1073	O
SE	-	1075	O
)	-	1077	O
,	-	1078	O
and	-	1080	O
no	-	1084	O
functional	-	1087	O
or	-	1098	O
morphologic	-	1101	O
evidence	-	1113	O
of	-	1122	O
renal	-	1125	B
dysfunction	-	1131	I
(	-	1143	O
baseline	-	1144	O
CCr	-	1153	O
2	-	1157	O
.	-	1158	O
1	-	1159	O
+	-	1161	O
/	-	1162	O
-	-	1163	O

0	2709684	1165	O
.	-	1166	O
1	-	1167	O
ml	-	1169	O
/	-	1171	O
min	-	1172	O
,	-	1175	O
undetectable	-	1177	O
lysozymuria	-	1190	O
)	-	1201	O
or	-	1203	O
damage	-	1206	O
(	-	1213	O
tubular	-	1214	B
necrosis	-	1222	I
score	-	1231	O
[	-	1237	O
maximum	-	1238	O
4	-	1246	O
]	-	1247	O
,	-	1248	O
zero	-	1250	O
)	-	1254	O
.	-	1255	O

In	2709684	1257	O
Group	-	1260	O
II	-	1266	O
,	-	1268	O
P	-	1270	O
did	-	1272	O
not	-	1276	O
prevent	-	1280	O
gentamicin	-	1288	O
-	-	1298	O
ARF	-	1299	B
(	-	1303	O
maximal	-	1304	O
decrease	-	1312	O
in	-	1321	O
CCr	-	1324	O
at	-	1328	O
day	-	1331	O
9	-	1335	O
.	-	1336	O
89	-	1337	O
%	-	1339	O
,	-	1340	O
P	-	1342	O
less	-	1344	O
than	-	1349	O
0	-	1354	O
.	-	1355	O
001	-	1356	O
;	-	1359	O
peak	-	1361	O
lysozymuria	-	1366	O
,	-	1377	O
1863	-	1379	O
+	-	1384	O
/	-	1385	O
-	-	1386	O

321	2709684	1388	O
micrograms	-	1392	O
/	-	1402	O
day	-	1403	O
;	-	1406	O
and	-	1408	O
tubular	-	1412	B
necrosis	-	1420	I
score	-	1429	O
,	-	1434	O
3	-	1436	O
.	-	1437	O
9	-	1438	O
+	-	1440	O
/	-	1441	O
-	-	1442	O
0	-	1444	O
.	-	1445	O
1	-	1446	O
)	-	1447	O
.	-	1448	O

These	2709684	1450	O
values	-	1456	O
were	-	1463	O
not	-	1468	O
different	-	1472	O
from	-	1482	O
those	-	1487	O
of	-	1493	O
Group	-	1496	O
III	-	1502	O
:	-	1505	O
maximal	-	1507	O
decrease	-	1515	O
in	-	1524	O
CCr	-	1527	O
73	-	1531	O
%	-	1533	O
(	-	1535	O
P	-	1536	O
less	-	1538	O
than	-	1543	O
0	-	1548	O
.	-	1549	O
001	-	1550	O
)	-	1553	O
;	-	1554	O
lysozymuria	-	1556	O
,	-	1567	O
2147	-	1569	O
+	-	1574	O
/	-	1575	O
-	-	1576	O

701	2709684	1578	O
micrograms	-	1582	O
/	-	1592	O
day	-	1593	O
;	-	1596	O
tubular	-	1598	B
necrosis	-	1606	I
score	-	1615	O
,	-	1620	O
3	-	1622	O
.	-	1623	O
8	-	1624	O
+	-	1626	O
/	-	1627	O
-	-	1628	O

0	2709684	1630	O
.	-	1631	O
1	-	1632	O
.	-	1633	O
(	-	1634	O
ABSTRACT	-	1635	O

TRUNCATED	2709684	1644	O
AT	-	1654	O
250	-	1657	O
WORDS	-	1661	O
)	-	1666	O

Tiapride	458486	0	O
in	-	9	O
levodopa	-	12	O
-	-	20	O
induced	-	21	O
involuntary	-	29	B
movements	-	41	I
.	-	50	O

Tiapride	458486	52	O
,	-	60	O
a	-	62	O
substituted	-	64	O
benzamide	-	76	O
derivative	-	86	O
closely	-	97	O
related	-	105	O
to	-	113	O
metoclopramide	-	116	O
,	-	130	O
reduced	-	132	O
levodopa	-	140	O
-	-	148	O
induced	-	149	O
peak	-	157	O
dose	-	162	O
involuntary	-	167	B
movements	-	179	I
in	-	189	O
16	-	192	O
patients	-	195	O
with	-	204	O
idiopathic	-	209	B
Parkinson	-	220	I
's	-	229	I
disease	-	232	I
.	-	239	O

However	458486	241	O
,	-	248	O
an	-	250	O
unacceptable	-	253	O
increase	-	266	O
in	-	275	O
disability	-	278	O
from	-	289	O
Parkinsonism	-	294	B
with	-	307	O
aggravation	-	312	O
of	-	324	O
end	-	327	O
-	-	330	O
of	-	331	O
-	-	333	O
dose	-	334	O
akinesia	-	339	B
led	-	348	O
to	-	352	O
its	-	355	O
cessation	-	359	O
in	-	369	O
14	-	372	O
patients	-	375	O
.	-	383	O

Tiapride	458486	385	O
had	-	394	O
no	-	398	O
effect	-	401	O
on	-	408	O
levodopa	-	411	O
-	-	419	O
induced	-	420	O
early	-	428	O
morning	-	434	O
of	-	442	O
""""	-	445	O
off	-	446	O
-	-	449	O
period	-	450	O
""""	-	456	O
segmental	-	458	O
dystonia	-	468	B
.	-	476	O

These	458486	478	O
results	-	484	O
fail	-	492	O
to	-	497	O
support	-	500	O
the	-	508	O
notion	-	512	O
that	-	519	O
levodopa	-	524	O
-	-	532	O
induced	-	533	O
dyskinesias	-	541	B
are	-	553	O
caused	-	557	O
by	-	564	O
overstimulation	-	567	O
of	-	583	O
a	-	586	O
separate	-	588	O
group	-	597	O
of	-	603	O
dopamine	-	606	O
receptors	-	615	O
.	-	624	O

Effects	21294084	0	O
of	-	8	O
the	-	11	O
hippocampal	-	15	O
deep	-	27	O
brain	-	32	O
stimulation	-	38	O
on	-	50	O
cortical	-	53	O
epileptic	-	62	B
discharges	-	72	O
in	-	83	O
penicillin	-	86	O
-	-	97	O
induced	-	99	O
epilepsy	-	107	B
model	-	116	O
in	-	122	O
rats	-	125	O
.	-	129	O

AIM	21294084	131	O
:	-	134	O

Experimental	21294084	136	O
and	-	149	O
clinical	-	153	O
studies	-	162	O
have	-	170	O
revealed	-	175	O
that	-	184	O
hippocampal	-	189	O
DBS	-	201	O
can	-	205	O
control	-	209	O
epileptic	-	217	B
activity	-	227	O
,	-	235	O
but	-	237	O
the	-	241	O
mechanism	-	245	O
of	-	255	O
action	-	258	O
is	-	265	O
obscure	-	268	O
and	-	276	O
optimal	-	280	O
stimulation	-	288	O
parameters	-	300	O
are	-	311	O
not	-	315	O
clearly	-	319	O
defined	-	327	O
.	-	334	O

The	21294084	336	O
aim	-	340	O
was	-	344	O
to	-	348	O
evaluate	-	351	O
the	-	360	O
effects	-	364	O
of	-	372	O
high	-	375	O
frequency	-	380	O
hippocampal	-	390	O
stimulation	-	402	O
on	-	414	O
cortical	-	417	O
epileptic	-	426	B
activity	-	436	O
in	-	445	O
penicillin	-	448	O
-	-	458	O
induced	-	459	O
epilepsy	-	467	B
model	-	476	O
.	-	481	O

MATERIAL	21294084	483	O
AND	-	492	O
METHODS	-	496	O
:	-	503	O

Twenty	21294084	505	O
-	-	511	O
five	-	512	O
Sprague	-	517	O
-	-	524	O
Dawley	-	525	O
rats	-	532	O
were	-	537	O
implanted	-	542	O
DBS	-	552	O
electrodes	-	556	O
.	-	566	O

In	21294084	568	O
group	-	571	O
-	-	576	O
1	-	577	O
(	-	579	O
n	-	580	O
=	-	581	O
10	-	582	O
)	-	584	O
hippocampal	-	586	O
DBS	-	598	O
was	-	602	O
off	-	606	O
and	-	610	O
in	-	614	O
the	-	617	O
group	-	621	O
-	-	626	O
2	-	627	O
(	-	629	O
n	-	630	O
=	-	631	O
10	-	632	O
)	-	634	O
hippocampal	-	636	O
DBS	-	648	O
was	-	652	O
on	-	656	O
(	-	659	O
185	-	660	O
Hz	-	664	O
,	-	666	O
0	-	668	O
.	-	669	O
5V	-	670	O
,	-	672	O
1V	-	674	O
,	-	676	O
2V	-	678	O
,	-	680	O
and	-	682	O
5V	-	686	O
for	-	689	O
60	-	693	O
sec	-	696	O
)	-	699	O
following	-	701	O
penicillin	-	711	O
G	-	722	O
injection	-	724	O
intracortically	-	734	O
.	-	749	O

In	21294084	751	O
the	-	754	O
control	-	758	O
group	-	766	O
hippocampal	-	772	O
DBS	-	784	O
was	-	788	O
on	-	792	O
following	-	795	O
8	-	805	O
l	-	808	O
saline	-	810	O
injection	-	817	O
intracortically	-	827	O
.	-	842	O

EEG	21294084	844	O
recordings	-	848	O
were	-	859	O
obtained	-	864	O
before	-	873	O
and	-	880	O
15	-	884	O
minutes	-	887	O
following	-	895	O
penicillin	-	905	O
-	-	915	O
G	-	916	O
injection	-	918	O
,	-	927	O
and	-	929	O
at	-	933	O
10th	-	936	O
minutes	-	941	O
following	-	949	O
each	-	959	O
stimulus	-	964	O
for	-	973	O
analysis	-	977	O
in	-	986	O
terms	-	989	O
of	-	995	O
frequency	-	998	O
,	-	1007	O
amplitude	-	1009	O
,	-	1018	O
and	-	1020	O
power	-	1024	O
spectrum	-	1030	O
.	-	1038	O

RESULTS	21294084	1040	O
:	-	1047	O

High	21294084	1049	O
frequency	-	1054	O
hippocampal	-	1064	O
DBS	-	1076	O
suppressed	-	1080	O
the	-	1091	O
acute	-	1095	O
penicillin	-	1101	O
-	-	1111	O
induced	-	1112	O
cortical	-	1120	O
epileptic	-	1129	B
activity	-	1139	O
independent	-	1148	O
from	-	1160	O
stimulus	-	1165	O
intensity	-	1174	O
.	-	1183	O

In	21294084	1185	O
the	-	1188	O
control	-	1192	O
group	-	1200	O
,	-	1205	O
hippocampal	-	1207	O
stimulation	-	1219	O
alone	-	1231	O
lead	-	1237	O
only	-	1242	O
to	-	1247	O
diffuse	-	1250	O
slowing	-	1258	O
of	-	1266	O
cerebral	-	1269	O
bioelectrical	-	1278	O
activity	-	1292	O
at	-	1301	O
5V	-	1304	O
stimulation	-	1307	O
.	-	1318	O

CONCLUSION	21294084	1320	O
:	-	1330	O

Our	21294084	1332	O
results	-	1336	O
revealed	-	1344	O
that	-	1353	O
continuous	-	1358	O
high	-	1369	O
frequency	-	1374	O
stimulation	-	1384	O
of	-	1396	O
the	-	1399	O
hippocampus	-	1403	O
suppressed	-	1415	O
acute	-	1426	O
cortical	-	1432	O
epileptic	-	1441	B
activity	-	1451	O
effectively	-	1460	O
without	-	1472	O
causing	-	1480	O
secondary	-	1488	O
epileptic	-	1498	B
discharges	-	1508	O
.	-	1518	O

These	21294084	1520	O
results	-	1526	O
are	-	1534	O
important	-	1538	O
in	-	1548	O
terms	-	1551	O
of	-	1557	O
defining	-	1560	O
the	-	1569	O
optimal	-	1573	O
parameters	-	1581	O
of	-	1592	O
hippocampal	-	1595	O
DBS	-	1607	O
in	-	1611	O
patients	-	1614	O
with	-	1623	O
epilepsy	-	1628	B
.	-	1636	O

Neural	20727411	0	O
correlates	-	7	O
of	-	18	O
S	-	21	O
-	-	22	O
ketamine	-	23	O
induced	-	32	O
psychosis	-	40	B
during	-	50	O
overt	-	57	O
continuous	-	63	O
verbal	-	74	O
fluency	-	81	O
.	-	88	O

The	20727411	90	O
glutamatergic	-	94	O
N	-	108	O
-	-	109	O
methyl	-	110	O
-	-	116	O
D	-	117	O
-	-	118	O
aspartate	-	119	O
(	-	129	O
NMDA	-	130	O
)	-	134	O
receptor	-	136	O
has	-	145	O
been	-	149	O
implicated	-	154	O
in	-	165	O
the	-	168	O
pathophysiology	-	172	O
of	-	188	O
schizophrenia	-	191	B
.	-	204	O

Administered	20727411	206	O
to	-	219	O
healthy	-	222	O
volunteers	-	230	O
,	-	240	O
a	-	242	O
subanesthetic	-	244	O
dose	-	258	O
of	-	263	O
the	-	266	O
non	-	270	O
-	-	273	O
competitive	-	274	O
NMDA	-	286	O
receptor	-	291	O
antagonist	-	300	O
ketamine	-	311	O
leads	-	320	O
to	-	326	O
psychopathological	-	329	O
symptoms	-	348	O
similar	-	357	O
to	-	365	O
those	-	368	O
observed	-	374	O
in	-	383	O
schizophrenia	-	386	B
.	-	399	O

In	20727411	401	O
patients	-	404	O
with	-	413	O
schizophrenia	-	418	B
,	-	431	O
ketamine	-	433	O
exacerbates	-	442	O
the	-	454	O
core	-	458	O
symptoms	-	463	O
of	-	472	O
illness	-	475	O
,	-	482	O
supporting	-	484	O
the	-	495	O
hypothesis	-	499	O
of	-	510	O
a	-	513	O
glutamatergic	-	515	B
dysfunction	-	529	I
.	-	540	O

In	20727411	542	O
a	-	545	O
counterbalanced	-	547	O
,	-	562	O
placebo	-	564	O
-	-	571	O
controlled	-	572	O
,	-	582	O
double	-	584	O
-	-	590	O
blind	-	591	O
study	-	597	O
design	-	603	O
,	-	609	O
healthy	-	611	O
subjects	-	619	O
were	-	628	O
administered	-	633	O
a	-	646	O
continuous	-	648	O
subanesthetic	-	659	O
S	-	673	O
-	-	674	O
ketamine	-	675	O
infusion	-	684	O
while	-	693	O
differences	-	699	O
in	-	711	O
BOLD	-	714	O
responses	-	719	O
measured	-	729	O
with	-	738	O
fMRI	-	743	O
were	-	748	O
detected	-	753	O
.	-	761	O

During	20727411	763	O
the	-	770	O
scanning	-	774	O
period	-	783	O
,	-	789	O
subjects	-	791	O
performed	-	800	O
continuous	-	810	O
overt	-	821	O
verbal	-	827	O
fluency	-	834	O
tasks	-	842	O
(	-	848	O
phonological	-	849	O
,	-	861	O
lexical	-	863	O
and	-	871	O
semantic	-	875	O
)	-	883	O
.	-	884	O

Ketamine	20727411	886	O
-	-	894	O
induced	-	895	O
psychopathological	-	903	O
symptoms	-	922	O
were	-	931	O
assessed	-	936	O
with	-	945	O
the	-	950	O
Positive	-	954	O
and	-	963	O
Negative	-	967	O
Syndrome	-	976	O
Scale	-	985	O
(	-	991	O
PANSS	-	992	O
)	-	997	O
.	-	998	O

Ketamine	20727411	1000	O
elicited	-	1009	O
psychosis	-	1018	B
like	-	1028	O
psychopathology	-	1033	O
.	-	1048	O

Post	20727411	1050	O
-	-	1054	O
hoc	-	1055	O
t	-	1059	O
-	-	1060	O
tests	-	1061	O
revealed	-	1067	O
significant	-	1076	O
differences	-	1088	O
between	-	1100	O
placebo	-	1108	O
and	-	1116	O
ketamine	-	1120	O
for	-	1129	O
the	-	1133	O
amounts	-	1137	O
of	-	1145	O
words	-	1148	O
generated	-	1154	O
during	-	1164	O
lexical	-	1171	O
and	-	1179	O
semantic	-	1183	O
verbal	-	1192	O
fluency	-	1199	O
,	-	1206	O
while	-	1208	O
the	-	1214	O
phonological	-	1218	O
domain	-	1231	O
remained	-	1238	O
unaffected	-	1247	O
.	-	1257	O

Ketamine	20727411	1259	O
led	-	1268	O
to	-	1272	O
enhanced	-	1275	O
cortical	-	1284	O
activations	-	1293	O
in	-	1305	O
supramarginal	-	1308	O
and	-	1322	O
frontal	-	1326	O
brain	-	1334	O
regions	-	1340	O
for	-	1348	O
phonological	-	1352	O
and	-	1365	O
lexical	-	1369	O
verbal	-	1377	O
fluency	-	1384	O
,	-	1391	O
but	-	1393	O
not	-	1397	O
for	-	1401	O
semantic	-	1405	O
verbal	-	1414	O
fluency	-	1421	O
.	-	1428	O

Ketamine	20727411	1430	O
induces	-	1439	O
activation	-	1447	O
changes	-	1458	O
in	-	1466	O
healthy	-	1469	O
subjects	-	1477	O
similar	-	1486	O
to	-	1494	O
those	-	1497	O
observed	-	1503	O
in	-	1512	O
patients	-	1515	O
with	-	1524	O
schizophrenia	-	1529	B
,	-	1542	O
particularly	-	1544	O
in	-	1557	O
frontal	-	1560	O
and	-	1568	O
temporal	-	1572	O
brain	-	1581	O
regions	-	1587	O
.	-	1594	O

Our	20727411	1596	O
results	-	1600	O
provide	-	1608	O
further	-	1616	O
support	-	1624	O
for	-	1632	O
the	-	1636	O
hypothesis	-	1640	O
of	-	1651	O
an	-	1654	O
NMDA	-	1657	O
receptor	-	1662	O
dysfunction	-	1671	O
in	-	1683	O
the	-	1686	O
pathophysiology	-	1690	O
of	-	1706	O
schizophrenia	-	1709	B
.	-	1722	O

Dopamine	20533999	0	O
is	-	9	O
not	-	12	O
essential	-	16	O
for	-	26	O
the	-	30	O
development	-	34	O
of	-	46	O
methamphetamine	-	49	O
-	-	64	O
induced	-	65	O
neurotoxicity	-	73	B
.	-	86	O

It	20533999	88	O
is	-	91	O
widely	-	94	O
believed	-	101	O
that	-	110	O
dopamine	-	115	O
(	-	124	O
DA	-	125	O
)	-	127	O
mediates	-	129	O
methamphetamine	-	138	O
(	-	154	O
METH	-	155	O
)	-	159	O
-	-	160	O
induced	-	161	O
toxicity	-	169	B
to	-	178	O
brain	-	181	O
dopaminergic	-	187	O
neurons	-	200	O
,	-	207	O
because	-	209	O
drugs	-	217	O
that	-	223	O
interfere	-	228	O
with	-	238	O
DA	-	243	O
neurotransmission	-	246	O
decrease	-	264	O
toxicity	-	273	B
,	-	281	O
whereas	-	283	O
drugs	-	291	O
that	-	297	O
increase	-	302	O
DA	-	311	O
neurotransmission	-	314	O
enhance	-	332	O
toxicity	-	340	B
.	-	348	O

However	20533999	350	O
,	-	357	O
temperature	-	359	O
effects	-	371	O
of	-	379	O
drugs	-	382	O
that	-	388	O
have	-	393	O
been	-	398	O
used	-	403	O
to	-	408	O
manipulate	-	411	O
brain	-	422	O
DA	-	428	O
neurotransmission	-	431	O
confound	-	449	O
interpretation	-	458	O
of	-	473	O
the	-	476	O
data	-	480	O
.	-	484	O

Here	20533999	486	O
we	-	491	O
show	-	494	O
that	-	499	O
the	-	504	O
recently	-	508	O
reported	-	517	O
ability	-	526	O
of	-	534	O
L	-	537	O
-	-	538	O
dihydroxyphenylalanine	-	539	O
to	-	562	O
reverse	-	565	O
the	-	573	O
protective	-	577	O
effect	-	588	O
of	-	595	O
alpha	-	598	O
-	-	603	O
methyl	-	604	O
-	-	610	O
para	-	611	O
-	-	615	O
tyrosine	-	616	O
on	-	625	O
METH	-	628	O
-	-	632	O
induced	-	633	O
DA	-	641	O
neurotoxicity	-	644	B
is	-	658	O
also	-	661	O
confounded	-	666	O
by	-	677	O
drug	-	680	O
effects	-	685	O
on	-	693	O
body	-	696	O
temperature	-	701	O
.	-	712	O

Further	20533999	714	O
,	-	721	O
we	-	723	O
show	-	726	O
that	-	731	O
mice	-	736	O
genetically	-	741	O
engineered	-	753	O
to	-	764	O
be	-	767	O
deficient	-	770	O
in	-	780	O
brain	-	783	O
DA	-	789	O
develop	-	792	O
METH	-	800	O
neurotoxicity	-	805	B
,	-	818	O
as	-	820	O
long	-	823	O
as	-	828	O
the	-	831	O
thermic	-	835	O
effects	-	843	O
of	-	851	O
METH	-	854	O
are	-	859	O
preserved	-	863	O
.	-	872	O

In	20533999	874	O
addition	-	877	O
,	-	885	O
we	-	887	O
demonstrate	-	890	O
that	-	902	O
mice	-	907	O
genetically	-	912	O
engineered	-	924	O
to	-	935	O
have	-	938	O
unilateral	-	943	O
brain	-	954	O
DA	-	960	O
deficits	-	963	O
develop	-	972	O
METH	-	980	O
-	-	984	O
induced	-	985	O
dopaminergic	-	993	B
deficits	-	1006	I
that	-	1015	O
are	-	1020	O
of	-	1024	O
comparable	-	1027	O
magnitude	-	1038	O
on	-	1048	O
both	-	1051	O
sides	-	1056	O
of	-	1062	O
the	-	1065	O
brain	-	1069	O
.	-	1074	O

Taken	20533999	1076	O
together	-	1082	O
,	-	1090	O
these	-	1092	O
findings	-	1098	O
demonstrate	-	1107	O
that	-	1119	O
DA	-	1124	O
is	-	1127	O
not	-	1130	O
essential	-	1134	O
for	-	1144	O
the	-	1148	O
development	-	1152	O
of	-	1164	O
METH	-	1167	O
-	-	1171	O
induced	-	1172	O
dopaminergic	-	1180	O
neurotoxicity	-	1193	B
and	-	1207	O
suggest	-	1211	O
that	-	1219	O
mechanisms	-	1224	O
independent	-	1235	O
of	-	1247	O
DA	-	1250	O
warrant	-	1253	O
more	-	1261	O
intense	-	1266	O
investigation	-	1274	O
.	-	1287	O

Brainstem	20304337	0	B
dysgenesis	-	10	I
in	-	21	O
an	-	24	O
infant	-	27	O
prenatally	-	34	O
exposed	-	45	O
to	-	53	O
cocaine	-	56	O
.	-	63	O

Many	20304337	65	O
authors	-	70	O
described	-	78	O
the	-	88	O
effects	-	92	O
on	-	100	O
the	-	103	O
fetus	-	107	O
of	-	113	O
maternal	-	116	O
cocaine	-	125	B
abuse	-	133	I
during	-	139	O
pregnancy	-	146	O
.	-	155	O

Vasoconstriction	20304337	157	O
appears	-	174	O
to	-	182	O
be	-	185	O
the	-	188	O
common	-	192	O
mechanism	-	199	O
of	-	209	O
action	-	212	O
leading	-	219	O
to	-	227	O
a	-	230	O
wide	-	232	O
range	-	237	O
of	-	243	O
fetal	-	246	B
anomalies	-	252	I
.	-	261	O

We	20304337	263	O
report	-	266	O
on	-	273	O
an	-	276	O
infant	-	279	O
with	-	286	O
multiple	-	291	B
cranial	-	300	I
-	-	307	I
nerve	-	308	I
involvement	-	314	I
attributable	-	326	O
to	-	339	O
brainstem	-	342	B
dysgenesis	-	352	I
,	-	362	O
born	-	364	O
to	-	369	O
a	-	372	O
cocaine	-	374	B
-	-	381	I
addicted	-	382	I
mother	-	391	O
.	-	397	O

The	20103708	0	O
protective	-	4	O
role	-	15	O
of	-	20	O
Nrf2	-	23	O
in	-	28	O
streptozotocin	-	31	O
-	-	45	O
induced	-	46	O
diabetic	-	54	B
nephropathy	-	63	I
.	-	74	O

OBJECTIVE	20103708	76	O
:	-	85	O
Diabetic	-	87	B
nephropathy	-	96	I
is	-	108	O
one	-	111	O
of	-	115	O
the	-	118	O
major	-	122	O
causes	-	128	O
of	-	135	O
renal	-	138	B
failure	-	144	I
,	-	151	O
which	-	153	O
is	-	159	O
accompanied	-	162	O
by	-	174	O
the	-	177	O
production	-	181	O
of	-	192	O
reactive	-	195	O
oxygen	-	204	O
species	-	211	O
(	-	219	O
ROS	-	220	O
)	-	223	O
.	-	224	O

Nrf2	20103708	226	O
is	-	231	O
the	-	234	O
primary	-	238	O
transcription	-	246	O
factor	-	260	O
that	-	267	O
controls	-	272	O
the	-	281	O
antioxidant	-	285	O
response	-	297	O
essential	-	306	O
for	-	316	O
maintaining	-	320	O
cellular	-	332	O
redox	-	341	O
homeostasis	-	347	O
.	-	358	O

Here	20103708	360	O
,	-	364	O
we	-	366	O
report	-	369	O
our	-	376	O
findings	-	380	O
demonstrating	-	389	O
a	-	403	O
protective	-	405	O
role	-	416	O
of	-	421	O
Nrf2	-	424	O
against	-	429	O
diabetic	-	437	B
nephropathy	-	446	I
.	-	457	O

RESEARCH	20103708	459	O
DESIGN	-	468	O
AND	-	475	O
METHODS	-	479	O
:	-	486	O

We	20103708	488	O
explore	-	491	O
the	-	499	O
protective	-	503	O
role	-	514	O
of	-	519	O
Nrf2	-	522	O
against	-	527	O
diabetic	-	535	B
nephropathy	-	544	I
using	-	556	O
human	-	562	O
kidney	-	568	O
biopsy	-	575	O
tissues	-	582	O
from	-	590	O
diabetic	-	595	B
nephropathy	-	604	I
patients	-	616	O
,	-	624	O
a	-	626	O
streptozotocin	-	628	O
-	-	642	O
induced	-	643	O
diabetic	-	651	B
nephropathy	-	660	I
model	-	672	O
in	-	678	O
Nrf2	-	681	O
(	-	685	O
-	-	686	O
/	-	687	O
-	-	688	O
)	-	689	O
mice	-	691	O
,	-	695	O
and	-	697	O
cultured	-	701	O
human	-	710	O
mesangial	-	716	O
cells	-	726	O
.	-	731	O

RESULTS	20103708	733	O
:	-	740	O

The	20103708	742	O
glomeruli	-	746	O
of	-	756	O
human	-	759	O
diabetic	-	765	B
nephropathy	-	774	I
patients	-	786	O
were	-	795	O
under	-	800	O
oxidative	-	806	O
stress	-	816	O
and	-	823	O
had	-	827	O
elevated	-	831	O
Nrf2	-	840	O
levels	-	845	O
.	-	851	O

In	20103708	853	O
the	-	856	O
animal	-	860	O
study	-	867	O
,	-	872	O
Nrf2	-	874	O
was	-	879	O
demonstrated	-	883	O
to	-	896	O
be	-	899	O
crucial	-	902	O
in	-	910	O
ameliorating	-	913	O
streptozotocin	-	926	O
-	-	940	O
induced	-	941	O
renal	-	949	B
damage	-	955	I
.	-	961	O

This	20103708	963	O
is	-	968	O
evident	-	971	O
by	-	979	O
Nrf2	-	982	O
(	-	986	O
-	-	987	O
/	-	988	O
-	-	989	O
)	-	990	O
mice	-	992	O
having	-	997	O
higher	-	1004	O
ROS	-	1011	O
production	-	1015	O
and	-	1026	O
suffering	-	1030	O
from	-	1040	O
greater	-	1045	O
oxidative	-	1053	O
DNA	-	1063	O
damage	-	1067	O
and	-	1074	O
renal	-	1078	B
injury	-	1084	I
compared	-	1091	O
with	-	1100	O
Nrf2	-	1105	O
(	-	1109	O
+	-	1110	O
/	-	1111	O
+	-	1112	O
)	-	1113	O
mice	-	1115	O
.	-	1119	O

Mechanistic	20103708	1121	O
studies	-	1133	O
in	-	1141	O
both	-	1144	O
in	-	1149	O
vivo	-	1152	O
and	-	1157	O
in	-	1161	O
vitro	-	1164	O
systems	-	1170	O
showed	-	1178	O
that	-	1185	O
the	-	1190	O
Nrf2	-	1194	O
-	-	1198	O
mediated	-	1199	O
protection	-	1208	O
against	-	1219	O
diabetic	-	1227	B
nephropathy	-	1236	I
is	-	1248	O
,	-	1250	O
at	-	1252	O
least	-	1255	O
,	-	1260	O
partially	-	1262	O
through	-	1272	O
inhibition	-	1280	O
of	-	1291	O
transforming	-	1294	O
growth	-	1307	O
factor	-	1314	O
-	-	1320	O
beta1	-	1321	O
(	-	1327	O
TGF	-	1328	O
-	-	1331	O
beta1	-	1332	O
)	-	1337	O
and	-	1339	O
reduction	-	1343	O
of	-	1353	O
extracellular	-	1356	O
matrix	-	1370	O
production	-	1377	O
.	-	1387	O

In	20103708	1389	O
human	-	1392	O
renal	-	1398	O
mesangial	-	1404	O
cells	-	1414	O
,	-	1419	O
high	-	1421	O
glucose	-	1426	O
induced	-	1434	O
ROS	-	1442	O
production	-	1446	O
and	-	1457	O
activated	-	1461	O
expression	-	1471	O
of	-	1482	O
Nrf2	-	1485	O
and	-	1490	O
its	-	1494	O
downstream	-	1498	O
genes	-	1509	O
.	-	1514	O

Furthermore	20103708	1516	O
,	-	1527	O
activation	-	1529	O
or	-	1540	O
overexpression	-	1543	O
of	-	1558	O
Nrf2	-	1561	O
inhibited	-	1566	O
the	-	1576	O
promoter	-	1580	O
activity	-	1589	O
of	-	1598	O
TGF	-	1601	O
-	-	1604	O
beta1	-	1605	O
in	-	1611	O
a	-	1614	O
dose	-	1616	O
-	-	1620	O
dependent	-	1621	O
manner	-	1631	O
,	-	1637	O
whereas	-	1639	O
knockdown	-	1647	O
of	-	1657	O
Nrf2	-	1660	O
by	-	1665	O
siRNA	-	1668	O
enhanced	-	1674	O
TGF	-	1683	O
-	-	1686	O
beta1	-	1687	O
transcription	-	1693	O
and	-	1707	O
fibronectin	-	1711	O
production	-	1723	O
.	-	1733	O

CONCLUSIONS	20103708	1735	O
:	-	1746	O

This	20103708	1748	O
work	-	1753	O
clearly	-	1758	O
indicates	-	1766	O
a	-	1776	O
protective	-	1778	O
role	-	1789	O
of	-	1794	O
Nrf2	-	1797	O
in	-	1802	O
diabetic	-	1805	B
nephropathy	-	1814	I
,	-	1825	O
suggesting	-	1827	O
that	-	1838	O
dietary	-	1843	O
or	-	1851	O
therapeutic	-	1854	O
activation	-	1866	O
of	-	1877	O
Nrf2	-	1880	O
could	-	1885	O
be	-	1891	O
used	-	1894	O
as	-	1899	O
a	-	1902	O
strategy	-	1904	O
to	-	1913	O
prevent	-	1916	O
or	-	1924	O
slow	-	1927	O
down	-	1932	O
the	-	1937	O
progression	-	1941	O
of	-	1953	O
diabetic	-	1956	B
nephropathy	-	1965	I
.	-	1976	O

High	19996135	0	O
-	-	4	O
dose	-	5	O
tranexamic	-	10	O
Acid	-	21	O
is	-	26	O
associated	-	29	O
with	-	40	O
nonischemic	-	45	O
clinical	-	57	O
seizures	-	66	B
in	-	75	O
cardiac	-	78	O
surgical	-	86	O
patients	-	95	O
.	-	103	O

BACKGROUND	19996135	105	O
:	-	115	O

In	19996135	117	O
2	-	120	O
separate	-	122	O
centers	-	131	O
,	-	138	O
we	-	140	O
observed	-	143	O
a	-	152	O
notable	-	154	O
increase	-	162	O
in	-	171	O
the	-	174	O
incidence	-	178	O
of	-	188	O
postoperative	-	191	O
convulsive	-	205	B
seizures	-	216	B
from	-	225	O
1	-	230	O
.	-	231	O
3	-	232	O
%	-	233	O
to	-	235	O
3	-	238	O
.	-	239	O
8	-	240	O
%	-	241	O
in	-	243	O
patients	-	246	O
having	-	255	O
undergone	-	262	O
major	-	272	O
cardiac	-	278	O
surgical	-	286	O
procedures	-	295	O
.	-	305	O

These	19996135	307	O
events	-	313	O
were	-	320	O
temporally	-	325	O
coincident	-	336	O
with	-	347	O
the	-	352	O
initial	-	356	O
use	-	364	O
of	-	368	O
high	-	371	O
-	-	375	O
dose	-	376	O
tranexamic	-	381	O
acid	-	392	O
(	-	397	O
TXA	-	398	O
)	-	401	O
therapy	-	403	O
after	-	411	O
withdrawal	-	417	O
of	-	428	O
aprotinin	-	431	O
from	-	441	O
general	-	446	O
clinical	-	454	O
usage	-	463	O
.	-	468	O

The	19996135	470	O
purpose	-	474	O
of	-	482	O
this	-	485	O
review	-	490	O
was	-	497	O
to	-	501	O
perform	-	504	O
a	-	512	O
retrospective	-	514	O
analysis	-	528	O
to	-	537	O
examine	-	540	O
whether	-	548	O
there	-	556	O
was	-	562	O
a	-	566	O
relation	-	568	O
between	-	577	O
TXA	-	585	O
usage	-	589	O
and	-	595	O
seizures	-	599	B
after	-	608	O
cardiac	-	614	O
surgery	-	622	O
.	-	629	O

METHODS	19996135	631	O
:	-	638	O

An	19996135	640	O
in	-	643	O
-	-	645	O
depth	-	646	O
chart	-	652	O
review	-	658	O
was	-	665	O
undertaken	-	669	O
in	-	680	O
all	-	683	O
24	-	687	O
patients	-	690	O
who	-	699	O
developed	-	703	O
perioperative	-	713	O
seizures	-	727	B
.	-	735	O

Electroencephalographic	19996135	737	O
activity	-	761	O
was	-	770	O
recorded	-	774	O
in	-	783	O
11	-	786	O
of	-	789	O
these	-	792	O
patients	-	798	O
,	-	806	O
and	-	808	O
all	-	812	O
patients	-	816	O
had	-	825	O
a	-	829	O
formal	-	831	O
neurological	-	838	O
evaluation	-	851	O
and	-	862	O
brain	-	866	O
imaging	-	872	O
studies	-	880	O
.	-	887	O

RESULTS	19996135	889	O
:	-	896	O

Twenty	19996135	898	O
-	-	904	O
one	-	905	O
of	-	909	O
the	-	912	O
24	-	916	O
patients	-	919	O
did	-	928	O
not	-	932	O
have	-	936	O
evidence	-	941	O
of	-	950	O
new	-	953	O
cerebral	-	957	B
ischemic	-	966	I
injury	-	975	I
,	-	981	O
but	-	983	O
seizures	-	987	B
were	-	996	O
likely	-	1001	O
due	-	1008	O
to	-	1012	O
ischemic	-	1015	B
brain	-	1024	I
injury	-	1030	I
in	-	1037	O
3	-	1040	O
patients	-	1042	O
.	-	1050	O

All	19996135	1052	O
patients	-	1056	O
with	-	1065	O
seizures	-	1070	B
did	-	1079	O
not	-	1083	O
have	-	1087	O
permanent	-	1092	O
neurological	-	1102	B
abnormalities	-	1115	I
.	-	1128	O

All	19996135	1130	O
24	-	1134	O
patients	-	1137	O
with	-	1146	O
seizures	-	1151	B
received	-	1160	O
high	-	1169	O
doses	-	1174	O
of	-	1180	O
TXA	-	1183	O
intraoperatively	-	1187	O
ranging	-	1204	O
from	-	1212	O
61	-	1217	O
to	-	1220	O
259	-	1223	O
mg	-	1227	O
/	-	1229	O
kg	-	1230	O
,	-	1232	O
had	-	1234	O
a	-	1238	O
mean	-	1240	O
age	-	1245	O
of	-	1249	O
69	-	1252	O
.	-	1254	O
9	-	1255	O
years	-	1257	O
,	-	1262	O
and	-	1264	O
21	-	1268	O
of	-	1271	O
24	-	1274	O
had	-	1277	O
undergone	-	1281	O
open	-	1291	O
chamber	-	1296	O
rather	-	1304	O
than	-	1311	O
coronary	-	1316	O
bypass	-	1325	O
procedures	-	1332	O
.	-	1342	O

All	19996135	1344	O
but	-	1348	O
one	-	1352	O
patient	-	1356	O
were	-	1364	O
managed	-	1369	O
using	-	1377	O
cardiopulmonary	-	1383	O
bypass	-	1399	O
.	-	1405	O

No	19996135	1407	O
evidence	-	1410	O
of	-	1419	O
brain	-	1422	B
ischemic	-	1428	I
,	-	1436	O
metabolic	-	1438	O
,	-	1447	O
or	-	1449	O
hyperthermia	-	1452	B
-	-	1464	O
induced	-	1465	O
causes	-	1473	O
for	-	1480	O
their	-	1484	O
seizures	-	1490	B
was	-	1499	O
apparent	-	1503	O
.	-	1511	O

CONCLUSION	19996135	1513	O
:	-	1523	O

Our	19996135	1525	O
results	-	1529	O
suggest	-	1537	O
that	-	1545	O
use	-	1550	O
of	-	1554	O
high	-	1557	O
-	-	1561	O
dose	-	1562	O
TXA	-	1567	O
in	-	1571	O
older	-	1574	O
patients	-	1580	O
in	-	1589	O
conjunction	-	1592	O
with	-	1604	O
cardiopulmonary	-	1609	O
bypass	-	1625	O
and	-	1632	O
open	-	1636	O
-	-	1640	O
chamber	-	1641	O
cardiac	-	1649	O
surgery	-	1657	O
is	-	1665	O
associated	-	1668	O
with	-	1679	O
clinical	-	1684	O
seizures	-	1693	B
in	-	1702	O
susceptible	-	1705	O
patients	-	1717	O
.	-	1725	O

Recurrent	19674115	0	O
dysosmia	-	10	B
induced	-	19	O
by	-	27	O
pyrazinamide	-	30	O
.	-	42	O

Pyrazinamide	19674115	44	O
can	-	57	O
have	-	61	O
adverse	-	66	O
effects	-	74	O
such	-	82	O
as	-	87	O
hepatic	-	90	B
toxicity	-	98	I
,	-	106	O
hyperuricemia	-	108	B
or	-	122	O
digestive	-	125	O
disorders	-	135	O
.	-	144	O

In	19674115	146	O
rare	-	149	O
cases	-	154	O
,	-	159	O
alterations	-	161	O
in	-	173	O
taste	-	176	O
and	-	182	O
smell	-	186	O
function	-	192	O
have	-	201	O
been	-	206	O
reported	-	211	O
for	-	220	O
pyrazinamide	-	224	O
when	-	237	O
combined	-	242	O
with	-	251	O
other	-	256	O
drugs	-	262	O
.	-	267	O

We	19674115	269	O
report	-	272	O
a	-	279	O
case	-	281	O
of	-	286	O
reversible	-	289	O
olfactory	-	300	B
disorder	-	310	I
related	-	319	O
to	-	327	O
pyrazinamide	-	330	O
in	-	343	O
a	-	346	O
woman	-	348	O
,	-	353	O
with	-	355	O
a	-	360	O
positive	-	362	O
rechallenge	-	371	O
.	-	382	O

The	19674115	384	O
patient	-	388	O
presented	-	396	O
every	-	406	O
day	-	412	O
a	-	416	O
sensation	-	418	O
of	-	428	O
smelling	-	431	O
something	-	440	O
burning	-	450	O
15	-	458	O
min	-	461	O
after	-	465	O
drug	-	471	O
intake	-	476	O
.	-	482	O

Dysosmia	19674115	484	B
disappeared	-	493	O
completely	-	505	O
after	-	516	O
pyrazinamide	-	522	O
withdrawal	-	535	O
and	-	546	O
recurred	-	550	O
after	-	559	O
its	-	565	O
rechallenge	-	569	O
.	-	580	O

The	19674115	582	O
case	-	586	O
was	-	591	O
reported	-	595	O
to	-	604	O
the	-	607	O
Tunisian	-	611	O
Centre	-	620	O
of	-	627	O
Pharmacovigilance	-	630	O
.	-	647	O

Longitudinal	19139001	0	O
assessment	-	13	O
of	-	24	O
air	-	27	O
conduction	-	31	O
audiograms	-	42	O
in	-	53	O
a	-	56	O
phase	-	58	O
III	-	64	O
clinical	-	68	O
trial	-	77	O
of	-	83	O
difluoromethylornithine	-	86	O
and	-	110	O
sulindac	-	114	O
for	-	123	O
prevention	-	127	O
of	-	138	O
sporadic	-	141	O
colorectal	-	150	B
adenomas	-	161	I
.	-	169	O

A	19139001	171	O
phase	-	173	O
III	-	179	O
clinical	-	183	O
trial	-	192	O
assessed	-	198	O
the	-	207	O
recurrence	-	211	O
of	-	222	O
adenomatous	-	225	B
polyps	-	237	I
after	-	244	O
treatment	-	250	O
for	-	260	O
36	-	264	O
months	-	267	O
with	-	274	O
difluoromethylornithine	-	279	O
(	-	303	O
DFMO	-	304	O
)	-	308	O
plus	-	310	O
sulindac	-	315	O
or	-	324	O
matched	-	327	O
placebos	-	335	O
.	-	343	O

Temporary	19139001	345	O
hearing	-	355	B
loss	-	363	I
is	-	368	O
a	-	371	O
known	-	373	O
toxicity	-	379	B
of	-	388	O
treatment	-	391	O
with	-	401	O
DFMO	-	406	O
,	-	410	O
thus	-	412	O
a	-	417	O
comprehensive	-	419	O
approach	-	433	O
was	-	442	O
developed	-	446	O
to	-	456	O
analyze	-	459	O
serial	-	467	O
air	-	474	O
conduction	-	478	O
audiograms	-	489	O
.	-	499	O

The	19139001	501	O
generalized	-	505	O
estimating	-	517	O
equation	-	528	O
method	-	537	O
estimated	-	544	O
the	-	554	O
mean	-	558	O
difference	-	563	O
between	-	574	O
treatment	-	582	O
arms	-	592	O
with	-	597	O
regard	-	602	O
to	-	609	O
change	-	612	O
in	-	619	O
air	-	622	O
conduction	-	626	O
pure	-	637	O
tone	-	642	O
thresholds	-	647	O
while	-	658	O
accounting	-	664	O
for	-	675	O
within	-	679	O
-	-	685	O
subject	-	686	O
correlation	-	694	O
due	-	706	O
to	-	710	O
repeated	-	713	O
measurements	-	722	O
at	-	735	O
frequencies	-	738	O
.	-	749	O

Based	19139001	751	O
on	-	757	O
290	-	760	O
subjects	-	764	O
,	-	772	O
there	-	774	O
was	-	780	O
an	-	784	O
average	-	787	O
difference	-	795	O
of	-	806	O
0	-	809	O
.	-	810	O
50	-	811	O
dB	-	814	O
between	-	817	O
subjects	-	825	O
treated	-	834	O
with	-	842	O
DFMO	-	847	O
plus	-	852	O
sulindac	-	857	O
compared	-	866	O
with	-	875	O
those	-	880	O
treated	-	886	O
with	-	894	O
placebo	-	899	O
(	-	907	O
95	-	908	O
%	-	910	O
confidence	-	912	O
interval	-	923	O
,	-	931	O
-	-	933	O
0	-	934	O
.	-	935	O
64	-	936	O
to	-	939	O
1	-	942	O
.	-	943	O
63	-	944	O
dB	-	947	O
;	-	949	O
P	-	951	O
=	-	953	O
0	-	955	O
.	-	956	O
39	-	957	O
)	-	959	O
,	-	960	O
adjusted	-	962	O
for	-	971	O
baseline	-	975	O
values	-	984	O
,	-	990	O
age	-	992	O
,	-	995	O
and	-	997	O
frequencies	-	1001	O
.	-	1012	O

In	19139001	1014	O
the	-	1017	O
normal	-	1021	O
speech	-	1028	O
range	-	1035	O
of	-	1041	O
500	-	1044	O
to	-	1048	O
3	-	1051	O
,	-	1052	O
000	-	1053	O
Hz	-	1057	O
,	-	1059	O
an	-	1061	O
estimated	-	1064	O
difference	-	1074	O
of	-	1085	O
0	-	1088	O
.	-	1089	O
99	-	1090	O
dB	-	1093	O
(	-	1096	O
-	-	1097	O
0	-	1098	O
.	-	1099	O
17	-	1100	O
to	-	1103	O
2	-	1106	O
.	-	1107	O
14	-	1108	O
dB	-	1111	O
;	-	1113	O
P	-	1115	O
=	-	1117	O
0	-	1119	O
.	-	1120	O
09	-	1121	O
)	-	1123	O
was	-	1125	O
detected	-	1129	O
.	-	1137	O

Dose	19139001	1139	O
intensity	-	1144	O
did	-	1154	O
not	-	1158	O
add	-	1162	O
information	-	1166	O
to	-	1178	O
models	-	1181	O
.	-	1187	O

There	19139001	1189	O
were	-	1195	O
14	-	1200	O
of	-	1203	O
151	-	1206	O
(	-	1210	O
9	-	1211	O
.	-	1212	O
3	-	1213	O
%	-	1214	O
)	-	1215	O
in	-	1217	O
the	-	1220	O
DFMO	-	1224	O
plus	-	1229	O
sulindac	-	1234	O
group	-	1243	O
and	-	1249	O
4	-	1253	O
of	-	1255	O
139	-	1258	O
(	-	1262	O
2	-	1263	O
.	-	1264	O
9	-	1265	O
%	-	1266	O
)	-	1267	O
in	-	1269	O
the	-	1272	O
placebo	-	1276	O
group	-	1284	O
who	-	1290	O
experienced	-	1294	O
at	-	1306	O
least	-	1309	O
15	-	1315	O
dB	-	1318	O
hearing	-	1321	O
reduction	-	1329	O
from	-	1339	O
baseline	-	1344	O
in	-	1353	O
2	-	1356	O
or	-	1358	O
more	-	1361	O
consecutive	-	1366	O
frequencies	-	1378	O
across	-	1390	O
the	-	1397	O
entire	-	1401	O
range	-	1408	O
tested	-	1414	O
(	-	1421	O
P	-	1422	O
=	-	1424	O
0	-	1426	O
.	-	1427	O
02	-	1428	O
)	-	1430	O
.	-	1431	O

Follow	19139001	1433	O
-	-	1439	O
up	-	1440	O
air	-	1443	O
conduction	-	1447	O
done	-	1458	O
at	-	1463	O
least	-	1466	O
6	-	1472	O
months	-	1474	O
after	-	1481	O
end	-	1487	O
of	-	1491	O
treatment	-	1494	O
showed	-	1504	O
an	-	1511	O
adjusted	-	1514	O
mean	-	1523	O
difference	-	1528	O
in	-	1539	O
hearing	-	1542	O
thresholds	-	1550	O
of	-	1561	O
1	-	1564	O
.	-	1565	O
08	-	1566	O
dB	-	1569	O
(	-	1572	O
-	-	1573	O
0	-	1574	O
.	-	1575	O
81	-	1576	O
to	-	1579	O
2	-	1582	O
.	-	1583	O
96	-	1584	O
dB	-	1587	O
;	-	1589	O
P	-	1591	O
=	-	1593	O
0	-	1595	O
.	-	1596	O
26	-	1597	O
)	-	1599	O
between	-	1601	O
treatment	-	1609	O
arms	-	1619	O
.	-	1623	O

There	19139001	1625	O
was	-	1631	O
no	-	1635	O
significant	-	1638	O
difference	-	1650	O
in	-	1661	O
the	-	1664	O
proportion	-	1668	O
of	-	1679	O
subjects	-	1682	O
in	-	1691	O
the	-	1694	O
DFMO	-	1698	O
plus	-	1703	O
sulindac	-	1708	O
group	-	1717	O
who	-	1723	O
experienced	-	1727	O
clinically	-	1739	O
significant	-	1750	O
hearing	-	1762	B
loss	-	1770	I
compared	-	1775	O
with	-	1784	O
the	-	1789	O
placebo	-	1793	O
group	-	1801	O
.	-	1806	O

The	19139001	1808	O
estimated	-	1812	O
attributable	-	1822	O
risk	-	1835	O
of	-	1840	O
ototoxicity	-	1843	B
from	-	1855	O
exposure	-	1860	O
to	-	1869	O
the	-	1872	O
drug	-	1876	O
is	-	1881	O
8	-	1884	O
.	-	1885	O
4	-	1886	O
%	-	1887	O
(	-	1889	O
95	-	1890	O
%	-	1892	O
confidence	-	1894	O
interval	-	1905	O
,	-	1913	O
-	-	1915	O
2	-	1916	O
.	-	1917	O
0	-	1918	O
%	-	1919	O
to	-	1921	O
18	-	1924	O
.	-	1926	O
8	-	1927	O
%	-	1928	O
;	-	1929	O
P	-	1931	O
=	-	1933	O
0	-	1935	O
.	-	1936	O
12	-	1937	O
)	-	1939	O
.	-	1940	O

There	19139001	1942	O
is	-	1948	O
a	-	1951	O
<	-	1953	O
2	-	1954	O
dB	-	1956	O
difference	-	1959	O
in	-	1970	O
mean	-	1973	O
threshold	-	1978	O
for	-	1988	O
patients	-	1992	O
treated	-	2001	O
with	-	2009	O
DFMO	-	2014	O
plus	-	2019	O
sulindac	-	2024	O
compared	-	2033	O
with	-	2042	O
those	-	2047	O
treated	-	2053	O
with	-	2061	O
placebo	-	2066	O
.	-	2073	O

Increased	18239197	0	O
mental	-	10	B
slowing	-	17	I
associated	-	25	O
with	-	36	O
the	-	41	O
APOE	-	45	O
epsilon4	-	50	O
allele	-	59	O
after	-	66	O
trihexyphenidyl	-	72	O
oral	-	88	O
anticholinergic	-	93	O
challenge	-	109	O
in	-	119	O
healthy	-	122	O
elderly	-	130	O
.	-	137	O

OBJECTIVES	18239197	139	O
:	-	149	O

The	18239197	151	O
objectives	-	155	O
of	-	166	O
this	-	169	O
study	-	174	O
were	-	180	O
to	-	185	O
examine	-	188	O
the	-	196	O
relationship	-	200	O
between	-	213	O
APOE	-	221	O
epsilon4	-	226	O
and	-	235	O
subjective	-	239	O
effects	-	250	O
of	-	258	O
trihexyphenidyl	-	261	O
on	-	277	O
measures	-	280	O
reflecting	-	289	O
sedation	-	300	O
and	-	309	O
confusion	-	313	B
and	-	323	O
to	-	327	O
investigate	-	330	O
the	-	342	O
relationship	-	346	O
between	-	359	O
trihexyphenidyl	-	367	O
-	-	382	O
induced	-	383	O
subjective	-	391	O
effects	-	402	O
and	-	410	O
objective	-	414	O
memory	-	424	O
performance	-	431	O
.	-	442	O

METHODS	18239197	444	O
:	-	451	O

This	18239197	453	O
study	-	458	O
comprised	-	464	O
24	-	474	O
cognitively	-	477	O
intact	-	489	O
,	-	495	O
health	-	497	O
elderly	-	504	O
adults	-	512	O
(	-	519	O
12	-	520	O
APOE	-	523	O
epsilon4	-	528	O
carriers	-	537	O
)	-	545	O
at	-	547	O
an	-	550	O
outpatient	-	553	O
geriatric	-	564	O
psychiatry	-	574	O
research	-	585	O
clinic	-	594	O
.	-	600	O

This	18239197	602	O
was	-	607	O
a	-	611	O
randomized	-	613	O
,	-	623	O
double	-	625	O
blind	-	632	O
,	-	637	O
placebo	-	639	O
-	-	646	O
controlled	-	647	O
,	-	657	O
three	-	659	O
-	-	664	O
way	-	665	O
,	-	668	O
crossover	-	670	O
experimental	-	680	O
design	-	693	O
.	-	699	O

All	18239197	701	O
participants	-	705	O
received	-	718	O
1	-	727	O
.	-	728	O
0	-	729	O
mg	-	731	O
or	-	734	O
2	-	737	O
.	-	738	O
0	-	739	O
mg	-	741	O
trihexyphenidyl	-	744	O
or	-	760	O
placebo	-	763	O
administered	-	771	O
in	-	784	O
counterbalanced	-	787	O
sequences	-	803	O
over	-	813	O
a	-	818	O
period	-	820	O
of	-	827	O
three	-	830	O
consecutive	-	836	O
weeks	-	848	O
.	-	853	O

Bond	18239197	855	O
and	-	860	O
Lader	-	864	O
's	-	869	O
visual	-	872	O
analog	-	879	O
scales	-	886	O
and	-	893	O
alternate	-	897	O
versions	-	907	O
of	-	916	O
the	-	919	O
Buschke	-	923	O
Selective	-	931	O
Reminding	-	941	O
Test	-	951	O
were	-	956	O
administered	-	961	O
in	-	974	O
a	-	977	O
repeated	-	979	O
measures	-	988	O
design	-	997	O
at	-	1004	O
baseline	-	1007	O
,	-	1015	O
1	-	1017	O
,	-	1018	O
2	-	1020	O
.	-	1021	O
5	-	1022	O
,	-	1023	O
and	-	1025	O
5	-	1029	O
hours	-	1031	O
postdrug	-	1037	O
administration	-	1046	O
.	-	1060	O

RESULTS	18239197	1062	O
:	-	1069	O

A	18239197	1071	O
2	-	1073	O
.	-	1074	O
0	-	1075	O
-	-	1076	O
mg	-	1077	O
oral	-	1080	O
dose	-	1085	O
of	-	1090	O
trihexyphenidyl	-	1093	O
resulted	-	1109	O
in	-	1118	O
increased	-	1121	O
subjective	-	1131	O
ratings	-	1142	O
of	-	1150	O
mental	-	1153	B
slowness	-	1160	I
in	-	1169	O
carriers	-	1172	O
of	-	1181	O
the	-	1184	O
APOE	-	1188	O
epsilon4	-	1193	O
allele	-	1202	O
only	-	1209	O
.	-	1213	O

Drug	18239197	1215	O
effects	-	1220	O
as	-	1228	O
determined	-	1231	O
by	-	1242	O
difference	-	1245	O
scores	-	1256	O
between	-	1263	O
2	-	1271	O
.	-	1272	O
0	-	1273	O
mg	-	1275	O
trihexyphenidyl	-	1278	O
and	-	1294	O
placebo	-	1298	O
on	-	1306	O
ratings	-	1309	O
of	-	1317	O
mental	-	1320	B
slowness	-	1327	I
significantly	-	1336	O
correlated	-	1350	O
with	-	1361	O
total	-	1366	O
and	-	1372	O
delayed	-	1376	O
recall	-	1384	O
on	-	1391	O
the	-	1394	O
Buschke	-	1398	O
Selective	-	1406	O
Reminding	-	1416	O
Test	-	1426	O
in	-	1431	O
carriers	-	1434	O
of	-	1443	O
the	-	1446	O
APOE	-	1450	O
epsilon4	-	1455	O
allele	-	1464	O
only	-	1471	O
.	-	1475	O

However	18239197	1477	O
,	-	1484	O
no	-	1486	O
significant	-	1489	O
effects	-	1501	O
were	-	1509	O
found	-	1514	O
with	-	1520	O
other	-	1525	O
visual	-	1531	O
analog	-	1538	O
scales	-	1545	O
reflecting	-	1552	O
subjective	-	1563	O
sedation	-	1574	O
and	-	1583	O
clear	-	1587	O
-	-	1592	O
headedness	-	1593	O
.	-	1603	O

CONCLUSION	18239197	1605	O
:	-	1615	O

The	18239197	1617	O
epsilon4	-	1621	O
allele	-	1630	O
in	-	1637	O
healthy	-	1640	O
elderly	-	1648	O
was	-	1656	O
associated	-	1660	O
with	-	1671	O
increased	-	1676	O
subjective	-	1686	O
mental	-	1697	B
slowing	-	1704	I
after	-	1712	O
trihexyphenidyl	-	1718	O
anticholinergic	-	1734	O
challenge	-	1750	O
.	-	1759	O

Behavioral	17194457	0	O
effects	-	11	O
of	-	19	O
pubertal	-	22	O
anabolic	-	31	O
androgenic	-	40	O
steroid	-	51	O
exposure	-	59	O
in	-	68	O
male	-	71	O
rats	-	76	O
with	-	81	O
low	-	86	O
serotonin	-	90	O
.	-	99	O

The	17194457	101	O
goal	-	105	O
of	-	110	O
this	-	113	O
study	-	118	O
was	-	124	O
to	-	128	O
assess	-	131	O
the	-	138	O
interactive	-	142	O
effects	-	154	O
of	-	162	O
chronic	-	165	O
anabolic	-	173	O
androgenic	-	182	O
steroid	-	193	O
(	-	201	O
AAS	-	202	O
)	-	205	O
exposure	-	207	O
and	-	216	O
brain	-	220	O
serotonin	-	226	O
(	-	236	O
5	-	237	O
-	-	238	O
hydroxytryptamine	-	239	O
,	-	256	O
5	-	258	O
-	-	259	O
HT	-	260	O
)	-	262	O
depletion	-	264	O
on	-	274	O
behavior	-	277	O
of	-	286	O
pubertal	-	289	O
male	-	298	O
rats	-	303	O
.	-	307	O

Serotonin	17194457	309	O
was	-	319	O
depleted	-	323	O
beginning	-	332	O
on	-	342	O
postnatal	-	345	O
day	-	355	O
26	-	359	O
with	-	362	O
parachlorophenylalanine	-	367	O
(	-	391	O
PCPA	-	392	O
100	-	397	O
mg	-	401	O
/	-	403	O
kg	-	404	O
,	-	406	O
every	-	408	O
other	-	414	O
day	-	420	O
)	-	423	O
;	-	424	O
controls	-	426	O
received	-	435	O
saline	-	444	O
.	-	450	O

At	17194457	452	O
puberty	-	455	O
(	-	463	O
P40	-	464	O
)	-	467	O
,	-	468	O
half	-	470	O
the	-	475	O
PCPA	-	479	O
-	-	483	O
treated	-	484	O
rats	-	492	O
and	-	497	O
half	-	501	O
the	-	506	O
saline	-	510	O
-	-	516	O
treated	-	517	O
rats	-	525	O
began	-	530	O
treatment	-	536	O
with	-	546	O
testosterone	-	551	O
(	-	564	O
T	-	565	O
,	-	566	O
5	-	568	O
mg	-	570	O
/	-	572	O
kg	-	573	O
,	-	575	O
5	-	577	O
days	-	579	O
/	-	583	O
week	-	584	O
)	-	588	O
.	-	589	O

Behavioral	17194457	591	O
measures	-	602	O
included	-	611	O
locomotion	-	620	O
,	-	630	O
irritability	-	632	B
,	-	644	O
copulation	-	646	O
,	-	656	O
partner	-	658	O
preference	-	666	O
,	-	676	O
and	-	678	O
aggression	-	682	B
.	-	692	O

Animals	17194457	694	O
were	-	702	O
tested	-	707	O
for	-	714	O
aggression	-	718	B
in	-	729	O
their	-	732	O
home	-	738	O
cage	-	743	O
,	-	747	O
both	-	749	O
with	-	754	O
and	-	759	O
without	-	763	O
physical	-	771	O
provocation	-	780	O
(	-	792	O
mild	-	793	O
tail	-	798	O
pinch	-	803	O
)	-	808	O
.	-	809	O

Brain	17194457	811	O
levels	-	817	O
of	-	824	O
5	-	827	O
-	-	828	O
HT	-	829	O
and	-	832	O
its	-	836	O
metabolite	-	840	O
,	-	850	O
5	-	852	O
-	-	853	O
hydroxyindoleacetic	-	854	O
acid	-	874	O
(	-	879	O
5	-	880	O
-	-	881	O
HIAA	-	882	O
)	-	886	O
,	-	887	O
were	-	889	O
determined	-	894	O
using	-	905	O
HPLC	-	911	O
.	-	915	O

PCPA	17194457	917	O
significantly	-	922	O
and	-	936	O
substantially	-	940	O
depleted	-	954	O
5	-	963	O
-	-	964	O
HT	-	965	O
and	-	968	O
5	-	972	O
-	-	973	O
HIAA	-	974	O
in	-	979	O
all	-	982	O
brain	-	986	O
regions	-	992	O
examined	-	1000	O
.	-	1008	O

Chronic	17194457	1010	O
T	-	1018	O
treatment	-	1020	O
significantly	-	1030	O
decreased	-	1044	O
5	-	1054	O
-	-	1055	O
HT	-	1056	O
and	-	1059	O
5	-	1063	O
-	-	1064	O
HIAA	-	1065	O
in	-	1070	O
certain	-	1073	O
brain	-	1081	O
areas	-	1087	O
,	-	1092	O
but	-	1094	O
to	-	1098	O
a	-	1101	O
much	-	1103	O
lesser	-	1108	O
extent	-	1115	O
than	-	1122	O
PCPA	-	1127	O
.	-	1131	O

Chronic	17194457	1133	O
exposure	-	1141	O
to	-	1150	O
PCPA	-	1153	O
alone	-	1158	O
significantly	-	1164	O
decreased	-	1178	O
locomotor	-	1188	O
activity	-	1198	O
and	-	1207	O
increased	-	1211	O
irritability	-	1221	B
but	-	1234	O
had	-	1238	O
no	-	1242	O
effect	-	1245	O
on	-	1252	O
sexual	-	1255	O
behavior	-	1262	O
,	-	1270	O
partner	-	1272	O
preference	-	1280	O
,	-	1290	O
or	-	1292	O
aggression	-	1295	B
.	-	1305	O

T	17194457	1307	O
alone	-	1309	O
had	-	1315	O
no	-	1319	O
effect	-	1322	O
on	-	1329	O
locomotion	-	1332	O
,	-	1342	O
irritability	-	1344	B
,	-	1356	O
or	-	1358	O
sexual	-	1361	O
behavior	-	1368	O
but	-	1377	O
increased	-	1381	O
partner	-	1391	O
preference	-	1399	O
and	-	1410	O
aggression	-	1414	B
.	-	1424	O

The	17194457	1426	O
most	-	1430	O
striking	-	1435	O
effect	-	1444	O
of	-	1451	O
combining	-	1454	O
T	-	1464	O
+	-	1465	O
PCPA	-	1466	O
was	-	1471	O
a	-	1475	O
significant	-	1477	O
increase	-	1489	O
in	-	1498	O
attack	-	1501	O
frequency	-	1508	O
as	-	1518	O
well	-	1521	O
as	-	1526	O
a	-	1529	O
significant	-	1531	O
decrease	-	1543	O
in	-	1552	O
the	-	1555	O
latency	-	1559	O
to	-	1567	O
attack	-	1570	O
,	-	1576	O
particularly	-	1578	O
following	-	1591	O
physical	-	1601	O
provocation	-	1610	O
.	-	1621	O

Based	17194457	1623	O
on	-	1629	O
these	-	1632	O
data	-	1638	O
,	-	1642	O
it	-	1644	O
can	-	1647	O
be	-	1651	O
speculated	-	1654	O
that	-	1665	O
pubertal	-	1670	O
AAS	-	1679	O
users	-	1683	O
with	-	1689	O
low	-	1694	O
central	-	1698	O
5	-	1706	O
-	-	1707	O
HT	-	1708	O
may	-	1711	O
be	-	1715	O
especially	-	1718	O
prone	-	1729	O
to	-	1735	O
exhibit	-	1738	O
aggressive	-	1746	B
behavior	-	1757	I
.	-	1765	O

Intracavitary	16132524	0	O
chemotherapy	-	14	O
(	-	27	O
paclitaxel	-	28	O
/	-	38	O
carboplatin	-	39	O
liquid	-	51	O
crystalline	-	58	O
cubic	-	70	O
phases	-	76	O
)	-	82	O
for	-	84	O
recurrent	-	88	O
glioblastoma	-	98	B
-	-	111	O
-	-	112	O
clinical	-	114	O
observations	-	123	O
.	-	135	O

Human	16132524	137	O
malignant	-	143	O
brain	-	153	B
tumors	-	159	I
have	-	166	O
a	-	171	O
poor	-	173	O
prognosis	-	178	O
in	-	188	O
spite	-	191	O
of	-	197	O
surgery	-	200	O
and	-	208	O
radiation	-	212	O
therapy	-	222	O
.	-	229	O

Cubic	16132524	231	O
phases	-	237	O
consist	-	244	O
of	-	252	O
curved	-	255	O
biocontinuous	-	262	O
lipid	-	276	O
bilayers	-	282	O
,	-	290	O
separating	-	292	O
two	-	303	O
congruent	-	307	O
networks	-	317	O
of	-	326	O
water	-	329	O
channels	-	335	O
.	-	343	O

Used	16132524	345	O
as	-	350	O
a	-	353	O
host	-	355	O
for	-	360	O
cytotoxic	-	364	O
drugs	-	374	O
,	-	379	O
the	-	381	O
gel	-	385	O
-	-	388	O
like	-	389	O
matrix	-	394	O
can	-	401	O
easily	-	405	O
be	-	412	O
applied	-	415	O
to	-	423	O
the	-	426	O
walls	-	430	O
of	-	436	O
a	-	439	O
surgical	-	441	O
resection	-	450	O
cavity	-	460	O
.	-	466	O

For	16132524	468	O
human	-	472	O
glioblastoma	-	478	B
recurrences	-	491	O
,	-	502	O
the	-	504	O
feasibility	-	508	O
,	-	519	O
safety	-	521	O
,	-	527	O
and	-	529	O
short	-	533	O
-	-	538	O
term	-	539	O
effects	-	544	O
of	-	552	O
a	-	555	O
surgical	-	557	O
intracavitary	-	566	O
application	-	580	O
of	-	592	O
paclitaxel	-	595	O
and	-	606	O
carboplatin	-	610	O
encapsulated	-	622	O
by	-	635	O
liquid	-	638	O
crystalline	-	645	O
cubic	-	657	O
phases	-	663	O
are	-	670	O
examined	-	674	O
in	-	683	O
a	-	686	O
pilot	-	688	O
study	-	694	O
.	-	699	O

A	16132524	701	O
total	-	703	O
of	-	709	O
12	-	712	O
patients	-	715	O
with	-	724	O
a	-	729	O
recurrence	-	731	O
of	-	742	O
a	-	745	O
glioblastoma	-	747	B
multiforme	-	760	O
underwent	-	771	O
re	-	781	O
-	-	783	O
resection	-	784	O
and	-	794	O
received	-	798	O
an	-	807	O
intracavitary	-	810	O
application	-	824	O
of	-	836	O
paclitaxel	-	839	O
and	-	850	O
carboplatin	-	854	O
cubic	-	866	O
phases	-	872	O
in	-	879	O
different	-	882	O
dosages	-	892	O
.	-	899	O

Six	16132524	901	O
of	-	905	O
the	-	908	O
patients	-	912	O
received	-	921	O
more	-	930	O
than	-	935	O
15	-	940	O
mg	-	943	O
paclitaxel	-	946	O
and	-	957	O
suffered	-	961	O
from	-	970	O
moderate	-	975	O
to	-	984	O
severe	-	987	O
brain	-	994	B
edema	-	1000	I
,	-	1005	O
while	-	1007	O
the	-	1013	O
remaining	-	1017	O
patients	-	1027	O
received	-	1036	O
only	-	1045	O
a	-	1050	O
total	-	1052	O
of	-	1058	O
15	-	1061	O
mg	-	1064	O
paclitaxel	-	1067	O
.	-	1077	O

In	16132524	1079	O
the	-	1082	O
latter	-	1086	O
group	-	1093	O
,	-	1098	O
brain	-	1100	B
edema	-	1106	I
was	-	1112	O
markedly	-	1116	O
reduced	-	1125	O
and	-	1133	O
dealt	-	1137	O
medically	-	1143	O
.	-	1152	O

Intracavitary	16132524	1154	O
chemotherapy	-	1168	O
in	-	1181	O
recurrent	-	1184	O
glioblastoma	-	1194	B
using	-	1207	O
cubic	-	1213	O
phases	-	1219	O
is	-	1226	O
feasible	-	1229	O
and	-	1238	O
safe	-	1242	O
,	-	1246	O
yet	-	1248	O
the	-	1252	O
clinical	-	1256	O
benefit	-	1265	O
remains	-	1273	O
to	-	1281	O
be	-	1284	O
examined	-	1287	O
in	-	1296	O
a	-	1299	O
clinical	-	1301	O
phase	-	1310	O
II	-	1316	O
study	-	1319	O
.	-	1324	O

Methylphenidate	12907924	0	O
-	-	15	O
induced	-	16	O
obsessive	-	24	B
-	-	33	I
compulsive	-	34	I
symptoms	-	45	I
in	-	54	O
an	-	57	O
elderly	-	60	O
man	-	68	O
.	-	71	O

An	12907924	73	O
82	-	76	O
-	-	78	O
year	-	79	O
-	-	83	O
old	-	84	O
man	-	88	O
with	-	92	O
treatment	-	97	B
-	-	106	I
resistant	-	107	I
depression	-	117	I
and	-	128	O
early	-	132	O
Alzheimer	-	138	B
's	-	147	I
disease	-	150	I
was	-	158	O
started	-	162	O
on	-	170	O
methylphenidate	-	173	O
.	-	188	O

Significant	12907924	190	O
obsessive	-	202	B
-	-	211	I
compulsive	-	212	I
behavior	-	223	I
ensued	-	232	O
but	-	239	O
diminished	-	243	O
over	-	254	O
several	-	259	O
weeks	-	267	O
when	-	273	O
methylphenidate	-	278	O
was	-	294	O
replaced	-	298	O
by	-	307	O
fluvoxamine	-	310	O
.	-	321	O

The	12907924	323	O
patient	-	327	O
had	-	335	O
no	-	339	O
prior	-	342	O
psychiatric	-	348	B
history	-	360	O
,	-	367	O
but	-	369	O
he	-	373	O
had	-	376	O
a	-	380	O
sister	-	382	O
with	-	389	O
obsessive	-	394	B
-	-	403	I
compulsive	-	404	I
disorder	-	415	I
.	-	423	O

It	12907924	425	O
appears	-	428	O
that	-	436	O
methylphenidate	-	441	O
precipitated	-	457	O
the	-	470	O
patient	-	474	O
's	-	481	O
pathological	-	484	O
behavior	-	497	O
.	-	505	O

Cardiac	12139551	0	B
arrest	-	8	I
after	-	15	O
intravenous	-	21	O
metoclopramide	-	33	O
-	-	48	O
a	-	50	O
case	-	52	O
of	-	57	O
five	-	60	O
repeated	-	65	O
injections	-	74	O
of	-	85	O
metoclopramide	-	88	O
causing	-	103	O
five	-	111	O
episodes	-	116	O
of	-	125	O
cardiac	-	128	B
arrest	-	136	I
.	-	142	O

We	12139551	144	O
describe	-	147	O
a	-	156	O
patient	-	158	O
where	-	166	O
intravenous	-	172	O
injection	-	184	O
of	-	194	O
metoclopramide	-	197	O
was	-	212	O
immediately	-	216	O
followed	-	228	O
by	-	237	O
asystole	-	240	B
repeatedly	-	249	O
.	-	259	O

The	12139551	261	O
patient	-	265	O
received	-	273	O
metoclopramide	-	282	O
10	-	297	O
mg	-	300	O
i	-	303	O
.	-	304	O
v	-	305	O
.	-	306	O

five	12139551	308	O
times	-	313	O
during	-	319	O
48	-	326	O
h	-	329	O
.	-	330	O

After	12139551	332	O
interviewing	-	338	O
the	-	351	O
attending	-	355	O
nurses	-	365	O
and	-	372	O
reviewing	-	376	O
the	-	386	O
written	-	390	O
documentation	-	398	O
,	-	411	O
it	-	413	O
is	-	416	O
clear	-	419	O
that	-	425	O
every	-	430	O
administration	-	436	O
of	-	451	O
metoclopramide	-	454	O
was	-	469	O
immediately	-	473	O
(	-	485	O
within	-	486	O
s	-	493	O
)	-	494	O
followed	-	496	O
by	-	505	O
asystole	-	508	B
.	-	516	O

The	12139551	518	O
asystole	-	522	B
lasted	-	531	O
15	-	538	O
-	-	540	O
30	-	541	O
s	-	544	O
on	-	546	O
four	-	549	O
occasions	-	554	O
,	-	563	O
on	-	565	O
one	-	568	O
occasion	-	572	O
it	-	581	O
lasted	-	584	O
2	-	591	O
min	-	593	O
.	-	596	O

The	12139551	598	O
patient	-	602	O
received	-	610	O
atropine	-	619	O
0	-	628	O
.	-	629	O
5	-	630	O
-	-	631	O
1	-	632	O
mg	-	634	O
and	-	637	O
chest	-	641	O
compressions	-	647	O
,	-	659	O
before	-	661	O
sinus	-	668	O
rhythm	-	674	O
again	-	681	O
took	-	687	O
over	-	692	O
.	-	696	O

We	12139551	698	O
interpret	-	701	O
this	-	711	O
as	-	716	O
episodes	-	719	O
of	-	728	O
cardiac	-	731	B
arrest	-	739	I
caused	-	746	O
by	-	753	O
metoclopramide	-	756	O
.	-	770	O

The	12139551	772	O
rapid	-	776	O
injection	-	782	O
via	-	792	O
the	-	796	O
central	-	800	O
venous	-	808	O
route	-	815	O
and	-	821	O
the	-	825	O
concomitant	-	829	O
tapering	-	841	O
of	-	850	O
dopamine	-	853	O
infusion	-	862	O
might	-	871	O
have	-	877	O
contributed	-	882	O
in	-	894	O
precipitating	-	897	O
the	-	911	O
adverse	-	915	O
drug	-	923	O
reaction	-	928	O
.	-	936	O

Severe	10411803	0	O
immune	-	7	O
hemolytic	-	14	B
anemia	-	24	I
associated	-	31	O
with	-	42	O
prophylactic	-	47	O
use	-	60	O
of	-	64	O
cefotetan	-	67	O
in	-	77	O
obstetric	-	80	O
and	-	90	O
gynecologic	-	94	O
procedures	-	106	O
.	-	116	O

Second	10411803	118	O
-	-	124	O
and	-	126	O
third	-	130	O
-	-	135	O
generation	-	136	O
cephalosporins	-	147	O
,	-	161	O
especially	-	163	O
cefotetan	-	174	O
,	-	183	O
are	-	185	O
increasingly	-	189	O
associated	-	202	O
with	-	213	O
severe	-	218	O
,	-	224	O
sometimes	-	226	O
fatal	-	236	O
immune	-	242	O
hemolytic	-	249	B
anemia	-	259	I
.	-	265	O

We	10411803	267	O
noticed	-	270	O
that	-	278	O
10	-	283	O
of	-	286	O
our	-	289	O
35	-	293	O
cases	-	296	O
of	-	302	O
cefotetan	-	305	O
-	-	314	O
induced	-	315	O
hemolytic	-	323	B
anemias	-	333	I
were	-	341	O
in	-	346	O
patients	-	349	O
who	-	358	O
had	-	362	O
received	-	366	O
cefotetan	-	375	O
prophylactically	-	385	O
for	-	402	O
obstetric	-	406	O
and	-	416	O
gynecologic	-	420	O
procedures	-	432	O
.	-	442	O

Eight	10411803	444	O
of	-	450	O
these	-	453	O
cases	-	459	O
of	-	465	O
severe	-	468	O
immune	-	475	O
hemolytic	-	482	B
anemia	-	492	I
are	-	499	O
described	-	503	O
.	-	512	O

Cauda	10225068	0	B
equina	-	6	I
syndrome	-	13	I
after	-	22	O
spinal	-	28	O
anaesthesia	-	35	O
with	-	47	O
hyperbaric	-	52	O
5	-	63	O
%	-	64	O
lignocaine	-	66	O
:	-	76	O
a	-	78	O
review	-	80	O
of	-	87	O
six	-	90	O
cases	-	94	O
of	-	100	O
cauda	-	103	B
equina	-	109	I
syndrome	-	116	I
reported	-	125	O
to	-	134	O
the	-	137	O
Swedish	-	141	O
Pharmaceutical	-	149	O
Insurance	-	164	O
1993	-	174	O
-	-	178	O
1997	-	179	O
.	-	183	O

Six	10225068	185	O
cases	-	189	O
of	-	195	O
cauda	-	198	B
equina	-	204	I
syndrome	-	211	I
with	-	220	O
varying	-	225	O
severity	-	233	O
were	-	242	O
reported	-	247	O
to	-	256	O
the	-	259	O
Swedish	-	263	O
Pharmaceutical	-	271	O
Insurance	-	286	O
during	-	296	O
the	-	303	O
period	-	307	O
1993	-	314	O
-	-	318	O
1997	-	319	O
.	-	323	O

All	10225068	325	O
were	-	329	O
associated	-	334	O
with	-	345	O
spinal	-	350	O
anaesthesia	-	357	O
using	-	369	O
hyperbaric	-	375	O
5	-	386	O
%	-	387	O
lignocaine	-	389	O
.	-	399	O

Five	10225068	401	O
cases	-	406	O
had	-	412	O
single	-	416	O
-	-	422	O
shot	-	423	O
spinal	-	428	O
anaesthesia	-	435	O
and	-	447	O
one	-	451	O
had	-	455	O
a	-	459	O
repeat	-	461	O
spinal	-	468	O
anaesthetic	-	475	O
due	-	487	O
to	-	491	O
inadequate	-	494	O
block	-	505	O
.	-	510	O

The	10225068	512	O
dose	-	516	O
of	-	521	O
hyperbaric	-	524	O
5	-	535	O
%	-	536	O
lignocaine	-	538	O
administered	-	549	O
ranged	-	562	O
from	-	569	O
60	-	574	O
to	-	577	O
120	-	580	O
mg	-	584	O
.	-	586	O

Three	10225068	588	O
of	-	594	O
the	-	597	O
cases	-	601	O
were	-	607	O
most	-	612	O
likely	-	617	O
caused	-	624	O
by	-	631	O
direct	-	634	O
neurotoxicity	-	641	B
of	-	655	O
hyperbaric	-	658	O
5	-	669	O
%	-	670	O
lignocaine	-	672	O
.	-	682	O

In	10225068	684	O
the	-	687	O
other	-	691	O
3	-	697	O
cases	-	699	O
,	-	704	O
direct	-	706	O
neurotoxicity	-	713	B
was	-	727	O
also	-	731	O
probable	-	736	O
,	-	744	O
but	-	746	O
unfortunately	-	750	O
radiological	-	764	O
investigations	-	777	O
were	-	792	O
not	-	797	O
done	-	801	O
to	-	806	O
definitely	-	809	O
exclude	-	820	O
a	-	828	O
compressive	-	830	O
aetiology	-	842	O
.	-	851	O

All	10225068	853	O
cases	-	857	O
sustained	-	863	O
permanent	-	873	O
neurological	-	883	B
deficits	-	896	I
.	-	904	O

We	10225068	906	O
recommend	-	909	O
that	-	919	O
hyperbaric	-	924	O
lignocaine	-	935	O
should	-	946	O
be	-	953	O
administered	-	956	O
in	-	969	O
concentrations	-	972	O
not	-	987	O
greater	-	991	O
than	-	999	O
2	-	1004	O
%	-	1005	O
and	-	1007	O
at	-	1011	O
a	-	1014	O
total	-	1016	O
dose	-	1022	O
preferably	-	1027	O
not	-	1038	O
exceeding	-	1042	O
60	-	1052	O
mg	-	1055	O
.	-	1057	O

Cortical	9549528	0	O
motor	-	9	O
overactivation	-	15	O
in	-	30	O
parkinsonian	-	33	B
patients	-	46	O
with	-	55	O
L	-	60	O
-	-	61	O
dopa	-	62	O
-	-	66	O
induced	-	67	O
peak	-	75	O
-	-	79	O
dose	-	80	O
dyskinesia	-	85	B
.	-	95	O

We	9549528	97	O
have	-	100	O
studied	-	105	O
the	-	113	O
regional	-	117	O
cerebral	-	126	O
blood	-	135	O
flow	-	141	O
(	-	146	O
rCBF	-	147	O
)	-	151	O
changes	-	153	O
induced	-	161	O
by	-	169	O
the	-	172	O
execution	-	176	O
of	-	186	O
a	-	189	O
finger	-	191	O
-	-	197	O
to	-	198	O
-	-	200	O
thumb	-	201	O
opposition	-	207	O
motor	-	218	O
task	-	224	O
in	-	229	O
the	-	232	O
supplementary	-	236	O
and	-	250	O
primary	-	254	O
motor	-	262	O
cortex	-	268	O
of	-	275	O
two	-	278	O
groups	-	282	O
of	-	289	O
parkinsonian	-	292	B
patients	-	305	O
on	-	314	O
L	-	317	O
-	-	318	O
dopa	-	319	O
medication	-	324	O
,	-	334	O
the	-	336	O
first	-	340	O
one	-	346	O
without	-	350	O
L	-	358	O
-	-	359	O
dopa	-	360	O
induced	-	365	O
dyskinesia	-	373	B
(	-	384	O
n	-	385	O
=	-	387	O
23	-	389	O
)	-	391	O
and	-	393	O
the	-	397	O
other	-	401	O
with	-	407	O
moderate	-	412	O
peak	-	421	O
-	-	425	O
dose	-	426	O
dyskinesia	-	431	B
(	-	442	O
n	-	443	O
=	-	445	O
15	-	447	O
)	-	449	O
,	-	450	O
and	-	452	O
of	-	456	O
a	-	459	O
group	-	461	O
of	-	467	O
14	-	470	O
normal	-	473	O
subjects	-	480	O
.	-	488	O

Single	9549528	490	O
photon	-	497	O
emission	-	504	O
tomography	-	513	O
with	-	524	O
i	-	529	O
.	-	530	O
v	-	531	O
.	-	532	O

133Xe	9549528	534	O
was	-	540	O
used	-	544	O
to	-	549	O
measure	-	552	O
the	-	560	O
rCBF	-	564	O
changes	-	569	O
.	-	576	O

The	9549528	578	O
dyskinetic	-	582	B
parkinsonian	-	593	B
patients	-	606	O
exhibited	-	615	O
a	-	625	O
pattern	-	627	O
of	-	635	O
response	-	638	O
which	-	647	O
was	-	653	O
markedly	-	657	O
different	-	666	O
from	-	676	O
those	-	681	O
of	-	687	O
the	-	690	O
normal	-	694	O
subjects	-	701	O
and	-	710	O
non	-	714	O
-	-	717	O
dyskinetic	-	718	B
parkinsonian	-	729	B
patients	-	742	O
,	-	750	O
with	-	752	O
a	-	757	O
significant	-	759	O
overactivation	-	771	O
in	-	786	O
the	-	789	O
supplementary	-	793	O
motor	-	807	O
area	-	813	O
and	-	818	O
the	-	822	O
ipsi	-	826	O
-	-	830	O
and	-	832	O
contralateral	-	836	O
primary	-	850	O
motor	-	858	O
areas	-	864	O
.	-	869	O

These	9549528	871	O
results	-	877	O
are	-	885	O
compatible	-	889	O
with	-	900	O
the	-	905	O
hypothesis	-	909	O
that	-	920	O
an	-	925	O
hyperkinetic	-	928	B
abnormal	-	941	B
involuntary	-	950	I
movement	-	962	I
,	-	970	O
like	-	972	O
L	-	977	O
-	-	978	O
dopa	-	979	O
-	-	983	O
induced	-	984	O
peak	-	992	O
dose	-	997	O
dyskinesia	-	1002	B
,	-	1012	O
is	-	1014	O
due	-	1017	O
to	-	1021	O
a	-	1024	O
disinhibition	-	1026	O
of	-	1040	O
the	-	1043	O
primary	-	1047	O
and	-	1055	O
associated	-	1059	O
motor	-	1070	O
cortex	-	1076	O
secondary	-	1083	O
to	-	1093	O
an	-	1096	O
excessive	-	1099	O
outflow	-	1109	O
of	-	1117	O
the	-	1120	O
pallidothalamocortical	-	1124	O
motor	-	1147	O
loop	-	1153	O
.	-	1157	O

Dexamethasone	7843916	0	O
-	-	13	O
induced	-	14	O
ocular	-	22	B
hypertension	-	29	I
in	-	42	O
perfusion	-	45	O
-	-	54	O
cultured	-	55	O
human	-	64	O
eyes	-	70	O
.	-	74	O

PURPOSE	7843916	76	O
:	-	83	O

Glucocorticoid	7843916	85	O
administration	-	100	O
can	-	115	O
lead	-	119	O
to	-	124	O
the	-	127	O
development	-	131	O
of	-	143	O
ocular	-	146	B
hypertension	-	153	I
and	-	166	O
corticosteroid	-	170	B
glaucoma	-	185	I
in	-	194	O
a	-	197	O
subset	-	199	O
of	-	206	O
the	-	209	O
population	-	213	O
through	-	224	O
a	-	232	O
decrease	-	234	O
in	-	243	O
the	-	246	O
aqueous	-	250	O
humor	-	258	O
outflow	-	264	O
facility	-	272	O
.	-	280	O

The	7843916	282	O
purpose	-	286	O
of	-	294	O
this	-	297	O
study	-	302	O
was	-	308	O
to	-	312	O
determine	-	315	O
whether	-	325	O
glucocorticoid	-	333	O
treatment	-	348	O
can	-	358	O
directly	-	362	O
affect	-	371	O
the	-	378	O
outflow	-	382	O
facility	-	390	O
of	-	399	O
isolated	-	402	O
,	-	410	O
perfusion	-	412	O
-	-	421	O
cultured	-	422	O
human	-	431	O
eyes	-	437	O
.	-	441	O

METHODS	7843916	443	O
:	-	450	O

The	7843916	452	O
anterior	-	456	O
segments	-	465	O
of	-	474	O
human	-	477	O
donor	-	483	O
eyes	-	489	O
from	-	494	O
regional	-	499	O
eye	-	508	O
banks	-	512	O
were	-	518	O
placed	-	523	O
in	-	530	O
a	-	533	O
constant	-	535	O
flow	-	544	O
,	-	548	O
variable	-	550	O
pressure	-	559	O
perfusion	-	568	O
culture	-	578	O
system	-	586	O
.	-	592	O

Paired	7843916	594	O
eyes	-	601	O
were	-	606	O
perfused	-	611	O
in	-	620	O
serum	-	623	O
-	-	628	O
free	-	629	O
media	-	634	O
with	-	640	O
or	-	645	O
without	-	648	O
10	-	656	O
(	-	658	O
-	-	659	O
7	-	660	O
)	-	661	O

M	7843916	663	O
dexamethasone	-	665	O
for	-	679	O
12	-	683	O
days	-	686	O
.	-	690	O

Intraocular	7843916	692	O
pressure	-	704	O
was	-	713	O
monitored	-	717	O
daily	-	727	O
.	-	732	O

After	7843916	734	O
incubation	-	740	O
,	-	750	O
the	-	752	O
eyes	-	756	O
were	-	761	O
morphologically	-	766	O
characterized	-	782	O
by	-	796	O
light	-	799	O
microscopy	-	805	O
,	-	815	O
transmission	-	817	O
and	-	830	O
scanning	-	834	O
electron	-	843	O
microscopy	-	852	O
,	-	862	O
and	-	864	O
scanning	-	868	O
laser	-	877	O
confocal	-	883	O
microscopy	-	892	O
.	-	902	O

RESULTS	7843916	904	O
:	-	911	O

A	7843916	913	O
significant	-	915	O
increase	-	927	O
in	-	936	O
intraocular	-	939	O
pressure	-	951	O
developed	-	960	O
in	-	970	O
13	-	973	O
of	-	976	O
the	-	979	O
44	-	983	O
pairs	-	986	O
of	-	992	O
eyes	-	995	O
perfused	-	1000	O
with	-	1009	O
dexamethasone	-	1014	O
with	-	1028	O
an	-	1033	O
average	-	1036	O
pressure	-	1044	O
rise	-	1053	O
of	-	1058	O
17	-	1061	O
.	-	1063	O
5	-	1064	O
+	-	1066	O
/	-	1067	O
-	-	1068	O

3	7843916	1070	O
.	-	1071	O
8	-	1072	O
mm	-	1074	O
Hg	-	1077	O
after	-	1080	O
12	-	1086	O
days	-	1089	O
of	-	1094	O
dexamethasone	-	1097	O
exposure	-	1111	O
.	-	1119	O

The	7843916	1121	O
contralateral	-	1125	O
control	-	1139	O
eyes	-	1147	O
,	-	1151	O
which	-	1153	O
did	-	1159	O
not	-	1163	O
receive	-	1167	O
dexamethasone	-	1175	O
,	-	1188	O
maintained	-	1190	O
a	-	1201	O
stable	-	1203	O
intraocular	-	1210	O
pressure	-	1222	O
during	-	1231	O
the	-	1238	O
same	-	1242	O
period	-	1247	O
.	-	1253	O

The	7843916	1255	O
outflow	-	1259	O
pathway	-	1267	O
of	-	1275	O
the	-	1278	O
untreated	-	1282	O
eyes	-	1292	O
appeared	-	1297	O
morphologically	-	1306	O
normal	-	1322	O
.	-	1328	O

In	7843916	1330	O
contrast	-	1333	O
,	-	1341	O
the	-	1343	O
dexamethasone	-	1347	O
-	-	1360	O
treated	-	1361	O
hypertensive	-	1369	B
eyes	-	1382	I
had	-	1387	O
thickened	-	1391	O
trabecular	-	1401	O
beams	-	1412	O
,	-	1417	O
decreased	-	1419	O
intertrabecular	-	1429	O
spaces	-	1445	O
,	-	1451	O
thickened	-	1453	O
juxtacanalicular	-	1463	O
tissue	-	1480	O
,	-	1486	O
activated	-	1488	O
trabecular	-	1498	O
meshwork	-	1509	O
cells	-	1518	O
,	-	1523	O
and	-	1525	O
increased	-	1529	O
amounts	-	1539	O
of	-	1547	O
amorphogranular	-	1550	O
extracellular	-	1566	O
material	-	1580	O
,	-	1588	O
especially	-	1590	O
in	-	1601	O
the	-	1604	O
juxtacanalicular	-	1608	O
tissue	-	1625	O
and	-	1632	O
beneath	-	1636	O
the	-	1644	O
endothelial	-	1648	O
lining	-	1660	O
of	-	1667	O
the	-	1670	O
canal	-	1674	O
of	-	1680	O
Schlemm	-	1683	O
.	-	1690	O

The	7843916	1692	O
dexamethasone	-	1696	O
-	-	1709	O
treated	-	1710	O
nonresponder	-	1718	O
eyes	-	1731	O
appeared	-	1736	O
to	-	1745	O
be	-	1748	O
morphologically	-	1751	O
similar	-	1767	O
to	-	1775	O
the	-	1778	O
untreated	-	1782	O
eyes	-	1792	O
,	-	1796	O
although	-	1798	O
several	-	1807	O
subtle	-	1815	O
dexamethasone	-	1822	O
-	-	1835	O
induced	-	1836	O
morphologic	-	1844	O
changes	-	1856	O
were	-	1864	O
evident	-	1869	O
.	-	1876	O

CONCLUSION	7843916	1878	O
:	-	1888	O

Dexamethasone	7843916	1890	O
treatment	-	1904	O
of	-	1914	O
isolated	-	1917	O
,	-	1925	O
perfusion	-	1927	O
-	-	1936	O
cultured	-	1937	O
human	-	1946	O
eyes	-	1952	O
led	-	1957	O
to	-	1961	O
the	-	1964	O
generation	-	1968	O
of	-	1979	O
ocular	-	1982	B
hypertension	-	1989	I
in	-	2002	O
approximately	-	2005	O
30	-	2019	O
%	-	2021	O
of	-	2023	O
the	-	2026	O
dexamethasone	-	2030	O
-	-	2043	O
treated	-	2044	O
eyes	-	2052	O
.	-	2056	O

Steroid	7843916	2058	O
treatment	-	2066	O
resulted	-	2076	O
in	-	2085	O
morphologic	-	2088	O
changes	-	2100	O
in	-	2108	O
the	-	2111	O
trabecular	-	2115	O
meshwork	-	2126	O
similar	-	2135	O
to	-	2143	O
those	-	2146	O
reported	-	2152	O
for	-	2161	O
corticosteroid	-	2165	B
glaucoma	-	2180	I
and	-	2189	O
open	-	2193	B
angle	-	2198	I
glaucoma	-	2204	I
.	-	2212	O

This	7843916	2214	O
system	-	2219	O
may	-	2226	O
provide	-	2230	O
an	-	2238	O
acute	-	2241	O
model	-	2247	O
in	-	2253	O
which	-	2256	O
to	-	2262	O
study	-	2265	O
the	-	2271	O
pathogenic	-	2275	O
mechanisms	-	2286	O
involved	-	2297	O
in	-	2306	O
steroid	-	2309	B
glaucoma	-	2317	I
and	-	2326	O
primary	-	2330	B
open	-	2338	I
angle	-	2343	I
glaucoma	-	2349	I
.	-	2357	O

Cognitive	7803371	0	B
deterioration	-	10	I
from	-	24	O
long	-	29	O
-	-	33	O
term	-	34	O
abuse	-	39	O
of	-	45	O
dextromethorphan	-	48	O
:	-	64	O
a	-	66	O
case	-	68	O
report	-	73	O
.	-	79	O

Dextromethorphan	7803371	81	O
(	-	98	O
DM	-	99	O
)	-	101	O
,	-	102	O
the	-	104	O
dextrorotatory	-	108	O
isomer	-	123	O
of	-	130	O
3	-	133	O
-	-	134	O
hydroxy	-	135	O
-	-	142	O
N	-	143	O
-	-	144	O
methylmorphinan	-	145	O
,	-	160	O
is	-	162	O
the	-	165	O
main	-	169	O
ingredient	-	174	O
in	-	185	O
a	-	188	O
number	-	190	O
of	-	197	O
widely	-	200	O
available	-	207	O
,	-	216	O
over	-	218	O
-	-	222	O
the	-	223	O
-	-	226	O
counter	-	227	O
antitussives	-	235	O
.	-	247	O

Initial	7803371	249	O
studies	-	257	O
(	-	265	O
Bornstein	-	266	O
1968	-	276	O
)	-	280	O
showed	-	282	O
that	-	289	O
it	-	294	O
possessed	-	297	O
no	-	307	O
respiratory	-	310	O
suppressant	-	322	O
effects	-	334	O
and	-	342	O
no	-	346	O
addiction	-	349	O
liability	-	359	O
.	-	368	O

Subsequently	7803371	370	O
,	-	382	O
however	-	384	O
,	-	391	O
several	-	393	O
articles	-	401	O
reporting	-	410	O
abuse	-	420	O
of	-	426	O
this	-	429	O
drug	-	434	O
have	-	439	O
appeared	-	444	O
in	-	453	O
the	-	456	O
literature	-	460	O
.	-	470	O

The	7803371	472	O
drug	-	476	O
is	-	481	O
known	-	484	O
to	-	490	O
cause	-	493	O
a	-	499	O
variety	-	501	O
of	-	509	O
acute	-	512	O
toxic	-	518	O
effects	-	524	O
,	-	531	O
ranging	-	533	O
from	-	541	O
nausea	-	546	B
,	-	552	O
restlessness	-	554	B
,	-	566	O
insomnia	-	568	B
,	-	576	O
ataxia	-	578	B
,	-	584	O
slurred	-	586	O
speech	-	594	O
and	-	601	O
nystagmus	-	605	B
to	-	615	O
mood	-	618	O
changes	-	623	O
,	-	630	O
perceptual	-	632	O
alterations	-	643	O
,	-	654	O
inattention	-	656	O
,	-	667	O
disorientation	-	669	O
and	-	684	O
aggressive	-	688	B
behavior	-	699	I
(	-	708	O
Rammer	-	709	O
et	-	716	O
al	-	719	O
1988	-	722	O
;	-	726	O

Katona	7803371	728	O
and	-	735	O
Watson	-	739	O
1986	-	746	O
;	-	750	O
Isbell	-	752	O
and	-	759	O
Fraser	-	763	O
1953	-	770	O
;	-	774	O
Devlin	-	776	O
et	-	783	O
al	-	786	O
1985	-	789	O
;	-	793	O
McCarthy	-	795	O
1971	-	804	O
;	-	808	O
Dodds	-	810	O
and	-	816	O
Revai	-	820	O
1967	-	826	O
;	-	830	O
Degkwitz	-	832	O
1964	-	841	O
;	-	845	O
Hildebrand	-	847	O
et	-	858	O
al	-	861	O
1989	-	864	O
)	-	868	O
.	-	869	O

There	7803371	871	O
have	-	877	O
also	-	882	O
been	-	887	O
two	-	892	O
reported	-	896	O
fatalities	-	905	O
from	-	916	O
DM	-	921	O
overdoses	-	924	O
(	-	934	O
Fleming	-	935	O
1986	-	943	O
)	-	947	O
.	-	948	O

However	7803371	950	O
,	-	957	O
there	-	959	O
are	-	965	O
no	-	969	O
reports	-	972	O
describing	-	980	O
the	-	991	O
effects	-	995	O
of	-	1003	O
chronic	-	1006	O
abuse	-	1014	O
.	-	1019	O

This	7803371	1021	O
report	-	1026	O
describes	-	1033	O
a	-	1043	O
case	-	1045	O
of	-	1050	O
cognitive	-	1053	B
deterioration	-	1063	I
resulting	-	1077	O
from	-	1087	O
prolonged	-	1092	O
use	-	1102	O
of	-	1106	O
DM	-	1109	O
.	-	1111	O

Long	7437994	0	O
-	-	4	O
term	-	5	O
lithium	-	10	O
treatment	-	18	O
and	-	28	O
the	-	32	O
kidney	-	36	O
.	-	42	O

Interim	7437994	44	O
report	-	52	O
on	-	59	O
fifty	-	62	O
patients	-	68	O
.	-	76	O

This	7437994	78	O
is	-	83	O
a	-	86	O
report	-	88	O
on	-	95	O
the	-	98	O
first	-	102	O
part	-	108	O
of	-	113	O
our	-	116	O
study	-	120	O
of	-	126	O
the	-	129	O
effects	-	133	O
of	-	141	O
long	-	144	O
-	-	148	O
term	-	149	O
lithium	-	154	O
treatment	-	162	O
on	-	172	O
the	-	175	O
kidney	-	179	O
.	-	185	O

Creatinine	7437994	187	O
clearance	-	198	O
,	-	207	O
maximum	-	209	O
urinary	-	217	O
osmolality	-	225	O
and	-	236	O
24	-	240	O
hour	-	243	O
urine	-	248	O
volume	-	254	O
have	-	261	O
been	-	266	O
tested	-	271	O
in	-	278	O
50	-	281	O
affectively	-	284	O
ill	-	296	O
patients	-	300	O
who	-	309	O
have	-	313	O
been	-	318	O
on	-	323	O
long	-	326	O
-	-	330	O
term	-	331	O
lithium	-	336	O
for	-	344	O
more	-	348	O
than	-	353	O
one	-	358	O
year	-	362	O
.	-	366	O

These	7437994	368	O
findings	-	374	O
have	-	383	O
been	-	388	O
compared	-	393	O
with	-	402	O
norms	-	407	O
and	-	413	O
with	-	417	O
values	-	422	O
of	-	429	O
the	-	432	O
same	-	436	O
tests	-	441	O
from	-	447	O
screening	-	452	O
prior	-	462	O
to	-	468	O
lithium	-	471	O
,	-	478	O
available	-	480	O
for	-	490	O
most	-	494	O
of	-	499	O
our	-	502	O
patients	-	506	O
.	-	514	O

No	7437994	516	O
evidence	-	519	O
was	-	528	O
found	-	532	O
for	-	538	O
any	-	542	O
reduction	-	546	O
of	-	556	O
glomerular	-	559	O
filtration	-	570	O
during	-	581	O
lithium	-	588	O
treatment	-	596	O
.	-	605	O

Low	7437994	607	O
clearance	-	611	O
values	-	621	O
found	-	628	O
in	-	634	O
several	-	637	O
patients	-	645	O
could	-	654	O
be	-	660	O
accounted	-	663	O
for	-	673	O
by	-	677	O
their	-	680	O
age	-	686	O
and	-	690	O
their	-	694	O
pre	-	700	O
-	-	703	O
lithium	-	704	O
values	-	712	O
.	-	718	O

Urinary	7437994	720	O
concentration	-	728	O
defect	-	742	O
appeared	-	749	O
frequent	-	758	O
but	-	767	O
the	-	771	O
extent	-	775	O
of	-	782	O
the	-	785	O
impairment	-	789	O
is	-	800	O
difficult	-	803	O
to	-	813	O
assess	-	816	O
because	-	823	O
of	-	831	O
the	-	834	O
uncertainty	-	838	O
about	-	850	O
the	-	856	O
norms	-	860	O
applicable	-	866	O
to	-	877	O
this	-	880	O
group	-	885	O
of	-	891	O
patients	-	894	O
.	-	902	O

The	7437994	904	O
concentration	-	908	O
defect	-	922	O
appeared	-	929	O
reversible	-	938	O
,	-	948	O
at	-	950	O
least	-	953	O
in	-	959	O
part	-	962	O
.	-	966	O

Polyuria	7437994	968	B
above	-	977	O
3	-	983	O
litres	-	985	O
/	-	991	O
24	-	992	O
hours	-	995	O
was	-	1001	O
found	-	1005	O
in	-	1011	O
10	-	1014	O
%	-	1016	O
of	-	1018	O
patients	-	1021	O
.	-	1029	O

An	7437994	1031	O
attempt	-	1034	O
is	-	1042	O
made	-	1045	O
to	-	1050	O
draw	-	1053	O
practical	-	1058	O
conclusions	-	1068	O
from	-	1080	O
the	-	1085	O
preliminary	-	1089	O
findings	-	1101	O
.	-	1109	O

Complete	6496797	0	O
heart	-	9	B
block	-	15	I
following	-	21	O
a	-	31	O
single	-	33	O
dose	-	40	O
of	-	45	O
trazodone	-	48	O
.	-	57	O

Forty	6496797	59	O
minutes	-	65	O
after	-	73	O
receiving	-	79	O
a	-	89	O
single	-	91	O
starting	-	98	O
dose	-	107	O
of	-	112	O
trazodone	-	115	O
,	-	124	O
a	-	126	O
patient	-	128	O
developed	-	136	O
complete	-	146	O
heart	-	155	B
block	-	161	I
.	-	166	O

The	6496797	168	O
case	-	172	O
illustrates	-	177	O
that	-	189	O
,	-	193	O
despite	-	195	O
the	-	203	O
results	-	207	O
of	-	215	O
earlier	-	218	O
studies	-	226	O
,	-	233	O
trazodone	-	235	O
's	-	244	O
effect	-	247	O
on	-	254	O
cardiac	-	257	O
conduction	-	265	O
may	-	276	O
be	-	280	O
severe	-	283	O
in	-	290	O
individuals	-	293	O
at	-	305	O
risk	-	308	O
for	-	313	O
conduction	-	317	O
delay	-	328	O
.	-	333	O

Quinidine	3411101	0	O
phenylethylbarbiturate	-	10	O
-	-	32	O
induced	-	33	O
fulminant	-	41	O
hepatitis	-	51	B
in	-	61	O
a	-	64	O
pregnant	-	66	O
woman	-	75	O
.	-	80	O

A	3411101	82	O
case	-	84	O
report	-	89	O
.	-	95	O

We	3411101	97	O
report	-	100	O
the	-	107	O
case	-	111	O
of	-	116	O
a	-	119	O
19	-	121	O
-	-	123	O
year	-	124	O
-	-	128	O
old	-	129	O
Laotian	-	133	O
patient	-	141	O
affected	-	149	O
by	-	158	O
fulminant	-	161	O
hepatitis	-	171	B
during	-	181	O
the	-	188	O
third	-	192	O
trimester	-	198	O
of	-	208	O
her	-	211	O
pregnancy	-	215	O
after	-	225	O
a	-	231	O
1	-	233	O
-	-	234	O
month	-	235	O
administration	-	241	O
of	-	256	O
quinidine	-	259	O
phenylethylbarbiturate	-	269	O
.	-	291	O

After	3411101	293	O
delivery	-	299	O
,	-	307	O
the	-	309	O
patient	-	313	O
underwent	-	321	O
orthotopic	-	331	O
liver	-	342	O
transplantation	-	348	O
.	-	363	O

The	3411101	365	O
patient	-	369	O
was	-	377	O
in	-	381	O
good	-	384	O
condition	-	389	O
16	-	399	O
months	-	402	O
after	-	409	O
liver	-	415	O
transplantation	-	421	O
.	-	436	O

Quinidine	3411101	438	O
itself	-	448	O
or	-	455	O
phenylethylbarbiturate	-	458	O
may	-	481	O
be	-	485	O
responsible	-	488	O
for	-	500	O
fulminant	-	504	O
hepatitis	-	514	B
in	-	524	O
this	-	527	O
patient	-	532	O
.	-	539	O

The	2598570	0	O
epidemiology	-	4	O
of	-	17	O
the	-	20	O
acute	-	24	O
flank	-	30	B
pain	-	36	I
syndrome	-	41	O
from	-	50	O
suprofen	-	55	O
.	-	63	O

Suprofen	2598570	65	O
,	-	73	O
a	-	75	O
new	-	77	O
nonsteroidal	-	81	O
anti	-	94	O
-	-	98	O
inflammatory	-	99	O
drug	-	112	O
,	-	116	O
was	-	118	O
marketed	-	122	O
in	-	131	O
early	-	134	O
1986	-	140	O
as	-	145	O
an	-	148	O
analgesic	-	151	O
agent	-	161	O
.	-	166	O

Until	2598570	168	O
physicians	-	174	O
began	-	185	O
reporting	-	191	O
an	-	201	O
unusual	-	204	O
acute	-	212	O
flank	-	218	B
pain	-	224	I
syndrome	-	229	O
to	-	238	O
the	-	241	O
spontaneous	-	245	O
reporting	-	257	O
system	-	267	O
,	-	273	O
700	-	275	O
,	-	278	O
000	-	279	O
persons	-	283	O
used	-	291	O
the	-	296	O
drug	-	300	O
in	-	305	O
the	-	308	O
United	-	312	O
States	-	319	O
.	-	325	O

Through	2598570	327	O
August	-	335	O
1986	-	342	O
,	-	346	O
a	-	348	O
total	-	350	O
of	-	356	O
163	-	359	O
cases	-	363	O
of	-	369	O
this	-	372	O
syndrome	-	377	O
were	-	386	O
reported	-	391	O
.	-	399	O

To	2598570	401	O
elucidate	-	404	O
the	-	414	O
epidemiology	-	418	O
of	-	431	O
the	-	434	O
syndrome	-	438	O
,	-	446	O
a	-	448	O
case	-	450	O
-	-	454	O
control	-	455	O
study	-	463	O
was	-	469	O
performed	-	473	O
,	-	482	O
comparing	-	484	O
62	-	494	O
of	-	497	O
the	-	500	O
case	-	504	O
patients	-	509	O
who	-	518	O
had	-	522	O
been	-	526	O
reported	-	531	O
to	-	540	O
the	-	543	O
spontaneous	-	547	O
reporting	-	559	O
system	-	569	O
to	-	576	O
185	-	579	O
suprofen	-	583	O
-	-	591	O
exposed	-	592	O
control	-	600	O
subjects	-	608	O
who	-	617	O
did	-	621	O
not	-	625	O
have	-	629	O
the	-	634	O
syndrome	-	638	O
.	-	646	O

Case	2598570	648	O
patients	-	653	O
were	-	662	O
more	-	667	O
likely	-	672	O
to	-	679	O
be	-	682	O
men	-	685	O
(	-	689	O
odds	-	690	O
ratio	-	695	O
,	-	700	O
3	-	702	O
.	-	703	O
8	-	704	O
;	-	705	O
95	-	707	O
%	-	709	O
confidence	-	711	O
interval	-	722	O
,	-	730	O
1	-	732	O
.	-	733	O
2	-	734	O
-	-	735	O
12	-	736	O
.	-	738	O
1	-	739	O
)	-	740	O
,	-	741	O
suffer	-	743	O
from	-	750	O
hay	-	755	B
fever	-	759	I
and	-	765	O
asthma	-	769	B
(	-	776	O
odds	-	777	O
ratio	-	782	O
,	-	787	O
3	-	789	O
.	-	790	O
4	-	791	O
;	-	792	O
95	-	794	O
%	-	796	O
confidence	-	798	O
interval	-	809	O
,	-	817	O
1	-	819	O
.	-	820	O
0	-	821	O
-	-	822	O
11	-	823	O
.	-	825	O
9	-	826	O
)	-	827	O
;	-	828	O
to	-	830	O
participate	-	833	O
in	-	845	O
regular	-	848	O
exercise	-	856	O
(	-	865	O
odds	-	866	O
ratio	-	871	O
,	-	876	O
5	-	878	O
.	-	879	O
9	-	880	O
;	-	881	O
95	-	883	O
%	-	885	O
confidence	-	887	O
interval	-	898	O
,	-	906	O
1	-	908	O
.	-	909	O
1	-	910	O
-	-	911	O
30	-	912	O
.	-	914	O
7	-	915	O
)	-	916	O
,	-	917	O
especially	-	919	O
in	-	930	O
the	-	933	O
use	-	937	O
of	-	941	O
Nautilus	-	944	O
equipment	-	953	O
(	-	963	O
p	-	964	O
=	-	966	O
0	-	968	O
.	-	969	O
02	-	970	O
)	-	972	O
;	-	973	O
and	-	975	O
to	-	979	O
use	-	982	O
alcohol	-	986	O
(	-	994	O
odds	-	995	O
ratio	-	1000	O
,	-	1005	O
4	-	1007	O
.	-	1008	O
4	-	1009	O
;	-	1010	O
95	-	1012	O
%	-	1014	O
confidence	-	1016	O
interval	-	1027	O
,	-	1035	O
1	-	1037	O
.	-	1038	O
1	-	1039	O
-	-	1040	O
17	-	1041	O
.	-	1043	O
5	-	1044	O
)	-	1045	O
.	-	1046	O

Possible	2598570	1048	O
risk	-	1057	O
factors	-	1062	O
included	-	1070	O
young	-	1079	O
age	-	1085	O
,	-	1088	O
concurrent	-	1090	O
use	-	1101	O
of	-	1105	O
other	-	1108	O
analgesic	-	1114	O
agents	-	1124	O
(	-	1131	O
especially	-	1132	O
ibuprofen	-	1143	O
)	-	1152	O
,	-	1153	O
preexisting	-	1155	O
renal	-	1167	B
disease	-	1173	I
,	-	1180	O
a	-	1182	O
history	-	1184	O
of	-	1192	O
kidney	-	1195	B
stones	-	1202	I
,	-	1208	O
a	-	1210	O
history	-	1212	O
of	-	1220	O
gout	-	1223	B
,	-	1227	O
a	-	1229	O
recent	-	1231	O
increase	-	1238	O
in	-	1247	O
activity	-	1250	O
,	-	1258	O
a	-	1260	O
recent	-	1262	O
increase	-	1269	O
in	-	1278	O
sun	-	1281	O
exposure	-	1285	O
,	-	1293	O
and	-	1295	O
residence	-	1299	O
in	-	1309	O
the	-	1312	O
Sunbelt	-	1316	O
.	-	1323	O

These	2598570	1325	O
were	-	1331	O
findings	-	1336	O
that	-	1345	O
were	-	1350	O
suggestive	-	1355	O
but	-	1366	O
did	-	1370	O
not	-	1374	O
reach	-	1378	O
conventional	-	1384	O
statistical	-	1397	O
significance	-	1409	O
.	-	1421	O

These	2598570	1423	O
findings	-	1429	O
are	-	1438	O
consistent	-	1442	O
with	-	1453	O
the	-	1458	O
postulated	-	1462	O
mechanism	-	1473	O
for	-	1483	O
this	-	1487	O
unusual	-	1492	O
syndrome	-	1500	O
:	-	1508	O
acute	-	1510	O
diffuse	-	1516	O
crystallization	-	1524	O
of	-	1540	O
uric	-	1543	O
acid	-	1548	O
in	-	1553	O
renal	-	1556	O
tubules	-	1562	O
.	-	1569	O

Hemolytic	1415380	0	B
-	-	9	I
uremic	-	10	I
syndrome	-	17	I
associated	-	26	O
with	-	37	O
ingestion	-	42	O
of	-	52	O
quinine	-	55	O
.	-	62	O

Hemolytic	1415380	64	B
-	-	73	I
uremic	-	74	I
syndrome	-	81	I
following	-	90	O
quinine	-	100	O
ingestion	-	108	O
is	-	118	O
a	-	121	O
newly	-	123	O
described	-	129	O
phenomenon	-	139	O
,	-	149	O
with	-	151	O
just	-	156	O
two	-	161	O
previous	-	165	O
descriptions	-	174	O
of	-	187	O
4	-	190	O
cases	-	192	O
in	-	198	O
the	-	201	O
literature	-	205	O
.	-	215	O

We	1415380	217	O
describe	-	220	O
a	-	229	O
5th	-	231	O
case	-	235	O
.	-	239	O

The	1415380	241	O
reaction	-	245	O
may	-	254	O
be	-	258	O
mediated	-	261	O
by	-	270	O
the	-	273	O
presence	-	277	O
of	-	286	O
antibodies	-	289	O
reactive	-	300	O
against	-	309	O
platelets	-	317	O
in	-	327	O
the	-	330	O
presence	-	334	O
of	-	343	O
quinine	-	346	O
.	-	353	O

Treatment	1415380	355	O
has	-	365	O
included	-	369	O
use	-	378	O
of	-	382	O
plasma	-	385	O
exchange	-	392	O
,	-	400	O
prednisone	-	402	O
,	-	412	O
aspirin	-	414	O
,	-	421	O
and	-	423	O
dipyridamole	-	427	O
.	-	439	O

The	1415380	441	O
patients	-	445	O
have	-	454	O
all	-	459	O
regained	-	463	O
some	-	472	O
degree	-	477	O
of	-	484	O
renal	-	487	O
function	-	493	O
.	-	501	O

However	1415380	503	O
,	-	510	O
it	-	512	O
is	-	515	O
unclear	-	518	O
whether	-	526	O
pharmacological	-	534	O
treatment	-	550	O
or	-	560	O
spontaneous	-	563	O
resolution	-	575	O
is	-	586	O
responsible	-	589	O
for	-	601	O
the	-	605	O
improvement	-	609	O
.	-	620	O

Quinine	1415380	622	O
-	-	629	O
associated	-	630	O
hemolytic	-	641	B
-	-	650	I
uremic	-	651	I
syndrome	-	658	I
probably	-	667	O
occurs	-	676	O
more	-	683	O
often	-	688	O
than	-	694	O
is	-	699	O
recognized	-	702	O
.	-	712	O

It	1415380	714	O
is	-	717	O
important	-	720	O
to	-	730	O
recognize	-	733	O
this	-	743	O
reaction	-	748	O
when	-	757	O
it	-	762	O
occurs	-	765	O
and	-	772	O
to	-	776	O
avoid	-	779	O
further	-	785	O
quinine	-	793	O
exposure	-	801	O
,	-	809	O
since	-	811	O
the	-	817	O
reaction	-	821	O
seems	-	830	O
to	-	836	O
be	-	839	O
recurrent	-	842	O
.	-	851	O

Pyeloureteral	1255900	0	O
filling	-	14	O
defects	-	22	O
associated	-	30	O
with	-	41	O
systemic	-	46	O
anticoagulation	-	55	O
:	-	70	O
a	-	72	O
case	-	74	O
report	-	79	O
.	-	85	O

The	1255900	87	O
etiology	-	91	O
of	-	100	O
pyeloureteritis	-	103	B
cystica	-	119	I
has	-	127	O
long	-	131	O
been	-	136	O
attributed	-	141	O
to	-	152	O
chronic	-	155	O
infection	-	163	B
and	-	173	O
inflammation	-	177	B
.	-	189	O

A	1255900	191	O
case	-	193	O
is	-	198	O
presented	-	201	O
that	-	211	O
is	-	216	O
unique	-	219	O
in	-	226	O
that	-	229	O
the	-	234	O
acute	-	238	O
onset	-	244	O
and	-	250	O
the	-	254	O
rapid	-	258	O
resolution	-	264	O
of	-	275	O
pyeloureteral	-	278	O
filling	-	292	O
defects	-	300	O
in	-	308	O
this	-	311	O
patient	-	316	O
were	-	324	O
documented	-	329	O
by	-	340	O
radiography	-	343	O
.	-	354	O

There	1255900	356	O
is	-	362	O
no	-	365	O
evidence	-	368	O
of	-	377	O
antecedent	-	380	O
or	-	391	O
concurrent	-	394	O
infection	-	405	B
in	-	415	O
this	-	418	O
patient	-	423	O
.	-	430	O

The	1255900	432	O
disease	-	436	O
occurred	-	444	O
subsequent	-	453	O
to	-	464	O
the	-	467	O
initiation	-	471	O
of	-	482	O
heparin	-	485	O
therapy	-	493	O
for	-	501	O
suspected	-	505	O
pelvic	-	515	O
thrombophlebitis	-	522	B
and	-	539	O
cleared	-	543	O
rapidly	-	551	O
subsequent	-	559	O
to	-	570	O
its	-	573	O
discontinuation	-	577	O
.	-	592	O

The	1255900	594	O
rate	-	598	O
of	-	603	O
resolution	-	606	O
of	-	617	O
the	-	620	O
radiographic	-	624	O
findings	-	637	O
may	-	646	O
be	-	650	O
helpful	-	653	O
in	-	661	O
distinguishing	-	664	O
between	-	679	O
true	-	687	O
pyeloureteritis	-	692	B
cystica	-	708	I
and	-	716	O
submucosal	-	720	B
hemorrhage	-	731	I
.	-	741	O

Changes	85485	0	O
in	-	8	O
peroxisomes	-	11	O
in	-	23	O
preneoplastic	-	26	O
liver	-	40	O
and	-	46	O
hepatoma	-	50	B
of	-	59	O
mice	-	62	O
induced	-	67	O
by	-	75	O
alpha	-	78	O
-	-	83	O
benzene	-	84	O
hexachloride	-	92	O
.	-	104	O

Peroxisomes	85485	106	O
in	-	118	O
hepatomas	-	121	B
and	-	131	O
hyperplastic	-	135	O
preneoplastic	-	148	O
liver	-	162	B
lesions	-	168	I
induced	-	176	O
in	-	184	O
mice	-	187	O
by	-	192	O
500	-	195	O
ppm	-	199	O
alpha	-	203	O
-	-	208	O
benzene	-	209	O
hexachloride	-	217	O
were	-	230	O
examined	-	235	O
histochemically	-	244	O
and	-	260	O
electron	-	264	O
microscopically	-	273	O
.	-	288	O

Although	85485	290	O
most	-	299	O
of	-	304	O
the	-	307	O
hepatomas	-	311	B
were	-	321	O
well	-	326	O
-	-	330	O
differentiated	-	331	O
tumors	-	346	B
and	-	353	O
contained	-	357	O
a	-	367	O
considerable	-	369	O
number	-	382	O
of	-	389	O
peroxisomes	-	392	O
,	-	403	O
the	-	405	O
tumor	-	409	B
cells	-	415	O
did	-	421	O
not	-	425	O
respond	-	429	O
to	-	437	O
ethyl	-	440	O
-	-	445	O
alpha	-	446	O
-	-	451	O
p	-	452	O
-	-	453	O
chlorophenoxyisobutyrate	-	454	O
with	-	479	O
proliferation	-	484	O
of	-	498	O
peroxisomes	-	501	O
.	-	512	O

At	85485	514	O
the	-	517	O
16th	-	521	O
week	-	526	O
of	-	531	O
carcinogen	-	534	O
feeding	-	545	O
,	-	552	O
hyperplastic	-	554	O
nodules	-	567	O
appeared	-	575	O
and	-	584	O
advanced	-	588	O
to	-	597	O
further	-	600	O
stages	-	608	O
.	-	614	O

A	85485	616	O
majority	-	618	O
of	-	627	O
the	-	630	O
nodules	-	634	O
showed	-	642	O
a	-	649	O
considerable	-	651	O
number	-	664	O
of	-	671	O
peroxisomes	-	674	O
and	-	686	O
the	-	690	O
inductive	-	694	O
proliferation	-	704	O
of	-	718	O
peroxisomes	-	721	O
.	-	732	O

Within	85485	734	O
the	-	741	O
nodules	-	745	O
,	-	752	O
foci	-	754	O
of	-	759	O
proliferation	-	762	O
of	-	776	O
the	-	779	O
cells	-	783	O
that	-	789	O
showed	-	794	O
no	-	801	O
inducibility	-	804	O
of	-	817	O
proliferation	-	820	O
of	-	834	O
peroxisomes	-	837	O
appeared	-	849	O
.	-	857	O

These	85485	859	O
cells	-	865	O
proliferated	-	871	O
further	-	884	O
,	-	891	O
replacing	-	893	O
the	-	903	O
most	-	907	O
part	-	912	O
of	-	917	O
the	-	920	O
nodules	-	924	O
,	-	931	O
and	-	933	O
with	-	937	O
this	-	942	O
process	-	947	O
hepatomas	-	955	B
appeared	-	965	O
to	-	974	O
have	-	977	O
been	-	982	O
formed	-	987	O
.	-	993	O

No	85485	995	O
abnormal	-	998	O
matrical	-	1007	O
inclusions	-	1016	O
of	-	1027	O
peroxisomes	-	1030	O
were	-	1042	O
formed	-	1047	O
in	-	1054	O
the	-	1057	O
cells	-	1061	O
of	-	1067	O
hyperplastic	-	1070	O
nodules	-	1083	O
by	-	1091	O
ethyl	-	1094	O
-	-	1099	O
alpha	-	1100	O
-	-	1105	O
p	-	1106	O
-	-	1107	O
chlorophenoxyisobutyrate	-	1108	O
unlike	-	1133	O
in	-	1140	O
the	-	1143	O
case	-	1147	O
of	-	1152	O
rats	-	1155	O
.	-	1159	O

Quinidine	48362	0	O
hepatitis	-	10	B
.	-	19	O

Long	48362	21	O
-	-	25	O
term	-	26	O
administration	-	31	O
of	-	46	O
quinidine	-	49	O
was	-	59	O
associated	-	63	O
with	-	74	O
persistent	-	79	O
elevation	-	90	O
of	-	100	O
serum	-	103	O
concentrations	-	109	O
of	-	124	O
SGOT	-	127	O
,	-	131	O
lactic	-	133	O
acid	-	140	O
dehydrogenase	-	145	O
,	-	158	O
and	-	160	O
alkaline	-	164	O
phosphatase	-	173	O
.	-	184	O

Liver	48362	186	O
biopsy	-	192	O
showed	-	199	O
active	-	206	O
hepatitis	-	213	B
.	-	222	O

Discontinuance	48362	224	O
of	-	239	O
quinidine	-	242	O
therapy	-	252	O
led	-	260	O
to	-	264	O
normalization	-	267	O
of	-	281	O
liver	-	284	O
function	-	290	O
tests	-	299	O
.	-	304	O

A	48362	306	O
challenge	-	308	O
dose	-	318	O
of	-	323	O
quinidine	-	326	O
caused	-	336	O
clinical	-	343	O
symptoms	-	352	O
and	-	361	O
abrupt	-	365	O
elevation	-	372	O
of	-	382	O
SGOT	-	385	O
,	-	389	O
alkaline	-	391	O
phosphatase	-	400	O
,	-	411	O
and	-	413	O
lactic	-	417	O
acid	-	424	O
dehydrogenase	-	429	O
values	-	443	O
.	-	449	O

We	48362	451	O
concluded	-	454	O
that	-	464	O
this	-	469	O
patient	-	474	O
had	-	482	O
quinidine	-	486	O
hepatotoxicity	-	496	B
and	-	511	O
believe	-	515	O
that	-	523	O
this	-	528	O
is	-	533	O
the	-	536	O
first	-	540	O
case	-	546	O
reported	-	551	O
with	-	560	O
liver	-	565	O
biopsy	-	571	O
documentation	-	578	O
.	-	591	O

This	48362	593	O
report	-	598	O
also	-	605	O
suggests	-	610	O
that	-	619	O
,	-	623	O
even	-	625	O
after	-	630	O
long	-	636	O
-	-	640	O
term	-	641	O
administration	-	646	O
,	-	660	O
the	-	662	O
hepatic	-	666	B
toxicity	-	674	I
is	-	683	O
reversible	-	686	O
.	-	696	O

Cholesteryl	9067481	0	O
hemisuccinate	-	12	O
treatment	-	26	O
protects	-	36	O
rodents	-	45	O
from	-	53	O
the	-	58	O
toxic	-	62	O
effects	-	68	O
of	-	76	O
acetaminophen	-	79	O
,	-	92	O
adriamycin	-	94	O
,	-	104	O
carbon	-	106	O
tetrachloride	-	113	O
,	-	126	O
chloroform	-	128	O
and	-	139	O
galactosamine	-	143	O
.	-	156	O

In	9067481	158	O
addition	-	161	O
to	-	170	O
its	-	173	O
use	-	177	O
as	-	181	O
a	-	184	O
stabilizer	-	186	O
/	-	196	O
rigidifier	-	197	O
of	-	208	O
membranes	-	211	O
,	-	220	O
cholesteryl	-	222	O
hemisuccinate	-	234	O
,	-	247	O
tris	-	249	O
salt	-	254	O
(	-	259	O
CS	-	260	O
)	-	262	O
administration	-	264	O
has	-	279	O
also	-	283	O
been	-	288	O
shown	-	293	O
to	-	299	O
protect	-	302	O
rats	-	310	O
from	-	315	O
the	-	320	O
hepatotoxic	-	324	B
effects	-	336	O
of	-	344	O
carbon	-	347	O
tetrachloride	-	354	O
(	-	368	O
CCl4	-	369	O
)	-	373	O
.	-	374	O

To	9067481	376	O
further	-	379	O
our	-	387	O
understanding	-	391	O
of	-	405	O
the	-	408	O
mechanism	-	412	O
of	-	422	O
CS	-	425	O
cytoprotection	-	428	O
,	-	442	O
we	-	444	O
examined	-	447	O
in	-	456	O
rats	-	459	O
and	-	464	O
mice	-	468	O
the	-	473	O
protective	-	477	O
abilities	-	488	O
of	-	498	O
CS	-	501	O
and	-	504	O
the	-	508	O
non	-	512	O
-	-	515	O
hydrolyzable	-	516	O
ether	-	529	O
form	-	535	O
of	-	540	O
CS	-	543	O
,	-	545	O
gamma	-	547	O
-	-	552	O
cholesteryloxybutyric	-	553	O
acid	-	575	O
,	-	579	O
tris	-	581	O
salt	-	586	O
(	-	591	O
CSE	-	592	O
)	-	595	O
against	-	597	O
acetaminophen	-	605	O
-	-	618	O
,	-	619	O
adriamycin	-	621	O
-	-	631	O
,	-	632	O
carbon	-	634	O
tetrachloride	-	641	O
-	-	654	O
,	-	655	O
chloroform	-	657	O
-	-	667	O
and	-	669	O
galactosamine	-	673	O
-	-	686	O
induced	-	687	O
toxicity	-	695	B
.	-	703	O

The	9067481	705	O
results	-	709	O
of	-	717	O
these	-	720	O
studies	-	726	O
demonstrated	-	734	O
that	-	747	O
CS	-	752	O
-	-	754	O
mediated	-	755	O
protection	-	764	O
is	-	775	O
not	-	778	O
selective	-	782	O
for	-	792	O
a	-	796	O
particular	-	798	O
species	-	809	O
,	-	816	O
organ	-	818	O
system	-	824	O
or	-	831	O
toxic	-	834	O
chemical	-	840	O
.	-	848	O

A	9067481	850	O
24	-	852	O
-	-	854	O
h	-	855	O
pretreatment	-	857	O
of	-	870	O
both	-	873	O
rats	-	878	O
and	-	883	O
mice	-	887	O
with	-	892	O
a	-	897	O
single	-	899	O
dose	-	906	O
of	-	911	O
CS	-	914	O
(	-	917	O
100mg	-	918	O
/	-	923	O
kg	-	924	O
,	-	926	O
i	-	928	O
.	-	929	O
p	-	930	O
.	-	931	O
)	-	932	O

,	9067481	933	O
resulted	-	935	O
in	-	944	O
significant	-	947	O
protection	-	959	O
against	-	970	O
the	-	978	O
hepatotoxic	-	982	B
effects	-	994	O
of	-	1002	O
CCl4	-	1005	O
,	-	1009	O
CHCl3	-	1011	O
,	-	1016	O
acetaminophen	-	1018	O
and	-	1032	O
galactosamine	-	1036	O
and	-	1050	O
against	-	1054	O
the	-	1062	O
lethal	-	1066	O
(	-	1073	O
and	-	1074	O
presumably	-	1078	O
cardiotoxic	-	1089	B
)	-	1100	O
effect	-	1102	O
of	-	1109	O
adriamycin	-	1112	O
administration	-	1123	O
.	-	1137	O

Maximal	9067481	1139	O
CS	-	1147	O
-	-	1149	O
mediated	-	1150	O
protection	-	1159	O
was	-	1170	O
observed	-	1174	O
in	-	1183	O
experimental	-	1186	O
animals	-	1199	O
pretreated	-	1207	O
24	-	1218	O
h	-	1221	O
prior	-	1223	O
to	-	1229	O
the	-	1232	O
toxic	-	1236	O
insult	-	1242	O
.	-	1248	O

These	9067481	1250	O
data	-	1256	O
suggest	-	1261	O
that	-	1269	O
CS	-	1274	O
intervenes	-	1277	O
in	-	1288	O
a	-	1291	O
critical	-	1293	O
cellular	-	1302	O
event	-	1311	O
that	-	1317	O
is	-	1322	O
an	-	1325	O
important	-	1328	O
common	-	1338	O
pathway	-	1345	O
to	-	1353	O
toxic	-	1356	O
cell	-	1362	O
death	-	1367	O
.	-	1372	O

The	9067481	1374	O
mechanism	-	1378	O
of	-	1388	O
CS	-	1391	O
protection	-	1394	O
does	-	1405	O
not	-	1410	O
appear	-	1414	O
to	-	1421	O
be	-	1424	O
dependent	-	1427	O
on	-	1437	O
the	-	1440	O
inhibition	-	1444	O
of	-	1455	O
chemical	-	1458	O
bioactivation	-	1467	O
to	-	1481	O
a	-	1484	O
toxic	-	1486	O
reactive	-	1492	O
intermediate	-	1501	O
(	-	1514	O
in	-	1515	O
light	-	1518	O
of	-	1524	O
the	-	1527	O
protection	-	1531	O
observed	-	1542	O
against	-	1551	O
galactosamine	-	1559	O
hepatotoxicity	-	1573	B
)	-	1587	O
.	-	1588	O

However	9067481	1590	O
,	-	1597	O
based	-	1599	O
on	-	1605	O
the	-	1608	O
data	-	1612	O
presented	-	1617	O
,	-	1626	O
we	-	1628	O
can	-	1631	O
not	-	1635	O
exclude	-	1639	O
the	-	1647	O
possibility	-	1651	O
that	-	1663	O
CS	-	1668	O
administration	-	1671	O
inhibits	-	1686	O
chemical	-	1695	O
bioactivation	-	1704	O
.	-	1717	O

Our	9067481	1719	O
findings	-	1723	O
do	-	1732	O
suggest	-	1735	O
that	-	1743	O
CS	-	1748	O
-	-	1750	O
mediated	-	1751	O
protection	-	1760	O
is	-	1771	O
dependent	-	1774	O
on	-	1784	O
the	-	1787	O
action	-	1791	O
of	-	1798	O
the	-	1801	O
intact	-	1805	O
anionic	-	1812	O
CS	-	1820	O
molecule	-	1823	O
(	-	1832	O
non	-	1833	O
-	-	1836	O
hydrolyzable	-	1837	O
CSE	-	1850	O
was	-	1854	O
as	-	1858	O
protective	-	1861	O
as	-	1872	O
CS	-	1875	O
)	-	1877	O
,	-	1878	O
whose	-	1880	O
mechanism	-	1886	O
has	-	1896	O
yet	-	1900	O
to	-	1904	O
be	-	1907	O
defined	-	1910	O
.	-	1917	O

DSMM	19274460	0	O
XI	-	5	O
study	-	8	O
:	-	13	O
dose	-	15	O
definition	-	20	O
for	-	31	O
intravenous	-	35	O
cyclophosphamide	-	47	O
in	-	64	O
combination	-	67	O
with	-	79	O
bortezomib	-	84	O
/	-	94	O
dexamethasone	-	95	O
for	-	109	O
remission	-	113	O
induction	-	123	O
in	-	133	O
patients	-	136	O
with	-	145	O
newly	-	150	O
diagnosed	-	156	O
myeloma	-	166	B
.	-	173	O

A	19274460	175	O
clinical	-	177	O
trial	-	186	O
was	-	192	O
initiated	-	196	O
to	-	206	O
evaluate	-	209	O
the	-	218	O
recommended	-	222	O
dose	-	234	O
of	-	239	O
cyclophosphamide	-	242	O
in	-	259	O
combination	-	262	O
with	-	274	O
bortezomib	-	279	O
and	-	290	O
dexamethasone	-	294	O
as	-	308	O
induction	-	311	O
treatment	-	321	O
before	-	331	O
stem	-	338	O
cell	-	343	O
transplantation	-	348	O
for	-	364	O
younger	-	368	O
patients	-	376	O
with	-	385	O
newly	-	390	O
diagnosed	-	396	O
multiple	-	406	B
myeloma	-	415	I
(	-	423	O
MM	-	424	B
)	-	426	O
.	-	427	O

Thirty	19274460	429	O
patients	-	436	O
were	-	445	O
treated	-	450	O
with	-	458	O
three	-	463	O
21	-	469	O
-	-	471	O
day	-	472	O
cycles	-	476	O
of	-	483	O
bortezomib	-	486	O
1	-	497	O
.	-	498	O
3	-	499	O
mg	-	501	O
/	-	503	O
m	-	504	O
(	-	505	O
2	-	506	O
)	-	507	O
on	-	509	O
days	-	512	O
1	-	517	O
,	-	518	O
4	-	520	O
,	-	521	O
8	-	523	O
,	-	524	O
and	-	526	O
11	-	530	O
plus	-	533	O
dexamethasone	-	538	O
40	-	552	O
mg	-	555	O
on	-	558	O
the	-	561	O
day	-	565	O
of	-	569	O
bortezomib	-	572	O
injection	-	583	O
and	-	593	O
the	-	597	O
day	-	601	O
after	-	605	O
plus	-	611	O
cyclophosphamide	-	616	O
at	-	633	O
900	-	636	O
,	-	639	O
1	-	641	O
,	-	642	O
200	-	643	O
,	-	646	O
or	-	648	O
1	-	651	O
,	-	652	O
500	-	653	O
mg	-	657	O
/	-	659	O
m	-	660	O
(	-	661	O
2	-	662	O
)	-	663	O
on	-	665	O
day	-	668	O
1	-	672	O
.	-	673	O

The	19274460	675	O
maximum	-	679	O
tolerated	-	687	O
dose	-	697	O
of	-	702	O
cyclophosphamide	-	705	O
was	-	722	O
defined	-	726	O
as	-	734	O
900	-	737	O
mg	-	741	O
/	-	743	O
m	-	744	O
(	-	745	O
2	-	746	O
)	-	747	O
.	-	748	O

At	19274460	750	O
this	-	753	O
dose	-	758	O
level	-	763	O
,	-	768	O
92	-	770	O
%	-	772	O
of	-	774	O
patients	-	777	O
achieved	-	786	O
at	-	795	O
least	-	798	O
a	-	804	O
partial	-	806	O
response	-	814	O
.	-	822	O

The	19274460	824	O
overall	-	828	O
response	-	836	O
rate	-	845	O
[	-	850	O
complete	-	851	O
response	-	860	O
(	-	869	O
CR	-	870	O
)	-	872	O
plus	-	874	O
partial	-	879	O
response	-	887	O
(	-	896	O
PR	-	897	O
)	-	899	O
]	-	900	O

across	19274460	902	O
all	-	909	O
dose	-	913	O
levels	-	918	O
was	-	925	O
77	-	929	O
%	-	931	O
,	-	932	O
with	-	934	O
a	-	939	O
10	-	941	O
%	-	943	O
CR	-	945	O
rate	-	948	O
.	-	952	O

No	19274460	954	O
patient	-	957	O
experienced	-	965	O
progressive	-	977	O
disease	-	989	O
.	-	996	O

The	19274460	998	O
most	-	1002	O
frequent	-	1007	O
adverse	-	1016	O
events	-	1024	O
were	-	1031	O
hematological	-	1036	B
and	-	1050	I
gastrointestinal	-	1054	I
toxicities	-	1071	I
as	-	1082	O
well	-	1085	O
as	-	1090	O
neuropathy	-	1093	B
.	-	1103	O

The	19274460	1105	O
results	-	1109	O
suggest	-	1117	O
that	-	1125	O
bortezomib	-	1130	O
in	-	1141	O
combination	-	1144	O
with	-	1156	O
cyclophosphamide	-	1161	O
at	-	1178	O
900	-	1181	O
mg	-	1185	O
/	-	1187	O
m	-	1188	O
(	-	1189	O
2	-	1190	O
)	-	1191	O
and	-	1193	O
dexamethasone	-	1197	O
is	-	1211	O
an	-	1214	O
effective	-	1217	O
induction	-	1227	O
treatment	-	1237	O
for	-	1247	O
patients	-	1251	O
with	-	1260	O
newly	-	1265	O
diagnosed	-	1271	O
MM	-	1281	B
that	-	1284	O
warrants	-	1289	O
further	-	1298	O
investigation	-	1306	O
.	-	1319	O

Results	18201582	0	O
of	-	8	O
a	-	11	O
comparative	-	13	O
,	-	24	O
phase	-	26	O
III	-	32	O
,	-	35	O
12	-	37	O
-	-	39	O
week	-	40	O
,	-	44	O
multicenter	-	46	O
,	-	57	O
prospective	-	59	O
,	-	70	O
randomized	-	72	O
,	-	82	O
double	-	84	O
-	-	90	O
blind	-	91	O
assessment	-	97	O
of	-	108	O
the	-	111	O
efficacy	-	115	O
and	-	124	O
tolerability	-	128	O
of	-	141	O
a	-	144	O
fixed	-	146	O
-	-	151	O
dose	-	152	O
combination	-	157	O
of	-	169	O
telmisartan	-	172	O
and	-	184	O
amlodipine	-	188	O
versus	-	199	O
amlodipine	-	206	O
monotherapy	-	217	O
in	-	229	O
Indian	-	232	O
adults	-	239	O
with	-	246	O
stage	-	251	O
II	-	257	O
hypertension	-	260	B
.	-	272	O

OBJECTIVE	18201582	274	O
:	-	283	O
The	-	285	O
aim	-	289	O
of	-	293	O
this	-	296	O
study	-	301	O
was	-	307	O
to	-	311	O
evaluate	-	314	O
the	-	323	O
efficacy	-	327	O
and	-	336	O
tolerability	-	340	O
of	-	353	O
a	-	356	O
new	-	358	O
fixed	-	362	O
-	-	367	O
dose	-	368	O
combination	-	373	O
(	-	385	O
FDC	-	386	O
)	-	389	O
of	-	391	O
telmisartan	-	394	O
40	-	406	O
mg	-	409	O
+	-	412	O
amlodipine	-	414	O
5	-	425	O
mg	-	427	O
(	-	430	O
T	-	431	O
+	-	432	O
A	-	433	O
)	-	434	O
compared	-	436	O
with	-	445	O
amlodipine	-	450	O
5	-	461	O
-	-	462	O
mg	-	463	O
monotherapy	-	466	O
(	-	478	O
A	-	479	O
)	-	480	O
in	-	482	O
adult	-	485	O
Indian	-	491	O
patients	-	498	O
with	-	507	O
stage	-	512	O
II	-	518	O
hypertension	-	521	B
.	-	533	O

METHODS	18201582	535	O
:	-	542	O

This	18201582	544	O
comparative	-	549	O
,	-	560	O
Phase	-	562	O
III	-	568	O

,	18201582	571	O
12	-	573	O
-	-	575	O
week	-	576	O
,	-	580	O
multicenter	-	582	O
,	-	593	O
prospective	-	595	O
,	-	606	O
randomized	-	608	O
,	-	618	O
double	-	620	O
-	-	626	O
blind	-	627	O
study	-	633	O
was	-	639	O
conducted	-	643	O
in	-	653	O
Indian	-	656	O
patients	-	663	O
aged	-	672	O
18	-	677	O
to	-	680	O
65	-	683	O
years	-	686	O
with	-	692	O
established	-	697	O
stage	-	709	O
II	-	715	O
hypertension	-	718	B
.	-	730	O

Patients	18201582	732	O
were	-	741	O
treated	-	746	O
with	-	754	O
oral	-	759	O
FDC	-	764	O
of	-	768	O
T	-	771	O
+	-	772	O
A	-	773	O
or	-	775	O
A	-	778	O
QD	-	780	O
before	-	783	O
breakfast	-	790	O
for	-	800	O
12	-	804	O
weeks	-	807	O
;	-	812	O
blood	-	814	O
pressure	-	820	O
(	-	829	O
BP	-	830	O
)	-	832	O
and	-	834	O
heart	-	838	O
rate	-	844	O
were	-	849	O
measured	-	854	O
in	-	863	O
the	-	866	O
sitting	-	870	O
position	-	878	O
.	-	886	O

Primary	18201582	888	O
efficacy	-	896	O
end	-	905	O
points	-	909	O
were	-	916	O
reduction	-	921	O
in	-	931	O
clinical	-	934	O
systolic	-	943	O
BP	-	952	O
(	-	955	O
SBP	-	956	O
)	-	959	O
/	-	960	O
diastolic	-	962	O
BP	-	972	O
(	-	975	O
DBP	-	976	O
)	-	979	O
from	-	981	O
baseline	-	986	O
to	-	995	O
study	-	998	O
end	-	1004	O
and	-	1008	O
number	-	1012	O
of	-	1019	O
responders	-	1022	O
(	-	1033	O
ie	-	1034	O
,	-	1036	O
patients	-	1038	O
who	-	1047	O
achieved	-	1051	O
target	-	1060	O
SBP	-	1067	O
/	-	1070	O
DBP	-	1072	O
<	-	1076	O
130	-	1077	O
/	-	1080	O
<	-	1081	O
80	-	1082	O
mm	-	1085	O
Hg	-	1088	O
)	-	1090	O
at	-	1092	O
end	-	1095	O
of	-	1099	O
study	-	1102	O
.	-	1107	O

Tolerability	18201582	1109	O
was	-	1122	O
assessed	-	1126	O
by	-	1135	O
treatment	-	1138	O
-	-	1147	O
emergent	-	1148	O
adverse	-	1157	O
events	-	1165	O
,	-	1171	O
identified	-	1173	O
using	-	1184	O
physical	-	1190	O
examination	-	1199	O
,	-	1210	O
laboratory	-	1212	O
analysis	-	1223	O
,	-	1231	O
and	-	1233	O
electrocardiography	-	1237	O
.	-	1256	O

RESULTS	18201582	1258	O
:	-	1265	O

A	18201582	1267	O
total	-	1269	O
of	-	1275	O
210	-	1278	O
patients	-	1282	O
were	-	1291	O
enrolled	-	1296	O
in	-	1305	O
the	-	1308	O
study	-	1312	O
;	-	1317	O
203	-	1319	O
patients	-	1323	O
(	-	1332	O
143	-	1333	O
men	-	1337	O
,	-	1340	O
60	-	1342	O
women	-	1345	O
)	-	1350	O
completed	-	1352	O
the	-	1362	O
study	-	1366	O
while	-	1372	O
7	-	1378	O
were	-	1380	O
lost	-	1385	O
to	-	1390	O
follow	-	1393	O
-	-	1399	O
up	-	1400	O
(	-	1403	O
4	-	1404	O
patients	-	1406	O
in	-	1415	O
the	-	1418	O
T	-	1422	O
+	-	1423	O
A	-	1424	O
group	-	1426	O
and	-	1432	O
3	-	1436	O
in	-	1438	O
the	-	1441	O
A	-	1445	O
group	-	1447	O
)	-	1452	O
and	-	1454	O
considered	-	1458	O
with	-	1469	O
-	-	1473	O
drawn	-	1474	O
.	-	1479	O

At	18201582	1481	O
study	-	1484	O
end	-	1490	O
,	-	1493	O
statistically	-	1495	O
significant	-	1509	O
percentage	-	1521	O
reductions	-	1532	O
from	-	1543	O
baseline	-	1548	O
within	-	1557	O
groups	-	1564	O
and	-	1571	O
between	-	1575	O
groups	-	1583	O
were	-	1590	O
observed	-	1595	O
in	-	1604	O
SBP	-	1607	O
(	-	1611	O
T	-	1612	O
+	-	1613	O
A	-	1614	O
[	-	1616	O
-	-	1617	O
27	-	1618	O
.	-	1620	O
4	-	1621	O
%	-	1622	O
]	-	1623	O
;	-	1624	O
A	-	1626	O
[	-	1628	O
-	-	1629	O
16	-	1630	O
.	-	1632	O
6	-	1633	O
%	-	1634	O
]	-	1635	O
)	-	1636	O
and	-	1638	O
DBP	-	1642	O

(	18201582	1646	O
T	-	1647	O
+	-	1648	O
A	-	1649	O
[	-	1651	O
-	-	1652	O
20	-	1653	O
.	-	1655	O
1	-	1656	O
%	-	1657	O
]	-	1658	O
;	-	1659	O
A	-	1661	O
[	-	1663	O
-	-	1664	O
13	-	1665	O
.	-	1667	O
3	-	1668	O
%	-	1669	O
]	-	1670	O
)	-	1671	O
(	-	1673	O
all	-	1674	O
,	-	1677	O
P	-	1679	O
<	-	1681	O
0	-	1683	O
.	-	1684	O
05	-	1685	O
)	-	1687	O
.	-	1688	O

Response	18201582	1690	O
rates	-	1699	O
were	-	1705	O
87	-	1710	O
.	-	1712	O
3	-	1713	O
%	-	1714	O
(	-	1716	O
89	-	1717	O
/	-	1719	O
102	-	1720	O
)	-	1723	O
in	-	1725	O
the	-	1728	O
T	-	1732	O
+	-	1733	O
A	-	1734	O
group	-	1736	O
and	-	1742	O
69	-	1746	O
.	-	1748	O
3	-	1749	O
%	-	1750	O
(	-	1752	O
70	-	1753	O
/	-	1755	O
101	-	1756	O
)	-	1759	O
in	-	1761	O
the	-	1764	O
A	-	1768	O
group	-	1770	O
(	-	1776	O
P	-	1777	O
<	-	1779	O
0	-	1781	O
.	-	1782	O
05	-	1783	O
)	-	1785	O
.	-	1786	O

The	18201582	1788	O
prevalences	-	1792	O
of	-	1804	O
adverse	-	1807	O
events	-	1815	O
were	-	1822	O
not	-	1827	O
significantly	-	1831	O
different	-	1845	O
between	-	1855	O
the	-	1863	O
2	-	1867	O
treatment	-	1869	O
groups	-	1879	O
(	-	1886	O
T	-	1887	O
+	-	1888	O
A	-	1889	O
,	-	1890	O
16	-	1892	O
.	-	1894	O
0	-	1895	O
%	-	1896	O
[	-	1898	O
17	-	1899	O
/	-	1901	O
106	-	1902	O
]	-	1905	O
;	-	1906	O
A	-	1908	O
,	-	1909	O
15	-	1911	O
.	-	1913	O
4	-	1914	O
%	-	1915	O
[	-	1917	O
16	-	1918	O
/	-	1920	O
104	-	1921	O
]	-	1924	O
)	-	1925	O
.	-	1926	O

Peripheral	18201582	1928	O
edema	-	1939	B
was	-	1945	O
reported	-	1949	O
in	-	1958	O
8	-	1961	O
.	-	1962	O
5	-	1963	O
%	-	1964	O
patients	-	1966	O
(	-	1975	O
9	-	1976	O
/	-	1977	O
106	-	1978	O
)	-	1981	O
in	-	1983	O
the	-	1986	O
T	-	1990	O
+	-	1991	O
A	-	1992	O
group	-	1994	O
compared	-	2000	O
with	-	2009	O
13	-	2014	O
.	-	2016	O
5	-	2017	O
%	-	2018	O
(	-	2020	O
14	-	2021	O
/	-	2023	O
104	-	2024	O
)	-	2027	O
in	-	2029	O
the	-	2032	O
A	-	2036	O
group	-	2038	O
,	-	2043	O
and	-	2045	O
cough	-	2049	B
was	-	2055	O
reported	-	2059	O
in	-	2068	O
3	-	2071	O
.	-	2072	O
8	-	2073	O
%	-	2074	O
patients	-	2076	O
(	-	2085	O
4	-	2086	O
/	-	2087	O
106	-	2088	O
)	-	2091	O
in	-	2093	O
the	-	2096	O
T	-	2100	O
+	-	2101	O
A	-	2102	O
group	-	2104	O
and	-	2110	O
1	-	2114	O
.	-	2115	O
0	-	2116	O
%	-	2117	O
(	-	2119	O
1	-	2120	O
/	-	2121	O
104	-	2122	O
)	-	2125	O
patients	-	2127	O
in	-	2136	O
the	-	2139	O
A	-	2143	O
group	-	2145	O
;	-	2150	O
these	-	2152	O
differences	-	2158	O
did	-	2170	O
not	-	2174	O
reach	-	2178	O
statistical	-	2184	O
significance	-	2196	O
.	-	2208	O

The	18201582	2210	O
incidences	-	2214	O
of	-	2225	O
headache	-	2228	B
,	-	2236	O
dizziness	-	2238	B
,	-	2247	O
and	-	2249	O
diarrhea	-	2253	B
were	-	2262	O
similar	-	2267	O
between	-	2275	O
the	-	2283	O
2	-	2287	O
groups	-	2289	O
.	-	2295	O

CONCLUSIONS	18201582	2297	O
:	-	2308	O

Among	18201582	2310	O
these	-	2316	O
Indian	-	2322	O
patients	-	2329	O
with	-	2338	O
stage	-	2343	O
II	-	2349	O
hypertension	-	2352	B
,	-	2364	O
the	-	2366	O
FDC	-	2370	O
of	-	2374	O
T	-	2377	O
+	-	2378	O
A	-	2379	O
was	-	2381	O
found	-	2385	O
to	-	2391	O
be	-	2394	O
significantly	-	2397	O
more	-	2411	O
effective	-	2416	O
,	-	2425	O
with	-	2427	O
regard	-	2432	O
to	-	2439	O
BP	-	2442	O
reductions	-	2445	O
,	-	2455	O
than	-	2457	O
A	-	2462	O
,	-	2463	O
and	-	2465	O
both	-	2469	O
treatments	-	2474	O
were	-	2485	O
well	-	2490	O
tolerated	-	2495	O
.	-	2504	O

Cutaneous	11337188	0	B
leucocytoclastic	-	10	I
vasculitis	-	27	I
associated	-	38	O
with	-	49	O
oxacillin	-	54	O
.	-	63	O

A	11337188	65	O
67	-	67	O
-	-	69	O
year	-	70	O
-	-	74	O
old	-	75	O
man	-	79	O
who	-	83	O
was	-	87	O
treated	-	91	O
with	-	99	O
oxacillin	-	104	O
for	-	114	O
one	-	118	O
week	-	122	O
because	-	127	O
of	-	135	O
Staphylococcus	-	138	B
aureus	-	153	I
bacteremia	-	160	I
,	-	170	O
developed	-	172	O
renal	-	182	B
failure	-	188	I
and	-	196	O
diffuse	-	200	O
,	-	207	O
symmetric	-	209	O
,	-	218	O
palpable	-	220	O
purpuric	-	229	B
lesions	-	238	I
on	-	246	O
his	-	249	O
feet	-	253	O
.	-	257	O

Necrotic	11337188	259	B
blisters	-	268	I
were	-	277	O
noted	-	282	O
on	-	288	O
his	-	291	O
fingers	-	295	O
.	-	302	O

Skin	11337188	304	O
biopsies	-	309	O
showed	-	318	O
findings	-	325	O
diagnostic	-	334	O
of	-	345	O
leucocytoclastic	-	348	B
vasculitis	-	365	I
.	-	375	O

Oxacillin	11337188	377	O
was	-	387	O
discontinued	-	391	O
and	-	404	O
patient	-	408	O
was	-	416	O
treated	-	420	O
with	-	428	O
corticosteroids	-	433	O
.	-	448	O

The	11337188	450	O
rash	-	454	B
disappeared	-	459	O
after	-	471	O
three	-	477	O
weeks	-	483	O
and	-	489	O
renal	-	493	O
function	-	499	O
returned	-	508	O
to	-	517	O
normal	-	520	O
.	-	526	O

Leucocytoclastic	11337188	528	B
vasculitis	-	545	I
presents	-	556	O
as	-	565	O
palpable	-	568	O
purpura	-	577	B
of	-	585	O
the	-	588	O
lower	-	592	O
extremities	-	598	O
often	-	610	O
accompanied	-	616	O
by	-	628	O
abdominal	-	631	B
pain	-	641	I
,	-	645	O
arthralgia	-	647	B
,	-	657	O
and	-	659	O
renal	-	663	B
involvement	-	669	I
.	-	680	O

Etiologic	11337188	682	O
factors	-	692	O
or	-	700	O
associated	-	703	O
disorders	-	714	O
include	-	724	O
infections	-	732	B
,	-	742	O
medications	-	744	O
,	-	755	O
collagen	-	757	B
vascular	-	766	I
disease	-	775	I
and	-	783	O
neoplasia	-	787	B
.	-	796	O

However	11337188	798	O
,	-	805	O
in	-	807	O
half	-	810	O
of	-	815	O
the	-	818	O
cases	-	822	O
no	-	828	O
etiologic	-	831	O
factor	-	841	O
is	-	848	O
identified	-	851	O
.	-	861	O

Usually	11337188	863	O
it	-	871	O
is	-	874	O
a	-	877	O
self	-	879	O
-	-	883	O
limited	-	884	O
disorder	-	892	O
,	-	900	O
but	-	902	O
corticosteroid	-	906	O
therapy	-	921	O
may	-	929	O
be	-	933	O
needed	-	936	O
in	-	943	O
life	-	946	O
-	-	950	O
threatening	-	951	O
cases	-	963	O
since	-	969	O
early	-	975	O
treatment	-	981	O
with	-	991	O
corticosteroids	-	996	O
in	-	1012	O
severe	-	1015	O
cases	-	1022	O
can	-	1028	O
prevent	-	1032	O
complications	-	1040	O
.	-	1053	O

Oxacillin	11337188	1055	O
should	-	1065	O
be	-	1072	O
included	-	1075	O
among	-	1084	O
the	-	1090	O
drugs	-	1094	O
that	-	1100	O
can	-	1105	O
cause	-	1109	O
leucocytoclastic	-	1115	B
vasculitis	-	1132	I
.	-	1142	O

Naloxazone	6308526	0	O
pretreatment	-	11	O
modifies	-	24	O
cardiorespiratory	-	33	O
,	-	50	O
temperature	-	52	O
,	-	63	O
and	-	65	O
behavioral	-	69	O
effects	-	80	O
of	-	88	O
morphine	-	91	O
.	-	99	O

Behavioral	6308526	101	O
and	-	112	O
cardiorespiratory	-	116	O
responses	-	134	O
to	-	144	O
a	-	147	O
lethal	-	149	O
dose	-	156	O
of	-	161	O
morphine	-	164	O
were	-	173	O
evaluated	-	178	O
in	-	188	O
rats	-	191	O
pretreated	-	196	O
with	-	207	O
saline	-	212	O
or	-	219	O
naloxazone	-	222	O
,	-	232	O
an	-	234	O
antagonist	-	237	O
of	-	248	O
high	-	251	O
-	-	255	O
affinity	-	256	O
mu	-	265	O
1	-	268	O
opioid	-	270	O
receptors	-	277	O
.	-	286	O

Pretreatment	6308526	288	O
with	-	301	O
naloxazone	-	306	O
significantly	-	317	O
blocked	-	331	O
morphine	-	339	O
analgesia	-	348	B
,	-	357	O
catalepsy	-	359	B
and	-	369	O
hypothermia	-	373	B
at	-	385	O
a	-	388	O
dose	-	390	O
which	-	395	O
completely	-	401	O
eliminated	-	412	O
high	-	423	O
-	-	427	O
affinity	-	428	O
binding	-	437	O
in	-	445	O
brain	-	448	O
membranes	-	454	O
.	-	463	O

Moreover	6308526	465	O
,	-	473	O
naloxazone	-	475	O
significantly	-	486	O
attenuated	-	500	O
the	-	511	O
morphine	-	515	O
-	-	523	O
induced	-	524	O
hypotension	-	532	B
and	-	544	O
respiratory	-	548	B
depression	-	560	I
,	-	570	O
whereas	-	572	O
morphine	-	580	O
-	-	588	O
induced	-	589	O
bradycardia	-	597	B
was	-	609	O
less	-	613	O
affected	-	618	O
.	-	626	O

Results	6308526	628	O
indicate	-	636	O
that	-	645	O
subpopulations	-	650	O
of	-	665	O
mu	-	668	O
receptors	-	671	O
may	-	681	O
mediate	-	685	O
selective	-	693	O
behavioral	-	703	O
and	-	714	O
cardiorespiratory	-	718	O
responses	-	736	O
to	-	746	O
morphine	-	749	O
.	-	757	O

Dexrazoxane	15897593	0	O
protects	-	12	O
against	-	21	O
myelosuppression	-	29	B
from	-	46	O
the	-	51	O
DNA	-	55	O
cleavage	-	59	O
-	-	67	O
enhancing	-	68	O
drugs	-	78	O
etoposide	-	84	O
and	-	94	O
daunorubicin	-	98	O
but	-	111	O
not	-	115	O
doxorubicin	-	119	O
.	-	130	O

PURPOSE	15897593	132	O
:	-	139	O

The	15897593	141	O
anthracyclines	-	145	O
daunorubicin	-	160	O
and	-	173	O
doxorubicin	-	177	O
and	-	189	O
the	-	193	O
epipodophyllotoxin	-	197	O
etoposide	-	216	O
are	-	226	O
potent	-	230	O
DNA	-	237	O
cleavage	-	241	O
-	-	249	O
enhancing	-	250	O
drugs	-	260	O
that	-	266	O
are	-	271	O
widely	-	275	O
used	-	282	O
in	-	287	O
clinical	-	290	O
oncology	-	299	O
;	-	307	O
however	-	309	O
,	-	316	O
myelosuppression	-	318	B
and	-	335	O
cardiac	-	339	B
toxicity	-	347	I
limit	-	356	O
their	-	362	O
use	-	368	O
.	-	371	O

Dexrazoxane	15897593	373	O
(	-	385	O
ICRF	-	386	O
-	-	390	O
187	-	391	O
)	-	394	O
is	-	396	O
recommended	-	399	O
for	-	411	O
protection	-	415	O
against	-	426	O
anthracycline	-	434	O
-	-	447	O
induced	-	448	O
cardiotoxicity	-	456	B
.	-	470	O

EXPERIMENTAL	15897593	472	O
DESIGN	-	485	O
:	-	491	O

Because	15897593	493	O
of	-	501	O
their	-	504	O
widespread	-	510	O
use	-	521	O
,	-	524	O
the	-	526	O
hematologic	-	530	B
toxicity	-	542	I
following	-	551	O
coadministration	-	561	O
of	-	578	O
dexrazoxane	-	581	O
and	-	593	O
these	-	597	O
three	-	603	O
structurally	-	609	O
different	-	622	O
DNA	-	632	O
cleavage	-	636	O
enhancers	-	645	O
was	-	655	O
investigated	-	659	O
:	-	671	O
Sensitivity	-	673	O
of	-	685	O
human	-	688	O
and	-	694	O
murine	-	698	O
blood	-	705	O
progenitor	-	711	O
cells	-	722	O
to	-	728	O
etoposide	-	731	O
,	-	740	O
daunorubicin	-	742	O
,	-	754	O
and	-	756	O
doxorubicin	-	760	O
+	-	772	O
/	-	773	O
-	-	774	O

dexrazoxane	15897593	776	O
was	-	788	O
determined	-	792	O
in	-	803	O
granulocyte	-	806	O
-	-	817	O
macrophage	-	818	O
colony	-	829	O
forming	-	836	O
assays	-	844	O
.	-	850	O

Likewise	15897593	852	O
,	-	860	O
in	-	862	O
vivo	-	865	O
,	-	869	O
B6D2F1	-	871	O
mice	-	878	O
were	-	883	O
treated	-	888	O
with	-	896	O
etoposide	-	901	O
,	-	910	O
daunorubicin	-	912	O
,	-	924	O
and	-	926	O
doxorubicin	-	930	O
,	-	941	O
with	-	943	O
or	-	948	O
without	-	951	O
dexrazoxane	-	959	O
over	-	971	O
a	-	976	O
wide	-	978	O
range	-	983	O
of	-	989	O
doses	-	992	O
:	-	997	O
posttreatment	-	999	O
,	-	1012	O
a	-	1014	O
full	-	1016	O
hematologic	-	1021	O
evaluation	-	1033	O
was	-	1044	O
done	-	1048	O
.	-	1052	O

RESULTS	15897593	1054	O
:	-	1061	O

Nontoxic	15897593	1063	O
doses	-	1072	O
of	-	1078	O
dexrazoxane	-	1081	O
reduced	-	1093	O
myelosuppression	-	1101	B
and	-	1118	O
weight	-	1122	B
loss	-	1129	I
from	-	1134	O
daunorubicin	-	1139	O
and	-	1152	O
etoposide	-	1156	O
in	-	1166	O
mice	-	1169	O
and	-	1174	O
antagonized	-	1178	O
their	-	1190	O
antiproliferative	-	1196	O
effects	-	1214	O
in	-	1222	O
the	-	1225	O
colony	-	1229	O
assay	-	1236	O
;	-	1241	O
however	-	1243	O
,	-	1250	O
dexrazoxane	-	1252	O
neither	-	1264	O
reduced	-	1272	O
myelosuppression	-	1280	B
,	-	1296	O
weight	-	1298	B
loss	-	1305	I
,	-	1309	O
nor	-	1311	O
the	-	1315	O
in	-	1319	O
vitro	-	1322	O
cytotoxicity	-	1328	B
from	-	1341	O
doxorubicin	-	1346	O
.	-	1357	O

CONCLUSION	15897593	1359	O
:	-	1369	O

Although	15897593	1371	O
our	-	1380	O
findings	-	1384	O
support	-	1393	O
the	-	1401	O
observation	-	1405	O
that	-	1417	O
dexrazoxane	-	1422	O
reduces	-	1434	O
neither	-	1442	O
hematologic	-	1450	O
activity	-	1462	O
nor	-	1471	O
antitumor	-	1475	O
activity	-	1485	O
from	-	1494	O
doxorubicin	-	1499	O
clinically	-	1511	O
,	-	1521	O
the	-	1523	O
potent	-	1527	O
antagonism	-	1534	O
of	-	1545	O
daunorubicin	-	1548	O
activity	-	1561	O
raises	-	1570	O
concern	-	1577	O
;	-	1584	O
a	-	1586	O
possible	-	1588	O
interference	-	1597	O
with	-	1610	O
anticancer	-	1615	O
efficacy	-	1626	O
certainly	-	1635	O
would	-	1645	O
call	-	1651	O
for	-	1656	O
renewed	-	1660	O
attention	-	1668	O
.	-	1677	O

Our	15897593	1679	O
data	-	1683	O
also	-	1688	O
suggest	-	1693	O
that	-	1701	O
significant	-	1706	O
etoposide	-	1718	O
dose	-	1728	O
escalation	-	1733	O
is	-	1744	O
perhaps	-	1747	O
possible	-	1755	O
by	-	1764	O
the	-	1767	O
use	-	1771	O
of	-	1775	O
dexrazoxane	-	1778	O
.	-	1789	O

Clinical	15897593	1791	O
trials	-	1800	O
in	-	1807	O
patients	-	1810	O
with	-	1819	O
brain	-	1824	O
metastases	-	1830	B
combining	-	1841	O
dexrazoxane	-	1851	O
and	-	1863	O
high	-	1867	O
doses	-	1872	O
of	-	1878	O
etoposide	-	1881	O
is	-	1891	O
ongoing	-	1894	O
with	-	1902	O
the	-	1907	O
aim	-	1911	O
of	-	1915	O
improving	-	1918	O
efficacy	-	1928	O
without	-	1937	O
aggravating	-	1945	O
hematologic	-	1957	B
toxicity	-	1969	I
.	-	1977	O

If	15897593	1979	O
successful	-	1982	O
,	-	1992	O
this	-	1994	O
represents	-	1999	O
an	-	2010	O
exciting	-	2013	O
mechanism	-	2022	O
for	-	2032	O
pharmacologic	-	2036	O
regulation	-	2050	O
of	-	2061	O
side	-	2064	O
effects	-	2069	O
from	-	2077	O
cytotoxic	-	2082	O
chemotherapy	-	2092	O
.	-	2104	O

Effects	6817363	0	O
of	-	8	O
the	-	11	O
novel	-	15	O
compound	-	21	O
aniracetam	-	30	O
(	-	41	O
Ro	-	42	O
13	-	45	O
-	-	47	O
5057	-	48	O
)	-	52	O
upon	-	54	O
impaired	-	59	B
learning	-	68	I
and	-	77	I
memory	-	81	I
in	-	88	O
rodents	-	91	O
.	-	98	O

The	6817363	100	O
effect	-	104	O
of	-	111	O
aniracetam	-	114	O
(	-	125	O
Ro	-	126	O
13	-	129	O
-	-	131	O
5057	-	132	O
,	-	136	O
1	-	138	O
-	-	139	O
anisoyl	-	140	O
-	-	147	O
2	-	148	O
-	-	149	O
pyrrolidinone	-	150	O
)	-	163	O
was	-	165	O
studied	-	169	O
on	-	177	O
various	-	180	O
forms	-	188	O
of	-	194	O
experimentally	-	197	O
impaired	-	212	B
cognitive	-	221	I
functions	-	231	I
(	-	241	O
learning	-	242	O
and	-	251	O
memory	-	255	O
)	-	261	O
in	-	263	O
rodents	-	266	O
and	-	274	O
produced	-	278	O
the	-	287	O
following	-	291	O
effects	-	301	O
:	-	308	O
(	-	310	O
1	-	311	O
)	-	312	O
almost	-	314	O
complete	-	321	O
prevention	-	330	O
of	-	341	O
the	-	344	O
incapacity	-	348	O
to	-	359	O
learn	-	362	O
a	-	368	O
discrete	-	370	O
escape	-	379	O
response	-	386	O
in	-	395	O
rats	-	398	O
exposed	-	403	O
to	-	411	O
sublethal	-	414	O
hypercapnia	-	424	B
immediately	-	436	O
before	-	448	O
the	-	455	O
acquisition	-	459	O
session	-	471	O
;	-	478	O
(	-	480	O
2	-	481	O
)	-	482	O
partial	-	484	O
(	-	492	O
rats	-	493	O
)	-	497	O
or	-	499	O
complete	-	502	O
(	-	511	O
mice	-	512	O
)	-	516	O
prevention	-	518	O
of	-	529	O
the	-	532	O
scopolamine	-	536	O
-	-	547	O
induced	-	548	O
short	-	556	O
-	-	561	O
term	-	562	O
amnesia	-	567	B
for	-	575	O
a	-	579	O
passive	-	581	O
avoidance	-	589	O
task	-	599	O
;	-	603	O
(	-	605	O
3	-	606	O
)	-	607	O
complete	-	609	O
protection	-	618	O
against	-	629	O
amnesia	-	637	B
for	-	645	O
a	-	649	O
passive	-	651	O
avoidance	-	659	O
task	-	669	O
in	-	674	O
rats	-	677	O
submitted	-	682	O
to	-	692	O
electroconvulsive	-	695	O
shock	-	713	O
immediately	-	719	O
after	-	731	O
avoidance	-	737	O
acquisition	-	747	O
;	-	758	O
(	-	760	O
4	-	761	O
)	-	762	O
prevention	-	764	O
of	-	775	O
the	-	778	O
long	-	782	O
-	-	786	O
term	-	787	O
retention	-	792	O
-	-	801	O
or	-	803	O
retrieval	-	806	O
-	-	815	O
deficit	-	816	O
for	-	824	O
a	-	828	O
passive	-	830	O
avoidance	-	838	O
task	-	848	O
induced	-	853	O
in	-	861	O
rats	-	864	O
and	-	869	O
mice	-	873	O
by	-	878	O
chloramphenicol	-	881	O
or	-	897	O
cycloheximide	-	900	O
administered	-	914	O
immediately	-	927	O
after	-	939	O
acquisition	-	945	O
;	-	956	O
(	-	958	O
5	-	959	O
)	-	960	O
reversal	-	962	O
,	-	970	O
when	-	972	O
administered	-	977	O
as	-	990	O
late	-	993	O
as	-	998	O
1	-	1001	O
h	-	1003	O
before	-	1005	O
the	-	1012	O
retention	-	1016	O
test	-	1026	O
,	-	1030	O
of	-	1032	O
the	-	1035	O
deficit	-	1039	O
in	-	1047	O
retention	-	1050	O
or	-	1060	O
retrieval	-	1063	O
of	-	1073	O
a	-	1076	O
passive	-	1078	O
avoidance	-	1086	O
task	-	1096	O
induced	-	1101	O
by	-	1109	O
cycloheximide	-	1112	O
injected	-	1126	O
2	-	1135	O
days	-	1137	O
previously	-	1142	O
;	-	1152	O
(	-	1154	O
6	-	1155	O
)	-	1156	O
prevention	-	1158	O
of	-	1169	O
the	-	1172	O
deficit	-	1176	O
in	-	1184	O
the	-	1187	O
retrieval	-	1191	O
of	-	1201	O
an	-	1204	O
active	-	1207	O
avoidance	-	1214	O
task	-	1224	O
induced	-	1229	O
in	-	1237	O
mice	-	1240	O
by	-	1245	O
subconvulsant	-	1248	O
electroshock	-	1262	O
or	-	1275	O
hypercapnia	-	1278	B
applied	-	1290	O
immediately	-	1298	O
before	-	1310	O
retrieval	-	1317	O
testing	-	1327	O
(	-	1335	O
24	-	1336	O
h	-	1339	O
after	-	1341	O
acquisition	-	1347	O
)	-	1358	O
.	-	1359	O

These	6817363	1361	O
improvements	-	1367	O
or	-	1380	O
normalizations	-	1383	O
of	-	1398	O
impaired	-	1401	B
cognitive	-	1410	I
functions	-	1420	I
were	-	1430	O
seen	-	1435	O
at	-	1440	O
oral	-	1443	O
aniracetam	-	1448	O
doses	-	1459	O
of	-	1465	O
10	-	1468	O
-	-	1470	O
100	-	1471	O
mg	-	1475	O
/	-	1477	O
kg	-	1478	O
.	-	1480	O

Generally	6817363	1482	O
,	-	1491	O
the	-	1493	O
dose	-	1497	O
-	-	1501	O
response	-	1502	O
curves	-	1511	O
were	-	1518	O
bell	-	1523	O
-	-	1527	O
shaped	-	1528	O
.	-	1534	O

The	6817363	1536	O
mechanisms	-	1540	O
underlying	-	1551	O
the	-	1562	O
activity	-	1566	O
of	-	1575	O
aniracetam	-	1578	O
and	-	1589	O
its	-	1593	O
'	-	1597	O
therapeutic	-	1598	O
window	-	1610	O
'	-	1616	O
are	-	1618	O
unknown	-	1622	O
.	-	1629	O

Piracetam	6817363	1631	O
,	-	1640	O
another	-	1642	O
pyrrolidinone	-	1650	O
derivative	-	1664	O
was	-	1675	O
used	-	1679	O
for	-	1684	O
comparison	-	1688	O
.	-	1698	O

It	6817363	1700	O
was	-	1703	O
active	-	1707	O
only	-	1714	O
in	-	1719	O
six	-	1722	O
of	-	1726	O
nine	-	1729	O
tests	-	1734	O
and	-	1740	O
had	-	1744	O
about	-	1748	O
one	-	1754	O
-	-	1757	O
tenth	-	1758	O
the	-	1764	O
potency	-	1768	O
of	-	1776	O
aniracetam	-	1779	O
.	-	1789	O

The	6817363	1791	O
results	-	1795	O
indicate	-	1803	O
that	-	1812	O
aniracetam	-	1817	O
improves	-	1828	O
cognitive	-	1837	O
functions	-	1847	O
which	-	1857	O
are	-	1863	O
impaired	-	1867	O
by	-	1876	O
different	-	1879	O
procedure	-	1889	O
and	-	1899	O
in	-	1903	O
different	-	1906	O
phases	-	1916	O
of	-	1923	O
the	-	1926	O
learning	-	1930	O
and	-	1939	O
memory	-	1943	O
process	-	1950	O
.	-	1957	O

Nicotine	11900788	0	O
potentiation	-	9	O
of	-	22	O
morphine	-	25	O
-	-	33	O
induced	-	34	O
catalepsy	-	42	B
in	-	52	O
mice	-	55	O
.	-	59	O

In	11900788	61	O
the	-	64	O
present	-	68	O
study	-	76	O
,	-	81	O
effects	-	83	O
of	-	91	O
nicotine	-	94	O
on	-	103	O
catalepsy	-	106	B
induced	-	116	O
by	-	124	O
morphine	-	127	O
in	-	136	O
mice	-	139	O
have	-	144	O
been	-	149	O
investigated	-	154	O
.	-	166	O

Morphine	11900788	168	O
but	-	177	O
not	-	181	O
nicotine	-	185	O
induced	-	194	O
a	-	202	O
dose	-	204	O
-	-	208	O
dependent	-	209	O
catalepsy	-	219	B
.	-	228	O

The	11900788	230	O
response	-	234	O
of	-	243	O
morphine	-	246	O
was	-	255	O
potentiated	-	259	O
by	-	271	O
nicotine	-	274	O
.	-	282	O

Intraperitoneal	11900788	284	O
administration	-	300	O
of	-	315	O
atropine	-	318	O
,	-	326	O
naloxone	-	328	O
,	-	336	O
mecamylamine	-	338	O
,	-	350	O
and	-	352	O
hexamethonium	-	356	O
to	-	370	O
mice	-	373	O
reduced	-	378	O
catalepsy	-	386	B
induced	-	396	O
by	-	404	O
a	-	407	O
combination	-	409	O
of	-	421	O
morphine	-	424	O
with	-	433	O
nicotine	-	438	O
.	-	446	O

Intracerebroventricular	11900788	448	O
injection	-	472	O
of	-	482	O
atropine	-	485	O
,	-	493	O
hexamethonium	-	495	O
,	-	508	O
and	-	510	O
naloxone	-	514	O
also	-	523	O
decreased	-	528	O
catalepsy	-	538	B
induced	-	548	O
by	-	556	O
morphine	-	559	O
plus	-	568	O
nicotine	-	573	O
.	-	581	O

Intraperitoneal	11900788	583	O
administration	-	599	O
of	-	614	O
atropine	-	617	O
,	-	625	O
but	-	627	O
not	-	631	O
intraperitoneal	-	635	O
or	-	651	O
intracerebroventricular	-	654	O
injection	-	678	O
of	-	688	O
hexamethonium	-	691	O
,	-	704	O
decreased	-	706	O
the	-	716	O
effect	-	720	O
of	-	727	O
a	-	730	O
single	-	732	O
dose	-	739	O
of	-	744	O
morphine	-	747	O
.	-	755	O

It	11900788	757	O
was	-	760	O
concluded	-	764	O
that	-	774	O
morphine	-	779	O
catalepsy	-	788	B
can	-	798	O
be	-	802	O
elicited	-	805	O
by	-	814	O
opioid	-	817	O
and	-	824	O
cholinergic	-	828	O
receptors	-	840	O
,	-	849	O
and	-	851	O
the	-	855	O
potentiation	-	859	O
of	-	872	O
morphine	-	875	O
induced	-	884	O
by	-	892	O
nicotine	-	895	O
may	-	904	O
also	-	908	O
be	-	913	O
mediated	-	916	O
through	-	925	O
cholinergic	-	933	O
receptor	-	945	O
mechanisms	-	954	O
.	-	964	O

Reduced	11230490	0	O
cardiotoxicity	-	8	B
and	-	23	O
preserved	-	27	O
antitumor	-	37	O
efficacy	-	47	O
of	-	56	O
liposome	-	59	O
-	-	67	O
encapsulated	-	68	O
doxorubicin	-	81	O
and	-	93	O
cyclophosphamide	-	97	O
compared	-	114	O
with	-	123	O
conventional	-	128	O
doxorubicin	-	141	O
and	-	153	O
cyclophosphamide	-	157	O
in	-	174	O
a	-	177	O
randomized	-	179	O
,	-	189	O
multicenter	-	191	O
trial	-	203	O
of	-	209	O
metastatic	-	212	O
breast	-	223	B
cancer	-	230	I
.	-	236	O

PURPOSE	11230490	238	O
:	-	245	O

To	11230490	247	O
determine	-	250	O
whether	-	260	O
Myocet	-	268	O
(	-	275	O
liposome	-	276	O
-	-	284	O
encapsulated	-	285	O
doxorubicin	-	298	O
;	-	309	O
The	-	311	O
Liposome	-	315	O
Company	-	324	O
,	-	331	O
Elan	-	333	O
Corporation	-	338	O
,	-	349	O
Princeton	-	351	O
,	-	360	O
NJ	-	362	O
)	-	364	O
in	-	366	O
combination	-	369	O
with	-	381	O
cyclophosphamide	-	386	O
significantly	-	403	O
reduces	-	417	O
doxorubicin	-	425	O
cardiotoxicity	-	437	B
while	-	452	O
providing	-	458	O
comparable	-	468	O
antitumor	-	479	O
efficacy	-	489	O
in	-	498	O
first	-	501	O
-	-	506	O
line	-	507	O
treatment	-	512	O
of	-	522	O
metastatic	-	525	O
breast	-	536	B
cancer	-	543	I
(	-	550	O
MBC	-	551	B
)	-	554	O
.	-	555	O

PATIENTS	11230490	557	O
AND	-	566	O
METHODS	-	570	O
:	-	577	O

Two	11230490	579	O
hundred	-	583	O
ninety	-	591	O
-	-	597	O
seven	-	598	O
patients	-	604	O
with	-	613	O
MBC	-	618	B
and	-	622	O
no	-	626	O
prior	-	629	O
chemotherapy	-	635	O
for	-	648	O
metastatic	-	652	O
disease	-	663	O
were	-	671	O
randomized	-	676	O
to	-	687	O
receive	-	690	O
either	-	698	O
60	-	705	O
mg	-	708	O
/	-	710	O
m	-	711	O
(	-	712	O
2	-	713	O
)	-	714	O
of	-	716	O
Myocet	-	719	O
(	-	726	O
M	-	727	O
)	-	728	O
or	-	730	O
conventional	-	733	O
doxorubicin	-	746	O
(	-	758	O
A	-	759	O
)	-	760	O
,	-	761	O
in	-	763	O
combination	-	766	O
with	-	778	O
600	-	783	O
mg	-	787	O
/	-	789	O
m	-	790	O
(	-	791	O
2	-	792	O
)	-	793	O
of	-	795	O
cyclophosphamide	-	798	O
(	-	815	O
C	-	816	O
)	-	817	O
,	-	818	O
every	-	820	O
3	-	826	O
weeks	-	828	O
until	-	834	O
disease	-	840	O
progression	-	848	O
or	-	860	O
unacceptable	-	863	O
toxicity	-	876	B
.	-	884	O

Cardiotoxicity	11230490	886	B
was	-	901	O
defined	-	905	O
by	-	913	O
reductions	-	916	O
in	-	927	O
left	-	930	O
-	-	934	O
ventricular	-	935	O
ejection	-	947	O
fraction	-	956	O
,	-	964	O
assessed	-	966	O
by	-	975	O
serial	-	978	O
multigated	-	985	O
radionuclide	-	996	O
angiography	-	1009	O
scans	-	1021	O
,	-	1026	O
or	-	1028	O
congestive	-	1031	B
heart	-	1042	I
failure	-	1048	I
(	-	1056	O
CHF	-	1057	B
)	-	1060	O
.	-	1061	O

Antitumor	11230490	1063	O
efficacy	-	1073	O
was	-	1082	O
assessed	-	1086	O
by	-	1095	O
objective	-	1098	O
tumor	-	1108	B
response	-	1114	O
rates	-	1123	O
(	-	1129	O
World	-	1130	O
Health	-	1136	O
Organization	-	1143	O
criteria	-	1156	O
)	-	1164	O
,	-	1165	O
time	-	1167	O
to	-	1172	O
progression	-	1175	O
,	-	1186	O
and	-	1188	O
survival	-	1192	O
.	-	1200	O

RESULTS	11230490	1202	O
:	-	1209	O

Six	11230490	1211	O
percent	-	1215	O
of	-	1223	O
MC	-	1226	O
patients	-	1229	O
versus	-	1238	O
21	-	1245	O
%	-	1247	O
(	-	1249	O
including	-	1250	O
five	-	1260	O
cases	-	1265	O
of	-	1271	O
CHF	-	1274	B
)	-	1277	O
of	-	1279	O
AC	-	1282	O
patients	-	1285	O
developed	-	1294	O
cardiotoxicity	-	1304	B
(	-	1319	O
P	-	1320	O
=	-	1322	O
.	-	1323	O
0002	-	1324	O
)	-	1328	O
.	-	1329	O

Median	11230490	1331	O
cumulative	-	1338	O
doxorubicin	-	1349	O
dose	-	1361	O
at	-	1366	O
onset	-	1369	O
was	-	1375	O
more	-	1379	O
than	-	1384	O
2	-	1389	O
,	-	1390	O
220	-	1391	O
mg	-	1395	O
/	-	1397	O
m	-	1398	O
(	-	1399	O
2	-	1400	O
)	-	1401	O
for	-	1403	O
MC	-	1407	O
versus	-	1410	O
480	-	1417	O
mg	-	1421	O
/	-	1423	O
m	-	1424	O
(	-	1425	O
2	-	1426	O
)	-	1427	O
for	-	1429	O
AC	-	1433	O
(	-	1436	O
P	-	1437	O
=	-	1439	O
.	-	1440	O
0001	-	1441	O

,	11230490	1445	O
hazard	-	1447	O
ratio	-	1454	O
,	-	1459	O
5	-	1461	O
.	-	1462	O
04	-	1463	O
)	-	1465	O
.	-	1466	O

MC	11230490	1468	O
patients	-	1471	O
also	-	1480	O
experienced	-	1485	O
less	-	1497	O
grade	-	1502	O
4	-	1508	O
neutropenia	-	1510	B
.	-	1521	O

Antitumor	11230490	1523	O
efficacy	-	1533	O
of	-	1542	O
MC	-	1545	O
versus	-	1548	O
AC	-	1555	O
was	-	1558	O
comparable	-	1562	O
:	-	1572	O
objective	-	1574	O
response	-	1584	O
rates	-	1593	O
,	-	1598	O
43	-	1600	O
%	-	1602	O
versus	-	1604	O
43	-	1611	O
%	-	1613	O
;	-	1614	O
median	-	1616	O
time	-	1623	O
to	-	1628	O
progression	-	1631	O
,	-	1642	O
5	-	1644	O
.	-	1645	O
1	-	1646	O
%	-	1647	O
versus	-	1649	O
5	-	1656	O
.	-	1657	O
5	-	1658	O
months	-	1660	O
;	-	1666	O
median	-	1668	O
time	-	1675	O
to	-	1680	O
treatment	-	1683	O
failure	-	1693	O
,	-	1700	O
4	-	1702	O
.	-	1703	O
6	-	1704	O
versus	-	1706	O
4	-	1713	O
.	-	1714	O
4	-	1715	O
months	-	1717	O
;	-	1723	O
and	-	1725	O
median	-	1729	O
survival	-	1736	O
,	-	1744	O
19	-	1746	O
versus	-	1749	O
16	-	1756	O
months	-	1759	O
.	-	1765	O

CONCLUSION	11230490	1767	O
:	-	1777	O

Myocet	11230490	1779	O
improves	-	1786	O
the	-	1795	O
therapeutic	-	1799	O
index	-	1811	O
of	-	1817	O
doxorubicin	-	1820	O
by	-	1832	O
significantly	-	1835	O
reducing	-	1849	O
cardiotoxicity	-	1858	B
and	-	1873	O
grade	-	1877	O
4	-	1883	O
neutropenia	-	1885	B
and	-	1897	O
provides	-	1901	O
comparable	-	1910	O
antitumor	-	1921	O
efficacy	-	1931	O
,	-	1939	O
when	-	1941	O
used	-	1946	O
in	-	1951	O
combination	-	1954	O
with	-	1966	O
cyclophosphamide	-	1971	O
as	-	1988	O
first	-	1991	O
-	-	1996	O
line	-	1997	O
therapy	-	2002	O
for	-	2010	O
MBC	-	2014	B
.	-	2017	O

Protective	2594614	0	O
effect	-	11	O
of	-	18	O
a	-	21	O
specific	-	23	O
platelet	-	32	O
-	-	40	O
activating	-	41	O
factor	-	52	O
antagonist	-	59	O
,	-	69	O
BN	-	71	O
52021	-	74	O
,	-	79	O
on	-	81	O
bupivacaine	-	84	O
-	-	95	O
induced	-	96	O
cardiovascular	-	104	B
impairments	-	119	I
in	-	131	O
rats	-	134	O
.	-	138	O

Administration	2594614	140	O
of	-	155	O
the	-	158	O
local	-	162	O
anaesthetic	-	168	O
bupivacaine	-	180	O
(	-	192	O
1	-	193	O
.	-	194	O
5	-	195	O
or	-	197	O
2	-	200	O
mg	-	202	O
/	-	204	O
kg	-	205	O
,	-	207	O
i	-	209	O
.	-	210	O
v	-	211	O
.	-	212	O
)	-	213	O
to	-	215	O
rats	-	218	O
elicited	-	223	O
a	-	232	O
marked	-	234	O
decrease	-	241	B
of	-	250	I
mean	-	253	I
arterial	-	258	I
blood	-	267	I
pressure	-	273	I
(	-	282	I
MBP	-	283	I
)	-	286	I
and	-	288	I
heart	-	292	I
rate	-	298	I
(	-	303	I
HR	-	304	I
)	-	306	I
leading	-	308	O
to	-	316	O
death	-	319	O
(	-	325	O
in	-	326	O
67	-	329	O
%	-	331	O
or	-	333	O
90	-	336	O
%	-	338	O
of	-	340	O
animals	-	343	O
respectively	-	351	O
)	-	363	O
.	-	364	O

Intravenous	2594614	366	O
injection	-	378	O
of	-	388	O
the	-	391	O
specific	-	395	O
platelet	-	404	O
-	-	412	O
activating	-	413	O
factor	-	424	O
(	-	431	O
PAF	-	432	O
)	-	435	O
antagonist	-	437	O
BN	-	448	O
52021	-	451	O
(	-	457	O
10	-	458	O
mg	-	461	O
/	-	463	O
kg	-	464	O
)	-	466	O
,	-	467	O
30	-	469	O
min	-	472	O
before	-	476	O
bupivacaine	-	483	O
administration	-	495	O
(	-	510	O
2	-	511	O
mg	-	513	O
/	-	515	O
kg	-	516	O
i	-	519	O
.	-	520	O
v	-	521	O
.	-	522	O
)	-	523	O
suppressed	-	525	O
both	-	536	O
the	-	541	O
decrease	-	545	B
of	-	554	I
MBP	-	557	I
and	-	561	I
HR	-	565	I
.	-	567	O

In	2594614	569	O
contrast	-	572	O
,	-	580	O
doses	-	582	O
of	-	588	O
1	-	591	O
mg	-	593	O
/	-	595	O
kg	-	596	O
BN	-	599	O
52021	-	602	O
given	-	608	O
30	-	614	O
min	-	617	O
before	-	621	O
or	-	628	O
10	-	631	O
mg	-	634	O
/	-	636	O
kg	-	637	O
administered	-	640	O
5	-	653	O
min	-	655	O
before	-	659	O
i	-	666	O
.	-	667	O
v	-	668	O
.	-	669	O

injection	2594614	671	O
of	-	681	O
bupivacaine	-	684	O
were	-	696	O
ineffective	-	701	O
.	-	712	O

When	2594614	714	O
BN	-	719	O
52021	-	722	O
(	-	728	O
20	-	729	O
mg	-	732	O
/	-	734	O
kg	-	735	O
i	-	738	O
.	-	739	O
v	-	740	O
.	-	741	O
)	-	742	O
was	-	744	O
injected	-	748	O
immediately	-	757	O
after	-	769	O
bupivacaine	-	775	O
(	-	787	O
2	-	788	O
mg	-	790	O
/	-	792	O
kg	-	793	O
)	-	795	O
,	-	796	O
a	-	798	O
partial	-	800	O
reversion	-	808	O
of	-	818	O
the	-	821	O
decrease	-	825	B
of	-	834	I
MBP	-	837	I
and	-	841	I
HR	-	845	I
was	-	848	O
observed	-	852	O
,	-	860	O
whereas	-	862	O
the	-	870	O
dose	-	874	O
of	-	879	O
10	-	882	O
mg	-	885	O
/	-	887	O
kg	-	888	O
was	-	891	O
ineffective	-	895	O
.	-	906	O

A	2594614	908	O
partial	-	910	O
recovery	-	918	O
of	-	927	O
bupivacaine	-	930	O
-	-	941	O
induced	-	942	O
ECG	-	950	O
alterations	-	954	O
was	-	966	O
observed	-	970	O
after	-	979	O
pretreatment	-	985	O
of	-	998	O
the	-	1001	O
rats	-	1005	O
with	-	1010	O
BN	-	1015	O
52021	-	1018	O
.	-	1023	O

Since	2594614	1025	O
the	-	1031	O
administration	-	1035	O
of	-	1050	O
BN	-	1053	O
52021	-	1056	O
,	-	1061	O
at	-	1063	O
all	-	1066	O
doses	-	1070	O
studied	-	1076	O
,	-	1083	O
did	-	1085	O
not	-	1089	O
alter	-	1093	O
MBP	-	1099	O
and	-	1103	O
HR	-	1107	O
at	-	1110	O
the	-	1113	O
doses	-	1117	O
used	-	1123	O
,	-	1127	O
the	-	1129	O
bulk	-	1133	O
of	-	1138	O
these	-	1141	O
results	-	1147	O
clearly	-	1155	O
demonstrate	-	1163	O
a	-	1175	O
protective	-	1177	O
action	-	1188	O
of	-	1195	O
BN	-	1198	O
52021	-	1201	O
,	-	1206	O
a	-	1208	O
specific	-	1210	O
antagonist	-	1219	O
of	-	1230	O
PAF	-	1233	O
,	-	1236	O
against	-	1238	O
bupivacaine	-	1246	O
-	-	1257	O
induced	-	1258	O
cardiovascular	-	1266	B
toxicity	-	1281	I
.	-	1289	O

Thus	2594614	1291	O
,	-	1295	O
consistent	-	1297	O
with	-	1308	O
its	-	1313	O
direct	-	1317	O
effect	-	1324	O
on	-	1331	O
heart	-	1334	O
,	-	1339	O
PAF	-	1341	O
appears	-	1345	O
to	-	1353	O
be	-	1356	O
implicated	-	1359	O
in	-	1370	O
bupivacaine	-	1373	O
-	-	1384	O
induced	-	1385	O
cardiovascular	-	1393	B
alterations	-	1408	I
.	-	1419	O

Benzylacyclouridine	2257294	0	O
reverses	-	20	O
azidothymidine	-	29	O
-	-	43	O
induced	-	44	O
marrow	-	52	B
suppression	-	59	I
without	-	71	O
impairment	-	79	O
of	-	90	O
anti	-	93	O
-	-	97	O
human	-	98	O
immunodeficiency	-	104	B
virus	-	121	O
activity	-	127	O
.	-	135	O

Increased	2257294	137	O
extracellular	-	147	O
concentrations	-	161	O
of	-	176	O
uridine	-	179	O

(	2257294	187	O
Urd	-	188	O
)	-	191	O
have	-	193	O
been	-	198	O
reported	-	203	O
to	-	212	O
reduce	-	215	O
,	-	221	O
in	-	223	O
vitro	-	226	O
,	-	231	O
azidothymidine	-	233	O
(	-	248	O
AZT	-	249	O
)	-	252	O
-	-	253	O
induced	-	254	O
inhibition	-	262	O
of	-	273	O
human	-	276	O
granulocyte	-	282	O
-	-	293	O
macrophage	-	294	O
progenitor	-	305	O
cells	-	316	O
without	-	322	O
impairment	-	330	O
of	-	341	O
its	-	344	O
antihuman	-	348	O
immunodeficiency	-	358	B
virus	-	375	O
(	-	381	O
HIV	-	382	O
)	-	385	O
activity	-	387	O
.	-	395	O

Because	2257294	397	O
of	-	405	O
the	-	408	O
clinical	-	412	O
toxicities	-	421	B
associated	-	432	O
with	-	443	O
chronic	-	448	O
Urd	-	456	O
administration	-	460	O
,	-	474	O
the	-	476	O
ability	-	480	O
of	-	488	O
benzylacyclouridine	-	491	O
(	-	511	O
BAU	-	512	O
)	-	515	O
to	-	517	O
effect	-	520	O
,	-	526	O
in	-	528	O
vivo	-	531	O
,	-	535	O
AZT	-	537	O
-	-	540	O
induced	-	541	O
anemia	-	549	B
and	-	556	O
leukopenia	-	560	B
was	-	571	O
assessed	-	575	O
.	-	583	O

This	2257294	585	O
agent	-	590	O
inhibits	-	596	O
Urd	-	605	O
catabolism	-	609	O
and	-	620	O
,	-	623	O
in	-	625	O
vivo	-	628	O
,	-	632	O
increases	-	634	O
the	-	644	O
plasma	-	648	O
concentration	-	655	O
of	-	669	O
Urd	-	672	O
in	-	676	O
a	-	679	O
dose	-	681	O
-	-	685	O
dependent	-	686	O
manner	-	696	O
,	-	702	O
without	-	704	O
Urd	-	712	O
-	-	715	O
related	-	716	O
toxicity	-	724	B
.	-	732	O

In	2257294	734	O
mice	-	737	O
rendered	-	742	O
anemic	-	751	B
and	-	758	O
leukopenic	-	762	B
by	-	773	O
the	-	776	O
administration	-	780	O
of	-	795	O
AZT	-	798	O
for	-	802	O
28	-	806	O
days	-	809	O
in	-	814	O
drinking	-	817	O
water	-	826	O
(	-	832	O
1	-	833	O
.	-	834	O
5	-	835	O
mg	-	837	O
/	-	839	O
mL	-	840	O
)	-	842	O
,	-	843	O
the	-	845	O
continued	-	849	O
administration	-	859	O
of	-	874	O
AZT	-	877	O
plus	-	881	O
daily	-	886	O
BAU	-	892	O
(	-	896	O
300	-	897	O
mg	-	901	O
/	-	903	O
kg	-	904	O
,	-	906	O
orally	-	908	O
)	-	914	O
partially	-	916	O
reversed	-	926	O
AZT	-	935	O
-	-	938	O
induced	-	939	O
anemia	-	947	B
and	-	954	O
leukopenia	-	958	B
(	-	969	O
P	-	970	O
less	-	972	O
than	-	977	O
.	-	982	O
05	-	983	O
)	-	985	O
,	-	986	O
increased	-	988	O
peripheral	-	998	O
reticulocytes	-	1009	O
(	-	1023	O
to	-	1024	O
4	-	1027	O
.	-	1028	O
9	-	1029	O
%	-	1030	O
,	-	1031	O
P	-	1033	O
less	-	1035	O
than	-	1040	O
.	-	1045	O
01	-	1046	O
)	-	1048	O
,	-	1049	O
increased	-	1051	O
cellularity	-	1061	O
in	-	1073	O
the	-	1076	O
marrow	-	1080	O
,	-	1086	O
and	-	1088	O
improved	-	1092	O
megaloblastosis	-	1101	B
.	-	1116	O

When	2257294	1118	O
coadministered	-	1123	O
with	-	1138	O
AZT	-	1143	O
from	-	1147	O
the	-	1152	O
onset	-	1156	O
of	-	1162	O
drug	-	1165	O
administration	-	1170	O
,	-	1184	O
BAU	-	1186	O
reduced	-	1190	O
AZT	-	1198	O
-	-	1201	O
induced	-	1202	O
marrow	-	1210	B
toxicity	-	1217	I
.	-	1225	O

In	2257294	1227	O
vitro	-	1230	O
,	-	1235	O
at	-	1237	O
a	-	1240	O
concentration	-	1242	O
of	-	1256	O
100	-	1259	O
mumol	-	1263	O
/	-	1268	O
L	-	1269	O
,	-	1270	O
BAU	-	1272	O
possesses	-	1276	O
minimal	-	1286	O
anti	-	1294	O
-	-	1298	O
HIV	-	1299	O
activity	-	1303	O
and	-	1312	O
has	-	1316	O
no	-	1320	O
effect	-	1323	O
on	-	1330	O
the	-	1333	O
ability	-	1337	O
of	-	1345	O
AZT	-	1348	O
to	-	1352	O
reverse	-	1355	O
the	-	1363	O
HIV	-	1367	O
-	-	1370	O
induced	-	1371	O
cytopathic	-	1379	O
effect	-	1390	O
in	-	1397	O
MT4	-	1400	O
cells	-	1404	O
.	-	1409	O

The	2257294	1411	O
clinical	-	1415	O
and	-	1424	O
biochemical	-	1428	O
implications	-	1440	O
of	-	1453	O
these	-	1456	O
findings	-	1462	O
are	-	1471	O
discussed	-	1475	O
.	-	1484	O

Cyclophosphamide	10840460	0	O
-	-	16	O
induced	-	17	O
cystitis	-	25	B
in	-	34	O
freely	-	37	O
-	-	43	O
moving	-	44	O
conscious	-	51	O
rats	-	61	O
:	-	65	O
behavioral	-	67	O
approach	-	78	O
to	-	87	O
a	-	90	O
new	-	92	O
model	-	96	O
of	-	102	O
visceral	-	105	B
pain	-	114	I
.	-	118	O

PURPOSE	10840460	120	O
:	-	127	O

To	10840460	129	O
develop	-	132	O
a	-	140	O
model	-	142	O
of	-	148	O
visceral	-	151	B
pain	-	160	I
in	-	165	O
rats	-	168	O
using	-	173	O
a	-	179	O
behavioral	-	181	O
approach	-	192	O
.	-	200	O

Cyclophosphamide	10840460	202	O
(	-	219	O
CP	-	220	O
)	-	222	O
,	-	223	O
an	-	225	O
antitumoral	-	228	O
agent	-	240	O
known	-	246	O
to	-	252	O
produce	-	255	O
toxic	-	263	O
effects	-	269	O
on	-	277	O
the	-	280	O
bladder	-	284	O
wall	-	292	O
through	-	297	O
its	-	305	O
main	-	309	O
toxic	-	314	O
metabolite	-	320	O
acrolein	-	331	O
,	-	339	O
was	-	341	O
used	-	345	O
to	-	350	O
induce	-	353	O
cystitis	-	360	B
.	-	368	O

MATERIALS	10840460	370	O
AND	-	380	O
METHODS	-	384	O
:	-	391	O

CP	10840460	393	O
was	-	396	O
administered	-	400	O
at	-	413	O
doses	-	416	O
of	-	422	O
50	-	425	O
,	-	427	O
100	-	429	O
and	-	433	O
200	-	437	O
mg	-	441	O
.	-	443	O
/	-	444	O
kg	-	445	O
.	-	447	O

i	10840460	449	O
.	-	450	O
p	-	451	O
.	-	452	O

to	10840460	454	O
male	-	457	O
rats	-	462	O
,	-	466	O
and	-	468	O
their	-	472	O
behavior	-	478	O
observed	-	487	O
and	-	496	O
scored	-	500	O
.	-	506	O

The	10840460	508	O
effects	-	512	O
of	-	520	O
morphine	-	523	O
(	-	532	O
0	-	533	O
.	-	534	O
5	-	535	O
to	-	537	O
4	-	540	O
mg	-	542	O
.	-	544	O
/	-	545	O
kg	-	546	O
.	-	548	O
i	-	550	O
.	-	551	O
v	-	552	O
.	-	553	O
)	-	554	O
on	-	556	O
CP	-	559	O
-	-	561	O
induced	-	562	O
behavioral	-	570	O
modifications	-	581	O
were	-	595	O
tested	-	600	O
administered	-	607	O
alone	-	620	O
and	-	626	O
after	-	630	O
naloxone	-	636	O
(	-	645	O
1	-	646	O
mg	-	648	O
.	-	650	O
/	-	651	O
kg	-	652	O
.	-	654	O
s	-	656	O
.	-	657	O
c	-	658	O
.	-	659	O
)	-	660	O
.	-	661	O

In	10840460	663	O
addition	-	666	O
,	-	674	O
90	-	676	O
minutes	-	679	O
after	-	687	O
CP	-	693	O
injection	-	696	O
,	-	705	O
that	-	707	O
is	-	712	O
,	-	714	O
at	-	716	O
the	-	719	O
time	-	723	O
of	-	728	O
administration	-	731	O
of	-	746	O
morphine	-	749	O
,	-	757	O
the	-	759	O
bladder	-	763	O
was	-	771	O
removed	-	775	O
in	-	783	O
some	-	786	O
rats	-	791	O
for	-	796	O
histological	-	800	O
examination	-	813	O
.	-	824	O

Finally	10840460	826	O
,	-	833	O
to	-	835	O
show	-	838	O
that	-	843	O
the	-	848	O
bladder	-	852	O
is	-	860	O
essential	-	863	O
for	-	873	O
the	-	877	O
CP	-	881	O
-	-	883	O
induced	-	884	O
behavioral	-	892	O
modifications	-	903	O
,	-	916	O
female	-	918	O
rats	-	925	O
also	-	930	O
received	-	935	O
CP	-	944	O
at	-	947	O
doses	-	950	O
of	-	956	O
200	-	959	O
mg	-	963	O
.	-	965	O
/	-	966	O
kg	-	967	O
.	-	969	O

i	10840460	971	O
.	-	972	O
p	-	973	O
.	-	974	O

and	10840460	976	O
of	-	980	O
20	-	983	O
mg	-	986	O
.	-	988	O

by	10840460	990	O
the	-	993	O
intravesical	-	997	O
route	-	1010	O
,	-	1015	O
and	-	1017	O
acrolein	-	1021	O
at	-	1030	O
doses	-	1033	O
of	-	1039	O
0	-	1042	O
.	-	1043	O
5	-	1044	O
mg	-	1046	O
.	-	1048	O

by	10840460	1050	O
the	-	1053	O
intravesical	-	1057	O
route	-	1070	O
and	-	1076	O
of	-	1080	O
5	-	1083	O
mg	-	1085	O
.	-	1087	O
/	-	1088	O
kg	-	1089	O
.	-	1091	O
i	-	1093	O
.	-	1094	O
v	-	1095	O
.	-	1096	O

RESULTS	10840460	1098	O
:	-	1105	O

CP	10840460	1107	O
dose	-	1110	O
-	-	1114	O
relatedly	-	1115	O
induced	-	1125	O
marked	-	1133	O
behavioral	-	1140	O
modifications	-	1151	O
in	-	1165	O
male	-	1168	O
rats	-	1173	O
:	-	1177	O
breathing	-	1179	O
rate	-	1189	O
decrease	-	1194	O
,	-	1202	O
closing	-	1204	O
of	-	1212	O
the	-	1215	O
eyes	-	1219	O
and	-	1224	O
occurrence	-	1228	O
of	-	1239	O
specific	-	1242	O
postures	-	1251	O
.	-	1259	O

Morphine	10840460	1261	O
dose	-	1270	O
-	-	1274	O
dependently	-	1275	O
reversed	-	1287	O
these	-	1296	O
behavioral	-	1302	B
disorders	-	1313	I
.	-	1322	O

A	10840460	1324	O
dose	-	1326	O
of	-	1331	O
0	-	1334	O
.	-	1335	O
5	-	1336	O
mg	-	1338	O
.	-	1340	O
/	-	1341	O
kg	-	1342	O
.	-	1344	O
produced	-	1346	O
a	-	1355	O
reduction	-	1357	O
of	-	1367	O
almost	-	1370	O
50	-	1377	O
%	-	1379	O
of	-	1381	O
the	-	1384	O
behavioral	-	1388	O
score	-	1399	O
induced	-	1405	O
by	-	1413	O
CP	-	1416	O
200	-	1419	O
mg	-	1423	O
.	-	1425	O
/	-	1426	O
kg	-	1427	O
.	-	1429	O

This	10840460	1431	O
effect	-	1436	O
was	-	1443	O
completely	-	1447	O
prevented	-	1458	O
by	-	1468	O
pretreatment	-	1471	O
with	-	1484	O
naloxone	-	1489	O
.	-	1497	O

At	10840460	1499	O
the	-	1502	O
time	-	1506	O
of	-	1511	O
administration	-	1514	O
of	-	1529	O
morphine	-	1532	O
,	-	1540	O
histological	-	1542	O
modifications	-	1555	O
of	-	1569	O
the	-	1572	O
bladder	-	1576	O
wall	-	1584	O
,	-	1588	O
such	-	1590	O
as	-	1595	O
chorionic	-	1598	O
and	-	1608	O
muscle	-	1612	O
layer	-	1619	O
edema	-	1625	B
,	-	1630	O
were	-	1632	O
observed	-	1637	O
.	-	1645	O

In	10840460	1647	O
female	-	1650	O
rats	-	1657	O
,	-	1661	O
CP	-	1663	O
200	-	1666	O
mg	-	1670	O
.	-	1672	O
/	-	1673	O
kg	-	1674	O
.	-	1676	O

i	10840460	1678	O
.	-	1679	O
p	-	1680	O
.	-	1681	O

produced	10840460	1683	O
the	-	1692	O
same	-	1696	O
marked	-	1701	O
behavioral	-	1708	O
modifications	-	1719	O
as	-	1733	O
those	-	1736	O
observed	-	1742	O
in	-	1751	O
male	-	1754	O
rats	-	1759	O
.	-	1763	O

Administered	10840460	1765	O
at	-	1778	O
the	-	1781	O
dose	-	1785	O
of	-	1790	O
20	-	1793	O
mg	-	1796	O
.	-	1798	O

intravesically	10840460	1800	O
,	-	1814	O
CP	-	1816	O
did	-	1819	O
not	-	1823	O
produce	-	1827	O
any	-	1835	O
behavioral	-	1839	O
effects	-	1850	O
,	-	1857	O
whereas	-	1859	O
acrolein	-	1867	O
at	-	1876	O
0	-	1879	O
.	-	1880	O
5	-	1881	O
mg	-	1883	O
.	-	1885	O

intravesically	10840460	1887	O
induced	-	1902	O
behavioral	-	1910	O
modifications	-	1921	O
identical	-	1935	O
to	-	1945	O
those	-	1948	O
under	-	1954	O
CP	-	1960	O
200	-	1963	O
mg	-	1967	O
.	-	1969	O
/	-	1970	O
kg	-	1971	O
.	-	1973	O

i	10840460	1975	O
.	-	1976	O
p	-	1977	O
.	-	1978	O

,	10840460	1979	O
with	-	1981	O
the	-	1986	O
same	-	1990	O
maximal	-	1995	O
levels	-	2003	O
.	-	2009	O

Conversely	10840460	2011	O
,	-	2021	O
acrolein	-	2023	O
5	-	2032	O
mg	-	2034	O
.	-	2036	O
/	-	2037	O
kg	-	2038	O
.	-	2040	O
i	-	2042	O
.	-	2043	O
v	-	2044	O
.	-	2045	O
did	-	2047	O
not	-	2051	O
produce	-	2055	O
any	-	2063	O
behavioral	-	2067	O
effects	-	2078	O
at	-	2086	O
all	-	2089	O
.	-	2092	O

CONCLUSIONS	10840460	2094	O
:	-	2105	O

Overall	10840460	2107	O
,	-	2114	O
these	-	2116	O
results	-	2122	O
indicate	-	2130	O
that	-	2139	O
this	-	2144	O
experimental	-	2149	O
model	-	2162	O
of	-	2168	O
CP	-	2171	O
-	-	2173	O
induced	-	2174	O
cystitis	-	2182	B
may	-	2191	O
be	-	2195	O
an	-	2198	O
interesting	-	2201	O
new	-	2213	O
behavioral	-	2217	O
model	-	2228	O
of	-	2234	O
inflammatory	-	2237	O
visceral	-	2250	B
pain	-	2259	I
,	-	2263	O
allowing	-	2265	O
a	-	2274	O
better	-	2276	O
understanding	-	2283	O
of	-	2297	O
these	-	2300	O
painful	-	2306	B
syndromes	-	2314	I
and	-	2324	O
thus	-	2328	O
a	-	2333	O
better	-	2335	O
therapeutic	-	2342	O
approach	-	2354	O
to	-	2363	O
them	-	2366	O
.	-	2370	O

Hyperalgesia	8278214	0	B
and	-	13	O
myoclonus	-	17	B
in	-	27	O
terminal	-	30	O
cancer	-	39	B
patients	-	46	O
treated	-	55	O
with	-	63	O
continuous	-	68	O
intravenous	-	79	O
morphine	-	91	O
.	-	99	O

Eight	8278214	101	O
cancer	-	107	B
patients	-	114	O
in	-	123	O
the	-	126	O
terminal	-	130	O
stages	-	139	O
of	-	146	O
the	-	149	O
disease	-	153	O
treated	-	161	O
with	-	169	O
high	-	174	O
doses	-	179	O
of	-	185	O
intravenous	-	188	O
morphine	-	200	O
developed	-	209	O
hyperalgesia	-	219	B
.	-	231	O

All	8278214	233	O
cases	-	237	O
were	-	243	O
retrospectively	-	248	O
sampled	-	264	O
from	-	272	O
three	-	277	O
different	-	283	O
hospitals	-	293	O
in	-	303	O
Copenhagen	-	306	O
.	-	316	O

Five	8278214	318	O
patients	-	323	O
developed	-	332	O
universal	-	342	O
hyperalgesia	-	352	B
and	-	365	O
hyperesthesia	-	369	B
which	-	383	O
in	-	389	O
2	-	392	O
cases	-	394	O
were	-	400	O
accompanied	-	405	O
by	-	417	O
myoclonus	-	420	B
.	-	429	O

In	8278214	431	O
3	-	434	O
patients	-	436	O
a	-	445	O
pre	-	447	O
-	-	450	O
existing	-	451	O
neuralgia	-	460	B
increased	-	470	O
to	-	480	O
excruciating	-	483	O
intensity	-	496	O
and	-	506	O
in	-	510	O
2	-	513	O
of	-	515	O
these	-	518	O
cases	-	524	O
myoclonus	-	530	B
occurred	-	540	O
simultaneously	-	549	O
.	-	563	O

Although	8278214	565	O
only	-	574	O
few	-	579	O
clinical	-	583	O
descriptions	-	592	O
of	-	605	O
the	-	608	O
relationship	-	612	O
between	-	625	O
hyperalgesia	-	633	B
/	-	645	O
myoclonus	-	646	B
and	-	656	O
high	-	660	O
doses	-	665	O
of	-	671	O
morphine	-	674	O
are	-	683	O
available	-	687	O
,	-	696	O
experimental	-	698	O
support	-	711	O
from	-	719	O
animal	-	724	O
studies	-	731	O
indicates	-	739	O
that	-	749	O
morphine	-	754	O
,	-	762	O
or	-	764	O
its	-	767	O
metabolites	-	771	O
,	-	782	O
plays	-	784	O
a	-	790	O
causative	-	792	O
role	-	802	O
for	-	807	O
the	-	811	O
observed	-	815	O
behavioural	-	824	O
syndrome	-	836	O
.	-	844	O

The	8278214	846	O
possible	-	850	O
mechanisms	-	859	O
are	-	870	O
discussed	-	874	O
and	-	884	O
treatment	-	888	O
proposals	-	898	O
given	-	908	O
suggesting	-	914	O
the	-	925	O
use	-	929	O
of	-	933	O
more	-	936	O
efficacious	-	941	O
opioids	-	953	O
with	-	961	O
less	-	966	O
excitatory	-	971	O
potency	-	982	O
in	-	990	O
these	-	993	O
situations	-	999	O
.	-	1009	O

A	3934126	0	O
prospective	-	2	O
study	-	14	O
of	-	20	O
adverse	-	23	O
reactions	-	31	O
associated	-	41	O
with	-	52	O
vancomycin	-	57	O
therapy	-	68	O
.	-	75	O

A	3934126	77	O
prospective	-	79	O
evaluation	-	91	O
of	-	102	O
the	-	105	O
efficacy	-	109	O
and	-	118	O
safety	-	122	O
of	-	129	O
vancomycin	-	132	O
was	-	143	O
conducted	-	147	O
in	-	157	O
54	-	160	O
consecutive	-	163	O
patients	-	175	O
over	-	184	O
a	-	189	O
16	-	191	O
-	-	193	O
month	-	194	O
period	-	200	O
.	-	206	O

Vancomycin	3934126	208	O
was	-	219	O
curative	-	223	O
in	-	232	O
95	-	235	O
%	-	237	O
of	-	239	O
43	-	242	O
patients	-	245	O
with	-	254	O
proven	-	259	O
infection	-	266	B
.	-	275	O

Drugs	3934126	277	O
were	-	283	O
ceased	-	288	O
in	-	295	O
six	-	298	O
patients	-	302	O
because	-	311	O
of	-	319	O
adverse	-	322	O
reactions	-	330	O
;	-	339	O
in	-	341	O
three	-	344	O
of	-	350	O
these	-	353	O
vancomycin	-	359	O
was	-	370	O
considered	-	374	O
the	-	385	O
likely	-	389	O
cause	-	396	O
.	-	401	O

Reactions	3934126	403	O
included	-	413	O
thrombophlebitis	-	422	B
(	-	439	O
20	-	440	O
of	-	443	O
54	-	446	O
patients	-	449	O
)	-	457	O
,	-	458	O
rash	-	460	B
(	-	465	O
4	-	466	O
of	-	468	O
54	-	471	O
)	-	473	O
,	-	474	O
nephrotoxicity	-	476	B
(	-	491	O
4	-	492	O
of	-	494	O
50	-	497	O
)	-	499	O
,	-	500	O
proteinuria	-	502	B
(	-	514	O
1	-	515	O
of	-	517	O
50	-	520	O
)	-	522	O
and	-	524	O
ototoxicity	-	528	B
(	-	540	O
1	-	541	O
of	-	543	O
11	-	546	O
patients	-	549	O
tested	-	558	O
by	-	565	O
audiometry	-	568	O
)	-	578	O
.	-	579	O

Thrombophlebitis	3934126	581	B
occurred	-	598	O
only	-	607	O
with	-	612	O
infusion	-	617	O
through	-	626	O
peripheral	-	634	O
cannulae	-	645	O
;	-	653	O
nephrotoxicity	-	655	B
and	-	670	O
ototoxicity	-	674	B
were	-	686	O
confined	-	691	O
to	-	700	O
patients	-	703	O
receiving	-	712	O
an	-	722	O
aminoglycoside	-	725	O
plus	-	740	O
vancomycin	-	745	O
.	-	755	O

We	3934126	757	O
conclude	-	760	O
that	-	769	O
vancomycin	-	774	O
,	-	784	O
administered	-	786	O
appropriately	-	799	O
,	-	812	O
constitutes	-	814	O
safe	-	826	O
,	-	830	O
effective	-	832	O
therapy	-	842	O
for	-	850	O
infections	-	854	B
caused	-	865	O
by	-	872	O
susceptible	-	875	O
bacteria	-	887	O
.	-	895	O

Blockade	1687392	0	O
of	-	9	O
both	-	12	O
D	-	17	O
-	-	18	O
1	-	19	O
and	-	21	O
D	-	25	O
-	-	26	O
2	-	27	O
dopamine	-	29	O
receptors	-	38	O
may	-	48	O
induce	-	52	O
catalepsy	-	59	B
in	-	69	O
mice	-	72	O
.	-	76	O

1	1687392	78	O
.	-	79	O

The	1687392	81	O
catalepsy	-	85	B
induced	-	95	O
by	-	103	O
dopamine	-	106	O
antagonists	-	115	O
has	-	127	O
been	-	131	O
tested	-	136	O
and	-	143	O
the	-	147	O
possible	-	151	O
dopamine	-	160	O
subtypes	-	169	O
involved	-	178	O
in	-	187	O
catalepsy	-	190	B
was	-	200	O
determined	-	204	O
.	-	214	O

2	1687392	216	O
.	-	217	O

Dopamine	1687392	219	O
antagonist	-	228	O
fluphenazine	-	239	O
,	-	251	O
D	-	253	O
-	-	254	O
1	-	255	O
antagonist	-	257	O
SCH	-	268	O
23390	-	272	O
or	-	278	O
D	-	281	O
-	-	282	O
2	-	283	O
antagonist	-	285	O
sulpiride	-	296	O
induced	-	306	O
catalepsy	-	314	B
.	-	323	O

The	1687392	325	O
effect	-	329	O
of	-	336	O
fluphenazine	-	339	O
and	-	352	O
sulpiride	-	356	O
was	-	366	O
dose	-	370	O
-	-	374	O
dependent	-	375	O
.	-	384	O

Combination	1687392	386	O
of	-	398	O
SCH	-	401	O
23390	-	405	O
with	-	411	O
sulpiride	-	416	O
did	-	426	O
not	-	430	O
induce	-	434	O
catalepsy	-	441	B
potentiation	-	451	O
.	-	463	O

3	1687392	465	O
.	-	466	O
D	-	468	O
-	-	469	O
1	-	470	O

agonist	1687392	472	O
SKF	-	480	O
38393	-	484	O
or	-	490	O
D	-	493	O
-	-	494	O
2	-	495	O
agonist	-	497	O
quinpirole	-	505	O
decreased	-	516	O
the	-	526	O
catalepsy	-	530	B
induced	-	540	O
by	-	548	O
fluphenazine	-	551	O
,	-	563	O
SCH	-	565	O
23390	-	569	O
or	-	575	O
sulpiride	-	578	O
.	-	587	O

4	1687392	589	O
.	-	590	O

Combination	1687392	592	O
of	-	604	O
SKF	-	607	O
38393	-	611	O
with	-	617	O
quinpirole	-	622	O
did	-	633	O
not	-	637	O
cause	-	641	O
potentiated	-	647	O
inhibitory	-	659	O
effect	-	670	O
on	-	677	O
catalepsy	-	680	B
induced	-	690	O
by	-	698	O
dopamine	-	701	O
antagonists	-	710	O
.	-	721	O

5	1687392	723	O
.	-	724	O

The	1687392	726	O
data	-	730	O
may	-	735	O
indicate	-	739	O
that	-	748	O
although	-	753	O
D	-	762	O
-	-	763	O
2	-	764	O
receptor	-	766	O
blockade	-	775	O
is	-	784	O
involved	-	787	O
in	-	796	O
catalepsy	-	799	B
,	-	808	O
the	-	810	O
D	-	814	O
-	-	815	O
1	-	816	O
receptor	-	818	O
may	-	827	O
plan	-	831	O
a	-	836	O
role	-	838	O
.	-	842	O

Dextran	19719056	0	O
-	-	7	O
etodolac	-	8	O
conjugates	-	17	O
:	-	27	O
synthesis	-	29	O
,	-	38	O
in	-	40	O
vitro	-	43	O
and	-	49	O
in	-	53	O
vivo	-	56	O
evaluation	-	61	O
.	-	71	O

Etodolac	19719056	73	O
(	-	82	O
E	-	83	O
)	-	84	O
,	-	85	O
is	-	87	O
a	-	90	O
non	-	92	O
-	-	95	O
narcotic	-	96	O
analgesic	-	105	O
and	-	115	O
antiinflammatory	-	119	O
drug	-	136	O
.	-	140	O

A	19719056	142	O
biodegradable	-	144	O
polymer	-	158	O
dextran	-	166	O
has	-	174	O
been	-	178	O
utilized	-	183	O
as	-	192	O
a	-	195	O
carrier	-	197	O
for	-	205	O
synthesis	-	209	O
of	-	219	O
etodolac	-	222	O
-	-	230	O
dextran	-	231	O
conjugates	-	239	O
(	-	250	O
ED	-	251	O
)	-	253	O
to	-	255	O
improve	-	258	O
its	-	266	O
aqueous	-	270	O
solubility	-	278	O
and	-	289	O
reduce	-	293	O
gastrointestinal	-	300	O
side	-	317	O
effects	-	322	O
.	-	329	O

An	19719056	331	O
activated	-	334	O
moiety	-	344	O
,	-	350	O
i	-	352	O
.	-	353	O
e	-	354	O
.	-	355	O
N	-	357	O
-	-	358	O
acylimidazole	-	359	O
derivative	-	373	O
of	-	384	O
etodolac	-	387	O
(	-	396	O
EAI	-	397	O
)	-	400	O
,	-	401	O
was	-	403	O
condensed	-	407	O
with	-	417	O
the	-	422	O
polysaccharide	-	426	O
polymer	-	441	O
dextran	-	449	O
of	-	457	O
different	-	460	O
molecular	-	470	O
weights	-	480	O
(	-	488	O
40000	-	489	O
,	-	494	O
60000	-	496	O
,	-	501	O
110000	-	503	O
and	-	510	O
200000	-	514	O
)	-	520	O
.	-	521	O

IR	19719056	523	O
spectral	-	526	O
data	-	535	O
confirmed	-	540	O
formation	-	550	O
of	-	560	O
ester	-	563	O
bonding	-	569	O
in	-	577	O
the	-	580	O
conjugates	-	584	O
.	-	594	O

Etodolac	19719056	596	O
contents	-	605	O
were	-	614	O
evaluated	-	619	O
by	-	629	O
UV	-	632	O
-	-	634	O
spectrophotometric	-	635	O
analysis	-	654	O
.	-	662	O

The	19719056	664	O
molecular	-	668	O
weights	-	678	O
were	-	686	O
determined	-	691	O
by	-	702	O
measuring	-	705	O
viscosity	-	715	O
using	-	725	O
the	-	731	O
Mark	-	735	O
-	-	739	O
Howink	-	740	O
-	-	746	O
Sakurada	-	747	O
equation	-	756	O
.	-	764	O

In	19719056	766	O
vitro	-	769	O
hydrolysis	-	775	O
of	-	786	O
ED	-	789	O
was	-	792	O
done	-	796	O
in	-	801	O
aqueous	-	804	O
buffers	-	812	O
(	-	820	O
pH	-	821	O
1	-	824	O
.	-	825	O
2	-	826	O
,	-	827	O
7	-	829	O
.	-	830	O
4	-	831	O
,	-	832	O
9	-	834	O
)	-	835	O
and	-	837	O
in	-	841	O
80	-	844	O
%	-	846	O
(	-	848	O
v	-	849	O
/	-	850	O
v	-	851	O
)	-	852	O
human	-	854	O
plasma	-	860	O
(	-	867	O
pH	-	868	O
7	-	871	O
.	-	872	O
4	-	873	O
)	-	874	O
.	-	875	O

At	19719056	877	O
pH	-	880	O
9	-	883	O
,	-	884	O
a	-	886	O
higher	-	888	O
rate	-	895	O
of	-	900	O
etodolac	-	903	O
release	-	912	O
from	-	920	O
ED	-	925	O
was	-	928	O
observed	-	932	O
as	-	941	O
compared	-	944	O
to	-	953	O
aqueous	-	956	O
buffer	-	964	O
of	-	971	O
pH	-	974	O
7	-	977	O
.	-	978	O
4	-	979	O
and	-	981	O
80	-	985	O
%	-	987	O
human	-	989	O
plasma	-	995	O
(	-	1002	O
pH	-	1003	O
7	-	1006	O
.	-	1007	O
4	-	1008	O
)	-	1009	O
,	-	1010	O
following	-	1012	O
first	-	1022	O
-	-	1027	O
order	-	1028	O
kinetics	-	1034	O
.	-	1042	O

In	19719056	1044	O
vivo	-	1047	O
investigations	-	1052	O
were	-	1067	O
performed	-	1072	O
in	-	1082	O
animals	-	1085	O
.	-	1092	O

Acute	19719056	1094	O
analgesic	-	1100	O
and	-	1110	O
antiinflammatory	-	1114	O
activities	-	1131	O
were	-	1142	O
ascertained	-	1147	O
using	-	1159	O
acetic	-	1165	O
acid	-	1172	O
induced	-	1177	O
writhing	-	1185	B
model	-	1194	O
(	-	1200	O
mice	-	1201	O
)	-	1205	O
and	-	1207	O
carrageenan	-	1211	O
-	-	1222	O
induced	-	1223	O
rat	-	1231	O
paw	-	1235	O
edema	-	1239	B
model	-	1245	O
,	-	1250	O
respectively	-	1252	O
.	-	1264	O

In	19719056	1266	O
comparison	-	1269	O
to	-	1280	O
control	-	1283	O
,	-	1290	O
E	-	1292	O
and	-	1294	O
ED1	-	1298	O
-	-	1301	O
ED4	-	1302	O
showed	-	1306	O
highly	-	1313	O
significant	-	1320	O
analgesic	-	1332	O
and	-	1342	O
antiinflammatory	-	1346	O
activities	-	1363	O
(	-	1374	O
p	-	1375	O
<	-	1377	O
0	-	1378	O
.	-	1379	O
001	-	1380	O
)	-	1383	O
.	-	1384	O

Biological	19719056	1386	O
evaluation	-	1397	O
suggested	-	1408	O
that	-	1418	O
conjugates	-	1423	O
(	-	1434	O
ED1	-	1435	O
-	-	1438	O
ED4	-	1439	O
)	-	1442	O
retained	-	1444	O
comparable	-	1453	O
analgesic	-	1464	O
and	-	1474	O
antiinflammatory	-	1478	O
activities	-	1495	O
with	-	1506	O
remarkably	-	1511	O
reduced	-	1522	O
ulcerogenicity	-	1530	O
as	-	1545	O
compared	-	1548	O
to	-	1557	O
their	-	1560	O
parent	-	1566	O
drug	-	1573	O
-	-	1577	O
-	-	1578	O
etodolac	-	1579	O
.	-	1587	O

Hypersensitivity	15266362	0	B
myocarditis	-	17	B
complicating	-	29	O
hypertrophic	-	42	B
cardiomyopathy	-	55	I
heart	-	70	O
.	-	75	O

The	15266362	77	O
present	-	81	O
report	-	89	O
describes	-	96	O
a	-	106	O
case	-	108	O
of	-	113	O
eosinophilic	-	116	B
myocarditis	-	129	I
complicating	-	141	O
hypertrophic	-	154	B
cardiomyopathy	-	167	I
.	-	181	O

The	15266362	183	O
47	-	187	O
-	-	189	O
year	-	190	O
-	-	194	O
old	-	195	O
female	-	199	O
patient	-	206	O
,	-	213	O
known	-	215	O
to	-	221	O
have	-	224	O
hypertrophic	-	229	B
cardiomyopathy	-	242	I
,	-	256	O
was	-	258	O
admitted	-	262	O
with	-	271	O
biventricular	-	276	B
failure	-	290	I
and	-	298	O
managed	-	302	O
aggressively	-	310	O
with	-	323	O
dobutamine	-	328	O
infusion	-	339	O
and	-	348	O
other	-	352	O
drugs	-	358	O
while	-	364	O
being	-	370	O
assessed	-	376	O
for	-	385	O
heart	-	389	O
transplantation	-	395	O
.	-	410	O

On	15266362	412	O
transthoracic	-	415	O
echocardiogram	-	429	O
,	-	443	O
she	-	445	O
had	-	449	O
moderate	-	453	O
left	-	462	B
ventricular	-	467	I
dysfunction	-	479	I
with	-	491	O
regional	-	496	O
variability	-	505	O
and	-	517	O
moderate	-	521	O
mitral	-	530	B
regurgitation	-	537	I
.	-	550	O

The	15266362	552	O
recipient	-	556	O
's	-	565	O
heart	-	568	O
showed	-	574	O
the	-	581	O
features	-	585	O
of	-	594	O
apical	-	597	O
hypertrophic	-	604	B
cardiomyopathy	-	617	I
and	-	632	O
myocarditis	-	636	B
with	-	648	O
abundant	-	653	O
eosinophils	-	662	O
.	-	673	O

Myocarditis	15266362	675	B
is	-	687	O
rare	-	690	O
and	-	695	O
eosinophilic	-	699	B
myocarditis	-	712	I
is	-	724	O
rarer	-	727	O
.	-	732	O

It	15266362	734	O
is	-	737	O
likely	-	740	O
that	-	747	O
the	-	752	O
hypersensitivity	-	756	B
(	-	773	O
eosinophilic	-	774	B
)	-	786	O
myocarditis	-	788	B
was	-	800	O
related	-	804	O
to	-	812	O
dobutamine	-	815	O
infusion	-	826	O
therapy	-	835	O
.	-	842	O

Eosinophilic	15266362	844	B
myocarditis	-	857	I
has	-	869	O
been	-	873	O
reported	-	878	O
with	-	887	O
an	-	892	O
incidence	-	895	O
of	-	905	O
2	-	908	O
.	-	909	O
4	-	910	O
%	-	911	O
to	-	913	O
7	-	916	O
.	-	917	O
2	-	918	O
%	-	919	O
in	-	921	O
explanted	-	924	O
hearts	-	934	O
and	-	941	O
may	-	945	O
be	-	949	O
related	-	952	O
to	-	960	O
multidrug	-	963	O
therapy	-	973	O
.	-	980	O

All	14648024	0	O
-	-	3	O
trans	-	5	O
-	-	10	O
retinoic	-	11	O
acid	-	20	O
-	-	24	O
induced	-	25	O
erythema	-	33	B
nodosum	-	42	I
in	-	50	O
patients	-	53	O
with	-	62	O
acute	-	67	B
promyelocytic	-	73	I
leukemia	-	87	I
.	-	95	O

Erythema	14648024	97	B
nodosum	-	106	I
associated	-	114	O
with	-	125	O
all	-	130	O
-	-	133	O
trans	-	135	O
-	-	140	O
retinoic	-	141	O
acid	-	150	O
(	-	155	O
ATRA	-	156	O
)	-	160	O
for	-	162	O
acute	-	166	B
promyelocytic	-	172	I
leukemia	-	186	I
(	-	195	O
APL	-	196	B
)	-	199	O
is	-	201	O
very	-	204	O
rare	-	209	O
.	-	213	O

We	14648024	215	O
describe	-	218	O
four	-	227	O
patients	-	232	O
with	-	241	O
classic	-	246	O
APL	-	254	B
who	-	258	O
developed	-	262	O
erythema	-	272	B
nodosum	-	281	I
during	-	289	O
ATRA	-	296	O
therapy	-	301	O
.	-	308	O

Fever	14648024	310	B
and	-	316	O
subsequent	-	320	O
multiple	-	331	O
painful	-	340	B
erythematous	-	348	B
nodules	-	361	I
over	-	369	O
extremities	-	374	O
developed	-	386	O
on	-	396	O
D11	-	399	O
,	-	402	O
D16	-	404	O
,	-	407	O
D17	-	409	O
,	-	412	O
and	-	414	O
D19	-	418	O
,	-	421	O
respectively	-	423	O
,	-	435	O
after	-	437	O
ATRA	-	443	O
therapy	-	448	O
.	-	455	O

The	14648024	457	O
skin	-	461	O
biopsy	-	466	O
taken	-	473	O
from	-	479	O
each	-	484	O
patient	-	489	O
was	-	497	O
consistent	-	501	O
with	-	512	O
erythema	-	517	B
nodosum	-	526	I
.	-	533	O

All	14648024	535	O
patients	-	539	O
received	-	548	O
short	-	557	O
course	-	563	O
of	-	570	O
steroids	-	573	O
.	-	581	O

Fever	14648024	583	B
subsided	-	589	O
rapidly	-	598	O
and	-	606	O
the	-	610	O
skin	-	614	O
lesions	-	619	O
regressed	-	627	O
completely	-	637	O
.	-	647	O

All	14648024	649	O
patients	-	653	O
achieved	-	662	O
complete	-	671	O
remission	-	680	O
without	-	690	O
withdrawal	-	698	O
of	-	709	O
ATRA	-	712	O
.	-	716	O

ATRA	14648024	718	O
seemed	-	723	O
to	-	730	O
be	-	733	O
the	-	736	O
most	-	740	O
possible	-	745	O
etiology	-	754	O
of	-	763	O
erythema	-	766	B
nodosum	-	775	I
in	-	783	O
our	-	786	O
patients	-	790	O
.	-	798	O

Short	14648024	800	O
-	-	805	O
term	-	806	O
use	-	811	O
of	-	815	O
steroid	-	818	O
is	-	826	O
very	-	829	O
effective	-	834	O
in	-	844	O
ATRA	-	847	O
-	-	851	O
induced	-	852	O
erythema	-	860	B
nodosum	-	869	I
.	-	876	O

Delayed	11827497	0	O
-	-	7	O
onset	-	8	O
heparin	-	14	O
-	-	21	O
induced	-	22	O
thrombocytopenia	-	30	B
.	-	46	O

BACKGROUND	11827497	48	O
:	-	58	O

Heparin	11827497	60	O
-	-	67	O
induced	-	68	O
thrombocytopenia	-	76	B
presents	-	93	O
5	-	102	O
to	-	104	O
12	-	107	O
days	-	110	O
after	-	115	O
heparin	-	121	O
exposure	-	129	O
,	-	137	O
with	-	139	O
or	-	144	O
without	-	147	O
arterial	-	155	B
or	-	164	I
venous	-	167	I
thromboemboli	-	174	I
.	-	187	O

Delayed	11827497	189	O
recognition	-	197	O
and	-	209	O
treatment	-	213	O
of	-	223	O
heparin	-	226	O
-	-	233	O
induced	-	234	O
thrombocytopenia	-	242	B
contribute	-	259	O
to	-	270	O
poor	-	273	O
patient	-	278	O
outcomes	-	286	O
.	-	294	O

OBJECTIVE	11827497	296	O
:	-	305	O

To	11827497	307	O
describe	-	310	O
and	-	319	O
increase	-	323	O
awareness	-	332	O
of	-	342	O
a	-	345	O
clinical	-	347	O
scenario	-	356	O
in	-	365	O
which	-	368	O
the	-	374	O
onset	-	378	O
or	-	384	O
manifestations	-	387	O
of	-	402	O
heparin	-	405	O
-	-	412	O
induced	-	413	O
thrombocytopenia	-	421	B
are	-	438	O
delayed	-	442	O
.	-	449	O

DESIGN	11827497	451	O
:	-	457	O

Retrospective	11827497	459	O
case	-	473	O
series	-	478	O
.	-	484	O

SETTING	11827497	486	O
:	-	493	O

Three	11827497	495	O
large	-	501	O
urban	-	507	O
hospitals	-	513	O
(	-	523	O
with	-	524	O
active	-	529	O
cardiovascular	-	536	O
surgery	-	551	O
programs	-	559	O
)	-	567	O
.	-	568	O

PATIENTS	11827497	570	O
:	-	578	O

14	11827497	580	O
patients	-	583	O
seen	-	592	O
over	-	597	O
a	-	602	O
3	-	604	O
-	-	605	O
year	-	606	O
period	-	611	O
in	-	618	O
whom	-	621	O
heparin	-	626	O
-	-	633	O
induced	-	634	O
thrombocytopenia	-	642	B
became	-	659	O
apparent	-	666	O
on	-	675	O
delayed	-	678	O
presentation	-	686	O
with	-	699	O
thromboembolic	-	704	B
complications	-	719	O
.	-	732	O

MEASUREMENTS	11827497	734	O
:	-	746	O

Platelet	11827497	748	O
counts	-	757	O
,	-	763	O
onset	-	765	O
of	-	771	O
objectively	-	774	O
determined	-	786	O
thromboembolism	-	797	B
,	-	812	O
results	-	814	O
of	-	822	O
heparin	-	825	O
-	-	832	O
induced	-	833	O
platelet	-	841	O
factor	-	850	O
4	-	857	O
antibody	-	859	O
tests	-	868	O
,	-	873	O
and	-	875	O
outcomes	-	879	O
.	-	887	O

RESULTS	11827497	889	O
:	-	896	O

Patients	11827497	898	O
went	-	907	O
home	-	912	O
after	-	917	O
hospitalizations	-	923	O
that	-	940	O
had	-	945	O
included	-	949	O
heparin	-	958	O
exposure	-	966	O
-	-	974	O
-	-	975	O
in	-	976	O
most	-	979	O
cases	-	984	O
,	-	989	O
with	-	991	O
no	-	996	O
thrombocytopenia	-	999	B
recognized	-	1016	O
-	-	1026	O
-	-	1027	O
only	-	1028	O
to	-	1033	O
return	-	1036	O
to	-	1043	O
the	-	1046	O
hospital	-	1050	O
(	-	1059	O
median	-	1060	O
,	-	1066	O
day	-	1068	O
14	-	1072	O
)	-	1074	O
with	-	1076	O
thromboembolic	-	1081	B
complications	-	1096	O
.	-	1109	O

Thromboemboli	11827497	1111	B
were	-	1125	O
venous	-	1130	O
(	-	1137	O
12	-	1138	O
patients	-	1141	O
,	-	1149	O
7	-	1151	O
with	-	1153	O
pulmonary	-	1158	B
emboli	-	1168	I
)	-	1174	O
or	-	1176	O
arterial	-	1179	O
(	-	1188	O
4	-	1189	O
patients	-	1191	O
)	-	1199	O
or	-	1201	O
both	-	1204	O
.	-	1208	O

Platelet	11827497	1210	O
counts	-	1219	O
were	-	1226	O
mildly	-	1231	O
decreased	-	1238	O
in	-	1248	O
all	-	1251	O
but	-	1255	O
2	-	1259	O
patients	-	1261	O
on	-	1270	O
second	-	1273	O
presentation	-	1280	O
.	-	1292	O

On	11827497	1294	O
readmission	-	1297	O
,	-	1308	O
11	-	1310	O
patients	-	1313	O
received	-	1322	O
therapeutic	-	1331	O
heparin	-	1343	O
,	-	1350	O
which	-	1352	O
worsened	-	1358	O
the	-	1367	O
patients	-	1371	O
'	-	1379	O
clinical	-	1381	O
condition	-	1390	O
and	-	1400	O
,	-	1403	O
in	-	1405	O
all	-	1408	O
11	-	1412	O
cases	-	1415	O
,	-	1420	O
decreased	-	1422	O
the	-	1432	O
platelet	-	1436	O
count	-	1445	O
(	-	1451	O
mean	-	1452	O
at	-	1457	O
readmission	-	1460	O
,	-	1471	O
143	-	1473	O
x	-	1477	O
10	-	1479	O
(	-	1481	O
9	-	1482	O
)	-	1483	O
cells	-	1485	O
/	-	1490	O
L	-	1491	O
;	-	1492	O
mean	-	1494	O
nadir	-	1499	O
after	-	1505	O
heparin	-	1511	O
re	-	1519	O
-	-	1521	O
exposure	-	1522	O
,	-	1530	O
39	-	1532	O
x	-	1535	O
10	-	1537	O
(	-	1539	O
9	-	1540	O
)	-	1541	O
cells	-	1543	O
/	-	1548	O
L	-	1549	O
)	-	1550	O
.	-	1551	O

Results	11827497	1553	O
of	-	1561	O
serologic	-	1564	O
tests	-	1574	O
for	-	1580	O
heparin	-	1584	O
-	-	1591	O
induced	-	1592	O
antibodies	-	1600	O
were	-	1611	O
positive	-	1616	O
in	-	1625	O
all	-	1628	O
patients	-	1632	O
.	-	1640	O

Subsequent	11827497	1642	O
treatments	-	1653	O
included	-	1664	O
alternative	-	1673	O
anticoagulants	-	1685	O
(	-	1700	O
11	-	1701	O
patients	-	1704	O
)	-	1712	O
,	-	1713	O
thrombolytic	-	1715	O
drugs	-	1728	O
(	-	1734	O
3	-	1735	O
patients	-	1737	O
)	-	1745	O
,	-	1746	O
inferior	-	1748	O
vena	-	1757	O
cava	-	1762	O
filters	-	1767	O
(	-	1775	O
3	-	1776	O
patients	-	1778	O
)	-	1786	O
and	-	1788	O
,	-	1791	O
eventually	-	1793	O
,	-	1803	O
warfarin	-	1805	O
(	-	1814	O
11	-	1815	O
patients	-	1818	O
)	-	1826	O
.	-	1827	O

Three	11827497	1829	O
patients	-	1835	O
died	-	1844	O
.	-	1848	O

CONCLUSIONS	11827497	1850	O
:	-	1861	O

Delayed	11827497	1863	O
-	-	1870	O
onset	-	1871	O
heparin	-	1877	O
-	-	1884	O
induced	-	1885	O
thrombocytopenia	-	1893	B
is	-	1910	O
increasingly	-	1913	O
being	-	1926	O
recognized	-	1932	O
.	-	1942	O

To	11827497	1944	O
avoid	-	1947	O
disastrous	-	1953	O
outcomes	-	1964	O
,	-	1972	O
physicians	-	1974	O
must	-	1985	O
consider	-	1990	O
heparin	-	1999	O
-	-	2006	O
induced	-	2007	O
thrombocytopenia	-	2015	B
whenever	-	2032	O
a	-	2041	O
recently	-	2043	O
hospitalized	-	2052	O
patient	-	2065	O
returns	-	2073	O
with	-	2081	O
thromboembolism	-	2086	B
;	-	2101	O
therapy	-	2103	O
with	-	2111	O
alternative	-	2116	O
anticoagulants	-	2128	O
,	-	2142	O
not	-	2144	O
heparin	-	2148	O
,	-	2155	O
should	-	2157	O
be	-	2164	O
initiated	-	2167	O
.	-	2176	O

Valsartan	8841157	0	O
,	-	9	O
a	-	11	O
new	-	13	O
angiotensin	-	17	O
II	-	29	O
antagonist	-	32	O
for	-	43	O
the	-	47	O
treatment	-	51	O
of	-	61	O
essential	-	64	O
hypertension	-	74	B
:	-	86	O
a	-	88	O
comparative	-	90	O
study	-	102	O
of	-	108	O
the	-	111	O
efficacy	-	115	O
and	-	124	O
safety	-	128	O
against	-	135	O
amlodipine	-	143	O
.	-	153	O

OBJECTIVE	8841157	155	O
:	-	164	O

To	8841157	166	O
compare	-	169	O
the	-	177	O
antihypertensive	-	181	O
efficacy	-	198	O
of	-	207	O
a	-	210	O
new	-	212	O
angiotensin	-	216	O
II	-	228	O
antagonist	-	231	O
,	-	241	O
valsartan	-	243	O
,	-	252	O
with	-	254	O
a	-	259	O
reference	-	261	O
therapy	-	271	O
,	-	278	O
amlodipine	-	280	O
.	-	290	O

METHODS	8841157	292	O
:	-	299	O

One	8841157	301	O
hundred	-	305	O
sixty	-	313	O
-	-	318	O
eight	-	319	O
adult	-	325	O
outpatients	-	331	O
with	-	343	O
mild	-	348	O
to	-	353	O
moderate	-	356	O
hypertension	-	365	B
were	-	378	O
randomly	-	383	O
allocated	-	392	O
in	-	402	O
double	-	405	O
-	-	411	O
blind	-	412	O
fashion	-	418	O
and	-	426	O
equal	-	430	O
number	-	436	O
to	-	443	O
receive	-	446	O
80	-	454	O
mg	-	457	O
valsartan	-	460	O
or	-	470	O
5	-	473	O
mg	-	475	O
amlodipine	-	478	O
for	-	489	O
12	-	493	O
weeks	-	496	O
.	-	501	O

After	8841157	503	O
8	-	509	O
weeks	-	511	O
of	-	517	O
therapy	-	520	O
,	-	527	O
in	-	529	O
patients	-	532	O
whose	-	541	O
blood	-	547	O
pressure	-	553	O
remained	-	562	O
uncontrolled	-	571	O
,	-	583	O
5	-	585	O
mg	-	587	O
amlodipine	-	590	O
was	-	601	O
added	-	605	O
to	-	611	O
the	-	614	O
initial	-	618	O
therapy	-	626	O
.	-	633	O

Patients	8841157	635	O
were	-	644	O
assessed	-	649	O
at	-	658	O
4	-	661	O
,	-	662	O
8	-	664	O
,	-	665	O
and	-	667	O
12	-	671	O
weeks	-	674	O
.	-	679	O

The	8841157	681	O
primary	-	685	O
efficacy	-	693	O
variable	-	702	O
was	-	711	O
change	-	715	O
from	-	722	O
baseline	-	727	O
in	-	736	O
mean	-	739	O
sitting	-	744	O
diastolic	-	752	O
blood	-	762	O
pressure	-	768	O
at	-	777	O
8	-	780	O
weeks	-	782	O
.	-	787	O

Secondary	8841157	789	O
variables	-	799	O
included	-	809	O
change	-	818	O
in	-	825	O
sitting	-	828	O
systolic	-	836	O
blood	-	845	O
pressure	-	851	O
and	-	860	O
responder	-	864	O
rates	-	874	O
.	-	879	O

RESULTS	8841157	881	O
:	-	888	O

Both	8841157	890	O
valsartan	-	895	O
and	-	905	O
amlodipine	-	909	O
were	-	920	O
effective	-	925	O
at	-	935	O
lowering	-	938	O
blood	-	947	O
pressure	-	953	O
at	-	962	O
4	-	965	O
,	-	966	O
8	-	968	O
,	-	969	O
and	-	971	O
12	-	975	O
weeks	-	978	O
.	-	983	O

Similar	8841157	985	O
decreases	-	993	O
were	-	1003	O
observed	-	1008	O
in	-	1017	O
both	-	1020	O
groups	-	1025	O
,	-	1031	O
with	-	1033	O
no	-	1038	O
statistically	-	1041	O
significant	-	1055	O
differences	-	1067	O
between	-	1079	O
the	-	1087	O
groups	-	1091	O
for	-	1098	O
any	-	1102	O
variable	-	1106	O
analyzed	-	1115	O
.	-	1123	O

For	8841157	1125	O
the	-	1129	O
primary	-	1133	O
variable	-	1141	O
the	-	1150	O
difference	-	1154	O
was	-	1165	O
0	-	1169	O
.	-	1170	O
5	-	1171	O
mm	-	1173	O
Hg	-	1176	O
in	-	1179	O
favor	-	1182	O
of	-	1188	O
valsartan	-	1191	O
(	-	1201	O
p	-	1202	O
=	-	1204	O
0	-	1206	O
.	-	1207	O
68	-	1208	O
;	-	1210	O
95	-	1212	O
%	-	1214	O
confidence	-	1216	O
interval	-	1227	O
,	-	1235	O
-	-	1237	O
2	-	1238	O
.	-	1239	O
7	-	1240	O
to	-	1242	O
1	-	1245	O
.	-	1246	O
7	-	1247	O
)	-	1248	O
.	-	1249	O

Responder	8841157	1251	O
rates	-	1261	O
at	-	1267	O
8	-	1270	O
weeks	-	1272	O
were	-	1278	O
66	-	1283	O
.	-	1285	O
7	-	1286	O
%	-	1287	O
for	-	1289	O
valsartan	-	1293	O
and	-	1303	O
60	-	1307	O
.	-	1309	O
2	-	1310	O
%	-	1311	O
for	-	1313	O
amlodipine	-	1317	O
(	-	1328	O
p	-	1329	O
=	-	1331	O
0	-	1333	O
.	-	1334	O
39	-	1335	O
)	-	1337	O
.	-	1338	O

Both	8841157	1340	O
treatments	-	1345	O
were	-	1356	O
well	-	1361	O
tolerated	-	1366	O
.	-	1375	O

The	8841157	1377	O
incidence	-	1381	O
of	-	1391	O
drug	-	1394	O
-	-	1398	O
related	-	1399	O
dependent	-	1407	O
edema	-	1417	B
was	-	1423	O
somewhat	-	1427	O
higher	-	1436	O
in	-	1443	O
the	-	1446	O
amlodipine	-	1450	O
group	-	1461	O
,	-	1466	O
particularly	-	1468	O
at	-	1481	O
a	-	1484	O
dose	-	1486	O
of	-	1491	O
10	-	1494	O
mg	-	1497	O
per	-	1500	O
day	-	1504	O
(	-	1508	O
2	-	1509	O
.	-	1510	O
4	-	1511	O
%	-	1512	O
for	-	1514	O
80	-	1518	O
mg	-	1521	O
valsartan	-	1524	O
;	-	1533	O
3	-	1535	O
.	-	1536	O
6	-	1537	O
%	-	1538	O
for	-	1540	O
5	-	1544	O
mg	-	1546	O
amlodipine	-	1549	O
;	-	1559	O
0	-	1561	O
%	-	1562	O
for	-	1564	O
valsartan	-	1568	O
plus	-	1578	O
5	-	1583	O
mg	-	1585	O
amlodipine	-	1588	O
;	-	1598	O
14	-	1600	O
.	-	1602	O
3	-	1603	O
%	-	1604	O
for	-	1606	O
10	-	1610	O
mg	-	1613	O
amlodipine	-	1616	O
)	-	1626	O
.	-	1627	O

CONCLUSIONS	8841157	1629	O
:	-	1640	O

The	8841157	1642	O
data	-	1646	O
show	-	1651	O
that	-	1656	O
valsartan	-	1661	O
is	-	1671	O
at	-	1674	O
least	-	1677	O
as	-	1683	O
effective	-	1686	O
as	-	1696	O
amlodipine	-	1699	O
in	-	1710	O
the	-	1713	O
treatment	-	1717	O
of	-	1727	O
mild	-	1730	O
to	-	1735	O
moderate	-	1738	O
hypertension	-	1747	B
.	-	1759	O

The	8841157	1761	O
results	-	1765	O
also	-	1773	O
show	-	1778	O
valsartan	-	1783	O
to	-	1793	O
be	-	1796	O
well	-	1799	O
tolerated	-	1804	O
and	-	1814	O
suggest	-	1818	O
that	-	1826	O
it	-	1831	O
is	-	1834	O
not	-	1837	O
associated	-	1841	O
with	-	1852	O
side	-	1857	O
effects	-	1862	O
characteristic	-	1870	O
of	-	1885	O
this	-	1888	O
comparator	-	1893	O
class	-	1904	O
,	-	1909	O
dihydropyridine	-	1911	O
calcium	-	1927	O
antagonists	-	1935	O
.	-	1946	O

KF17837	8045270	0	O
:	-	7	O
a	-	9	O
novel	-	11	O
selective	-	17	O
adenosine	-	27	O
A2A	-	37	O
receptor	-	41	O
antagonist	-	50	O
with	-	61	O
anticataleptic	-	66	O
activity	-	81	O
.	-	89	O

KF17837	8045270	91	O
is	-	99	O
a	-	102	O
novel	-	104	O
selective	-	110	O
adenosine	-	120	O
A2A	-	130	O
receptor	-	134	O
antagonist	-	143	O
.	-	153	O

Oral	8045270	155	O
administration	-	160	O
of	-	175	O
KF17837	-	178	O
(	-	186	O
2	-	187	O
.	-	188	O
5	-	189	O
,	-	190	O
10	-	192	O
.	-	194	O
0	-	195	O
and	-	197	O
30	-	201	O
.	-	203	O
0	-	204	O
mg	-	206	O
/	-	208	O
kg	-	209	O
)	-	211	O
significantly	-	213	O
ameliorated	-	227	O
the	-	239	O
cataleptic	-	243	B
responses	-	254	O
induced	-	264	O
by	-	272	O
intracerebroventricular	-	275	O
administration	-	299	O
of	-	314	O
an	-	317	O
adenosine	-	320	O
A2A	-	330	O
receptor	-	334	O
agonist	-	343	O
,	-	350	O
CGS	-	352	O
21680	-	356	O
(	-	362	O
10	-	363	O
micrograms	-	366	O
)	-	376	O
,	-	377	O
in	-	379	O
a	-	382	O
dose	-	384	O
-	-	388	O
dependent	-	389	O
manner	-	399	O
.	-	405	O

KF17837	8045270	407	O
also	-	415	O
reduced	-	420	O
the	-	428	O
catalepsy	-	432	B
induced	-	442	O
by	-	450	O
haloperidol	-	453	O
(	-	465	O
1	-	466	O
mg	-	468	O
/	-	470	O
kg	-	471	O
i	-	474	O
.	-	475	O
p	-	476	O
.	-	477	O
)	-	478	O
and	-	480	O
by	-	484	O
reserpine	-	487	O
(	-	497	O
5	-	498	O
mg	-	500	O
/	-	502	O
kg	-	503	O
i	-	506	O
.	-	507	O
p	-	508	O
.	-	509	O
)	-	510	O
.	-	511	O

These	8045270	513	O
anticataleptic	-	519	O
effects	-	534	O
were	-	542	O
exhibited	-	547	O
dose	-	557	O
dependently	-	562	O
at	-	574	O
doses	-	577	O
from	-	583	O
0	-	588	O
.	-	589	O
625	-	590	O
and	-	594	O
2	-	598	O
.	-	599	O
5	-	600	O
mg	-	602	O
/	-	604	O
kg	-	605	O
p	-	608	O
.	-	609	O
o	-	610	O
.	-	611	O
,	-	612	O
respectively	-	614	O
.	-	626	O

Moreover	8045270	628	O
,	-	636	O
KF17837	-	638	O
(	-	646	O
0	-	647	O
.	-	648	O
625	-	649	O
mg	-	653	O
/	-	655	O
kg	-	656	O
p	-	659	O
.	-	660	O
o	-	661	O
.	-	662	O
)	-	663	O

potentiated	8045270	665	O
the	-	677	O
anticataleptic	-	681	O
effects	-	696	O
of	-	704	O
a	-	707	O
subthreshold	-	709	O
dose	-	722	O
of	-	727	O
L	-	730	O
-	-	731	O
3	-	732	O
,	-	733	O
4	-	734	O
-	-	735	O
dihydroxyphenylalanine	-	736	O
(	-	759	O
L	-	760	O
-	-	761	O
DOPA	-	762	O
;	-	766	O
25	-	768	O
mg	-	771	O
/	-	773	O
kg	-	774	O
i	-	777	O
.	-	778	O
p	-	779	O
.	-	780	O
)	-	781	O
plus	-	783	O
benserazide	-	788	O
(	-	800	O
6	-	801	O
.	-	802	O
25	-	803	O
mg	-	806	O
/	-	808	O
kg	-	809	O
i	-	812	O
.	-	813	O
p	-	814	O
.	-	815	O
)	-	816	O
.	-	817	O

These	8045270	819	O
results	-	825	O
suggested	-	833	O
that	-	843	O
KF17837	-	848	O
is	-	856	O
a	-	859	O
centrally	-	861	O
active	-	871	O
adenosine	-	878	O
A2A	-	888	O
receptor	-	892	O
antagonist	-	901	O
and	-	912	O
that	-	916	O
the	-	921	O
dopaminergic	-	925	O
function	-	938	O
of	-	947	O
the	-	950	O
nigrostriatal	-	954	O
pathway	-	968	O
is	-	976	O
potentiated	-	979	O
by	-	991	O
adenosine	-	994	O
A2A	-	1004	O
receptor	-	1008	O
antagonists	-	1017	O
.	-	1028	O

Furthermore	8045270	1030	O
,	-	1041	O
KF17837	-	1043	O
may	-	1051	O
be	-	1055	O
a	-	1058	O
useful	-	1060	O
drug	-	1067	O
in	-	1072	O
the	-	1075	O
treatment	-	1079	O
of	-	1089	O
parkinsonism	-	1092	B
.	-	1104	O

Some	2576810	0	O
central	-	5	O
effects	-	13	O
of	-	21	O
repeated	-	24	O
treatment	-	33	O
with	-	43	O
fluvoxamine	-	48	O
.	-	59	O

We	2576810	61	O
investigated	-	64	O
the	-	77	O
effect	-	81	O
of	-	88	O
repeated	-	91	O
treatment	-	100	O
with	-	110	O
fluvoxamine	-	115	O
,	-	126	O
a	-	128	O
selective	-	130	O
serotonin	-	140	O
uptake	-	150	O
inhibitor	-	157	O
,	-	166	O
on	-	168	O
behavioral	-	171	O
effects	-	182	O
of	-	190	O
dopaminomimetics	-	193	O
and	-	210	O
methoxamine	-	214	O
and	-	226	O
on	-	230	O
the	-	233	O
animal	-	237	O
behavior	-	244	O
in	-	253	O
the	-	256	O
""""	-	260	O
behavioral	-	261	O
despair	-	272	O
""""	-	279	O
test	-	281	O
.	-	285	O

A	2576810	287	O
repeated	-	289	O
treatment	-	298	O
with	-	308	O
fluvoxamine	-	313	O
(	-	325	O
twice	-	326	O
daily	-	332	O
for	-	338	O
14	-	342	O
days	-	345	O
)	-	349	O
potentiated	-	351	O
in	-	363	O
mice	-	366	O
and	-	371	O
in	-	375	O
rats	-	378	O
(	-	383	O
weaker	-	384	O
)	-	390	O
the	-	392	O
amphetamine	-	396	O
-	-	407	O
induced	-	408	O
hyperactivity	-	416	B
.	-	429	O

The	2576810	431	O
hyperactivity	-	435	B
induced	-	449	O
by	-	457	O
nomifensine	-	460	O
in	-	472	O
mice	-	475	O
remained	-	480	O
unaffected	-	489	O
by	-	500	O
fluvoxamine	-	503	O
.	-	514	O

The	2576810	516	O
stimulation	-	520	O
of	-	532	O
locomotor	-	535	O
activity	-	545	O
by	-	554	O
intracerebroventricularly	-	557	O
administered	-	583	O
methoxamine	-	596	O
was	-	608	O
not	-	612	O
affected	-	616	O
by	-	625	O
repeated	-	628	O
treatment	-	637	O
with	-	647	O
fluvoxamine	-	652	O
.	-	663	O

Given	2576810	665	O
three	-	671	O
times	-	677	O
fluvoxamine	-	683	O
had	-	695	O
no	-	699	O
effect	-	702	O
on	-	709	O
the	-	712	O
immobilization	-	716	O
time	-	731	O
in	-	736	O
the	-	739	O
""""	-	743	O
behavioral	-	744	O
despair	-	755	O
""""	-	762	O
test	-	764	O
in	-	769	O
rats	-	772	O
.	-	776	O

The	2576810	778	O
results	-	782	O
indicate	-	790	O
that	-	799	O
fluvoxamine	-	804	O
given	-	816	O
repeatedly	-	822	O
acts	-	833	O
differently	-	838	O
than	-	850	O
citalopram	-	855	O
,	-	865	O
another	-	867	O
selective	-	875	O
serotonin	-	885	O
uptake	-	895	O
inhibitor	-	902	O
,	-	911	O
and	-	913	O
differs	-	917	O
also	-	925	O
from	-	930	O
other	-	935	O
antidepressant	-	941	O
drugs	-	956	O
.	-	961	O

Severe	20635749	0	O
congestive	-	7	B
heart	-	18	I
failure	-	24	I
patient	-	32	O
on	-	40	O
amiodarone	-	43	O
presenting	-	54	O
with	-	65	O
myxedemic	-	70	B
coma	-	80	I
:	-	84	O
a	-	86	O
case	-	88	O
report	-	93	O
.	-	99	O

This	20635749	101	O
is	-	106	O
a	-	109	O
case	-	111	O
report	-	116	O
of	-	123	O
myxedema	-	126	B
coma	-	135	I
secondary	-	140	O
to	-	150	O
amiodarone	-	153	O
-	-	163	O
induced	-	164	O
hypothyroidism	-	172	B
in	-	187	O
a	-	190	O
patient	-	192	O
with	-	200	O
severe	-	205	O
congestive	-	212	B
heart	-	223	I
failure	-	229	I
(	-	237	O
CHF	-	238	B
)	-	241	O
.	-	242	O

To	20635749	244	O
our	-	247	O
knowledge	-	251	O
and	-	261	O
after	-	265	O
reviewing	-	271	O
the	-	281	O
literature	-	285	O
there	-	296	O
is	-	302	O
one	-	305	O
case	-	309	O
report	-	314	O
of	-	321	O
myxedema	-	324	B
coma	-	333	I
during	-	338	O
long	-	345	O
term	-	350	O
amiodarone	-	355	O
therapy	-	366	O
.	-	373	O

Myxedema	20635749	375	B
coma	-	384	I
is	-	389	O
a	-	392	O
life	-	394	O
threatening	-	399	O
condition	-	411	O
that	-	421	O
carries	-	426	O
a	-	434	O
mortality	-	436	O
reaching	-	446	O
as	-	455	O
high	-	458	O
as	-	463	O
20	-	466	O
%	-	468	O
with	-	470	O
treatment	-	475	O
.	-	484	O

The	20635749	486	O
condition	-	490	O
is	-	500	O
treated	-	503	O
with	-	511	O
intravenous	-	516	O
thyroxine	-	528	O
(	-	538	O
T4	-	539	O
)	-	541	O
or	-	543	O
intravenous	-	546	O
tri	-	558	O
-	-	561	O
iodo	-	562	O
-	-	566	O
thyronine	-	567	O
(	-	577	O
T3	-	578	O
)	-	580	O
.	-	581	O

Patients	20635749	583	O
with	-	592	O
CHF	-	597	B
on	-	601	O
amiodarone	-	604	O
may	-	615	O
suffer	-	619	O
serious	-	626	O
morbidity	-	634	O
and	-	644	O
mortality	-	648	O
from	-	658	O
hypothyroidism	-	663	B
,	-	677	O
and	-	679	O
thus	-	683	O
may	-	688	O
deserve	-	692	O
closer	-	700	O
follow	-	707	O
up	-	714	O
for	-	717	O
thyroid	-	721	O
stimulating	-	729	O
hormone	-	741	O
(	-	749	O
TSH	-	750	O
)	-	753	O
levels	-	755	O
.	-	761	O

This	20635749	763	O
case	-	768	O
report	-	773	O
carries	-	780	O
an	-	788	O
important	-	791	O
clinical	-	801	O
application	-	810	O
given	-	822	O
the	-	828	O
frequent	-	832	O
usage	-	841	O
of	-	847	O
amiodarone	-	850	O
among	-	861	O
CHF	-	867	B
patients	-	871	O
.	-	879	O

The	20635749	881	O
myriad	-	885	O
clinical	-	892	O
presentation	-	901	O
of	-	914	O
myxedema	-	917	B
coma	-	926	I
and	-	931	O
its	-	935	O
serious	-	939	O
morbidity	-	947	O
and	-	957	O
mortality	-	961	O
stresses	-	971	O
the	-	980	O
need	-	984	O
to	-	989	O
suspect	-	992	O
this	-	1000	O
clinical	-	1005	O
syndrome	-	1014	O
among	-	1023	O
CHF	-	1029	B
patients	-	1033	O
presenting	-	1042	O
with	-	1053	O
hypotension	-	1058	B
,	-	1069	O
weakness	-	1071	B
or	-	1080	O
other	-	1083	O
unexplained	-	1089	O
symptoms	-	1101	O
.	-	1109	O

Fear	20394767	0	O
-	-	4	O
potentiated	-	5	O
startle	-	17	B
,	-	24	O
but	-	26	O
not	-	30	O
light	-	34	O
-	-	39	O
enhanced	-	40	O
startle	-	49	B
,	-	56	O
is	-	58	O
enhanced	-	61	O
by	-	70	O
anxiogenic	-	73	O
drugs	-	84	O
.	-	89	O

RATIONALE	20394767	91	O
AND	-	101	O
OBJECTIVES	-	105	O
:	-	115	O
The	-	117	O
light	-	121	O
-	-	126	O
enhanced	-	127	O
startle	-	136	B
paradigm	-	144	O
(	-	153	O
LES	-	154	O
)	-	157	O
is	-	159	O
suggested	-	162	O
to	-	172	O
model	-	175	O
anxiety	-	181	B
,	-	188	O
because	-	190	O
of	-	198	O
the	-	201	O
non	-	205	O
-	-	208	O
specific	-	209	O
cue	-	218	O
and	-	222	O
the	-	226	O
long	-	230	O
-	-	234	O
term	-	235	O
effect	-	240	O
.	-	246	O

In	20394767	248	O
contrast	-	251	O
,	-	259	O
the	-	261	O
fear	-	265	O
-	-	269	O
potentiated	-	270	O
startle	-	282	B
(	-	290	O
FPS	-	291	O
)	-	294	O
is	-	296	O
suggested	-	299	O
to	-	309	O
model	-	312	O
conditioned	-	318	O
fear	-	330	O
.	-	334	O

However	20394767	336	O
,	-	343	O
the	-	345	O
pharmacological	-	349	O
profiles	-	365	O
of	-	374	O
these	-	377	O
two	-	383	O
paradigms	-	387	O
are	-	397	O
very	-	401	O
similar	-	406	O
.	-	413	O

The	20394767	415	O
present	-	419	O
study	-	427	O
investigated	-	433	O
the	-	446	O
effects	-	450	O
of	-	458	O
putative	-	461	O
anxiogenic	-	470	O
drugs	-	481	O
on	-	487	O
LES	-	490	O
and	-	494	O
FPS	-	498	O
and	-	502	O
aimed	-	506	O
at	-	512	O
determining	-	515	O
the	-	527	O
sensitivity	-	531	O
of	-	543	O
LES	-	546	O
for	-	550	O
anxiogenic	-	554	O
drugs	-	565	O
and	-	571	O
to	-	575	O
potentially	-	578	O
showing	-	590	O
a	-	598	O
pharmacological	-	600	O
differentiation	-	616	O
between	-	632	O
these	-	640	O
two	-	646	O
paradigms	-	650	O
.	-	659	O

METHODS	20394767	661	O
:	-	668	O

Male	20394767	670	O
Wistar	-	675	O
rats	-	682	O
received	-	687	O
each	-	696	O
dose	-	701	O
of	-	706	O
the	-	709	O
alpha	-	713	O
(	-	718	O
2	-	719	O
)	-	720	O
-	-	721	O
adrenoceptor	-	722	O
antagonist	-	735	O
yohimbine	-	746	O
(	-	756	O
0	-	757	O
.	-	758	O
25	-	759	O
-	-	761	O
1	-	762	O
.	-	763	O
0mg	-	764	O
/	-	767	O
kg	-	768	O
)	-	770	O
,	-	771	O
the	-	773	O
5	-	777	O
-	-	778	O
HT	-	779	O
(	-	781	O
2C	-	782	O
)	-	784	O
receptor	-	786	O
agonist	-	795	O
m	-	803	O
-	-	804	O
chlorophenylpiperazine	-	805	O
(	-	828	O
mCPP	-	829	O
,	-	833	O
0	-	835	O
.	-	836	O
5	-	837	O
-	-	838	O
2	-	839	O
.	-	840	O
0mg	-	841	O
/	-	844	O
kg	-	845	O
)	-	847	O
or	-	849	O
the	-	852	O
GABA	-	856	O
(	-	860	O
A	-	861	O
)	-	862	O
inverse	-	864	O
receptor	-	872	O
agonist	-	881	O
pentylenetetrazole	-	889	O
(	-	908	O
PTZ	-	909	O
,	-	912	O
3	-	914	O
-	-	915	O
30mg	-	916	O
/	-	920	O
kg	-	921	O
)	-	923	O
and	-	925	O
were	-	929	O
subsequently	-	934	O
tested	-	947	O
in	-	954	O
either	-	957	O
LES	-	964	O
or	-	968	O
FPS	-	971	O
.	-	974	O

RESULTS	20394767	976	O
:	-	983	O

None	20394767	985	O
of	-	990	O
the	-	993	O
drugs	-	997	O
enhanced	-	1003	O
LES	-	1012	O
,	-	1015	O
whereas	-	1017	O
mCPP	-	1025	O
increased	-	1030	O
percentage	-	1040	O
FPS	-	1051	O
and	-	1055	O
yohimbine	-	1059	O
increased	-	1069	O
absolute	-	1079	O
FPS	-	1088	O
values	-	1092	O
.	-	1098	O

Furthermore	20394767	1100	O
,	-	1111	O
yohimbine	-	1113	O
increased	-	1123	O
baseline	-	1133	O
startle	-	1142	B
amplitude	-	1150	O
in	-	1160	O
the	-	1163	O
LES	-	1167	O
,	-	1170	O
while	-	1172	O
mCPP	-	1178	O
suppressed	-	1183	O
baseline	-	1194	O
startle	-	1203	B
in	-	1211	O
both	-	1214	O
the	-	1219	O
LES	-	1223	O
and	-	1227	O
FPS	-	1231	O
and	-	1235	O
PTZ	-	1239	O
suppressed	-	1243	O
baseline	-	1254	O
startle	-	1263	B
in	-	1271	O
the	-	1274	O
FPS	-	1278	O
.	-	1281	O

CONCLUSIONS	20394767	1283	O
:	-	1294	O

In	20394767	1296	O
contrast	-	1299	O
to	-	1308	O
findings	-	1311	O
in	-	1320	O
the	-	1323	O
FPS	-	1327	O
paradigm	-	1331	O
,	-	1339	O
none	-	1341	O
of	-	1346	O
the	-	1349	O
drugs	-	1353	O
were	-	1359	O
able	-	1364	O
to	-	1369	O
exacerbate	-	1372	O
the	-	1383	O
LES	-	1387	O
response	-	1391	O
.	-	1399	O

Thus	20394767	1401	O
,	-	1405	O
a	-	1407	O
clear	-	1409	O
pharmacological	-	1415	O
differentiation	-	1431	O
was	-	1447	O
found	-	1451	O
between	-	1457	O
LES	-	1465	O
and	-	1469	O
FPS	-	1473	O
.	-	1476	O

Proteinase	19203554	0	O
3	-	11	O
-	-	12	O
antineutrophil	-	13	O
cytoplasmic	-	28	O
antibody	-	40	O
-	-	48	O
(	-	49	O
PR3	-	50	O
-	-	53	O
ANCA	-	54	O
)	-	58	O
positive	-	60	O
necrotizing	-	69	O
glomerulonephritis	-	81	B
after	-	100	O
restarting	-	106	O
sulphasalazine	-	117	O
treatment	-	132	O
.	-	141	O

A	19203554	143	O
59	-	145	O
-	-	147	O
year	-	148	O
-	-	152	O
old	-	153	O
woman	-	157	O
with	-	163	O
ulcerative	-	168	B
colitis	-	179	I
developed	-	187	O
red	-	197	B
eyes	-	201	I
,	-	205	O
pleural	-	207	B
effusion	-	215	I
,	-	223	O
eosinophilia	-	225	B
and	-	238	O
urinary	-	242	B
abnormalities	-	250	I
after	-	264	O
restarting	-	270	O
of	-	281	O
sulphasalazine	-	284	O
treatment	-	299	O
.	-	308	O

Light	19203554	310	O
microscopy	-	316	O
of	-	327	O
a	-	330	O
kidney	-	332	O
biopsy	-	339	O
revealed	-	346	O
segmental	-	355	B
necrotizing	-	365	I
glomerulonephritis	-	377	I
without	-	396	O
deposition	-	404	O
of	-	415	O
immunoglobulin	-	418	O
or	-	433	O
complement	-	436	O
.	-	446	O

Proteinase	19203554	448	O
3	-	459	O
-	-	460	O
antineutrophil	-	461	O
cytoplasmic	-	476	O
antibody	-	488	O
(	-	497	O
PR3	-	498	O
-	-	501	O
ANCA	-	502	O
)	-	506	O
titer	-	508	O
was	-	514	O
elevated	-	518	O
at	-	527	O
183	-	530	O
ELISA	-	534	O
units	-	540	O
(	-	546	O
EU	-	547	O
)	-	549	O
in	-	551	O
sera	-	554	O
(	-	559	O
normal	-	560	O
range	-	567	O
less	-	573	O
than	-	578	O
10	-	583	O
EU	-	586	O
)	-	588	O
,	-	589	O
myeloperoxidase	-	591	O
-	-	606	O
ANCA	-	607	O
was	-	612	O
negative	-	616	O
.	-	624	O

PR3	19203554	626	O
-	-	629	O
ANCA	-	630	O
titer	-	635	O
was	-	641	O
250	-	645	O
and	-	649	O
1	-	653	O
,	-	654	O
070	-	655	O
EU	-	659	O
in	-	662	O
pleural	-	665	B
effusions	-	673	I
on	-	683	O
right	-	686	O
and	-	692	O
left	-	696	O
side	-	701	O
,	-	705	O
respectively	-	707	O
.	-	719	O

Although	19203554	721	O
cessation	-	730	O
of	-	740	O
sulphasalazine	-	743	O
treatment	-	758	O
resulted	-	768	O
in	-	777	O
improvements	-	780	O
in	-	793	O
fever	-	796	B
,	-	801	O
red	-	803	B
eyes	-	807	I
,	-	811	O
chest	-	813	B
pain	-	819	I
,	-	823	O
titer	-	825	O
of	-	831	O
C	-	834	O
-	-	835	O
reactive	-	836	O
protein	-	845	O
and	-	853	O
volume	-	857	O
of	-	864	O
the	-	867	O
pleural	-	871	B
effusions	-	879	I
,	-	888	O
we	-	890	O
initiated	-	893	O
steroid	-	903	O
therapy	-	911	O
,	-	918	O
because	-	920	O
PR3	-	928	O
-	-	931	O
ANCA	-	932	O
titer	-	937	O
rose	-	943	O
to	-	948	O
320	-	951	O
EU	-	955	O
,	-	957	O
eosinophil	-	959	O
count	-	970	O
increased	-	976	O
to	-	986	O
1	-	989	O
,	-	990	O
100	-	991	O
cells	-	995	O
/	-	1000	O
microl	-	1001	O
,	-	1007	O
and	-	1009	O
the	-	1013	O
pleural	-	1017	B
effusion	-	1025	I
remained	-	1034	O
.	-	1042	O

One	19203554	1044	O
month	-	1048	O
after	-	1054	O
steroid	-	1060	O
therapy	-	1068	O
,	-	1075	O
the	-	1077	O
pleural	-	1081	B
effusion	-	1089	I
disappeared	-	1098	O
,	-	1109	O
and	-	1111	O
PR3	-	1115	O
-	-	1118	O
ANCA	-	1119	O
titer	-	1124	O
normalized	-	1130	O
3	-	1141	O
months	-	1143	O
later	-	1150	O
.	-	1155	O

This	19203554	1157	O
case	-	1162	O
suggests	-	1167	O
that	-	1176	O
sulphasalazine	-	1181	O
can	-	1196	O
induce	-	1200	O
PR3	-	1207	O
-	-	1210	O
ANCA	-	1211	O
-	-	1215	O
positive	-	1216	O
necrotizing	-	1225	O
glomerulonephritis	-	1237	B
.	-	1255	O

Is	17049862	0	O
phenytoin	-	3	O
administration	-	13	O
safe	-	28	O
in	-	33	O
a	-	36	O
hypothermic	-	38	B
child	-	50	O
?	-	55	O

A	17049862	57	O
male	-	59	O
neonate	-	64	O
with	-	72	O
a	-	77	O
Chiari	-	79	B
malformation	-	86	I
and	-	99	O
a	-	103	O
leaking	-	105	O
myelomeningocoele	-	113	O
underwent	-	131	O
ventriculoperitoneal	-	141	O
shunt	-	162	O
insertion	-	168	O
followed	-	178	O
by	-	187	O
repair	-	190	O
of	-	197	O
myelomeningocoele	-	200	O
.	-	217	O

During	17049862	219	O
anaesthesia	-	226	O
and	-	238	O
surgery	-	242	O
,	-	249	O
he	-	251	O
inadvertently	-	254	O
became	-	268	O
moderately	-	275	O
hypothermic	-	286	B
.	-	297	O

Intravenous	17049862	299	O
phenytoin	-	311	O
was	-	321	O
administered	-	325	O
during	-	338	O
the	-	345	O
later	-	349	O
part	-	355	O
of	-	360	O
the	-	363	O
surgery	-	367	O
for	-	375	O
seizure	-	379	B
prophylaxis	-	387	O
.	-	398	O

Following	17049862	400	O
phenytoin	-	410	O
administration	-	420	O
,	-	434	O
the	-	436	O
patient	-	440	O
developed	-	448	O
acute	-	458	O
severe	-	464	O
bradycardia	-	471	B
,	-	482	O
refractory	-	484	O
to	-	495	O
atropine	-	498	O
and	-	507	O
adrenaline	-	511	O
.	-	521	O

The	17049862	523	O
cardiac	-	527	O
depressant	-	535	O
actions	-	546	O
of	-	554	O
phenytoin	-	557	O
and	-	567	O
hypothermia	-	571	B
can	-	583	O
be	-	587	O
additive	-	590	O
.	-	598	O

Administration	17049862	600	O
of	-	615	O
phenytoin	-	618	O
in	-	628	O
the	-	631	O
presence	-	635	O
of	-	644	O
hypothermia	-	647	B
may	-	659	O
lead	-	663	O
to	-	668	O
an	-	671	O
adverse	-	674	O
cardiac	-	682	O
event	-	690	O
in	-	696	O
children	-	699	O
.	-	707	O

As	17049862	709	O
phenytoin	-	712	O
is	-	722	O
a	-	725	O
commonly	-	727	O
used	-	736	O
drug	-	741	O
,	-	745	O
clinicians	-	747	O
need	-	758	O
to	-	763	O
be	-	766	O
aware	-	769	O
of	-	775	O
this	-	778	O
interaction	-	783	O
.	-	794	O

Amisulpride	16225977	0	O
related	-	12	O
tic	-	20	B
-	-	23	I
like	-	24	I
symptoms	-	29	I
in	-	38	O
an	-	41	O
adolescent	-	44	O
schizophrenic	-	55	B
.	-	68	O

Tic	16225977	70	B
disorders	-	74	I
can	-	84	O
be	-	88	O
effectively	-	91	O
treated	-	103	O
by	-	111	O
atypical	-	114	O
antipsychotics	-	123	O
such	-	138	O
as	-	143	O
risperidone	-	146	O
,	-	157	O
olanzapine	-	159	O
and	-	170	O
ziprasidone	-	174	O
.	-	185	O

However	16225977	187	O
,	-	194	O
there	-	196	O
are	-	202	O
two	-	206	O
case	-	210	O
reports	-	215	O
that	-	223	O
show	-	228	O
tic	-	233	B
-	-	236	I
like	-	237	I
symptoms	-	242	I
,	-	250	O
including	-	252	O
motor	-	262	O
and	-	268	O
phonic	-	272	O
variants	-	279	O
,	-	287	O
occurring	-	289	O
during	-	299	O
treatment	-	306	O
with	-	316	O
quetiapine	-	321	O
or	-	332	O
clozapine	-	335	O
.	-	344	O

We	16225977	346	O
present	-	349	O
a	-	357	O
15	-	359	O
-	-	361	O
year	-	362	O
-	-	366	O
old	-	367	O
girl	-	371	O
schizophrenic	-	376	B
who	-	390	O
developed	-	394	O
frequent	-	404	O
involuntary	-	413	B
eye	-	425	I
-	-	428	I
blinking	-	429	I
movements	-	438	I
after	-	448	O
5	-	454	O
months	-	456	O
of	-	463	O
amisulpride	-	466	O
treatment	-	478	O
(	-	488	O
1000	-	489	O
mg	-	494	O
per	-	497	O
day	-	501	O
)	-	504	O
.	-	505	O

The	16225977	507	O
tic	-	511	B
-	-	514	I
like	-	515	I
symptoms	-	520	I
resolved	-	529	O
completely	-	538	O
after	-	549	O
we	-	555	O
reduced	-	558	O
the	-	566	O
dose	-	570	O
of	-	575	O
amisulpride	-	578	O
down	-	590	O
to	-	595	O
800	-	598	O
mg	-	602	O
per	-	605	O
day	-	609	O
.	-	612	O

However	16225977	614	O
,	-	621	O
her	-	623	O
psychosis	-	627	B
recurred	-	637	O
after	-	646	O
the	-	652	O
dose	-	656	O
reduction	-	661	O
.	-	670	O

We	16225977	672	O
then	-	675	O
placed	-	680	O
her	-	687	O
on	-	691	O
an	-	694	O
additional	-	697	O
100	-	708	O
mg	-	712	O
per	-	715	O
day	-	719	O
of	-	723	O
quetiapine	-	726	O
.	-	736	O

She	16225977	738	O
has	-	742	O
been	-	746	O
in	-	751	O
complete	-	754	O
remission	-	763	O
under	-	773	O
the	-	779	O
combined	-	783	O
medications	-	792	O
for	-	804	O
more	-	808	O
than	-	813	O
one	-	818	O
year	-	822	O
and	-	827	O
maintains	-	831	O
a	-	841	O
fair	-	843	O
role	-	848	O
function	-	853	O
.	-	861	O

No	16225977	863	O
more	-	866	O
tic	-	871	B
-	-	874	I
like	-	875	I
symptoms	-	880	I
or	-	889	O
other	-	892	O
side	-	898	O
effects	-	903	O
have	-	911	O
been	-	916	O
reported	-	921	O
.	-	929	O

Together	16225977	931	O
with	-	940	O
previously	-	945	O
reported	-	956	O
cases	-	965	O
,	-	970	O
our	-	972	O
patient	-	976	O
suggests	-	984	O
that	-	993	O
tic	-	998	B
-	-	1001	I
like	-	1002	I
symptoms	-	1007	I
might	-	1016	O
occur	-	1022	O
in	-	1028	O
certain	-	1031	O
vulnerable	-	1039	O
individuals	-	1050	O
during	-	1062	O
treatment	-	1069	O
with	-	1079	O
atypical	-	1084	O
antipsychotics	-	1093	O
such	-	1108	O
as	-	1113	O
quetiapine	-	1116	O
,	-	1126	O
clozapine	-	1128	O
,	-	1137	O
or	-	1139	O
amisulpride	-	1142	O
.	-	1153	O

Comparison	12852481	0	O
of	-	11	O
developmental	-	14	O
toxicology	-	28	O
of	-	39	O
aspirin	-	42	O
(	-	50	O
acetylsalicylic	-	51	O
acid	-	67	O
)	-	71	O
in	-	73	O
rats	-	76	O
using	-	81	O
selected	-	87	O
dosing	-	96	O
paradigms	-	103	O
.	-	112	O

BACKGROUND	12852481	114	O
:	-	124	O

Analysis	12852481	126	O
of	-	135	O
the	-	138	O
literature	-	142	O
for	-	153	O
nonsteroidal	-	157	O
anti	-	170	O
-	-	174	O
inflammatory	-	175	O
drugs	-	188	O
(	-	194	O
NSAIDs	-	195	O
)	-	201	O
suggests	-	203	O
that	-	212	O
a	-	217	O
low	-	219	O
incidence	-	223	O
of	-	233	O
developmental	-	236	B
anomalies	-	250	I
occurs	-	260	O
in	-	267	O
rats	-	270	O
given	-	275	O
NSAIDs	-	281	O
on	-	288	O
specific	-	291	O
days	-	300	O
during	-	305	O
organogenesis	-	312	O
.	-	325	O

Aspirin	12852481	327	O
(	-	335	O
acetylsalicylic	-	336	O
acid	-	352	O
[	-	357	O
ASA	-	358	O
]	-	361	O
)	-	362	O
,	-	363	O
an	-	365	O
irreversible	-	368	O
cyclooxygenase	-	381	O
1	-	396	O
and	-	398	O
2	-	402	O
inhibitor	-	404	O
,	-	413	O
induces	-	415	O
developmental	-	423	B
anomalies	-	437	I
when	-	447	O
administered	-	452	O
to	-	465	O
Wistar	-	468	O
rats	-	475	O
on	-	480	O
gestational	-	483	O
day	-	495	O
(	-	499	O
GD	-	500	O
)	-	502	O
9	-	504	O
,	-	505	O
10	-	507	O
,	-	509	O
or	-	511	O
11	-	514	O
(	-	517	O
Kimmel	-	518	O
CA	-	525	O
,	-	527	O
Wilson	-	529	O
JG	-	536	O
,	-	538	O
Schumacher	-	540	O
HJ	-	551	O
.	-	553	O

Teratology	12852481	555	O
4	-	566	O
:	-	567	O
15	-	568	O
-	-	570	O
24	-	571	O
,	-	573	O
1971	-	575	O
)	-	579	O
.	-	580	O

There	12852481	582	O
are	-	588	O
no	-	592	O
published	-	595	O
ASA	-	605	O
studies	-	609	O
using	-	617	O
the	-	623	O
multiple	-	627	O
dosing	-	636	O
paradigm	-	643	O
of	-	652	O
GDs	-	655	O
6	-	659	O
to	-	661	O
17	-	664	O
.	-	666	O

Objectives	12852481	668	O
of	-	679	O
the	-	682	O
current	-	686	O
study	-	694	O
were	-	700	O
to	-	705	O
compare	-	708	O
results	-	716	O
between	-	724	O
Sprague	-	732	O
-	-	739	O
Dawley	-	740	O
(	-	747	O
SD	-	748	O
)	-	750	O
and	-	752	O
Wistar	-	756	O
strains	-	763	O
when	-	771	O
ASA	-	776	O
is	-	780	O
administered	-	783	O
on	-	796	O
GD	-	799	O
9	-	802	O
,	-	803	O
10	-	805	O
,	-	807	O
or	-	809	O
11	-	812	O
;	-	814	O
to	-	816	O
compare	-	819	O
the	-	827	O
malformation	-	831	O
patterns	-	844	O
following	-	853	O
single	-	863	O
and	-	870	O
multiple	-	874	O
dosings	-	883	O
during	-	891	O
organogenesis	-	898	O
in	-	912	O
SD	-	915	O
rats	-	918	O
;	-	922	O
and	-	924	O
to	-	928	O
test	-	931	O
the	-	936	O
hypothesis	-	940	O
that	-	951	O
maternal	-	956	O
gastrointestinal	-	965	B
toxicity	-	982	I
confounds	-	991	O
the	-	1001	O
detection	-	1005	O
of	-	1015	O
low	-	1018	O
incidence	-	1022	O
malformations	-	1032	B
with	-	1046	O
ASA	-	1051	O
when	-	1055	O
a	-	1060	O
multiple	-	1062	O
dosing	-	1071	O
paradigm	-	1078	O
is	-	1087	O
used	-	1090	O
.	-	1094	O

METHODS	12852481	1096	O
:	-	1103	O

ASA	12852481	1105	O
was	-	1109	O
administered	-	1113	O
as	-	1126	O
a	-	1129	O
single	-	1131	O
dose	-	1138	O
on	-	1143	O
GD	-	1146	O
9	-	1149	O
(	-	1151	O
0	-	1152	O
,	-	1153	O
250	-	1155	O
,	-	1158	O
500	-	1160	O
,	-	1163	O
or	-	1165	O
625	-	1168	O
mg	-	1172	O
/	-	1174	O
kg	-	1175	O
)	-	1177	O
,	-	1178	O
10	-	1180	O
(	-	1183	O
0	-	1184	O
,	-	1185	O
500	-	1187	O
,	-	1190	O
625	-	1192	O
,	-	1195	O
or	-	1197	O
750	-	1200	O
mg	-	1204	O
/	-	1206	O
kg	-	1207	O
)	-	1209	O
,	-	1210	O
or	-	1212	O
11	-	1215	O
(	-	1218	O
0	-	1219	O
,	-	1220	O
500	-	1222	O
,	-	1225	O
750	-	1227	O
,	-	1230	O
or	-	1232	O
1000	-	1235	O
mg	-	1240	O
/	-	1242	O
kg	-	1243	O
)	-	1245	O
and	-	1247	O
from	-	1251	O
GD	-	1256	O
6	-	1259	O
to	-	1261	O
GD	-	1264	O
17	-	1267	O
(	-	1270	O
0	-	1271	O
,	-	1272	O
50	-	1274	O
,	-	1276	O
125	-	1278	O
,	-	1281	O
or	-	1283	O
250	-	1286	O
mg	-	1290	O
/	-	1292	O
kg	-	1293	O
a	-	1296	O
day	-	1298	O
)	-	1301	O
in	-	1303	O
the	-	1306	O
multiple	-	1310	O
dose	-	1319	O
study	-	1324	O
to	-	1330	O
SD	-	1333	O
rats	-	1336	O
.	-	1340	O

Animals	12852481	1342	O
were	-	1350	O
killed	-	1355	O
on	-	1362	O
GD	-	1365	O
21	-	1368	O
,	-	1370	O
and	-	1372	O
fetuses	-	1376	O
were	-	1384	O
examined	-	1389	O
viscerally	-	1398	O
.	-	1408	O

RESULTS	12852481	1410	O
:	-	1417	O

The	12852481	1419	O
literature	-	1423	O
evaluation	-	1434	O
suggested	-	1445	O
that	-	1455	O
NSAIDs	-	1460	O
induce	-	1467	O
ventricular	-	1474	B
septal	-	1486	I
defects	-	1493	I
(	-	1501	O
VSDs	-	1502	B
)	-	1506	O
and	-	1508	O
midline	-	1512	B
defects	-	1520	I
(	-	1528	O
MDs	-	1529	B
)	-	1532	O
in	-	1534	O
rats	-	1537	O
and	-	1542	O
diaphragmatic	-	1546	B
hernia	-	1560	I
(	-	1567	O
DH	-	1568	B
)	-	1570	O
,	-	1571	O
MDs	-	1573	B
,	-	1576	O
and	-	1578	O
VSDs	-	1582	B
in	-	1587	O
rabbits	-	1590	O
(	-	1598	O
Cook	-	1599	O
JC	-	1604	O
et	-	1607	O
al	-	1610	O
.	-	1612	O
,	-	1613	O
2003	-	1615	O
)	-	1619	O
;	-	1620	O
hence	-	1622	O
,	-	1627	O
the	-	1629	O
present	-	1633	O
study	-	1641	O
focused	-	1647	O
on	-	1655	O
these	-	1658	O
malformations	-	1664	B
,	-	1677	O
even	-	1679	O
though	-	1684	O
ASA	-	1691	O
induces	-	1695	O
several	-	1703	O
other	-	1711	O
low	-	1717	O
-	-	1720	O
incidence	-	1721	O
malformations	-	1731	B
.	-	1744	O

In	12852481	1746	O
single	-	1749	O
dose	-	1756	O
studies	-	1761	O
,	-	1768	O
DH	-	1770	B
,	-	1772	O
MD	-	1774	B
,	-	1776	O
and	-	1778	O
VSD	-	1782	B
were	-	1786	O
induced	-	1791	O
on	-	1799	O
GDs	-	1802	O
9	-	1806	O
and	-	1808	O
10	-	1812	O
.	-	1814	O

VSD	12852481	1816	B
also	-	1820	O
was	-	1825	O
noted	-	1829	O
following	-	1835	O
treatment	-	1845	O
on	-	1855	O
GD	-	1858	O
11	-	1861	O
.	-	1863	O

In	12852481	1865	O
contrast	-	1868	O
,	-	1876	O
DH	-	1878	B
and	-	1881	O
MD	-	1885	B
were	-	1888	O
noted	-	1893	O
in	-	1899	O
the	-	1902	O
multiple	-	1906	O
dose	-	1915	O
study	-	1920	O
design	-	1926	O
only	-	1933	O
in	-	1938	O
the	-	1941	O
high	-	1945	O
-	-	1949	O
dose	-	1950	O
group	-	1955	O
,	-	1960	O
and	-	1962	O
VSD	-	1966	B
was	-	1970	O
noted	-	1974	O
across	-	1980	O
all	-	1987	O
dose	-	1991	O
groups	-	1996	O
.	-	2002	O

CONCLUSIONS	12852481	2004	O
:	-	2015	O

High	12852481	2017	O
concordance	-	2022	O
in	-	2034	O
major	-	2037	O
developmental	-	2043	B
anomalies	-	2057	I
between	-	2067	O
Wistar	-	2075	O
and	-	2082	O
SD	-	2086	O
rats	-	2089	O
were	-	2094	O
noted	-	2099	O
with	-	2105	O
the	-	2110	O
exception	-	2114	O
of	-	2124	O
VSD	-	2127	B
in	-	2131	O
the	-	2134	O
SD	-	2138	O
rats	-	2141	O
and	-	2146	O
hydrocephalus	-	2150	B
in	-	2164	O
the	-	2167	O
Wistar	-	2171	O
rats	-	2178	O
.	-	2182	O

Variations	12852481	2184	O
and	-	2195	O
malformations	-	2199	B
were	-	2213	O
similar	-	2218	O
when	-	2226	O
ASA	-	2231	O
was	-	2235	O
administered	-	2239	O
as	-	2252	O
a	-	2255	O
single	-	2257	O
dose	-	2264	O
or	-	2269	O
during	-	2272	O
the	-	2279	O
period	-	2283	O
of	-	2290	O
organogenesis	-	2293	O
(	-	2307	O
GDs	-	2308	O
6	-	2312	O
to	-	2314	O
17	-	2317	O
)	-	2319	O
.	-	2320	O

It	12852481	2322	O
was	-	2325	O
also	-	2329	O
evident	-	2334	O
that	-	2342	O
,	-	2346	O
by	-	2348	O
titrating	-	2351	O
the	-	2361	O
dose	-	2365	O
to	-	2370	O
achieve	-	2373	O
a	-	2381	O
maximum	-	2383	O
tolerated	-	2391	O
dose	-	2401	O
,	-	2405	O
malformations	-	2407	B
that	-	2421	O
normally	-	2426	O
occur	-	2435	O
at	-	2441	O
low	-	2444	O
incidence	-	2448	O
,	-	2457	O
as	-	2459	O
reported	-	2462	O
from	-	2471	O
previous	-	2476	O
single	-	2485	O
dose	-	2492	O
studies	-	2497	O
,	-	2504	O
could	-	2506	O
also	-	2512	O
be	-	2517	O
induced	-	2520	O
with	-	2528	O
ASA	-	2533	O
given	-	2537	O
at	-	2543	O
multiple	-	2546	O
doses	-	2555	O
.	-	2560	O

Torsade	11858397	0	B
de	-	8	I
pointes	-	11	I
induced	-	19	O
by	-	27	O
metoclopramide	-	30	O
in	-	45	O
an	-	48	O
elderly	-	51	O
woman	-	59	O
with	-	65	O
preexisting	-	70	O
complete	-	82	O
left	-	91	B
bundle	-	96	I
branch	-	103	I
block	-	110	I
.	-	115	O

There	11858397	117	O
is	-	123	O
a	-	126	O
growing	-	128	O
list	-	136	O
of	-	141	O
drugs	-	144	O
implicated	-	150	O
in	-	161	O
acquired	-	164	O
long	-	173	B
QT	-	178	I
syndrome	-	181	I
and	-	190	O
torsade	-	194	B
de	-	202	I
pointes	-	205	I
.	-	212	O

However	11858397	214	O
,	-	221	O
the	-	223	O
torsadogenic	-	227	O
potential	-	240	O
of	-	250	O
metoclopramide	-	253	O
,	-	267	O
a	-	269	O
commonly	-	271	O
used	-	280	O
antiemetic	-	285	O
and	-	296	O
prokinetic	-	300	O
drug	-	311	O
,	-	315	O
has	-	317	O
not	-	321	O
been	-	325	O
reported	-	330	O
in	-	339	O
the	-	342	O
literature	-	346	O
,	-	356	O
despite	-	358	O
its	-	366	O
chemical	-	370	O
similarity	-	379	O
to	-	390	O
procainamide	-	393	O
.	-	405	O

We	11858397	407	O
report	-	410	O
on	-	417	O
a	-	420	O
92	-	422	O
-	-	424	O
year	-	425	O
-	-	429	O
old	-	430	O
woman	-	434	O
with	-	440	O
preexisting	-	445	O
complete	-	457	O
left	-	466	B
bundle	-	471	I
branch	-	478	I
block	-	485	I
who	-	491	O
developed	-	495	O
torsade	-	505	B
de	-	513	I
pointes	-	516	I
after	-	524	O
intravenous	-	530	O
and	-	542	O
oral	-	546	O
administration	-	551	O
of	-	566	O
metoclopramide	-	569	O
.	-	583	O

This	11858397	585	O
patient	-	590	O
also	-	598	O
developed	-	603	O
torsade	-	613	B
de	-	621	I
pointes	-	624	I
when	-	632	O
cisapride	-	637	O
and	-	647	O
erythromycin	-	651	O
were	-	664	O
given	-	669	O
simultaneously	-	675	O
.	-	689	O

These	11858397	691	O
two	-	697	O
episodes	-	701	O
were	-	710	O
suppressed	-	715	O
successfully	-	726	O
after	-	739	O
discontinuing	-	745	O
the	-	759	O
offending	-	763	O
drugs	-	773	O
and	-	779	O
administering	-	783	O
class	-	797	O
IB	-	803	O
drugs	-	806	O
.	-	811	O

This	11858397	813	O
is	-	818	O
the	-	821	O
first	-	825	O
documentation	-	831	O
that	-	845	O
metoclopramide	-	850	O
provokes	-	865	O
torsade	-	874	B
de	-	882	I
pointes	-	885	I
clinically	-	893	O
.	-	903	O

Metoclopramide	11858397	905	O
should	-	920	O
be	-	927	O
used	-	930	O
cautiously	-	935	O
in	-	946	O
patients	-	949	O
with	-	958	O
a	-	963	O
risk	-	965	O
of	-	970	O
torsade	-	973	B
de	-	981	I
pointes	-	984	I
.	-	991	O

Apomorphine	11009181	0	O
:	-	11	O
an	-	13	O
underutilized	-	16	O
therapy	-	30	O
for	-	38	O
Parkinson	-	42	B
's	-	51	I
disease	-	54	I
.	-	61	O

Apomorphine	11009181	63	O
was	-	75	O
the	-	79	O
first	-	83	O
dopaminergic	-	89	O
drug	-	102	O
ever	-	107	O
used	-	112	O
to	-	117	O
treat	-	120	O
symptoms	-	126	O
of	-	135	O
Parkinson	-	138	B
's	-	147	I
disease	-	150	I
.	-	157	O

While	11009181	159	O
powerful	-	165	O
antiparkinsonian	-	174	O
effects	-	191	O
had	-	199	O
been	-	203	O
observed	-	208	O
as	-	217	O
early	-	220	O
as	-	226	O
1951	-	229	O
,	-	233	O
the	-	235	O
potential	-	239	O
of	-	249	O
treating	-	252	O
fluctuating	-	261	O
Parkinson	-	273	B
's	-	282	I
disease	-	285	I
by	-	293	O
subcutaneous	-	296	O
administration	-	309	O
of	-	324	O
apomorphine	-	327	O
has	-	339	O
only	-	343	O
recently	-	348	O
become	-	357	O
the	-	364	O
subject	-	368	O
of	-	376	O
systematic	-	379	O
study	-	390	O
.	-	395	O

A	11009181	397	O
number	-	399	O
of	-	406	O
small	-	409	O
scale	-	415	O
clinical	-	421	O
trials	-	430	O
have	-	437	O
unequivocally	-	442	O
shown	-	456	O
that	-	462	O
intermittent	-	467	O
subcutaneous	-	480	O
apomorphine	-	493	O
injections	-	505	O
produce	-	516	O
antiparkinsonian	-	524	O
benefit	-	541	O
close	-	549	O
if	-	555	O
not	-	558	O
identical	-	562	O
to	-	572	O
that	-	575	O
seen	-	580	O
with	-	585	O
levodopa	-	590	O
and	-	599	O
that	-	603	O
apomorphine	-	608	O
rescue	-	620	O
injections	-	627	O
can	-	638	O
reliably	-	642	O
revert	-	651	O
off	-	658	O
-	-	661	O
periods	-	662	O
even	-	670	O
in	-	675	O
patients	-	678	O
with	-	687	O
complex	-	692	O
on	-	700	O
-	-	702	O
off	-	703	O
motor	-	707	O
swings	-	713	O
.	-	719	O

Continuous	11009181	721	O
subcutaneous	-	732	O
apomorphine	-	745	O
infusions	-	757	O
can	-	767	O
reduce	-	771	O
daily	-	778	O
off	-	784	O
-	-	787	O
time	-	788	O
by	-	793	O
more	-	796	O
than	-	801	O
50	-	806	O
%	-	808	O
in	-	810	O
this	-	813	O
group	-	818	O
of	-	824	O
patients	-	827	O
,	-	835	O
which	-	837	O
appears	-	843	O
to	-	851	O
be	-	854	O
a	-	857	O
stronger	-	859	O
effect	-	868	O
than	-	875	O
that	-	880	O
generally	-	885	O
seen	-	895	O
with	-	900	O
add	-	905	O
-	-	908	O
on	-	909	O
therapy	-	912	O
with	-	920	O
oral	-	925	O
dopamine	-	930	O
agonists	-	939	O
or	-	948	O
COMT	-	951	O
inhibitors	-	956	O
.	-	966	O

Extended	11009181	968	O
follow	-	977	O
-	-	983	O
up	-	984	O
studies	-	987	O
of	-	995	O
up	-	998	O
to	-	1001	O
8	-	1004	O
years	-	1006	O
have	-	1012	O
demonstrated	-	1017	O
long	-	1030	O
-	-	1034	O
term	-	1035	O
persistence	-	1040	O
of	-	1052	O
apomorphine	-	1055	O
efficacy	-	1067	O
.	-	1075	O

In	11009181	1077	O
addition	-	1080	O
,	-	1088	O
there	-	1090	O
is	-	1096	O
convincing	-	1099	O
clinical	-	1110	O
evidence	-	1119	O
that	-	1128	O
monotherapy	-	1133	O
with	-	1145	O
continuous	-	1150	O
subcutaneous	-	1161	O
apomorphine	-	1174	O
infusions	-	1186	O
is	-	1196	O
associated	-	1199	O
with	-	1210	O
marked	-	1215	O
reductions	-	1222	O
of	-	1233	O
preexisting	-	1236	O
levodopa	-	1248	O
-	-	1256	O
induced	-	1257	O
dyskinesias	-	1265	B
.	-	1276	O

The	11009181	1278	O
main	-	1282	O
side	-	1287	O
effects	-	1292	O
of	-	1300	O
subcutaneous	-	1303	O
apomorphine	-	1316	O
treatment	-	1328	O
are	-	1338	O
related	-	1342	O
to	-	1350	O
cutaneous	-	1353	O
tolerability	-	1363	O
problems	-	1376	O
,	-	1384	O
whereas	-	1386	O
sedation	-	1394	O
and	-	1403	O
psychiatric	-	1407	B
complications	-	1419	O
play	-	1433	O
a	-	1438	O
lesser	-	1440	O
role	-	1447	O
.	-	1451	O

Given	11009181	1453	O
the	-	1459	O
marked	-	1463	O
degree	-	1470	O
of	-	1477	O
efficacy	-	1480	O
of	-	1489	O
subcutaneous	-	1492	O
apomorphine	-	1505	O
treatment	-	1517	O
in	-	1527	O
fluctuating	-	1530	O
Parkinson	-	1542	B
's	-	1551	I
disease	-	1554	I
,	-	1561	O
this	-	1563	O
approach	-	1568	O
seems	-	1577	O
to	-	1583	O
deserve	-	1586	O
more	-	1594	O
widespread	-	1599	O
clinical	-	1610	O
use	-	1619	O
.	-	1622	O

Fatal	8988571	0	O
excited	-	6	O
delirium	-	14	B
following	-	23	O
cocaine	-	33	O
use	-	41	O
:	-	44	O

epidemiologic	8988571	46	O
findings	-	60	O
provide	-	69	O
new	-	77	O
evidence	-	81	O
for	-	90	O
mechanisms	-	94	O
of	-	105	O
cocaine	-	108	O
toxicity	-	116	B
.	-	124	O

We	8988571	126	O
describe	-	129	O
an	-	138	O
outbreak	-	141	O
of	-	150	O
deaths	-	153	O
from	-	160	O
cocaine	-	165	O
-	-	172	O
induced	-	173	O
excited	-	181	O
delirium	-	189	B
(	-	198	O
EDDs	-	199	B
)	-	203	O
in	-	205	O
Dade	-	208	O
County	-	213	O
,	-	219	O
Florida	-	221	O
between	-	229	O
1979	-	237	O
and	-	242	O
1990	-	246	O
.	-	250	O

From	8988571	252	O
a	-	257	O
registry	-	259	O
of	-	268	O
all	-	271	O
cocaine	-	275	O
-	-	282	O
related	-	283	O
deaths	-	291	O
in	-	298	O
Dade	-	301	O
County	-	306	O
,	-	312	O
Florida	-	314	O
,	-	321	O
from	-	323	O
1969	-	328	O
-	-	332	O
1990	-	333	O
,	-	337	O
58	-	339	O
EDDs	-	342	B
were	-	347	O
compared	-	352	O
with	-	361	O
125	-	366	O
victims	-	370	O
of	-	378	O
accidental	-	381	O
cocaine	-	392	O
overdose	-	400	B
without	-	409	O
excited	-	417	O
delirium	-	425	B
.	-	433	O

Compared	8988571	435	O
with	-	444	O
controls	-	449	O
,	-	457	O
EDDs	-	459	B
were	-	464	O
more	-	469	O
frequently	-	474	O
black	-	485	O
,	-	490	O
male	-	492	O
,	-	496	O
and	-	498	O
younger	-	502	O
.	-	509	O

They	8988571	511	O
were	-	516	O
less	-	521	O
likely	-	526	O
to	-	533	O
have	-	536	O
a	-	541	O
low	-	543	O
body	-	547	O
mass	-	552	O
index	-	557	O
,	-	562	O
and	-	564	O
more	-	568	O
likely	-	573	O
to	-	580	O
have	-	583	O
died	-	588	O
in	-	593	O
police	-	596	O
custody	-	603	O
,	-	610	O
to	-	612	O
have	-	615	O
received	-	620	O
medical	-	629	O
treatment	-	637	O
immediately	-	647	O
before	-	659	O
death	-	666	O
,	-	671	O
to	-	673	O
have	-	676	O
survived	-	681	O
for	-	690	O
a	-	694	O
longer	-	696	O
period	-	703	O
,	-	709	O
to	-	711	O
have	-	714	O
developed	-	719	O
hyperthermia	-	729	B
,	-	741	O
and	-	743	O
to	-	747	O
have	-	750	O
died	-	755	O
in	-	760	O
summer	-	763	O
months	-	770	O
.	-	776	O

EDDs	8988571	778	B
had	-	783	O
concentrations	-	787	O
of	-	802	O
cocaine	-	805	O
and	-	813	O
benzoylecgonine	-	817	O
in	-	833	O
autopsy	-	836	O
blood	-	844	O
that	-	850	O
were	-	855	O
similar	-	860	O
to	-	868	O
those	-	871	O
for	-	877	O
controls	-	881	O
.	-	889	O

The	8988571	891	O
epidemiologic	-	895	O
findings	-	909	O
are	-	918	O
most	-	922	O
consistent	-	927	O
with	-	938	O
the	-	943	O
hypothesis	-	947	O
that	-	958	O
chronic	-	963	O
cocaine	-	971	O
use	-	979	O
disrupts	-	983	O
dopaminergic	-	992	O
function	-	1005	O
and	-	1014	O
,	-	1017	O
when	-	1019	O
coupled	-	1024	O
with	-	1032	O
recent	-	1037	O
cocaine	-	1044	O
use	-	1052	O
,	-	1055	O
may	-	1057	O
precipitate	-	1061	O
agitation	-	1073	B
,	-	1082	O
delirium	-	1084	B
,	-	1092	O
aberrant	-	1094	O
thermoregulation	-	1103	O
,	-	1119	O
rhabdomyolysis	-	1121	B
,	-	1135	O
and	-	1137	O
sudden	-	1141	B
death	-	1148	I
.	-	1153	O

Heparin	6615052	0	O
-	-	7	O
induced	-	8	O
thrombocytopenia	-	16	B
,	-	32	O
thrombosis	-	34	B
,	-	44	O
and	-	46	O
hemorrhage	-	50	B
.	-	60	O

Sixty	6615052	62	O
-	-	67	O
two	-	68	O
patients	-	72	O
with	-	81	O
a	-	86	O
heparin	-	88	O
-	-	95	O
induced	-	96	O
thrombocytopenia	-	104	B
are	-	121	O
reported	-	125	O
.	-	133	O

Clinical	6615052	135	O
manifestations	-	144	O
of	-	159	O
this	-	162	O
disorder	-	167	O
include	-	176	O
hemorrhage	-	184	B
or	-	195	O
,	-	197	O
more	-	199	O
frequently	-	204	O
,	-	214	O
thromboembolic	-	216	B
events	-	231	O
in	-	238	O
patients	-	241	O
receiving	-	250	O
heparin	-	260	O
.	-	267	O

Laboratory	6615052	269	O
testing	-	280	O
has	-	288	O
revealed	-	292	O
a	-	301	B
falling	-	303	I
platelet	-	311	I
count	-	320	I
,	-	325	O
increased	-	327	O
resistance	-	337	O
to	-	348	O
heparin	-	351	O
,	-	358	O
and	-	360	O
aggregation	-	364	O
of	-	376	O
platelets	-	379	O
by	-	389	O
the	-	392	O
patient	-	396	O
's	-	403	O
plasma	-	406	O
when	-	413	O
heparin	-	418	O
is	-	426	O
added	-	429	O
.	-	434	O

Immunologic	6615052	436	O
testing	-	448	O
has	-	456	O
demonstrated	-	460	O
the	-	473	O
presence	-	477	O
of	-	486	O
a	-	489	O
heparin	-	491	O
-	-	498	O
dependent	-	499	O
platelet	-	509	O
membrane	-	518	O
antibody	-	527	O
.	-	535	O

The	6615052	537	O
20	-	541	O
deaths	-	544	O
,	-	550	O
52	-	552	O
hemorrhagic	-	555	B
and	-	567	I
thromboembolic	-	571	I
complications	-	586	I
,	-	599	O
and	-	601	O
21	-	605	O
surgical	-	608	O
procedures	-	617	O
to	-	628	O
manage	-	631	O
the	-	638	O
complications	-	642	O
confirm	-	656	O
the	-	664	O
seriousness	-	668	O
of	-	680	O
the	-	683	O
disorder	-	687	O
.	-	695	O

Specific	6615052	697	O
risk	-	706	O
factors	-	711	O
have	-	719	O
not	-	724	O
been	-	728	O
identified	-	733	O
;	-	743	O
therefore	-	745	O
,	-	754	O
all	-	756	O
patients	-	760	O
receiving	-	769	O
heparin	-	779	O
should	-	787	O
be	-	794	O
monitored	-	797	O
.	-	806	O

If	6615052	808	O
the	-	811	O
platelet	-	815	O
count	-	824	O
falls	-	830	O
to	-	836	O
less	-	839	O
than	-	844	O
100	-	849	O
,	-	852	O
000	-	853	O
/	-	856	O
mm3	-	857	O
,	-	860	O
while	-	862	O
the	-	868	O
patient	-	872	O
is	-	880	O
receiving	-	883	O
heparin	-	893	O
,	-	900	O
platelet	-	902	B
aggregation	-	911	I
testing	-	923	O
,	-	930	O
using	-	932	O
the	-	938	O
patient	-	942	O
's	-	949	O
plasma	-	952	O
,	-	958	O
is	-	960	O
indicated	-	963	O
.	-	972	O

Management	6615052	974	O
consists	-	985	O
of	-	994	O
cessation	-	997	O
of	-	1007	O
heparin	-	1010	O
,	-	1017	O
platelet	-	1019	O
anti	-	1028	O
-	-	1032	O
aggregating	-	1033	O
agents	-	1045	O
,	-	1051	O
and	-	1053	O
alternate	-	1057	O
forms	-	1067	O
of	-	1073	O
anticoagulation	-	1076	O
when	-	1092	O
indicated	-	1097	O
.	-	1106	O

Cardiac	3952818	0	B
toxicity	-	8	I
of	-	17	O
5	-	20	O
-	-	21	O
fluorouracil	-	22	O
.	-	34	O

Report	3952818	36	O
of	-	43	O
a	-	46	O
case	-	48	O
of	-	53	O
spontaneous	-	56	O
angina	-	68	B
.	-	74	O

We	3952818	76	O
report	-	79	O
a	-	86	O
case	-	88	O
of	-	93	O
a	-	96	O
patient	-	98	O
with	-	106	O
colon	-	111	B
carcinoma	-	117	I
and	-	127	O
liver	-	131	O
metastasis	-	137	B
who	-	148	O
presented	-	152	O
chest	-	162	B
pain	-	168	I
after	-	173	O
5	-	179	O
-	-	180	O
fluorouracil	-	181	O
(	-	194	O
5	-	195	O
-	-	196	O
FU	-	197	O
)	-	199	O
administration	-	201	O
.	-	215	O

Clinical	3952818	217	O
electrocardiographic	-	226	O
evolution	-	247	O
was	-	257	O
similar	-	261	O
to	-	269	O
that	-	272	O
observed	-	277	O
in	-	286	O
Prinzmetal	-	289	B
's	-	299	I
angina	-	302	I
,	-	308	O
and	-	310	O
chest	-	314	B
pain	-	320	I
promptly	-	325	O
resolved	-	334	O
with	-	343	O
nifedipine	-	348	O
.	-	358	O

These	3952818	360	O
data	-	366	O
suggest	-	371	O
that	-	379	O
coronary	-	384	B
spasm	-	393	I
may	-	399	O
be	-	403	O
the	-	406	O
cause	-	410	O
of	-	416	O
cardiotoxicity	-	419	B
due	-	434	O
to	-	438	O
5	-	441	O
-	-	442	O
FU	-	443	O
,	-	445	O
and	-	447	O
that	-	451	O
calcium	-	456	O
antagonists	-	464	O
may	-	476	O
probably	-	480	O
be	-	489	O
used	-	492	O
in	-	497	O
the	-	500	O
prevention	-	504	O
or	-	515	O
treatment	-	518	O
of	-	528	O
5	-	531	O
-	-	532	O
FU	-	533	O
cardiotoxicity	-	536	B
.	-	550	O

Toxicity	3084782	0	B
due	-	9	O
to	-	13	O
remission	-	16	O
inducing	-	26	O
drugs	-	35	O
in	-	41	O
rheumatoid	-	44	B
arthritis	-	55	I
.	-	64	O

Association	3084782	66	O
with	-	78	O
HLA	-	83	O
-	-	86	O
B35	-	87	O
and	-	91	O
Cw4	-	95	O
antigens	-	99	O
.	-	107	O

Twenty	3084782	109	O
-	-	115	O
five	-	116	O
patients	-	121	O
with	-	130	O
rheumatoid	-	135	B
arthritis	-	146	I
(	-	156	O
RA	-	157	B
)	-	159	O
who	-	161	O
developed	-	165	O
toxicity	-	175	B
while	-	184	O
taking	-	190	O
remission	-	197	O
inducing	-	207	O
drugs	-	216	O
and	-	222	O
30	-	226	O
without	-	229	O
toxicity	-	237	B
were	-	246	O
studied	-	251	O
for	-	259	O
possible	-	263	O
associations	-	272	O
with	-	285	O
class	-	290	O
I	-	296	O
and	-	298	O
II	-	302	O
HLA	-	305	O
antigens	-	309	O
.	-	317	O

A	3084782	319	O
strong	-	321	O
association	-	328	O
has	-	340	O
been	-	344	O
found	-	349	O
between	-	355	O
nephritis	-	363	B
and	-	373	O
dermatitis	-	377	B
due	-	388	O
to	-	392	O
Tiopronin	-	395	O
(	-	405	O
a	-	406	O
D	-	408	O
-	-	409	O
Penicillamine	-	410	O
like	-	424	O
compound	-	429	O
)	-	437	O
and	-	439	O
class	-	443	O
I	-	449	O
antigens	-	451	O
B35	-	460	O
-	-	463	O
Cw4	-	464	O
,	-	467	O
and	-	469	O
between	-	473	O
dermatitis	-	481	B
due	-	492	O
to	-	496	O
gold	-	499	O
thiosulphate	-	504	O
and	-	517	O
B35	-	521	O
.	-	524	O

Compared	3084782	526	O
to	-	535	O
healthy	-	538	O
controls	-	546	O
a	-	555	O
lower	-	557	O
DR5	-	563	O
frequency	-	567	O
was	-	577	O
observed	-	581	O
in	-	590	O
patients	-	593	O
with	-	602	O
RA	-	607	B
except	-	610	O
for	-	617	O
the	-	621	O
Tiopronin	-	625	O
related	-	635	O
nephritis	-	643	B
group	-	653	O
.	-	658	O

Transient	430165	0	O
hemiparesis	-	10	B
:	-	21	O
a	-	23	O
rare	-	25	O
manifestation	-	30	O
of	-	44	O
diphenylhydantoin	-	47	O
toxicity	-	65	B
.	-	73	O

Report	430165	75	O
of	-	82	O
two	-	85	O
cases	-	89	O
.	-	94	O

Among	430165	96	O
the	-	102	O
common	-	106	O
side	-	113	O
effects	-	118	O
of	-	126	O
diphenylhydantoin	-	129	O
(	-	147	O
DPH	-	148	O
)	-	151	O
overdose	-	153	B
,	-	161	O
the	-	163	O
most	-	167	O
frequently	-	172	O
encountered	-	183	O
neurological	-	195	O
signs	-	208	O
are	-	214	O
those	-	218	O
of	-	224	O
cerebellar	-	227	B
dysfunction	-	238	I
.	-	249	O

Very	430165	251	O
rarely	-	256	O
,	-	262	O
the	-	264	O
toxic	-	268	O
neurological	-	274	O
manifestations	-	287	O
of	-	302	O
this	-	305	O
drug	-	310	O
are	-	315	O
of	-	319	O
cerebral	-	322	O
origin	-	331	O
.	-	337	O

Two	430165	339	O
patients	-	343	O
are	-	352	O
presented	-	356	O
who	-	366	O
suffered	-	370	O
progressive	-	379	O
hemiparesis	-	391	B
due	-	403	O
to	-	407	O
DPH	-	410	O
overdose	-	414	B
.	-	422	O

Both	430165	424	O
had	-	429	O
brain	-	433	O
surgery	-	439	O
before	-	447	O
DPH	-	454	O
treatment	-	458	O
.	-	467	O

It	430165	469	O
is	-	472	O
assumed	-	475	O
that	-	483	O
patients	-	488	O
with	-	497	O
some	-	502	O
cerebral	-	507	B
damage	-	516	I
are	-	523	O
liable	-	527	O
to	-	534	O
manifest	-	537	O
DPH	-	546	O
toxicity	-	550	B
as	-	559	O
focal	-	562	O
neurological	-	568	O
signs	-	581	O
.	-	586	O

Nerve	16600756	0	O
growth	-	6	O
factor	-	13	O
and	-	20	O
prostaglandins	-	24	O
in	-	39	O
the	-	42	O
urine	-	46	O
of	-	52	O
female	-	55	O
patients	-	62	O
with	-	71	O
overactive	-	76	B
bladder	-	87	I
.	-	94	O

PURPOSE	16600756	96	O
:	-	103	O

NGF	16600756	105	O
and	-	109	O
PGs	-	113	O
in	-	117	O
the	-	120	O
bladder	-	124	O
can	-	132	O
be	-	136	O
affected	-	139	O
by	-	148	O
pathological	-	151	O
changes	-	164	O
in	-	172	O
the	-	175	O
bladder	-	179	O
and	-	187	O
these	-	191	O
changes	-	197	O
can	-	205	O
be	-	209	O
detected	-	212	O
in	-	221	O
urine	-	224	O
.	-	229	O

We	16600756	231	O
investigated	-	234	O
changes	-	247	O
in	-	255	O
urinary	-	258	O
NGF	-	266	O
and	-	270	O
PGs	-	274	O
in	-	278	O
women	-	281	O
with	-	287	O
OAB	-	292	B
.	-	295	O

MATERIALS	16600756	297	O
AND	-	307	O
METHODS	-	311	O
:	-	318	O

The	16600756	320	O
study	-	324	O
groups	-	330	O
included	-	337	O
65	-	346	O
women	-	349	O
with	-	355	O
OAB	-	360	B
and	-	364	O
20	-	368	O
without	-	371	O
bladder	-	379	O
symptoms	-	387	O
who	-	396	O
served	-	400	O
as	-	407	O
controls	-	410	O
.	-	418	O

Evaluation	16600756	420	O
included	-	431	O
patient	-	440	O
history	-	448	O
,	-	455	O
urinalysis	-	457	O
,	-	467	O
a	-	469	O
voiding	-	471	O
diary	-	479	O
and	-	485	O
urodynamic	-	489	O
studies	-	500	O
.	-	507	O

Urine	16600756	509	O
samples	-	515	O
were	-	523	O
collected	-	528	O
.	-	537	O

NGF	16600756	539	O
,	-	542	O
PGE2	-	544	O
,	-	548	O
PGF2alpha	-	550	O

and	16600756	560	O
PGI2	-	564	O
were	-	569	O
measured	-	574	O
using	-	583	O
enzyme	-	589	O
-	-	595	O
linked	-	596	O
immunosorbent	-	603	O
assay	-	617	O
and	-	623	O
compared	-	627	O
between	-	636	O
the	-	644	O
groups	-	648	O
.	-	654	O

In	16600756	656	O
addition	-	659	O
,	-	667	O
correlations	-	669	O
between	-	682	O
urinary	-	690	O
NGF	-	698	O
and	-	702	O
PG	-	706	O
,	-	708	O
and	-	710	O
urodynamic	-	714	O
parameters	-	725	O
in	-	736	O
patients	-	739	O
with	-	748	O
OAB	-	753	B
were	-	757	O
examined	-	762	O
.	-	770	O

RESULTS	16600756	772	O
:	-	779	O

Urinary	16600756	781	O
NGF	-	789	O
,	-	792	O
PGE2	-	794	O
and	-	799	O
PGF2alpha	-	803	O
were	-	813	O
significantly	-	818	O
increased	-	832	O
in	-	842	O
patients	-	845	O
with	-	854	O
OAB	-	859	B
compared	-	863	O
with	-	872	O
controls	-	877	O
(	-	886	O
p	-	887	O
<	-	889	O
0	-	890	O
.	-	891	O
05	-	892	O
)	-	894	O
.	-	895	O

However	16600756	897	O
,	-	904	O
urinary	-	906	O
PGI2	-	914	O
was	-	919	O
not	-	923	O
different	-	927	O
between	-	937	O
controls	-	945	O
and	-	954	O
patients	-	958	O
with	-	967	O
OAB	-	972	B
.	-	975	O

In	16600756	977	O
patients	-	980	O
with	-	989	O
OAB	-	994	B
urinary	-	998	O
PGE2	-	1006	O
positively	-	1011	O
correlated	-	1022	O
with	-	1033	O
volume	-	1038	O
at	-	1045	O
first	-	1048	O
desire	-	1054	O
to	-	1061	O
void	-	1064	O
and	-	1069	O
maximum	-	1073	O
cystometric	-	1081	O
capacity	-	1093	O
(	-	1102	O
p	-	1103	O
<	-	1105	O
0	-	1106	O
.	-	1107	O
05	-	1108	O
)	-	1110	O
.	-	1111	O

Urinary	16600756	1113	O
NGF	-	1121	O
,	-	1124	O

PGF2alpha	16600756	1126	O

and	16600756	1136	O
PGI2	-	1140	O
did	-	1145	O
not	-	1149	O
correlate	-	1153	O
with	-	1163	O
urodynamic	-	1168	O
parameters	-	1179	O
in	-	1190	O
patients	-	1193	O
with	-	1202	O
OAB	-	1207	B
.	-	1210	O

CONCLUSIONS	16600756	1212	O
:	-	1223	O

NGF	16600756	1225	O
and	-	1229	O
PGs	-	1233	O
have	-	1237	O
important	-	1242	O
roles	-	1252	O
in	-	1258	O
the	-	1261	O
development	-	1265	O
of	-	1277	O
OAB	-	1280	B
symptoms	-	1284	O
in	-	1293	O
female	-	1296	O
patients	-	1303	O
.	-	1311	O

Urinary	16600756	1313	O
levels	-	1321	O
of	-	1328	O
these	-	1331	O
factors	-	1337	O
may	-	1345	O
be	-	1349	O
used	-	1352	O
as	-	1357	O
markers	-	1360	O
to	-	1368	O
evaluate	-	1371	O
OAB	-	1380	B
symptoms	-	1384	O
.	-	1392	O

Acute	15686794	0	O
low	-	6	B
back	-	10	I
pain	-	15	I
during	-	20	O
intravenous	-	27	O
administration	-	39	O
of	-	54	O
amiodarone	-	57	O
:	-	67	O
a	-	69	O
report	-	71	O
of	-	78	O
two	-	81	O
cases	-	85	O
.	-	90	O

Amiodarone	15686794	92	O
represents	-	103	O
an	-	114	O
effective	-	117	O
antiarrhythmic	-	127	O
drug	-	142	O
for	-	147	O
cardioversion	-	151	O
of	-	165	O
recent	-	168	O
-	-	174	O
onset	-	175	O
atrial	-	181	B
fibrillation	-	188	I
(	-	201	O
AF	-	202	B
)	-	204	O
and	-	206	O
maintenance	-	210	O
of	-	222	O
sinus	-	225	O
rhythm	-	231	O
.	-	237	O

We	15686794	239	O
briefly	-	242	O
describe	-	250	O
two	-	259	O
patients	-	263	O
suffering	-	272	O
from	-	282	O
recent	-	287	O
-	-	293	O
onset	-	294	O
atrial	-	300	B
fibrillation	-	307	I
,	-	319	O
who	-	321	O
experienced	-	325	O
an	-	337	O
acute	-	340	O
devastating	-	346	O
low	-	358	B
back	-	362	I
pain	-	367	I
a	-	372	O
few	-	374	O
minutes	-	378	O
after	-	386	O
initiation	-	392	O
of	-	403	O
intravenous	-	406	O
amiodarone	-	418	O
loading	-	429	O
.	-	436	O

Notably	15686794	438	O
,	-	445	O
this	-	447	O
side	-	452	O
effect	-	457	O
has	-	464	O
not	-	468	O
been	-	472	O
ever	-	477	O
reported	-	482	O
in	-	491	O
the	-	494	O
medical	-	498	O
literature	-	506	O
.	-	516	O

Clinicians	15686794	518	O
should	-	529	O
be	-	536	O
aware	-	539	O
of	-	545	O
this	-	548	O
reaction	-	553	O
since	-	562	O
prompt	-	568	O
termination	-	575	O
of	-	587	O
parenteral	-	590	O
administration	-	601	O
leads	-	616	O
to	-	622	O
complete	-	625	O
resolution	-	634	O
.	-	644	O

Postoperative	12760988	0	B
myalgia	-	14	I
after	-	22	O
succinylcholine	-	28	O
:	-	43	O
no	-	45	O
evidence	-	48	O
for	-	57	O
an	-	61	O
inflammatory	-	64	O
origin	-	77	O
.	-	83	O

A	12760988	85	O
common	-	87	O
side	-	94	O
effect	-	99	O
associated	-	106	O
with	-	117	O
succinylcholine	-	122	O
is	-	138	O
postoperative	-	141	B
myalgia	-	155	I
.	-	162	O

The	12760988	164	O
pathogenesis	-	168	O
of	-	181	O
this	-	184	O
myalgia	-	189	B
is	-	197	O
still	-	200	O
unclear	-	206	O
;	-	213	O
inflammation	-	215	B
has	-	228	O
been	-	232	O
suggested	-	237	O
but	-	247	O
without	-	251	O
convincing	-	259	O
evidence	-	270	O
.	-	278	O

We	12760988	280	O
designed	-	283	O
the	-	292	O
present	-	296	O
study	-	304	O
to	-	310	O
investigate	-	313	O
whether	-	325	O
an	-	333	O
inflammatory	-	336	O
reaction	-	349	O
contributes	-	358	O
to	-	370	O
this	-	373	O
myalgia	-	378	B
.	-	385	O

The	12760988	387	O
incidence	-	391	O
and	-	401	O
severity	-	405	O
of	-	414	O
succinylcholine	-	417	O
-	-	432	O
associated	-	433	O
myalgia	-	444	B
was	-	452	O
determined	-	456	O
in	-	467	O
64	-	470	O
patients	-	473	O
pretreated	-	482	O
with	-	493	O
saline	-	498	O
or	-	505	O
dexamethasone	-	508	O
before	-	522	O
succinylcholine	-	529	O
(	-	545	O
n	-	546	O
=	-	548	O
32	-	550	O
for	-	553	O
each	-	557	O
)	-	561	O
.	-	562	O

Incidence	12760988	564	O
and	-	574	O
severity	-	578	O
of	-	587	O
myalgia	-	590	B
did	-	598	O
not	-	602	O
differ	-	606	O
significantly	-	613	O
between	-	627	O
the	-	635	O
two	-	639	O
groups	-	643	O
:	-	649	O
15	-	651	O
patients	-	654	O
in	-	663	O
the	-	666	O
dexamethasone	-	670	O
group	-	684	O
complained	-	690	O
of	-	701	O
myalgia	-	704	B
compared	-	712	O
with	-	721	O
18	-	726	O
patients	-	729	O
in	-	738	O
the	-	741	O
saline	-	745	O
group	-	752	O
,	-	757	O
and	-	759	O
severe	-	763	O
myalgia	-	770	B
was	-	778	O
reported	-	782	O
by	-	791	O
five	-	794	O
patients	-	799	O
and	-	808	O
three	-	812	O
patients	-	818	O
,	-	826	O
respectively	-	828	O
(	-	841	O
not	-	842	O
significant	-	846	O
)	-	857	O
.	-	858	O

At	12760988	860	O
48	-	863	O
h	-	866	O
after	-	868	O
surgery	-	874	O
,	-	881	O
12	-	883	O
patients	-	886	O
in	-	895	O
both	-	898	O
groups	-	903	O
still	-	910	O
suffered	-	916	O
from	-	925	O
myalgia	-	930	B
(	-	938	O
not	-	939	O
significant	-	943	O
)	-	954	O
.	-	955	O

In	12760988	957	O
addition	-	960	O
,	-	968	O
interleukin	-	970	O
-	-	981	O
6	-	982	O
(	-	984	O
IL	-	985	O
-	-	987	O
6	-	988	O
)	-	989	O
as	-	991	O
an	-	994	O
early	-	997	O
marker	-	1003	O
of	-	1010	O
inflammation	-	1013	B
was	-	1026	O
assessed	-	1030	O
in	-	1039	O
a	-	1042	O
subgroup	-	1044	O
of	-	1053	O
10	-	1056	O
patients	-	1059	O
pretreated	-	1068	O
with	-	1079	O
saline	-	1084	O
.	-	1090	O

We	12760988	1092	O
found	-	1095	O
an	-	1101	O
increase	-	1104	O
of	-	1113	O
IL	-	1116	O
-	-	1118	O
6	-	1119	O
for	-	1121	O
only	-	1125	O
three	-	1130	O
patients	-	1136	O
,	-	1144	O
but	-	1146	O
only	-	1150	O
one	-	1155	O
patient	-	1159	O
reported	-	1167	O
myalgia	-	1176	B
;	-	1183	O
no	-	1185	O
relationship	-	1188	O
between	-	1201	O
myalgia	-	1209	B
and	-	1217	O
the	-	1221	O
increase	-	1225	O
of	-	1234	O
IL	-	1237	O
-	-	1239	O
6	-	1240	O
was	-	1242	O
found	-	1246	O
.	-	1251	O

In	12760988	1253	O
conclusion	-	1256	O
,	-	1266	O
there	-	1268	O
is	-	1274	O
no	-	1277	O
evidence	-	1280	O
for	-	1289	O
an	-	1293	O
inflammatory	-	1296	O
origin	-	1309	O
of	-	1316	O
succinylcholine	-	1319	O
-	-	1334	O
associated	-	1335	O
myalgia	-	1346	B
.	-	1353	O

IMPLICATIONS	12760988	1355	O
:	-	1367	O

Administration	12760988	1369	O
of	-	1384	O
dexamethasone	-	1387	O
before	-	1401	O
succinylcholine	-	1408	O
was	-	1424	O
not	-	1428	O
effective	-	1432	O
in	-	1442	O
decreasing	-	1445	O
the	-	1456	O
incidence	-	1460	O
or	-	1470	O
the	-	1473	O
severity	-	1477	O
of	-	1486	O
succinylcholine	-	1489	O
-	-	1504	O
induced	-	1505	O
postoperative	-	1513	B
myalgia	-	1527	I
.	-	1534	O

Furthermore	12760988	1536	O
,	-	1547	O
there	-	1549	O
was	-	1555	O
no	-	1559	O
significant	-	1562	O
relationship	-	1574	O
between	-	1587	O
postoperative	-	1595	B
myalgia	-	1609	I
and	-	1617	O
time	-	1621	O
course	-	1626	O
of	-	1633	O
interleukin	-	1636	O
-	-	1647	O
6	-	1648	O
concentrations	-	1650	O
,	-	1664	O
a	-	1666	O
marker	-	1668	O
of	-	1675	O
inflammation	-	1678	B
.	-	1690	O

Pretreatment	12760988	1692	O
with	-	1705	O
dexamethasone	-	1710	O
is	-	1724	O
not	-	1727	O
justified	-	1731	O
to	-	1741	O
prevent	-	1744	O
postoperative	-	1752	B
myalgia	-	1766	I
after	-	1774	O
succinylcholine	-	1780	O
.	-	1795	O

Levodopa	12691807	0	O
-	-	8	O
induced	-	9	O
oromandibular	-	17	O
dystonia	-	31	B
in	-	40	O
progressive	-	43	B
supranuclear	-	55	I
palsy	-	68	I
.	-	73	O

Levodopa	12691807	75	O
-	-	83	O
induced	-	84	O
dyskinesias	-	92	B
have	-	104	O
been	-	109	O
reported	-	114	O
in	-	123	O
Parkinson	-	126	B
's	-	135	I
disease	-	138	I
and	-	146	O
multiple	-	150	B
system	-	159	I
atrophy	-	166	I
.	-	173	O

Cranial	12691807	175	O
dystonias	-	183	B
are	-	193	O
rare	-	197	O
in	-	202	O
patients	-	205	O
with	-	214	O
progressive	-	219	B
supranuclear	-	231	I
palsy	-	244	I
(	-	250	O
PSP	-	251	B
)	-	254	O
.	-	255	O

In	12691807	257	O
this	-	260	O
report	-	265	O
we	-	272	O
describe	-	275	O
an	-	284	O
unusual	-	287	O
case	-	295	O
of	-	300	O
reversible	-	303	O
levodopa	-	314	O
-	-	322	O
induced	-	323	O
Oromandibular	-	331	B
dystonia	-	345	I
(	-	354	O
OMD	-	355	B
)	-	358	O
in	-	360	O
a	-	363	O
PSP	-	365	B
patient	-	369	O
to	-	377	O
highlight	-	380	O
the	-	390	O
importance	-	394	O
of	-	405	O
recognizing	-	408	O
this	-	420	O
drug	-	425	O
related	-	430	O
complication	-	438	O
in	-	451	O
the	-	454	O
management	-	458	O
of	-	469	O
PSP	-	472	B
,	-	475	O
and	-	477	O
discuss	-	481	O
the	-	489	O
possible	-	493	O
underlying	-	502	O
pathophysiology	-	513	O
.	-	528	O

Protective	12600698	0	O
effect	-	11	O
of	-	18	O
edaravone	-	21	O
against	-	31	O
streptomycin	-	39	O
-	-	51	O
induced	-	52	O
vestibulotoxicity	-	60	B
in	-	78	O
the	-	81	O
guinea	-	85	O
pig	-	92	O
.	-	95	O

This	12600698	97	O
study	-	102	O
investigated	-	108	O
alleviation	-	121	O
of	-	133	O
streptomycin	-	136	O
-	-	148	O
induced	-	149	O
vestibulotoxicity	-	157	B
by	-	175	O
edaravone	-	178	O
in	-	188	O
guinea	-	191	O
pigs	-	198	O
.	-	202	O

Edaravone	12600698	204	O
,	-	213	O
a	-	215	O
free	-	217	O
radical	-	222	O
scavenger	-	230	O
,	-	239	O
has	-	241	O
potent	-	245	O
free	-	252	O
radical	-	257	O
quenching	-	265	O
action	-	275	O
and	-	282	O
is	-	286	O
used	-	289	O
in	-	294	O
clinical	-	297	O
practice	-	306	O
to	-	315	O
treat	-	318	O
cerebral	-	324	B
infarction	-	333	I
.	-	343	O

Streptomycin	12600698	345	O
was	-	358	O
administered	-	362	O
to	-	375	O
the	-	378	O
inner	-	382	O
ear	-	388	O
by	-	392	O
osmotic	-	395	O
pump	-	403	O
for	-	408	O
24	-	412	O
h	-	415	O
,	-	416	O
and	-	418	O
edaravone	-	422	O
(	-	432	O
n	-	433	O
=	-	434	O
8	-	435	O
)	-	436	O
or	-	438	O
saline	-	441	O
(	-	448	O
n	-	449	O
=	-	450	O
6	-	451	O
)	-	452	O
was	-	454	O
intraperitoneally	-	458	O
injected	-	476	O
once	-	485	O
a	-	490	O
day	-	492	O
for	-	496	O
7	-	500	O
days	-	502	O
.	-	506	O

We	12600698	508	O
observed	-	511	O
horizontal	-	520	O
vestibulo	-	531	O
-	-	540	O
ocular	-	541	O
reflex	-	548	O
as	-	555	O
a	-	558	O
marker	-	560	O
of	-	567	O
postoperative	-	570	O
vestibular	-	584	O
function	-	595	O
.	-	603	O

Animals	12600698	605	O
injected	-	613	O
with	-	622	O
saline	-	627	O
showed	-	634	O
statistically	-	641	O
smaller	-	655	O
gains	-	663	O
than	-	669	O
those	-	674	O
injected	-	680	O
with	-	689	O
edaravone	-	694	O
.	-	703	O

These	12600698	705	O
results	-	711	O
suggest	-	719	O
that	-	727	O
edaravone	-	732	O
suppresses	-	742	O
streptomycin	-	753	O
-	-	765	O
induced	-	766	O
vestibulotoxicity	-	774	B
.	-	791	O

Ketamine	12091028	0	O
in	-	9	O
war	-	12	O
/	-	15	O
tropical	-	16	O
surgery	-	25	O
(	-	33	O
a	-	34	O
final	-	36	O
tribute	-	42	O
to	-	50	O
the	-	53	O
racemic	-	57	O
mixture	-	65	O
)	-	72	O
.	-	73	O

A	12091028	75	O
technique	-	77	O
of	-	87	O
continuous	-	90	O
intravenous	-	101	O
anaesthesia	-	113	O
with	-	125	O
ketamine	-	130	O
was	-	139	O
used	-	143	O
successfully	-	148	O
during	-	161	O
the	-	168	O
Somalia	-	172	O
civil	-	180	O
war	-	186	O
in	-	190	O
1994	-	193	O
and	-	198	O
in	-	202	O
north	-	205	O
Uganda	-	211	O
in	-	218	O
1999	-	221	O
for	-	226	O
64	-	230	O
operations	-	233	O
in	-	244	O
62	-	247	O
patients	-	250	O
,	-	258	O
aged	-	260	O
from	-	265	O
6	-	270	O
weeks	-	272	O
to	-	278	O
70	-	281	O
years	-	284	O
,	-	289	O
undergoing	-	291	O
limb	-	302	O
and	-	307	O
abdominal	-	311	O
surgery	-	321	O
including	-	329	O
caesarian	-	339	O
sections	-	349	O
and	-	358	O
interventions	-	362	O
in	-	376	O
neonates	-	379	O
.	-	387	O

Operations	12091028	389	O
lasting	-	400	O
up	-	408	O
to	-	411	O
2h	-	414	O
could	-	417	O
be	-	423	O
performed	-	426	O
in	-	436	O
the	-	439	O
absence	-	443	O
of	-	451	O
sophisticated	-	454	O
equipment	-	468	O
such	-	478	O
as	-	483	O
pulse	-	486	O
oximeters	-	492	O
or	-	502	O
ventilators	-	505	O
in	-	517	O
patients	-	520	O
on	-	529	O
spontaneous	-	532	O
ventilation	-	544	O
breathing	-	556	O
air	-	566	O
/	-	569	O
oxygen	-	570	O
only	-	577	O
.	-	581	O

After	12091028	583	O
premedication	-	589	O
with	-	603	O
diazepam	-	608	O
,	-	616	O
glycopyrrolate	-	618	O
and	-	633	O
local	-	637	O
anaesthesia	-	643	O
,	-	654	O
and	-	656	O
induction	-	660	O
with	-	670	O
standard	-	675	O
doses	-	684	O
of	-	690	O
ketamine	-	693	O
,	-	701	O
a	-	703	O
maintenance	-	705	O
dose	-	717	O
of	-	722	O
10	-	725	O
-	-	727	O
20	-	728	O
microg	-	731	O
/	-	737	O
kg	-	738	O
/	-	740	O
min	-	741	O
of	-	745	O
ketamine	-	748	O
proved	-	757	O
safe	-	764	O
and	-	769	O
effective	-	773	O
.	-	782	O

Emphasis	12091028	784	O
was	-	793	O
placed	-	797	O
on	-	804	O
bedside	-	807	O
clinical	-	815	O
monitoring	-	824	O
,	-	834	O
relying	-	836	O
heavily	-	844	O
on	-	852	O
the	-	855	O
heart	-	859	O
rate	-	865	O
.	-	869	O

Diazepam	12091028	871	O
,	-	879	O
unless	-	881	O
contraindicated	-	888	O
or	-	904	O
risky	-	907	O
,	-	912	O
remains	-	914	O
the	-	922	O
only	-	926	O
necessary	-	931	O
complementary	-	941	O
drug	-	955	O
to	-	960	O
ketamine	-	963	O
as	-	972	O
it	-	975	O
buffers	-	978	O
its	-	986	O
cardiovascular	-	990	O
response	-	1005	O
and	-	1014	O
decreases	-	1018	O
the	-	1028	O
duration	-	1032	O
and	-	1041	O
intensity	-	1045	O
of	-	1055	O
operative	-	1058	O
and	-	1068	O
postoperative	-	1072	O
hallucinations	-	1086	B
.	-	1100	O

Local	12091028	1102	O
anaesthetic	-	1108	O
blocks	-	1120	O
were	-	1127	O
useful	-	1132	O
in	-	1139	O
decreasing	-	1142	O
the	-	1153	O
requirement	-	1157	O
for	-	1169	O
postoperative	-	1173	O
analgesia	-	1187	B
.	-	1196	O

An	12091028	1198	O
antisialogue	-	1201	O
was	-	1214	O
usually	-	1218	O
unnecessary	-	1226	O
in	-	1238	O
operations	-	1241	O
lasting	-	1252	O
up	-	1260	O
to	-	1263	O
2	-	1266	O
h	-	1268	O
,	-	1269	O
glycopyrrolate	-	1271	O
being	-	1286	O
the	-	1292	O
best	-	1296	O
choice	-	1301	O
for	-	1308	O
its	-	1312	O
lowest	-	1316	O
psychotropic	-	1323	O
and	-	1336	O
chronotropic	-	1340	O
effects	-	1353	O
,	-	1360	O
especially	-	1362	O
in	-	1373	O
a	-	1376	O
hot	-	1378	O
climate	-	1382	O
.	-	1389	O

Experience	12091028	1391	O
in	-	1402	O
war	-	1405	O
/	-	1408	O
tropical	-	1409	O
settings	-	1418	O
suggests	-	1427	O
this	-	1436	O
technique	-	1441	O
could	-	1451	O
be	-	1457	O
useful	-	1460	O
in	-	1467	O
civilian	-	1470	O
contexts	-	1479	O
such	-	1488	O
as	-	1493	O
outdoor	-	1496	O
life	-	1504	O
-	-	1508	O
saving	-	1509	O
emergency	-	1516	O
surgery	-	1526	O
or	-	1534	O
in	-	1537	O
mass	-	1540	O
casualties	-	1545	O
where	-	1556	O
,	-	1561	O
e	-	1563	O
.	-	1564	O
g	-	1565	O
.	-	1566	O
amputation	-	1568	O
and	-	1579	O
rapid	-	1583	O
extrication	-	1589	O
were	-	1601	O
required	-	1606	O
.	-	1614	O

Steroid	11860495	0	O
structure	-	8	O
and	-	18	O
pharmacological	-	22	O
properties	-	38	O
determine	-	49	O
the	-	59	O
anti	-	63	O
-	-	67	O
amnesic	-	68	B
effects	-	76	O
of	-	84	O
pregnenolone	-	87	O
sulphate	-	100	O
in	-	109	O
the	-	112	O
passive	-	116	O
avoidance	-	124	O
task	-	134	O
in	-	139	O
rats	-	142	O
.	-	146	O

Pregnenolone	11860495	148	O
sulphate	-	161	O
(	-	170	O
PREGS	-	171	O
)	-	176	O
has	-	178	O
generated	-	182	O
interest	-	192	O
as	-	201	O
one	-	204	O
of	-	208	O
the	-	211	O
most	-	215	O
potent	-	220	O
memory	-	227	O
-	-	233	O
enhancing	-	234	O
neurosteroids	-	244	O
to	-	258	O
be	-	261	O
examined	-	264	O
in	-	273	O
rodent	-	276	O
learning	-	283	O
studies	-	292	O
,	-	299	O
with	-	301	O
particular	-	306	O
importance	-	317	O
in	-	328	O
the	-	331	O
ageing	-	335	O
process	-	342	O
.	-	349	O

The	11860495	351	O
mechanism	-	355	O
by	-	365	O
which	-	368	O
this	-	374	O
endogenous	-	379	O
steroid	-	390	O
enhances	-	398	O
memory	-	407	O
formation	-	414	O
is	-	424	O
hypothesized	-	427	O
to	-	440	O
involve	-	443	O
actions	-	451	O
on	-	459	O
glutamatergic	-	462	O
and	-	476	O
GABAergic	-	480	O
systems	-	490	O
.	-	497	O

This	11860495	499	O
hypothesis	-	504	O
stems	-	515	O
from	-	521	O
findings	-	526	O
that	-	535	O
PREGS	-	540	O
is	-	546	O
a	-	549	O
potent	-	551	O
positive	-	558	O
modulator	-	567	O
of	-	577	O
N	-	580	O
-	-	581	O
methyl	-	582	O
-	-	588	O
d	-	589	O
-	-	590	O
aspartate	-	591	O
receptors	-	601	O
(	-	611	O
NMDARs	-	612	O
)	-	618	O
and	-	620	O
a	-	624	O
negative	-	626	O
modulator	-	635	O
of	-	645	O
gamma	-	648	O
-	-	653	O
aminobutyric	-	654	O
acid	-	667	O
(	-	671	O
A	-	672	O
)	-	673	O
receptors	-	675	O
(	-	685	O
GABA	-	686	O
(	-	690	O
A	-	691	O
)	-	692	O
Rs	-	693	O
)	-	695	O
.	-	696	O

Moreover	11860495	698	O
,	-	706	O
PREGS	-	708	O
is	-	714	O
able	-	717	O
to	-	722	O
reverse	-	725	O
the	-	733	O
amnesic	-	737	B
-	-	744	O
like	-	745	O
effects	-	750	O
of	-	758	O
NMDAR	-	761	O
and	-	767	O
GABA	-	771	O
(	-	775	O
A	-	776	O
)	-	777	O
R	-	778	O
ligands	-	780	O
.	-	787	O

To	11860495	789	O
investigate	-	792	O
this	-	804	O
hypothesis	-	809	O
,	-	819	O
the	-	821	O
present	-	825	O
study	-	833	O
in	-	839	O
rats	-	842	O
examined	-	847	O
the	-	856	O
memory	-	860	O
-	-	866	O
altering	-	867	O
abilities	-	876	O
of	-	886	O
structural	-	889	O
analogs	-	900	O
of	-	908	O
PREGS	-	911	O
,	-	916	O
which	-	918	O
differ	-	924	O
in	-	931	O
their	-	934	O
modulation	-	940	O
of	-	951	O
NMDAR	-	954	O
and	-	960	O
/	-	963	O
or	-	964	O
GABA	-	967	O
(	-	971	O
A	-	972	O
)	-	973	O
R	-	974	O
function	-	976	O
.	-	984	O

The	11860495	986	O
analogs	-	990	O
tested	-	998	O
were	-	1005	O
:	-	1009	O
11	-	1011	O
-	-	1013	O
ketopregnenolone	-	1014	O
sulphate	-	1031	O
(	-	1040	O
an	-	1041	O
agent	-	1044	O
that	-	1050	O
is	-	1055	O
inactive	-	1058	O
at	-	1067	O
GABA	-	1070	O
(	-	1074	O
A	-	1075	O
)	-	1076	O
Rs	-	1077	O
and	-	1080	O
NMDARs	-	1084	O
)	-	1090	O
,	-	1091	O
epipregnanolone	-	1093	O
(	-	1109	O
[	-	1110	O
3beta	-	1111	O
-	-	1116	O
hydroxy	-	1117	O
-	-	1124	O
5beta	-	1125	O
-	-	1130	O
pregnan	-	1131	O
-	-	1138	O
20	-	1139	O
-	-	1141	O
one	-	1142	O
]	-	1145	O
sulphate	-	1147	O
,	-	1155	O
an	-	1157	O
inhibitor	-	1160	O
of	-	1170	O
both	-	1173	O
GABA	-	1178	O
(	-	1182	O
A	-	1183	O
)	-	1184	O
Rs	-	1185	O
and	-	1188	O
NMDARs	-	1192	O
)	-	1198	O
,	-	1199	O
and	-	1201	O
a	-	1205	O
newly	-	1207	O
synthesized	-	1213	O
(	-	1225	O
-	-	1226	O
)	-	1227	O
PREGS	-	1229	O
enantiomer	-	1235	O
(	-	1246	O
which	-	1247	O
is	-	1253	O
identical	-	1256	O
to	-	1266	O
PREGS	-	1269	O
in	-	1275	O
effects	-	1278	O
on	-	1286	O
GABA	-	1289	O
(	-	1293	O
A	-	1294	O
)	-	1295	O
Rs	-	1296	O
and	-	1299	O
NMDARs	-	1303	O
)	-	1309	O
.	-	1310	O

The	11860495	1312	O
memory	-	1316	O
-	-	1322	O
enhancing	-	1323	O
effects	-	1333	O
of	-	1341	O
PREGS	-	1344	O
and	-	1350	O
its	-	1354	O
analogs	-	1358	O
were	-	1366	O
tested	-	1371	O
in	-	1378	O
the	-	1381	O
passive	-	1385	O
avoidance	-	1393	O
task	-	1403	O
using	-	1408	O
the	-	1414	O
model	-	1418	O
of	-	1424	O
scopolamine	-	1427	O
-	-	1438	O
induced	-	1439	O
amnesia	-	1447	B
.	-	1454	O

Both	11860495	1456	O
PREGS	-	1461	O
and	-	1467	O
its	-	1471	O
(	-	1475	O
-	-	1476	O
)	-	1477	O
enantiomer	-	1479	O
blocked	-	1490	O
the	-	1498	O
effects	-	1502	O
of	-	1510	O
scopolamine	-	1513	O
.	-	1524	O

The	11860495	1526	O
results	-	1530	O
show	-	1538	O
that	-	1543	O
,	-	1547	O
unlike	-	1549	O
PREGS	-	1556	O
,	-	1561	O
11	-	1563	O
-	-	1565	O
ketopregnenolone	-	1566	O
sulphate	-	1583	O
and	-	1592	O
epipregnanolone	-	1596	O
sulphate	-	1612	O
failed	-	1621	O
to	-	1628	O
block	-	1631	O
the	-	1637	O
effect	-	1641	O
of	-	1648	O
scopolamine	-	1651	O
,	-	1662	O
suggesting	-	1664	O
that	-	1675	O
altering	-	1680	O
the	-	1689	O
modulation	-	1693	O
of	-	1704	O
NMDA	-	1707	O
receptors	-	1712	O
diminishes	-	1722	O
the	-	1733	O
memory	-	1737	O
-	-	1743	O
enhancing	-	1744	O
effects	-	1754	O
of	-	1762	O
PREGS	-	1765	O
.	-	1770	O

Moreover	11860495	1772	O
,	-	1780	O
enantioselectivity	-	1782	O
was	-	1801	O
demonstrated	-	1805	O
by	-	1818	O
the	-	1821	O
ability	-	1825	O
of	-	1833	O
natural	-	1836	O
PREGS	-	1844	O
to	-	1850	O
be	-	1853	O
an	-	1856	O
order	-	1859	O
of	-	1865	O
magnitude	-	1868	O
more	-	1878	O
effective	-	1883	O
than	-	1893	O
its	-	1898	O
synthetic	-	1902	O
enantiomer	-	1912	O
in	-	1923	O
reversing	-	1926	O
scopolamine	-	1936	O
-	-	1947	O
induced	-	1948	O
amnesia	-	1956	B
.	-	1963	O

These	11860495	1965	O
results	-	1971	O
identify	-	1979	O
a	-	1988	O
novel	-	1990	O
neuropharmacological	-	1996	O
site	-	2017	O
for	-	2022	O
the	-	2026	O
modulation	-	2030	O
of	-	2041	O
memory	-	2044	O
processes	-	2051	O
by	-	2061	O
neuroactive	-	2064	O
steroids	-	2076	O
.	-	2084	O

Preliminary	11752998	0	O
efficacy	-	12	O
assessment	-	21	O
of	-	32	O
intrathecal	-	35	O
injection	-	47	O
of	-	57	O
an	-	60	O
American	-	63	O
formulation	-	72	O
of	-	84	O
adenosine	-	87	O
in	-	97	O
humans	-	100	O
.	-	106	O

BACKGROUND	11752998	108	O
:	-	118	O

Preclinical	11752998	120	O
studies	-	132	O
of	-	140	O
intrathecal	-	143	O
adenosine	-	155	O
suggest	-	165	O
it	-	173	O
may	-	176	O
be	-	180	O
effective	-	183	O
in	-	193	O
the	-	196	O
treatment	-	200	O
of	-	210	O
acute	-	213	B
and	-	219	I
chronic	-	223	I
pain	-	231	I
in	-	236	O
humans	-	239	O
,	-	245	O
and	-	247	O
preliminary	-	251	O
studies	-	263	O
in	-	271	O
volunteers	-	274	O
and	-	285	O
patients	-	289	O
with	-	298	O
a	-	303	O
Swedish	-	305	O
formulation	-	313	O
of	-	325	O
adenosine	-	328	O
suggests	-	338	O
it	-	347	O
may	-	350	O
be	-	354	O
effective	-	357	O
in	-	367	O
hypersensitivity	-	370	B
states	-	387	O
but	-	394	O
not	-	398	O
with	-	402	O
acute	-	407	O
noxious	-	413	O
stimulation	-	421	O
.	-	432	O

The	11752998	434	O
purpose	-	438	O
of	-	446	O
this	-	449	O
study	-	454	O
was	-	460	O
to	-	464	O
screen	-	467	O
for	-	474	O
efficacy	-	478	O
of	-	487	O
a	-	490	O
different	-	492	O
formulation	-	502	O
of	-	514	O
adenosine	-	517	O
marketed	-	527	O
in	-	536	O
the	-	539	O
US	-	543	O
,	-	545	O
using	-	547	O
both	-	553	O
acute	-	558	O
noxious	-	564	O
stimulation	-	572	O
and	-	584	O
capsaicin	-	588	O
-	-	597	O
evoked	-	598	O
mechanical	-	605	O
hypersensitivity	-	616	B
.	-	632	O

METHODS	11752998	634	O
:	-	641	O

Following	11752998	643	O
Food	-	653	O
and	-	658	O
Drug	-	662	O
Administration	-	667	O
and	-	682	O
institutional	-	686	O
review	-	700	O
board	-	707	O
approval	-	713	O
and	-	722	O
written	-	726	O
informed	-	734	O
consent	-	743	O
,	-	750	O
65	-	752	O
volunteers	-	755	O
were	-	766	O
studied	-	771	O
in	-	779	O
two	-	782	O
trials	-	786	O
:	-	792	O
an	-	794	O
open	-	797	O
-	-	801	O
label	-	802	O
,	-	807	O
dose	-	809	O
-	-	813	O
escalating	-	814	O
trial	-	825	O
with	-	831	O
intrathecal	-	836	O
adenosine	-	848	O
doses	-	858	O
of	-	864	O
0	-	867	O
.	-	868	O
25	-	869	O
-	-	871	O
2	-	872	O
.	-	873	O
0	-	874	O
mg	-	876	O
and	-	879	O
a	-	883	O
double	-	885	O
-	-	891	O
blind	-	892	O
,	-	897	O
placebo	-	899	O
-	-	906	O
controlled	-	907	O
trial	-	918	O
of	-	924	O
adenosine	-	927	O
,	-	936	O
2	-	938	O
mg	-	940	O
.	-	942	O

Cerebrospinal	11752998	944	O
fluid	-	958	O
was	-	964	O
obtained	-	968	O
for	-	977	O
pharmacokinetic	-	981	O
analysis	-	997	O
,	-	1005	O
and	-	1007	O
pain	-	1011	B
ratings	-	1016	O
in	-	1024	O
response	-	1027	O
to	-	1036	O
acute	-	1039	O
heat	-	1045	O
stimuli	-	1050	O
and	-	1058	O
areas	-	1062	O
of	-	1068	O
mechanical	-	1071	B
hyperalgesia	-	1082	I
and	-	1095	O
allodynia	-	1099	B
after	-	1109	O
intradermal	-	1115	O
capsaicin	-	1127	O
injection	-	1137	O
were	-	1147	O
determined	-	1152	O
.	-	1162	O

RESULTS	11752998	1164	O
:	-	1171	O

Adenosine	11752998	1173	O
produced	-	1183	O
no	-	1192	O
effect	-	1195	O
on	-	1202	O
pain	-	1205	B
report	-	1210	O
to	-	1217	O
acute	-	1220	O
noxious	-	1226	O
thermal	-	1234	O
or	-	1242	O
chemical	-	1245	O
stimulation	-	1254	O
but	-	1266	O
reduced	-	1270	O
mechanical	-	1278	B
hyperalgesia	-	1289	I
and	-	1302	O
allodynia	-	1306	B
from	-	1316	O
intradermal	-	1321	O
capsaicin	-	1333	O
injection	-	1343	O
for	-	1353	O
at	-	1357	O
least	-	1360	O
24	-	1366	O
h	-	1369	O
.	-	1370	O

In	11752998	1372	O
contrast	-	1375	O
,	-	1383	O
residence	-	1385	O
time	-	1395	O
of	-	1400	O
adenosine	-	1403	O
in	-	1413	O
cerebrospinal	-	1416	O
fluid	-	1430	O
was	-	1436	O
short	-	1440	O
(	-	1446	O
<	-	1447	O
4	-	1449	O
h	-	1451	O
)	-	1452	O
.	-	1453	O

CONCLUSIONS	11752998	1455	O
:	-	1466	O

These	11752998	1468	O
results	-	1474	O
show	-	1482	O
selective	-	1487	O
inhibition	-	1497	O
by	-	1508	O
intrathecal	-	1511	O
adenosine	-	1523	O
of	-	1533	O
hypersensitivity	-	1536	B
,	-	1552	O
presumed	-	1554	O
to	-	1563	O
reflect	-	1566	O
central	-	1574	O
sensitization	-	1582	O
in	-	1596	O
humans	-	1599	O
after	-	1606	O
peripheral	-	1612	O
capsaicin	-	1623	O
injection	-	1633	O
.	-	1642	O

The	11752998	1644	O
long	-	1648	O
-	-	1652	O
lasting	-	1653	O
effect	-	1661	O
is	-	1668	O
consistent	-	1671	O
with	-	1682	O
that	-	1687	O
observed	-	1692	O
in	-	1701	O
preliminary	-	1704	O
reports	-	1716	O
of	-	1724	O
patients	-	1727	O
with	-	1736	O
chronic	-	1741	O
neuropathic	-	1749	B
pain	-	1761	I
and	-	1766	O
is	-	1770	O
not	-	1773	O
due	-	1777	O
to	-	1781	O
prolonged	-	1784	O
residence	-	1794	O
of	-	1804	O
adenosine	-	1807	O
in	-	1817	O
cerebrospinal	-	1820	O
fluid	-	1834	O
.	-	1839	O

Effect	10354657	0	O
of	-	7	O
lithium	-	10	O
maintenance	-	18	O
therapy	-	30	O
on	-	38	O
thyroid	-	41	O
and	-	49	O
parathyroid	-	53	O
function	-	65	O
.	-	73	O

OBJECTIVES	10354657	75	O
:	-	85	O

To	10354657	87	O
assess	-	90	O
changes	-	97	O
induced	-	105	O
by	-	113	O
lithium	-	116	O
maintenance	-	124	O
therapy	-	136	O
on	-	144	O
the	-	147	O
incidence	-	151	O
of	-	161	O
thyroid	-	164	O
,	-	171	O
parathyroid	-	173	O
and	-	185	O
ion	-	189	O
alterations	-	193	O
.	-	204	O

These	10354657	206	O
were	-	212	O
evaluated	-	217	O
with	-	227	O
respect	-	232	O
to	-	240	O
the	-	243	O
duration	-	247	O
of	-	256	O
lithium	-	259	O
therapy	-	267	O
,	-	274	O
age	-	276	O
,	-	279	O
sex	-	281	O
,	-	284	O
and	-	286	O
family	-	290	O
history	-	297	O
(	-	305	O
whether	-	306	O
or	-	314	O
not	-	317	O
the	-	321	O
patient	-	325	O
had	-	333	O
a	-	337	O
first	-	339	O
-	-	344	O
degree	-	345	O
relative	-	352	O
with	-	361	O
thyroid	-	366	B
disease	-	374	I
)	-	381	O
.	-	382	O

DESIGN	10354657	384	O
:	-	390	O

Prospective	10354657	392	O
study	-	404	O
.	-	409	O

SETTING	10354657	411	O
:	-	418	O

Affective	10354657	420	O
Disorders	-	430	O
Clinic	-	440	O
at	-	447	O
St	-	450	O
.	-	452	O
Mary	-	454	O
's	-	458	O
Hospital	-	461	O
,	-	469	O
Montreal	-	471	O
.	-	479	O

PATIENTS	10354657	481	O
:	-	489	O

One	10354657	491	O
hundred	-	495	O
and	-	503	O
one	-	507	O
patients	-	511	O
(	-	520	O
28	-	521	O
men	-	524	O
and	-	528	O
73	-	532	O
women	-	535	O
)	-	540	O
with	-	542	O
bipolar	-	547	B
disorder	-	555	I
receiving	-	564	O
lithium	-	574	O
maintenance	-	582	O
therapy	-	594	O
ranging	-	602	O
from	-	610	O
1	-	615	O
year	-	617	O
's	-	621	O
to	-	624	O
32	-	627	O
years	-	630	O
'	-	635	O
duration	-	637	O
.	-	645	O

The	10354657	647	O
control	-	651	O
group	-	659	O
consisted	-	665	O
of	-	675	O
82	-	678	O
patients	-	681	O
with	-	690	O
no	-	695	O
psychiatric	-	698	B
or	-	710	O
endocrinological	-	713	O
diagnoses	-	730	O
from	-	740	O
the	-	745	O
hospital	-	749	O
's	-	757	O
out	-	760	O
-	-	763	O
patient	-	764	O
clinics	-	772	O
.	-	779	O

OUTCOME	10354657	781	O
MEASURES	-	789	O
:	-	797	O

Laboratory	10354657	799	O
analyses	-	810	O
of	-	819	O
calcium	-	822	O
,	-	829	O
magnesium	-	831	O
and	-	841	O
thyroid	-	845	O
-	-	852	O
stimulating	-	853	O
hormone	-	865	O
levels	-	873	O
performed	-	880	O
before	-	890	O
beginning	-	897	O
lithium	-	907	O
therapy	-	915	O
and	-	923	O
at	-	927	O
biannual	-	930	O
follow	-	939	O
-	-	945	O
up	-	946	O
.	-	948	O

RESULTS	10354657	950	O
:	-	957	O

Hypothyroidism	10354657	959	B
developed	-	974	O
in	-	984	O
40	-	987	O
patients	-	990	O
,	-	998	O
excluding	-	1000	O
8	-	1010	O
patients	-	1012	O
who	-	1021	O
were	-	1025	O
hypothyroid	-	1030	B
at	-	1042	O
baseline	-	1045	O
.	-	1053	O

All	10354657	1055	O
patients	-	1059	O
having	-	1068	O
first	-	1075	O
-	-	1080	O
degree	-	1081	O
relatives	-	1088	O
affected	-	1098	O
by	-	1107	O
thyroid	-	1110	B
illness	-	1118	I
had	-	1126	O
accelerated	-	1130	O
onset	-	1142	O
of	-	1148	O
hypothyroidism	-	1151	B
(	-	1166	O
3	-	1167	O
.	-	1168	O
7	-	1169	O
years	-	1171	O
after	-	1177	O
onset	-	1183	O
of	-	1189	O
lithium	-	1192	O
therapy	-	1200	O
)	-	1207	O
compared	-	1209	O
with	-	1218	O
patients	-	1223	O
without	-	1232	O
a	-	1240	O
family	-	1242	O
history	-	1249	O
(	-	1257	O
8	-	1258	O
.	-	1259	O
6	-	1260	O
years	-	1262	O
after	-	1268	O
onset	-	1274	O
of	-	1280	O
lithium	-	1283	O
therapy	-	1291	O
)	-	1298	O
.	-	1299	O

Women	10354657	1301	O
over	-	1307	O
60	-	1312	O
years	-	1315	O
of	-	1321	O
age	-	1324	O
were	-	1328	O
more	-	1333	O
often	-	1338	O
affected	-	1344	O
by	-	1353	O
hypothyroidism	-	1356	B
than	-	1371	O
women	-	1376	O
under	-	1382	O
60	-	1388	O
years	-	1391	O
of	-	1397	O
age	-	1400	O
(	-	1404	O
34	-	1405	O
.	-	1407	O
6	-	1408	O
%	-	1409	O
versus	-	1411	O
31	-	1418	O
.	-	1420	O
9	-	1421	O
%	-	1422	O
)	-	1423	O
.	-	1424	O

Magnesium	10354657	1426	O
levels	-	1436	O
in	-	1443	O
patients	-	1446	O
on	-	1455	O
lithium	-	1458	O
treatment	-	1466	O
were	-	1476	O
unchanged	-	1481	O
from	-	1491	O
baseline	-	1496	O
levels	-	1505	O
.	-	1511	O

After	10354657	1513	O
lithium	-	1519	O
treatment	-	1527	O
,	-	1536	O
calcium	-	1538	O
levels	-	1546	O
were	-	1553	O
higher	-	1558	O
than	-	1565	O
either	-	1570	O
baseline	-	1577	O
levels	-	1586	O
or	-	1593	O
control	-	1596	O
levels	-	1604	O
.	-	1610	O

Thus	10354657	1612	O
,	-	1616	O
lithium	-	1618	O
treatment	-	1626	O
counteracted	-	1636	O
the	-	1649	O
decrease	-	1653	O
in	-	1662	O
plasma	-	1665	O
calcium	-	1672	O
levels	-	1680	O
associated	-	1687	O
with	-	1698	O
aging	-	1703	O
.	-	1708	O

CONCLUSIONS	10354657	1710	O
:	-	1721	O

Familial	10354657	1723	O
thyroid	-	1732	B
illness	-	1740	I
is	-	1748	O
a	-	1751	O
risk	-	1753	O
factor	-	1758	O
for	-	1765	O
hypothyroidism	-	1769	B
and	-	1784	O
hypercalcemia	-	1788	B
during	-	1802	O
lithium	-	1809	O
therapy	-	1817	O
.	-	1824	O

Systemic	10328196	0	O
toxicity	-	9	B
following	-	18	O
administration	-	28	O
of	-	43	O
sirolimus	-	46	O
(	-	56	O
formerly	-	57	O
rapamycin	-	66	O
)	-	75	O
for	-	77	O
psoriasis	-	81	B
:	-	90	O
association	-	92	O
of	-	104	O
capillary	-	107	B
leak	-	117	I
syndrome	-	122	I
with	-	131	O
apoptosis	-	136	O
of	-	146	O
lesional	-	149	O
lymphocytes	-	158	O
.	-	169	O

BACKGROUND	10328196	171	O
:	-	181	O
Sirolimus	-	183	O
(	-	193	O
formerly	-	194	O
rapamycin	-	203	O
)	-	212	O
is	-	214	O
an	-	217	O
immunosuppressive	-	220	O
agent	-	238	O
that	-	244	O
interferes	-	249	O
with	-	260	O
T	-	265	O
-	-	266	O
cell	-	267	O
activation	-	272	O
.	-	282	O

After	10328196	284	O
2	-	290	O
individuals	-	292	O
with	-	304	O
psoriasis	-	309	B
developed	-	319	O
a	-	329	O
capillary	-	331	B
leak	-	341	I
syndrome	-	346	I
following	-	355	O
treatment	-	365	O
with	-	375	O
oral	-	380	O
sirolimus	-	385	O
lesional	-	395	O
skin	-	404	O
cells	-	409	O
and	-	415	O
activated	-	419	O
peripheral	-	429	O
blood	-	440	O
cells	-	446	O
were	-	452	O
analyzed	-	457	O
for	-	466	O
induction	-	470	O
of	-	480	O
apoptosis	-	483	O
.	-	492	O

OBSERVATIONS	10328196	494	O
:	-	506	O

A	10328196	508	O
keratome	-	510	O
skin	-	519	O
specimen	-	524	O
from	-	533	O
1	-	538	O
patient	-	540	O
with	-	548	O
sirolimus	-	553	O
-	-	562	O
induced	-	563	O
capillary	-	571	B
leak	-	581	I
syndrome	-	586	I
had	-	595	O
a	-	599	O
2	-	601	O
.	-	602	O
3	-	603	O
-	-	604	O
fold	-	605	O
increase	-	610	O
in	-	619	O
percentage	-	622	O
of	-	633	O
apoptotic	-	636	O
cells	-	646	O
(	-	652	O
to	-	653	O
48	-	656	O
%	-	658	O
)	-	659	O
compared	-	661	O
with	-	670	O
an	-	675	O
unaffected	-	678	O
sirolimus	-	689	O
-	-	698	O
treated	-	699	O
patient	-	707	O
with	-	715	O
psoriasis	-	720	B
(	-	730	O
21	-	731	O
%	-	733	O
)	-	734	O
.	-	735	O

Activated	10328196	737	O
peripheral	-	747	O
blood	-	758	O
T	-	764	O
cells	-	766	O
from	-	772	O
patients	-	777	O
with	-	786	O
psoriasis	-	791	B
tended	-	801	O
to	-	808	O
exhibit	-	811	O
greater	-	819	O
spontaneous	-	827	O
or	-	839	O
dexamethasone	-	842	O
-	-	855	O
induced	-	856	O
apoptosis	-	864	O
than	-	874	O
did	-	879	O
normal	-	883	O
T	-	890	O
cells	-	892	O
,	-	897	O
particularly	-	899	O
in	-	912	O
the	-	915	O
presence	-	919	O
of	-	928	O
sirolimus	-	931	O
.	-	940	O

CONCLUSIONS	10328196	942	O
:	-	953	O

Severe	10328196	955	O
adverse	-	962	O
effects	-	970	O
of	-	978	O
sirolimus	-	981	O
include	-	991	O
fever	-	999	B
,	-	1004	O
anemia	-	1006	B
,	-	1012	O
and	-	1014	O
capillary	-	1018	B
leak	-	1028	I
syndrome	-	1033	I
.	-	1041	O

These	10328196	1043	O
symptoms	-	1049	O
may	-	1058	O
be	-	1062	O
the	-	1065	O
result	-	1069	O
of	-	1076	O
drug	-	1079	O
-	-	1083	O
induced	-	1084	O
apoptosis	-	1092	O
of	-	1102	O
lesional	-	1105	O
leukocytes	-	1114	O
,	-	1124	O
especially	-	1126	O
activated	-	1137	O
T	-	1147	O
lymphocytes	-	1149	O
,	-	1160	O
and	-	1162	O
possibly	-	1166	O
release	-	1175	O
of	-	1183	O
inflammatory	-	1186	O
mediators	-	1199	O
.	-	1208	O

Because	10328196	1210	O
patients	-	1218	O
with	-	1227	O
severe	-	1232	O
psoriasis	-	1239	B
may	-	1249	O
develop	-	1253	O
capillary	-	1261	B
leak	-	1271	I
from	-	1276	O
various	-	1281	O
systemic	-	1289	O
therapies	-	1298	O
,	-	1307	O
clinical	-	1309	O
monitoring	-	1318	O
is	-	1329	O
advisable	-	1332	O
for	-	1342	O
patients	-	1346	O
with	-	1355	O
inflammatory	-	1360	B
diseases	-	1373	I
who	-	1382	O
are	-	1386	O
treated	-	1390	O
with	-	1398	O
immune	-	1403	O
modulators	-	1410	O
.	-	1420	O

Contribution	9630698	0	O
of	-	13	O
the	-	16	O
glycine	-	20	O
site	-	28	O
of	-	33	O
NMDA	-	36	O
receptors	-	41	O
in	-	51	O
rostral	-	54	O
and	-	62	O
intermediate	-	66	O
-	-	78	O
caudal	-	79	O
parts	-	86	O
of	-	92	O
the	-	95	O
striatum	-	99	O
to	-	108	O
the	-	111	O
regulation	-	115	O
of	-	126	O
muscle	-	129	O
tone	-	136	O
in	-	141	O
rats	-	144	O
.	-	148	O

The	9630698	150	O
aim	-	154	O
of	-	158	O
the	-	161	O
present	-	165	O
study	-	173	O
was	-	179	O
to	-	183	O
assess	-	186	O
the	-	193	O
contribution	-	197	O
of	-	210	O
the	-	213	O
glycine	-	217	O
site	-	225	O
of	-	230	O
NMDA	-	233	O
receptors	-	238	O
in	-	248	O
the	-	251	O
striatum	-	255	O
to	-	264	O
the	-	267	O
regulation	-	271	O
of	-	282	O
muscle	-	285	O
tone	-	292	O
.	-	296	O

Muscle	9630698	298	O
tone	-	305	O
was	-	310	O
examined	-	314	O
using	-	323	O
a	-	329	O
combined	-	331	O
mechanoand	-	340	O
electromyographic	-	351	O
method	-	369	O
,	-	375	O
which	-	377	O
measured	-	383	O
simultaneously	-	392	O
the	-	407	O
muscle	-	411	O
resistance	-	418	O
(	-	429	O
MMG	-	430	O
)	-	433	O
of	-	435	O
the	-	438	O
rat	-	442	O
's	-	445	O
hind	-	448	O
foot	-	453	O
to	-	458	O
passive	-	461	O
extension	-	469	O
and	-	479	O
flexion	-	483	O
in	-	491	O
the	-	494	O
ankle	-	498	O
joint	-	504	O
and	-	510	O
the	-	514	O
electromyographic	-	518	O
activity	-	536	O
(	-	545	O
EMG	-	546	O
)	-	549	O
of	-	551	O
the	-	554	O
antagonistic	-	558	O
muscles	-	571	O
of	-	579	O
that	-	582	O
joint	-	587	O
:	-	592	O
gastrocnemius	-	594	O
and	-	608	O
tibialis	-	612	O
anterior	-	621	O
.	-	629	O

Muscle	9630698	631	B
rigidity	-	638	I
was	-	647	O
induced	-	651	O
by	-	659	O
haloperidol	-	662	O
(	-	674	O
2	-	675	O
.	-	676	O
5	-	677	O
mg	-	679	O
/	-	681	O
kg	-	682	O
i	-	685	O
.	-	686	O
p	-	687	O
.	-	688	O
)	-	689	O
.	-	690	O

5	9630698	692	O
,	-	693	O
7	-	694	O
-	-	695	O
dichlorokynurenic	-	696	O
acid	-	714	O
(	-	719	O
5	-	720	O
,	-	721	O
7	-	722	O
-	-	723	O
DCKA	-	724	O
)	-	728	O
,	-	729	O
a	-	731	O
selective	-	733	O
glycine	-	743	O
site	-	751	O
antagonist	-	756	O
,	-	766	O
injected	-	768	O
in	-	777	O
doses	-	780	O
of	-	786	O
2	-	789	O
.	-	790	O
5	-	791	O
and	-	793	O
4	-	797	O
.	-	798	O
5	-	799	O
microg	-	801	O
/	-	807	O
0	-	808	O
.	-	809	O
5	-	810	O
microl	-	812	O
bilaterally	-	819	O
,	-	830	O
into	-	832	O
the	-	837	O
rostral	-	841	O
region	-	849	O
of	-	856	O
the	-	859	O
striatum	-	863	O
,	-	871	O
decreased	-	873	O
both	-	883	O
the	-	888	O
haloperidol	-	892	O
-	-	903	O
induced	-	904	O
muscle	-	912	B
rigidity	-	919	I
(	-	928	O
MMG	-	929	O
)	-	932	O
and	-	934	O
the	-	938	O
enhanced	-	942	O
electromyographic	-	951	O
activity	-	969	O
(	-	978	O
EMG	-	979	O
)	-	982	O
.	-	983	O

5	9630698	985	O
,	-	986	O
7	-	987	O
-	-	988	O
DCKA	-	989	O
injected	-	994	O
bilaterally	-	1003	O
in	-	1015	O
a	-	1018	O
dose	-	1020	O
of	-	1025	O
4	-	1028	O
.	-	1029	O
5	-	1030	O
microg	-	1032	O
/	-	1038	O
0	-	1039	O
.	-	1040	O
5	-	1041	O
microl	-	1043	O
into	-	1050	O
the	-	1055	O
intermediate	-	1059	O
-	-	1071	O
caudal	-	1072	O
region	-	1079	O
of	-	1086	O
the	-	1089	O
striatum	-	1093	O
of	-	1102	O
rats	-	1105	O
not	-	1110	O
pretreated	-	1114	O
with	-	1125	O
haloperidol	-	1130	O
had	-	1142	O
no	-	1146	O
effect	-	1149	O
on	-	1156	O
the	-	1159	O
muscle	-	1163	O
tone	-	1170	O
.	-	1174	O

The	9630698	1176	O
present	-	1180	O
results	-	1188	O
suggest	-	1196	O
that	-	1204	O
blockade	-	1209	O
of	-	1218	O
the	-	1221	O
glycine	-	1225	O
site	-	1233	O
of	-	1238	O
NMDA	-	1241	O
receptors	-	1246	O
in	-	1256	O
the	-	1259	O
rostral	-	1263	O
part	-	1271	O
of	-	1276	O
the	-	1279	O
striatum	-	1283	O
may	-	1292	O
be	-	1296	O
mainly	-	1299	O
responsible	-	1306	O
for	-	1318	O
the	-	1322	O
antiparkinsonian	-	1326	O
action	-	1343	O
of	-	1350	O
this	-	1353	O
drug	-	1358	O
.	-	1362	O

Efficacy	8480959	0	O
and	-	9	O
tolerability	-	13	O
of	-	26	O
lovastatin	-	29	O
in	-	40	O
3390	-	43	O
women	-	48	O
with	-	54	O
moderate	-	59	O
hypercholesterolemia	-	68	B
.	-	88	O

OBJECTIVE	8480959	90	O
:	-	99	O

To	8480959	101	O
evaluate	-	104	O
the	-	113	O
efficacy	-	117	O
and	-	126	O
safety	-	130	O
of	-	137	O
lovastatin	-	140	O
in	-	151	O
women	-	154	O
with	-	160	O
moderate	-	165	O
hypercholesterolemia	-	174	B
.	-	194	O

DESIGN	8480959	196	O
:	-	202	O

The	8480959	204	O
Expanded	-	208	O
Clinical	-	217	O
Evaluation	-	226	O
of	-	237	O
Lovastatin	-	240	O
(	-	251	O
EXCEL	-	252	O
)	-	257	O
Study	-	259	O
,	-	264	O
a	-	266	O
multicenter	-	268	O
,	-	279	O
double	-	281	O
-	-	287	O
blind	-	288	O
,	-	293	O
diet	-	295	O
-	-	299	O
and	-	301	O
placebo	-	305	O
-	-	312	O
controlled	-	313	O
trial	-	324	O
,	-	329	O
in	-	331	O
which	-	334	O
participants	-	340	O
were	-	353	O
randomly	-	358	O
assigned	-	367	O
to	-	376	O
receive	-	379	O
placebo	-	387	O
or	-	395	O
lovastatin	-	398	O
at	-	409	O
doses	-	412	O
of	-	418	O
20	-	421	O
or	-	424	O
40	-	427	O
mg	-	430	O
once	-	433	O
daily	-	438	O
,	-	443	O
or	-	445	O
20	-	448	O
or	-	451	O
40	-	454	O
mg	-	457	O
twice	-	460	O
daily	-	466	O
for	-	472	O
48	-	476	O
weeks	-	479	O
.	-	484	O

SETTING	8480959	486	O
:	-	493	O

Ambulatory	8480959	495	O
patients	-	506	O
recruited	-	515	O
by	-	525	O
362	-	528	O
participating	-	532	O
centers	-	546	O
throughout	-	554	O
the	-	565	O
United	-	569	O
States	-	576	O
.	-	582	O

PATIENTS	8480959	584	O
:	-	592	O
Women	-	594	O
(	-	600	O
n	-	601	O
=	-	603	O
3390	-	605	O
)	-	609	O
from	-	611	O
the	-	616	O
total	-	620	O
cohort	-	626	O
of	-	633	O
8245	-	636	O
volunteers	-	641	O
.	-	651	O

MEASUREMENTS	8480959	653	O
:	-	665	O

Plasma	8480959	667	O
total	-	674	O
,	-	679	O
low	-	681	O
-	-	684	O
density	-	685	O
lipoprotein	-	693	O
(	-	705	O
LDL	-	706	O
)	-	709	O
,	-	710	O
and	-	712	O
high	-	716	O
-	-	720	O
density	-	721	O
lipoprotein	-	729	O
(	-	741	O
HDL	-	742	O
)	-	745	O
cholesterol	-	747	O
,	-	758	O
and	-	760	O
triglycerides	-	764	O
;	-	777	O
and	-	779	O
laboratory	-	783	O
and	-	794	O
clinical	-	798	O
evidence	-	807	O
of	-	816	O
adverse	-	819	O
events	-	827	O
monitored	-	834	O
periodically	-	844	O
throughout	-	857	O
the	-	868	O
study	-	872	O
.	-	877	O

RESULTS	8480959	879	O
:	-	886	O

Among	8480959	888	O
women	-	894	O
,	-	899	O
lovastatin	-	901	O
(	-	912	O
20	-	913	O
to	-	916	O
80	-	919	O
mg	-	922	O
/	-	924	O
d	-	925	O
)	-	926	O
produced	-	928	O
sustained	-	937	O
(	-	947	O
12	-	948	O
-	-	950	O
to	-	952	O
48	-	955	O
-	-	957	O
week	-	958	O
)	-	962	O
,	-	963	O
dose	-	965	O
-	-	969	O
related	-	970	O
changes	-	978	O
(	-	986	O
P	-	987	O
<	-	989	O
0	-	991	O
.	-	992	O
001	-	993	O
)	-	996	O
:	-	997	O
decreases	-	999	O
in	-	1009	O
LDL	-	1012	O
cholesterol	-	1016	O
(	-	1028	O
24	-	1029	O
%	-	1031	O
to	-	1033	O
40	-	1036	O
%	-	1038	O
)	-	1039	O
and	-	1041	O
triglycerides	-	1045	O
(	-	1059	O
9	-	1060	O
%	-	1061	O
to	-	1063	O
18	-	1066	O
%	-	1068	O
)	-	1069	O
,	-	1070	O
and	-	1072	O
increases	-	1076	O
in	-	1086	O
HDL	-	1089	O
cholesterol	-	1093	O
(	-	1105	O
6	-	1106	O
.	-	1107	O
7	-	1108	O
%	-	1109	O
to	-	1111	O
8	-	1114	O
.	-	1115	O
6	-	1116	O
%	-	1117	O
)	-	1118	O
.	-	1119	O

Depending	8480959	1121	O
on	-	1131	O
the	-	1134	O
dose	-	1138	O
,	-	1142	O
from	-	1144	O
82	-	1149	O
%	-	1151	O
to	-	1153	O
95	-	1156	O
%	-	1158	O
of	-	1160	O
lovastatin	-	1163	O
-	-	1173	O
treated	-	1174	O
women	-	1182	O
achieved	-	1188	O
the	-	1197	O
National	-	1201	O
Cholesterol	-	1210	O
Education	-	1222	O
Program	-	1232	O
goal	-	1240	O
of	-	1245	O
LDL	-	1248	O
cholesterol	-	1252	O
levels	-	1264	O
less	-	1271	O
than	-	1276	O
4	-	1281	O
.	-	1282	O
14	-	1283	O
mmol	-	1286	O
/	-	1290	O
L	-	1291	O
(	-	1293	O
160	-	1294	O
mg	-	1298	O
/	-	1300	O
dL	-	1301	O
)	-	1303	O
,	-	1304	O
and	-	1306	O
40	-	1310	O
%	-	1312	O
to	-	1314	O
87	-	1317	O
%	-	1319	O
achieved	-	1321	O
the	-	1330	O
goal	-	1334	O
of	-	1339	O
3	-	1342	O
.	-	1343	O
36	-	1344	O
mmol	-	1347	O
/	-	1351	O
L	-	1352	O
(	-	1354	O
130	-	1355	O
mg	-	1359	O
/	-	1361	O
dL	-	1362	O
)	-	1364	O
.	-	1365	O

Successive	8480959	1367	O
transaminase	-	1378	O
elevations	-	1391	O
greater	-	1402	O
than	-	1410	O
three	-	1415	O
times	-	1421	O
the	-	1427	O
upper	-	1431	O
limit	-	1437	O
of	-	1443	O
normal	-	1446	O
occurred	-	1453	O
in	-	1462	O
0	-	1465	O
.	-	1466	O
1	-	1467	O
%	-	1468	O
of	-	1470	O
women	-	1473	O
and	-	1479	O
were	-	1483	O
dose	-	1488	O
dependent	-	1493	O
above	-	1503	O
the	-	1509	O
20	-	1513	O
-	-	1515	O
mg	-	1516	O
dose	-	1519	O
.	-	1523	O

Myopathy	8480959	1525	B
,	-	1533	O
defined	-	1535	O
as	-	1543	O
muscle	-	1546	O
symptoms	-	1553	O
with	-	1562	O
creatine	-	1567	O
kinase	-	1576	O
elevations	-	1583	O
greater	-	1594	O
than	-	1602	O
10	-	1607	O
times	-	1610	O
the	-	1616	O
upper	-	1620	O
limit	-	1626	O
of	-	1632	O
normal	-	1635	O
,	-	1641	O
was	-	1643	O
rare	-	1647	O
and	-	1652	O
associated	-	1656	O
with	-	1667	O
the	-	1672	O
highest	-	1676	O
recommended	-	1684	O
daily	-	1696	O
dose	-	1702	O
of	-	1707	O
lovastatin	-	1710	O
(	-	1721	O
80	-	1722	O
mg	-	1725	O
)	-	1727	O
.	-	1728	O

Estrogen	8480959	1730	O
-	-	1738	O
replacement	-	1739	O
therapy	-	1751	O
appeared	-	1759	O
to	-	1768	O
have	-	1771	O
no	-	1776	O
effect	-	1779	O
on	-	1786	O
either	-	1789	O
the	-	1796	O
efficacy	-	1800	O
or	-	1809	O
safety	-	1812	O
profile	-	1819	O
of	-	1827	O
lovastatin	-	1830	O
.	-	1840	O

CONCLUSION	8480959	1842	O
:	-	1852	O

Lovastatin	8480959	1854	O
is	-	1865	O
highly	-	1868	O
effective	-	1875	O
and	-	1885	O
generally	-	1889	O
well	-	1899	O
tolerated	-	1904	O
as	-	1914	O
therapy	-	1917	O
for	-	1925	O
primary	-	1929	O
hypercholesterolemia	-	1937	B
in	-	1958	O
women	-	1961	O
.	-	1966	O

REM	7197363	0	B
sleep	-	4	I
deprivation	-	10	I
changes	-	22	O
behavioral	-	30	O
response	-	41	O
to	-	50	O
catecholaminergic	-	53	O
and	-	71	O
serotonergic	-	75	O
receptor	-	88	O
activation	-	97	O
in	-	108	O
rats	-	111	O
.	-	115	O

The	7197363	117	O
effects	-	121	O
of	-	129	O
REM	-	132	B
sleep	-	136	I
deprivation	-	142	I
(	-	154	O
REMD	-	155	B
)	-	159	O
on	-	161	O
apomorphine	-	164	O
-	-	175	O
induced	-	176	O
aggressiveness	-	184	B
and	-	199	O
quipazine	-	203	O
-	-	212	O
induced	-	213	O
head	-	221	B
twitches	-	226	I
in	-	235	O
rats	-	238	O
were	-	243	O
determined	-	248	O
.	-	258	O

Forty	7197363	260	O
-	-	265	O
eight	-	266	O
hr	-	272	O
of	-	275	O
REMD	-	278	B
increased	-	283	O
apomorphine	-	293	O
-	-	304	O
induced	-	305	O
aggressiveness	-	313	B
,	-	327	O
and	-	329	O
reduced	-	333	O
(	-	341	O
immediately	-	342	O
after	-	354	O
completing	-	360	O
of	-	371	O
REMD	-	374	B
)	-	378	O
or	-	380	O
increased	-	383	O
(	-	393	O
96	-	394	O
hr	-	397	O
after	-	400	O
completing	-	406	O
of	-	417	O
REMD	-	420	B
)	-	424	O
quipazine	-	426	O
-	-	435	O
induced	-	436	O
head	-	444	B
twitches	-	449	I
.	-	457	O

Results	7197363	459	O
are	-	467	O
discussed	-	471	O
in	-	481	O
terms	-	484	O
of	-	490	O
similarity	-	493	O
to	-	504	O
pharmacological	-	507	O
effects	-	523	O
of	-	531	O
other	-	534	O
antidepressive	-	540	O
treatments	-	555	O
.	-	565	O

Extrapyramidal	7161250	0	O
side	-	15	O
effects	-	20	O
and	-	28	O
oral	-	32	O
haloperidol	-	37	O
:	-	48	O
an	-	50	O
analysis	-	53	O
of	-	62	O
explanatory	-	65	O
patient	-	77	O
and	-	85	O
treatment	-	89	O
characteristics	-	99	O
.	-	114	O

The	7161250	116	O
incidence	-	120	O
of	-	130	O
extrapyramidal	-	133	O
side	-	148	O
effects	-	153	O
(	-	161	O
EPS	-	162	O
)	-	165	O
was	-	167	O
evaluated	-	171	O
in	-	181	O
98	-	184	O
patients	-	187	O
treated	-	196	O
with	-	204	O
haloperidol	-	209	O
.	-	220	O

The	7161250	222	O
incidence	-	226	O
of	-	236	O
parkinsonism	-	239	B
was	-	252	O
higher	-	256	O
at	-	263	O
higher	-	266	O
doses	-	273	O
of	-	279	O
haloperidol	-	282	O
and	-	294	O
in	-	298	O
younger	-	301	O
patients	-	309	O
.	-	317	O

Prophylactic	7161250	319	O
antiparkinsonian	-	332	O
medication	-	349	O
was	-	360	O
effective	-	364	O
in	-	374	O
younger	-	377	O
but	-	385	O
not	-	389	O
in	-	393	O
older	-	396	O
patients	-	402	O
.	-	410	O

However	7161250	412	O
,	-	419	O
these	-	421	O
medications	-	427	O
were	-	439	O
more	-	444	O
effective	-	449	O
in	-	459	O
both	-	462	O
young	-	467	O
and	-	473	O
old	-	477	O
patients	-	481	O
when	-	490	O
given	-	495	O
after	-	501	O
parkinsonism	-	507	B
developed	-	520	O
.	-	529	O

Akathisia	7161250	531	B
was	-	541	O
controlled	-	545	O
by	-	556	O
the	-	559	O
benzodiazepine	-	563	O
lorazepam	-	578	O
in	-	588	O
14	-	591	O
out	-	594	O
of	-	598	O
16	-	601	O
patients	-	604	O
,	-	612	O
while	-	614	O
prophylactic	-	620	O
antiparkinsonians	-	633	O
were	-	651	O
ineffective	-	656	O
.	-	667	O

The	7161250	669	O
present	-	673	O
study	-	681	O
points	-	687	O
to	-	694	O
patient	-	697	O
characteristics	-	705	O
that	-	721	O
may	-	726	O
be	-	730	O
of	-	733	O
significance	-	736	O
in	-	749	O
the	-	752	O
development	-	756	O
of	-	768	O
EPS	-	771	O
due	-	775	O
to	-	779	O
haloperidol	-	782	O
.	-	793	O

Hepatic	7053705	0	B
veno	-	8	I
-	-	12	I
occlusive	-	13	I
disease	-	23	I
caused	-	31	O
by	-	38	O
6	-	41	O
-	-	42	O
thioguanine	-	43	O
.	-	54	O

Clinically	7053705	56	O
reversible	-	67	O
veno	-	78	B
-	-	82	I
occlusive	-	83	I
disease	-	93	I
of	-	101	I
the	-	104	I
liver	-	108	I
developed	-	114	O
in	-	124	O
a	-	127	O
23	-	129	O
-	-	131	O
year	-	132	O
-	-	136	O
old	-	137	O
man	-	141	O
with	-	145	O
acute	-	150	B
lymphocytic	-	156	I
leukemia	-	168	I
after	-	177	O
10	-	183	O
months	-	186	O
of	-	193	O
maintenance	-	196	O
therapy	-	208	O
with	-	216	O
6	-	221	O
-	-	222	O
thioguanine	-	223	O
.	-	234	O

Serial	7053705	236	O
liver	-	243	O
biopsies	-	249	O
showed	-	258	O
the	-	265	O
development	-	269	O
and	-	281	O
resolution	-	285	O
of	-	296	O
intense	-	299	O
sinusoidal	-	307	O
engorgement	-	318	O
.	-	329	O

Although	7053705	331	O
this	-	340	O
disease	-	345	O
was	-	353	O
clinically	-	357	O
reversible	-	368	O
,	-	378	O
some	-	380	O
subintimal	-	385	O
fibrosis	-	396	B
about	-	405	O
the	-	411	O
terminal	-	415	O
hepatic	-	424	O
veins	-	432	O
persisted	-	438	O
.	-	447	O

This	7053705	449	O
case	-	454	O
presented	-	459	O
a	-	469	O
unique	-	471	O
opportunity	-	478	O
to	-	490	O
observe	-	493	O
the	-	501	O
histologic	-	505	O
features	-	516	O
of	-	525	O
clinically	-	528	O
reversible	-	539	O
hepatic	-	550	B
veno	-	558	I
-	-	562	I
occlusive	-	563	I
disease	-	573	I
over	-	581	O
time	-	586	O
,	-	590	O
and	-	592	O
may	-	596	O
be	-	600	O
the	-	603	O
first	-	607	O
case	-	613	O
of	-	618	O
veno	-	621	O
-	-	625	O
occlusive	-	626	O
related	-	636	O
solely	-	644	O
to	-	651	O
6	-	654	O
-	-	655	O
thioguanine	-	656	O
.	-	667	O

Treatment	6402369	0	O
of	-	10	O
ifosfamide	-	13	O
-	-	23	O
induced	-	24	O
urothelial	-	32	B
toxicity	-	43	I
by	-	52	O
oral	-	55	O
administration	-	60	O
of	-	75	O
sodium	-	78	O
2	-	85	O
-	-	86	O
mercaptoethane	-	87	O
sulphonate	-	102	O
(	-	113	O
MESNA	-	114	O
)	-	119	O
to	-	121	O
patients	-	124	O
with	-	133	O
inoperable	-	138	O
lung	-	149	B
cancer	-	154	I
.	-	160	O

The	6402369	162	O
protective	-	166	O
effect	-	177	O
of	-	184	O
oral	-	187	O
administration	-	192	O
of	-	207	O
the	-	210	O
thiol	-	214	O
compound	-	220	O
sodium	-	229	O
2	-	236	O
-	-	237	O
mercaptoethane	-	238	O
sulphonate	-	253	O
(	-	264	O
MESNA	-	265	O
)	-	270	O
against	-	272	O
urothelial	-	280	B
toxicity	-	291	I
induced	-	300	O
by	-	308	O
ifosfamide	-	311	O
(	-	322	O
IF	-	323	O
)	-	325	O
was	-	327	O
tested	-	331	O
in	-	338	O
a	-	341	O
group	-	343	O
of	-	349	O
45	-	352	O
patients	-	355	O
with	-	364	O
inoperable	-	369	O
lung	-	380	B
cancer	-	385	I
under	-	392	O
treatment	-	398	O
with	-	408	O
IF	-	413	O
(	-	416	O
2250	-	417	O
mg	-	422	O
/	-	424	O
m2	-	425	O
on	-	428	O
days	-	431	O
2	-	436	O
-	-	437	O
5	-	438	O
)	-	439	O
as	-	441	O
part	-	444	O
of	-	449	O
a	-	452	O
polychemotherapy	-	454	O
regimen	-	471	O
repeated	-	479	O
in	-	488	O
a	-	491	O
4	-	493	O
-	-	494	O
week	-	495	O
cycle	-	500	O
.	-	505	O

MESNA	6402369	507	O
was	-	513	O
given	-	517	O
orally	-	523	O
on	-	530	O
the	-	533	O
days	-	537	O
of	-	542	O
treatment	-	545	O
with	-	555	O
IF	-	560	O
in	-	563	O
3	-	566	O
doses	-	568	O
of	-	574	O
840	-	577	O
mg	-	581	O
/	-	583	O
m2	-	584	O
,	-	586	O
each	-	588	O
administered	-	593	O
at	-	606	O
0	-	609	O

hr	6402369	611	O
(	-	614	O
=	-	615	O
injection	-	617	O
of	-	627	O
IF	-	630	O
)	-	632	O
,	-	633	O
4	-	635	O
hr	-	637	O
and	-	640	O
8	-	644	O
hr	-	646	O
p	-	649	O
.	-	650	O
i	-	651	O
.	-	652	O

Out	6402369	654	O
of	-	658	O
a	-	661	O
total	-	663	O
of	-	669	O
88	-	672	O
courses	-	675	O
of	-	683	O
this	-	686	O
treatment	-	691	O
we	-	701	O
observed	-	704	O
10	-	713	O
episodes	-	716	O
of	-	725	O
asymptomatic	-	728	O
microscopic	-	741	O
haematuria	-	753	B
and	-	764	O
no	-	768	O
episodes	-	771	O
of	-	780	O
gross	-	783	O
haematuria	-	789	B
.	-	799	O

In	6402369	801	O
this	-	804	O
group	-	809	O
of	-	815	O
45	-	818	O
patients	-	821	O
under	-	830	O
protection	-	836	O
with	-	847	O
MESNA	-	852	O
there	-	858	O
were	-	864	O
5	-	869	O
complete	-	871	O
remissions	-	880	O
and	-	891	O
9	-	895	O
partial	-	897	O
remissions	-	905	O
(	-	916	O
total	-	917	O
31	-	923	O
%	-	925	O
)	-	926	O
.	-	927	O

A	6402369	929	O
further	-	931	O
group	-	939	O
of	-	945	O
25	-	948	O
patients	-	951	O
under	-	960	O
polychemotherapy	-	966	O
with	-	983	O
IF	-	988	O
were	-	991	O
treated	-	996	O
by	-	1004	O
conventional	-	1007	O
prophylactic	-	1020	O
measures	-	1033	O
(	-	1042	O
raised	-	1043	O
fluid	-	1050	O
intake	-	1056	O
and	-	1063	O
forced	-	1067	O
diuresis	-	1074	O
)	-	1082	O
.	-	1083	O

In	6402369	1085	O
this	-	1088	O
group	-	1093	O
there	-	1099	O
were	-	1105	O
1	-	1110	O
complete	-	1112	O
and	-	1121	O
5	-	1125	O
partial	-	1127	O
remissions	-	1135	O
(	-	1146	O
total	-	1147	O
24	-	1153	O
%	-	1155	O
)	-	1156	O
,	-	1157	O
but	-	1159	O
nearly	-	1163	O
all	-	1170	O
patients	-	1174	O
developed	-	1183	O
either	-	1193	O
gross	-	1200	O
haematuria	-	1206	B
and	-	1217	O
/	-	1220	O
or	-	1221	O
symptoms	-	1224	O
of	-	1233	O
bladder	-	1236	B
irritation	-	1244	I
(	-	1255	O
cystitis	-	1256	B
and	-	1265	O
pollakisuria	-	1269	B
)	-	1281	O
.	-	1282	O

There	6402369	1284	O
were	-	1290	O
no	-	1295	O
appreciable	-	1298	O
differences	-	1310	O
between	-	1322	O
the	-	1330	O
MESNA	-	1334	O
series	-	1340	O
and	-	1347	O
the	-	1351	O
conventional	-	1355	O
prophylaxis	-	1368	O
series	-	1380	O
with	-	1387	O
respect	-	1392	O
to	-	1400	O
either	-	1403	O
haematological	-	1410	O
or	-	1425	O
systemic	-	1428	O
toxicity	-	1437	B
of	-	1446	O
the	-	1449	O
cytostatic	-	1453	O
treatment	-	1464	O
.	-	1473	O

Our	6402369	1475	O
results	-	1479	O
support	-	1487	O
the	-	1495	O
view	-	1499	O
that	-	1504	O
MESNA	-	1509	O
,	-	1514	O
given	-	1516	O
orally	-	1522	O
in	-	1529	O
conjunction	-	1532	O
with	-	1544	O
combined	-	1549	O
cytostatic	-	1558	O
regimens	-	1569	O
which	-	1578	O
include	-	1584	O
IF	-	1592	O
,	-	1594	O
simplifies	-	1596	O
the	-	1607	O
treatment	-	1611	O
and	-	1621	O
provides	-	1625	O
optimum	-	1634	O
protection	-	1642	O
for	-	1653	O
the	-	1657	O
urinary	-	1661	O
epithelium	-	1669	O
.	-	1679	O

Protection	6402369	1681	O
with	-	1692	O
oral	-	1697	O
MESNA	-	1702	O
is	-	1708	O
particularly	-	1711	O
suitable	-	1724	O
for	-	1733	O
outpatients	-	1737	O
.	-	1748	O

Time	3973521	0	O
course	-	5	O
alterations	-	12	O
of	-	24	O
QTC	-	27	O
interval	-	31	O
due	-	40	O
to	-	44	O
hypaque	-	47	O
76	-	55	O
.	-	57	O

Sequential	3973521	59	O
measurement	-	70	O
of	-	82	O
QT	-	85	O
interval	-	88	O
during	-	97	O
left	-	104	O
ventricular	-	109	O
angiography	-	121	O
was	-	133	O
made	-	137	O
30	-	142	O
seconds	-	145	O
and	-	153	O
one	-	157	O
,	-	160	O
three	-	162	O
,	-	167	O
five	-	169	O
and	-	174	O
ten	-	178	O
minutes	-	182	O
after	-	190	O
injection	-	196	O
of	-	206	O
hypaque	-	209	O
76	-	217	O
.	-	219	O

The	3973521	221	O
subjects	-	225	O
were	-	234	O
ten	-	239	O
patients	-	243	O
found	-	252	O
to	-	258	O
have	-	261	O
normal	-	266	O
left	-	273	O
ventricles	-	278	O
and	-	289	O
coronary	-	293	O
arteries	-	302	O
.	-	310	O

Significant	3973521	312	O
QTC	-	324	B
prolongation	-	328	I
occurred	-	341	O
in	-	350	O
30	-	353	O
seconds	-	356	O
to	-	364	O
one	-	367	O
minute	-	371	O
in	-	378	O
association	-	381	O
with	-	393	O
marked	-	398	O
hypotension	-	405	B
and	-	417	O
elevation	-	421	O
of	-	431	O
cardiac	-	434	O
output	-	442	O
.	-	448	O

Production	3461217	0	O
of	-	11	O
autochthonous	-	14	O
prostate	-	28	B
cancer	-	37	I
in	-	44	O
Lobund	-	47	O
-	-	53	O
Wistar	-	54	O
rats	-	61	O
by	-	66	O
treatments	-	69	O
with	-	80	O
N	-	85	O
-	-	86	O
nitroso	-	87	O
-	-	94	O
N	-	95	O
-	-	96	O
methylurea	-	97	O
and	-	108	O
testosterone	-	112	O
.	-	124	O

More	3461217	126	O
than	-	131	O
50	-	136	O
%	-	138	O
of	-	140	O
Lobund	-	143	O
-	-	149	O
Wistar	-	150	O
(	-	157	O
L	-	158	O
-	-	159	O
W	-	160	O
)	-	161	O
strain	-	163	O
rats	-	170	O
developed	-	175	O
large	-	185	O
,	-	190	O
palpable	-	192	O
prostate	-	201	B
adenocarcinomas	-	210	I
(	-	226	O
PAs	-	227	B
)	-	230	O
following	-	232	O
treatments	-	242	O
with	-	253	O
N	-	258	O
-	-	259	O
nitroso	-	260	O
-	-	267	O
N	-	268	O
-	-	269	O
methylurea	-	270	O
(	-	281	O
CAS	-	282	O
:	-	285	O
684	-	287	O
-	-	290	O
93	-	291	O
-	-	293	O
5	-	294	O
)	-	295	O
and	-	297	O

testosterone	3461217	301	O
propionate	-	314	O
[	-	325	O
(	-	326	O
TP	-	327	O
)	-	329	O
CAS	-	331	O
:	-	334	O
57	-	336	O
-	-	338	O
85	-	339	O
-	-	341	O
2	-	342	O
]	-	343	O
,	-	344	O
and	-	346	O
most	-	350	O
of	-	355	O
the	-	358	O
tumor	-	362	B
-	-	367	O
bearing	-	368	O
rats	-	376	O
manifested	-	381	O
metastatic	-	392	O
lesions	-	403	O
.	-	410	O

The	3461217	412	O
incubation	-	416	O
periods	-	427	O
averaged	-	435	O
10	-	444	O
.	-	446	O
6	-	447	O
months	-	449	O
.	-	455	O

Within	3461217	457	O
the	-	464	O
same	-	468	O
timeframe	-	473	O
,	-	482	O
no	-	484	O
L	-	487	O
-	-	488	O
W	-	489	O
rat	-	491	O
developed	-	495	O
a	-	505	O
similar	-	507	O
palpable	-	515	O
PA	-	524	B
when	-	527	O
treated	-	532	O
only	-	540	O
with	-	545	O
TP	-	550	O
.	-	552	O

In	3461217	554	O
L	-	557	O
-	-	558	O
W	-	559	O
rats	-	561	O
,	-	565	O
TP	-	567	O
acted	-	570	O
as	-	576	O
a	-	579	O
tumor	-	581	B
enhancement	-	587	O
agent	-	599	O
,	-	604	O
with	-	606	O
primary	-	611	O
emphasis	-	619	O
on	-	628	O
the	-	631	O
development	-	635	O
of	-	647	O
prostate	-	650	B
cancer	-	659	I
.	-	665	O

A	2840807	0	O
dystonia	-	2	B
-	-	10	O
like	-	11	O
syndrome	-	16	O
after	-	25	O
neuropeptide	-	31	O
(	-	44	O
MSH	-	45	O
/	-	48	O
ACTH	-	49	O
)	-	53	O
stimulation	-	55	O
of	-	67	O
the	-	70	O
rat	-	74	O
locus	-	78	O
ceruleus	-	84	O
.	-	92	O

The	2840807	94	O
movement	-	98	B
disorder	-	107	I
investigated	-	116	O
in	-	129	O
these	-	132	O
studies	-	138	O
has	-	146	O
some	-	150	O
features	-	155	O
in	-	164	O
common	-	167	O
with	-	174	O
human	-	179	O
idiopathic	-	185	O
dystonia	-	196	B
,	-	204	O
and	-	206	O
information	-	210	O
obtained	-	222	O
in	-	231	O
these	-	234	O
studies	-	240	O
may	-	248	O
be	-	252	O
of	-	255	O
potential	-	258	O
clinical	-	268	O
benefit	-	277	O
.	-	284	O

The	2840807	286	O
present	-	290	O
experimental	-	298	O
results	-	311	O
indicated	-	319	O
that	-	329	O
peptidergic	-	334	O
stimulation	-	346	O
of	-	358	O
the	-	361	O
LC	-	365	O
resulted	-	368	O
in	-	377	O
a	-	380	O
NE	-	382	O
-	-	384	O
mediated	-	385	O
inhibition	-	394	O
of	-	405	O
cerebellar	-	408	O
Purkinje	-	419	O
cells	-	428	O
located	-	434	O
at	-	442	O
terminals	-	445	O
of	-	455	O
the	-	458	O
ceruleo	-	462	O
-	-	469	O
cerebellar	-	470	O
pathway	-	481	O
.	-	488	O

However	2840807	490	O
,	-	497	O
it	-	499	O
is	-	502	O
not	-	505	O
certain	-	509	O
as	-	517	O
to	-	520	O
the	-	523	O
following	-	527	O
:	-	536	O
(	-	538	O
a	-	539	O
)	-	540	O
what	-	542	O
receptors	-	547	O
were	-	557	O
stimulated	-	562	O
by	-	573	O
the	-	576	O
ACTH	-	580	O
N	-	585	O
-	-	586	O
terminal	-	587	O
fragments	-	596	O
at	-	606	O
the	-	609	O
LC	-	613	O
that	-	616	O
resulted	-	621	O
in	-	630	O
this	-	633	O
disorder	-	638	O
;	-	646	O
(	-	648	O
b	-	649	O
)	-	650	O
whether	-	652	O
NE	-	660	O
,	-	662	O
released	-	664	O
onto	-	673	O
Purkinje	-	678	O
cell	-	687	O
synapses	-	692	O
located	-	701	O
at	-	709	O
terminals	-	712	O
of	-	722	O
the	-	725	O
ceruleo	-	729	O
-	-	736	O
cerebellar	-	737	O
pathway	-	748	O
,	-	755	O
did	-	757	O
indeed	-	761	O
cause	-	768	O
the	-	774	O
long	-	778	O
-	-	782	O
term	-	783	O
depression	-	788	B
at	-	799	O
Purkinje	-	802	O
cell	-	811	O
synapses	-	816	O
(	-	825	O
previously	-	826	O
described	-	837	O
by	-	847	O
others	-	850	O
)	-	856	O
that	-	858	O
resulted	-	863	O
in	-	872	O
the	-	875	O
long	-	879	O
duration	-	884	O
of	-	893	O
the	-	896	O
movement	-	900	B
disorder	-	909	I
;	-	917	O
(	-	919	O
c	-	920	O
)	-	921	O
whether	-	923	O
the	-	931	O
inhibition	-	935	O
of	-	946	O
inhibitory	-	949	O
Purkinje	-	960	O
cells	-	969	O
resulted	-	975	O
in	-	984	O
disinhibition	-	987	O
or	-	1001	O
increased	-	1004	O
excitability	-	1014	O
of	-	1027	O
the	-	1030	O
unilateral	-	1034	O
cerebellar	-	1045	O
fastigial	-	1056	O
or	-	1066	O
interpositus	-	1069	O
nuclei	-	1082	O
,	-	1088	O
the	-	1090	O
output	-	1094	O
targets	-	1101	O
of	-	1109	O
the	-	1112	O
Purkinje	-	1116	O
cell	-	1125	O
axons	-	1130	O
,	-	1135	O
that	-	1137	O
may	-	1142	O
have	-	1146	O
been	-	1151	O
an	-	1156	O
important	-	1159	O
contributing	-	1169	O
factor	-	1182	O
to	-	1189	O
this	-	1192	O
disorder	-	1197	O
.	-	1205	O

These	2840807	1207	O
questions	-	1213	O
are	-	1223	O
currently	-	1227	O
being	-	1237	O
investigated	-	1243	O
.	-	1255	O

Dexmedetomidine	2569282	0	O
,	-	15	O
acting	-	17	O
through	-	24	O
central	-	32	O
alpha	-	40	O
-	-	45	O
2	-	46	O
adrenoceptors	-	48	O
,	-	61	O
prevents	-	63	O
opiate	-	72	O
-	-	78	O
induced	-	79	O
muscle	-	87	B
rigidity	-	94	I
in	-	103	O
the	-	106	O
rat	-	110	O
.	-	113	O

The	2569282	115	O
highly	-	119	O
-	-	125	O
selective	-	126	O
alpha	-	136	O
-	-	141	O
2	-	142	O
adrenergic	-	144	O
agonist	-	155	O
dexmedetomidine	-	163	O
(	-	179	O
D	-	180	O
-	-	181	O
MED	-	182	O
)	-	185	O
is	-	187	O
capable	-	190	O
of	-	198	O
inducing	-	201	O
muscle	-	210	B
flaccidity	-	217	I
and	-	228	O
anesthesia	-	232	O
in	-	243	O
rats	-	246	O
and	-	251	O
dogs	-	255	O
.	-	259	O

Intense	2569282	261	O
generalized	-	269	O
muscle	-	281	B
rigidity	-	288	I
is	-	297	O
an	-	300	O
undesirable	-	303	O
side	-	315	O
effect	-	320	O
of	-	327	O
potent	-	330	O
opiate	-	337	O
agonists	-	344	O
.	-	352	O

Although	2569282	354	O
the	-	363	O
neurochemistry	-	367	O
of	-	382	O
opiate	-	385	O
-	-	391	O
induced	-	392	O
rigidity	-	400	B
has	-	409	O
yet	-	413	O
to	-	417	O
be	-	420	O
fully	-	423	O
elucidated	-	429	O
,	-	439	O
recent	-	441	O
work	-	448	O
suggests	-	453	O
a	-	462	O
role	-	464	O
for	-	469	O
a	-	473	O
central	-	475	O
adrenergic	-	483	O
mechanism	-	494	O
.	-	503	O

In	2569282	505	O
the	-	508	O
present	-	512	O
study	-	520	O
,	-	525	O
the	-	527	O
authors	-	531	O
determined	-	539	O
if	-	550	O
treatment	-	553	O
with	-	563	O
D	-	568	O
-	-	569	O
MED	-	570	O
prevents	-	574	O
the	-	583	O
muscle	-	587	B
rigidity	-	594	I
caused	-	603	O
by	-	610	O
high	-	613	O
-	-	617	O
dose	-	618	O
alfentanil	-	623	O
anesthesia	-	634	O
in	-	645	O
the	-	648	O
rat	-	652	O
.	-	655	O

Animals	2569282	657	O
(	-	665	O
n	-	666	O
=	-	668	O
42	-	670	O
)	-	672	O
were	-	674	O
treated	-	679	O
intraperitoneally	-	687	O
with	-	705	O
one	-	710	O
of	-	714	O
the	-	717	O
following	-	721	O
six	-	731	O
regimens	-	735	O
:	-	743	O
1	-	745	O
)	-	746	O
L	-	748	O
-	-	749	O
MED	-	750	O
(	-	754	O
the	-	755	O
inactive	-	759	O
L	-	768	O
-	-	769	O
isomer	-	770	O
of	-	777	O
medetomidine	-	780	O
)	-	792	O
,	-	793	O
30	-	795	O
micrograms	-	798	O
/	-	808	O
kg	-	809	O
;	-	811	O
2	-	813	O
)	-	814	O
D	-	816	O
-	-	817	O
MED	-	818	O
,	-	821	O
10	-	823	O
micrograms	-	826	O
/	-	836	O
kg	-	837	O
;	-	839	O
3	-	841	O
)	-	842	O
D	-	844	O
-	-	845	O
MED	-	846	O
,	-	849	O
30	-	851	O
micrograms	-	854	O
/	-	864	O
kg	-	865	O
;	-	867	O
4	-	869	O
)	-	870	O
D	-	872	O
-	-	873	O
MED	-	874	O
[	-	878	O
30	-	879	O
micrograms	-	882	O
/	-	892	O
kg	-	893	O
]	-	895	O
and	-	897	O
the	-	901	O
central	-	905	O
-	-	912	O
acting	-	913	O
alpha	-	920	O
-	-	925	O
2	-	926	O
antagonist	-	928	O
,	-	938	O
idazoxan	-	940	O
[	-	949	O
10	-	950	O
mg	-	953	O
/	-	955	O
kg	-	956	O
]	-	958	O
;	-	959	O
5	-	961	O
)	-	962	O
D	-	964	O
-	-	965	O
MED	-	966	O
[	-	970	O
30	-	971	O
micrograms	-	974	O
/	-	984	O
kg	-	985	O
]	-	987	O
and	-	989	O
the	-	993	O
peripheral	-	997	O
-	-	1007	O
acting	-	1008	O
alpha	-	1015	O
-	-	1020	O
2	-	1021	O
antagonist	-	1023	O
DG	-	1034	O
-	-	1036	O
5128	-	1037	O
[	-	1042	O
10	-	1043	O
mg	-	1046	O
/	-	1048	O
kg	-	1049	O
]	-	1051	O
,	-	1052	O
or	-	1054	O
;	-	1056	O
6	-	1058	O
)	-	1059	O
saline	-	1061	O
.	-	1067	O

Baseline	2569282	1069	O
electromyographic	-	1078	O
activity	-	1096	O
was	-	1105	O
recorded	-	1109	O
from	-	1118	O
the	-	1123	O
gastrocnemius	-	1127	O
muscle	-	1141	O
before	-	1148	O
and	-	1155	O
after	-	1159	O
drug	-	1165	O
treatment	-	1170	O
.	-	1179	O

Each	2569282	1181	O
rat	-	1186	O
was	-	1190	O
then	-	1194	O
injected	-	1199	O
with	-	1208	O
alfentanil	-	1213	O
(	-	1224	O
ALF	-	1225	O
,	-	1228	O
0	-	1230	O
.	-	1231	O
5	-	1232	O
mg	-	1234	O
/	-	1236	O
kg	-	1237	O
sc	-	1240	O
)	-	1242	O
.	-	1243	O

ALF	2569282	1245	O
injection	-	1249	O
resulted	-	1259	O
in	-	1268	O
a	-	1271	O
marked	-	1273	O
increase	-	1280	O
in	-	1289	O
hindlimb	-	1292	O
EMG	-	1301	O
activity	-	1305	O
in	-	1314	O
the	-	1317	O
L	-	1321	O
-	-	1322	O
MED	-	1323	O
treatment	-	1327	O
group	-	1337	O
which	-	1343	O
was	-	1349	O
indistinguishable	-	1353	O
from	-	1371	O
that	-	1376	O
seen	-	1381	O
in	-	1386	O
animals	-	1389	O
treated	-	1397	O
with	-	1405	O
saline	-	1410	O
.	-	1416	O

In	2569282	1418	O
contrast	-	1421	O
,	-	1429	O
D	-	1431	O
-	-	1432	O
MED	-	1433	O
prevented	-	1437	O
alfentanil	-	1447	O
-	-	1457	O
induced	-	1458	O
muscle	-	1466	B
rigidity	-	1473	I
in	-	1482	O
a	-	1485	O
dose	-	1487	O
-	-	1491	O
dependent	-	1492	O
fashion	-	1502	O
.	-	1509	O

The	2569282	1511	O
small	-	1515	O
EMG	-	1521	O
values	-	1525	O
obtained	-	1532	O
in	-	1541	O
the	-	1544	O
high	-	1548	O
-	-	1552	O
dose	-	1553	O
D	-	1558	O
-	-	1559	O
MED	-	1560	O
group	-	1564	O
were	-	1570	O
comparable	-	1575	O
with	-	1586	O
those	-	1591	O
recorded	-	1597	O
in	-	1606	O
earlier	-	1609	O
studies	-	1617	O
from	-	1625	O
control	-	1630	O
animals	-	1638	O
not	-	1646	O
given	-	1650	O
any	-	1656	O
opiate	-	1660	O
.	-	1666	O

The	2569282	1668	O
high	-	1672	O
-	-	1676	O
dose	-	1677	O
D	-	1682	O
-	-	1683	O
MED	-	1684	O
animals	-	1688	O
were	-	1696	O
flaccid	-	1701	O
,	-	1708	O
akinetic	-	1710	B
,	-	1718	O
and	-	1720	O
lacked	-	1724	O
a	-	1731	O
startle	-	1733	B
response	-	1741	O
during	-	1750	O
the	-	1757	O
entire	-	1761	O
experimental	-	1768	O
period	-	1781	O
.	-	1787	O
(	-	1788	O
ABSTRACT	-	1789	O
TRUNCATED	-	1798	O
AT	-	1808	O
250	-	1811	O
WORDS	-	1815	O
)	-	1820	O

Seizure	2343592	0	B
activity	-	8	O
with	-	17	O
imipenem	-	22	O
therapy	-	31	O
:	-	38	O
incidence	-	40	O
and	-	50	O
risk	-	54	O
factors	-	59	O
.	-	66	O

Two	2343592	68	O
elderly	-	72	O
patients	-	80	O
with	-	89	O
a	-	94	O
history	-	96	O
of	-	104	O
either	-	107	O
cerebral	-	114	B
vascular	-	123	I
accident	-	132	I
(	-	141	O
CVA	-	142	B
)	-	145	O
or	-	147	O
head	-	150	B
trauma	-	155	I
and	-	162	O
no	-	166	O
evidence	-	169	O
of	-	178	O
renal	-	181	B
disease	-	187	I
developed	-	195	O
seizures	-	205	B
while	-	214	O
receiving	-	220	O
maximum	-	230	O
doses	-	238	O
of	-	244	O
imipenem	-	247	O
/	-	255	O
cilastatin	-	256	O
.	-	266	O

Neither	2343592	268	O
patient	-	276	O
had	-	284	O
reported	-	288	O
previous	-	297	O
seizures	-	306	B
or	-	315	O
seizure	-	318	B
-	-	325	O
like	-	326	O
activity	-	331	O
nor	-	340	O
was	-	344	O
receiving	-	348	O
anticonvulsant	-	358	O
agents	-	373	O
.	-	379	O

All	2343592	381	O
seizures	-	385	B
were	-	394	O
controlled	-	399	O
with	-	410	O
therapeutic	-	415	O
doses	-	427	O
of	-	433	O
phenytoin	-	436	O
.	-	445	O

Both	2343592	447	O
patients	-	452	O
had	-	461	O
received	-	465	O
maximum	-	474	O
doses	-	482	O
of	-	488	O
other	-	491	O
beta	-	497	O
-	-	501	O
lactam	-	502	O
antibiotics	-	509	O
without	-	521	O
evidence	-	529	O
of	-	538	O
seizure	-	541	B
activity	-	549	O
.	-	557	O

The	2055425	0	O
ability	-	4	O
of	-	12	O
insulin	-	15	O
treatment	-	23	O
to	-	33	O
reverse	-	36	O
or	-	44	O
prevent	-	47	O
the	-	55	O
changes	-	59	O
in	-	67	O
urinary	-	70	O
bladder	-	78	O
function	-	86	O
caused	-	95	O
by	-	102	O
streptozotocin	-	105	O
-	-	119	O
induced	-	120	O
diabetes	-	128	B
mellitus	-	137	I
.	-	145	O

1	2055425	147	O
.	-	148	O

The	2055425	150	O
effects	-	154	O
of	-	162	O
insulin	-	165	O
treatment	-	173	O
on	-	183	O
in	-	186	O
vivo	-	189	O
and	-	194	O
in	-	198	O
vitro	-	201	O
urinary	-	207	O
bladder	-	215	O
function	-	223	O
in	-	232	O
streptozotocin	-	235	O
-	-	249	O
diabetic	-	250	B
rats	-	259	O
were	-	264	O
investigated	-	269	O
.	-	281	O

2	2055425	283	O
.	-	284	O

Diabetes	2055425	286	B
of	-	295	O
2	-	298	O
months	-	300	O
duration	-	307	O
resulted	-	316	O
in	-	325	O
decreases	-	328	O
in	-	338	O
body	-	341	O
weight	-	346	O
and	-	353	O
increases	-	357	O
in	-	367	O
fluid	-	370	O
consumption	-	376	O
,	-	387	O
urine	-	389	O
volume	-	395	O
,	-	401	O
frequency	-	403	O
of	-	413	O
micturition	-	416	O
,	-	427	O
and	-	429	O
average	-	433	O
volume	-	441	O
per	-	448	O
micturition	-	452	O
;	-	463	O
effects	-	465	O
which	-	473	O
were	-	479	O
prevented	-	484	O
by	-	494	O
insulin	-	497	O
treatment	-	505	O
.	-	514	O

3	2055425	516	O
.	-	517	O

Insulin	2055425	519	O
treatment	-	527	O
also	-	537	O
prevented	-	542	O
the	-	552	O
increases	-	556	O
in	-	566	O
contractile	-	569	O
responses	-	581	O
of	-	591	O
bladder	-	594	O
body	-	602	O
strips	-	607	O
from	-	614	O
diabetic	-	619	B
rats	-	628	O
to	-	633	O
nerve	-	636	O
stimulation	-	642	O
,	-	653	O
ATP	-	655	O
,	-	658	O
and	-	660	O
bethanechol	-	664	O
.	-	675	O

4	2055425	677	O
.	-	678	O

Diabetes	2055425	680	B
of	-	689	O
4	-	692	O
months	-	694	O
duration	-	701	O
also	-	710	O
resulted	-	715	O
in	-	724	O
decreases	-	727	O
in	-	737	O
body	-	740	O
weight	-	745	O
,	-	751	O
and	-	753	O
increases	-	757	O
in	-	767	O
fluid	-	770	O
consumption	-	776	O
,	-	787	O
urine	-	789	O
volume	-	795	O
,	-	801	O
frequency	-	803	O
of	-	813	O
micturition	-	816	O
,	-	827	O
and	-	829	O
average	-	833	O
volume	-	841	O
per	-	848	O
micturition	-	852	O
,	-	863	O
effects	-	865	O
which	-	873	O
were	-	879	O
reversed	-	884	O
by	-	893	O
insulin	-	896	O
treatment	-	904	O
for	-	914	O
the	-	918	O
final	-	922	O
2	-	928	O
months	-	930	O
of	-	937	O
the	-	940	O
study	-	944	O
.	-	949	O

5	2055425	951	O
.	-	952	O

Insulin	2055425	954	O
treatment	-	962	O
reversed	-	972	O
the	-	981	O
increases	-	985	O
in	-	995	O
contractile	-	998	O
responses	-	1010	O
of	-	1020	O
bladder	-	1023	O
body	-	1031	O
strips	-	1036	O
from	-	1043	O
diabetic	-	1048	B
rats	-	1057	O
to	-	1062	O
nerve	-	1065	O
stimulation	-	1071	O
,	-	1082	O
ATP	-	1084	O
,	-	1087	O
and	-	1089	O
bethanechol	-	1093	O
.	-	1104	O

6	2055425	1106	O
.	-	1107	O

The	2055425	1109	O
data	-	1113	O
indicate	-	1118	O
that	-	1127	O
the	-	1132	O
effects	-	1136	O
of	-	1144	O
streptozotocin	-	1147	O
-	-	1161	O
induced	-	1162	O
diabetes	-	1170	B
on	-	1179	O
urinary	-	1182	O
bladder	-	1190	O
function	-	1198	O
are	-	1207	O
both	-	1211	O
prevented	-	1216	O
and	-	1226	O
reversed	-	1230	O
by	-	1239	O
insulin	-	1242	O
treatment	-	1250	O
.	-	1259	O

Delayed	1711760	0	O
institution	-	8	O
of	-	20	O
hypertension	-	23	B
during	-	36	O
focal	-	43	O
cerebral	-	49	B
ischemia	-	58	I
:	-	66	O
effect	-	68	O
on	-	75	O
brain	-	78	B
edema	-	84	I
.	-	89	O

The	1711760	91	O
effect	-	95	O
of	-	102	O
induced	-	105	O
hypertension	-	113	B
instituted	-	126	O
after	-	137	O
a	-	143	O
2	-	145	O
-	-	146	O
h	-	147	O
delay	-	149	O
following	-	155	O
middle	-	165	B
cerebral	-	172	I
artery	-	181	I
occlusion	-	188	I
(	-	198	O
MCAO	-	199	B
)	-	203	O
on	-	205	O
brain	-	208	B
edema	-	214	I
formation	-	220	O
and	-	230	O
histochemical	-	234	O
injury	-	248	O
was	-	255	O
studied	-	259	O
.	-	266	O

Under	1711760	268	O
isoflurane	-	274	O
anesthesia	-	285	O
,	-	295	O
the	-	297	O
MCA	-	301	O
of	-	305	O
14	-	308	O
spontaneously	-	311	O
hypertensive	-	325	B
rats	-	338	O
was	-	343	O
occluded	-	347	O
.	-	355	O

In	1711760	357	O
the	-	360	O
control	-	364	O
group	-	372	O
(	-	378	O
n	-	379	O
=	-	381	O
7	-	383	O
)	-	384	O
,	-	385	O
the	-	387	O
mean	-	391	O
arterial	-	396	O
pressure	-	405	O
(	-	414	O
MAP	-	415	O
)	-	418	O
was	-	420	O
not	-	424	O
manipulated	-	428	O
.	-	439	O

In	1711760	441	O
the	-	444	O
hypertensive	-	448	B
group	-	461	O
(	-	467	O
n	-	468	O
=	-	470	O
7	-	472	O
)	-	473	O
,	-	474	O
the	-	476	O
MAP	-	480	O
was	-	484	O
elevated	-	488	O
by	-	497	O
25	-	500	O
-	-	502	O
30	-	503	O
mm	-	506	O
Hg	-	509	O
beginning	-	512	O
2	-	522	O
h	-	524	O
after	-	526	O
MCAO	-	532	B
.	-	536	O

Four	1711760	538	O
hours	-	543	O
after	-	549	O
MCAO	-	555	B
,	-	559	O
the	-	561	O
rats	-	565	O
were	-	570	O
killed	-	575	O
and	-	582	O
the	-	586	O
brains	-	590	O
harvested	-	597	O
.	-	606	O

The	1711760	608	O
brains	-	612	O
were	-	619	O
sectioned	-	624	O
along	-	634	O
coronal	-	640	O
planes	-	648	O
spanning	-	655	O
the	-	664	O
distribution	-	668	O
of	-	681	O
ischemia	-	684	B
produced	-	693	O
by	-	702	O
MCAO	-	705	B
.	-	709	O

Specific	1711760	711	O
gravity	-	720	O
(	-	728	O
SG	-	729	O
)	-	731	O
was	-	733	O
determined	-	737	O
in	-	748	O
the	-	751	O
subcortex	-	755	O
and	-	765	O
in	-	769	O
two	-	772	O
sites	-	776	O
in	-	782	O
the	-	785	O
cortex	-	789	O
(	-	796	O
core	-	797	O
and	-	802	O
periphery	-	806	O
of	-	816	O
the	-	819	O
ischemic	-	823	B
territory	-	832	O
)	-	841	O
.	-	842	O

The	1711760	844	O
extent	-	848	O
of	-	855	O
neuronal	-	858	B
injury	-	867	I
was	-	874	O
determined	-	878	O
by	-	889	O
2	-	892	O
,	-	893	O
3	-	894	O
,	-	895	O
5	-	896	O
-	-	897	O
triphenyltetrazolium	-	898	O
staining	-	919	O
.	-	927	O

In	1711760	929	O
the	-	932	O
ischemic	-	936	B
core	-	945	O
,	-	949	O
there	-	951	O
was	-	957	O
no	-	961	O
difference	-	964	O
in	-	975	O
SG	-	978	O
in	-	981	O
the	-	984	O
subcortex	-	988	O
and	-	998	O
cortex	-	1002	O
in	-	1009	O
the	-	1012	O
two	-	1016	O
groups	-	1020	O
.	-	1026	O

In	1711760	1028	O
the	-	1031	O
periphery	-	1035	O
of	-	1045	O
the	-	1048	O
ischemic	-	1052	B
territory	-	1061	O
,	-	1070	O
SG	-	1072	O
in	-	1075	O
the	-	1078	O
cortex	-	1082	O
was	-	1089	O
greater	-	1093	O
(	-	1101	O
less	-	1102	O
edema	-	1107	B
accumulation	-	1113	O
)	-	1125	O
in	-	1127	O
the	-	1130	O
hypertensive	-	1134	B
group	-	1147	O
(	-	1153	O
1	-	1154	O
.	-	1155	O
041	-	1156	O
+	-	1160	O
/	-	1161	O
-	-	1162	O

0	1711760	1164	O
.	-	1165	O
001	-	1166	O
vs	-	1170	O
1	-	1173	O
.	-	1174	O
039	-	1175	O
+	-	1179	O
/	-	1180	O
-	-	1181	O

0	1711760	1183	O
.	-	1184	O
001	-	1185	O
,	-	1188	O
P	-	1190	O
less	-	1192	O
than	-	1197	O
0	-	1202	O
.	-	1203	O
05	-	1204	O
)	-	1206	O
.	-	1207	O

The	1711760	1209	O
area	-	1213	O
of	-	1218	O
histochemical	-	1221	O
injury	-	1235	O
(	-	1242	O
as	-	1243	O
a	-	1246	O
percent	-	1248	O
of	-	1256	O
the	-	1259	O
cross	-	1263	O
-	-	1268	O
sectional	-	1269	O
area	-	1279	O
of	-	1284	O
the	-	1287	O
hemisphere	-	1291	O
)	-	1301	O
was	-	1303	O
less	-	1307	O
in	-	1312	O
the	-	1315	O
hypertensive	-	1319	B
group	-	1332	O
(	-	1338	O
33	-	1339	O
+	-	1342	O
/	-	1343	O
-	-	1344	O

3	1711760	1346	O
%	-	1347	O
vs	-	1349	O
21	-	1352	O
+	-	1355	O
/	-	1356	O
-	-	1357	O

2	1711760	1359	O
%	-	1360	O
,	-	1361	O
P	-	1363	O
less	-	1365	O
than	-	1370	O
0	-	1375	O
.	-	1376	O
05	-	1377	O
)	-	1379	O
.	-	1380	O

The	1711760	1382	O
data	-	1386	O
indicate	-	1391	O
that	-	1400	O
phenylephrine	-	1405	O
-	-	1418	O
induced	-	1419	O
hypertension	-	1427	B
instituted	-	1440	O
2	-	1451	O
h	-	1453	O
after	-	1455	O
MCAO	-	1461	B
does	-	1466	O
not	-	1471	O
aggravate	-	1475	O
edema	-	1485	B
in	-	1491	O
the	-	1494	O
ischemic	-	1498	B
core	-	1507	O
,	-	1511	O
that	-	1513	O
it	-	1518	O
improves	-	1521	O
edema	-	1530	B
in	-	1536	O
the	-	1539	O
periphery	-	1543	O
of	-	1553	O
the	-	1556	O
ischemic	-	1560	B
territory	-	1569	O
,	-	1578	O
and	-	1580	O
that	-	1584	O
it	-	1589	O
reduces	-	1592	O
the	-	1600	O
area	-	1604	O
of	-	1609	O
histochemical	-	1612	O
neuronal	-	1626	B
dysfunction	-	1635	I
.	-	1646	O

Amiodarone	1595783	0	O
pulmonary	-	11	B
toxicity	-	21	I
.	-	29	O

Amiodarone	1595783	31	O
is	-	42	O
an	-	45	O
effective	-	48	O
antiarrhythmic	-	58	O
agent	-	73	O
whose	-	79	O
utility	-	85	O
is	-	93	O
limited	-	96	O
by	-	104	O
many	-	107	O
side	-	112	O
-	-	116	O
effects	-	117	O
,	-	124	O
the	-	126	O
most	-	130	O
problematic	-	135	O
being	-	147	O
pneumonitis	-	153	B
.	-	164	O

The	1595783	166	O
pulmonary	-	170	B
toxicity	-	180	I
of	-	189	O
amiodarone	-	192	O
is	-	203	O
thought	-	206	O
to	-	214	O
result	-	217	O
from	-	224	O
direct	-	229	O
injury	-	236	O
related	-	243	O
to	-	251	O
the	-	254	O
intracellular	-	258	O
accumulation	-	272	O
of	-	285	O
phospholipid	-	288	O
and	-	301	O
T	-	305	O
cell	-	307	O
-	-	311	O
mediated	-	312	O
hypersensitivity	-	321	B
pneumonitis	-	338	I
.	-	349	O

The	1595783	351	O
clinical	-	355	O
and	-	364	O
radiographic	-	368	O
features	-	381	O
of	-	390	O
amiodarone	-	393	O
-	-	403	O
induced	-	404	O
pulmonary	-	412	B
toxicity	-	422	I
are	-	431	O
characteristic	-	435	O
but	-	450	O
nonspecific	-	454	O
.	-	465	O

The	1595783	467	O
diagnosis	-	471	O
depends	-	481	O
on	-	489	O
exclusion	-	492	O
of	-	502	O
other	-	505	O
entities	-	511	O
,	-	519	O
such	-	521	O
as	-	526	O
heart	-	529	B
failure	-	535	I
,	-	542	O
infection	-	544	B
,	-	553	O
and	-	555	O
malignancy	-	559	B
.	-	569	O

While	1595783	571	O
withdrawal	-	577	O
of	-	588	O
amiodarone	-	591	O
leads	-	602	O
to	-	608	O
clinical	-	611	O
improvement	-	620	O
in	-	632	O
majority	-	635	O
of	-	644	O
cases	-	647	O
,	-	652	O
this	-	654	O
is	-	659	O
not	-	662	O
always	-	666	O
possible	-	673	O
or	-	682	O
advisable	-	685	O
.	-	694	O

Dose	1595783	696	O
reduction	-	701	O
or	-	711	O
concomitant	-	714	O
steroid	-	726	O
therapy	-	734	O
may	-	742	O
have	-	746	O
a	-	751	O
role	-	753	O
in	-	758	O
selected	-	761	O
patients	-	770	O
.	-	778	O

Light	804391	0	O
chain	-	6	O
proteinuria	-	12	B
and	-	24	O
cellular	-	28	O
mediated	-	37	O
immunity	-	46	O
in	-	55	O
rifampin	-	58	O
treated	-	67	O
patients	-	75	O
with	-	84	O
tuberculosis	-	89	B
.	-	101	O

Light	804391	103	O
chain	-	109	O
proteinuria	-	115	B
was	-	127	O
found	-	131	O
in	-	137	O
9	-	140	O
of	-	142	O
17	-	145	O
tuberculosis	-	148	B
patients	-	161	O
treated	-	170	O
with	-	178	O
rifampin	-	183	O
.	-	191	O

Concomitant	804391	193	O
assay	-	205	O
of	-	211	O
cellular	-	214	O
mediated	-	223	O
immunity	-	232	O
in	-	241	O
these	-	244	O
patients	-	250	O
using	-	259	O
skin	-	265	O
test	-	270	O
antigen	-	275	O
and	-	283	O
a	-	287	O
lymphokine	-	289	O
in	-	300	O
vitro	-	303	O
test	-	309	O
provided	-	314	O
results	-	323	O
that	-	331	O
were	-	336	O
different	-	341	O
.	-	350	O

Response	804391	352	O
to	-	361	O
Varidase	-	364	O
skin	-	373	O
test	-	378	O
antigen	-	383	O
was	-	391	O
negative	-	395	O
for	-	404	O
all	-	408	O
eight	-	412	O
tuberculosis	-	418	B
patients	-	431	O
tested	-	440	O
,	-	446	O
but	-	448	O
there	-	452	O
occurred	-	458	O
a	-	467	O
hyper	-	469	O
-	-	474	O
responsiveness	-	475	O
of	-	490	O
the	-	493	O
lymphocytes	-	497	O
of	-	509	O
these	-	512	O
eight	-	518	O
patients	-	524	O
to	-	533	O
phytomitogen	-	536	O
(	-	549	O
PHA	-	550	O
-	-	553	O
P	-	554	O
)	-	555	O
.	-	556	O

as	804391	558	O
well	-	561	O
as	-	566	O
of	-	569	O
those	-	572	O
of	-	578	O
seven	-	581	O
other	-	587	O
tuberculous	-	593	B
patients	-	605	O
.	-	613	O

This	804391	615	O
last	-	620	O
finding	-	625	O
may	-	633	O
be	-	637	O
related	-	640	O
to	-	648	O
time	-	651	O
of	-	656	O
testing	-	659	O
and	-	667	O
/	-	670	O
or	-	671	O
endogenous	-	674	O
serum	-	685	O
binding	-	691	O
of	-	699	O
rifampin	-	702	O
which	-	711	O
could	-	717	O
have	-	723	O
inhibited	-	728	O
mitogen	-	738	O
activity	-	746	O
for	-	755	O
the	-	759	O
lymphocyte	-	763	O
.	-	773	O

Initial	28952	0	O
potassium	-	8	O
loss	-	18	O
and	-	23	O
hypokalaemia	-	27	B
during	-	40	O
chlorthalidone	-	47	O
administration	-	62	O
in	-	77	O
patients	-	80	O
with	-	89	O
essential	-	94	O
hypertension	-	104	B
:	-	116	O
the	-	118	O
influence	-	122	O
of	-	132	O
dietary	-	135	O
sodium	-	143	O
restriction	-	150	O
.	-	161	O

To	28952	163	O
investigate	-	166	O
the	-	178	O
initial	-	182	O
potassium	-	190	O
loss	-	200	O
and	-	205	O
development	-	209	O
of	-	221	O
hypokalaemia	-	224	B
during	-	237	O
the	-	244	O
administration	-	248	O
of	-	263	O
an	-	266	O
oral	-	269	O
diuretic	-	274	O
,	-	282	O
metabolic	-	284	O
balance	-	294	O
studies	-	302	O
were	-	310	O
performed	-	315	O
in	-	325	O
ten	-	328	O
patients	-	332	O
with	-	341	O
essential	-	346	O
hypertension	-	356	B
who	-	369	O
had	-	373	O
shown	-	377	O
hypokalaemia	-	383	B
under	-	396	O
prior	-	402	O
oral	-	408	O
diuretic	-	413	O
treatment	-	422	O
.	-	431	O

Chlorthalidone	28952	433	O
(	-	448	O
50	-	449	O
mg	-	452	O
daily	-	455	O
)	-	460	O
was	-	462	O
given	-	466	O
for	-	472	O
14	-	476	O
days	-	479	O
.	-	483	O

Six	28952	485	O
patients	-	489	O
received	-	498	O
a	-	507	O
normal	-	509	O
-	-	515	O
sodium	-	516	O
diet	-	523	O
and	-	528	O
four	-	532	O
a	-	537	O
low	-	539	O
-	-	542	O
sodium	-	543	O
(	-	550	O
17	-	551	O
mmol	-	554	O
/	-	558	O
day	-	559	O
)	-	562	O
diet	-	564	O
.	-	568	O

All	28952	570	O
patients	-	574	O
had	-	583	O
a	-	587	O
normal	-	589	O
initial	-	596	O
total	-	604	O
body	-	610	O
potassium	-	615	O
(	-	625	O
40	-	626	O
K	-	628	O
)	-	629	O
.	-	630	O

The	28952	632	O
electrolyte	-	636	O
balances	-	648	O
,	-	656	O
weight	-	658	O
,	-	664	O
bromide	-	666	O
space	-	674	O
,	-	679	O
plasma	-	681	O
renin	-	688	O
activity	-	694	O
,	-	702	O
and	-	704	O
aldosterone	-	708	O
secretion	-	720	O
rate	-	730	O
were	-	735	O
measured	-	740	O
.	-	748	O

In	28952	750	O
both	-	753	O
groups	-	758	O
a	-	765	O
potassium	-	767	O
deficit	-	777	O
developed	-	785	O
,	-	794	O
with	-	796	O
proportionally	-	801	O
larger	-	816	O
losses	-	823	O
from	-	830	O
the	-	835	O
extracellular	-	839	O
than	-	853	O
from	-	858	O
the	-	863	O
intracellular	-	867	O
compartment	-	881	O
.	-	892	O

In	28952	894	O
the	-	897	O
normal	-	901	O
-	-	907	O
sodium	-	908	O
group	-	915	O
the	-	921	O
highest	-	925	O
mean	-	933	O
potassium	-	938	O
deficit	-	948	O
was	-	956	O
176	-	960	O
mmol	-	964	O
on	-	969	O
day	-	972	O
9	-	976	O
,	-	977	O
after	-	979	O
which	-	985	O
some	-	991	O
potassium	-	996	O
was	-	1006	O
regained	-	1010	O
;	-	1018	O
in	-	1020	O
the	-	1023	O
low	-	1027	O
-	-	1030	O
sodium	-	1031	O
group	-	1038	O
the	-	1044	O
highest	-	1048	O
deficit	-	1056	O
was	-	1064	O
276	-	1068	O
mmol	-	1072	O
on	-	1077	O
day	-	1080	O
13	-	1084	O
.	-	1086	O

The	28952	1088	O
normal	-	1092	O
-	-	1098	O
sodium	-	1099	O
group	-	1106	O
showed	-	1112	O
an	-	1119	O
immediate	-	1122	O
but	-	1132	O
temporary	-	1136	O
rise	-	1146	O
of	-	1151	O
the	-	1154	O
renin	-	1158	O
and	-	1164	O
aldosterone	-	1168	O
levels	-	1180	O
;	-	1186	O
in	-	1188	O
the	-	1191	O
low	-	1195	O
-	-	1198	O
sodium	-	1199	O
group	-	1206	O
renin	-	1212	O
and	-	1218	O
aldosterone	-	1222	O
increased	-	1234	O
more	-	1244	O
slowly	-	1249	O
but	-	1256	O
remained	-	1260	O
elevated	-	1269	O
.	-	1277	O

It	28952	1279	O
is	-	1282	O
concluded	-	1285	O
that	-	1295	O
dietary	-	1300	O
sodium	-	1308	O
restriction	-	1315	O
increases	-	1327	O
diuretic	-	1337	O
-	-	1345	O
induced	-	1346	O
potassium	-	1354	O
loss	-	1364	O
,	-	1368	O
presumably	-	1370	O
by	-	1381	O
an	-	1384	O
increased	-	1387	O
activity	-	1397	O
of	-	1406	O
the	-	1409	O
renin	-	1413	O
-	-	1418	O
angiotensin	-	1419	O
-	-	1430	O
aldosterone	-	1431	O
system	-	1443	O
,	-	1449	O
while	-	1451	O
sodium	-	1457	O
delivery	-	1464	O
to	-	1473	O
the	-	1476	O
distal	-	1480	O
renal	-	1487	O
tubules	-	1493	O
remains	-	1501	O
sufficiently	-	1509	O
high	-	1522	O
to	-	1527	O
allow	-	1530	O
increased	-	1536	O
potassium	-	1546	O
secretion	-	1556	O
.	-	1565	O

Dynamic	19893084	0	O
response	-	8	O
of	-	17	O
blood	-	20	O
vessel	-	26	O
in	-	33	O
acute	-	36	B
renal	-	42	I
failure	-	48	I
.	-	55	O

In	19893084	57	O
this	-	60	O
study	-	65	O
we	-	71	O
postulated	-	74	O
that	-	85	O
during	-	90	O
acute	-	97	B
renal	-	103	I
failure	-	109	I
induced	-	117	O
by	-	125	O
gentamicin	-	128	O
the	-	139	O
transient	-	143	O
or	-	153	O
dynamic	-	156	O
response	-	164	O
of	-	173	O
blood	-	176	O
vessels	-	182	O
could	-	190	O
be	-	196	O
affected	-	199	O
,	-	207	O
and	-	209	O
that	-	213	O
antioxidants	-	218	O
can	-	231	O
prevent	-	235	O
the	-	243	O
changes	-	247	O
in	-	255	O
dynamic	-	258	O
responses	-	266	O
of	-	276	O
blood	-	279	O
vessels	-	285	O
.	-	292	O

The	19893084	294	O
new	-	298	O
approach	-	302	O
to	-	311	O
ex	-	314	O
vivo	-	317	O
blood	-	322	O
vessel	-	328	O
experiments	-	335	O
in	-	347	O
which	-	350	O
not	-	356	O
only	-	360	O
the	-	365	O
end	-	369	O
points	-	373	O
of	-	380	O
vessels	-	383	O
response	-	391	O
within	-	400	O
the	-	407	O
time	-	411	O
interval	-	416	O
is	-	425	O
considered	-	428	O
,	-	438	O
but	-	440	O
also	-	444	O
dynamics	-	449	O
of	-	458	O
this	-	461	O
response	-	466	O
,	-	474	O
was	-	476	O
used	-	480	O
in	-	485	O
this	-	488	O
paper	-	493	O
.	-	498	O

Our	19893084	500	O
results	-	504	O
confirm	-	512	O
the	-	520	O
alteration	-	524	O
in	-	535	O
dynamic	-	538	O
response	-	546	O
of	-	555	O
blood	-	558	O
vessels	-	564	O
during	-	572	O
the	-	579	O
change	-	583	O
of	-	590	O
pressure	-	593	O
in	-	602	O
gentamicin	-	605	O
-	-	615	O
treated	-	616	O
animals	-	624	O
.	-	631	O

The	19893084	633	O
beneficial	-	637	O
effects	-	648	O
of	-	656	O
vitamin	-	659	O
C	-	667	O
administration	-	669	O
to	-	684	O
gentamicin	-	687	O
-	-	697	O
treated	-	698	O
animals	-	706	O
are	-	714	O
also	-	718	O
confirmed	-	723	O
through	-	733	O
:	-	740	O
lower	-	742	O
level	-	748	O
of	-	754	O
blood	-	757	O
urea	-	763	O
and	-	768	O
creatinine	-	772	O
and	-	783	O
higher	-	787	O
level	-	794	O
of	-	800	O
potassium	-	803	O
.	-	812	O

The	19893084	814	O
pressure	-	818	O
dynamic	-	827	O
responses	-	835	O
of	-	845	O
isolated	-	848	O
blood	-	857	O
vessels	-	863	O
show	-	871	O
a	-	876	O
faster	-	878	O
pressure	-	885	O
change	-	894	O
in	-	901	O
gentamicin	-	904	O
-	-	914	O
treated	-	915	O
animals	-	923	O
(	-	931	O
8	-	932	O
.	-	933	O
07	-	934	O
+	-	937	O
/	-	938	O
-	-	939	O

1	19893084	941	O
.	-	942	O
7	-	943	O
s	-	945	O
vs	-	947	O
.	-	949	O
5	-	951	O
.	-	952	O
64	-	953	O
+	-	956	O
/	-	957	O
-	-	958	O

0	19893084	960	O
.	-	961	O
18	-	962	O
s	-	965	O
)	-	966	O
.	-	967	O

Vitamin	19893084	969	O
C	-	977	O
administration	-	979	O
induced	-	994	O
slowdown	-	1002	O
of	-	1011	O
pressure	-	1014	O
change	-	1023	O
back	-	1030	O
to	-	1035	O
the	-	1038	O
control	-	1042	O
values	-	1050	O
.	-	1056	O

The	19893084	1058	O
pressure	-	1062	O
dynamic	-	1071	O
properties	-	1079	O
,	-	1089	O
quantitatively	-	1091	O
defined	-	1106	O
by	-	1114	O
comparative	-	1117	O
pressure	-	1129	O
dynamic	-	1138	O
and	-	1146	O
total	-	1150	O
pressure	-	1156	O
dynamic	-	1165	O
,	-	1172	O
confirm	-	1174	O
the	-	1182	O
alteration	-	1186	O
in	-	1197	O
dynamic	-	1200	O
response	-	1208	O
of	-	1217	O
blood	-	1220	O
vessels	-	1226	O
during	-	1234	O
the	-	1241	O
change	-	1245	O
of	-	1252	O
pressure	-	1255	O
in	-	1264	O
gentamicin	-	1267	O
-	-	1277	O
treated	-	1278	O
animals	-	1286	O
and	-	1294	O
beneficial	-	1298	O
effects	-	1309	O
of	-	1317	O
vitamin	-	1320	O
C	-	1328	O
administration	-	1330	O
.	-	1344	O

The	18513945	0	O
hemodynamics	-	4	O
of	-	17	O
oxytocin	-	20	O
and	-	29	O
other	-	33	O
vasoactive	-	39	O
agents	-	50	O
during	-	57	O
neuraxial	-	64	O
anesthesia	-	74	O
for	-	85	O
cesarean	-	89	O
delivery	-	98	O
:	-	106	O
findings	-	108	O
in	-	117	O
six	-	120	O
cases	-	124	O
.	-	129	O

Oxytocin	18513945	131	O
is	-	140	O
a	-	143	O
commonly	-	145	O
used	-	154	O
uterotonic	-	159	O
that	-	170	O
can	-	175	O
cause	-	179	O
significant	-	185	O
and	-	197	O
even	-	201	O
fatal	-	206	O
hypotension	-	212	B
,	-	223	O
particularly	-	225	O
when	-	238	O
given	-	243	O
as	-	249	O
a	-	252	O
bolus	-	254	O
.	-	259	O

The	18513945	261	O
resulting	-	265	O
hypotension	-	275	B
can	-	287	O
be	-	291	O
produced	-	294	O
by	-	303	O
a	-	306	O
decrease	-	308	O
in	-	317	O
systemic	-	320	O
vascular	-	329	O
resistance	-	338	O
or	-	349	O
cardiac	-	352	O
output	-	360	O
through	-	367	O
a	-	375	O
decrease	-	377	O
in	-	386	O
venous	-	389	O
return	-	396	O
.	-	402	O

Parturients	18513945	404	O
with	-	416	O
normal	-	421	O
volume	-	428	O
status	-	435	O
,	-	441	O
heart	-	443	O
valves	-	449	O
and	-	456	O
pulmonary	-	460	O
vasculature	-	470	O
most	-	482	O
often	-	487	O
respond	-	493	O
to	-	501	O
this	-	504	O
hypotension	-	509	B
with	-	521	O
a	-	526	O
compensatory	-	528	O
increase	-	541	O
in	-	550	O
heart	-	553	O
rate	-	559	O
and	-	564	O
stroke	-	568	B
volume	-	575	O
.	-	581	O

Oxytocin	18513945	583	O
-	-	591	O
induced	-	592	O
hypotension	-	600	B
at	-	612	O
cesarean	-	615	O
delivery	-	624	O
may	-	633	O
be	-	637	O
incorrectly	-	640	O
attributed	-	652	O
to	-	663	O
blood	-	666	B
loss	-	672	I
.	-	676	O

Pulse	18513945	678	O
power	-	684	O
analysis	-	690	O
(	-	699	O
also	-	700	O
called	-	705	O
""""	-	712	O
pulse	-	713	O
contour	-	719	O
analysis	-	727	O
""""	-	735	O
)	-	736	O
of	-	738	O
an	-	741	O
arterial	-	744	O
pressure	-	753	O
wave	-	762	O
form	-	767	O
allows	-	772	O
continuous	-	779	O
evaluation	-	790	O
of	-	801	O
systemic	-	804	O
vascular	-	813	O
resistance	-	822	O
and	-	833	O
cardiac	-	837	O
output	-	845	O
in	-	852	O
real	-	855	O
time	-	860	O
,	-	864	O
thereby	-	866	O
elucidating	-	874	O
the	-	886	O
causative	-	890	O
factors	-	900	O
behind	-	908	O
changes	-	915	O
in	-	923	O
blood	-	926	O
pressure	-	932	O
.	-	940	O

Pulse	18513945	942	O
power	-	948	O
analysis	-	954	O
was	-	963	O
conducted	-	967	O
in	-	977	O
six	-	980	O
cases	-	984	O
of	-	990	O
cesarean	-	993	O
delivery	-	1002	O
performed	-	1011	O
under	-	1021	O
neuraxial	-	1027	O
anesthesia	-	1037	O
.	-	1047	O

Hypotension	18513945	1049	B
in	-	1061	O
response	-	1064	O
to	-	1073	O
oxytocin	-	1076	O
was	-	1085	O
associated	-	1089	O
with	-	1100	O
a	-	1105	O
decrease	-	1107	O
in	-	1116	O
systemic	-	1119	O
vascular	-	1128	O
resistance	-	1137	O
and	-	1148	O
a	-	1152	O
compensatory	-	1154	O
increase	-	1167	O
in	-	1176	O
stroke	-	1179	B
volume	-	1186	O
,	-	1192	O
heart	-	1194	O
rate	-	1200	O
and	-	1205	O
cardiac	-	1209	O
output	-	1217	O
.	-	1223	O

Pulse	18513945	1225	O
power	-	1231	O
analysis	-	1237	O
may	-	1246	O
be	-	1250	O
helpful	-	1253	O
in	-	1261	O
determining	-	1264	O
the	-	1276	O
etiology	-	1280	O
of	-	1289	O
and	-	1292	O
treating	-	1296	O
hypotension	-	1305	B
during	-	1317	O
cesarean	-	1324	O
delivery	-	1333	O
under	-	1342	O
neuraxial	-	1348	O
anesthesia	-	1358	O
.	-	1368	O

Exaggerated	18483878	0	O
expression	-	12	O
of	-	23	O
inflammatory	-	26	O
mediators	-	39	O
in	-	49	O
vasoactive	-	52	O
intestinal	-	63	O
polypeptide	-	74	O
knockout	-	86	O
(	-	95	O
VIP	-	96	O
-	-	99	O
/	-	100	O
-	-	101	O
)	-	102	O
mice	-	104	O
with	-	109	O
cyclophosphamide	-	114	O
(	-	131	O
CYP	-	132	O
)	-	135	O
-	-	136	O
induced	-	137	O
cystitis	-	145	B
.	-	153	O

Vasoactive	18483878	155	O
intestinal	-	166	O
polypeptide	-	177	O
(	-	189	O
VIP	-	190	O
)	-	193	O
is	-	195	O
an	-	198	O
immunomodulatory	-	201	O
neuropeptide	-	218	O
distributed	-	231	O
in	-	243	O
micturition	-	246	O
pathways	-	258	O
.	-	266	O

VIP	18483878	268	O
(	-	271	O
-	-	272	O
/	-	273	O
-	-	274	O
)	-	275	O
mice	-	277	O
exhibit	-	282	O
altered	-	290	O
bladder	-	298	O
function	-	306	O
and	-	315	O
neurochemical	-	319	O
properties	-	333	O
in	-	344	O
micturition	-	347	O
pathways	-	359	O
after	-	368	O
cyclophosphamide	-	374	O
(	-	391	O
CYP	-	392	O
)	-	395	O
-	-	396	O
induced	-	397	O
cystitis	-	405	B
.	-	413	O

Given	18483878	415	O
VIP	-	421	O
's	-	424	O
role	-	427	O
as	-	432	O
an	-	435	O
anti	-	438	O
-	-	442	O
inflammatory	-	443	O
mediator	-	456	O
,	-	464	O
we	-	466	O
hypothesized	-	469	O
that	-	482	O
VIP	-	487	O
(	-	490	O
-	-	491	O
/	-	492	O
-	-	493	O
)	-	494	O
mice	-	496	O
would	-	501	O
exhibit	-	507	O
enhanced	-	515	O
inflammatory	-	524	O
mediator	-	537	O
expression	-	546	O
after	-	557	O
cystitis	-	563	B
.	-	571	O

A	18483878	573	O
mouse	-	575	O
inflammatory	-	581	O
cytokine	-	594	O
and	-	603	O
receptor	-	607	O
RT2	-	616	O
profiler	-	620	O
array	-	629	O
was	-	635	O
used	-	639	O
to	-	644	O
determine	-	647	O
regulated	-	657	O
transcripts	-	667	O
in	-	679	O
the	-	682	O
urinary	-	686	O
bladder	-	694	O
of	-	702	O
wild	-	705	O
type	-	710	O
(	-	715	O
WT	-	716	O
)	-	718	O
and	-	720	O
VIP	-	724	O
(	-	727	O
-	-	728	O
/	-	729	O
-	-	730	O
)	-	731	O
mice	-	733	O
with	-	738	O
or	-	743	O
without	-	746	O
CYP	-	754	O
-	-	757	O
induced	-	758	O
cystitis	-	766	B
(	-	775	O
150	-	776	O
mg	-	780	O
/	-	782	O
kg	-	783	O
;	-	785	O
i	-	787	O
.	-	788	O
p	-	789	O
.	-	790	O

;	18483878	791	O
48	-	793	O
h	-	796	O
)	-	797	O
.	-	798	O

Four	18483878	800	O
binary	-	805	O
comparisons	-	812	O
were	-	824	O
made	-	829	O
:	-	833	O

WT	18483878	835	O
control	-	838	O
versus	-	846	O
CYP	-	853	O
treatment	-	857	O
(	-	867	O
48	-	868	O
h	-	871	O
)	-	872	O
,	-	873	O
VIP	-	875	O
(	-	878	O
-	-	879	O
/	-	880	O
-	-	881	O
)	-	882	O
control	-	884	O
versus	-	892	O
CYP	-	899	O
treatment	-	903	O
(	-	913	O
48	-	914	O
h	-	917	O
)	-	918	O
,	-	919	O
WT	-	921	O
control	-	924	O
versus	-	932	O
VIP	-	939	O
(	-	942	O
-	-	943	O
/	-	944	O
-	-	945	O
)	-	946	O
control	-	948	O
,	-	955	O
and	-	957	O
WT	-	961	O
with	-	964	O
CYP	-	969	O
treatment	-	973	O
(	-	983	O
48	-	984	O
h	-	987	O
)	-	988	O
versus	-	990	O
VIP	-	997	O
(	-	1000	O
-	-	1001	O
/	-	1002	O
-	-	1003	O
)	-	1004	O
with	-	1006	O
CYP	-	1011	O
treatment	-	1015	O
(	-	1025	O
48	-	1026	O
h	-	1029	O
)	-	1030	O
.	-	1031	O

The	18483878	1033	O
genes	-	1037	O
presented	-	1043	O
represent	-	1053	O
(	-	1063	O
1	-	1064	O
)	-	1065	O
greater	-	1067	O
than	-	1075	O
1	-	1080	O
.	-	1081	O
5	-	1082	O
-	-	1083	O
fold	-	1084	O
change	-	1089	O
in	-	1096	O
either	-	1099	O
direction	-	1106	O
and	-	1116	O
(	-	1120	O
2	-	1121	O
)	-	1122	O
the	-	1124	O
p	-	1128	O
value	-	1130	O
is	-	1136	O
less	-	1139	O
than	-	1144	O
0	-	1149	O
.	-	1150	O
05	-	1151	O
for	-	1154	O
the	-	1158	O
comparison	-	1162	O
being	-	1173	O
made	-	1179	O
.	-	1183	O

Several	18483878	1185	O
regulated	-	1193	O
genes	-	1203	O
were	-	1209	O
validated	-	1214	O
using	-	1224	O
enzyme	-	1230	O
-	-	1236	O
linked	-	1237	O
immunoassays	-	1244	O
including	-	1257	O
IL	-	1267	O
-	-	1269	O
1beta	-	1270	O
and	-	1276	O
CXCL1	-	1280	O
.	-	1285	O

CYP	18483878	1287	O
treatment	-	1291	O
significantly	-	1301	O
(	-	1315	O
p	-	1316	O
<	-	1318	O
or	-	1320	O
=	-	1323	O
0	-	1325	O
.	-	1326	O
001	-	1327	O
)	-	1330	O
increased	-	1332	O
expression	-	1342	O
of	-	1353	O
CXCL1	-	1356	O
and	-	1362	O
IL	-	1366	O
-	-	1368	O
1beta	-	1369	O
in	-	1375	O
the	-	1378	O
urinary	-	1382	O
bladder	-	1390	O
of	-	1398	O
WT	-	1401	O
and	-	1404	O
VIP	-	1408	O
(	-	1411	O
-	-	1412	O
/	-	1413	O
-	-	1414	O
)	-	1415	O
mice	-	1417	O
,	-	1421	O
but	-	1423	O
expression	-	1427	O
in	-	1438	O
VIP	-	1441	O
(	-	1444	O
-	-	1445	O
/	-	1446	O
-	-	1447	O

)	18483878	1448	O
mice	-	1450	O
with	-	1455	O
CYP	-	1460	O
treatment	-	1464	O
was	-	1474	O
significantly	-	1478	O
(	-	1492	O
p	-	1493	O
<	-	1495	O
or	-	1497	O
=	-	1500	O
0	-	1502	O
.	-	1503	O
001	-	1504	O
)	-	1507	O
greater	-	1509	O
(	-	1517	O
4	-	1518	O
.	-	1519	O
2	-	1520	O
-	-	1521	O
to	-	1523	O
13	-	1526	O
-	-	1528	O
fold	-	1529	O
increase	-	1534	O
)	-	1542	O
than	-	1544	O
that	-	1549	O
observed	-	1554	O
in	-	1563	O
WT	-	1566	O
urinary	-	1569	O
bladder	-	1577	O
(	-	1585	O
3	-	1586	O
.	-	1587	O
6	-	1588	O
-	-	1589	O
to	-	1591	O
5	-	1594	O
-	-	1595	O
fold	-	1596	O
increase	-	1601	O
)	-	1609	O
.	-	1610	O

The	18483878	1612	O
data	-	1616	O
suggest	-	1621	O
that	-	1629	O
in	-	1634	O
VIP	-	1637	O
(	-	1640	O
-	-	1641	O
/	-	1642	O
-	-	1643	O
)	-	1644	O
mice	-	1646	O
with	-	1651	O
bladder	-	1656	B
inflammation	-	1664	I
,	-	1676	O
inflammatory	-	1678	O
mediators	-	1691	O
are	-	1701	O
increased	-	1705	O
above	-	1715	O
that	-	1721	O
observed	-	1726	O
in	-	1735	O
WT	-	1738	O
with	-	1741	O
CYP	-	1746	O
.	-	1749	O

This	18483878	1751	O
shift	-	1756	O
in	-	1762	O
balance	-	1765	O
may	-	1773	O
contribute	-	1777	O
to	-	1788	O
increased	-	1791	O
bladder	-	1801	B
dysfunction	-	1809	I
in	-	1821	O
VIP	-	1824	O
(	-	1827	O
-	-	1828	O
/	-	1829	O
-	-	1830	O
)	-	1831	O
mice	-	1833	O
with	-	1838	O
bladder	-	1843	B
inflammation	-	1851	I
and	-	1864	O
altered	-	1868	O
neurochemical	-	1876	O
expression	-	1890	O
in	-	1901	O
micturition	-	1904	O
pathways	-	1916	O
.	-	1924	O

Intraocular	17923537	0	O
pressure	-	12	O
in	-	21	O
patients	-	24	O
with	-	33	O
uveitis	-	38	B
treated	-	46	O
with	-	54	O
fluocinolone	-	59	O
acetonide	-	72	O
implants	-	82	O
.	-	90	O

OBJECTIVE	17923537	92	O
:	-	101	O

To	17923537	103	O
report	-	106	O
the	-	113	O
incidence	-	117	O
and	-	127	O
management	-	131	O
of	-	142	O
elevated	-	145	B
intraocular	-	154	I
pressure	-	166	I
(	-	175	O
IOP	-	176	O
)	-	179	O
in	-	181	O
patients	-	184	O
with	-	193	O
uveitis	-	198	B
treated	-	206	O
with	-	214	O
the	-	219	O
fluocinolone	-	223	O
acetonide	-	236	O
(	-	246	O
FA	-	247	O
)	-	249	O
intravitreal	-	251	O
implant	-	264	O
.	-	271	O

DESIGN	17923537	273	O
:	-	279	O

Pooled	17923537	281	O
data	-	288	O
from	-	293	O
3	-	298	O
multicenter	-	300	O
,	-	311	O
double	-	313	O
-	-	319	O
masked	-	320	O
,	-	326	O
randomized	-	328	O
,	-	338	O
controlled	-	340	O
,	-	350	O
phase	-	352	O
2b	-	358	O
/	-	360	O
3	-	361	O
clinical	-	363	O
trials	-	372	O
evaluating	-	379	O
the	-	390	O
safety	-	394	O
and	-	401	O
efficacy	-	405	O
of	-	414	O
the	-	417	O
0	-	421	O
.	-	422	O
59	-	423	O
-	-	425	O
mg	-	426	O
or	-	429	O
2	-	432	O
.	-	433	O
1	-	434	O
-	-	435	O
mg	-	436	O
FA	-	439	O
intravitreal	-	442	O
implant	-	455	O
or	-	463	O
standard	-	466	O
therapy	-	475	O
were	-	483	O
analyzed	-	488	O
.	-	496	O

RESULTS	17923537	498	O
:	-	505	O

During	17923537	507	O
the	-	514	O
3	-	518	O
-	-	519	O
year	-	520	O
follow	-	525	O
-	-	531	O
up	-	532	O
,	-	534	O
71	-	536	O
.	-	538	O
0	-	539	O
%	-	540	O
of	-	542	O
implanted	-	545	O
eyes	-	555	O
had	-	560	O
an	-	564	O
IOP	-	567	O
increase	-	571	O
of	-	580	O
10	-	583	O
mm	-	586	O
Hg	-	589	O
or	-	592	O
more	-	595	O
than	-	600	O
baseline	-	605	O
and	-	614	O
55	-	618	O
.	-	620	O
1	-	621	O
%	-	622	O
,	-	623	O
24	-	625	O
.	-	627	O
7	-	628	O
%	-	629	O
,	-	630	O
and	-	632	O
6	-	636	O
.	-	637	O
2	-	638	O
%	-	639	O
of	-	641	O
eyes	-	644	O
reached	-	649	O
an	-	657	O
IOP	-	660	O
of	-	664	O
30	-	667	O
mm	-	670	O
Hg	-	673	O
or	-	676	O
more	-	679	O
,	-	683	O
40	-	685	O
mm	-	688	O
Hg	-	691	O
or	-	694	O
more	-	697	O
,	-	701	O
and	-	703	O
50	-	707	O
mm	-	710	O
Hg	-	713	O
or	-	716	O
more	-	719	O
,	-	723	O
respectively	-	725	O
.	-	737	O

Topical	17923537	739	O
IOP	-	747	O
-	-	750	O
lowering	-	751	O
medication	-	760	O
was	-	771	O
administered	-	775	O
in	-	788	O
74	-	791	O
.	-	793	O
8	-	794	O
%	-	795	O
of	-	797	O
implanted	-	800	O
eyes	-	810	O
,	-	814	O
and	-	816	O
IOP	-	820	O
-	-	823	O
lowering	-	824	O
surgeries	-	833	O
,	-	842	O
most	-	844	O
of	-	849	O
which	-	852	O
were	-	858	O
trabeculectomies	-	863	O
(	-	880	O
76	-	881	O
.	-	883	O
2	-	884	O
%	-	885	O
)	-	886	O
,	-	887	O
were	-	889	O
performed	-	894	O
on	-	904	O
36	-	907	O
.	-	909	O
6	-	910	O
%	-	911	O
of	-	913	O
implanted	-	916	O
eyes	-	926	O
.	-	930	O

Intraocular	17923537	932	O
pressure	-	944	O
-	-	952	O
lowering	-	953	O
surgeries	-	962	O
were	-	972	O
considered	-	977	O
a	-	988	O
success	-	990	O
(	-	998	O
postoperative	-	999	O
IOP	-	1013	O
of	-	1017	O
6	-	1020	O
-	-	1021	O
21	-	1022	O
mm	-	1025	O
Hg	-	1028	O
with	-	1031	O
or	-	1036	O
without	-	1039	O
additional	-	1047	O
IOP	-	1058	O
-	-	1061	O
lowering	-	1062	O
medication	-	1071	O
)	-	1081	O
in	-	1083	O
85	-	1086	O
.	-	1088	O
1	-	1089	O
%	-	1090	O
of	-	1092	O
eyes	-	1095	O
at	-	1100	O
1	-	1103	O
year	-	1105	O
.	-	1109	O

The	17923537	1111	O
rate	-	1115	O
of	-	1120	O
hypotony	-	1123	B
(	-	1132	O
IOP	-	1133	O
<	-	1137	O
/	-	1138	O
=	-	1139	O
5	-	1141	O
mm	-	1143	O
Hg	-	1146	O
)	-	1148	O
following	-	1150	O
IOP	-	1160	O
-	-	1163	O
lowering	-	1164	O
surgery	-	1173	O
(	-	1181	O
42	-	1182	O
.	-	1184	O
5	-	1185	O
%	-	1186	O
)	-	1187	O
was	-	1189	O
not	-	1193	O
different	-	1197	O
from	-	1207	O
that	-	1212	O
of	-	1217	O
implanted	-	1220	O
eyes	-	1230	O
not	-	1235	O
subjected	-	1239	O
to	-	1249	O
surgery	-	1252	O
(	-	1260	O
35	-	1261	O
.	-	1263	O
4	-	1264	O
%	-	1265	O
)	-	1266	O
(	-	1268	O
P	-	1269	O
=	-	1271	O
.	-	1273	O
09	-	1274	O
)	-	1276	O
.	-	1277	O

CONCLUSION	17923537	1279	O
:	-	1289	O

Elevated	17923537	1291	O
IOP	-	1300	O
is	-	1304	O
a	-	1307	O
significant	-	1309	O
complication	-	1321	O
with	-	1334	O
the	-	1339	O
FA	-	1343	O
intravitreal	-	1346	O
implant	-	1359	O
but	-	1367	O
may	-	1371	O
be	-	1375	O
controlled	-	1378	O
with	-	1389	O
medication	-	1394	O
and	-	1405	O
surgery	-	1409	O
.	-	1416	O

Pallidal	15096016	0	O
stimulation	-	9	O
:	-	20	O
an	-	22	O
alternative	-	25	O
to	-	37	O
pallidotomy	-	40	O
?	-	51	O

A	15096016	53	O
resurgence	-	55	O
of	-	66	O
interest	-	69	O
in	-	78	O
the	-	81	O
surgical	-	85	O
treatment	-	94	O
of	-	104	O
Parkinson	-	107	B
's	-	116	I
disease	-	119	I
(	-	127	O
PD	-	128	B
)	-	130	O
came	-	132	O
with	-	137	O
the	-	142	O
rediscovery	-	146	O
of	-	158	O
posteroventral	-	161	O
pallidotomy	-	176	O
by	-	188	O
Laitinen	-	191	O
in	-	200	O
1985	-	203	O
.	-	207	O

Laitinen	15096016	209	O
's	-	217	O
procedure	-	220	O
improved	-	230	O
most	-	239	O
symptoms	-	244	O
in	-	253	O
drug	-	256	O
-	-	260	O
resistant	-	261	O
PD	-	271	B
,	-	273	O
which	-	275	O
engendered	-	281	O
wide	-	292	O
interest	-	297	O
in	-	306	O
the	-	309	O
neurosurgical	-	313	O
community	-	327	O
.	-	336	O

Another	15096016	338	O
lesioning	-	346	O
procedure	-	356	O
,	-	365	O
ventrolateral	-	367	O
thalamotomy	-	381	O
,	-	392	O
has	-	394	O
become	-	398	O
a	-	405	O
powerful	-	407	O
alternative	-	416	O
to	-	428	O
stimulate	-	431	O
the	-	441	O
nucleus	-	445	O
ventralis	-	453	O
intermedius	-	463	O
,	-	474	O
producing	-	476	O
high	-	486	O
long	-	491	O
-	-	495	O
term	-	496	O
success	-	501	O
rates	-	509	O
and	-	515	O
low	-	519	O
morbidity	-	523	O
rates	-	533	O
.	-	538	O

Pallidal	15096016	540	O
stimulation	-	549	O
has	-	561	O
not	-	565	O
met	-	569	O
with	-	573	O
the	-	578	O
same	-	582	O
success	-	587	O
.	-	594	O

According	15096016	596	O
to	-	606	O
the	-	609	O
literature	-	613	O
pallidotomy	-	624	O
improves	-	636	O
the	-	645	O
""""	-	649	O
on	-	650	O
""""	-	652	O
symptoms	-	654	O
of	-	663	O
PD	-	666	B
,	-	668	O
such	-	670	O
as	-	675	O
dyskinesias	-	678	B
,	-	689	O
as	-	691	O
well	-	694	O
as	-	699	O
the	-	702	O
""""	-	706	O
off	-	707	O
""""	-	710	O
symptoms	-	712	O
,	-	720	O
such	-	722	O
as	-	727	O
rigidity	-	730	B
,	-	738	O
bradykinesia	-	740	B
,	-	752	O
and	-	754	O
on	-	758	O
-	-	760	O
off	-	761	O
fluctuations	-	765	O
.	-	777	O

Pallidal	15096016	779	O
stimulation	-	788	O
improves	-	800	O
bradykinesia	-	809	B
and	-	822	O
rigidity	-	826	B
to	-	835	O
a	-	838	O
minor	-	840	O
extent	-	846	O
;	-	852	O
however	-	854	O
,	-	861	O
its	-	863	O
strength	-	867	O
seems	-	876	O
to	-	882	O
be	-	885	O
in	-	888	O
improving	-	891	O
levodopa	-	901	O
-	-	909	O
induced	-	910	O
dyskinesias	-	918	B
.	-	929	O

Stimulation	15096016	931	O
often	-	943	O
produces	-	949	O
an	-	958	O
improvement	-	961	O
in	-	973	O
the	-	976	O
hyper	-	980	B
-	-	985	I
or	-	987	I
dyskinetic	-	990	I
upper	-	1001	O
limbs	-	1007	O
,	-	1012	O
but	-	1014	O
increases	-	1018	O
the	-	1028	O
""""	-	1032	O
freezing	-	1033	O
""""	-	1041	O
phenomenon	-	1043	O
in	-	1054	O
the	-	1057	O
lower	-	1061	O
limbs	-	1067	O
at	-	1073	O
the	-	1076	O
same	-	1080	O
time	-	1085	O
.	-	1089	O

Considering	15096016	1091	O
the	-	1103	O
small	-	1107	O
increase	-	1113	O
in	-	1122	O
the	-	1125	O
patient	-	1129	O
's	-	1136	O
independence	-	1139	O
,	-	1151	O
the	-	1153	O
high	-	1157	O
costs	-	1162	O
of	-	1168	O
bilateral	-	1171	O
implants	-	1181	O
,	-	1189	O
and	-	1191	O
the	-	1195	O
difficulty	-	1199	O
most	-	1210	O
patients	-	1215	O
experience	-	1224	O
in	-	1235	O
handling	-	1238	O
the	-	1247	O
devices	-	1251	O
,	-	1258	O
the	-	1260	O
question	-	1264	O
arises	-	1273	O
as	-	1280	O
to	-	1283	O
whether	-	1286	O
bilateral	-	1294	O
pallidal	-	1304	O
stimulation	-	1313	O
is	-	1325	O
a	-	1328	O
real	-	1330	O
alternative	-	1335	O
to	-	1347	O
pallidotomy	-	1350	O
.	-	1361	O

Case	12734532	0	O
report	-	5	O
:	-	11	O
Dexatrim	-	13	O
(	-	22	O
Phenylpropanolamine	-	23	O
)	-	42	O
as	-	44	O
a	-	47	O
cause	-	49	O
of	-	55	O
myocardial	-	58	B
infarction	-	69	I
.	-	79	O

Phenylpropanolamine	12734532	81	O
(	-	101	O
PPA	-	102	O
)	-	105	O
is	-	107	O
a	-	110	O
sympathetic	-	112	O
amine	-	124	O
used	-	130	O
in	-	135	O
over	-	138	O
-	-	142	O
the	-	143	O
-	-	146	O
counter	-	147	O
cold	-	155	O
remedies	-	160	O
and	-	169	O
weight	-	173	O
-	-	179	O
control	-	180	O
preparations	-	188	O
worldwide	-	201	O
.	-	210	O

Its	12734532	212	O
use	-	216	O
has	-	220	O
been	-	224	O
associated	-	229	O
with	-	240	O
hypertensive	-	245	B
episodes	-	258	O
and	-	267	O
hemorrhagic	-	271	B
strokes	-	283	I
in	-	291	O
younger	-	294	O
women	-	302	O
.	-	307	O

Several	12734532	309	O
reports	-	317	O
have	-	325	O
linked	-	330	O
the	-	337	O
abuse	-	341	O
of	-	347	O
PPA	-	350	O
with	-	354	O
myocardial	-	359	B
injury	-	370	I
,	-	376	O
especially	-	378	O
when	-	389	O
overdose	-	394	B
is	-	403	O
involved	-	406	O
.	-	414	O

We	12734532	416	O
report	-	419	O
here	-	426	O
the	-	431	O
first	-	435	O
case	-	441	O
of	-	446	O
Dexatrim	-	449	O
(	-	458	O
PPA	-	459	O
)	-	462	O
-	-	463	O
induced	-	464	O
myocardial	-	472	B
injury	-	483	I
in	-	490	O
a	-	493	O
young	-	495	O
woman	-	501	O
who	-	507	O
was	-	511	O
using	-	515	O
it	-	521	O
at	-	524	O
recommended	-	527	O
doses	-	539	O
for	-	545	O
weight	-	549	O
control	-	556	O
.	-	563	O

In	12734532	565	O
addition	-	568	O
,	-	576	O
we	-	578	O
review	-	581	O
the	-	588	O
7	-	592	O
other	-	594	O
cases	-	600	O
of	-	606	O
PPA	-	609	O
related	-	613	O
myocardial	-	621	B
injury	-	632	I
that	-	639	O
have	-	644	O
been	-	649	O
reported	-	654	O
so	-	663	O
far	-	666	O
.	-	669	O

Physicians	12734532	671	O
and	-	682	O
patients	-	686	O
should	-	695	O
be	-	702	O
alert	-	705	O
to	-	711	O
the	-	714	O
potential	-	718	O
cardiac	-	728	O
risk	-	736	O
associated	-	741	O
with	-	752	O
the	-	757	O
use	-	761	O
of	-	765	O
PPA	-	768	O
,	-	771	O
even	-	773	O
at	-	778	O
doses	-	781	O
generally	-	787	O
considered	-	797	O
to	-	808	O
be	-	811	O
safe	-	814	O
.	-	818	O

Risperidone	12013711	0	O
-	-	11	O
associated	-	12	O
,	-	22	O
benign	-	24	O
transient	-	31	O
visual	-	41	B
disturbances	-	48	I
in	-	61	O
schizophrenic	-	64	B
patients	-	78	O
with	-	87	O
a	-	92	O
past	-	94	O
history	-	99	O
of	-	107	O
LSD	-	110	O
abuse	-	114	O
.	-	119	O

Two	12013711	121	O
schizophrenic	-	125	B
patients	-	139	O
,	-	147	O
who	-	149	O
had	-	153	O
a	-	157	O
prior	-	159	O
history	-	165	O
of	-	173	O
LSD	-	176	O
abuse	-	180	O
and	-	186	O
who	-	190	O
had	-	194	O
previously	-	198	O
developed	-	209	O
EPS	-	219	B
with	-	223	O
classic	-	228	O
antipsychotics	-	236	O
,	-	250	O
were	-	252	O
successfully	-	257	O
treated	-	270	O
with	-	278	O
risperidone	-	283	O
.	-	294	O

They	12013711	296	O
both	-	301	O
reported	-	306	O
short	-	315	O
episodes	-	321	O
of	-	330	O
transient	-	333	O
visual	-	343	B
disturbances	-	350	I
,	-	362	O
which	-	364	O
appeared	-	370	O
immediately	-	379	O
after	-	391	O
starting	-	397	O
treatment	-	406	O
with	-	416	O
risperidone	-	421	O
.	-	432	O

This	12013711	434	O
imagery	-	439	O
resembled	-	447	O
visual	-	457	B
disturbances	-	464	I
previously	-	477	O
experienced	-	488	O
as	-	500	O
""""	-	503	O
flashbacks	-	504	O
""""	-	514	O
related	-	516	O
to	-	524	O
prior	-	527	O
LSD	-	533	O
consumption	-	537	O
.	-	548	O

Risperidone	12013711	550	O
administration	-	562	O
was	-	577	O
continued	-	581	O
and	-	591	O
the	-	595	O
visual	-	599	B
disturbances	-	606	I
gradually	-	619	O
wore	-	629	O
off	-	634	O
.	-	637	O

During	12013711	639	O
a	-	646	O
six	-	648	O
-	-	651	O
month	-	652	O
follow	-	658	O
-	-	664	O
up	-	665	O
period	-	668	O
,	-	674	O
there	-	676	O
was	-	682	O
no	-	686	O
recurrence	-	689	O
of	-	700	O
visual	-	703	B
disturbances	-	710	I
.	-	722	O

This	12013711	724	O
phenomenon	-	729	O
may	-	740	O
be	-	744	O
interpreted	-	747	O
as	-	759	O
a	-	762	O
benign	-	764	O
,	-	770	O
short	-	772	O
-	-	777	O
term	-	778	O
and	-	783	O
self	-	787	O
-	-	791	O
limiting	-	792	O
side	-	801	O
effect	-	806	O
which	-	813	O
does	-	819	O
not	-	824	O
contraindicate	-	828	O
the	-	843	O
use	-	847	O
of	-	851	O
risperidone	-	854	O
or	-	866	O
interfere	-	869	O
with	-	879	O
treatment	-	884	O
.	-	893	O

Conclusions	12013711	895	O
based	-	907	O
on	-	913	O
two	-	916	O
case	-	920	O
reports	-	925	O
should	-	933	O
be	-	940	O
taken	-	943	O
with	-	949	O
appropriate	-	954	O
caution	-	966	O
.	-	973	O

Activation	11861791	0	O
of	-	11	O
poly	-	14	O
(	-	18	O
ADP	-	19	O
-	-	22	O
ribose	-	23	O
)	-	29	O
polymerase	-	31	O
contributes	-	42	O
to	-	54	O
development	-	57	O
of	-	69	O
doxorubicin	-	72	O
-	-	83	O
induced	-	84	O
heart	-	92	B
failure	-	98	I
.	-	105	O

Activation	11861791	107	O
of	-	118	O
the	-	121	O
nuclear	-	125	O
enzyme	-	133	O
poly	-	140	O
(	-	144	O
ADP	-	145	O
-	-	148	O
ribose	-	149	O
)	-	155	O
polymerase	-	157	O
(	-	168	O
PARP	-	169	O
)	-	173	O
by	-	175	O
oxidant	-	178	O
-	-	185	O
mediated	-	186	O
DNA	-	195	O
damage	-	199	O
is	-	206	O
an	-	209	O
important	-	212	O
pathway	-	222	O
of	-	230	O
cell	-	233	O
dysfunction	-	238	O
and	-	250	O
tissue	-	254	O
injury	-	261	O
in	-	268	O
conditions	-	271	O
associated	-	282	O
with	-	293	O
oxidative	-	298	O
stress	-	308	O
.	-	314	O

Increased	11861791	316	O
oxidative	-	326	O
stress	-	336	O
is	-	343	O
a	-	346	O
major	-	348	O
factor	-	354	O
implicated	-	361	O
in	-	372	O
the	-	375	O
cardiotoxicity	-	379	B
of	-	394	O
doxorubicin	-	397	O
(	-	409	O
DOX	-	410	O
)	-	413	O
,	-	414	O
a	-	416	O
widely	-	418	O
used	-	425	O
antitumor	-	430	O
anthracycline	-	440	O
antibiotic	-	454	O
.	-	464	O

Thus	11861791	466	O
,	-	470	O
we	-	472	O
hypothesized	-	475	O
that	-	488	O
the	-	493	O
activation	-	497	O
of	-	508	O
PARP	-	511	O
may	-	516	O
contribute	-	520	O
to	-	531	O
the	-	534	O
DOX	-	538	O
-	-	541	O
induced	-	542	O
cardiotoxicity	-	550	B
.	-	564	O

Using	11861791	566	O
a	-	572	O
dual	-	574	O
approach	-	579	O
of	-	588	O
PARP	-	591	O
-	-	595	O
1	-	596	O
suppression	-	598	O
,	-	609	O
by	-	611	O
genetic	-	614	O
deletion	-	622	O
or	-	631	O
pharmacological	-	634	O
inhibition	-	650	O
with	-	661	O
the	-	666	O
phenanthridinone	-	670	O
PARP	-	687	O
inhibitor	-	692	O
PJ34	-	702	O
,	-	706	O
we	-	708	O
now	-	711	O
demonstrate	-	715	O
the	-	727	O
role	-	731	O
of	-	736	O
PARP	-	739	O
in	-	744	O
the	-	747	O
development	-	751	O
of	-	763	O
cardiac	-	766	B
dysfunction	-	774	I
induced	-	786	O
by	-	794	O
DOX	-	797	O
.	-	800	O
PARP	-	802	O
-	-	806	O
1	-	807	O
+	-	808	O
/	-	809	O
+	-	810	O
and	-	812	O
PARP	-	816	O
-	-	820	O
1	-	821	O
-	-	822	O
/	-	823	O
-	-	824	O
mice	-	826	O
received	-	831	O
a	-	840	O
single	-	842	O
injection	-	849	O
of	-	859	O
DOX	-	862	O
(	-	866	O
25	-	867	O
mg	-	870	O
/	-	872	O
kg	-	873	O
i	-	876	O
.	-	877	O
p	-	878	O
)	-	879	O
.	-	880	O

Five	11861791	882	O
days	-	887	O
after	-	892	O
DOX	-	898	O
administration	-	902	O
,	-	916	O
left	-	918	O
ventricular	-	923	O
performance	-	935	O
was	-	947	O
significantly	-	951	O
depressed	-	965	O
in	-	975	O
PARP	-	978	O
-	-	982	O
1	-	983	O
+	-	984	O
/	-	985	O
+	-	986	O
mice	-	988	O
,	-	992	O
but	-	994	O
only	-	998	O
to	-	1003	O
a	-	1006	O
smaller	-	1008	O
extent	-	1016	O
in	-	1023	O
PARP	-	1026	O
-	-	1030	O
1	-	1031	O
-	-	1032	O
/	-	1033	O
-	-	1034	O
ones	-	1036	O
.	-	1040	O

Similar	11861791	1042	O
experiments	-	1050	O
were	-	1062	O
conducted	-	1067	O
in	-	1077	O
BALB	-	1080	O
/	-	1084	O
c	-	1085	O
mice	-	1087	O
treated	-	1092	O
with	-	1100	O
PJ34	-	1105	O
or	-	1110	O
vehicle	-	1113	O
.	-	1120	O

Treatment	11861791	1122	O
with	-	1132	O
a	-	1137	O
PJ34	-	1139	O
significantly	-	1144	O
improved	-	1158	O
cardiac	-	1167	B
dysfunction	-	1175	I
and	-	1187	O
increased	-	1191	O
the	-	1201	O
survival	-	1205	O
of	-	1214	O
the	-	1217	O
animals	-	1221	O
.	-	1228	O

In	11861791	1230	O
addition	-	1233	O
PJ34	-	1242	O
significantly	-	1247	O
reduced	-	1261	O
the	-	1269	O
DOX	-	1273	O
-	-	1276	O
induced	-	1277	O
increase	-	1285	O
in	-	1294	O
the	-	1297	O
serum	-	1301	O
lactate	-	1307	O
dehydrogenase	-	1315	O
and	-	1329	O
creatine	-	1333	O
kinase	-	1342	O
activities	-	1349	O
but	-	1360	O
not	-	1364	O
metalloproteinase	-	1368	O
activation	-	1386	O
in	-	1397	O
the	-	1400	O
heart	-	1404	O
.	-	1409	O

Thus	11861791	1411	O
,	-	1415	O
PARP	-	1417	O
activation	-	1422	O
contributes	-	1433	O
to	-	1445	O
the	-	1448	O
cardiotoxicity	-	1452	B
of	-	1467	O
DOX	-	1470	O
.	-	1473	O

PARP	11861791	1475	O
inhibitors	-	1480	O
may	-	1491	O
exert	-	1495	O
protective	-	1501	O
effects	-	1512	O
against	-	1520	O
the	-	1528	O
development	-	1532	O
of	-	1544	O
severe	-	1547	O
cardiac	-	1554	B
complications	-	1562	I
associated	-	1576	O
with	-	1587	O
the	-	1592	O
DOX	-	1596	O
treatment	-	1600	O
.	-	1609	O

Fluconazole	11302406	0	O
-	-	11	O
induced	-	12	O
torsade	-	20	B
de	-	28	I
pointes	-	31	I
.	-	38	O

OBJECTIVE	11302406	40	O
:	-	49	O

To	11302406	51	O
present	-	54	O
a	-	62	O
case	-	64	O
of	-	69	O
fluconazole	-	72	O
-	-	83	O
associated	-	84	O
torsade	-	95	B
de	-	103	I
pointes	-	106	I
(	-	114	O
TDP	-	115	B
)	-	118	O
and	-	120	O
discuss	-	124	O
fluconazole	-	132	O
's	-	143	O
role	-	146	O
in	-	151	O
causing	-	154	O
TDP	-	162	B
.	-	165	O

CASE	11302406	167	O
SUMMARY	-	172	O
:	-	179	O

A	11302406	181	O
68	-	183	O
-	-	185	O
year	-	186	O
-	-	190	O
old	-	191	O
white	-	195	O
woman	-	201	O
with	-	207	O
Candida	-	212	O
glabrata	-	220	O
isolated	-	229	O
from	-	238	O
a	-	243	O
presacral	-	245	O
abscess	-	255	O
developed	-	263	O
TDP	-	273	B
eight	-	277	O
days	-	283	O
after	-	288	O
commencing	-	294	O
oral	-	305	O
fluconazole	-	310	O

The	11302406	322	O
patient	-	326	O
had	-	334	O
no	-	338	O
other	-	341	O
risk	-	347	O
factors	-	352	O
for	-	360	O
TDP	-	364	B
,	-	367	O
including	-	369	O
coronary	-	379	B
artery	-	388	I
disease	-	395	I
,	-	402	O
cardiomyopathy	-	404	B
,	-	418	O
congestive	-	420	B
heart	-	431	I
failure	-	437	I
,	-	444	O
and	-	446	O
electrolyte	-	450	O
abnormalities	-	462	O
There	-	476	O
was	-	482	O
a	-	486	O
temporal	-	488	O
association	-	497	O
between	-	509	O
the	-	517	O
initiation	-	521	O
of	-	532	O
fluconazole	-	535	O
and	-	547	O
TDP	-	551	B
.	-	554	O

The	11302406	556	O
TDP	-	560	B
resolved	-	564	O
when	-	573	O
fluconazole	-	578	O
was	-	590	O
discontinued	-	594	O
;	-	606	O
however	-	608	O
,	-	615	O
the	-	617	O
patient	-	621	O
continued	-	629	O
to	-	639	O
have	-	642	O
premature	-	647	B
ventricular	-	657	I
contractions	-	669	I
and	-	682	O
nonsustained	-	686	O
ventricular	-	699	B
tachycardia	-	711	I
(	-	723	O
NSVT	-	724	B
)	-	728	O
until	-	730	O
six	-	736	O
days	-	740	O
after	-	745	O
drug	-	751	O
cessation	-	756	O
DISCUSSION	-	766	O

:	11302406	776	O
Use	-	778	O
of	-	782	O
the	-	785	O
Naranjo	-	789	O
probability	-	797	O
scale	-	809	O
indicates	-	815	O
a	-	825	O
probable	-	827	O
relationship	-	836	O
between	-	849	O
the	-	857	O
use	-	861	O
of	-	865	O
fluconazole	-	868	O
and	-	880	O
the	-	884	O
development	-	888	O
of	-	900	O
TDP	-	903	B
.	-	906	O

The	11302406	908	O
possible	-	912	O
mechanism	-	921	O
is	-	931	O
depression	-	934	B
of	-	945	O
rapidly	-	948	O
activating	-	956	O
delayed	-	967	O
rectifier	-	975	O
potassium	-	985	O
currents	-	995	O
.	-	1003	O

In	11302406	1005	O
our	-	1008	O
patient	-	1012	O
,	-	1019	O
there	-	1021	O
was	-	1027	O
no	-	1031	O
other	-	1034	O
etiology	-	1040	O
identified	-	1049	O
that	-	1060	O
could	-	1065	O
explain	-	1071	O
QT	-	1079	B
prolongation	-	1082	I
or	-	1095	O
TDP	-	1098	B

The	11302406	1102	O
complete	-	1106	O
disappearance	-	1115	O
of	-	1129	O
NSVT	-	1132	B
and	-	1137	O
premature	-	1141	B
ventricular	-	1151	I
contractions	-	1163	I
followed	-	1176	O
by	-	1185	O
normalization	-	1188	O
of	-	1202	O
QT	-	1205	O
interval	-	1208	O
after	-	1217	O
the	-	1223	O
drug	-	1227	O
was	-	1232	O
stopped	-	1236	O
strongly	-	1244	O
suggests	-	1253	O
fluconazole	-	1262	O
as	-	1274	O
the	-	1277	O
etiology	-	1281	O
.	-	1289	O

CONCLUSIONS	11302406	1291	O
:	-	1302	O

Clinicians	11302406	1304	O
should	-	1315	O
be	-	1322	O
aware	-	1325	O
that	-	1331	O
fluconazole	-	1336	O
,	-	1347	O
even	-	1349	O
at	-	1354	O
low	-	1357	O
doses	-	1361	O
,	-	1366	O
may	-	1368	O
cause	-	1372	O
prolongation	-	1378	B
of	-	1391	I
the	-	1394	I
QT	-	1398	I
interval	-	1401	I
,	-	1409	O
leading	-	1411	O
to	-	1419	O
TDP	-	1422	B
.	-	1425	O

Serial	11302406	1427	O
electrocardiographic	-	1434	O
monitoring	-	1455	O
may	-	1466	O
be	-	1470	O
considered	-	1473	O
when	-	1484	O
fluconazole	-	1489	O
is	-	1501	O
administered	-	1504	O
in	-	1517	O
patients	-	1520	O
who	-	1529	O
are	-	1533	O
at	-	1537	O
risk	-	1540	O
for	-	1545	O
ventricular	-	1549	B
arrhythmias	-	1561	I
.	-	1572	O

High	11058428	0	O
-	-	4	O
dose	-	5	O
methylprednisolone	-	10	O
may	-	29	O
do	-	33	O
more	-	36	O
harm	-	41	O
for	-	46	O
spinal	-	50	B
cord	-	57	I
injury	-	62	I
.	-	68	O

Because	11058428	70	O
of	-	78	O
the	-	81	O
National	-	85	O
Acute	-	94	O
Spinal	-	100	B
Cord	-	107	I
Injury	-	112	I
Studies	-	119	O
(	-	127	O
NASCIS	-	128	O
)	-	134	O
,	-	135	O
high	-	137	O
-	-	141	O
dose	-	142	O
methylprednisolone	-	147	O
became	-	166	O
the	-	173	O
standard	-	177	O
of	-	186	O
care	-	189	O
for	-	194	O
the	-	198	O
acute	-	202	O
spinal	-	208	B
cord	-	215	I
injury	-	220	I
.	-	226	O

In	11058428	228	O
the	-	231	O
NASCIS	-	235	O
,	-	241	O
there	-	243	O
was	-	249	O
no	-	253	O
mention	-	256	O
regarding	-	264	O
the	-	274	O
possibility	-	278	O
of	-	290	O
acute	-	293	O
corticosteroid	-	299	O
myopathy	-	314	B
that	-	323	O
high	-	328	O
-	-	332	O
dose	-	333	O
methylprednisolone	-	338	O
may	-	357	O
cause	-	361	O
.	-	366	O

The	11058428	368	O
dosage	-	372	O
of	-	379	O
methylprednisolone	-	382	O
recommended	-	401	O
by	-	413	O
the	-	416	O
NASCIS	-	420	O
3	-	427	O
is	-	429	O
the	-	432	O
highest	-	436	O
dose	-	444	O
of	-	449	O
steroids	-	452	O
ever	-	461	O
being	-	466	O
used	-	472	O
during	-	477	O
a	-	484	O
2	-	486	O
-	-	487	O
day	-	488	O
period	-	492	O
for	-	499	O
any	-	503	O
clinical	-	507	O
condition	-	516	O
.	-	525	O

We	11058428	527	O
hypothesize	-	530	O
that	-	542	O
it	-	547	O
may	-	550	O
cause	-	554	O
some	-	560	O
damage	-	565	B
to	-	572	I
the	-	575	I
muscle	-	579	I
of	-	586	O
spinal	-	589	B
cord	-	596	I
injury	-	601	I
patients	-	608	O
.	-	616	O

Further	11058428	618	O
,	-	625	O
steroid	-	627	O
myopathy	-	635	B
recovers	-	644	O
naturally	-	653	O
and	-	663	O
the	-	667	O
neurological	-	671	O
improvement	-	684	O
shown	-	696	O
in	-	702	O
the	-	705	O
NASCIS	-	709	O
may	-	716	O
be	-	720	O
just	-	723	O
a	-	728	O
recording	-	730	O
of	-	740	O
this	-	743	O
natural	-	748	O
motor	-	756	O
recovery	-	762	O
from	-	771	O
the	-	776	O
steroid	-	780	O
myopathy	-	788	B
,	-	796	O
instead	-	798	O
of	-	806	O
any	-	809	O
protection	-	813	O
that	-	824	O
methylprednisolone	-	829	O
offers	-	848	O
to	-	855	O
the	-	858	O
spinal	-	862	B
cord	-	869	I
injury	-	874	I
.	-	880	O

To	11058428	882	O
our	-	885	O
knowledge	-	889	O
,	-	898	O
this	-	900	O
is	-	905	O
the	-	908	O
first	-	912	O
discussion	-	918	O
considering	-	929	O
the	-	941	O
possibility	-	945	O
that	-	957	O
the	-	962	O
methylprednisolone	-	966	O
recommended	-	985	O
by	-	997	O
NASCIS	-	1000	O
may	-	1007	O
cause	-	1011	O
acute	-	1017	O
corticosteroid	-	1023	O
myopathy	-	1038	B
.	-	1046	O

Probing	11022397	0	O
peripheral	-	8	O
and	-	19	O
central	-	23	O
cholinergic	-	31	O
system	-	43	O
responses	-	50	O
.	-	59	O

OBJECTIVE	11022397	61	O
:	-	70	O
The	-	72	O
pharmacological	-	76	O
response	-	92	O
to	-	101	O
drugs	-	104	O
that	-	110	O
act	-	115	O
on	-	119	O
the	-	122	O
cholinergic	-	126	O
system	-	138	O
of	-	145	O
the	-	148	O
iris	-	152	O
has	-	157	O
been	-	161	O
used	-	166	O
to	-	171	O
predict	-	174	O
deficits	-	182	O
in	-	191	O
central	-	194	O
cholinergic	-	202	O
functioning	-	214	O
due	-	226	O
to	-	230	O
diseases	-	233	O
such	-	242	O
as	-	247	O
Alzheimer	-	250	B
's	-	259	I
disease	-	262	I
,	-	269	O
yet	-	271	O
correlations	-	275	O
between	-	288	O
central	-	296	O
and	-	304	O
peripheral	-	308	O
responses	-	319	O
have	-	329	O
not	-	334	O
been	-	338	O
properly	-	343	O
studied	-	352	O
.	-	359	O

This	11022397	361	O
study	-	366	O
assessed	-	372	O
the	-	381	O
effect	-	385	O
of	-	392	O
normal	-	395	O
aging	-	402	O
on	-	408	O
(	-	411	O
1	-	412	O
)	-	413	O
the	-	415	O
tropicamide	-	419	O
-	-	430	O
induced	-	431	O
increase	-	439	O
in	-	448	O
pupil	-	451	O
diameter	-	457	O
,	-	465	O
and	-	467	O
(	-	471	O
2	-	472	O
)	-	473	O
the	-	475	O
reversal	-	479	O
of	-	488	O
this	-	491	O
effect	-	496	O
with	-	503	O
pilocarpine	-	508	O
.	-	519	O

Scopolamine	11022397	521	O
was	-	533	O
used	-	537	O
as	-	542	O
a	-	545	O
positive	-	547	O
control	-	556	O
to	-	564	O
detect	-	567	O
age	-	574	O
-	-	577	O
dependent	-	578	O
changes	-	588	O
in	-	596	O
central	-	599	O
cholinergic	-	607	O
functioning	-	619	O
in	-	631	O
the	-	634	O
elderly	-	638	O
.	-	645	O

DESIGN	11022397	647	O
:	-	653	O

Randomized	11022397	655	O
double	-	666	O
-	-	672	O
blind	-	673	O
controlled	-	679	O
trial	-	690	O
.	-	695	O

PARTICIPANTS	11022397	697	O
:	-	709	O

Ten	11022397	711	O
healthy	-	715	O
elderly	-	723	O
(	-	731	O
mean	-	732	O
age	-	737	O
70	-	741	O
)	-	743	O
and	-	745	O
9	-	749	O
young	-	751	O
(	-	757	O
mean	-	758	O
age	-	763	O
33	-	767	O
)	-	769	O
volunteers	-	771	O
.	-	781	O

INTERVENTIONS	11022397	783	O
:	-	796	O

Pupil	11022397	798	O
diameter	-	804	O
was	-	813	O
monitored	-	817	O
using	-	827	O
a	-	833	O
computerized	-	835	O
infrared	-	848	O
pupillometer	-	857	O
over	-	870	O
4	-	875	O
hours	-	877	O
.	-	882	O

The	11022397	884	O
study	-	888	O
involved	-	894	O
4	-	903	O
sessions	-	905	O
.	-	913	O

In	11022397	915	O
1	-	918	O
session	-	920	O
,	-	927	O
tropicamide	-	929	O
(	-	941	O
20	-	942	O
microL	-	945	O
,	-	951	O
0	-	953	O
.	-	954	O
01	-	955	O
%	-	957	O
)	-	958	O
was	-	960	O
administered	-	964	O
to	-	977	O
one	-	980	O
eye	-	984	O
and	-	988	O
placebo	-	992	O
to	-	1000	O
the	-	1003	O
other	-	1007	O
.	-	1012	O

In	11022397	1014	O
another	-	1017	O
session	-	1025	O
,	-	1032	O
tropicamide	-	1034	O
(	-	1046	O
20	-	1047	O
microL	-	1050	O
,	-	1056	O
0	-	1058	O
.	-	1059	O
01	-	1060	O
%	-	1062	O
)	-	1063	O
was	-	1065	O
administered	-	1069	O
to	-	1082	O
both	-	1085	O
eyes	-	1090	O
,	-	1094	O
followed	-	1096	O
23	-	1105	O
minutes	-	1108	O
later	-	1116	O
by	-	1122	O
the	-	1125	O
application	-	1129	O
of	-	1141	O
pilocarpine	-	1144	O
(	-	1156	O
20	-	1157	O
microL	-	1160	O
,	-	1166	O
0	-	1168	O
.	-	1169	O
1	-	1170	O
%	-	1171	O
)	-	1172	O
to	-	1174	O
one	-	1177	O
eye	-	1181	O
and	-	1185	O
placebo	-	1189	O
to	-	1197	O
the	-	1200	O
other	-	1204	O
.	-	1209	O

All	11022397	1211	O
eye	-	1215	O
drops	-	1219	O
were	-	1225	O
given	-	1230	O
in	-	1236	O
a	-	1239	O
randomized	-	1241	O
order	-	1252	O
.	-	1257	O

In	11022397	1259	O
2	-	1262	O
separate	-	1264	O
sessions	-	1273	O
,	-	1281	O
a	-	1283	O
single	-	1285	O
dose	-	1292	O
of	-	1297	O
scopolamine	-	1300	O
(	-	1312	O
0	-	1313	O
.	-	1314	O
5	-	1315	O
mg	-	1317	O
,	-	1319	O
intravenously	-	1321	O
)	-	1334	O
or	-	1336	O
placebo	-	1339	O
was	-	1347	O
administered	-	1351	O
,	-	1363	O
and	-	1365	O
the	-	1369	O
effects	-	1373	O
on	-	1381	O
word	-	1384	O
recall	-	1389	O
were	-	1396	O
measured	-	1401	O
using	-	1410	O
the	-	1416	O
Buschke	-	1420	O
Selective	-	1428	O
Reminding	-	1438	O
Test	-	1448	O
over	-	1453	O
2	-	1458	O
hours	-	1460	O
.	-	1465	O

OUTCOME	11022397	1467	O
MEASURES	-	1475	O
:	-	1483	O

Pupil	11022397	1485	O
size	-	1491	O
at	-	1496	O
time	-	1499	O
points	-	1504	O
after	-	1511	O
administration	-	1517	O
of	-	1532	O
tropicamide	-	1535	O
and	-	1547	O
pilocarpine	-	1551	O
;	-	1562	O
scopolamine	-	1564	O
-	-	1575	O
induced	-	1576	O
impairment	-	1584	B
in	-	1595	I
word	-	1598	I
recall	-	1603	I
.	-	1609	O

RESULTS	11022397	1611	O
:	-	1618	O

There	11022397	1620	O
was	-	1626	O
no	-	1630	O
significant	-	1633	O
difference	-	1645	O
between	-	1656	O
elderly	-	1664	O
and	-	1672	O
young	-	1676	O
volunteers	-	1682	O
in	-	1693	O
pupillary	-	1696	O
response	-	1706	O
to	-	1715	O
tropicamide	-	1718	O
at	-	1730	O
any	-	1733	O
time	-	1737	O
point	-	1742	O
(	-	1748	O
p	-	1749	O
>	-	1751	O
0	-	1753	O
.	-	1754	O
05	-	1755	O
)	-	1757	O
.	-	1758	O

The	11022397	1760	O
elderly	-	1764	O
group	-	1772	O
had	-	1778	O
a	-	1782	O
significantly	-	1784	O
greater	-	1798	O
pilocarpine	-	1806	O
-	-	1817	O
induced	-	1818	O
net	-	1826	O
decrease	-	1830	O
in	-	1839	O
pupil	-	1842	O
size	-	1848	O
85	-	1853	O
,	-	1855	O
125	-	1857	O
,	-	1860	O
165	-	1862	O
and	-	1866	O
215	-	1870	O
minutes	-	1874	O
after	-	1882	O
administration	-	1888	O
,	-	1902	O
compared	-	1904	O
with	-	1913	O
the	-	1918	O
young	-	1922	O
group	-	1928	O
(	-	1934	O
p	-	1935	O
<	-	1937	O
0	-	1939	O
.	-	1940	O
05	-	1941	O
)	-	1943	O
.	-	1944	O

Compared	11022397	1946	O
with	-	1955	O
the	-	1960	O
young	-	1964	O
group	-	1970	O
,	-	1975	O
the	-	1977	O
elderly	-	1981	O
group	-	1989	O
had	-	1995	O
greater	-	1999	O
scopolamine	-	2007	O
-	-	2018	O
induced	-	2019	O
impairment	-	2027	B
in	-	2038	I
word	-	2041	I
recall	-	2046	I
60	-	2053	O
,	-	2055	O
90	-	2057	O
and	-	2060	O
120	-	2064	O
minutes	-	2068	O
after	-	2076	O
administration	-	2082	O
(	-	2097	O
p	-	2098	O
<	-	2100	O
0	-	2102	O
.	-	2103	O
05	-	2104	O
)	-	2106	O
.	-	2107	O

CONCLUSION	11022397	2109	O
:	-	2119	O

There	11022397	2121	O
is	-	2127	O
an	-	2130	O
age	-	2133	O
-	-	2136	O
related	-	2137	O
pupillary	-	2145	O
response	-	2155	O
to	-	2164	O
pilocarpine	-	2167	O
that	-	2179	O
is	-	2184	O
not	-	2187	O
found	-	2191	O
with	-	2197	O
tropicamide	-	2202	O
.	-	2213	O

Thus	11022397	2215	O
,	-	2219	O
pilocarpine	-	2221	O
may	-	2233	O
be	-	2237	O
useful	-	2240	O
to	-	2247	O
assess	-	2250	O
variations	-	2257	O
in	-	2268	O
central	-	2271	O
cholinergic	-	2279	O
function	-	2291	O
in	-	2300	O
elderly	-	2303	O
patients	-	2311	O
.	-	2319	O

Acetazolamide	10692744	0	O
-	-	13	O
induced	-	14	O
Gerstmann	-	22	B
syndrome	-	32	I
.	-	40	O

Acute	10692744	42	O
confusion	-	48	B
induced	-	58	O
by	-	66	O
acetazolamide	-	69	O
is	-	83	O
a	-	86	O
well	-	88	O
known	-	93	O
adverse	-	99	O
drug	-	107	O
reaction	-	112	O
in	-	121	O
patients	-	124	O
with	-	133	O
renal	-	138	B
impairment	-	144	I
.	-	154	O

We	10692744	156	O
report	-	159	O
a	-	166	O
case	-	168	O
of	-	173	O
acetazolamide	-	176	O
-	-	189	O
induced	-	190	O
Gerstmann	-	198	B
syndrome	-	208	I
in	-	217	O
a	-	220	O
patient	-	222	O
with	-	230	O
normal	-	235	O
renal	-	242	O
function	-	248	O
,	-	256	O
to	-	258	O
highlight	-	261	O
predisposing	-	271	O
factors	-	284	O
that	-	292	O
are	-	297	O
frequently	-	301	O
overlooked	-	312	O
.	-	322	O

Hypomania	10565806	0	B
-	-	9	O
like	-	10	O
syndrome	-	15	O
induced	-	24	O
by	-	32	O
olanzapine	-	35	O
.	-	45	O

We	10565806	47	O
report	-	50	O
a	-	57	O
female	-	59	O
patient	-	66	O
with	-	74	O
a	-	79	O
diagnosis	-	81	O
of	-	91	O
a	-	94	O
not	-	96	O
otherwise	-	100	O
specified	-	110	O
psychotic	-	120	B
disorder	-	130	I
(	-	139	O
DSM	-	140	O
-	-	143	O
IV	-	144	O
)	-	146	O
who	-	148	O
developed	-	152	O
hypomania	-	162	B
shortly	-	172	O
after	-	180	O
the	-	186	O
introduction	-	190	O
of	-	203	O
olanzapine	-	206	O
treatment	-	217	O
.	-	226	O

Neutrophil	9061311	0	O
superoxide	-	11	O
and	-	22	O
hydrogen	-	26	O
peroxide	-	35	O
production	-	44	O
in	-	55	O
patients	-	58	O
with	-	67	O
acute	-	72	B
liver	-	78	I
failure	-	84	I
.	-	91	O

Defects	9061311	93	O
in	-	101	O
superoxide	-	104	O
and	-	115	O
hydrogen	-	119	O
peroxide	-	128	O
production	-	137	O
may	-	148	O
be	-	152	O
implicated	-	155	O
in	-	166	O
the	-	169	O
high	-	173	O
incidence	-	178	O
of	-	188	O
bacterial	-	191	B
infections	-	201	I
in	-	212	O
patients	-	215	O
with	-	224	O
acute	-	229	B
liver	-	235	I
failure	-	241	I
(	-	249	O
ALF	-	250	B
)	-	253	O
.	-	254	O

In	9061311	256	O
the	-	259	O
present	-	263	O
study	-	271	O
,	-	276	O
oxygen	-	278	O
radical	-	285	O
production	-	293	O
in	-	304	O
patients	-	307	O
with	-	316	O
ALF	-	321	B
due	-	325	O
to	-	329	O
paracetamol	-	332	O
overdose	-	344	B
was	-	353	O
compared	-	357	O
with	-	366	O
that	-	371	O
of	-	376	O
healthy	-	379	O
volunteers	-	387	O
.	-	397	O

Neutrophils	9061311	399	O
from	-	411	O
14	-	416	O
ALF	-	419	B
patients	-	423	O
were	-	432	O
stimulated	-	437	O
via	-	448	O
the	-	452	O
complement	-	456	O
receptors	-	467	O
using	-	477	O
zymosan	-	483	O
opsonized	-	491	O
with	-	501	O
ALF	-	506	B
or	-	510	O
control	-	513	O
serum	-	521	O
.	-	526	O

Superoxide	9061311	528	O
and	-	539	O
hydrogen	-	543	O
peroxide	-	552	O
production	-	561	O
by	-	572	O
ALF	-	575	B
neutrophils	-	579	O
stimulated	-	591	O
with	-	602	O
zymosan	-	607	O
opsonized	-	615	O
with	-	625	O
ALF	-	630	B
serum	-	634	O
was	-	640	O
significantly	-	644	O
reduced	-	658	O
compared	-	666	O
with	-	675	O
the	-	680	O
control	-	684	O
subjects	-	692	O
(	-	701	O
P	-	702	O
<	-	704	O
0	-	706	O
.	-	707	O
01	-	708	O
)	-	710	O
.	-	711	O

This	9061311	713	O
defect	-	718	O
persisted	-	725	O
when	-	735	O
zymosan	-	740	O
opsonized	-	748	O
by	-	758	O
control	-	761	O
serum	-	769	O
was	-	775	O
used	-	779	O
(	-	784	O
P	-	785	O
<	-	787	O
0	-	789	O
.	-	790	O
05	-	791	O
)	-	793	O
.	-	794	O

Superoxide	9061311	796	O
and	-	807	O
hydrogen	-	811	O
peroxide	-	820	O
production	-	829	O
in	-	840	O
neutrophils	-	843	O
stimulated	-	855	O
with	-	866	O
formyl	-	871	O
-	-	877	O
methionyl	-	878	O
-	-	887	O
leucyl	-	888	O
-	-	894	O
phenylalanine	-	895	O
(	-	909	O
fMLP	-	910	O
)	-	914	O
from	-	916	O
a	-	921	O
further	-	923	O
18	-	931	O
ALF	-	934	B
patients	-	938	O
was	-	947	O
unaffected	-	951	O
compared	-	962	O
with	-	971	O
control	-	976	O
neutrophils	-	984	O
.	-	995	O

Serum	9061311	997	O
C3	-	1003	O
complement	-	1006	O
levels	-	1017	O
were	-	1024	O
significantly	-	1029	O
reduced	-	1043	O
in	-	1051	O
ALF	-	1054	B
patients	-	1058	O
compared	-	1067	O
with	-	1076	O
control	-	1081	O
subjects	-	1089	O
(	-	1098	O
P	-	1099	O
<	-	1101	O
0	-	1103	O
.	-	1104	O
0005	-	1105	O
)	-	1109	O
.	-	1110	O

These	9061311	1112	O
results	-	1118	O
demonstrate	-	1126	O
a	-	1138	O
neutrophil	-	1140	O
defect	-	1151	O
in	-	1158	O
ALF	-	1161	B
due	-	1165	O
to	-	1169	O
paracetamol	-	1172	O
overdose	-	1184	B
,	-	1192	O
that	-	1194	O
is	-	1199	O
complement	-	1202	O
dependent	-	1213	O
but	-	1223	O
independent	-	1227	O
of	-	1239	O
serum	-	1242	O
complement	-	1248	O
,	-	1258	O
possibly	-	1260	O
connected	-	1269	O
to	-	1279	O
the	-	1282	O
complement	-	1286	O
receptor	-	1297	O
.	-	1305	O

Absence	8617710	0	O
of	-	8	O
effect	-	11	O
of	-	18	O
sertraline	-	21	O
on	-	32	O
time	-	35	O
-	-	39	O
based	-	40	O
sensitization	-	46	O
of	-	60	O
cognitive	-	63	B
impairment	-	73	I
with	-	84	O
haloperidol	-	89	O
.	-	100	O

This	8617710	102	O
double	-	107	O
-	-	113	O
blind	-	114	O
,	-	119	O
randomized	-	121	O
,	-	131	O
placebo	-	133	O
-	-	140	O
controlled	-	141	O
study	-	152	O
evaluated	-	158	O
the	-	168	O
effects	-	172	O
of	-	180	O
haloperidol	-	183	O
alone	-	195	O
and	-	201	O
haloperidol	-	205	O
plus	-	217	O
sertraline	-	222	O
on	-	233	O
cognitive	-	236	O
and	-	246	O
psychomotor	-	250	O
function	-	262	O
in	-	271	O
24	-	274	O
healthy	-	277	O
male	-	285	O
subjects	-	290	O
.	-	298	O

METHOD	8617710	300	O
:	-	306	O

All	8617710	308	O
subjects	-	312	O
received	-	321	O
placebo	-	330	O
on	-	338	O
Day	-	341	O
1	-	345	O
and	-	347	O
haloperidol	-	351	O
2	-	363	O
mg	-	365	O
on	-	368	O
Days	-	371	O
2	-	376	O
and	-	378	O
25	-	382	O
.	-	384	O

From	8617710	386	O
Days	-	391	O
9	-	396	O
to	-	398	O
25	-	401	O
,	-	403	O
subjects	-	405	O
were	-	414	O
randomly	-	419	O
assigned	-	428	O
to	-	437	O
either	-	440	O
sertraline	-	447	O
(	-	458	O
12	-	459	O
subjects	-	462	O
)	-	470	O
or	-	472	O
placebo	-	475	O
(	-	483	O
12	-	484	O
subjects	-	487	O
)	-	495	O
;	-	496	O
the	-	498	O
sertraline	-	502	O
dose	-	513	O
was	-	518	O
titrated	-	522	O
from	-	531	O
50	-	536	O
to	-	539	O
200	-	542	O
mg	-	546	O
/	-	548	O
day	-	549	O
from	-	553	O
Days	-	558	O
9	-	563	O
to	-	565	O
16	-	568	O
,	-	570	O
and	-	572	O
remained	-	576	O
at	-	585	O
200	-	588	O
mg	-	592	O
/	-	594	O
day	-	595	O
for	-	599	O
the	-	603	O
final	-	607	O
10	-	613	O
days	-	616	O
of	-	621	O
the	-	624	O
drug	-	628	O
administration	-	633	O
period	-	648	O
.	-	654	O

Cognitive	8617710	656	O
function	-	666	O
testing	-	675	O
was	-	683	O
performed	-	687	O
before	-	697	O
dosing	-	704	O
and	-	711	O
over	-	715	O
a	-	720	O
24	-	722	O
-	-	724	O
hour	-	725	O
period	-	730	O
after	-	737	O
dosing	-	743	O
on	-	750	O
Days	-	753	O
1	-	758	O
,	-	759	O
2	-	761	O
,	-	762	O
and	-	764	O
25	-	768	O
.	-	770	O

RESULTS	8617710	772	O
:	-	779	O

Impairment	8617710	781	B
of	-	792	I
cognitive	-	795	I
function	-	805	I
was	-	814	O
observed	-	818	O
6	-	827	O
to	-	829	O
8	-	832	O
hours	-	834	O
after	-	840	O
administration	-	846	O
of	-	861	O
haloperidol	-	864	O
on	-	876	O
Day	-	879	O
2	-	883	O
but	-	885	O
was	-	889	O
not	-	893	O
evident	-	897	O
23	-	905	O
hours	-	908	O
after	-	914	O
dosing	-	920	O
.	-	926	O

When	8617710	928	O
single	-	933	O
-	-	939	O
dose	-	940	O
haloperidol	-	945	O
was	-	957	O
given	-	961	O
again	-	967	O
25	-	973	O
days	-	976	O
later	-	981	O
,	-	986	O
greater	-	988	O
impairment	-	996	O
with	-	1007	O
earlier	-	1012	O
onset	-	1020	O
was	-	1026	O
noted	-	1030	O
in	-	1036	O
several	-	1039	O
tests	-	1047	O
in	-	1053	O
both	-	1056	O
treatment	-	1061	O
groups	-	1071	O
,	-	1077	O
suggesting	-	1079	O
enhancement	-	1090	O
of	-	1102	O
this	-	1105	O
effect	-	1110	O
.	-	1116	O

There	8617710	1118	O
was	-	1124	O
no	-	1128	O
indication	-	1131	O
that	-	1142	O
sertraline	-	1147	O
exacerbated	-	1158	O
the	-	1170	O
impairment	-	1174	O
produced	-	1185	O
by	-	1194	O
haloperidol	-	1197	O
since	-	1209	O
an	-	1215	O
equivalent	-	1218	O
effect	-	1229	O
also	-	1236	O
occurred	-	1241	O
in	-	1250	O
the	-	1253	O
placebo	-	1257	O
group	-	1265	O
.	-	1270	O

Three	8617710	1272	O
subjects	-	1278	O
(	-	1287	O
2	-	1288	O
on	-	1290	O
sertraline	-	1293	O
and	-	1304	O
1	-	1308	O
on	-	1310	O
placebo	-	1313	O
)	-	1320	O
withdrew	-	1322	O
from	-	1331	O
the	-	1336	O
study	-	1340	O
because	-	1346	O
of	-	1354	O
side	-	1357	O
effects	-	1362	O
.	-	1369	O

Ten	8617710	1371	O
subjects	-	1375	O
in	-	1384	O
each	-	1387	O
group	-	1392	O
reported	-	1398	O
side	-	1407	O
effects	-	1412	O
related	-	1420	O
to	-	1428	O
treatment	-	1431	O
.	-	1440	O

The	8617710	1442	O
side	-	1446	O
effect	-	1451	O
profiles	-	1458	O
of	-	1467	O
sertraline	-	1470	O
and	-	1481	O
of	-	1485	O
placebo	-	1488	O
were	-	1496	O
similar	-	1501	O
.	-	1508	O

CONCLUSION	8617710	1510	O
:	-	1520	O

Haloperidol	8617710	1522	O
produced	-	1534	O
a	-	1543	O
clear	-	1545	O
profile	-	1551	O
of	-	1559	O
cognitive	-	1562	B
impairment	-	1572	I
that	-	1583	O
was	-	1588	O
not	-	1592	O
worsened	-	1596	O
by	-	1605	O
concomitant	-	1608	O
sertraline	-	1620	O
administration	-	1631	O
.	-	1645	O

Ciprofloxacin	8494478	0	O
-	-	13	O
induced	-	14	O
nephrotoxicity	-	22	B
in	-	37	O
patients	-	40	O
with	-	49	O
cancer	-	54	B
.	-	60	O

Nephrotoxicity	8494478	62	B
associated	-	77	O
with	-	88	O
ciprofloxacin	-	93	O
is	-	107	O
uncommon	-	110	O
.	-	118	O

Five	8494478	120	O
patients	-	125	O
with	-	134	O
cancer	-	139	B
who	-	146	O
developed	-	150	O
acute	-	160	B
renal	-	166	I
failure	-	172	I
that	-	180	O
followed	-	185	O
treatment	-	194	O
with	-	204	O
ciprofloxacin	-	209	O
are	-	223	O
described	-	227	O
and	-	237	O
an	-	241	O
additional	-	244	O
15	-	255	O
cases	-	258	O
reported	-	264	O
in	-	273	O
the	-	276	O
literature	-	280	O
are	-	291	O
reviewed	-	295	O
.	-	303	O

Other	8494478	305	O
than	-	311	O
elevation	-	316	O
of	-	326	O
serum	-	329	O
creatinine	-	335	O
levels	-	346	O
,	-	352	O
characteristic	-	354	O
clinical	-	369	O
manifestations	-	378	O
and	-	393	O
abnormal	-	397	O
laboratory	-	406	O
findings	-	417	O
are	-	426	O
not	-	430	O
frequently	-	434	O
present	-	445	O
.	-	452	O

Allergic	8494478	454	O
interstitial	-	463	B
nephritis	-	476	I
is	-	486	O
believed	-	489	O
to	-	498	O
be	-	501	O
the	-	504	O
underlying	-	508	O
pathological	-	519	O
-	-	531	O
process	-	532	O
.	-	539	O

Definitive	8494478	541	O
diagnosis	-	552	O
requires	-	562	O
performance	-	571	O
of	-	583	O
renal	-	586	O
biopsy	-	592	O
,	-	598	O
although	-	600	O
this	-	609	O
is	-	614	O
not	-	617	O
always	-	621	O
feasible	-	628	O
.	-	636	O

An	8494478	638	O
improvement	-	641	O
in	-	653	O
renal	-	656	O
function	-	662	O
that	-	671	O
followed	-	676	O
the	-	685	O
discontinuation	-	689	O
of	-	705	O
the	-	708	O
offending	-	712	O
antibiotic	-	722	O
supports	-	733	O
the	-	742	O
presumptive	-	746	O
diagnosis	-	758	O
of	-	768	O
ciprofloxacin	-	771	O
-	-	784	O
induced	-	785	O
acute	-	793	B
renal	-	799	I
failure	-	805	I
.	-	812	O

Case	8475949	0	O
report	-	5	O
:	-	11	O
pentamidine	-	13	O
and	-	25	O
polymorphic	-	29	O
ventricular	-	41	B
tachycardia	-	53	I
revisited	-	65	O
.	-	74	O

Pentamidine	8475949	76	O
isethionate	-	88	O
has	-	100	O
been	-	104	O
associated	-	109	O
with	-	120	O
ventricular	-	125	B
tachyarrhythmias	-	137	I
,	-	153	O
including	-	155	O
torsade	-	165	B
de	-	173	I
pointes	-	176	I
.	-	183	O

This	8475949	185	O
article	-	190	O
reports	-	198	O
two	-	206	O
cases	-	210	O
of	-	216	O
this	-	219	O
complication	-	224	O
and	-	237	O
reviews	-	241	O
all	-	249	O
reported	-	253	O
cases	-	262	O
to	-	268	O
date	-	271	O
.	-	275	O

Pentamidine	8475949	277	O
-	-	288	O
induced	-	289	O
torsade	-	297	B
de	-	305	I
pointes	-	308	I
may	-	316	O
be	-	320	O
related	-	323	O
to	-	331	O
serum	-	334	O
magnesium	-	340	O
levels	-	350	O
and	-	357	O
hypomagnesemia	-	361	B
may	-	376	O
synergistically	-	380	O
induce	-	396	O
torsade	-	403	O
.	-	410	O

Torsade	8475949	412	B
de	-	420	I
pointes	-	423	I
occurred	-	431	O
after	-	440	O
an	-	446	O
average	-	449	O
of	-	457	O
10	-	460	O
days	-	463	O
of	-	468	O
treatment	-	471	O
with	-	481	O
pentamidine	-	486	O
.	-	497	O

In	8475949	499	O
these	-	502	O
patients	-	508	O
,	-	516	O
no	-	518	O
other	-	521	O
acute	-	527	O
side	-	533	O
effects	-	538	O
of	-	546	O
pentamidine	-	549	O
were	-	561	O
observed	-	566	O
.	-	574	O

Torsade	8475949	576	B
de	-	584	I
pointes	-	587	I
can	-	595	O
be	-	599	O
treated	-	602	O
when	-	610	O
recognized	-	615	O
early	-	626	O
,	-	631	O
possibly	-	633	O
without	-	642	O
discontinuation	-	650	O
of	-	666	O
pentamidine	-	669	O
.	-	680	O

When	8475949	682	O
QTc	-	687	B
interval	-	691	I
prolongation	-	700	I
is	-	713	O
observed	-	716	O
,	-	724	O
early	-	726	O
magnesium	-	732	O
supplementation	-	742	O
is	-	758	O
advocated	-	761	O
.	-	770	O

Time	7710775	0	O
dependence	-	5	O
of	-	16	O
plasma	-	19	O
malondialdehyde	-	26	O
,	-	41	O
oxypurines	-	43	O
,	-	53	O
and	-	55	O
nucleosides	-	59	O
during	-	71	O
incomplete	-	78	O
cerebral	-	89	B
ischemia	-	98	I
in	-	107	O
the	-	110	O
rat	-	114	O
.	-	117	O

Incomplete	7710775	119	O
cerebral	-	130	B
ischemia	-	139	I
(	-	148	O
30	-	149	O
min	-	152	O
)	-	155	O
was	-	157	O
induced	-	161	O
in	-	169	O
the	-	172	O
rat	-	176	O
by	-	180	O
bilaterally	-	183	O
clamping	-	195	O
the	-	204	O
common	-	208	O
carotid	-	215	O
arteries	-	223	O
.	-	231	O

Peripheral	7710775	233	O
venous	-	244	O
blood	-	251	O
samples	-	257	O
were	-	265	O
withdrawn	-	270	O
from	-	280	O
the	-	285	O
femoral	-	289	O
vein	-	297	O
four	-	302	O
times	-	307	O
(	-	313	O
once	-	314	O
every	-	319	O
5	-	325	O
min	-	327	O
)	-	330	O
before	-	332	O
ischemia	-	339	B
(	-	348	O
0	-	349	O
time	-	351	O
)	-	355	O
and	-	357	O
5	-	361	O
,	-	362	O
15	-	364	O
,	-	366	O
and	-	368	O
30	-	372	O
min	-	375	O
after	-	379	O
ischemia	-	385	B
.	-	393	O

Plasma	7710775	395	O
extracts	-	402	O
were	-	411	O
analyzed	-	416	O
by	-	425	O
a	-	428	O
highly	-	430	O
sensitive	-	437	O
high	-	447	O
-	-	451	O
performance	-	452	O
liquid	-	464	O
chromatographic	-	471	O
method	-	487	O
for	-	494	O
the	-	498	O
direct	-	502	O
determination	-	509	O
of	-	523	O
malondialdehyde	-	526	O
,	-	541	O
oxypurines	-	543	O
,	-	553	O
and	-	555	O
nucleosides	-	559	O
.	-	570	O

During	7710775	572	O
ischemia	-	579	B
,	-	587	O
a	-	589	O
time	-	591	O
-	-	595	O
dependent	-	596	O
increase	-	606	O
of	-	615	O
plasma	-	618	O
oxypurines	-	625	O
and	-	636	O
nucleosides	-	640	O
was	-	652	O
observed	-	656	O
.	-	664	O

Plasma	7710775	666	O
malondialdehyde	-	673	O
,	-	688	O
which	-	690	O
was	-	696	O
present	-	700	O
in	-	708	O
minimal	-	711	O
amount	-	719	O
at	-	726	O
zero	-	729	O
time	-	734	O
(	-	739	O
0	-	740	O
.	-	741	O
058	-	742	O
mumol	-	746	O
/	-	751	O
liter	-	752	O
plasma	-	758	O
;	-	764	O
SD	-	766	O
0	-	769	O
.	-	770	O
015	-	771	O
)	-	774	O
,	-	775	O
increased	-	777	O
after	-	787	O
5	-	793	O
min	-	795	O
of	-	799	O
ischemia	-	802	B
,	-	810	O
resulting	-	812	O
in	-	822	O
a	-	825	O
fivefold	-	827	O
increase	-	836	O
after	-	845	O
30	-	851	O
min	-	854	O
of	-	858	O
carotid	-	861	O
occlusion	-	869	O
(	-	879	O
0	-	880	O
.	-	881	O
298	-	882	O
mumol	-	886	O
/	-	891	O
liter	-	892	O
plasma	-	898	O
;	-	904	O
SD	-	906	O
0	-	909	O
.	-	910	O
078	-	911	O
)	-	914	O
.	-	915	O

Increased	7710775	917	O
plasma	-	927	O
malondialdehyde	-	934	O
was	-	950	O
also	-	954	O
recorded	-	959	O
in	-	968	O
two	-	971	O
other	-	975	O
groups	-	981	O
of	-	988	O
animals	-	991	O
subjected	-	999	O
to	-	1009	O
the	-	1012	O
same	-	1016	O
experimental	-	1021	O
model	-	1034	O
,	-	1039	O
one	-	1041	O
receiving	-	1045	O
20	-	1055	O
mg	-	1058	O
/	-	1060	O
kg	-	1061	O
b	-	1064	O
.	-	1065	O
w	-	1066	O
.	-	1067	O

of	7710775	1069	O
the	-	1072	O
cyclooxygenase	-	1076	O
inhibitor	-	1091	O
acetylsalicylate	-	1101	O
intravenously	-	1118	O
immediately	-	1132	O
before	-	1144	O
ischemia	-	1151	B
,	-	1159	O
the	-	1161	O
other	-	1165	O
receiving	-	1171	O
650	-	1181	O
micrograms	-	1185	O
/	-	1195	O
kg	-	1196	O
b	-	1199	O
.	-	1200	O
w	-	1201	O
.	-	1202	O

of	7710775	1204	O
the	-	1207	O
hypotensive	-	1211	B
drug	-	1223	O
nitroprusside	-	1228	O
at	-	1242	O
a	-	1245	O
flow	-	1247	O
rate	-	1252	O
of	-	1257	O
103	-	1260	O
microliters	-	1264	O
/	-	1275	O
min	-	1276	O
intravenously	-	1280	O
during	-	1294	O
ischemia	-	1301	B
,	-	1309	O

although	7710775	1311	O
in	-	1320	O
this	-	1323	O
latter	-	1328	O
group	-	1335	O
malondialdehyde	-	1341	O
was	-	1357	O
significantly	-	1361	O
higher	-	1375	O
.	-	1381	O

The	7710775	1383	O
present	-	1387	O
data	-	1395	O
indicate	-	1400	O
that	-	1409	O
the	-	1414	O
determination	-	1418	O
of	-	1432	O
malondialdehyde	-	1435	O
,	-	1450	O
oxypurines	-	1452	O
,	-	1462	O
and	-	1464	O
nucleosides	-	1468	O
in	-	1480	O
peripheral	-	1483	O
blood	-	1494	O
,	-	1499	O
may	-	1501	O
be	-	1505	O
used	-	1508	O
to	-	1513	O
monitor	-	1516	O
the	-	1524	O
metabolic	-	1528	O
alterations	-	1538	O
of	-	1550	O
tissues	-	1553	O
occurring	-	1561	O
during	-	1571	O
ischemic	-	1578	B
phenomena	-	1587	O
.	-	1596	O
(	-	1597	O
ABSTRACT	-	1598	O
TRUNCATED	-	1607	O
AT	-	1617	O
250	-	1620	O
WORDS	-	1624	O
)	-	1629	O

Cholinergic	7650771	0	O
toxicity	-	12	B
resulting	-	21	O
from	-	31	O
ocular	-	36	O
instillation	-	43	O
of	-	56	O
echothiophate	-	59	O
iodide	-	73	O
eye	-	80	O
drops	-	84	O
.	-	89	O

A	7650771	91	O
patient	-	93	O
developed	-	101	O
a	-	111	O
severe	-	113	O
cholinergic	-	120	O
syndrome	-	132	O
from	-	141	O
the	-	146	O
use	-	150	O
of	-	154	O
echothiophate	-	157	O
iodide	-	171	O
ophthalmic	-	178	O
drops	-	189	O
,	-	194	O
presented	-	196	O
with	-	206	O
profound	-	211	O
muscle	-	220	B
weakness	-	227	I
and	-	236	O
was	-	240	O
initially	-	244	O
given	-	254	O
the	-	260	O
diagnosis	-	264	O
of	-	274	O
myasthenia	-	277	B
gravis	-	288	I
.	-	294	O

Red	7650771	296	O
blood	-	300	O
cell	-	306	O
and	-	311	O
serum	-	315	O
cholinesterase	-	321	O
levels	-	336	O
were	-	343	O
severely	-	348	O
depressed	-	357	O
and	-	367	O
symptoms	-	371	O
resolved	-	380	O
spontaneously	-	389	O
following	-	403	O
discontinuation	-	413	O
of	-	429	O
the	-	432	O
eye	-	436	O
drops	-	440	O
.	-	445	O

Acute	7565311	0	B
renal	-	6	I
failure	-	12	I
in	-	20	O
high	-	23	O
dose	-	28	O
carboplatin	-	33	O
chemotherapy	-	45	O
.	-	57	O

Carboplatin	7565311	59	O
has	-	71	O
been	-	75	O
reported	-	80	O
to	-	89	O
cause	-	92	O
acute	-	98	B
renal	-	104	I
failure	-	110	I
when	-	118	O
administered	-	123	O
in	-	136	O
high	-	139	O
doses	-	144	O
to	-	150	O
adult	-	153	O
patients	-	159	O
.	-	167	O

We	7565311	169	O
report	-	172	O
a	-	179	O
4	-	181	O
1	-	183	O
/	-	184	O
2	-	185	O
-	-	186	O
year	-	187	O
-	-	191	O
old	-	192	O
girl	-	196	O
who	-	201	O
was	-	205	O
treated	-	209	O
with	-	217	O
high	-	222	O
-	-	226	O
dose	-	227	O
carboplatin	-	232	O
for	-	244	O
metastatic	-	248	O
parameningeal	-	259	O
embryonal	-	273	B
rhabdomyosarcoma	-	283	I
.	-	299	O

Acute	7565311	301	B
renal	-	307	I
failure	-	313	I
developed	-	321	O
followed	-	331	O
by	-	340	O
a	-	343	O
slow	-	345	O
partial	-	350	O
recovery	-	358	O
of	-	367	O
renal	-	370	O
function	-	376	O
.	-	384	O

Possible	7565311	386	O
contributing	-	395	O
factors	-	408	O
are	-	416	O
discussed	-	420	O
.	-	429	O

Endometrial	7421734	0	B
carcinoma	-	12	I
after	-	22	O
Hodgkin	-	28	B
disease	-	36	I
in	-	44	O
childhood	-	47	O
.	-	56	O

A	7421734	58	O
34	-	60	O
-	-	62	O
year	-	63	O
-	-	67	O
old	-	68	O
patient	-	72	O
developed	-	80	O
metastic	-	90	O
endometrial	-	99	B
carcinoma	-	111	I
after	-	121	O
Hodgkin	-	127	B
disease	-	135	I
in	-	143	O
childhood	-	146	O
.	-	155	O

She	7421734	157	O
had	-	161	O
ovarian	-	165	B
failure	-	173	I
after	-	181	O
abdominal	-	187	O
irradiation	-	197	O
and	-	209	O
chemotherapy	-	213	O
for	-	226	O
Hodgkin	-	230	B
disease	-	238	I
,	-	245	O
and	-	247	O
received	-	251	O
exogenous	-	260	O
estrogens	-	270	O
,	-	279	O
a	-	281	O
treatment	-	283	O
implicated	-	293	O
in	-	304	O
the	-	307	O
development	-	311	O
of	-	323	O
endometrial	-	326	B
cancer	-	338	I
in	-	345	O
menopausal	-	348	O
women	-	359	O
.	-	364	O

Young	7421734	366	O
women	-	372	O
on	-	378	O
replacement	-	381	O
estrogens	-	393	O
for	-	403	O
ovarian	-	407	B
failure	-	415	I
after	-	423	O
cancer	-	429	B
therapy	-	436	O
may	-	444	O
also	-	448	O
have	-	453	O
increased	-	458	O
risk	-	468	O
of	-	473	O
endometrial	-	476	B
carcinoma	-	488	I
and	-	498	O
should	-	502	O
be	-	509	O
examined	-	512	O
periodically	-	521	O
.	-	533	O

Induction	6732043	0	O
of	-	10	O
the	-	13	O
obstructive	-	17	B
sleep	-	29	I
apnea	-	35	I
syndrome	-	41	I
in	-	50	O
a	-	53	O
woman	-	55	O
by	-	61	O
exogenous	-	64	O
androgen	-	74	O
administration	-	83	O
.	-	97	O

We	6732043	99	O
documented	-	102	O
airway	-	113	O
occlusion	-	120	O
during	-	130	O
sleep	-	137	O
and	-	143	O
an	-	147	O
abnormally	-	150	O
high	-	161	O
supraglottic	-	166	O
resistance	-	179	O
while	-	190	O
awake	-	196	O
in	-	202	O
a	-	205	O
54	-	207	O
-	-	209	O
yr	-	210	O
-	-	212	O
old	-	213	O
woman	-	217	O
who	-	223	O
had	-	227	O
developed	-	231	O
physical	-	241	O
changes	-	250	O
and	-	258	O
the	-	262	O
syndrome	-	266	B
of	-	275	I
obstructive	-	278	I
sleep	-	290	I
apnea	-	296	I
while	-	302	O
being	-	308	O
administered	-	314	O
exogenous	-	327	O
androgens	-	337	O
.	-	346	O

When	6732043	348	O
the	-	353	O
androgens	-	357	O
were	-	367	O
withdrawn	-	372	O
,	-	381	O
the	-	383	O
patient	-	387	O
's	-	394	O
physical	-	397	O
changes	-	406	O
,	-	413	O
symptoms	-	415	O
,	-	423	O
sleep	-	425	O
study	-	431	O
,	-	436	O
and	-	438	O
supraglottic	-	442	O
resistance	-	455	O
all	-	466	O
returned	-	470	O
to	-	479	O
normal	-	482	O
.	-	488	O

A	6732043	490	O
rechallenge	-	492	O
with	-	504	O
androgen	-	509	O
produced	-	518	O
symptoms	-	527	O
of	-	536	O
obstructive	-	539	B
sleep	-	551	I
apnea	-	557	I
that	-	563	O
abated	-	568	O
upon	-	575	O
withdrawal	-	580	O
of	-	591	O
the	-	594	O
hormone	-	598	O
.	-	605	O

Previous	6732043	607	O
reports	-	616	O
have	-	624	O
favored	-	629	O
a	-	637	O
role	-	639	O
of	-	644	O
androgens	-	647	O
in	-	657	O
the	-	660	O
pathogenesis	-	664	O
of	-	677	O
sleep	-	680	B
apnea	-	686	I
.	-	691	O

Our	6732043	693	O
report	-	697	O
provides	-	704	O
direct	-	713	O
evidence	-	720	O
for	-	729	O
this	-	733	O
role	-	738	O
.	-	742	O

Structural	6732043	744	O
and	-	755	O
functional	-	759	O
measurements	-	770	O
indicate	-	783	O
that	-	792	O
androgens	-	797	O
exert	-	807	O
a	-	813	O
permissive	-	815	O
or	-	826	O
necessary	-	829	O
action	-	839	O
on	-	846	O
the	-	849	O
structural	-	853	O
configuration	-	864	O
of	-	878	O
the	-	881	O
oropharynx	-	885	O
that	-	896	O
predisposes	-	901	O
to	-	913	O
obstruction	-	916	O
during	-	928	O
sleep	-	935	O
.	-	940	O

Development	6732043	942	O
of	-	954	O
the	-	957	O
obstructive	-	961	B
sleep	-	973	I
apnea	-	979	I
syndrome	-	985	I
must	-	994	O
be	-	999	O
considered	-	1002	O
a	-	1013	O
possible	-	1015	O
side	-	1024	O
effect	-	1029	O
of	-	1036	O
androgen	-	1039	O
therapy	-	1048	O
.	-	1055	O

Effect	6454943	0	O
of	-	7	O
captopril	-	10	O
on	-	20	O
pre	-	23	O
-	-	26	O
existing	-	27	O
and	-	36	O
aminonucleoside	-	40	O
-	-	55	O
induced	-	56	O
proteinuria	-	64	B
in	-	76	O
spontaneously	-	79	O
hypertensive	-	93	B
rats	-	106	O
.	-	110	O

Proteinuria	6454943	112	B
is	-	124	O
a	-	127	O
side	-	129	O
effect	-	134	O
of	-	141	O
captopril	-	144	O
treatment	-	154	O
in	-	164	O
hypertensive	-	167	B
patients	-	180	O
.	-	188	O

The	6454943	190	O
possibility	-	194	O
of	-	206	O
reproducing	-	209	O
the	-	221	O
same	-	225	O
renal	-	230	B
abnormality	-	236	I
with	-	248	O
captopril	-	253	O
was	-	263	O
examined	-	267	O
in	-	276	O
SHR	-	279	O
.	-	282	O

Oral	6454943	284	O
administration	-	289	O
of	-	304	O
captopril	-	307	O
at	-	317	O
100	-	320	O
mg	-	324	O
/	-	326	O
kg	-	327	O
for	-	330	O
14	-	334	O
days	-	337	O
failed	-	342	O
to	-	349	O
aggravate	-	352	O
proteinuria	-	362	B
pre	-	374	O
-	-	377	O
existing	-	378	O
in	-	387	O
SHR	-	390	O
.	-	393	O

Also	6454943	395	O
,	-	399	O
captopril	-	401	O
treatment	-	411	O
failed	-	421	O
to	-	428	O
potentiate	-	431	O
or	-	442	O
facilitate	-	445	O
development	-	456	O
of	-	468	O
massive	-	471	O
proteinuria	-	479	B
invoked	-	491	O
by	-	499	O
puromycin	-	502	O
aminonucleoside	-	512	O
in	-	528	O
SHR	-	531	O
.	-	534	O

Captopril	6454943	536	O
had	-	546	O
little	-	550	O
or	-	557	O
no	-	560	O
demonstrable	-	563	O
effects	-	576	O
on	-	584	O
serum	-	587	O
electrolyte	-	593	O
concentrations	-	605	O
,	-	619	O
excretion	-	621	O
of	-	631	O
urine	-	634	O
,	-	639	O
sodium	-	641	O
and	-	648	O
potassium	-	652	O
,	-	661	O
endogenous	-	663	O
creatinine	-	674	O
clearance	-	685	O
,	-	694	O
body	-	696	O
weight	-	701	O
,	-	707	O
and	-	709	O
food	-	713	O
and	-	718	O
water	-	722	O
consumption	-	728	O
.	-	739	O

However	6454943	741	O
,	-	748	O
ketone	-	750	O
bodies	-	757	O
were	-	764	O
consistently	-	769	O
present	-	782	O
in	-	790	O
urine	-	793	O
and	-	799	O
several	-	803	O
lethalities	-	811	O
occurred	-	823	O
during	-	832	O
multiple	-	839	O
dosing	-	848	O
of	-	855	O
captopril	-	858	O
in	-	868	O
SHR	-	871	O
.	-	874	O

Epileptogenic	6153967	0	O
properties	-	14	O
of	-	25	O
enflurane	-	28	O
and	-	38	O
their	-	42	O
clinical	-	48	O
interpretation	-	57	O
.	-	71	O

Three	6153967	73	O
cases	-	79	O
of	-	85	O
EEG	-	88	O
changes	-	92	O
induced	-	100	O
by	-	108	O
single	-	111	O
exposure	-	118	O
to	-	127	O
enflurane	-	130	O
anesthesia	-	140	O
are	-	151	O
reported	-	155	O
.	-	163	O

In	6153967	165	O
one	-	168	O
patient	-	172	O
,	-	179	O
enflurane	-	181	O
administered	-	191	O
during	-	204	O
a	-	211	O
donor	-	213	O
nephrectomy	-	219	O
resulted	-	231	O
in	-	240	O
unexpected	-	243	O
partial	-	254	O
motor	-	262	O
seizures	-	268	B
.	-	276	O

Until	6153967	278	O
the	-	284	O
cause	-	288	O
of	-	294	O
the	-	297	O
seizures	-	301	B
was	-	310	O
correctly	-	314	O
identified	-	324	O
,	-	334	O
the	-	336	O
patient	-	340	O
was	-	348	O
inappropriately	-	352	O
treated	-	368	O
with	-	376	O
anticonvulsants	-	381	O
.	-	396	O

Two	6153967	398	O
other	-	402	O
patients	-	408	O
suffered	-	417	O
from	-	426	O
partial	-	431	O
,	-	438	O
complex	-	440	O
and	-	448	O
generalized	-	452	O
seizures	-	464	B
uncontrolled	-	473	O
by	-	486	O
medication	-	489	O
.	-	499	O

Epileptic	6153967	501	B
foci	-	511	O
delineated	-	516	O
and	-	527	O
activated	-	531	O
by	-	541	O
enflurane	-	544	O
were	-	554	O
surgically	-	559	O
ablated	-	570	O
and	-	578	O
the	-	582	O
patients	-	586	O
are	-	595	O
now	-	599	O
seizure	-	603	B
-	-	610	O
free	-	611	O
.	-	615	O

Previous	6153967	617	O
exposures	-	626	O
to	-	636	O
enflurane	-	639	O
have	-	649	O
to	-	654	O
be	-	657	O
disclosed	-	660	O
to	-	670	O
avoid	-	673	O
mistakes	-	679	O
in	-	688	O
clinical	-	691	O
interpretation	-	700	O
of	-	715	O
the	-	718	O
EEG	-	722	O
.	-	725	O

On	6153967	727	O
the	-	730	O
other	-	734	O
hand	-	740	O
,	-	744	O
enflurane	-	746	O
may	-	756	O
prove	-	760	O
to	-	766	O
be	-	769	O
a	-	772	O
safe	-	774	O
fast	-	779	O
acting	-	784	O
activator	-	791	O
of	-	801	O
epileptic	-	804	B
foci	-	814	O
during	-	819	O
corticography	-	826	O
or	-	840	O
depth	-	843	O
electrode	-	849	O
intraoperative	-	859	O
recordings	-	874	O
.	-	884	O

Reversible	3183120	0	O
cerebral	-	11	B
lesions	-	20	I
associated	-	28	O
with	-	39	O
tiazofurin	-	44	O
usage	-	55	O
:	-	60	O
MR	-	62	O
demonstration	-	65	O
.	-	78	O

Tiazofurin	3183120	80	O
is	-	91	O
an	-	94	O
experimental	-	97	O
chemotherapeutic	-	110	O
agent	-	127	O
currently	-	133	O
undergoing	-	143	O
clinical	-	154	O
evaluation	-	163	O
.	-	173	O

We	3183120	175	O
report	-	178	O
our	-	185	O
results	-	189	O
with	-	197	O
magnetic	-	202	O
resonance	-	211	O
(	-	221	O
MR	-	222	O
)	-	224	O
in	-	226	O
demonstrating	-	229	O
reversible	-	243	O
cerebral	-	254	B
abnormalities	-	263	I
concurrent	-	277	O
with	-	288	O
the	-	293	O
use	-	297	O
of	-	301	O
this	-	304	O
drug	-	309	O
.	-	313	O

The	3183120	315	O
abnormalities	-	319	O
on	-	333	O
MR	-	336	O
were	-	339	O
correlated	-	344	O
with	-	355	O
findings	-	360	O
on	-	369	O
CT	-	372	O
as	-	375	O
well	-	378	O
as	-	383	O
with	-	386	O
cerebral	-	391	O
angiography	-	400	O
.	-	411	O

The	3183120	413	O
utility	-	417	O
of	-	425	O
MR	-	428	O
in	-	431	O
the	-	434	O
evaluation	-	438	O
of	-	449	O
patients	-	452	O
receiving	-	461	O
this	-	471	O
new	-	476	O
agent	-	480	O
is	-	486	O
illustrated	-	489	O
.	-	500	O

Antagonism	3120485	0	O
of	-	11	O
diazepam	-	14	O
-	-	22	O
induced	-	23	O
sedative	-	31	O
effects	-	40	O
by	-	48	O
Ro15	-	51	O
-	-	55	O
1788	-	56	O
in	-	61	O
patients	-	64	O
after	-	73	O
surgery	-	79	O
under	-	87	O
lumbar	-	93	O
epidural	-	100	O
block	-	109	O
.	-	114	O

A	3120485	116	O
double	-	118	O
-	-	124	O
blind	-	125	O
placebo	-	131	O
-	-	138	O
controlled	-	139	O
investigation	-	150	O
of	-	164	O
efficacy	-	167	O
and	-	176	O
safety	-	180	O
.	-	186	O

The	3120485	188	O
aim	-	192	O
of	-	196	O
this	-	199	O
study	-	204	O
was	-	210	O
to	-	214	O
assess	-	217	O
the	-	224	O
efficacy	-	228	O
of	-	237	O
Ro15	-	240	O
-	-	244	O
1788	-	245	O
and	-	250	O
a	-	254	O
placebo	-	256	O
in	-	264	O
reversing	-	267	O
diazepam	-	277	O
-	-	285	O
induced	-	286	O
effects	-	294	O
after	-	302	O
surgery	-	308	O
under	-	316	O
epidural	-	322	O
block	-	331	O
,	-	336	O
and	-	338	O
to	-	342	O
evaluate	-	345	O
the	-	354	O
local	-	358	O
tolerance	-	364	O
and	-	374	O
general	-	378	O
safety	-	386	O
of	-	393	O
Ro15	-	396	O
-	-	400	O
1788	-	401	O
.	-	405	O

Fifty	3120485	407	O
-	-	412	O
seven	-	413	O
patients	-	419	O
were	-	428	O
sedated	-	433	O
with	-	441	O
diazepam	-	446	O
for	-	455	O
surgery	-	459	O
under	-	467	O
epidural	-	473	O
anaesthesia	-	482	O
.	-	493	O

Antagonism	3120485	495	O
of	-	506	O
diazepam	-	509	O
-	-	517	O
induced	-	518	O
effects	-	526	O
by	-	534	O
Ro15	-	537	O
-	-	541	O
1788	-	542	O
was	-	547	O
investigated	-	551	O
postoperatively	-	564	O
in	-	580	O
a	-	583	O
double	-	585	O
-	-	591	O
blind	-	592	O
placebo	-	598	O
-	-	605	O
controlled	-	606	O
trial	-	617	O
.	-	622	O

The	3120485	624	O
patient	-	628	O
's	-	635	O
subjective	-	638	O
assessment	-	649	O
of	-	660	O
mood	-	663	O
rating	-	668	O
,	-	674	O
an	-	676	O
objective	-	679	O
test	-	689	O
of	-	694	O
performance	-	697	O
,	-	708	O
a	-	710	O
test	-	712	O
for	-	717	O
amnesia	-	721	B
,	-	728	O
and	-	730	O
vital	-	734	O
signs	-	740	O
were	-	746	O
recorded	-	751	O
for	-	760	O
up	-	764	O
to	-	767	O
300	-	770	O
min	-	774	O
after	-	778	O
administration	-	784	O
of	-	799	O
the	-	802	O
trial	-	806	O
drug	-	812	O
.	-	816	O

No	3120485	818	O
significant	-	821	O
differences	-	833	O
between	-	845	O
the	-	853	O
two	-	857	O
groups	-	861	O
were	-	868	O
observed	-	873	O
for	-	882	O
mood	-	886	O
rating	-	891	O
,	-	897	O
amnesia	-	899	B
,	-	906	O
or	-	908	O
vital	-	911	O
signs	-	917	O
.	-	922	O

The	3120485	924	O
Ro15	-	928	O
-	-	932	O
1788	-	933	O
group	-	938	O
showed	-	944	O
a	-	951	O
significant	-	953	O
improvement	-	965	O
in	-	977	O
the	-	980	O
performance	-	984	O
test	-	996	O
up	-	1001	O
to	-	1004	O
120	-	1007	O
min	-	1011	O
after	-	1015	O
administration	-	1021	O
of	-	1036	O
the	-	1039	O
drug	-	1043	O
.	-	1047	O

There	3120485	1049	O
was	-	1055	O
no	-	1059	O
evidence	-	1062	O
of	-	1071	O
reaction	-	1074	O
at	-	1083	O
the	-	1086	O
injection	-	1090	O
site	-	1100	O
.	-	1104	O

Enhanced	2886572	0	O
stimulus	-	9	O
-	-	17	O
induced	-	18	O
neurotransmitter	-	26	O
overflow	-	43	O
in	-	52	O
epinephrine	-	55	O
-	-	66	O
induced	-	67	O
hypertensive	-	75	B
rats	-	88	O
is	-	93	O
not	-	96	O
mediated	-	100	O
by	-	109	O
prejunctional	-	112	O
beta	-	126	O
-	-	130	O
adrenoceptor	-	131	O
activation	-	144	O
.	-	154	O

The	2886572	156	O
present	-	160	O
study	-	168	O
examines	-	174	O
the	-	183	O
effect	-	187	O
of	-	194	O
6	-	197	O
-	-	198	O
day	-	199	O
epinephrine	-	203	O
treatment	-	215	O
(	-	225	O
100	-	226	O
micrograms	-	230	O
/	-	240	O
kg	-	241	O
per	-	244	O
h	-	248	O
,	-	249	O
s	-	251	O
.	-	252	O
c	-	253	O
.	-	254	O
)	-	255	O
on	-	257	O
stimulus	-	260	O
-	-	268	O
induced	-	269	O
(	-	277	O
1	-	278	O
Hz	-	280	O
)	-	282	O
endogenous	-	284	O
neurotransmitter	-	295	O
overflow	-	312	O
from	-	321	O
the	-	326	O
isolated	-	330	O
perfused	-	339	O
kidney	-	348	O
of	-	355	O
vehicle	-	358	O
-	-	365	O
and	-	367	O
epinephrine	-	371	O
-	-	382	O
treated	-	383	O
rats	-	391	O
.	-	395	O

Renal	2886572	397	O
catecholamine	-	403	O
stores	-	417	O
and	-	424	O
stimulus	-	428	O
-	-	436	O
induced	-	437	O
overflow	-	445	O
in	-	454	O
the	-	457	O
vehicle	-	461	O
-	-	468	O
treated	-	469	O
group	-	477	O
consisted	-	483	O
of	-	493	O
norepinephrine	-	496	O
only	-	511	O
.	-	515	O

However	2886572	517	O
,	-	524	O
epinephrine	-	526	O
treatment	-	538	O
resulted	-	548	O
in	-	557	O
the	-	560	O
incorporation	-	564	O
of	-	578	O
epinephrine	-	581	O
into	-	593	O
renal	-	598	O
catecholamine	-	604	O
stores	-	618	O
such	-	625	O
that	-	630	O
approximately	-	635	O
40	-	649	O
%	-	651	O
of	-	653	O
the	-	656	O
catecholamine	-	660	O
present	-	674	O
was	-	682	O
epinephrine	-	686	O
while	-	698	O
the	-	704	O
norepinephrine	-	708	O
content	-	723	O
was	-	731	O
reduced	-	735	O
by	-	743	O
a	-	746	O
similar	-	748	O
degree	-	756	O
.	-	762	O

Total	2886572	764	O
tissue	-	770	O
catecholamine	-	777	O
content	-	791	O
of	-	799	O
the	-	802	O
kidney	-	806	O
on	-	813	O
a	-	816	O
molar	-	818	O
basis	-	824	O
was	-	830	O
unchanged	-	834	O
.	-	843	O

Stimulus	2886572	845	O
-	-	853	O
induced	-	854	O
fractional	-	862	O
overflow	-	873	O
of	-	882	O
neurotransmitter	-	885	O
from	-	902	O
the	-	907	O
epinephrine	-	911	O
-	-	922	O
treated	-	923	O
kidneys	-	931	O
was	-	939	O
approximately	-	943	O
twice	-	957	O
normal	-	963	O
and	-	970	O
consisted	-	974	O
of	-	984	O
both	-	987	O
norepinephrine	-	992	O
and	-	1007	O
epinephrine	-	1011	O
in	-	1023	O
proportions	-	1026	O
similar	-	1038	O
to	-	1046	O
those	-	1049	O
found	-	1055	O
in	-	1061	O
the	-	1064	O
kidney	-	1068	O
.	-	1074	O

This	2886572	1076	O
difference	-	1081	O
in	-	1092	O
fractional	-	1095	O
overflow	-	1106	O
between	-	1115	O
groups	-	1123	O
was	-	1130	O
not	-	1134	O
affected	-	1138	O
by	-	1147	O
neuronal	-	1150	O
and	-	1159	O
extraneuronal	-	1163	O
uptake	-	1177	O
blockade	-	1184	O
.	-	1192	O

Propranolol	2886572	1194	O
had	-	1206	O
no	-	1210	O
effect	-	1213	O
on	-	1220	O
stimulus	-	1223	O
-	-	1231	O
induced	-	1232	O
overflow	-	1240	O
in	-	1249	O
either	-	1252	O
group	-	1259	O
.	-	1264	O

Phentolamine	2886572	1266	O
increased	-	1279	O
stimulus	-	1289	O
-	-	1297	O
induced	-	1298	O
overflow	-	1306	O
in	-	1315	O
both	-	1318	O
groups	-	1323	O
although	-	1330	O
the	-	1339	O
increment	-	1343	O
in	-	1353	O
overflow	-	1356	O
was	-	1365	O
greater	-	1369	O
in	-	1377	O
the	-	1380	O
epinephrine	-	1384	O
-	-	1395	O
treated	-	1396	O
group	-	1404	O
.	-	1409	O

In	2886572	1411	O
conclusion	-	1414	O
,	-	1424	O
chronic	-	1426	O
epinephrine	-	1434	O
treatment	-	1446	O
results	-	1456	O
in	-	1464	O
enhanced	-	1467	O
fractional	-	1476	O
neurotransmitter	-	1487	O
overflow	-	1504	O
.	-	1512	O

However	2886572	1514	O
,	-	1521	O
neither	-	1523	O
alterations	-	1531	O
in	-	1543	O
prejunctional	-	1546	O
beta	-	1560	O
-	-	1564	O
adrenoceptor	-	1565	O
influences	-	1578	O
nor	-	1589	O
alterations	-	1593	O
in	-	1605	O
neuronal	-	1608	O
and	-	1617	O
extraneuronal	-	1621	O
uptake	-	1635	O
mechanisms	-	1642	O
appear	-	1653	O
to	-	1660	O
be	-	1663	O
responsible	-	1666	O
for	-	1678	O
this	-	1682	O
alteration	-	1687	O
.	-	1697	O

Furthermore	2886572	1699	O
,	-	1710	O
data	-	1712	O
obtained	-	1717	O
with	-	1726	O
phentolamine	-	1731	O
alone	-	1744	O
do	-	1750	O
not	-	1753	O
suggest	-	1757	O
alpha	-	1765	O
-	-	1770	O
adrenoceptor	-	1771	O
desensitization	-	1784	O
as	-	1800	O
the	-	1803	O
cause	-	1807	O
of	-	1813	O
the	-	1816	O
enhanced	-	1820	O
neurotransmitter	-	1829	O
overflow	-	1846	O
after	-	1855	O
epinephrine	-	1861	O
treatment	-	1873	O
.	-	1882	O

Ocular	1079693	0	O
manifestations	-	7	O
of	-	22	O
juvenile	-	25	B
rheumatoid	-	34	I
arthritis	-	45	I
.	-	54	O

We	1079693	56	O
followed	-	59	O
210	-	68	O
cases	-	72	O
of	-	78	O
juvenile	-	81	B
rheumatoid	-	90	I
arthritis	-	101	I
closely	-	111	O
for	-	119	O
eleven	-	123	O
years	-	130	O
.	-	135	O

Thirty	1079693	137	O
-	-	143	O
six	-	144	O
of	-	148	O
the	-	151	O
210	-	155	O
patients	-	159	O
(	-	168	O
17	-	169	O
.	-	171	O
2	-	172	O
%	-	173	O
)	-	174	O
developed	-	176	O
iridocyclitis	-	186	B
.	-	199	O

Iridocyclitis	1079693	201	B
was	-	215	O
seen	-	219	O
most	-	224	O
frequently	-	229	O
in	-	240	O
young	-	243	O
female	-	249	O
patients	-	256	O
(	-	265	O
0	-	266	O
to	-	268	O
4	-	271	O
years	-	273	O
)	-	278	O
with	-	280	O
the	-	285	O
monoarticular	-	289	O
or	-	303	O
pauciatricular	-	306	O
form	-	321	O
of	-	326	O
the	-	329	O
arthritis	-	333	B
.	-	342	O

However	1079693	344	O
,	-	351	O
30	-	353	O
%	-	355	O
of	-	357	O
the	-	360	O
patients	-	364	O
developed	-	373	O
uveitis	-	383	B
after	-	391	O
16	-	397	O
years	-	400	O
of	-	406	O
age	-	409	O
.	-	412	O

Although	1079693	414	O
61	-	423	O
%	-	425	O
of	-	427	O
patients	-	430	O
had	-	439	O
a	-	443	O
noncontributory	-	445	O
ocular	-	461	O
history	-	468	O
on	-	476	O
entry	-	479	O
,	-	484	O
42	-	486	O
%	-	488	O
had	-	490	O
active	-	494	O
uveitis	-	501	B
on	-	509	O
entry	-	512	O
.	-	517	O

Our	1079693	519	O
approach	-	523	O
was	-	532	O
effective	-	536	O
in	-	546	O
detecting	-	549	O
uveitis	-	559	B
in	-	567	O
new	-	570	O
cases	-	574	O
and	-	580	O
exacerbations	-	584	O
of	-	598	O
uveitis	-	601	B
in	-	609	O
established	-	612	O
cases	-	624	O
.	-	629	O

Forty	1079693	631	O
-	-	636	O
four	-	637	O
percent	-	642	O
of	-	650	O
patients	-	653	O
with	-	662	O
uveitis	-	667	B
had	-	675	O
one	-	679	O
or	-	683	O
more	-	686	O
identifiable	-	691	O
signs	-	704	O
or	-	710	O
symptoms	-	713	O
,	-	721	O
such	-	723	O
as	-	728	O
red	-	731	O
eye	-	735	O
,	-	738	O
ocular	-	740	B
pain	-	747	I
,	-	751	O
decreased	-	753	B
visual	-	763	I
acuity	-	770	I
,	-	776	O
or	-	778	O
photophobia	-	781	B
,	-	792	O
in	-	794	O
order	-	797	O
of	-	803	O
decreasing	-	806	O
frequency	-	817	O
.	-	826	O

Even	1079693	828	O
after	-	833	O
early	-	839	O
detection	-	845	O
and	-	855	O
prompt	-	859	O
treatment	-	866	O
,	-	875	O
41	-	877	O
%	-	879	O
of	-	881	O
cases	-	884	O
of	-	890	O
uveitis	-	893	B
did	-	901	O
not	-	905	O
respond	-	909	O
to	-	917	O
more	-	920	O
than	-	925	O
six	-	930	O
months	-	934	O
of	-	941	O
intensive	-	944	O
topical	-	954	O
treatment	-	962	O
with	-	972	O
corticosteroids	-	977	O
and	-	993	O
mydriatics	-	997	O
.	-	1007	O

Despite	1079693	1009	O
this	-	1017	O
,	-	1021	O
there	-	1023	O
was	-	1029	O
a	-	1033	O
dramatic	-	1035	O
decrease	-	1044	O
in	-	1053	O
the	-	1056	O
50	-	1060	O
%	-	1062	O
incidence	-	1064	O
of	-	1074	O
blinding	-	1077	O
complications	-	1086	O
of	-	1100	O
uveitis	-	1103	B
cited	-	1111	O
in	-	1117	O
earlier	-	1120	O
studies	-	1128	O
.	-	1135	O

Cataract	1079693	1137	B
and	-	1146	O
band	-	1150	B
keratopathy	-	1155	I
occurred	-	1167	O
in	-	1176	O
only	-	1179	O
22	-	1184	O
and	-	1187	O
13	-	1191	O
%	-	1193	O
of	-	1195	O
our	-	1198	O
group	-	1202	O
,	-	1207	O
respectively	-	1209	O
.	-	1221	O

We	1079693	1223	O
used	-	1226	O
chloroquine	-	1231	O
or	-	1243	O
hydroxychloroquine	-	1246	O
in	-	1265	O
173	-	1268	O
of	-	1272	O
210	-	1275	O
cases	-	1279	O
and	-	1285	O
found	-	1289	O
only	-	1295	O
one	-	1300	O
case	-	1304	O
of	-	1309	O
chorioretinopathy	-	1312	B
attributable	-	1330	O
to	-	1343	O
these	-	1346	O
drugs	-	1352	O
.	-	1357	O

Systemically	1079693	1359	O
administered	-	1372	O
corticosteroids	-	1385	O
were	-	1401	O
used	-	1406	O
in	-	1411	O
75	-	1414	O
of	-	1417	O
210	-	1420	O
cases	-	1424	O
;	-	1429	O
a	-	1431	O
significant	-	1433	O
number	-	1445	O
of	-	1452	O
posterior	-	1455	O
subcapsular	-	1465	O
cataracts	-	1477	B
was	-	1487	O
found	-	1491	O
.	-	1496	O

Typical	1079693	1498	O
keratoconjunctivitis	-	1506	B
sicca	-	1527	O
developed	-	1533	O
in	-	1543	O
three	-	1546	O
of	-	1552	O
the	-	1555	O
uveitis	-	1559	B
cases	-	1567	O
.	-	1572	O

This	1079693	1574	O
association	-	1579	O
with	-	1591	O
uveitis	-	1596	B
and	-	1604	O
JRA	-	1608	O
was	-	1612	O
not	-	1616	O
noted	-	1620	O
previously	-	1626	O
.	-	1636	O

Surgical	1079693	1638	O
treatment	-	1647	O
of	-	1657	O
cataracts	-	1660	B
,	-	1669	O
band	-	1671	B
keratopathy	-	1676	I
,	-	1687	O
and	-	1689	O
glaucoma	-	1693	B
achieved	-	1702	O
uniformly	-	1711	O
discouraging	-	1721	O
results	-	1734	O
.	-	1741	O

Water	803783	0	B
intoxication	-	6	I
associated	-	19	O
with	-	30	O
oxytocin	-	35	O
administration	-	44	O
during	-	59	O
saline	-	66	O
-	-	72	O
induced	-	73	O
abortion	-	81	B
.	-	89	O

Four	803783	91	O
cases	-	96	O
of	-	102	O
water	-	105	B
intoxication	-	111	I
in	-	124	O
connection	-	127	O
with	-	138	O
oxytocin	-	143	O
administration	-	152	O
during	-	167	O
saline	-	174	O
-	-	180	O
induced	-	181	O
abortions	-	189	B
are	-	199	O
described	-	203	O
.	-	212	O

The	803783	214	O
mechanism	-	218	O
of	-	228	O
water	-	231	B
intoxication	-	237	I
is	-	250	O
discussed	-	253	O
in	-	263	O
regard	-	266	O
to	-	273	O
these	-	276	O
cases	-	282	O
.	-	287	O

Oxytocin	803783	289	O
administration	-	298	O
during	-	313	O
midtrimester	-	320	O
-	-	332	O
induced	-	333	O
abortions	-	341	B
is	-	351	O
advocated	-	354	O
only	-	364	O
if	-	369	O
it	-	372	O
can	-	375	O
be	-	379	O
carried	-	382	O
out	-	390	O
under	-	394	O
careful	-	400	O
observations	-	408	O
of	-	421	O
an	-	424	O
alert	-	427	O
nursing	-	433	O
staff	-	441	O
,	-	446	O
aware	-	448	O
of	-	454	O
the	-	457	O
symptoms	-	461	O
of	-	470	O
water	-	473	B
intoxication	-	479	I
and	-	492	O
instructed	-	496	O
to	-	507	O
watch	-	510	O
the	-	516	O
diuresis	-	520	O
and	-	529	O
report	-	533	O
such	-	540	O
early	-	545	O
signs	-	551	O
of	-	557	O
the	-	560	O
syndrome	-	564	O
as	-	573	O
asthenia	-	576	B
,	-	584	O
muscular	-	586	O
irritability	-	595	B
,	-	607	O
or	-	609	O
headaches	-	612	B
.	-	621	O

The	803783	623	O
oxytocin	-	627	O
should	-	636	O
be	-	643	O
given	-	646	O
only	-	652	O
in	-	657	O
Ringers	-	660	O
lactate	-	668	O
or	-	676	O
,	-	678	O
alternately	-	680	O
,	-	691	O
in	-	693	O
Ringers	-	696	O
lactate	-	704	O
and	-	712	O
a	-	716	O
5	-	718	O
per	-	720	O
cent	-	724	O
dextrose	-	729	O
and	-	738	O
water	-	742	O
solutions	-	748	O
.	-	757	O

The	803783	759	O
urinary	-	763	O
output	-	771	O
should	-	778	O
be	-	785	O
monitored	-	788	O
and	-	798	O
the	-	802	O
oxytocin	-	806	O
administration	-	815	O
discontinued	-	830	O
and	-	843	O
the	-	847	O
serum	-	851	O
electrolytes	-	857	O
checked	-	870	O
if	-	878	O
the	-	881	O
urinary	-	885	O
output	-	893	O
decreases	-	900	O
.	-	909	O

The	803783	911	O
oxytocin	-	915	O
should	-	924	O
not	-	931	O
be	-	935	O
administered	-	938	O
in	-	951	O
excess	-	954	O
of	-	961	O
36	-	964	O
hours	-	967	O
.	-	972	O

If	803783	974	O
the	-	977	O
patient	-	981	O
has	-	989	O
not	-	993	O
aborted	-	997	O
by	-	1005	O
then	-	1008	O
the	-	1013	O
oxytocin	-	1017	O
should	-	1026	O
be	-	1033	O
discontinued	-	1036	O
for	-	1049	O
10	-	1053	O
to	-	1056	O
12	-	1059	O
hours	-	1062	O
in	-	1068	O
order	-	1071	O
to	-	1077	O
perform	-	1080	O
electrolyte	-	1088	O
determinations	-	1100	O
and	-	1115	O
correct	-	1119	O
any	-	1127	O
electrolyte	-	1131	O
imbalance	-	1143	O
.	-	1152	O

